{"context": "In eukaryotes, co-translational insertion of selenocysteine into selenoproteins necessitates the participation of the selenocysteine insertion sequence (SECIS), an element lying in the 3'-untranslated region of selenoprotein mRNAs. We report a detailed experimental study of the secondary structures of the SECIS elements of three selenoprotein mRNAs, the rat and human type I iodothyronine deiodinase (5'DI) and rat glutathione peroxidase (GPx). Based on RNase and chemical probing, a new secondary structure model is established. It is characterized by a stem-loop structure, comprising two helices (I and II) separated by an internal loop, with an apical loop surmounting helix II. Sequence comparisons of 20 SECIS elements, arising from 2 5'DI, 13 GPx, 2 selenoprotein P, and 1 selenoprotein W mRNAs, confirm the secondary structure model. The most striking finding of the experimental study concerns a set of conserved sequences in helix II that interact to form a novel RNA structural motif consisting of a quartet composed of non-Watson-Crick base pairs 5'UGAY3': 5'UGAU3'. The potential for forming the quartet is preserved in 15 SECIS elements, but three consecutive non-Watson-Crick base pairs can nevertheless form in the other five SECIS, the central G.A tandem being invariant in all cases. A 3D model, derived by computer modeling with the use of the solution data, suggests that the base pairing interactions in the G.A tandem are of the type found in GNRA loops. The 3D model displays the quartet lying in an accessible position at the foot of helix II, which is bent at the internal loop, suggesting that the non-Watson-Crick base pair arrangement provides an unusual pattern of chemical groups for putative ligand interaction.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "3fe09fafae1c4200bf36faea155c3c62", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[123, 123], [205, 205], [20, 20], [46, 46], [225, 225]], "char_spans": [[712, 716], [1138, 1142], [153, 157], [307, 311], [1244, 1248]]}]}], "context_tokens": [["In", 0], ["eukaryotes", 3], [",", 13], ["co", 15], ["-", 17], ["translational", 18], ["insertion", 32], ["of", 42], ["selenocysteine", 45], ["into", 60], ["selenoproteins", 65], ["necessitates", 80], ["the", 93], ["participation", 97], ["of", 111], ["the", 114], ["selenocysteine", 118], ["insertion", 133], ["sequence", 143], ["(", 152], ["SECIS", 153], [")", 158], [",", 159], ["an", 161], ["element", 164], ["lying", 172], ["in", 178], ["the", 181], ["3'-untranslated", 185], ["region", 201], ["of", 208], ["selenoprotein", 211], ["mRNAs", 225], [".", 230], ["We", 232], ["report", 235], ["a", 242], ["detailed", 244], ["experimental", 253], ["study", 266], ["of", 272], ["the", 275], ["secondary", 279], ["structures", 289], ["of", 300], ["the", 303], ["SECIS", 307], ["elements", 313], ["of", 322], ["three", 325], ["selenoprotein", 331], ["mRNAs", 345], [",", 350], ["the", 352], ["rat", 356], ["and", 360], ["human", 364], ["type", 370], ["I", 375], ["iodothyronine", 377], ["deiodinase", 391], ["(", 402], ["5'DI", 403], [")", 407], ["and", 409], ["rat", 413], ["glutathione", 417], ["peroxidase", 429], ["(", 440], ["GPx", 441], [")", 444], [".", 445], ["Based", 447], ["on", 453], ["RNase", 456], ["and", 462], ["chemical", 466], ["probing", 475], [",", 482], ["a", 484], ["new", 486], ["secondary", 490], ["structure", 500], ["model", 510], ["is", 516], ["established", 519], [".", 530], ["It", 532], ["is", 535], ["characterized", 538], ["by", 552], ["a", 555], ["stem", 557], ["-", 561], ["loop", 562], ["structure", 567], [",", 576], ["comprising", 578], ["two", 589], ["helices", 593], ["(", 601], ["I", 602], ["and", 604], ["II", 608], [")", 610], ["separated", 612], ["by", 622], ["an", 625], ["internal", 628], ["loop", 637], [",", 641], ["with", 643], ["an", 648], ["apical", 651], ["loop", 658], ["surmounting", 663], ["helix", 675], ["II", 681], [".", 683], ["Sequence", 685], ["comparisons", 694], ["of", 706], ["20", 709], ["SECIS", 712], ["elements", 718], [",", 726], ["arising", 728], ["from", 736], ["2", 741], ["5'DI", 743], [",", 747], ["13", 749], ["GPx", 752], [",", 755], ["2", 757], ["selenoprotein", 759], ["P", 773], [",", 774], ["and", 776], ["1", 780], ["selenoprotein", 782], ["W", 796], ["mRNAs", 798], [",", 803], ["confirm", 805], ["the", 813], ["secondary", 817], ["structure", 827], ["model", 837], [".", 842], ["The", 844], ["most", 848], ["striking", 853], ["finding", 862], ["of", 870], ["the", 873], ["experimental", 877], ["study", 890], ["concerns", 896], ["a", 905], ["set", 907], ["of", 911], ["conserved", 914], ["sequences", 924], ["in", 934], ["helix", 937], ["II", 943], ["that", 946], ["interact", 951], ["to", 960], ["form", 963], ["a", 968], ["novel", 970], ["RNA", 976], ["structural", 980], ["motif", 991], ["consisting", 997], ["of", 1008], ["a", 1011], ["quartet", 1013], ["composed", 1021], ["of", 1030], ["non", 1033], ["-", 1036], ["Watson", 1037], ["-", 1043], ["Crick", 1044], ["base", 1050], ["pairs", 1055], ["5'UGAY3", 1061], ["'", 1068], [":", 1069], ["5'UGAU3", 1071], ["'", 1078], [".", 1079], ["The", 1081], ["potential", 1085], ["for", 1095], ["forming", 1099], ["the", 1107], ["quartet", 1111], ["is", 1119], ["preserved", 1122], ["in", 1132], ["15", 1135], ["SECIS", 1138], ["elements", 1144], [",", 1152], ["but", 1154], ["three", 1158], ["consecutive", 1164], ["non", 1176], ["-", 1179], ["Watson", 1180], ["-", 1186], ["Crick", 1187], ["base", 1193], ["pairs", 1198], ["can", 1204], ["nevertheless", 1208], ["form", 1221], ["in", 1226], ["the", 1229], ["other", 1233], ["five", 1239], ["SECIS", 1244], [",", 1249], ["the", 1251], ["central", 1255], ["G.A", 1263], ["tandem", 1267], ["being", 1274], ["invariant", 1280], ["in", 1290], ["all", 1293], ["cases", 1297], [".", 1302], ["A", 1304], ["3D", 1306], ["model", 1309], [",", 1314], ["derived", 1316], ["by", 1324], ["computer", 1327], ["modeling", 1336], ["with", 1345], ["the", 1350], ["use", 1354], ["of", 1358], ["the", 1361], ["solution", 1365], ["data", 1374], [",", 1378], ["suggests", 1380], ["that", 1389], ["the", 1394], ["base", 1398], ["pairing", 1403], ["interactions", 1411], ["in", 1424], ["the", 1427], ["G.A", 1431], ["tandem", 1435], ["are", 1442], ["of", 1446], ["the", 1449], ["type", 1453], ["found", 1458], ["in", 1464], ["GNRA", 1467], ["loops", 1472], [".", 1477], ["The", 1479], ["3D", 1483], ["model", 1486], ["displays", 1492], ["the", 1501], ["quartet", 1505], ["lying", 1513], ["in", 1519], ["an", 1522], ["accessible", 1525], ["position", 1536], ["at", 1545], ["the", 1548], ["foot", 1552], ["of", 1557], ["helix", 1560], ["II", 1566], [",", 1568], ["which", 1570], ["is", 1576], ["bent", 1579], ["at", 1584], ["the", 1587], ["internal", 1591], ["loop", 1600], [",", 1604], ["suggesting", 1606], ["that", 1617], ["the", 1622], ["non", 1626], ["-", 1629], ["Watson", 1630], ["-", 1636], ["Crick", 1637], ["base", 1643], ["pair", 1648], ["arrangement", 1653], ["provides", 1665], ["an", 1674], ["unusual", 1677], ["pattern", 1685], ["of", 1693], ["chemical", 1696], ["groups", 1705], ["for", 1712], ["putative", 1716], ["ligand", 1725], ["interaction", 1732], [".", 1743]]}
{"context": "Canonical primary microRNA (pri-miRNA) precursors are transcribed by RNA polymerase II and then processed by the Drosha endonuclease to generate approximately 60 nt pre-miRNA hairpins. Pre-miRNAs in turn are cleaved by Dicer to generate mature miRNAs. Previously, some short introns, called miRtrons, were reported to fold into pre-miRNA hairpins after splicing and debranching, and miRNAs can also be excised by Dicer cleavage of rare endogenous short hairpin RNAs. Here we report that the miRNAs encoded by murine gamma-herpesvirus 68 (MHV68) are also generated via atypical mechanisms. Specifically, MHV68 miRNAs are transcribed from RNA polymerase III promoters located within adjacent viral tRNA-like sequences. The resultant pri-miRNAs, which bear a 5' tRNA moiety, are not processed by Drosha but instead by cellular tRNase Z, which cleaves 3' to the tRNA to liberate pre-miRNA hairpins that are then processed by Dicer to yield the mature viral miRNAs.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "354a06365eb5430db7d04eb6bea5af55", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[12, 14]], "char_spans": [[69, 85]]}]}], "context_tokens": [["Canonical", 0], ["primary", 10], ["microRNA", 18], ["(", 27], ["pri", 28], ["-", 31], ["miRNA", 32], [")", 37], ["precursors", 39], ["are", 50], ["transcribed", 54], ["by", 66], ["RNA", 69], ["polymerase", 73], ["II", 84], ["and", 87], ["then", 91], ["processed", 96], ["by", 106], ["the", 109], ["Drosha", 113], ["endonuclease", 120], ["to", 133], ["generate", 136], ["approximately", 145], ["60", 159], ["nt", 162], ["pre", 165], ["-", 168], ["miRNA", 169], ["hairpins", 175], [".", 183], ["Pre", 185], ["-", 188], ["miRNAs", 189], ["in", 196], ["turn", 199], ["are", 204], ["cleaved", 208], ["by", 216], ["Dicer", 219], ["to", 225], ["generate", 228], ["mature", 237], ["miRNAs", 244], [".", 250], ["Previously", 252], [",", 262], ["some", 264], ["short", 269], ["introns", 275], [",", 282], ["called", 284], ["miRtrons", 291], [",", 299], ["were", 301], ["reported", 306], ["to", 315], ["fold", 318], ["into", 323], ["pre", 328], ["-", 331], ["miRNA", 332], ["hairpins", 338], ["after", 347], ["splicing", 353], ["and", 362], ["debranching", 366], [",", 377], ["and", 379], ["miRNAs", 383], ["can", 390], ["also", 394], ["be", 399], ["excised", 402], ["by", 410], ["Dicer", 413], ["cleavage", 419], ["of", 428], ["rare", 431], ["endogenous", 436], ["short", 447], ["hairpin", 453], ["RNAs", 461], [".", 465], ["Here", 467], ["we", 472], ["report", 475], ["that", 482], ["the", 487], ["miRNAs", 491], ["encoded", 498], ["by", 506], ["murine", 509], ["gamma", 516], ["-", 521], ["herpesvirus", 522], ["68", 534], ["(", 537], ["MHV68", 538], [")", 543], ["are", 545], ["also", 549], ["generated", 554], ["via", 564], ["atypical", 568], ["mechanisms", 577], [".", 587], ["Specifically", 589], [",", 601], ["MHV68", 603], ["miRNAs", 609], ["are", 616], ["transcribed", 620], ["from", 632], ["RNA", 637], ["polymerase", 641], ["III", 652], ["promoters", 656], ["located", 666], ["within", 674], ["adjacent", 681], ["viral", 690], ["tRNA", 696], ["-", 700], ["like", 701], ["sequences", 706], [".", 715], ["The", 717], ["resultant", 721], ["pri", 731], ["-", 734], ["miRNAs", 735], [",", 741], ["which", 743], ["bear", 749], ["a", 754], ["5", 756], ["'", 757], ["tRNA", 759], ["moiety", 764], [",", 770], ["are", 772], ["not", 776], ["processed", 780], ["by", 790], ["Drosha", 793], ["but", 800], ["instead", 804], ["by", 812], ["cellular", 815], ["tRNase", 824], ["Z", 831], [",", 832], ["which", 834], ["cleaves", 840], ["3", 848], ["'", 849], ["to", 851], ["the", 854], ["tRNA", 858], ["to", 863], ["liberate", 866], ["pre", 875], ["-", 878], ["miRNA", 879], ["hairpins", 885], ["that", 894], ["are", 899], ["then", 903], ["processed", 908], ["by", 918], ["Dicer", 921], ["to", 927], ["yield", 930], ["the", 936], ["mature", 940], ["viral", 947], ["miRNAs", 953], [".", 959]]}
{"context": "Scientists have been aware for many years of genetic programs that get activated under stress and produce genetic variants in cells that escape non-proliferating conditions. These programs are well conserved in all organisms and expand our view of evolution. They mediate genome instability, create diversity in antibody formation, expand metabolism and increase fitness of pathogens within host environments. Error-prone DNA replication and repair are genetic variability-causing agents that get stimulated by the onset of cellular stresses. Embedded in these programs is the ability to limit mutagenesis to defined genomic regions and times, ensuring integrity of most of the genome. Recent evidence suggests that factors involved in RNA polymerase (RNAP) processivity or transcriptional derepression contribute to the generation of stress-induced mutations. In Bacillus subtilis, transcription-associated mutagenesis has been shown to be independent of recombination-dependent repair and, in some cases, of the Y DNA polymerases. Central to stationary-phase mutagenesis in B. subtilis is the requirement for Mfd, transcription coupling repair factor, which suggests a novel mechanism from those described in other model systems.", "qas": [{"question": "In which phase of cell cycle does  stress-induced transcription-associated mutagenesis (TAM) occur?", "answers": ["stationary phase", "stationary-phase"], "qid": "1126a2a0c1ae4863844e2b5cc811f042", "question_tokens": [["In", 0], ["which", 3], ["phase", 9], ["of", 15], ["cell", 18], ["cycle", 23], ["does", 29], [" ", 34], ["stress", 35], ["-", 41], ["induced", 42], ["transcription", 50], ["-", 63], ["associated", 64], ["mutagenesis", 75], ["(", 87], ["TAM", 88], [")", 91], ["occur", 93], ["?", 98]], "detected_answers": [{"text": "stationary phase", "token_spans": [[172, 174]], "char_spans": [[1044, 1059]]}]}], "context_tokens": [["Scientists", 0], ["have", 11], ["been", 16], ["aware", 21], ["for", 27], ["many", 31], ["years", 36], ["of", 42], ["genetic", 45], ["programs", 53], ["that", 62], ["get", 67], ["activated", 71], ["under", 81], ["stress", 87], ["and", 94], ["produce", 98], ["genetic", 106], ["variants", 114], ["in", 123], ["cells", 126], ["that", 132], ["escape", 137], ["non", 144], ["-", 147], ["proliferating", 148], ["conditions", 162], [".", 172], ["These", 174], ["programs", 180], ["are", 189], ["well", 193], ["conserved", 198], ["in", 208], ["all", 211], ["organisms", 215], ["and", 225], ["expand", 229], ["our", 236], ["view", 240], ["of", 245], ["evolution", 248], [".", 257], ["They", 259], ["mediate", 264], ["genome", 272], ["instability", 279], [",", 290], ["create", 292], ["diversity", 299], ["in", 309], ["antibody", 312], ["formation", 321], [",", 330], ["expand", 332], ["metabolism", 339], ["and", 350], ["increase", 354], ["fitness", 363], ["of", 371], ["pathogens", 374], ["within", 384], ["host", 391], ["environments", 396], [".", 408], ["Error", 410], ["-", 415], ["prone", 416], ["DNA", 422], ["replication", 426], ["and", 438], ["repair", 442], ["are", 449], ["genetic", 453], ["variability", 461], ["-", 472], ["causing", 473], ["agents", 481], ["that", 488], ["get", 493], ["stimulated", 497], ["by", 508], ["the", 511], ["onset", 515], ["of", 521], ["cellular", 524], ["stresses", 533], [".", 541], ["Embedded", 543], ["in", 552], ["these", 555], ["programs", 561], ["is", 570], ["the", 573], ["ability", 577], ["to", 585], ["limit", 588], ["mutagenesis", 594], ["to", 606], ["defined", 609], ["genomic", 617], ["regions", 625], ["and", 633], ["times", 637], [",", 642], ["ensuring", 644], ["integrity", 653], ["of", 663], ["most", 666], ["of", 671], ["the", 674], ["genome", 678], [".", 684], ["Recent", 686], ["evidence", 693], ["suggests", 702], ["that", 711], ["factors", 716], ["involved", 724], ["in", 733], ["RNA", 736], ["polymerase", 740], ["(", 751], ["RNAP", 752], [")", 756], ["processivity", 758], ["or", 771], ["transcriptional", 774], ["derepression", 790], ["contribute", 803], ["to", 814], ["the", 817], ["generation", 821], ["of", 832], ["stress", 835], ["-", 841], ["induced", 842], ["mutations", 850], [".", 859], ["In", 861], ["Bacillus", 864], ["subtilis", 873], [",", 881], ["transcription", 883], ["-", 896], ["associated", 897], ["mutagenesis", 908], ["has", 920], ["been", 924], ["shown", 929], ["to", 935], ["be", 938], ["independent", 941], ["of", 953], ["recombination", 956], ["-", 969], ["dependent", 970], ["repair", 980], ["and", 987], [",", 990], ["in", 992], ["some", 995], ["cases", 1000], [",", 1005], ["of", 1007], ["the", 1010], ["Y", 1014], ["DNA", 1016], ["polymerases", 1020], [".", 1031], ["Central", 1033], ["to", 1041], ["stationary", 1044], ["-", 1054], ["phase", 1055], ["mutagenesis", 1061], ["in", 1073], ["B.", 1076], ["subtilis", 1079], ["is", 1088], ["the", 1091], ["requirement", 1095], ["for", 1107], ["Mfd", 1111], [",", 1114], ["transcription", 1116], ["coupling", 1130], ["repair", 1139], ["factor", 1146], [",", 1152], ["which", 1154], ["suggests", 1160], ["a", 1169], ["novel", 1171], ["mechanism", 1177], ["from", 1187], ["those", 1192], ["described", 1198], ["in", 1208], ["other", 1211], ["model", 1217], ["systems", 1223], [".", 1230]]}
{"context": "To define the relationship between body indices of healthy adults and cross-sectional areas of the carpal tunnel and median nerve and to obtain the nerve/tunnel index, which represents a new standard for diagnosing carpal tunnel syndrome using sonography. Body indices (height, weight, and body mass index) were analyzed in 60 healthy adults, and electromyography and sonography were also performed. The cross-sectional areas of the proximal and distal median nerve and carpal tunnel were obtained by sonography. The proximal and distal nerve/tunnel indices were obtained by calculating the ratio between the proximal and distal cross-sectional areas of the median nerve to those of the carpal tunnel and multiplying the value by 100. Although the proximal cross-sectional areas of the median nerve and body indices showed statistically significant relationships with weak positive correlations, the proximal and distal areas of the carpal tunnel showed relatively stronger correlations with body indices. Between sexes, there were significant differences in the proximal median nerve cross-sectional area (mean \u00b1 SD: male, 10.48 \u00b1 3.21 mm(2); female, 8.81 \u00b1 3.21 mm(2); P < .05) and proximal carpal tunnel area (male, 182.50 \u00b1 21.15 mm(2); female, 151.23 \u00b1 21.14 mm(2); P < .05). There was no difference in the proximal nerve/tunnel index (male, 5.80% \u00b1 1.72%; female, 5.91% \u00b1 1.63%). There was a statistically significant difference in the distal carpal tunnel cross-sectional area (male, 138.90 \u00b1 20.95 mm(2); female, 121.50 \u00b1 18.99 mm(2); P < .05) between sexes, but the distal median area (male, 9.99 \u00b1 3.42 mm(2); female, 8.46 \u00b1 1.84 mm(2)) and distal nerve/tunnel index (male, 7.15% \u00b1 2.00%; female, 7.01% \u00b1 1.38%) showed no significant differences. The proximal index was significantly higher than the distal index (proximal, 5.85% \u00b1 1.66%; distal, 7.08% \u00b1 1.71%). The nerve/tunnel index is unaffected by body indices or sex and thus may be a useful and objective standard for diagnosing carpal tunnel syndrome.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "75f0878c248e4bbab73420d14772e958", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[181, 181], [310, 310], [116, 116], [140, 140], [20, 20], [81, 81]], "char_spans": [[1072, 1077], [1582, 1587], [658, 663], [786, 791], [117, 122], [453, 458]]}]}], "context_tokens": [["To", 0], ["define", 3], ["the", 10], ["relationship", 14], ["between", 27], ["body", 35], ["indices", 40], ["of", 48], ["healthy", 51], ["adults", 59], ["and", 66], ["cross", 70], ["-", 75], ["sectional", 76], ["areas", 86], ["of", 92], ["the", 95], ["carpal", 99], ["tunnel", 106], ["and", 113], ["median", 117], ["nerve", 124], ["and", 130], ["to", 134], ["obtain", 137], ["the", 144], ["nerve", 148], ["/", 153], ["tunnel", 154], ["index", 161], [",", 166], ["which", 168], ["represents", 174], ["a", 185], ["new", 187], ["standard", 191], ["for", 200], ["diagnosing", 204], ["carpal", 215], ["tunnel", 222], ["syndrome", 229], ["using", 238], ["sonography", 244], [".", 254], ["Body", 256], ["indices", 261], ["(", 269], ["height", 270], [",", 276], ["weight", 278], [",", 284], ["and", 286], ["body", 290], ["mass", 295], ["index", 300], [")", 305], ["were", 307], ["analyzed", 312], ["in", 321], ["60", 324], ["healthy", 327], ["adults", 335], [",", 341], ["and", 343], ["electromyography", 347], ["and", 364], ["sonography", 368], ["were", 379], ["also", 384], ["performed", 389], [".", 398], ["The", 400], ["cross", 404], ["-", 409], ["sectional", 410], ["areas", 420], ["of", 426], ["the", 429], ["proximal", 433], ["and", 442], ["distal", 446], ["median", 453], ["nerve", 460], ["and", 466], ["carpal", 470], ["tunnel", 477], ["were", 484], ["obtained", 489], ["by", 498], ["sonography", 501], [".", 511], ["The", 513], ["proximal", 517], ["and", 526], ["distal", 530], ["nerve", 537], ["/", 542], ["tunnel", 543], ["indices", 550], ["were", 558], ["obtained", 563], ["by", 572], ["calculating", 575], ["the", 587], ["ratio", 591], ["between", 597], ["the", 605], ["proximal", 609], ["and", 618], ["distal", 622], ["cross", 629], ["-", 634], ["sectional", 635], ["areas", 645], ["of", 651], ["the", 654], ["median", 658], ["nerve", 665], ["to", 671], ["those", 674], ["of", 680], ["the", 683], ["carpal", 687], ["tunnel", 694], ["and", 701], ["multiplying", 705], ["the", 717], ["value", 721], ["by", 727], ["100", 730], [".", 733], ["Although", 735], ["the", 744], ["proximal", 748], ["cross", 757], ["-", 762], ["sectional", 763], ["areas", 773], ["of", 779], ["the", 782], ["median", 786], ["nerve", 793], ["and", 799], ["body", 803], ["indices", 808], ["showed", 816], ["statistically", 823], ["significant", 837], ["relationships", 849], ["with", 863], ["weak", 868], ["positive", 873], ["correlations", 882], [",", 894], ["the", 896], ["proximal", 900], ["and", 909], ["distal", 913], ["areas", 920], ["of", 926], ["the", 929], ["carpal", 933], ["tunnel", 940], ["showed", 947], ["relatively", 954], ["stronger", 965], ["correlations", 974], ["with", 987], ["body", 992], ["indices", 997], [".", 1004], ["Between", 1006], ["sexes", 1014], [",", 1019], ["there", 1021], ["were", 1027], ["significant", 1032], ["differences", 1044], ["in", 1056], ["the", 1059], ["proximal", 1063], ["median", 1072], ["nerve", 1079], ["cross", 1085], ["-", 1090], ["sectional", 1091], ["area", 1101], ["(", 1106], ["mean", 1107], ["\u00b1", 1112], ["SD", 1114], [":", 1116], ["male", 1118], [",", 1122], ["10.48", 1124], ["\u00b1", 1130], ["3.21", 1132], ["mm(2", 1137], [")", 1141], [";", 1142], ["female", 1144], [",", 1150], ["8.81", 1152], ["\u00b1", 1157], ["3.21", 1159], ["mm(2", 1164], [")", 1168], [";", 1169], ["P", 1171], ["<", 1173], [".05", 1175], [")", 1178], ["and", 1180], ["proximal", 1184], ["carpal", 1193], ["tunnel", 1200], ["area", 1207], ["(", 1212], ["male", 1213], [",", 1217], ["182.50", 1219], ["\u00b1", 1226], ["21.15", 1228], ["mm(2", 1234], [")", 1238], [";", 1239], ["female", 1241], [",", 1247], ["151.23", 1249], ["\u00b1", 1256], ["21.14", 1258], ["mm(2", 1264], [")", 1268], [";", 1269], ["P", 1271], ["<", 1273], [".05", 1275], [")", 1278], [".", 1279], ["There", 1281], ["was", 1287], ["no", 1291], ["difference", 1294], ["in", 1305], ["the", 1308], ["proximal", 1312], ["nerve", 1321], ["/", 1326], ["tunnel", 1327], ["index", 1334], ["(", 1340], ["male", 1341], [",", 1345], ["5.80", 1347], ["%", 1351], ["\u00b1", 1353], ["1.72", 1355], ["%", 1359], [";", 1360], ["female", 1362], [",", 1368], ["5.91", 1370], ["%", 1374], ["\u00b1", 1376], ["1.63", 1378], ["%", 1382], [")", 1383], [".", 1384], ["There", 1386], ["was", 1392], ["a", 1396], ["statistically", 1398], ["significant", 1412], ["difference", 1424], ["in", 1435], ["the", 1438], ["distal", 1442], ["carpal", 1449], ["tunnel", 1456], ["cross", 1463], ["-", 1468], ["sectional", 1469], ["area", 1479], ["(", 1484], ["male", 1485], [",", 1489], ["138.90", 1491], ["\u00b1", 1498], ["20.95", 1500], ["mm(2", 1506], [")", 1510], [";", 1511], ["female", 1513], [",", 1519], ["121.50", 1521], ["\u00b1", 1528], ["18.99", 1530], ["mm(2", 1536], [")", 1540], [";", 1541], ["P", 1543], ["<", 1545], [".05", 1547], [")", 1550], ["between", 1552], ["sexes", 1560], [",", 1565], ["but", 1567], ["the", 1571], ["distal", 1575], ["median", 1582], ["area", 1589], ["(", 1594], ["male", 1595], [",", 1599], ["9.99", 1601], ["\u00b1", 1606], ["3.42", 1608], ["mm(2", 1613], [")", 1617], [";", 1618], ["female", 1620], [",", 1626], ["8.46", 1628], ["\u00b1", 1633], ["1.84", 1635], ["mm(2", 1640], [")", 1644], [")", 1645], ["and", 1647], ["distal", 1651], ["nerve", 1658], ["/", 1663], ["tunnel", 1664], ["index", 1671], ["(", 1677], ["male", 1678], [",", 1682], ["7.15", 1684], ["%", 1688], ["\u00b1", 1690], ["2.00", 1692], ["%", 1696], [";", 1697], ["female", 1699], [",", 1705], ["7.01", 1707], ["%", 1711], ["\u00b1", 1713], ["1.38", 1715], ["%", 1719], [")", 1720], ["showed", 1722], ["no", 1729], ["significant", 1732], ["differences", 1744], [".", 1755], ["The", 1757], ["proximal", 1761], ["index", 1770], ["was", 1776], ["significantly", 1780], ["higher", 1794], ["than", 1801], ["the", 1806], ["distal", 1810], ["index", 1817], ["(", 1823], ["proximal", 1824], [",", 1832], ["5.85", 1834], ["%", 1838], ["\u00b1", 1840], ["1.66", 1842], ["%", 1846], [";", 1847], ["distal", 1849], [",", 1855], ["7.08", 1857], ["%", 1861], ["\u00b1", 1863], ["1.71", 1865], ["%", 1869], [")", 1870], [".", 1871], ["The", 1873], ["nerve", 1877], ["/", 1882], ["tunnel", 1883], ["index", 1890], ["is", 1896], ["unaffected", 1899], ["by", 1910], ["body", 1913], ["indices", 1918], ["or", 1926], ["sex", 1929], ["and", 1933], ["thus", 1937], ["may", 1942], ["be", 1946], ["a", 1949], ["useful", 1951], ["and", 1958], ["objective", 1962], ["standard", 1972], ["for", 1981], ["diagnosing", 1985], ["carpal", 1996], ["tunnel", 2003], ["syndrome", 2010], [".", 2018]]}
{"context": "Interleukin-6 (IL6) plays a central role in multiple myeloma pathogenesis and confers resistance to corticosteroid-induced apoptosis. We therefore evaluated the efficacy and safety of siltuximab, an anti-IL6 monoclonal antibody, alone and in combination with dexamethasone, for patients with relapsed or refractory multiple myeloma who had \u2265 2 prior lines of therapy, one of which had to be bortezomib-based. Fourteen initial patients received siltuximab alone, 10 of whom had dexamethasone added for suboptimal response; 39 subsequent patients were treated with concurrent siltuximab and dexamethasone. Patients received a median of four prior lines of therapy, 83% were relapsed and refractory, and 70% refractory to their last dexamethasone-containing regimen. Suppression of serum C-reactive protein levels, a surrogate marker of IL6 inhibition, was demonstrated. There were no responses to siltuximab but combination therapy yielded a partial (17%) + minimal (6%) response rate of 23%, with responses seen in dexamethasone-refractory disease. The median time to progression, progression-free survival and overall survival for combination therapy was 4.4, 3.7 and 20.4 months respectively. Haematological toxicity was common but manageable. Infections occurred in 57% of combination-treated patients, including \u2265 grade 3 infections in 18%. Further study of siltuximab in modern corticosteroid-containing myeloma regimens is warranted, with special attention to infection-related toxicity.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "1e1ef110e6154949bc822e542fff38e2", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[0, 0]], "char_spans": [[0, 12]]}]}], "context_tokens": [["Interleukin-6", 0], ["(", 14], ["IL6", 15], [")", 18], ["plays", 20], ["a", 26], ["central", 28], ["role", 36], ["in", 41], ["multiple", 44], ["myeloma", 53], ["pathogenesis", 61], ["and", 74], ["confers", 78], ["resistance", 86], ["to", 97], ["corticosteroid", 100], ["-", 114], ["induced", 115], ["apoptosis", 123], [".", 132], ["We", 134], ["therefore", 137], ["evaluated", 147], ["the", 157], ["efficacy", 161], ["and", 170], ["safety", 174], ["of", 181], ["siltuximab", 184], [",", 194], ["an", 196], ["anti", 199], ["-", 203], ["IL6", 204], ["monoclonal", 208], ["antibody", 219], [",", 227], ["alone", 229], ["and", 235], ["in", 239], ["combination", 242], ["with", 254], ["dexamethasone", 259], [",", 272], ["for", 274], ["patients", 278], ["with", 287], ["relapsed", 292], ["or", 301], ["refractory", 304], ["multiple", 315], ["myeloma", 324], ["who", 332], ["had", 336], ["\u2265", 340], ["2", 342], ["prior", 344], ["lines", 350], ["of", 356], ["therapy", 359], [",", 366], ["one", 368], ["of", 372], ["which", 375], ["had", 381], ["to", 385], ["be", 388], ["bortezomib", 391], ["-", 401], ["based", 402], [".", 407], ["Fourteen", 409], ["initial", 418], ["patients", 426], ["received", 435], ["siltuximab", 444], ["alone", 455], [",", 460], ["10", 462], ["of", 465], ["whom", 468], ["had", 473], ["dexamethasone", 477], ["added", 491], ["for", 497], ["suboptimal", 501], ["response", 512], [";", 520], ["39", 522], ["subsequent", 525], ["patients", 536], ["were", 545], ["treated", 550], ["with", 558], ["concurrent", 563], ["siltuximab", 574], ["and", 585], ["dexamethasone", 589], [".", 602], ["Patients", 604], ["received", 613], ["a", 622], ["median", 624], ["of", 631], ["four", 634], ["prior", 639], ["lines", 645], ["of", 651], ["therapy", 654], [",", 661], ["83", 663], ["%", 665], ["were", 667], ["relapsed", 672], ["and", 681], ["refractory", 685], [",", 695], ["and", 697], ["70", 701], ["%", 703], ["refractory", 705], ["to", 716], ["their", 719], ["last", 725], ["dexamethasone", 730], ["-", 743], ["containing", 744], ["regimen", 755], [".", 762], ["Suppression", 764], ["of", 776], ["serum", 779], ["C", 785], ["-", 786], ["reactive", 787], ["protein", 796], ["levels", 804], [",", 810], ["a", 812], ["surrogate", 814], ["marker", 824], ["of", 831], ["IL6", 834], ["inhibition", 838], [",", 848], ["was", 850], ["demonstrated", 854], [".", 866], ["There", 868], ["were", 874], ["no", 879], ["responses", 882], ["to", 892], ["siltuximab", 895], ["but", 906], ["combination", 910], ["therapy", 922], ["yielded", 930], ["a", 938], ["partial", 940], ["(", 948], ["17", 949], ["%", 951], [")", 952], ["+", 954], ["minimal", 956], ["(", 964], ["6", 965], ["%", 966], [")", 967], ["response", 969], ["rate", 978], ["of", 983], ["23", 986], ["%", 988], [",", 989], ["with", 991], ["responses", 996], ["seen", 1006], ["in", 1011], ["dexamethasone", 1014], ["-", 1027], ["refractory", 1028], ["disease", 1039], [".", 1046], ["The", 1048], ["median", 1052], ["time", 1059], ["to", 1064], ["progression", 1067], [",", 1078], ["progression", 1080], ["-", 1091], ["free", 1092], ["survival", 1097], ["and", 1106], ["overall", 1110], ["survival", 1118], ["for", 1127], ["combination", 1131], ["therapy", 1143], ["was", 1151], ["4.4", 1155], [",", 1158], ["3.7", 1160], ["and", 1164], ["20.4", 1168], ["months", 1173], ["respectively", 1180], [".", 1192], ["Haematological", 1194], ["toxicity", 1209], ["was", 1218], ["common", 1222], ["but", 1229], ["manageable", 1233], [".", 1243], ["Infections", 1245], ["occurred", 1256], ["in", 1265], ["57", 1268], ["%", 1270], ["of", 1272], ["combination", 1275], ["-", 1286], ["treated", 1287], ["patients", 1295], [",", 1303], ["including", 1305], ["\u2265", 1315], ["grade", 1317], ["3", 1323], ["infections", 1325], ["in", 1336], ["18", 1339], ["%", 1341], [".", 1342], ["Further", 1344], ["study", 1352], ["of", 1358], ["siltuximab", 1361], ["in", 1372], ["modern", 1375], ["corticosteroid", 1382], ["-", 1396], ["containing", 1397], ["myeloma", 1408], ["regimens", 1416], ["is", 1425], ["warranted", 1428], [",", 1437], ["with", 1439], ["special", 1444], ["attention", 1452], ["to", 1462], ["infection", 1465], ["-", 1474], ["related", 1475], ["toxicity", 1483], [".", 1491]]}
{"context": "Fibrillar \u03b1-synuclein (\u03b1-Syn) is the principal component of Lewy bodies, which are evident in individuals affected by Parkinson disease (PD). This neuropathologic form of \u03b1-Syn plays a central role in PD progression as it has been shown to propagate between neurons. Tools that interfere with \u03b1-Syn assembly or change the physicochemical properties of the fibrils have potential therapeutic properties as they may be sufficient to interfere with and/or halt cell-to-cell transmission and the systematic spread of \u03b1-Syn assemblies within the central nervous system. Vertebrate molecular chaperones from the constitutive/heat-inducible heat shock protein 70 (Hsc/p70) family have been shown to hinder the assembly of soluble \u03b1-Syn into fibrils and to bind to the fibrils and very significantly reduce their toxicity. To understand how Hsc70 family members sequester soluble \u03b1-Syn, we set up experiments to identify the molecular chaperone-\u03b1-Syn surface interfaces. We cross-linked human Hsc70 and its yeast homologue Ssa1p and \u03b1-Syn using a chemical cross-linker and mapped the Hsc70- and Ssa1p-\u03b1-Syn interface. We show that the client binding domain of Hsc70 and Ssa1p binds two regions within \u03b1-Syn similar to a tweezer, with the first spanning residues 10-45 and the second spanning residues 97-102. Our findings define what is necessary and sufficient for engineering Hsc70- and Ssa1p-derived polypeptide with minichaperone properties with a potential as therapeutic agents in Parkinson disease through their ability to affect \u03b1-Syn assembly and/or toxicity.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "344f79431db040ea8cbbb6cb3a1b171a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[1, 3]], "char_spans": [[10, 20]]}]}], "context_tokens": [["Fibrillar", 0], ["\u03b1", 10], ["-", 11], ["synuclein", 12], ["(", 22], ["\u03b1", 23], ["-", 24], ["Syn", 25], [")", 28], ["is", 30], ["the", 33], ["principal", 37], ["component", 47], ["of", 57], ["Lewy", 60], ["bodies", 65], [",", 71], ["which", 73], ["are", 79], ["evident", 83], ["in", 91], ["individuals", 94], ["affected", 106], ["by", 115], ["Parkinson", 118], ["disease", 128], ["(", 136], ["PD", 137], [")", 139], [".", 140], ["This", 142], ["neuropathologic", 147], ["form", 163], ["of", 168], ["\u03b1", 171], ["-", 172], ["Syn", 173], ["plays", 177], ["a", 183], ["central", 185], ["role", 193], ["in", 198], ["PD", 201], ["progression", 204], ["as", 216], ["it", 219], ["has", 222], ["been", 226], ["shown", 231], ["to", 237], ["propagate", 240], ["between", 250], ["neurons", 258], [".", 265], ["Tools", 267], ["that", 273], ["interfere", 278], ["with", 288], ["\u03b1", 293], ["-", 294], ["Syn", 295], ["assembly", 299], ["or", 308], ["change", 311], ["the", 318], ["physicochemical", 322], ["properties", 338], ["of", 349], ["the", 352], ["fibrils", 356], ["have", 364], ["potential", 369], ["therapeutic", 379], ["properties", 391], ["as", 402], ["they", 405], ["may", 410], ["be", 414], ["sufficient", 417], ["to", 428], ["interfere", 431], ["with", 441], ["and/or", 446], ["halt", 453], ["cell", 458], ["-", 462], ["to", 463], ["-", 465], ["cell", 466], ["transmission", 471], ["and", 484], ["the", 488], ["systematic", 492], ["spread", 503], ["of", 510], ["\u03b1", 513], ["-", 514], ["Syn", 515], ["assemblies", 519], ["within", 530], ["the", 537], ["central", 541], ["nervous", 549], ["system", 557], [".", 563], ["Vertebrate", 565], ["molecular", 576], ["chaperones", 586], ["from", 597], ["the", 602], ["constitutive", 606], ["/", 618], ["heat", 619], ["-", 623], ["inducible", 624], ["heat", 634], ["shock", 639], ["protein", 645], ["70", 653], ["(", 656], ["Hsc", 657], ["/", 660], ["p70", 661], [")", 664], ["family", 666], ["have", 673], ["been", 678], ["shown", 683], ["to", 689], ["hinder", 692], ["the", 699], ["assembly", 703], ["of", 712], ["soluble", 715], ["\u03b1", 723], ["-", 724], ["Syn", 725], ["into", 729], ["fibrils", 734], ["and", 742], ["to", 746], ["bind", 749], ["to", 754], ["the", 757], ["fibrils", 761], ["and", 769], ["very", 773], ["significantly", 778], ["reduce", 792], ["their", 799], ["toxicity", 805], [".", 813], ["To", 815], ["understand", 818], ["how", 829], ["Hsc70", 833], ["family", 839], ["members", 846], ["sequester", 854], ["soluble", 864], ["\u03b1", 872], ["-", 873], ["Syn", 874], [",", 877], ["we", 879], ["set", 882], ["up", 886], ["experiments", 889], ["to", 901], ["identify", 904], ["the", 913], ["molecular", 917], ["chaperone", 927], ["-", 936], ["\u03b1", 937], ["-", 938], ["Syn", 939], ["surface", 943], ["interfaces", 951], [".", 961], ["We", 963], ["cross", 966], ["-", 971], ["linked", 972], ["human", 979], ["Hsc70", 985], ["and", 991], ["its", 995], ["yeast", 999], ["homologue", 1005], ["Ssa1p", 1015], ["and", 1021], ["\u03b1", 1025], ["-", 1026], ["Syn", 1027], ["using", 1031], ["a", 1037], ["chemical", 1039], ["cross", 1048], ["-", 1053], ["linker", 1054], ["and", 1061], ["mapped", 1065], ["the", 1072], ["Hsc70-", 1076], ["and", 1083], ["Ssa1p", 1087], ["-", 1092], ["\u03b1", 1093], ["-", 1094], ["Syn", 1095], ["interface", 1099], [".", 1108], ["We", 1110], ["show", 1113], ["that", 1118], ["the", 1123], ["client", 1127], ["binding", 1134], ["domain", 1142], ["of", 1149], ["Hsc70", 1152], ["and", 1158], ["Ssa1p", 1162], ["binds", 1168], ["two", 1174], ["regions", 1178], ["within", 1186], ["\u03b1", 1193], ["-", 1194], ["Syn", 1195], ["similar", 1199], ["to", 1207], ["a", 1210], ["tweezer", 1212], [",", 1219], ["with", 1221], ["the", 1226], ["first", 1230], ["spanning", 1236], ["residues", 1245], ["10", 1254], ["-", 1256], ["45", 1257], ["and", 1260], ["the", 1264], ["second", 1268], ["spanning", 1275], ["residues", 1284], ["97", 1293], ["-", 1295], ["102", 1296], [".", 1299], ["Our", 1301], ["findings", 1305], ["define", 1314], ["what", 1321], ["is", 1326], ["necessary", 1329], ["and", 1339], ["sufficient", 1343], ["for", 1354], ["engineering", 1358], ["Hsc70-", 1370], ["and", 1377], ["Ssa1p", 1381], ["-", 1386], ["derived", 1387], ["polypeptide", 1395], ["with", 1407], ["minichaperone", 1412], ["properties", 1426], ["with", 1437], ["a", 1442], ["potential", 1444], ["as", 1454], ["therapeutic", 1457], ["agents", 1469], ["in", 1476], ["Parkinson", 1479], ["disease", 1489], ["through", 1497], ["their", 1505], ["ability", 1511], ["to", 1519], ["affect", 1522], ["\u03b1", 1529], ["-", 1530], ["Syn", 1531], ["assembly", 1535], ["and/or", 1544], ["toxicity", 1551], [".", 1559]]}
{"context": "Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disorder (incidence around 1 in 106 births), characterised by a complex immunologic defects, reduced pigmentation, and presence of giant granules in many different cell types. It most likely results from defective organellar trafficking or protein sorting. The causative gene (LYST) has recently been identified and shown to be homologous to the beige locus in the mouse. CHS has always been reported associated with premature-termination-codon mutations in both alleles of LYST. We report a unique patient with CHS, who was homozygous for a stop codon in the LYST gene on chromosome 1 and who had a normal 46,XY karyotype. The mother was found to be a carrier of the mutation, whereas the father had two normal LYST alleles. Non-paternity was excluded by the analysis of microsatellite markers from different chromosomes. The results of 13 informative microsatellite markers spanning the entire chromosome 1 revealed that the proband had a maternal isodisomy of chromosome 1 encompassing the LYST mutation. The proband's clinical presentation also confirms the absence of imprinted genes on chromosome 1.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "ba84f91cf9b6461d9ee02be446bcdffc", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["a", 34], ["rare", 36], ["autosomal", 41], ["recessive", 51], ["disorder", 61], ["(", 70], ["incidence", 71], ["around", 81], ["1", 88], ["in", 90], ["106", 93], ["births", 97], [")", 103], [",", 104], ["characterised", 106], ["by", 120], ["a", 123], ["complex", 125], ["immunologic", 133], ["defects", 145], [",", 152], ["reduced", 154], ["pigmentation", 162], [",", 174], ["and", 176], ["presence", 180], ["of", 189], ["giant", 192], ["granules", 198], ["in", 207], ["many", 210], ["different", 215], ["cell", 225], ["types", 230], [".", 235], ["It", 237], ["most", 240], ["likely", 245], ["results", 252], ["from", 260], ["defective", 265], ["organellar", 275], ["trafficking", 286], ["or", 298], ["protein", 301], ["sorting", 309], [".", 316], ["The", 318], ["causative", 322], ["gene", 332], ["(", 337], ["LYST", 338], [")", 342], ["has", 344], ["recently", 348], ["been", 357], ["identified", 362], ["and", 373], ["shown", 377], ["to", 383], ["be", 386], ["homologous", 389], ["to", 400], ["the", 403], ["beige", 407], ["locus", 413], ["in", 419], ["the", 422], ["mouse", 426], [".", 431], ["CHS", 433], ["has", 437], ["always", 441], ["been", 448], ["reported", 453], ["associated", 462], ["with", 473], ["premature", 478], ["-", 487], ["termination", 488], ["-", 499], ["codon", 500], ["mutations", 506], ["in", 516], ["both", 519], ["alleles", 524], ["of", 532], ["LYST", 535], [".", 539], ["We", 541], ["report", 544], ["a", 551], ["unique", 553], ["patient", 560], ["with", 568], ["CHS", 573], [",", 576], ["who", 578], ["was", 582], ["homozygous", 586], ["for", 597], ["a", 601], ["stop", 603], ["codon", 608], ["in", 614], ["the", 617], ["LYST", 621], ["gene", 626], ["on", 631], ["chromosome", 634], ["1", 645], ["and", 647], ["who", 651], ["had", 655], ["a", 659], ["normal", 661], ["46,XY", 668], ["karyotype", 674], [".", 683], ["The", 685], ["mother", 689], ["was", 696], ["found", 700], ["to", 706], ["be", 709], ["a", 712], ["carrier", 714], ["of", 722], ["the", 725], ["mutation", 729], [",", 737], ["whereas", 739], ["the", 747], ["father", 751], ["had", 758], ["two", 762], ["normal", 766], ["LYST", 773], ["alleles", 778], [".", 785], ["Non", 787], ["-", 790], ["paternity", 791], ["was", 801], ["excluded", 805], ["by", 814], ["the", 817], ["analysis", 821], ["of", 830], ["microsatellite", 833], ["markers", 848], ["from", 856], ["different", 861], ["chromosomes", 871], [".", 882], ["The", 884], ["results", 888], ["of", 896], ["13", 899], ["informative", 902], ["microsatellite", 914], ["markers", 929], ["spanning", 937], ["the", 946], ["entire", 950], ["chromosome", 957], ["1", 968], ["revealed", 970], ["that", 979], ["the", 984], ["proband", 988], ["had", 996], ["a", 1000], ["maternal", 1002], ["isodisomy", 1011], ["of", 1021], ["chromosome", 1024], ["1", 1035], ["encompassing", 1037], ["the", 1050], ["LYST", 1054], ["mutation", 1059], [".", 1067], ["The", 1069], ["proband", 1073], ["'s", 1080], ["clinical", 1083], ["presentation", 1092], ["also", 1105], ["confirms", 1110], ["the", 1119], ["absence", 1123], ["of", 1131], ["imprinted", 1134], ["genes", 1144], ["on", 1150], ["chromosome", 1153], ["1", 1164], [".", 1165]]}
{"context": "The availability of tyrosine kinase inhibitors (TKIs) has considerably changed the management of Philadelphia chromosome positive leukemia. The BCR-ABL inhibitor imatinib is also known to inhibit the tyrosine kinase of the stem cell factor receptor, c-Kit. Nilotinib is 30 times more potent than imatinib towards BCR-ABL in vitro. Studies in healthy volunteers and patients with chronic myelogenous leukemia or gastrointestinal stromal tumors have shown that therapeutic doses of nilotinib deliver drug levels similar to those of imatinib. The aim of this study was to compare the inhibitory effects of imatinib and nilotinib on proliferation, differentiation, adhesion, migration and engraftment capacities of human cord blood CD34(+) cells. After a 48-hour cell culture with or without TKIs, CFC, LTC-IC, migration, adhesion and cell cycle analysis were performed. In a second time, the impact of these TKIs on engraftment was assessed in a xenotransplantation model using NOD/SCID/IL-2R\u03b3 (null) mice. TKIs did not affect LTC-IC frequencies despite in vitro inhibition of CFC formation due to inhibition of CD34(+) cell cycle entry. Adhesion of CD34(+) cells to retronectin was reduced in the presence of either imatinib or nilotinib but only at high concentrations. Migration through a SDF-1\u03b1 gradient was not changed by cell culture in the presence of TKIs. Finally, bone marrow cellularity and human chimerism were not affected by daily doses of imatinib and nilotinib in a xenogenic transplantation model. No significant difference was seen between TKIs given the equivalent affinity of imatinib and nilotinib for KIT. These data suggest that combining non-myeloablative conditioning regimen with TKIs starting the day of the transplantation could be safe.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "345ca0bfb3974062abd3ec10a6cbc84a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[21, 23], [54, 56]], "char_spans": [[144, 150], [313, 319]]}]}], "context_tokens": [["The", 0], ["availability", 4], ["of", 17], ["tyrosine", 20], ["kinase", 29], ["inhibitors", 36], ["(", 47], ["TKIs", 48], [")", 52], ["has", 54], ["considerably", 58], ["changed", 71], ["the", 79], ["management", 83], ["of", 94], ["Philadelphia", 97], ["chromosome", 110], ["positive", 121], ["leukemia", 130], [".", 138], ["The", 140], ["BCR", 144], ["-", 147], ["ABL", 148], ["inhibitor", 152], ["imatinib", 162], ["is", 171], ["also", 174], ["known", 179], ["to", 185], ["inhibit", 188], ["the", 196], ["tyrosine", 200], ["kinase", 209], ["of", 216], ["the", 219], ["stem", 223], ["cell", 228], ["factor", 233], ["receptor", 240], [",", 248], ["c", 250], ["-", 251], ["Kit", 252], [".", 255], ["Nilotinib", 257], ["is", 267], ["30", 270], ["times", 273], ["more", 279], ["potent", 284], ["than", 291], ["imatinib", 296], ["towards", 305], ["BCR", 313], ["-", 316], ["ABL", 317], ["in", 321], ["vitro", 324], [".", 329], ["Studies", 331], ["in", 339], ["healthy", 342], ["volunteers", 350], ["and", 361], ["patients", 365], ["with", 374], ["chronic", 379], ["myelogenous", 387], ["leukemia", 399], ["or", 408], ["gastrointestinal", 411], ["stromal", 428], ["tumors", 436], ["have", 443], ["shown", 448], ["that", 454], ["therapeutic", 459], ["doses", 471], ["of", 477], ["nilotinib", 480], ["deliver", 490], ["drug", 498], ["levels", 503], ["similar", 510], ["to", 518], ["those", 521], ["of", 527], ["imatinib", 530], [".", 538], ["The", 540], ["aim", 544], ["of", 548], ["this", 551], ["study", 556], ["was", 562], ["to", 566], ["compare", 569], ["the", 577], ["inhibitory", 581], ["effects", 592], ["of", 600], ["imatinib", 603], ["and", 612], ["nilotinib", 616], ["on", 626], ["proliferation", 629], [",", 642], ["differentiation", 644], [",", 659], ["adhesion", 661], [",", 669], ["migration", 671], ["and", 681], ["engraftment", 685], ["capacities", 697], ["of", 708], ["human", 711], ["cord", 717], ["blood", 722], ["CD34(+", 728], [")", 734], ["cells", 736], [".", 741], ["After", 743], ["a", 749], ["48-hour", 751], ["cell", 759], ["culture", 764], ["with", 772], ["or", 777], ["without", 780], ["TKIs", 788], [",", 792], ["CFC", 794], [",", 797], ["LTC", 799], ["-", 802], ["IC", 803], [",", 805], ["migration", 807], [",", 816], ["adhesion", 818], ["and", 827], ["cell", 831], ["cycle", 836], ["analysis", 842], ["were", 851], ["performed", 856], [".", 865], ["In", 867], ["a", 870], ["second", 872], ["time", 879], [",", 883], ["the", 885], ["impact", 889], ["of", 896], ["these", 899], ["TKIs", 905], ["on", 910], ["engraftment", 913], ["was", 925], ["assessed", 929], ["in", 938], ["a", 941], ["xenotransplantation", 943], ["model", 963], ["using", 969], ["NOD", 975], ["/", 978], ["SCID", 979], ["/", 983], ["IL-2R\u03b3", 984], ["(", 991], ["null", 992], [")", 996], ["mice", 998], [".", 1002], ["TKIs", 1004], ["did", 1009], ["not", 1013], ["affect", 1017], ["LTC", 1024], ["-", 1027], ["IC", 1028], ["frequencies", 1031], ["despite", 1043], ["in", 1051], ["vitro", 1054], ["inhibition", 1060], ["of", 1071], ["CFC", 1074], ["formation", 1078], ["due", 1088], ["to", 1092], ["inhibition", 1095], ["of", 1106], ["CD34(+", 1109], [")", 1115], ["cell", 1117], ["cycle", 1122], ["entry", 1128], [".", 1133], ["Adhesion", 1135], ["of", 1144], ["CD34(+", 1147], [")", 1153], ["cells", 1155], ["to", 1161], ["retronectin", 1164], ["was", 1176], ["reduced", 1180], ["in", 1188], ["the", 1191], ["presence", 1195], ["of", 1204], ["either", 1207], ["imatinib", 1214], ["or", 1223], ["nilotinib", 1226], ["but", 1236], ["only", 1240], ["at", 1245], ["high", 1248], ["concentrations", 1253], [".", 1267], ["Migration", 1269], ["through", 1279], ["a", 1287], ["SDF-1\u03b1", 1289], ["gradient", 1296], ["was", 1305], ["not", 1309], ["changed", 1313], ["by", 1321], ["cell", 1324], ["culture", 1329], ["in", 1337], ["the", 1340], ["presence", 1344], ["of", 1353], ["TKIs", 1356], [".", 1360], ["Finally", 1362], [",", 1369], ["bone", 1371], ["marrow", 1376], ["cellularity", 1383], ["and", 1395], ["human", 1399], ["chimerism", 1405], ["were", 1415], ["not", 1420], ["affected", 1424], ["by", 1433], ["daily", 1436], ["doses", 1442], ["of", 1448], ["imatinib", 1451], ["and", 1460], ["nilotinib", 1464], ["in", 1474], ["a", 1477], ["xenogenic", 1479], ["transplantation", 1489], ["model", 1505], [".", 1510], ["No", 1512], ["significant", 1515], ["difference", 1527], ["was", 1538], ["seen", 1542], ["between", 1547], ["TKIs", 1555], ["given", 1560], ["the", 1566], ["equivalent", 1570], ["affinity", 1581], ["of", 1590], ["imatinib", 1593], ["and", 1602], ["nilotinib", 1606], ["for", 1616], ["KIT", 1620], [".", 1623], ["These", 1625], ["data", 1631], ["suggest", 1636], ["that", 1644], ["combining", 1649], ["non", 1659], ["-", 1662], ["myeloablative", 1663], ["conditioning", 1677], ["regimen", 1690], ["with", 1698], ["TKIs", 1703], ["starting", 1708], ["the", 1717], ["day", 1721], ["of", 1725], ["the", 1728], ["transplantation", 1732], ["could", 1748], ["be", 1754], ["safe", 1757], [".", 1761]]}
{"context": "We have determined sequences of PCR-amplified B1 elements from hamster and rat (Myomorpha), chipmunk (Sciuromorpha), and guinea pig (Caviomorpha). Between three and six B1 subfamilies were found in these species. In the phylogenetic analysis B1 sequences of hamster, mouse, and rat clustered separately from those of chipmunk and those of guinea pig. This is consistent with an independent evolution of B1 elements in separate rodent lineages. We exclude the possibility of convergent mutations to explain certain diagnostic characters within the modern B1 quasi-dimers and view these elements as mosaic structures assembling preexisting mutations. Furthermore, the presence of Alu-like structural motifs supports the hypothesis of the monophyletic origin of Alu and B1 repeats, i.e., from a common 7SL RNA-derived retroposing monomeric element.", "qas": [{"question": "From which sequence does the Alu repeat originate from?", "answers": ["7SL RNA"], "qid": "e4f9aab09e074c42b56d239bd1ea6bf9", "question_tokens": [["From", 0], ["which", 5], ["sequence", 11], ["does", 20], ["the", 25], ["Alu", 29], ["repeat", 33], ["originate", 40], ["from", 50], ["?", 54]], "detected_answers": [{"text": "7SL RNA", "token_spans": [[140, 141]], "char_spans": [[799, 805]]}]}], "context_tokens": [["We", 0], ["have", 3], ["determined", 8], ["sequences", 19], ["of", 29], ["PCR", 32], ["-", 35], ["amplified", 36], ["B1", 46], ["elements", 49], ["from", 58], ["hamster", 63], ["and", 71], ["rat", 75], ["(", 79], ["Myomorpha", 80], [")", 89], [",", 90], ["chipmunk", 92], ["(", 101], ["Sciuromorpha", 102], [")", 114], [",", 115], ["and", 117], ["guinea", 121], ["pig", 128], ["(", 132], ["Caviomorpha", 133], [")", 144], [".", 145], ["Between", 147], ["three", 155], ["and", 161], ["six", 165], ["B1", 169], ["subfamilies", 172], ["were", 184], ["found", 189], ["in", 195], ["these", 198], ["species", 204], [".", 211], ["In", 213], ["the", 216], ["phylogenetic", 220], ["analysis", 233], ["B1", 242], ["sequences", 245], ["of", 255], ["hamster", 258], [",", 265], ["mouse", 267], [",", 272], ["and", 274], ["rat", 278], ["clustered", 282], ["separately", 292], ["from", 303], ["those", 308], ["of", 314], ["chipmunk", 317], ["and", 326], ["those", 330], ["of", 336], ["guinea", 339], ["pig", 346], [".", 349], ["This", 351], ["is", 356], ["consistent", 359], ["with", 370], ["an", 375], ["independent", 378], ["evolution", 390], ["of", 400], ["B1", 403], ["elements", 406], ["in", 415], ["separate", 418], ["rodent", 427], ["lineages", 434], [".", 442], ["We", 444], ["exclude", 447], ["the", 455], ["possibility", 459], ["of", 471], ["convergent", 474], ["mutations", 485], ["to", 495], ["explain", 498], ["certain", 506], ["diagnostic", 514], ["characters", 525], ["within", 536], ["the", 543], ["modern", 547], ["B1", 554], ["quasi", 557], ["-", 562], ["dimers", 563], ["and", 570], ["view", 574], ["these", 579], ["elements", 585], ["as", 594], ["mosaic", 597], ["structures", 604], ["assembling", 615], ["preexisting", 626], ["mutations", 638], [".", 647], ["Furthermore", 649], [",", 660], ["the", 662], ["presence", 666], ["of", 675], ["Alu", 678], ["-", 681], ["like", 682], ["structural", 687], ["motifs", 698], ["supports", 705], ["the", 714], ["hypothesis", 718], ["of", 729], ["the", 732], ["monophyletic", 736], ["origin", 749], ["of", 756], ["Alu", 759], ["and", 763], ["B1", 767], ["repeats", 770], [",", 777], ["i.e.", 779], [",", 783], ["from", 785], ["a", 790], ["common", 792], ["7SL", 799], ["RNA", 803], ["-", 806], ["derived", 807], ["retroposing", 815], ["monomeric", 827], ["element", 837], [".", 844]]}
{"context": "Prostate cancer is the most common cancer in men in Europe and the United             States, and the third leading cause of death from cancer in Europe. Survival of             prostate cancer cells is dependent on the activation of androgen receptors (AR),             that are overexpressed in this tumor. Furthermore, ~90% of prostate cancer patients             that respond to first-line androgen deprivation therapy (ADT) undergo rapid progression.             This condition is defined as castration-resistant prostate cancer (CRPC). Docetaxel-based             regimens significantly improve overall survival (OS) in patients with CRPC and             represent the only treatment strategy approved by the Food and Drug Administration             (FDA). Recently, abiraterone (second hormonal therapy) and cabazitaxel (new taxane)             have been shown to improve survival in patients with CRPC who progressed following             docetaxel-based chemotherapy. Vaccine therapy has also been demonstrated to improve             OS in patients with asymptomatic or minimally symptomatic metastatic CRPC. Additional             therapeutic targets have been analyzed in prostate cancer, including apoptosis,             angiogenic receptors, vitamin D and Src pathways. Several phase II studies are             ongoing. The high frequency of prostate cancer-related metastatic bone disease             has led to consider this pathway as a therapeutic target. To this end, several             bone-targeted agents have been investigated, most notably zoledronic acid, which             is highly effective at stabilizing the bone and preventing skeletal complications.             More recently, a nuclear factor-\u03b2 ligand (RANKL) inhibitor, denosumab, has been             developed for the treatment of bone metastases.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "db3d5700fb404c9d9b22de58652e441b", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[265, 265]], "char_spans": [[1736, 1740]]}]}], "context_tokens": [["Prostate", 0], ["cancer", 9], ["is", 16], ["the", 19], ["most", 23], ["common", 28], ["cancer", 35], ["in", 42], ["men", 45], ["in", 49], ["Europe", 52], ["and", 59], ["the", 63], ["United", 67], ["States", 86], [",", 92], ["and", 94], ["the", 98], ["third", 102], ["leading", 108], ["cause", 116], ["of", 122], ["death", 125], ["from", 131], ["cancer", 136], ["in", 143], ["Europe", 146], [".", 152], ["Survival", 154], ["of", 163], ["prostate", 178], ["cancer", 187], ["cells", 194], ["is", 200], ["dependent", 203], ["on", 213], ["the", 216], ["activation", 220], ["of", 231], ["androgen", 234], ["receptors", 243], ["(", 253], ["AR", 254], [")", 256], [",", 257], ["that", 271], ["are", 276], ["overexpressed", 280], ["in", 294], ["this", 297], ["tumor", 302], [".", 307], ["Furthermore", 309], [",", 320], ["~90", 322], ["%", 325], ["of", 327], ["prostate", 330], ["cancer", 339], ["patients", 346], ["that", 367], ["respond", 372], ["to", 380], ["first", 383], ["-", 388], ["line", 389], ["androgen", 394], ["deprivation", 403], ["therapy", 415], ["(", 423], ["ADT", 424], [")", 427], ["undergo", 429], ["rapid", 437], ["progression", 443], [".", 454], ["This", 468], ["condition", 473], ["is", 483], ["defined", 486], ["as", 494], ["castration", 497], ["-", 507], ["resistant", 508], ["prostate", 518], ["cancer", 527], ["(", 534], ["CRPC", 535], [")", 539], [".", 540], ["Docetaxel", 542], ["-", 551], ["based", 552], ["regimens", 570], ["significantly", 579], ["improve", 593], ["overall", 601], ["survival", 609], ["(", 618], ["OS", 619], [")", 621], ["in", 623], ["patients", 626], ["with", 635], ["CRPC", 640], ["and", 645], ["represent", 661], ["the", 671], ["only", 675], ["treatment", 680], ["strategy", 690], ["approved", 699], ["by", 708], ["the", 711], ["Food", 715], ["and", 720], ["Drug", 724], ["Administration", 729], ["(", 756], ["FDA", 757], [")", 760], [".", 761], ["Recently", 763], [",", 771], ["abiraterone", 773], ["(", 785], ["second", 786], ["hormonal", 793], ["therapy", 802], [")", 809], ["and", 811], ["cabazitaxel", 815], ["(", 827], ["new", 828], ["taxane", 832], [")", 838], ["have", 852], ["been", 857], ["shown", 862], ["to", 868], ["improve", 871], ["survival", 879], ["in", 888], ["patients", 891], ["with", 900], ["CRPC", 905], ["who", 910], ["progressed", 914], ["following", 925], ["docetaxel", 947], ["-", 956], ["based", 957], ["chemotherapy", 963], [".", 975], ["Vaccine", 977], ["therapy", 985], ["has", 993], ["also", 997], ["been", 1002], ["demonstrated", 1007], ["to", 1020], ["improve", 1023], ["OS", 1043], ["in", 1046], ["patients", 1049], ["with", 1058], ["asymptomatic", 1063], ["or", 1076], ["minimally", 1079], ["symptomatic", 1089], ["metastatic", 1101], ["CRPC", 1112], [".", 1116], ["Additional", 1118], ["therapeutic", 1141], ["targets", 1153], ["have", 1161], ["been", 1166], ["analyzed", 1171], ["in", 1180], ["prostate", 1183], ["cancer", 1192], [",", 1198], ["including", 1200], ["apoptosis", 1210], [",", 1219], ["angiogenic", 1233], ["receptors", 1244], [",", 1253], ["vitamin", 1255], ["D", 1263], ["and", 1265], ["Src", 1269], ["pathways", 1273], [".", 1281], ["Several", 1283], ["phase", 1291], ["II", 1297], ["studies", 1300], ["are", 1308], ["ongoing", 1324], [".", 1331], ["The", 1333], ["high", 1337], ["frequency", 1342], ["of", 1352], ["prostate", 1355], ["cancer", 1364], ["-", 1370], ["related", 1371], ["metastatic", 1379], ["bone", 1390], ["disease", 1395], ["has", 1415], ["led", 1419], ["to", 1423], ["consider", 1426], ["this", 1435], ["pathway", 1440], ["as", 1448], ["a", 1451], ["therapeutic", 1453], ["target", 1465], [".", 1471], ["To", 1473], ["this", 1476], ["end", 1481], [",", 1484], ["several", 1486], ["bone", 1506], ["-", 1510], ["targeted", 1511], ["agents", 1520], ["have", 1527], ["been", 1532], ["investigated", 1537], [",", 1549], ["most", 1551], ["notably", 1556], ["zoledronic", 1564], ["acid", 1575], [",", 1579], ["which", 1581], ["is", 1599], ["highly", 1602], ["effective", 1609], ["at", 1619], ["stabilizing", 1622], ["the", 1634], ["bone", 1638], ["and", 1643], ["preventing", 1647], ["skeletal", 1658], ["complications", 1667], [".", 1680], ["More", 1694], ["recently", 1699], [",", 1707], ["a", 1709], ["nuclear", 1711], ["factor", 1719], ["-", 1725], ["\u03b2", 1726], ["ligand", 1728], ["(", 1735], ["RANKL", 1736], [")", 1741], ["inhibitor", 1743], [",", 1752], ["denosumab", 1754], [",", 1763], ["has", 1765], ["been", 1769], ["developed", 1786], ["for", 1796], ["the", 1800], ["treatment", 1804], ["of", 1814], ["bone", 1817], ["metastases", 1822], [".", 1832]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensorimotor disorder that can result in considerable sleep disruption. This narrative review provides an overview of RLS diagnosis and reports epidemiologic evidence for an association between RLS and mood disorders. Possible links between RLS, sleep disturbances, and mood disorders are considered, and theoretical pathophysiologic pathways are discussed. Finally, pharmacologic therapies for RLS are summarized. A PubMed search was performed using the search term restless legs syndrome in combination with affective/anxiety, antidepressants, anxiety/anxiety disorder, attention deficit hyperactivity disorder, depression/depressive disorder, mood/mood disorder, neuropsychiatric, panic/panic disorder, psychiatric disorder, and psychosis. English-language articles published between January 1993 and May 2013 were retrieved. Additional studies were identified from the reference lists of relevant publications. 173 publications were retrieved. Articles related to the association between idiopathic RLS and depression, anxiety, and mood disorders were reviewed. In total, 32 epidemiologic studies were identified. These studies were reviewed in detail and ranked according to quality. Data were extracted on the basis of relevance to the topic. Epidemiologic studies were assessed using 3 parameters: methodology, data quality, and generalizability of the results. Each factor was scored from 1 (high quality) to 4 (low quality), giving a total score of between 3 and 12 for each study. RLS and mood disorders are frequently comorbid. Recognition and appropriate treatment of comorbid RLS are particularly important in patients with psychiatric disorders, as RLS is a common medical reason for insomnia, and antidepressant use may exacerbate sensory symptoms.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "f69aed865e4f4461b59e86ff393595b6", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2], [88, 90]], "char_spans": [[0, 21], [538, 559]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], [",", 64], ["is", 66], ["a", 69], ["sensorimotor", 71], ["disorder", 84], ["that", 93], ["can", 98], ["result", 102], ["in", 109], ["considerable", 112], ["sleep", 125], ["disruption", 131], [".", 141], ["This", 143], ["narrative", 148], ["review", 158], ["provides", 165], ["an", 174], ["overview", 177], ["of", 186], ["RLS", 189], ["diagnosis", 193], ["and", 203], ["reports", 207], ["epidemiologic", 215], ["evidence", 229], ["for", 238], ["an", 242], ["association", 245], ["between", 257], ["RLS", 265], ["and", 269], ["mood", 273], ["disorders", 278], [".", 287], ["Possible", 289], ["links", 298], ["between", 304], ["RLS", 312], [",", 315], ["sleep", 317], ["disturbances", 323], [",", 335], ["and", 337], ["mood", 341], ["disorders", 346], ["are", 356], ["considered", 360], [",", 370], ["and", 372], ["theoretical", 376], ["pathophysiologic", 388], ["pathways", 405], ["are", 414], ["discussed", 418], [".", 427], ["Finally", 429], [",", 436], ["pharmacologic", 438], ["therapies", 452], ["for", 462], ["RLS", 466], ["are", 470], ["summarized", 474], [".", 484], ["A", 486], ["PubMed", 488], ["search", 495], ["was", 502], ["performed", 506], ["using", 516], ["the", 522], ["search", 526], ["term", 533], ["restless", 538], ["legs", 547], ["syndrome", 552], ["in", 561], ["combination", 564], ["with", 576], ["affective", 581], ["/", 590], ["anxiety", 591], [",", 598], ["antidepressants", 600], [",", 615], ["anxiety", 617], ["/", 624], ["anxiety", 625], ["disorder", 633], [",", 641], ["attention", 643], ["deficit", 653], ["hyperactivity", 661], ["disorder", 675], [",", 683], ["depression", 685], ["/", 695], ["depressive", 696], ["disorder", 707], [",", 715], ["mood", 717], ["/", 721], ["mood", 722], ["disorder", 727], [",", 735], ["neuropsychiatric", 737], [",", 753], ["panic", 755], ["/", 760], ["panic", 761], ["disorder", 767], [",", 775], ["psychiatric", 777], ["disorder", 789], [",", 797], ["and", 799], ["psychosis", 803], [".", 812], ["English", 814], ["-", 821], ["language", 822], ["articles", 831], ["published", 840], ["between", 850], ["January", 858], ["1993", 866], ["and", 871], ["May", 875], ["2013", 879], ["were", 884], ["retrieved", 889], [".", 898], ["Additional", 900], ["studies", 911], ["were", 919], ["identified", 924], ["from", 935], ["the", 940], ["reference", 944], ["lists", 954], ["of", 960], ["relevant", 963], ["publications", 972], [".", 984], ["173", 986], ["publications", 990], ["were", 1003], ["retrieved", 1008], [".", 1017], ["Articles", 1019], ["related", 1028], ["to", 1036], ["the", 1039], ["association", 1043], ["between", 1055], ["idiopathic", 1063], ["RLS", 1074], ["and", 1078], ["depression", 1082], [",", 1092], ["anxiety", 1094], [",", 1101], ["and", 1103], ["mood", 1107], ["disorders", 1112], ["were", 1122], ["reviewed", 1127], [".", 1135], ["In", 1137], ["total", 1140], [",", 1145], ["32", 1147], ["epidemiologic", 1150], ["studies", 1164], ["were", 1172], ["identified", 1177], [".", 1187], ["These", 1189], ["studies", 1195], ["were", 1203], ["reviewed", 1208], ["in", 1217], ["detail", 1220], ["and", 1227], ["ranked", 1231], ["according", 1238], ["to", 1248], ["quality", 1251], [".", 1258], ["Data", 1260], ["were", 1265], ["extracted", 1270], ["on", 1280], ["the", 1283], ["basis", 1287], ["of", 1293], ["relevance", 1296], ["to", 1306], ["the", 1309], ["topic", 1313], [".", 1318], ["Epidemiologic", 1320], ["studies", 1334], ["were", 1342], ["assessed", 1347], ["using", 1356], ["3", 1362], ["parameters", 1364], [":", 1374], ["methodology", 1376], [",", 1387], ["data", 1389], ["quality", 1394], [",", 1401], ["and", 1403], ["generalizability", 1407], ["of", 1424], ["the", 1427], ["results", 1431], [".", 1438], ["Each", 1440], ["factor", 1445], ["was", 1452], ["scored", 1456], ["from", 1463], ["1", 1468], ["(", 1470], ["high", 1471], ["quality", 1476], [")", 1483], ["to", 1485], ["4", 1488], ["(", 1490], ["low", 1491], ["quality", 1495], [")", 1502], [",", 1503], ["giving", 1505], ["a", 1512], ["total", 1514], ["score", 1520], ["of", 1526], ["between", 1529], ["3", 1537], ["and", 1539], ["12", 1543], ["for", 1546], ["each", 1550], ["study", 1555], [".", 1560], ["RLS", 1562], ["and", 1566], ["mood", 1570], ["disorders", 1575], ["are", 1585], ["frequently", 1589], ["comorbid", 1600], [".", 1608], ["Recognition", 1610], ["and", 1622], ["appropriate", 1626], ["treatment", 1638], ["of", 1648], ["comorbid", 1651], ["RLS", 1660], ["are", 1664], ["particularly", 1668], ["important", 1681], ["in", 1691], ["patients", 1694], ["with", 1703], ["psychiatric", 1708], ["disorders", 1720], [",", 1729], ["as", 1731], ["RLS", 1734], ["is", 1738], ["a", 1741], ["common", 1743], ["medical", 1750], ["reason", 1758], ["for", 1765], ["insomnia", 1769], [",", 1777], ["and", 1779], ["antidepressant", 1783], ["use", 1798], ["may", 1802], ["exacerbate", 1806], ["sensory", 1817], ["symptoms", 1825], [".", 1833]]}
{"context": "Mutations in rfx6 were recently associated with Mitchell-Riley syndrome, which involves neonatal diabetes, and other digestive system defects. To better define the function of Rfx6 in early endoderm development we cloned the Xenopus homologue. Expression of rfx6 begins early, showing broad expression throughout the anterior endoderm; at later stages rfx6 expression becomes restricted to the endocrine cells of the gut and pancreas. Morpholino knockdown of rfx6 caused a loss of pancreas marker expression, as well as other abnormalities. Co-injection of exogenous wild-type rfx6 rescued the morpholino phenotype in Xenopus tadpoles, whereas attempts to rescue the loss-of-function phenotype using mutant rfx6 based on Mitchell-Riley patients were unsuccessful. To better define the pleiotropic effects, we performed microarray analyses of gene expression in knockdown foregut tissue. In addition to pancreatic defects, the microarray analyses revealed downregulation of lung, stomach and heart markers and an upregulation of kidney markers. We verified these results using RT-PCR and in situ hybridization. Based on the different rfx6 expression patterns and our functional analyses, we propose that rfx6 has both early and late functions. In early development Rfx6 plays a broad role, being essential for development of most anterior endodermal organs. At later stages however, Rfx6 function is restricted to endocrine cells.", "qas": [{"question": "Which gene is associated with the Mitchell-Riley syndrome?", "answers": ["RFX6"], "qid": "23231ba1735c46b7b4dbacd35b95a111", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["the", 30], ["Mitchell", 34], ["-", 42], ["Riley", 43], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "RFX6", "token_spans": [[29, 29], [42, 42], [74, 74], [212, 212], [57, 57], [119, 119], [201, 201], [233, 233], [190, 190], [2, 2], [97, 97]], "char_spans": [[176, 179], [258, 261], [459, 462], [1264, 1267], [352, 355], [707, 710], [1203, 1206], [1382, 1385], [1133, 1136], [13, 16], [577, 580]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["rfx6", 13], ["were", 18], ["recently", 23], ["associated", 32], ["with", 43], ["Mitchell", 48], ["-", 56], ["Riley", 57], ["syndrome", 63], [",", 71], ["which", 73], ["involves", 79], ["neonatal", 88], ["diabetes", 97], [",", 105], ["and", 107], ["other", 111], ["digestive", 117], ["system", 127], ["defects", 134], [".", 141], ["To", 143], ["better", 146], ["define", 153], ["the", 160], ["function", 164], ["of", 173], ["Rfx6", 176], ["in", 181], ["early", 184], ["endoderm", 190], ["development", 199], ["we", 211], ["cloned", 214], ["the", 221], ["Xenopus", 225], ["homologue", 233], [".", 242], ["Expression", 244], ["of", 255], ["rfx6", 258], ["begins", 263], ["early", 270], [",", 275], ["showing", 277], ["broad", 285], ["expression", 291], ["throughout", 302], ["the", 313], ["anterior", 317], ["endoderm", 326], [";", 334], ["at", 336], ["later", 339], ["stages", 345], ["rfx6", 352], ["expression", 357], ["becomes", 368], ["restricted", 376], ["to", 387], ["the", 390], ["endocrine", 394], ["cells", 404], ["of", 410], ["the", 413], ["gut", 417], ["and", 421], ["pancreas", 425], [".", 433], ["Morpholino", 435], ["knockdown", 446], ["of", 456], ["rfx6", 459], ["caused", 464], ["a", 471], ["loss", 473], ["of", 478], ["pancreas", 481], ["marker", 490], ["expression", 497], [",", 507], ["as", 509], ["well", 512], ["as", 517], ["other", 520], ["abnormalities", 526], [".", 539], ["Co", 541], ["-", 543], ["injection", 544], ["of", 554], ["exogenous", 557], ["wild", 567], ["-", 571], ["type", 572], ["rfx6", 577], ["rescued", 582], ["the", 590], ["morpholino", 594], ["phenotype", 605], ["in", 615], ["Xenopus", 618], ["tadpoles", 626], [",", 634], ["whereas", 636], ["attempts", 644], ["to", 653], ["rescue", 656], ["the", 663], ["loss", 667], ["-", 671], ["of", 672], ["-", 674], ["function", 675], ["phenotype", 684], ["using", 694], ["mutant", 700], ["rfx6", 707], ["based", 712], ["on", 718], ["Mitchell", 721], ["-", 729], ["Riley", 730], ["patients", 736], ["were", 745], ["unsuccessful", 750], [".", 762], ["To", 764], ["better", 767], ["define", 774], ["the", 781], ["pleiotropic", 785], ["effects", 797], [",", 804], ["we", 806], ["performed", 809], ["microarray", 819], ["analyses", 830], ["of", 839], ["gene", 842], ["expression", 847], ["in", 858], ["knockdown", 861], ["foregut", 871], ["tissue", 879], [".", 885], ["In", 887], ["addition", 890], ["to", 899], ["pancreatic", 902], ["defects", 913], [",", 920], ["the", 922], ["microarray", 926], ["analyses", 937], ["revealed", 946], ["downregulation", 955], ["of", 970], ["lung", 973], [",", 977], ["stomach", 979], ["and", 987], ["heart", 991], ["markers", 997], ["and", 1005], ["an", 1009], ["upregulation", 1012], ["of", 1025], ["kidney", 1028], ["markers", 1035], [".", 1042], ["We", 1044], ["verified", 1047], ["these", 1056], ["results", 1062], ["using", 1070], ["RT", 1076], ["-", 1078], ["PCR", 1079], ["and", 1083], ["in", 1087], ["situ", 1090], ["hybridization", 1095], [".", 1108], ["Based", 1110], ["on", 1116], ["the", 1119], ["different", 1123], ["rfx6", 1133], ["expression", 1138], ["patterns", 1149], ["and", 1158], ["our", 1162], ["functional", 1166], ["analyses", 1177], [",", 1185], ["we", 1187], ["propose", 1190], ["that", 1198], ["rfx6", 1203], ["has", 1208], ["both", 1212], ["early", 1217], ["and", 1223], ["late", 1227], ["functions", 1232], [".", 1241], ["In", 1243], ["early", 1246], ["development", 1252], ["Rfx6", 1264], ["plays", 1269], ["a", 1275], ["broad", 1277], ["role", 1283], [",", 1287], ["being", 1289], ["essential", 1295], ["for", 1305], ["development", 1309], ["of", 1321], ["most", 1324], ["anterior", 1329], ["endodermal", 1338], ["organs", 1349], [".", 1355], ["At", 1357], ["later", 1360], ["stages", 1366], ["however", 1373], [",", 1380], ["Rfx6", 1382], ["function", 1387], ["is", 1396], ["restricted", 1399], ["to", 1410], ["endocrine", 1413], ["cells", 1423], [".", 1428]]}
{"context": "The similarities of the larval and nymph stages of the tick and louse (Pthirus pubis) may lead to misdiagnosis in rare cases of infestation of the eyelashes. The most frequent manifestations of tick in the eye are conjunctivitis, uveitis, keratitis, and vasculitis. Tick inoculation of the skin can locally lead to formation of granuloma and abscess. More concerning is the potential systemic sequelae that can result from transmission of zoonoses such as Lyme disease. P. pubis can cause pruritic eyelid margins or unusual blepharoconjunctivitis. We present a case of phthiriasis palpebrarum in a 4-year-old boy.", "qas": [{"question": "What is the cause of Phthiriasis Palpebrarum?", "answers": ["Pthirus pubis"], "qid": "d99ab786d2ec4d17b1540cf721370ef0", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["cause", 12], ["of", 18], ["Phthiriasis", 21], ["Palpebrarum", 33], ["?", 44]], "detected_answers": [{"text": "Pthirus pubis", "token_spans": [[14, 15]], "char_spans": [[71, 83]]}]}], "context_tokens": [["The", 0], ["similarities", 4], ["of", 17], ["the", 20], ["larval", 24], ["and", 31], ["nymph", 35], ["stages", 41], ["of", 48], ["the", 51], ["tick", 55], ["and", 60], ["louse", 64], ["(", 70], ["Pthirus", 71], ["pubis", 79], [")", 84], ["may", 86], ["lead", 90], ["to", 95], ["misdiagnosis", 98], ["in", 111], ["rare", 114], ["cases", 119], ["of", 125], ["infestation", 128], ["of", 140], ["the", 143], ["eyelashes", 147], [".", 156], ["The", 158], ["most", 162], ["frequent", 167], ["manifestations", 176], ["of", 191], ["tick", 194], ["in", 199], ["the", 202], ["eye", 206], ["are", 210], ["conjunctivitis", 214], [",", 228], ["uveitis", 230], [",", 237], ["keratitis", 239], [",", 248], ["and", 250], ["vasculitis", 254], [".", 264], ["Tick", 266], ["inoculation", 271], ["of", 283], ["the", 286], ["skin", 290], ["can", 295], ["locally", 299], ["lead", 307], ["to", 312], ["formation", 315], ["of", 325], ["granuloma", 328], ["and", 338], ["abscess", 342], [".", 349], ["More", 351], ["concerning", 356], ["is", 367], ["the", 370], ["potential", 374], ["systemic", 384], ["sequelae", 393], ["that", 402], ["can", 407], ["result", 411], ["from", 418], ["transmission", 423], ["of", 436], ["zoonoses", 439], ["such", 448], ["as", 453], ["Lyme", 456], ["disease", 461], [".", 468], ["P.", 470], ["pubis", 473], ["can", 479], ["cause", 483], ["pruritic", 489], ["eyelid", 498], ["margins", 505], ["or", 513], ["unusual", 516], ["blepharoconjunctivitis", 524], [".", 546], ["We", 548], ["present", 551], ["a", 559], ["case", 561], ["of", 566], ["phthiriasis", 569], ["palpebrarum", 581], ["in", 593], ["a", 596], ["4-year", 598], ["-", 604], ["old", 605], ["boy", 609], [".", 612]]}
{"context": "A malaria vaccine could be an important addition to current control strategies. We report the safety and vaccine efficacy (VE) of the RTS,S/AS01 vaccine during 18 mo following vaccination at 11 African sites with varying malaria transmission. 6,537 infants aged 6-12 wk and 8,923 children aged 5-17 mo were randomized to receive three doses of RTS,S/AS01 or comparator vaccine. VE against clinical malaria in children during the 18 mo after vaccine dose 3 (per protocol) was 46% (95% CI 42% to 50%) (range 40% to 77%; VE, p<0.01 across all sites). VE during the 20 mo after vaccine dose 1 (intention to treat [ITT]) was 45% (95% CI 41% to 49%). VE against severe malaria, malaria hospitalization, and all-cause hospitalization was 34% (95% CI 15% to 48%), 41% (95% CI 30% to 50%), and 19% (95% CI 11% to 27%), respectively (ITT). VE against clinical malaria in infants was 27% (95% CI 20% to 32%, per protocol; 27% [95% CI 21% to 33%], ITT), with no significant protection against severe malaria, malaria hospitalization, or all-cause hospitalization. Post-vaccination anti-circumsporozoite antibody geometric mean titer varied from 348 to 787 EU/ml across sites in children and from 117 to 335 EU/ml in infants (per protocol). VE waned over time in both age categories (Schoenfeld residuals p<0.001). The number of clinical and severe malaria cases averted per 1,000 children vaccinated ranged across sites from 37 to 2,365 and from -1 to 49, respectively; corresponding ranges among infants were -10 to 1,402 and -13 to 37, respectively (ITT). Meningitis was reported as a serious adverse event in 16/5,949 and 1/2,974 children and in 9/4,358 and 3/2,179 infants in the RTS,S/AS01 and control groups, respectively. RTS,S/AS01 prevented many cases of clinical and severe malaria over the 18 mo after vaccine dose 3, with the highest impact in areas with the greatest malaria incidence. VE was higher in children than in infants, but even at modest levels of VE, the number of malaria cases averted was substantial. RTS,S/AS01 could be an important addition to current malaria control in Africa. www.ClinicalTrials.gov NCT00866619 Please see later in the article for the Editors' Summary.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "83bbfe9e1ba04ab5b0d56e7dbde01a22", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[157, 157], [259, 259], [42, 42], [325, 325], [451, 451], [469, 469], [428, 428], [409, 409], [1, 1], [216, 216], [159, 159], [257, 257], [79, 79]], "char_spans": [[663, 669], [997, 1003], [221, 227], [1336, 1342], [1977, 1983], [2069, 2075], [1868, 1874], [1772, 1778], [2, 8], [850, 856], [672, 678], [988, 994], [398, 404]]}]}], "context_tokens": [["A", 0], ["malaria", 2], ["vaccine", 10], ["could", 18], ["be", 24], ["an", 27], ["important", 30], ["addition", 40], ["to", 49], ["current", 52], ["control", 60], ["strategies", 68], [".", 78], ["We", 80], ["report", 83], ["the", 90], ["safety", 94], ["and", 101], ["vaccine", 105], ["efficacy", 113], ["(", 122], ["VE", 123], [")", 125], ["of", 127], ["the", 130], ["RTS", 134], [",", 137], ["S", 138], ["/", 139], ["AS01", 140], ["vaccine", 145], ["during", 153], ["18", 160], ["mo", 163], ["following", 166], ["vaccination", 176], ["at", 188], ["11", 191], ["African", 194], ["sites", 202], ["with", 208], ["varying", 213], ["malaria", 221], ["transmission", 229], [".", 241], ["6,537", 243], ["infants", 249], ["aged", 257], ["6", 262], ["-", 263], ["12", 264], ["wk", 267], ["and", 270], ["8,923", 274], ["children", 280], ["aged", 289], ["5", 294], ["-", 295], ["17", 296], ["mo", 299], ["were", 302], ["randomized", 307], ["to", 318], ["receive", 321], ["three", 329], ["doses", 335], ["of", 341], ["RTS", 344], [",", 347], ["S", 348], ["/", 349], ["AS01", 350], ["or", 355], ["comparator", 358], ["vaccine", 369], [".", 376], ["VE", 378], ["against", 381], ["clinical", 389], ["malaria", 398], ["in", 406], ["children", 409], ["during", 418], ["the", 425], ["18", 429], ["mo", 432], ["after", 435], ["vaccine", 441], ["dose", 449], ["3", 454], ["(", 456], ["per", 457], ["protocol", 461], [")", 469], ["was", 471], ["46", 475], ["%", 477], ["(", 479], ["95", 480], ["%", 482], ["CI", 484], ["42", 487], ["%", 489], ["to", 491], ["50", 494], ["%", 496], [")", 497], ["(", 499], ["range", 500], ["40", 506], ["%", 508], ["to", 510], ["77", 513], ["%", 515], [";", 516], ["VE", 518], [",", 520], ["p<0.01", 522], ["across", 529], ["all", 536], ["sites", 540], [")", 545], [".", 546], ["VE", 548], ["during", 551], ["the", 558], ["20", 562], ["mo", 565], ["after", 568], ["vaccine", 574], ["dose", 582], ["1", 587], ["(", 589], ["intention", 590], ["to", 600], ["treat", 603], ["[", 609], ["ITT", 610], ["]", 613], [")", 614], ["was", 616], ["45", 620], ["%", 622], ["(", 624], ["95", 625], ["%", 627], ["CI", 629], ["41", 632], ["%", 634], ["to", 636], ["49", 639], ["%", 641], [")", 642], [".", 643], ["VE", 645], ["against", 648], ["severe", 656], ["malaria", 663], [",", 670], ["malaria", 672], ["hospitalization", 680], [",", 695], ["and", 697], ["all", 701], ["-", 704], ["cause", 705], ["hospitalization", 711], ["was", 727], ["34", 731], ["%", 733], ["(", 735], ["95", 736], ["%", 738], ["CI", 740], ["15", 743], ["%", 745], ["to", 747], ["48", 750], ["%", 752], [")", 753], [",", 754], ["41", 756], ["%", 758], ["(", 760], ["95", 761], ["%", 763], ["CI", 765], ["30", 768], ["%", 770], ["to", 772], ["50", 775], ["%", 777], [")", 778], [",", 779], ["and", 781], ["19", 785], ["%", 787], ["(", 789], ["95", 790], ["%", 792], ["CI", 794], ["11", 797], ["%", 799], ["to", 801], ["27", 804], ["%", 806], [")", 807], [",", 808], ["respectively", 810], ["(", 823], ["ITT", 824], [")", 827], [".", 828], ["VE", 830], ["against", 833], ["clinical", 841], ["malaria", 850], ["in", 858], ["infants", 861], ["was", 869], ["27", 873], ["%", 875], ["(", 877], ["95", 878], ["%", 880], ["CI", 882], ["20", 885], ["%", 887], ["to", 889], ["32", 892], ["%", 894], [",", 895], ["per", 897], ["protocol", 901], [";", 909], ["27", 911], ["%", 913], ["[", 915], ["95", 916], ["%", 918], ["CI", 920], ["21", 923], ["%", 925], ["to", 927], ["33", 930], ["%", 932], ["]", 933], [",", 934], ["ITT", 936], [")", 939], [",", 940], ["with", 942], ["no", 947], ["significant", 950], ["protection", 962], ["against", 973], ["severe", 981], ["malaria", 988], [",", 995], ["malaria", 997], ["hospitalization", 1005], [",", 1020], ["or", 1022], ["all", 1025], ["-", 1028], ["cause", 1029], ["hospitalization", 1035], [".", 1050], ["Post", 1052], ["-", 1056], ["vaccination", 1057], ["anti", 1069], ["-", 1073], ["circumsporozoite", 1074], ["antibody", 1091], ["geometric", 1100], ["mean", 1110], ["titer", 1115], ["varied", 1121], ["from", 1128], ["348", 1133], ["to", 1137], ["787", 1140], ["EU", 1144], ["/", 1146], ["ml", 1147], ["across", 1150], ["sites", 1157], ["in", 1163], ["children", 1166], ["and", 1175], ["from", 1179], ["117", 1184], ["to", 1188], ["335", 1191], ["EU", 1195], ["/", 1197], ["ml", 1198], ["in", 1201], ["infants", 1204], ["(", 1212], ["per", 1213], ["protocol", 1217], [")", 1225], [".", 1226], ["VE", 1228], ["waned", 1231], ["over", 1237], ["time", 1242], ["in", 1247], ["both", 1250], ["age", 1255], ["categories", 1259], ["(", 1270], ["Schoenfeld", 1271], ["residuals", 1282], ["p<0.001", 1292], [")", 1299], [".", 1300], ["The", 1302], ["number", 1306], ["of", 1313], ["clinical", 1316], ["and", 1325], ["severe", 1329], ["malaria", 1336], ["cases", 1344], ["averted", 1350], ["per", 1358], ["1,000", 1362], ["children", 1368], ["vaccinated", 1377], ["ranged", 1388], ["across", 1395], ["sites", 1402], ["from", 1408], ["37", 1413], ["to", 1416], ["2,365", 1419], ["and", 1425], ["from", 1429], ["-1", 1434], ["to", 1437], ["49", 1440], [",", 1442], ["respectively", 1444], [";", 1456], ["corresponding", 1458], ["ranges", 1472], ["among", 1479], ["infants", 1485], ["were", 1493], ["-10", 1498], ["to", 1502], ["1,402", 1505], ["and", 1511], ["-13", 1515], ["to", 1519], ["37", 1522], [",", 1524], ["respectively", 1526], ["(", 1539], ["ITT", 1540], [")", 1543], [".", 1544], ["Meningitis", 1546], ["was", 1557], ["reported", 1561], ["as", 1570], ["a", 1573], ["serious", 1575], ["adverse", 1583], ["event", 1591], ["in", 1597], ["16/5,949", 1600], ["and", 1609], ["1/2,974", 1613], ["children", 1621], ["and", 1630], ["in", 1634], ["9/4,358", 1637], ["and", 1645], ["3/2,179", 1649], ["infants", 1657], ["in", 1665], ["the", 1668], ["RTS", 1672], [",", 1675], ["S", 1676], ["/", 1677], ["AS01", 1678], ["and", 1683], ["control", 1687], ["groups", 1695], [",", 1701], ["respectively", 1703], [".", 1715], ["RTS", 1717], [",", 1720], ["S", 1721], ["/", 1722], ["AS01", 1723], ["prevented", 1728], ["many", 1738], ["cases", 1743], ["of", 1749], ["clinical", 1752], ["and", 1761], ["severe", 1765], ["malaria", 1772], ["over", 1780], ["the", 1785], ["18", 1789], ["mo", 1792], ["after", 1795], ["vaccine", 1801], ["dose", 1809], ["3", 1814], [",", 1815], ["with", 1817], ["the", 1822], ["highest", 1826], ["impact", 1834], ["in", 1841], ["areas", 1844], ["with", 1850], ["the", 1855], ["greatest", 1859], ["malaria", 1868], ["incidence", 1876], [".", 1885], ["VE", 1887], ["was", 1890], ["higher", 1894], ["in", 1901], ["children", 1904], ["than", 1913], ["in", 1918], ["infants", 1921], [",", 1928], ["but", 1930], ["even", 1934], ["at", 1939], ["modest", 1942], ["levels", 1949], ["of", 1956], ["VE", 1959], [",", 1961], ["the", 1963], ["number", 1967], ["of", 1974], ["malaria", 1977], ["cases", 1985], ["averted", 1991], ["was", 1999], ["substantial", 2003], [".", 2014], ["RTS", 2016], [",", 2019], ["S", 2020], ["/", 2021], ["AS01", 2022], ["could", 2027], ["be", 2033], ["an", 2036], ["important", 2039], ["addition", 2049], ["to", 2058], ["current", 2061], ["malaria", 2069], ["control", 2077], ["in", 2085], ["Africa", 2088], [".", 2094], ["www", 2096], [".", 2099], ["ClinicalTrials.gov", 2100], ["NCT00866619", 2119], ["Please", 2131], ["see", 2138], ["later", 2142], ["in", 2148], ["the", 2151], ["article", 2155], ["for", 2163], ["the", 2167], ["Editors", 2171], ["'", 2178], ["Summary", 2180], [".", 2187]]}
{"context": "The Romano-Ward long QT syndrome, an autosomal dominant inherited disorder, is an increasingly recognized cause of sudden cardiac death in children and adults. Sudden death may or may not be preceded by a history of \"seizures\" and recurrent syncope; the diagnosis relies on electrocardiographic evidence, including prolongation of the QT interval corrected for heart rate, T wave abnormalities, sinus bradycardia, and polymorphous ventricular tachycardia (torsades de pointes). Recently, a gene responsible for causing long QT syndrome was localized (using molecular genetic methods) to the short arm of chromosome 11 (11p15.5) in the region near the Harvey ras-1 locus. The purpose of this report is to describe the current molecular genetic understanding of long QT syndrome, including information regarding gene mapping, genetic heterogeneity, and prenatal or presymptomatic diagnosis.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "c56e3d34c08a4d009fb83d8ed37c636a", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[9, 10]], "char_spans": [[37, 54]]}]}], "context_tokens": [["The", 0], ["Romano", 4], ["-", 10], ["Ward", 11], ["long", 16], ["QT", 21], ["syndrome", 24], [",", 32], ["an", 34], ["autosomal", 37], ["dominant", 47], ["inherited", 56], ["disorder", 66], [",", 74], ["is", 76], ["an", 79], ["increasingly", 82], ["recognized", 95], ["cause", 106], ["of", 112], ["sudden", 115], ["cardiac", 122], ["death", 130], ["in", 136], ["children", 139], ["and", 148], ["adults", 152], [".", 158], ["Sudden", 160], ["death", 167], ["may", 173], ["or", 177], ["may", 180], ["not", 184], ["be", 188], ["preceded", 191], ["by", 200], ["a", 203], ["history", 205], ["of", 213], ["\"", 216], ["seizures", 217], ["\"", 225], ["and", 227], ["recurrent", 231], ["syncope", 241], [";", 248], ["the", 250], ["diagnosis", 254], ["relies", 264], ["on", 271], ["electrocardiographic", 274], ["evidence", 295], [",", 303], ["including", 305], ["prolongation", 315], ["of", 328], ["the", 331], ["QT", 335], ["interval", 338], ["corrected", 347], ["for", 357], ["heart", 361], ["rate", 367], [",", 371], ["T", 373], ["wave", 375], ["abnormalities", 380], [",", 393], ["sinus", 395], ["bradycardia", 401], [",", 412], ["and", 414], ["polymorphous", 418], ["ventricular", 431], ["tachycardia", 443], ["(", 455], ["torsades", 456], ["de", 465], ["pointes", 468], [")", 475], [".", 476], ["Recently", 478], [",", 486], ["a", 488], ["gene", 490], ["responsible", 495], ["for", 507], ["causing", 511], ["long", 519], ["QT", 524], ["syndrome", 527], ["was", 536], ["localized", 540], ["(", 550], ["using", 551], ["molecular", 557], ["genetic", 567], ["methods", 575], [")", 582], ["to", 584], ["the", 587], ["short", 591], ["arm", 597], ["of", 601], ["chromosome", 604], ["11", 615], ["(", 618], ["11p15.5", 619], [")", 626], ["in", 628], ["the", 631], ["region", 635], ["near", 642], ["the", 647], ["Harvey", 651], ["ras-1", 658], ["locus", 664], [".", 669], ["The", 671], ["purpose", 675], ["of", 683], ["this", 686], ["report", 691], ["is", 698], ["to", 701], ["describe", 704], ["the", 713], ["current", 717], ["molecular", 725], ["genetic", 735], ["understanding", 743], ["of", 757], ["long", 760], ["QT", 765], ["syndrome", 768], [",", 776], ["including", 778], ["information", 788], ["regarding", 800], ["gene", 810], ["mapping", 815], [",", 822], ["genetic", 824], ["heterogeneity", 832], [",", 845], ["and", 847], ["prenatal", 851], ["or", 860], ["presymptomatic", 863], ["diagnosis", 878], [".", 887]]}
{"context": "Nox3, a member of the superoxide-producing NADPH oxidase (Nox) family, participates in otoconia formation in mouse inner ears, which is required for perception of balance and gravity. The activity of other Nox enzymes such as gp91(phox)/Nox2 and Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactivatorprotein (p67(phox) or Noxa1); for the p47(phox)-dependent activation of these oxidases, treatment of cells with stimulants such as phorbol 12-myristate 13-acetate is also indispensable. Here we show that ectopic expression of Nox3 in various types of cells leads to phorbol 12-myristate 13-acetate-independent constitutive production of a substantial amount of superoxide under the conditions where gp91(phox) and Nox1 fail to generate superoxide, i.e. in the absence of the oxidase organizers and activators. Nox3 likely forms a functional complex with p22(phox); Nox3 physically interacts with and stabilizes p22(phox), and the Nox3-dependent superoxide production is totally dependent on p22(phox). The organizers p47(phox) and Noxo1 are capable of enhancing the superoxide production by Nox3 in the absence of the activators, and the enhancement requires the interaction of the organizers with p22(phox), further indicating a link between Nox3 and p22(phox). The p47(phox)-enhanced Nox3 activity is further facilitated by p67(phox) or Noxa1, whereas the activators cancel the Noxo1-induced enhancement. On the other hand, the small GTPase Rac, essential for the gp91(phox) activity, is likely dispensable to the Nox3 system. Thus Nox3 functions together with p22(phox) as an enzyme constitutively producing superoxide, which can be distinctly regulated by combinatorial use of the organizers and activators.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "e662d0daac3047e6bbb879f08d0a56eb", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[45, 45], [126, 126]], "char_spans": [[246, 249], [757, 760]]}]}], "context_tokens": [["Nox3", 0], [",", 4], ["a", 6], ["member", 8], ["of", 15], ["the", 18], ["superoxide", 22], ["-", 32], ["producing", 33], ["NADPH", 43], ["oxidase", 49], ["(", 57], ["Nox", 58], [")", 61], ["family", 63], [",", 69], ["participates", 71], ["in", 84], ["otoconia", 87], ["formation", 96], ["in", 106], ["mouse", 109], ["inner", 115], ["ears", 121], [",", 125], ["which", 127], ["is", 133], ["required", 136], ["for", 145], ["perception", 149], ["of", 160], ["balance", 163], ["and", 171], ["gravity", 175], [".", 182], ["The", 184], ["activity", 188], ["of", 197], ["other", 200], ["Nox", 206], ["enzymes", 210], ["such", 218], ["as", 223], ["gp91(phox)/Nox2", 226], ["and", 242], ["Nox1", 246], ["is", 251], ["known", 254], ["to", 260], ["absolutely", 263], ["require", 274], ["both", 282], ["an", 287], ["organizer", 290], ["protein", 300], ["(", 308], ["p47(phox", 309], [")", 317], ["or", 319], ["Noxo1", 322], [")", 327], ["andanactivatorprotein", 329], ["(", 351], ["p67(phox", 352], [")", 360], ["or", 362], ["Noxa1", 365], [")", 370], [";", 371], ["for", 373], ["the", 377], ["p47(phox)-dependent", 381], ["activation", 401], ["of", 412], ["these", 415], ["oxidases", 421], [",", 429], ["treatment", 431], ["of", 441], ["cells", 444], ["with", 450], ["stimulants", 455], ["such", 466], ["as", 471], ["phorbol", 474], ["12-myristate", 482], ["13-acetate", 495], ["is", 506], ["also", 509], ["indispensable", 514], [".", 527], ["Here", 529], ["we", 534], ["show", 537], ["that", 542], ["ectopic", 547], ["expression", 555], ["of", 566], ["Nox3", 569], ["in", 574], ["various", 577], ["types", 585], ["of", 591], ["cells", 594], ["leads", 600], ["to", 606], ["phorbol", 609], ["12-myristate", 617], ["13-acetate", 630], ["-", 640], ["independent", 641], ["constitutive", 653], ["production", 666], ["of", 677], ["a", 680], ["substantial", 682], ["amount", 694], ["of", 701], ["superoxide", 704], ["under", 715], ["the", 721], ["conditions", 725], ["where", 736], ["gp91(phox", 742], [")", 751], ["and", 753], ["Nox1", 757], ["fail", 762], ["to", 767], ["generate", 770], ["superoxide", 779], [",", 789], ["i.e.", 791], ["in", 796], ["the", 799], ["absence", 803], ["of", 811], ["the", 814], ["oxidase", 818], ["organizers", 826], ["and", 837], ["activators", 841], [".", 851], ["Nox3", 853], ["likely", 858], ["forms", 865], ["a", 871], ["functional", 873], ["complex", 884], ["with", 892], ["p22(phox", 897], [")", 905], [";", 906], ["Nox3", 908], ["physically", 913], ["interacts", 924], ["with", 934], ["and", 939], ["stabilizes", 943], ["p22(phox", 954], [")", 962], [",", 963], ["and", 965], ["the", 969], ["Nox3-dependent", 973], ["superoxide", 988], ["production", 999], ["is", 1010], ["totally", 1013], ["dependent", 1021], ["on", 1031], ["p22(phox", 1034], [")", 1042], [".", 1043], ["The", 1045], ["organizers", 1049], ["p47(phox", 1060], [")", 1068], ["and", 1070], ["Noxo1", 1074], ["are", 1080], ["capable", 1084], ["of", 1092], ["enhancing", 1095], ["the", 1105], ["superoxide", 1109], ["production", 1120], ["by", 1131], ["Nox3", 1134], ["in", 1139], ["the", 1142], ["absence", 1146], ["of", 1154], ["the", 1157], ["activators", 1161], [",", 1171], ["and", 1173], ["the", 1177], ["enhancement", 1181], ["requires", 1193], ["the", 1202], ["interaction", 1206], ["of", 1218], ["the", 1221], ["organizers", 1225], ["with", 1236], ["p22(phox", 1241], [")", 1249], [",", 1250], ["further", 1252], ["indicating", 1260], ["a", 1271], ["link", 1273], ["between", 1278], ["Nox3", 1286], ["and", 1291], ["p22(phox", 1295], [")", 1303], [".", 1304], ["The", 1306], ["p47(phox)-enhanced", 1310], ["Nox3", 1329], ["activity", 1334], ["is", 1343], ["further", 1346], ["facilitated", 1354], ["by", 1366], ["p67(phox", 1369], [")", 1377], ["or", 1379], ["Noxa1", 1382], [",", 1387], ["whereas", 1389], ["the", 1397], ["activators", 1401], ["cancel", 1412], ["the", 1419], ["Noxo1-induced", 1423], ["enhancement", 1437], [".", 1448], ["On", 1450], ["the", 1453], ["other", 1457], ["hand", 1463], [",", 1467], ["the", 1469], ["small", 1473], ["GTPase", 1479], ["Rac", 1486], [",", 1489], ["essential", 1491], ["for", 1501], ["the", 1505], ["gp91(phox", 1509], [")", 1518], ["activity", 1520], [",", 1528], ["is", 1530], ["likely", 1533], ["dispensable", 1540], ["to", 1552], ["the", 1555], ["Nox3", 1559], ["system", 1564], [".", 1570], ["Thus", 1572], ["Nox3", 1577], ["functions", 1582], ["together", 1592], ["with", 1601], ["p22(phox", 1606], [")", 1614], ["as", 1616], ["an", 1619], ["enzyme", 1622], ["constitutively", 1629], ["producing", 1644], ["superoxide", 1654], [",", 1664], ["which", 1666], ["can", 1672], ["be", 1676], ["distinctly", 1679], ["regulated", 1690], ["by", 1700], ["combinatorial", 1703], ["use", 1717], ["of", 1721], ["the", 1724], ["organizers", 1728], ["and", 1739], ["activators", 1743], [".", 1753]]}
{"context": "The SP790 study (ClinicalTrials.gov, NCT00136045) showed benefits of rotigotine over placebo in improving symptom severity of restless legs syndrome (RLS), also known as Willis-Ekbom disease, on the International Restless Legs Syndrome Study Group rating scale (IRLS), Clinical Global Impression item 1 (CGI-1), RLS 6-item questionnaire (RLS-6), and the RLS-quality of life questionnaire (RLS-QoL) in patients with moderate to severe idiopathic RLS. To provide clinical context for the IRLS and to guide the choice of assessment scales for RLS studies, our post hoc analysis of SP790 data evaluated associations between the IRLS and the CGI-1, IRLS and RLS-6, and the IRLS and RLS-QoL. Scale associations were analyzed at baseline and at the end of maintenance (EoM) using data from the safety set (rotigotine and placebo groups combined [n=458]). Changes from baseline to EoM in IRLS score vs comparator scale scores also were analyzed. There was a trend towards increasing IRLS severity category with increasing CGI-1, RLS-6, and RLS-QoL score. Pearson product moment correlation coefficients showed correlations between IRLS and comparator scale scores at baseline and EoM as well as correlations for change from baseline to EoM. Correlations between the IRLS and comparator scales were substantial. These data indicate that the IRLS is clinically meaningful. The IRLS and CGI-1 are generally sufficient to evaluate the overall severity and impact of RLS symptoms in clinical trials.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "ad2342b8121d4fafa653d33df74f5afc", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[37, 39], [19, 21]], "char_spans": [[213, 234], [126, 147]]}]}], "context_tokens": [["The", 0], ["SP790", 4], ["study", 10], ["(", 16], ["ClinicalTrials.gov", 17], [",", 35], ["NCT00136045", 37], [")", 48], ["showed", 50], ["benefits", 57], ["of", 66], ["rotigotine", 69], ["over", 80], ["placebo", 85], ["in", 93], ["improving", 96], ["symptom", 106], ["severity", 114], ["of", 123], ["restless", 126], ["legs", 135], ["syndrome", 140], ["(", 149], ["RLS", 150], [")", 153], [",", 154], ["also", 156], ["known", 161], ["as", 167], ["Willis", 170], ["-", 176], ["Ekbom", 177], ["disease", 183], [",", 190], ["on", 192], ["the", 195], ["International", 199], ["Restless", 213], ["Legs", 222], ["Syndrome", 227], ["Study", 236], ["Group", 242], ["rating", 248], ["scale", 255], ["(", 261], ["IRLS", 262], [")", 266], [",", 267], ["Clinical", 269], ["Global", 278], ["Impression", 285], ["item", 296], ["1", 301], ["(", 303], ["CGI-1", 304], [")", 309], [",", 310], ["RLS", 312], ["6-item", 316], ["questionnaire", 323], ["(", 337], ["RLS-6", 338], [")", 343], [",", 344], ["and", 346], ["the", 350], ["RLS", 354], ["-", 357], ["quality", 358], ["of", 366], ["life", 369], ["questionnaire", 374], ["(", 388], ["RLS", 389], ["-", 392], ["QoL", 393], [")", 396], ["in", 398], ["patients", 401], ["with", 410], ["moderate", 415], ["to", 424], ["severe", 427], ["idiopathic", 434], ["RLS", 445], [".", 448], ["To", 450], ["provide", 453], ["clinical", 461], ["context", 470], ["for", 478], ["the", 482], ["IRLS", 486], ["and", 491], ["to", 495], ["guide", 498], ["the", 504], ["choice", 508], ["of", 515], ["assessment", 518], ["scales", 529], ["for", 536], ["RLS", 540], ["studies", 544], [",", 551], ["our", 553], ["post", 557], ["hoc", 562], ["analysis", 566], ["of", 575], ["SP790", 578], ["data", 584], ["evaluated", 589], ["associations", 599], ["between", 612], ["the", 620], ["IRLS", 624], ["and", 629], ["the", 633], ["CGI-1", 637], [",", 642], ["IRLS", 644], ["and", 649], ["RLS-6", 653], [",", 658], ["and", 660], ["the", 664], ["IRLS", 668], ["and", 673], ["RLS", 677], ["-", 680], ["QoL.", 681], ["Scale", 686], ["associations", 692], ["were", 705], ["analyzed", 710], ["at", 719], ["baseline", 722], ["and", 731], ["at", 735], ["the", 738], ["end", 742], ["of", 746], ["maintenance", 749], ["(", 761], ["EoM", 762], [")", 765], ["using", 767], ["data", 773], ["from", 778], ["the", 783], ["safety", 787], ["set", 794], ["(", 798], ["rotigotine", 799], ["and", 810], ["placebo", 814], ["groups", 822], ["combined", 829], ["[", 838], ["n=458", 839], ["]", 844], [")", 845], [".", 846], ["Changes", 848], ["from", 856], ["baseline", 861], ["to", 870], ["EoM", 873], ["in", 877], ["IRLS", 880], ["score", 885], ["vs", 891], ["comparator", 894], ["scale", 905], ["scores", 911], ["also", 918], ["were", 923], ["analyzed", 928], [".", 936], ["There", 938], ["was", 944], ["a", 948], ["trend", 950], ["towards", 956], ["increasing", 964], ["IRLS", 975], ["severity", 980], ["category", 989], ["with", 998], ["increasing", 1003], ["CGI-1", 1014], [",", 1019], ["RLS-6", 1021], [",", 1026], ["and", 1028], ["RLS", 1032], ["-", 1035], ["QoL", 1036], ["score", 1040], [".", 1045], ["Pearson", 1047], ["product", 1055], ["moment", 1063], ["correlation", 1070], ["coefficients", 1082], ["showed", 1095], ["correlations", 1102], ["between", 1115], ["IRLS", 1123], ["and", 1128], ["comparator", 1132], ["scale", 1143], ["scores", 1149], ["at", 1156], ["baseline", 1159], ["and", 1168], ["EoM", 1172], ["as", 1176], ["well", 1179], ["as", 1184], ["correlations", 1187], ["for", 1200], ["change", 1204], ["from", 1211], ["baseline", 1216], ["to", 1225], ["EoM.", 1228], ["Correlations", 1233], ["between", 1246], ["the", 1254], ["IRLS", 1258], ["and", 1263], ["comparator", 1267], ["scales", 1278], ["were", 1285], ["substantial", 1290], [".", 1301], ["These", 1303], ["data", 1309], ["indicate", 1314], ["that", 1323], ["the", 1328], ["IRLS", 1332], ["is", 1337], ["clinically", 1340], ["meaningful", 1351], [".", 1361], ["The", 1363], ["IRLS", 1367], ["and", 1372], ["CGI-1", 1376], ["are", 1382], ["generally", 1386], ["sufficient", 1396], ["to", 1407], ["evaluate", 1410], ["the", 1419], ["overall", 1423], ["severity", 1431], ["and", 1440], ["impact", 1444], ["of", 1451], ["RLS", 1454], ["symptoms", 1458], ["in", 1467], ["clinical", 1470], ["trials", 1479], [".", 1485]]}
{"context": "An intervention trial found a trend for shorter length of stay (LOS) in patients with community-acquired pneumonia (CAP) when the CURB65 score was combined with the prognostic biomarker proadrenomedullin (ProADM) (CURB65-A). However, the efficacy and safety of CURB65-A in real life situations remains unclear. From September, 2011, until April, 2012, we performed a post-study prospective observational quality control survey at the cantonal Hospital of Aarau, Switzerland of consecutive adults with CAP. The primary endpoint was length of stay (LOS) during the index hospitalization and within 30 days. We compared the results with two well-defined historic cohorts of CAP patients hospitalized in the same hospital with the use of multivariate regression, namely 83 patients in the observation study without ProADM (OPTIMA I) and the 169 patients in the intervention study (OPTIMA II RCT). A total of 89 patients with confirmed CAP were included. As compared to patients with CURB65 only observed in the OPTIMA I study, adjusted regression analysis showed a significant shorter initial LOS (7.5 vs. 10.4 days; -2.32; 95% CI, -4.51 to -0.13; p = 0.04) when CURB65-A was used in clinical routine. No significant differences were found for LOS within 30 days. There were no significant differences in safety outcomes in regard to mortality and ICU admission between the cohorts. This post-study survey provides evidence that the use of ProADM in combination with CURB65 (CURB65-A) in \"real life\" situations reduces initial LOS compared to the CURB65 score alone without apparent negative effects on patient safety.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "071541cdeb9e4d6c9a4b372f6a11c778", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[20, 20]], "char_spans": [[105, 113]]}]}], "context_tokens": [["An", 0], ["intervention", 3], ["trial", 16], ["found", 22], ["a", 28], ["trend", 30], ["for", 36], ["shorter", 40], ["length", 48], ["of", 55], ["stay", 58], ["(", 63], ["LOS", 64], [")", 67], ["in", 69], ["patients", 72], ["with", 81], ["community", 86], ["-", 95], ["acquired", 96], ["pneumonia", 105], ["(", 115], ["CAP", 116], [")", 119], ["when", 121], ["the", 126], ["CURB65", 130], ["score", 137], ["was", 143], ["combined", 147], ["with", 156], ["the", 161], ["prognostic", 165], ["biomarker", 176], ["proadrenomedullin", 186], ["(", 204], ["ProADM", 205], [")", 211], ["(", 213], ["CURB65-A", 214], [")", 222], [".", 223], ["However", 225], [",", 232], ["the", 234], ["efficacy", 238], ["and", 247], ["safety", 251], ["of", 258], ["CURB65-A", 261], ["in", 270], ["real", 273], ["life", 278], ["situations", 283], ["remains", 294], ["unclear", 302], [".", 309], ["From", 311], ["September", 316], [",", 325], ["2011", 327], [",", 331], ["until", 333], ["April", 339], [",", 344], ["2012", 346], [",", 350], ["we", 352], ["performed", 355], ["a", 365], ["post", 367], ["-", 371], ["study", 372], ["prospective", 378], ["observational", 390], ["quality", 404], ["control", 412], ["survey", 420], ["at", 427], ["the", 430], ["cantonal", 434], ["Hospital", 443], ["of", 452], ["Aarau", 455], [",", 460], ["Switzerland", 462], ["of", 474], ["consecutive", 477], ["adults", 489], ["with", 496], ["CAP", 501], [".", 504], ["The", 506], ["primary", 510], ["endpoint", 518], ["was", 527], ["length", 531], ["of", 538], ["stay", 541], ["(", 546], ["LOS", 547], [")", 550], ["during", 552], ["the", 559], ["index", 563], ["hospitalization", 569], ["and", 585], ["within", 589], ["30", 596], ["days", 599], [".", 603], ["We", 605], ["compared", 608], ["the", 617], ["results", 621], ["with", 629], ["two", 634], ["well", 638], ["-", 642], ["defined", 643], ["historic", 651], ["cohorts", 660], ["of", 668], ["CAP", 671], ["patients", 675], ["hospitalized", 684], ["in", 697], ["the", 700], ["same", 704], ["hospital", 709], ["with", 718], ["the", 723], ["use", 727], ["of", 731], ["multivariate", 734], ["regression", 747], [",", 757], ["namely", 759], ["83", 766], ["patients", 769], ["in", 778], ["the", 781], ["observation", 785], ["study", 797], ["without", 803], ["ProADM", 811], ["(", 818], ["OPTIMA", 819], ["I", 826], [")", 827], ["and", 829], ["the", 833], ["169", 837], ["patients", 841], ["in", 850], ["the", 853], ["intervention", 857], ["study", 870], ["(", 876], ["OPTIMA", 877], ["II", 884], ["RCT", 887], [")", 890], [".", 891], ["A", 893], ["total", 895], ["of", 901], ["89", 904], ["patients", 907], ["with", 916], ["confirmed", 921], ["CAP", 931], ["were", 935], ["included", 940], [".", 948], ["As", 950], ["compared", 953], ["to", 962], ["patients", 965], ["with", 974], ["CURB65", 979], ["only", 986], ["observed", 991], ["in", 1000], ["the", 1003], ["OPTIMA", 1007], ["I", 1014], ["study", 1016], [",", 1021], ["adjusted", 1023], ["regression", 1032], ["analysis", 1043], ["showed", 1052], ["a", 1059], ["significant", 1061], ["shorter", 1073], ["initial", 1081], ["LOS", 1089], ["(", 1093], ["7.5", 1094], ["vs.", 1098], ["10.4", 1102], ["days", 1107], [";", 1111], ["-2.32", 1113], [";", 1118], ["95", 1120], ["%", 1122], ["CI", 1124], [",", 1126], ["-4.51", 1128], ["to", 1134], ["-0.13", 1137], [";", 1142], ["p", 1144], ["=", 1146], ["0.04", 1148], [")", 1152], ["when", 1154], ["CURB65-A", 1159], ["was", 1168], ["used", 1172], ["in", 1177], ["clinical", 1180], ["routine", 1189], [".", 1196], ["No", 1198], ["significant", 1201], ["differences", 1213], ["were", 1225], ["found", 1230], ["for", 1236], ["LOS", 1240], ["within", 1244], ["30", 1251], ["days", 1254], [".", 1258], ["There", 1260], ["were", 1266], ["no", 1271], ["significant", 1274], ["differences", 1286], ["in", 1298], ["safety", 1301], ["outcomes", 1308], ["in", 1317], ["regard", 1320], ["to", 1327], ["mortality", 1330], ["and", 1340], ["ICU", 1344], ["admission", 1348], ["between", 1358], ["the", 1366], ["cohorts", 1370], [".", 1377], ["This", 1379], ["post", 1384], ["-", 1388], ["study", 1389], ["survey", 1395], ["provides", 1402], ["evidence", 1411], ["that", 1420], ["the", 1425], ["use", 1429], ["of", 1433], ["ProADM", 1436], ["in", 1443], ["combination", 1446], ["with", 1458], ["CURB65", 1463], ["(", 1470], ["CURB65-A", 1471], [")", 1479], ["in", 1481], ["\"", 1484], ["real", 1485], ["life", 1490], ["\"", 1494], ["situations", 1496], ["reduces", 1507], ["initial", 1515], ["LOS", 1523], ["compared", 1527], ["to", 1536], ["the", 1539], ["CURB65", 1543], ["score", 1550], ["alone", 1556], ["without", 1562], ["apparent", 1570], ["negative", 1579], ["effects", 1588], ["on", 1596], ["patient", 1599], ["safety", 1607], [".", 1613]]}
{"context": "The glycoprotein sclerostin (Scl; 22 kDa), which is involved in bone metabolism, may play a role in vascular calcification in haemodialysis (HD) patients. In the present study, we investigated the relation between serum Scl (sScl) and mortality. The effects of dialysis modality and the magnitude of the convection volume in haemodiafiltration (HDF) on sScl were also investigated. In a subset of patients from the CONTRAST study, a randomized controlled trial comparing HDF with HD, sScl was measured at baseline and at intervals of 6, 12, 24 and 36 months. Patients were divided into quartiles, according to their baseline sScl. The relation between time-varying sScl and mortality with a 4-year follow-up period was investigated using crude and adjusted Cox regression models. Linear mixed models were used for longitudinal measurements of sScl. The mean (\u00b1standard deviation) age of 396 test subjects was 63.6 (\u00b113.9 years), 61.6% were male and the median follow-up was 2.9 years. Subjects with the highest sScl had a lower mortality risk than those with the lowest concentrations [adjusted hazard ratio 0.51 (95% confidence interval, CI, 0.31-0.86, P = 0.01)]. Stratified models showed a stable sScl in patients treated with HD (\u0394 +2.9 pmol/L/year, 95% CI -0.5 to +6.3, P = 0.09) and a decreasing concentration in those treated with HDF (\u0394 -4.5 pmol/L/year, 95% CI -8.0 to -0.9, P = 0.02). The relative change in the latter group was related to the magnitude of the convection volume. (i) A high sScl is associated with a lower mortality risk in patients with end-stage kidney disease; (ii) treatment with HDF causes sScl to fall; and (iii) the relative decline in patients treated with HDF is dependent on the magnitude of the convection volume.", "qas": [{"question": "Sclerostin regulates what process?", "answers": ["bone metabolism"], "qid": "0029838703954d16a57a5cc158fd86d5", "question_tokens": [["Sclerostin", 0], ["regulates", 11], ["what", 21], ["process", 26], ["?", 33]], "detected_answers": [{"text": "bone metabolism", "token_spans": [[14, 15]], "char_spans": [[64, 78]]}]}], "context_tokens": [["The", 0], ["glycoprotein", 4], ["sclerostin", 17], ["(", 28], ["Scl", 29], [";", 32], ["22", 34], ["kDa", 37], [")", 40], [",", 41], ["which", 43], ["is", 49], ["involved", 52], ["in", 61], ["bone", 64], ["metabolism", 69], [",", 79], ["may", 81], ["play", 85], ["a", 90], ["role", 92], ["in", 97], ["vascular", 100], ["calcification", 109], ["in", 123], ["haemodialysis", 126], ["(", 140], ["HD", 141], [")", 143], ["patients", 145], [".", 153], ["In", 155], ["the", 158], ["present", 162], ["study", 170], [",", 175], ["we", 177], ["investigated", 180], ["the", 193], ["relation", 197], ["between", 206], ["serum", 214], ["Scl", 220], ["(", 224], ["sScl", 225], [")", 229], ["and", 231], ["mortality", 235], [".", 244], ["The", 246], ["effects", 250], ["of", 258], ["dialysis", 261], ["modality", 270], ["and", 279], ["the", 283], ["magnitude", 287], ["of", 297], ["the", 300], ["convection", 304], ["volume", 315], ["in", 322], ["haemodiafiltration", 325], ["(", 344], ["HDF", 345], [")", 348], ["on", 350], ["sScl", 353], ["were", 358], ["also", 363], ["investigated", 368], [".", 380], ["In", 382], ["a", 385], ["subset", 387], ["of", 394], ["patients", 397], ["from", 406], ["the", 411], ["CONTRAST", 415], ["study", 424], [",", 429], ["a", 431], ["randomized", 433], ["controlled", 444], ["trial", 455], ["comparing", 461], ["HDF", 471], ["with", 475], ["HD", 480], [",", 482], ["sScl", 484], ["was", 489], ["measured", 493], ["at", 502], ["baseline", 505], ["and", 514], ["at", 518], ["intervals", 521], ["of", 531], ["6", 534], [",", 535], ["12", 537], [",", 539], ["24", 541], ["and", 544], ["36", 548], ["months", 551], [".", 557], ["Patients", 559], ["were", 568], ["divided", 573], ["into", 581], ["quartiles", 586], [",", 595], ["according", 597], ["to", 607], ["their", 610], ["baseline", 616], ["sScl", 625], [".", 629], ["The", 631], ["relation", 635], ["between", 644], ["time", 652], ["-", 656], ["varying", 657], ["sScl", 665], ["and", 670], ["mortality", 674], ["with", 684], ["a", 689], ["4-year", 691], ["follow", 698], ["-", 704], ["up", 705], ["period", 708], ["was", 715], ["investigated", 719], ["using", 732], ["crude", 738], ["and", 744], ["adjusted", 748], ["Cox", 757], ["regression", 761], ["models", 772], [".", 778], ["Linear", 780], ["mixed", 787], ["models", 793], ["were", 800], ["used", 805], ["for", 810], ["longitudinal", 814], ["measurements", 827], ["of", 840], ["sScl", 843], [".", 847], ["The", 849], ["mean", 853], ["(", 858], ["\u00b1standard", 859], ["deviation", 869], [")", 878], ["age", 880], ["of", 884], ["396", 887], ["test", 891], ["subjects", 896], ["was", 905], ["63.6", 909], ["(", 914], ["\u00b113.9", 915], ["years", 921], [")", 926], [",", 927], ["61.6", 929], ["%", 933], ["were", 935], ["male", 940], ["and", 945], ["the", 949], ["median", 953], ["follow", 960], ["-", 966], ["up", 967], ["was", 970], ["2.9", 974], ["years", 978], [".", 983], ["Subjects", 985], ["with", 994], ["the", 999], ["highest", 1003], ["sScl", 1011], ["had", 1016], ["a", 1020], ["lower", 1022], ["mortality", 1028], ["risk", 1038], ["than", 1043], ["those", 1048], ["with", 1054], ["the", 1059], ["lowest", 1063], ["concentrations", 1070], ["[", 1085], ["adjusted", 1086], ["hazard", 1095], ["ratio", 1102], ["0.51", 1108], ["(", 1113], ["95", 1114], ["%", 1116], ["confidence", 1118], ["interval", 1129], [",", 1137], ["CI", 1139], [",", 1141], ["0.31", 1143], ["-", 1147], ["0.86", 1148], [",", 1152], ["P", 1154], ["=", 1156], ["0.01)].", 1158], ["Stratified", 1166], ["models", 1177], ["showed", 1184], ["a", 1191], ["stable", 1193], ["sScl", 1200], ["in", 1205], ["patients", 1208], ["treated", 1217], ["with", 1225], ["HD", 1230], ["(", 1233], ["\u0394", 1234], ["+2.9", 1236], ["pmol", 1241], ["/", 1245], ["L", 1246], ["/", 1247], ["year", 1248], [",", 1252], ["95", 1254], ["%", 1256], ["CI", 1258], ["-0.5", 1261], ["to", 1266], ["+6.3", 1269], [",", 1273], ["P", 1275], ["=", 1277], ["0.09", 1279], [")", 1283], ["and", 1285], ["a", 1289], ["decreasing", 1291], ["concentration", 1302], ["in", 1316], ["those", 1319], ["treated", 1325], ["with", 1333], ["HDF", 1338], ["(", 1342], ["\u0394", 1343], ["-4.5", 1345], ["pmol", 1350], ["/", 1354], ["L", 1355], ["/", 1356], ["year", 1357], [",", 1361], ["95", 1363], ["%", 1365], ["CI", 1367], ["-8.0", 1370], ["to", 1375], ["-0.9", 1378], [",", 1382], ["P", 1384], ["=", 1386], ["0.02", 1388], [")", 1392], [".", 1393], ["The", 1395], ["relative", 1399], ["change", 1408], ["in", 1415], ["the", 1418], ["latter", 1422], ["group", 1429], ["was", 1435], ["related", 1439], ["to", 1447], ["the", 1450], ["magnitude", 1454], ["of", 1464], ["the", 1467], ["convection", 1471], ["volume", 1482], [".", 1488], ["(", 1490], ["i", 1491], [")", 1492], ["A", 1494], ["high", 1496], ["sScl", 1501], ["is", 1506], ["associated", 1509], ["with", 1520], ["a", 1525], ["lower", 1527], ["mortality", 1533], ["risk", 1543], ["in", 1548], ["patients", 1551], ["with", 1560], ["end", 1565], ["-", 1568], ["stage", 1569], ["kidney", 1575], ["disease", 1582], [";", 1589], ["(", 1591], ["ii", 1592], [")", 1594], ["treatment", 1596], ["with", 1606], ["HDF", 1611], ["causes", 1615], ["sScl", 1622], ["to", 1627], ["fall", 1630], [";", 1634], ["and", 1636], ["(", 1640], ["iii", 1641], [")", 1644], ["the", 1646], ["relative", 1650], ["decline", 1659], ["in", 1667], ["patients", 1670], ["treated", 1679], ["with", 1687], ["HDF", 1692], ["is", 1696], ["dependent", 1699], ["on", 1709], ["the", 1712], ["magnitude", 1716], ["of", 1726], ["the", 1729], ["convection", 1733], ["volume", 1744], [".", 1750]]}
{"context": "Two forms of the inherited long QT syndrome have been known for many years: the autosomal recessive Jervell and Lange-Nielsen form and the autosomal dominant Romano-Ward form. A gene marker at the 11p 15.5 locus has been identified for some, but not all, families with the autosomal dominant form, but as yet the gene has not been identified. It is apparent that mutations of at least four genes, and possibly more, can cause the syndrome. The molecular biology of the syndrome is not yet clarified, but abnormalities of ion channel function are likely, particularly the potassium delayed rectifier current. Proposals for the pathophysiology include an abnormality of a G protein which controls ion channel and adrenergic pathway function, as well as a disturbance of the sympathetic nervous system. The identification of the abnormal gene(s) and the gene products will provide precise information on the molecular physiology of the syndrome.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "83d7f282309948759aa19ff5ddcdd45c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[26, 27], [54, 55]], "char_spans": [[139, 156], [273, 290]]}]}], "context_tokens": [["Two", 0], ["forms", 4], ["of", 10], ["the", 13], ["inherited", 17], ["long", 27], ["QT", 32], ["syndrome", 35], ["have", 44], ["been", 49], ["known", 54], ["for", 60], ["many", 64], ["years", 69], [":", 74], ["the", 76], ["autosomal", 80], ["recessive", 90], ["Jervell", 100], ["and", 108], ["Lange", 112], ["-", 117], ["Nielsen", 118], ["form", 126], ["and", 131], ["the", 135], ["autosomal", 139], ["dominant", 149], ["Romano", 158], ["-", 164], ["Ward", 165], ["form", 170], [".", 174], ["A", 176], ["gene", 178], ["marker", 183], ["at", 190], ["the", 193], ["11p", 197], ["15.5", 201], ["locus", 206], ["has", 212], ["been", 216], ["identified", 221], ["for", 232], ["some", 236], [",", 240], ["but", 242], ["not", 246], ["all", 250], [",", 253], ["families", 255], ["with", 264], ["the", 269], ["autosomal", 273], ["dominant", 283], ["form", 292], [",", 296], ["but", 298], ["as", 302], ["yet", 305], ["the", 309], ["gene", 313], ["has", 318], ["not", 322], ["been", 326], ["identified", 331], [".", 341], ["It", 343], ["is", 346], ["apparent", 349], ["that", 358], ["mutations", 363], ["of", 373], ["at", 376], ["least", 379], ["four", 385], ["genes", 390], [",", 395], ["and", 397], ["possibly", 401], ["more", 410], [",", 414], ["can", 416], ["cause", 420], ["the", 426], ["syndrome", 430], [".", 438], ["The", 440], ["molecular", 444], ["biology", 454], ["of", 462], ["the", 465], ["syndrome", 469], ["is", 478], ["not", 481], ["yet", 485], ["clarified", 489], [",", 498], ["but", 500], ["abnormalities", 504], ["of", 518], ["ion", 521], ["channel", 525], ["function", 533], ["are", 542], ["likely", 546], [",", 552], ["particularly", 554], ["the", 567], ["potassium", 571], ["delayed", 581], ["rectifier", 589], ["current", 599], [".", 606], ["Proposals", 608], ["for", 618], ["the", 622], ["pathophysiology", 626], ["include", 642], ["an", 650], ["abnormality", 653], ["of", 665], ["a", 668], ["G", 670], ["protein", 672], ["which", 680], ["controls", 686], ["ion", 695], ["channel", 699], ["and", 707], ["adrenergic", 711], ["pathway", 722], ["function", 730], [",", 738], ["as", 740], ["well", 743], ["as", 748], ["a", 751], ["disturbance", 753], ["of", 765], ["the", 768], ["sympathetic", 772], ["nervous", 784], ["system", 792], [".", 798], ["The", 800], ["identification", 804], ["of", 819], ["the", 822], ["abnormal", 826], ["gene(s", 835], [")", 841], ["and", 843], ["the", 847], ["gene", 851], ["products", 856], ["will", 865], ["provide", 870], ["precise", 878], ["information", 886], ["on", 898], ["the", 901], ["molecular", 905], ["physiology", 915], ["of", 926], ["the", 929], ["syndrome", 933], [".", 941]]}
{"context": "An effective malaria vaccine, deployed in conjunction with other malaria interventions, is likely to substantially reduce the malaria burden. Efficacy against severe malaria will be a key driver for decisions on implementation. An initial study of an RTS, S vaccine candidate showed promising efficacy against severe malaria in children in Mozambique. Further evidence of its protective efficacy will be gained in a pivotal, multi-centre, phase III study. This paper describes the case definitions of severe malaria used in this study and the programme for standardized assessment of severe malaria according to the case definition. Case definitions of severe malaria were developed from a literature review and a consensus meeting of expert consultants and the RTS, S Clinical Trial Partnership Committee, in collaboration with the World Health Organization and the Malaria Clinical Trials Alliance. The same groups, with input from an Independent Data Monitoring Committee, developed and implemented a programme for standardized data collection.The case definitions developed reflect the typical presentations of severe malaria in African hospitals. Markers of disease severity were chosen on the basis of their association with poor outcome, occurrence in a significant proportion of cases and on an ability to standardize their measurement across research centres. For the primary case definition, one or more clinical and/or laboratory markers of disease severity have to be present, four major co-morbidities (pneumonia, meningitis, bacteraemia or gastroenteritis with severe dehydration) are excluded, and a Plasmodium falciparum parasite density threshold is introduced, in order to maximize the specificity of the case definition. Secondary case definitions allow inclusion of co-morbidities and/or allow for the presence of parasitaemia at any density. The programmatic implementation of standardized case assessment included a clinical algorithm for evaluating seriously sick children, improvements to care delivery and a robust training and evaluation programme for clinicians. The case definition developed for the pivotal phase III RTS, S vaccine study is consistent with WHO recommendations, is locally applicable and appropriately balances sensitivity and specificity in the diagnosis of severe malaria. Processes set up to standardize severe malaria data collection will allow robust assessment of the efficacy of the RTS, S vaccine against severe malaria, strengthen local capacity and benefit patient care for subjects in the trial. Clinicaltrials.gov NCT00866619.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "94fef0193ac04cd1bd0618898b7f9efd", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[368, 368], [19, 19], [51, 51], [10, 10], [86, 86], [99, 99], [181, 181], [394, 394], [25, 25], [376, 376], [2, 2], [143, 143], [110, 110]], "char_spans": [[2311, 2317], [126, 132], [317, 323], [65, 71], [508, 514], [591, 597], [1122, 1128], [2465, 2471], [166, 172], [2359, 2365], [13, 19], [867, 873], [660, 666]]}]}], "context_tokens": [["An", 0], ["effective", 3], ["malaria", 13], ["vaccine", 21], [",", 28], ["deployed", 30], ["in", 39], ["conjunction", 42], ["with", 54], ["other", 59], ["malaria", 65], ["interventions", 73], [",", 86], ["is", 88], ["likely", 91], ["to", 98], ["substantially", 101], ["reduce", 115], ["the", 122], ["malaria", 126], ["burden", 134], [".", 140], ["Efficacy", 142], ["against", 151], ["severe", 159], ["malaria", 166], ["will", 174], ["be", 179], ["a", 182], ["key", 184], ["driver", 188], ["for", 195], ["decisions", 199], ["on", 209], ["implementation", 212], [".", 226], ["An", 228], ["initial", 231], ["study", 239], ["of", 245], ["an", 248], ["RTS", 251], [",", 254], ["S", 256], ["vaccine", 258], ["candidate", 266], ["showed", 276], ["promising", 283], ["efficacy", 293], ["against", 302], ["severe", 310], ["malaria", 317], ["in", 325], ["children", 328], ["in", 337], ["Mozambique", 340], [".", 350], ["Further", 352], ["evidence", 360], ["of", 369], ["its", 372], ["protective", 376], ["efficacy", 387], ["will", 396], ["be", 401], ["gained", 404], ["in", 411], ["a", 414], ["pivotal", 416], [",", 423], ["multi", 425], ["-", 430], ["centre", 431], [",", 437], ["phase", 439], ["III", 445], ["study", 449], [".", 454], ["This", 456], ["paper", 461], ["describes", 467], ["the", 477], ["case", 481], ["definitions", 486], ["of", 498], ["severe", 501], ["malaria", 508], ["used", 516], ["in", 521], ["this", 524], ["study", 529], ["and", 535], ["the", 539], ["programme", 543], ["for", 553], ["standardized", 557], ["assessment", 570], ["of", 581], ["severe", 584], ["malaria", 591], ["according", 599], ["to", 609], ["the", 612], ["case", 616], ["definition", 621], [".", 631], ["Case", 633], ["definitions", 638], ["of", 650], ["severe", 653], ["malaria", 660], ["were", 668], ["developed", 673], ["from", 683], ["a", 688], ["literature", 690], ["review", 701], ["and", 708], ["a", 712], ["consensus", 714], ["meeting", 724], ["of", 732], ["expert", 735], ["consultants", 742], ["and", 754], ["the", 758], ["RTS", 762], [",", 765], ["S", 767], ["Clinical", 769], ["Trial", 778], ["Partnership", 784], ["Committee", 796], [",", 805], ["in", 807], ["collaboration", 810], ["with", 824], ["the", 829], ["World", 833], ["Health", 839], ["Organization", 846], ["and", 859], ["the", 863], ["Malaria", 867], ["Clinical", 875], ["Trials", 884], ["Alliance", 891], [".", 899], ["The", 901], ["same", 905], ["groups", 910], [",", 916], ["with", 918], ["input", 923], ["from", 929], ["an", 934], ["Independent", 937], ["Data", 949], ["Monitoring", 954], ["Committee", 965], [",", 974], ["developed", 976], ["and", 986], ["implemented", 990], ["a", 1002], ["programme", 1004], ["for", 1014], ["standardized", 1018], ["data", 1031], ["collection", 1036], [".", 1046], ["The", 1047], ["case", 1051], ["definitions", 1056], ["developed", 1068], ["reflect", 1078], ["the", 1086], ["typical", 1090], ["presentations", 1098], ["of", 1112], ["severe", 1115], ["malaria", 1122], ["in", 1130], ["African", 1133], ["hospitals", 1141], [".", 1150], ["Markers", 1152], ["of", 1160], ["disease", 1163], ["severity", 1171], ["were", 1180], ["chosen", 1185], ["on", 1192], ["the", 1195], ["basis", 1199], ["of", 1205], ["their", 1208], ["association", 1214], ["with", 1226], ["poor", 1231], ["outcome", 1236], [",", 1243], ["occurrence", 1245], ["in", 1256], ["a", 1259], ["significant", 1261], ["proportion", 1273], ["of", 1284], ["cases", 1287], ["and", 1293], ["on", 1297], ["an", 1300], ["ability", 1303], ["to", 1311], ["standardize", 1314], ["their", 1326], ["measurement", 1332], ["across", 1344], ["research", 1351], ["centres", 1360], [".", 1367], ["For", 1369], ["the", 1373], ["primary", 1377], ["case", 1385], ["definition", 1390], [",", 1400], ["one", 1402], ["or", 1406], ["more", 1409], ["clinical", 1414], ["and/or", 1423], ["laboratory", 1430], ["markers", 1441], ["of", 1449], ["disease", 1452], ["severity", 1460], ["have", 1469], ["to", 1474], ["be", 1477], ["present", 1480], [",", 1487], ["four", 1489], ["major", 1494], ["co", 1500], ["-", 1502], ["morbidities", 1503], ["(", 1515], ["pneumonia", 1516], [",", 1525], ["meningitis", 1527], [",", 1537], ["bacteraemia", 1539], ["or", 1551], ["gastroenteritis", 1554], ["with", 1570], ["severe", 1575], ["dehydration", 1582], [")", 1593], ["are", 1595], ["excluded", 1599], [",", 1607], ["and", 1609], ["a", 1613], ["Plasmodium", 1615], ["falciparum", 1626], ["parasite", 1637], ["density", 1646], ["threshold", 1654], ["is", 1664], ["introduced", 1667], [",", 1677], ["in", 1679], ["order", 1682], ["to", 1688], ["maximize", 1691], ["the", 1700], ["specificity", 1704], ["of", 1716], ["the", 1719], ["case", 1723], ["definition", 1728], [".", 1738], ["Secondary", 1740], ["case", 1750], ["definitions", 1755], ["allow", 1767], ["inclusion", 1773], ["of", 1783], ["co", 1786], ["-", 1788], ["morbidities", 1789], ["and/or", 1801], ["allow", 1808], ["for", 1814], ["the", 1818], ["presence", 1822], ["of", 1831], ["parasitaemia", 1834], ["at", 1847], ["any", 1850], ["density", 1854], [".", 1861], ["The", 1863], ["programmatic", 1867], ["implementation", 1880], ["of", 1895], ["standardized", 1898], ["case", 1911], ["assessment", 1916], ["included", 1927], ["a", 1936], ["clinical", 1938], ["algorithm", 1947], ["for", 1957], ["evaluating", 1961], ["seriously", 1972], ["sick", 1982], ["children", 1987], [",", 1995], ["improvements", 1997], ["to", 2010], ["care", 2013], ["delivery", 2018], ["and", 2027], ["a", 2031], ["robust", 2033], ["training", 2040], ["and", 2049], ["evaluation", 2053], ["programme", 2064], ["for", 2074], ["clinicians", 2078], [".", 2088], ["The", 2090], ["case", 2094], ["definition", 2099], ["developed", 2110], ["for", 2120], ["the", 2124], ["pivotal", 2128], ["phase", 2136], ["III", 2142], ["RTS", 2146], [",", 2149], ["S", 2151], ["vaccine", 2153], ["study", 2161], ["is", 2167], ["consistent", 2170], ["with", 2181], ["WHO", 2186], ["recommendations", 2190], [",", 2205], ["is", 2207], ["locally", 2210], ["applicable", 2218], ["and", 2229], ["appropriately", 2233], ["balances", 2247], ["sensitivity", 2256], ["and", 2268], ["specificity", 2272], ["in", 2284], ["the", 2287], ["diagnosis", 2291], ["of", 2301], ["severe", 2304], ["malaria", 2311], [".", 2318], ["Processes", 2320], ["set", 2330], ["up", 2334], ["to", 2337], ["standardize", 2340], ["severe", 2352], ["malaria", 2359], ["data", 2367], ["collection", 2372], ["will", 2383], ["allow", 2388], ["robust", 2394], ["assessment", 2401], ["of", 2412], ["the", 2415], ["efficacy", 2419], ["of", 2428], ["the", 2431], ["RTS", 2435], [",", 2438], ["S", 2440], ["vaccine", 2442], ["against", 2450], ["severe", 2458], ["malaria", 2465], [",", 2472], ["strengthen", 2474], ["local", 2485], ["capacity", 2491], ["and", 2500], ["benefit", 2504], ["patient", 2512], ["care", 2520], ["for", 2525], ["subjects", 2529], ["in", 2538], ["the", 2541], ["trial", 2545], [".", 2550], ["Clinicaltrials.gov", 2552], ["NCT00866619", 2571], [".", 2582]]}
{"context": "To determine the change in prevalence of posttraumatic stress disorder (PTSD) symptoms in victims of the March 11 attacks and their relatives, 1 and 6 months after the attacks. Evaluation of PTSD symptoms using the Davidson Trauma Scale (DTS) and General Health Questionnaire (GHQ) in a sample of 56 patients admitted to an emergency room of a general hospital, and assessment of PTSD symptoms in relatives of the patients. At Month 1, 41.1% of patients (31.3% of males and 54.2% of females) presented with PTSD. At Month 6, this figure was 40.9% (30.4% of males and 52.4% of females). There was a significant improvement in perception of health among females between Month 1 and Month 6. Relatives presented similar DTS scores at baseline and at 6 months. We verified that rates of PTSD did not vary substantively between the two evaluations. PTSD symptoms positively correlated with psychological health involvement. This correlation points out that both PTSD symptoms and subjective general health involvement are part of the psychological response to trauma. The prevalence of PTSD symptoms was high and remained stable between Month 1 and Month 6, while subjective perception of health improved significantly.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "c35f27d4167846e1adc3aadd2981e4dc", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[35, 35], [11, 11], [202, 202], [100, 100], [71, 71], [183, 183], [168, 168], [158, 158]], "char_spans": [[191, 194], [72, 75], [1081, 1084], [507, 510], [380, 383], [957, 960], [844, 847], [783, 786]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["change", 17], ["in", 24], ["prevalence", 27], ["of", 38], ["posttraumatic", 41], ["stress", 55], ["disorder", 62], ["(", 71], ["PTSD", 72], [")", 76], ["symptoms", 78], ["in", 87], ["victims", 90], ["of", 98], ["the", 101], ["March", 105], ["11", 111], ["attacks", 114], ["and", 122], ["their", 126], ["relatives", 132], [",", 141], ["1", 143], ["and", 145], ["6", 149], ["months", 151], ["after", 158], ["the", 164], ["attacks", 168], [".", 175], ["Evaluation", 177], ["of", 188], ["PTSD", 191], ["symptoms", 196], ["using", 205], ["the", 211], ["Davidson", 215], ["Trauma", 224], ["Scale", 231], ["(", 237], ["DTS", 238], [")", 241], ["and", 243], ["General", 247], ["Health", 255], ["Questionnaire", 262], ["(", 276], ["GHQ", 277], [")", 280], ["in", 282], ["a", 285], ["sample", 287], ["of", 294], ["56", 297], ["patients", 300], ["admitted", 309], ["to", 318], ["an", 321], ["emergency", 324], ["room", 334], ["of", 339], ["a", 342], ["general", 344], ["hospital", 352], [",", 360], ["and", 362], ["assessment", 366], ["of", 377], ["PTSD", 380], ["symptoms", 385], ["in", 394], ["relatives", 397], ["of", 407], ["the", 410], ["patients", 414], [".", 422], ["At", 424], ["Month", 427], ["1", 433], [",", 434], ["41.1", 436], ["%", 440], ["of", 442], ["patients", 445], ["(", 454], ["31.3", 455], ["%", 459], ["of", 461], ["males", 464], ["and", 470], ["54.2", 474], ["%", 478], ["of", 480], ["females", 483], [")", 490], ["presented", 492], ["with", 502], ["PTSD", 507], [".", 511], ["At", 513], ["Month", 516], ["6", 522], [",", 523], ["this", 525], ["figure", 530], ["was", 537], ["40.9", 541], ["%", 545], ["(", 547], ["30.4", 548], ["%", 552], ["of", 554], ["males", 557], ["and", 563], ["52.4", 567], ["%", 571], ["of", 573], ["females", 576], [")", 583], [".", 584], ["There", 586], ["was", 592], ["a", 596], ["significant", 598], ["improvement", 610], ["in", 622], ["perception", 625], ["of", 636], ["health", 639], ["among", 646], ["females", 652], ["between", 660], ["Month", 668], ["1", 674], ["and", 676], ["Month", 680], ["6", 686], [".", 687], ["Relatives", 689], ["presented", 699], ["similar", 709], ["DTS", 717], ["scores", 721], ["at", 728], ["baseline", 731], ["and", 740], ["at", 744], ["6", 747], ["months", 749], [".", 755], ["We", 757], ["verified", 760], ["that", 769], ["rates", 774], ["of", 780], ["PTSD", 783], ["did", 788], ["not", 792], ["vary", 796], ["substantively", 801], ["between", 815], ["the", 823], ["two", 827], ["evaluations", 831], [".", 842], ["PTSD", 844], ["symptoms", 849], ["positively", 858], ["correlated", 869], ["with", 880], ["psychological", 885], ["health", 899], ["involvement", 906], [".", 917], ["This", 919], ["correlation", 924], ["points", 936], ["out", 943], ["that", 947], ["both", 952], ["PTSD", 957], ["symptoms", 962], ["and", 971], ["subjective", 975], ["general", 986], ["health", 994], ["involvement", 1001], ["are", 1013], ["part", 1017], ["of", 1022], ["the", 1025], ["psychological", 1029], ["response", 1043], ["to", 1052], ["trauma", 1055], [".", 1061], ["The", 1063], ["prevalence", 1067], ["of", 1078], ["PTSD", 1081], ["symptoms", 1086], ["was", 1095], ["high", 1099], ["and", 1104], ["remained", 1108], ["stable", 1117], ["between", 1124], ["Month", 1132], ["1", 1138], ["and", 1140], ["Month", 1144], ["6", 1150], [",", 1151], ["while", 1153], ["subjective", 1159], ["perception", 1170], ["of", 1181], ["health", 1184], ["improved", 1191], ["significantly", 1200], [".", 1213]]}
{"context": "Mutations of presenilin 1 (PS1) causing Alzheimer's disease selectively increase the secretion of the amyloidogenic betaA4(1-42), whereas knocking out the gene results in decreased production of both betaA4(1-40) and (1-42) amyloid peptides (De Strooper et al. 1998). Therefore, PS1 function is closely linked to the gamma-secretase processing of the amyloid precursor protein (APP). Given the ongoing controversy on the subcellular localization of PS1, it remains unclear at what level of the secretory and endocytic pathways PS1 exerts its activity on APP and on the APP carboxy-terminal fragments that are the direct substrates for gamma-secretase. Therefore, we have reinvestigated the subcellular localization of endogenously expressed PS1 in neurons in vitro and in vivo using confocal microscopy and fine-tuned subcellular fractionation. We show that uncleaved PS1 holoprotein is recovered in the nuclear envelope fraction, whereas the cleaved PS fragments are found mainly in post-ER membranes including the intermediate compartment (IC). PS1 is concentrated in discrete sec23p- and p58/ERGIC-53-positive patches, suggesting its localization in subdomains involved in ER export. PS1 is not found to significant amounts beyond the cis-Golgi. Surprisingly, we found that APP carboxy-terminal fragments also coenrich in the pre-Golgi membrane fractions, consistent with the idea that these fragments are the real substrates for gamma-secretase. Functional evidence that PS1 exerts its effects on gamma-secretase processing of APP in the ER/IC was obtained using a series of APP trafficking mutants. These mutants were investigated in hippocampal neurons derived from transgenic mice expressing PS1wt or PS1 containing clinical mutations (PS1(M146L) and PS1(L286V)) at physiologically relevant levels. We demonstrate that the APP-London and PS1 mutations have additive effects on the increased secretion of betaA4(1-42) relative to betaA4(1-40), indicating that both mutations operate independently. Overall, our data clearly establish that PS1 controls gamma(42)-secretase activity in pre-Golgi compartments. We discuss models that reconcile this conclusion with the effects of PS1 deficiency on the generation of betaA4(1-40) peptide in the late biosynthetic and endocytic pathways.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "c6a3fb62d44040b1a6fe442b2aadc722", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[8, 10]], "char_spans": [[40, 58]]}]}], "context_tokens": [["Mutations", 0], ["of", 10], ["presenilin", 13], ["1", 24], ["(", 26], ["PS1", 27], [")", 30], ["causing", 32], ["Alzheimer", 40], ["'s", 49], ["disease", 52], ["selectively", 60], ["increase", 72], ["the", 81], ["secretion", 85], ["of", 95], ["the", 98], ["amyloidogenic", 102], ["betaA4(1", 116], ["-", 124], ["42", 125], [")", 127], [",", 128], ["whereas", 130], ["knocking", 138], ["out", 147], ["the", 151], ["gene", 155], ["results", 160], ["in", 168], ["decreased", 171], ["production", 181], ["of", 192], ["both", 195], ["betaA4(1", 200], ["-", 208], ["40", 209], [")", 211], ["and", 213], ["(", 217], ["1", 218], ["-", 219], ["42", 220], [")", 222], ["amyloid", 224], ["peptides", 232], ["(", 241], ["De", 242], ["Strooper", 245], ["et", 254], ["al", 257], [".", 259], ["1998", 261], [")", 265], [".", 266], ["Therefore", 268], [",", 277], ["PS1", 279], ["function", 283], ["is", 292], ["closely", 295], ["linked", 303], ["to", 310], ["the", 313], ["gamma", 317], ["-", 322], ["secretase", 323], ["processing", 333], ["of", 344], ["the", 347], ["amyloid", 351], ["precursor", 359], ["protein", 369], ["(", 377], ["APP", 378], [")", 381], [".", 382], ["Given", 384], ["the", 390], ["ongoing", 394], ["controversy", 402], ["on", 414], ["the", 417], ["subcellular", 421], ["localization", 433], ["of", 446], ["PS1", 449], [",", 452], ["it", 454], ["remains", 457], ["unclear", 465], ["at", 473], ["what", 476], ["level", 481], ["of", 487], ["the", 490], ["secretory", 494], ["and", 504], ["endocytic", 508], ["pathways", 518], ["PS1", 527], ["exerts", 531], ["its", 538], ["activity", 542], ["on", 551], ["APP", 554], ["and", 558], ["on", 562], ["the", 565], ["APP", 569], ["carboxy", 573], ["-", 580], ["terminal", 581], ["fragments", 590], ["that", 600], ["are", 605], ["the", 609], ["direct", 613], ["substrates", 620], ["for", 631], ["gamma", 635], ["-", 640], ["secretase", 641], [".", 650], ["Therefore", 652], [",", 661], ["we", 663], ["have", 666], ["reinvestigated", 671], ["the", 686], ["subcellular", 690], ["localization", 702], ["of", 715], ["endogenously", 718], ["expressed", 731], ["PS1", 741], ["in", 745], ["neurons", 748], ["in", 756], ["vitro", 759], ["and", 765], ["in", 769], ["vivo", 772], ["using", 777], ["confocal", 783], ["microscopy", 792], ["and", 803], ["fine", 807], ["-", 811], ["tuned", 812], ["subcellular", 818], ["fractionation", 830], [".", 843], ["We", 845], ["show", 848], ["that", 853], ["uncleaved", 858], ["PS1", 868], ["holoprotein", 872], ["is", 884], ["recovered", 887], ["in", 897], ["the", 900], ["nuclear", 904], ["envelope", 912], ["fraction", 921], [",", 929], ["whereas", 931], ["the", 939], ["cleaved", 943], ["PS", 951], ["fragments", 954], ["are", 964], ["found", 968], ["mainly", 974], ["in", 981], ["post", 984], ["-", 988], ["ER", 989], ["membranes", 992], ["including", 1002], ["the", 1012], ["intermediate", 1016], ["compartment", 1029], ["(", 1041], ["IC", 1042], [")", 1044], [".", 1045], ["PS1", 1047], ["is", 1051], ["concentrated", 1054], ["in", 1067], ["discrete", 1070], ["sec23p-", 1079], ["and", 1087], ["p58/ERGIC-53-positive", 1091], ["patches", 1113], [",", 1120], ["suggesting", 1122], ["its", 1133], ["localization", 1137], ["in", 1150], ["subdomains", 1153], ["involved", 1164], ["in", 1173], ["ER", 1176], ["export", 1179], [".", 1185], ["PS1", 1187], ["is", 1191], ["not", 1194], ["found", 1198], ["to", 1204], ["significant", 1207], ["amounts", 1219], ["beyond", 1227], ["the", 1234], ["cis", 1238], ["-", 1241], ["Golgi", 1242], [".", 1247], ["Surprisingly", 1249], [",", 1261], ["we", 1263], ["found", 1266], ["that", 1272], ["APP", 1277], ["carboxy", 1281], ["-", 1288], ["terminal", 1289], ["fragments", 1298], ["also", 1308], ["coenrich", 1313], ["in", 1322], ["the", 1325], ["pre", 1329], ["-", 1332], ["Golgi", 1333], ["membrane", 1339], ["fractions", 1348], [",", 1357], ["consistent", 1359], ["with", 1370], ["the", 1375], ["idea", 1379], ["that", 1384], ["these", 1389], ["fragments", 1395], ["are", 1405], ["the", 1409], ["real", 1413], ["substrates", 1418], ["for", 1429], ["gamma", 1433], ["-", 1438], ["secretase", 1439], [".", 1448], ["Functional", 1450], ["evidence", 1461], ["that", 1470], ["PS1", 1475], ["exerts", 1479], ["its", 1486], ["effects", 1490], ["on", 1498], ["gamma", 1501], ["-", 1506], ["secretase", 1507], ["processing", 1517], ["of", 1528], ["APP", 1531], ["in", 1535], ["the", 1538], ["ER", 1542], ["/", 1544], ["IC", 1545], ["was", 1548], ["obtained", 1552], ["using", 1561], ["a", 1567], ["series", 1569], ["of", 1576], ["APP", 1579], ["trafficking", 1583], ["mutants", 1595], [".", 1602], ["These", 1604], ["mutants", 1610], ["were", 1618], ["investigated", 1623], ["in", 1636], ["hippocampal", 1639], ["neurons", 1651], ["derived", 1659], ["from", 1667], ["transgenic", 1672], ["mice", 1683], ["expressing", 1688], ["PS1wt", 1699], ["or", 1705], ["PS1", 1708], ["containing", 1712], ["clinical", 1723], ["mutations", 1732], ["(", 1742], ["PS1(M146L", 1743], [")", 1752], ["and", 1754], ["PS1(L286V", 1758], [")", 1767], [")", 1768], ["at", 1770], ["physiologically", 1773], ["relevant", 1789], ["levels", 1798], [".", 1804], ["We", 1806], ["demonstrate", 1809], ["that", 1821], ["the", 1826], ["APP", 1830], ["-", 1833], ["London", 1834], ["and", 1841], ["PS1", 1845], ["mutations", 1849], ["have", 1859], ["additive", 1864], ["effects", 1873], ["on", 1881], ["the", 1884], ["increased", 1888], ["secretion", 1898], ["of", 1908], ["betaA4(1", 1911], ["-", 1919], ["42", 1920], [")", 1922], ["relative", 1924], ["to", 1933], ["betaA4(1", 1936], ["-", 1944], ["40", 1945], [")", 1947], [",", 1948], ["indicating", 1950], ["that", 1961], ["both", 1966], ["mutations", 1971], ["operate", 1981], ["independently", 1989], [".", 2002], ["Overall", 2004], [",", 2011], ["our", 2013], ["data", 2017], ["clearly", 2022], ["establish", 2030], ["that", 2040], ["PS1", 2045], ["controls", 2049], ["gamma(42)-secretase", 2058], ["activity", 2078], ["in", 2087], ["pre", 2090], ["-", 2093], ["Golgi", 2094], ["compartments", 2100], [".", 2112], ["We", 2114], ["discuss", 2117], ["models", 2125], ["that", 2132], ["reconcile", 2137], ["this", 2147], ["conclusion", 2152], ["with", 2163], ["the", 2168], ["effects", 2172], ["of", 2180], ["PS1", 2183], ["deficiency", 2187], ["on", 2198], ["the", 2201], ["generation", 2205], ["of", 2216], ["betaA4(1", 2219], ["-", 2227], ["40", 2228], [")", 2230], ["peptide", 2232], ["in", 2240], ["the", 2243], ["late", 2247], ["biosynthetic", 2252], ["and", 2265], ["endocytic", 2269], ["pathways", 2279], [".", 2287]]}
{"context": "Flumazenil (Ro 15-1788) proved to be a very efficacious competitive antagonist of benzodiazepines that reliably counteracts their pharmacological actions within 1-2 min as could be demonstrated in clinical and EEG studies. In general, a total dose of 0.3-0.8 mg will be sufficient in clinical practice, avoiding side effects like nausea, tremor, sweating, or transient anxiety that could be observed when higher dosages were administered. Its therapeutic range is very high as could be demonstrated in experimental animal in which up to 8.000-fold the clinical dose was administered. The total volume of distribution (Vdes) amounts to nearly 1.000 ml/kg BW and the total clearance exceeds 1.200 ml/min, resulting in a biological half-life of less than 60 min. According to the benzodiazepine dosage and the rapid plasma concentration decline of flumazenil, in some cases a resedation could be observed. Hence, a careful observation of the antagonised patient on the ward is mandatory for 1.5-2 h, even if at first sight the antagonization seemed successful and the patient fully awake and cooperative. In anaesthesia, indications to administer flumazenil are adverse drug reactions and prolonged recovery after adequate benzodiazepine dosage. In intensive care medicine, the antagonist may be used in the treatment of benzodiazepine overdose as well as in the differential diagnosis of a coma of unknown origin. Additionally, the antagonist may be administered to interrupt benzodiazepine sedation e.g. for neurological examination.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "767ca74416ef41738a08d2aef5208410", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [208, 208], [154, 154]], "char_spans": [[0, 9], [1144, 1153], [845, 854]]}]}], "context_tokens": [["Flumazenil", 0], ["(", 11], ["Ro", 12], ["15", 15], ["-", 17], ["1788", 18], [")", 22], ["proved", 24], ["to", 31], ["be", 34], ["a", 37], ["very", 39], ["efficacious", 44], ["competitive", 56], ["antagonist", 68], ["of", 79], ["benzodiazepines", 82], ["that", 98], ["reliably", 103], ["counteracts", 112], ["their", 124], ["pharmacological", 130], ["actions", 146], ["within", 154], ["1", 161], ["-", 162], ["2", 163], ["min", 165], ["as", 169], ["could", 172], ["be", 178], ["demonstrated", 181], ["in", 194], ["clinical", 197], ["and", 206], ["EEG", 210], ["studies", 214], [".", 221], ["In", 223], ["general", 226], [",", 233], ["a", 235], ["total", 237], ["dose", 243], ["of", 248], ["0.3", 251], ["-", 254], ["0.8", 255], ["mg", 259], ["will", 262], ["be", 267], ["sufficient", 270], ["in", 281], ["clinical", 284], ["practice", 293], [",", 301], ["avoiding", 303], ["side", 312], ["effects", 317], ["like", 325], ["nausea", 330], [",", 336], ["tremor", 338], [",", 344], ["sweating", 346], [",", 354], ["or", 356], ["transient", 359], ["anxiety", 369], ["that", 377], ["could", 382], ["be", 388], ["observed", 391], ["when", 400], ["higher", 405], ["dosages", 412], ["were", 420], ["administered", 425], [".", 437], ["Its", 439], ["therapeutic", 443], ["range", 455], ["is", 461], ["very", 464], ["high", 469], ["as", 474], ["could", 477], ["be", 483], ["demonstrated", 486], ["in", 499], ["experimental", 502], ["animal", 515], ["in", 522], ["which", 525], ["up", 531], ["to", 534], ["8.000-fold", 537], ["the", 548], ["clinical", 552], ["dose", 561], ["was", 566], ["administered", 570], [".", 582], ["The", 584], ["total", 588], ["volume", 594], ["of", 601], ["distribution", 604], ["(", 617], ["Vdes", 618], [")", 622], ["amounts", 624], ["to", 632], ["nearly", 635], ["1.000", 642], ["ml", 648], ["/", 650], ["kg", 651], ["BW", 654], ["and", 657], ["the", 661], ["total", 665], ["clearance", 671], ["exceeds", 681], ["1.200", 689], ["ml", 695], ["/", 697], ["min", 698], [",", 701], ["resulting", 703], ["in", 713], ["a", 716], ["biological", 718], ["half", 729], ["-", 733], ["life", 734], ["of", 739], ["less", 742], ["than", 747], ["60", 752], ["min", 755], [".", 758], ["According", 760], ["to", 770], ["the", 773], ["benzodiazepine", 777], ["dosage", 792], ["and", 799], ["the", 803], ["rapid", 807], ["plasma", 813], ["concentration", 820], ["decline", 834], ["of", 842], ["flumazenil", 845], [",", 855], ["in", 857], ["some", 860], ["cases", 865], ["a", 871], ["resedation", 873], ["could", 884], ["be", 890], ["observed", 893], [".", 901], ["Hence", 903], [",", 908], ["a", 910], ["careful", 912], ["observation", 920], ["of", 932], ["the", 935], ["antagonised", 939], ["patient", 951], ["on", 959], ["the", 962], ["ward", 966], ["is", 971], ["mandatory", 974], ["for", 984], ["1.5", 988], ["-", 991], ["2", 992], ["h", 994], [",", 995], ["even", 997], ["if", 1002], ["at", 1005], ["first", 1008], ["sight", 1014], ["the", 1020], ["antagonization", 1024], ["seemed", 1039], ["successful", 1046], ["and", 1057], ["the", 1061], ["patient", 1065], ["fully", 1073], ["awake", 1079], ["and", 1085], ["cooperative", 1089], [".", 1100], ["In", 1102], ["anaesthesia", 1105], [",", 1116], ["indications", 1118], ["to", 1130], ["administer", 1133], ["flumazenil", 1144], ["are", 1155], ["adverse", 1159], ["drug", 1167], ["reactions", 1172], ["and", 1182], ["prolonged", 1186], ["recovery", 1196], ["after", 1205], ["adequate", 1211], ["benzodiazepine", 1220], ["dosage", 1235], [".", 1241], ["In", 1243], ["intensive", 1246], ["care", 1256], ["medicine", 1261], [",", 1269], ["the", 1271], ["antagonist", 1275], ["may", 1286], ["be", 1290], ["used", 1293], ["in", 1298], ["the", 1301], ["treatment", 1305], ["of", 1315], ["benzodiazepine", 1318], ["overdose", 1333], ["as", 1342], ["well", 1345], ["as", 1350], ["in", 1353], ["the", 1356], ["differential", 1360], ["diagnosis", 1373], ["of", 1383], ["a", 1386], ["coma", 1388], ["of", 1393], ["unknown", 1396], ["origin", 1404], [".", 1410], ["Additionally", 1412], [",", 1424], ["the", 1426], ["antagonist", 1430], ["may", 1441], ["be", 1445], ["administered", 1448], ["to", 1461], ["interrupt", 1464], ["benzodiazepine", 1474], ["sedation", 1489], ["e.g.", 1498], ["for", 1503], ["neurological", 1507], ["examination", 1520], [".", 1531]]}
{"context": "A 45-year-old man developed chorea, behavioural changes, moderate amyotrophy and polyneuropathy. Hypertrophic cardiomyopathy and increased serum lactate dehydrogenase and creatine kinase (CK) were found. Acanthocytes were not detected. The absence of XK protein and faintly expressed Kell antigens on erythrocytes were found. Genetic test revealed a R133X mutation of the XK gene, confirming the McLeod syndrome. After 7 years he suddenly developed delirium followed by severe hypoglycaemia, hyperthermia, rhabdomyolysis, hepatic and renal failure. Malignant arrhythmia caused death.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "b5b0517d354847768bfb0266b7052a80", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[60, 60], [40, 40]], "char_spans": [[372, 373], [251, 252]]}]}], "context_tokens": [["A", 0], ["45-year", 2], ["-", 9], ["old", 10], ["man", 14], ["developed", 18], ["chorea", 28], [",", 34], ["behavioural", 36], ["changes", 48], [",", 55], ["moderate", 57], ["amyotrophy", 66], ["and", 77], ["polyneuropathy", 81], [".", 95], ["Hypertrophic", 97], ["cardiomyopathy", 110], ["and", 125], ["increased", 129], ["serum", 139], ["lactate", 145], ["dehydrogenase", 153], ["and", 167], ["creatine", 171], ["kinase", 180], ["(", 187], ["CK", 188], [")", 190], ["were", 192], ["found", 197], [".", 202], ["Acanthocytes", 204], ["were", 217], ["not", 222], ["detected", 226], [".", 234], ["The", 236], ["absence", 240], ["of", 248], ["XK", 251], ["protein", 254], ["and", 262], ["faintly", 266], ["expressed", 274], ["Kell", 284], ["antigens", 289], ["on", 298], ["erythrocytes", 301], ["were", 314], ["found", 319], [".", 324], ["Genetic", 326], ["test", 334], ["revealed", 339], ["a", 348], ["R133X", 350], ["mutation", 356], ["of", 365], ["the", 368], ["XK", 372], ["gene", 375], [",", 379], ["confirming", 381], ["the", 392], ["McLeod", 396], ["syndrome", 403], [".", 411], ["After", 413], ["7", 419], ["years", 421], ["he", 427], ["suddenly", 430], ["developed", 439], ["delirium", 449], ["followed", 458], ["by", 467], ["severe", 470], ["hypoglycaemia", 477], [",", 490], ["hyperthermia", 492], [",", 504], ["rhabdomyolysis", 506], [",", 520], ["hepatic", 522], ["and", 530], ["renal", 534], ["failure", 540], [".", 547], ["Malignant", 549], ["arrhythmia", 559], ["caused", 570], ["death", 577], [".", 582]]}
{"context": "The authors describe a family with six patients with muscular dystrophy with a variable course. One is a compound heterozygote for CAPN3 mutations (calpainopathy) and the others have a single CAPN3 mutation. Linkage analysis and sequencing revealed a XK gene mutation (McLeod syndrome). This illustrates the variable phenotype of XK mutations and suggests the possibility that CAPN3 heterozygotes may have their condition caused by nonallelic mutations in other unrelated genes.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "30982bbba290475cadfbcc0116b0d9c4", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[56, 56], [42, 42]], "char_spans": [[330, 331], [251, 252]]}]}], "context_tokens": [["The", 0], ["authors", 4], ["describe", 12], ["a", 21], ["family", 23], ["with", 30], ["six", 35], ["patients", 39], ["with", 48], ["muscular", 53], ["dystrophy", 62], ["with", 72], ["a", 77], ["variable", 79], ["course", 88], [".", 94], ["One", 96], ["is", 100], ["a", 103], ["compound", 105], ["heterozygote", 114], ["for", 127], ["CAPN3", 131], ["mutations", 137], ["(", 147], ["calpainopathy", 148], [")", 161], ["and", 163], ["the", 167], ["others", 171], ["have", 178], ["a", 183], ["single", 185], ["CAPN3", 192], ["mutation", 198], [".", 206], ["Linkage", 208], ["analysis", 216], ["and", 225], ["sequencing", 229], ["revealed", 240], ["a", 249], ["XK", 251], ["gene", 254], ["mutation", 259], ["(", 268], ["McLeod", 269], ["syndrome", 276], [")", 284], [".", 285], ["This", 287], ["illustrates", 292], ["the", 304], ["variable", 308], ["phenotype", 317], ["of", 327], ["XK", 330], ["mutations", 333], ["and", 343], ["suggests", 347], ["the", 356], ["possibility", 360], ["that", 372], ["CAPN3", 377], ["heterozygotes", 383], ["may", 397], ["have", 401], ["their", 406], ["condition", 412], ["caused", 422], ["by", 429], ["nonallelic", 432], ["mutations", 443], ["in", 453], ["other", 456], ["unrelated", 462], ["genes", 472], [".", 477]]}
{"context": "NADPH oxidase (Nox) family enzymes are one of the main sources of cellular reactive oxygen species (ROS), which have been shown to function as second messenger molecules. To date, seven members of this family have been reported, including Nox1-5 and Duox1 and -2. With the exception of Nox2, the regulation of the Nox enzymes is still poorly understood. Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase, for its activity. In this study, we investigate the role of the tyrosine kinase c-Src in the regulation of ROS formation by Nox1. We show that c-Src induces Nox1-mediated ROS generation in the HT29 human colon carcinoma cell line through a Rac-dependent mechanism. Treatment of HT29 cells with the Src inhibitor PP2, expression of a kinase-inactive form of c-Src, and c-Src depletion by small interfering RNA (siRNA) reduce both ROS generation and the levels of active Rac1. This is associated with decreased Src-mediated phosphorylation and activation of the Rac1-guanine nucleotide exchange factor Vav2. Consistent with this, Vav2 siRNA that specifically reduces endogenous Vav2 protein is able to dramatically decrease Nox1-dependent ROS generation and abolish c-Src-induced Nox1 activity. Together, these results establish c-Src as an important regulator of Nox1 activity, and they may provide insight into the mechanisms of tumor formation in colon cancers.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "fdc8771a13204b6eb28d48a0e3f1d6c5", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[259, 259], [125, 125], [243, 243], [71, 71], [46, 46]], "char_spans": [[1353, 1356], [615, 618], [1269, 1272], [354, 357], [239, 242]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["(", 14], ["Nox", 15], [")", 18], ["family", 20], ["enzymes", 27], ["are", 35], ["one", 39], ["of", 43], ["the", 46], ["main", 50], ["sources", 55], ["of", 63], ["cellular", 66], ["reactive", 75], ["oxygen", 84], ["species", 91], ["(", 99], ["ROS", 100], [")", 103], [",", 104], ["which", 106], ["have", 112], ["been", 117], ["shown", 122], ["to", 128], ["function", 131], ["as", 140], ["second", 143], ["messenger", 150], ["molecules", 160], [".", 169], ["To", 171], ["date", 174], [",", 178], ["seven", 180], ["members", 186], ["of", 194], ["this", 197], ["family", 202], ["have", 209], ["been", 214], ["reported", 219], [",", 227], ["including", 229], ["Nox1", 239], ["-", 243], ["5", 244], ["and", 246], ["Duox1", 250], ["and", 256], ["-2", 260], [".", 262], ["With", 264], ["the", 269], ["exception", 273], ["of", 283], ["Nox2", 286], [",", 290], ["the", 292], ["regulation", 296], ["of", 307], ["the", 310], ["Nox", 314], ["enzymes", 318], ["is", 326], ["still", 329], ["poorly", 335], ["understood", 342], [".", 352], ["Nox1", 354], ["is", 359], ["highly", 362], ["expressed", 369], ["in", 379], ["the", 382], ["colon", 386], [",", 391], ["and", 393], ["it", 397], ["requires", 400], ["two", 409], ["cytosolic", 413], ["regulators", 423], [",", 433], ["NoxO1", 435], ["and", 441], ["NoxA1", 445], [",", 450], ["as", 452], ["well", 455], ["as", 460], ["the", 463], ["binding", 467], ["of", 475], ["Rac1", 478], ["GTPase", 483], [",", 489], ["for", 491], ["its", 495], ["activity", 499], [".", 507], ["In", 509], ["this", 512], ["study", 517], [",", 522], ["we", 524], ["investigate", 527], ["the", 539], ["role", 543], ["of", 548], ["the", 551], ["tyrosine", 555], ["kinase", 564], ["c", 571], ["-", 572], ["Src", 573], ["in", 577], ["the", 580], ["regulation", 584], ["of", 595], ["ROS", 598], ["formation", 602], ["by", 612], ["Nox1", 615], [".", 619], ["We", 621], ["show", 624], ["that", 629], ["c", 634], ["-", 635], ["Src", 636], ["induces", 640], ["Nox1-mediated", 648], ["ROS", 662], ["generation", 666], ["in", 677], ["the", 680], ["HT29", 684], ["human", 689], ["colon", 695], ["carcinoma", 701], ["cell", 711], ["line", 716], ["through", 721], ["a", 729], ["Rac", 731], ["-", 734], ["dependent", 735], ["mechanism", 745], [".", 754], ["Treatment", 756], ["of", 766], ["HT29", 769], ["cells", 774], ["with", 780], ["the", 785], ["Src", 789], ["inhibitor", 793], ["PP2", 803], [",", 806], ["expression", 808], ["of", 819], ["a", 822], ["kinase", 824], ["-", 830], ["inactive", 831], ["form", 840], ["of", 845], ["c", 848], ["-", 849], ["Src", 850], [",", 853], ["and", 855], ["c", 859], ["-", 860], ["Src", 861], ["depletion", 865], ["by", 875], ["small", 878], ["interfering", 884], ["RNA", 896], ["(", 900], ["siRNA", 901], [")", 906], ["reduce", 908], ["both", 915], ["ROS", 920], ["generation", 924], ["and", 935], ["the", 939], ["levels", 943], ["of", 950], ["active", 953], ["Rac1", 960], [".", 964], ["This", 966], ["is", 971], ["associated", 974], ["with", 985], ["decreased", 990], ["Src", 1000], ["-", 1003], ["mediated", 1004], ["phosphorylation", 1013], ["and", 1029], ["activation", 1033], ["of", 1044], ["the", 1047], ["Rac1-guanine", 1051], ["nucleotide", 1064], ["exchange", 1075], ["factor", 1084], ["Vav2", 1091], [".", 1095], ["Consistent", 1097], ["with", 1108], ["this", 1113], [",", 1117], ["Vav2", 1119], ["siRNA", 1124], ["that", 1130], ["specifically", 1135], ["reduces", 1148], ["endogenous", 1156], ["Vav2", 1167], ["protein", 1172], ["is", 1180], ["able", 1183], ["to", 1188], ["dramatically", 1191], ["decrease", 1204], ["Nox1-dependent", 1213], ["ROS", 1228], ["generation", 1232], ["and", 1243], ["abolish", 1247], ["c", 1255], ["-", 1256], ["Src", 1257], ["-", 1260], ["induced", 1261], ["Nox1", 1269], ["activity", 1274], [".", 1282], ["Together", 1284], [",", 1292], ["these", 1294], ["results", 1300], ["establish", 1308], ["c", 1318], ["-", 1319], ["Src", 1320], ["as", 1324], ["an", 1327], ["important", 1330], ["regulator", 1340], ["of", 1350], ["Nox1", 1353], ["activity", 1358], [",", 1366], ["and", 1368], ["they", 1372], ["may", 1377], ["provide", 1381], ["insight", 1389], ["into", 1397], ["the", 1402], ["mechanisms", 1406], ["of", 1417], ["tumor", 1420], ["formation", 1426], ["in", 1436], ["colon", 1439], ["cancers", 1445], [".", 1452]]}
{"context": "Atrial fibrillation (AF), a common cardiac arrhythmia associated with increased risk of heart failure, thromboembolic phenomena and death, is a leading cause of hospitalization of adults. A major complication of AF is an increased risk of ischemic stroke leading to long-term disability and in severe cases, death. Historically, Coumadin has been the drug of choice for chronic anticoagulation and stroke prevention in AF patients however, given the need for constant monitoring and multiple drug interactions, newer anticoagulants have been developed. One such drug is dabigatran, with the promise of less frequent monitoring and decreased bleeding tendencies as compared to Coumadin. The main disadvantage of dabigatran has been the lack of a reversal agent in case of severe bleeding or emergent surgical intervention. This was until the recent The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran. In this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "d6e9cee2def349948db2eae4577d1aaa", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[158, 158], [120, 120], [180, 180], [98, 98]], "char_spans": [[938, 947], [711, 720], [1077, 1086], [570, 579]]}]}], "context_tokens": [["Atrial", 0], ["fibrillation", 7], ["(", 20], ["AF", 21], [")", 23], [",", 24], ["a", 26], ["common", 28], ["cardiac", 35], ["arrhythmia", 43], ["associated", 54], ["with", 65], ["increased", 70], ["risk", 80], ["of", 85], ["heart", 88], ["failure", 94], [",", 101], ["thromboembolic", 103], ["phenomena", 118], ["and", 128], ["death", 132], [",", 137], ["is", 139], ["a", 142], ["leading", 144], ["cause", 152], ["of", 158], ["hospitalization", 161], ["of", 177], ["adults", 180], [".", 186], ["A", 188], ["major", 190], ["complication", 196], ["of", 209], ["AF", 212], ["is", 215], ["an", 218], ["increased", 221], ["risk", 231], ["of", 236], ["ischemic", 239], ["stroke", 248], ["leading", 255], ["to", 263], ["long", 266], ["-", 270], ["term", 271], ["disability", 276], ["and", 287], ["in", 291], ["severe", 294], ["cases", 301], [",", 306], ["death", 308], [".", 313], ["Historically", 315], [",", 327], ["Coumadin", 329], ["has", 338], ["been", 342], ["the", 347], ["drug", 351], ["of", 356], ["choice", 359], ["for", 366], ["chronic", 370], ["anticoagulation", 378], ["and", 394], ["stroke", 398], ["prevention", 405], ["in", 416], ["AF", 419], ["patients", 422], ["however", 431], [",", 438], ["given", 440], ["the", 446], ["need", 450], ["for", 455], ["constant", 459], ["monitoring", 468], ["and", 479], ["multiple", 483], ["drug", 492], ["interactions", 497], [",", 509], ["newer", 511], ["anticoagulants", 517], ["have", 532], ["been", 537], ["developed", 542], [".", 551], ["One", 553], ["such", 557], ["drug", 562], ["is", 567], ["dabigatran", 570], [",", 580], ["with", 582], ["the", 587], ["promise", 591], ["of", 599], ["less", 602], ["frequent", 607], ["monitoring", 616], ["and", 627], ["decreased", 631], ["bleeding", 641], ["tendencies", 650], ["as", 661], ["compared", 664], ["to", 673], ["Coumadin", 676], [".", 684], ["The", 686], ["main", 690], ["disadvantage", 695], ["of", 708], ["dabigatran", 711], ["has", 722], ["been", 726], ["the", 731], ["lack", 735], ["of", 740], ["a", 743], ["reversal", 745], ["agent", 754], ["in", 760], ["case", 763], ["of", 768], ["severe", 771], ["bleeding", 778], ["or", 787], ["emergent", 790], ["surgical", 799], ["intervention", 808], [".", 820], ["This", 822], ["was", 827], ["until", 831], ["the", 837], ["recent", 841], ["The", 848], ["Food", 852], ["and", 857], ["Drug", 861], ["Administration", 866], ["approval", 881], ["of", 890], ["idarucizumab", 893], [",", 905], ["a", 907], ["potential", 909], ["reversal", 919], ["agent", 928], ["for", 934], ["dabigatran", 938], [".", 948], ["In", 950], ["this", 953], ["article", 958], [",", 965], ["we", 967], ["discuss", 970], ["the", 978], ["evidence", 982], ["addressing", 991], ["idarucizumab", 1002], ["safety", 1015], [",", 1021], ["tolerability", 1023], ["and", 1036], ["its", 1040], ["efficacy", 1044], ["for", 1053], ["reversing", 1057], ["effect", 1067], ["of", 1074], ["dabigatran", 1077], [".", 1087]]}
{"context": "Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Noxa1. However, the role of the small GTPase Rac remained to be clarified. Here we show that Rac directly participates in Nox1 activation via interacting with Noxa1. Electropermeabilized HeLa cells, ectopically expressing Nox1, Noxo1, and Noxa1, produce superoxide in a GTP-dependent manner, which is abrogated by expression of a mutant Noxa1(R103E), defective in Rac binding. Superoxide production in Nox1-expressing HeLa and Caco-2 cells is decreased by depletion or sequestration of Rac; on the other hand, it is enhanced by expression of the constitutively active Rac1(Q61L), but not by that of a mutant Rac1 with the A27K substitution, deficient in binding to Noxa1. We also demonstrate that Nox1 activation requires membrane recruitment of Noxa1, which is normally mediated via Noxa1 binding to Noxo1, a protein tethered to the Nox1 partner p22(phox): the Noxa1-Noxo1 and Noxo1-p22(phox) interactions are both essential for Nox1 activity. Rac likely facilitates the membrane localization of Noxa1: although Noxa1(W436R), defective in Noxo1 binding, neither associates with the membrane nor activates Nox1, the effects of the W436R substitution are restored by expression of Rac1(Q61L). The Rac-Noxa1 interaction also serves at a step different from the Noxa1 localization, because the binding-defective Noxa1(R103E), albeit targeted to the membrane, does not support superoxide production by Nox1. Furthermore, a mutant Noxa1 carrying the substitution of Ala for Val-205 in the activation domain, which is expected to undergo a conformational change upon Rac binding, fully localizes to the membrane but fails to activate Nox1.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "7b72b7fbe25641d2afc299fbcc7284d8", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[11, 11], [155, 155], [221, 221], [52, 52], [313, 313], [178, 178], [273, 273], [193, 193], [65, 65]], "char_spans": [[68, 71], [864, 867], [1273, 1276], [289, 292], [1795, 1798], [1001, 1004], [1565, 1568], [1097, 1100], [389, 392]]}]}], "context_tokens": [["Activation", 0], ["of", 11], ["the", 14], ["non", 18], ["-", 21], ["phagocytic", 22], ["superoxide", 33], ["-", 43], ["producing", 44], ["NADPH", 54], ["oxidase", 60], ["Nox1", 68], [",", 72], ["complexed", 74], ["with", 84], ["p22(phox", 89], [")", 97], ["at", 99], ["the", 102], ["membrane", 106], [",", 114], ["requires", 116], ["its", 125], ["regulatory", 129], ["soluble", 140], ["proteins", 148], ["Noxo1", 157], ["and", 163], ["Noxa1", 167], [".", 172], ["However", 174], [",", 181], ["the", 183], ["role", 187], ["of", 192], ["the", 195], ["small", 199], ["GTPase", 205], ["Rac", 212], ["remained", 216], ["to", 225], ["be", 228], ["clarified", 231], [".", 240], ["Here", 242], ["we", 247], ["show", 250], ["that", 255], ["Rac", 260], ["directly", 264], ["participates", 273], ["in", 286], ["Nox1", 289], ["activation", 294], ["via", 305], ["interacting", 309], ["with", 321], ["Noxa1", 326], [".", 331], ["Electropermeabilized", 333], ["HeLa", 354], ["cells", 359], [",", 364], ["ectopically", 366], ["expressing", 378], ["Nox1", 389], [",", 393], ["Noxo1", 395], [",", 400], ["and", 402], ["Noxa1", 406], [",", 411], ["produce", 413], ["superoxide", 421], ["in", 432], ["a", 435], ["GTP", 437], ["-", 440], ["dependent", 441], ["manner", 451], [",", 457], ["which", 459], ["is", 465], ["abrogated", 468], ["by", 478], ["expression", 481], ["of", 492], ["a", 495], ["mutant", 497], ["Noxa1(R103E", 504], [")", 515], [",", 516], ["defective", 518], ["in", 528], ["Rac", 531], ["binding", 535], [".", 542], ["Superoxide", 544], ["production", 555], ["in", 566], ["Nox1-expressing", 569], ["HeLa", 585], ["and", 590], ["Caco-2", 594], ["cells", 601], ["is", 607], ["decreased", 610], ["by", 620], ["depletion", 623], ["or", 633], ["sequestration", 636], ["of", 650], ["Rac", 653], [";", 656], ["on", 658], ["the", 661], ["other", 665], ["hand", 671], [",", 675], ["it", 677], ["is", 680], ["enhanced", 683], ["by", 692], ["expression", 695], ["of", 706], ["the", 709], ["constitutively", 713], ["active", 728], ["Rac1(Q61L", 735], [")", 744], [",", 745], ["but", 747], ["not", 751], ["by", 755], ["that", 758], ["of", 763], ["a", 766], ["mutant", 768], ["Rac1", 775], ["with", 780], ["the", 785], ["A27", 789], ["K", 792], ["substitution", 794], [",", 806], ["deficient", 808], ["in", 818], ["binding", 821], ["to", 829], ["Noxa1", 832], [".", 837], ["We", 839], ["also", 842], ["demonstrate", 847], ["that", 859], ["Nox1", 864], ["activation", 869], ["requires", 880], ["membrane", 889], ["recruitment", 898], ["of", 910], ["Noxa1", 913], [",", 918], ["which", 920], ["is", 926], ["normally", 929], ["mediated", 938], ["via", 947], ["Noxa1", 951], ["binding", 957], ["to", 965], ["Noxo1", 968], [",", 973], ["a", 975], ["protein", 977], ["tethered", 985], ["to", 994], ["the", 997], ["Nox1", 1001], ["partner", 1006], ["p22(phox", 1014], [")", 1022], [":", 1023], ["the", 1025], ["Noxa1-Noxo1", 1029], ["and", 1041], ["Noxo1-p22(phox", 1045], [")", 1059], ["interactions", 1061], ["are", 1074], ["both", 1078], ["essential", 1083], ["for", 1093], ["Nox1", 1097], ["activity", 1102], [".", 1110], ["Rac", 1112], ["likely", 1116], ["facilitates", 1123], ["the", 1135], ["membrane", 1139], ["localization", 1148], ["of", 1161], ["Noxa1", 1164], [":", 1169], ["although", 1171], ["Noxa1(W436R", 1180], [")", 1191], [",", 1192], ["defective", 1194], ["in", 1204], ["Noxo1", 1207], ["binding", 1213], [",", 1220], ["neither", 1222], ["associates", 1230], ["with", 1241], ["the", 1246], ["membrane", 1250], ["nor", 1259], ["activates", 1263], ["Nox1", 1273], [",", 1277], ["the", 1279], ["effects", 1283], ["of", 1291], ["the", 1294], ["W436R", 1298], ["substitution", 1304], ["are", 1317], ["restored", 1321], ["by", 1330], ["expression", 1333], ["of", 1344], ["Rac1(Q61L", 1347], [")", 1356], [".", 1357], ["The", 1359], ["Rac", 1363], ["-", 1366], ["Noxa1", 1367], ["interaction", 1373], ["also", 1385], ["serves", 1390], ["at", 1397], ["a", 1400], ["step", 1402], ["different", 1407], ["from", 1417], ["the", 1422], ["Noxa1", 1426], ["localization", 1432], [",", 1444], ["because", 1446], ["the", 1454], ["binding", 1458], ["-", 1465], ["defective", 1466], ["Noxa1(R103E", 1476], [")", 1487], [",", 1488], ["albeit", 1490], ["targeted", 1497], ["to", 1506], ["the", 1509], ["membrane", 1513], [",", 1521], ["does", 1523], ["not", 1528], ["support", 1532], ["superoxide", 1540], ["production", 1551], ["by", 1562], ["Nox1", 1565], [".", 1569], ["Furthermore", 1571], [",", 1582], ["a", 1584], ["mutant", 1586], ["Noxa1", 1593], ["carrying", 1599], ["the", 1608], ["substitution", 1612], ["of", 1625], ["Ala", 1628], ["for", 1632], ["Val-205", 1636], ["in", 1644], ["the", 1647], ["activation", 1651], ["domain", 1662], [",", 1668], ["which", 1670], ["is", 1676], ["expected", 1679], ["to", 1688], ["undergo", 1691], ["a", 1699], ["conformational", 1701], ["change", 1716], ["upon", 1723], ["Rac", 1728], ["binding", 1732], [",", 1739], ["fully", 1741], ["localizes", 1747], ["to", 1757], ["the", 1760], ["membrane", 1764], ["but", 1773], ["fails", 1777], ["to", 1783], ["activate", 1786], ["Nox1", 1795], [".", 1799]]}
{"context": "Kx is lacking in the RBCs of patients with the McLeod syndrome. This condition is sometimes associated with chronic granulomatous disease (CGD). If given allogeneic RBCs, CGD patients with the McLeod phenotype may produce anti-Kx and anti-Km, and only phenotypically matched McLeod blood would be compatible. McLeod phenotype persons without CGD have made anti-Km but not anti-Kx (2 examples), and thus both McLeod and K(O) blood would be compatible. RBCs from a transfused patient with the McLeod phenotype but not with CGD (non-CGD McLeod) were typed for the Kell blood group antigens, and the plasma was analyzed for the presence of antibody by agglutination. The molecular basis was determined by analyzing for XK protein on RBC membranes by Western immunoblotting, by sequencing the XK gene, and by RFLP. The RBCs did not react with anti-Kx + anti-Km and showed weakening of Kell system antigens. The patient's plasma reacted moderately (2+) with RBCs of common Kell type and strongly (4+) with K(O) RBCs and RBCs of common Kell type treated with dithiothreitol, and did not react with McLeod RBCs. XK protein was absent from the RBC membranes. The XK gene had a point mutation in the donor splice site of intron 1 (G>C). This is the first report describing the molecular alteration in a non-CGD McLeod patient who has made anti-Kx. The immune response of people with the McLeod phenotype can vary, and K(O) blood may not always be compatible.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "ae5bb34ab378486298ab61b3973ece7b", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[232, 232], [150, 150], [222, 222], [138, 138]], "char_spans": [[1154, 1155], [788, 789], [1104, 1105], [715, 716]]}]}], "context_tokens": [["Kx", 0], ["is", 3], ["lacking", 6], ["in", 14], ["the", 17], ["RBCs", 21], ["of", 26], ["patients", 29], ["with", 38], ["the", 43], ["McLeod", 47], ["syndrome", 54], [".", 62], ["This", 64], ["condition", 69], ["is", 79], ["sometimes", 82], ["associated", 92], ["with", 103], ["chronic", 108], ["granulomatous", 116], ["disease", 130], ["(", 138], ["CGD", 139], [")", 142], [".", 143], ["If", 145], ["given", 148], ["allogeneic", 154], ["RBCs", 165], [",", 169], ["CGD", 171], ["patients", 175], ["with", 184], ["the", 189], ["McLeod", 193], ["phenotype", 200], ["may", 210], ["produce", 214], ["anti", 222], ["-", 226], ["Kx", 227], ["and", 230], ["anti", 234], ["-", 238], ["Km", 239], [",", 241], ["and", 243], ["only", 247], ["phenotypically", 252], ["matched", 267], ["McLeod", 275], ["blood", 282], ["would", 288], ["be", 294], ["compatible", 297], [".", 307], ["McLeod", 309], ["phenotype", 316], ["persons", 326], ["without", 334], ["CGD", 342], ["have", 346], ["made", 351], ["anti", 356], ["-", 360], ["Km", 361], ["but", 364], ["not", 368], ["anti", 372], ["-", 376], ["Kx", 377], ["(", 380], ["2", 381], ["examples", 383], [")", 391], [",", 392], ["and", 394], ["thus", 398], ["both", 403], ["McLeod", 408], ["and", 415], ["K(O", 419], [")", 422], ["blood", 424], ["would", 430], ["be", 436], ["compatible", 439], [".", 449], ["RBCs", 451], ["from", 456], ["a", 461], ["transfused", 463], ["patient", 474], ["with", 482], ["the", 487], ["McLeod", 491], ["phenotype", 498], ["but", 508], ["not", 512], ["with", 516], ["CGD", 521], ["(", 525], ["non", 526], ["-", 529], ["CGD", 530], ["McLeod", 534], [")", 540], ["were", 542], ["typed", 547], ["for", 553], ["the", 557], ["Kell", 561], ["blood", 566], ["group", 572], ["antigens", 578], [",", 586], ["and", 588], ["the", 592], ["plasma", 596], ["was", 603], ["analyzed", 607], ["for", 616], ["the", 620], ["presence", 624], ["of", 633], ["antibody", 636], ["by", 645], ["agglutination", 648], [".", 661], ["The", 663], ["molecular", 667], ["basis", 677], ["was", 683], ["determined", 687], ["by", 698], ["analyzing", 701], ["for", 711], ["XK", 715], ["protein", 718], ["on", 726], ["RBC", 729], ["membranes", 733], ["by", 743], ["Western", 746], ["immunoblotting", 754], [",", 768], ["by", 770], ["sequencing", 773], ["the", 784], ["XK", 788], ["gene", 791], [",", 795], ["and", 797], ["by", 801], ["RFLP", 804], [".", 808], ["The", 810], ["RBCs", 814], ["did", 819], ["not", 823], ["react", 827], ["with", 833], ["anti", 838], ["-", 842], ["Kx", 843], ["+", 846], ["anti", 848], ["-", 852], ["Km", 853], ["and", 856], ["showed", 860], ["weakening", 867], ["of", 877], ["Kell", 880], ["system", 885], ["antigens", 892], [".", 900], ["The", 902], ["patient", 906], ["'s", 913], ["plasma", 916], ["reacted", 923], ["moderately", 931], ["(", 942], ["2", 943], ["+", 944], [")", 945], ["with", 947], ["RBCs", 952], ["of", 957], ["common", 960], ["Kell", 967], ["type", 972], ["and", 977], ["strongly", 981], ["(", 990], ["4", 991], ["+", 992], [")", 993], ["with", 995], ["K(O", 1000], [")", 1003], ["RBCs", 1005], ["and", 1010], ["RBCs", 1014], ["of", 1019], ["common", 1022], ["Kell", 1029], ["type", 1034], ["treated", 1039], ["with", 1047], ["dithiothreitol", 1052], [",", 1066], ["and", 1068], ["did", 1072], ["not", 1076], ["react", 1080], ["with", 1086], ["McLeod", 1091], ["RBCs", 1098], [".", 1102], ["XK", 1104], ["protein", 1107], ["was", 1115], ["absent", 1119], ["from", 1126], ["the", 1131], ["RBC", 1135], ["membranes", 1139], [".", 1148], ["The", 1150], ["XK", 1154], ["gene", 1157], ["had", 1162], ["a", 1166], ["point", 1168], ["mutation", 1174], ["in", 1183], ["the", 1186], ["donor", 1190], ["splice", 1196], ["site", 1203], ["of", 1208], ["intron", 1211], ["1", 1218], ["(", 1220], ["G", 1221], [">", 1222], ["C", 1223], [")", 1224], [".", 1225], ["This", 1227], ["is", 1232], ["the", 1235], ["first", 1239], ["report", 1245], ["describing", 1252], ["the", 1263], ["molecular", 1267], ["alteration", 1277], ["in", 1288], ["a", 1291], ["non", 1293], ["-", 1296], ["CGD", 1297], ["McLeod", 1301], ["patient", 1308], ["who", 1316], ["has", 1320], ["made", 1324], ["anti", 1329], ["-", 1333], ["Kx", 1334], [".", 1336], ["The", 1338], ["immune", 1342], ["response", 1349], ["of", 1358], ["people", 1361], ["with", 1368], ["the", 1373], ["McLeod", 1377], ["phenotype", 1384], ["can", 1394], ["vary", 1398], [",", 1402], ["and", 1404], ["K(O", 1408], [")", 1411], ["blood", 1413], ["may", 1419], ["not", 1423], ["always", 1427], ["be", 1434], ["compatible", 1437], [".", 1447]]}
{"context": "The identification of the alpha-synuclein gene on chromosome 4q as a locus for familial Lewy-body parkinsonism and of alpha-synuclein as a component of Lewy bodies has heralded a new era in the study of Parkinson's disease. We have identified a large family with Lewy body parkinsonism linked to a novel locus on chromosome 4p15 that does not have a mutation in the alpha-synuclein gene. Here we report the clinical and neuropathological findings in an individual from this family and describe unusual high molecular weight alpha-synuclein-immunoreactive proteins in brain homogenates from brain regions with the most marked neuropathology. Distinctive histopathology was revealed with alpha-synuclein immunostaining, including pleomorphic Lewy bodies, synuclein-positive glial inclusions and widespread, severe neuritic dystrophy. We also discuss the relationship of this familial disorder to a Lewy body disease clinical spectrum, ranging from Parkinson's disease to dementia with psychosis.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "89d94b385eb34bc8ba92ccfb2605442f", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[22, 24], [70, 72], [118, 120], [4, 6], [95, 97]], "char_spans": [[118, 132], [366, 380], [686, 700], [26, 40], [524, 538]]}]}], "context_tokens": [["The", 0], ["identification", 4], ["of", 19], ["the", 22], ["alpha", 26], ["-", 31], ["synuclein", 32], ["gene", 42], ["on", 47], ["chromosome", 50], ["4q", 61], ["as", 64], ["a", 67], ["locus", 69], ["for", 75], ["familial", 79], ["Lewy", 88], ["-", 92], ["body", 93], ["parkinsonism", 98], ["and", 111], ["of", 115], ["alpha", 118], ["-", 123], ["synuclein", 124], ["as", 134], ["a", 137], ["component", 139], ["of", 149], ["Lewy", 152], ["bodies", 157], ["has", 164], ["heralded", 168], ["a", 177], ["new", 179], ["era", 183], ["in", 187], ["the", 190], ["study", 194], ["of", 200], ["Parkinson", 203], ["'s", 212], ["disease", 215], [".", 222], ["We", 224], ["have", 227], ["identified", 232], ["a", 243], ["large", 245], ["family", 251], ["with", 258], ["Lewy", 263], ["body", 268], ["parkinsonism", 273], ["linked", 286], ["to", 293], ["a", 296], ["novel", 298], ["locus", 304], ["on", 310], ["chromosome", 313], ["4p15", 324], ["that", 329], ["does", 334], ["not", 339], ["have", 343], ["a", 348], ["mutation", 350], ["in", 359], ["the", 362], ["alpha", 366], ["-", 371], ["synuclein", 372], ["gene", 382], [".", 386], ["Here", 388], ["we", 393], ["report", 396], ["the", 403], ["clinical", 407], ["and", 416], ["neuropathological", 420], ["findings", 438], ["in", 447], ["an", 450], ["individual", 453], ["from", 464], ["this", 469], ["family", 474], ["and", 481], ["describe", 485], ["unusual", 494], ["high", 502], ["molecular", 507], ["weight", 517], ["alpha", 524], ["-", 529], ["synuclein", 530], ["-", 539], ["immunoreactive", 540], ["proteins", 555], ["in", 564], ["brain", 567], ["homogenates", 573], ["from", 585], ["brain", 590], ["regions", 596], ["with", 604], ["the", 609], ["most", 613], ["marked", 618], ["neuropathology", 625], [".", 639], ["Distinctive", 641], ["histopathology", 653], ["was", 668], ["revealed", 672], ["with", 681], ["alpha", 686], ["-", 691], ["synuclein", 692], ["immunostaining", 702], [",", 716], ["including", 718], ["pleomorphic", 728], ["Lewy", 740], ["bodies", 745], [",", 751], ["synuclein", 753], ["-", 762], ["positive", 763], ["glial", 772], ["inclusions", 778], ["and", 789], ["widespread", 793], [",", 803], ["severe", 805], ["neuritic", 812], ["dystrophy", 821], [".", 830], ["We", 832], ["also", 835], ["discuss", 840], ["the", 848], ["relationship", 852], ["of", 865], ["this", 868], ["familial", 873], ["disorder", 882], ["to", 891], ["a", 894], ["Lewy", 896], ["body", 901], ["disease", 906], ["clinical", 914], ["spectrum", 923], [",", 931], ["ranging", 933], ["from", 941], ["Parkinson", 946], ["'s", 955], ["disease", 958], ["to", 966], ["dementia", 969], ["with", 978], ["psychosis", 983], [".", 992]]}
{"context": "Ehlers-Danlos syndromes (EDS) are a heterogeneous group of hereditary connective tissue disorders characterized by joint hypermobility, widespread musculoskeletal pain and tissue fragility. Psychiatric disorders and psychosocial impairment are common, yet poorly characterized, findings in EDS patients. We investigated the frequency and types of psychiatric disorders and their relationship to systemic manifestations in a cohort of 106 classic and hypermobility type EDS patients. In this retrospective study, extensive medical chart review was performed for patients referred at two genetics clinics who were diagnosed with EDS. Statistical analysis was undertaken to determine the frequency of psychiatric disorders and association with systemic findings. Psychiatric disorders were found in 42.5% of the EDS cohort, with 22.7% of patients affected with 2 or more psychiatric diagnoses. Anxiety and depression were most commonly reported, with frequencies of 23.6 and 25.5%, respectively. A variety of other psychiatric diagnoses were also identified. Abdominal pain [odds ratio (OR) 7.38], neuropathic pain (OR 4.07), migraines (OR 5.21), joint pain (OR 2.85) and fatigue (OR 5.55) were significantly associated with the presence of a psychiatric disorder. The presence of any pain symptom was significantly associated with having a psychiatric disorder (OR 9.68). Muscle pain (OR 2.79), abdominal pain (OR 5.78), neuropathic pain (OR 3.91), migraines (OR 2.63) and fatigue (OR 3.78) were significantly associated with having an anxiety or mood disorder. Joint hypermobility and the classic dermatological features of EDS showed no significant association with having a psychiatric disorder. Our findings demonstrate a high frequency of psychiatric disorders and an association with pain symptoms in EDS.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "09a953250a1f4db4816c782183c4fa89", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14]], "char_spans": [[70, 86]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndromes", 14], ["(", 24], ["EDS", 25], [")", 28], ["are", 30], ["a", 34], ["heterogeneous", 36], ["group", 50], ["of", 56], ["hereditary", 59], ["connective", 70], ["tissue", 81], ["disorders", 88], ["characterized", 98], ["by", 112], ["joint", 115], ["hypermobility", 121], [",", 134], ["widespread", 136], ["musculoskeletal", 147], ["pain", 163], ["and", 168], ["tissue", 172], ["fragility", 179], [".", 188], ["Psychiatric", 190], ["disorders", 202], ["and", 212], ["psychosocial", 216], ["impairment", 229], ["are", 240], ["common", 244], [",", 250], ["yet", 252], ["poorly", 256], ["characterized", 263], [",", 276], ["findings", 278], ["in", 287], ["EDS", 290], ["patients", 294], [".", 302], ["We", 304], ["investigated", 307], ["the", 320], ["frequency", 324], ["and", 334], ["types", 338], ["of", 344], ["psychiatric", 347], ["disorders", 359], ["and", 369], ["their", 373], ["relationship", 379], ["to", 392], ["systemic", 395], ["manifestations", 404], ["in", 419], ["a", 422], ["cohort", 424], ["of", 431], ["106", 434], ["classic", 438], ["and", 446], ["hypermobility", 450], ["type", 464], ["EDS", 469], ["patients", 473], [".", 481], ["In", 483], ["this", 486], ["retrospective", 491], ["study", 505], [",", 510], ["extensive", 512], ["medical", 522], ["chart", 530], ["review", 536], ["was", 543], ["performed", 547], ["for", 557], ["patients", 561], ["referred", 570], ["at", 579], ["two", 582], ["genetics", 586], ["clinics", 595], ["who", 603], ["were", 607], ["diagnosed", 612], ["with", 622], ["EDS", 627], [".", 630], ["Statistical", 632], ["analysis", 644], ["was", 653], ["undertaken", 657], ["to", 668], ["determine", 671], ["the", 681], ["frequency", 685], ["of", 695], ["psychiatric", 698], ["disorders", 710], ["and", 720], ["association", 724], ["with", 736], ["systemic", 741], ["findings", 750], [".", 758], ["Psychiatric", 760], ["disorders", 772], ["were", 782], ["found", 787], ["in", 793], ["42.5", 796], ["%", 800], ["of", 802], ["the", 805], ["EDS", 809], ["cohort", 813], [",", 819], ["with", 821], ["22.7", 826], ["%", 830], ["of", 832], ["patients", 835], ["affected", 844], ["with", 853], ["2", 858], ["or", 860], ["more", 863], ["psychiatric", 868], ["diagnoses", 880], [".", 889], ["Anxiety", 891], ["and", 899], ["depression", 903], ["were", 914], ["most", 919], ["commonly", 924], ["reported", 933], [",", 941], ["with", 943], ["frequencies", 948], ["of", 960], ["23.6", 963], ["and", 968], ["25.5", 972], ["%", 976], [",", 977], ["respectively", 979], [".", 991], ["A", 993], ["variety", 995], ["of", 1003], ["other", 1006], ["psychiatric", 1012], ["diagnoses", 1024], ["were", 1034], ["also", 1039], ["identified", 1044], [".", 1054], ["Abdominal", 1056], ["pain", 1066], ["[", 1071], ["odds", 1072], ["ratio", 1077], ["(", 1083], ["OR", 1084], [")", 1086], ["7.38", 1088], ["]", 1092], [",", 1093], ["neuropathic", 1095], ["pain", 1107], ["(", 1112], ["OR", 1113], ["4.07", 1116], [")", 1120], [",", 1121], ["migraines", 1123], ["(", 1133], ["OR", 1134], ["5.21", 1137], [")", 1141], [",", 1142], ["joint", 1144], ["pain", 1150], ["(", 1155], ["OR", 1156], ["2.85", 1159], [")", 1163], ["and", 1165], ["fatigue", 1169], ["(", 1177], ["OR", 1178], ["5.55", 1181], [")", 1185], ["were", 1187], ["significantly", 1192], ["associated", 1206], ["with", 1217], ["the", 1222], ["presence", 1226], ["of", 1235], ["a", 1238], ["psychiatric", 1240], ["disorder", 1252], [".", 1260], ["The", 1262], ["presence", 1266], ["of", 1275], ["any", 1278], ["pain", 1282], ["symptom", 1287], ["was", 1295], ["significantly", 1299], ["associated", 1313], ["with", 1324], ["having", 1329], ["a", 1336], ["psychiatric", 1338], ["disorder", 1350], ["(", 1359], ["OR", 1360], ["9.68", 1363], [")", 1367], [".", 1368], ["Muscle", 1370], ["pain", 1377], ["(", 1382], ["OR", 1383], ["2.79", 1386], [")", 1390], [",", 1391], ["abdominal", 1393], ["pain", 1403], ["(", 1408], ["OR", 1409], ["5.78", 1412], [")", 1416], [",", 1417], ["neuropathic", 1419], ["pain", 1431], ["(", 1436], ["OR", 1437], ["3.91", 1440], [")", 1444], [",", 1445], ["migraines", 1447], ["(", 1457], ["OR", 1458], ["2.63", 1461], [")", 1465], ["and", 1467], ["fatigue", 1471], ["(", 1479], ["OR", 1480], ["3.78", 1483], [")", 1487], ["were", 1489], ["significantly", 1494], ["associated", 1508], ["with", 1519], ["having", 1524], ["an", 1531], ["anxiety", 1534], ["or", 1542], ["mood", 1545], ["disorder", 1550], [".", 1558], ["Joint", 1560], ["hypermobility", 1566], ["and", 1580], ["the", 1584], ["classic", 1588], ["dermatological", 1596], ["features", 1611], ["of", 1620], ["EDS", 1623], ["showed", 1627], ["no", 1634], ["significant", 1637], ["association", 1649], ["with", 1661], ["having", 1666], ["a", 1673], ["psychiatric", 1675], ["disorder", 1687], [".", 1695], ["Our", 1697], ["findings", 1701], ["demonstrate", 1710], ["a", 1722], ["high", 1724], ["frequency", 1729], ["of", 1739], ["psychiatric", 1742], ["disorders", 1754], ["and", 1764], ["an", 1768], ["association", 1771], ["with", 1783], ["pain", 1788], ["symptoms", 1793], ["in", 1802], ["EDS", 1805], [".", 1808]]}
{"context": "Species-specific sets of chromosomes-karyotypes-are traditionally depicted as linear ideograms with individual chromosomes represented by vertical bars. However, linear visualization has its limitations when the shared collinearity and/or chromosomal rearrangements differentiating two or more karyotypes need to be demonstrated. In these instances, circular visualization might provide easier comprehension and interpretation of inter-species chromosomal collinearity. The chromDraw graphical tool was developed as a user-friendly graphical tool for visualizing both linear and circular karyotypes based on the same input data matrix. The output graphics, saved in two different formats (EPS and SVG), can be easily imported to and modified in presentation and image-editing computer programs. The tool is freely distributed under GNU General Public License (GPL) and can be installed from Bioconductor or from the chromDraw home page.", "qas": [{"question": "Which R package is used for visualization of linear and circular karyotypes?", "answers": ["chromDraw"], "qid": "9c678887061c48e688347d3c09889e6c", "question_tokens": [["Which", 0], ["R", 6], ["package", 8], ["is", 16], ["used", 19], ["for", 24], ["visualization", 28], ["of", 42], ["linear", 45], ["and", 52], ["circular", 56], ["karyotypes", 65], ["?", 75]], "detected_answers": [{"text": "chromDraw", "token_spans": [[147, 147], [67, 67]], "char_spans": [[916, 924], [474, 482]]}]}], "context_tokens": [["Species", 0], ["-", 7], ["specific", 8], ["sets", 17], ["of", 22], ["chromosomes", 25], ["-", 36], ["karyotypes", 37], ["-", 47], ["are", 48], ["traditionally", 52], ["depicted", 66], ["as", 75], ["linear", 78], ["ideograms", 85], ["with", 95], ["individual", 100], ["chromosomes", 111], ["represented", 123], ["by", 135], ["vertical", 138], ["bars", 147], [".", 151], ["However", 153], [",", 160], ["linear", 162], ["visualization", 169], ["has", 183], ["its", 187], ["limitations", 191], ["when", 203], ["the", 208], ["shared", 212], ["collinearity", 219], ["and/or", 232], ["chromosomal", 239], ["rearrangements", 251], ["differentiating", 266], ["two", 282], ["or", 286], ["more", 289], ["karyotypes", 294], ["need", 305], ["to", 310], ["be", 313], ["demonstrated", 316], [".", 328], ["In", 330], ["these", 333], ["instances", 339], [",", 348], ["circular", 350], ["visualization", 359], ["might", 373], ["provide", 379], ["easier", 387], ["comprehension", 394], ["and", 408], ["interpretation", 412], ["of", 427], ["inter", 430], ["-", 435], ["species", 436], ["chromosomal", 444], ["collinearity", 456], [".", 468], ["The", 470], ["chromDraw", 474], ["graphical", 484], ["tool", 494], ["was", 499], ["developed", 503], ["as", 513], ["a", 516], ["user", 518], ["-", 522], ["friendly", 523], ["graphical", 532], ["tool", 542], ["for", 547], ["visualizing", 551], ["both", 563], ["linear", 568], ["and", 575], ["circular", 579], ["karyotypes", 588], ["based", 599], ["on", 605], ["the", 608], ["same", 612], ["input", 617], ["data", 623], ["matrix", 628], [".", 634], ["The", 636], ["output", 640], ["graphics", 647], [",", 655], ["saved", 657], ["in", 663], ["two", 666], ["different", 670], ["formats", 680], ["(", 688], ["EPS", 689], ["and", 693], ["SVG", 697], [")", 700], [",", 701], ["can", 703], ["be", 707], ["easily", 710], ["imported", 717], ["to", 726], ["and", 729], ["modified", 733], ["in", 742], ["presentation", 745], ["and", 758], ["image", 762], ["-", 767], ["editing", 768], ["computer", 776], ["programs", 785], [".", 793], ["The", 795], ["tool", 799], ["is", 804], ["freely", 807], ["distributed", 814], ["under", 826], ["GNU", 832], ["General", 836], ["Public", 844], ["License", 851], ["(", 859], ["GPL", 860], [")", 863], ["and", 865], ["can", 869], ["be", 873], ["installed", 876], ["from", 886], ["Bioconductor", 891], ["or", 904], ["from", 907], ["the", 912], ["chromDraw", 916], ["home", 926], ["page", 931], [".", 935]]}
{"context": "Increased nerve growth factor levels are associated with chronic pain conditions, including chronic low back pain (LBP). This study examined safety and analgesic efficacy of tanezumab, a humanized anti-nerve growth factor antibody, in adults with chronic LBP. Patients received intravenous tanezumab 200 \u03bcg/kg plus oral placebo (n=88), intravenous placebo plus oral naproxen 500 mg twice a day (n=88), or intravenous placebo plus oral placebo (n=41). Primary outcome was average LBP intensity (aLBPI) at Week 6. Secondary outcomes were proportion of patients with \u226530% or \u226550% reduction in aLBPI, Roland-Morris Disability Questionnaire and Brief Pain Inventory-short form scores, Patients' Global Assessment of LBP, Patients' Global Evaluation of study medication, and rescue medication use. Mean aLBPI change from baseline to Week 6 was greater with tanezumab vs naproxen (P=0.004) and placebo (P<0.001). Greater proportions of patients reported \u226530% and \u226550% reduction in aLBPI with tanezumab vs naproxen (P\u22640.013) and placebo (P<0.001), and greater improvements in Roland-Morris Disability Questionnaire (P<0.001) and other secondary outcomes except rescue medication use. Tanezumab was associated with adverse events (AEs) of abnormal peripheral sensation that were generally mild and resolved before study completion; however, there were no serious AEs. Nine patients (4 of whom were tanezumab-treated) discontinued due to AEs. In conclusion, tanezumab resulted in analgesic efficacy that was clinically and statistically superior to placebo and naproxen in patients with chronic LBP. Tanezumab clinical development is on regulatory hold due to AEs in osteoarthritis patients.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "b57cadd16f7a4c1795c6018b46b69e57", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[1, 3], [35, 37]], "char_spans": [[10, 28], [202, 220]]}]}], "context_tokens": [["Increased", 0], ["nerve", 10], ["growth", 16], ["factor", 23], ["levels", 30], ["are", 37], ["associated", 41], ["with", 52], ["chronic", 57], ["pain", 65], ["conditions", 70], [",", 80], ["including", 82], ["chronic", 92], ["low", 100], ["back", 104], ["pain", 109], ["(", 114], ["LBP", 115], [")", 118], [".", 119], ["This", 121], ["study", 126], ["examined", 132], ["safety", 141], ["and", 148], ["analgesic", 152], ["efficacy", 162], ["of", 171], ["tanezumab", 174], [",", 183], ["a", 185], ["humanized", 187], ["anti", 197], ["-", 201], ["nerve", 202], ["growth", 208], ["factor", 215], ["antibody", 222], [",", 230], ["in", 232], ["adults", 235], ["with", 242], ["chronic", 247], ["LBP", 255], [".", 258], ["Patients", 260], ["received", 269], ["intravenous", 278], ["tanezumab", 290], ["200", 300], ["\u03bcg", 304], ["/", 306], ["kg", 307], ["plus", 310], ["oral", 315], ["placebo", 320], ["(", 328], ["n=88", 329], [")", 333], [",", 334], ["intravenous", 336], ["placebo", 348], ["plus", 356], ["oral", 361], ["naproxen", 366], ["500", 375], ["mg", 379], ["twice", 382], ["a", 388], ["day", 390], ["(", 394], ["n=88", 395], [")", 399], [",", 400], ["or", 402], ["intravenous", 405], ["placebo", 417], ["plus", 425], ["oral", 430], ["placebo", 435], ["(", 443], ["n=41", 444], [")", 448], [".", 449], ["Primary", 451], ["outcome", 459], ["was", 467], ["average", 471], ["LBP", 479], ["intensity", 483], ["(", 493], ["aLBPI", 494], [")", 499], ["at", 501], ["Week", 504], ["6", 509], [".", 510], ["Secondary", 512], ["outcomes", 522], ["were", 531], ["proportion", 536], ["of", 547], ["patients", 550], ["with", 559], ["\u226530", 564], ["%", 567], ["or", 569], ["\u226550", 572], ["%", 575], ["reduction", 577], ["in", 587], ["aLBPI", 590], [",", 595], ["Roland", 597], ["-", 603], ["Morris", 604], ["Disability", 611], ["Questionnaire", 622], ["and", 636], ["Brief", 640], ["Pain", 646], ["Inventory", 651], ["-", 660], ["short", 661], ["form", 667], ["scores", 672], [",", 678], ["Patients", 680], ["'", 688], ["Global", 690], ["Assessment", 697], ["of", 708], ["LBP", 711], [",", 714], ["Patients", 716], ["'", 724], ["Global", 726], ["Evaluation", 733], ["of", 744], ["study", 747], ["medication", 753], [",", 763], ["and", 765], ["rescue", 769], ["medication", 776], ["use", 787], [".", 790], ["Mean", 792], ["aLBPI", 797], ["change", 803], ["from", 810], ["baseline", 815], ["to", 824], ["Week", 827], ["6", 832], ["was", 834], ["greater", 838], ["with", 846], ["tanezumab", 851], ["vs", 861], ["naproxen", 864], ["(", 873], ["P=0.004", 874], [")", 881], ["and", 883], ["placebo", 887], ["(", 895], ["P<0.001", 896], [")", 903], [".", 904], ["Greater", 906], ["proportions", 914], ["of", 926], ["patients", 929], ["reported", 938], ["\u226530", 947], ["%", 950], ["and", 952], ["\u226550", 956], ["%", 959], ["reduction", 961], ["in", 971], ["aLBPI", 974], ["with", 980], ["tanezumab", 985], ["vs", 995], ["naproxen", 998], ["(", 1007], ["P\u22640.013", 1008], [")", 1015], ["and", 1017], ["placebo", 1021], ["(", 1029], ["P<0.001", 1030], [")", 1037], [",", 1038], ["and", 1040], ["greater", 1044], ["improvements", 1052], ["in", 1065], ["Roland", 1068], ["-", 1074], ["Morris", 1075], ["Disability", 1082], ["Questionnaire", 1093], ["(", 1107], ["P<0.001", 1108], [")", 1115], ["and", 1117], ["other", 1121], ["secondary", 1127], ["outcomes", 1137], ["except", 1146], ["rescue", 1153], ["medication", 1160], ["use", 1171], [".", 1174], ["Tanezumab", 1176], ["was", 1186], ["associated", 1190], ["with", 1201], ["adverse", 1206], ["events", 1214], ["(", 1221], ["AEs", 1222], [")", 1225], ["of", 1227], ["abnormal", 1230], ["peripheral", 1239], ["sensation", 1250], ["that", 1260], ["were", 1265], ["generally", 1270], ["mild", 1280], ["and", 1285], ["resolved", 1289], ["before", 1298], ["study", 1305], ["completion", 1311], [";", 1321], ["however", 1323], [",", 1330], ["there", 1332], ["were", 1338], ["no", 1343], ["serious", 1346], ["AEs", 1354], [".", 1357], ["Nine", 1359], ["patients", 1364], ["(", 1373], ["4", 1374], ["of", 1376], ["whom", 1379], ["were", 1384], ["tanezumab", 1389], ["-", 1398], ["treated", 1399], [")", 1406], ["discontinued", 1408], ["due", 1421], ["to", 1425], ["AEs", 1428], [".", 1431], ["In", 1433], ["conclusion", 1436], [",", 1446], ["tanezumab", 1448], ["resulted", 1458], ["in", 1467], ["analgesic", 1470], ["efficacy", 1480], ["that", 1489], ["was", 1494], ["clinically", 1498], ["and", 1509], ["statistically", 1513], ["superior", 1527], ["to", 1536], ["placebo", 1539], ["and", 1547], ["naproxen", 1551], ["in", 1560], ["patients", 1563], ["with", 1572], ["chronic", 1577], ["LBP", 1585], [".", 1588], ["Tanezumab", 1590], ["clinical", 1600], ["development", 1609], ["is", 1621], ["on", 1624], ["regulatory", 1627], ["hold", 1638], ["due", 1643], ["to", 1647], ["AEs", 1650], ["in", 1654], ["osteoarthritis", 1657], ["patients", 1672], [".", 1680]]}
{"context": "Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to evaluate the tolerability, pharmacokinetics (including the effect of food) and pharmacodynamics (effect on COMT activity) following single oral doses of opicapone in young healthy male volunteers. Single rising oral doses of opicapone (10, 25, 50, 100, 200, 400, 800 and 1,200 mg) were administered to eight groups of eight subjects per group (two subjects randomized to placebo and six subjects to opicapone), under a double-blind, randomized, placebo-controlled design. In an additional group of 12 subjects, a 50 mg single dose of opicapone was administered on two occasions, once having fasted overnight and once with a high-fat high-calorie meal. Opicapone was well tolerated at all doses tested. The extent of systemic exposure (area under the plasma concentration-time curve and maximum plasma concentration) to opicapone and metabolites increased in an approximately dose-proportional manner and showed a decrease following concomitant ingestion of a high-fat high-calorie meal. The apparent terminal elimination half-life of opicapone was 0.8-3.2 h. Sulphation appeared to be the main metabolic pathway for opicapone, and both opicapone and the main sulphated metabolite are likely excreted by the biliary route. Maximum COMT inhibition by opicapone was dose dependent, ranged from 36.1% (10 mg) to 100% (200 mg and above), and reached statistical significance at all doses tested. The long duration of COMT inhibition by opicapone, however, tended to be independent from the dose taken. The observed half-life of opicapone-induced COMT inhibition in human erythrocytes was 61.6 h (standard deviation [SD] = 37.6 h), which reflects an underlying dissociative process with a kinetic rate constant of 3.1 \u00d7 10(-6) s(-1) (SD = 1.9 \u00d7 10(-6) s(-1)). Such a process compares well to the estimated dissociation rate constant (k(off)) of the COMT-opicapone molecular complex (k(off) = 1.9 \u00d7 10(-6) s(-1)). Opicapone was well-tolerated and presented dose-proportional kinetics. Opicapone demonstrated marked and sustained inhibition of erythrocyte soluble COMT activity. Based on the observation that the half-life of COMT inhibition is independent of the dose and that it reflects an underlying kinetic process that is consistent with the k(off) value of the COMT-opicapone complex, we propose that the sustained COMT inhibition, far beyond the observable point of clearance of circulating drug, is due to the long residence time of the reversible complex formed between COMT and opicapone. Globally, these promising results provide a basis for further clinical development of opicapone.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "27c5cce16a694b1292f9a384c43beab6", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[4, 8]], "char_spans": [[21, 48]]}]}], "context_tokens": [["Opicapone", 0], ["is", 10], ["a", 13], ["novel", 15], ["catechol", 21], ["-", 29], ["O", 30], ["-", 31], ["methyltransferase", 32], ["(", 50], ["COMT", 51], [")", 55], ["inhibitor", 57], [".", 66], ["The", 68], ["purpose", 72], ["of", 80], ["this", 83], ["study", 88], ["was", 94], ["to", 98], ["evaluate", 101], ["the", 110], ["tolerability", 114], [",", 126], ["pharmacokinetics", 128], ["(", 145], ["including", 146], ["the", 156], ["effect", 160], ["of", 167], ["food", 170], [")", 174], ["and", 176], ["pharmacodynamics", 180], ["(", 197], ["effect", 198], ["on", 205], ["COMT", 208], ["activity", 213], [")", 221], ["following", 223], ["single", 233], ["oral", 240], ["doses", 245], ["of", 251], ["opicapone", 254], ["in", 264], ["young", 267], ["healthy", 273], ["male", 281], ["volunteers", 286], [".", 296], ["Single", 298], ["rising", 305], ["oral", 312], ["doses", 317], ["of", 323], ["opicapone", 326], ["(", 336], ["10", 337], [",", 339], ["25", 341], [",", 343], ["50", 345], [",", 347], ["100", 349], [",", 352], ["200", 354], [",", 357], ["400", 359], [",", 362], ["800", 364], ["and", 368], ["1,200", 372], ["mg", 378], [")", 380], ["were", 382], ["administered", 387], ["to", 400], ["eight", 403], ["groups", 409], ["of", 416], ["eight", 419], ["subjects", 425], ["per", 434], ["group", 438], ["(", 444], ["two", 445], ["subjects", 449], ["randomized", 458], ["to", 469], ["placebo", 472], ["and", 480], ["six", 484], ["subjects", 488], ["to", 497], ["opicapone", 500], [")", 509], [",", 510], ["under", 512], ["a", 518], ["double", 520], ["-", 526], ["blind", 527], [",", 532], ["randomized", 534], [",", 544], ["placebo", 546], ["-", 553], ["controlled", 554], ["design", 565], [".", 571], ["In", 573], ["an", 576], ["additional", 579], ["group", 590], ["of", 596], ["12", 599], ["subjects", 602], [",", 610], ["a", 612], ["50", 614], ["mg", 617], ["single", 620], ["dose", 627], ["of", 632], ["opicapone", 635], ["was", 645], ["administered", 649], ["on", 662], ["two", 665], ["occasions", 669], [",", 678], ["once", 680], ["having", 685], ["fasted", 692], ["overnight", 699], ["and", 709], ["once", 713], ["with", 718], ["a", 723], ["high", 725], ["-", 729], ["fat", 730], ["high", 734], ["-", 738], ["calorie", 739], ["meal", 747], [".", 751], ["Opicapone", 753], ["was", 763], ["well", 767], ["tolerated", 772], ["at", 782], ["all", 785], ["doses", 789], ["tested", 795], [".", 801], ["The", 803], ["extent", 807], ["of", 814], ["systemic", 817], ["exposure", 826], ["(", 835], ["area", 836], ["under", 841], ["the", 847], ["plasma", 851], ["concentration", 858], ["-", 871], ["time", 872], ["curve", 877], ["and", 883], ["maximum", 887], ["plasma", 895], ["concentration", 902], [")", 915], ["to", 917], ["opicapone", 920], ["and", 930], ["metabolites", 934], ["increased", 946], ["in", 956], ["an", 959], ["approximately", 962], ["dose", 976], ["-", 980], ["proportional", 981], ["manner", 994], ["and", 1001], ["showed", 1005], ["a", 1012], ["decrease", 1014], ["following", 1023], ["concomitant", 1033], ["ingestion", 1045], ["of", 1055], ["a", 1058], ["high", 1060], ["-", 1064], ["fat", 1065], ["high", 1069], ["-", 1073], ["calorie", 1074], ["meal", 1082], [".", 1086], ["The", 1088], ["apparent", 1092], ["terminal", 1101], ["elimination", 1110], ["half", 1122], ["-", 1126], ["life", 1127], ["of", 1132], ["opicapone", 1135], ["was", 1145], ["0.8", 1149], ["-", 1152], ["3.2", 1153], ["h.", 1157], ["Sulphation", 1160], ["appeared", 1171], ["to", 1180], ["be", 1183], ["the", 1186], ["main", 1190], ["metabolic", 1195], ["pathway", 1205], ["for", 1213], ["opicapone", 1217], [",", 1226], ["and", 1228], ["both", 1232], ["opicapone", 1237], ["and", 1247], ["the", 1251], ["main", 1255], ["sulphated", 1260], ["metabolite", 1270], ["are", 1281], ["likely", 1285], ["excreted", 1292], ["by", 1301], ["the", 1304], ["biliary", 1308], ["route", 1316], [".", 1321], ["Maximum", 1323], ["COMT", 1331], ["inhibition", 1336], ["by", 1347], ["opicapone", 1350], ["was", 1360], ["dose", 1364], ["dependent", 1369], [",", 1378], ["ranged", 1380], ["from", 1387], ["36.1", 1392], ["%", 1396], ["(", 1398], ["10", 1399], ["mg", 1402], [")", 1404], ["to", 1406], ["100", 1409], ["%", 1412], ["(", 1414], ["200", 1415], ["mg", 1419], ["and", 1422], ["above", 1426], [")", 1431], [",", 1432], ["and", 1434], ["reached", 1438], ["statistical", 1446], ["significance", 1458], ["at", 1471], ["all", 1474], ["doses", 1478], ["tested", 1484], [".", 1490], ["The", 1492], ["long", 1496], ["duration", 1501], ["of", 1510], ["COMT", 1513], ["inhibition", 1518], ["by", 1529], ["opicapone", 1532], [",", 1541], ["however", 1543], [",", 1550], ["tended", 1552], ["to", 1559], ["be", 1562], ["independent", 1565], ["from", 1577], ["the", 1582], ["dose", 1586], ["taken", 1591], [".", 1596], ["The", 1598], ["observed", 1602], ["half", 1611], ["-", 1615], ["life", 1616], ["of", 1621], ["opicapone", 1624], ["-", 1633], ["induced", 1634], ["COMT", 1642], ["inhibition", 1647], ["in", 1658], ["human", 1661], ["erythrocytes", 1667], ["was", 1680], ["61.6", 1684], ["h", 1689], ["(", 1691], ["standard", 1692], ["deviation", 1701], ["[", 1711], ["SD", 1712], ["]", 1714], ["=", 1716], ["37.6", 1718], ["h", 1723], [")", 1724], [",", 1725], ["which", 1727], ["reflects", 1733], ["an", 1742], ["underlying", 1745], ["dissociative", 1756], ["process", 1769], ["with", 1777], ["a", 1782], ["kinetic", 1784], ["rate", 1792], ["constant", 1797], ["of", 1806], ["3.1", 1809], ["\u00d7", 1813], ["10(-6", 1815], [")", 1820], ["s(-1", 1822], [")", 1826], ["(", 1828], ["SD", 1829], ["=", 1832], ["1.9", 1834], ["\u00d7", 1838], ["10(-6", 1840], [")", 1845], ["s(-1", 1847], [")", 1851], [")", 1852], [".", 1853], ["Such", 1855], ["a", 1860], ["process", 1862], ["compares", 1870], ["well", 1879], ["to", 1884], ["the", 1887], ["estimated", 1891], ["dissociation", 1901], ["rate", 1914], ["constant", 1919], ["(", 1928], ["k(off", 1929], [")", 1934], [")", 1935], ["of", 1937], ["the", 1940], ["COMT", 1944], ["-", 1948], ["opicapone", 1949], ["molecular", 1959], ["complex", 1969], ["(", 1977], ["k(off", 1978], [")", 1983], ["=", 1985], ["1.9", 1987], ["\u00d7", 1991], ["10(-6", 1993], [")", 1998], ["s(-1", 2000], [")", 2004], [")", 2005], [".", 2006], ["Opicapone", 2008], ["was", 2018], ["well", 2022], ["-", 2026], ["tolerated", 2027], ["and", 2037], ["presented", 2041], ["dose", 2051], ["-", 2055], ["proportional", 2056], ["kinetics", 2069], [".", 2077], ["Opicapone", 2079], ["demonstrated", 2089], ["marked", 2102], ["and", 2109], ["sustained", 2113], ["inhibition", 2123], ["of", 2134], ["erythrocyte", 2137], ["soluble", 2149], ["COMT", 2157], ["activity", 2162], [".", 2170], ["Based", 2172], ["on", 2178], ["the", 2181], ["observation", 2185], ["that", 2197], ["the", 2202], ["half", 2206], ["-", 2210], ["life", 2211], ["of", 2216], ["COMT", 2219], ["inhibition", 2224], ["is", 2235], ["independent", 2238], ["of", 2250], ["the", 2253], ["dose", 2257], ["and", 2262], ["that", 2266], ["it", 2271], ["reflects", 2274], ["an", 2283], ["underlying", 2286], ["kinetic", 2297], ["process", 2305], ["that", 2313], ["is", 2318], ["consistent", 2321], ["with", 2332], ["the", 2337], ["k(off", 2341], [")", 2346], ["value", 2348], ["of", 2354], ["the", 2357], ["COMT", 2361], ["-", 2365], ["opicapone", 2366], ["complex", 2376], [",", 2383], ["we", 2385], ["propose", 2388], ["that", 2396], ["the", 2401], ["sustained", 2405], ["COMT", 2415], ["inhibition", 2420], [",", 2430], ["far", 2432], ["beyond", 2436], ["the", 2443], ["observable", 2447], ["point", 2458], ["of", 2464], ["clearance", 2467], ["of", 2477], ["circulating", 2480], ["drug", 2492], [",", 2496], ["is", 2498], ["due", 2501], ["to", 2505], ["the", 2508], ["long", 2512], ["residence", 2517], ["time", 2527], ["of", 2532], ["the", 2535], ["reversible", 2539], ["complex", 2550], ["formed", 2558], ["between", 2565], ["COMT", 2573], ["and", 2578], ["opicapone", 2582], [".", 2591], ["Globally", 2593], [",", 2601], ["these", 2603], ["promising", 2609], ["results", 2619], ["provide", 2627], ["a", 2635], ["basis", 2637], ["for", 2643], ["further", 2647], ["clinical", 2655], ["development", 2664], ["of", 2676], ["opicapone", 2679], [".", 2688]]}
{"context": "The selective degradation of cytosolic proteins in lysosomes by chaperone-mediated autophagy depends, at least in part, on the levels of a substrate receptor at the lysosomal membrane. We have previously identified this receptor as the lysosome-associated membrane protein type 2a (lamp2a) and showed that levels of lamp2a at the lysosomal membrane directly correlate with the activity of the proteolytic pathway. Here we show that levels of lamp2a at the lysosomal membrane are mainly controlled by changes in its half-life and its distribution between the lysosomal membrane and the matrix. The lysosomal degradation of lamp2a requires the combined action of at least two different proteolytic activities at the lysosomal membrane. Lamp2a is released from the membrane by the action of these proteases, and then the truncated lamp2a is rapidly degraded within the lysosomal matrix. Membrane degradation of lamp2a is a regulated process that is inhibited in the presence of substrates for chaperone-mediated autophagy and under conditions that activate that type of autophagy. Uptake of substrate proteins also results in transport of some intact lamp2a from the lysosomal membrane into the matrix. This fraction of lamp2a can be reinserted back into the lysosomal membrane. The traffic of lamp2a through the lysosomal matrix is not mediated by vesicles, and lamp2a reinsertion requires the lysosomal membrane potential and protein components of the lysosomal membrane. The distribution of lamp2a between the lysosomal membrane and matrix is a dynamic process that contributes to the regulation of lysosomal membrane levels of lamp2a and consequently to the activity of the chaperone-mediated autophagic pathway.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "f33d6fecbf754206bd68d7fc7adad530", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[48, 48], [123, 123], [203, 203], [106, 106], [246, 246], [267, 267], [76, 76], [140, 140], [55, 55], [228, 228], [152, 152], [216, 216], [191, 191]], "char_spans": [[282, 287], [734, 739], [1217, 1222], [622, 627], [1491, 1496], [1628, 1633], [442, 447], [828, 833], [316, 321], [1360, 1365], [908, 913], [1291, 1296], [1148, 1153]]}]}], "context_tokens": [["The", 0], ["selective", 4], ["degradation", 14], ["of", 26], ["cytosolic", 29], ["proteins", 39], ["in", 48], ["lysosomes", 51], ["by", 61], ["chaperone", 64], ["-", 73], ["mediated", 74], ["autophagy", 83], ["depends", 93], [",", 100], ["at", 102], ["least", 105], ["in", 111], ["part", 114], [",", 118], ["on", 120], ["the", 123], ["levels", 127], ["of", 134], ["a", 137], ["substrate", 139], ["receptor", 149], ["at", 158], ["the", 161], ["lysosomal", 165], ["membrane", 175], [".", 183], ["We", 185], ["have", 188], ["previously", 193], ["identified", 204], ["this", 215], ["receptor", 220], ["as", 229], ["the", 232], ["lysosome", 236], ["-", 244], ["associated", 245], ["membrane", 256], ["protein", 265], ["type", 273], ["2a", 278], ["(", 281], ["lamp2a", 282], [")", 288], ["and", 290], ["showed", 294], ["that", 301], ["levels", 306], ["of", 313], ["lamp2a", 316], ["at", 323], ["the", 326], ["lysosomal", 330], ["membrane", 340], ["directly", 349], ["correlate", 358], ["with", 368], ["the", 373], ["activity", 377], ["of", 386], ["the", 389], ["proteolytic", 393], ["pathway", 405], [".", 412], ["Here", 414], ["we", 419], ["show", 422], ["that", 427], ["levels", 432], ["of", 439], ["lamp2a", 442], ["at", 449], ["the", 452], ["lysosomal", 456], ["membrane", 466], ["are", 475], ["mainly", 479], ["controlled", 486], ["by", 497], ["changes", 500], ["in", 508], ["its", 511], ["half", 515], ["-", 519], ["life", 520], ["and", 525], ["its", 529], ["distribution", 533], ["between", 546], ["the", 554], ["lysosomal", 558], ["membrane", 568], ["and", 577], ["the", 581], ["matrix", 585], [".", 591], ["The", 593], ["lysosomal", 597], ["degradation", 607], ["of", 619], ["lamp2a", 622], ["requires", 629], ["the", 638], ["combined", 642], ["action", 651], ["of", 658], ["at", 661], ["least", 664], ["two", 670], ["different", 674], ["proteolytic", 684], ["activities", 696], ["at", 707], ["the", 710], ["lysosomal", 714], ["membrane", 724], [".", 732], ["Lamp2a", 734], ["is", 741], ["released", 744], ["from", 753], ["the", 758], ["membrane", 762], ["by", 771], ["the", 774], ["action", 778], ["of", 785], ["these", 788], ["proteases", 794], [",", 803], ["and", 805], ["then", 809], ["the", 814], ["truncated", 818], ["lamp2a", 828], ["is", 835], ["rapidly", 838], ["degraded", 846], ["within", 855], ["the", 862], ["lysosomal", 866], ["matrix", 876], [".", 882], ["Membrane", 884], ["degradation", 893], ["of", 905], ["lamp2a", 908], ["is", 915], ["a", 918], ["regulated", 920], ["process", 930], ["that", 938], ["is", 943], ["inhibited", 946], ["in", 956], ["the", 959], ["presence", 963], ["of", 972], ["substrates", 975], ["for", 986], ["chaperone", 990], ["-", 999], ["mediated", 1000], ["autophagy", 1009], ["and", 1019], ["under", 1023], ["conditions", 1029], ["that", 1040], ["activate", 1045], ["that", 1054], ["type", 1059], ["of", 1064], ["autophagy", 1067], [".", 1076], ["Uptake", 1078], ["of", 1085], ["substrate", 1088], ["proteins", 1098], ["also", 1107], ["results", 1112], ["in", 1120], ["transport", 1123], ["of", 1133], ["some", 1136], ["intact", 1141], ["lamp2a", 1148], ["from", 1155], ["the", 1160], ["lysosomal", 1164], ["membrane", 1174], ["into", 1183], ["the", 1188], ["matrix", 1192], [".", 1198], ["This", 1200], ["fraction", 1205], ["of", 1214], ["lamp2a", 1217], ["can", 1224], ["be", 1228], ["reinserted", 1231], ["back", 1242], ["into", 1247], ["the", 1252], ["lysosomal", 1256], ["membrane", 1266], [".", 1274], ["The", 1276], ["traffic", 1280], ["of", 1288], ["lamp2a", 1291], ["through", 1298], ["the", 1306], ["lysosomal", 1310], ["matrix", 1320], ["is", 1327], ["not", 1330], ["mediated", 1334], ["by", 1343], ["vesicles", 1346], [",", 1354], ["and", 1356], ["lamp2a", 1360], ["reinsertion", 1367], ["requires", 1379], ["the", 1388], ["lysosomal", 1392], ["membrane", 1402], ["potential", 1411], ["and", 1421], ["protein", 1425], ["components", 1433], ["of", 1444], ["the", 1447], ["lysosomal", 1451], ["membrane", 1461], [".", 1469], ["The", 1471], ["distribution", 1475], ["of", 1488], ["lamp2a", 1491], ["between", 1498], ["the", 1506], ["lysosomal", 1510], ["membrane", 1520], ["and", 1529], ["matrix", 1533], ["is", 1540], ["a", 1543], ["dynamic", 1545], ["process", 1553], ["that", 1561], ["contributes", 1566], ["to", 1578], ["the", 1581], ["regulation", 1585], ["of", 1596], ["lysosomal", 1599], ["membrane", 1609], ["levels", 1618], ["of", 1625], ["lamp2a", 1628], ["and", 1635], ["consequently", 1639], ["to", 1652], ["the", 1655], ["activity", 1659], ["of", 1668], ["the", 1671], ["chaperone", 1675], ["-", 1684], ["mediated", 1685], ["autophagic", 1694], ["pathway", 1705], [".", 1712]]}
{"context": "Human erythrocyte spectrin is an antiparallel heterodimer comprised of a 280 kDa alpha subunit and a 246 kDa beta subunit which further associates into tetramers in the red cell membrane cytoskeleton. Lateral association of the flexible rodlike monomers involves a multiple-step process that is initiated by a high affinity association near the actin-binding end of the molecule (dimer nucleation site). In this study, recombinant alpha and beta proteins comprising two or four \"spectrin type\" motifs with and without adjacent, terminal nonhomologous domains were evaluated for their relative contributions to dimer initiation, and the thermodynamic properties of these heterodimer complexes were measured. Sedimentation equilibrium studies showed that in the absence of the heterologous subunit, individual recombinant proteins formed weak homodimers (K(d) > 0.3 mM). When 2-motif (alpha20-21 and beta1-2) and 4-motif (alpha18-21 and beta1-4) recombinants lacking the terminal nonhomologous domains were paired with the complementary protein, high affinity heterodimers were formed in sedimentation equilibrium analysis. Both the alpha20-21/beta1-2 complex and the alpha20-21EF/betaABD1-2 complex showed stoichiometric binding with similar binding affinities (K(d) approximately 10 nM) using isothermal titration calorimetry. The alpha20-21/beta1-2 complex showed an enthalpy of -10 kcal/mol, while the alpha20-21EF/betaABD1-2 complex showed an enthalpy of -13 kcal/mol. Pull-down assays using alpha spectrin GST fusion proteins showed strong associations between all heterodimer complexes in physiological buffer, but all heterodimer complexes were destabilized by the presence of Triton X-100 and other detergents. Complexes lacking the nonhomologous domains were destabilized to a greater extent than complexes that included the nonhomologous domains. The detergent effect appears to be responsible for the apparent essential role of the nonhomologous domains in prior reports. Taken together, our results indicate that the terminal nonhomologous domains do not contribute to dimer initiation nor are they required for formation of high affinity spectrin heterodimers in physiological buffers.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "fe7f78eec1aa4f8ebb0a554fd87ebe06", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[5, 5]], "char_spans": [[33, 44]]}]}], "context_tokens": [["Human", 0], ["erythrocyte", 6], ["spectrin", 18], ["is", 27], ["an", 30], ["antiparallel", 33], ["heterodimer", 46], ["comprised", 58], ["of", 68], ["a", 71], ["280", 73], ["kDa", 77], ["alpha", 81], ["subunit", 87], ["and", 95], ["a", 99], ["246", 101], ["kDa", 105], ["beta", 109], ["subunit", 114], ["which", 122], ["further", 128], ["associates", 136], ["into", 147], ["tetramers", 152], ["in", 162], ["the", 165], ["red", 169], ["cell", 173], ["membrane", 178], ["cytoskeleton", 187], [".", 199], ["Lateral", 201], ["association", 209], ["of", 221], ["the", 224], ["flexible", 228], ["rodlike", 237], ["monomers", 245], ["involves", 254], ["a", 263], ["multiple", 265], ["-", 273], ["step", 274], ["process", 279], ["that", 287], ["is", 292], ["initiated", 295], ["by", 305], ["a", 308], ["high", 310], ["affinity", 315], ["association", 324], ["near", 336], ["the", 341], ["actin", 345], ["-", 350], ["binding", 351], ["end", 359], ["of", 363], ["the", 366], ["molecule", 370], ["(", 379], ["dimer", 380], ["nucleation", 386], ["site", 397], [")", 401], [".", 402], ["In", 404], ["this", 407], ["study", 412], [",", 417], ["recombinant", 419], ["alpha", 431], ["and", 437], ["beta", 441], ["proteins", 446], ["comprising", 455], ["two", 466], ["or", 470], ["four", 473], ["\"", 478], ["spectrin", 479], ["type", 488], ["\"", 492], ["motifs", 494], ["with", 501], ["and", 506], ["without", 510], ["adjacent", 518], [",", 526], ["terminal", 528], ["nonhomologous", 537], ["domains", 551], ["were", 559], ["evaluated", 564], ["for", 574], ["their", 578], ["relative", 584], ["contributions", 593], ["to", 607], ["dimer", 610], ["initiation", 616], [",", 626], ["and", 628], ["the", 632], ["thermodynamic", 636], ["properties", 650], ["of", 661], ["these", 664], ["heterodimer", 670], ["complexes", 682], ["were", 692], ["measured", 697], [".", 705], ["Sedimentation", 707], ["equilibrium", 721], ["studies", 733], ["showed", 741], ["that", 748], ["in", 753], ["the", 756], ["absence", 760], ["of", 768], ["the", 771], ["heterologous", 775], ["subunit", 788], [",", 795], ["individual", 797], ["recombinant", 808], ["proteins", 820], ["formed", 829], ["weak", 836], ["homodimers", 841], ["(", 852], ["K(d", 853], [")", 856], [">", 858], ["0.3", 860], ["mM", 864], [")", 866], [".", 867], ["When", 869], ["2-motif", 874], ["(", 882], ["alpha20", 883], ["-", 890], ["21", 891], ["and", 894], ["beta1", 898], ["-", 903], ["2", 904], [")", 905], ["and", 907], ["4-motif", 911], ["(", 919], ["alpha18", 920], ["-", 927], ["21", 928], ["and", 931], ["beta1", 935], ["-", 940], ["4", 941], [")", 942], ["recombinants", 944], ["lacking", 957], ["the", 965], ["terminal", 969], ["nonhomologous", 978], ["domains", 992], ["were", 1000], ["paired", 1005], ["with", 1012], ["the", 1017], ["complementary", 1021], ["protein", 1035], [",", 1042], ["high", 1044], ["affinity", 1049], ["heterodimers", 1058], ["were", 1071], ["formed", 1076], ["in", 1083], ["sedimentation", 1086], ["equilibrium", 1100], ["analysis", 1112], [".", 1120], ["Both", 1122], ["the", 1127], ["alpha20", 1131], ["-", 1138], ["21/beta1", 1139], ["-", 1147], ["2", 1148], ["complex", 1150], ["and", 1158], ["the", 1162], ["alpha20", 1166], ["-", 1173], ["21EF", 1174], ["/", 1178], ["betaABD1", 1179], ["-", 1187], ["2", 1188], ["complex", 1190], ["showed", 1198], ["stoichiometric", 1205], ["binding", 1220], ["with", 1228], ["similar", 1233], ["binding", 1241], ["affinities", 1249], ["(", 1260], ["K(d", 1261], [")", 1264], ["approximately", 1266], ["10", 1280], ["nM", 1283], [")", 1285], ["using", 1287], ["isothermal", 1293], ["titration", 1304], ["calorimetry", 1314], [".", 1325], ["The", 1327], ["alpha20", 1331], ["-", 1338], ["21/beta1", 1339], ["-", 1347], ["2", 1348], ["complex", 1350], ["showed", 1358], ["an", 1365], ["enthalpy", 1368], ["of", 1377], ["-10", 1380], ["kcal", 1384], ["/", 1388], ["mol", 1389], [",", 1392], ["while", 1394], ["the", 1400], ["alpha20", 1404], ["-", 1411], ["21EF", 1412], ["/", 1416], ["betaABD1", 1417], ["-", 1425], ["2", 1426], ["complex", 1428], ["showed", 1436], ["an", 1443], ["enthalpy", 1446], ["of", 1455], ["-13", 1458], ["kcal", 1462], ["/", 1466], ["mol", 1467], [".", 1470], ["Pull", 1472], ["-", 1476], ["down", 1477], ["assays", 1482], ["using", 1489], ["alpha", 1495], ["spectrin", 1501], ["GST", 1510], ["fusion", 1514], ["proteins", 1521], ["showed", 1530], ["strong", 1537], ["associations", 1544], ["between", 1557], ["all", 1565], ["heterodimer", 1569], ["complexes", 1581], ["in", 1591], ["physiological", 1594], ["buffer", 1608], [",", 1614], ["but", 1616], ["all", 1620], ["heterodimer", 1624], ["complexes", 1636], ["were", 1646], ["destabilized", 1651], ["by", 1664], ["the", 1667], ["presence", 1671], ["of", 1680], ["Triton", 1683], ["X-100", 1690], ["and", 1696], ["other", 1700], ["detergents", 1706], [".", 1716], ["Complexes", 1718], ["lacking", 1728], ["the", 1736], ["nonhomologous", 1740], ["domains", 1754], ["were", 1762], ["destabilized", 1767], ["to", 1780], ["a", 1783], ["greater", 1785], ["extent", 1793], ["than", 1800], ["complexes", 1805], ["that", 1815], ["included", 1820], ["the", 1829], ["nonhomologous", 1833], ["domains", 1847], [".", 1854], ["The", 1856], ["detergent", 1860], ["effect", 1870], ["appears", 1877], ["to", 1885], ["be", 1888], ["responsible", 1891], ["for", 1903], ["the", 1907], ["apparent", 1911], ["essential", 1920], ["role", 1930], ["of", 1935], ["the", 1938], ["nonhomologous", 1942], ["domains", 1956], ["in", 1964], ["prior", 1967], ["reports", 1973], [".", 1980], ["Taken", 1982], ["together", 1988], [",", 1996], ["our", 1998], ["results", 2002], ["indicate", 2010], ["that", 2019], ["the", 2024], ["terminal", 2028], ["nonhomologous", 2037], ["domains", 2051], ["do", 2059], ["not", 2062], ["contribute", 2066], ["to", 2077], ["dimer", 2080], ["initiation", 2086], ["nor", 2097], ["are", 2101], ["they", 2105], ["required", 2110], ["for", 2119], ["formation", 2123], ["of", 2133], ["high", 2136], ["affinity", 2141], ["spectrin", 2150], ["heterodimers", 2159], ["in", 2172], ["physiological", 2175], ["buffers", 2189], [".", 2196]]}
{"context": "Willis-Ekbom disease (WED), also called restless legs syndrome (RLS), is a neurologic sensorimotor disease that may be associated with cardiovascular disease. Given high morbidity and mortality rates of cardiovascular disease worldwide, we assessed the relation between WED/RLS and cardiovascular health risks in a native South American population. We prospectively analyzed data from The Atahualpa Project of Ecuadorian adults aged 40\u00a0years and older. Physicians interviewed consented persons on the health behavior and health factors of the American Heart Association (AHA) for ideal cardiovascular health in adults and underwent fasting laboratory blood collection and blood pressure evaluation. Certified neurologists conducted face-to-face interviews using the International Restless Legs Syndrome Study Group (IRLSSG) field instrument. Persons testing positive for WED/RLS and age-and sex-matched controls underwent confirmatory physical examinations conducted by a neurologist and a sleep specialist to whom IRLSSG designation was blinded. Of 665 persons, 94 (14\u00a0%) tested positive in IRLSSG; 40 (6\u00a0%) had a diagnosis of WED/RLS after neurologic examination and interview. Patients with WED/RLS were younger (53.5 vs 59.9\u00a0years, P\u2009=\u2009.001), without significant differences in sex ratios. Among AHA risk factors, only obesity was significantly more prevalent among patients with WED/RLS (42.5\u00a0% vs 23.5\u00a0%, P\u2009=\u2009.01). However, after adjustment for confounders, body mass index was not significantly associated with WED/RLS. In adult Amerindians, although obesity and body mass index were associated with WED/RLS on univariate analyses, the association was not present after adjustment for confounders. No other significant associations were found between WED/RLS and AHA cardiovascular metrics.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "2218c4979008424a9f948a7b71448a42", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[125, 127], [10, 12]], "char_spans": [[780, 801], [40, 61]]}]}], "context_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["(", 21], ["WED", 22], [")", 25], [",", 26], ["also", 28], ["called", 33], ["restless", 40], ["legs", 49], ["syndrome", 54], ["(", 63], ["RLS", 64], [")", 67], [",", 68], ["is", 70], ["a", 73], ["neurologic", 75], ["sensorimotor", 86], ["disease", 99], ["that", 107], ["may", 112], ["be", 116], ["associated", 119], ["with", 130], ["cardiovascular", 135], ["disease", 150], [".", 157], ["Given", 159], ["high", 165], ["morbidity", 170], ["and", 180], ["mortality", 184], ["rates", 194], ["of", 200], ["cardiovascular", 203], ["disease", 218], ["worldwide", 226], [",", 235], ["we", 237], ["assessed", 240], ["the", 249], ["relation", 253], ["between", 262], ["WED", 270], ["/", 273], ["RLS", 274], ["and", 278], ["cardiovascular", 282], ["health", 297], ["risks", 304], ["in", 310], ["a", 313], ["native", 315], ["South", 322], ["American", 328], ["population", 337], [".", 347], ["We", 349], ["prospectively", 352], ["analyzed", 366], ["data", 375], ["from", 380], ["The", 385], ["Atahualpa", 389], ["Project", 399], ["of", 407], ["Ecuadorian", 410], ["adults", 421], ["aged", 428], ["40", 433], ["years", 436], ["and", 442], ["older", 446], [".", 451], ["Physicians", 453], ["interviewed", 464], ["consented", 476], ["persons", 486], ["on", 494], ["the", 497], ["health", 501], ["behavior", 508], ["and", 517], ["health", 521], ["factors", 528], ["of", 536], ["the", 539], ["American", 543], ["Heart", 552], ["Association", 558], ["(", 570], ["AHA", 571], [")", 574], ["for", 576], ["ideal", 580], ["cardiovascular", 586], ["health", 601], ["in", 608], ["adults", 611], ["and", 618], ["underwent", 622], ["fasting", 632], ["laboratory", 640], ["blood", 651], ["collection", 657], ["and", 668], ["blood", 672], ["pressure", 678], ["evaluation", 687], [".", 697], ["Certified", 699], ["neurologists", 709], ["conducted", 722], ["face", 732], ["-", 736], ["to", 737], ["-", 739], ["face", 740], ["interviews", 745], ["using", 756], ["the", 762], ["International", 766], ["Restless", 780], ["Legs", 789], ["Syndrome", 794], ["Study", 803], ["Group", 809], ["(", 815], ["IRLSSG", 816], [")", 822], ["field", 824], ["instrument", 830], [".", 840], ["Persons", 842], ["testing", 850], ["positive", 858], ["for", 867], ["WED", 871], ["/", 874], ["RLS", 875], ["and", 879], ["age", 883], ["-", 886], ["and", 887], ["sex", 891], ["-", 894], ["matched", 895], ["controls", 903], ["underwent", 912], ["confirmatory", 922], ["physical", 935], ["examinations", 944], ["conducted", 957], ["by", 967], ["a", 970], ["neurologist", 972], ["and", 984], ["a", 988], ["sleep", 990], ["specialist", 996], ["to", 1007], ["whom", 1010], ["IRLSSG", 1015], ["designation", 1022], ["was", 1034], ["blinded", 1038], [".", 1045], ["Of", 1047], ["665", 1050], ["persons", 1054], [",", 1061], ["94", 1063], ["(", 1066], ["14", 1067], ["%", 1070], [")", 1071], ["tested", 1073], ["positive", 1080], ["in", 1089], ["IRLSSG", 1092], [";", 1098], ["40", 1100], ["(", 1103], ["6", 1104], ["%", 1106], [")", 1107], ["had", 1109], ["a", 1113], ["diagnosis", 1115], ["of", 1125], ["WED", 1128], ["/", 1131], ["RLS", 1132], ["after", 1136], ["neurologic", 1142], ["examination", 1153], ["and", 1165], ["interview", 1169], [".", 1178], ["Patients", 1180], ["with", 1189], ["WED", 1194], ["/", 1197], ["RLS", 1198], ["were", 1202], ["younger", 1207], ["(", 1215], ["53.5", 1216], ["vs", 1221], ["59.9", 1224], ["years", 1229], [",", 1234], ["P", 1236], ["=", 1238], [".001", 1240], [")", 1244], [",", 1245], ["without", 1247], ["significant", 1255], ["differences", 1267], ["in", 1279], ["sex", 1282], ["ratios", 1286], [".", 1292], ["Among", 1294], ["AHA", 1300], ["risk", 1304], ["factors", 1309], [",", 1316], ["only", 1318], ["obesity", 1323], ["was", 1331], ["significantly", 1335], ["more", 1349], ["prevalent", 1354], ["among", 1364], ["patients", 1370], ["with", 1379], ["WED", 1384], ["/", 1387], ["RLS", 1388], ["(", 1392], ["42.5", 1393], ["%", 1398], ["vs", 1400], ["23.5", 1403], ["%", 1408], [",", 1409], ["P", 1411], ["=", 1413], [".01", 1415], [")", 1418], [".", 1419], ["However", 1421], [",", 1428], ["after", 1430], ["adjustment", 1436], ["for", 1447], ["confounders", 1451], [",", 1462], ["body", 1464], ["mass", 1469], ["index", 1474], ["was", 1480], ["not", 1484], ["significantly", 1488], ["associated", 1502], ["with", 1513], ["WED", 1518], ["/", 1521], ["RLS", 1522], [".", 1525], ["In", 1527], ["adult", 1530], ["Amerindians", 1536], [",", 1547], ["although", 1549], ["obesity", 1558], ["and", 1566], ["body", 1570], ["mass", 1575], ["index", 1580], ["were", 1586], ["associated", 1591], ["with", 1602], ["WED", 1607], ["/", 1610], ["RLS", 1611], ["on", 1615], ["univariate", 1618], ["analyses", 1629], [",", 1637], ["the", 1639], ["association", 1643], ["was", 1655], ["not", 1659], ["present", 1663], ["after", 1671], ["adjustment", 1677], ["for", 1688], ["confounders", 1692], [".", 1703], ["No", 1705], ["other", 1708], ["significant", 1714], ["associations", 1726], ["were", 1739], ["found", 1744], ["between", 1750], ["WED", 1758], ["/", 1761], ["RLS", 1762], ["and", 1766], ["AHA", 1770], ["cardiovascular", 1774], ["metrics", 1789], [".", 1796]]}
{"context": "Malaria continues to be a worldwide leading cause of morbidity and mortality, and the development of an effective malaria vaccine remains a research imperative. Of the multiple approaches that have been pursued, the RTS,S/AS01 vaccine candidate represents the most developed and clinically validated malaria vaccine formulation. Throughout its development, increasingly more effective adjuvants have been key in improving the potency of the vaccine. RTS,S-based vaccine formulations have been demonstrated to be safe, well tolerated, immunogenic, and to confer partial efficacy in both malaria-naive and -experienced adults as well as children. Further research to optimize and improve vaccine efficacy is ongoing.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "e20b24502922481885eab94b612f374d", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[99, 99], [0, 0], [19, 19], [50, 50]], "char_spans": [[586, 592], [0, 6], [114, 120], [300, 306]]}]}], "context_tokens": [["Malaria", 0], ["continues", 8], ["to", 18], ["be", 21], ["a", 24], ["worldwide", 26], ["leading", 36], ["cause", 44], ["of", 50], ["morbidity", 53], ["and", 63], ["mortality", 67], [",", 76], ["and", 78], ["the", 82], ["development", 86], ["of", 98], ["an", 101], ["effective", 104], ["malaria", 114], ["vaccine", 122], ["remains", 130], ["a", 138], ["research", 140], ["imperative", 149], [".", 159], ["Of", 161], ["the", 164], ["multiple", 168], ["approaches", 177], ["that", 188], ["have", 193], ["been", 198], ["pursued", 203], [",", 210], ["the", 212], ["RTS", 216], [",", 219], ["S", 220], ["/", 221], ["AS01", 222], ["vaccine", 227], ["candidate", 235], ["represents", 245], ["the", 256], ["most", 260], ["developed", 265], ["and", 275], ["clinically", 279], ["validated", 290], ["malaria", 300], ["vaccine", 308], ["formulation", 316], [".", 327], ["Throughout", 329], ["its", 340], ["development", 344], [",", 355], ["increasingly", 357], ["more", 370], ["effective", 375], ["adjuvants", 385], ["have", 395], ["been", 400], ["key", 405], ["in", 409], ["improving", 412], ["the", 422], ["potency", 426], ["of", 434], ["the", 437], ["vaccine", 441], [".", 448], ["RTS", 450], [",", 453], ["S", 454], ["-", 455], ["based", 456], ["vaccine", 462], ["formulations", 470], ["have", 483], ["been", 488], ["demonstrated", 493], ["to", 506], ["be", 509], ["safe", 512], [",", 516], ["well", 518], ["tolerated", 523], [",", 532], ["immunogenic", 534], [",", 545], ["and", 547], ["to", 551], ["confer", 554], ["partial", 561], ["efficacy", 569], ["in", 578], ["both", 581], ["malaria", 586], ["-", 593], ["naive", 594], ["and", 600], ["-experienced", 604], ["adults", 617], ["as", 624], ["well", 627], ["as", 632], ["children", 635], [".", 643], ["Further", 645], ["research", 653], ["to", 662], ["optimize", 665], ["and", 674], ["improve", 678], ["vaccine", 686], ["efficacy", 694], ["is", 703], ["ongoing", 706], [".", 713]]}
{"context": "Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of both hospital and community infections globally. It's important to illuminate the differences between community-acquired MRSA (CA-MRSA) and hospital-acquired MRSA (HA-MRSA), but there have been confusions on the definition, especially for the MRSA isolates identified within 48\u00a0h of admission. This study aimed to determine the molecular characteristics and virulence genes profile of CA and HA-MRSA isolates identified less than 48\u00a0h after hospital admission in our region. A total 62 MRSA isolates identified within 48\u00a0h after admission and the clinical data were collected. Antimicrobial susceptibility test (AST) of collected isolates were performed according to the guidelines of Clinical and Laboratory Standards Institute (CLSI) 2015, and staphylococcal cassette chromosome mec (SCCmec) typing, multilocus sequence typing (MLST), pulsed-field gel electrophoresis (PFGE) and virulence gene profiling were performed to explore the molecular diversity. SCCmec III and sequence type (ST) 239 were the most prevalent SCCmec type and ST in both CA and HA-MRSA groups. HA-MRSA group had higher prevalence of SCCmec III (87.2\u00a0%) and ST239 (79.5\u00a0%) compared with CA-MRSA (60.9 and 43.4\u00a0%, both P\u2009<\u20090.001), while the frequency of SCCmec IV (26.0\u00a0%) and ST59 (21.7\u00a0%) were higher in CA-MRSA than its counterpart (P\u2009<\u20090.001 and P\u2009=\u20090.003). MRSA-ST239-III was the predominant type in this study (61.3\u00a0%, 38/62), especially in HA-MRSA group (76.9\u00a0%, 30/39). However, CA-MRSA strains exhibited more diversity in genotypes in this study. Meanwhile, CA-MRSA tended to have lower resistant percentage to non-\u03b2-lactams antibiotics but more virulence genes carriage, especially the staphylococcal enterotoxins (SE) genes. Notably, seb gene was only detected in CA-MRSA isolates (52.2\u00a0%), likely a significant marker for CA-MRSA isolates. Panton-Valentine leukocidin gene (PVL) was highly detected in both groups, while appeared no significantly different between CA-MRSA (47.8\u00a0%) and HA-MRSA (43.6\u00a0%). Our findings support a difference in the molecular epidemiology and virulence genes profile of CA-MRSA and HA-MRSA. Furthermore, this study indicates a possible transmission from HA-MRSA to CA-MRSA, which may cause the overlap of the definition.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "f98dd7a57739471cb2db2af4ebffa125", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[45, 45], [437, 437], [6, 6], [454, 454], [204, 204], [300, 300], [313, 313], [441, 441], [209, 209], [381, 381], [31, 31], [60, 60], [415, 415], [103, 103], [231, 231], [35, 35], [86, 86], [458, 458], [41, 41], [265, 265], [279, 279], [407, 407], [328, 328], [367, 367]], "char_spans": [[238, 241], [2158, 2161], [45, 48], [2242, 2245], [1127, 1130], [1494, 1497], [1534, 1537], [2170, 2173], [1143, 1146], [1881, 1884], [192, 195], [314, 317], [2045, 2048], [557, 560], [1235, 1238], [201, 204], [466, 469], [2253, 2256], [229, 232], [1353, 1356], [1406, 1409], [2024, 2027], [1614, 1617], [1822, 1825]]}]}], "context_tokens": [["Methicillin", 0], ["-", 11], ["resistant", 12], ["Staphylococcus", 22], ["aureus", 37], ["(", 44], ["MRSA", 45], [")", 49], ["is", 51], ["a", 54], ["major", 56], ["cause", 62], ["of", 68], ["both", 71], ["hospital", 76], ["and", 85], ["community", 89], ["infections", 99], ["globally", 110], [".", 118], ["It", 120], ["'s", 122], ["important", 125], ["to", 135], ["illuminate", 138], ["the", 149], ["differences", 153], ["between", 165], ["community", 173], ["-", 182], ["acquired", 183], ["MRSA", 192], ["(", 197], ["CA", 198], ["-", 200], ["MRSA", 201], [")", 205], ["and", 207], ["hospital", 211], ["-", 219], ["acquired", 220], ["MRSA", 229], ["(", 234], ["HA", 235], ["-", 237], ["MRSA", 238], [")", 242], [",", 243], ["but", 245], ["there", 249], ["have", 255], ["been", 260], ["confusions", 265], ["on", 276], ["the", 279], ["definition", 283], [",", 293], ["especially", 295], ["for", 306], ["the", 310], ["MRSA", 314], ["isolates", 319], ["identified", 328], ["within", 339], ["48", 346], ["h", 349], ["of", 351], ["admission", 354], [".", 363], ["This", 365], ["study", 370], ["aimed", 376], ["to", 382], ["determine", 385], ["the", 395], ["molecular", 399], ["characteristics", 409], ["and", 425], ["virulence", 429], ["genes", 439], ["profile", 445], ["of", 453], ["CA", 456], ["and", 459], ["HA", 463], ["-", 465], ["MRSA", 466], ["isolates", 471], ["identified", 480], ["less", 491], ["than", 496], ["48", 501], ["h", 504], ["after", 506], ["hospital", 512], ["admission", 521], ["in", 531], ["our", 534], ["region", 538], [".", 544], ["A", 546], ["total", 548], ["62", 554], ["MRSA", 557], ["isolates", 562], ["identified", 571], ["within", 582], ["48", 589], ["h", 592], ["after", 594], ["admission", 600], ["and", 610], ["the", 614], ["clinical", 618], ["data", 627], ["were", 632], ["collected", 637], [".", 646], ["Antimicrobial", 648], ["susceptibility", 662], ["test", 677], ["(", 682], ["AST", 683], [")", 686], ["of", 688], ["collected", 691], ["isolates", 701], ["were", 710], ["performed", 715], ["according", 725], ["to", 735], ["the", 738], ["guidelines", 742], ["of", 753], ["Clinical", 756], ["and", 765], ["Laboratory", 769], ["Standards", 780], ["Institute", 790], ["(", 800], ["CLSI", 801], [")", 805], ["2015", 807], [",", 811], ["and", 813], ["staphylococcal", 817], ["cassette", 832], ["chromosome", 841], ["mec", 852], ["(", 856], ["SCCmec", 857], [")", 863], ["typing", 865], [",", 871], ["multilocus", 873], ["sequence", 884], ["typing", 893], ["(", 900], ["MLST", 901], [")", 905], [",", 906], ["pulsed", 908], ["-", 914], ["field", 915], ["gel", 921], ["electrophoresis", 925], ["(", 941], ["PFGE", 942], [")", 946], ["and", 948], ["virulence", 952], ["gene", 962], ["profiling", 967], ["were", 977], ["performed", 982], ["to", 992], ["explore", 995], ["the", 1003], ["molecular", 1007], ["diversity", 1017], [".", 1026], ["SCCmec", 1028], ["III", 1035], ["and", 1039], ["sequence", 1043], ["type", 1052], ["(", 1057], ["ST", 1058], [")", 1060], ["239", 1062], ["were", 1066], ["the", 1071], ["most", 1075], ["prevalent", 1080], ["SCCmec", 1090], ["type", 1097], ["and", 1102], ["ST", 1106], ["in", 1109], ["both", 1112], ["CA", 1117], ["and", 1120], ["HA", 1124], ["-", 1126], ["MRSA", 1127], ["groups", 1132], [".", 1138], ["HA", 1140], ["-", 1142], ["MRSA", 1143], ["group", 1148], ["had", 1154], ["higher", 1158], ["prevalence", 1165], ["of", 1176], ["SCCmec", 1179], ["III", 1186], ["(", 1190], ["87.2", 1191], ["%", 1196], [")", 1197], ["and", 1199], ["ST239", 1203], ["(", 1209], ["79.5", 1210], ["%", 1215], [")", 1216], ["compared", 1218], ["with", 1227], ["CA", 1232], ["-", 1234], ["MRSA", 1235], ["(", 1240], ["60.9", 1241], ["and", 1246], ["43.4", 1250], ["%", 1255], [",", 1256], ["both", 1258], ["P", 1263], ["<", 1265], ["0.001", 1267], [")", 1272], [",", 1273], ["while", 1275], ["the", 1281], ["frequency", 1285], ["of", 1295], ["SCCmec", 1298], ["IV", 1305], ["(", 1308], ["26.0", 1309], ["%", 1314], [")", 1315], ["and", 1317], ["ST59", 1321], ["(", 1326], ["21.7", 1327], ["%", 1332], [")", 1333], ["were", 1335], ["higher", 1340], ["in", 1347], ["CA", 1350], ["-", 1352], ["MRSA", 1353], ["than", 1358], ["its", 1363], ["counterpart", 1367], ["(", 1379], ["P", 1380], ["<", 1382], ["0.001", 1384], ["and", 1390], ["P", 1394], ["=", 1396], ["0.003", 1398], [")", 1403], [".", 1404], ["MRSA", 1406], ["-", 1410], ["ST239-III", 1411], ["was", 1421], ["the", 1425], ["predominant", 1429], ["type", 1441], ["in", 1446], ["this", 1449], ["study", 1454], ["(", 1460], ["61.3", 1461], ["%", 1466], [",", 1467], ["38/62", 1469], [")", 1474], [",", 1475], ["especially", 1477], ["in", 1488], ["HA", 1491], ["-", 1493], ["MRSA", 1494], ["group", 1499], ["(", 1505], ["76.9", 1506], ["%", 1511], [",", 1512], ["30/39", 1514], [")", 1519], [".", 1520], ["However", 1522], [",", 1529], ["CA", 1531], ["-", 1533], ["MRSA", 1534], ["strains", 1539], ["exhibited", 1547], ["more", 1557], ["diversity", 1562], ["in", 1572], ["genotypes", 1575], ["in", 1585], ["this", 1588], ["study", 1593], [".", 1598], ["Meanwhile", 1600], [",", 1609], ["CA", 1611], ["-", 1613], ["MRSA", 1614], ["tended", 1619], ["to", 1626], ["have", 1629], ["lower", 1634], ["resistant", 1640], ["percentage", 1650], ["to", 1661], ["non", 1664], ["-", 1667], ["\u03b2", 1668], ["-", 1669], ["lactams", 1670], ["antibiotics", 1678], ["but", 1690], ["more", 1694], ["virulence", 1699], ["genes", 1709], ["carriage", 1715], [",", 1723], ["especially", 1725], ["the", 1736], ["staphylococcal", 1740], ["enterotoxins", 1755], ["(", 1768], ["SE", 1769], [")", 1771], ["genes", 1773], [".", 1778], ["Notably", 1780], [",", 1787], ["seb", 1789], ["gene", 1793], ["was", 1798], ["only", 1802], ["detected", 1807], ["in", 1816], ["CA", 1819], ["-", 1821], ["MRSA", 1822], ["isolates", 1827], ["(", 1836], ["52.2", 1837], ["%", 1842], [")", 1843], [",", 1844], ["likely", 1846], ["a", 1853], ["significant", 1855], ["marker", 1867], ["for", 1874], ["CA", 1878], ["-", 1880], ["MRSA", 1881], ["isolates", 1886], [".", 1894], ["Panton", 1896], ["-", 1902], ["Valentine", 1903], ["leukocidin", 1913], ["gene", 1924], ["(", 1929], ["PVL", 1930], [")", 1933], ["was", 1935], ["highly", 1939], ["detected", 1946], ["in", 1955], ["both", 1958], ["groups", 1963], [",", 1969], ["while", 1971], ["appeared", 1977], ["no", 1986], ["significantly", 1989], ["different", 2003], ["between", 2013], ["CA", 2021], ["-", 2023], ["MRSA", 2024], ["(", 2029], ["47.8", 2030], ["%", 2035], [")", 2036], ["and", 2038], ["HA", 2042], ["-", 2044], ["MRSA", 2045], ["(", 2050], ["43.6", 2051], ["%", 2056], [")", 2057], [".", 2058], ["Our", 2060], ["findings", 2064], ["support", 2073], ["a", 2081], ["difference", 2083], ["in", 2094], ["the", 2097], ["molecular", 2101], ["epidemiology", 2111], ["and", 2124], ["virulence", 2128], ["genes", 2138], ["profile", 2144], ["of", 2152], ["CA", 2155], ["-", 2157], ["MRSA", 2158], ["and", 2163], ["HA", 2167], ["-", 2169], ["MRSA", 2170], [".", 2174], ["Furthermore", 2176], [",", 2187], ["this", 2189], ["study", 2194], ["indicates", 2200], ["a", 2210], ["possible", 2212], ["transmission", 2221], ["from", 2234], ["HA", 2239], ["-", 2241], ["MRSA", 2242], ["to", 2247], ["CA", 2250], ["-", 2252], ["MRSA", 2253], [",", 2257], ["which", 2259], ["may", 2265], ["cause", 2269], ["the", 2275], ["overlap", 2279], ["of", 2287], ["the", 2290], ["definition", 2294], [".", 2304]]}
{"context": "Pakistan's 2005 earthquake claimed almost 87,000 lives and displaced millions. The present study sought to assess PTSD prevalence among earthquake survivors, to evaluate its determinants, and to identify protective factors that suggest future interventions in the aftermath of disasters. In a cross-sectional survey, three districts were selected based on their proximity to the epicenter and the presence, accessibility, and security of refugees, 300 earthquake survivors were enrolled. Analysis revealed that after 30months, PTSD prevalence was high. Being female, older, unmarried, head of the family, and currently unemployed and having low income and living in temporary housing confer higher risks of PTSD. Having a high social capital and religious inclination seem to have protective, buffer effect and increase resilience against PTSD. This is the first post-quake study in Pakistan that has utilized, adapted and validated Davidson Trauma Scale in the local context. Results imply the significance of continued psychological support, of drawing on resilience factors in PTSD management. Implications and directions for future research are discussed.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "fda25d478d054f8bb5e7cf002113e5e8", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[139, 139], [85, 85], [118, 118], [181, 181], [18, 18]], "char_spans": [[839, 842], [527, 530], [707, 710], [1080, 1083], [114, 117]]}]}], "context_tokens": [["Pakistan", 0], ["'s", 8], ["2005", 11], ["earthquake", 16], ["claimed", 27], ["almost", 35], ["87,000", 42], ["lives", 49], ["and", 55], ["displaced", 59], ["millions", 69], [".", 77], ["The", 79], ["present", 83], ["study", 91], ["sought", 97], ["to", 104], ["assess", 107], ["PTSD", 114], ["prevalence", 119], ["among", 130], ["earthquake", 136], ["survivors", 147], [",", 156], ["to", 158], ["evaluate", 161], ["its", 170], ["determinants", 174], [",", 186], ["and", 188], ["to", 192], ["identify", 195], ["protective", 204], ["factors", 215], ["that", 223], ["suggest", 228], ["future", 236], ["interventions", 243], ["in", 257], ["the", 260], ["aftermath", 264], ["of", 274], ["disasters", 277], [".", 286], ["In", 288], ["a", 291], ["cross", 293], ["-", 298], ["sectional", 299], ["survey", 309], [",", 315], ["three", 317], ["districts", 323], ["were", 333], ["selected", 338], ["based", 347], ["on", 353], ["their", 356], ["proximity", 362], ["to", 372], ["the", 375], ["epicenter", 379], ["and", 389], ["the", 393], ["presence", 397], [",", 405], ["accessibility", 407], [",", 420], ["and", 422], ["security", 426], ["of", 435], ["refugees", 438], [",", 446], ["300", 448], ["earthquake", 452], ["survivors", 463], ["were", 473], ["enrolled", 478], [".", 486], ["Analysis", 488], ["revealed", 497], ["that", 506], ["after", 511], ["30months", 517], [",", 525], ["PTSD", 527], ["prevalence", 532], ["was", 543], ["high", 547], [".", 551], ["Being", 553], ["female", 559], [",", 565], ["older", 567], [",", 572], ["unmarried", 574], [",", 583], ["head", 585], ["of", 590], ["the", 593], ["family", 597], [",", 603], ["and", 605], ["currently", 609], ["unemployed", 619], ["and", 630], ["having", 634], ["low", 641], ["income", 645], ["and", 652], ["living", 656], ["in", 663], ["temporary", 666], ["housing", 676], ["confer", 684], ["higher", 691], ["risks", 698], ["of", 704], ["PTSD", 707], [".", 711], ["Having", 713], ["a", 720], ["high", 722], ["social", 727], ["capital", 734], ["and", 742], ["religious", 746], ["inclination", 756], ["seem", 768], ["to", 773], ["have", 776], ["protective", 781], [",", 791], ["buffer", 793], ["effect", 800], ["and", 807], ["increase", 811], ["resilience", 820], ["against", 831], ["PTSD", 839], [".", 843], ["This", 845], ["is", 850], ["the", 853], ["first", 857], ["post", 863], ["-", 867], ["quake", 868], ["study", 874], ["in", 880], ["Pakistan", 883], ["that", 892], ["has", 897], ["utilized", 901], [",", 909], ["adapted", 911], ["and", 919], ["validated", 923], ["Davidson", 933], ["Trauma", 942], ["Scale", 949], ["in", 955], ["the", 958], ["local", 962], ["context", 968], [".", 975], ["Results", 977], ["imply", 985], ["the", 991], ["significance", 995], ["of", 1008], ["continued", 1011], ["psychological", 1021], ["support", 1035], [",", 1042], ["of", 1044], ["drawing", 1047], ["on", 1055], ["resilience", 1058], ["factors", 1069], ["in", 1077], ["PTSD", 1080], ["management", 1085], [".", 1095], ["Implications", 1097], ["and", 1110], ["directions", 1114], ["for", 1125], ["future", 1129], ["research", 1136], ["are", 1145], ["discussed", 1149], [".", 1158]]}
{"context": "Romano-Ward syndrome is a subtype of prolonged QT syndrome with autosomal dominant inheritance. Stress-induced syncope and sudden death are secondary to ventricular tachydysrhythmias. A case report of Romano-Ward syndrome complicating pregnancy is presented. Successful therapy with propranolol for life-threatening dysrhythmias was achieved. An excellent neonatal outcome occurred.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "34757c8e5ca444a192856060543f7791", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[12, 13]], "char_spans": [[64, 81]]}]}], "context_tokens": [["Romano", 0], ["-", 6], ["Ward", 7], ["syndrome", 12], ["is", 21], ["a", 24], ["subtype", 26], ["of", 34], ["prolonged", 37], ["QT", 47], ["syndrome", 50], ["with", 59], ["autosomal", 64], ["dominant", 74], ["inheritance", 83], [".", 94], ["Stress", 96], ["-", 102], ["induced", 103], ["syncope", 111], ["and", 119], ["sudden", 123], ["death", 130], ["are", 136], ["secondary", 140], ["to", 150], ["ventricular", 153], ["tachydysrhythmias", 165], [".", 182], ["A", 184], ["case", 186], ["report", 191], ["of", 198], ["Romano", 201], ["-", 207], ["Ward", 208], ["syndrome", 213], ["complicating", 222], ["pregnancy", 235], ["is", 245], ["presented", 248], [".", 257], ["Successful", 259], ["therapy", 270], ["with", 278], ["propranolol", 283], ["for", 295], ["life", 299], ["-", 303], ["threatening", 304], ["dysrhythmias", 316], ["was", 329], ["achieved", 333], [".", 341], ["An", 343], ["excellent", 346], ["neonatal", 356], ["outcome", 365], ["occurred", 373], [".", 381]]}
{"context": "The efficacy and safety of flumazenil were assessed in comparison to placebo in a double-blind randomised study of 31 adults intoxicated with benzodiazepines. The criteria of efficacy were the degree of sedation, and orientation in time and space. Patients who received flumazenil awoke within minutes but central depression returned partly one hour later, which reflects the short elimination half-life of the drug. Side effects were few and the results indicate that flumazenil is effective in the primary management of benzodiazepine overdose and in states where benzodiazepines have been taken with other drugs.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "6e6cc6752f9047989d4703ae6d6c8051", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[80, 80], [5, 5], [46, 46]], "char_spans": [[469, 478], [27, 36], [270, 279]]}]}], "context_tokens": [["The", 0], ["efficacy", 4], ["and", 13], ["safety", 17], ["of", 24], ["flumazenil", 27], ["were", 38], ["assessed", 43], ["in", 52], ["comparison", 55], ["to", 66], ["placebo", 69], ["in", 77], ["a", 80], ["double", 82], ["-", 88], ["blind", 89], ["randomised", 95], ["study", 106], ["of", 112], ["31", 115], ["adults", 118], ["intoxicated", 125], ["with", 137], ["benzodiazepines", 142], [".", 157], ["The", 159], ["criteria", 163], ["of", 172], ["efficacy", 175], ["were", 184], ["the", 189], ["degree", 193], ["of", 200], ["sedation", 203], [",", 211], ["and", 213], ["orientation", 217], ["in", 229], ["time", 232], ["and", 237], ["space", 241], [".", 246], ["Patients", 248], ["who", 257], ["received", 261], ["flumazenil", 270], ["awoke", 281], ["within", 287], ["minutes", 294], ["but", 302], ["central", 306], ["depression", 314], ["returned", 325], ["partly", 334], ["one", 341], ["hour", 345], ["later", 350], [",", 355], ["which", 357], ["reflects", 363], ["the", 372], ["short", 376], ["elimination", 382], ["half", 394], ["-", 398], ["life", 399], ["of", 404], ["the", 407], ["drug", 411], [".", 415], ["Side", 417], ["effects", 422], ["were", 430], ["few", 435], ["and", 439], ["the", 443], ["results", 447], ["indicate", 455], ["that", 464], ["flumazenil", 469], ["is", 480], ["effective", 483], ["in", 493], ["the", 496], ["primary", 500], ["management", 508], ["of", 519], ["benzodiazepine", 522], ["overdose", 537], ["and", 546], ["in", 550], ["states", 553], ["where", 560], ["benzodiazepines", 566], ["have", 582], ["been", 587], ["taken", 592], ["with", 598], ["other", 603], ["drugs", 609], [".", 614]]}
{"context": "The actin-cross-linking protein spectrin is a prominent component of the membrane cytoskeleton. Spectrin is a tetramer of two antiparallel alphabeta-dimers which share a unique and ancient gene structure. The alpha-spectrin and beta-spectrin genes are composed primarily of tandemly repeated 106-amino-acid segments, each of which forms a triple alpha-helical coiled coil. Both the genes and the repeats themselves are homologous. The two genes are thought to be the result of a gene duplication event, and each gene is the product of duplications of the 106-amino-acid repeats. In this work we compare the process of molecular evolution across the repeated segments of the alpha- and beta-spectrin genes. We find that the alpha-spectrin segments have, for the most part, evolved in a homogeneous fashion, while considerable heterogeneity is found among beta-spectrin segments. Several segments with unique known functions are found to have evolved differently than the others. On the basis of heterogeneity of the evolutionary process, we suggest that at least one repeat has a unique function that has yet to be documented. We also present new statistical methods for comparing the evolutionary process between different regions of DNA sequences.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "b37db289ef2948e9b5e75fbc0cbd66bf", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[23, 23]], "char_spans": [[126, 137]]}]}], "context_tokens": [["The", 0], ["actin", 4], ["-", 9], ["cross", 10], ["-", 15], ["linking", 16], ["protein", 24], ["spectrin", 32], ["is", 41], ["a", 44], ["prominent", 46], ["component", 56], ["of", 66], ["the", 69], ["membrane", 73], ["cytoskeleton", 82], [".", 94], ["Spectrin", 96], ["is", 105], ["a", 108], ["tetramer", 110], ["of", 119], ["two", 122], ["antiparallel", 126], ["alphabeta", 139], ["-", 148], ["dimers", 149], ["which", 156], ["share", 162], ["a", 168], ["unique", 170], ["and", 177], ["ancient", 181], ["gene", 189], ["structure", 194], [".", 203], ["The", 205], ["alpha", 209], ["-", 214], ["spectrin", 215], ["and", 224], ["beta", 228], ["-", 232], ["spectrin", 233], ["genes", 242], ["are", 248], ["composed", 252], ["primarily", 261], ["of", 271], ["tandemly", 274], ["repeated", 283], ["106-amino", 292], ["-", 301], ["acid", 302], ["segments", 307], [",", 315], ["each", 317], ["of", 322], ["which", 325], ["forms", 331], ["a", 337], ["triple", 339], ["alpha", 346], ["-", 351], ["helical", 352], ["coiled", 360], ["coil", 367], [".", 371], ["Both", 373], ["the", 378], ["genes", 382], ["and", 388], ["the", 392], ["repeats", 396], ["themselves", 404], ["are", 415], ["homologous", 419], [".", 429], ["The", 431], ["two", 435], ["genes", 439], ["are", 445], ["thought", 449], ["to", 457], ["be", 460], ["the", 463], ["result", 467], ["of", 474], ["a", 477], ["gene", 479], ["duplication", 484], ["event", 496], [",", 501], ["and", 503], ["each", 507], ["gene", 512], ["is", 517], ["the", 520], ["product", 524], ["of", 532], ["duplications", 535], ["of", 548], ["the", 551], ["106-amino", 555], ["-", 564], ["acid", 565], ["repeats", 570], [".", 577], ["In", 579], ["this", 582], ["work", 587], ["we", 592], ["compare", 595], ["the", 603], ["process", 607], ["of", 615], ["molecular", 618], ["evolution", 628], ["across", 638], ["the", 645], ["repeated", 649], ["segments", 658], ["of", 667], ["the", 670], ["alpha-", 674], ["and", 681], ["beta", 685], ["-", 689], ["spectrin", 690], ["genes", 699], [".", 704], ["We", 706], ["find", 709], ["that", 714], ["the", 719], ["alpha", 723], ["-", 728], ["spectrin", 729], ["segments", 738], ["have", 747], [",", 751], ["for", 753], ["the", 757], ["most", 761], ["part", 766], [",", 770], ["evolved", 772], ["in", 780], ["a", 783], ["homogeneous", 785], ["fashion", 797], [",", 804], ["while", 806], ["considerable", 812], ["heterogeneity", 825], ["is", 839], ["found", 842], ["among", 848], ["beta", 854], ["-", 858], ["spectrin", 859], ["segments", 868], [".", 876], ["Several", 878], ["segments", 886], ["with", 895], ["unique", 900], ["known", 907], ["functions", 913], ["are", 923], ["found", 927], ["to", 933], ["have", 936], ["evolved", 941], ["differently", 949], ["than", 961], ["the", 966], ["others", 970], [".", 976], ["On", 978], ["the", 981], ["basis", 985], ["of", 991], ["heterogeneity", 994], ["of", 1008], ["the", 1011], ["evolutionary", 1015], ["process", 1028], [",", 1035], ["we", 1037], ["suggest", 1040], ["that", 1048], ["at", 1053], ["least", 1056], ["one", 1062], ["repeat", 1066], ["has", 1073], ["a", 1077], ["unique", 1079], ["function", 1086], ["that", 1095], ["has", 1100], ["yet", 1104], ["to", 1108], ["be", 1111], ["documented", 1114], [".", 1124], ["We", 1126], ["also", 1129], ["present", 1134], ["new", 1142], ["statistical", 1146], ["methods", 1158], ["for", 1166], ["comparing", 1170], ["the", 1180], ["evolutionary", 1184], ["process", 1197], ["between", 1205], ["different", 1213], ["regions", 1223], ["of", 1231], ["DNA", 1234], ["sequences", 1238], [".", 1247]]}
{"context": "The mechanism of neurodegeneration in CAG/polyglutamine repeat expansion diseases is unknown but is thought to occur at the protein level. Here, in studies of spinocerebellar ataxia type 3, also known as Machado-Joseph disease (SCA3/MJD), we show that the disease protein ataxin-3 accumulates in ubiquitinated intranuclear inclusions selectively in neurons of affected brain regions. We further provide evidence in vitro for a model of disease in which an expanded polyglutamine-containing fragment recruits full-length protein into insoluble aggregates. Together with recent findings from transgenic models, our results suggest that intranuclear aggregation of the expanded protein is a unifying feature of CAG/polyglutamine diseases and may be initiated or catalyzed by a glutamine-containing fragment of the disease protein.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "353a222964794361bdaaf8ea481c12ee", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[50, 50]], "char_spans": [[272, 279]]}]}], "context_tokens": [["The", 0], ["mechanism", 4], ["of", 14], ["neurodegeneration", 17], ["in", 35], ["CAG", 38], ["/", 41], ["polyglutamine", 42], ["repeat", 56], ["expansion", 63], ["diseases", 73], ["is", 82], ["unknown", 85], ["but", 93], ["is", 97], ["thought", 100], ["to", 108], ["occur", 111], ["at", 117], ["the", 120], ["protein", 124], ["level", 132], [".", 137], ["Here", 139], [",", 143], ["in", 145], ["studies", 148], ["of", 156], ["spinocerebellar", 159], ["ataxia", 175], ["type", 182], ["3", 187], [",", 188], ["also", 190], ["known", 195], ["as", 201], ["Machado", 204], ["-", 211], ["Joseph", 212], ["disease", 219], ["(", 227], ["SCA3/MJD", 228], [")", 236], [",", 237], ["we", 239], ["show", 242], ["that", 247], ["the", 252], ["disease", 256], ["protein", 264], ["ataxin-3", 272], ["accumulates", 281], ["in", 293], ["ubiquitinated", 296], ["intranuclear", 310], ["inclusions", 323], ["selectively", 334], ["in", 346], ["neurons", 349], ["of", 357], ["affected", 360], ["brain", 369], ["regions", 375], [".", 382], ["We", 384], ["further", 387], ["provide", 395], ["evidence", 403], ["in", 412], ["vitro", 415], ["for", 421], ["a", 425], ["model", 427], ["of", 433], ["disease", 436], ["in", 444], ["which", 447], ["an", 453], ["expanded", 456], ["polyglutamine", 465], ["-", 478], ["containing", 479], ["fragment", 490], ["recruits", 499], ["full", 508], ["-", 512], ["length", 513], ["protein", 520], ["into", 528], ["insoluble", 533], ["aggregates", 543], [".", 553], ["Together", 555], ["with", 564], ["recent", 569], ["findings", 576], ["from", 585], ["transgenic", 590], ["models", 601], [",", 607], ["our", 609], ["results", 613], ["suggest", 621], ["that", 629], ["intranuclear", 634], ["aggregation", 647], ["of", 659], ["the", 662], ["expanded", 666], ["protein", 675], ["is", 683], ["a", 686], ["unifying", 688], ["feature", 697], ["of", 705], ["CAG", 708], ["/", 711], ["polyglutamine", 712], ["diseases", 726], ["and", 735], ["may", 739], ["be", 743], ["initiated", 746], ["or", 756], ["catalyzed", 759], ["by", 769], ["a", 772], ["glutamine", 774], ["-", 783], ["containing", 784], ["fragment", 795], ["of", 804], ["the", 807], ["disease", 811], ["protein", 819], [".", 826]]}
{"context": "Transactivation response DNA-binding protein 43 (TDP-43) proteinopathies are classified based upon the extent of modified TDP-43 and include a growing number of neurodegenerative diseases such as amyotrophic lateral sclerosis, frontotemporal lobar degeneration with ubiquitin-immunoreactive, tau-negative inclusions and frontotemporal lobar degeneration with motor neuron disease. The purpose of the study was to examine whether proteolytic modifications of TDP-43 are a relevant finding in Parkinson's disease (PD) and dementia with Lewy bodies (DLB). A novel site-directed caspase cleavage antibody, termed TDP caspase cleavage product antibody (TDPccp), was utilized based upon a known caspase 3 cleavage consensus site within TDP-43 at position 219. Application of this antibody to postmortem brain sections from PD and DLB patients revealed the presence of caspase-cleaved TDP-43 in Lewy bodies and Hirano bodies in all cases examined. Colocalization of TDPccp with an antibody to alpha-synuclein (alpha-Syn), which served as a general marker for Lewy bodies, was evident within the substantia nigra in both alpha-synucleinopathies. Interestingly, the TDPccp antibody detected a greater number of Lewy bodies in PD and DLB compared to the alpha-Syn antibody. In addition, a semiquantitative analysis in both diseases confirmed this finding by indicating that the percentage of caspase-cleaved TDP-43 single-labeled Lewy bodies was approximately twice that of alpha-Syn labeling (in DLB 13.4 vs. 5.5%, while in PD 34.6 vs. 17.6%). Collectively, these data have identified caspase-cleaved TDP-43 as a primary component of Lewy and Hirano bodies in PD and DLB, and suggest that the TDPccp antibody is an effective marker for the detection of Lewy bodies in these neurodegenerative diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "4a93e831ea4b4c5fb6f059f0b2cca5be", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[163, 165]], "char_spans": [[986, 1000]]}]}], "context_tokens": [["Transactivation", 0], ["response", 16], ["DNA", 25], ["-", 28], ["binding", 29], ["protein", 37], ["43", 45], ["(", 48], ["TDP-43", 49], [")", 55], ["proteinopathies", 57], ["are", 73], ["classified", 77], ["based", 88], ["upon", 94], ["the", 99], ["extent", 103], ["of", 110], ["modified", 113], ["TDP-43", 122], ["and", 129], ["include", 133], ["a", 141], ["growing", 143], ["number", 151], ["of", 158], ["neurodegenerative", 161], ["diseases", 179], ["such", 188], ["as", 193], ["amyotrophic", 196], ["lateral", 208], ["sclerosis", 216], [",", 225], ["frontotemporal", 227], ["lobar", 242], ["degeneration", 248], ["with", 261], ["ubiquitin", 266], ["-", 275], ["immunoreactive", 276], [",", 290], ["tau", 292], ["-", 295], ["negative", 296], ["inclusions", 305], ["and", 316], ["frontotemporal", 320], ["lobar", 335], ["degeneration", 341], ["with", 354], ["motor", 359], ["neuron", 365], ["disease", 372], [".", 379], ["The", 381], ["purpose", 385], ["of", 393], ["the", 396], ["study", 400], ["was", 406], ["to", 410], ["examine", 413], ["whether", 421], ["proteolytic", 429], ["modifications", 441], ["of", 455], ["TDP-43", 458], ["are", 465], ["a", 469], ["relevant", 471], ["finding", 480], ["in", 488], ["Parkinson", 491], ["'s", 500], ["disease", 503], ["(", 511], ["PD", 512], [")", 514], ["and", 516], ["dementia", 520], ["with", 529], ["Lewy", 534], ["bodies", 539], ["(", 546], ["DLB", 547], [")", 550], [".", 551], ["A", 553], ["novel", 555], ["site", 561], ["-", 565], ["directed", 566], ["caspase", 575], ["cleavage", 583], ["antibody", 592], [",", 600], ["termed", 602], ["TDP", 609], ["caspase", 613], ["cleavage", 621], ["product", 630], ["antibody", 638], ["(", 647], ["TDPccp", 648], [")", 654], [",", 655], ["was", 657], ["utilized", 661], ["based", 670], ["upon", 676], ["a", 681], ["known", 683], ["caspase", 689], ["3", 697], ["cleavage", 699], ["consensus", 708], ["site", 718], ["within", 723], ["TDP-43", 730], ["at", 737], ["position", 740], ["219", 749], [".", 752], ["Application", 754], ["of", 766], ["this", 769], ["antibody", 774], ["to", 783], ["postmortem", 786], ["brain", 797], ["sections", 803], ["from", 812], ["PD", 817], ["and", 820], ["DLB", 824], ["patients", 828], ["revealed", 837], ["the", 846], ["presence", 850], ["of", 859], ["caspase", 862], ["-", 869], ["cleaved", 870], ["TDP-43", 878], ["in", 885], ["Lewy", 888], ["bodies", 893], ["and", 900], ["Hirano", 904], ["bodies", 911], ["in", 918], ["all", 921], ["cases", 925], ["examined", 931], [".", 939], ["Colocalization", 941], ["of", 956], ["TDPccp", 959], ["with", 966], ["an", 971], ["antibody", 974], ["to", 983], ["alpha", 986], ["-", 991], ["synuclein", 992], ["(", 1002], ["alpha", 1003], ["-", 1008], ["Syn", 1009], [")", 1012], [",", 1013], ["which", 1015], ["served", 1021], ["as", 1028], ["a", 1031], ["general", 1033], ["marker", 1041], ["for", 1048], ["Lewy", 1052], ["bodies", 1057], [",", 1063], ["was", 1065], ["evident", 1069], ["within", 1077], ["the", 1084], ["substantia", 1088], ["nigra", 1099], ["in", 1105], ["both", 1108], ["alpha", 1113], ["-", 1118], ["synucleinopathies", 1119], [".", 1136], ["Interestingly", 1138], [",", 1151], ["the", 1153], ["TDPccp", 1157], ["antibody", 1164], ["detected", 1173], ["a", 1182], ["greater", 1184], ["number", 1192], ["of", 1199], ["Lewy", 1202], ["bodies", 1207], ["in", 1214], ["PD", 1217], ["and", 1220], ["DLB", 1224], ["compared", 1228], ["to", 1237], ["the", 1240], ["alpha", 1244], ["-", 1249], ["Syn", 1250], ["antibody", 1254], [".", 1262], ["In", 1264], ["addition", 1267], [",", 1275], ["a", 1277], ["semiquantitative", 1279], ["analysis", 1296], ["in", 1305], ["both", 1308], ["diseases", 1313], ["confirmed", 1322], ["this", 1332], ["finding", 1337], ["by", 1345], ["indicating", 1348], ["that", 1359], ["the", 1364], ["percentage", 1368], ["of", 1379], ["caspase", 1382], ["-", 1389], ["cleaved", 1390], ["TDP-43", 1398], ["single", 1405], ["-", 1411], ["labeled", 1412], ["Lewy", 1420], ["bodies", 1425], ["was", 1432], ["approximately", 1436], ["twice", 1450], ["that", 1456], ["of", 1461], ["alpha", 1464], ["-", 1469], ["Syn", 1470], ["labeling", 1474], ["(", 1483], ["in", 1484], ["DLB", 1487], ["13.4", 1491], ["vs.", 1496], ["5.5", 1500], ["%", 1503], [",", 1504], ["while", 1506], ["in", 1512], ["PD", 1515], ["34.6", 1518], ["vs.", 1523], ["17.6", 1527], ["%", 1531], [")", 1532], [".", 1533], ["Collectively", 1535], [",", 1547], ["these", 1549], ["data", 1555], ["have", 1560], ["identified", 1565], ["caspase", 1576], ["-", 1583], ["cleaved", 1584], ["TDP-43", 1592], ["as", 1599], ["a", 1602], ["primary", 1604], ["component", 1612], ["of", 1622], ["Lewy", 1625], ["and", 1630], ["Hirano", 1634], ["bodies", 1641], ["in", 1648], ["PD", 1651], ["and", 1654], ["DLB", 1658], [",", 1661], ["and", 1663], ["suggest", 1667], ["that", 1675], ["the", 1680], ["TDPccp", 1684], ["antibody", 1691], ["is", 1700], ["an", 1703], ["effective", 1706], ["marker", 1716], ["for", 1723], ["the", 1727], ["detection", 1731], ["of", 1741], ["Lewy", 1744], ["bodies", 1749], ["in", 1756], ["these", 1759], ["neurodegenerative", 1765], ["diseases", 1783], [".", 1791]]}
{"context": "Accumulation and deposition of \u03b2-amyloid peptides (A\u03b2) in the brain is a central event in the pathogenesis of Alzheimer's disease (AD). Besides the parenchymal pathology, A\u03b2 is known to undergo active transport across the blood-brain barrier and cerebral amyloid angiopathy (CAA) is a prominent feature in the majority of AD. Although impaired cerebral blood flow (CBF) has been implicated in faulty A\u03b2 transport and clearance, and cerebral hypoperfusion can exist in the pre-clinical phase of Alzheimer's disease (AD), it is still unclear whether it is one of the causal factors for AD pathogenesis, or an early consequence of a multi-factor condition that would lead to AD at late stage. To study the potential interaction between faulty CBF and amyloid accumulation in clinical-relevant situation, we generated a new amyloid precursor protein (APP) knock-in allele that expresses humanized A\u03b2 and a Dutch mutation in addition to Swedish/London mutations and compared this line with an equivalent knock-in line but in the absence of the Dutch mutation, both crossed onto the PS1M146V knock-in background. Introduction of the Dutch mutation results in robust CAA and parenchymal A\u03b2 pathology, age-dependent reduction of spatial learning and memory deficits, and CBF reduction as detected by fMRI. Direct manipulation of CBF by transverse aortic constriction surgery on the left common carotid artery caused differential changes in CBF in the anterior and middle region of the cortex, where it is reduced on the left side and increased on the right side. However these perturbations in CBF resulted in the same effect: both significantly exacerbate CAA and amyloid pathology. Our study reveals a direct and positive link between vascular and parenchymal A\u03b2; both can be modulated by CBF. The new APP knock-in mouse model recapitulates many symptoms of AD including progressive vascular and parenchymal A\u03b2 pathology and behavioral deficits in the absence of APP overexpression.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "fd787f32d19848dbb65fe34c00222562", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[22, 24], [94, 96]], "char_spans": [[110, 128], [494, 512]]}, {"text": "AD", "token_spans": [[131, 131], [98, 98], [26, 26], [342, 342], [62, 62], [114, 114]], "char_spans": [[672, 673], [515, 516], [131, 132], [1852, 1853], [322, 323], [584, 585]]}]}], "context_tokens": [["Accumulation", 0], ["and", 13], ["deposition", 17], ["of", 28], ["\u03b2", 31], ["-", 32], ["amyloid", 33], ["peptides", 41], ["(", 50], ["A\u03b2", 51], [")", 53], ["in", 55], ["the", 58], ["brain", 62], ["is", 68], ["a", 71], ["central", 73], ["event", 81], ["in", 87], ["the", 90], ["pathogenesis", 94], ["of", 107], ["Alzheimer", 110], ["'s", 119], ["disease", 122], ["(", 130], ["AD", 131], [")", 133], [".", 134], ["Besides", 136], ["the", 144], ["parenchymal", 148], ["pathology", 160], [",", 169], ["A\u03b2", 171], ["is", 174], ["known", 177], ["to", 183], ["undergo", 186], ["active", 194], ["transport", 201], ["across", 211], ["the", 218], ["blood", 222], ["-", 227], ["brain", 228], ["barrier", 234], ["and", 242], ["cerebral", 246], ["amyloid", 255], ["angiopathy", 263], ["(", 274], ["CAA", 275], [")", 278], ["is", 280], ["a", 283], ["prominent", 285], ["feature", 295], ["in", 303], ["the", 306], ["majority", 310], ["of", 319], ["AD", 322], [".", 324], ["Although", 326], ["impaired", 335], ["cerebral", 344], ["blood", 353], ["flow", 359], ["(", 364], ["CBF", 365], [")", 368], ["has", 370], ["been", 374], ["implicated", 379], ["in", 390], ["faulty", 393], ["A\u03b2", 400], ["transport", 403], ["and", 413], ["clearance", 417], [",", 426], ["and", 428], ["cerebral", 432], ["hypoperfusion", 441], ["can", 455], ["exist", 459], ["in", 465], ["the", 468], ["pre", 472], ["-", 475], ["clinical", 476], ["phase", 485], ["of", 491], ["Alzheimer", 494], ["'s", 503], ["disease", 506], ["(", 514], ["AD", 515], [")", 517], [",", 518], ["it", 520], ["is", 523], ["still", 526], ["unclear", 532], ["whether", 540], ["it", 548], ["is", 551], ["one", 554], ["of", 558], ["the", 561], ["causal", 565], ["factors", 572], ["for", 580], ["AD", 584], ["pathogenesis", 587], [",", 599], ["or", 601], ["an", 604], ["early", 607], ["consequence", 613], ["of", 625], ["a", 628], ["multi", 630], ["-", 635], ["factor", 636], ["condition", 643], ["that", 653], ["would", 658], ["lead", 664], ["to", 669], ["AD", 672], ["at", 675], ["late", 678], ["stage", 683], [".", 688], ["To", 690], ["study", 693], ["the", 699], ["potential", 703], ["interaction", 713], ["between", 725], ["faulty", 733], ["CBF", 740], ["and", 744], ["amyloid", 748], ["accumulation", 756], ["in", 769], ["clinical", 772], ["-", 780], ["relevant", 781], ["situation", 790], [",", 799], ["we", 801], ["generated", 804], ["a", 814], ["new", 816], ["amyloid", 820], ["precursor", 828], ["protein", 838], ["(", 846], ["APP", 847], [")", 850], ["knock", 852], ["-", 857], ["in", 858], ["allele", 861], ["that", 868], ["expresses", 873], ["humanized", 883], ["A\u03b2", 893], ["and", 896], ["a", 900], ["Dutch", 902], ["mutation", 908], ["in", 917], ["addition", 920], ["to", 929], ["Swedish", 932], ["/", 939], ["London", 940], ["mutations", 947], ["and", 957], ["compared", 961], ["this", 970], ["line", 975], ["with", 980], ["an", 985], ["equivalent", 988], ["knock", 999], ["-", 1004], ["in", 1005], ["line", 1008], ["but", 1013], ["in", 1017], ["the", 1020], ["absence", 1024], ["of", 1032], ["the", 1035], ["Dutch", 1039], ["mutation", 1045], [",", 1053], ["both", 1055], ["crossed", 1060], ["onto", 1068], ["the", 1073], ["PS1M146V", 1077], ["knock", 1086], ["-", 1091], ["in", 1092], ["background", 1095], [".", 1105], ["Introduction", 1107], ["of", 1120], ["the", 1123], ["Dutch", 1127], ["mutation", 1133], ["results", 1142], ["in", 1150], ["robust", 1153], ["CAA", 1160], ["and", 1164], ["parenchymal", 1168], ["A\u03b2", 1180], ["pathology", 1183], [",", 1192], ["age", 1194], ["-", 1197], ["dependent", 1198], ["reduction", 1208], ["of", 1218], ["spatial", 1221], ["learning", 1229], ["and", 1238], ["memory", 1242], ["deficits", 1249], [",", 1257], ["and", 1259], ["CBF", 1263], ["reduction", 1267], ["as", 1277], ["detected", 1280], ["by", 1289], ["fMRI", 1292], [".", 1296], ["Direct", 1298], ["manipulation", 1305], ["of", 1318], ["CBF", 1321], ["by", 1325], ["transverse", 1328], ["aortic", 1339], ["constriction", 1346], ["surgery", 1359], ["on", 1367], ["the", 1370], ["left", 1374], ["common", 1379], ["carotid", 1386], ["artery", 1394], ["caused", 1401], ["differential", 1408], ["changes", 1421], ["in", 1429], ["CBF", 1432], ["in", 1436], ["the", 1439], ["anterior", 1443], ["and", 1452], ["middle", 1456], ["region", 1463], ["of", 1470], ["the", 1473], ["cortex", 1477], [",", 1483], ["where", 1485], ["it", 1491], ["is", 1494], ["reduced", 1497], ["on", 1505], ["the", 1508], ["left", 1512], ["side", 1517], ["and", 1522], ["increased", 1526], ["on", 1536], ["the", 1539], ["right", 1543], ["side", 1549], [".", 1553], ["However", 1555], ["these", 1563], ["perturbations", 1569], ["in", 1583], ["CBF", 1586], ["resulted", 1590], ["in", 1599], ["the", 1602], ["same", 1606], ["effect", 1611], [":", 1617], ["both", 1619], ["significantly", 1624], ["exacerbate", 1638], ["CAA", 1649], ["and", 1653], ["amyloid", 1657], ["pathology", 1665], [".", 1674], ["Our", 1676], ["study", 1680], ["reveals", 1686], ["a", 1694], ["direct", 1696], ["and", 1703], ["positive", 1707], ["link", 1716], ["between", 1721], ["vascular", 1729], ["and", 1738], ["parenchymal", 1742], ["A\u03b2", 1754], [";", 1756], ["both", 1758], ["can", 1763], ["be", 1767], ["modulated", 1770], ["by", 1780], ["CBF", 1783], [".", 1786], ["The", 1788], ["new", 1792], ["APP", 1796], ["knock", 1800], ["-", 1805], ["in", 1806], ["mouse", 1809], ["model", 1815], ["recapitulates", 1821], ["many", 1835], ["symptoms", 1840], ["of", 1849], ["AD", 1852], ["including", 1855], ["progressive", 1865], ["vascular", 1877], ["and", 1886], ["parenchymal", 1890], ["A\u03b2", 1902], ["pathology", 1905], ["and", 1915], ["behavioral", 1919], ["deficits", 1930], ["in", 1939], ["the", 1942], ["absence", 1946], ["of", 1954], ["APP", 1957], ["overexpression", 1961], [".", 1975]]}
{"context": "Neurofibromatosis type 1 (NF1) is a common genetic disease caused by haploinsufficiency of the NF1 tumor-suppressor gene. Different pathogenetic mechanisms have been identified, with the majority (95%) causing intragenic lesions. Single or multiexon NF1 copy number changes occur in about 2% of patients, but little is known about the molecular mechanisms behind these intragenic deletions. We report here on the molecular characterization of a novel NF1 multiexonic deletion. The application of a multidisciplinary approach including multiplex ligation-dependent probe amplification, allelic segregation analysis, and fluorescent in situ hybridization allowed us to map the breakpoints in IVS27b and IVS48. Furthermore, the breakpoint junction was characterized by sequencing. Using bioinformatic analysis, we identified some recombinogenic motifs in close proximity to the centromeric and telomeric breakpoints and predicted the presence of a mutated messenger ribonucleic acid, which was deleted between exons 28 and 48 and encodes a neurofibromin that lacks some domains essential for its function. Through reverse transcriptase-polymerase chain reaction, the expression of the mutated allele was verified, showing the junction between exons 27b and 49 and, as expected, was not subjected to nonsense-mediated decay. Multiexonic deletions represent 2% of NF1 mutations, and until now, the breakpoint has been identified in only a few cases. The fine characterization of multiexonic deletions broadens the mutational repertoire of the NF1 gene, allowing for the identification of different pathogenetic mechanisms causing NF1.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "354f714bfea84f6b8e02e7acba3f7d67", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[16, 16], [221, 221], [43, 43], [251, 251], [4, 4], [263, 263], [78, 78]], "char_spans": [[95, 97], [1359, 1361], [250, 252], [1538, 1540], [26, 28], [1625, 1627], [451, 453]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["common", 36], ["genetic", 43], ["disease", 51], ["caused", 59], ["by", 66], ["haploinsufficiency", 69], ["of", 88], ["the", 91], ["NF1", 95], ["tumor", 99], ["-", 104], ["suppressor", 105], ["gene", 116], [".", 120], ["Different", 122], ["pathogenetic", 132], ["mechanisms", 145], ["have", 156], ["been", 161], ["identified", 166], [",", 176], ["with", 178], ["the", 183], ["majority", 187], ["(", 196], ["95", 197], ["%", 199], [")", 200], ["causing", 202], ["intragenic", 210], ["lesions", 221], [".", 228], ["Single", 230], ["or", 237], ["multiexon", 240], ["NF1", 250], ["copy", 254], ["number", 259], ["changes", 266], ["occur", 274], ["in", 280], ["about", 283], ["2", 289], ["%", 290], ["of", 292], ["patients", 295], [",", 303], ["but", 305], ["little", 309], ["is", 316], ["known", 319], ["about", 325], ["the", 331], ["molecular", 335], ["mechanisms", 345], ["behind", 356], ["these", 363], ["intragenic", 369], ["deletions", 380], [".", 389], ["We", 391], ["report", 394], ["here", 401], ["on", 406], ["the", 409], ["molecular", 413], ["characterization", 423], ["of", 440], ["a", 443], ["novel", 445], ["NF1", 451], ["multiexonic", 455], ["deletion", 467], [".", 475], ["The", 477], ["application", 481], ["of", 493], ["a", 496], ["multidisciplinary", 498], ["approach", 516], ["including", 525], ["multiplex", 535], ["ligation", 545], ["-", 553], ["dependent", 554], ["probe", 564], ["amplification", 570], [",", 583], ["allelic", 585], ["segregation", 593], ["analysis", 605], [",", 613], ["and", 615], ["fluorescent", 619], ["in", 631], ["situ", 634], ["hybridization", 639], ["allowed", 653], ["us", 661], ["to", 664], ["map", 667], ["the", 671], ["breakpoints", 675], ["in", 687], ["IVS27b", 690], ["and", 697], ["IVS48", 701], [".", 706], ["Furthermore", 708], [",", 719], ["the", 721], ["breakpoint", 725], ["junction", 736], ["was", 745], ["characterized", 749], ["by", 763], ["sequencing", 766], [".", 776], ["Using", 778], ["bioinformatic", 784], ["analysis", 798], [",", 806], ["we", 808], ["identified", 811], ["some", 822], ["recombinogenic", 827], ["motifs", 842], ["in", 849], ["close", 852], ["proximity", 858], ["to", 868], ["the", 871], ["centromeric", 875], ["and", 887], ["telomeric", 891], ["breakpoints", 901], ["and", 913], ["predicted", 917], ["the", 927], ["presence", 931], ["of", 940], ["a", 943], ["mutated", 945], ["messenger", 953], ["ribonucleic", 963], ["acid", 975], [",", 979], ["which", 981], ["was", 987], ["deleted", 991], ["between", 999], ["exons", 1007], ["28", 1013], ["and", 1016], ["48", 1020], ["and", 1023], ["encodes", 1027], ["a", 1035], ["neurofibromin", 1037], ["that", 1051], ["lacks", 1056], ["some", 1062], ["domains", 1067], ["essential", 1075], ["for", 1085], ["its", 1089], ["function", 1093], [".", 1101], ["Through", 1103], ["reverse", 1111], ["transcriptase", 1119], ["-", 1132], ["polymerase", 1133], ["chain", 1144], ["reaction", 1150], [",", 1158], ["the", 1160], ["expression", 1164], ["of", 1175], ["the", 1178], ["mutated", 1182], ["allele", 1190], ["was", 1197], ["verified", 1201], [",", 1209], ["showing", 1211], ["the", 1219], ["junction", 1223], ["between", 1232], ["exons", 1240], ["27b", 1246], ["and", 1250], ["49", 1254], ["and", 1257], [",", 1260], ["as", 1262], ["expected", 1265], [",", 1273], ["was", 1275], ["not", 1279], ["subjected", 1283], ["to", 1293], ["nonsense", 1296], ["-", 1304], ["mediated", 1305], ["decay", 1314], [".", 1319], ["Multiexonic", 1321], ["deletions", 1333], ["represent", 1343], ["2", 1353], ["%", 1354], ["of", 1356], ["NF1", 1359], ["mutations", 1363], [",", 1372], ["and", 1374], ["until", 1378], ["now", 1384], [",", 1387], ["the", 1389], ["breakpoint", 1393], ["has", 1404], ["been", 1408], ["identified", 1413], ["in", 1424], ["only", 1427], ["a", 1432], ["few", 1434], ["cases", 1438], [".", 1443], ["The", 1445], ["fine", 1449], ["characterization", 1454], ["of", 1471], ["multiexonic", 1474], ["deletions", 1486], ["broadens", 1496], ["the", 1505], ["mutational", 1509], ["repertoire", 1520], ["of", 1531], ["the", 1534], ["NF1", 1538], ["gene", 1542], [",", 1546], ["allowing", 1548], ["for", 1557], ["the", 1561], ["identification", 1565], ["of", 1580], ["different", 1583], ["pathogenetic", 1593], ["mechanisms", 1606], ["causing", 1617], ["NF1", 1625], [".", 1628]]}
{"context": "Previously, autosomal dominant catecholaminergic polymorphic ventricular tachycardia (CPVT [1]) was mapped to chromosome 1q42-43 with identification of pathogenic mutations in RYR2. Autosomal recessive CPVT (2) was mapped to chromosome 1p13-21, leading to the identification of mutations in CASQ2. In this study, we aimed to elucidate clinical phenotypes of a new variant of CPVT (3) in an inbred Arab family and also delineate the chromosomal location of the gene causing CPVT (3). In a highly inbred family, clinical symptoms of CPVT appeared early in childhood (7-12 years) and in three of the four cases, the first appearance of symptoms turned into a fatal outcome. Parents of the affected children were first-degree cousins and without any symptoms. Segregation analysis suggested an autosomal recessive inheritance. A genome-wide search using polymorphic DNA markers mapped the disease locus to a 25-Mb interval on chromosome 7p14-p22. A maximal multipoint LOD score of 3.17 was obtained at marker D7S493. Sequencing of putative candidate genes, SP4, NPY, FKBP9, FKBP14, PDE1C, and TBX20, in and around this locus, did not reveal any mutation. We have identified a novel highly malignant autosomal recessive form of CPVT and mapped this disorder to a 25-Mb interval on chromosome 7p14-p22.", "qas": [{"question": "What is the inheritance pattern of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) caused by RYR2 mutations?", "answers": ["autosomal dominant"], "qid": "67b5647fc6814b5d880a3bc12a5c419c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["inheritance", 12], ["pattern", 24], ["of", 32], ["Catecholaminergic", 35], ["Polymorphic", 53], ["Ventricular", 65], ["Tachycardia", 77], ["(", 89], ["CPVT", 90], [")", 94], ["caused", 96], ["by", 103], ["RYR2", 106], ["mutations", 111], ["?", 120]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[2, 3]], "char_spans": [[12, 29]]}]}], "context_tokens": [["Previously", 0], [",", 10], ["autosomal", 12], ["dominant", 22], ["catecholaminergic", 31], ["polymorphic", 49], ["ventricular", 61], ["tachycardia", 73], ["(", 85], ["CPVT", 86], ["[", 91], ["1", 92], ["]", 93], [")", 94], ["was", 96], ["mapped", 100], ["to", 107], ["chromosome", 110], ["1q42", 121], ["-", 125], ["43", 126], ["with", 129], ["identification", 134], ["of", 149], ["pathogenic", 152], ["mutations", 163], ["in", 173], ["RYR2", 176], [".", 180], ["Autosomal", 182], ["recessive", 192], ["CPVT", 202], ["(", 207], ["2", 208], [")", 209], ["was", 211], ["mapped", 215], ["to", 222], ["chromosome", 225], ["1p13", 236], ["-", 240], ["21", 241], [",", 243], ["leading", 245], ["to", 253], ["the", 256], ["identification", 260], ["of", 275], ["mutations", 278], ["in", 288], ["CASQ2", 291], [".", 296], ["In", 298], ["this", 301], ["study", 306], [",", 311], ["we", 313], ["aimed", 316], ["to", 322], ["elucidate", 325], ["clinical", 335], ["phenotypes", 344], ["of", 355], ["a", 358], ["new", 360], ["variant", 364], ["of", 372], ["CPVT", 375], ["(", 380], ["3", 381], [")", 382], ["in", 384], ["an", 387], ["inbred", 390], ["Arab", 397], ["family", 402], ["and", 409], ["also", 413], ["delineate", 418], ["the", 428], ["chromosomal", 432], ["location", 444], ["of", 453], ["the", 456], ["gene", 460], ["causing", 465], ["CPVT", 473], ["(", 478], ["3", 479], [")", 480], [".", 481], ["In", 483], ["a", 486], ["highly", 488], ["inbred", 495], ["family", 502], [",", 508], ["clinical", 510], ["symptoms", 519], ["of", 528], ["CPVT", 531], ["appeared", 536], ["early", 545], ["in", 551], ["childhood", 554], ["(", 564], ["7", 565], ["-", 566], ["12", 567], ["years", 570], [")", 575], ["and", 577], ["in", 581], ["three", 584], ["of", 590], ["the", 593], ["four", 597], ["cases", 602], [",", 607], ["the", 609], ["first", 613], ["appearance", 619], ["of", 630], ["symptoms", 633], ["turned", 642], ["into", 649], ["a", 654], ["fatal", 656], ["outcome", 662], [".", 669], ["Parents", 671], ["of", 679], ["the", 682], ["affected", 686], ["children", 695], ["were", 704], ["first", 709], ["-", 714], ["degree", 715], ["cousins", 722], ["and", 730], ["without", 734], ["any", 742], ["symptoms", 746], [".", 754], ["Segregation", 756], ["analysis", 768], ["suggested", 777], ["an", 787], ["autosomal", 790], ["recessive", 800], ["inheritance", 810], [".", 821], ["A", 823], ["genome", 825], ["-", 831], ["wide", 832], ["search", 837], ["using", 844], ["polymorphic", 850], ["DNA", 862], ["markers", 866], ["mapped", 874], ["the", 881], ["disease", 885], ["locus", 893], ["to", 899], ["a", 902], ["25-Mb", 904], ["interval", 910], ["on", 919], ["chromosome", 922], ["7p14-p22", 933], [".", 941], ["A", 943], ["maximal", 945], ["multipoint", 953], ["LOD", 964], ["score", 968], ["of", 974], ["3.17", 977], ["was", 982], ["obtained", 986], ["at", 995], ["marker", 998], ["D7S493", 1005], [".", 1011], ["Sequencing", 1013], ["of", 1024], ["putative", 1027], ["candidate", 1036], ["genes", 1046], [",", 1051], ["SP4", 1053], [",", 1056], ["NPY", 1058], [",", 1061], ["FKBP9", 1063], [",", 1068], ["FKBP14", 1070], [",", 1076], ["PDE1C", 1078], [",", 1083], ["and", 1085], ["TBX20", 1089], [",", 1094], ["in", 1096], ["and", 1099], ["around", 1103], ["this", 1110], ["locus", 1115], [",", 1120], ["did", 1122], ["not", 1126], ["reveal", 1130], ["any", 1137], ["mutation", 1141], [".", 1149], ["We", 1151], ["have", 1154], ["identified", 1159], ["a", 1170], ["novel", 1172], ["highly", 1178], ["malignant", 1185], ["autosomal", 1195], ["recessive", 1205], ["form", 1215], ["of", 1220], ["CPVT", 1223], ["and", 1228], ["mapped", 1232], ["this", 1239], ["disorder", 1244], ["to", 1253], ["a", 1256], ["25-Mb", 1258], ["interval", 1264], ["on", 1273], ["chromosome", 1276], ["7p14-p22", 1287], [".", 1295]]}
{"context": "The completeness of meningioma resection depends on the resection of dura mater invaded by the tumor. The pathological changes of the dura around the tumor can be interpreted by evaluating the dural tail sign (DTS) on MRI studies. The goal of this study was to clarify the pathological characteristics of the DTSs, propose a classification based on the histopathological and radiological correlation, and identify the invasive range of tumor cells in different types of DTS. The authors retrospectively reviewed 179 patients with convexity meningiomas who underwent Simpson Grade I resection. All patients underwent an enhanced MRI examination preoperatively. The convexity meningiomas were dichotomized into various subtypes in accordance with the 2007 WHO classification of tumors of the CNS, and the DTS was identified based on the Goldsher criteria. The range of resection of the involved dura was 3 cm from the base of the tumor, which corresponded with the length of DTS on MRI studies. Histopathological examination of dura at 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 cm from the base of the tumor was conducted, and the findings were correlated with the preoperative MRI appearance of the DTS. A total of 154 (86%) of 179 convexity meningiomas were classified into WHO Grade I subtype, including transitional (44 [28.6%] of 154), meningothelial (36 [23.4%] of 154), fibrous (23 [14.9%] of 154), psammomatous (22 [14.3%] of 154), secretory (10 [6.5%] of 154), and angiomatous (19 [12.3%] of 154). The other 25 (14%) were non-Grade I (WHO) tumors, including atypical (12 [48%] of 25), anaplastic (5 [20%] of 25), and papillary (8 [32%] of 25). The DTS was classified into 5 types: smooth (16 [8.9%] of 179), nodular (36 [20.1%] of 179), mixed (57 [31.8%] of 179), symmetrical multipolar (15 [8.4%] of 179), and asymmetrical multipolar (55 [30.7%] of 179). There was a significant difference in distribution of DTS type between Grade I and non-Grade I tumors (p = 0.004), whereas the difference was not significant among Grade I tumors (0.841) or among non-Grade I tumors (p = 0.818). All smooth-type DTSs were encountered in Grade I tumors, and the mixed DTS (52 [33.8%] of 154) was the most common type in these tumors. Nodular-type DTS was more commonly seen in non-Grade I tumors (12 [48%] of 25). Tumor invasion was found in 88.3% (158 of 179) of convexity meningiomas, of which the range of invasion in 82.3% (130 of 158) was within 2 cm and that in 94.9% (150 of 158) was within 2.5 cm. The incidence of invasion and the range invaded by tumor cells varied in different types of DTS, and differences were statistically significant (p < 0.001). Nodular-type DTS on MRI studies might be associated with non-Grade I tumors. The range of dural resection for convexity meningiomas should be 2.5 cm from the tumor base, and if this extent of resection is not feasible, the type of DTS should be considered. However, for skull base meningiomas, in which mostly Simpson Grade II resection is achieved, the use of this classification should be further validated. The classification of DTS enables the surgeon to predict preoperatively and then to achieve the optimal range of dural resection that might significantly reduce the recurrence rate of meningiomas.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "dfc371178f7740ec80686c0baf2ecc3a", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[3, 3]], "char_spans": [[20, 29]]}]}], "context_tokens": [["The", 0], ["completeness", 4], ["of", 17], ["meningioma", 20], ["resection", 31], ["depends", 41], ["on", 49], ["the", 52], ["resection", 56], ["of", 66], ["dura", 69], ["mater", 74], ["invaded", 80], ["by", 88], ["the", 91], ["tumor", 95], [".", 100], ["The", 102], ["pathological", 106], ["changes", 119], ["of", 127], ["the", 130], ["dura", 134], ["around", 139], ["the", 146], ["tumor", 150], ["can", 156], ["be", 160], ["interpreted", 163], ["by", 175], ["evaluating", 178], ["the", 189], ["dural", 193], ["tail", 199], ["sign", 204], ["(", 209], ["DTS", 210], [")", 213], ["on", 215], ["MRI", 218], ["studies", 222], [".", 229], ["The", 231], ["goal", 235], ["of", 240], ["this", 243], ["study", 248], ["was", 254], ["to", 258], ["clarify", 261], ["the", 269], ["pathological", 273], ["characteristics", 286], ["of", 302], ["the", 305], ["DTSs", 309], [",", 313], ["propose", 315], ["a", 323], ["classification", 325], ["based", 340], ["on", 346], ["the", 349], ["histopathological", 353], ["and", 371], ["radiological", 375], ["correlation", 388], [",", 399], ["and", 401], ["identify", 405], ["the", 414], ["invasive", 418], ["range", 427], ["of", 433], ["tumor", 436], ["cells", 442], ["in", 448], ["different", 451], ["types", 461], ["of", 467], ["DTS", 470], [".", 473], ["The", 475], ["authors", 479], ["retrospectively", 487], ["reviewed", 503], ["179", 512], ["patients", 516], ["with", 525], ["convexity", 530], ["meningiomas", 540], ["who", 552], ["underwent", 556], ["Simpson", 566], ["Grade", 574], ["I", 580], ["resection", 582], [".", 591], ["All", 593], ["patients", 597], ["underwent", 606], ["an", 616], ["enhanced", 619], ["MRI", 628], ["examination", 632], ["preoperatively", 644], [".", 658], ["The", 660], ["convexity", 664], ["meningiomas", 674], ["were", 686], ["dichotomized", 691], ["into", 704], ["various", 709], ["subtypes", 717], ["in", 726], ["accordance", 729], ["with", 740], ["the", 745], ["2007", 749], ["WHO", 754], ["classification", 758], ["of", 773], ["tumors", 776], ["of", 783], ["the", 786], ["CNS", 790], [",", 793], ["and", 795], ["the", 799], ["DTS", 803], ["was", 807], ["identified", 811], ["based", 822], ["on", 828], ["the", 831], ["Goldsher", 835], ["criteria", 844], [".", 852], ["The", 854], ["range", 858], ["of", 864], ["resection", 867], ["of", 877], ["the", 880], ["involved", 884], ["dura", 893], ["was", 898], ["3", 902], ["cm", 904], ["from", 907], ["the", 912], ["base", 916], ["of", 921], ["the", 924], ["tumor", 928], [",", 933], ["which", 935], ["corresponded", 941], ["with", 954], ["the", 959], ["length", 963], ["of", 970], ["DTS", 973], ["on", 977], ["MRI", 980], ["studies", 984], [".", 991], ["Histopathological", 993], ["examination", 1011], ["of", 1023], ["dura", 1026], ["at", 1031], ["0.5", 1034], [",", 1037], ["1.0", 1039], [",", 1042], ["1.5", 1044], [",", 1047], ["2.0", 1049], [",", 1052], ["2.5", 1054], [",", 1057], ["and", 1059], ["3.0", 1063], ["cm", 1067], ["from", 1070], ["the", 1075], ["base", 1079], ["of", 1084], ["the", 1087], ["tumor", 1091], ["was", 1097], ["conducted", 1101], [",", 1110], ["and", 1112], ["the", 1116], ["findings", 1120], ["were", 1129], ["correlated", 1134], ["with", 1145], ["the", 1150], ["preoperative", 1154], ["MRI", 1167], ["appearance", 1171], ["of", 1182], ["the", 1185], ["DTS", 1189], [".", 1192], ["A", 1194], ["total", 1196], ["of", 1202], ["154", 1205], ["(", 1209], ["86", 1210], ["%", 1212], [")", 1213], ["of", 1215], ["179", 1218], ["convexity", 1222], ["meningiomas", 1232], ["were", 1244], ["classified", 1249], ["into", 1260], ["WHO", 1265], ["Grade", 1269], ["I", 1275], ["subtype", 1277], [",", 1284], ["including", 1286], ["transitional", 1296], ["(", 1309], ["44", 1310], ["[", 1313], ["28.6", 1314], ["%", 1318], ["]", 1319], ["of", 1321], ["154", 1324], [")", 1327], [",", 1328], ["meningothelial", 1330], ["(", 1345], ["36", 1346], ["[", 1349], ["23.4", 1350], ["%", 1354], ["]", 1355], ["of", 1357], ["154", 1360], [")", 1363], [",", 1364], ["fibrous", 1366], ["(", 1374], ["23", 1375], ["[", 1378], ["14.9", 1379], ["%", 1383], ["]", 1384], ["of", 1386], ["154", 1389], [")", 1392], [",", 1393], ["psammomatous", 1395], ["(", 1408], ["22", 1409], ["[", 1412], ["14.3", 1413], ["%", 1417], ["]", 1418], ["of", 1420], ["154", 1423], [")", 1426], [",", 1427], ["secretory", 1429], ["(", 1439], ["10", 1440], ["[", 1443], ["6.5", 1444], ["%", 1447], ["]", 1448], ["of", 1450], ["154", 1453], [")", 1456], [",", 1457], ["and", 1459], ["angiomatous", 1463], ["(", 1475], ["19", 1476], ["[", 1479], ["12.3", 1480], ["%", 1484], ["]", 1485], ["of", 1487], ["154", 1490], [")", 1493], [".", 1494], ["The", 1496], ["other", 1500], ["25", 1506], ["(", 1509], ["14", 1510], ["%", 1512], [")", 1513], ["were", 1515], ["non", 1520], ["-", 1523], ["Grade", 1524], ["I", 1530], ["(", 1532], ["WHO", 1533], [")", 1536], ["tumors", 1538], [",", 1544], ["including", 1546], ["atypical", 1556], ["(", 1565], ["12", 1566], ["[", 1569], ["48", 1570], ["%", 1572], ["]", 1573], ["of", 1575], ["25", 1578], [")", 1580], [",", 1581], ["anaplastic", 1583], ["(", 1594], ["5", 1595], ["[", 1597], ["20", 1598], ["%", 1600], ["]", 1601], ["of", 1603], ["25", 1606], [")", 1608], [",", 1609], ["and", 1611], ["papillary", 1615], ["(", 1625], ["8", 1626], ["[", 1628], ["32", 1629], ["%", 1631], ["]", 1632], ["of", 1634], ["25", 1637], [")", 1639], [".", 1640], ["The", 1642], ["DTS", 1646], ["was", 1650], ["classified", 1654], ["into", 1665], ["5", 1670], ["types", 1672], [":", 1677], ["smooth", 1679], ["(", 1686], ["16", 1687], ["[", 1690], ["8.9", 1691], ["%", 1694], ["]", 1695], ["of", 1697], ["179", 1700], [")", 1703], [",", 1704], ["nodular", 1706], ["(", 1714], ["36", 1715], ["[", 1718], ["20.1", 1719], ["%", 1723], ["]", 1724], ["of", 1726], ["179", 1729], [")", 1732], [",", 1733], ["mixed", 1735], ["(", 1741], ["57", 1742], ["[", 1745], ["31.8", 1746], ["%", 1750], ["]", 1751], ["of", 1753], ["179", 1756], [")", 1759], [",", 1760], ["symmetrical", 1762], ["multipolar", 1774], ["(", 1785], ["15", 1786], ["[", 1789], ["8.4", 1790], ["%", 1793], ["]", 1794], ["of", 1796], ["179", 1799], [")", 1802], [",", 1803], ["and", 1805], ["asymmetrical", 1809], ["multipolar", 1822], ["(", 1833], ["55", 1834], ["[", 1837], ["30.7", 1838], ["%", 1842], ["]", 1843], ["of", 1845], ["179", 1848], [")", 1851], [".", 1852], ["There", 1854], ["was", 1860], ["a", 1864], ["significant", 1866], ["difference", 1878], ["in", 1889], ["distribution", 1892], ["of", 1905], ["DTS", 1908], ["type", 1912], ["between", 1917], ["Grade", 1925], ["I", 1931], ["and", 1933], ["non", 1937], ["-", 1940], ["Grade", 1941], ["I", 1947], ["tumors", 1949], ["(", 1956], ["p", 1957], ["=", 1959], ["0.004", 1961], [")", 1966], [",", 1967], ["whereas", 1969], ["the", 1977], ["difference", 1981], ["was", 1992], ["not", 1996], ["significant", 2000], ["among", 2012], ["Grade", 2018], ["I", 2024], ["tumors", 2026], ["(", 2033], ["0.841", 2034], [")", 2039], ["or", 2041], ["among", 2044], ["non", 2050], ["-", 2053], ["Grade", 2054], ["I", 2060], ["tumors", 2062], ["(", 2069], ["p", 2070], ["=", 2072], ["0.818", 2074], [")", 2079], [".", 2080], ["All", 2082], ["smooth", 2086], ["-", 2092], ["type", 2093], ["DTSs", 2098], ["were", 2103], ["encountered", 2108], ["in", 2120], ["Grade", 2123], ["I", 2129], ["tumors", 2131], [",", 2137], ["and", 2139], ["the", 2143], ["mixed", 2147], ["DTS", 2153], ["(", 2157], ["52", 2158], ["[", 2161], ["33.8", 2162], ["%", 2166], ["]", 2167], ["of", 2169], ["154", 2172], [")", 2175], ["was", 2177], ["the", 2181], ["most", 2185], ["common", 2190], ["type", 2197], ["in", 2202], ["these", 2205], ["tumors", 2211], [".", 2217], ["Nodular", 2219], ["-", 2226], ["type", 2227], ["DTS", 2232], ["was", 2236], ["more", 2240], ["commonly", 2245], ["seen", 2254], ["in", 2259], ["non", 2262], ["-", 2265], ["Grade", 2266], ["I", 2272], ["tumors", 2274], ["(", 2281], ["12", 2282], ["[", 2285], ["48", 2286], ["%", 2288], ["]", 2289], ["of", 2291], ["25", 2294], [")", 2296], [".", 2297], ["Tumor", 2299], ["invasion", 2305], ["was", 2314], ["found", 2318], ["in", 2324], ["88.3", 2327], ["%", 2331], ["(", 2333], ["158", 2334], ["of", 2338], ["179", 2341], [")", 2344], ["of", 2346], ["convexity", 2349], ["meningiomas", 2359], [",", 2370], ["of", 2372], ["which", 2375], ["the", 2381], ["range", 2385], ["of", 2391], ["invasion", 2394], ["in", 2403], ["82.3", 2406], ["%", 2410], ["(", 2412], ["130", 2413], ["of", 2417], ["158", 2420], [")", 2423], ["was", 2425], ["within", 2429], ["2", 2436], ["cm", 2438], ["and", 2441], ["that", 2445], ["in", 2450], ["94.9", 2453], ["%", 2457], ["(", 2459], ["150", 2460], ["of", 2464], ["158", 2467], [")", 2470], ["was", 2472], ["within", 2476], ["2.5", 2483], ["cm", 2487], [".", 2489], ["The", 2491], ["incidence", 2495], ["of", 2505], ["invasion", 2508], ["and", 2517], ["the", 2521], ["range", 2525], ["invaded", 2531], ["by", 2539], ["tumor", 2542], ["cells", 2548], ["varied", 2554], ["in", 2561], ["different", 2564], ["types", 2574], ["of", 2580], ["DTS", 2583], [",", 2586], ["and", 2588], ["differences", 2592], ["were", 2604], ["statistically", 2609], ["significant", 2623], ["(", 2635], ["p", 2636], ["<", 2638], ["0.001", 2640], [")", 2645], [".", 2646], ["Nodular", 2648], ["-", 2655], ["type", 2656], ["DTS", 2661], ["on", 2665], ["MRI", 2668], ["studies", 2672], ["might", 2680], ["be", 2686], ["associated", 2689], ["with", 2700], ["non", 2705], ["-", 2708], ["Grade", 2709], ["I", 2715], ["tumors", 2717], [".", 2723], ["The", 2725], ["range", 2729], ["of", 2735], ["dural", 2738], ["resection", 2744], ["for", 2754], ["convexity", 2758], ["meningiomas", 2768], ["should", 2780], ["be", 2787], ["2.5", 2790], ["cm", 2794], ["from", 2797], ["the", 2802], ["tumor", 2806], ["base", 2812], [",", 2816], ["and", 2818], ["if", 2822], ["this", 2825], ["extent", 2830], ["of", 2837], ["resection", 2840], ["is", 2850], ["not", 2853], ["feasible", 2857], [",", 2865], ["the", 2867], ["type", 2871], ["of", 2876], ["DTS", 2879], ["should", 2883], ["be", 2890], ["considered", 2893], [".", 2903], ["However", 2905], [",", 2912], ["for", 2914], ["skull", 2918], ["base", 2924], ["meningiomas", 2929], [",", 2940], ["in", 2942], ["which", 2945], ["mostly", 2951], ["Simpson", 2958], ["Grade", 2966], ["II", 2972], ["resection", 2975], ["is", 2985], ["achieved", 2988], [",", 2996], ["the", 2998], ["use", 3002], ["of", 3006], ["this", 3009], ["classification", 3014], ["should", 3029], ["be", 3036], ["further", 3039], ["validated", 3047], [".", 3056], ["The", 3058], ["classification", 3062], ["of", 3077], ["DTS", 3080], ["enables", 3084], ["the", 3092], ["surgeon", 3096], ["to", 3104], ["predict", 3107], ["preoperatively", 3115], ["and", 3130], ["then", 3134], ["to", 3139], ["achieve", 3142], ["the", 3150], ["optimal", 3154], ["range", 3162], ["of", 3168], ["dural", 3171], ["resection", 3177], ["that", 3187], ["might", 3192], ["significantly", 3198], ["reduce", 3212], ["the", 3219], ["recurrence", 3223], ["rate", 3234], ["of", 3239], ["meningiomas", 3242], [".", 3253]]}
{"context": "To identify and compare the operating characteristics of existing prehospital stroke scales to predict true strokes in the hospital. We searched MEDLINE, EMBASE, and CINAHL databases for articles that evaluated the performance of prehospital stroke scales. Quality of the included studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. We abstracted the operating characteristics of published prehospital stroke scales and compared them statistically and graphically. We retrieved 254 articles from MEDLINE, 66 articles from EMBASE, and 32 articles from CINAHL Plus database. Of these, 8 studies met all our inclusion criteria, and they studied Cincinnati Pre-Hospital Stroke Scale (CPSS), Los Angeles Pre-Hospital Stroke Screen (LAPSS), Melbourne Ambulance Stroke Screen (MASS), Medic Prehospital Assessment for Code Stroke (Med PACS), Ontario Prehospital Stroke Screening Tool (OPSS), Recognition of Stroke in the Emergency Room (ROSIER), and Face Arm Speech Test (FAST). Although the point estimates for LAPSS accuracy were better than CPSS, they had overlapping confidence intervals on the symmetric summary receiver operating characteristic curve. OPSS performed similar to LAPSS whereas MASS, Med PACS, ROSIER, and FAST had less favorable overall operating characteristics. Prehospital stroke scales varied in their accuracy and missed up to 30% of acute strokes in the field. Inconsistencies in performance may be due to sample size disparity, variability in stroke scale training, and divergent provider educational standards. Although LAPSS performed more consistently, visual comparison of graphical analysis revealed that LAPSS and CPSS had similar diagnostic capabilities.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "4499cb8591df4db39618e8fc1992e197", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[112, 112], [226, 226], [123, 123], [37, 37], [10, 10], [131, 131], [150, 150], [258, 258], [159, 159], [142, 142], [65, 65]], "char_spans": [[703, 708], [1326, 1331], [749, 754], [242, 247], [78, 83], [792, 797], [891, 896], [1500, 1505], [936, 941], [852, 857], [439, 444]]}]}], "context_tokens": [["To", 0], ["identify", 3], ["and", 12], ["compare", 16], ["the", 24], ["operating", 28], ["characteristics", 38], ["of", 54], ["existing", 57], ["prehospital", 66], ["stroke", 78], ["scales", 85], ["to", 92], ["predict", 95], ["true", 103], ["strokes", 108], ["in", 116], ["the", 119], ["hospital", 123], [".", 131], ["We", 133], ["searched", 136], ["MEDLINE", 145], [",", 152], ["EMBASE", 154], [",", 160], ["and", 162], ["CINAHL", 166], ["databases", 173], ["for", 183], ["articles", 187], ["that", 196], ["evaluated", 201], ["the", 211], ["performance", 215], ["of", 227], ["prehospital", 230], ["stroke", 242], ["scales", 249], [".", 255], ["Quality", 257], ["of", 265], ["the", 268], ["included", 272], ["studies", 281], ["was", 289], ["assessed", 293], ["using", 302], ["the", 308], ["Quality", 312], ["Assessment", 320], ["of", 331], ["Diagnostic", 334], ["Accuracy", 345], ["Studies-2", 354], ["tool", 364], [".", 368], ["We", 370], ["abstracted", 373], ["the", 384], ["operating", 388], ["characteristics", 398], ["of", 414], ["published", 417], ["prehospital", 427], ["stroke", 439], ["scales", 446], ["and", 453], ["compared", 457], ["them", 466], ["statistically", 471], ["and", 485], ["graphically", 489], [".", 500], ["We", 502], ["retrieved", 505], ["254", 515], ["articles", 519], ["from", 528], ["MEDLINE", 533], [",", 540], ["66", 542], ["articles", 545], ["from", 554], ["EMBASE", 559], [",", 565], ["and", 567], ["32", 571], ["articles", 574], ["from", 583], ["CINAHL", 588], ["Plus", 595], ["database", 600], [".", 608], ["Of", 610], ["these", 613], [",", 618], ["8", 620], ["studies", 622], ["met", 630], ["all", 634], ["our", 638], ["inclusion", 642], ["criteria", 652], [",", 660], ["and", 662], ["they", 666], ["studied", 671], ["Cincinnati", 679], ["Pre", 690], ["-", 693], ["Hospital", 694], ["Stroke", 703], ["Scale", 710], ["(", 716], ["CPSS", 717], [")", 721], [",", 722], ["Los", 724], ["Angeles", 728], ["Pre", 736], ["-", 739], ["Hospital", 740], ["Stroke", 749], ["Screen", 756], ["(", 763], ["LAPSS", 764], [")", 769], [",", 770], ["Melbourne", 772], ["Ambulance", 782], ["Stroke", 792], ["Screen", 799], ["(", 806], ["MASS", 807], [")", 811], [",", 812], ["Medic", 814], ["Prehospital", 820], ["Assessment", 832], ["for", 843], ["Code", 847], ["Stroke", 852], ["(", 859], ["Med", 860], ["PACS", 864], [")", 868], [",", 869], ["Ontario", 871], ["Prehospital", 879], ["Stroke", 891], ["Screening", 898], ["Tool", 908], ["(", 913], ["OPSS", 914], [")", 918], [",", 919], ["Recognition", 921], ["of", 933], ["Stroke", 936], ["in", 943], ["the", 946], ["Emergency", 950], ["Room", 960], ["(", 965], ["ROSIER", 966], [")", 972], [",", 973], ["and", 975], ["Face", 979], ["Arm", 984], ["Speech", 988], ["Test", 995], ["(", 1000], ["FAST", 1001], [")", 1005], [".", 1006], ["Although", 1008], ["the", 1017], ["point", 1021], ["estimates", 1027], ["for", 1037], ["LAPSS", 1041], ["accuracy", 1047], ["were", 1056], ["better", 1061], ["than", 1068], ["CPSS", 1073], [",", 1077], ["they", 1079], ["had", 1084], ["overlapping", 1088], ["confidence", 1100], ["intervals", 1111], ["on", 1121], ["the", 1124], ["symmetric", 1128], ["summary", 1138], ["receiver", 1146], ["operating", 1155], ["characteristic", 1165], ["curve", 1180], [".", 1185], ["OPSS", 1187], ["performed", 1192], ["similar", 1202], ["to", 1210], ["LAPSS", 1213], ["whereas", 1219], ["MASS", 1227], [",", 1231], ["Med", 1233], ["PACS", 1237], [",", 1241], ["ROSIER", 1243], [",", 1249], ["and", 1251], ["FAST", 1255], ["had", 1260], ["less", 1264], ["favorable", 1269], ["overall", 1279], ["operating", 1287], ["characteristics", 1297], [".", 1312], ["Prehospital", 1314], ["stroke", 1326], ["scales", 1333], ["varied", 1340], ["in", 1347], ["their", 1350], ["accuracy", 1356], ["and", 1365], ["missed", 1369], ["up", 1376], ["to", 1379], ["30", 1382], ["%", 1384], ["of", 1386], ["acute", 1389], ["strokes", 1395], ["in", 1403], ["the", 1406], ["field", 1410], [".", 1415], ["Inconsistencies", 1417], ["in", 1433], ["performance", 1436], ["may", 1448], ["be", 1452], ["due", 1455], ["to", 1459], ["sample", 1462], ["size", 1469], ["disparity", 1474], [",", 1483], ["variability", 1485], ["in", 1497], ["stroke", 1500], ["scale", 1507], ["training", 1513], [",", 1521], ["and", 1523], ["divergent", 1527], ["provider", 1537], ["educational", 1546], ["standards", 1558], [".", 1567], ["Although", 1569], ["LAPSS", 1578], ["performed", 1584], ["more", 1594], ["consistently", 1599], [",", 1611], ["visual", 1613], ["comparison", 1620], ["of", 1631], ["graphical", 1634], ["analysis", 1644], ["revealed", 1653], ["that", 1662], ["LAPSS", 1667], ["and", 1673], ["CPSS", 1677], ["had", 1682], ["similar", 1686], ["diagnostic", 1694], ["capabilities", 1705], [".", 1717]]}
{"context": "Selenocysteine is incorporated into proteins via \"recoding\" of UGA from a stop codon to a sense codon, a process that requires specific secondary structures in the 3' untranslated region, termed selenocysteine incorporation sequence (SECIS) elements, and the protein factors that they recruit. Whereas most selenoprotein mRNAs contain a single UGA codon and a single SECIS element, selenoprotein P genes encode multiple UGAs and two SECIS elements. We have identified evolutionary adaptations in selenoprotein P genes that contribute to the efficiency of incorporating multiple selenocysteine residues in this protein. The first is a conserved, inefficiently decoded UGA codon in the N-terminal region, which appears to serve both as a checkpoint for the presence of factors required for selenocysteine incorporation and as a \"bottleneck,\" slowing down the progress of elongating ribosomes. The second adaptation involves the presence of introns downstream of this inefficiently decoded UGA which confer the potential for nonsense-mediated decay when factors required for selenocysteine incorporation are limiting. Third, the two SECIS elements in selenoprotein P mRNA function with differing efficiencies, affecting both the rate and the efficiency of decoding different UGAs. The implications for how these factors contribute to the decoding of multiple selenocysteine residues are discussed.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "47da715dad124f3690dc1764042458cc", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[188, 189], [83, 84], [66, 67]], "char_spans": [[1148, 1162], [496, 510], [382, 396]]}]}], "context_tokens": [["Selenocysteine", 0], ["is", 15], ["incorporated", 18], ["into", 31], ["proteins", 36], ["via", 45], ["\"", 49], ["recoding", 50], ["\"", 58], ["of", 60], ["UGA", 63], ["from", 67], ["a", 72], ["stop", 74], ["codon", 79], ["to", 85], ["a", 88], ["sense", 90], ["codon", 96], [",", 101], ["a", 103], ["process", 105], ["that", 113], ["requires", 118], ["specific", 127], ["secondary", 136], ["structures", 146], ["in", 157], ["the", 160], ["3", 164], ["'", 165], ["untranslated", 167], ["region", 180], [",", 186], ["termed", 188], ["selenocysteine", 195], ["incorporation", 210], ["sequence", 224], ["(", 233], ["SECIS", 234], [")", 239], ["elements", 241], [",", 249], ["and", 251], ["the", 255], ["protein", 259], ["factors", 267], ["that", 275], ["they", 280], ["recruit", 285], [".", 292], ["Whereas", 294], ["most", 302], ["selenoprotein", 307], ["mRNAs", 321], ["contain", 327], ["a", 335], ["single", 337], ["UGA", 344], ["codon", 348], ["and", 354], ["a", 358], ["single", 360], ["SECIS", 367], ["element", 373], [",", 380], ["selenoprotein", 382], ["P", 396], ["genes", 398], ["encode", 404], ["multiple", 411], ["UGAs", 420], ["and", 425], ["two", 429], ["SECIS", 433], ["elements", 439], [".", 447], ["We", 449], ["have", 452], ["identified", 457], ["evolutionary", 468], ["adaptations", 481], ["in", 493], ["selenoprotein", 496], ["P", 510], ["genes", 512], ["that", 518], ["contribute", 523], ["to", 534], ["the", 537], ["efficiency", 541], ["of", 552], ["incorporating", 555], ["multiple", 569], ["selenocysteine", 578], ["residues", 593], ["in", 602], ["this", 605], ["protein", 610], [".", 617], ["The", 619], ["first", 623], ["is", 629], ["a", 632], ["conserved", 634], [",", 643], ["inefficiently", 645], ["decoded", 659], ["UGA", 667], ["codon", 671], ["in", 677], ["the", 680], ["N", 684], ["-", 685], ["terminal", 686], ["region", 695], [",", 701], ["which", 703], ["appears", 709], ["to", 717], ["serve", 720], ["both", 726], ["as", 731], ["a", 734], ["checkpoint", 736], ["for", 747], ["the", 751], ["presence", 755], ["of", 764], ["factors", 767], ["required", 775], ["for", 784], ["selenocysteine", 788], ["incorporation", 803], ["and", 817], ["as", 821], ["a", 824], ["\"", 826], ["bottleneck", 827], [",", 837], ["\"", 838], ["slowing", 840], ["down", 848], ["the", 853], ["progress", 857], ["of", 866], ["elongating", 869], ["ribosomes", 880], [".", 889], ["The", 891], ["second", 895], ["adaptation", 902], ["involves", 913], ["the", 922], ["presence", 926], ["of", 935], ["introns", 938], ["downstream", 946], ["of", 957], ["this", 960], ["inefficiently", 965], ["decoded", 979], ["UGA", 987], ["which", 991], ["confer", 997], ["the", 1004], ["potential", 1008], ["for", 1018], ["nonsense", 1022], ["-", 1030], ["mediated", 1031], ["decay", 1040], ["when", 1046], ["factors", 1051], ["required", 1059], ["for", 1068], ["selenocysteine", 1072], ["incorporation", 1087], ["are", 1101], ["limiting", 1105], [".", 1113], ["Third", 1115], [",", 1120], ["the", 1122], ["two", 1126], ["SECIS", 1130], ["elements", 1136], ["in", 1145], ["selenoprotein", 1148], ["P", 1162], ["mRNA", 1164], ["function", 1169], ["with", 1178], ["differing", 1183], ["efficiencies", 1193], [",", 1205], ["affecting", 1207], ["both", 1217], ["the", 1222], ["rate", 1226], ["and", 1231], ["the", 1235], ["efficiency", 1239], ["of", 1250], ["decoding", 1253], ["different", 1262], ["UGAs", 1272], [".", 1276], ["The", 1278], ["implications", 1282], ["for", 1295], ["how", 1299], ["these", 1303], ["factors", 1309], ["contribute", 1317], ["to", 1328], ["the", 1331], ["decoding", 1335], ["of", 1344], ["multiple", 1347], ["selenocysteine", 1356], ["residues", 1371], ["are", 1380], ["discussed", 1384], [".", 1393]]}
{"context": "Venous thromboembolism (VTE) is associated with significant morbidity and mortality. Factors such as the presence of transient risk factors for VTE, risk of bleeding, and location of deep vein thrombosis (DVT) determine the duration of anticoagulation. Extended anticoagulation is offered to patients with unprovoked pulmonary embolism (PE) or proximal DVT and a low risk of bleeding. Anticoagulation for 3 months is advised in patients with provoked DVT or PE, high risk of bleeding, and isolated distal or upper extremity DVT. In patients with unprovoked PE or proximal DVT and a low risk of bleeding, who want to stop anticoagulation after 3 months, further risk stratification is necessary. Clinical scoring system, and thrombophilia testing otherwise not routinely performed, may be considered to measure risk of annual recurrence in such cases. Short-term anticoagulation may be considered in subsegmental PE and superficial vein thrombosis, particularly if patients are at low risk of bleeding and have persistent risk factors for recurrent VTE. In cases of catheter-associated thrombosis, the catheter need not be removed routinely, and the patient may be anticoagulated for 3 months or longer if the catheter is maintained in patients with cancer. Extensive screening for occult cancer in cases of unprovoked VTE is not beneficial. New oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "db97a187c75442e883f177344a687937", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[243, 243]], "char_spans": [[1399, 1408]]}]}], "context_tokens": [["Venous", 0], ["thromboembolism", 7], ["(", 23], ["VTE", 24], [")", 27], ["is", 29], ["associated", 32], ["with", 43], ["significant", 48], ["morbidity", 60], ["and", 70], ["mortality", 74], [".", 83], ["Factors", 85], ["such", 93], ["as", 98], ["the", 101], ["presence", 105], ["of", 114], ["transient", 117], ["risk", 127], ["factors", 132], ["for", 140], ["VTE", 144], [",", 147], ["risk", 149], ["of", 154], ["bleeding", 157], [",", 165], ["and", 167], ["location", 171], ["of", 180], ["deep", 183], ["vein", 188], ["thrombosis", 193], ["(", 204], ["DVT", 205], [")", 208], ["determine", 210], ["the", 220], ["duration", 224], ["of", 233], ["anticoagulation", 236], [".", 251], ["Extended", 253], ["anticoagulation", 262], ["is", 278], ["offered", 281], ["to", 289], ["patients", 292], ["with", 301], ["unprovoked", 306], ["pulmonary", 317], ["embolism", 327], ["(", 336], ["PE", 337], [")", 339], ["or", 341], ["proximal", 344], ["DVT", 353], ["and", 357], ["a", 361], ["low", 363], ["risk", 367], ["of", 372], ["bleeding", 375], [".", 383], ["Anticoagulation", 385], ["for", 401], ["3", 405], ["months", 407], ["is", 414], ["advised", 417], ["in", 425], ["patients", 428], ["with", 437], ["provoked", 442], ["DVT", 451], ["or", 455], ["PE", 458], [",", 460], ["high", 462], ["risk", 467], ["of", 472], ["bleeding", 475], [",", 483], ["and", 485], ["isolated", 489], ["distal", 498], ["or", 505], ["upper", 508], ["extremity", 514], ["DVT", 524], [".", 527], ["In", 529], ["patients", 532], ["with", 541], ["unprovoked", 546], ["PE", 557], ["or", 560], ["proximal", 563], ["DVT", 572], ["and", 576], ["a", 580], ["low", 582], ["risk", 586], ["of", 591], ["bleeding", 594], [",", 602], ["who", 604], ["want", 608], ["to", 613], ["stop", 616], ["anticoagulation", 621], ["after", 637], ["3", 643], ["months", 645], [",", 651], ["further", 653], ["risk", 661], ["stratification", 666], ["is", 681], ["necessary", 684], [".", 693], ["Clinical", 695], ["scoring", 704], ["system", 712], [",", 718], ["and", 720], ["thrombophilia", 724], ["testing", 738], ["otherwise", 746], ["not", 756], ["routinely", 760], ["performed", 770], [",", 779], ["may", 781], ["be", 785], ["considered", 788], ["to", 799], ["measure", 802], ["risk", 810], ["of", 815], ["annual", 818], ["recurrence", 825], ["in", 836], ["such", 839], ["cases", 844], [".", 849], ["Short", 851], ["-", 856], ["term", 857], ["anticoagulation", 862], ["may", 878], ["be", 882], ["considered", 885], ["in", 896], ["subsegmental", 899], ["PE", 912], ["and", 915], ["superficial", 919], ["vein", 931], ["thrombosis", 936], [",", 946], ["particularly", 948], ["if", 961], ["patients", 964], ["are", 973], ["at", 977], ["low", 980], ["risk", 984], ["of", 989], ["bleeding", 992], ["and", 1001], ["have", 1005], ["persistent", 1010], ["risk", 1021], ["factors", 1026], ["for", 1034], ["recurrent", 1038], ["VTE", 1048], [".", 1051], ["In", 1053], ["cases", 1056], ["of", 1062], ["catheter", 1065], ["-", 1073], ["associated", 1074], ["thrombosis", 1085], [",", 1095], ["the", 1097], ["catheter", 1101], ["need", 1110], ["not", 1115], ["be", 1119], ["removed", 1122], ["routinely", 1130], [",", 1139], ["and", 1141], ["the", 1145], ["patient", 1149], ["may", 1157], ["be", 1161], ["anticoagulated", 1164], ["for", 1179], ["3", 1183], ["months", 1185], ["or", 1192], ["longer", 1195], ["if", 1202], ["the", 1205], ["catheter", 1209], ["is", 1218], ["maintained", 1221], ["in", 1232], ["patients", 1235], ["with", 1244], ["cancer", 1249], [".", 1255], ["Extensive", 1257], ["screening", 1267], ["for", 1277], ["occult", 1281], ["cancer", 1288], ["in", 1295], ["cases", 1298], ["of", 1304], ["unprovoked", 1307], ["VTE", 1318], ["is", 1322], ["not", 1325], ["beneficial", 1329], [".", 1339], ["New", 1341], ["oral", 1345], ["anticoagulants", 1350], ["such", 1365], ["as", 1370], ["apixaban", 1373], [",", 1381], ["rivaroxaban", 1383], [",", 1394], ["or", 1396], ["dabigatran", 1399], ["may", 1410], ["be", 1414], ["preferred", 1417], ["to", 1427], ["vitamin", 1430], ["K", 1438], ["antagonists", 1440], ["in", 1452], ["patients", 1455], ["without", 1464], ["cancer", 1472], ["or", 1479], ["renal", 1482], ["failure", 1488], [",", 1495], ["more", 1497], ["so", 1502], ["after", 1505], ["the", 1511], ["development", 1515], ["of", 1527], ["reversal", 1530], ["agents", 1539], ["such", 1546], ["as", 1551], ["idarucizumab", 1554], ["and", 1567], ["andexanet", 1571], ["alfa", 1581], [".", 1585]]}
{"context": "Interleukin-1\u03b2 (IL-1\u03b2) is a proinflammatory cytokine that is implicated in many autoinflammatory disorders, but is also important in defense against pathogens. Thus, there is a need to safely and effectively modulate IL-1\u03b2 activity to reduce pathology while maintaining function. Gevokizumab is a potent anti-IL-1\u03b2 antibody being developed as a treatment for diseases in which IL-1\u03b2 has been associated with pathogenesis. Previous data indicated that gevokizumab negatively modulates IL-1\u03b2 signaling through an allosteric mechanism. Because IL-1\u03b2 signaling is a complex, dynamic process involving multiple components, it is important to understand the kinetics of IL-1\u03b2 signaling and the impact of gevokizumab on this process. In the present study, we measured the impact of gevokizumab on the IL-1\u03b2 system using Schild analysis and surface plasmon resonance studies, both of which demonstrated that gevokizumab decreases the binding affinity of IL-1\u03b2 for the IL-1 receptor type I (IL-1RI) signaling receptor, but not the IL-1 counter-regulatory decoy receptor (IL-1 receptor type II). Gevokizumab inhibits both the binding of IL-1\u03b2 to IL-1RI and the subsequent recruitment of IL-1 accessory protein primarily by reducing the association rates of these interactions. Based on this information and recently published structural data, we propose that gevokizumab decreases the association rate for binding of IL-1\u03b2 to its receptor by altering the electrostatic surface potential of IL-1\u03b2, thus reducing the contribution of electrostatic steering to the rapid association rate. These data indicate, therefore, that gevokizumab is a unique inhibitor of IL-1\u03b2 signaling that may offer an alternative to current therapies for IL-1\u03b2-associated autoinflammatory diseases.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "5389373ddbe048119c1dbeb0494dd528", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[128, 128], [51, 51], [227, 227], [150, 150], [266, 266], [2, 2], [277, 277], [36, 36], [76, 76], [84, 84], [185, 185], [238, 238], [104, 104], [62, 62]], "char_spans": [[794, 798], [309, 313], [1407, 1411], [946, 950], [1649, 1653], [16, 20], [1720, 1724], [217, 221], [484, 488], [541, 545], [1127, 1131], [1480, 1484], [664, 668], [377, 381]]}]}], "context_tokens": [["Interleukin-1\u03b2", 0], ["(", 15], ["IL-1\u03b2", 16], [")", 21], ["is", 23], ["a", 26], ["proinflammatory", 28], ["cytokine", 44], ["that", 53], ["is", 58], ["implicated", 61], ["in", 72], ["many", 75], ["autoinflammatory", 80], ["disorders", 97], [",", 106], ["but", 108], ["is", 112], ["also", 115], ["important", 120], ["in", 130], ["defense", 133], ["against", 141], ["pathogens", 149], [".", 158], ["Thus", 160], [",", 164], ["there", 166], ["is", 172], ["a", 175], ["need", 177], ["to", 182], ["safely", 185], ["and", 192], ["effectively", 196], ["modulate", 208], ["IL-1\u03b2", 217], ["activity", 223], ["to", 232], ["reduce", 235], ["pathology", 242], ["while", 252], ["maintaining", 258], ["function", 270], [".", 278], ["Gevokizumab", 280], ["is", 292], ["a", 295], ["potent", 297], ["anti", 304], ["-", 308], ["IL-1\u03b2", 309], ["antibody", 315], ["being", 324], ["developed", 330], ["as", 340], ["a", 343], ["treatment", 345], ["for", 355], ["diseases", 359], ["in", 368], ["which", 371], ["IL-1\u03b2", 377], ["has", 383], ["been", 387], ["associated", 392], ["with", 403], ["pathogenesis", 408], [".", 420], ["Previous", 422], ["data", 431], ["indicated", 436], ["that", 446], ["gevokizumab", 451], ["negatively", 463], ["modulates", 474], ["IL-1\u03b2", 484], ["signaling", 490], ["through", 500], ["an", 508], ["allosteric", 511], ["mechanism", 522], [".", 531], ["Because", 533], ["IL-1\u03b2", 541], ["signaling", 547], ["is", 557], ["a", 560], ["complex", 562], [",", 569], ["dynamic", 571], ["process", 579], ["involving", 587], ["multiple", 597], ["components", 606], [",", 616], ["it", 618], ["is", 621], ["important", 624], ["to", 634], ["understand", 637], ["the", 648], ["kinetics", 652], ["of", 661], ["IL-1\u03b2", 664], ["signaling", 670], ["and", 680], ["the", 684], ["impact", 688], ["of", 695], ["gevokizumab", 698], ["on", 710], ["this", 713], ["process", 718], [".", 725], ["In", 727], ["the", 730], ["present", 734], ["study", 742], [",", 747], ["we", 749], ["measured", 752], ["the", 761], ["impact", 765], ["of", 772], ["gevokizumab", 775], ["on", 787], ["the", 790], ["IL-1\u03b2", 794], ["system", 800], ["using", 807], ["Schild", 813], ["analysis", 820], ["and", 829], ["surface", 833], ["plasmon", 841], ["resonance", 849], ["studies", 859], [",", 866], ["both", 868], ["of", 873], ["which", 876], ["demonstrated", 882], ["that", 895], ["gevokizumab", 900], ["decreases", 912], ["the", 922], ["binding", 926], ["affinity", 934], ["of", 943], ["IL-1\u03b2", 946], ["for", 952], ["the", 956], ["IL-1", 960], ["receptor", 965], ["type", 974], ["I", 979], ["(", 981], ["IL-1RI", 982], [")", 988], ["signaling", 990], ["receptor", 1000], [",", 1008], ["but", 1010], ["not", 1014], ["the", 1018], ["IL-1", 1022], ["counter", 1027], ["-", 1034], ["regulatory", 1035], ["decoy", 1046], ["receptor", 1052], ["(", 1061], ["IL-1", 1062], ["receptor", 1067], ["type", 1076], ["II", 1081], [")", 1083], [".", 1084], ["Gevokizumab", 1086], ["inhibits", 1098], ["both", 1107], ["the", 1112], ["binding", 1116], ["of", 1124], ["IL-1\u03b2", 1127], ["to", 1133], ["IL-1RI", 1136], ["and", 1143], ["the", 1147], ["subsequent", 1151], ["recruitment", 1162], ["of", 1174], ["IL-1", 1177], ["accessory", 1182], ["protein", 1192], ["primarily", 1200], ["by", 1210], ["reducing", 1213], ["the", 1222], ["association", 1226], ["rates", 1238], ["of", 1244], ["these", 1247], ["interactions", 1253], [".", 1265], ["Based", 1267], ["on", 1273], ["this", 1276], ["information", 1281], ["and", 1293], ["recently", 1297], ["published", 1306], ["structural", 1316], ["data", 1327], [",", 1331], ["we", 1333], ["propose", 1336], ["that", 1344], ["gevokizumab", 1349], ["decreases", 1361], ["the", 1371], ["association", 1375], ["rate", 1387], ["for", 1392], ["binding", 1396], ["of", 1404], ["IL-1\u03b2", 1407], ["to", 1413], ["its", 1416], ["receptor", 1420], ["by", 1429], ["altering", 1432], ["the", 1441], ["electrostatic", 1445], ["surface", 1459], ["potential", 1467], ["of", 1477], ["IL-1\u03b2", 1480], [",", 1485], ["thus", 1487], ["reducing", 1492], ["the", 1501], ["contribution", 1505], ["of", 1518], ["electrostatic", 1521], ["steering", 1535], ["to", 1544], ["the", 1547], ["rapid", 1551], ["association", 1557], ["rate", 1569], [".", 1573], ["These", 1575], ["data", 1581], ["indicate", 1586], [",", 1594], ["therefore", 1596], [",", 1605], ["that", 1607], ["gevokizumab", 1612], ["is", 1624], ["a", 1627], ["unique", 1629], ["inhibitor", 1636], ["of", 1646], ["IL-1\u03b2", 1649], ["signaling", 1655], ["that", 1665], ["may", 1670], ["offer", 1674], ["an", 1680], ["alternative", 1683], ["to", 1695], ["current", 1698], ["therapies", 1706], ["for", 1716], ["IL-1\u03b2", 1720], ["-", 1725], ["associated", 1726], ["autoinflammatory", 1737], ["diseases", 1754], [".", 1762]]}
{"context": "\u03b1-Synuclein is the major protein component of Lewy bodies--the pathological hallmark of Parkinson's disease (PD) and Dementia with Lewy bodies (DLB). Its accumulation into intracellular aggregates is implicated in the process of Lewy body formation. However, its roles in both normal function, and disease, remain controversial. Using a novel model of chronic oxidative stress in cultured dopaminergic and cortical neurons, we report that endogenous \u03b1-synuclein is upregulated in response to low dose toxicity. This response is conserved between subpopulations of cortical and dopaminergic neurons, and confers relative resistance to apoptosis following secondary insult. Additional acute oxidative stress leads to intracellular accumulation of \u03b1-synuclein. These punctate deposits colocalize with ubiquitin, which is central to proteosome-mediated protein degeneration, and is the second major component of Lewy bodies. The current results imply that differential levels of \u03b1-synuclein expression may influence neuronal vulnerability in chronic neurodegenerative diseases. They further support a 'two hit' hypothesis for Lewy body formation, whereby mild stress causes a protective upregulation of \u03b1-synuclein. However, such increased levels of \u03b1-synuclein may drive its accumulation, following additional toxic insult. Finally, these results support a common mechanism for degeneration of dopaminergic and cortical neurons, affected in PD, and DLB, respectively.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "4504ae5e0d41435984b259c276b8cf7f", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[80, 82], [0, 2], [197, 199], [207, 209], [162, 164], [123, 125]], "char_spans": [[450, 460], [0, 10], [1199, 1209], [1246, 1256], [975, 985], [745, 755]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["is", 12], ["the", 15], ["major", 19], ["protein", 25], ["component", 33], ["of", 43], ["Lewy", 46], ["bodies", 51], ["--", 57], ["the", 59], ["pathological", 63], ["hallmark", 76], ["of", 85], ["Parkinson", 88], ["'s", 97], ["disease", 100], ["(", 108], ["PD", 109], [")", 111], ["and", 113], ["Dementia", 117], ["with", 126], ["Lewy", 131], ["bodies", 136], ["(", 143], ["DLB", 144], [")", 147], [".", 148], ["Its", 150], ["accumulation", 154], ["into", 167], ["intracellular", 172], ["aggregates", 186], ["is", 197], ["implicated", 200], ["in", 211], ["the", 214], ["process", 218], ["of", 226], ["Lewy", 229], ["body", 234], ["formation", 239], [".", 248], ["However", 250], [",", 257], ["its", 259], ["roles", 263], ["in", 269], ["both", 272], ["normal", 277], ["function", 284], [",", 292], ["and", 294], ["disease", 298], [",", 305], ["remain", 307], ["controversial", 314], [".", 327], ["Using", 329], ["a", 335], ["novel", 337], ["model", 343], ["of", 349], ["chronic", 352], ["oxidative", 360], ["stress", 370], ["in", 377], ["cultured", 380], ["dopaminergic", 389], ["and", 402], ["cortical", 406], ["neurons", 415], [",", 422], ["we", 424], ["report", 427], ["that", 434], ["endogenous", 439], ["\u03b1", 450], ["-", 451], ["synuclein", 452], ["is", 462], ["upregulated", 465], ["in", 477], ["response", 480], ["to", 489], ["low", 492], ["dose", 496], ["toxicity", 501], [".", 509], ["This", 511], ["response", 516], ["is", 525], ["conserved", 528], ["between", 538], ["subpopulations", 546], ["of", 561], ["cortical", 564], ["and", 573], ["dopaminergic", 577], ["neurons", 590], [",", 597], ["and", 599], ["confers", 603], ["relative", 611], ["resistance", 620], ["to", 631], ["apoptosis", 634], ["following", 644], ["secondary", 654], ["insult", 664], [".", 670], ["Additional", 672], ["acute", 683], ["oxidative", 689], ["stress", 699], ["leads", 706], ["to", 712], ["intracellular", 715], ["accumulation", 729], ["of", 742], ["\u03b1", 745], ["-", 746], ["synuclein", 747], [".", 756], ["These", 758], ["punctate", 764], ["deposits", 773], ["colocalize", 782], ["with", 793], ["ubiquitin", 798], [",", 807], ["which", 809], ["is", 815], ["central", 818], ["to", 826], ["proteosome", 829], ["-", 839], ["mediated", 840], ["protein", 849], ["degeneration", 857], [",", 869], ["and", 871], ["is", 875], ["the", 878], ["second", 882], ["major", 889], ["component", 895], ["of", 905], ["Lewy", 908], ["bodies", 913], [".", 919], ["The", 921], ["current", 925], ["results", 933], ["imply", 941], ["that", 947], ["differential", 952], ["levels", 965], ["of", 972], ["\u03b1", 975], ["-", 976], ["synuclein", 977], ["expression", 987], ["may", 998], ["influence", 1002], ["neuronal", 1012], ["vulnerability", 1021], ["in", 1035], ["chronic", 1038], ["neurodegenerative", 1046], ["diseases", 1064], [".", 1072], ["They", 1074], ["further", 1079], ["support", 1087], ["a", 1095], ["'", 1097], ["two", 1098], ["hit", 1102], ["'", 1105], ["hypothesis", 1107], ["for", 1118], ["Lewy", 1122], ["body", 1127], ["formation", 1132], [",", 1141], ["whereby", 1143], ["mild", 1151], ["stress", 1156], ["causes", 1163], ["a", 1170], ["protective", 1172], ["upregulation", 1183], ["of", 1196], ["\u03b1", 1199], ["-", 1200], ["synuclein", 1201], [".", 1210], ["However", 1212], [",", 1219], ["such", 1221], ["increased", 1226], ["levels", 1236], ["of", 1243], ["\u03b1", 1246], ["-", 1247], ["synuclein", 1248], ["may", 1258], ["drive", 1262], ["its", 1268], ["accumulation", 1272], [",", 1284], ["following", 1286], ["additional", 1296], ["toxic", 1307], ["insult", 1313], [".", 1319], ["Finally", 1321], [",", 1328], ["these", 1330], ["results", 1336], ["support", 1344], ["a", 1352], ["common", 1354], ["mechanism", 1361], ["for", 1371], ["degeneration", 1375], ["of", 1388], ["dopaminergic", 1391], ["and", 1404], ["cortical", 1408], ["neurons", 1417], [",", 1424], ["affected", 1426], ["in", 1435], ["PD", 1438], [",", 1440], ["and", 1442], ["DLB", 1446], [",", 1449], ["respectively", 1451], [".", 1463]]}
{"context": "Minors with a stated age <18 years unaccompanied by a responsible adult form an increasing part of refugees to Europe. They are older than other asylum-seeking children and many come from countries with a high tuberculosis (TB) incidence. During the 2015 refugee crisis, 35,369 of 162,877 refugees (22%) seeking asylum in Sweden were unaccompanied minors, which gave us the opportunity to study their burden of TB infection and disease. Of the unaccompanied minors seeking asylum in Sweden during 2015, 2936 (8.3%) were allocated to northern Stockholm. Of these, 2422 were from countries with an incidence of TB exceeding 100/10 Of those screened, 349 had a positive test and were referred to the northern paediatric TB clinic at Astrid Lindgren Children's Hospital. Of these, 16 had TB disease and 278 latent tuberculosis infection (LTBI), while we considered 53 uninfected. In addition, eight sought medical attention with symptomatic TB outside the screening system. Cohort rates were 6.8% of LTBI and 0.5% of TB in minors from Afghanistan and 26-32% of LTBI and 3.4-3.5% of TB among those from Eritrea, Ethiopia or Somalia. We conclude that TB infection and disease is common among asylum-seeking unaccompanied minors, especially among those from the Horn of Africa.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "4b0eb00ff2664722917b55ccb33b9689", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[153, 153], [39, 39]], "char_spans": [[810, 821], [210, 221]]}]}], "context_tokens": [["Minors", 0], ["with", 7], ["a", 12], ["stated", 14], ["age", 21], ["<", 25], ["18", 26], ["years", 29], ["unaccompanied", 35], ["by", 49], ["a", 52], ["responsible", 54], ["adult", 66], ["form", 72], ["an", 77], ["increasing", 80], ["part", 91], ["of", 96], ["refugees", 99], ["to", 108], ["Europe", 111], [".", 117], ["They", 119], ["are", 124], ["older", 128], ["than", 134], ["other", 139], ["asylum", 145], ["-", 151], ["seeking", 152], ["children", 160], ["and", 169], ["many", 173], ["come", 178], ["from", 183], ["countries", 188], ["with", 198], ["a", 203], ["high", 205], ["tuberculosis", 210], ["(", 223], ["TB", 224], [")", 226], ["incidence", 228], [".", 237], ["During", 239], ["the", 246], ["2015", 250], ["refugee", 255], ["crisis", 263], [",", 269], ["35,369", 271], ["of", 278], ["162,877", 281], ["refugees", 289], ["(", 298], ["22", 299], ["%", 301], [")", 302], ["seeking", 304], ["asylum", 312], ["in", 319], ["Sweden", 322], ["were", 329], ["unaccompanied", 334], ["minors", 348], [",", 354], ["which", 356], ["gave", 362], ["us", 367], ["the", 370], ["opportunity", 374], ["to", 386], ["study", 389], ["their", 395], ["burden", 401], ["of", 408], ["TB", 411], ["infection", 414], ["and", 424], ["disease", 428], [".", 435], ["Of", 437], ["the", 440], ["unaccompanied", 444], ["minors", 458], ["seeking", 465], ["asylum", 473], ["in", 480], ["Sweden", 483], ["during", 490], ["2015", 497], [",", 501], ["2936", 503], ["(", 508], ["8.3", 509], ["%", 512], [")", 513], ["were", 515], ["allocated", 520], ["to", 530], ["northern", 533], ["Stockholm", 542], [".", 551], ["Of", 553], ["these", 556], [",", 561], ["2422", 563], ["were", 568], ["from", 573], ["countries", 578], ["with", 588], ["an", 593], ["incidence", 596], ["of", 606], ["TB", 609], ["exceeding", 612], ["100/10", 622], ["Of", 629], ["those", 632], ["screened", 638], [",", 646], ["349", 648], ["had", 652], ["a", 656], ["positive", 658], ["test", 667], ["and", 672], ["were", 676], ["referred", 681], ["to", 690], ["the", 693], ["northern", 697], ["paediatric", 706], ["TB", 717], ["clinic", 720], ["at", 727], ["Astrid", 730], ["Lindgren", 737], ["Children", 746], ["'s", 754], ["Hospital", 757], [".", 765], ["Of", 767], ["these", 770], [",", 775], ["16", 777], ["had", 780], ["TB", 784], ["disease", 787], ["and", 795], ["278", 799], ["latent", 803], ["tuberculosis", 810], ["infection", 823], ["(", 833], ["LTBI", 834], [")", 838], [",", 839], ["while", 841], ["we", 847], ["considered", 850], ["53", 861], ["uninfected", 864], [".", 874], ["In", 876], ["addition", 879], [",", 887], ["eight", 889], ["sought", 895], ["medical", 902], ["attention", 910], ["with", 920], ["symptomatic", 925], ["TB", 937], ["outside", 940], ["the", 948], ["screening", 952], ["system", 962], [".", 968], ["Cohort", 970], ["rates", 977], ["were", 983], ["6.8", 988], ["%", 991], ["of", 993], ["LTBI", 996], ["and", 1001], ["0.5", 1005], ["%", 1008], ["of", 1010], ["TB", 1013], ["in", 1016], ["minors", 1019], ["from", 1026], ["Afghanistan", 1031], ["and", 1043], ["26", 1047], ["-", 1049], ["32", 1050], ["%", 1052], ["of", 1054], ["LTBI", 1057], ["and", 1062], ["3.4", 1066], ["-", 1069], ["3.5", 1070], ["%", 1073], ["of", 1075], ["TB", 1078], ["among", 1081], ["those", 1087], ["from", 1093], ["Eritrea", 1098], [",", 1105], ["Ethiopia", 1107], ["or", 1116], ["Somalia", 1119], [".", 1126], ["We", 1128], ["conclude", 1131], ["that", 1140], ["TB", 1145], ["infection", 1148], ["and", 1158], ["disease", 1162], ["is", 1170], ["common", 1173], ["among", 1180], ["asylum", 1186], ["-", 1192], ["seeking", 1193], ["unaccompanied", 1201], ["minors", 1215], [",", 1221], ["especially", 1223], ["among", 1234], ["those", 1240], ["from", 1246], ["the", 1251], ["Horn", 1255], ["of", 1260], ["Africa", 1263], [".", 1269]]}
{"context": "Desmosomes are cell-cell adhesion structures that integrate cytoskeletal networks. In addition to binding intermediate filaments, the desmosomal protein desmoplakin (DP) regulates microtubule reorganization in the epidermis. In this paper, we identify a specific subset of centrosomal proteins that are recruited to the cell cortex by DP upon epidermal differentiation. These include Lis1 and Ndel1, which are centrosomal proteins that regulate microtubule organization and anchoring in other cell types. This recruitment was mediated by a region of DP specific to a single isoform, DPI. Furthermore, we demonstrate that the epidermal-specific loss of Lis1 results in dramatic defects in microtubule reorganization. Lis1 ablation also causes desmosomal defects, characterized by decreased levels of desmosomal components, decreased attachment of keratin filaments, and increased turnover of desmosomal proteins at the cell cortex. This contributes to loss of epidermal barrier activity, resulting in completely penetrant perinatal lethality. This work reveals essential desmosome-associated components that control cortical microtubule organization and unexpected roles for centrosomal proteins in epidermal function.", "qas": [{"question": "What are the structures formed when keratin molecules come together?", "answers": ["Intermediate filaments"], "qid": "d4ee2e1fb7364cd6bb5931d72186c5bb", "question_tokens": [["What", 0], ["are", 5], ["the", 9], ["structures", 13], ["formed", 24], ["when", 31], ["keratin", 36], ["molecules", 44], ["come", 54], ["together", 59], ["?", 67]], "detected_answers": [{"text": "Intermediate filaments", "token_spans": [[16, 17]], "char_spans": [[106, 127]]}]}], "context_tokens": [["Desmosomes", 0], ["are", 11], ["cell", 15], ["-", 19], ["cell", 20], ["adhesion", 25], ["structures", 34], ["that", 45], ["integrate", 50], ["cytoskeletal", 60], ["networks", 73], [".", 81], ["In", 83], ["addition", 86], ["to", 95], ["binding", 98], ["intermediate", 106], ["filaments", 119], [",", 128], ["the", 130], ["desmosomal", 134], ["protein", 145], ["desmoplakin", 153], ["(", 165], ["DP", 166], [")", 168], ["regulates", 170], ["microtubule", 180], ["reorganization", 192], ["in", 207], ["the", 210], ["epidermis", 214], [".", 223], ["In", 225], ["this", 228], ["paper", 233], [",", 238], ["we", 240], ["identify", 243], ["a", 252], ["specific", 254], ["subset", 263], ["of", 270], ["centrosomal", 273], ["proteins", 285], ["that", 294], ["are", 299], ["recruited", 303], ["to", 313], ["the", 316], ["cell", 320], ["cortex", 325], ["by", 332], ["DP", 335], ["upon", 338], ["epidermal", 343], ["differentiation", 353], [".", 368], ["These", 370], ["include", 376], ["Lis1", 384], ["and", 389], ["Ndel1", 393], [",", 398], ["which", 400], ["are", 406], ["centrosomal", 410], ["proteins", 422], ["that", 431], ["regulate", 436], ["microtubule", 445], ["organization", 457], ["and", 470], ["anchoring", 474], ["in", 484], ["other", 487], ["cell", 493], ["types", 498], [".", 503], ["This", 505], ["recruitment", 510], ["was", 522], ["mediated", 526], ["by", 535], ["a", 538], ["region", 540], ["of", 547], ["DP", 550], ["specific", 553], ["to", 562], ["a", 565], ["single", 567], ["isoform", 574], [",", 581], ["DPI", 583], [".", 586], ["Furthermore", 588], [",", 599], ["we", 601], ["demonstrate", 604], ["that", 616], ["the", 621], ["epidermal", 625], ["-", 634], ["specific", 635], ["loss", 644], ["of", 649], ["Lis1", 652], ["results", 657], ["in", 665], ["dramatic", 668], ["defects", 677], ["in", 685], ["microtubule", 688], ["reorganization", 700], [".", 714], ["Lis1", 716], ["ablation", 721], ["also", 730], ["causes", 735], ["desmosomal", 742], ["defects", 753], [",", 760], ["characterized", 762], ["by", 776], ["decreased", 779], ["levels", 789], ["of", 796], ["desmosomal", 799], ["components", 810], [",", 820], ["decreased", 822], ["attachment", 832], ["of", 843], ["keratin", 846], ["filaments", 854], [",", 863], ["and", 865], ["increased", 869], ["turnover", 879], ["of", 888], ["desmosomal", 891], ["proteins", 902], ["at", 911], ["the", 914], ["cell", 918], ["cortex", 923], [".", 929], ["This", 931], ["contributes", 936], ["to", 948], ["loss", 951], ["of", 956], ["epidermal", 959], ["barrier", 969], ["activity", 977], [",", 985], ["resulting", 987], ["in", 997], ["completely", 1000], ["penetrant", 1011], ["perinatal", 1021], ["lethality", 1031], [".", 1040], ["This", 1042], ["work", 1047], ["reveals", 1052], ["essential", 1060], ["desmosome", 1070], ["-", 1079], ["associated", 1080], ["components", 1091], ["that", 1102], ["control", 1107], ["cortical", 1115], ["microtubule", 1124], ["organization", 1136], ["and", 1149], ["unexpected", 1153], ["roles", 1164], ["for", 1170], ["centrosomal", 1174], ["proteins", 1186], ["in", 1195], ["epidermal", 1198], ["function", 1208], [".", 1216]]}
{"context": "A blinded, retrospective study was performed to determine the value of supine abdominal radiographs in diagnosing pneumoperitoneum. Supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including Rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-V sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant). One or more of these signs were present in 26 cases (59%) of pneumoperitoneum, including the right-upper-quadrant gas sign in 18 cases (41%), Rigler's sign in 14 cases (32%), and the falciform ligament and football signs in one case each (2%). Unfortunately, there were frequent errors in the interpretation of the right-upper-quadrant gas sign and Rigler's sign, with a total of 11 false-positive cases (13%). Further analysis of the true-positive right-upper-quadrant gas signs showed that these gas collections were always triangular or linear with an inferolateral to superomedial orientation and, if triangular, a concave superolateral border. In the true-positive Rigler's signs, the bowel wall thickness ranged from 1 to 8 mm, whereas the false positives all had a bowel wall thickness of 1 mm or less. Proper interpretation of the various signs of pneumoperitoneum on supine films should lead to more accurate diagnosis of this condition.", "qas": [{"question": "Falciform ligament sign is characteristic to which disease?", "answers": ["pneumoperitoneum"], "qid": "9305f4338a854725ab83e9b81c3c35b4", "question_tokens": [["Falciform", 0], ["ligament", 10], ["sign", 19], ["is", 24], ["characteristic", 27], ["to", 42], ["which", 45], ["disease", 51], ["?", 58]], "detected_answers": [{"text": "pneumoperitoneum", "token_spans": [[309, 309], [54, 54], [25, 25], [17, 17], [143, 143]], "char_spans": [[1553, 1568], [344, 359], [162, 177], [114, 129], [758, 773]]}]}], "context_tokens": [["A", 0], ["blinded", 2], [",", 9], ["retrospective", 11], ["study", 25], ["was", 31], ["performed", 35], ["to", 45], ["determine", 48], ["the", 58], ["value", 62], ["of", 68], ["supine", 71], ["abdominal", 78], ["radiographs", 88], ["in", 100], ["diagnosing", 103], ["pneumoperitoneum", 114], [".", 130], ["Supine", 132], ["films", 139], ["from", 145], ["44", 150], ["cases", 153], ["of", 159], ["pneumoperitoneum", 162], ["were", 179], ["randomly", 184], ["interspersed", 193], ["among", 206], ["supine", 212], ["films", 219], ["from", 225], ["87", 230], ["control", 233], ["subjects", 241], ["without", 250], ["free", 258], ["air", 263], [",", 266], ["and", 268], ["the", 272], ["films", 276], ["were", 282], ["reviewed", 287], ["for", 296], ["the", 300], ["presence", 304], ["or", 313], ["absence", 316], ["of", 324], ["various", 327], ["signs", 335], ["of", 341], ["pneumoperitoneum", 344], [",", 360], ["including", 362], ["Rigler", 372], ["'s", 378], ["sign", 381], ["(", 386], ["gas", 387], ["on", 391], ["both", 394], ["sides", 399], ["of", 405], ["the", 408], ["bowel", 412], ["wall", 418], [")", 422], [",", 423], ["the", 425], ["falciform", 429], ["ligament", 439], ["sign", 448], ["(", 453], ["gas", 454], ["outlining", 458], ["the", 468], ["falciform", 472], ["ligament", 482], [")", 490], [",", 491], ["the", 493], ["football", 497], ["sign", 506], ["(", 511], ["gas", 512], ["outlining", 516], ["the", 526], ["peritoneal", 530], ["cavity", 541], [")", 547], [",", 548], ["the", 550], ["inverted", 554], ["-", 562], ["V", 563], ["sign", 565], ["(", 570], ["gas", 571], ["outlining", 575], ["the", 585], ["medial", 589], ["umbilical", 596], ["folds", 606], [")", 611], [",", 612], ["and", 614], ["the", 618], ["right", 622], ["-", 627], ["upper", 628], ["-", 633], ["quadrant", 634], ["gas", 643], ["sign", 647], ["(", 652], ["localized", 653], ["gas", 663], ["in", 667], ["the", 670], ["right", 674], ["upper", 680], ["quadrant", 686], [")", 694], [".", 695], ["One", 697], ["or", 701], ["more", 704], ["of", 709], ["these", 712], ["signs", 718], ["were", 724], ["present", 729], ["in", 737], ["26", 740], ["cases", 743], ["(", 749], ["59", 750], ["%", 752], [")", 753], ["of", 755], ["pneumoperitoneum", 758], [",", 774], ["including", 776], ["the", 786], ["right", 790], ["-", 795], ["upper", 796], ["-", 801], ["quadrant", 802], ["gas", 811], ["sign", 815], ["in", 820], ["18", 823], ["cases", 826], ["(", 832], ["41", 833], ["%", 835], [")", 836], [",", 837], ["Rigler", 839], ["'s", 845], ["sign", 848], ["in", 853], ["14", 856], ["cases", 859], ["(", 865], ["32", 866], ["%", 868], [")", 869], [",", 870], ["and", 872], ["the", 876], ["falciform", 880], ["ligament", 890], ["and", 899], ["football", 903], ["signs", 912], ["in", 918], ["one", 921], ["case", 925], ["each", 930], ["(", 935], ["2", 936], ["%", 937], [")", 938], [".", 939], ["Unfortunately", 941], [",", 954], ["there", 956], ["were", 962], ["frequent", 967], ["errors", 976], ["in", 983], ["the", 986], ["interpretation", 990], ["of", 1005], ["the", 1008], ["right", 1012], ["-", 1017], ["upper", 1018], ["-", 1023], ["quadrant", 1024], ["gas", 1033], ["sign", 1037], ["and", 1042], ["Rigler", 1046], ["'s", 1052], ["sign", 1055], [",", 1059], ["with", 1061], ["a", 1066], ["total", 1068], ["of", 1074], ["11", 1077], ["false", 1080], ["-", 1085], ["positive", 1086], ["cases", 1095], ["(", 1101], ["13", 1102], ["%", 1104], [")", 1105], [".", 1106], ["Further", 1108], ["analysis", 1116], ["of", 1125], ["the", 1128], ["true", 1132], ["-", 1136], ["positive", 1137], ["right", 1146], ["-", 1151], ["upper", 1152], ["-", 1157], ["quadrant", 1158], ["gas", 1167], ["signs", 1171], ["showed", 1177], ["that", 1184], ["these", 1189], ["gas", 1195], ["collections", 1199], ["were", 1211], ["always", 1216], ["triangular", 1223], ["or", 1234], ["linear", 1237], ["with", 1244], ["an", 1249], ["inferolateral", 1252], ["to", 1266], ["superomedial", 1269], ["orientation", 1282], ["and", 1294], [",", 1297], ["if", 1299], ["triangular", 1302], [",", 1312], ["a", 1314], ["concave", 1316], ["superolateral", 1324], ["border", 1338], [".", 1344], ["In", 1346], ["the", 1349], ["true", 1353], ["-", 1357], ["positive", 1358], ["Rigler", 1367], ["'s", 1373], ["signs", 1376], [",", 1381], ["the", 1383], ["bowel", 1387], ["wall", 1393], ["thickness", 1398], ["ranged", 1408], ["from", 1415], ["1", 1420], ["to", 1422], ["8", 1425], ["mm", 1427], [",", 1429], ["whereas", 1431], ["the", 1439], ["false", 1443], ["positives", 1449], ["all", 1459], ["had", 1463], ["a", 1467], ["bowel", 1469], ["wall", 1475], ["thickness", 1480], ["of", 1490], ["1", 1493], ["mm", 1495], ["or", 1498], ["less", 1501], [".", 1505], ["Proper", 1507], ["interpretation", 1514], ["of", 1529], ["the", 1532], ["various", 1536], ["signs", 1544], ["of", 1550], ["pneumoperitoneum", 1553], ["on", 1570], ["supine", 1573], ["films", 1580], ["should", 1586], ["lead", 1593], ["to", 1598], ["more", 1601], ["accurate", 1606], ["diagnosis", 1615], ["of", 1625], ["this", 1628], ["condition", 1633], [".", 1642]]}
{"context": "Aggregation of \u03b1-synuclein (\u03b1Syn), the primary protein component in Lewy body inclusions of patients with Parkinson's disease, arises when the normally soluble intrinsically disordered protein converts to amyloid fibrils. In this work, we provide a mechanistic view of the role of N-terminal acetylation on fibrillation by first establishing a quantitative relationship between monomer secondary structural propensity and fibril assembly kinetics, and secondly by demonstrating in the N-terminal acetylated form of the early onset A53T mutation, that N-terminal transient helices formed and/or inhibited by N-terminal acetylation modulate the fibril assembly rates. Using NMR chemical shifts and fluorescence experiments, we report that secondary structural propensity in residues 5-8, 14-31, and 50-57 are highly correlated to fibril growth rate. A four-way comparison of secondary structure propensity and fibril growth rates of N-terminally acetylated A53T and WT \u03b1Syn with non-acetylated A53T and WT \u03b1Syn present novel mechanistic insight into the role of N-terminal acetylation in amyloid fibril formation. We show that N-terminal acetylation inhibits the formation of the \"fibrillation promoting\" transient helix at residues 14-31 resulting from the A53T mutation in the non-acetylated variant and supports the formation of the \"fibrillation inhibiting\" transient helix in residues 1-12 thereby resulting in slower fibrillation rates relative to the previously studied non-acetylated A53T variant. Our results highlight the critical interplay of the region-specific transient secondary structure of the N-terminal region with fibrillation, and the inhibitory role of the N-terminal acetyl group in fibril formation.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "98e46197609848b39e1fb5db6b9f7fa8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[2, 4]], "char_spans": [[15, 25]]}, {"text": "\u03b1Syn", "token_spans": [[169, 169], [178, 178], [6, 6]], "char_spans": [[967, 970], [1004, 1007], [28, 31]]}]}], "context_tokens": [["Aggregation", 0], ["of", 12], ["\u03b1", 15], ["-", 16], ["synuclein", 17], ["(", 27], ["\u03b1Syn", 28], [")", 32], [",", 33], ["the", 35], ["primary", 39], ["protein", 47], ["component", 55], ["in", 65], ["Lewy", 68], ["body", 73], ["inclusions", 78], ["of", 89], ["patients", 92], ["with", 101], ["Parkinson", 106], ["'s", 115], ["disease", 118], [",", 125], ["arises", 127], ["when", 134], ["the", 139], ["normally", 143], ["soluble", 152], ["intrinsically", 160], ["disordered", 174], ["protein", 185], ["converts", 193], ["to", 202], ["amyloid", 205], ["fibrils", 213], [".", 220], ["In", 222], ["this", 225], ["work", 230], [",", 234], ["we", 236], ["provide", 239], ["a", 247], ["mechanistic", 249], ["view", 261], ["of", 266], ["the", 269], ["role", 273], ["of", 278], ["N", 281], ["-", 282], ["terminal", 283], ["acetylation", 292], ["on", 304], ["fibrillation", 307], ["by", 320], ["first", 323], ["establishing", 329], ["a", 342], ["quantitative", 344], ["relationship", 357], ["between", 370], ["monomer", 378], ["secondary", 386], ["structural", 396], ["propensity", 407], ["and", 418], ["fibril", 422], ["assembly", 429], ["kinetics", 438], [",", 446], ["and", 448], ["secondly", 452], ["by", 461], ["demonstrating", 464], ["in", 478], ["the", 481], ["N", 485], ["-", 486], ["terminal", 487], ["acetylated", 496], ["form", 507], ["of", 512], ["the", 515], ["early", 519], ["onset", 525], ["A53", 531], ["T", 534], ["mutation", 536], [",", 544], ["that", 546], ["N", 551], ["-", 552], ["terminal", 553], ["transient", 562], ["helices", 572], ["formed", 580], ["and/or", 587], ["inhibited", 594], ["by", 604], ["N", 607], ["-", 608], ["terminal", 609], ["acetylation", 618], ["modulate", 630], ["the", 639], ["fibril", 643], ["assembly", 650], ["rates", 659], [".", 664], ["Using", 666], ["NMR", 672], ["chemical", 676], ["shifts", 685], ["and", 692], ["fluorescence", 696], ["experiments", 709], [",", 720], ["we", 722], ["report", 725], ["that", 732], ["secondary", 737], ["structural", 747], ["propensity", 758], ["in", 769], ["residues", 772], ["5", 781], ["-", 782], ["8", 783], [",", 784], ["14", 786], ["-", 788], ["31", 789], [",", 791], ["and", 793], ["50", 797], ["-", 799], ["57", 800], ["are", 803], ["highly", 807], ["correlated", 814], ["to", 825], ["fibril", 828], ["growth", 835], ["rate", 842], [".", 846], ["A", 848], ["four", 850], ["-", 854], ["way", 855], ["comparison", 859], ["of", 870], ["secondary", 873], ["structure", 883], ["propensity", 893], ["and", 904], ["fibril", 908], ["growth", 915], ["rates", 922], ["of", 928], ["N", 931], ["-", 932], ["terminally", 933], ["acetylated", 944], ["A53", 955], ["T", 958], ["and", 960], ["WT", 964], ["\u03b1Syn", 967], ["with", 972], ["non", 977], ["-", 980], ["acetylated", 981], ["A53", 992], ["T", 995], ["and", 997], ["WT", 1001], ["\u03b1Syn", 1004], ["present", 1009], ["novel", 1017], ["mechanistic", 1023], ["insight", 1035], ["into", 1043], ["the", 1048], ["role", 1052], ["of", 1057], ["N", 1060], ["-", 1061], ["terminal", 1062], ["acetylation", 1071], ["in", 1083], ["amyloid", 1086], ["fibril", 1094], ["formation", 1101], [".", 1110], ["We", 1112], ["show", 1115], ["that", 1120], ["N", 1125], ["-", 1126], ["terminal", 1127], ["acetylation", 1136], ["inhibits", 1148], ["the", 1157], ["formation", 1161], ["of", 1171], ["the", 1174], ["\"", 1178], ["fibrillation", 1179], ["promoting", 1192], ["\"", 1201], ["transient", 1203], ["helix", 1213], ["at", 1219], ["residues", 1222], ["14", 1231], ["-", 1233], ["31", 1234], ["resulting", 1237], ["from", 1247], ["the", 1252], ["A53", 1256], ["T", 1259], ["mutation", 1261], ["in", 1270], ["the", 1273], ["non", 1277], ["-", 1280], ["acetylated", 1281], ["variant", 1292], ["and", 1300], ["supports", 1304], ["the", 1313], ["formation", 1317], ["of", 1327], ["the", 1330], ["\"", 1334], ["fibrillation", 1335], ["inhibiting", 1348], ["\"", 1358], ["transient", 1360], ["helix", 1370], ["in", 1376], ["residues", 1379], ["1", 1388], ["-", 1389], ["12", 1390], ["thereby", 1393], ["resulting", 1401], ["in", 1411], ["slower", 1414], ["fibrillation", 1421], ["rates", 1434], ["relative", 1440], ["to", 1449], ["the", 1452], ["previously", 1456], ["studied", 1467], ["non", 1475], ["-", 1478], ["acetylated", 1479], ["A53", 1490], ["T", 1493], ["variant", 1495], [".", 1502], ["Our", 1504], ["results", 1508], ["highlight", 1516], ["the", 1526], ["critical", 1530], ["interplay", 1539], ["of", 1549], ["the", 1552], ["region", 1556], ["-", 1562], ["specific", 1563], ["transient", 1572], ["secondary", 1582], ["structure", 1592], ["of", 1602], ["the", 1605], ["N", 1609], ["-", 1610], ["terminal", 1611], ["region", 1620], ["with", 1627], ["fibrillation", 1632], [",", 1644], ["and", 1646], ["the", 1650], ["inhibitory", 1654], ["role", 1665], ["of", 1670], ["the", 1673], ["N", 1677], ["-", 1678], ["terminal", 1679], ["acetyl", 1688], ["group", 1695], ["in", 1701], ["fibril", 1704], ["formation", 1711], [".", 1720]]}
{"context": "Prader-Willi syndrome (PWS) results from a deletion of the paternal genes in the region of chromosome 15q11-q13. PWS develops hyperphagia, which when left unmanaged, leads to an excessive ingestion of food. To date there is inadequate pharmacological treatment or supplementation for modification of the PWS hyperphagia and/or the associated behaviors. Therefore, the best practice is familial supervision and restriction of diet and environment. We aimed to determine if the natural supplement of Caralluma fimbriata extract (CFE) could attenuate hyperphagia or the associated appetite behaviors in children and adolescents with PWS over the 4-week pilot trial period. We conducted a placebo-controlled, double-blind, randomized crossover trial over a 10-week period to investigate the effects of CFE on hunger control, in a cohort of children and adolescents with confirmed PWS (n =15, mean age 9.27 \u00b1 3.16 years, body weight 43.98 \u00b1 23.99 kg). Participants from Australia and New Zealand ingested CFE or a placebo of maltodextrin/cabbage leaf over a 4-week period, with a 2-week washout before the crossover to the other treatment. Weekly comparisons in appetite behavior, severity, and drive were recorded by parents, as scaled time-point measures on a hyperphagia questionnaire validated for PWS. CFE administration was found to induce a significant accumulative easing of hyperphagia (P = 0.05), with decreases evident in one-third of the participants. Furthermore due to CFE supplementation, a significant decrease (P \u2264 0.05) was recorded in the category of behavior and a decrease in hyperphagia (n = 8, P = 0.009) was observed at the highest dose 1,000 mg/day (recommended adult dose). There were no reported adverse effects at any dose. We demonstrate that an extract of the Indian cactus succulent Caralluma fimbriata eases hyperphagic appetite behavior within a cohort of children and adolescents (n = 15) with PWS without notable adverse effects. The outcomes of this study will have a potential positive impact on PWS management.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "8b979d0ca3aa47dbbd35ea426dc78be3", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 20]]}]}], "context_tokens": [["Prader", 0], ["-", 6], ["Willi", 7], ["syndrome", 13], ["(", 22], ["PWS", 23], [")", 26], ["results", 28], ["from", 36], ["a", 41], ["deletion", 43], ["of", 52], ["the", 55], ["paternal", 59], ["genes", 68], ["in", 74], ["the", 77], ["region", 81], ["of", 88], ["chromosome", 91], ["15q11-q13", 102], [".", 111], ["PWS", 113], ["develops", 117], ["hyperphagia", 126], [",", 137], ["which", 139], ["when", 145], ["left", 150], ["unmanaged", 155], [",", 164], ["leads", 166], ["to", 172], ["an", 175], ["excessive", 178], ["ingestion", 188], ["of", 198], ["food", 201], [".", 205], ["To", 207], ["date", 210], ["there", 215], ["is", 221], ["inadequate", 224], ["pharmacological", 235], ["treatment", 251], ["or", 261], ["supplementation", 264], ["for", 280], ["modification", 284], ["of", 297], ["the", 300], ["PWS", 304], ["hyperphagia", 308], ["and/or", 320], ["the", 327], ["associated", 331], ["behaviors", 342], [".", 351], ["Therefore", 353], [",", 362], ["the", 364], ["best", 368], ["practice", 373], ["is", 382], ["familial", 385], ["supervision", 394], ["and", 406], ["restriction", 410], ["of", 422], ["diet", 425], ["and", 430], ["environment", 434], [".", 445], ["We", 447], ["aimed", 450], ["to", 456], ["determine", 459], ["if", 469], ["the", 472], ["natural", 476], ["supplement", 484], ["of", 495], ["Caralluma", 498], ["fimbriata", 508], ["extract", 518], ["(", 526], ["CFE", 527], [")", 530], ["could", 532], ["attenuate", 538], ["hyperphagia", 548], ["or", 560], ["the", 563], ["associated", 567], ["appetite", 578], ["behaviors", 587], ["in", 597], ["children", 600], ["and", 609], ["adolescents", 613], ["with", 625], ["PWS", 630], ["over", 634], ["the", 639], ["4-week", 643], ["pilot", 650], ["trial", 656], ["period", 662], [".", 668], ["We", 670], ["conducted", 673], ["a", 683], ["placebo", 685], ["-", 692], ["controlled", 693], [",", 703], ["double", 705], ["-", 711], ["blind", 712], [",", 717], ["randomized", 719], ["crossover", 730], ["trial", 740], ["over", 746], ["a", 751], ["10-week", 753], ["period", 761], ["to", 768], ["investigate", 771], ["the", 783], ["effects", 787], ["of", 795], ["CFE", 798], ["on", 802], ["hunger", 805], ["control", 812], [",", 819], ["in", 821], ["a", 824], ["cohort", 826], ["of", 833], ["children", 836], ["and", 845], ["adolescents", 849], ["with", 861], ["confirmed", 866], ["PWS", 876], ["(", 880], ["n", 881], ["=", 883], ["15", 884], [",", 886], ["mean", 888], ["age", 893], ["9.27", 897], ["\u00b1", 902], ["3.16", 904], ["years", 909], [",", 914], ["body", 916], ["weight", 921], ["43.98", 928], ["\u00b1", 934], ["23.99", 936], ["kg", 942], [")", 944], [".", 945], ["Participants", 947], ["from", 960], ["Australia", 965], ["and", 975], ["New", 979], ["Zealand", 983], ["ingested", 991], ["CFE", 1000], ["or", 1004], ["a", 1007], ["placebo", 1009], ["of", 1017], ["maltodextrin", 1020], ["/", 1032], ["cabbage", 1033], ["leaf", 1041], ["over", 1046], ["a", 1051], ["4-week", 1053], ["period", 1060], [",", 1066], ["with", 1068], ["a", 1073], ["2-week", 1075], ["washout", 1082], ["before", 1090], ["the", 1097], ["crossover", 1101], ["to", 1111], ["the", 1114], ["other", 1118], ["treatment", 1124], [".", 1133], ["Weekly", 1135], ["comparisons", 1142], ["in", 1154], ["appetite", 1157], ["behavior", 1166], [",", 1174], ["severity", 1176], [",", 1184], ["and", 1186], ["drive", 1190], ["were", 1196], ["recorded", 1201], ["by", 1210], ["parents", 1213], [",", 1220], ["as", 1222], ["scaled", 1225], ["time", 1232], ["-", 1236], ["point", 1237], ["measures", 1243], ["on", 1252], ["a", 1255], ["hyperphagia", 1257], ["questionnaire", 1269], ["validated", 1283], ["for", 1293], ["PWS", 1297], [".", 1300], ["CFE", 1302], ["administration", 1306], ["was", 1321], ["found", 1325], ["to", 1331], ["induce", 1334], ["a", 1341], ["significant", 1343], ["accumulative", 1355], ["easing", 1368], ["of", 1375], ["hyperphagia", 1378], ["(", 1390], ["P", 1391], ["=", 1393], ["0.05", 1395], [")", 1399], [",", 1400], ["with", 1402], ["decreases", 1407], ["evident", 1417], ["in", 1425], ["one", 1428], ["-", 1431], ["third", 1432], ["of", 1438], ["the", 1441], ["participants", 1445], [".", 1457], ["Furthermore", 1459], ["due", 1471], ["to", 1475], ["CFE", 1478], ["supplementation", 1482], [",", 1497], ["a", 1499], ["significant", 1501], ["decrease", 1513], ["(", 1522], ["P", 1523], ["\u2264", 1525], ["0.05", 1527], [")", 1531], ["was", 1533], ["recorded", 1537], ["in", 1546], ["the", 1549], ["category", 1553], ["of", 1562], ["behavior", 1565], ["and", 1574], ["a", 1578], ["decrease", 1580], ["in", 1589], ["hyperphagia", 1592], ["(", 1604], ["n", 1605], ["=", 1607], ["8", 1609], [",", 1610], ["P", 1612], ["=", 1614], ["0.009", 1616], [")", 1621], ["was", 1623], ["observed", 1627], ["at", 1636], ["the", 1639], ["highest", 1643], ["dose", 1651], ["1,000", 1656], ["mg", 1662], ["/", 1664], ["day", 1665], ["(", 1669], ["recommended", 1670], ["adult", 1682], ["dose", 1688], [")", 1692], [".", 1693], ["There", 1695], ["were", 1701], ["no", 1706], ["reported", 1709], ["adverse", 1718], ["effects", 1726], ["at", 1734], ["any", 1737], ["dose", 1741], [".", 1745], ["We", 1747], ["demonstrate", 1750], ["that", 1762], ["an", 1767], ["extract", 1770], ["of", 1778], ["the", 1781], ["Indian", 1785], ["cactus", 1792], ["succulent", 1799], ["Caralluma", 1809], ["fimbriata", 1819], ["eases", 1829], ["hyperphagic", 1835], ["appetite", 1847], ["behavior", 1856], ["within", 1865], ["a", 1872], ["cohort", 1874], ["of", 1881], ["children", 1884], ["and", 1893], ["adolescents", 1897], ["(", 1909], ["n", 1910], ["=", 1912], ["15", 1914], [")", 1916], ["with", 1918], ["PWS", 1923], ["without", 1927], ["notable", 1935], ["adverse", 1943], ["effects", 1951], [".", 1958], ["The", 1960], ["outcomes", 1964], ["of", 1973], ["this", 1976], ["study", 1981], ["will", 1987], ["have", 1992], ["a", 1997], ["potential", 1999], ["positive", 2009], ["impact", 2018], ["on", 2025], ["PWS", 2028], ["management", 2032], [".", 2042]]}
{"context": "Urgent surgery or life-threatening bleeding requires prompt reversal of the anticoagulant effects of dabigatran. This study assessed the ability of three- and four-factor prothrombin complex concentrate (PCC) and idarucizumab (specific antidote for dabigatran) to reverse the anticoagulant effects of dabigatran in a porcine model of trauma. Twelve animals were given dabigatran etexilate (DE) orally and dabigatran intravenously, before infliction of trauma. Six animals received tranexamic acid plus fibrinogen concentrate 12 minutes post-injury. Six PCCs (each 30 and 60 U/kg) and idarucizumab (30 and 60 mg/kg) were added to blood samples ex vivo. Coagulation was assessed by several coagulation assays. All coagulation parameters were altered after dabigatran infusion (plasma level: 442 \u00b1 138 ng/ml). Both three- and four-factor PCCs mostly or completely reversed the effects of dabigatran on thromboelastometry variables and PT but not on aPTT. Idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables. Thrombin generation showed dose-dependent over-correction following the addition of PCC, implying that elevated levels of thrombin are required to overcome dabigatran-induced coagulopathy. In contrast, treatment with idarucizumab returned thrombin generation to baseline levels. Following trauma, therapy with tranexamic acid plus fibrinogen improved correction of coagulation parameters by PCC, and thromboelastometry parameters by idarucizumab. All investigated PCCs improved dabigatran- and trauma-induced coagulopathy to a similar degree. In conclusion, this study shows that three- and four-factor PCCs are similarly effective for dabigatran reversal. Idarucizumab also reversed the effects of dabigatran and, unlike PCCs, was not associated with over-correction of thrombin generation.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "6c15c6c5007f4bac9ec1454df2719dfa", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[48, 48], [160, 160], [67, 67], [176, 176], [214, 214], [259, 259], [60, 60], [132, 132], [40, 40], [296, 296], [287, 287], [15, 15]], "char_spans": [[301, 310], [885, 894], [405, 414], [1002, 1011], [1233, 1242], [1555, 1565], [368, 377], [754, 763], [249, 258], [1776, 1785], [1713, 1722], [101, 110]]}]}], "context_tokens": [["Urgent", 0], ["surgery", 7], ["or", 15], ["life", 18], ["-", 22], ["threatening", 23], ["bleeding", 35], ["requires", 44], ["prompt", 53], ["reversal", 60], ["of", 69], ["the", 72], ["anticoagulant", 76], ["effects", 90], ["of", 98], ["dabigatran", 101], [".", 111], ["This", 113], ["study", 118], ["assessed", 124], ["the", 133], ["ability", 137], ["of", 145], ["three-", 148], ["and", 155], ["four", 159], ["-", 163], ["factor", 164], ["prothrombin", 171], ["complex", 183], ["concentrate", 191], ["(", 203], ["PCC", 204], [")", 207], ["and", 209], ["idarucizumab", 213], ["(", 226], ["specific", 227], ["antidote", 236], ["for", 245], ["dabigatran", 249], [")", 259], ["to", 261], ["reverse", 264], ["the", 272], ["anticoagulant", 276], ["effects", 290], ["of", 298], ["dabigatran", 301], ["in", 312], ["a", 315], ["porcine", 317], ["model", 325], ["of", 331], ["trauma", 334], [".", 340], ["Twelve", 342], ["animals", 349], ["were", 357], ["given", 362], ["dabigatran", 368], ["etexilate", 379], ["(", 389], ["DE", 390], [")", 392], ["orally", 394], ["and", 401], ["dabigatran", 405], ["intravenously", 416], [",", 429], ["before", 431], ["infliction", 438], ["of", 449], ["trauma", 452], [".", 458], ["Six", 460], ["animals", 464], ["received", 472], ["tranexamic", 481], ["acid", 492], ["plus", 497], ["fibrinogen", 502], ["concentrate", 513], ["12", 525], ["minutes", 528], ["post", 536], ["-", 540], ["injury", 541], [".", 547], ["Six", 549], ["PCCs", 553], ["(", 558], ["each", 559], ["30", 564], ["and", 567], ["60", 571], ["U", 574], ["/", 575], ["kg", 576], [")", 578], ["and", 580], ["idarucizumab", 584], ["(", 597], ["30", 598], ["and", 601], ["60", 605], ["mg", 608], ["/", 610], ["kg", 611], [")", 613], ["were", 615], ["added", 620], ["to", 626], ["blood", 629], ["samples", 635], ["ex", 643], ["vivo", 646], [".", 650], ["Coagulation", 652], ["was", 664], ["assessed", 668], ["by", 677], ["several", 680], ["coagulation", 688], ["assays", 700], [".", 706], ["All", 708], ["coagulation", 712], ["parameters", 724], ["were", 735], ["altered", 740], ["after", 748], ["dabigatran", 754], ["infusion", 765], ["(", 774], ["plasma", 775], ["level", 782], [":", 787], ["442", 789], ["\u00b1", 793], ["138", 795], ["ng", 799], ["/", 801], ["ml", 802], [")", 804], [".", 805], ["Both", 807], ["three-", 812], ["and", 819], ["four", 823], ["-", 827], ["factor", 828], ["PCCs", 835], ["mostly", 840], ["or", 847], ["completely", 850], ["reversed", 861], ["the", 870], ["effects", 874], ["of", 882], ["dabigatran", 885], ["on", 896], ["thromboelastometry", 899], ["variables", 918], ["and", 928], ["PT", 932], ["but", 935], ["not", 939], ["on", 943], ["aPTT", 946], [".", 950], ["Idarucizumab", 952], ["neutralised", 965], ["plasma", 977], ["concentrations", 984], ["of", 999], ["dabigatran", 1002], [",", 1012], ["and", 1014], ["reversed", 1018], ["the", 1027], ["effects", 1031], ["of", 1039], ["the", 1042], ["drug", 1046], ["on", 1051], ["coagulation", 1054], ["variables", 1066], [".", 1075], ["Thrombin", 1077], ["generation", 1086], ["showed", 1097], ["dose", 1104], ["-", 1108], ["dependent", 1109], ["over", 1119], ["-", 1123], ["correction", 1124], ["following", 1135], ["the", 1145], ["addition", 1149], ["of", 1158], ["PCC", 1161], [",", 1164], ["implying", 1166], ["that", 1175], ["elevated", 1180], ["levels", 1189], ["of", 1196], ["thrombin", 1199], ["are", 1208], ["required", 1212], ["to", 1221], ["overcome", 1224], ["dabigatran", 1233], ["-", 1243], ["induced", 1244], ["coagulopathy", 1252], [".", 1264], ["In", 1266], ["contrast", 1269], [",", 1277], ["treatment", 1279], ["with", 1289], ["idarucizumab", 1294], ["returned", 1307], ["thrombin", 1316], ["generation", 1325], ["to", 1336], ["baseline", 1339], ["levels", 1348], [".", 1354], ["Following", 1356], ["trauma", 1366], [",", 1372], ["therapy", 1374], ["with", 1382], ["tranexamic", 1387], ["acid", 1398], ["plus", 1403], ["fibrinogen", 1408], ["improved", 1419], ["correction", 1428], ["of", 1439], ["coagulation", 1442], ["parameters", 1454], ["by", 1465], ["PCC", 1468], [",", 1471], ["and", 1473], ["thromboelastometry", 1477], ["parameters", 1496], ["by", 1507], ["idarucizumab", 1510], [".", 1522], ["All", 1524], ["investigated", 1528], ["PCCs", 1541], ["improved", 1546], ["dabigatran-", 1555], ["and", 1567], ["trauma", 1571], ["-", 1577], ["induced", 1578], ["coagulopathy", 1586], ["to", 1599], ["a", 1602], ["similar", 1604], ["degree", 1612], [".", 1618], ["In", 1620], ["conclusion", 1623], [",", 1633], ["this", 1635], ["study", 1640], ["shows", 1646], ["that", 1652], ["three-", 1657], ["and", 1664], ["four", 1668], ["-", 1672], ["factor", 1673], ["PCCs", 1680], ["are", 1685], ["similarly", 1689], ["effective", 1699], ["for", 1709], ["dabigatran", 1713], ["reversal", 1724], [".", 1732], ["Idarucizumab", 1734], ["also", 1747], ["reversed", 1752], ["the", 1761], ["effects", 1765], ["of", 1773], ["dabigatran", 1776], ["and", 1787], [",", 1790], ["unlike", 1792], ["PCCs", 1799], [",", 1803], ["was", 1805], ["not", 1809], ["associated", 1813], ["with", 1824], ["over", 1829], ["-", 1833], ["correction", 1834], ["of", 1845], ["thrombin", 1848], ["generation", 1857], [".", 1867]]}
{"context": "Spinocerebellar ataxia type 3 is a neurodegenerative disorder caused by the expansion of the polyglutamine repeat region within the ataxin-3 protein. The mutant protein forms intracellular aggregates in the brain. However, the cellular mechanisms causing toxicity are still poorly understood and there are currently no effective treatments. In this study we show that administration of a rapamycin ester (cell cycle inhibitor-779, temsirolimus) improves motor performance in a transgenic mouse model of spinocerebellar ataxia type 3. Temsirolimus inhibits mammalian target of rapamycin and hence upregulates protein degradation by autophagy. Temsirolimus reduces the number of aggregates seen in the brains of transgenic mice and decreases levels of cytosolic soluble mutant ataxin-3, while endogenous wild-type protein levels remain unaffected. Temsirolimus is designed for long-term use in patients and therefore represents a possible therapeutic strategy for the treatment of spinocerebellar ataxia type 3. Using this disease model and treatment paradigm, we employed a microarray approach to investigate transcriptional changes that might be important in the pathogenesis of spinocerebellar ataxia type 3. This identified ubiquitin specific peptidase-15, which showed expression changes at both the messenger ribonucleic acid and protein level. Ubiquitin specific peptidase-15 levels were also changed in mice expressing another mutant polyglutamine protein, huntingtin. In total we identified 16 transcripts that were decreased in transgenic ataxin-3 mice that were normalized following temsirolimus treatment. In this mouse model with relatively mild disease progression, the number of transcripts changed was low and the magnitude of these changes was small. However, the importance of these transcriptional alterations in the pathogenesis of spinocerebellar ataxia type 3 remains unclear.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "179e834f3f064c7188755ef9596db9d9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[233, 233], [117, 117], [19, 19]], "char_spans": [[1547, 1554], [775, 782], [132, 139]]}]}], "context_tokens": [["Spinocerebellar", 0], ["ataxia", 16], ["type", 23], ["3", 28], ["is", 30], ["a", 33], ["neurodegenerative", 35], ["disorder", 53], ["caused", 62], ["by", 69], ["the", 72], ["expansion", 76], ["of", 86], ["the", 89], ["polyglutamine", 93], ["repeat", 107], ["region", 114], ["within", 121], ["the", 128], ["ataxin-3", 132], ["protein", 141], [".", 148], ["The", 150], ["mutant", 154], ["protein", 161], ["forms", 169], ["intracellular", 175], ["aggregates", 189], ["in", 200], ["the", 203], ["brain", 207], [".", 212], ["However", 214], [",", 221], ["the", 223], ["cellular", 227], ["mechanisms", 236], ["causing", 247], ["toxicity", 255], ["are", 264], ["still", 268], ["poorly", 274], ["understood", 281], ["and", 292], ["there", 296], ["are", 302], ["currently", 306], ["no", 316], ["effective", 319], ["treatments", 329], [".", 339], ["In", 341], ["this", 344], ["study", 349], ["we", 355], ["show", 358], ["that", 363], ["administration", 368], ["of", 383], ["a", 386], ["rapamycin", 388], ["ester", 398], ["(", 404], ["cell", 405], ["cycle", 410], ["inhibitor-779", 416], [",", 429], ["temsirolimus", 431], [")", 443], ["improves", 445], ["motor", 454], ["performance", 460], ["in", 472], ["a", 475], ["transgenic", 477], ["mouse", 488], ["model", 494], ["of", 500], ["spinocerebellar", 503], ["ataxia", 519], ["type", 526], ["3", 531], [".", 532], ["Temsirolimus", 534], ["inhibits", 547], ["mammalian", 556], ["target", 566], ["of", 573], ["rapamycin", 576], ["and", 586], ["hence", 590], ["upregulates", 596], ["protein", 608], ["degradation", 616], ["by", 628], ["autophagy", 631], [".", 640], ["Temsirolimus", 642], ["reduces", 655], ["the", 663], ["number", 667], ["of", 674], ["aggregates", 677], ["seen", 688], ["in", 693], ["the", 696], ["brains", 700], ["of", 707], ["transgenic", 710], ["mice", 721], ["and", 726], ["decreases", 730], ["levels", 740], ["of", 747], ["cytosolic", 750], ["soluble", 760], ["mutant", 768], ["ataxin-3", 775], [",", 783], ["while", 785], ["endogenous", 791], ["wild", 802], ["-", 806], ["type", 807], ["protein", 812], ["levels", 820], ["remain", 827], ["unaffected", 834], [".", 844], ["Temsirolimus", 846], ["is", 859], ["designed", 862], ["for", 871], ["long", 875], ["-", 879], ["term", 880], ["use", 885], ["in", 889], ["patients", 892], ["and", 901], ["therefore", 905], ["represents", 915], ["a", 926], ["possible", 928], ["therapeutic", 937], ["strategy", 949], ["for", 958], ["the", 962], ["treatment", 966], ["of", 976], ["spinocerebellar", 979], ["ataxia", 995], ["type", 1002], ["3", 1007], [".", 1008], ["Using", 1010], ["this", 1016], ["disease", 1021], ["model", 1029], ["and", 1035], ["treatment", 1039], ["paradigm", 1049], [",", 1057], ["we", 1059], ["employed", 1062], ["a", 1071], ["microarray", 1073], ["approach", 1084], ["to", 1093], ["investigate", 1096], ["transcriptional", 1108], ["changes", 1124], ["that", 1132], ["might", 1137], ["be", 1143], ["important", 1146], ["in", 1156], ["the", 1159], ["pathogenesis", 1163], ["of", 1176], ["spinocerebellar", 1179], ["ataxia", 1195], ["type", 1202], ["3", 1207], [".", 1208], ["This", 1210], ["identified", 1215], ["ubiquitin", 1226], ["specific", 1236], ["peptidase-15", 1245], [",", 1257], ["which", 1259], ["showed", 1265], ["expression", 1272], ["changes", 1283], ["at", 1291], ["both", 1294], ["the", 1299], ["messenger", 1303], ["ribonucleic", 1313], ["acid", 1325], ["and", 1330], ["protein", 1334], ["level", 1342], [".", 1347], ["Ubiquitin", 1349], ["specific", 1359], ["peptidase-15", 1368], ["levels", 1381], ["were", 1388], ["also", 1393], ["changed", 1398], ["in", 1406], ["mice", 1409], ["expressing", 1414], ["another", 1425], ["mutant", 1433], ["polyglutamine", 1440], ["protein", 1454], [",", 1461], ["huntingtin", 1463], [".", 1473], ["In", 1475], ["total", 1478], ["we", 1484], ["identified", 1487], ["16", 1498], ["transcripts", 1501], ["that", 1513], ["were", 1518], ["decreased", 1523], ["in", 1533], ["transgenic", 1536], ["ataxin-3", 1547], ["mice", 1556], ["that", 1561], ["were", 1566], ["normalized", 1571], ["following", 1582], ["temsirolimus", 1592], ["treatment", 1605], [".", 1614], ["In", 1616], ["this", 1619], ["mouse", 1624], ["model", 1630], ["with", 1636], ["relatively", 1641], ["mild", 1652], ["disease", 1657], ["progression", 1665], [",", 1676], ["the", 1678], ["number", 1682], ["of", 1689], ["transcripts", 1692], ["changed", 1704], ["was", 1712], ["low", 1716], ["and", 1720], ["the", 1724], ["magnitude", 1728], ["of", 1738], ["these", 1741], ["changes", 1747], ["was", 1755], ["small", 1759], [".", 1764], ["However", 1766], [",", 1773], ["the", 1775], ["importance", 1779], ["of", 1790], ["these", 1793], ["transcriptional", 1799], ["alterations", 1815], ["in", 1827], ["the", 1830], ["pathogenesis", 1834], ["of", 1847], ["spinocerebellar", 1850], ["ataxia", 1866], ["type", 1873], ["3", 1878], ["remains", 1880], ["unclear", 1888], [".", 1895]]}
{"context": "Anticoagulation therapy is indicated for management of various clinical conditions to prevent adverse events and introduction of direct oral anticoagulants (DOACs) has ushered in a new era in anticoagulation therapy. Major advantages of DOACS include fewer drug interactions and that they do not need periodic monitoring. Several patients who were not on anticoagulation before due to older age, polypharmacy/drug interaction concerns, and logistics of periodic monitoring are now on anticoagulation with DOACs. Despite their many advantages, a challenge while prescribing DOACs is very limited availability of specific reversal agents and lack of understanding or guidance about the treatment strategy in case of major life threatening bleeding or need for urgent surgery. So far only one reversal agent has been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran. Several other reversal agents are under final phases of development such as andexanet alfa and PER977 (ciraparantag) and will help in developing specific strategies for reversal of these agents. In this article, we review current strategies to manage bleeding with DOACs and provide guidance to clinicians of inhibiting LF activity in vitro and in cells, as well as in animal models of anthrax infection.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "92d38fcd3d864c5aa90a01fe0e5787f2", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[149, 149]], "char_spans": [[906, 915]]}]}], "context_tokens": [["Anticoagulation", 0], ["therapy", 16], ["is", 24], ["indicated", 27], ["for", 37], ["management", 41], ["of", 52], ["various", 55], ["clinical", 63], ["conditions", 72], ["to", 83], ["prevent", 86], ["adverse", 94], ["events", 102], ["and", 109], ["introduction", 113], ["of", 126], ["direct", 129], ["oral", 136], ["anticoagulants", 141], ["(", 156], ["DOACs", 157], [")", 162], ["has", 164], ["ushered", 168], ["in", 176], ["a", 179], ["new", 181], ["era", 185], ["in", 189], ["anticoagulation", 192], ["therapy", 208], [".", 215], ["Major", 217], ["advantages", 223], ["of", 234], ["DOACS", 237], ["include", 243], ["fewer", 251], ["drug", 257], ["interactions", 262], ["and", 275], ["that", 279], ["they", 284], ["do", 289], ["not", 292], ["need", 296], ["periodic", 301], ["monitoring", 310], [".", 320], ["Several", 322], ["patients", 330], ["who", 339], ["were", 343], ["not", 348], ["on", 352], ["anticoagulation", 355], ["before", 371], ["due", 378], ["to", 382], ["older", 385], ["age", 391], [",", 394], ["polypharmacy", 396], ["/", 408], ["drug", 409], ["interaction", 414], ["concerns", 426], [",", 434], ["and", 436], ["logistics", 440], ["of", 450], ["periodic", 453], ["monitoring", 462], ["are", 473], ["now", 477], ["on", 481], ["anticoagulation", 484], ["with", 500], ["DOACs", 505], [".", 510], ["Despite", 512], ["their", 520], ["many", 526], ["advantages", 531], [",", 541], ["a", 543], ["challenge", 545], ["while", 555], ["prescribing", 561], ["DOACs", 573], ["is", 579], ["very", 582], ["limited", 587], ["availability", 595], ["of", 608], ["specific", 611], ["reversal", 620], ["agents", 629], ["and", 636], ["lack", 640], ["of", 645], ["understanding", 648], ["or", 662], ["guidance", 665], ["about", 674], ["the", 680], ["treatment", 684], ["strategy", 694], ["in", 703], ["case", 706], ["of", 711], ["major", 714], ["life", 720], ["threatening", 725], ["bleeding", 737], ["or", 746], ["need", 749], ["for", 754], ["urgent", 758], ["surgery", 765], [".", 772], ["So", 774], ["far", 777], ["only", 781], ["one", 786], ["reversal", 790], ["agent", 799], ["has", 805], ["been", 809], ["approved", 814], ["by", 823], ["the", 826], ["Food", 830], ["and", 835], ["Drug", 839], ["Administration", 844], ["(", 859], ["FDA", 860], [")", 863], [",", 864], ["idarucizumab", 866], ["for", 879], ["one", 883], ["of", 887], ["the", 890], ["DOACs", 894], ["i.e.", 900], [",", 904], ["dabigatran", 906], [".", 916], ["Several", 918], ["other", 926], ["reversal", 932], ["agents", 941], ["are", 948], ["under", 952], ["final", 958], ["phases", 964], ["of", 971], ["development", 974], ["such", 986], ["as", 991], ["andexanet", 994], ["alfa", 1004], ["and", 1009], ["PER977", 1013], ["(", 1020], ["ciraparantag", 1021], [")", 1033], ["and", 1035], ["will", 1039], ["help", 1044], ["in", 1049], ["developing", 1052], ["specific", 1063], ["strategies", 1072], ["for", 1083], ["reversal", 1087], ["of", 1096], ["these", 1099], ["agents", 1105], [".", 1111], ["In", 1113], ["this", 1116], ["article", 1121], [",", 1128], ["we", 1130], ["review", 1133], ["current", 1140], ["strategies", 1148], ["to", 1159], ["manage", 1162], ["bleeding", 1169], ["with", 1178], ["DOACs", 1183], ["and", 1189], ["provide", 1193], ["guidance", 1201], ["to", 1210], ["clinicians", 1213], ["of", 1224], ["inhibiting", 1227], ["LF", 1238], ["activity", 1241], ["in", 1250], ["vitro", 1253], ["and", 1259], ["in", 1263], ["cells", 1266], [",", 1271], ["as", 1273], ["well", 1276], ["as", 1281], ["in", 1284], ["animal", 1287], ["models", 1294], ["of", 1301], ["anthrax", 1304], ["infection", 1312], [".", 1321]]}
{"context": "Lewy bodies, the characteristic pathological lesion of substantia nigra neurons in Parkinson's disease (PD), are frequently observed to accompany the amyloid plaque and neurofibrillary tangle pathology of Alzheimer's disease (AD). However the typical anatomic distribution of Lewy bodies in AD is distinct from PD. The most common site of occurrence is the amygdala, where Lewy bodies are observed in approximately 60% of both sporadic and familial AD. Other common sites of occurrence include the periamygdaloid and entorhinal cortex, while neocortical and brainstem areas develop Lewy bodies in a lower percentage of cases. In contrast, dementia with Lewy bodies (DLB), defined by widespread neocortical and brainstem Lewy bodies but frequently accompanied by variable levels of AD-type pathology, represents the other end of a spectrum of pathology associated with dementia. The observation of Lewy bodies in familial AD cases suggests that like neurofibrillary tangles, the formation of Lewy bodies can be induced by the pathological state caused by Abeta-amyloid overproduction. The role of Lewy body formation in the dysfunction and degeneration of neurons remains unclear. The protein alpha-synuclein appears to be an important structural component of Lewy bodies, an observation spurred by the discovery of point mutations in the alpha-synuclein gene linked to rare cases of autosomal dominant PD. Further investigation of alpha-synuclein and its relationship to pathological conditions promoting Lewy body formation in AD, PD, and DLB may yield further insight into pathogenesis of these diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "842999d9925347eca644cb9699a36b65", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[244, 246], [228, 230], [203, 205]], "char_spans": [[1431, 1445], [1338, 1352], [1192, 1206]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], [",", 11], ["the", 13], ["characteristic", 17], ["pathological", 32], ["lesion", 45], ["of", 52], ["substantia", 55], ["nigra", 66], ["neurons", 72], ["in", 80], ["Parkinson", 83], ["'s", 92], ["disease", 95], ["(", 103], ["PD", 104], [")", 106], [",", 107], ["are", 109], ["frequently", 113], ["observed", 124], ["to", 133], ["accompany", 136], ["the", 146], ["amyloid", 150], ["plaque", 158], ["and", 165], ["neurofibrillary", 169], ["tangle", 185], ["pathology", 192], ["of", 202], ["Alzheimer", 205], ["'s", 214], ["disease", 217], ["(", 225], ["AD", 226], [")", 228], [".", 229], ["However", 231], ["the", 239], ["typical", 243], ["anatomic", 251], ["distribution", 260], ["of", 273], ["Lewy", 276], ["bodies", 281], ["in", 288], ["AD", 291], ["is", 294], ["distinct", 297], ["from", 306], ["PD", 311], [".", 313], ["The", 315], ["most", 319], ["common", 324], ["site", 331], ["of", 336], ["occurrence", 339], ["is", 350], ["the", 353], ["amygdala", 357], [",", 365], ["where", 367], ["Lewy", 373], ["bodies", 378], ["are", 385], ["observed", 389], ["in", 398], ["approximately", 401], ["60", 415], ["%", 417], ["of", 419], ["both", 422], ["sporadic", 427], ["and", 436], ["familial", 440], ["AD", 449], [".", 451], ["Other", 453], ["common", 459], ["sites", 466], ["of", 472], ["occurrence", 475], ["include", 486], ["the", 494], ["periamygdaloid", 498], ["and", 513], ["entorhinal", 517], ["cortex", 528], [",", 534], ["while", 536], ["neocortical", 542], ["and", 554], ["brainstem", 558], ["areas", 568], ["develop", 574], ["Lewy", 582], ["bodies", 587], ["in", 594], ["a", 597], ["lower", 599], ["percentage", 605], ["of", 616], ["cases", 619], [".", 624], ["In", 626], ["contrast", 629], [",", 637], ["dementia", 639], ["with", 648], ["Lewy", 653], ["bodies", 658], ["(", 665], ["DLB", 666], [")", 669], [",", 670], ["defined", 672], ["by", 680], ["widespread", 683], ["neocortical", 694], ["and", 706], ["brainstem", 710], ["Lewy", 720], ["bodies", 725], ["but", 732], ["frequently", 736], ["accompanied", 747], ["by", 759], ["variable", 762], ["levels", 771], ["of", 778], ["AD", 781], ["-", 783], ["type", 784], ["pathology", 789], [",", 798], ["represents", 800], ["the", 811], ["other", 815], ["end", 821], ["of", 825], ["a", 828], ["spectrum", 830], ["of", 839], ["pathology", 842], ["associated", 852], ["with", 863], ["dementia", 868], [".", 876], ["The", 878], ["observation", 882], ["of", 894], ["Lewy", 897], ["bodies", 902], ["in", 909], ["familial", 912], ["AD", 921], ["cases", 924], ["suggests", 930], ["that", 939], ["like", 944], ["neurofibrillary", 949], ["tangles", 965], [",", 972], ["the", 974], ["formation", 978], ["of", 988], ["Lewy", 991], ["bodies", 996], ["can", 1003], ["be", 1007], ["induced", 1010], ["by", 1018], ["the", 1021], ["pathological", 1025], ["state", 1038], ["caused", 1044], ["by", 1051], ["Abeta", 1054], ["-", 1059], ["amyloid", 1060], ["overproduction", 1068], [".", 1082], ["The", 1084], ["role", 1088], ["of", 1093], ["Lewy", 1096], ["body", 1101], ["formation", 1106], ["in", 1116], ["the", 1119], ["dysfunction", 1123], ["and", 1135], ["degeneration", 1139], ["of", 1152], ["neurons", 1155], ["remains", 1163], ["unclear", 1171], [".", 1178], ["The", 1180], ["protein", 1184], ["alpha", 1192], ["-", 1197], ["synuclein", 1198], ["appears", 1208], ["to", 1216], ["be", 1219], ["an", 1222], ["important", 1225], ["structural", 1235], ["component", 1246], ["of", 1256], ["Lewy", 1259], ["bodies", 1264], [",", 1270], ["an", 1272], ["observation", 1275], ["spurred", 1287], ["by", 1295], ["the", 1298], ["discovery", 1302], ["of", 1312], ["point", 1315], ["mutations", 1321], ["in", 1331], ["the", 1334], ["alpha", 1338], ["-", 1343], ["synuclein", 1344], ["gene", 1354], ["linked", 1359], ["to", 1366], ["rare", 1369], ["cases", 1374], ["of", 1380], ["autosomal", 1383], ["dominant", 1393], ["PD", 1402], [".", 1404], ["Further", 1406], ["investigation", 1414], ["of", 1428], ["alpha", 1431], ["-", 1436], ["synuclein", 1437], ["and", 1447], ["its", 1451], ["relationship", 1455], ["to", 1468], ["pathological", 1471], ["conditions", 1484], ["promoting", 1495], ["Lewy", 1505], ["body", 1510], ["formation", 1515], ["in", 1525], ["AD", 1528], [",", 1530], ["PD", 1532], [",", 1534], ["and", 1536], ["DLB", 1540], ["may", 1544], ["yield", 1548], ["further", 1554], ["insight", 1562], ["into", 1570], ["pathogenesis", 1575], ["of", 1588], ["these", 1591], ["diseases", 1597], [".", 1605]]}
{"context": "Microbicides are being developed in order to prevent sexual transmission of HIV. Dapivirine, a non-nucleoside reverse transcriptase inhibitor, is one of the leading drug candidates in the field, currently being tested in various dosage forms, namely vaginal rings, gels, and films. In particular, a ring allowing sustained drug release for 1month is in an advanced stage of clinical testing. Two parallel phase III clinical trials are underway in sub-Saharan Africa and results are expected to be released in early 2016. This article overviews the development of dapivirine and its multiple products as potential microbicides, with particular emphasis being placed on clinical evaluation. Also, critical aspects regarding regulatory approval, manufacturing, distribution, and access are discussed.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "a9c0c53d05f1474083e2f1ad8ea28756", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[11, 11]], "char_spans": [[76, 78]]}]}], "context_tokens": [["Microbicides", 0], ["are", 13], ["being", 17], ["developed", 23], ["in", 33], ["order", 36], ["to", 42], ["prevent", 45], ["sexual", 53], ["transmission", 60], ["of", 73], ["HIV", 76], [".", 79], ["Dapivirine", 81], [",", 91], ["a", 93], ["non", 95], ["-", 98], ["nucleoside", 99], ["reverse", 110], ["transcriptase", 118], ["inhibitor", 132], [",", 141], ["is", 143], ["one", 146], ["of", 150], ["the", 153], ["leading", 157], ["drug", 165], ["candidates", 170], ["in", 181], ["the", 184], ["field", 188], [",", 193], ["currently", 195], ["being", 205], ["tested", 211], ["in", 218], ["various", 221], ["dosage", 229], ["forms", 236], [",", 241], ["namely", 243], ["vaginal", 250], ["rings", 258], [",", 263], ["gels", 265], [",", 269], ["and", 271], ["films", 275], [".", 280], ["In", 282], ["particular", 285], [",", 295], ["a", 297], ["ring", 299], ["allowing", 304], ["sustained", 313], ["drug", 323], ["release", 328], ["for", 336], ["1month", 340], ["is", 347], ["in", 350], ["an", 353], ["advanced", 356], ["stage", 365], ["of", 371], ["clinical", 374], ["testing", 383], [".", 390], ["Two", 392], ["parallel", 396], ["phase", 405], ["III", 411], ["clinical", 415], ["trials", 424], ["are", 431], ["underway", 435], ["in", 444], ["sub", 447], ["-", 450], ["Saharan", 451], ["Africa", 459], ["and", 466], ["results", 470], ["are", 478], ["expected", 482], ["to", 491], ["be", 494], ["released", 497], ["in", 506], ["early", 509], ["2016", 515], [".", 519], ["This", 521], ["article", 526], ["overviews", 534], ["the", 544], ["development", 548], ["of", 560], ["dapivirine", 563], ["and", 574], ["its", 578], ["multiple", 582], ["products", 591], ["as", 600], ["potential", 603], ["microbicides", 613], [",", 625], ["with", 627], ["particular", 632], ["emphasis", 643], ["being", 652], ["placed", 658], ["on", 665], ["clinical", 668], ["evaluation", 677], [".", 687], ["Also", 689], [",", 693], ["critical", 695], ["aspects", 704], ["regarding", 712], ["regulatory", 722], ["approval", 733], [",", 741], ["manufacturing", 743], [",", 756], ["distribution", 758], [",", 770], ["and", 772], ["access", 776], ["are", 783], ["discussed", 787], [".", 796]]}
{"context": "Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies. These inclusion bodies are the characteristic pathologic lesions of Parkinson disease. Here we define the role of phosphorylation of Ser129 in alpha-synuclein toxicity and inclusion formation using a Drosophila model of Parkinson disease. Mutation of Ser129 to alanine to prevent phosphorylation completely suppresses dopaminergic neuronal loss produced by expression of human alpha-synuclein. In contrast, altering Ser129 to the negatively charged residue aspartate, to mimic phosphorylation, significantly enhances alpha-synuclein toxicity. The G protein-coupled receptor kinase 2 (Gprk2) phosphorylates Ser129 in vivo and enhances alpha-synuclein toxicity. Blocking phosphorylation at Ser129 substantially increases aggregate formation. Thus Ser129 phosphorylation status is crucial in mediating alpha-synuclein neurotoxicity and inclusion formation. Because increased number of inclusion bodies correlates with reduced toxicity, inclusion bodies may protect neurons from alpha-synuclein toxicity.", "qas": [{"question": "Which residue of alpha-synuclein was found to be phosphorylated in Lewy bodies?", "answers": ["Serine 129"], "qid": "7161d325e39f4f4884391fb5e3adb5db", "question_tokens": [["Which", 0], ["residue", 6], ["of", 14], ["alpha", 17], ["-", 22], ["synuclein", 23], ["was", 33], ["found", 37], ["to", 43], ["be", 46], ["phosphorylated", 49], ["in", 64], ["Lewy", 67], ["bodies", 72], ["?", 78]], "detected_answers": [{"text": "Serine 129", "token_spans": [[6, 7]], "char_spans": [[37, 46]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["is", 16], ["phosphorylated", 19], ["at", 34], ["serine", 37], ["129", 44], ["(", 48], ["Ser129", 49], [")", 55], ["in", 57], ["intracellular", 60], ["protein", 74], ["aggregates", 82], ["called", 93], ["Lewy", 100], ["bodies", 105], [".", 111], ["These", 113], ["inclusion", 119], ["bodies", 129], ["are", 136], ["the", 140], ["characteristic", 144], ["pathologic", 159], ["lesions", 170], ["of", 178], ["Parkinson", 181], ["disease", 191], [".", 198], ["Here", 200], ["we", 205], ["define", 208], ["the", 215], ["role", 219], ["of", 224], ["phosphorylation", 227], ["of", 243], ["Ser129", 246], ["in", 253], ["alpha", 256], ["-", 261], ["synuclein", 262], ["toxicity", 272], ["and", 281], ["inclusion", 285], ["formation", 295], ["using", 305], ["a", 311], ["Drosophila", 313], ["model", 324], ["of", 330], ["Parkinson", 333], ["disease", 343], [".", 350], ["Mutation", 352], ["of", 361], ["Ser129", 364], ["to", 371], ["alanine", 374], ["to", 382], ["prevent", 385], ["phosphorylation", 393], ["completely", 409], ["suppresses", 420], ["dopaminergic", 431], ["neuronal", 444], ["loss", 453], ["produced", 458], ["by", 467], ["expression", 470], ["of", 481], ["human", 484], ["alpha", 490], ["-", 495], ["synuclein", 496], [".", 505], ["In", 507], ["contrast", 510], [",", 518], ["altering", 520], ["Ser129", 529], ["to", 536], ["the", 539], ["negatively", 543], ["charged", 554], ["residue", 562], ["aspartate", 570], [",", 579], ["to", 581], ["mimic", 584], ["phosphorylation", 590], [",", 605], ["significantly", 607], ["enhances", 621], ["alpha", 630], ["-", 635], ["synuclein", 636], ["toxicity", 646], [".", 654], ["The", 656], ["G", 660], ["protein", 662], ["-", 669], ["coupled", 670], ["receptor", 678], ["kinase", 687], ["2", 694], ["(", 696], ["Gprk2", 697], [")", 702], ["phosphorylates", 704], ["Ser129", 719], ["in", 726], ["vivo", 729], ["and", 734], ["enhances", 738], ["alpha", 747], ["-", 752], ["synuclein", 753], ["toxicity", 763], [".", 771], ["Blocking", 773], ["phosphorylation", 782], ["at", 798], ["Ser129", 801], ["substantially", 808], ["increases", 822], ["aggregate", 832], ["formation", 842], [".", 851], ["Thus", 853], ["Ser129", 858], ["phosphorylation", 865], ["status", 881], ["is", 888], ["crucial", 891], ["in", 899], ["mediating", 902], ["alpha", 912], ["-", 917], ["synuclein", 918], ["neurotoxicity", 928], ["and", 942], ["inclusion", 946], ["formation", 956], [".", 965], ["Because", 967], ["increased", 975], ["number", 985], ["of", 992], ["inclusion", 995], ["bodies", 1005], ["correlates", 1012], ["with", 1023], ["reduced", 1028], ["toxicity", 1036], [",", 1044], ["inclusion", 1046], ["bodies", 1056], ["may", 1063], ["protect", 1067], ["neurons", 1075], ["from", 1083], ["alpha", 1088], ["-", 1093], ["synuclein", 1094], ["toxicity", 1104], [".", 1112]]}
{"context": "Adenosine deaminases that act on RNA [adenosine deaminase, RNA specific (ADAR)] catalyze the site-specific conversion of adenosine to inosine in primary mRNA transcripts. These re-coding events affect coding potential, splice sites, and stability of mature mRNAs. ADAR is an essential gene, and studies in mouse, Caenorhabditis elegans, and Drosophila suggest that its primary function is to modify adult behavior by altering signaling components in the nervous system. By comparing the sequence of isogenic cDNAs to genomic DNA, we have identified and experimentally verified 27 new targets of Drosophila ADAR. Our analyses led us to identify new classes of genes whose transcripts are targets of ADAR, including components of the actin cytoskeleton and genes involved in ion homeostasis and signal transduction. Our results indicate that editing in Drosophila increases the diversity of the proteome, and does so in a manner that has direct functional consequences on protein function.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["adenosine deaminase, RNA-specific", "ADAR", "adenosine deaminase, RNA specific"], "qid": "39ab6d3436864e6ea8cc1a577a441db5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[106, 106], [13, 13], [123, 123], [49, 49]], "char_spans": [[606, 609], [73, 76], [698, 701], [264, 267]]}, {"text": "adenosine deaminase, RNA-specific", "token_spans": [[7, 11]], "char_spans": [[38, 70]]}]}], "context_tokens": [["Adenosine", 0], ["deaminases", 10], ["that", 21], ["act", 26], ["on", 30], ["RNA", 33], ["[", 37], ["adenosine", 38], ["deaminase", 48], [",", 57], ["RNA", 59], ["specific", 63], ["(", 72], ["ADAR", 73], [")", 77], ["]", 78], ["catalyze", 80], ["the", 89], ["site", 93], ["-", 97], ["specific", 98], ["conversion", 107], ["of", 118], ["adenosine", 121], ["to", 131], ["inosine", 134], ["in", 142], ["primary", 145], ["mRNA", 153], ["transcripts", 158], [".", 169], ["These", 171], ["re", 177], ["-", 179], ["coding", 180], ["events", 187], ["affect", 194], ["coding", 201], ["potential", 208], [",", 217], ["splice", 219], ["sites", 226], [",", 231], ["and", 233], ["stability", 237], ["of", 247], ["mature", 250], ["mRNAs", 257], [".", 262], ["ADAR", 264], ["is", 269], ["an", 272], ["essential", 275], ["gene", 285], [",", 289], ["and", 291], ["studies", 295], ["in", 303], ["mouse", 306], [",", 311], ["Caenorhabditis", 313], ["elegans", 328], [",", 335], ["and", 337], ["Drosophila", 341], ["suggest", 352], ["that", 360], ["its", 365], ["primary", 369], ["function", 377], ["is", 386], ["to", 389], ["modify", 392], ["adult", 399], ["behavior", 405], ["by", 414], ["altering", 417], ["signaling", 426], ["components", 436], ["in", 447], ["the", 450], ["nervous", 454], ["system", 462], [".", 468], ["By", 470], ["comparing", 473], ["the", 483], ["sequence", 487], ["of", 496], ["isogenic", 499], ["cDNAs", 508], ["to", 514], ["genomic", 517], ["DNA", 525], [",", 528], ["we", 530], ["have", 533], ["identified", 538], ["and", 549], ["experimentally", 553], ["verified", 568], ["27", 577], ["new", 580], ["targets", 584], ["of", 592], ["Drosophila", 595], ["ADAR", 606], [".", 610], ["Our", 612], ["analyses", 616], ["led", 625], ["us", 629], ["to", 632], ["identify", 635], ["new", 644], ["classes", 648], ["of", 656], ["genes", 659], ["whose", 665], ["transcripts", 671], ["are", 683], ["targets", 687], ["of", 695], ["ADAR", 698], [",", 702], ["including", 704], ["components", 714], ["of", 725], ["the", 728], ["actin", 732], ["cytoskeleton", 738], ["and", 751], ["genes", 755], ["involved", 761], ["in", 770], ["ion", 773], ["homeostasis", 777], ["and", 789], ["signal", 793], ["transduction", 800], [".", 812], ["Our", 814], ["results", 818], ["indicate", 826], ["that", 835], ["editing", 840], ["in", 848], ["Drosophila", 851], ["increases", 862], ["the", 872], ["diversity", 876], ["of", 886], ["the", 889], ["proteome", 893], [",", 901], ["and", 903], ["does", 907], ["so", 912], ["in", 915], ["a", 918], ["manner", 920], ["that", 927], ["has", 932], ["direct", 936], ["functional", 943], ["consequences", 954], ["on", 967], ["protein", 970], ["function", 978], [".", 986]]}
{"context": "The Long QT syndrome (LQTS) is a relatively rare disorder. It has a major clinical impact as affected individuals are prone to syncope and sudden arrhythmogenic cardiac death. The LQTS comprises three groups of patients. The Jervell-Lange-Nielsen syndrome is characterized by an autosomal recessive pattern of inheritance and congenital neural deafness. The Romano-Ward syndrome shows an autosomal dominant pattern of inheritance and normal hearing. Patients with the sporadic form of LQTS have no evidence of familial transmission and have normal hearing. Imbalance of sympathetic cardiac innervation with predominance of the left stellate ganglion and an intrinsic myocardial defect leading to early afterdepolarization are the two pathogenetic mechanisms of LQTS discussed today. More recently a genetic basis for the Romano-Ward LQTS has been reported. The genetic linkage to the Harvey ras-1 gene provides the basis for a new hypothesis that an impairment of guanine nucleotide binding proteins is responsible for symptoms observed in LQTS. This paper discusses the genetic basis, pathology and pathophysiology of LQTS and tries to unify the different theories.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "26694e93ebbc4962895a9d5377a2e4e8", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[68, 69]], "char_spans": [[388, 405]]}]}], "context_tokens": [["The", 0], ["Long", 4], ["QT", 9], ["syndrome", 12], ["(", 21], ["LQTS", 22], [")", 26], ["is", 28], ["a", 31], ["relatively", 33], ["rare", 44], ["disorder", 49], [".", 57], ["It", 59], ["has", 62], ["a", 66], ["major", 68], ["clinical", 74], ["impact", 83], ["as", 90], ["affected", 93], ["individuals", 102], ["are", 114], ["prone", 118], ["to", 124], ["syncope", 127], ["and", 135], ["sudden", 139], ["arrhythmogenic", 146], ["cardiac", 161], ["death", 169], [".", 174], ["The", 176], ["LQTS", 180], ["comprises", 185], ["three", 195], ["groups", 201], ["of", 208], ["patients", 211], [".", 219], ["The", 221], ["Jervell", 225], ["-", 232], ["Lange", 233], ["-", 238], ["Nielsen", 239], ["syndrome", 247], ["is", 256], ["characterized", 259], ["by", 273], ["an", 276], ["autosomal", 279], ["recessive", 289], ["pattern", 299], ["of", 307], ["inheritance", 310], ["and", 322], ["congenital", 326], ["neural", 337], ["deafness", 344], [".", 352], ["The", 354], ["Romano", 358], ["-", 364], ["Ward", 365], ["syndrome", 370], ["shows", 379], ["an", 385], ["autosomal", 388], ["dominant", 398], ["pattern", 407], ["of", 415], ["inheritance", 418], ["and", 430], ["normal", 434], ["hearing", 441], [".", 448], ["Patients", 450], ["with", 459], ["the", 464], ["sporadic", 468], ["form", 477], ["of", 482], ["LQTS", 485], ["have", 490], ["no", 495], ["evidence", 498], ["of", 507], ["familial", 510], ["transmission", 519], ["and", 532], ["have", 536], ["normal", 541], ["hearing", 548], [".", 555], ["Imbalance", 557], ["of", 567], ["sympathetic", 570], ["cardiac", 582], ["innervation", 590], ["with", 602], ["predominance", 607], ["of", 620], ["the", 623], ["left", 627], ["stellate", 632], ["ganglion", 641], ["and", 650], ["an", 654], ["intrinsic", 657], ["myocardial", 667], ["defect", 678], ["leading", 685], ["to", 693], ["early", 696], ["afterdepolarization", 702], ["are", 722], ["the", 726], ["two", 730], ["pathogenetic", 734], ["mechanisms", 747], ["of", 758], ["LQTS", 761], ["discussed", 766], ["today", 776], [".", 781], ["More", 783], ["recently", 788], ["a", 797], ["genetic", 799], ["basis", 807], ["for", 813], ["the", 817], ["Romano", 821], ["-", 827], ["Ward", 828], ["LQTS", 833], ["has", 838], ["been", 842], ["reported", 847], [".", 855], ["The", 857], ["genetic", 861], ["linkage", 869], ["to", 877], ["the", 880], ["Harvey", 884], ["ras-1", 891], ["gene", 897], ["provides", 902], ["the", 911], ["basis", 915], ["for", 921], ["a", 925], ["new", 927], ["hypothesis", 931], ["that", 942], ["an", 947], ["impairment", 950], ["of", 961], ["guanine", 964], ["nucleotide", 972], ["binding", 983], ["proteins", 991], ["is", 1000], ["responsible", 1003], ["for", 1015], ["symptoms", 1019], ["observed", 1028], ["in", 1037], ["LQTS", 1040], [".", 1044], ["This", 1046], ["paper", 1051], ["discusses", 1057], ["the", 1067], ["genetic", 1071], ["basis", 1079], [",", 1084], ["pathology", 1086], ["and", 1096], ["pathophysiology", 1100], ["of", 1116], ["LQTS", 1119], ["and", 1124], ["tries", 1128], ["to", 1134], ["unify", 1137], ["the", 1143], ["different", 1147], ["theories", 1157], [".", 1165]]}
{"context": "We evaluated the new, fully automated molecular BD Max methicillin-resistant Staphylococcus aureus (MRSA) assay for detection of methicillin-resistant S. aureus in a low-prevalence (4.1%) setting. Sensitivity, specificity, and positive and negative predictive values were 93.9%, 99.2%, 83.8%, and 99.7%, respectively. The assay reported fewer unresolved results than the BD GeneOhm MRSA ACP assay.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "66854406960a4a4ba4cff23625202de8", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "methicillin-resistant S. aureus", "token_spans": [[22, 26]], "char_spans": [[129, 159]]}, {"text": "MRSA", "token_spans": [[16, 16], [74, 74]], "char_spans": [[100, 103], [382, 385]]}]}], "context_tokens": [["We", 0], ["evaluated", 3], ["the", 13], ["new", 17], [",", 20], ["fully", 22], ["automated", 28], ["molecular", 38], ["BD", 48], ["Max", 51], ["methicillin", 55], ["-", 66], ["resistant", 67], ["Staphylococcus", 77], ["aureus", 92], ["(", 99], ["MRSA", 100], [")", 104], ["assay", 106], ["for", 112], ["detection", 116], ["of", 126], ["methicillin", 129], ["-", 140], ["resistant", 141], ["S.", 151], ["aureus", 154], ["in", 161], ["a", 164], ["low", 166], ["-", 169], ["prevalence", 170], ["(", 181], ["4.1", 182], ["%", 185], [")", 186], ["setting", 188], [".", 195], ["Sensitivity", 197], [",", 208], ["specificity", 210], [",", 221], ["and", 223], ["positive", 227], ["and", 236], ["negative", 240], ["predictive", 249], ["values", 260], ["were", 267], ["93.9", 272], ["%", 276], [",", 277], ["99.2", 279], ["%", 283], [",", 284], ["83.8", 286], ["%", 290], [",", 291], ["and", 293], ["99.7", 297], ["%", 301], [",", 302], ["respectively", 304], [".", 316], ["The", 318], ["assay", 322], ["reported", 328], ["fewer", 337], ["unresolved", 343], ["results", 354], ["than", 362], ["the", 367], ["BD", 371], ["GeneOhm", 374], ["MRSA", 382], ["ACP", 387], ["assay", 391], [".", 396]]}
{"context": "The BCR/ABL gene fusion, the hallmark of chronic myelogenous leukemia (CML) is generated in 2-10% of patients by a variant Ph translocation involving 9q34, 22q11.2, and one or more additional genomic regions. The objective of this study was the characterization by conventional and molecular cytogenetics of complex variant Ph translocations present at diagnosis. FISH studies were performed in 7 cases using the LSI BCR/ABL ES probe allowing the detection of the fusion BCR/ABL gene on the Ph chromosome in all of them and 9q34 deletions in 2 cases. Three cryptic complex rearrangements were detected by FISH studies. The third and the fourth chromosome regions involved in the 8 complex variant translocations were: 1q21, 1p36, 5q31, 11q13, 12q13, 12p13, and 20q12. In conclusion, FISH studies have been useful in the detection of the BCR/ABL rearrangements and 9q34 deletions, and to identify complex rearrangements that differ from the ones previously established by conventional cytogenetics.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "85a18e64fb2d47b0afeee4832c599891", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[1, 5]], "char_spans": [[4, 22]]}]}], "context_tokens": [["The", 0], ["BCR", 4], ["/", 7], ["ABL", 8], ["gene", 12], ["fusion", 17], [",", 23], ["the", 25], ["hallmark", 29], ["of", 38], ["chronic", 41], ["myelogenous", 49], ["leukemia", 61], ["(", 70], ["CML", 71], [")", 74], ["is", 76], ["generated", 79], ["in", 89], ["2", 92], ["-", 93], ["10", 94], ["%", 96], ["of", 98], ["patients", 101], ["by", 110], ["a", 113], ["variant", 115], ["Ph", 123], ["translocation", 126], ["involving", 140], ["9q34", 150], [",", 154], ["22q11.2", 156], [",", 163], ["and", 165], ["one", 169], ["or", 173], ["more", 176], ["additional", 181], ["genomic", 192], ["regions", 200], [".", 207], ["The", 209], ["objective", 213], ["of", 223], ["this", 226], ["study", 231], ["was", 237], ["the", 241], ["characterization", 245], ["by", 262], ["conventional", 265], ["and", 278], ["molecular", 282], ["cytogenetics", 292], ["of", 305], ["complex", 308], ["variant", 316], ["Ph", 324], ["translocations", 327], ["present", 342], ["at", 350], ["diagnosis", 353], [".", 362], ["FISH", 364], ["studies", 369], ["were", 377], ["performed", 382], ["in", 392], ["7", 395], ["cases", 397], ["using", 403], ["the", 409], ["LSI", 413], ["BCR", 417], ["/", 420], ["ABL", 421], ["ES", 425], ["probe", 428], ["allowing", 434], ["the", 443], ["detection", 447], ["of", 457], ["the", 460], ["fusion", 464], ["BCR", 471], ["/", 474], ["ABL", 475], ["gene", 479], ["on", 484], ["the", 487], ["Ph", 491], ["chromosome", 494], ["in", 505], ["all", 508], ["of", 512], ["them", 515], ["and", 520], ["9q34", 524], ["deletions", 529], ["in", 539], ["2", 542], ["cases", 544], [".", 549], ["Three", 551], ["cryptic", 557], ["complex", 565], ["rearrangements", 573], ["were", 588], ["detected", 593], ["by", 602], ["FISH", 605], ["studies", 610], [".", 617], ["The", 619], ["third", 623], ["and", 629], ["the", 633], ["fourth", 637], ["chromosome", 644], ["regions", 655], ["involved", 663], ["in", 672], ["the", 675], ["8", 679], ["complex", 681], ["variant", 689], ["translocations", 697], ["were", 712], [":", 716], ["1q21", 718], [",", 722], ["1p36", 724], [",", 728], ["5q31", 730], [",", 734], ["11q13", 736], [",", 741], ["12q13", 743], [",", 748], ["12p13", 750], [",", 755], ["and", 757], ["20q12", 761], [".", 766], ["In", 768], ["conclusion", 771], [",", 781], ["FISH", 783], ["studies", 788], ["have", 796], ["been", 801], ["useful", 806], ["in", 813], ["the", 816], ["detection", 820], ["of", 830], ["the", 833], ["BCR", 837], ["/", 840], ["ABL", 841], ["rearrangements", 845], ["and", 860], ["9q34", 864], ["deletions", 869], [",", 878], ["and", 880], ["to", 884], ["identify", 887], ["complex", 896], ["rearrangements", 904], ["that", 919], ["differ", 924], ["from", 931], ["the", 936], ["ones", 940], ["previously", 945], ["established", 956], ["by", 968], ["conventional", 971], ["cytogenetics", 984], [".", 996]]}
{"context": "Mowat-Wilson syndrome is a genetic disease caused by heterozygous mutations or deletions of the zinc finger E-box-binding homeobox 2 (ZEB2) gene. The syndrome is characterized by typical facial features, moderate-to-severe mental retardation, epilepsy and variable congenital malformations, including Hirschsprung disease, genital anomalies, congenital heart disease, agenesis of the corpus callosum, and eye defects. The prevalence of Mowat-Wilson syndrome is currently unknown, but it seems that Mowat-Wilson syndrome is underdiagnosed, particularly in patients without Hirschsprung disease. We report here the first Egyptian case of Mowat-Wilson syndrome who was conceived by intracytoplasmic sperm injection. The patient manifested bilateral sensorineural hearing loss--a new feature not previously reported in cases of Mowat-Wilson syndrome. This report describes the first Egyptian patient of Mowat-Wilson syndrome who was conceived after intracytoplasmic sperm injection, and provides a new evidence for the inclusion of deafness among the congenital defects of the syndrome.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "c3272be6bdea40c9ac22dfe5337dc311", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[26, 26]], "char_spans": [[134, 137]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["is", 22], ["a", 25], ["genetic", 27], ["disease", 35], ["caused", 43], ["by", 50], ["heterozygous", 53], ["mutations", 66], ["or", 76], ["deletions", 79], ["of", 89], ["the", 92], ["zinc", 96], ["finger", 101], ["E", 108], ["-", 109], ["box", 110], ["-", 113], ["binding", 114], ["homeobox", 122], ["2", 131], ["(", 133], ["ZEB2", 134], [")", 138], ["gene", 140], [".", 144], ["The", 146], ["syndrome", 150], ["is", 159], ["characterized", 162], ["by", 176], ["typical", 179], ["facial", 187], ["features", 194], [",", 202], ["moderate", 204], ["-", 212], ["to", 213], ["-", 215], ["severe", 216], ["mental", 223], ["retardation", 230], [",", 241], ["epilepsy", 243], ["and", 252], ["variable", 256], ["congenital", 265], ["malformations", 276], [",", 289], ["including", 291], ["Hirschsprung", 301], ["disease", 314], [",", 321], ["genital", 323], ["anomalies", 331], [",", 340], ["congenital", 342], ["heart", 353], ["disease", 359], [",", 366], ["agenesis", 368], ["of", 377], ["the", 380], ["corpus", 384], ["callosum", 391], [",", 399], ["and", 401], ["eye", 405], ["defects", 409], [".", 416], ["The", 418], ["prevalence", 422], ["of", 433], ["Mowat", 436], ["-", 441], ["Wilson", 442], ["syndrome", 449], ["is", 458], ["currently", 461], ["unknown", 471], [",", 478], ["but", 480], ["it", 484], ["seems", 487], ["that", 493], ["Mowat", 498], ["-", 503], ["Wilson", 504], ["syndrome", 511], ["is", 520], ["underdiagnosed", 523], [",", 537], ["particularly", 539], ["in", 552], ["patients", 555], ["without", 564], ["Hirschsprung", 572], ["disease", 585], [".", 592], ["We", 594], ["report", 597], ["here", 604], ["the", 609], ["first", 613], ["Egyptian", 619], ["case", 628], ["of", 633], ["Mowat", 636], ["-", 641], ["Wilson", 642], ["syndrome", 649], ["who", 658], ["was", 662], ["conceived", 666], ["by", 676], ["intracytoplasmic", 679], ["sperm", 696], ["injection", 702], [".", 711], ["The", 713], ["patient", 717], ["manifested", 725], ["bilateral", 736], ["sensorineural", 746], ["hearing", 760], ["loss", 768], ["--", 772], ["a", 774], ["new", 776], ["feature", 780], ["not", 788], ["previously", 792], ["reported", 803], ["in", 812], ["cases", 815], ["of", 821], ["Mowat", 824], ["-", 829], ["Wilson", 830], ["syndrome", 837], [".", 845], ["This", 847], ["report", 852], ["describes", 859], ["the", 869], ["first", 873], ["Egyptian", 879], ["patient", 888], ["of", 896], ["Mowat", 899], ["-", 904], ["Wilson", 905], ["syndrome", 912], ["who", 921], ["was", 925], ["conceived", 929], ["after", 939], ["intracytoplasmic", 945], ["sperm", 962], ["injection", 968], [",", 977], ["and", 979], ["provides", 983], ["a", 992], ["new", 994], ["evidence", 998], ["for", 1007], ["the", 1011], ["inclusion", 1015], ["of", 1025], ["deafness", 1028], ["among", 1037], ["the", 1043], ["congenital", 1047], ["defects", 1058], ["of", 1066], ["the", 1069], ["syndrome", 1073], [".", 1081]]}
{"context": "Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disorder in which an immune deficiency occurs in association with pigmentation abnormalities. Most patients who do not undergo bone marrow transplantation die of a lymphoproliferative syndrome, though some patients with CHS have a relatively milder clinical course of the disease. The large size of the LYST gene, defective in CHS, has made it difficult to screen for mutations in a large number of patients. Only 8 mutations have been identified so far, and all lead to a truncated LYST protein. We conducted protein truncation tests on this gene in 8 patients with CHS. Different LYST mutations were identified in all subjects through this approach, strengthening the observation of a high frequency of truncated LYST proteins as the genetic cause of CHS.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "7b387c3302ca4a718ed588d6618acea4", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["a", 34], ["rare", 36], ["autosomal", 41], ["recessive", 51], ["disorder", 61], ["in", 70], ["which", 73], ["an", 79], ["immune", 82], ["deficiency", 89], ["occurs", 100], ["in", 107], ["association", 110], ["with", 122], ["pigmentation", 127], ["abnormalities", 140], [".", 153], ["Most", 155], ["patients", 160], ["who", 169], ["do", 173], ["not", 176], ["undergo", 180], ["bone", 188], ["marrow", 193], ["transplantation", 200], ["die", 216], ["of", 220], ["a", 223], ["lymphoproliferative", 225], ["syndrome", 245], [",", 253], ["though", 255], ["some", 262], ["patients", 267], ["with", 276], ["CHS", 281], ["have", 285], ["a", 290], ["relatively", 292], ["milder", 303], ["clinical", 310], ["course", 319], ["of", 326], ["the", 329], ["disease", 333], [".", 340], ["The", 342], ["large", 346], ["size", 352], ["of", 357], ["the", 360], ["LYST", 364], ["gene", 369], [",", 373], ["defective", 375], ["in", 385], ["CHS", 388], [",", 391], ["has", 393], ["made", 397], ["it", 402], ["difficult", 405], ["to", 415], ["screen", 418], ["for", 425], ["mutations", 429], ["in", 439], ["a", 442], ["large", 444], ["number", 450], ["of", 457], ["patients", 460], [".", 468], ["Only", 470], ["8", 475], ["mutations", 477], ["have", 487], ["been", 492], ["identified", 497], ["so", 508], ["far", 511], [",", 514], ["and", 516], ["all", 520], ["lead", 524], ["to", 529], ["a", 532], ["truncated", 534], ["LYST", 544], ["protein", 549], [".", 556], ["We", 558], ["conducted", 561], ["protein", 571], ["truncation", 579], ["tests", 590], ["on", 596], ["this", 599], ["gene", 604], ["in", 609], ["8", 612], ["patients", 614], ["with", 623], ["CHS", 628], [".", 631], ["Different", 633], ["LYST", 643], ["mutations", 648], ["were", 658], ["identified", 663], ["in", 674], ["all", 677], ["subjects", 681], ["through", 690], ["this", 698], ["approach", 703], [",", 711], ["strengthening", 713], ["the", 727], ["observation", 731], ["of", 743], ["a", 746], ["high", 748], ["frequency", 753], ["of", 763], ["truncated", 766], ["LYST", 776], ["proteins", 781], ["as", 790], ["the", 793], ["genetic", 797], ["cause", 805], ["of", 811], ["CHS", 814], [".", 817]]}
{"context": "Cytoskeletal proteins belonging to the spectrin family have an elongated structure composed of repetitive units. The three-dimensional solution structure of the 16th repeat from chicken brain alpha-spectrin (R16) has been determined by NMR spectroscopy and distance geometry-simulated annealing calculations. We used a total of 1035 distance restraints, which included 719 NOE-based values obtained by applying the ambiguous restraints for iterative assignment (ARIA) method. In addition, we performed a direct refinement against 1H-chemical shifts. The final ensemble of 20 structures shows an average RMSD of 1.52 A from the mean for the backbone atoms, excluding loops and N and C termini. R16 is made up of three antiparallel alpha-helices separated by two loops, and folds into a left-handed coiled-coil. The basic unit of spectrin is an antiparallel heterodimer composed of two homologous chains, beta and alpha. These assemble a tetramer via a mechanism that relies on the completion of a single repeat by association of the partial repeats located at the C terminus of the beta-chain (two helices) and at the N terminus of the alpha-chain (one helix). This tetramer is the assemblage able to cross-link actin filaments. Model building by homology of the \"tetramerization\" repeat from human erythrocyte spectrin illuminates the possible role of point mutations which cause hemolytic anemias.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "792b104e025543b5b32f47d3bb1b5c44", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[128, 128], [155, 155]], "char_spans": [[717, 728], [843, 854]]}]}], "context_tokens": [["Cytoskeletal", 0], ["proteins", 13], ["belonging", 22], ["to", 32], ["the", 35], ["spectrin", 39], ["family", 48], ["have", 55], ["an", 60], ["elongated", 63], ["structure", 73], ["composed", 83], ["of", 92], ["repetitive", 95], ["units", 106], [".", 111], ["The", 113], ["three", 117], ["-", 122], ["dimensional", 123], ["solution", 135], ["structure", 144], ["of", 154], ["the", 157], ["16th", 161], ["repeat", 166], ["from", 173], ["chicken", 178], ["brain", 186], ["alpha", 192], ["-", 197], ["spectrin", 198], ["(", 207], ["R16", 208], [")", 211], ["has", 213], ["been", 217], ["determined", 222], ["by", 233], ["NMR", 236], ["spectroscopy", 240], ["and", 253], ["distance", 257], ["geometry", 266], ["-", 274], ["simulated", 275], ["annealing", 285], ["calculations", 295], [".", 307], ["We", 309], ["used", 312], ["a", 317], ["total", 319], ["of", 325], ["1035", 328], ["distance", 333], ["restraints", 342], [",", 352], ["which", 354], ["included", 360], ["719", 369], ["NOE", 373], ["-", 376], ["based", 377], ["values", 383], ["obtained", 390], ["by", 399], ["applying", 402], ["the", 411], ["ambiguous", 415], ["restraints", 425], ["for", 436], ["iterative", 440], ["assignment", 450], ["(", 461], ["ARIA", 462], [")", 466], ["method", 468], [".", 474], ["In", 476], ["addition", 479], [",", 487], ["we", 489], ["performed", 492], ["a", 502], ["direct", 504], ["refinement", 511], ["against", 522], ["1H", 530], ["-", 532], ["chemical", 533], ["shifts", 542], [".", 548], ["The", 550], ["final", 554], ["ensemble", 560], ["of", 569], ["20", 572], ["structures", 575], ["shows", 586], ["an", 592], ["average", 595], ["RMSD", 603], ["of", 608], ["1.52", 611], ["A", 616], ["from", 618], ["the", 623], ["mean", 627], ["for", 632], ["the", 636], ["backbone", 640], ["atoms", 649], [",", 654], ["excluding", 656], ["loops", 666], ["and", 672], ["N", 676], ["and", 678], ["C", 682], ["termini", 684], [".", 691], ["R16", 693], ["is", 697], ["made", 700], ["up", 705], ["of", 708], ["three", 711], ["antiparallel", 717], ["alpha", 730], ["-", 735], ["helices", 736], ["separated", 744], ["by", 754], ["two", 757], ["loops", 761], [",", 766], ["and", 768], ["folds", 772], ["into", 778], ["a", 783], ["left", 785], ["-", 789], ["handed", 790], ["coiled", 797], ["-", 803], ["coil", 804], [".", 808], ["The", 810], ["basic", 814], ["unit", 820], ["of", 825], ["spectrin", 828], ["is", 837], ["an", 840], ["antiparallel", 843], ["heterodimer", 856], ["composed", 868], ["of", 877], ["two", 880], ["homologous", 884], ["chains", 895], [",", 901], ["beta", 903], ["and", 908], ["alpha", 912], [".", 917], ["These", 919], ["assemble", 925], ["a", 934], ["tetramer", 936], ["via", 945], ["a", 949], ["mechanism", 951], ["that", 961], ["relies", 966], ["on", 973], ["the", 976], ["completion", 980], ["of", 991], ["a", 994], ["single", 996], ["repeat", 1003], ["by", 1010], ["association", 1013], ["of", 1025], ["the", 1028], ["partial", 1032], ["repeats", 1040], ["located", 1048], ["at", 1056], ["the", 1059], ["C", 1063], ["terminus", 1065], ["of", 1074], ["the", 1077], ["beta", 1081], ["-", 1085], ["chain", 1086], ["(", 1092], ["two", 1093], ["helices", 1097], [")", 1104], ["and", 1106], ["at", 1110], ["the", 1113], ["N", 1117], ["terminus", 1119], ["of", 1128], ["the", 1131], ["alpha", 1135], ["-", 1140], ["chain", 1141], ["(", 1147], ["one", 1148], ["helix", 1152], [")", 1157], [".", 1158], ["This", 1160], ["tetramer", 1165], ["is", 1174], ["the", 1177], ["assemblage", 1181], ["able", 1192], ["to", 1197], ["cross", 1200], ["-", 1205], ["link", 1206], ["actin", 1211], ["filaments", 1217], [".", 1226], ["Model", 1228], ["building", 1234], ["by", 1243], ["homology", 1246], ["of", 1255], ["the", 1258], ["\"", 1262], ["tetramerization", 1263], ["\"", 1278], ["repeat", 1280], ["from", 1287], ["human", 1292], ["erythrocyte", 1298], ["spectrin", 1310], ["illuminates", 1319], ["the", 1331], ["possible", 1335], ["role", 1344], ["of", 1349], ["point", 1352], ["mutations", 1358], ["which", 1368], ["cause", 1374], ["hemolytic", 1380], ["anemias", 1390], [".", 1397]]}
{"context": "In this study, the epidemiological characteristics of malaria cases in Edirne province were investigated. Between the years of 1994-2002, a total of 317,087 blood samples were collected from soldiers in the province with selective active surveillance and from the resident population with active or passive surveillance methods, by the medical staff of Malaria Control Department and Health Centers, to search the presence of Plasmodium. In 281 of them Plasmodium spp. were detected, and the characteristics of malaria cases were investigated. Of the cases, 238 (84.7%) were detected in the first three years and mostly in September. While the indigenous cases were detected in the districts where rice planted intensely, the imported cases were detected in the districts heavily populated by military staff. Of the imported cases, 62% originated from Diyarbakir, Batman and Sanliurfa provinces (Southeast part of Turkey). P. vivax was detected as the causative agent in all blood samples except one P. ovale. This latter case has been the only one in Turkey so far and he was a student from Afghanistan. Attaching importance to fight off mosquitoes in intensely rice planted districts and strictly surveying the military staff, particularly from the region of Southern-East Anatolia, have led to successful control of the malaria cases in Edirne region.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "62dfb0f0049641648b339a94e27b7262", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium spp.", "token_spans": [[76, 77]], "char_spans": [[453, 466]]}]}], "context_tokens": [["In", 0], ["this", 3], ["study", 8], [",", 13], ["the", 15], ["epidemiological", 19], ["characteristics", 35], ["of", 51], ["malaria", 54], ["cases", 62], ["in", 68], ["Edirne", 71], ["province", 78], ["were", 87], ["investigated", 92], [".", 104], ["Between", 106], ["the", 114], ["years", 118], ["of", 124], ["1994", 127], ["-", 131], ["2002", 132], [",", 136], ["a", 138], ["total", 140], ["of", 146], ["317,087", 149], ["blood", 157], ["samples", 163], ["were", 171], ["collected", 176], ["from", 186], ["soldiers", 191], ["in", 200], ["the", 203], ["province", 207], ["with", 216], ["selective", 221], ["active", 231], ["surveillance", 238], ["and", 251], ["from", 255], ["the", 260], ["resident", 264], ["population", 273], ["with", 284], ["active", 289], ["or", 296], ["passive", 299], ["surveillance", 307], ["methods", 320], [",", 327], ["by", 329], ["the", 332], ["medical", 336], ["staff", 344], ["of", 350], ["Malaria", 353], ["Control", 361], ["Department", 369], ["and", 380], ["Health", 384], ["Centers", 391], [",", 398], ["to", 400], ["search", 403], ["the", 410], ["presence", 414], ["of", 423], ["Plasmodium", 426], [".", 436], ["In", 438], ["281", 441], ["of", 445], ["them", 448], ["Plasmodium", 453], ["spp", 464], [".", 467], ["were", 469], ["detected", 474], [",", 482], ["and", 484], ["the", 488], ["characteristics", 492], ["of", 508], ["malaria", 511], ["cases", 519], ["were", 525], ["investigated", 530], [".", 542], ["Of", 544], ["the", 547], ["cases", 551], [",", 556], ["238", 558], ["(", 562], ["84.7", 563], ["%", 567], [")", 568], ["were", 570], ["detected", 575], ["in", 584], ["the", 587], ["first", 591], ["three", 597], ["years", 603], ["and", 609], ["mostly", 613], ["in", 620], ["September", 623], [".", 632], ["While", 634], ["the", 640], ["indigenous", 644], ["cases", 655], ["were", 661], ["detected", 666], ["in", 675], ["the", 678], ["districts", 682], ["where", 692], ["rice", 698], ["planted", 703], ["intensely", 711], [",", 720], ["the", 722], ["imported", 726], ["cases", 735], ["were", 741], ["detected", 746], ["in", 755], ["the", 758], ["districts", 762], ["heavily", 772], ["populated", 780], ["by", 790], ["military", 793], ["staff", 802], [".", 807], ["Of", 809], ["the", 812], ["imported", 816], ["cases", 825], [",", 830], ["62", 832], ["%", 834], ["originated", 836], ["from", 847], ["Diyarbakir", 852], [",", 862], ["Batman", 864], ["and", 871], ["Sanliurfa", 875], ["provinces", 885], ["(", 895], ["Southeast", 896], ["part", 906], ["of", 911], ["Turkey", 914], [")", 920], [".", 921], ["P.", 923], ["vivax", 926], ["was", 932], ["detected", 936], ["as", 945], ["the", 948], ["causative", 952], ["agent", 962], ["in", 968], ["all", 971], ["blood", 975], ["samples", 981], ["except", 989], ["one", 996], ["P.", 1000], ["ovale", 1003], [".", 1008], ["This", 1010], ["latter", 1015], ["case", 1022], ["has", 1027], ["been", 1031], ["the", 1036], ["only", 1040], ["one", 1045], ["in", 1049], ["Turkey", 1052], ["so", 1059], ["far", 1062], ["and", 1066], ["he", 1070], ["was", 1073], ["a", 1077], ["student", 1079], ["from", 1087], ["Afghanistan", 1092], [".", 1103], ["Attaching", 1105], ["importance", 1115], ["to", 1126], ["fight", 1129], ["off", 1135], ["mosquitoes", 1139], ["in", 1150], ["intensely", 1153], ["rice", 1163], ["planted", 1168], ["districts", 1176], ["and", 1186], ["strictly", 1190], ["surveying", 1199], ["the", 1209], ["military", 1213], ["staff", 1222], [",", 1227], ["particularly", 1229], ["from", 1242], ["the", 1247], ["region", 1251], ["of", 1258], ["Southern", 1261], ["-", 1269], ["East", 1270], ["Anatolia", 1275], [",", 1283], ["have", 1285], ["led", 1290], ["to", 1294], ["successful", 1297], ["control", 1308], ["of", 1316], ["the", 1319], ["malaria", 1323], ["cases", 1331], ["in", 1337], ["Edirne", 1340], ["region", 1347], [".", 1353]]}
{"context": "To study the mechanism of centrosome duplication in cycling cells, we established a novel system of multiple centrosome formation in two types of cells: CHO cells treated with RO3306, a Cyclin-dependent kinase 1 (Cdk1) inhibitor and DT40 cells, in which Cdks were knocked out by chemical genetics. Cdk1-inactivated cells initiated DNA replication and centrosome duplication at the onset of S phase. They became arrested at the end of G2, but the centrosome cycle continued to produce supernumerary centrioles/centrosomes without DNA endoreplication in those cells. Centrosomes were amplified in a highly synchronous and reproducible manner: all of them were located next to the nucleus and spread widely apart from each other with several \u03bcm in distance. Double knockout of Cdk1 and Cdk2 caused cell cycle arrest at G1/S and centrosomes were no longer duplicated. However, cells continued to grow and increased their volume over 10-fold during 48 hr of culture. Centrosome components, including \u03b3-tubulin and Cep135, were synthesized and accumulated during the arrest, allowing rapid centrosome multiplication upon recovery from the cell cycle arrest or expression of exogenous Plk4 in G1/S cells. Thus centrosome amplification results from the discoordination of the centrosome cycle from the progression of other cell cycle events, which is controlled by different levels of Cdk activities.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "0c06ab7dd90c4dad83de126afa2b4101", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[5, 5], [82, 82], [188, 188], [215, 215], [18, 18], [168, 168], [62, 62], [207, 207]], "char_spans": [[26, 35], [446, 455], [1084, 1093], [1268, 1277], [109, 118], [962, 971], [351, 360], [1203, 1212]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["mechanism", 13], ["of", 23], ["centrosome", 26], ["duplication", 37], ["in", 49], ["cycling", 52], ["cells", 60], [",", 65], ["we", 67], ["established", 70], ["a", 82], ["novel", 84], ["system", 90], ["of", 97], ["multiple", 100], ["centrosome", 109], ["formation", 120], ["in", 130], ["two", 133], ["types", 137], ["of", 143], ["cells", 146], [":", 151], ["CHO", 153], ["cells", 157], ["treated", 163], ["with", 171], ["RO3306", 176], [",", 182], ["a", 184], ["Cyclin", 186], ["-", 192], ["dependent", 193], ["kinase", 203], ["1", 210], ["(", 212], ["Cdk1", 213], [")", 217], ["inhibitor", 219], ["and", 229], ["DT40", 233], ["cells", 238], [",", 243], ["in", 245], ["which", 248], ["Cdks", 254], ["were", 259], ["knocked", 264], ["out", 272], ["by", 276], ["chemical", 279], ["genetics", 288], [".", 296], ["Cdk1-inactivated", 298], ["cells", 315], ["initiated", 321], ["DNA", 331], ["replication", 335], ["and", 347], ["centrosome", 351], ["duplication", 362], ["at", 374], ["the", 377], ["onset", 381], ["of", 387], ["S", 390], ["phase", 392], [".", 397], ["They", 399], ["became", 404], ["arrested", 411], ["at", 420], ["the", 423], ["end", 427], ["of", 431], ["G2", 434], [",", 436], ["but", 438], ["the", 442], ["centrosome", 446], ["cycle", 457], ["continued", 463], ["to", 473], ["produce", 476], ["supernumerary", 484], ["centrioles", 498], ["/", 508], ["centrosomes", 509], ["without", 521], ["DNA", 529], ["endoreplication", 533], ["in", 549], ["those", 552], ["cells", 558], [".", 563], ["Centrosomes", 565], ["were", 577], ["amplified", 582], ["in", 592], ["a", 595], ["highly", 597], ["synchronous", 604], ["and", 616], ["reproducible", 620], ["manner", 633], [":", 639], ["all", 641], ["of", 645], ["them", 648], ["were", 653], ["located", 658], ["next", 666], ["to", 671], ["the", 674], ["nucleus", 678], ["and", 686], ["spread", 690], ["widely", 697], ["apart", 704], ["from", 710], ["each", 715], ["other", 720], ["with", 726], ["several", 731], ["\u03bcm", 739], ["in", 742], ["distance", 745], [".", 753], ["Double", 755], ["knockout", 762], ["of", 771], ["Cdk1", 774], ["and", 779], ["Cdk2", 783], ["caused", 788], ["cell", 795], ["cycle", 800], ["arrest", 806], ["at", 813], ["G1/S", 816], ["and", 821], ["centrosomes", 825], ["were", 837], ["no", 842], ["longer", 845], ["duplicated", 852], [".", 862], ["However", 864], [",", 871], ["cells", 873], ["continued", 879], ["to", 889], ["grow", 892], ["and", 897], ["increased", 901], ["their", 911], ["volume", 917], ["over", 924], ["10-fold", 929], ["during", 937], ["48", 944], ["hr", 947], ["of", 950], ["culture", 953], [".", 960], ["Centrosome", 962], ["components", 973], [",", 983], ["including", 985], ["\u03b3", 995], ["-", 996], ["tubulin", 997], ["and", 1005], ["Cep135", 1009], [",", 1015], ["were", 1017], ["synthesized", 1022], ["and", 1034], ["accumulated", 1038], ["during", 1050], ["the", 1057], ["arrest", 1061], [",", 1067], ["allowing", 1069], ["rapid", 1078], ["centrosome", 1084], ["multiplication", 1095], ["upon", 1110], ["recovery", 1115], ["from", 1124], ["the", 1129], ["cell", 1133], ["cycle", 1138], ["arrest", 1144], ["or", 1151], ["expression", 1154], ["of", 1165], ["exogenous", 1168], ["Plk4", 1178], ["in", 1183], ["G1/S", 1186], ["cells", 1191], [".", 1196], ["Thus", 1198], ["centrosome", 1203], ["amplification", 1214], ["results", 1228], ["from", 1236], ["the", 1241], ["discoordination", 1245], ["of", 1261], ["the", 1264], ["centrosome", 1268], ["cycle", 1279], ["from", 1285], ["the", 1290], ["progression", 1294], ["of", 1306], ["other", 1309], ["cell", 1315], ["cycle", 1320], ["events", 1326], [",", 1332], ["which", 1334], ["is", 1340], ["controlled", 1343], ["by", 1354], ["different", 1357], ["levels", 1367], ["of", 1374], ["Cdk", 1377], ["activities", 1381], [".", 1391]]}
{"context": "An outbreak of Clostridium difficile ribotype 027 infection (CDI) occurred at an university hospital, involving 19 departments. To determine what hospital-associated factors drove the outbreak of this particular strain we performed a case-control study. Cases (n = 79), diagnosed with CDI due to C. difficile ribotype 027 were matched for age and treating medical specialty to four control patients (n = 316). Patients diagnosed with CDI due to other ribotypes were included as a second control group. A random selection of C. difficile ribotype 027 strains (n = 10) was genotyped by Whole Genome Sequencing (WGS). WGS showed the outbreak was likely caused by a single strain of C. difficile (two or less single-nucleotide variants between isolates). Ninety-five percent of cases had used antibiotics, compared to 56% of controls. Previous admission to the intensive care unit (ICU) (OR: 2.4, 95% CI 1.0-5.6), longer length of stay (LOS), and recent hospital admission were associated with CDI ribotype 027. Cases were less likely to have been admitted to a ward with a known isolated CDI patient (OR: 0.2, 95% CI 0.1-0.6). Analysis of patients who stayed at the ICU (35 cases; 51 controls), indicated that the use of selective decontamination of the digestive tract (SDD) and a longer LOS in the ICU were associated with CDI risk. In this large outbreak, any antibiotic use, including SDD use, appeared as a prerequisite for acquisition of the outbreak strain. The role of use of SDD and prolonged stay on the ICU could not be disentangled, but both factors can play a biologically plausible role in C. difficile acquisition and infection.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "3624fe9b9dca47c98be7dc8c2d2db870", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[5, 6], [57, 58], [199, 200], [99, 100]], "char_spans": [[37, 48], [309, 320], [994, 1005], [537, 548]]}]}], "context_tokens": [["An", 0], ["outbreak", 3], ["of", 12], ["Clostridium", 15], ["difficile", 27], ["ribotype", 37], ["027", 46], ["infection", 50], ["(", 60], ["CDI", 61], [")", 64], ["occurred", 66], ["at", 75], ["an", 78], ["university", 81], ["hospital", 92], [",", 100], ["involving", 102], ["19", 112], ["departments", 115], [".", 126], ["To", 128], ["determine", 131], ["what", 141], ["hospital", 146], ["-", 154], ["associated", 155], ["factors", 166], ["drove", 174], ["the", 180], ["outbreak", 184], ["of", 193], ["this", 196], ["particular", 201], ["strain", 212], ["we", 219], ["performed", 222], ["a", 232], ["case", 234], ["-", 238], ["control", 239], ["study", 247], [".", 252], ["Cases", 254], ["(", 260], ["n", 261], ["=", 263], ["79", 265], [")", 267], [",", 268], ["diagnosed", 270], ["with", 280], ["CDI", 285], ["due", 289], ["to", 293], ["C.", 296], ["difficile", 299], ["ribotype", 309], ["027", 318], ["were", 322], ["matched", 327], ["for", 335], ["age", 339], ["and", 343], ["treating", 347], ["medical", 356], ["specialty", 364], ["to", 374], ["four", 377], ["control", 382], ["patients", 390], ["(", 399], ["n", 400], ["=", 402], ["316", 404], [")", 407], [".", 408], ["Patients", 410], ["diagnosed", 419], ["with", 429], ["CDI", 434], ["due", 438], ["to", 442], ["other", 445], ["ribotypes", 451], ["were", 461], ["included", 466], ["as", 475], ["a", 478], ["second", 480], ["control", 487], ["group", 495], [".", 500], ["A", 502], ["random", 504], ["selection", 511], ["of", 521], ["C.", 524], ["difficile", 527], ["ribotype", 537], ["027", 546], ["strains", 550], ["(", 558], ["n", 559], ["=", 561], ["10", 563], [")", 565], ["was", 567], ["genotyped", 571], ["by", 581], ["Whole", 584], ["Genome", 590], ["Sequencing", 597], ["(", 608], ["WGS", 609], [")", 612], [".", 613], ["WGS", 615], ["showed", 619], ["the", 626], ["outbreak", 630], ["was", 639], ["likely", 643], ["caused", 650], ["by", 657], ["a", 660], ["single", 662], ["strain", 669], ["of", 676], ["C.", 679], ["difficile", 682], ["(", 692], ["two", 693], ["or", 697], ["less", 700], ["single", 705], ["-", 711], ["nucleotide", 712], ["variants", 723], ["between", 732], ["isolates", 740], [")", 748], [".", 749], ["Ninety", 751], ["-", 757], ["five", 758], ["percent", 763], ["of", 771], ["cases", 774], ["had", 780], ["used", 784], ["antibiotics", 789], [",", 800], ["compared", 802], ["to", 811], ["56", 814], ["%", 816], ["of", 818], ["controls", 821], [".", 829], ["Previous", 831], ["admission", 840], ["to", 850], ["the", 853], ["intensive", 857], ["care", 867], ["unit", 872], ["(", 877], ["ICU", 878], [")", 881], ["(", 883], ["OR", 884], [":", 886], ["2.4", 888], [",", 891], ["95", 893], ["%", 895], ["CI", 897], ["1.0", 900], ["-", 903], ["5.6", 904], [")", 907], [",", 908], ["longer", 910], ["length", 917], ["of", 924], ["stay", 927], ["(", 932], ["LOS", 933], [")", 936], [",", 937], ["and", 939], ["recent", 943], ["hospital", 950], ["admission", 959], ["were", 969], ["associated", 974], ["with", 985], ["CDI", 990], ["ribotype", 994], ["027", 1003], [".", 1006], ["Cases", 1008], ["were", 1014], ["less", 1019], ["likely", 1024], ["to", 1031], ["have", 1034], ["been", 1039], ["admitted", 1044], ["to", 1053], ["a", 1056], ["ward", 1058], ["with", 1063], ["a", 1068], ["known", 1070], ["isolated", 1076], ["CDI", 1085], ["patient", 1089], ["(", 1097], ["OR", 1098], [":", 1100], ["0.2", 1102], [",", 1105], ["95", 1107], ["%", 1109], ["CI", 1111], ["0.1", 1114], ["-", 1117], ["0.6", 1118], [")", 1121], [".", 1122], ["Analysis", 1124], ["of", 1133], ["patients", 1136], ["who", 1145], ["stayed", 1149], ["at", 1156], ["the", 1159], ["ICU", 1163], ["(", 1167], ["35", 1168], ["cases", 1171], [";", 1176], ["51", 1178], ["controls", 1181], [")", 1189], [",", 1190], ["indicated", 1192], ["that", 1202], ["the", 1207], ["use", 1211], ["of", 1215], ["selective", 1218], ["decontamination", 1228], ["of", 1244], ["the", 1247], ["digestive", 1251], ["tract", 1261], ["(", 1267], ["SDD", 1268], [")", 1271], ["and", 1273], ["a", 1277], ["longer", 1279], ["LOS", 1286], ["in", 1290], ["the", 1293], ["ICU", 1297], ["were", 1301], ["associated", 1306], ["with", 1317], ["CDI", 1322], ["risk", 1326], [".", 1330], ["In", 1332], ["this", 1335], ["large", 1340], ["outbreak", 1346], [",", 1354], ["any", 1356], ["antibiotic", 1360], ["use", 1371], [",", 1374], ["including", 1376], ["SDD", 1386], ["use", 1390], [",", 1393], ["appeared", 1395], ["as", 1404], ["a", 1407], ["prerequisite", 1409], ["for", 1422], ["acquisition", 1426], ["of", 1438], ["the", 1441], ["outbreak", 1445], ["strain", 1454], [".", 1460], ["The", 1462], ["role", 1466], ["of", 1471], ["use", 1474], ["of", 1478], ["SDD", 1481], ["and", 1485], ["prolonged", 1489], ["stay", 1499], ["on", 1504], ["the", 1507], ["ICU", 1511], ["could", 1515], ["not", 1521], ["be", 1525], ["disentangled", 1528], [",", 1540], ["but", 1542], ["both", 1546], ["factors", 1551], ["can", 1559], ["play", 1563], ["a", 1568], ["biologically", 1570], ["plausible", 1583], ["role", 1593], ["in", 1598], ["C.", 1601], ["difficile", 1604], ["acquisition", 1614], ["and", 1626], ["infection", 1630], [".", 1639]]}
{"context": "Recently the relevance of Simpson resection grade as a prognostic factor for recurrence of WHO Grade I meningiomas was challenged, contradicting many previous scientific reports and traditional neurosurgical teaching. The objective of this study was to determine whether the predictive value of Simpson resection grade is outdated or remains valid with respect to meningioma recurrence and overall survival. All patients at least 16 years old who underwent primary craniotomies for convexity meningiomas at Oslo University-affiliated hospitals (Rikshospitalet and Ullev\u00e5l University Hospitals) in the period between January 1, 1990, and January 27, 2011, were included. Overall survival and retreatment-free survival rates were correlated with patient- and surgery-specific factors. Three hundred ninety-one consecutive patients were included in the study. The median patient age was 60.1 years (range 19-92 years). The female-to-male ratio was 2.1:1. The WHO grades were Grade I in 353 (90.3%), Grade II in 22 (5.6%), and Grade III in 16 (4.1%). The follow-up rate was 100%. Median follow-up time was 7.1 years (range 0.0-20.9 years) and total observation time was 3147 patient-years. The 1-, 5-, and 10-year overall survival rates were 96%, 89%, and 78%, respectively. Age, sex, WHO grade, and Simpson grade were significantly associated with overall survival. The 1-, 5-, and 10-year retreatment-free survival rates were 99%, 94%, and 90%, respectively. Simpson resection grade and WHO grade were significantly associated with retreatment-free survival. The hazard ratios for retreatment after combined Simpson resection Grades II+III and IV+V were 4.9- and 13.2-times higher than after Simpson Grade I resection, respectively. Simpson Grade I resection should continue to be the goal for convexity meningiomas.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "e876f360fb1c426aaf2c11c8f1ff0327", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[55, 55]], "char_spans": [[364, 373]]}]}], "context_tokens": [["Recently", 0], ["the", 9], ["relevance", 13], ["of", 23], ["Simpson", 26], ["resection", 34], ["grade", 44], ["as", 50], ["a", 53], ["prognostic", 55], ["factor", 66], ["for", 73], ["recurrence", 77], ["of", 88], ["WHO", 91], ["Grade", 95], ["I", 101], ["meningiomas", 103], ["was", 115], ["challenged", 119], [",", 129], ["contradicting", 131], ["many", 145], ["previous", 150], ["scientific", 159], ["reports", 170], ["and", 178], ["traditional", 182], ["neurosurgical", 194], ["teaching", 208], [".", 216], ["The", 218], ["objective", 222], ["of", 232], ["this", 235], ["study", 240], ["was", 246], ["to", 250], ["determine", 253], ["whether", 263], ["the", 271], ["predictive", 275], ["value", 286], ["of", 292], ["Simpson", 295], ["resection", 303], ["grade", 313], ["is", 319], ["outdated", 322], ["or", 331], ["remains", 334], ["valid", 342], ["with", 348], ["respect", 353], ["to", 361], ["meningioma", 364], ["recurrence", 375], ["and", 386], ["overall", 390], ["survival", 398], [".", 406], ["All", 408], ["patients", 412], ["at", 421], ["least", 424], ["16", 430], ["years", 433], ["old", 439], ["who", 443], ["underwent", 447], ["primary", 457], ["craniotomies", 465], ["for", 478], ["convexity", 482], ["meningiomas", 492], ["at", 504], ["Oslo", 507], ["University", 512], ["-", 522], ["affiliated", 523], ["hospitals", 534], ["(", 544], ["Rikshospitalet", 545], ["and", 560], ["Ullev\u00e5l", 564], ["University", 572], ["Hospitals", 583], [")", 592], ["in", 594], ["the", 597], ["period", 601], ["between", 608], ["January", 616], ["1", 624], [",", 625], ["1990", 627], [",", 631], ["and", 633], ["January", 637], ["27", 645], [",", 647], ["2011", 649], [",", 653], ["were", 655], ["included", 660], [".", 668], ["Overall", 670], ["survival", 678], ["and", 687], ["retreatment", 691], ["-", 702], ["free", 703], ["survival", 708], ["rates", 717], ["were", 723], ["correlated", 728], ["with", 739], ["patient-", 744], ["and", 753], ["surgery", 757], ["-", 764], ["specific", 765], ["factors", 774], [".", 781], ["Three", 783], ["hundred", 789], ["ninety", 797], ["-", 803], ["one", 804], ["consecutive", 808], ["patients", 820], ["were", 829], ["included", 834], ["in", 843], ["the", 846], ["study", 850], [".", 855], ["The", 857], ["median", 861], ["patient", 868], ["age", 876], ["was", 880], ["60.1", 884], ["years", 889], ["(", 895], ["range", 896], ["19", 902], ["-", 904], ["92", 905], ["years", 908], [")", 913], [".", 914], ["The", 916], ["female", 920], ["-", 926], ["to", 927], ["-", 929], ["male", 930], ["ratio", 935], ["was", 941], ["2.1:1", 945], [".", 950], ["The", 952], ["WHO", 956], ["grades", 960], ["were", 967], ["Grade", 972], ["I", 978], ["in", 980], ["353", 983], ["(", 987], ["90.3", 988], ["%", 992], [")", 993], [",", 994], ["Grade", 996], ["II", 1002], ["in", 1005], ["22", 1008], ["(", 1011], ["5.6", 1012], ["%", 1015], [")", 1016], [",", 1017], ["and", 1019], ["Grade", 1023], ["III", 1029], ["in", 1033], ["16", 1036], ["(", 1039], ["4.1", 1040], ["%", 1043], [")", 1044], [".", 1045], ["The", 1047], ["follow", 1051], ["-", 1057], ["up", 1058], ["rate", 1061], ["was", 1066], ["100", 1070], ["%", 1073], [".", 1074], ["Median", 1076], ["follow", 1083], ["-", 1089], ["up", 1090], ["time", 1093], ["was", 1098], ["7.1", 1102], ["years", 1106], ["(", 1112], ["range", 1113], ["0.0", 1119], ["-", 1122], ["20.9", 1123], ["years", 1128], [")", 1133], ["and", 1135], ["total", 1139], ["observation", 1145], ["time", 1157], ["was", 1162], ["3147", 1166], ["patient", 1171], ["-", 1178], ["years", 1179], [".", 1184], ["The", 1186], ["1-", 1190], [",", 1192], ["5-", 1194], [",", 1196], ["and", 1198], ["10-year", 1202], ["overall", 1210], ["survival", 1218], ["rates", 1227], ["were", 1233], ["96", 1238], ["%", 1240], [",", 1241], ["89", 1243], ["%", 1245], [",", 1246], ["and", 1248], ["78", 1252], ["%", 1254], [",", 1255], ["respectively", 1257], [".", 1269], ["Age", 1271], [",", 1274], ["sex", 1276], [",", 1279], ["WHO", 1281], ["grade", 1285], [",", 1290], ["and", 1292], ["Simpson", 1296], ["grade", 1304], ["were", 1310], ["significantly", 1315], ["associated", 1329], ["with", 1340], ["overall", 1345], ["survival", 1353], [".", 1361], ["The", 1363], ["1-", 1367], [",", 1369], ["5-", 1371], [",", 1373], ["and", 1375], ["10-year", 1379], ["retreatment", 1387], ["-", 1398], ["free", 1399], ["survival", 1404], ["rates", 1413], ["were", 1419], ["99", 1424], ["%", 1426], [",", 1427], ["94", 1429], ["%", 1431], [",", 1432], ["and", 1434], ["90", 1438], ["%", 1440], [",", 1441], ["respectively", 1443], [".", 1455], ["Simpson", 1457], ["resection", 1465], ["grade", 1475], ["and", 1481], ["WHO", 1485], ["grade", 1489], ["were", 1495], ["significantly", 1500], ["associated", 1514], ["with", 1525], ["retreatment", 1530], ["-", 1541], ["free", 1542], ["survival", 1547], [".", 1555], ["The", 1557], ["hazard", 1561], ["ratios", 1568], ["for", 1575], ["retreatment", 1579], ["after", 1591], ["combined", 1597], ["Simpson", 1606], ["resection", 1614], ["Grades", 1624], ["II+III", 1631], ["and", 1638], ["IV+V", 1642], ["were", 1647], ["4.9-", 1652], ["and", 1657], ["13.2-times", 1661], ["higher", 1672], ["than", 1679], ["after", 1684], ["Simpson", 1690], ["Grade", 1698], ["I", 1704], ["resection", 1706], [",", 1715], ["respectively", 1717], [".", 1729], ["Simpson", 1731], ["Grade", 1739], ["I", 1745], ["resection", 1747], ["should", 1757], ["continue", 1764], ["to", 1773], ["be", 1776], ["the", 1779], ["goal", 1783], ["for", 1788], ["convexity", 1792], ["meningiomas", 1802], [".", 1813]]}
{"context": "There are few more compelling questions in clinical microbiology today than the issue of whether or not to screen for the presence of methicillin-resistant Staphylococcus aureus (MRSA), with the results being used to institute infection control interventions aimed at preventing transmission of MRSA in health care environments. Numerous different matters must be addressed when considering a screening program. Who is to be screened, what method is to be employed to detect MRSA, and what sites should be sampled? When and how often should the screening be performed? Who is going to pay for the screening, and, finally and perhaps most importantly, how are screening results to be communicated to health care providers and what kind of interventions are best undertaken based on the results? Numerous governmental agencies have mandated MRSA screening programs, and yet several authorities in infection control organizations have questioned the appropriateness of mandated screening. In this Point-Counterpoint feature, Dr. Lance Peterson of Evanston Hospital (Evanston, IL) offers his perspective on why screening for MRSA is to be encouraged. Dr. Daniel Diekema of the University of Iowa Carver College of Medicine (Iowa City, IA) offers an opposing view.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "072774d22d1943ada30195f317483bf3", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[144, 144], [189, 189], [29, 29], [79, 79], [47, 47]], "char_spans": [[839, 842], [1121, 1124], [179, 182], [475, 478], [295, 298]]}]}], "context_tokens": [["There", 0], ["are", 6], ["few", 10], ["more", 14], ["compelling", 19], ["questions", 30], ["in", 40], ["clinical", 43], ["microbiology", 52], ["today", 65], ["than", 71], ["the", 76], ["issue", 80], ["of", 86], ["whether", 89], ["or", 97], ["not", 100], ["to", 104], ["screen", 107], ["for", 114], ["the", 118], ["presence", 122], ["of", 131], ["methicillin", 134], ["-", 145], ["resistant", 146], ["Staphylococcus", 156], ["aureus", 171], ["(", 178], ["MRSA", 179], [")", 183], [",", 184], ["with", 186], ["the", 191], ["results", 195], ["being", 203], ["used", 209], ["to", 214], ["institute", 217], ["infection", 227], ["control", 237], ["interventions", 245], ["aimed", 259], ["at", 265], ["preventing", 268], ["transmission", 279], ["of", 292], ["MRSA", 295], ["in", 300], ["health", 303], ["care", 310], ["environments", 315], [".", 327], ["Numerous", 329], ["different", 338], ["matters", 348], ["must", 356], ["be", 361], ["addressed", 364], ["when", 374], ["considering", 379], ["a", 391], ["screening", 393], ["program", 403], [".", 410], ["Who", 412], ["is", 416], ["to", 419], ["be", 422], ["screened", 425], [",", 433], ["what", 435], ["method", 440], ["is", 447], ["to", 450], ["be", 453], ["employed", 456], ["to", 465], ["detect", 468], ["MRSA", 475], [",", 479], ["and", 481], ["what", 485], ["sites", 490], ["should", 496], ["be", 503], ["sampled", 506], ["?", 513], ["When", 515], ["and", 520], ["how", 524], ["often", 528], ["should", 534], ["the", 541], ["screening", 545], ["be", 555], ["performed", 558], ["?", 567], ["Who", 569], ["is", 573], ["going", 576], ["to", 582], ["pay", 585], ["for", 589], ["the", 593], ["screening", 597], [",", 606], ["and", 608], [",", 611], ["finally", 613], ["and", 621], ["perhaps", 625], ["most", 633], ["importantly", 638], [",", 649], ["how", 651], ["are", 655], ["screening", 659], ["results", 669], ["to", 677], ["be", 680], ["communicated", 683], ["to", 696], ["health", 699], ["care", 706], ["providers", 711], ["and", 721], ["what", 725], ["kind", 730], ["of", 735], ["interventions", 738], ["are", 752], ["best", 756], ["undertaken", 761], ["based", 772], ["on", 778], ["the", 781], ["results", 785], ["?", 792], ["Numerous", 794], ["governmental", 803], ["agencies", 816], ["have", 825], ["mandated", 830], ["MRSA", 839], ["screening", 844], ["programs", 854], [",", 862], ["and", 864], ["yet", 868], ["several", 872], ["authorities", 880], ["in", 892], ["infection", 895], ["control", 905], ["organizations", 913], ["have", 927], ["questioned", 932], ["the", 943], ["appropriateness", 947], ["of", 963], ["mandated", 966], ["screening", 975], [".", 984], ["In", 986], ["this", 989], ["Point", 994], ["-", 999], ["Counterpoint", 1000], ["feature", 1013], [",", 1020], ["Dr.", 1022], ["Lance", 1026], ["Peterson", 1032], ["of", 1041], ["Evanston", 1044], ["Hospital", 1053], ["(", 1062], ["Evanston", 1063], [",", 1071], ["IL", 1073], [")", 1075], ["offers", 1077], ["his", 1084], ["perspective", 1088], ["on", 1100], ["why", 1103], ["screening", 1107], ["for", 1117], ["MRSA", 1121], ["is", 1126], ["to", 1129], ["be", 1132], ["encouraged", 1135], [".", 1145], ["Dr.", 1147], ["Daniel", 1151], ["Diekema", 1158], ["of", 1166], ["the", 1169], ["University", 1173], ["of", 1184], ["Iowa", 1187], ["Carver", 1192], ["College", 1199], ["of", 1207], ["Medicine", 1210], ["(", 1219], ["Iowa", 1220], ["City", 1225], [",", 1229], ["IA", 1231], [")", 1233], ["offers", 1235], ["an", 1242], ["opposing", 1245], ["view", 1254], [".", 1258]]}
{"context": "Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia chromosome, which is associated with a balanced translocation involving chromosomes 9 and 22 to produce a fusion gene (bcr-abl) that gives rise to a constitutively activated Abl tyrosine kinase. This kinase led to the discovery of several small-molecule inhibitors, imatinib being the first and most successful of these. Resistance to imatinib results in some patients from Abl kinase point mutations. Overcoming imatinib resistance represents one of the biggest challenges facing clinicians in the modern management of CML. In this review, we discuss the current understanding of CML pathophysiology and mechanisms of imatinib resistance and how advancing this knowledge has led to the design of novel therapies in the area of blastic phase CML and Philadelphia chromosome-positive acute lymphoblastic leukemia with previous imatinib failure.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "0c2e363266584674a6c79cd1c7d3e1eb", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[34, 36]], "char_spans": [[203, 209]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["characterized", 34], ["by", 48], ["the", 51], ["presence", 55], ["of", 64], ["the", 67], ["Philadelphia", 71], ["chromosome", 84], [",", 94], ["which", 96], ["is", 102], ["associated", 105], ["with", 116], ["a", 121], ["balanced", 123], ["translocation", 132], ["involving", 146], ["chromosomes", 156], ["9", 168], ["and", 170], ["22", 174], ["to", 177], ["produce", 180], ["a", 188], ["fusion", 190], ["gene", 197], ["(", 202], ["bcr", 203], ["-", 206], ["abl", 207], [")", 210], ["that", 212], ["gives", 217], ["rise", 223], ["to", 228], ["a", 231], ["constitutively", 233], ["activated", 248], ["Abl", 258], ["tyrosine", 262], ["kinase", 271], [".", 277], ["This", 279], ["kinase", 284], ["led", 291], ["to", 295], ["the", 298], ["discovery", 302], ["of", 312], ["several", 315], ["small", 323], ["-", 328], ["molecule", 329], ["inhibitors", 338], [",", 348], ["imatinib", 350], ["being", 359], ["the", 365], ["first", 369], ["and", 375], ["most", 379], ["successful", 384], ["of", 395], ["these", 398], [".", 403], ["Resistance", 405], ["to", 416], ["imatinib", 419], ["results", 428], ["in", 436], ["some", 439], ["patients", 444], ["from", 453], ["Abl", 458], ["kinase", 462], ["point", 469], ["mutations", 475], [".", 484], ["Overcoming", 486], ["imatinib", 497], ["resistance", 506], ["represents", 517], ["one", 528], ["of", 532], ["the", 535], ["biggest", 539], ["challenges", 547], ["facing", 558], ["clinicians", 565], ["in", 576], ["the", 579], ["modern", 583], ["management", 590], ["of", 601], ["CML", 604], [".", 607], ["In", 609], ["this", 612], ["review", 617], [",", 623], ["we", 625], ["discuss", 628], ["the", 636], ["current", 640], ["understanding", 648], ["of", 662], ["CML", 665], ["pathophysiology", 669], ["and", 685], ["mechanisms", 689], ["of", 700], ["imatinib", 703], ["resistance", 712], ["and", 723], ["how", 727], ["advancing", 731], ["this", 741], ["knowledge", 746], ["has", 756], ["led", 760], ["to", 764], ["the", 767], ["design", 771], ["of", 778], ["novel", 781], ["therapies", 787], ["in", 797], ["the", 800], ["area", 804], ["of", 809], ["blastic", 812], ["phase", 820], ["CML", 826], ["and", 830], ["Philadelphia", 834], ["chromosome", 847], ["-", 857], ["positive", 858], ["acute", 867], ["lymphoblastic", 873], ["leukemia", 887], ["with", 896], ["previous", 901], ["imatinib", 910], ["failure", 919], [".", 926]]}
{"context": "The focus of this article is acrokeratosis paraneoplastica, one of two disorders that have acquired the eponym Bazex syndrome. To date, all of the patients reported in the literature have had an underlying neoplasm, most commonly squamous cell carcinoma of the upper aerodigestive tract. In this review of 113 cases of acrokeratosis paraneoplastica (mean age, 61 years; 105 males, 8 females), the psoriasiform lesions preceded the diagnosis of the associated malignancy in 73 (67%) of 109 patients, whereas the cutaneous manifestations followed the diagnosis of the neoplasm in only 16 (15%) of 109; in the remainder, the onset of the skin lesions and the diagnosis of the tumor occurred simultaneously. Therefore, awareness of the cutaneous signs of Bazex syndrome is of obvious importance to dermatologists. Evidence in favor of the paraneoplastic nature of this disease is as follows: in 81 (93%) of 87 patients with adequate clinical descriptions, the skin lesions either improved significantly (or resolved) when the underlying neoplasm was treated or they remained unchanged in the setting of persistent disease. Occasionally, the reappearance of skin lesions has signaled a recurrence of the tumor.", "qas": [{"question": "Name synonym of Acrokeratosis paraneoplastica.", "answers": ["Bazex syndrome"], "qid": "d451ee65e0e14baaa98a29b68092c5fc", "question_tokens": [["Name", 0], ["synonym", 5], ["of", 13], ["Acrokeratosis", 16], ["paraneoplastica", 30], [".", 45]], "detected_answers": [{"text": "Bazex syndrome", "token_spans": [[139, 140], [18, 19]], "char_spans": [[751, 764], [111, 124]]}]}], "context_tokens": [["The", 0], ["focus", 4], ["of", 10], ["this", 13], ["article", 18], ["is", 26], ["acrokeratosis", 29], ["paraneoplastica", 43], [",", 58], ["one", 60], ["of", 64], ["two", 67], ["disorders", 71], ["that", 81], ["have", 86], ["acquired", 91], ["the", 100], ["eponym", 104], ["Bazex", 111], ["syndrome", 117], [".", 125], ["To", 127], ["date", 130], [",", 134], ["all", 136], ["of", 140], ["the", 143], ["patients", 147], ["reported", 156], ["in", 165], ["the", 168], ["literature", 172], ["have", 183], ["had", 188], ["an", 192], ["underlying", 195], ["neoplasm", 206], [",", 214], ["most", 216], ["commonly", 221], ["squamous", 230], ["cell", 239], ["carcinoma", 244], ["of", 254], ["the", 257], ["upper", 261], ["aerodigestive", 267], ["tract", 281], [".", 286], ["In", 288], ["this", 291], ["review", 296], ["of", 303], ["113", 306], ["cases", 310], ["of", 316], ["acrokeratosis", 319], ["paraneoplastica", 333], ["(", 349], ["mean", 350], ["age", 355], [",", 358], ["61", 360], ["years", 363], [";", 368], ["105", 370], ["males", 374], [",", 379], ["8", 381], ["females", 383], [")", 390], [",", 391], ["the", 393], ["psoriasiform", 397], ["lesions", 410], ["preceded", 418], ["the", 427], ["diagnosis", 431], ["of", 441], ["the", 444], ["associated", 448], ["malignancy", 459], ["in", 470], ["73", 473], ["(", 476], ["67", 477], ["%", 479], [")", 480], ["of", 482], ["109", 485], ["patients", 489], [",", 497], ["whereas", 499], ["the", 507], ["cutaneous", 511], ["manifestations", 521], ["followed", 536], ["the", 545], ["diagnosis", 549], ["of", 559], ["the", 562], ["neoplasm", 566], ["in", 575], ["only", 578], ["16", 583], ["(", 586], ["15", 587], ["%", 589], [")", 590], ["of", 592], ["109", 595], [";", 598], ["in", 600], ["the", 603], ["remainder", 607], [",", 616], ["the", 618], ["onset", 622], ["of", 628], ["the", 631], ["skin", 635], ["lesions", 640], ["and", 648], ["the", 652], ["diagnosis", 656], ["of", 666], ["the", 669], ["tumor", 673], ["occurred", 679], ["simultaneously", 688], [".", 702], ["Therefore", 704], [",", 713], ["awareness", 715], ["of", 725], ["the", 728], ["cutaneous", 732], ["signs", 742], ["of", 748], ["Bazex", 751], ["syndrome", 757], ["is", 766], ["of", 769], ["obvious", 772], ["importance", 780], ["to", 791], ["dermatologists", 794], [".", 808], ["Evidence", 810], ["in", 819], ["favor", 822], ["of", 828], ["the", 831], ["paraneoplastic", 835], ["nature", 850], ["of", 857], ["this", 860], ["disease", 865], ["is", 873], ["as", 876], ["follows", 879], [":", 886], ["in", 888], ["81", 891], ["(", 894], ["93", 895], ["%", 897], [")", 898], ["of", 900], ["87", 903], ["patients", 906], ["with", 915], ["adequate", 920], ["clinical", 929], ["descriptions", 938], [",", 950], ["the", 952], ["skin", 956], ["lesions", 961], ["either", 969], ["improved", 976], ["significantly", 985], ["(", 999], ["or", 1000], ["resolved", 1003], [")", 1011], ["when", 1013], ["the", 1018], ["underlying", 1022], ["neoplasm", 1033], ["was", 1042], ["treated", 1046], ["or", 1054], ["they", 1057], ["remained", 1062], ["unchanged", 1071], ["in", 1081], ["the", 1084], ["setting", 1088], ["of", 1096], ["persistent", 1099], ["disease", 1110], [".", 1117], ["Occasionally", 1119], [",", 1131], ["the", 1133], ["reappearance", 1137], ["of", 1150], ["skin", 1153], ["lesions", 1158], ["has", 1166], ["signaled", 1170], ["a", 1179], ["recurrence", 1181], ["of", 1192], ["the", 1195], ["tumor", 1199], [".", 1204]]}
{"context": "The Sotos syndrome gene product, NSD1, is a SET domain histone methyltransferase that primarily dimethylates nucleosomal histone H3 lysine 36 (H3K36). To date, the intrinsic properties of NSD1 that determine its nucleosomal substrate selectivity and dimethyl H3K36 product specificity remain unknown. The 1.7 \u00c5 structure of the catalytic domain of NSD1 presented here shows that a regulatory loop adopts a conformation that prevents free access of H3K36 to the bound S-adenosyl-L-methionine. Molecular dynamics simulation and computational docking revealed that this normally inhibitory loop can adopt an active conformation, allowing H3K36 access to the active site, and that the nucleosome may stabilize the active conformation of the regulatory loop. Hence, our study reveals an autoregulatory mechanism of NSD1 and provides insight into the molecular mechanism of the nucleosomal substrate selectivity of this disease-related H3K36 methyltransferase.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "d8dc6dcb02604df98e1a216e74a229fa", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[10, 11]], "char_spans": [[44, 53]]}]}], "context_tokens": [["The", 0], ["Sotos", 4], ["syndrome", 10], ["gene", 19], ["product", 24], [",", 31], ["NSD1", 33], [",", 37], ["is", 39], ["a", 42], ["SET", 44], ["domain", 48], ["histone", 55], ["methyltransferase", 63], ["that", 81], ["primarily", 86], ["dimethylates", 96], ["nucleosomal", 109], ["histone", 121], ["H3", 129], ["lysine", 132], ["36", 139], ["(", 142], ["H3K36", 143], [")", 148], [".", 149], ["To", 151], ["date", 154], [",", 158], ["the", 160], ["intrinsic", 164], ["properties", 174], ["of", 185], ["NSD1", 188], ["that", 193], ["determine", 198], ["its", 208], ["nucleosomal", 212], ["substrate", 224], ["selectivity", 234], ["and", 246], ["dimethyl", 250], ["H3K36", 259], ["product", 265], ["specificity", 273], ["remain", 285], ["unknown", 292], [".", 299], ["The", 301], ["1.7", 305], ["\u00c5", 309], ["structure", 311], ["of", 321], ["the", 324], ["catalytic", 328], ["domain", 338], ["of", 345], ["NSD1", 348], ["presented", 353], ["here", 363], ["shows", 368], ["that", 374], ["a", 379], ["regulatory", 381], ["loop", 392], ["adopts", 397], ["a", 404], ["conformation", 406], ["that", 419], ["prevents", 424], ["free", 433], ["access", 438], ["of", 445], ["H3K36", 448], ["to", 454], ["the", 457], ["bound", 461], ["S", 467], ["-", 468], ["adenosyl", 469], ["-", 477], ["L", 478], ["-", 479], ["methionine", 480], [".", 490], ["Molecular", 492], ["dynamics", 502], ["simulation", 511], ["and", 522], ["computational", 526], ["docking", 540], ["revealed", 548], ["that", 557], ["this", 562], ["normally", 567], ["inhibitory", 576], ["loop", 587], ["can", 592], ["adopt", 596], ["an", 602], ["active", 605], ["conformation", 612], [",", 624], ["allowing", 626], ["H3K36", 635], ["access", 641], ["to", 648], ["the", 651], ["active", 655], ["site", 662], [",", 666], ["and", 668], ["that", 672], ["the", 677], ["nucleosome", 681], ["may", 692], ["stabilize", 696], ["the", 706], ["active", 710], ["conformation", 717], ["of", 730], ["the", 733], ["regulatory", 737], ["loop", 748], [".", 752], ["Hence", 754], [",", 759], ["our", 761], ["study", 765], ["reveals", 771], ["an", 779], ["autoregulatory", 782], ["mechanism", 797], ["of", 807], ["NSD1", 810], ["and", 815], ["provides", 819], ["insight", 828], ["into", 836], ["the", 841], ["molecular", 845], ["mechanism", 855], ["of", 865], ["the", 868], ["nucleosomal", 872], ["substrate", 884], ["selectivity", 894], ["of", 906], ["this", 909], ["disease", 914], ["-", 921], ["related", 922], ["H3K36", 930], ["methyltransferase", 936], [".", 953]]}
{"context": "The advent of antibiotics for the treatment of tuberculosis (TB) represented a major breakthrough in the fight against the disease. However, since its first use, antibiotic therapy has been associated with the emergence of resistance to drugs. The incorrect use of anti-TB drugs, either due to prescription errors, low patient compliance, or poor quality of drugs, led to the widespread emergence of Mycobacterium tuberculosis strains with an expanding spectrum of resistance. The spread of multidrug-resistant (MDR) strains (ie, strains resistant to both isoniazid and rifampicin) has represented a major threat to TB control since the 1990s. In 2006, the first cases of MDR strains with further resistance to fluoroquinolone and injectable drugs were described and named extensively drug-resistant TB (XDR-TB). The emergence of XDR-TB strains is a result of mismanagement of MDR cases, and treatment relies on drugs that are less potent and more toxic than those used to treat drug-susceptible or MDR strains. Furthermore, treatment success is lower and mortality higher than achieved in MDR-TB cases, and the number of drugs necessary in the intensive phase of treatment may be higher than the four drugs recommended for MDR-TB. Linezolid may represent a valuable drug to treat cases of XDR-TB. Delamanid, bedaquiline, and PA-824 are new anti-TB agents in the development pipeline that have the potential to enhance the cure rate of XDR-TB. The best measures to prevent new cases of XDR-TB are the correct management of MDR-TB patients, early detection, and proper treatment of existing patients with XDR-TB.", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "e7dd43f614bd4a44808e13eb2dbde1f6", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[8, 8], [75, 75]], "char_spans": [[47, 58], [414, 425]]}]}], "context_tokens": [["The", 0], ["advent", 4], ["of", 11], ["antibiotics", 14], ["for", 26], ["the", 30], ["treatment", 34], ["of", 44], ["tuberculosis", 47], ["(", 60], ["TB", 61], [")", 63], ["represented", 65], ["a", 77], ["major", 79], ["breakthrough", 85], ["in", 98], ["the", 101], ["fight", 105], ["against", 111], ["the", 119], ["disease", 123], [".", 130], ["However", 132], [",", 139], ["since", 141], ["its", 147], ["first", 151], ["use", 157], [",", 160], ["antibiotic", 162], ["therapy", 173], ["has", 181], ["been", 185], ["associated", 190], ["with", 201], ["the", 206], ["emergence", 210], ["of", 220], ["resistance", 223], ["to", 234], ["drugs", 237], [".", 242], ["The", 244], ["incorrect", 248], ["use", 258], ["of", 262], ["anti", 265], ["-", 269], ["TB", 270], ["drugs", 273], [",", 278], ["either", 280], ["due", 287], ["to", 291], ["prescription", 294], ["errors", 307], [",", 313], ["low", 315], ["patient", 319], ["compliance", 327], [",", 337], ["or", 339], ["poor", 342], ["quality", 347], ["of", 355], ["drugs", 358], [",", 363], ["led", 365], ["to", 369], ["the", 372], ["widespread", 376], ["emergence", 387], ["of", 397], ["Mycobacterium", 400], ["tuberculosis", 414], ["strains", 427], ["with", 435], ["an", 440], ["expanding", 443], ["spectrum", 453], ["of", 462], ["resistance", 465], [".", 475], ["The", 477], ["spread", 481], ["of", 488], ["multidrug", 491], ["-", 500], ["resistant", 501], ["(", 511], ["MDR", 512], [")", 515], ["strains", 517], ["(", 525], ["ie", 526], [",", 528], ["strains", 530], ["resistant", 538], ["to", 548], ["both", 551], ["isoniazid", 556], ["and", 566], ["rifampicin", 570], [")", 580], ["has", 582], ["represented", 586], ["a", 598], ["major", 600], ["threat", 606], ["to", 613], ["TB", 616], ["control", 619], ["since", 627], ["the", 633], ["1990s", 637], [".", 642], ["In", 644], ["2006", 647], [",", 651], ["the", 653], ["first", 657], ["cases", 663], ["of", 669], ["MDR", 672], ["strains", 676], ["with", 684], ["further", 689], ["resistance", 697], ["to", 708], ["fluoroquinolone", 711], ["and", 727], ["injectable", 731], ["drugs", 742], ["were", 748], ["described", 753], ["and", 763], ["named", 767], ["extensively", 773], ["drug", 785], ["-", 789], ["resistant", 790], ["TB", 800], ["(", 803], ["XDR", 804], ["-", 807], ["TB", 808], [")", 810], [".", 811], ["The", 813], ["emergence", 817], ["of", 827], ["XDR", 830], ["-", 833], ["TB", 834], ["strains", 837], ["is", 845], ["a", 848], ["result", 850], ["of", 857], ["mismanagement", 860], ["of", 874], ["MDR", 877], ["cases", 881], [",", 886], ["and", 888], ["treatment", 892], ["relies", 902], ["on", 909], ["drugs", 912], ["that", 918], ["are", 923], ["less", 927], ["potent", 932], ["and", 939], ["more", 943], ["toxic", 948], ["than", 954], ["those", 959], ["used", 965], ["to", 970], ["treat", 973], ["drug", 979], ["-", 983], ["susceptible", 984], ["or", 996], ["MDR", 999], ["strains", 1003], [".", 1010], ["Furthermore", 1012], [",", 1023], ["treatment", 1025], ["success", 1035], ["is", 1043], ["lower", 1046], ["and", 1052], ["mortality", 1056], ["higher", 1066], ["than", 1073], ["achieved", 1078], ["in", 1087], ["MDR", 1090], ["-", 1093], ["TB", 1094], ["cases", 1097], [",", 1102], ["and", 1104], ["the", 1108], ["number", 1112], ["of", 1119], ["drugs", 1122], ["necessary", 1128], ["in", 1138], ["the", 1141], ["intensive", 1145], ["phase", 1155], ["of", 1161], ["treatment", 1164], ["may", 1174], ["be", 1178], ["higher", 1181], ["than", 1188], ["the", 1193], ["four", 1197], ["drugs", 1202], ["recommended", 1208], ["for", 1220], ["MDR", 1224], ["-", 1227], ["TB", 1228], [".", 1230], ["Linezolid", 1232], ["may", 1242], ["represent", 1246], ["a", 1256], ["valuable", 1258], ["drug", 1267], ["to", 1272], ["treat", 1275], ["cases", 1281], ["of", 1287], ["XDR", 1290], ["-", 1293], ["TB", 1294], [".", 1296], ["Delamanid", 1298], [",", 1307], ["bedaquiline", 1309], [",", 1320], ["and", 1322], ["PA-824", 1326], ["are", 1333], ["new", 1337], ["anti", 1341], ["-", 1345], ["TB", 1346], ["agents", 1349], ["in", 1356], ["the", 1359], ["development", 1363], ["pipeline", 1375], ["that", 1384], ["have", 1389], ["the", 1394], ["potential", 1398], ["to", 1408], ["enhance", 1411], ["the", 1419], ["cure", 1423], ["rate", 1428], ["of", 1433], ["XDR", 1436], ["-", 1439], ["TB", 1440], [".", 1442], ["The", 1444], ["best", 1448], ["measures", 1453], ["to", 1462], ["prevent", 1465], ["new", 1473], ["cases", 1477], ["of", 1483], ["XDR", 1486], ["-", 1489], ["TB", 1490], ["are", 1493], ["the", 1497], ["correct", 1501], ["management", 1509], ["of", 1520], ["MDR", 1523], ["-", 1526], ["TB", 1527], ["patients", 1530], [",", 1538], ["early", 1540], ["detection", 1546], [",", 1555], ["and", 1557], ["proper", 1561], ["treatment", 1568], ["of", 1578], ["existing", 1581], ["patients", 1590], ["with", 1599], ["XDR", 1604], ["-", 1607], ["TB", 1608], [".", 1610]]}
{"context": "Thirty-two female patients with clinical and urodynamic findings of genuine stress urinary incontinence were evaluated before and 6 months after surgery for stress urinary incontinence. Twenty-nine control patients had identical evaluations before and 6 months after surgery which did not involve the urethrovesical junction. Twenty-four patients with primary bladder instability had similar evaluations and served as a second control group. Anatomical landmarks indicating support to the urethrovesical junction were evaluated by the position of the urethra at the most dependent point in the bladder on straining and the urethral descent on straining to beneath the posterior ramus of the symphysis pubis on bead chain cystography. The urethrovesical junction drop on straining was evaluated by transrectal ultrasonography. Cystographic and ultrasonographic tests for the position of the urethrovesical junction at the most dependent position in the bladder during straining were very sensitive in women with stress urinary incontinence (94 and 87% respectively) but much less specific (45 and 48% respectively). When evaluating anatomical support to the urethrovesical junction and its descent on straining, these tests were both highly sensitive (97 and 94% respectively) and specific (76 and 96% respectively) in women with genuine stress urinary incontinence. Simple clinical tests for support of the urethrovesical junction, such as the Q tip test, are non-specific in patients with stress urinary incontinence. Transrectal ultrasonography is a simple and quick out-patient procedure. The availability of ultrasound equipment in most clinics and the high sensitivity and specificity of the test make it an attractive and cost-effective alternative to X-ray cystography in the pre-operative evaluation of anatomical support to the urethrovesical junction.", "qas": [{"question": "Which type of urinary incontinence is diagnosed with the Q tip test?", "answers": ["stress urinary incontinence"], "qid": "7612f12628274b6dbdc14d2f9a22855f", "question_tokens": [["Which", 0], ["type", 6], ["of", 11], ["urinary", 14], ["incontinence", 22], ["is", 35], ["diagnosed", 38], ["with", 48], ["the", 53], ["Q", 57], ["tip", 59], ["test", 63], ["?", 67]], "detected_answers": [{"text": "stress urinary incontinence", "token_spans": [[244, 246], [12, 14], [216, 218], [154, 156], [24, 26]], "char_spans": [[1490, 1516], [76, 102], [1337, 1363], [1011, 1037], [157, 183]]}]}], "context_tokens": [["Thirty", 0], ["-", 6], ["two", 7], ["female", 11], ["patients", 18], ["with", 27], ["clinical", 32], ["and", 41], ["urodynamic", 45], ["findings", 56], ["of", 65], ["genuine", 68], ["stress", 76], ["urinary", 83], ["incontinence", 91], ["were", 104], ["evaluated", 109], ["before", 119], ["and", 126], ["6", 130], ["months", 132], ["after", 139], ["surgery", 145], ["for", 153], ["stress", 157], ["urinary", 164], ["incontinence", 172], [".", 184], ["Twenty", 186], ["-", 192], ["nine", 193], ["control", 198], ["patients", 206], ["had", 215], ["identical", 219], ["evaluations", 229], ["before", 241], ["and", 248], ["6", 252], ["months", 254], ["after", 261], ["surgery", 267], ["which", 275], ["did", 281], ["not", 285], ["involve", 289], ["the", 297], ["urethrovesical", 301], ["junction", 316], [".", 324], ["Twenty", 326], ["-", 332], ["four", 333], ["patients", 338], ["with", 347], ["primary", 352], ["bladder", 360], ["instability", 368], ["had", 380], ["similar", 384], ["evaluations", 392], ["and", 404], ["served", 408], ["as", 415], ["a", 418], ["second", 420], ["control", 427], ["group", 435], [".", 440], ["Anatomical", 442], ["landmarks", 453], ["indicating", 463], ["support", 474], ["to", 482], ["the", 485], ["urethrovesical", 489], ["junction", 504], ["were", 513], ["evaluated", 518], ["by", 528], ["the", 531], ["position", 535], ["of", 544], ["the", 547], ["urethra", 551], ["at", 559], ["the", 562], ["most", 566], ["dependent", 571], ["point", 581], ["in", 587], ["the", 590], ["bladder", 594], ["on", 602], ["straining", 605], ["and", 615], ["the", 619], ["urethral", 623], ["descent", 632], ["on", 640], ["straining", 643], ["to", 653], ["beneath", 656], ["the", 664], ["posterior", 668], ["ramus", 678], ["of", 684], ["the", 687], ["symphysis", 691], ["pubis", 701], ["on", 707], ["bead", 710], ["chain", 715], ["cystography", 721], [".", 732], ["The", 734], ["urethrovesical", 738], ["junction", 753], ["drop", 762], ["on", 767], ["straining", 770], ["was", 780], ["evaluated", 784], ["by", 794], ["transrectal", 797], ["ultrasonography", 809], [".", 824], ["Cystographic", 826], ["and", 839], ["ultrasonographic", 843], ["tests", 860], ["for", 866], ["the", 870], ["position", 874], ["of", 883], ["the", 886], ["urethrovesical", 890], ["junction", 905], ["at", 914], ["the", 917], ["most", 921], ["dependent", 926], ["position", 936], ["in", 945], ["the", 948], ["bladder", 952], ["during", 960], ["straining", 967], ["were", 977], ["very", 982], ["sensitive", 987], ["in", 997], ["women", 1000], ["with", 1006], ["stress", 1011], ["urinary", 1018], ["incontinence", 1026], ["(", 1039], ["94", 1040], ["and", 1043], ["87", 1047], ["%", 1049], ["respectively", 1051], [")", 1063], ["but", 1065], ["much", 1069], ["less", 1074], ["specific", 1079], ["(", 1088], ["45", 1089], ["and", 1092], ["48", 1096], ["%", 1098], ["respectively", 1100], [")", 1112], [".", 1113], ["When", 1115], ["evaluating", 1120], ["anatomical", 1131], ["support", 1142], ["to", 1150], ["the", 1153], ["urethrovesical", 1157], ["junction", 1172], ["and", 1181], ["its", 1185], ["descent", 1189], ["on", 1197], ["straining", 1200], [",", 1209], ["these", 1211], ["tests", 1217], ["were", 1223], ["both", 1228], ["highly", 1233], ["sensitive", 1240], ["(", 1250], ["97", 1251], ["and", 1254], ["94", 1258], ["%", 1260], ["respectively", 1262], [")", 1274], ["and", 1276], ["specific", 1280], ["(", 1289], ["76", 1290], ["and", 1293], ["96", 1297], ["%", 1299], ["respectively", 1301], [")", 1313], ["in", 1315], ["women", 1318], ["with", 1324], ["genuine", 1329], ["stress", 1337], ["urinary", 1344], ["incontinence", 1352], [".", 1364], ["Simple", 1366], ["clinical", 1373], ["tests", 1382], ["for", 1388], ["support", 1392], ["of", 1400], ["the", 1403], ["urethrovesical", 1407], ["junction", 1422], [",", 1430], ["such", 1432], ["as", 1437], ["the", 1440], ["Q", 1444], ["tip", 1446], ["test", 1450], [",", 1454], ["are", 1456], ["non", 1460], ["-", 1463], ["specific", 1464], ["in", 1473], ["patients", 1476], ["with", 1485], ["stress", 1490], ["urinary", 1497], ["incontinence", 1505], [".", 1517], ["Transrectal", 1519], ["ultrasonography", 1531], ["is", 1547], ["a", 1550], ["simple", 1552], ["and", 1559], ["quick", 1563], ["out", 1569], ["-", 1572], ["patient", 1573], ["procedure", 1581], [".", 1590], ["The", 1592], ["availability", 1596], ["of", 1609], ["ultrasound", 1612], ["equipment", 1623], ["in", 1633], ["most", 1636], ["clinics", 1641], ["and", 1649], ["the", 1653], ["high", 1657], ["sensitivity", 1662], ["and", 1674], ["specificity", 1678], ["of", 1690], ["the", 1693], ["test", 1697], ["make", 1702], ["it", 1707], ["an", 1710], ["attractive", 1713], ["and", 1724], ["cost", 1728], ["-", 1732], ["effective", 1733], ["alternative", 1743], ["to", 1755], ["X", 1758], ["-", 1759], ["ray", 1760], ["cystography", 1764], ["in", 1776], ["the", 1779], ["pre", 1783], ["-", 1786], ["operative", 1787], ["evaluation", 1797], ["of", 1808], ["anatomical", 1811], ["support", 1822], ["to", 1830], ["the", 1833], ["urethrovesical", 1837], ["junction", 1852], [".", 1860]]}
{"context": "This was the first microbicide trial conducted in Africa to evaluate an antiretroviral-containing vaginal ring as an HIV prevention technology for women. The trial assessed and compared the safety, acceptability and adherence to product use of a 4-weekly administered vaginal ring containing the antiretroviral microbicide, dapivirine, with a matching placebo ring among women from four countries in sub-Saharan Africa. 280 Healthy, sexually active, HIV-negative women, aged 18 to 40 years were enrolled with 140 women randomised to a dapivirine vaginal ring (25 mg) and 140 women to a matching placebo ring, inserted 4-weekly and used over a 12-week period. Safety was evaluated by pelvic examination, colposcopy, clinical laboratory assessments, and adverse events. Blood samples for determination of plasma concentrations of dapivirine were collected at Weeks 0, 4 and 12. Residual dapivirine levels in returned rings from dapivirine ring users were determined post-trial. Participant acceptability and adherence to ring use were assessed by self-reports. No safety concerns or clinically relevant differences were observed between the dapivirine and placebo ring groups. Plasma dapivirine concentrations immediately prior to ring removal were similar after removal of the first and third ring, suggesting consistent ring use over the 12-week period. No clear relationship was observed between the residual amount of dapivirine in used rings and corresponding plasma concentrations. Self-reported adherence to daily use of the vaginal rings over the 12-week trial period was very high. At the end of the trial, 96% of participants reported that the ring was usually comfortable to wear, and 97% reported that they would be willing to use it in the future if proven effective. The dapivirine vaginal ring has a favourable safety and acceptability profile. If proven safe and effective in large-scale trials, it will be an important component of combination HIV prevention approaches for women. ClinicalTrials.gov NCT01071174.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "c83c84f9c33345268a80de699a70104f", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[338, 338], [19, 19], [74, 74]], "char_spans": [[1959, 1961], [117, 119], [450, 452]]}]}], "context_tokens": [["This", 0], ["was", 5], ["the", 9], ["first", 13], ["microbicide", 19], ["trial", 31], ["conducted", 37], ["in", 47], ["Africa", 50], ["to", 57], ["evaluate", 60], ["an", 69], ["antiretroviral", 72], ["-", 86], ["containing", 87], ["vaginal", 98], ["ring", 106], ["as", 111], ["an", 114], ["HIV", 117], ["prevention", 121], ["technology", 132], ["for", 143], ["women", 147], [".", 152], ["The", 154], ["trial", 158], ["assessed", 164], ["and", 173], ["compared", 177], ["the", 186], ["safety", 190], [",", 196], ["acceptability", 198], ["and", 212], ["adherence", 216], ["to", 226], ["product", 229], ["use", 237], ["of", 241], ["a", 244], ["4-weekly", 246], ["administered", 255], ["vaginal", 268], ["ring", 276], ["containing", 281], ["the", 292], ["antiretroviral", 296], ["microbicide", 311], [",", 322], ["dapivirine", 324], [",", 334], ["with", 336], ["a", 341], ["matching", 343], ["placebo", 352], ["ring", 360], ["among", 365], ["women", 371], ["from", 377], ["four", 382], ["countries", 387], ["in", 397], ["sub", 400], ["-", 403], ["Saharan", 404], ["Africa", 412], [".", 418], ["280", 420], ["Healthy", 424], [",", 431], ["sexually", 433], ["active", 442], [",", 448], ["HIV", 450], ["-", 453], ["negative", 454], ["women", 463], [",", 468], ["aged", 470], ["18", 475], ["to", 478], ["40", 481], ["years", 484], ["were", 490], ["enrolled", 495], ["with", 504], ["140", 509], ["women", 513], ["randomised", 519], ["to", 530], ["a", 533], ["dapivirine", 535], ["vaginal", 546], ["ring", 554], ["(", 559], ["25", 560], ["mg", 563], [")", 565], ["and", 567], ["140", 571], ["women", 575], ["to", 581], ["a", 584], ["matching", 586], ["placebo", 595], ["ring", 603], [",", 607], ["inserted", 609], ["4-weekly", 618], ["and", 627], ["used", 631], ["over", 636], ["a", 641], ["12-week", 643], ["period", 651], [".", 657], ["Safety", 659], ["was", 666], ["evaluated", 670], ["by", 680], ["pelvic", 683], ["examination", 690], [",", 701], ["colposcopy", 703], [",", 713], ["clinical", 715], ["laboratory", 724], ["assessments", 735], [",", 746], ["and", 748], ["adverse", 752], ["events", 760], [".", 766], ["Blood", 768], ["samples", 774], ["for", 782], ["determination", 786], ["of", 800], ["plasma", 803], ["concentrations", 810], ["of", 825], ["dapivirine", 828], ["were", 839], ["collected", 844], ["at", 854], ["Weeks", 857], ["0", 863], [",", 864], ["4", 866], ["and", 868], ["12", 872], [".", 874], ["Residual", 876], ["dapivirine", 885], ["levels", 896], ["in", 903], ["returned", 906], ["rings", 915], ["from", 921], ["dapivirine", 926], ["ring", 937], ["users", 942], ["were", 948], ["determined", 953], ["post", 964], ["-", 968], ["trial", 969], [".", 974], ["Participant", 976], ["acceptability", 988], ["and", 1002], ["adherence", 1006], ["to", 1016], ["ring", 1019], ["use", 1024], ["were", 1028], ["assessed", 1033], ["by", 1042], ["self", 1045], ["-", 1049], ["reports", 1050], [".", 1057], ["No", 1059], ["safety", 1062], ["concerns", 1069], ["or", 1078], ["clinically", 1081], ["relevant", 1092], ["differences", 1101], ["were", 1113], ["observed", 1118], ["between", 1127], ["the", 1135], ["dapivirine", 1139], ["and", 1150], ["placebo", 1154], ["ring", 1162], ["groups", 1167], [".", 1173], ["Plasma", 1175], ["dapivirine", 1182], ["concentrations", 1193], ["immediately", 1208], ["prior", 1220], ["to", 1226], ["ring", 1229], ["removal", 1234], ["were", 1242], ["similar", 1247], ["after", 1255], ["removal", 1261], ["of", 1269], ["the", 1272], ["first", 1276], ["and", 1282], ["third", 1286], ["ring", 1292], [",", 1296], ["suggesting", 1298], ["consistent", 1309], ["ring", 1320], ["use", 1325], ["over", 1329], ["the", 1334], ["12-week", 1338], ["period", 1346], [".", 1352], ["No", 1354], ["clear", 1357], ["relationship", 1363], ["was", 1376], ["observed", 1380], ["between", 1389], ["the", 1397], ["residual", 1401], ["amount", 1410], ["of", 1417], ["dapivirine", 1420], ["in", 1431], ["used", 1434], ["rings", 1439], ["and", 1445], ["corresponding", 1449], ["plasma", 1463], ["concentrations", 1470], [".", 1484], ["Self", 1486], ["-", 1490], ["reported", 1491], ["adherence", 1500], ["to", 1510], ["daily", 1513], ["use", 1519], ["of", 1523], ["the", 1526], ["vaginal", 1530], ["rings", 1538], ["over", 1544], ["the", 1549], ["12-week", 1553], ["trial", 1561], ["period", 1567], ["was", 1574], ["very", 1578], ["high", 1583], [".", 1587], ["At", 1589], ["the", 1592], ["end", 1596], ["of", 1600], ["the", 1603], ["trial", 1607], [",", 1612], ["96", 1614], ["%", 1616], ["of", 1618], ["participants", 1621], ["reported", 1634], ["that", 1643], ["the", 1648], ["ring", 1652], ["was", 1657], ["usually", 1661], ["comfortable", 1669], ["to", 1681], ["wear", 1684], [",", 1688], ["and", 1690], ["97", 1694], ["%", 1696], ["reported", 1698], ["that", 1707], ["they", 1712], ["would", 1717], ["be", 1723], ["willing", 1726], ["to", 1734], ["use", 1737], ["it", 1741], ["in", 1744], ["the", 1747], ["future", 1751], ["if", 1758], ["proven", 1761], ["effective", 1768], [".", 1777], ["The", 1779], ["dapivirine", 1783], ["vaginal", 1794], ["ring", 1802], ["has", 1807], ["a", 1811], ["favourable", 1813], ["safety", 1824], ["and", 1831], ["acceptability", 1835], ["profile", 1849], [".", 1856], ["If", 1858], ["proven", 1861], ["safe", 1868], ["and", 1873], ["effective", 1877], ["in", 1887], ["large", 1890], ["-", 1895], ["scale", 1896], ["trials", 1902], [",", 1908], ["it", 1910], ["will", 1913], ["be", 1918], ["an", 1921], ["important", 1924], ["component", 1934], ["of", 1944], ["combination", 1947], ["HIV", 1959], ["prevention", 1963], ["approaches", 1974], ["for", 1985], ["women", 1989], [".", 1994], ["ClinicalTrials.gov", 1996], ["NCT01071174", 2015], [".", 2026]]}
{"context": "Parkinson's disease (PD) is characterized as a neurodegenerative movement disorder presenting with rigidity, resting tremor, disturbances in balance and slowness in movement. An important pathologic feature of PD is the presence of Lewy bodies. The primary structural component of Lewy bodies are fibrils composed primarily of alpha-synuclein, a highly conserved 140 amino acid protein that is predominantly expressed in neurons and which may play a role in synaptic plasticity and neurotransmission. Numerous studies suggest the aggregation and modification of alpha-synuclein as a key step leading to Lewy body formation and neuronal cell loss associated with PD. Because of the central role of alpha-synuclein in PD, it represents a novel drug target for the possible treatment of this disease. In this review, an overview of the role of alpha-synuclein in PD will be discussed with an emphasis on recent studies utilizing an immunization approach against alpha-synuclein as a possible treatment option for this debilitating disease.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "8cb2d5ed371845bdbc1aef1bc23e2418", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[116, 118], [165, 167], [53, 55], [90, 92], [146, 148]], "char_spans": [[697, 711], [959, 973], [327, 341], [562, 576], [841, 855]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["characterized", 28], ["as", 42], ["a", 45], ["neurodegenerative", 47], ["movement", 65], ["disorder", 74], ["presenting", 83], ["with", 94], ["rigidity", 99], [",", 107], ["resting", 109], ["tremor", 117], [",", 123], ["disturbances", 125], ["in", 138], ["balance", 141], ["and", 149], ["slowness", 153], ["in", 162], ["movement", 165], [".", 173], ["An", 175], ["important", 178], ["pathologic", 188], ["feature", 199], ["of", 207], ["PD", 210], ["is", 213], ["the", 216], ["presence", 220], ["of", 229], ["Lewy", 232], ["bodies", 237], [".", 243], ["The", 245], ["primary", 249], ["structural", 257], ["component", 268], ["of", 278], ["Lewy", 281], ["bodies", 286], ["are", 293], ["fibrils", 297], ["composed", 305], ["primarily", 314], ["of", 324], ["alpha", 327], ["-", 332], ["synuclein", 333], [",", 342], ["a", 344], ["highly", 346], ["conserved", 353], ["140", 363], ["amino", 367], ["acid", 373], ["protein", 378], ["that", 386], ["is", 391], ["predominantly", 394], ["expressed", 408], ["in", 418], ["neurons", 421], ["and", 429], ["which", 433], ["may", 439], ["play", 443], ["a", 448], ["role", 450], ["in", 455], ["synaptic", 458], ["plasticity", 467], ["and", 478], ["neurotransmission", 482], [".", 499], ["Numerous", 501], ["studies", 510], ["suggest", 518], ["the", 526], ["aggregation", 530], ["and", 542], ["modification", 546], ["of", 559], ["alpha", 562], ["-", 567], ["synuclein", 568], ["as", 578], ["a", 581], ["key", 583], ["step", 587], ["leading", 592], ["to", 600], ["Lewy", 603], ["body", 608], ["formation", 613], ["and", 623], ["neuronal", 627], ["cell", 636], ["loss", 641], ["associated", 646], ["with", 657], ["PD", 662], [".", 664], ["Because", 666], ["of", 674], ["the", 677], ["central", 681], ["role", 689], ["of", 694], ["alpha", 697], ["-", 702], ["synuclein", 703], ["in", 713], ["PD", 716], [",", 718], ["it", 720], ["represents", 723], ["a", 734], ["novel", 736], ["drug", 742], ["target", 747], ["for", 754], ["the", 758], ["possible", 762], ["treatment", 771], ["of", 781], ["this", 784], ["disease", 789], [".", 796], ["In", 798], ["this", 801], ["review", 806], [",", 812], ["an", 814], ["overview", 817], ["of", 826], ["the", 829], ["role", 833], ["of", 838], ["alpha", 841], ["-", 846], ["synuclein", 847], ["in", 857], ["PD", 860], ["will", 863], ["be", 868], ["discussed", 871], ["with", 881], ["an", 886], ["emphasis", 889], ["on", 898], ["recent", 901], ["studies", 908], ["utilizing", 916], ["an", 926], ["immunization", 929], ["approach", 942], ["against", 951], ["alpha", 959], ["-", 964], ["synuclein", 965], ["as", 975], ["a", 978], ["possible", 980], ["treatment", 989], ["option", 999], ["for", 1006], ["this", 1010], ["debilitating", 1015], ["disease", 1028], [".", 1035]]}
{"context": "A 70 year old woman presented with a 6 year history of medically refractory severe tardive dystonia. After informed consent, a bilateral stereotactic electrode placement targeting the ventral intermediate thalamic nucleus (VIM) and the globus pallidus internus (GPi) was performed. After bilateral stimulation of the GPi, the patient showed a clear and stable improvement of the painful dystonic syndrome within hours. Stimulation of the VIM did not improve the hyperkinetic movements and simultaneous stimulation of both the GPi and the VIM did not result in any additional benefit. The possible pathophysiological mechanisms are discussed.", "qas": [{"question": "Neurostimulation of which nucleus is used for treatment of dystonia?", "answers": ["globus pallidus internus"], "qid": "a02c851b01e7465280df78b10bd835f5", "question_tokens": [["Neurostimulation", 0], ["of", 17], ["which", 20], ["nucleus", 26], ["is", 34], ["used", 37], ["for", 42], ["treatment", 46], ["of", 56], ["dystonia", 59], ["?", 67]], "detected_answers": [{"text": "globus pallidus internus", "token_spans": [[38, 40]], "char_spans": [[236, 259]]}]}], "context_tokens": [["A", 0], ["70", 2], ["year", 5], ["old", 10], ["woman", 14], ["presented", 20], ["with", 30], ["a", 35], ["6", 37], ["year", 39], ["history", 44], ["of", 52], ["medically", 55], ["refractory", 65], ["severe", 76], ["tardive", 83], ["dystonia", 91], [".", 99], ["After", 101], ["informed", 107], ["consent", 116], [",", 123], ["a", 125], ["bilateral", 127], ["stereotactic", 137], ["electrode", 150], ["placement", 160], ["targeting", 170], ["the", 180], ["ventral", 184], ["intermediate", 192], ["thalamic", 205], ["nucleus", 214], ["(", 222], ["VIM", 223], [")", 226], ["and", 228], ["the", 232], ["globus", 236], ["pallidus", 243], ["internus", 252], ["(", 261], ["GPi", 262], [")", 265], ["was", 267], ["performed", 271], [".", 280], ["After", 282], ["bilateral", 288], ["stimulation", 298], ["of", 310], ["the", 313], ["GPi", 317], [",", 320], ["the", 322], ["patient", 326], ["showed", 334], ["a", 341], ["clear", 343], ["and", 349], ["stable", 353], ["improvement", 360], ["of", 372], ["the", 375], ["painful", 379], ["dystonic", 387], ["syndrome", 396], ["within", 405], ["hours", 412], [".", 417], ["Stimulation", 419], ["of", 431], ["the", 434], ["VIM", 438], ["did", 442], ["not", 446], ["improve", 450], ["the", 458], ["hyperkinetic", 462], ["movements", 475], ["and", 485], ["simultaneous", 489], ["stimulation", 502], ["of", 514], ["both", 517], ["the", 522], ["GPi", 526], ["and", 530], ["the", 534], ["VIM", 538], ["did", 542], ["not", 546], ["result", 550], ["in", 557], ["any", 560], ["additional", 564], ["benefit", 575], [".", 582], ["The", 584], ["possible", 588], ["pathophysiological", 597], ["mechanisms", 616], ["are", 627], ["discussed", 631], [".", 640]]}
{"context": "Willis-Ekbom's disease (WED), formerly called restless legs syndrome, is more common in pregnant than in non-pregnant women, implying that the physiological and biochemical changes during pregnancy influence its development. During pregnancy, many hormone levels undergo significant changes, and some hormones significantly increase in activity and can interfere with other hormones. For example, the steroid hormone estradiol interferes with the neuroendocrine hormone dopamine. During pregnancy, the activity of the thyroid axis is enhanced to meet the increased demand for thyroid hormones during this state. Dopamine is a neuroendocrine hormone that diminishes the levels of thyrotropin and consequently of thyroxine, and one of the roles of the dopaminergic system is to counteract the activity of thyroid hormones. When the activity of dopamine is not sufficient to modulate thyroid hormones, WED may occur. Robust evidence in the medical literature suggests that an imbalance between thyroid hormones and the dopaminergic system underpins WED pathophysiology. In this article, we present evidence that this imbalance may also mediate transient WED during pregnancy. It is possible that the main hormonal alteration responsible for transient WED of pregnancy is the excessive modulation of dopamine release in the pituitary stalk by estradiol. The reduced quantities of dopamine then cause decreased modulation of thyrotropin, leading to enhanced thyroid axis activity and subsequent WED symptoms. Iron deficiency may also be a predisposing factor for WED during pregnancy, as it can both diminish dopamine and increase thyroid hormone.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "3216ab3e241a45eea283765e3bee89ef", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[242, 242]], "char_spans": [[1504, 1507]]}]}], "context_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["'s", 12], ["disease", 15], ["(", 23], ["WED", 24], [")", 27], [",", 28], ["formerly", 30], ["called", 39], ["restless", 46], ["legs", 55], ["syndrome", 60], [",", 68], ["is", 70], ["more", 73], ["common", 78], ["in", 85], ["pregnant", 88], ["than", 97], ["in", 102], ["non", 105], ["-", 108], ["pregnant", 109], ["women", 118], [",", 123], ["implying", 125], ["that", 134], ["the", 139], ["physiological", 143], ["and", 157], ["biochemical", 161], ["changes", 173], ["during", 181], ["pregnancy", 188], ["influence", 198], ["its", 208], ["development", 212], [".", 223], ["During", 225], ["pregnancy", 232], [",", 241], ["many", 243], ["hormone", 248], ["levels", 256], ["undergo", 263], ["significant", 271], ["changes", 283], [",", 290], ["and", 292], ["some", 296], ["hormones", 301], ["significantly", 310], ["increase", 324], ["in", 333], ["activity", 336], ["and", 345], ["can", 349], ["interfere", 353], ["with", 363], ["other", 368], ["hormones", 374], [".", 382], ["For", 384], ["example", 388], [",", 395], ["the", 397], ["steroid", 401], ["hormone", 409], ["estradiol", 417], ["interferes", 427], ["with", 438], ["the", 443], ["neuroendocrine", 447], ["hormone", 462], ["dopamine", 470], [".", 478], ["During", 480], ["pregnancy", 487], [",", 496], ["the", 498], ["activity", 502], ["of", 511], ["the", 514], ["thyroid", 518], ["axis", 526], ["is", 531], ["enhanced", 534], ["to", 543], ["meet", 546], ["the", 551], ["increased", 555], ["demand", 565], ["for", 572], ["thyroid", 576], ["hormones", 584], ["during", 593], ["this", 600], ["state", 605], [".", 610], ["Dopamine", 612], ["is", 621], ["a", 624], ["neuroendocrine", 626], ["hormone", 641], ["that", 649], ["diminishes", 654], ["the", 665], ["levels", 669], ["of", 676], ["thyrotropin", 679], ["and", 691], ["consequently", 695], ["of", 708], ["thyroxine", 711], [",", 720], ["and", 722], ["one", 726], ["of", 730], ["the", 733], ["roles", 737], ["of", 743], ["the", 746], ["dopaminergic", 750], ["system", 763], ["is", 770], ["to", 773], ["counteract", 776], ["the", 787], ["activity", 791], ["of", 800], ["thyroid", 803], ["hormones", 811], [".", 819], ["When", 821], ["the", 826], ["activity", 830], ["of", 839], ["dopamine", 842], ["is", 851], ["not", 854], ["sufficient", 858], ["to", 869], ["modulate", 872], ["thyroid", 881], ["hormones", 889], [",", 897], ["WED", 899], ["may", 903], ["occur", 907], [".", 912], ["Robust", 914], ["evidence", 921], ["in", 930], ["the", 933], ["medical", 937], ["literature", 945], ["suggests", 956], ["that", 965], ["an", 970], ["imbalance", 973], ["between", 983], ["thyroid", 991], ["hormones", 999], ["and", 1008], ["the", 1012], ["dopaminergic", 1016], ["system", 1029], ["underpins", 1036], ["WED", 1046], ["pathophysiology", 1050], [".", 1065], ["In", 1067], ["this", 1070], ["article", 1075], [",", 1082], ["we", 1084], ["present", 1087], ["evidence", 1095], ["that", 1104], ["this", 1109], ["imbalance", 1114], ["may", 1124], ["also", 1128], ["mediate", 1133], ["transient", 1141], ["WED", 1151], ["during", 1155], ["pregnancy", 1162], [".", 1171], ["It", 1173], ["is", 1176], ["possible", 1179], ["that", 1188], ["the", 1193], ["main", 1197], ["hormonal", 1202], ["alteration", 1211], ["responsible", 1222], ["for", 1234], ["transient", 1238], ["WED", 1248], ["of", 1252], ["pregnancy", 1255], ["is", 1265], ["the", 1268], ["excessive", 1272], ["modulation", 1282], ["of", 1293], ["dopamine", 1296], ["release", 1305], ["in", 1313], ["the", 1316], ["pituitary", 1320], ["stalk", 1330], ["by", 1336], ["estradiol", 1339], [".", 1348], ["The", 1350], ["reduced", 1354], ["quantities", 1362], ["of", 1373], ["dopamine", 1376], ["then", 1385], ["cause", 1390], ["decreased", 1396], ["modulation", 1406], ["of", 1417], ["thyrotropin", 1420], [",", 1431], ["leading", 1433], ["to", 1441], ["enhanced", 1444], ["thyroid", 1453], ["axis", 1461], ["activity", 1466], ["and", 1475], ["subsequent", 1479], ["WED", 1490], ["symptoms", 1494], [".", 1502], ["Iron", 1504], ["deficiency", 1509], ["may", 1520], ["also", 1524], ["be", 1529], ["a", 1532], ["predisposing", 1534], ["factor", 1547], ["for", 1554], ["WED", 1558], ["during", 1562], ["pregnancy", 1569], [",", 1578], ["as", 1580], ["it", 1583], ["can", 1586], ["both", 1590], ["diminish", 1595], ["dopamine", 1604], ["and", 1613], ["increase", 1617], ["thyroid", 1626], ["hormone", 1634], [".", 1641]]}
{"context": "Stress signals elicit a wide variety of cellular responses, many of which converge on the phosphorylation of JNK and p38 kinases, the activation of which has been well-characterized. How these kinases are switched off by dephosphorylation is not well understood. Here we describe how diverse cellular stresses affect differently the stability and activity of a JNK-inactivating dual-specificity threonine-tyrosine phosphatase M3/6. Both anisomycin and arsenite activate the JNK pathway and, in addition, inactivate the M3/6 phosphatase. However, while anisomycin treatment of cells leads to M3/6 protein degradation, arsenite appears to inactivate M3/6 directly. These results might have implications for the mechanism of tumour promotion by arsenic.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "b7441dc6481f4a8c8ea767fe70d618bb", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[79, 79], [61, 61], [18, 18]], "char_spans": [[474, 476], [361, 363], [109, 111]]}]}], "context_tokens": [["Stress", 0], ["signals", 7], ["elicit", 15], ["a", 22], ["wide", 24], ["variety", 29], ["of", 37], ["cellular", 40], ["responses", 49], [",", 58], ["many", 60], ["of", 65], ["which", 68], ["converge", 74], ["on", 83], ["the", 86], ["phosphorylation", 90], ["of", 106], ["JNK", 109], ["and", 113], ["p38", 117], ["kinases", 121], [",", 128], ["the", 130], ["activation", 134], ["of", 145], ["which", 148], ["has", 154], ["been", 158], ["well", 163], ["-", 167], ["characterized", 168], [".", 181], ["How", 183], ["these", 187], ["kinases", 193], ["are", 201], ["switched", 205], ["off", 214], ["by", 218], ["dephosphorylation", 221], ["is", 239], ["not", 242], ["well", 246], ["understood", 251], [".", 261], ["Here", 263], ["we", 268], ["describe", 271], ["how", 280], ["diverse", 284], ["cellular", 292], ["stresses", 301], ["affect", 310], ["differently", 317], ["the", 329], ["stability", 333], ["and", 343], ["activity", 347], ["of", 356], ["a", 359], ["JNK", 361], ["-", 364], ["inactivating", 365], ["dual", 378], ["-", 382], ["specificity", 383], ["threonine", 395], ["-", 404], ["tyrosine", 405], ["phosphatase", 414], ["M3/6", 426], [".", 430], ["Both", 432], ["anisomycin", 437], ["and", 448], ["arsenite", 452], ["activate", 461], ["the", 470], ["JNK", 474], ["pathway", 478], ["and", 486], [",", 489], ["in", 491], ["addition", 494], [",", 502], ["inactivate", 504], ["the", 515], ["M3/6", 519], ["phosphatase", 524], [".", 535], ["However", 537], [",", 544], ["while", 546], ["anisomycin", 552], ["treatment", 563], ["of", 573], ["cells", 576], ["leads", 582], ["to", 588], ["M3/6", 591], ["protein", 596], ["degradation", 604], [",", 615], ["arsenite", 617], ["appears", 626], ["to", 634], ["inactivate", 637], ["M3/6", 648], ["directly", 653], [".", 661], ["These", 663], ["results", 669], ["might", 677], ["have", 683], ["implications", 688], ["for", 701], ["the", 705], ["mechanism", 709], ["of", 719], ["tumour", 722], ["promotion", 729], ["by", 739], ["arsenic", 742], [".", 749]]}
{"context": "Despite numerous reports implicating NADPH oxidases (Nox) in the pathogenesis of many diseases, precise regulation of this family of professional reactive oxygen species (ROS) producers remains unclear. A unique member of this family, Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or p47(phox), respectively, the latter of which is functional in vascular smooth muscle cells (VSMC). In this manuscript, we identify critical requirement of ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50; aka NHERF1) for Nox1 activation and downstream responses. Superoxide (O2 (\u2022-)) production induced by angiotensin II (AngII) was absent in mouse EBP50 KO VSMC vs. WT. Moreover, ex vivo incubation of aortas with AngII showed a significant increase in O2 (\u2022-) in WT but not EBP50 or Nox1 nulls. Similarly, lipopolysaccharide (LPS)-induced oxidative stress was attenuated in femoral arteries from EBP50 KO vs. WT. In silico analyses confirmed by confocal microscopy, immunoprecipitation, proximity ligation assay, FRET, and gain-/loss-of-function mutagenesis revealed binding of EBP50, via its PDZ domains, to a specific motif in p47(phox) Functional studies revealed AngII-induced hypertrophy was absent in EBP50 KOs, and in VSMC overexpressing EBP50, Nox1 gene silencing abolished VSMC hypertrophy. Finally, ex vivo measurement of lumen diameter in mouse resistance arteries exhibited attenuated AngII-induced vasoconstriction in EBP50 KO vs. WT. Taken together, our data identify EBP50 as a previously unidentified regulator of Nox1 and support that it promotes Nox1 activity by binding p47(phox) This interaction is pivotal for agonist-induced smooth muscle ROS, hypertrophy, and vasoconstriction and has implications for ROS-mediated physiological and pathophysiological processes.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "3d080e8520c34ceca932d863f5e88a76", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[160, 160], [240, 240], [284, 284], [105, 105], [40, 40], [290, 290]], "char_spans": [[830, 833], [1299, 1302], [1577, 1580], [566, 569], [235, 238], [1611, 1614]]}]}], "context_tokens": [["Despite", 0], ["numerous", 8], ["reports", 17], ["implicating", 25], ["NADPH", 37], ["oxidases", 43], ["(", 52], ["Nox", 53], [")", 56], ["in", 58], ["the", 61], ["pathogenesis", 65], ["of", 78], ["many", 81], ["diseases", 86], [",", 94], ["precise", 96], ["regulation", 104], ["of", 115], ["this", 118], ["family", 123], ["of", 130], ["professional", 133], ["reactive", 146], ["oxygen", 155], ["species", 162], ["(", 170], ["ROS", 171], [")", 174], ["producers", 176], ["remains", 186], ["unclear", 194], [".", 201], ["A", 203], ["unique", 205], ["member", 212], ["of", 219], ["this", 222], ["family", 227], [",", 233], ["Nox1", 235], ["oxidase", 240], [",", 247], ["functions", 249], ["as", 259], ["either", 262], ["a", 269], ["canonical", 271], ["or", 281], ["hybrid", 284], ["system", 291], ["using", 298], ["Nox", 304], ["organizing", 308], ["subunit", 319], ["1", 327], ["(", 329], ["NoxO1", 330], [")", 335], ["or", 337], ["p47(phox", 340], [")", 348], [",", 349], ["respectively", 351], [",", 363], ["the", 365], ["latter", 369], ["of", 376], ["which", 379], ["is", 385], ["functional", 388], ["in", 399], ["vascular", 402], ["smooth", 411], ["muscle", 418], ["cells", 425], ["(", 431], ["VSMC", 432], [")", 436], [".", 437], ["In", 439], ["this", 442], ["manuscript", 447], [",", 457], ["we", 459], ["identify", 462], ["critical", 471], ["requirement", 480], ["of", 492], ["ezrin", 495], ["-", 500], ["radixin", 501], ["-", 508], ["moesin", 509], ["-", 515], ["binding", 516], ["phosphoprotein", 524], ["50", 539], ["(", 542], ["EBP50", 543], [";", 548], ["aka", 550], ["NHERF1", 554], [")", 560], ["for", 562], ["Nox1", 566], ["activation", 571], ["and", 582], ["downstream", 586], ["responses", 597], [".", 606], ["Superoxide", 608], ["(", 619], ["O2", 620], ["(", 623], ["\u2022-", 624], [")", 626], [")", 627], ["production", 629], ["induced", 640], ["by", 648], ["angiotensin", 651], ["II", 663], ["(", 666], ["AngII", 667], [")", 672], ["was", 674], ["absent", 678], ["in", 685], ["mouse", 688], ["EBP50", 694], ["KO", 700], ["VSMC", 703], ["vs.", 708], ["WT", 712], [".", 714], ["Moreover", 716], [",", 724], ["ex", 726], ["vivo", 729], ["incubation", 734], ["of", 745], ["aortas", 748], ["with", 755], ["AngII", 760], ["showed", 766], ["a", 773], ["significant", 775], ["increase", 787], ["in", 796], ["O2", 799], ["(", 802], ["\u2022-", 803], [")", 805], ["in", 807], ["WT", 810], ["but", 813], ["not", 817], ["EBP50", 821], ["or", 827], ["Nox1", 830], ["nulls", 835], [".", 840], ["Similarly", 842], [",", 851], ["lipopolysaccharide", 853], ["(", 872], ["LPS)-induced", 873], ["oxidative", 886], ["stress", 896], ["was", 903], ["attenuated", 907], ["in", 918], ["femoral", 921], ["arteries", 929], ["from", 938], ["EBP50", 943], ["KO", 949], ["vs.", 952], ["WT", 956], [".", 958], ["In", 960], ["silico", 963], ["analyses", 970], ["confirmed", 979], ["by", 989], ["confocal", 992], ["microscopy", 1001], [",", 1011], ["immunoprecipitation", 1013], [",", 1032], ["proximity", 1034], ["ligation", 1044], ["assay", 1053], [",", 1058], ["FRET", 1060], [",", 1064], ["and", 1066], ["gain-/loss", 1070], ["-", 1080], ["of", 1081], ["-", 1083], ["function", 1084], ["mutagenesis", 1093], ["revealed", 1105], ["binding", 1114], ["of", 1122], ["EBP50", 1125], [",", 1130], ["via", 1132], ["its", 1136], ["PDZ", 1140], ["domains", 1144], [",", 1151], ["to", 1153], ["a", 1156], ["specific", 1158], ["motif", 1167], ["in", 1173], ["p47(phox", 1176], [")", 1184], ["Functional", 1186], ["studies", 1197], ["revealed", 1205], ["AngII", 1214], ["-", 1219], ["induced", 1220], ["hypertrophy", 1228], ["was", 1240], ["absent", 1244], ["in", 1251], ["EBP50", 1254], ["KOs", 1260], [",", 1263], ["and", 1265], ["in", 1269], ["VSMC", 1272], ["overexpressing", 1277], ["EBP50", 1292], [",", 1297], ["Nox1", 1299], ["gene", 1304], ["silencing", 1309], ["abolished", 1319], ["VSMC", 1329], ["hypertrophy", 1334], [".", 1345], ["Finally", 1347], [",", 1354], ["ex", 1356], ["vivo", 1359], ["measurement", 1364], ["of", 1376], ["lumen", 1379], ["diameter", 1385], ["in", 1394], ["mouse", 1397], ["resistance", 1403], ["arteries", 1414], ["exhibited", 1423], ["attenuated", 1433], ["AngII", 1444], ["-", 1449], ["induced", 1450], ["vasoconstriction", 1458], ["in", 1475], ["EBP50", 1478], ["KO", 1484], ["vs.", 1487], ["WT", 1491], [".", 1493], ["Taken", 1495], ["together", 1501], [",", 1509], ["our", 1511], ["data", 1515], ["identify", 1520], ["EBP50", 1529], ["as", 1535], ["a", 1538], ["previously", 1540], ["unidentified", 1551], ["regulator", 1564], ["of", 1574], ["Nox1", 1577], ["and", 1582], ["support", 1586], ["that", 1594], ["it", 1599], ["promotes", 1602], ["Nox1", 1611], ["activity", 1616], ["by", 1625], ["binding", 1628], ["p47(phox", 1636], [")", 1644], ["This", 1646], ["interaction", 1651], ["is", 1663], ["pivotal", 1666], ["for", 1674], ["agonist", 1678], ["-", 1685], ["induced", 1686], ["smooth", 1694], ["muscle", 1701], ["ROS", 1708], [",", 1711], ["hypertrophy", 1713], [",", 1724], ["and", 1726], ["vasoconstriction", 1730], ["and", 1747], ["has", 1751], ["implications", 1755], ["for", 1768], ["ROS", 1772], ["-", 1775], ["mediated", 1776], ["physiological", 1785], ["and", 1799], ["pathophysiological", 1803], ["processes", 1822], [".", 1831]]}
{"context": "Idarucizumab is a monoclonal antibody fragment that binds dabigatran with high affinity in a 1:1 molar ratio. We investigated the safety, tolerability, and efficacy of increasing doses of idarucizumab for the reversal of anticoagulant effects of dabigatran in a two-part phase 1 study (rising-dose assessment and dose-finding, proof-of-concept investigation). Here we present the results of the proof-of-concept part of the study. In this randomised, placebo-controlled, double-blind, proof-of-concept phase 1 study, we enrolled healthy volunteers (aged 18-45 years) with a body-mass index of 18\u00b75-29\u00b79 kg/m(2) into one of four dose groups at SGS Life Sciences Clinical Research Services, Belgium. Participants were randomly assigned within groups in a 3:1 ratio to idarucizumab or placebo using a pseudorandom number generator and a supplied seed number. Participants and care providers were masked to treatment assignment. All participants received oral dabigatran etexilate 220 mg twice daily for 3 days and a final dose on day 4. Idarucizumab (1 g, 2 g, or 4 g 5-min infusion, or 5 g plus 2\u00b75 g in two 5-min infusions given 1 h apart) was administered about 2 h after the final dabigatran etexilate dose. The primary endpoint was incidence of drug-related adverse events, analysed in all randomly assigned participants who received at least one dose of dabigatran etexilate. Reversal of diluted thrombin time (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and thrombin time (TT) were secondary endpoints assessed by measuring the area under the effect curve from 2 h to 12 h (AUEC2-12) after dabigatran etexilate ingestion on days 3 and 4. This trial is registered with ClinicalTrials.gov, number NCT01688830. Between Feb 23, and Nov 29, 2013, 47 men completed this part of the study. 12 were enrolled into each of the 1 g, 2 g, or 5 g plus 2\u00b75 g idarucizumab groups (nine to idarucizumab and three to placebo in each group), and 11 were enrolled into the 4 g idarucizumab group (eight to idarucizumab and three to placebo). Drug-related adverse events were all of mild intensity and reported in seven participants: one in the 1 g idarucizumab group (infusion site erythema and hot flushes), one in the 5 g plus 2\u00b75 g idarucizumab group (epistaxis); one receiving placebo (infusion site haematoma), and four during dabigatran etexilate pretreatment (three haematuria and one epistaxis). Idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 AUEC2-12 to day 3 AUEC2-12 for dTT was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction). No serious or severe adverse events were reported, no adverse event led to discontinuation of treatment, and no clinically relevant difference in incidence of adverse events was noted between treatment groups. These phase 1 results show that idarucizumab was associated with immediate, complete, and sustained reversal of dabigatran-induced anticoagulation in healthy men, and was well tolerated with no unexpected or clinically relevant safety concerns, supporting further testing. Further clinical studies are in progress. Boehringer Ingelheim Pharma GmbH & Co KG.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "2997ce0116fe4da1afc9fa4cdf7e48d6", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[267, 267], [474, 474], [490, 490], [324, 324], [39, 39], [184, 184], [8, 8], [238, 238], [623, 623]], "char_spans": [[1357, 1366], [2353, 2362], [2474, 2483], [1630, 1639], [246, 255], [956, 965], [58, 67], [1182, 1191], [3132, 3141]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["a", 16], ["monoclonal", 18], ["antibody", 29], ["fragment", 38], ["that", 47], ["binds", 52], ["dabigatran", 58], ["with", 69], ["high", 74], ["affinity", 79], ["in", 88], ["a", 91], ["1:1", 93], ["molar", 97], ["ratio", 103], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["safety", 130], [",", 136], ["tolerability", 138], [",", 150], ["and", 152], ["efficacy", 156], ["of", 165], ["increasing", 168], ["doses", 179], ["of", 185], ["idarucizumab", 188], ["for", 201], ["the", 205], ["reversal", 209], ["of", 218], ["anticoagulant", 221], ["effects", 235], ["of", 243], ["dabigatran", 246], ["in", 257], ["a", 260], ["two", 262], ["-", 265], ["part", 266], ["phase", 271], ["1", 277], ["study", 279], ["(", 285], ["rising", 286], ["-", 292], ["dose", 293], ["assessment", 298], ["and", 309], ["dose", 313], ["-", 317], ["finding", 318], [",", 325], ["proof", 327], ["-", 332], ["of", 333], ["-", 335], ["concept", 336], ["investigation", 344], [")", 357], [".", 358], ["Here", 360], ["we", 365], ["present", 368], ["the", 376], ["results", 380], ["of", 388], ["the", 391], ["proof", 395], ["-", 400], ["of", 401], ["-", 403], ["concept", 404], ["part", 412], ["of", 417], ["the", 420], ["study", 424], [".", 429], ["In", 431], ["this", 434], ["randomised", 439], [",", 449], ["placebo", 451], ["-", 458], ["controlled", 459], [",", 469], ["double", 471], ["-", 477], ["blind", 478], [",", 483], ["proof", 485], ["-", 490], ["of", 491], ["-", 493], ["concept", 494], ["phase", 502], ["1", 508], ["study", 510], [",", 515], ["we", 517], ["enrolled", 520], ["healthy", 529], ["volunteers", 537], ["(", 548], ["aged", 549], ["18", 554], ["-", 556], ["45", 557], ["years", 560], [")", 565], ["with", 567], ["a", 572], ["body", 574], ["-", 578], ["mass", 579], ["index", 584], ["of", 590], ["18\u00b75", 593], ["-", 597], ["29\u00b79", 598], ["kg", 603], ["/", 605], ["m(2", 606], [")", 609], ["into", 611], ["one", 616], ["of", 620], ["four", 623], ["dose", 628], ["groups", 633], ["at", 640], ["SGS", 643], ["Life", 647], ["Sciences", 652], ["Clinical", 661], ["Research", 670], ["Services", 679], [",", 687], ["Belgium", 689], [".", 696], ["Participants", 698], ["were", 711], ["randomly", 716], ["assigned", 725], ["within", 734], ["groups", 741], ["in", 748], ["a", 751], ["3:1", 753], ["ratio", 757], ["to", 763], ["idarucizumab", 766], ["or", 779], ["placebo", 782], ["using", 790], ["a", 796], ["pseudorandom", 798], ["number", 811], ["generator", 818], ["and", 828], ["a", 832], ["supplied", 834], ["seed", 843], ["number", 848], [".", 854], ["Participants", 856], ["and", 869], ["care", 873], ["providers", 878], ["were", 888], ["masked", 893], ["to", 900], ["treatment", 903], ["assignment", 913], [".", 923], ["All", 925], ["participants", 929], ["received", 942], ["oral", 951], ["dabigatran", 956], ["etexilate", 967], ["220", 977], ["mg", 981], ["twice", 984], ["daily", 990], ["for", 996], ["3", 1000], ["days", 1002], ["and", 1007], ["a", 1011], ["final", 1013], ["dose", 1019], ["on", 1024], ["day", 1027], ["4", 1031], [".", 1032], ["Idarucizumab", 1034], ["(", 1047], ["1", 1048], ["g", 1050], [",", 1051], ["2", 1053], ["g", 1055], [",", 1056], ["or", 1058], ["4", 1061], ["g", 1063], ["5-min", 1065], ["infusion", 1071], [",", 1079], ["or", 1081], ["5", 1084], ["g", 1086], ["plus", 1088], ["2\u00b75", 1093], ["g", 1097], ["in", 1099], ["two", 1102], ["5-min", 1106], ["infusions", 1112], ["given", 1122], ["1", 1128], ["h", 1130], ["apart", 1132], [")", 1137], ["was", 1139], ["administered", 1143], ["about", 1156], ["2", 1162], ["h", 1164], ["after", 1166], ["the", 1172], ["final", 1176], ["dabigatran", 1182], ["etexilate", 1193], ["dose", 1203], [".", 1207], ["The", 1209], ["primary", 1213], ["endpoint", 1221], ["was", 1230], ["incidence", 1234], ["of", 1244], ["drug", 1247], ["-", 1251], ["related", 1252], ["adverse", 1260], ["events", 1268], [",", 1274], ["analysed", 1276], ["in", 1285], ["all", 1288], ["randomly", 1292], ["assigned", 1301], ["participants", 1310], ["who", 1323], ["received", 1327], ["at", 1336], ["least", 1339], ["one", 1345], ["dose", 1349], ["of", 1354], ["dabigatran", 1357], ["etexilate", 1368], [".", 1377], ["Reversal", 1379], ["of", 1388], ["diluted", 1391], ["thrombin", 1399], ["time", 1408], ["(", 1413], ["dTT", 1414], [")", 1417], [",", 1418], ["ecarin", 1420], ["clotting", 1427], ["time", 1436], ["(", 1441], ["ECT", 1442], [")", 1445], [",", 1446], ["activated", 1448], ["partial", 1458], ["thromboplastin", 1466], ["time", 1481], ["(", 1486], ["aPTT", 1487], [")", 1491], [",", 1492], ["and", 1494], ["thrombin", 1498], ["time", 1507], ["(", 1512], ["TT", 1513], [")", 1515], ["were", 1517], ["secondary", 1522], ["endpoints", 1532], ["assessed", 1542], ["by", 1551], ["measuring", 1554], ["the", 1564], ["area", 1568], ["under", 1573], ["the", 1579], ["effect", 1583], ["curve", 1590], ["from", 1596], ["2", 1601], ["h", 1603], ["to", 1605], ["12", 1608], ["h", 1611], ["(", 1613], ["AUEC2", 1614], ["-", 1619], ["12", 1620], [")", 1622], ["after", 1624], ["dabigatran", 1630], ["etexilate", 1641], ["ingestion", 1651], ["on", 1661], ["days", 1664], ["3", 1669], ["and", 1671], ["4", 1675], [".", 1676], ["This", 1678], ["trial", 1683], ["is", 1689], ["registered", 1692], ["with", 1703], ["ClinicalTrials.gov", 1708], [",", 1726], ["number", 1728], ["NCT01688830", 1735], [".", 1746], ["Between", 1748], ["Feb", 1756], ["23", 1760], [",", 1762], ["and", 1764], ["Nov", 1768], ["29", 1772], [",", 1774], ["2013", 1776], [",", 1780], ["47", 1782], ["men", 1785], ["completed", 1789], ["this", 1799], ["part", 1804], ["of", 1809], ["the", 1812], ["study", 1816], [".", 1821], ["12", 1823], ["were", 1826], ["enrolled", 1831], ["into", 1840], ["each", 1845], ["of", 1850], ["the", 1853], ["1", 1857], ["g", 1859], [",", 1860], ["2", 1862], ["g", 1864], [",", 1865], ["or", 1867], ["5", 1870], ["g", 1872], ["plus", 1874], ["2\u00b75", 1879], ["g", 1883], ["idarucizumab", 1885], ["groups", 1898], ["(", 1905], ["nine", 1906], ["to", 1911], ["idarucizumab", 1914], ["and", 1927], ["three", 1931], ["to", 1937], ["placebo", 1940], ["in", 1948], ["each", 1951], ["group", 1956], [")", 1961], [",", 1962], ["and", 1964], ["11", 1968], ["were", 1971], ["enrolled", 1976], ["into", 1985], ["the", 1990], ["4", 1994], ["g", 1996], ["idarucizumab", 1998], ["group", 2011], ["(", 2017], ["eight", 2018], ["to", 2024], ["idarucizumab", 2027], ["and", 2040], ["three", 2044], ["to", 2050], ["placebo", 2053], [")", 2060], [".", 2061], ["Drug", 2063], ["-", 2067], ["related", 2068], ["adverse", 2076], ["events", 2084], ["were", 2091], ["all", 2096], ["of", 2100], ["mild", 2103], ["intensity", 2108], ["and", 2118], ["reported", 2122], ["in", 2131], ["seven", 2134], ["participants", 2140], [":", 2152], ["one", 2154], ["in", 2158], ["the", 2161], ["1", 2165], ["g", 2167], ["idarucizumab", 2169], ["group", 2182], ["(", 2188], ["infusion", 2189], ["site", 2198], ["erythema", 2203], ["and", 2212], ["hot", 2216], ["flushes", 2220], [")", 2227], [",", 2228], ["one", 2230], ["in", 2234], ["the", 2237], ["5", 2241], ["g", 2243], ["plus", 2245], ["2\u00b75", 2250], ["g", 2254], ["idarucizumab", 2256], ["group", 2269], ["(", 2275], ["epistaxis", 2276], [")", 2285], [";", 2286], ["one", 2288], ["receiving", 2292], ["placebo", 2302], ["(", 2310], ["infusion", 2311], ["site", 2320], ["haematoma", 2325], [")", 2334], [",", 2335], ["and", 2337], ["four", 2341], ["during", 2346], ["dabigatran", 2353], ["etexilate", 2364], ["pretreatment", 2374], ["(", 2387], ["three", 2388], ["haematuria", 2394], ["and", 2405], ["one", 2409], ["epistaxis", 2413], [")", 2422], [".", 2423], ["Idarucizumab", 2425], ["immediately", 2438], ["and", 2450], ["completely", 2454], ["reversed", 2465], ["dabigatran", 2474], ["-", 2484], ["induced", 2485], ["anticoagulation", 2493], ["in", 2509], ["a", 2512], ["dose", 2514], ["-", 2518], ["dependent", 2519], ["manner", 2529], [";", 2535], ["the", 2537], ["mean", 2541], ["ratio", 2546], ["of", 2552], ["day", 2555], ["4", 2559], ["AUEC2", 2561], ["-", 2566], ["12", 2567], ["to", 2570], ["day", 2573], ["3", 2577], ["AUEC2", 2579], ["-", 2584], ["12", 2585], ["for", 2588], ["dTT", 2592], ["was", 2596], ["1\u00b701", 2600], ["with", 2605], ["placebo", 2610], [",", 2617], ["0\u00b726", 2619], ["with", 2624], ["1", 2629], ["g", 2631], ["idarucizumab", 2633], ["(", 2646], ["74", 2647], ["%", 2649], ["reduction", 2651], [")", 2660], [",", 2661], ["0\u00b706", 2663], ["with", 2668], ["2", 2673], ["g", 2675], ["idarucizumab", 2677], ["(", 2690], ["94", 2691], ["%", 2693], ["reduction", 2695], [")", 2704], [",", 2705], ["0\u00b702", 2707], ["with", 2712], ["4", 2717], ["g", 2719], ["idarucizumab", 2721], ["(", 2734], ["98", 2735], ["%", 2737], ["reduction", 2739], [")", 2748], [",", 2749], ["and", 2751], ["0\u00b701", 2755], ["with", 2760], ["5", 2765], ["g", 2767], ["plus", 2769], ["2\u00b75", 2774], ["g", 2778], ["idarucizumab", 2780], ["(", 2793], ["99", 2794], ["%", 2796], ["reduction", 2798], [")", 2807], [".", 2808], ["No", 2810], ["serious", 2813], ["or", 2821], ["severe", 2824], ["adverse", 2831], ["events", 2839], ["were", 2846], ["reported", 2851], [",", 2859], ["no", 2861], ["adverse", 2864], ["event", 2872], ["led", 2878], ["to", 2882], ["discontinuation", 2885], ["of", 2901], ["treatment", 2904], [",", 2913], ["and", 2915], ["no", 2919], ["clinically", 2922], ["relevant", 2933], ["difference", 2942], ["in", 2953], ["incidence", 2956], ["of", 2966], ["adverse", 2969], ["events", 2977], ["was", 2984], ["noted", 2988], ["between", 2994], ["treatment", 3002], ["groups", 3012], [".", 3018], ["These", 3020], ["phase", 3026], ["1", 3032], ["results", 3034], ["show", 3042], ["that", 3047], ["idarucizumab", 3052], ["was", 3065], ["associated", 3069], ["with", 3080], ["immediate", 3085], [",", 3094], ["complete", 3096], [",", 3104], ["and", 3106], ["sustained", 3110], ["reversal", 3120], ["of", 3129], ["dabigatran", 3132], ["-", 3142], ["induced", 3143], ["anticoagulation", 3151], ["in", 3167], ["healthy", 3170], ["men", 3178], [",", 3181], ["and", 3183], ["was", 3187], ["well", 3191], ["tolerated", 3196], ["with", 3206], ["no", 3211], ["unexpected", 3214], ["or", 3225], ["clinically", 3228], ["relevant", 3239], ["safety", 3248], ["concerns", 3255], [",", 3263], ["supporting", 3265], ["further", 3276], ["testing", 3284], [".", 3291], ["Further", 3293], ["clinical", 3301], ["studies", 3310], ["are", 3318], ["in", 3322], ["progress", 3325], [".", 3333], ["Boehringer", 3335], ["Ingelheim", 3346], ["Pharma", 3356], ["GmbH", 3363], ["&", 3368], ["Co", 3370], ["KG", 3373], [".", 3375]]}
{"context": "Accurate cell division requires the proper assembly of high-order septin structures. In fission yeast (Schizosaccharomyces pombe), Spn1-Spn4 are assembled into a primary septin ring at the division site, and the subsequent recruitment of Mid2 to the structure results in a stable septin ring. However, not much is known about the regulation of this key process. Here, we found that deletion of Spt20, a structural subunit of the Spt-Ada-Gcn5-acetyltransferase (SAGA) transcriptional activation complex, caused a severe cell separation defect. The defect was mainly due to impaired septin ring assembly, as 80% of spt20\u0394 cells lost septin rings at the division sites. Spt20 regulates septin ring assembly partially through the transcriptional activation of mid2(+). Spt20 also interacted with Spn2 and Mid2 in vitro and was associated with other components of the ring in vivo. Spt20 colocalized with the septin ring, but did not separate when the septin ring split. Importantly, Spt20 regulated the stability of the septin ring and was required for the recruitment of Mid2. The transcription-dependent and -independent roles of Spt20 in septin ring assembly highlight a multifaceted regulation of one process by a SAGA subunit.", "qas": [{"question": "What does the SAGA complex acronym stands for?", "answers": ["Spt-Ada-Gcn5-acetyltransferase"], "qid": "8879689c14314feb9629e3d724500547", "question_tokens": [["What", 0], ["does", 5], ["the", 10], ["SAGA", 14], ["complex", 19], ["acronym", 27], ["stands", 35], ["for", 42], ["?", 45]], "detected_answers": [{"text": "Spt-Ada-Gcn5-acetyltransferase", "token_spans": [[79, 83]], "char_spans": [[429, 458]]}]}], "context_tokens": [["Accurate", 0], ["cell", 9], ["division", 14], ["requires", 23], ["the", 32], ["proper", 36], ["assembly", 43], ["of", 52], ["high", 55], ["-", 59], ["order", 60], ["septin", 66], ["structures", 73], [".", 83], ["In", 85], ["fission", 88], ["yeast", 96], ["(", 102], ["Schizosaccharomyces", 103], ["pombe", 123], [")", 128], [",", 129], ["Spn1-Spn4", 131], ["are", 141], ["assembled", 145], ["into", 155], ["a", 160], ["primary", 162], ["septin", 170], ["ring", 177], ["at", 182], ["the", 185], ["division", 189], ["site", 198], [",", 202], ["and", 204], ["the", 208], ["subsequent", 212], ["recruitment", 223], ["of", 235], ["Mid2", 238], ["to", 243], ["the", 246], ["structure", 250], ["results", 260], ["in", 268], ["a", 271], ["stable", 273], ["septin", 280], ["ring", 287], [".", 291], ["However", 293], [",", 300], ["not", 302], ["much", 306], ["is", 311], ["known", 314], ["about", 320], ["the", 326], ["regulation", 330], ["of", 341], ["this", 344], ["key", 349], ["process", 353], [".", 360], ["Here", 362], [",", 366], ["we", 368], ["found", 371], ["that", 377], ["deletion", 382], ["of", 391], ["Spt20", 394], [",", 399], ["a", 401], ["structural", 403], ["subunit", 414], ["of", 422], ["the", 425], ["Spt", 429], ["-", 432], ["Ada", 433], ["-", 436], ["Gcn5-acetyltransferase", 437], ["(", 460], ["SAGA", 461], [")", 465], ["transcriptional", 467], ["activation", 483], ["complex", 494], [",", 501], ["caused", 503], ["a", 510], ["severe", 512], ["cell", 519], ["separation", 524], ["defect", 535], [".", 541], ["The", 543], ["defect", 547], ["was", 554], ["mainly", 558], ["due", 565], ["to", 569], ["impaired", 572], ["septin", 581], ["ring", 588], ["assembly", 593], [",", 601], ["as", 603], ["80", 606], ["%", 608], ["of", 610], ["spt20\u0394", 613], ["cells", 620], ["lost", 626], ["septin", 631], ["rings", 638], ["at", 644], ["the", 647], ["division", 651], ["sites", 660], [".", 665], ["Spt20", 667], ["regulates", 673], ["septin", 683], ["ring", 690], ["assembly", 695], ["partially", 704], ["through", 714], ["the", 722], ["transcriptional", 726], ["activation", 742], ["of", 753], ["mid2(+", 756], [")", 762], [".", 763], ["Spt20", 765], ["also", 771], ["interacted", 776], ["with", 787], ["Spn2", 792], ["and", 797], ["Mid2", 801], ["in", 806], ["vitro", 809], ["and", 815], ["was", 819], ["associated", 823], ["with", 834], ["other", 839], ["components", 845], ["of", 856], ["the", 859], ["ring", 863], ["in", 868], ["vivo", 871], [".", 875], ["Spt20", 877], ["colocalized", 883], ["with", 895], ["the", 900], ["septin", 904], ["ring", 911], [",", 915], ["but", 917], ["did", 921], ["not", 925], ["separate", 929], ["when", 938], ["the", 943], ["septin", 947], ["ring", 954], ["split", 959], [".", 964], ["Importantly", 966], [",", 977], ["Spt20", 979], ["regulated", 985], ["the", 995], ["stability", 999], ["of", 1009], ["the", 1012], ["septin", 1016], ["ring", 1023], ["and", 1028], ["was", 1032], ["required", 1036], ["for", 1045], ["the", 1049], ["recruitment", 1053], ["of", 1065], ["Mid2", 1068], [".", 1072], ["The", 1074], ["transcription", 1078], ["-", 1091], ["dependent", 1092], ["and", 1102], ["-independent", 1106], ["roles", 1119], ["of", 1125], ["Spt20", 1128], ["in", 1134], ["septin", 1137], ["ring", 1144], ["assembly", 1149], ["highlight", 1158], ["a", 1168], ["multifaceted", 1170], ["regulation", 1183], ["of", 1194], ["one", 1197], ["process", 1201], ["by", 1209], ["a", 1212], ["SAGA", 1214], ["subunit", 1219], [".", 1226]]}
{"context": "Bazex syndrome, or acrokeratosis paraneoplastica, is a cutaneous paraneoplastic syndrome characterized by psoriasiform lesions associated with, usually, a squamous cell carcinoma of the upper aerodigestive tract. We present a case of Bazex syndrome associated with metastatic cervical squamous cell carcinoma with an unknown primary. The features of the condition are discussed in the light of current knowledge.", "qas": [{"question": "Name synonym of Acrokeratosis paraneoplastica.", "answers": ["Bazex syndrome"], "qid": "13712b1db9094ec2bd023d0036495b5d", "question_tokens": [["Name", 0], ["synonym", 5], ["of", 13], ["Acrokeratosis", 16], ["paraneoplastica", 30], [".", 45]], "detected_answers": [{"text": "Bazex syndrome", "token_spans": [[0, 1], [36, 37]], "char_spans": [[0, 13], [234, 247]]}]}], "context_tokens": [["Bazex", 0], ["syndrome", 6], [",", 14], ["or", 16], ["acrokeratosis", 19], ["paraneoplastica", 33], [",", 48], ["is", 50], ["a", 53], ["cutaneous", 55], ["paraneoplastic", 65], ["syndrome", 80], ["characterized", 89], ["by", 103], ["psoriasiform", 106], ["lesions", 119], ["associated", 127], ["with", 138], [",", 142], ["usually", 144], [",", 151], ["a", 153], ["squamous", 155], ["cell", 164], ["carcinoma", 169], ["of", 179], ["the", 182], ["upper", 186], ["aerodigestive", 192], ["tract", 206], [".", 211], ["We", 213], ["present", 216], ["a", 224], ["case", 226], ["of", 231], ["Bazex", 234], ["syndrome", 240], ["associated", 249], ["with", 260], ["metastatic", 265], ["cervical", 276], ["squamous", 285], ["cell", 294], ["carcinoma", 299], ["with", 309], ["an", 314], ["unknown", 317], ["primary", 325], [".", 332], ["The", 334], ["features", 338], ["of", 347], ["the", 350], ["condition", 354], ["are", 364], ["discussed", 368], ["in", 378], ["the", 381], ["light", 385], ["of", 391], ["current", 394], ["knowledge", 402], [".", 411]]}
{"context": "Our previous work has shown that gene knockout of the sodium-glucose cotransporter SGLT2 modestly lowered blood glucose in streptozotocin-diabetic mice (BG; from 470 to 300 mg/dl) and prevented glomerular hyperfiltration but did not attenuate albuminuria or renal growth and inflammation. Here we determined effects of the SGLT2 inhibitor empagliflozin (300 mg/kg of diet for 15 wk; corresponding to 60-80 mg\u00b7kg(-1)\u00b7day(-1)) in type 1 diabetic Akita mice that, opposite to streptozotocin-diabetes, upregulate renal SGLT2 expression. Akita diabetes, empagliflozin, and Akita + empagliflozin similarly increased renal membrane SGLT2 expression (by 38-56%) and reduced the expression of SGLT1 (by 33-37%) vs. vehicle-treated wild-type controls (WT). The diabetes-induced changes in SGLT2/SGLT1 protein expression are expected to enhance the BG-lowering potential of SGLT2 inhibition, and empagliflozin strongly lowered BG in Akita (means of 187-237 vs. 517-535 mg/dl in vehicle group; 100-140 mg/dl in WT). Empagliflozin modestly reduced GFR in WT (250 vs. 306 \u03bcl/min) and completely prevented the diabetes-induced increase in glomerular filtration rate (GFR) (255 vs. 397 \u03bcl/min). Empagliflozin attenuated increases in kidney weight and urinary albumin/creatinine ratio in Akita in proportion to hyperglycemia. Empagliflozin did not increase urinary glucose/creatinine ratios in Akita, indicating the reduction in filtered glucose balanced the inhibition of glucose reabsorption. Empagliflozin attenuated/prevented the increase in systolic blood pressure, glomerular size, and molecular markers of kidney growth, inflammation, and gluconeogenesis in Akita. We propose that SGLT2 inhibition can lower GFR independent of reducing BG (consistent with the tubular hypothesis of diabetic glomerular hyperfiltration), while attenuation of albuminuria, kidney growth, and inflammation in the early diabetic kidney may mostly be secondary to lower BG.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "9be314d9fc724bababf59b5df8079c8c", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[14, 14], [163, 163], [313, 313], [56, 56], [94, 94], [110, 110]], "char_spans": [[83, 87], [863, 867], [1671, 1675], [323, 327], [515, 519], [625, 629]]}]}], "context_tokens": [["Our", 0], ["previous", 4], ["work", 13], ["has", 18], ["shown", 22], ["that", 28], ["gene", 33], ["knockout", 38], ["of", 47], ["the", 50], ["sodium", 54], ["-", 60], ["glucose", 61], ["cotransporter", 69], ["SGLT2", 83], ["modestly", 89], ["lowered", 98], ["blood", 106], ["glucose", 112], ["in", 120], ["streptozotocin", 123], ["-", 137], ["diabetic", 138], ["mice", 147], ["(", 152], ["BG", 153], [";", 155], ["from", 157], ["470", 162], ["to", 166], ["300", 169], ["mg", 173], ["/", 175], ["dl", 176], [")", 178], ["and", 180], ["prevented", 184], ["glomerular", 194], ["hyperfiltration", 205], ["but", 221], ["did", 225], ["not", 229], ["attenuate", 233], ["albuminuria", 243], ["or", 255], ["renal", 258], ["growth", 264], ["and", 271], ["inflammation", 275], [".", 287], ["Here", 289], ["we", 294], ["determined", 297], ["effects", 308], ["of", 316], ["the", 319], ["SGLT2", 323], ["inhibitor", 329], ["empagliflozin", 339], ["(", 353], ["300", 354], ["mg", 358], ["/", 360], ["kg", 361], ["of", 364], ["diet", 367], ["for", 372], ["15", 376], ["wk", 379], [";", 381], ["corresponding", 383], ["to", 397], ["60", 400], ["-", 402], ["80", 403], ["mg\u00b7kg(-1)\u00b7day(-1", 406], [")", 422], [")", 423], ["in", 425], ["type", 428], ["1", 433], ["diabetic", 435], ["Akita", 444], ["mice", 450], ["that", 455], [",", 459], ["opposite", 461], ["to", 470], ["streptozotocin", 473], ["-", 487], ["diabetes", 488], [",", 496], ["upregulate", 498], ["renal", 509], ["SGLT2", 515], ["expression", 521], [".", 531], ["Akita", 533], ["diabetes", 539], [",", 547], ["empagliflozin", 549], [",", 562], ["and", 564], ["Akita", 568], ["+", 574], ["empagliflozin", 576], ["similarly", 590], ["increased", 600], ["renal", 610], ["membrane", 616], ["SGLT2", 625], ["expression", 631], ["(", 642], ["by", 643], ["38", 646], ["-", 648], ["56", 649], ["%", 651], [")", 652], ["and", 654], ["reduced", 658], ["the", 666], ["expression", 670], ["of", 681], ["SGLT1", 684], ["(", 690], ["by", 691], ["33", 694], ["-", 696], ["37", 697], ["%", 699], [")", 700], ["vs.", 702], ["vehicle", 706], ["-", 713], ["treated", 714], ["wild", 722], ["-", 726], ["type", 727], ["controls", 732], ["(", 741], ["WT", 742], [")", 744], [".", 745], ["The", 747], ["diabetes", 751], ["-", 759], ["induced", 760], ["changes", 768], ["in", 776], ["SGLT2/SGLT1", 779], ["protein", 791], ["expression", 799], ["are", 810], ["expected", 814], ["to", 823], ["enhance", 826], ["the", 834], ["BG", 838], ["-", 840], ["lowering", 841], ["potential", 850], ["of", 860], ["SGLT2", 863], ["inhibition", 869], [",", 879], ["and", 881], ["empagliflozin", 885], ["strongly", 899], ["lowered", 908], ["BG", 916], ["in", 919], ["Akita", 922], ["(", 928], ["means", 929], ["of", 935], ["187", 938], ["-", 941], ["237", 942], ["vs.", 946], ["517", 950], ["-", 953], ["535", 954], ["mg", 958], ["/", 960], ["dl", 961], ["in", 964], ["vehicle", 967], ["group", 975], [";", 980], ["100", 982], ["-", 985], ["140", 986], ["mg", 990], ["/", 992], ["dl", 993], ["in", 996], ["WT", 999], [")", 1001], [".", 1002], ["Empagliflozin", 1004], ["modestly", 1018], ["reduced", 1027], ["GFR", 1035], ["in", 1039], ["WT", 1042], ["(", 1045], ["250", 1046], ["vs.", 1050], ["306", 1054], ["\u03bcl", 1058], ["/", 1060], ["min", 1061], [")", 1064], ["and", 1066], ["completely", 1070], ["prevented", 1081], ["the", 1091], ["diabetes", 1095], ["-", 1103], ["induced", 1104], ["increase", 1112], ["in", 1121], ["glomerular", 1124], ["filtration", 1135], ["rate", 1146], ["(", 1151], ["GFR", 1152], [")", 1155], ["(", 1157], ["255", 1158], ["vs.", 1162], ["397", 1166], ["\u03bcl", 1170], ["/", 1172], ["min", 1173], [")", 1176], [".", 1177], ["Empagliflozin", 1179], ["attenuated", 1193], ["increases", 1204], ["in", 1214], ["kidney", 1217], ["weight", 1224], ["and", 1231], ["urinary", 1235], ["albumin", 1243], ["/", 1250], ["creatinine", 1251], ["ratio", 1262], ["in", 1268], ["Akita", 1271], ["in", 1277], ["proportion", 1280], ["to", 1291], ["hyperglycemia", 1294], [".", 1307], ["Empagliflozin", 1309], ["did", 1323], ["not", 1327], ["increase", 1331], ["urinary", 1340], ["glucose", 1348], ["/", 1355], ["creatinine", 1356], ["ratios", 1367], ["in", 1374], ["Akita", 1377], [",", 1382], ["indicating", 1384], ["the", 1395], ["reduction", 1399], ["in", 1409], ["filtered", 1412], ["glucose", 1421], ["balanced", 1429], ["the", 1438], ["inhibition", 1442], ["of", 1453], ["glucose", 1456], ["reabsorption", 1464], [".", 1476], ["Empagliflozin", 1478], ["attenuated", 1492], ["/", 1502], ["prevented", 1503], ["the", 1513], ["increase", 1517], ["in", 1526], ["systolic", 1529], ["blood", 1538], ["pressure", 1544], [",", 1552], ["glomerular", 1554], ["size", 1565], [",", 1569], ["and", 1571], ["molecular", 1575], ["markers", 1585], ["of", 1593], ["kidney", 1596], ["growth", 1603], [",", 1609], ["inflammation", 1611], [",", 1623], ["and", 1625], ["gluconeogenesis", 1629], ["in", 1645], ["Akita", 1648], [".", 1653], ["We", 1655], ["propose", 1658], ["that", 1666], ["SGLT2", 1671], ["inhibition", 1677], ["can", 1688], ["lower", 1692], ["GFR", 1698], ["independent", 1702], ["of", 1714], ["reducing", 1717], ["BG", 1726], ["(", 1729], ["consistent", 1730], ["with", 1741], ["the", 1746], ["tubular", 1750], ["hypothesis", 1758], ["of", 1769], ["diabetic", 1772], ["glomerular", 1781], ["hyperfiltration", 1792], [")", 1807], [",", 1808], ["while", 1810], ["attenuation", 1816], ["of", 1828], ["albuminuria", 1831], [",", 1842], ["kidney", 1844], ["growth", 1851], [",", 1857], ["and", 1859], ["inflammation", 1863], ["in", 1876], ["the", 1879], ["early", 1883], ["diabetic", 1889], ["kidney", 1898], ["may", 1905], ["mostly", 1909], ["be", 1916], ["secondary", 1919], ["to", 1929], ["lower", 1932], ["BG", 1938], [".", 1940]]}
{"context": "The pathogenesis of RA is a complex and ever-changing landscape but amid the chaos of the disease process we have found effective treatment regimes. However, our current therapeutics, although targeting various components of both the innate and adaptive immune response, do not result in disease remission. Protein kinase inhibitors are attractive targets due to their ability to influence downstream signalling and their oral bioavailability. Fostamatinib (R788) inhibits spleen tyrosine kinase (Syk) and has been in clinical trials involving both MTX inadequate responders (MTX-IRs) and biologic inadequate responders. Studies on the MTX-IR population revealed ACR20 responses of 67-72% at higher doses (150 mg bd and 100 mg bd), ACR50 responses of 43-57% and ACR70 responses of 28-40%. The trial in the biologic non-responder population showed no efficacy, however, post hoc analyses of the data suggested that a further trial in this population is warranted. The most common adverse events included gastrointestinal effects, hypertension, neutropenia and transaminitis. Many adverse effects were dose responsive and hypertension was amenable to treatment. Upper respiratory tract infections were more likely at higher doses, but no serious infections with tuberculosis, fungi or opportunistic infections were reported. The oral availability of these agents makes them attractive treatment options for our patients, although the literature from the oncology field suggests that patients will only choose the oral route if efficacy is equivalent. Long-term follow-up studies are ongoing and will be critical for rare side effects. The role of these agents in our current arsenal is unclear and economic analyses are awaited.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "817590b6c9a647a5aef10b85199aef9b", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[77, 79]], "char_spans": [[473, 494]]}]}], "context_tokens": [["The", 0], ["pathogenesis", 4], ["of", 17], ["RA", 20], ["is", 23], ["a", 26], ["complex", 28], ["and", 36], ["ever", 40], ["-", 44], ["changing", 45], ["landscape", 54], ["but", 64], ["amid", 68], ["the", 73], ["chaos", 77], ["of", 83], ["the", 86], ["disease", 90], ["process", 98], ["we", 106], ["have", 109], ["found", 114], ["effective", 120], ["treatment", 130], ["regimes", 140], [".", 147], ["However", 149], [",", 156], ["our", 158], ["current", 162], ["therapeutics", 170], [",", 182], ["although", 184], ["targeting", 193], ["various", 203], ["components", 211], ["of", 222], ["both", 225], ["the", 230], ["innate", 234], ["and", 241], ["adaptive", 245], ["immune", 254], ["response", 261], [",", 269], ["do", 271], ["not", 274], ["result", 278], ["in", 285], ["disease", 288], ["remission", 296], [".", 305], ["Protein", 307], ["kinase", 315], ["inhibitors", 322], ["are", 333], ["attractive", 337], ["targets", 348], ["due", 356], ["to", 360], ["their", 363], ["ability", 369], ["to", 377], ["influence", 380], ["downstream", 390], ["signalling", 401], ["and", 412], ["their", 416], ["oral", 422], ["bioavailability", 427], [".", 442], ["Fostamatinib", 444], ["(", 457], ["R788", 458], [")", 462], ["inhibits", 464], ["spleen", 473], ["tyrosine", 480], ["kinase", 489], ["(", 496], ["Syk", 497], [")", 500], ["and", 502], ["has", 506], ["been", 510], ["in", 515], ["clinical", 518], ["trials", 527], ["involving", 534], ["both", 544], ["MTX", 549], ["inadequate", 553], ["responders", 564], ["(", 575], ["MTX", 576], ["-", 579], ["IRs", 580], [")", 583], ["and", 585], ["biologic", 589], ["inadequate", 598], ["responders", 609], [".", 619], ["Studies", 621], ["on", 629], ["the", 632], ["MTX", 636], ["-", 639], ["IR", 640], ["population", 643], ["revealed", 654], ["ACR20", 663], ["responses", 669], ["of", 679], ["67", 682], ["-", 684], ["72", 685], ["%", 687], ["at", 689], ["higher", 692], ["doses", 699], ["(", 705], ["150", 706], ["mg", 710], ["bd", 713], ["and", 716], ["100", 720], ["mg", 724], ["bd", 727], [")", 729], [",", 730], ["ACR50", 732], ["responses", 738], ["of", 748], ["43", 751], ["-", 753], ["57", 754], ["%", 756], ["and", 758], ["ACR70", 762], ["responses", 768], ["of", 778], ["28", 781], ["-", 783], ["40", 784], ["%", 786], [".", 787], ["The", 789], ["trial", 793], ["in", 799], ["the", 802], ["biologic", 806], ["non", 815], ["-", 818], ["responder", 819], ["population", 829], ["showed", 840], ["no", 847], ["efficacy", 850], [",", 858], ["however", 860], [",", 867], ["post", 869], ["hoc", 874], ["analyses", 878], ["of", 887], ["the", 890], ["data", 894], ["suggested", 899], ["that", 909], ["a", 914], ["further", 916], ["trial", 924], ["in", 930], ["this", 933], ["population", 938], ["is", 949], ["warranted", 952], [".", 961], ["The", 963], ["most", 967], ["common", 972], ["adverse", 979], ["events", 987], ["included", 994], ["gastrointestinal", 1003], ["effects", 1020], [",", 1027], ["hypertension", 1029], [",", 1041], ["neutropenia", 1043], ["and", 1055], ["transaminitis", 1059], [".", 1072], ["Many", 1074], ["adverse", 1079], ["effects", 1087], ["were", 1095], ["dose", 1100], ["responsive", 1105], ["and", 1116], ["hypertension", 1120], ["was", 1133], ["amenable", 1137], ["to", 1146], ["treatment", 1149], [".", 1158], ["Upper", 1160], ["respiratory", 1166], ["tract", 1178], ["infections", 1184], ["were", 1195], ["more", 1200], ["likely", 1205], ["at", 1212], ["higher", 1215], ["doses", 1222], [",", 1227], ["but", 1229], ["no", 1233], ["serious", 1236], ["infections", 1244], ["with", 1255], ["tuberculosis", 1260], [",", 1272], ["fungi", 1274], ["or", 1280], ["opportunistic", 1283], ["infections", 1297], ["were", 1308], ["reported", 1313], [".", 1321], ["The", 1323], ["oral", 1327], ["availability", 1332], ["of", 1345], ["these", 1348], ["agents", 1354], ["makes", 1361], ["them", 1367], ["attractive", 1372], ["treatment", 1383], ["options", 1393], ["for", 1401], ["our", 1405], ["patients", 1409], [",", 1417], ["although", 1419], ["the", 1428], ["literature", 1432], ["from", 1443], ["the", 1448], ["oncology", 1452], ["field", 1461], ["suggests", 1467], ["that", 1476], ["patients", 1481], ["will", 1490], ["only", 1495], ["choose", 1500], ["the", 1507], ["oral", 1511], ["route", 1516], ["if", 1522], ["efficacy", 1525], ["is", 1534], ["equivalent", 1537], [".", 1547], ["Long", 1549], ["-", 1553], ["term", 1554], ["follow", 1559], ["-", 1565], ["up", 1566], ["studies", 1569], ["are", 1577], ["ongoing", 1581], ["and", 1589], ["will", 1593], ["be", 1598], ["critical", 1601], ["for", 1610], ["rare", 1614], ["side", 1619], ["effects", 1624], [".", 1631], ["The", 1633], ["role", 1637], ["of", 1642], ["these", 1645], ["agents", 1651], ["in", 1658], ["our", 1661], ["current", 1665], ["arsenal", 1673], ["is", 1681], ["unclear", 1684], ["and", 1692], ["economic", 1696], ["analyses", 1705], ["are", 1714], ["awaited", 1718], [".", 1725]]}
{"context": "The McLeod syndrome is an X-linked neuroacanthocytosis manifesting with myopathy and progressive chorea. It is caused by mutations of the XK gene encoding the XK protein, a putative membrane transport protein of yet unknown function. In erythroid tissues, XK forms a functional complex with the Kell glycoprotein. Here, we present an immunohistochemical study in skeletal muscle of normal controls and a McLeod patient with a XK gene point mutation (C977T) using affinity-purified antibodies against XK and Kell proteins. Histological examination of the affected muscle revealed the typical pattern of McLeod myopathy including type 2 fiber atrophy. In control muscles, Kell immunohistochemistry stained sarcoplasmic membranes. XK immunohistochemistry resulted in a type 2 fiber-specific intracellular staining that was most probably confined to the sarcoplasmic reticulum. In contrast, there was only a weak background signal without a specific staining pattern for XK and Kell in the McLeod muscle. Our results demonstrate that the lack of physiological XK expression correlates to the type 2 fiber atrophy in McLeod myopathy, and suggest that the XK protein represents a crucial factor for the maintenance of normal muscle structure and function.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "f252703de7194f1983547f4bf860ba40", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[192, 192], [27, 27], [44, 44], [87, 87], [23, 23], [73, 73], [121, 121], [175, 175], [159, 159]], "char_spans": [[1150, 1151], [159, 160], [256, 257], [500, 501], [138, 139], [426, 427], [728, 729], [1056, 1057], [967, 968]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["syndrome", 11], ["is", 20], ["an", 23], ["X", 26], ["-", 27], ["linked", 28], ["neuroacanthocytosis", 35], ["manifesting", 55], ["with", 67], ["myopathy", 72], ["and", 81], ["progressive", 85], ["chorea", 97], [".", 103], ["It", 105], ["is", 108], ["caused", 111], ["by", 118], ["mutations", 121], ["of", 131], ["the", 134], ["XK", 138], ["gene", 141], ["encoding", 146], ["the", 155], ["XK", 159], ["protein", 162], [",", 169], ["a", 171], ["putative", 173], ["membrane", 182], ["transport", 191], ["protein", 201], ["of", 209], ["yet", 212], ["unknown", 216], ["function", 224], [".", 232], ["In", 234], ["erythroid", 237], ["tissues", 247], [",", 254], ["XK", 256], ["forms", 259], ["a", 265], ["functional", 267], ["complex", 278], ["with", 286], ["the", 291], ["Kell", 295], ["glycoprotein", 300], [".", 312], ["Here", 314], [",", 318], ["we", 320], ["present", 323], ["an", 331], ["immunohistochemical", 334], ["study", 354], ["in", 360], ["skeletal", 363], ["muscle", 372], ["of", 379], ["normal", 382], ["controls", 389], ["and", 398], ["a", 402], ["McLeod", 404], ["patient", 411], ["with", 419], ["a", 424], ["XK", 426], ["gene", 429], ["point", 434], ["mutation", 440], ["(", 449], ["C977", 450], ["T", 454], [")", 455], ["using", 457], ["affinity", 463], ["-", 471], ["purified", 472], ["antibodies", 481], ["against", 492], ["XK", 500], ["and", 503], ["Kell", 507], ["proteins", 512], [".", 520], ["Histological", 522], ["examination", 535], ["of", 547], ["the", 550], ["affected", 554], ["muscle", 563], ["revealed", 570], ["the", 579], ["typical", 583], ["pattern", 591], ["of", 599], ["McLeod", 602], ["myopathy", 609], ["including", 618], ["type", 628], ["2", 633], ["fiber", 635], ["atrophy", 641], [".", 648], ["In", 650], ["control", 653], ["muscles", 661], [",", 668], ["Kell", 670], ["immunohistochemistry", 675], ["stained", 696], ["sarcoplasmic", 704], ["membranes", 717], [".", 726], ["XK", 728], ["immunohistochemistry", 731], ["resulted", 752], ["in", 761], ["a", 764], ["type", 766], ["2", 771], ["fiber", 773], ["-", 778], ["specific", 779], ["intracellular", 788], ["staining", 802], ["that", 811], ["was", 816], ["most", 820], ["probably", 825], ["confined", 834], ["to", 843], ["the", 846], ["sarcoplasmic", 850], ["reticulum", 863], [".", 872], ["In", 874], ["contrast", 877], [",", 885], ["there", 887], ["was", 893], ["only", 897], ["a", 902], ["weak", 904], ["background", 909], ["signal", 920], ["without", 927], ["a", 935], ["specific", 937], ["staining", 946], ["pattern", 955], ["for", 963], ["XK", 967], ["and", 970], ["Kell", 974], ["in", 979], ["the", 982], ["McLeod", 986], ["muscle", 993], [".", 999], ["Our", 1001], ["results", 1005], ["demonstrate", 1013], ["that", 1025], ["the", 1030], ["lack", 1034], ["of", 1039], ["physiological", 1042], ["XK", 1056], ["expression", 1059], ["correlates", 1070], ["to", 1081], ["the", 1084], ["type", 1088], ["2", 1093], ["fiber", 1095], ["atrophy", 1101], ["in", 1109], ["McLeod", 1112], ["myopathy", 1119], [",", 1127], ["and", 1129], ["suggest", 1133], ["that", 1141], ["the", 1146], ["XK", 1150], ["protein", 1153], ["represents", 1161], ["a", 1172], ["crucial", 1174], ["factor", 1182], ["for", 1189], ["the", 1193], ["maintenance", 1197], ["of", 1209], ["normal", 1212], ["muscle", 1219], ["structure", 1226], ["and", 1236], ["function", 1240], [".", 1248]]}
{"context": "Common cellular and molecular mechanisms including protein aggregation and inclusion body formation are involved in many neurodegenerative diseases. \u03b1-Synuclein is a major component of Lewy bodies in Parkinson's disease (PD) as well as in glial cytoplasmic inclusions in multiple system atrophy (MSA). Tau is a principal component of neurofibrillary and glial tangles in tauopathies. Recently, TDP-43 was identified as a component of ubiquitinated inclusions in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PD is traditionally considered a movement disorder with hallmark lesions in the brainstem pigmented nuclei. However, pathological changes occur in widespread regions of the central and peripheral nervous systems in this disease. Furthermore, primary glial involvement (\"gliodegeneration\") can be observed in PD and MSA as well as in tauopathy. The present article reviews abnormal protein accumulation and inclusion body formation inside and outside the central nervous system.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "1943cdaa336f472f827be07ba6e57bb5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[19, 21]], "char_spans": [[149, 159]]}]}], "context_tokens": [["Common", 0], ["cellular", 7], ["and", 16], ["molecular", 20], ["mechanisms", 30], ["including", 41], ["protein", 51], ["aggregation", 59], ["and", 71], ["inclusion", 75], ["body", 85], ["formation", 90], ["are", 100], ["involved", 104], ["in", 113], ["many", 116], ["neurodegenerative", 121], ["diseases", 139], [".", 147], ["\u03b1", 149], ["-", 150], ["Synuclein", 151], ["is", 161], ["a", 164], ["major", 166], ["component", 172], ["of", 182], ["Lewy", 185], ["bodies", 190], ["in", 197], ["Parkinson", 200], ["'s", 209], ["disease", 212], ["(", 220], ["PD", 221], [")", 223], ["as", 225], ["well", 228], ["as", 233], ["in", 236], ["glial", 239], ["cytoplasmic", 245], ["inclusions", 257], ["in", 268], ["multiple", 271], ["system", 280], ["atrophy", 287], ["(", 295], ["MSA", 296], [")", 299], [".", 300], ["Tau", 302], ["is", 306], ["a", 309], ["principal", 311], ["component", 321], ["of", 331], ["neurofibrillary", 334], ["and", 350], ["glial", 354], ["tangles", 360], ["in", 368], ["tauopathies", 371], [".", 382], ["Recently", 384], [",", 392], ["TDP-43", 394], ["was", 401], ["identified", 405], ["as", 416], ["a", 419], ["component", 421], ["of", 431], ["ubiquitinated", 434], ["inclusions", 448], ["in", 459], ["amyotrophic", 462], ["lateral", 474], ["sclerosis", 482], ["and", 492], ["frontotemporal", 496], ["lobar", 511], ["degeneration", 517], [".", 529], ["PD", 531], ["is", 534], ["traditionally", 537], ["considered", 551], ["a", 562], ["movement", 564], ["disorder", 573], ["with", 582], ["hallmark", 587], ["lesions", 596], ["in", 604], ["the", 607], ["brainstem", 611], ["pigmented", 621], ["nuclei", 631], [".", 637], ["However", 639], [",", 646], ["pathological", 648], ["changes", 661], ["occur", 669], ["in", 675], ["widespread", 678], ["regions", 689], ["of", 697], ["the", 700], ["central", 704], ["and", 712], ["peripheral", 716], ["nervous", 727], ["systems", 735], ["in", 743], ["this", 746], ["disease", 751], [".", 758], ["Furthermore", 760], [",", 771], ["primary", 773], ["glial", 781], ["involvement", 787], ["(", 799], ["\"", 800], ["gliodegeneration", 801], ["\"", 817], [")", 818], ["can", 820], ["be", 824], ["observed", 827], ["in", 836], ["PD", 839], ["and", 842], ["MSA", 846], ["as", 850], ["well", 853], ["as", 858], ["in", 861], ["tauopathy", 864], [".", 873], ["The", 875], ["present", 879], ["article", 887], ["reviews", 895], ["abnormal", 903], ["protein", 912], ["accumulation", 920], ["and", 933], ["inclusion", 937], ["body", 947], ["formation", 952], ["inside", 962], ["and", 969], ["outside", 973], ["the", 981], ["central", 985], ["nervous", 993], ["system", 1001], [".", 1007]]}
{"context": "The Swc4p protein, encoded by an essential gene, is shared by two chromatin-remodeling complexes in Saccharomyces cerevisiae cells: NuA4 (nucleosome acetyltransferase of H4) and SWR1. The SWR1 complex catalyzes ATP-dependent exchange of the nucleosomal histone H2A for H2AZ (Htz1p). The activity of NuA4 is responsible mainly for the acetylation of the H4 histone but also for the acetylation of H2A and H2AZ. In this work we investigated the role of the Swc4p protein. Using random mutagenesis we isolated a collection of swc4 mutants and showed that the essential function of Swc4p resides in its N-terminal part, within the first 269 amino acids of the 476-amino acid-long protein. We also demonstrated that Swc4p is able to accommodate numerous mutations without losing its functionality under standard growth conditions. However, when swc4 mutants were exposed to methyl methanesulfonate (MMS), hydroxyurea or benomyl, severe growth deficiencies appeared, pointing to an involvement of Swc4p in many chromatin-based processes. The mutants' phenotypes did not result from an impairment of histone acetylation, as in the mutant which bears the shortest isolated variant of truncated Swc4p, the level of overall H4 acetylation was unchanged.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "464136c1262c4537a73e251dcc6d6f54", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[31, 31], [34, 34]], "char_spans": [[178, 181], [188, 191]]}]}], "context_tokens": [["The", 0], ["Swc4p", 4], ["protein", 10], [",", 17], ["encoded", 19], ["by", 27], ["an", 30], ["essential", 33], ["gene", 43], [",", 47], ["is", 49], ["shared", 52], ["by", 59], ["two", 62], ["chromatin", 66], ["-", 75], ["remodeling", 76], ["complexes", 87], ["in", 97], ["Saccharomyces", 100], ["cerevisiae", 114], ["cells", 125], [":", 130], ["NuA4", 132], ["(", 137], ["nucleosome", 138], ["acetyltransferase", 149], ["of", 167], ["H4", 170], [")", 172], ["and", 174], ["SWR1", 178], [".", 182], ["The", 184], ["SWR1", 188], ["complex", 193], ["catalyzes", 201], ["ATP", 211], ["-", 214], ["dependent", 215], ["exchange", 225], ["of", 234], ["the", 237], ["nucleosomal", 241], ["histone", 253], ["H2A", 261], ["for", 265], ["H2AZ", 269], ["(", 274], ["Htz1p", 275], [")", 280], [".", 281], ["The", 283], ["activity", 287], ["of", 296], ["NuA4", 299], ["is", 304], ["responsible", 307], ["mainly", 319], ["for", 326], ["the", 330], ["acetylation", 334], ["of", 346], ["the", 349], ["H4", 353], ["histone", 356], ["but", 364], ["also", 368], ["for", 373], ["the", 377], ["acetylation", 381], ["of", 393], ["H2A", 396], ["and", 400], ["H2AZ", 404], [".", 408], ["In", 410], ["this", 413], ["work", 418], ["we", 423], ["investigated", 426], ["the", 439], ["role", 443], ["of", 448], ["the", 451], ["Swc4p", 455], ["protein", 461], [".", 468], ["Using", 470], ["random", 476], ["mutagenesis", 483], ["we", 495], ["isolated", 498], ["a", 507], ["collection", 509], ["of", 520], ["swc4", 523], ["mutants", 528], ["and", 536], ["showed", 540], ["that", 547], ["the", 552], ["essential", 556], ["function", 566], ["of", 575], ["Swc4p", 578], ["resides", 584], ["in", 592], ["its", 595], ["N", 599], ["-", 600], ["terminal", 601], ["part", 610], [",", 614], ["within", 616], ["the", 623], ["first", 627], ["269", 633], ["amino", 637], ["acids", 643], ["of", 649], ["the", 652], ["476-amino", 656], ["acid", 666], ["-", 670], ["long", 671], ["protein", 676], [".", 683], ["We", 685], ["also", 688], ["demonstrated", 693], ["that", 706], ["Swc4p", 711], ["is", 717], ["able", 720], ["to", 725], ["accommodate", 728], ["numerous", 740], ["mutations", 749], ["without", 759], ["losing", 767], ["its", 774], ["functionality", 778], ["under", 792], ["standard", 798], ["growth", 807], ["conditions", 814], [".", 824], ["However", 826], [",", 833], ["when", 835], ["swc4", 840], ["mutants", 845], ["were", 853], ["exposed", 858], ["to", 866], ["methyl", 869], ["methanesulfonate", 876], ["(", 893], ["MMS", 894], [")", 897], [",", 898], ["hydroxyurea", 900], ["or", 912], ["benomyl", 915], [",", 922], ["severe", 924], ["growth", 931], ["deficiencies", 938], ["appeared", 951], [",", 959], ["pointing", 961], ["to", 970], ["an", 973], ["involvement", 976], ["of", 988], ["Swc4p", 991], ["in", 997], ["many", 1000], ["chromatin", 1005], ["-", 1014], ["based", 1015], ["processes", 1021], [".", 1030], ["The", 1032], ["mutants", 1036], ["'", 1043], ["phenotypes", 1045], ["did", 1056], ["not", 1060], ["result", 1064], ["from", 1071], ["an", 1076], ["impairment", 1079], ["of", 1090], ["histone", 1093], ["acetylation", 1101], [",", 1112], ["as", 1114], ["in", 1117], ["the", 1120], ["mutant", 1124], ["which", 1131], ["bears", 1137], ["the", 1143], ["shortest", 1147], ["isolated", 1156], ["variant", 1165], ["of", 1173], ["truncated", 1176], ["Swc4p", 1186], [",", 1191], ["the", 1193], ["level", 1197], ["of", 1203], ["overall", 1206], ["H4", 1214], ["acetylation", 1217], ["was", 1229], ["unchanged", 1233], [".", 1242]]}
{"context": "Bone destruction is a prominent feature of multiple myeloma, but conflicting data exist on the expression and pathophysiologic involvement of the bone remodeling ligand RANKL in this disease and the potential therapeutic benefits of its targeted inhibition. Here, we show that RANKL is expressed by primary multiple myeloma and chronic lymphocytic leukemia (CLL) cells, whereas release of soluble RANKL was observed exclusively with multiple myeloma cells and was strongly influenced by posttranscriptional/posttranslational regulation. Signaling via RANKL into multiple myeloma and CLL cells induced release of cytokines involved in disease pathophysiology. Both the effects of RANKL on osteoclastogenesis and cytokine production by malignant cells could be blocked by disruption of RANK-RANKL interaction with denosumab. As we aimed to combine neutralization of RANKL with induction of antibody-dependent cellular cytotoxicity of natural killer (NK) cells against RANKL-expressing malignant cells and as denosumab does not stimulate NK reactivity, we generated RANK-Fc fusion proteins with modified Fc moieties. The latter displayed similar capacity compared with denosumab to neutralize the effects of RANKL on osteoclastogenesis in vitro, but also potently stimulated NK cell reactivity against primary RANKL-expressing malignant B cells, which was dependent on their engineered affinity to CD16. Our findings introduce Fc-optimized RANK-Ig fusion proteins as attractive tools to neutralize the detrimental function of RANKL while at the same time potently stimulating NK cell antitumor immunity.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "513ee6b7112740b7afa36d176c0f833f", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[64, 64], [133, 133], [189, 189], [150, 150], [44, 44], [84, 84], [25, 25], [121, 121], [204, 204], [104, 104], [241, 241]], "char_spans": [[397, 401], [864, 868], [1205, 1209], [966, 970], [277, 281], [551, 555], [169, 173], [789, 793], [1307, 1311], [679, 683], [1523, 1527]]}]}], "context_tokens": [["Bone", 0], ["destruction", 5], ["is", 17], ["a", 20], ["prominent", 22], ["feature", 32], ["of", 40], ["multiple", 43], ["myeloma", 52], [",", 59], ["but", 61], ["conflicting", 65], ["data", 77], ["exist", 82], ["on", 88], ["the", 91], ["expression", 95], ["and", 106], ["pathophysiologic", 110], ["involvement", 127], ["of", 139], ["the", 142], ["bone", 146], ["remodeling", 151], ["ligand", 162], ["RANKL", 169], ["in", 175], ["this", 178], ["disease", 183], ["and", 191], ["the", 195], ["potential", 199], ["therapeutic", 209], ["benefits", 221], ["of", 230], ["its", 233], ["targeted", 237], ["inhibition", 246], [".", 256], ["Here", 258], [",", 262], ["we", 264], ["show", 267], ["that", 272], ["RANKL", 277], ["is", 283], ["expressed", 286], ["by", 296], ["primary", 299], ["multiple", 307], ["myeloma", 316], ["and", 324], ["chronic", 328], ["lymphocytic", 336], ["leukemia", 348], ["(", 357], ["CLL", 358], [")", 361], ["cells", 363], [",", 368], ["whereas", 370], ["release", 378], ["of", 386], ["soluble", 389], ["RANKL", 397], ["was", 403], ["observed", 407], ["exclusively", 416], ["with", 428], ["multiple", 433], ["myeloma", 442], ["cells", 450], ["and", 456], ["was", 460], ["strongly", 464], ["influenced", 473], ["by", 484], ["posttranscriptional", 487], ["/", 506], ["posttranslational", 507], ["regulation", 525], [".", 535], ["Signaling", 537], ["via", 547], ["RANKL", 551], ["into", 557], ["multiple", 562], ["myeloma", 571], ["and", 579], ["CLL", 583], ["cells", 587], ["induced", 593], ["release", 601], ["of", 609], ["cytokines", 612], ["involved", 622], ["in", 631], ["disease", 634], ["pathophysiology", 642], [".", 657], ["Both", 659], ["the", 664], ["effects", 668], ["of", 676], ["RANKL", 679], ["on", 685], ["osteoclastogenesis", 688], ["and", 707], ["cytokine", 711], ["production", 720], ["by", 731], ["malignant", 734], ["cells", 744], ["could", 750], ["be", 756], ["blocked", 759], ["by", 767], ["disruption", 770], ["of", 781], ["RANK", 784], ["-", 788], ["RANKL", 789], ["interaction", 795], ["with", 807], ["denosumab", 812], [".", 821], ["As", 823], ["we", 826], ["aimed", 829], ["to", 835], ["combine", 838], ["neutralization", 846], ["of", 861], ["RANKL", 864], ["with", 870], ["induction", 875], ["of", 885], ["antibody", 888], ["-", 896], ["dependent", 897], ["cellular", 907], ["cytotoxicity", 916], ["of", 929], ["natural", 932], ["killer", 940], ["(", 947], ["NK", 948], [")", 950], ["cells", 952], ["against", 958], ["RANKL", 966], ["-", 971], ["expressing", 972], ["malignant", 983], ["cells", 993], ["and", 999], ["as", 1003], ["denosumab", 1006], ["does", 1016], ["not", 1021], ["stimulate", 1025], ["NK", 1035], ["reactivity", 1038], [",", 1048], ["we", 1050], ["generated", 1053], ["RANK", 1063], ["-", 1067], ["Fc", 1068], ["fusion", 1071], ["proteins", 1078], ["with", 1087], ["modified", 1092], ["Fc", 1101], ["moieties", 1104], [".", 1112], ["The", 1114], ["latter", 1118], ["displayed", 1125], ["similar", 1135], ["capacity", 1143], ["compared", 1152], ["with", 1161], ["denosumab", 1166], ["to", 1176], ["neutralize", 1179], ["the", 1190], ["effects", 1194], ["of", 1202], ["RANKL", 1205], ["on", 1211], ["osteoclastogenesis", 1214], ["in", 1233], ["vitro", 1236], [",", 1241], ["but", 1243], ["also", 1247], ["potently", 1252], ["stimulated", 1261], ["NK", 1272], ["cell", 1275], ["reactivity", 1280], ["against", 1291], ["primary", 1299], ["RANKL", 1307], ["-", 1312], ["expressing", 1313], ["malignant", 1324], ["B", 1334], ["cells", 1336], [",", 1341], ["which", 1343], ["was", 1349], ["dependent", 1353], ["on", 1363], ["their", 1366], ["engineered", 1372], ["affinity", 1383], ["to", 1392], ["CD16", 1395], [".", 1399], ["Our", 1401], ["findings", 1405], ["introduce", 1414], ["Fc", 1424], ["-", 1426], ["optimized", 1427], ["RANK", 1437], ["-", 1441], ["Ig", 1442], ["fusion", 1445], ["proteins", 1452], ["as", 1461], ["attractive", 1464], ["tools", 1475], ["to", 1481], ["neutralize", 1484], ["the", 1495], ["detrimental", 1499], ["function", 1511], ["of", 1520], ["RANKL", 1523], ["while", 1529], ["at", 1535], ["the", 1538], ["same", 1542], ["time", 1547], ["potently", 1552], ["stimulating", 1561], ["NK", 1573], ["cell", 1576], ["antitumor", 1581], ["immunity", 1591], [".", 1599]]}
{"context": "Clostridium difficile infection (CDI) is the main cause of nosocomial diarrhea in industrialized countries and the source of a growing number of cases of diarrhea in the community. The outbreak of the hypervirulent strain belonging to ribotype 027 has increased the incidence and severity of CDI in some countries. Although CDI usually courses as a mild diarrhea it can lead to severe forms such as toxic megacolon or septic shock. One of every 2 episodes of CDI is not diagnosed in Spanish hospitals due to a lack of clinical suspicion or the use of insensitive diagnostic methods. The diagnostic techniques of choice are algorithms based on the detection of glutamate dehydrogenase and molecular detection of the genes of the toxins with or without the direct detection of the toxins. The recommended treatment for CDI depends on the type of infection and the characteristics of the patient.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "08f0df88d96347d39f79a425ef636d4b", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[39, 40]], "char_spans": [[235, 246]]}]}], "context_tokens": [["Clostridium", 0], ["difficile", 12], ["infection", 22], ["(", 32], ["CDI", 33], [")", 36], ["is", 38], ["the", 41], ["main", 45], ["cause", 50], ["of", 56], ["nosocomial", 59], ["diarrhea", 70], ["in", 79], ["industrialized", 82], ["countries", 97], ["and", 107], ["the", 111], ["source", 115], ["of", 122], ["a", 125], ["growing", 127], ["number", 135], ["of", 142], ["cases", 145], ["of", 151], ["diarrhea", 154], ["in", 163], ["the", 166], ["community", 170], [".", 179], ["The", 181], ["outbreak", 185], ["of", 194], ["the", 197], ["hypervirulent", 201], ["strain", 215], ["belonging", 222], ["to", 232], ["ribotype", 235], ["027", 244], ["has", 248], ["increased", 252], ["the", 262], ["incidence", 266], ["and", 276], ["severity", 280], ["of", 289], ["CDI", 292], ["in", 296], ["some", 299], ["countries", 304], [".", 313], ["Although", 315], ["CDI", 324], ["usually", 328], ["courses", 336], ["as", 344], ["a", 347], ["mild", 349], ["diarrhea", 354], ["it", 363], ["can", 366], ["lead", 370], ["to", 375], ["severe", 378], ["forms", 385], ["such", 391], ["as", 396], ["toxic", 399], ["megacolon", 405], ["or", 415], ["septic", 418], ["shock", 425], [".", 430], ["One", 432], ["of", 436], ["every", 439], ["2", 445], ["episodes", 447], ["of", 456], ["CDI", 459], ["is", 463], ["not", 466], ["diagnosed", 470], ["in", 480], ["Spanish", 483], ["hospitals", 491], ["due", 501], ["to", 505], ["a", 508], ["lack", 510], ["of", 515], ["clinical", 518], ["suspicion", 527], ["or", 537], ["the", 540], ["use", 544], ["of", 548], ["insensitive", 551], ["diagnostic", 563], ["methods", 574], [".", 581], ["The", 583], ["diagnostic", 587], ["techniques", 598], ["of", 609], ["choice", 612], ["are", 619], ["algorithms", 623], ["based", 634], ["on", 640], ["the", 643], ["detection", 647], ["of", 657], ["glutamate", 660], ["dehydrogenase", 670], ["and", 684], ["molecular", 688], ["detection", 698], ["of", 708], ["the", 711], ["genes", 715], ["of", 721], ["the", 724], ["toxins", 728], ["with", 735], ["or", 740], ["without", 743], ["the", 751], ["direct", 755], ["detection", 762], ["of", 772], ["the", 775], ["toxins", 779], [".", 785], ["The", 787], ["recommended", 791], ["treatment", 803], ["for", 813], ["CDI", 817], ["depends", 821], ["on", 829], ["the", 832], ["type", 836], ["of", 841], ["infection", 844], ["and", 854], ["the", 858], ["characteristics", 862], ["of", 878], ["the", 881], ["patient", 885], [".", 892]]}
{"context": "Peroxiredoxin-2 (PRDX-2) is an antioxidant and chaperone-like protein critical for cell function. This study examined whether the levels of lymphocyte PRDX-2 are altered over 1 month following ultra-endurance exercise. Nine middle-aged men undertook a single-stage, multi-day 233 km (145 mile) ultra-endurance running race. Blood was collected immediately before (Pre), upon completion/retirement (Post), and following the race at Day 1, Day 7 and Day 28. Lymphocyte lysates were examined for PRDX-2 by reducing and non-reducing SDS-PAGE with western blotting. In a sub-group of men who completed the race (n = 4), PRDX-2 oligomeric state (indicative of redox status) was investigated. Ultra-endurance exercise caused significant changes in lymphocyte PRDX-2 (F(4,32) 3.409, p = 0.020, \u03b7(2) = 0.299): 7 days after the race, PRDX-2 levels in lymphocytes had fallen to 30% of pre-race values (p = 0.013) and returned to near-normal levels at Day 28. Non-reducing gels demonstrated that dimeric PRDX-2 (intracellular reduced PRDX-2 monomers) was increased in three of four race completers immediately post-race, indicative of an 'antioxidant response'. Moreover, monomeric PRDX-2 was also increased immediately post-race in two of four race-completing subjects, indicative of oxidative damage, which was not detectable by Day 7. Lymphocyte PRDX-2 was decreased below normal levels 7 days after ultra-endurance exercise. Excessive accumulation of reactive oxygen species induced by ultra-endurance exercise may underlie depletion of lymphocyte PRDX-2 by triggering its turnover after oxidation. Low levels of lymphocyte PRDX-2 could influence cell function and might, in part, explain reports of dysregulated immunity following ultra-endurance exercise.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "5972815d8210470eb84c3da30f0aa090", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[234, 234], [6, 6]], "char_spans": [[1127, 1137], [31, 41]]}]}], "context_tokens": [["Peroxiredoxin-2", 0], ["(", 16], ["PRDX-2", 17], [")", 23], ["is", 25], ["an", 28], ["antioxidant", 31], ["and", 43], ["chaperone", 47], ["-", 56], ["like", 57], ["protein", 62], ["critical", 70], ["for", 79], ["cell", 83], ["function", 88], [".", 96], ["This", 98], ["study", 103], ["examined", 109], ["whether", 118], ["the", 126], ["levels", 130], ["of", 137], ["lymphocyte", 140], ["PRDX-2", 151], ["are", 158], ["altered", 162], ["over", 170], ["1", 175], ["month", 177], ["following", 183], ["ultra", 193], ["-", 198], ["endurance", 199], ["exercise", 209], [".", 217], ["Nine", 219], ["middle", 224], ["-", 230], ["aged", 231], ["men", 236], ["undertook", 240], ["a", 250], ["single", 252], ["-", 258], ["stage", 259], [",", 264], ["multi", 266], ["-", 271], ["day", 272], ["233", 276], ["km", 280], ["(", 283], ["145", 284], ["mile", 288], [")", 292], ["ultra", 294], ["-", 299], ["endurance", 300], ["running", 310], ["race", 318], [".", 322], ["Blood", 324], ["was", 330], ["collected", 334], ["immediately", 344], ["before", 356], ["(", 363], ["Pre", 364], [")", 367], [",", 368], ["upon", 370], ["completion", 375], ["/", 385], ["retirement", 386], ["(", 397], ["Post", 398], [")", 402], [",", 403], ["and", 405], ["following", 409], ["the", 419], ["race", 423], ["at", 428], ["Day", 431], ["1", 435], [",", 436], ["Day", 438], ["7", 442], ["and", 444], ["Day", 448], ["28", 452], [".", 454], ["Lymphocyte", 456], ["lysates", 467], ["were", 475], ["examined", 480], ["for", 489], ["PRDX-2", 493], ["by", 500], ["reducing", 503], ["and", 512], ["non", 516], ["-", 519], ["reducing", 520], ["SDS", 529], ["-", 532], ["PAGE", 533], ["with", 538], ["western", 543], ["blotting", 551], [".", 559], ["In", 561], ["a", 564], ["sub", 566], ["-", 569], ["group", 570], ["of", 576], ["men", 579], ["who", 583], ["completed", 587], ["the", 597], ["race", 601], ["(", 606], ["n", 607], ["=", 609], ["4", 611], [")", 612], [",", 613], ["PRDX-2", 615], ["oligomeric", 622], ["state", 633], ["(", 639], ["indicative", 640], ["of", 651], ["redox", 654], ["status", 660], [")", 666], ["was", 668], ["investigated", 672], [".", 684], ["Ultra", 686], ["-", 691], ["endurance", 692], ["exercise", 702], ["caused", 711], ["significant", 718], ["changes", 730], ["in", 738], ["lymphocyte", 741], ["PRDX-2", 752], ["(", 759], ["F(4,32", 760], [")", 766], ["3.409", 768], [",", 773], ["p", 775], ["=", 777], ["0.020", 779], [",", 784], ["\u03b7(2", 786], [")", 789], ["=", 791], ["0.299", 793], [")", 798], [":", 799], ["7", 801], ["days", 803], ["after", 808], ["the", 814], ["race", 818], [",", 822], ["PRDX-2", 824], ["levels", 831], ["in", 838], ["lymphocytes", 841], ["had", 853], ["fallen", 857], ["to", 864], ["30", 867], ["%", 869], ["of", 871], ["pre", 874], ["-", 877], ["race", 878], ["values", 883], ["(", 890], ["p", 891], ["=", 893], ["0.013", 895], [")", 900], ["and", 902], ["returned", 906], ["to", 915], ["near", 918], ["-", 922], ["normal", 923], ["levels", 930], ["at", 937], ["Day", 940], ["28", 944], [".", 946], ["Non", 948], ["-", 951], ["reducing", 952], ["gels", 961], ["demonstrated", 966], ["that", 979], ["dimeric", 984], ["PRDX-2", 992], ["(", 999], ["intracellular", 1000], ["reduced", 1014], ["PRDX-2", 1022], ["monomers", 1029], [")", 1037], ["was", 1039], ["increased", 1043], ["in", 1053], ["three", 1056], ["of", 1062], ["four", 1065], ["race", 1070], ["completers", 1075], ["immediately", 1086], ["post", 1098], ["-", 1102], ["race", 1103], [",", 1107], ["indicative", 1109], ["of", 1120], ["an", 1123], ["'", 1126], ["antioxidant", 1127], ["response", 1139], ["'", 1147], [".", 1148], ["Moreover", 1150], [",", 1158], ["monomeric", 1160], ["PRDX-2", 1170], ["was", 1177], ["also", 1181], ["increased", 1186], ["immediately", 1196], ["post", 1208], ["-", 1212], ["race", 1213], ["in", 1218], ["two", 1221], ["of", 1225], ["four", 1228], ["race", 1233], ["-", 1237], ["completing", 1238], ["subjects", 1249], [",", 1257], ["indicative", 1259], ["of", 1270], ["oxidative", 1273], ["damage", 1283], [",", 1289], ["which", 1291], ["was", 1297], ["not", 1301], ["detectable", 1305], ["by", 1316], ["Day", 1319], ["7", 1323], [".", 1324], ["Lymphocyte", 1326], ["PRDX-2", 1337], ["was", 1344], ["decreased", 1348], ["below", 1358], ["normal", 1364], ["levels", 1371], ["7", 1378], ["days", 1380], ["after", 1385], ["ultra", 1391], ["-", 1396], ["endurance", 1397], ["exercise", 1407], [".", 1415], ["Excessive", 1417], ["accumulation", 1427], ["of", 1440], ["reactive", 1443], ["oxygen", 1452], ["species", 1459], ["induced", 1467], ["by", 1475], ["ultra", 1478], ["-", 1483], ["endurance", 1484], ["exercise", 1494], ["may", 1503], ["underlie", 1507], ["depletion", 1516], ["of", 1526], ["lymphocyte", 1529], ["PRDX-2", 1540], ["by", 1547], ["triggering", 1550], ["its", 1561], ["turnover", 1565], ["after", 1574], ["oxidation", 1580], [".", 1589], ["Low", 1591], ["levels", 1595], ["of", 1602], ["lymphocyte", 1605], ["PRDX-2", 1616], ["could", 1623], ["influence", 1629], ["cell", 1639], ["function", 1644], ["and", 1653], ["might", 1657], [",", 1662], ["in", 1664], ["part", 1667], [",", 1671], ["explain", 1673], ["reports", 1681], ["of", 1689], ["dysregulated", 1692], ["immunity", 1705], ["following", 1714], ["ultra", 1724], ["-", 1729], ["endurance", 1730], ["exercise", 1740], [".", 1748]]}
{"context": "Variant histone H2AZ-containing nucleosomes are involved in the regulation of gene expression. In Saccharomyces cerevisiae, chromatin deposition of histone H2AZ is mediated by the fourteen-subunit SWR1 complex, which catalyzes ATP-dependent exchange of nucleosomal histone H2A for H2AZ. Previous work defined the role of seven SWR1 subunits (Swr1 ATPase, Swc2, Swc3, Arp6, Swc5, Yaf9, and Swc6) in maintaining complex integrity and H2AZ histone replacement activity. Here we examined the function of three additional SWR1 subunits, bromodomain containing Bdf1, actin-related protein Arp4 and Swc7, by analyzing affinity-purified mutant SWR1 complexes. We observed that depletion of Arp4 (arp4-td) substantially impaired the association of Bdf1, Yaf9, and Swc4. In contrast, loss of either Bdf1 or Swc7 had minimal effects on overall complex integrity. Furthermore, the basic H2AZ histone replacement activity of SWR1 in vitro required Arp4, but not Bdf1 or Swc7. Thus, three out of fourteen SWR1 subunits, Bdf1, Swc7, and previously noted Swc3, appear to have roles auxiliary to the basic histone replacement activity. The N-terminal region of the Swr1 ATPase subunit is necessary and sufficient to direct association of Bdf1 and Swc7, as well as Arp4, Act1, Yaf9 and Swc4. This same region contains an additional H2AZ-H2B specific binding site, distinct from the previously identified Swc2 subunit. These findings suggest that one SWR1 enzyme might be capable of binding two H2AZ-H2B dimers, and provide further insight on the hierarchy and interdependency of molecular interactions within the SWR1 complex.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "76475db3f85f4bccba0b5febb2054087", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[112, 112], [91, 91], [211, 211], [54, 54], [180, 180], [57, 57], [263, 263], [290, 290], [162, 162], [31, 31]], "char_spans": [[636, 639], [517, 520], [1148, 1151], [327, 330], [991, 994], [342, 345], [1432, 1435], [1595, 1598], [912, 915], [197, 200]]}]}], "context_tokens": [["Variant", 0], ["histone", 8], ["H2AZ", 16], ["-", 20], ["containing", 21], ["nucleosomes", 32], ["are", 44], ["involved", 48], ["in", 57], ["the", 60], ["regulation", 64], ["of", 75], ["gene", 78], ["expression", 83], [".", 93], ["In", 95], ["Saccharomyces", 98], ["cerevisiae", 112], [",", 122], ["chromatin", 124], ["deposition", 134], ["of", 145], ["histone", 148], ["H2AZ", 156], ["is", 161], ["mediated", 164], ["by", 173], ["the", 176], ["fourteen", 180], ["-", 188], ["subunit", 189], ["SWR1", 197], ["complex", 202], [",", 209], ["which", 211], ["catalyzes", 217], ["ATP", 227], ["-", 230], ["dependent", 231], ["exchange", 241], ["of", 250], ["nucleosomal", 253], ["histone", 265], ["H2A", 273], ["for", 277], ["H2AZ", 281], [".", 285], ["Previous", 287], ["work", 296], ["defined", 301], ["the", 309], ["role", 313], ["of", 318], ["seven", 321], ["SWR1", 327], ["subunits", 332], ["(", 341], ["Swr1", 342], ["ATPase", 347], [",", 353], ["Swc2", 355], [",", 359], ["Swc3", 361], [",", 365], ["Arp6", 367], [",", 371], ["Swc5", 373], [",", 377], ["Yaf9", 379], [",", 383], ["and", 385], ["Swc6", 389], [")", 393], ["in", 395], ["maintaining", 398], ["complex", 410], ["integrity", 418], ["and", 428], ["H2AZ", 432], ["histone", 437], ["replacement", 445], ["activity", 457], [".", 465], ["Here", 467], ["we", 472], ["examined", 475], ["the", 484], ["function", 488], ["of", 497], ["three", 500], ["additional", 506], ["SWR1", 517], ["subunits", 522], [",", 530], ["bromodomain", 532], ["containing", 544], ["Bdf1", 555], [",", 559], ["actin", 561], ["-", 566], ["related", 567], ["protein", 575], ["Arp4", 583], ["and", 588], ["Swc7", 592], [",", 596], ["by", 598], ["analyzing", 601], ["affinity", 611], ["-", 619], ["purified", 620], ["mutant", 629], ["SWR1", 636], ["complexes", 641], [".", 650], ["We", 652], ["observed", 655], ["that", 664], ["depletion", 669], ["of", 679], ["Arp4", 682], ["(", 687], ["arp4-td", 688], [")", 695], ["substantially", 697], ["impaired", 711], ["the", 720], ["association", 724], ["of", 736], ["Bdf1", 739], [",", 743], ["Yaf9", 745], [",", 749], ["and", 751], ["Swc4", 755], [".", 759], ["In", 761], ["contrast", 764], [",", 772], ["loss", 774], ["of", 779], ["either", 782], ["Bdf1", 789], ["or", 794], ["Swc7", 797], ["had", 802], ["minimal", 806], ["effects", 814], ["on", 822], ["overall", 825], ["complex", 833], ["integrity", 841], [".", 850], ["Furthermore", 852], [",", 863], ["the", 865], ["basic", 869], ["H2AZ", 875], ["histone", 880], ["replacement", 888], ["activity", 900], ["of", 909], ["SWR1", 912], ["in", 917], ["vitro", 920], ["required", 926], ["Arp4", 935], [",", 939], ["but", 941], ["not", 945], ["Bdf1", 949], ["or", 954], ["Swc7", 957], [".", 961], ["Thus", 963], [",", 967], ["three", 969], ["out", 975], ["of", 979], ["fourteen", 982], ["SWR1", 991], ["subunits", 996], [",", 1004], ["Bdf1", 1006], [",", 1010], ["Swc7", 1012], [",", 1016], ["and", 1018], ["previously", 1022], ["noted", 1033], ["Swc3", 1039], [",", 1043], ["appear", 1045], ["to", 1052], ["have", 1055], ["roles", 1060], ["auxiliary", 1066], ["to", 1076], ["the", 1079], ["basic", 1083], ["histone", 1089], ["replacement", 1097], ["activity", 1109], [".", 1117], ["The", 1119], ["N", 1123], ["-", 1124], ["terminal", 1125], ["region", 1134], ["of", 1141], ["the", 1144], ["Swr1", 1148], ["ATPase", 1153], ["subunit", 1160], ["is", 1168], ["necessary", 1171], ["and", 1181], ["sufficient", 1185], ["to", 1196], ["direct", 1199], ["association", 1206], ["of", 1218], ["Bdf1", 1221], ["and", 1226], ["Swc7", 1230], [",", 1234], ["as", 1236], ["well", 1239], ["as", 1244], ["Arp4", 1247], [",", 1251], ["Act1", 1253], [",", 1257], ["Yaf9", 1259], ["and", 1264], ["Swc4", 1268], [".", 1272], ["This", 1274], ["same", 1279], ["region", 1284], ["contains", 1291], ["an", 1300], ["additional", 1303], ["H2AZ", 1314], ["-", 1318], ["H2B", 1319], ["specific", 1323], ["binding", 1332], ["site", 1340], [",", 1344], ["distinct", 1346], ["from", 1355], ["the", 1360], ["previously", 1364], ["identified", 1375], ["Swc2", 1386], ["subunit", 1391], [".", 1398], ["These", 1400], ["findings", 1406], ["suggest", 1415], ["that", 1423], ["one", 1428], ["SWR1", 1432], ["enzyme", 1437], ["might", 1444], ["be", 1450], ["capable", 1453], ["of", 1461], ["binding", 1464], ["two", 1472], ["H2AZ", 1476], ["-", 1480], ["H2B", 1481], ["dimers", 1485], [",", 1491], ["and", 1493], ["provide", 1497], ["further", 1505], ["insight", 1513], ["on", 1521], ["the", 1524], ["hierarchy", 1528], ["and", 1538], ["interdependency", 1542], ["of", 1558], ["molecular", 1561], ["interactions", 1571], ["within", 1584], ["the", 1591], ["SWR1", 1595], ["complex", 1600], [".", 1607]]}
{"context": "Polycystic kidney disease (PKD) includes a group of disorders that are characterized by the presence of cysts in the kidney and other organs, including the pancreas. Here we show that in orpk mice, a model system for PKD that harbors a mutation in the gene that encodes the polaris protein, pancreatic defects start to occur at the end of gestation, with an initial expansion of the developing pancreatic ducts. Ductal dilation continues rapidly after birth and results in the formation of large, interconnected cysts. Expansion of pancreatic ducts is accompanied by apoptosis of neighboring acinar cells, whereas endocrine cell differentiation and islet formation appears to be unaffected. Polaris has been shown to co-localize with primary cilia, and these structures have been implicated in the formation of renal cysts. In the orpk pancreas, cilia numbers are reduced and cilia length is decreased. Expression of polycystin-2, a protein involved in PKD, is mislocalized in orpk mice. Furthermore, the cellular localization of beta-catenin, a protein involved in cell adhesion and Wnt signaling, is altered. Thus, polaris and primary cilia function are required for the maturation and maintenance of proper tissue organization in the pancreas.", "qas": [{"question": "Which is the most common disease attributed to malfunction or absence of primary cilia?", "answers": ["Polycystic kidney disease (PKD)"], "qid": "88255af0d4234ad09cdee7305967cf18", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["disease", 25], ["attributed", 33], ["to", 44], ["malfunction", 47], ["or", 59], ["absence", 62], ["of", 70], ["primary", 73], ["cilia", 81], ["?", 86]], "detected_answers": [{"text": "Polycystic kidney disease (PKD)", "token_spans": [[0, 4]], "char_spans": [[0, 29]]}]}], "context_tokens": [["Polycystic", 0], ["kidney", 11], ["disease", 18], ["(", 26], ["PKD", 27], [")", 30], ["includes", 32], ["a", 41], ["group", 43], ["of", 49], ["disorders", 52], ["that", 62], ["are", 67], ["characterized", 71], ["by", 85], ["the", 88], ["presence", 92], ["of", 101], ["cysts", 104], ["in", 110], ["the", 113], ["kidney", 117], ["and", 124], ["other", 128], ["organs", 134], [",", 140], ["including", 142], ["the", 152], ["pancreas", 156], [".", 164], ["Here", 166], ["we", 171], ["show", 174], ["that", 179], ["in", 184], ["orpk", 187], ["mice", 192], [",", 196], ["a", 198], ["model", 200], ["system", 206], ["for", 213], ["PKD", 217], ["that", 221], ["harbors", 226], ["a", 234], ["mutation", 236], ["in", 245], ["the", 248], ["gene", 252], ["that", 257], ["encodes", 262], ["the", 270], ["polaris", 274], ["protein", 282], [",", 289], ["pancreatic", 291], ["defects", 302], ["start", 310], ["to", 316], ["occur", 319], ["at", 325], ["the", 328], ["end", 332], ["of", 336], ["gestation", 339], [",", 348], ["with", 350], ["an", 355], ["initial", 358], ["expansion", 366], ["of", 376], ["the", 379], ["developing", 383], ["pancreatic", 394], ["ducts", 405], [".", 410], ["Ductal", 412], ["dilation", 419], ["continues", 428], ["rapidly", 438], ["after", 446], ["birth", 452], ["and", 458], ["results", 462], ["in", 470], ["the", 473], ["formation", 477], ["of", 487], ["large", 490], [",", 495], ["interconnected", 497], ["cysts", 512], [".", 517], ["Expansion", 519], ["of", 529], ["pancreatic", 532], ["ducts", 543], ["is", 549], ["accompanied", 552], ["by", 564], ["apoptosis", 567], ["of", 577], ["neighboring", 580], ["acinar", 592], ["cells", 599], [",", 604], ["whereas", 606], ["endocrine", 614], ["cell", 624], ["differentiation", 629], ["and", 645], ["islet", 649], ["formation", 655], ["appears", 665], ["to", 673], ["be", 676], ["unaffected", 679], [".", 689], ["Polaris", 691], ["has", 699], ["been", 703], ["shown", 708], ["to", 714], ["co", 717], ["-", 719], ["localize", 720], ["with", 729], ["primary", 734], ["cilia", 742], [",", 747], ["and", 749], ["these", 753], ["structures", 759], ["have", 770], ["been", 775], ["implicated", 780], ["in", 791], ["the", 794], ["formation", 798], ["of", 808], ["renal", 811], ["cysts", 817], [".", 822], ["In", 824], ["the", 827], ["orpk", 831], ["pancreas", 836], [",", 844], ["cilia", 846], ["numbers", 852], ["are", 860], ["reduced", 864], ["and", 872], ["cilia", 876], ["length", 882], ["is", 889], ["decreased", 892], [".", 901], ["Expression", 903], ["of", 914], ["polycystin-2", 917], [",", 929], ["a", 931], ["protein", 933], ["involved", 941], ["in", 950], ["PKD", 953], [",", 956], ["is", 958], ["mislocalized", 961], ["in", 974], ["orpk", 977], ["mice", 982], [".", 986], ["Furthermore", 988], [",", 999], ["the", 1001], ["cellular", 1005], ["localization", 1014], ["of", 1027], ["beta", 1030], ["-", 1034], ["catenin", 1035], [",", 1042], ["a", 1044], ["protein", 1046], ["involved", 1054], ["in", 1063], ["cell", 1066], ["adhesion", 1071], ["and", 1080], ["Wnt", 1084], ["signaling", 1088], [",", 1097], ["is", 1099], ["altered", 1102], [".", 1109], ["Thus", 1111], [",", 1115], ["polaris", 1117], ["and", 1125], ["primary", 1129], ["cilia", 1137], ["function", 1143], ["are", 1152], ["required", 1156], ["for", 1165], ["the", 1169], ["maturation", 1173], ["and", 1184], ["maintenance", 1188], ["of", 1200], ["proper", 1203], ["tissue", 1210], ["organization", 1217], ["in", 1230], ["the", 1233], ["pancreas", 1237], [".", 1245]]}
{"context": "The antiparallel side-to-side association of spectrin alpha and beta monomers is a two-step process which occurs in seconds even at 0 degrees C and at low concentrations. Assembly involves initial contact of complementary nucleation sites on each subunit, which are located near the actin binding end of the long, flexible heterodimer rod. The minimum nucleation sites are comprised of approximately four contiguous 106-residue homologous segments or repeats. Three repeats in the nucleation site contain an 8-residue insertion and have the highest homology to the four spectrin-like repeats in alpha-actinin. The adjacent actin binding domain on the beta subunit and the adjacent EF hand motifs on the alpha subunit are not required for heterodimer assembly. The nucleation sites probably have a specific lock and key structure which defines the unique side-to-side pairing of the many homologous segments in both subunits. Assembly of spectrin heterodimers is probably most analogous to a zipper. After initial nucleation site binding, the remainder of the subunits quickly associate along their full lengths to reconstitute a normal dimer by supercoiling around each other to form a rope-like, flexible rod. Assembly is terminated if either polypeptide is interrupted by a protease cleavage. Heterozygotic mutations involving either nucleation site are predicted to affect allele incorporation into the mature membrane skeleton.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "6f535f0663104aabbe0325e73769505f", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[1, 1]], "char_spans": [[4, 15]]}]}], "context_tokens": [["The", 0], ["antiparallel", 4], ["side", 17], ["-", 21], ["to", 22], ["-", 24], ["side", 25], ["association", 30], ["of", 42], ["spectrin", 45], ["alpha", 54], ["and", 60], ["beta", 64], ["monomers", 69], ["is", 78], ["a", 81], ["two", 83], ["-", 86], ["step", 87], ["process", 92], ["which", 100], ["occurs", 106], ["in", 113], ["seconds", 116], ["even", 124], ["at", 129], ["0", 132], ["degrees", 134], ["C", 142], ["and", 144], ["at", 148], ["low", 151], ["concentrations", 155], [".", 169], ["Assembly", 171], ["involves", 180], ["initial", 189], ["contact", 197], ["of", 205], ["complementary", 208], ["nucleation", 222], ["sites", 233], ["on", 239], ["each", 242], ["subunit", 247], [",", 254], ["which", 256], ["are", 262], ["located", 266], ["near", 274], ["the", 279], ["actin", 283], ["binding", 289], ["end", 297], ["of", 301], ["the", 304], ["long", 308], [",", 312], ["flexible", 314], ["heterodimer", 323], ["rod", 335], [".", 338], ["The", 340], ["minimum", 344], ["nucleation", 352], ["sites", 363], ["are", 369], ["comprised", 373], ["of", 383], ["approximately", 386], ["four", 400], ["contiguous", 405], ["106-residue", 416], ["homologous", 428], ["segments", 439], ["or", 448], ["repeats", 451], [".", 458], ["Three", 460], ["repeats", 466], ["in", 474], ["the", 477], ["nucleation", 481], ["site", 492], ["contain", 497], ["an", 505], ["8-residue", 508], ["insertion", 518], ["and", 528], ["have", 532], ["the", 537], ["highest", 541], ["homology", 549], ["to", 558], ["the", 561], ["four", 565], ["spectrin", 570], ["-", 578], ["like", 579], ["repeats", 584], ["in", 592], ["alpha", 595], ["-", 600], ["actinin", 601], [".", 608], ["The", 610], ["adjacent", 614], ["actin", 623], ["binding", 629], ["domain", 637], ["on", 644], ["the", 647], ["beta", 651], ["subunit", 656], ["and", 664], ["the", 668], ["adjacent", 672], ["EF", 681], ["hand", 684], ["motifs", 689], ["on", 696], ["the", 699], ["alpha", 703], ["subunit", 709], ["are", 717], ["not", 721], ["required", 725], ["for", 734], ["heterodimer", 738], ["assembly", 750], [".", 758], ["The", 760], ["nucleation", 764], ["sites", 775], ["probably", 781], ["have", 790], ["a", 795], ["specific", 797], ["lock", 806], ["and", 811], ["key", 815], ["structure", 819], ["which", 829], ["defines", 835], ["the", 843], ["unique", 847], ["side", 854], ["-", 858], ["to", 859], ["-", 861], ["side", 862], ["pairing", 867], ["of", 875], ["the", 878], ["many", 882], ["homologous", 887], ["segments", 898], ["in", 907], ["both", 910], ["subunits", 915], [".", 923], ["Assembly", 925], ["of", 934], ["spectrin", 937], ["heterodimers", 946], ["is", 959], ["probably", 962], ["most", 971], ["analogous", 976], ["to", 986], ["a", 989], ["zipper", 991], [".", 997], ["After", 999], ["initial", 1005], ["nucleation", 1013], ["site", 1024], ["binding", 1029], [",", 1036], ["the", 1038], ["remainder", 1042], ["of", 1052], ["the", 1055], ["subunits", 1059], ["quickly", 1068], ["associate", 1076], ["along", 1086], ["their", 1092], ["full", 1098], ["lengths", 1103], ["to", 1111], ["reconstitute", 1114], ["a", 1127], ["normal", 1129], ["dimer", 1136], ["by", 1142], ["supercoiling", 1145], ["around", 1158], ["each", 1165], ["other", 1170], ["to", 1176], ["form", 1179], ["a", 1184], ["rope", 1186], ["-", 1190], ["like", 1191], [",", 1195], ["flexible", 1197], ["rod", 1206], [".", 1209], ["Assembly", 1211], ["is", 1220], ["terminated", 1223], ["if", 1234], ["either", 1237], ["polypeptide", 1244], ["is", 1256], ["interrupted", 1259], ["by", 1271], ["a", 1274], ["protease", 1276], ["cleavage", 1285], [".", 1293], ["Heterozygotic", 1295], ["mutations", 1309], ["involving", 1319], ["either", 1329], ["nucleation", 1336], ["site", 1347], ["are", 1352], ["predicted", 1356], ["to", 1366], ["affect", 1369], ["allele", 1376], ["incorporation", 1383], ["into", 1397], ["the", 1402], ["mature", 1406], ["membrane", 1413], ["skeleton", 1422], [".", 1430]]}
{"context": "Lamp2a acts as a receptor in the lysosomal membrane for substrate proteins of chaperone-mediated autophagy. Using antibodies specific for the cytosolic tail of lamp2a and others recognizing all lamp2 isoforms, we found that in rat liver lamp2a represents 25% of lamp2s in the lysosome. We show that lamp2a levels in the lysosomal membrane in rat liver and fibroblasts in culture directly correlate with rates of chaperone-mediated autophagy in a variety of physiological and pathological conditions. The concentration of other lamp2s in the lysosomal membrane show no correlation under the same conditions. Furthermore, substrate proteins bind to lamp2a but not to other lamp2s. Four positively-charged amino acids uniquely present in the cytosolic tail of lamp2a are required for the binding of substrate proteins. Lamp2a also distributes to an unique subpopulation of perinuclear lysosomes in cultured fibroblasts in response to serum withdrawal, and lamp2a, more than other lamp2s, tends to multimerize. These characteristics may be important for lamp2a to act as a receptor for chaperone-mediated autophagy.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "4688b81a249a4edd87b46d5ce300cfcf", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[0, 0], [107, 107], [53, 53], [26, 26], [157, 157], [137, 137], [40, 40], [174, 174], [127, 127]], "char_spans": [[0, 5], [647, 652], [299, 304], [160, 165], [953, 958], [816, 821], [237, 242], [1050, 1055], [757, 762]]}]}], "context_tokens": [["Lamp2a", 0], ["acts", 7], ["as", 12], ["a", 15], ["receptor", 17], ["in", 26], ["the", 29], ["lysosomal", 33], ["membrane", 43], ["for", 52], ["substrate", 56], ["proteins", 66], ["of", 75], ["chaperone", 78], ["-", 87], ["mediated", 88], ["autophagy", 97], [".", 106], ["Using", 108], ["antibodies", 114], ["specific", 125], ["for", 134], ["the", 138], ["cytosolic", 142], ["tail", 152], ["of", 157], ["lamp2a", 160], ["and", 167], ["others", 171], ["recognizing", 178], ["all", 190], ["lamp2", 194], ["isoforms", 200], [",", 208], ["we", 210], ["found", 213], ["that", 219], ["in", 224], ["rat", 227], ["liver", 231], ["lamp2a", 237], ["represents", 244], ["25", 255], ["%", 257], ["of", 259], ["lamp2s", 262], ["in", 269], ["the", 272], ["lysosome", 276], [".", 284], ["We", 286], ["show", 289], ["that", 294], ["lamp2a", 299], ["levels", 306], ["in", 313], ["the", 316], ["lysosomal", 320], ["membrane", 330], ["in", 339], ["rat", 342], ["liver", 346], ["and", 352], ["fibroblasts", 356], ["in", 368], ["culture", 371], ["directly", 379], ["correlate", 388], ["with", 398], ["rates", 403], ["of", 409], ["chaperone", 412], ["-", 421], ["mediated", 422], ["autophagy", 431], ["in", 441], ["a", 444], ["variety", 446], ["of", 454], ["physiological", 457], ["and", 471], ["pathological", 475], ["conditions", 488], [".", 498], ["The", 500], ["concentration", 504], ["of", 518], ["other", 521], ["lamp2s", 527], ["in", 534], ["the", 537], ["lysosomal", 541], ["membrane", 551], ["show", 560], ["no", 565], ["correlation", 568], ["under", 580], ["the", 586], ["same", 590], ["conditions", 595], [".", 605], ["Furthermore", 607], [",", 618], ["substrate", 620], ["proteins", 630], ["bind", 639], ["to", 644], ["lamp2a", 647], ["but", 654], ["not", 658], ["to", 662], ["other", 665], ["lamp2s", 671], [".", 677], ["Four", 679], ["positively", 684], ["-", 694], ["charged", 695], ["amino", 703], ["acids", 709], ["uniquely", 715], ["present", 724], ["in", 732], ["the", 735], ["cytosolic", 739], ["tail", 749], ["of", 754], ["lamp2a", 757], ["are", 764], ["required", 768], ["for", 777], ["the", 781], ["binding", 785], ["of", 793], ["substrate", 796], ["proteins", 806], [".", 814], ["Lamp2a", 816], ["also", 823], ["distributes", 828], ["to", 840], ["an", 843], ["unique", 846], ["subpopulation", 853], ["of", 867], ["perinuclear", 870], ["lysosomes", 882], ["in", 892], ["cultured", 895], ["fibroblasts", 904], ["in", 916], ["response", 919], ["to", 928], ["serum", 931], ["withdrawal", 937], [",", 947], ["and", 949], ["lamp2a", 953], [",", 959], ["more", 961], ["than", 966], ["other", 971], ["lamp2s", 977], [",", 983], ["tends", 985], ["to", 991], ["multimerize", 994], [".", 1005], ["These", 1007], ["characteristics", 1013], ["may", 1029], ["be", 1033], ["important", 1036], ["for", 1046], ["lamp2a", 1050], ["to", 1057], ["act", 1060], ["as", 1064], ["a", 1067], ["receptor", 1069], ["for", 1078], ["chaperone", 1082], ["-", 1091], ["mediated", 1092], ["autophagy", 1101], [".", 1110]]}
{"context": "Selenoproteins contain the 21st amino acid selenocysteine which is encoded by an inframe UGA codon, usually read as a stop. In eukaryotes, its co-translational recoding requires the presence of an RNA stem-loop structure, the SECIS element in the 3 untranslated region of (UTR) selenoprotein mRNAs. Despite little sequence conservation, SECIS elements share the same overall secondary structure. Until recently, the lack of a significantly high number of selenoprotein mRNA sequences hampered the identification of other potential sequence conservation. In this work, the web-based tool SECISaln provides for the first time an extensive structure-based sequence alignment of SECIS elements resulting from the well-defined secondary structure of the SECIS RNA and the increased size of the eukaryotic selenoproteome. We have used SECISaln to improve our knowledge of SECIS secondary structure and to discover novel, conserved nucleotide positions and we believe it will be a useful tool for the selenoprotein and RNA scientific communities. SECISaln is freely available as a web-based tool at http://genome.crg.es/software/secisaln/.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "8708371a1d3b41c89c378772ccbe6fb2", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[128, 128], [61, 61], [42, 42], [148, 148], [116, 116]], "char_spans": [[749, 753], [337, 341], [226, 230], [866, 870], [675, 679]]}]}], "context_tokens": [["Selenoproteins", 0], ["contain", 15], ["the", 23], ["21st", 27], ["amino", 32], ["acid", 38], ["selenocysteine", 43], ["which", 58], ["is", 64], ["encoded", 67], ["by", 75], ["an", 78], ["inframe", 81], ["UGA", 89], ["codon", 93], [",", 98], ["usually", 100], ["read", 108], ["as", 113], ["a", 116], ["stop", 118], [".", 122], ["In", 124], ["eukaryotes", 127], [",", 137], ["its", 139], ["co", 143], ["-", 145], ["translational", 146], ["recoding", 160], ["requires", 169], ["the", 178], ["presence", 182], ["of", 191], ["an", 194], ["RNA", 197], ["stem", 201], ["-", 205], ["loop", 206], ["structure", 211], [",", 220], ["the", 222], ["SECIS", 226], ["element", 232], ["in", 240], ["the", 243], ["3", 247], ["untranslated", 249], ["region", 262], ["of", 269], ["(", 272], ["UTR", 273], [")", 276], ["selenoprotein", 278], ["mRNAs", 292], [".", 297], ["Despite", 299], ["little", 307], ["sequence", 314], ["conservation", 323], [",", 335], ["SECIS", 337], ["elements", 343], ["share", 352], ["the", 358], ["same", 362], ["overall", 367], ["secondary", 375], ["structure", 385], [".", 394], ["Until", 396], ["recently", 402], [",", 410], ["the", 412], ["lack", 416], ["of", 421], ["a", 424], ["significantly", 426], ["high", 440], ["number", 445], ["of", 452], ["selenoprotein", 455], ["mRNA", 469], ["sequences", 474], ["hampered", 484], ["the", 493], ["identification", 497], ["of", 512], ["other", 515], ["potential", 521], ["sequence", 531], ["conservation", 540], [".", 552], ["In", 554], ["this", 557], ["work", 562], [",", 566], ["the", 568], ["web", 572], ["-", 575], ["based", 576], ["tool", 582], ["SECISaln", 587], ["provides", 596], ["for", 605], ["the", 609], ["first", 613], ["time", 619], ["an", 624], ["extensive", 627], ["structure", 637], ["-", 646], ["based", 647], ["sequence", 653], ["alignment", 662], ["of", 672], ["SECIS", 675], ["elements", 681], ["resulting", 690], ["from", 700], ["the", 705], ["well", 709], ["-", 713], ["defined", 714], ["secondary", 722], ["structure", 732], ["of", 742], ["the", 745], ["SECIS", 749], ["RNA", 755], ["and", 759], ["the", 763], ["increased", 767], ["size", 777], ["of", 782], ["the", 785], ["eukaryotic", 789], ["selenoproteome", 800], [".", 814], ["We", 816], ["have", 819], ["used", 824], ["SECISaln", 829], ["to", 838], ["improve", 841], ["our", 849], ["knowledge", 853], ["of", 863], ["SECIS", 866], ["secondary", 872], ["structure", 882], ["and", 892], ["to", 896], ["discover", 899], ["novel", 908], [",", 913], ["conserved", 915], ["nucleotide", 925], ["positions", 936], ["and", 946], ["we", 950], ["believe", 953], ["it", 961], ["will", 964], ["be", 969], ["a", 972], ["useful", 974], ["tool", 981], ["for", 986], ["the", 990], ["selenoprotein", 994], ["and", 1008], ["RNA", 1012], ["scientific", 1016], ["communities", 1027], [".", 1038], ["SECISaln", 1040], ["is", 1049], ["freely", 1052], ["available", 1059], ["as", 1069], ["a", 1072], ["web", 1074], ["-", 1077], ["based", 1078], ["tool", 1084], ["at", 1089], ["http://genome.crg.es", 1092], ["/", 1112], ["software", 1113], ["/", 1121], ["secisaln/.", 1122]]}
{"context": "This study examined the accuracy of the 17-item Dutch version of the Davidson Trauma Scale (DTS) and the four-item SPAN (Startle, Physiological Arousal, Anger and Numbness) to detect survivors at risk for posttraumatic stress disorder (PTSD) within the first 2 weeks after the trauma. 203 civilian survivors of recent trauma with relatively mild symptoms completed the DTS a mean of 8.7 days after experiencing trauma. SPAN scores were computed from the DTS. At a mean of 64.6 days posttrauma, 160 respondents were assessed for diagnosis of PTSD with the Structured Interview for PTSD. Receiver operating characteristic curves showed that the DTS showed good overall screening accuracy (84%). At a cut-off value of 64, the DTS demonstrated a sensitivity of 0.86, a specificity of 0.70, a positive predictive value (PPV) of 0.12, and a negative predictive value (NPV) of 0.98. Overall accuracy of the SPAN was good (89%). At a cut-off of 10 the SPAN showed a sensitivity of 0.86, a specificity of 0.86, a PPV of 0.22, and a NPV of 0.98. The low PPVs were possibly due to the low of prevalence of PTSD in our sample (4.4%). This study shows that both the DTS and the SPAN are comparably accurate in screening early trauma survivors at risk for developing PTSD. The very brief four-item SPAN may be preferred over the longer 17-item DTS especially in settings in which time and resources are limited. Future studies should aim to cross-validate these results in random samples.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "f39ba0ef13d74fbbbee6b6a7495a7da1", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[224, 224], [106, 106], [44, 44], [100, 100], [255, 255]], "char_spans": [[1095, 1098], [580, 583], [236, 239], [541, 544], [1253, 1256]]}]}], "context_tokens": [["This", 0], ["study", 5], ["examined", 11], ["the", 20], ["accuracy", 24], ["of", 33], ["the", 36], ["17-item", 40], ["Dutch", 48], ["version", 54], ["of", 62], ["the", 65], ["Davidson", 69], ["Trauma", 78], ["Scale", 85], ["(", 91], ["DTS", 92], [")", 95], ["and", 97], ["the", 101], ["four", 105], ["-", 109], ["item", 110], ["SPAN", 115], ["(", 120], ["Startle", 121], [",", 128], ["Physiological", 130], ["Arousal", 144], [",", 151], ["Anger", 153], ["and", 159], ["Numbness", 163], [")", 171], ["to", 173], ["detect", 176], ["survivors", 183], ["at", 193], ["risk", 196], ["for", 201], ["posttraumatic", 205], ["stress", 219], ["disorder", 226], ["(", 235], ["PTSD", 236], [")", 240], ["within", 242], ["the", 249], ["first", 253], ["2", 259], ["weeks", 261], ["after", 267], ["the", 273], ["trauma", 277], [".", 283], ["203", 285], ["civilian", 289], ["survivors", 298], ["of", 308], ["recent", 311], ["trauma", 318], ["with", 325], ["relatively", 330], ["mild", 341], ["symptoms", 346], ["completed", 355], ["the", 365], ["DTS", 369], ["a", 373], ["mean", 375], ["of", 380], ["8.7", 383], ["days", 387], ["after", 392], ["experiencing", 398], ["trauma", 411], [".", 417], ["SPAN", 419], ["scores", 424], ["were", 431], ["computed", 436], ["from", 445], ["the", 450], ["DTS", 454], [".", 457], ["At", 459], ["a", 462], ["mean", 464], ["of", 469], ["64.6", 472], ["days", 477], ["posttrauma", 482], [",", 492], ["160", 494], ["respondents", 498], ["were", 510], ["assessed", 515], ["for", 524], ["diagnosis", 528], ["of", 538], ["PTSD", 541], ["with", 546], ["the", 551], ["Structured", 555], ["Interview", 566], ["for", 576], ["PTSD", 580], [".", 584], ["Receiver", 586], ["operating", 595], ["characteristic", 605], ["curves", 620], ["showed", 627], ["that", 634], ["the", 639], ["DTS", 643], ["showed", 647], ["good", 654], ["overall", 659], ["screening", 667], ["accuracy", 677], ["(", 686], ["84", 687], ["%", 689], [")", 690], [".", 691], ["At", 693], ["a", 696], ["cut", 698], ["-", 701], ["off", 702], ["value", 706], ["of", 712], ["64", 715], [",", 717], ["the", 719], ["DTS", 723], ["demonstrated", 727], ["a", 740], ["sensitivity", 742], ["of", 754], ["0.86", 757], [",", 761], ["a", 763], ["specificity", 765], ["of", 777], ["0.70", 780], [",", 784], ["a", 786], ["positive", 788], ["predictive", 797], ["value", 808], ["(", 814], ["PPV", 815], [")", 818], ["of", 820], ["0.12", 823], [",", 827], ["and", 829], ["a", 833], ["negative", 835], ["predictive", 844], ["value", 855], ["(", 861], ["NPV", 862], [")", 865], ["of", 867], ["0.98", 870], [".", 874], ["Overall", 876], ["accuracy", 884], ["of", 893], ["the", 896], ["SPAN", 900], ["was", 905], ["good", 909], ["(", 914], ["89", 915], ["%", 917], [")", 918], [".", 919], ["At", 921], ["a", 924], ["cut", 926], ["-", 929], ["off", 930], ["of", 934], ["10", 937], ["the", 940], ["SPAN", 944], ["showed", 949], ["a", 956], ["sensitivity", 958], ["of", 970], ["0.86", 973], [",", 977], ["a", 979], ["specificity", 981], ["of", 993], ["0.86", 996], [",", 1000], ["a", 1002], ["PPV", 1004], ["of", 1008], ["0.22", 1011], [",", 1015], ["and", 1017], ["a", 1021], ["NPV", 1023], ["of", 1027], ["0.98", 1030], [".", 1034], ["The", 1036], ["low", 1040], ["PPVs", 1044], ["were", 1049], ["possibly", 1054], ["due", 1063], ["to", 1067], ["the", 1070], ["low", 1074], ["of", 1078], ["prevalence", 1081], ["of", 1092], ["PTSD", 1095], ["in", 1100], ["our", 1103], ["sample", 1107], ["(", 1114], ["4.4", 1115], ["%", 1118], [")", 1119], [".", 1120], ["This", 1122], ["study", 1127], ["shows", 1133], ["that", 1139], ["both", 1144], ["the", 1149], ["DTS", 1153], ["and", 1157], ["the", 1161], ["SPAN", 1165], ["are", 1170], ["comparably", 1174], ["accurate", 1185], ["in", 1194], ["screening", 1197], ["early", 1207], ["trauma", 1213], ["survivors", 1220], ["at", 1230], ["risk", 1233], ["for", 1238], ["developing", 1242], ["PTSD", 1253], [".", 1257], ["The", 1259], ["very", 1263], ["brief", 1268], ["four", 1274], ["-", 1278], ["item", 1279], ["SPAN", 1284], ["may", 1289], ["be", 1293], ["preferred", 1296], ["over", 1306], ["the", 1311], ["longer", 1315], ["17-item", 1322], ["DTS", 1330], ["especially", 1334], ["in", 1345], ["settings", 1348], ["in", 1357], ["which", 1360], ["time", 1366], ["and", 1371], ["resources", 1375], ["are", 1385], ["limited", 1389], [".", 1396], ["Future", 1398], ["studies", 1405], ["should", 1413], ["aim", 1420], ["to", 1424], ["cross", 1427], ["-", 1432], ["validate", 1433], ["these", 1442], ["results", 1448], ["in", 1456], ["random", 1459], ["samples", 1466], [".", 1473]]}
{"context": "Disturbance of intracellular trafficking plays a major role in several neurodegenerative disorders including Alzheimer or Parkinson's disease. The Chediak-Higashi syndrome (CHS), a life-threatening autosomal recessive disease with frequent mutations in the LYST gene, and its animal model, the beige mouse, are both characterized by lysosomal defects with accumulation of giant lysosomes. Clinically they manifest as hypopigmentation, abnormal bleeding and increased susceptibility to infection with various degrees of involvement of the nervous system. In the course of a recessive N-ethyl-N-nitrosurea (ENU) mutagenesis screen, we identified the first murine missense mutation in the lysosomal trafficking regulator gene (Lyst(Ing3618)) located at a highly conserved position in the WD40 protein domain. Nearly all described human Lyst alleles lead to protein truncation and fatal childhood CHS. Only four different missense mutations have been reported in patients with adolescent or adult forms of CHS involving the nervous system. Interestingly, the Lyst(Ing3618) model presents with a predominant neurodegenerative phenotype with progressive degeneration and loss of Purkinje cells and lacks severe impairment of the immune system. Therefore, the Lyst(Ing3618 )allele could represent a new model for adult CHS with neurological impairment. It could also provide an important tool to elucidate the role of neuronal lysosomal trafficking in the pathophysiology of neurodegeneration.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "d6994d74aee440879b8c68ca849fa9db", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[20, 23]], "char_spans": [[147, 170]]}]}], "context_tokens": [["Disturbance", 0], ["of", 12], ["intracellular", 15], ["trafficking", 29], ["plays", 41], ["a", 47], ["major", 49], ["role", 55], ["in", 60], ["several", 63], ["neurodegenerative", 71], ["disorders", 89], ["including", 99], ["Alzheimer", 109], ["or", 119], ["Parkinson", 122], ["'s", 131], ["disease", 134], [".", 141], ["The", 143], ["Chediak", 147], ["-", 154], ["Higashi", 155], ["syndrome", 163], ["(", 172], ["CHS", 173], [")", 176], [",", 177], ["a", 179], ["life", 181], ["-", 185], ["threatening", 186], ["autosomal", 198], ["recessive", 208], ["disease", 218], ["with", 226], ["frequent", 231], ["mutations", 240], ["in", 250], ["the", 253], ["LYST", 257], ["gene", 262], [",", 266], ["and", 268], ["its", 272], ["animal", 276], ["model", 283], [",", 288], ["the", 290], ["beige", 294], ["mouse", 300], [",", 305], ["are", 307], ["both", 311], ["characterized", 316], ["by", 330], ["lysosomal", 333], ["defects", 343], ["with", 351], ["accumulation", 356], ["of", 369], ["giant", 372], ["lysosomes", 378], [".", 387], ["Clinically", 389], ["they", 400], ["manifest", 405], ["as", 414], ["hypopigmentation", 417], [",", 433], ["abnormal", 435], ["bleeding", 444], ["and", 453], ["increased", 457], ["susceptibility", 467], ["to", 482], ["infection", 485], ["with", 495], ["various", 500], ["degrees", 508], ["of", 516], ["involvement", 519], ["of", 531], ["the", 534], ["nervous", 538], ["system", 546], [".", 552], ["In", 554], ["the", 557], ["course", 561], ["of", 568], ["a", 571], ["recessive", 573], ["N", 583], ["-", 584], ["ethyl", 585], ["-", 590], ["N", 591], ["-", 592], ["nitrosurea", 593], ["(", 604], ["ENU", 605], [")", 608], ["mutagenesis", 610], ["screen", 622], [",", 628], ["we", 630], ["identified", 633], ["the", 644], ["first", 648], ["murine", 654], ["missense", 661], ["mutation", 670], ["in", 679], ["the", 682], ["lysosomal", 686], ["trafficking", 696], ["regulator", 708], ["gene", 718], ["(", 723], ["Lyst(Ing3618", 724], [")", 736], [")", 737], ["located", 739], ["at", 747], ["a", 750], ["highly", 752], ["conserved", 759], ["position", 769], ["in", 778], ["the", 781], ["WD40", 785], ["protein", 790], ["domain", 798], [".", 804], ["Nearly", 806], ["all", 813], ["described", 817], ["human", 827], ["Lyst", 833], ["alleles", 838], ["lead", 846], ["to", 851], ["protein", 854], ["truncation", 862], ["and", 873], ["fatal", 877], ["childhood", 883], ["CHS", 893], [".", 896], ["Only", 898], ["four", 903], ["different", 908], ["missense", 918], ["mutations", 927], ["have", 937], ["been", 942], ["reported", 947], ["in", 956], ["patients", 959], ["with", 968], ["adolescent", 973], ["or", 984], ["adult", 987], ["forms", 993], ["of", 999], ["CHS", 1002], ["involving", 1006], ["the", 1016], ["nervous", 1020], ["system", 1028], [".", 1034], ["Interestingly", 1036], [",", 1049], ["the", 1051], ["Lyst(Ing3618", 1055], [")", 1067], ["model", 1069], ["presents", 1075], ["with", 1084], ["a", 1089], ["predominant", 1091], ["neurodegenerative", 1103], ["phenotype", 1121], ["with", 1131], ["progressive", 1136], ["degeneration", 1148], ["and", 1161], ["loss", 1165], ["of", 1170], ["Purkinje", 1173], ["cells", 1182], ["and", 1188], ["lacks", 1192], ["severe", 1198], ["impairment", 1205], ["of", 1216], ["the", 1219], ["immune", 1223], ["system", 1230], [".", 1236], ["Therefore", 1238], [",", 1247], ["the", 1249], ["Lyst(Ing3618", 1253], [")", 1266], ["allele", 1267], ["could", 1274], ["represent", 1280], ["a", 1290], ["new", 1292], ["model", 1296], ["for", 1302], ["adult", 1306], ["CHS", 1312], ["with", 1316], ["neurological", 1321], ["impairment", 1334], [".", 1344], ["It", 1346], ["could", 1349], ["also", 1355], ["provide", 1360], ["an", 1368], ["important", 1371], ["tool", 1381], ["to", 1386], ["elucidate", 1389], ["the", 1399], ["role", 1403], ["of", 1408], ["neuronal", 1411], ["lysosomal", 1420], ["trafficking", 1430], ["in", 1442], ["the", 1445], ["pathophysiology", 1449], ["of", 1465], ["neurodegeneration", 1468], [".", 1485]]}
{"context": "Upon oxygen shift-down, Mycobacterium tuberculosis complex bacteria can induce a genetic program characterized by halted duplication, which is called Non-replicating persistence (NRP). During this phase, at least 48 genes, collectively named Dormancy survival regulator (DosR) regulon, are important for the long-term survival of bacilli under a non-respiring state, a condition that bacilli encounter inside granulomatous lesions. It remains unclear whether expression of NRP genes occurs within the tissue of Mycobacterium bovis naturally infected cattle. In order to start dissecting this question, total RNA from bovine lymph node tissues of sacrificed tuberculin reacting animals was isolated and transcription of genes required for in\u00a0vivo duplication (esxB and fbpB) and in\u00a0vitro NRP (hspX, pfkB, and mb2660c) were analyzed by RT-PCR approaches. Detection of transcripts was positive in bovine tissue samples for genes hspX, pfkB, and mb2660c in 84, 32, and 21%, respectively. NRP genes were upregulated even in animals with a negative IFN-\u03b3 in\u00a0vitro test, and the expression of NRP genes occurred more often than expression of the esxB gene.", "qas": [{"question": "How many genes constitute the DosR regulon, controlled by the dormancy survival regulator (DosR) in Mycobacterium tuberculosis?", "answers": ["48 genes"], "qid": "34689931e2824bf58d7aa234d7a4eed3", "question_tokens": [["How", 0], ["many", 4], ["genes", 9], ["constitute", 15], ["the", 26], ["DosR", 30], ["regulon", 35], [",", 42], ["controlled", 44], ["by", 55], ["the", 58], ["dormancy", 62], ["survival", 71], ["regulator", 80], ["(", 90], ["DosR", 91], [")", 95], ["in", 97], ["Mycobacterium", 100], ["tuberculosis", 114], ["?", 126]], "detected_answers": [{"text": "48 genes", "token_spans": [[37, 38]], "char_spans": [[213, 220]]}]}], "context_tokens": [["Upon", 0], ["oxygen", 5], ["shift", 12], ["-", 17], ["down", 18], [",", 22], ["Mycobacterium", 24], ["tuberculosis", 38], ["complex", 51], ["bacteria", 59], ["can", 68], ["induce", 72], ["a", 79], ["genetic", 81], ["program", 89], ["characterized", 97], ["by", 111], ["halted", 114], ["duplication", 121], [",", 132], ["which", 134], ["is", 140], ["called", 143], ["Non", 150], ["-", 153], ["replicating", 154], ["persistence", 166], ["(", 178], ["NRP", 179], [")", 182], [".", 183], ["During", 185], ["this", 192], ["phase", 197], [",", 202], ["at", 204], ["least", 207], ["48", 213], ["genes", 216], [",", 221], ["collectively", 223], ["named", 236], ["Dormancy", 242], ["survival", 251], ["regulator", 260], ["(", 270], ["DosR", 271], [")", 275], ["regulon", 277], [",", 284], ["are", 286], ["important", 290], ["for", 300], ["the", 304], ["long", 308], ["-", 312], ["term", 313], ["survival", 318], ["of", 327], ["bacilli", 330], ["under", 338], ["a", 344], ["non", 346], ["-", 349], ["respiring", 350], ["state", 360], [",", 365], ["a", 367], ["condition", 369], ["that", 379], ["bacilli", 384], ["encounter", 392], ["inside", 402], ["granulomatous", 409], ["lesions", 423], [".", 430], ["It", 432], ["remains", 435], ["unclear", 443], ["whether", 451], ["expression", 459], ["of", 470], ["NRP", 473], ["genes", 477], ["occurs", 483], ["within", 490], ["the", 497], ["tissue", 501], ["of", 508], ["Mycobacterium", 511], ["bovis", 525], ["naturally", 531], ["infected", 541], ["cattle", 550], [".", 556], ["In", 558], ["order", 561], ["to", 567], ["start", 570], ["dissecting", 576], ["this", 587], ["question", 592], [",", 600], ["total", 602], ["RNA", 608], ["from", 612], ["bovine", 617], ["lymph", 624], ["node", 630], ["tissues", 635], ["of", 643], ["sacrificed", 646], ["tuberculin", 657], ["reacting", 668], ["animals", 677], ["was", 685], ["isolated", 689], ["and", 698], ["transcription", 702], ["of", 716], ["genes", 719], ["required", 725], ["for", 734], ["in", 738], ["vivo", 741], ["duplication", 746], ["(", 758], ["esxB", 759], ["and", 764], ["fbpB", 768], [")", 772], ["and", 774], ["in", 778], ["vitro", 781], ["NRP", 787], ["(", 791], ["hspX", 792], [",", 796], ["pfkB", 798], [",", 802], ["and", 804], ["mb2660c", 808], [")", 815], ["were", 817], ["analyzed", 822], ["by", 831], ["RT", 834], ["-", 836], ["PCR", 837], ["approaches", 841], [".", 851], ["Detection", 853], ["of", 863], ["transcripts", 866], ["was", 878], ["positive", 882], ["in", 891], ["bovine", 894], ["tissue", 901], ["samples", 908], ["for", 916], ["genes", 920], ["hspX", 926], [",", 930], ["pfkB", 932], [",", 936], ["and", 938], ["mb2660c", 942], ["in", 950], ["84", 953], [",", 955], ["32", 957], [",", 959], ["and", 961], ["21", 965], ["%", 967], [",", 968], ["respectively", 970], [".", 982], ["NRP", 984], ["genes", 988], ["were", 994], ["upregulated", 999], ["even", 1011], ["in", 1016], ["animals", 1019], ["with", 1027], ["a", 1032], ["negative", 1034], ["IFN", 1043], ["-", 1046], ["\u03b3", 1047], ["in", 1049], ["vitro", 1052], ["test", 1058], [",", 1062], ["and", 1064], ["the", 1068], ["expression", 1072], ["of", 1083], ["NRP", 1086], ["genes", 1090], ["occurred", 1096], ["more", 1105], ["often", 1110], ["than", 1116], ["expression", 1121], ["of", 1132], ["the", 1135], ["esxB", 1139], ["gene", 1144], [".", 1148]]}
{"context": "Protein-protein interactions are essential for many cellular processes. We have developed a technology called light-activated dimerization (LAD) to artificially induce protein hetero- and homodimerization in live cells using light. Using the FKF1 and GIGANTEA (GI) proteins of Arabidopsis thaliana, we have generated protein tags whose interaction is controlled by blue light. We demonstrated the utility of this system with LAD constructs that can recruit the small G-protein Rac1 to the plasma membrane and induce the local formation of lamellipodia in response to focal illumination. We also generated a light-activated transcription factor by fusing domains of GI and FKF1 to the DNA binding domain of Gal4 and the transactivation domain of VP16, respectively, showing that this technology is easily adapted to other systems. These studies set the stage for the development of light-regulated signaling molecules for controlling receptor activation, synapse formation and other signaling events in organisms.", "qas": [{"question": "Which G protein is essential in the formation and function of lamellipodia?", "answers": ["Rac1"], "qid": "9bf503906c3b425bb54cf156d27e9101", "question_tokens": [["Which", 0], ["G", 6], ["protein", 8], ["is", 16], ["essential", 19], ["in", 29], ["the", 32], ["formation", 36], ["and", 46], ["function", 50], ["of", 59], ["lamellipodia", 62], ["?", 74]], "detected_answers": [{"text": "Rac1", "token_spans": [[81, 81]], "char_spans": [[477, 480]]}]}], "context_tokens": [["Protein", 0], ["-", 7], ["protein", 8], ["interactions", 16], ["are", 29], ["essential", 33], ["for", 43], ["many", 47], ["cellular", 52], ["processes", 61], [".", 70], ["We", 72], ["have", 75], ["developed", 80], ["a", 90], ["technology", 92], ["called", 103], ["light", 110], ["-", 115], ["activated", 116], ["dimerization", 126], ["(", 139], ["LAD", 140], [")", 143], ["to", 145], ["artificially", 148], ["induce", 161], ["protein", 168], ["hetero-", 176], ["and", 184], ["homodimerization", 188], ["in", 205], ["live", 208], ["cells", 213], ["using", 219], ["light", 225], [".", 230], ["Using", 232], ["the", 238], ["FKF1", 242], ["and", 247], ["GIGANTEA", 251], ["(", 260], ["GI", 261], [")", 263], ["proteins", 265], ["of", 274], ["Arabidopsis", 277], ["thaliana", 289], [",", 297], ["we", 299], ["have", 302], ["generated", 307], ["protein", 317], ["tags", 325], ["whose", 330], ["interaction", 336], ["is", 348], ["controlled", 351], ["by", 362], ["blue", 365], ["light", 370], [".", 375], ["We", 377], ["demonstrated", 380], ["the", 393], ["utility", 397], ["of", 405], ["this", 408], ["system", 413], ["with", 420], ["LAD", 425], ["constructs", 429], ["that", 440], ["can", 445], ["recruit", 449], ["the", 457], ["small", 461], ["G", 467], ["-", 468], ["protein", 469], ["Rac1", 477], ["to", 482], ["the", 485], ["plasma", 489], ["membrane", 496], ["and", 505], ["induce", 509], ["the", 516], ["local", 520], ["formation", 526], ["of", 536], ["lamellipodia", 539], ["in", 552], ["response", 555], ["to", 564], ["focal", 567], ["illumination", 573], [".", 585], ["We", 587], ["also", 590], ["generated", 595], ["a", 605], ["light", 607], ["-", 612], ["activated", 613], ["transcription", 623], ["factor", 637], ["by", 644], ["fusing", 647], ["domains", 654], ["of", 662], ["GI", 665], ["and", 668], ["FKF1", 672], ["to", 677], ["the", 680], ["DNA", 684], ["binding", 688], ["domain", 696], ["of", 703], ["Gal4", 706], ["and", 711], ["the", 715], ["transactivation", 719], ["domain", 735], ["of", 742], ["VP16", 745], [",", 749], ["respectively", 751], [",", 763], ["showing", 765], ["that", 773], ["this", 778], ["technology", 783], ["is", 794], ["easily", 797], ["adapted", 804], ["to", 812], ["other", 815], ["systems", 821], [".", 828], ["These", 830], ["studies", 836], ["set", 844], ["the", 848], ["stage", 852], ["for", 858], ["the", 862], ["development", 866], ["of", 878], ["light", 881], ["-", 886], ["regulated", 887], ["signaling", 897], ["molecules", 907], ["for", 917], ["controlling", 921], ["receptor", 933], ["activation", 942], [",", 952], ["synapse", 954], ["formation", 962], ["and", 972], ["other", 976], ["signaling", 982], ["events", 992], ["in", 999], ["organisms", 1002], [".", 1011]]}
{"context": "To evaluate gender differences in score on 28-joint Disease Activity Score (DAS28), Health Assessment Questionnaire (HAQ) and Signals Of Functional Impairment (SOFI) and to relate these scores to radiographic joint destruction. In all, 549 patients with early RA (62% women) from the BARFOT (for \"Better Anti-Rheumatic FarmacOTherapy\") study were included. At baseline, 1, 2 and 5 years DAS28, HAQ and SOFI scoring, and radiographs of hands and feet were performed. The radiographs were scored using the van der Heijde-Sharp score. In women the DAS28 was significantly higher than in men due to higher scores for general health and tender joints. Likewise, HAQ and VAS pain were rated significantly higher in women. The SOFI score was worse in men during the first 2 years, depending on higher upper limb scores. Total Sharp score (TotSharp), erosion score and joint space narrowing score did not differ between the sexes at any time point. The DAS28 area under the curve (AUC) correlated significantly with TotSharp at 5 years in both genders (r = 0.316, r = 0.313) mainly owing to swollen joints and erythrocyte sedimentation rate (ESR). The SOFI AUC correlated significantly with TotSharp in women (r = 0.135 to 0.220) but not in men. Despite a similar degree of radiographic joint destruction women had, compared with men, worse scores for DAS28 and HAQ, possibly due to higher pain perception and less muscular strength and perhaps because men overestimate their functional capacity.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "3a09c991f94d49ac9f85560e9ef63b8f", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[256, 256], [139, 139], [235, 235], [108, 108], [50, 50]], "char_spans": [[1297, 1301], [709, 713], [1195, 1199], [535, 539], [268, 272]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["gender", 12], ["differences", 19], ["in", 31], ["score", 34], ["on", 40], ["28-joint", 43], ["Disease", 52], ["Activity", 60], ["Score", 69], ["(", 75], ["DAS28", 76], [")", 81], [",", 82], ["Health", 84], ["Assessment", 91], ["Questionnaire", 102], ["(", 116], ["HAQ", 117], [")", 120], ["and", 122], ["Signals", 126], ["Of", 134], ["Functional", 137], ["Impairment", 148], ["(", 159], ["SOFI", 160], [")", 164], ["and", 166], ["to", 170], ["relate", 173], ["these", 180], ["scores", 186], ["to", 193], ["radiographic", 196], ["joint", 209], ["destruction", 215], [".", 226], ["In", 228], ["all", 231], [",", 234], ["549", 236], ["patients", 240], ["with", 249], ["early", 254], ["RA", 260], ["(", 263], ["62", 264], ["%", 266], ["women", 268], [")", 273], ["from", 275], ["the", 280], ["BARFOT", 284], ["(", 291], ["for", 292], ["\"", 296], ["Better", 297], ["Anti", 304], ["-", 308], ["Rheumatic", 309], ["FarmacOTherapy", 319], ["\"", 333], [")", 334], ["study", 336], ["were", 342], ["included", 347], [".", 355], ["At", 357], ["baseline", 360], [",", 368], ["1", 370], [",", 371], ["2", 373], ["and", 375], ["5", 379], ["years", 381], ["DAS28", 387], [",", 392], ["HAQ", 394], ["and", 398], ["SOFI", 402], ["scoring", 407], [",", 414], ["and", 416], ["radiographs", 420], ["of", 432], ["hands", 435], ["and", 441], ["feet", 445], ["were", 450], ["performed", 455], [".", 464], ["The", 466], ["radiographs", 470], ["were", 482], ["scored", 487], ["using", 494], ["the", 500], ["van", 504], ["der", 508], ["Heijde", 512], ["-", 518], ["Sharp", 519], ["score", 525], [".", 530], ["In", 532], ["women", 535], ["the", 541], ["DAS28", 545], ["was", 551], ["significantly", 555], ["higher", 569], ["than", 576], ["in", 581], ["men", 584], ["due", 588], ["to", 592], ["higher", 595], ["scores", 602], ["for", 609], ["general", 613], ["health", 621], ["and", 628], ["tender", 632], ["joints", 639], [".", 645], ["Likewise", 647], [",", 655], ["HAQ", 657], ["and", 661], ["VAS", 665], ["pain", 669], ["were", 674], ["rated", 679], ["significantly", 685], ["higher", 699], ["in", 706], ["women", 709], [".", 714], ["The", 716], ["SOFI", 720], ["score", 725], ["was", 731], ["worse", 735], ["in", 741], ["men", 744], ["during", 748], ["the", 755], ["first", 759], ["2", 765], ["years", 767], [",", 772], ["depending", 774], ["on", 784], ["higher", 787], ["upper", 794], ["limb", 800], ["scores", 805], [".", 811], ["Total", 813], ["Sharp", 819], ["score", 825], ["(", 831], ["TotSharp", 832], [")", 840], [",", 841], ["erosion", 843], ["score", 851], ["and", 857], ["joint", 861], ["space", 867], ["narrowing", 873], ["score", 883], ["did", 889], ["not", 893], ["differ", 897], ["between", 904], ["the", 912], ["sexes", 916], ["at", 922], ["any", 925], ["time", 929], ["point", 934], [".", 939], ["The", 941], ["DAS28", 945], ["area", 951], ["under", 956], ["the", 962], ["curve", 966], ["(", 972], ["AUC", 973], [")", 976], ["correlated", 978], ["significantly", 989], ["with", 1003], ["TotSharp", 1008], ["at", 1017], ["5", 1020], ["years", 1022], ["in", 1028], ["both", 1031], ["genders", 1036], ["(", 1044], ["r", 1045], ["=", 1047], ["0.316", 1049], [",", 1054], ["r", 1056], ["=", 1058], ["0.313", 1060], [")", 1065], ["mainly", 1067], ["owing", 1074], ["to", 1080], ["swollen", 1083], ["joints", 1091], ["and", 1098], ["erythrocyte", 1102], ["sedimentation", 1114], ["rate", 1128], ["(", 1133], ["ESR", 1134], [")", 1137], [".", 1138], ["The", 1140], ["SOFI", 1144], ["AUC", 1149], ["correlated", 1153], ["significantly", 1164], ["with", 1178], ["TotSharp", 1183], ["in", 1192], ["women", 1195], ["(", 1201], ["r", 1202], ["=", 1204], ["0.135", 1206], ["to", 1212], ["0.220", 1215], [")", 1220], ["but", 1222], ["not", 1226], ["in", 1230], ["men", 1233], [".", 1236], ["Despite", 1238], ["a", 1246], ["similar", 1248], ["degree", 1256], ["of", 1263], ["radiographic", 1266], ["joint", 1279], ["destruction", 1285], ["women", 1297], ["had", 1303], [",", 1306], ["compared", 1308], ["with", 1317], ["men", 1322], [",", 1325], ["worse", 1327], ["scores", 1333], ["for", 1340], ["DAS28", 1344], ["and", 1350], ["HAQ", 1354], [",", 1357], ["possibly", 1359], ["due", 1368], ["to", 1372], ["higher", 1375], ["pain", 1382], ["perception", 1387], ["and", 1398], ["less", 1402], ["muscular", 1407], ["strength", 1416], ["and", 1425], ["perhaps", 1429], ["because", 1437], ["men", 1445], ["overestimate", 1449], ["their", 1462], ["functional", 1468], ["capacity", 1479], [".", 1487]]}
{"context": "Restless leg syndrome (RLS) and periodic limb movement disorder (PLMD) are considered to be a continuum of a neurological sleep disorder associated with abnormal iron metabolism or deficiency. I describe a case of RLS and PLMD in a cystic fibrosis patient with iron deficiency from chronic hemoptysis. This is the first case that reports RLS and PLMD manifesting from iron deficiency caused by chronic hemoptysis in advanced cystic fibrosis lung disease.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "cecd920cbb724d98aaf99c70c2dcc371", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[65, 65], [28, 28], [47, 47]], "char_spans": [[368, 371], [162, 165], [261, 264]]}]}], "context_tokens": [["Restless", 0], ["leg", 9], ["syndrome", 13], ["(", 22], ["RLS", 23], [")", 26], ["and", 28], ["periodic", 32], ["limb", 41], ["movement", 46], ["disorder", 55], ["(", 64], ["PLMD", 65], [")", 69], ["are", 71], ["considered", 75], ["to", 86], ["be", 89], ["a", 92], ["continuum", 94], ["of", 104], ["a", 107], ["neurological", 109], ["sleep", 122], ["disorder", 128], ["associated", 137], ["with", 148], ["abnormal", 153], ["iron", 162], ["metabolism", 167], ["or", 178], ["deficiency", 181], [".", 191], ["I", 193], ["describe", 195], ["a", 204], ["case", 206], ["of", 211], ["RLS", 214], ["and", 218], ["PLMD", 222], ["in", 227], ["a", 230], ["cystic", 232], ["fibrosis", 239], ["patient", 248], ["with", 256], ["iron", 261], ["deficiency", 266], ["from", 277], ["chronic", 282], ["hemoptysis", 290], [".", 300], ["This", 302], ["is", 307], ["the", 310], ["first", 314], ["case", 320], ["that", 325], ["reports", 330], ["RLS", 338], ["and", 342], ["PLMD", 346], ["manifesting", 351], ["from", 363], ["iron", 368], ["deficiency", 373], ["caused", 384], ["by", 391], ["chronic", 394], ["hemoptysis", 402], ["in", 413], ["advanced", 416], ["cystic", 425], ["fibrosis", 432], ["lung", 441], ["disease", 446], [".", 453]]}
{"context": "alpha-Synuclein is a presynaptic protein recently identified as a specific component of Lewy bodies (LB) and Lewy neurites. The aim of this study was to assess the morphology and distribution of alpha-synuclein immunoreactivity in cases of dementia with LB (DLB), and to compare alpha-synuclein with ubiquitin immunostaining. We examined substantia nigra, paralimbic regions (entorhinal cortex, cingulate gyrus, insula and hippocampus), and neocortex (frontal and occipital association cortices) with double alpha-synuclein and ubiquitin immunostaining in 25 cases meeting neuropathological criteria for DLB. alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in that it differentiated LB from globose tangles. It was also slightly more sensitive, staining 4-5% more intracytoplasmic structures, especially diffuse alpha-synuclein deposits that were ubiquitin negative. In addition to LB, alpha-synuclein staining showed filiform and globose neurites in the substantia nigra, CA2-3 regions of the hippocampus, and entorhinal cortex. A spectrum of alpha-synuclein staining was seen in substantia nigra: from diffuse \"cloud-like\" inclusions to aggregated intracytoplasmic inclusions with variable ubiquitin staining to classic LB. We hypothesize that these represent different stages in LB formation.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "657d5d7eecf249cb96e36f5b3a818fcf", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[36, 38], [142, 144], [156, 158], [53, 55], [90, 92], [105, 107], [185, 187], [0, 2]], "char_spans": [[195, 209], [843, 857], [917, 931], [279, 293], [508, 522], [609, 623], [1075, 1089], [0, 14]]}]}], "context_tokens": [["alpha", 0], ["-", 5], ["Synuclein", 6], ["is", 16], ["a", 19], ["presynaptic", 21], ["protein", 33], ["recently", 41], ["identified", 50], ["as", 61], ["a", 64], ["specific", 66], ["component", 75], ["of", 85], ["Lewy", 88], ["bodies", 93], ["(", 100], ["LB", 101], [")", 103], ["and", 105], ["Lewy", 109], ["neurites", 114], [".", 122], ["The", 124], ["aim", 128], ["of", 132], ["this", 135], ["study", 140], ["was", 146], ["to", 150], ["assess", 153], ["the", 160], ["morphology", 164], ["and", 175], ["distribution", 179], ["of", 192], ["alpha", 195], ["-", 200], ["synuclein", 201], ["immunoreactivity", 211], ["in", 228], ["cases", 231], ["of", 237], ["dementia", 240], ["with", 249], ["LB", 254], ["(", 257], ["DLB", 258], [")", 261], [",", 262], ["and", 264], ["to", 268], ["compare", 271], ["alpha", 279], ["-", 284], ["synuclein", 285], ["with", 295], ["ubiquitin", 300], ["immunostaining", 310], [".", 324], ["We", 326], ["examined", 329], ["substantia", 338], ["nigra", 349], [",", 354], ["paralimbic", 356], ["regions", 367], ["(", 375], ["entorhinal", 376], ["cortex", 387], [",", 393], ["cingulate", 395], ["gyrus", 405], [",", 410], ["insula", 412], ["and", 419], ["hippocampus", 423], [")", 434], [",", 435], ["and", 437], ["neocortex", 441], ["(", 451], ["frontal", 452], ["and", 460], ["occipital", 464], ["association", 474], ["cortices", 486], [")", 494], ["with", 496], ["double", 501], ["alpha", 508], ["-", 513], ["synuclein", 514], ["and", 524], ["ubiquitin", 528], ["immunostaining", 538], ["in", 553], ["25", 556], ["cases", 559], ["meeting", 565], ["neuropathological", 573], ["criteria", 591], ["for", 600], ["DLB", 604], [".", 607], ["alpha", 609], ["-", 614], ["Synuclein", 615], ["immunostaining", 625], ["was", 640], ["more", 644], ["specific", 649], ["than", 658], ["ubiquitin", 663], ["immunostaining", 673], ["in", 688], ["that", 691], ["it", 696], ["differentiated", 699], ["LB", 714], ["from", 717], ["globose", 722], ["tangles", 730], [".", 737], ["It", 739], ["was", 742], ["also", 746], ["slightly", 751], ["more", 760], ["sensitive", 765], [",", 774], ["staining", 776], ["4", 785], ["-", 786], ["5", 787], ["%", 788], ["more", 790], ["intracytoplasmic", 795], ["structures", 812], [",", 822], ["especially", 824], ["diffuse", 835], ["alpha", 843], ["-", 848], ["synuclein", 849], ["deposits", 859], ["that", 868], ["were", 873], ["ubiquitin", 878], ["negative", 888], [".", 896], ["In", 898], ["addition", 901], ["to", 910], ["LB", 913], [",", 915], ["alpha", 917], ["-", 922], ["synuclein", 923], ["staining", 933], ["showed", 942], ["filiform", 949], ["and", 958], ["globose", 962], ["neurites", 970], ["in", 979], ["the", 982], ["substantia", 986], ["nigra", 997], [",", 1002], ["CA2", 1004], ["-", 1007], ["3", 1008], ["regions", 1010], ["of", 1018], ["the", 1021], ["hippocampus", 1025], [",", 1036], ["and", 1038], ["entorhinal", 1042], ["cortex", 1053], [".", 1059], ["A", 1061], ["spectrum", 1063], ["of", 1072], ["alpha", 1075], ["-", 1080], ["synuclein", 1081], ["staining", 1091], ["was", 1100], ["seen", 1104], ["in", 1109], ["substantia", 1112], ["nigra", 1123], [":", 1128], ["from", 1130], ["diffuse", 1135], ["\"", 1143], ["cloud", 1144], ["-", 1149], ["like", 1150], ["\"", 1154], ["inclusions", 1156], ["to", 1167], ["aggregated", 1170], ["intracytoplasmic", 1181], ["inclusions", 1198], ["with", 1209], ["variable", 1214], ["ubiquitin", 1223], ["staining", 1233], ["to", 1242], ["classic", 1245], ["LB", 1253], [".", 1255], ["We", 1257], ["hypothesize", 1260], ["that", 1272], ["these", 1277], ["represent", 1283], ["different", 1293], ["stages", 1303], ["in", 1310], ["LB", 1313], ["formation", 1316], [".", 1325]]}
{"context": "Alpha-synuclein forms the major component of Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies. Here we show that alpha-synuclein is also the major component of the filamentous inclusions of multiple system atrophy which comprises several neurodegenerative diseases with a shared filamentous pathology in nerve cells and glial cells. These findings provide an unexpected link between multiple system atrophy and Lewy body disorders and establish that alpha-synucleinopathies constitute a major class of human neurodegenerative disorder.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a4da3f3b9ad440b69aaf79b7d6f6f893", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2], [32, 34]], "char_spans": [[0, 14], [195, 209]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["forms", 16], ["the", 22], ["major", 26], ["component", 32], ["of", 42], ["Lewy", 45], ["bodies", 50], ["and", 57], ["Lewy", 61], ["neurites", 66], [",", 74], ["the", 76], ["defining", 80], ["neuropathological", 89], ["characteristics", 107], ["of", 123], ["Parkinson", 126], ["'s", 135], ["disease", 138], ["and", 146], ["dementia", 150], ["with", 159], ["Lewy", 164], ["bodies", 169], [".", 175], ["Here", 177], ["we", 182], ["show", 185], ["that", 190], ["alpha", 195], ["-", 200], ["synuclein", 201], ["is", 211], ["also", 214], ["the", 219], ["major", 223], ["component", 229], ["of", 239], ["the", 242], ["filamentous", 246], ["inclusions", 258], ["of", 269], ["multiple", 272], ["system", 281], ["atrophy", 288], ["which", 296], ["comprises", 302], ["several", 312], ["neurodegenerative", 320], ["diseases", 338], ["with", 347], ["a", 352], ["shared", 354], ["filamentous", 361], ["pathology", 373], ["in", 383], ["nerve", 386], ["cells", 392], ["and", 398], ["glial", 402], ["cells", 408], [".", 413], ["These", 415], ["findings", 421], ["provide", 430], ["an", 438], ["unexpected", 441], ["link", 452], ["between", 457], ["multiple", 465], ["system", 474], ["atrophy", 481], ["and", 489], ["Lewy", 493], ["body", 498], ["disorders", 503], ["and", 513], ["establish", 517], ["that", 527], ["alpha", 532], ["-", 537], ["synucleinopathies", 538], ["constitute", 556], ["a", 567], ["major", 569], ["class", 575], ["of", 581], ["human", 584], ["neurodegenerative", 590], ["disorder", 608], [".", 616]]}
{"context": "zfhz1b is the causative gene for Mowat-Wilson syndrome, in which patients demonstrate developmental delay and Hirschsprung disease, as well as other anomalies. We identified a patient with Mowat-Wilson syndrome who also developed cholestasis and histopathologic features consistent with biliary atresia, suggesting that mutations involving zfhz1b may lead to biliary developmental anomalies or injury to the biliary tract. We used the zebrafish model system to determine whether zfhx1b has a role in vertebrate biliary development. Using zebrafish we determined that zfhx1b was expressed in the developing liver during biliary growth and remodeling, and that morpholino antisense oligonucleotide-mediated knockdown of zfhx1b led to defects in biliary development. These findings were associated with decreased expression of vhnf1, a transcription factor known to be important in biliary development in zebrafish and in mammals. Our studies underscore the importance of genetic contributions in the etiology of infantile hepatobiliary disorders, including biliary atresia.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "e29d0b192b44413e95a08a2afa14fcbc", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[111, 111], [89, 89], [75, 75]], "char_spans": [[718, 723], [567, 572], [479, 484]]}]}], "context_tokens": [["zfhz1b", 0], ["is", 7], ["the", 10], ["causative", 14], ["gene", 24], ["for", 29], ["Mowat", 33], ["-", 38], ["Wilson", 39], ["syndrome", 46], [",", 54], ["in", 56], ["which", 59], ["patients", 65], ["demonstrate", 74], ["developmental", 86], ["delay", 100], ["and", 106], ["Hirschsprung", 110], ["disease", 123], [",", 130], ["as", 132], ["well", 135], ["as", 140], ["other", 143], ["anomalies", 149], [".", 158], ["We", 160], ["identified", 163], ["a", 174], ["patient", 176], ["with", 184], ["Mowat", 189], ["-", 194], ["Wilson", 195], ["syndrome", 202], ["who", 211], ["also", 215], ["developed", 220], ["cholestasis", 230], ["and", 242], ["histopathologic", 246], ["features", 262], ["consistent", 271], ["with", 282], ["biliary", 287], ["atresia", 295], [",", 302], ["suggesting", 304], ["that", 315], ["mutations", 320], ["involving", 330], ["zfhz1b", 340], ["may", 347], ["lead", 351], ["to", 356], ["biliary", 359], ["developmental", 367], ["anomalies", 381], ["or", 391], ["injury", 394], ["to", 401], ["the", 404], ["biliary", 408], ["tract", 416], [".", 421], ["We", 423], ["used", 426], ["the", 431], ["zebrafish", 435], ["model", 445], ["system", 451], ["to", 458], ["determine", 461], ["whether", 471], ["zfhx1b", 479], ["has", 486], ["a", 490], ["role", 492], ["in", 497], ["vertebrate", 500], ["biliary", 511], ["development", 519], [".", 530], ["Using", 532], ["zebrafish", 538], ["we", 548], ["determined", 551], ["that", 562], ["zfhx1b", 567], ["was", 574], ["expressed", 578], ["in", 588], ["the", 591], ["developing", 595], ["liver", 606], ["during", 612], ["biliary", 619], ["growth", 627], ["and", 634], ["remodeling", 638], [",", 648], ["and", 650], ["that", 654], ["morpholino", 659], ["antisense", 670], ["oligonucleotide", 680], ["-", 695], ["mediated", 696], ["knockdown", 705], ["of", 715], ["zfhx1b", 718], ["led", 725], ["to", 729], ["defects", 732], ["in", 740], ["biliary", 743], ["development", 751], [".", 762], ["These", 764], ["findings", 770], ["were", 779], ["associated", 784], ["with", 795], ["decreased", 800], ["expression", 810], ["of", 821], ["vhnf1", 824], [",", 829], ["a", 831], ["transcription", 833], ["factor", 847], ["known", 854], ["to", 860], ["be", 863], ["important", 866], ["in", 876], ["biliary", 879], ["development", 887], ["in", 899], ["zebrafish", 902], ["and", 912], ["in", 916], ["mammals", 919], [".", 926], ["Our", 928], ["studies", 932], ["underscore", 940], ["the", 951], ["importance", 955], ["of", 966], ["genetic", 969], ["contributions", 977], ["in", 991], ["the", 994], ["etiology", 998], ["of", 1007], ["infantile", 1010], ["hepatobiliary", 1020], ["disorders", 1034], [",", 1043], ["including", 1045], ["biliary", 1055], ["atresia", 1063], [".", 1070]]}
{"context": "Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis. In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 patients (nearly all of whom were negative for the human immunodeficiency virus) with pulmonary multidrug-resistant tuberculosis to receive delamanid, at a dose of 100 mg twice daily (161 patients) or 200 mg twice daily (160 patients), or placebo (160 patients) for 2 months in combination with a background drug regimen developed according to World Health Organization guidelines. Sputum cultures were assessed weekly with the use of both liquid broth and solid medium; sputum-culture conversion was defined as a series of five or more consecutive cultures that were negative for growth of M. tuberculosis. The primary efficacy end point was the proportion of patients with sputum-culture conversion in liquid broth medium at 2 months. Among patients who received a background drug regimen plus 100 mg of delamanid twice daily, 45.4% had sputum-culture conversion in liquid broth at 2 months, as compared with 29.6% of patients who received a background drug regimen plus placebo (P=0.008). Likewise, as compared with the placebo group, the group that received the background drug regimen plus 200 mg of delamanid twice daily had a higher proportion of patients with sputum-culture conversion (41.9%, P=0.04). The findings were similar with assessment of sputum-culture conversion in solid medium. Most adverse events were mild to moderate in severity and were evenly distributed across groups. Although no clinical events due to QT prolongation on electrocardiography were observed, QT prolongation was reported significantly more frequently in the groups that received delamanid. Delamanid was associated with an increase in sputum-culture conversion at 2 months among patients with multidrug-resistant tuberculosis. This finding suggests that delamanid could enhance treatment options for multidrug-resistant tuberculosis. (Funded by Otsuka Pharmaceutical Development and Commercialization; ClinicalTrials.gov number, NCT00685360.).", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "9dd06b2102304cdc8188c97c503ffb35", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[165, 165], [374, 374], [76, 76], [359, 359], [40, 40]], "char_spans": [[933, 944], [2152, 2163], [455, 466], [2045, 2056], [239, 250]]}]}], "context_tokens": [["Delamanid", 0], ["(", 10], ["OPC-67683", 11], [")", 20], [",", 21], ["a", 23], ["nitro", 25], ["-", 30], ["dihydro", 31], ["-", 38], ["imidazooxazole", 39], ["derivative", 54], [",", 64], ["is", 66], ["a", 69], ["new", 71], ["antituberculosis", 75], ["medication", 92], ["that", 103], ["inhibits", 108], ["mycolic", 117], ["acid", 125], ["synthesis", 130], ["and", 140], ["has", 144], ["shown", 148], ["potent", 154], ["in", 161], ["vitro", 164], ["and", 170], ["in", 174], ["vivo", 177], ["activity", 182], ["against", 191], ["drug", 199], ["-", 203], ["resistant", 204], ["strains", 214], ["of", 222], ["Mycobacterium", 225], ["tuberculosis", 239], [".", 251], ["In", 253], ["this", 256], ["randomized", 261], [",", 271], ["placebo", 273], ["-", 280], ["controlled", 281], [",", 291], ["multinational", 293], ["clinical", 307], ["trial", 316], [",", 321], ["we", 323], ["assigned", 326], ["481", 335], ["patients", 339], ["(", 348], ["nearly", 349], ["all", 356], ["of", 360], ["whom", 363], ["were", 368], ["negative", 373], ["for", 382], ["the", 386], ["human", 390], ["immunodeficiency", 396], ["virus", 413], [")", 418], ["with", 420], ["pulmonary", 425], ["multidrug", 435], ["-", 444], ["resistant", 445], ["tuberculosis", 455], ["to", 468], ["receive", 471], ["delamanid", 479], [",", 488], ["at", 490], ["a", 493], ["dose", 495], ["of", 500], ["100", 503], ["mg", 507], ["twice", 510], ["daily", 516], ["(", 522], ["161", 523], ["patients", 527], [")", 535], ["or", 537], ["200", 540], ["mg", 544], ["twice", 547], ["daily", 553], ["(", 559], ["160", 560], ["patients", 564], [")", 572], [",", 573], ["or", 575], ["placebo", 578], ["(", 586], ["160", 587], ["patients", 591], [")", 599], ["for", 601], ["2", 605], ["months", 607], ["in", 614], ["combination", 617], ["with", 629], ["a", 634], ["background", 636], ["drug", 647], ["regimen", 652], ["developed", 660], ["according", 670], ["to", 680], ["World", 683], ["Health", 689], ["Organization", 696], ["guidelines", 709], [".", 719], ["Sputum", 721], ["cultures", 728], ["were", 737], ["assessed", 742], ["weekly", 751], ["with", 758], ["the", 763], ["use", 767], ["of", 771], ["both", 774], ["liquid", 779], ["broth", 786], ["and", 792], ["solid", 796], ["medium", 802], [";", 808], ["sputum", 810], ["-", 816], ["culture", 817], ["conversion", 825], ["was", 836], ["defined", 840], ["as", 848], ["a", 851], ["series", 853], ["of", 860], ["five", 863], ["or", 868], ["more", 871], ["consecutive", 876], ["cultures", 888], ["that", 897], ["were", 902], ["negative", 907], ["for", 916], ["growth", 920], ["of", 927], ["M.", 930], ["tuberculosis", 933], [".", 945], ["The", 947], ["primary", 951], ["efficacy", 959], ["end", 968], ["point", 972], ["was", 978], ["the", 982], ["proportion", 986], ["of", 997], ["patients", 1000], ["with", 1009], ["sputum", 1014], ["-", 1020], ["culture", 1021], ["conversion", 1029], ["in", 1040], ["liquid", 1043], ["broth", 1050], ["medium", 1056], ["at", 1063], ["2", 1066], ["months", 1068], [".", 1074], ["Among", 1076], ["patients", 1082], ["who", 1091], ["received", 1095], ["a", 1104], ["background", 1106], ["drug", 1117], ["regimen", 1122], ["plus", 1130], ["100", 1135], ["mg", 1139], ["of", 1142], ["delamanid", 1145], ["twice", 1155], ["daily", 1161], [",", 1166], ["45.4", 1168], ["%", 1172], ["had", 1174], ["sputum", 1178], ["-", 1184], ["culture", 1185], ["conversion", 1193], ["in", 1204], ["liquid", 1207], ["broth", 1214], ["at", 1220], ["2", 1223], ["months", 1225], [",", 1231], ["as", 1233], ["compared", 1236], ["with", 1245], ["29.6", 1250], ["%", 1254], ["of", 1256], ["patients", 1259], ["who", 1268], ["received", 1272], ["a", 1281], ["background", 1283], ["drug", 1294], ["regimen", 1299], ["plus", 1307], ["placebo", 1312], ["(", 1320], ["P=0.008", 1321], [")", 1328], [".", 1329], ["Likewise", 1331], [",", 1339], ["as", 1341], ["compared", 1344], ["with", 1353], ["the", 1358], ["placebo", 1362], ["group", 1370], [",", 1375], ["the", 1377], ["group", 1381], ["that", 1387], ["received", 1392], ["the", 1401], ["background", 1405], ["drug", 1416], ["regimen", 1421], ["plus", 1429], ["200", 1434], ["mg", 1438], ["of", 1441], ["delamanid", 1444], ["twice", 1454], ["daily", 1460], ["had", 1466], ["a", 1470], ["higher", 1472], ["proportion", 1479], ["of", 1490], ["patients", 1493], ["with", 1502], ["sputum", 1507], ["-", 1513], ["culture", 1514], ["conversion", 1522], ["(", 1533], ["41.9", 1534], ["%", 1538], [",", 1539], ["P=0.04", 1541], [")", 1547], [".", 1548], ["The", 1550], ["findings", 1554], ["were", 1563], ["similar", 1568], ["with", 1576], ["assessment", 1581], ["of", 1592], ["sputum", 1595], ["-", 1601], ["culture", 1602], ["conversion", 1610], ["in", 1621], ["solid", 1624], ["medium", 1630], [".", 1636], ["Most", 1638], ["adverse", 1643], ["events", 1651], ["were", 1658], ["mild", 1663], ["to", 1668], ["moderate", 1671], ["in", 1680], ["severity", 1683], ["and", 1692], ["were", 1696], ["evenly", 1701], ["distributed", 1708], ["across", 1720], ["groups", 1727], [".", 1733], ["Although", 1735], ["no", 1744], ["clinical", 1747], ["events", 1756], ["due", 1763], ["to", 1767], ["QT", 1770], ["prolongation", 1773], ["on", 1786], ["electrocardiography", 1789], ["were", 1809], ["observed", 1814], [",", 1822], ["QT", 1824], ["prolongation", 1827], ["was", 1840], ["reported", 1844], ["significantly", 1853], ["more", 1867], ["frequently", 1872], ["in", 1883], ["the", 1886], ["groups", 1890], ["that", 1897], ["received", 1902], ["delamanid", 1911], [".", 1920], ["Delamanid", 1922], ["was", 1932], ["associated", 1936], ["with", 1947], ["an", 1952], ["increase", 1955], ["in", 1964], ["sputum", 1967], ["-", 1973], ["culture", 1974], ["conversion", 1982], ["at", 1993], ["2", 1996], ["months", 1998], ["among", 2005], ["patients", 2011], ["with", 2020], ["multidrug", 2025], ["-", 2034], ["resistant", 2035], ["tuberculosis", 2045], [".", 2057], ["This", 2059], ["finding", 2064], ["suggests", 2072], ["that", 2081], ["delamanid", 2086], ["could", 2096], ["enhance", 2102], ["treatment", 2110], ["options", 2120], ["for", 2128], ["multidrug", 2132], ["-", 2141], ["resistant", 2142], ["tuberculosis", 2152], [".", 2164], ["(", 2166], ["Funded", 2167], ["by", 2174], ["Otsuka", 2177], ["Pharmaceutical", 2184], ["Development", 2199], ["and", 2211], ["Commercialization", 2215], [";", 2232], ["ClinicalTrials.gov", 2234], ["number", 2253], [",", 2259], ["NCT00685360", 2261], [".", 2272], [")", 2273], [".", 2274]]}
{"context": "Chronic myeloid leukemia (CML) is caused by Bcr-Abl, a constitutively active tyrosine kinase that is the result of a reciprocal translocation between chromosomes 9 and 22 and cytogenetically evident as the Philadelphia chromosome. Imatinib (Glivec, Gleevec), a specific small molecule inhibitor of Bcr-Abl, has become the standard drug therapy for CML, and has dramatically diminished the use of allogeneic stem cell transplantation. Despite unprecedented rates of complete cytogenetic response, residual disease remains detectable in the majority of patients, suggesting that imatinib fails to eradicate leukemic stem cells. In this publication, the current perspectives for CML patients treated with imatinib are reviewed, focusing on the results of both standard and high-dose therapy. Monitoring of time-dependent prognostic factors is reviewed. The reasons imatinib may not be able to eradicate the disease are discussed, and potential strategies to achieve disease elimination are presented. Lastly, resistance to imatinib and the potential of second-generation Abl kinase inhibitors in the setting of clinical resistance are considered.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "04cb5e56a4624e849a6e56966d0d643e", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[9, 11], [52, 54]], "char_spans": [[44, 50], [298, 304]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["caused", 34], ["by", 41], ["Bcr", 44], ["-", 47], ["Abl", 48], [",", 51], ["a", 53], ["constitutively", 55], ["active", 70], ["tyrosine", 77], ["kinase", 86], ["that", 93], ["is", 98], ["the", 101], ["result", 105], ["of", 112], ["a", 115], ["reciprocal", 117], ["translocation", 128], ["between", 142], ["chromosomes", 150], ["9", 162], ["and", 164], ["22", 168], ["and", 171], ["cytogenetically", 175], ["evident", 191], ["as", 199], ["the", 202], ["Philadelphia", 206], ["chromosome", 219], [".", 229], ["Imatinib", 231], ["(", 240], ["Glivec", 241], [",", 247], ["Gleevec", 249], [")", 256], [",", 257], ["a", 259], ["specific", 261], ["small", 270], ["molecule", 276], ["inhibitor", 285], ["of", 295], ["Bcr", 298], ["-", 301], ["Abl", 302], [",", 305], ["has", 307], ["become", 311], ["the", 318], ["standard", 322], ["drug", 331], ["therapy", 336], ["for", 344], ["CML", 348], [",", 351], ["and", 353], ["has", 357], ["dramatically", 361], ["diminished", 374], ["the", 385], ["use", 389], ["of", 393], ["allogeneic", 396], ["stem", 407], ["cell", 412], ["transplantation", 417], [".", 432], ["Despite", 434], ["unprecedented", 442], ["rates", 456], ["of", 462], ["complete", 465], ["cytogenetic", 474], ["response", 486], [",", 494], ["residual", 496], ["disease", 505], ["remains", 513], ["detectable", 521], ["in", 532], ["the", 535], ["majority", 539], ["of", 548], ["patients", 551], [",", 559], ["suggesting", 561], ["that", 572], ["imatinib", 577], ["fails", 586], ["to", 592], ["eradicate", 595], ["leukemic", 605], ["stem", 614], ["cells", 619], [".", 624], ["In", 626], ["this", 629], ["publication", 634], [",", 645], ["the", 647], ["current", 651], ["perspectives", 659], ["for", 672], ["CML", 676], ["patients", 680], ["treated", 689], ["with", 697], ["imatinib", 702], ["are", 711], ["reviewed", 715], [",", 723], ["focusing", 725], ["on", 734], ["the", 737], ["results", 741], ["of", 749], ["both", 752], ["standard", 757], ["and", 766], ["high", 770], ["-", 774], ["dose", 775], ["therapy", 780], [".", 787], ["Monitoring", 789], ["of", 800], ["time", 803], ["-", 807], ["dependent", 808], ["prognostic", 818], ["factors", 829], ["is", 837], ["reviewed", 840], [".", 848], ["The", 850], ["reasons", 854], ["imatinib", 862], ["may", 871], ["not", 875], ["be", 879], ["able", 882], ["to", 887], ["eradicate", 890], ["the", 900], ["disease", 904], ["are", 912], ["discussed", 916], [",", 925], ["and", 927], ["potential", 931], ["strategies", 941], ["to", 952], ["achieve", 955], ["disease", 963], ["elimination", 971], ["are", 983], ["presented", 987], [".", 996], ["Lastly", 998], [",", 1004], ["resistance", 1006], ["to", 1017], ["imatinib", 1020], ["and", 1029], ["the", 1033], ["potential", 1037], ["of", 1047], ["second", 1050], ["-", 1056], ["generation", 1057], ["Abl", 1068], ["kinase", 1072], ["inhibitors", 1079], ["in", 1090], ["the", 1093], ["setting", 1097], ["of", 1105], ["clinical", 1108], ["resistance", 1117], ["are", 1128], ["considered", 1132], [".", 1142]]}
{"context": "Neural stem/progenitor cells (NSCs) reside in the subventricular zone (SVZ) and subgranular zone of the hippocampal dentate gyrus in adult mammals. The ubiquitin ligase HRD1 is associated with degradation of amyloid precursor protein and believed to be specifically expressed in neurons and not in astrocytes. We investigated expression of HRD1 using immunohistochemistry and found colocalization of HRD1 with the NSC marker protein nestin and glial fibrillary acidic protein in the NSCs of the SVZ (the SVZ astrocytes) but not in the hippocampus. In the hippocampal dentate gyrus, HRD1 is localized in the nucleus of nestin-positive cells.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "2955684affa14660b9c3b54689b9b2d2", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[106, 106], [70, 70]], "char_spans": [[618, 623], [433, 438]]}]}], "context_tokens": [["Neural", 0], ["stem", 7], ["/", 11], ["progenitor", 12], ["cells", 23], ["(", 29], ["NSCs", 30], [")", 34], ["reside", 36], ["in", 43], ["the", 46], ["subventricular", 50], ["zone", 65], ["(", 70], ["SVZ", 71], [")", 74], ["and", 76], ["subgranular", 80], ["zone", 92], ["of", 97], ["the", 100], ["hippocampal", 104], ["dentate", 116], ["gyrus", 124], ["in", 130], ["adult", 133], ["mammals", 139], [".", 146], ["The", 148], ["ubiquitin", 152], ["ligase", 162], ["HRD1", 169], ["is", 174], ["associated", 177], ["with", 188], ["degradation", 193], ["of", 205], ["amyloid", 208], ["precursor", 216], ["protein", 226], ["and", 234], ["believed", 238], ["to", 247], ["be", 250], ["specifically", 253], ["expressed", 266], ["in", 276], ["neurons", 279], ["and", 287], ["not", 291], ["in", 295], ["astrocytes", 298], [".", 308], ["We", 310], ["investigated", 313], ["expression", 326], ["of", 337], ["HRD1", 340], ["using", 345], ["immunohistochemistry", 351], ["and", 372], ["found", 376], ["colocalization", 382], ["of", 397], ["HRD1", 400], ["with", 405], ["the", 410], ["NSC", 414], ["marker", 418], ["protein", 425], ["nestin", 433], ["and", 440], ["glial", 444], ["fibrillary", 450], ["acidic", 461], ["protein", 468], ["in", 476], ["the", 479], ["NSCs", 483], ["of", 488], ["the", 491], ["SVZ", 495], ["(", 499], ["the", 500], ["SVZ", 504], ["astrocytes", 508], [")", 518], ["but", 520], ["not", 524], ["in", 528], ["the", 531], ["hippocampus", 535], [".", 546], ["In", 548], ["the", 551], ["hippocampal", 555], ["dentate", 567], ["gyrus", 575], [",", 580], ["HRD1", 582], ["is", 587], ["localized", 590], ["in", 600], ["the", 603], ["nucleus", 607], ["of", 615], ["nestin", 618], ["-", 624], ["positive", 625], ["cells", 634], [".", 639]]}
{"context": "In vivo brain microdialysis was used to assess the effects of tolcapone, a novel central and peripheral inhibitor of catechol-O-methyltransferase on striatal 3,4-dihydroxyphenyl-L-alanine (L-dopa) and dopamine metabolism. The oral administration of 30 mg/kg of tolcapone failed to change dopamine output but elicited a marked and long-lasting decrease of the extracellular levels of homovanillic acid (HVA) and 3-methoxytyramine with a concomitant increase of 3,4-dihydroxyphenylacetic acid (DOPAC). The administration of L-dopa (20 and 60 mg/kg p.o.) + benserazide (15 mg/kg p.o.) resulted in dose-dependent increase of dialysate levels of L-dopa and 3-O-methyl-DOPA. Tolcapone (30 mg/kg p.o.), given as adjunct to both doses of L-dopa, markedly enhanced the elevation or extracellular L-dopa, while it completely prevented the formation of 3-O-methyl-DOPA. In another experiment, the administration of L-dopa + benserazide (30 + 15 mg/kg p.o.) resulted in increased extracellular levels of dopamine, DOPAC, HVA and 3-methoxytyramine. The co-administration of tolcapone (30 mg/kg p.o.) further increased dopamine and DOPAC levels, whereas HVA and 3-methoxytyramine effluxes were reduced. These findings support the notion that tolcapone has the ability to enhance striatal dopamine neurotransmission by increasing L-dopa bioavailability through peripheral and central inhibition of L-dopa O-methylation, as well as by blocking the central conversion of dopamine into 3-methoxytyramine.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "08994280294d46b78596738f2a8bd39a", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[33, 35], [161, 163], [124, 126], [91, 93], [260, 262], [270, 272], [185, 187], [151, 153]], "char_spans": [[189, 194], [787, 792], [641, 646], [522, 527], [1315, 1320], [1383, 1388], [904, 909], [730, 735]]}]}], "context_tokens": [["In", 0], ["vivo", 3], ["brain", 8], ["microdialysis", 14], ["was", 28], ["used", 32], ["to", 37], ["assess", 40], ["the", 47], ["effects", 51], ["of", 59], ["tolcapone", 62], [",", 71], ["a", 73], ["novel", 75], ["central", 81], ["and", 89], ["peripheral", 93], ["inhibitor", 104], ["of", 114], ["catechol", 117], ["-", 125], ["O", 126], ["-", 127], ["methyltransferase", 128], ["on", 146], ["striatal", 149], ["3,4-dihydroxyphenyl", 158], ["-", 177], ["L", 178], ["-", 179], ["alanine", 180], ["(", 188], ["L", 189], ["-", 190], ["dopa", 191], [")", 195], ["and", 197], ["dopamine", 201], ["metabolism", 210], [".", 220], ["The", 222], ["oral", 226], ["administration", 231], ["of", 246], ["30", 249], ["mg", 252], ["/", 254], ["kg", 255], ["of", 258], ["tolcapone", 261], ["failed", 271], ["to", 278], ["change", 281], ["dopamine", 288], ["output", 297], ["but", 304], ["elicited", 308], ["a", 317], ["marked", 319], ["and", 326], ["long", 330], ["-", 334], ["lasting", 335], ["decrease", 343], ["of", 352], ["the", 355], ["extracellular", 359], ["levels", 373], ["of", 380], ["homovanillic", 383], ["acid", 396], ["(", 401], ["HVA", 402], [")", 405], ["and", 407], ["3-methoxytyramine", 411], ["with", 429], ["a", 434], ["concomitant", 436], ["increase", 448], ["of", 457], ["3,4-dihydroxyphenylacetic", 460], ["acid", 486], ["(", 491], ["DOPAC", 492], [")", 497], [".", 498], ["The", 500], ["administration", 504], ["of", 519], ["L", 522], ["-", 523], ["dopa", 524], ["(", 529], ["20", 530], ["and", 533], ["60", 537], ["mg", 540], ["/", 542], ["kg", 543], ["p.o", 546], [".", 549], [")", 550], ["+", 552], ["benserazide", 554], ["(", 566], ["15", 567], ["mg", 570], ["/", 572], ["kg", 573], ["p.o", 576], [".", 579], [")", 580], ["resulted", 582], ["in", 591], ["dose", 594], ["-", 598], ["dependent", 599], ["increase", 609], ["of", 618], ["dialysate", 621], ["levels", 631], ["of", 638], ["L", 641], ["-", 642], ["dopa", 643], ["and", 648], ["3-O", 652], ["-", 655], ["methyl", 656], ["-", 662], ["DOPA", 663], [".", 667], ["Tolcapone", 669], ["(", 679], ["30", 680], ["mg", 683], ["/", 685], ["kg", 686], ["p.o", 689], [".", 692], [")", 693], [",", 694], ["given", 696], ["as", 702], ["adjunct", 705], ["to", 713], ["both", 716], ["doses", 721], ["of", 727], ["L", 730], ["-", 731], ["dopa", 732], [",", 736], ["markedly", 738], ["enhanced", 747], ["the", 756], ["elevation", 760], ["or", 770], ["extracellular", 773], ["L", 787], ["-", 788], ["dopa", 789], [",", 793], ["while", 795], ["it", 801], ["completely", 804], ["prevented", 815], ["the", 825], ["formation", 829], ["of", 839], ["3-O", 842], ["-", 845], ["methyl", 846], ["-", 852], ["DOPA", 853], [".", 857], ["In", 859], ["another", 862], ["experiment", 870], [",", 880], ["the", 882], ["administration", 886], ["of", 901], ["L", 904], ["-", 905], ["dopa", 906], ["+", 911], ["benserazide", 913], ["(", 925], ["30", 926], ["+", 929], ["15", 931], ["mg", 934], ["/", 936], ["kg", 937], ["p.o", 940], [".", 943], [")", 944], ["resulted", 946], ["in", 955], ["increased", 958], ["extracellular", 968], ["levels", 982], ["of", 989], ["dopamine", 992], [",", 1000], ["DOPAC", 1002], [",", 1007], ["HVA", 1009], ["and", 1013], ["3-methoxytyramine", 1017], [".", 1034], ["The", 1036], ["co", 1040], ["-", 1042], ["administration", 1043], ["of", 1058], ["tolcapone", 1061], ["(", 1071], ["30", 1072], ["mg", 1075], ["/", 1077], ["kg", 1078], ["p.o", 1081], [".", 1084], [")", 1085], ["further", 1087], ["increased", 1095], ["dopamine", 1105], ["and", 1114], ["DOPAC", 1118], ["levels", 1124], [",", 1130], ["whereas", 1132], ["HVA", 1140], ["and", 1144], ["3-methoxytyramine", 1148], ["effluxes", 1166], ["were", 1175], ["reduced", 1180], [".", 1187], ["These", 1189], ["findings", 1195], ["support", 1204], ["the", 1212], ["notion", 1216], ["that", 1223], ["tolcapone", 1228], ["has", 1238], ["the", 1242], ["ability", 1246], ["to", 1254], ["enhance", 1257], ["striatal", 1265], ["dopamine", 1274], ["neurotransmission", 1283], ["by", 1301], ["increasing", 1304], ["L", 1315], ["-", 1316], ["dopa", 1317], ["bioavailability", 1322], ["through", 1338], ["peripheral", 1346], ["and", 1357], ["central", 1361], ["inhibition", 1369], ["of", 1380], ["L", 1383], ["-", 1384], ["dopa", 1385], ["O", 1390], ["-", 1391], ["methylation", 1392], [",", 1403], ["as", 1405], ["well", 1408], ["as", 1413], ["by", 1416], ["blocking", 1419], ["the", 1428], ["central", 1432], ["conversion", 1440], ["of", 1451], ["dopamine", 1454], ["into", 1463], ["3-methoxytyramine", 1468], [".", 1485]]}
{"context": "To investigate the influence of age and gender on the components of the 28-joint Disease Activity Score (DAS28) in patients with rheumatoid arthritis (RA), and to clarify whether a high DAS28 can be equally interpreted in all age groups, independent of gender. A prospective cohort of 553 patients with RA was studied for approximately 20 years after diagnosis. The single measures of disease activity and the share of different components of the DAS28 (eg, erythrocyte sedimentation rate; ESR) were analysed and compared between three age groups (<45, 45-65 and >65 years) and per gender, using analysis of variance (ANOVA). The performance of the DAS28 and its components was explored in moderate to high and low DAS28 categories. Linear mixed model analysis was used to design the models best predicting ESR and the share of ESR. ESR significantly increased with age, independent of other variables of disease activity. This increase was more pronounced in male than in female patients. Nevertheless, the share of ESR increased with age only in male patients with a low DAS28 (<3.2). If the DAS28 score was >3.2, age and gender did not have a significant effect on any components of the DAS28. C-reactive protein (CRP) and DAS28(CRP) were not influenced by age. A high DAS28 was found to perform equally in all age groups, in men and women, despite the elevating effect of age on ESR. In elderly men with low disease activity, remission rate could be underestimated by an elevated ESR.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "a41b67e4e4004aa6a155ea9bb5d45fc4", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[264, 264]], "char_spans": [[1337, 1341]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["influence", 19], ["of", 29], ["age", 32], ["and", 36], ["gender", 40], ["on", 47], ["the", 50], ["components", 54], ["of", 65], ["the", 68], ["28-joint", 72], ["Disease", 81], ["Activity", 89], ["Score", 98], ["(", 104], ["DAS28", 105], [")", 110], ["in", 112], ["patients", 115], ["with", 124], ["rheumatoid", 129], ["arthritis", 140], ["(", 150], ["RA", 151], [")", 153], [",", 154], ["and", 156], ["to", 160], ["clarify", 163], ["whether", 171], ["a", 179], ["high", 181], ["DAS28", 186], ["can", 192], ["be", 196], ["equally", 199], ["interpreted", 207], ["in", 219], ["all", 222], ["age", 226], ["groups", 230], [",", 236], ["independent", 238], ["of", 250], ["gender", 253], [".", 259], ["A", 261], ["prospective", 263], ["cohort", 275], ["of", 282], ["553", 285], ["patients", 289], ["with", 298], ["RA", 303], ["was", 306], ["studied", 310], ["for", 318], ["approximately", 322], ["20", 336], ["years", 339], ["after", 345], ["diagnosis", 351], [".", 360], ["The", 362], ["single", 366], ["measures", 373], ["of", 382], ["disease", 385], ["activity", 393], ["and", 402], ["the", 406], ["share", 410], ["of", 416], ["different", 419], ["components", 429], ["of", 440], ["the", 443], ["DAS28", 447], ["(", 453], ["eg", 454], [",", 456], ["erythrocyte", 458], ["sedimentation", 470], ["rate", 484], [";", 488], ["ESR", 490], [")", 493], ["were", 495], ["analysed", 500], ["and", 509], ["compared", 513], ["between", 522], ["three", 530], ["age", 536], ["groups", 540], ["(", 547], ["<", 548], ["45", 549], [",", 551], ["45", 553], ["-", 555], ["65", 556], ["and", 559], [">", 563], ["65", 564], ["years", 567], [")", 572], ["and", 574], ["per", 578], ["gender", 582], [",", 588], ["using", 590], ["analysis", 596], ["of", 605], ["variance", 608], ["(", 617], ["ANOVA", 618], [")", 623], [".", 624], ["The", 626], ["performance", 630], ["of", 642], ["the", 645], ["DAS28", 649], ["and", 655], ["its", 659], ["components", 663], ["was", 674], ["explored", 678], ["in", 687], ["moderate", 690], ["to", 699], ["high", 702], ["and", 707], ["low", 711], ["DAS28", 715], ["categories", 721], [".", 731], ["Linear", 733], ["mixed", 740], ["model", 746], ["analysis", 752], ["was", 761], ["used", 765], ["to", 770], ["design", 773], ["the", 780], ["models", 784], ["best", 791], ["predicting", 796], ["ESR", 807], ["and", 811], ["the", 815], ["share", 819], ["of", 825], ["ESR", 828], [".", 831], ["ESR", 833], ["significantly", 837], ["increased", 851], ["with", 861], ["age", 866], [",", 869], ["independent", 871], ["of", 883], ["other", 886], ["variables", 892], ["of", 902], ["disease", 905], ["activity", 913], [".", 921], ["This", 923], ["increase", 928], ["was", 937], ["more", 941], ["pronounced", 946], ["in", 957], ["male", 960], ["than", 965], ["in", 970], ["female", 973], ["patients", 980], [".", 988], ["Nevertheless", 990], [",", 1002], ["the", 1004], ["share", 1008], ["of", 1014], ["ESR", 1017], ["increased", 1021], ["with", 1031], ["age", 1036], ["only", 1040], ["in", 1045], ["male", 1048], ["patients", 1053], ["with", 1062], ["a", 1067], ["low", 1069], ["DAS28", 1073], ["(", 1079], ["<", 1080], ["3.2", 1081], [")", 1084], [".", 1085], ["If", 1087], ["the", 1090], ["DAS28", 1094], ["score", 1100], ["was", 1106], [">", 1110], ["3.2", 1111], [",", 1114], ["age", 1116], ["and", 1120], ["gender", 1124], ["did", 1131], ["not", 1135], ["have", 1139], ["a", 1144], ["significant", 1146], ["effect", 1158], ["on", 1165], ["any", 1168], ["components", 1172], ["of", 1183], ["the", 1186], ["DAS28", 1190], [".", 1195], ["C", 1197], ["-", 1198], ["reactive", 1199], ["protein", 1208], ["(", 1216], ["CRP", 1217], [")", 1220], ["and", 1222], ["DAS28(CRP", 1226], [")", 1235], ["were", 1237], ["not", 1242], ["influenced", 1246], ["by", 1257], ["age", 1260], [".", 1263], ["A", 1265], ["high", 1267], ["DAS28", 1272], ["was", 1278], ["found", 1282], ["to", 1288], ["perform", 1291], ["equally", 1299], ["in", 1307], ["all", 1310], ["age", 1314], ["groups", 1318], [",", 1324], ["in", 1326], ["men", 1329], ["and", 1333], ["women", 1337], [",", 1342], ["despite", 1344], ["the", 1352], ["elevating", 1356], ["effect", 1366], ["of", 1373], ["age", 1376], ["on", 1380], ["ESR", 1383], [".", 1386], ["In", 1388], ["elderly", 1391], ["men", 1399], ["with", 1403], ["low", 1408], ["disease", 1412], ["activity", 1420], [",", 1428], ["remission", 1430], ["rate", 1440], ["could", 1445], ["be", 1451], ["underestimated", 1454], ["by", 1469], ["an", 1472], ["elevated", 1475], ["ESR", 1484], [".", 1487]]}
{"context": "alpha-Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles in the pathogenesis of Lewy bodies. We examined the relationship between alpha-synuclein, ubiquitin, and lipids in Lewy bodies of fixed brain sections or isolated from cortical tissues of dementia with Lewy bodies. Lewy bodies exhibited a range of labeling patterns for alpha-synuclein and ubiquitin, from a homogeneous pattern in which alpha-synuclein and ubiquitin were evenly distributed and overlapped across the inclusion body to a concentric pattern in which alpha-synuclein and ubiquitin were partially segregated, with alpha-synuclein labeling concentrated in the peripheral domain and ubiquitin in the central domain of the Lewy body. Lipids represented a significant component in both homogeneous and concentric Lewy bodies. These results suggest that Lewy bodies are heterogeneous in their subregional composition. The segregation of alpha-synuclein to Lewy body peripheral domain is consistent with the hypothesis that alpha-synuclein is continually deposited onto Lewy bodies.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "84268ced61744024a40b6f8d2316d275", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[63, 65], [28, 30], [154, 156], [168, 170], [95, 97], [105, 107], [0, 2], [75, 77]], "char_spans": [[370, 384], [173, 187], [945, 959], [1031, 1045], [565, 579], [627, 641], [0, 14], [437, 451]]}]}], "context_tokens": [["alpha", 0], ["-", 5], ["Synuclein", 6], ["and", 16], ["ubiquitin", 20], ["are", 30], ["two", 34], ["Lewy", 38], ["body", 43], ["protein", 48], ["components", 56], ["that", 67], ["may", 72], ["play", 76], ["antagonistic", 81], ["roles", 94], ["in", 100], ["the", 103], ["pathogenesis", 107], ["of", 120], ["Lewy", 123], ["bodies", 128], [".", 134], ["We", 136], ["examined", 139], ["the", 148], ["relationship", 152], ["between", 165], ["alpha", 173], ["-", 178], ["synuclein", 179], [",", 188], ["ubiquitin", 190], [",", 199], ["and", 201], ["lipids", 205], ["in", 212], ["Lewy", 215], ["bodies", 220], ["of", 227], ["fixed", 230], ["brain", 236], ["sections", 242], ["or", 251], ["isolated", 254], ["from", 263], ["cortical", 268], ["tissues", 277], ["of", 285], ["dementia", 288], ["with", 297], ["Lewy", 302], ["bodies", 307], [".", 313], ["Lewy", 315], ["bodies", 320], ["exhibited", 327], ["a", 337], ["range", 339], ["of", 345], ["labeling", 348], ["patterns", 357], ["for", 366], ["alpha", 370], ["-", 375], ["synuclein", 376], ["and", 386], ["ubiquitin", 390], [",", 399], ["from", 401], ["a", 406], ["homogeneous", 408], ["pattern", 420], ["in", 428], ["which", 431], ["alpha", 437], ["-", 442], ["synuclein", 443], ["and", 453], ["ubiquitin", 457], ["were", 467], ["evenly", 472], ["distributed", 479], ["and", 491], ["overlapped", 495], ["across", 506], ["the", 513], ["inclusion", 517], ["body", 527], ["to", 532], ["a", 535], ["concentric", 537], ["pattern", 548], ["in", 556], ["which", 559], ["alpha", 565], ["-", 570], ["synuclein", 571], ["and", 581], ["ubiquitin", 585], ["were", 595], ["partially", 600], ["segregated", 610], [",", 620], ["with", 622], ["alpha", 627], ["-", 632], ["synuclein", 633], ["labeling", 643], ["concentrated", 652], ["in", 665], ["the", 668], ["peripheral", 672], ["domain", 683], ["and", 690], ["ubiquitin", 694], ["in", 704], ["the", 707], ["central", 711], ["domain", 719], ["of", 726], ["the", 729], ["Lewy", 733], ["body", 738], [".", 742], ["Lipids", 744], ["represented", 751], ["a", 763], ["significant", 765], ["component", 777], ["in", 787], ["both", 790], ["homogeneous", 795], ["and", 807], ["concentric", 811], ["Lewy", 822], ["bodies", 827], [".", 833], ["These", 835], ["results", 841], ["suggest", 849], ["that", 857], ["Lewy", 862], ["bodies", 867], ["are", 874], ["heterogeneous", 878], ["in", 892], ["their", 895], ["subregional", 901], ["composition", 913], [".", 924], ["The", 926], ["segregation", 930], ["of", 942], ["alpha", 945], ["-", 950], ["synuclein", 951], ["to", 961], ["Lewy", 964], ["body", 969], ["peripheral", 974], ["domain", 985], ["is", 992], ["consistent", 995], ["with", 1006], ["the", 1011], ["hypothesis", 1015], ["that", 1026], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], ["is", 1047], ["continually", 1050], ["deposited", 1062], ["onto", 1072], ["Lewy", 1077], ["bodies", 1082], [".", 1088]]}
{"context": "The Chinese version of the Davidson Trauma Scale (DTS-C) was developed to respond to the need of Chinese-speaking individuals. The DTS is a validated self-rating scale used in the diagnosis of posttraumatic stress disorder (PTSD). The DTS-C is translated from DTS through a two-stage translation. Subjects were drawn from a sample of 210 survivors of the 21 September 1999, Chi-Chi Earthquake. The scale showed good internal consistency (Cronbach's alpha = 0.97) and test-retest reliability (r = 0.88). Concurrent validity was obtained against the clinical diagnostic interview, with a diagnostic accuracy of 0.85 at DTS-C score of 44. It showed that the sensitivity was 0.9, specificity 0.81, positive likelihood ratio 4.74, and negative likelihood ratio 0.12. The recommended stratum-specific likelihood ratios were 0.10 (95% CI: 0.05-0.20) for the score range 0-39, 4 (2.22-7.23) for the score range of 40-59, and 6.14 (3.42-11.02) for the scores above 60. In PTSD diagnosed subjects, the factor structures closely resembled the DSM-IV grouping of PTSD symptoms. The psychometric strength of DTS-C is reliable for its future use, particularly for screening for subjects with possible diagnosis of PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "bba18f5535f945b98b8a82421bcbe956", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[44, 44], [248, 248], [207, 207], [222, 222]], "char_spans": [[224, 227], [1200, 1203], [963, 966], [1051, 1054]]}]}], "context_tokens": [["The", 0], ["Chinese", 4], ["version", 12], ["of", 20], ["the", 23], ["Davidson", 27], ["Trauma", 36], ["Scale", 43], ["(", 49], ["DTS", 50], ["-", 53], ["C", 54], [")", 55], ["was", 57], ["developed", 61], ["to", 71], ["respond", 74], ["to", 82], ["the", 85], ["need", 89], ["of", 94], ["Chinese", 97], ["-", 104], ["speaking", 105], ["individuals", 114], [".", 125], ["The", 127], ["DTS", 131], ["is", 135], ["a", 138], ["validated", 140], ["self", 150], ["-", 154], ["rating", 155], ["scale", 162], ["used", 168], ["in", 173], ["the", 176], ["diagnosis", 180], ["of", 190], ["posttraumatic", 193], ["stress", 207], ["disorder", 214], ["(", 223], ["PTSD", 224], [")", 228], [".", 229], ["The", 231], ["DTS", 235], ["-", 238], ["C", 239], ["is", 241], ["translated", 244], ["from", 255], ["DTS", 260], ["through", 264], ["a", 272], ["two", 274], ["-", 277], ["stage", 278], ["translation", 284], [".", 295], ["Subjects", 297], ["were", 306], ["drawn", 311], ["from", 317], ["a", 322], ["sample", 324], ["of", 331], ["210", 334], ["survivors", 338], ["of", 348], ["the", 351], ["21", 355], ["September", 358], ["1999", 368], [",", 372], ["Chi", 374], ["-", 377], ["Chi", 378], ["Earthquake", 382], [".", 392], ["The", 394], ["scale", 398], ["showed", 404], ["good", 411], ["internal", 416], ["consistency", 425], ["(", 437], ["Cronbach", 438], ["'s", 446], ["alpha", 449], ["=", 455], ["0.97", 457], [")", 461], ["and", 463], ["test", 467], ["-", 471], ["retest", 472], ["reliability", 479], ["(", 491], ["r", 492], ["=", 494], ["0.88", 496], [")", 500], [".", 501], ["Concurrent", 503], ["validity", 514], ["was", 523], ["obtained", 527], ["against", 536], ["the", 544], ["clinical", 548], ["diagnostic", 557], ["interview", 568], [",", 577], ["with", 579], ["a", 584], ["diagnostic", 586], ["accuracy", 597], ["of", 606], ["0.85", 609], ["at", 614], ["DTS", 617], ["-", 620], ["C", 621], ["score", 623], ["of", 629], ["44", 632], [".", 634], ["It", 636], ["showed", 639], ["that", 646], ["the", 651], ["sensitivity", 655], ["was", 667], ["0.9", 671], [",", 674], ["specificity", 676], ["0.81", 688], [",", 692], ["positive", 694], ["likelihood", 703], ["ratio", 714], ["4.74", 720], [",", 724], ["and", 726], ["negative", 730], ["likelihood", 739], ["ratio", 750], ["0.12", 756], [".", 760], ["The", 762], ["recommended", 766], ["stratum", 778], ["-", 785], ["specific", 786], ["likelihood", 795], ["ratios", 806], ["were", 813], ["0.10", 818], ["(", 823], ["95", 824], ["%", 826], ["CI", 828], [":", 830], ["0.05", 832], ["-", 836], ["0.20", 837], [")", 841], ["for", 843], ["the", 847], ["score", 851], ["range", 857], ["0", 863], ["-", 864], ["39", 865], [",", 867], ["4", 869], ["(", 871], ["2.22", 872], ["-", 876], ["7.23", 877], [")", 881], ["for", 883], ["the", 887], ["score", 891], ["range", 897], ["of", 903], ["40", 906], ["-", 908], ["59", 909], [",", 911], ["and", 913], ["6.14", 917], ["(", 922], ["3.42", 923], ["-", 927], ["11.02", 928], [")", 933], ["for", 935], ["the", 939], ["scores", 943], ["above", 950], ["60", 956], [".", 958], ["In", 960], ["PTSD", 963], ["diagnosed", 968], ["subjects", 978], [",", 986], ["the", 988], ["factor", 992], ["structures", 999], ["closely", 1010], ["resembled", 1018], ["the", 1028], ["DSM", 1032], ["-", 1035], ["IV", 1036], ["grouping", 1039], ["of", 1048], ["PTSD", 1051], ["symptoms", 1056], [".", 1064], ["The", 1066], ["psychometric", 1070], ["strength", 1083], ["of", 1092], ["DTS", 1095], ["-", 1098], ["C", 1099], ["is", 1101], ["reliable", 1104], ["for", 1113], ["its", 1117], ["future", 1121], ["use", 1128], [",", 1131], ["particularly", 1133], ["for", 1146], ["screening", 1150], ["for", 1160], ["subjects", 1164], ["with", 1173], ["possible", 1178], ["diagnosis", 1187], ["of", 1197], ["PTSD", 1200], [".", 1204]]}
{"context": "We have recently shown that the Na(+)/Ca(2+) exchanger (NCX) is involved in nitric oxide (NO)-induced cytotoxicity in cultured astrocytes and neurons. However, there is no in vivo evidence suggesting the role of NCX in neurodegenerative disorders associated with NO. NO is implicated in the pathogenesis of neurodegenerative disorders such as Parkinson's disease. This study examined the effect of SEA0400, the specific NCX inhibitor, on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity, a model of Parkinson's disease, in C57BL/6J mice. MPTP treatment (10 mg/kg, four times at 2-h intervals) decreased dopamine levels in the midbrain and impaired motor coordination, and these effects were counteracted by S-methylthiocitrulline, a selective neuronal NO synthase inhibitor. SEA0400 protected against the dopaminergic neurotoxicity (determined by dopamine levels in the midbrain and striatum, tyrosine hydroxylase immunoreactivity in the substantia nigra and striatum, striatal dopamine release, and motor deficits) in MPTP-treated mice. SEA0400 had no radical-scavenging activity. SEA0400 did not affect MPTP metabolism and MPTP-induced NO production and microglial activation, while it attenuated MPTP-induced increases in extracellular signal-regulated kinase (ERK) phosphorylation and lipid peroxidation product, thiobarbituric acid reactive substance. These findings suggest that SEA0400 protects against MPTP-induced neurotoxicity probably by blocking ERK phosphorylation and lipid peroxidation which are downstream of NCX-mediated Ca(2+) influx.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "da32f12980d845719c03c2c03494afe1", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[6, 9]], "char_spans": [[32, 53]]}, {"text": "NCX", "token_spans": [[72, 72], [39, 39], [11, 11], [250, 250]], "char_spans": [[420, 422], [212, 214], [56, 58], [1563, 1565]]}]}], "context_tokens": [["We", 0], ["have", 3], ["recently", 8], ["shown", 17], ["that", 23], ["the", 28], ["Na(+)/Ca(2", 32], ["+", 42], [")", 43], ["exchanger", 45], ["(", 55], ["NCX", 56], [")", 59], ["is", 61], ["involved", 64], ["in", 73], ["nitric", 76], ["oxide", 83], ["(", 89], ["NO)-induced", 90], ["cytotoxicity", 102], ["in", 115], ["cultured", 118], ["astrocytes", 127], ["and", 138], ["neurons", 142], [".", 149], ["However", 151], [",", 158], ["there", 160], ["is", 166], ["no", 169], ["in", 172], ["vivo", 175], ["evidence", 180], ["suggesting", 189], ["the", 200], ["role", 204], ["of", 209], ["NCX", 212], ["in", 216], ["neurodegenerative", 219], ["disorders", 237], ["associated", 247], ["with", 258], ["NO", 263], [".", 265], ["NO", 267], ["is", 270], ["implicated", 273], ["in", 284], ["the", 287], ["pathogenesis", 291], ["of", 304], ["neurodegenerative", 307], ["disorders", 325], ["such", 335], ["as", 340], ["Parkinson", 343], ["'s", 352], ["disease", 355], [".", 362], ["This", 364], ["study", 369], ["examined", 375], ["the", 384], ["effect", 388], ["of", 395], ["SEA0400", 398], [",", 405], ["the", 407], ["specific", 411], ["NCX", 420], ["inhibitor", 424], [",", 433], ["on", 435], ["1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", 438], ["(", 483], ["MPTP)-induced", 484], ["dopaminergic", 498], ["neurotoxicity", 511], [",", 524], ["a", 526], ["model", 528], ["of", 534], ["Parkinson", 537], ["'s", 546], ["disease", 549], [",", 556], ["in", 558], ["C57BL/6J", 561], ["mice", 570], [".", 574], ["MPTP", 576], ["treatment", 581], ["(", 591], ["10", 592], ["mg", 595], ["/", 597], ["kg", 598], [",", 600], ["four", 602], ["times", 607], ["at", 613], ["2-h", 616], ["intervals", 620], [")", 629], ["decreased", 631], ["dopamine", 641], ["levels", 650], ["in", 657], ["the", 660], ["midbrain", 664], ["and", 673], ["impaired", 677], ["motor", 686], ["coordination", 692], [",", 704], ["and", 706], ["these", 710], ["effects", 716], ["were", 724], ["counteracted", 729], ["by", 742], ["S", 745], ["-", 746], ["methylthiocitrulline", 747], [",", 767], ["a", 769], ["selective", 771], ["neuronal", 781], ["NO", 790], ["synthase", 793], ["inhibitor", 802], [".", 811], ["SEA0400", 813], ["protected", 821], ["against", 831], ["the", 839], ["dopaminergic", 843], ["neurotoxicity", 856], ["(", 870], ["determined", 871], ["by", 882], ["dopamine", 885], ["levels", 894], ["in", 901], ["the", 904], ["midbrain", 908], ["and", 917], ["striatum", 921], [",", 929], ["tyrosine", 931], ["hydroxylase", 940], ["immunoreactivity", 952], ["in", 969], ["the", 972], ["substantia", 976], ["nigra", 987], ["and", 993], ["striatum", 997], [",", 1005], ["striatal", 1007], ["dopamine", 1016], ["release", 1025], [",", 1032], ["and", 1034], ["motor", 1038], ["deficits", 1044], [")", 1052], ["in", 1054], ["MPTP", 1057], ["-", 1061], ["treated", 1062], ["mice", 1070], [".", 1074], ["SEA0400", 1076], ["had", 1084], ["no", 1088], ["radical", 1091], ["-", 1098], ["scavenging", 1099], ["activity", 1110], [".", 1118], ["SEA0400", 1120], ["did", 1128], ["not", 1132], ["affect", 1136], ["MPTP", 1143], ["metabolism", 1148], ["and", 1159], ["MPTP", 1163], ["-", 1167], ["induced", 1168], ["NO", 1176], ["production", 1179], ["and", 1190], ["microglial", 1194], ["activation", 1205], [",", 1215], ["while", 1217], ["it", 1223], ["attenuated", 1226], ["MPTP", 1237], ["-", 1241], ["induced", 1242], ["increases", 1250], ["in", 1260], ["extracellular", 1263], ["signal", 1277], ["-", 1283], ["regulated", 1284], ["kinase", 1294], ["(", 1301], ["ERK", 1302], [")", 1305], ["phosphorylation", 1307], ["and", 1323], ["lipid", 1327], ["peroxidation", 1333], ["product", 1346], [",", 1353], ["thiobarbituric", 1355], ["acid", 1370], ["reactive", 1375], ["substance", 1384], [".", 1393], ["These", 1395], ["findings", 1401], ["suggest", 1410], ["that", 1418], ["SEA0400", 1423], ["protects", 1431], ["against", 1440], ["MPTP", 1448], ["-", 1452], ["induced", 1453], ["neurotoxicity", 1461], ["probably", 1475], ["by", 1484], ["blocking", 1487], ["ERK", 1496], ["phosphorylation", 1500], ["and", 1516], ["lipid", 1520], ["peroxidation", 1526], ["which", 1539], ["are", 1545], ["downstream", 1549], ["of", 1560], ["NCX", 1563], ["-", 1566], ["mediated", 1567], ["Ca(2", 1576], ["+", 1580], [")", 1581], ["influx", 1583], [".", 1589]]}
{"context": "Mowat-Wilson syndrome (MWS) is a relatively newly described multiple congenital anomaly/mental retardation syndrome. Haploinsufficiency of a gene termed ZFHX1B (also known as SIP1) on chromosome 2 is responsible for this condition, and clinical genetic testing for MWS recently became available. The majority of reports in the literature originate from Northern Europe and Australia. Here we report our clinical experience with 12 patients diagnosed with MWS within a 2-year period of time in the United States, with particular emphasis on clinical characteristics and management strategies. Individuals with this condition have characteristic facial features, including microcephaly, hypertelorism, medially flared and broad eyebrows, prominent columella, pointed chin, and uplifted earlobes, which typically prompt the clinician to consider the diagnosis. Medical issues in our cohort of patients included seizures (75%) with no predeliction for any particular seizure type; agenesis of the corpus callosum (60% of our patients studied); congenital heart defects (75%), particularly involving the pulmonary arteries and/or valves; hypospadias (55% of males); severely impaired or absent speech (100% of individuals over 1 year of age) with relatively spared receptive language; and Hirschsprung disease (50%) or chronic constipation (25%). The incidence of MWS is unknown, but based on the number of patients identified in a short period of time within the US, it is likely greatly under recognized. MWS should be considered in any individual with severely impaired or absent speech, especially in the presence of seizures and anomalies involving the pulmonary arteries (particularly pulmonary artery sling) or pulmonary valves.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "ba508f5b8dfb4fbc83ecf9831706b686", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[25, 25]], "char_spans": [[153, 158]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["relatively", 33], ["newly", 44], ["described", 50], ["multiple", 60], ["congenital", 69], ["anomaly", 80], ["/", 87], ["mental", 88], ["retardation", 95], ["syndrome", 107], [".", 115], ["Haploinsufficiency", 117], ["of", 136], ["a", 139], ["gene", 141], ["termed", 146], ["ZFHX1B", 153], ["(", 160], ["also", 161], ["known", 166], ["as", 172], ["SIP1", 175], [")", 179], ["on", 181], ["chromosome", 184], ["2", 195], ["is", 197], ["responsible", 200], ["for", 212], ["this", 216], ["condition", 221], [",", 230], ["and", 232], ["clinical", 236], ["genetic", 245], ["testing", 253], ["for", 261], ["MWS", 265], ["recently", 269], ["became", 278], ["available", 285], [".", 294], ["The", 296], ["majority", 300], ["of", 309], ["reports", 312], ["in", 320], ["the", 323], ["literature", 327], ["originate", 338], ["from", 348], ["Northern", 353], ["Europe", 362], ["and", 369], ["Australia", 373], [".", 382], ["Here", 384], ["we", 389], ["report", 392], ["our", 399], ["clinical", 403], ["experience", 412], ["with", 423], ["12", 428], ["patients", 431], ["diagnosed", 440], ["with", 450], ["MWS", 455], ["within", 459], ["a", 466], ["2-year", 468], ["period", 475], ["of", 482], ["time", 485], ["in", 490], ["the", 493], ["United", 497], ["States", 504], [",", 510], ["with", 512], ["particular", 517], ["emphasis", 528], ["on", 537], ["clinical", 540], ["characteristics", 549], ["and", 565], ["management", 569], ["strategies", 580], [".", 590], ["Individuals", 592], ["with", 604], ["this", 609], ["condition", 614], ["have", 624], ["characteristic", 629], ["facial", 644], ["features", 651], [",", 659], ["including", 661], ["microcephaly", 671], [",", 683], ["hypertelorism", 685], [",", 698], ["medially", 700], ["flared", 709], ["and", 716], ["broad", 720], ["eyebrows", 726], [",", 734], ["prominent", 736], ["columella", 746], [",", 755], ["pointed", 757], ["chin", 765], [",", 769], ["and", 771], ["uplifted", 775], ["earlobes", 784], [",", 792], ["which", 794], ["typically", 800], ["prompt", 810], ["the", 817], ["clinician", 821], ["to", 831], ["consider", 834], ["the", 843], ["diagnosis", 847], [".", 856], ["Medical", 858], ["issues", 866], ["in", 873], ["our", 876], ["cohort", 880], ["of", 887], ["patients", 890], ["included", 899], ["seizures", 908], ["(", 917], ["75", 918], ["%", 920], [")", 921], ["with", 923], ["no", 928], ["predeliction", 931], ["for", 944], ["any", 948], ["particular", 952], ["seizure", 963], ["type", 971], [";", 975], ["agenesis", 977], ["of", 986], ["the", 989], ["corpus", 993], ["callosum", 1000], ["(", 1009], ["60", 1010], ["%", 1012], ["of", 1014], ["our", 1017], ["patients", 1021], ["studied", 1030], [")", 1037], [";", 1038], ["congenital", 1040], ["heart", 1051], ["defects", 1057], ["(", 1065], ["75", 1066], ["%", 1068], [")", 1069], [",", 1070], ["particularly", 1072], ["involving", 1085], ["the", 1095], ["pulmonary", 1099], ["arteries", 1109], ["and/or", 1118], ["valves", 1125], [";", 1131], ["hypospadias", 1133], ["(", 1145], ["55", 1146], ["%", 1148], ["of", 1150], ["males", 1153], [")", 1158], [";", 1159], ["severely", 1161], ["impaired", 1170], ["or", 1179], ["absent", 1182], ["speech", 1189], ["(", 1196], ["100", 1197], ["%", 1200], ["of", 1202], ["individuals", 1205], ["over", 1217], ["1", 1222], ["year", 1224], ["of", 1229], ["age", 1232], [")", 1235], ["with", 1237], ["relatively", 1242], ["spared", 1253], ["receptive", 1260], ["language", 1270], [";", 1278], ["and", 1280], ["Hirschsprung", 1284], ["disease", 1297], ["(", 1305], ["50", 1306], ["%", 1308], [")", 1309], ["or", 1311], ["chronic", 1314], ["constipation", 1322], ["(", 1335], ["25", 1336], ["%", 1338], [")", 1339], [".", 1340], ["The", 1342], ["incidence", 1346], ["of", 1356], ["MWS", 1359], ["is", 1363], ["unknown", 1366], [",", 1373], ["but", 1375], ["based", 1379], ["on", 1385], ["the", 1388], ["number", 1392], ["of", 1399], ["patients", 1402], ["identified", 1411], ["in", 1422], ["a", 1425], ["short", 1427], ["period", 1433], ["of", 1440], ["time", 1443], ["within", 1448], ["the", 1455], ["US", 1459], [",", 1461], ["it", 1463], ["is", 1466], ["likely", 1469], ["greatly", 1476], ["under", 1484], ["recognized", 1490], [".", 1500], ["MWS", 1502], ["should", 1506], ["be", 1513], ["considered", 1516], ["in", 1527], ["any", 1530], ["individual", 1534], ["with", 1545], ["severely", 1550], ["impaired", 1559], ["or", 1568], ["absent", 1571], ["speech", 1578], [",", 1584], ["especially", 1586], ["in", 1597], ["the", 1600], ["presence", 1604], ["of", 1613], ["seizures", 1616], ["and", 1625], ["anomalies", 1629], ["involving", 1639], ["the", 1649], ["pulmonary", 1653], ["arteries", 1663], ["(", 1672], ["particularly", 1673], ["pulmonary", 1686], ["artery", 1696], ["sling", 1703], [")", 1708], ["or", 1710], ["pulmonary", 1713], ["valves", 1723], [".", 1729]]}
{"context": "Genetic alteration of the adaptor protein (AP)-3 complex is responsible for the type 2 Hermansky-Pudlak syndrome, a lysosomal storage disease similar to the Chediak-Higashi syndrome (CHS). AP-3 presumably participates in the biogenesis of late endosomal compartments and may also be critical for the regulated secretion of lysosomes by specialized cells. Here, Dictyostelium discoideum cells defective for the mu3 subunit of the AP-3 complex were used and their phenotype analyzed. In mu3 mutant cells, endosomal maturation and lysosome secretion were markedly slower than that in wild-type cells. This phenotype is similar to that reported previously in lvsB mutant cells where the ortholog of the LYST gene, involved in CHS, is mutated. Detailed analysis revealed however significant differences between these two isogenic mutant cells: in lvsB mutant cells, the primary defect is an inefficient biogenesis of otherwise normal secretory lysosomes, while in mu3 mutant cells, the biogenesis and also the composition and the fusion properties of secretory lysosomes are affected. These results suggest that in D. discoideum, AP-3 controls both the efficiency and the specificity of postlysosome maturation, which represent two critical elements in the control of lysosome secretion.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "c24c1289233c489691969ee391245427", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[119, 120]], "char_spans": [[699, 707]]}]}], "context_tokens": [["Genetic", 0], ["alteration", 8], ["of", 19], ["the", 22], ["adaptor", 26], ["protein", 34], ["(", 42], ["AP)-3", 43], ["complex", 49], ["is", 57], ["responsible", 60], ["for", 72], ["the", 76], ["type", 80], ["2", 85], ["Hermansky", 87], ["-", 96], ["Pudlak", 97], ["syndrome", 104], [",", 112], ["a", 114], ["lysosomal", 116], ["storage", 126], ["disease", 134], ["similar", 142], ["to", 150], ["the", 153], ["Chediak", 157], ["-", 164], ["Higashi", 165], ["syndrome", 173], ["(", 182], ["CHS", 183], [")", 186], [".", 187], ["AP-3", 189], ["presumably", 194], ["participates", 205], ["in", 218], ["the", 221], ["biogenesis", 225], ["of", 236], ["late", 239], ["endosomal", 244], ["compartments", 254], ["and", 267], ["may", 271], ["also", 275], ["be", 280], ["critical", 283], ["for", 292], ["the", 296], ["regulated", 300], ["secretion", 310], ["of", 320], ["lysosomes", 323], ["by", 333], ["specialized", 336], ["cells", 348], [".", 353], ["Here", 355], [",", 359], ["Dictyostelium", 361], ["discoideum", 375], ["cells", 386], ["defective", 392], ["for", 402], ["the", 406], ["mu3", 410], ["subunit", 414], ["of", 422], ["the", 425], ["AP-3", 429], ["complex", 434], ["were", 442], ["used", 447], ["and", 452], ["their", 456], ["phenotype", 462], ["analyzed", 472], [".", 480], ["In", 482], ["mu3", 485], ["mutant", 489], ["cells", 496], [",", 501], ["endosomal", 503], ["maturation", 513], ["and", 524], ["lysosome", 528], ["secretion", 537], ["were", 547], ["markedly", 552], ["slower", 561], ["than", 568], ["that", 573], ["in", 578], ["wild", 581], ["-", 585], ["type", 586], ["cells", 591], [".", 596], ["This", 598], ["phenotype", 603], ["is", 613], ["similar", 616], ["to", 624], ["that", 627], ["reported", 632], ["previously", 641], ["in", 652], ["lvsB", 655], ["mutant", 660], ["cells", 667], ["where", 673], ["the", 679], ["ortholog", 683], ["of", 692], ["the", 695], ["LYST", 699], ["gene", 704], [",", 708], ["involved", 710], ["in", 719], ["CHS", 722], [",", 725], ["is", 727], ["mutated", 730], [".", 737], ["Detailed", 739], ["analysis", 748], ["revealed", 757], ["however", 766], ["significant", 774], ["differences", 786], ["between", 798], ["these", 806], ["two", 812], ["isogenic", 816], ["mutant", 825], ["cells", 832], [":", 837], ["in", 839], ["lvsB", 842], ["mutant", 847], ["cells", 854], [",", 859], ["the", 861], ["primary", 865], ["defect", 873], ["is", 880], ["an", 883], ["inefficient", 886], ["biogenesis", 898], ["of", 909], ["otherwise", 912], ["normal", 922], ["secretory", 929], ["lysosomes", 939], [",", 948], ["while", 950], ["in", 956], ["mu3", 959], ["mutant", 963], ["cells", 970], [",", 975], ["the", 977], ["biogenesis", 981], ["and", 992], ["also", 996], ["the", 1001], ["composition", 1005], ["and", 1017], ["the", 1021], ["fusion", 1025], ["properties", 1032], ["of", 1043], ["secretory", 1046], ["lysosomes", 1056], ["are", 1066], ["affected", 1070], [".", 1078], ["These", 1080], ["results", 1086], ["suggest", 1094], ["that", 1102], ["in", 1107], ["D.", 1110], ["discoideum", 1113], [",", 1123], ["AP-3", 1125], ["controls", 1130], ["both", 1139], ["the", 1144], ["efficiency", 1148], ["and", 1159], ["the", 1163], ["specificity", 1167], ["of", 1179], ["postlysosome", 1182], ["maturation", 1195], [",", 1205], ["which", 1207], ["represent", 1213], ["two", 1223], ["critical", 1227], ["elements", 1236], ["in", 1245], ["the", 1248], ["control", 1252], ["of", 1260], ["lysosome", 1263], ["secretion", 1272], [".", 1281]]}
{"context": "The protein alpha-synuclein (AS) is the primary fibrillar component of Lewy bodies, the pathological hallmark of Parkinson's disease. Wild-type human AS and the three mutant forms linked to Parkinson's disease (A53T, A30P, and E46K) all form fibrils through a nucleation-dependent pathway; however, the biophysical details of these fibrillation events are not yet well understood. Atomic-level structural insight is required in order to elucidate the potential role of AS fibrils in Parkinson's disease. Here we show that low temperature acquisition of magic-angle spinning NMR spectra of wild type AS fibrils-greatly enhances spectral sensitivity, enabling the detection of a substantially larger number of spin systems. At 0 +/- 3 degrees C sample temperature, cross polarization (CP) experiments yield weak signals. Lower temperature spectra (-40 +/- 3 degrees C) demonstrated several times greater signal intensity, an effect further amplified in 3D 15N-13C-13C experiments, which are required to perform backbone assignments on this sample. Thus 3D experiments enabled assignments of most amino acids in the rigid part of the fibril (approximately residues 64 to 94), as well as tentative site-specific assignments for T22, V26, A27, Y39, G41, S42, H50, V52, A53, T54, V55, V63, A107, I112, and S129. Most of these signals were not observed in 2D or 3D spectra at 0 +/- 3 degrees C. Spectra acquired at low temperatures therefore permitted more complete chemical shift assignments. Observation of the majority of residues in AS fibrils represents an important step towards solving the 3D structure.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "d74834afd23a4192b6b88ed137c2ea87", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[2, 4]], "char_spans": [[12, 26]]}]}], "context_tokens": [["The", 0], ["protein", 4], ["alpha", 12], ["-", 17], ["synuclein", 18], ["(", 28], ["AS", 29], [")", 31], ["is", 33], ["the", 36], ["primary", 40], ["fibrillar", 48], ["component", 58], ["of", 68], ["Lewy", 71], ["bodies", 76], [",", 82], ["the", 84], ["pathological", 88], ["hallmark", 101], ["of", 110], ["Parkinson", 113], ["'s", 122], ["disease", 125], [".", 132], ["Wild", 134], ["-", 138], ["type", 139], ["human", 144], ["AS", 150], ["and", 153], ["the", 157], ["three", 161], ["mutant", 167], ["forms", 174], ["linked", 180], ["to", 187], ["Parkinson", 190], ["'s", 199], ["disease", 202], ["(", 210], ["A53", 211], ["T", 214], [",", 215], ["A30P", 217], [",", 221], ["and", 223], ["E46", 227], ["K", 230], [")", 231], ["all", 233], ["form", 237], ["fibrils", 242], ["through", 250], ["a", 258], ["nucleation", 260], ["-", 270], ["dependent", 271], ["pathway", 281], [";", 288], ["however", 290], [",", 297], ["the", 299], ["biophysical", 303], ["details", 315], ["of", 323], ["these", 326], ["fibrillation", 332], ["events", 345], ["are", 352], ["not", 356], ["yet", 360], ["well", 364], ["understood", 369], [".", 379], ["Atomic", 381], ["-", 387], ["level", 388], ["structural", 394], ["insight", 405], ["is", 413], ["required", 416], ["in", 425], ["order", 428], ["to", 434], ["elucidate", 437], ["the", 447], ["potential", 451], ["role", 461], ["of", 466], ["AS", 469], ["fibrils", 472], ["in", 480], ["Parkinson", 483], ["'s", 492], ["disease", 495], [".", 502], ["Here", 504], ["we", 509], ["show", 512], ["that", 517], ["low", 522], ["temperature", 526], ["acquisition", 538], ["of", 550], ["magic", 553], ["-", 558], ["angle", 559], ["spinning", 565], ["NMR", 574], ["spectra", 578], ["of", 586], ["wild", 589], ["type", 594], ["AS", 599], ["fibrils", 602], ["-", 609], ["greatly", 610], ["enhances", 618], ["spectral", 627], ["sensitivity", 636], [",", 647], ["enabling", 649], ["the", 658], ["detection", 662], ["of", 672], ["a", 675], ["substantially", 677], ["larger", 691], ["number", 698], ["of", 705], ["spin", 708], ["systems", 713], [".", 720], ["At", 722], ["0", 725], ["+", 727], ["/-", 728], ["3", 731], ["degrees", 733], ["C", 741], ["sample", 743], ["temperature", 750], [",", 761], ["cross", 763], ["polarization", 769], ["(", 782], ["CP", 783], [")", 785], ["experiments", 787], ["yield", 799], ["weak", 805], ["signals", 810], [".", 817], ["Lower", 819], ["temperature", 825], ["spectra", 837], ["(", 845], ["-40", 846], ["+", 850], ["/-", 851], ["3", 854], ["degrees", 856], ["C", 864], [")", 865], ["demonstrated", 867], ["several", 880], ["times", 888], ["greater", 894], ["signal", 902], ["intensity", 909], [",", 918], ["an", 920], ["effect", 923], ["further", 930], ["amplified", 938], ["in", 948], ["3D", 951], ["15N-13C-13C", 954], ["experiments", 966], [",", 977], ["which", 979], ["are", 985], ["required", 989], ["to", 998], ["perform", 1001], ["backbone", 1009], ["assignments", 1018], ["on", 1030], ["this", 1033], ["sample", 1038], [".", 1044], ["Thus", 1046], ["3D", 1051], ["experiments", 1054], ["enabled", 1066], ["assignments", 1074], ["of", 1086], ["most", 1089], ["amino", 1094], ["acids", 1100], ["in", 1106], ["the", 1109], ["rigid", 1113], ["part", 1119], ["of", 1124], ["the", 1127], ["fibril", 1131], ["(", 1138], ["approximately", 1139], ["residues", 1153], ["64", 1162], ["to", 1165], ["94", 1168], [")", 1170], [",", 1171], ["as", 1173], ["well", 1176], ["as", 1181], ["tentative", 1184], ["site", 1194], ["-", 1198], ["specific", 1199], ["assignments", 1208], ["for", 1220], ["T22", 1224], [",", 1227], ["V26", 1229], [",", 1232], ["A27", 1234], [",", 1237], ["Y39", 1239], [",", 1242], ["G41", 1244], [",", 1247], ["S42", 1249], [",", 1252], ["H50", 1254], [",", 1257], ["V52", 1259], [",", 1262], ["A53", 1264], [",", 1267], ["T54", 1269], [",", 1272], ["V55", 1274], [",", 1277], ["V63", 1279], [",", 1282], ["A107", 1284], [",", 1288], ["I112", 1290], [",", 1294], ["and", 1296], ["S129", 1300], [".", 1304], ["Most", 1306], ["of", 1311], ["these", 1314], ["signals", 1320], ["were", 1328], ["not", 1333], ["observed", 1337], ["in", 1346], ["2D", 1349], ["or", 1352], ["3D", 1355], ["spectra", 1358], ["at", 1366], ["0", 1369], ["+", 1371], ["/-", 1372], ["3", 1375], ["degrees", 1377], ["C.", 1385], ["Spectra", 1388], ["acquired", 1396], ["at", 1405], ["low", 1408], ["temperatures", 1412], ["therefore", 1425], ["permitted", 1435], ["more", 1445], ["complete", 1450], ["chemical", 1459], ["shift", 1468], ["assignments", 1474], [".", 1485], ["Observation", 1487], ["of", 1499], ["the", 1502], ["majority", 1506], ["of", 1515], ["residues", 1518], ["in", 1527], ["AS", 1530], ["fibrils", 1533], ["represents", 1541], ["an", 1552], ["important", 1555], ["step", 1565], ["towards", 1570], ["solving", 1578], ["the", 1586], ["3D", 1590], ["structure", 1593], [".", 1602]]}
{"context": "Sotos syndrome is a genetic disorder characterized by a typical facial appearance, macrocephaly, accelerated growth, developmental delay, and a variable range of associated abnormalities. The NSD1 gene was recently found to be responsible for Sotos syndrome, and more than 150 patients with NSD1 alterations have been identified. A significant ethnic difference is found in the prevalence of different types of mutation, with a high percentage of microdeletions identified in Japanese Sotos syndrome patients and with intragenic mutations in most non-Japanese patients. NSD1 aberrations are rather specific for Sotos syndrome, but have also been detected in patients lacking one or more major criteria of the disorder, namely overgrowth, macrocephaly, and advanced bone age. Thus, new diagnostic criteria should be considered. Studies have reported different frequencies of mutations versus non-mutations in Sotos syndrome, thus indicating allelic or locus hetereogeneity. Although some authors have suggested genotype/phenotype correlations, further studies are needed.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "e3fcd872a2a34c279d4633b77cd0d266", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[30, 31]], "char_spans": [[192, 200]]}]}], "context_tokens": [["Sotos", 0], ["syndrome", 6], ["is", 15], ["a", 18], ["genetic", 20], ["disorder", 28], ["characterized", 37], ["by", 51], ["a", 54], ["typical", 56], ["facial", 64], ["appearance", 71], [",", 81], ["macrocephaly", 83], [",", 95], ["accelerated", 97], ["growth", 109], [",", 115], ["developmental", 117], ["delay", 131], [",", 136], ["and", 138], ["a", 142], ["variable", 144], ["range", 153], ["of", 159], ["associated", 162], ["abnormalities", 173], [".", 186], ["The", 188], ["NSD1", 192], ["gene", 197], ["was", 202], ["recently", 206], ["found", 215], ["to", 221], ["be", 224], ["responsible", 227], ["for", 239], ["Sotos", 243], ["syndrome", 249], [",", 257], ["and", 259], ["more", 263], ["than", 268], ["150", 273], ["patients", 277], ["with", 286], ["NSD1", 291], ["alterations", 296], ["have", 308], ["been", 313], ["identified", 318], [".", 328], ["A", 330], ["significant", 332], ["ethnic", 344], ["difference", 351], ["is", 362], ["found", 365], ["in", 371], ["the", 374], ["prevalence", 378], ["of", 389], ["different", 392], ["types", 402], ["of", 408], ["mutation", 411], [",", 419], ["with", 421], ["a", 426], ["high", 428], ["percentage", 433], ["of", 444], ["microdeletions", 447], ["identified", 462], ["in", 473], ["Japanese", 476], ["Sotos", 485], ["syndrome", 491], ["patients", 500], ["and", 509], ["with", 513], ["intragenic", 518], ["mutations", 529], ["in", 539], ["most", 542], ["non", 547], ["-", 550], ["Japanese", 551], ["patients", 560], [".", 568], ["NSD1", 570], ["aberrations", 575], ["are", 587], ["rather", 591], ["specific", 598], ["for", 607], ["Sotos", 611], ["syndrome", 617], [",", 625], ["but", 627], ["have", 631], ["also", 636], ["been", 641], ["detected", 646], ["in", 655], ["patients", 658], ["lacking", 667], ["one", 675], ["or", 679], ["more", 682], ["major", 687], ["criteria", 693], ["of", 702], ["the", 705], ["disorder", 709], [",", 717], ["namely", 719], ["overgrowth", 726], [",", 736], ["macrocephaly", 738], [",", 750], ["and", 752], ["advanced", 756], ["bone", 765], ["age", 770], [".", 773], ["Thus", 775], [",", 779], ["new", 781], ["diagnostic", 785], ["criteria", 796], ["should", 805], ["be", 812], ["considered", 815], [".", 825], ["Studies", 827], ["have", 835], ["reported", 840], ["different", 849], ["frequencies", 859], ["of", 871], ["mutations", 874], ["versus", 884], ["non", 891], ["-", 894], ["mutations", 895], ["in", 905], ["Sotos", 908], ["syndrome", 914], [",", 922], ["thus", 924], ["indicating", 929], ["allelic", 940], ["or", 948], ["locus", 951], ["hetereogeneity", 957], [".", 971], ["Although", 973], ["some", 982], ["authors", 987], ["have", 995], ["suggested", 1000], ["genotype", 1010], ["/", 1018], ["phenotype", 1019], ["correlations", 1029], [",", 1041], ["further", 1043], ["studies", 1051], ["are", 1059], ["needed", 1063], [".", 1069]]}
{"context": "Peripheral neuropathy (PN) has been reported in idiopathic and hereditary forms of parkinsonism, but the pathogenic mechanisms are unclear and likely heterogeneous. Levodopa-induced vitamin B12 deficiency has been discussed as a causal factor of PN in idiopathic Parkinson's disease, but peripheral nervous system involvement might also be a consequence of the underlying neurodegenerative process. Occurrence of PN with parkinsonism has been associated with a panel of mitochondrial cytopathies, more frequently related to a nuclear gene defect and mainly polymerase gamma (POLG1) gene. Parkin (PARK2) gene mutations are responsible for juvenile parkinsonism, and possible peripheral nervous system involvement has been reported. Rarely, an association of parkinsonism with PN may be encountered in other neurodegenerative diseases such as fragile X-associated tremor and ataxia syndrome related to premutation CGG repeat expansion in the fragile X mental retardation (FMR1) gene, Machado-Joseph disease related to an abnormal CAG repeat expansion in ataxin-3 (ATXN3) gene, Kufor-Rakeb syndrome caused by mutations in ATP13A2 gene, or in hereditary systemic disorders such as Gaucher disease due to mutations in the \u03b2-glucocerebrosidase (GBA) gene and Chediak-Higashi syndrome due to LYST gene mutations. This article reviews conditions in which PN may coexist with parkinsonism.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "ccaf40e8947045dbb86dafd325b2f626", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[216, 217]], "char_spans": [[1285, 1293]]}]}], "context_tokens": [["Peripheral", 0], ["neuropathy", 11], ["(", 22], ["PN", 23], [")", 25], ["has", 27], ["been", 31], ["reported", 36], ["in", 45], ["idiopathic", 48], ["and", 59], ["hereditary", 63], ["forms", 74], ["of", 80], ["parkinsonism", 83], [",", 95], ["but", 97], ["the", 101], ["pathogenic", 105], ["mechanisms", 116], ["are", 127], ["unclear", 131], ["and", 139], ["likely", 143], ["heterogeneous", 150], [".", 163], ["Levodopa", 165], ["-", 173], ["induced", 174], ["vitamin", 182], ["B12", 190], ["deficiency", 194], ["has", 205], ["been", 209], ["discussed", 214], ["as", 224], ["a", 227], ["causal", 229], ["factor", 236], ["of", 243], ["PN", 246], ["in", 249], ["idiopathic", 252], ["Parkinson", 263], ["'s", 272], ["disease", 275], [",", 282], ["but", 284], ["peripheral", 288], ["nervous", 299], ["system", 307], ["involvement", 314], ["might", 326], ["also", 332], ["be", 337], ["a", 340], ["consequence", 342], ["of", 354], ["the", 357], ["underlying", 361], ["neurodegenerative", 372], ["process", 390], [".", 397], ["Occurrence", 399], ["of", 410], ["PN", 413], ["with", 416], ["parkinsonism", 421], ["has", 434], ["been", 438], ["associated", 443], ["with", 454], ["a", 459], ["panel", 461], ["of", 467], ["mitochondrial", 470], ["cytopathies", 484], [",", 495], ["more", 497], ["frequently", 502], ["related", 513], ["to", 521], ["a", 524], ["nuclear", 526], ["gene", 534], ["defect", 539], ["and", 546], ["mainly", 550], ["polymerase", 557], ["gamma", 568], ["(", 574], ["POLG1", 575], [")", 580], ["gene", 582], [".", 586], ["Parkin", 588], ["(", 595], ["PARK2", 596], [")", 601], ["gene", 603], ["mutations", 608], ["are", 618], ["responsible", 622], ["for", 634], ["juvenile", 638], ["parkinsonism", 647], [",", 659], ["and", 661], ["possible", 665], ["peripheral", 674], ["nervous", 685], ["system", 693], ["involvement", 700], ["has", 712], ["been", 716], ["reported", 721], [".", 729], ["Rarely", 731], [",", 737], ["an", 739], ["association", 742], ["of", 754], ["parkinsonism", 757], ["with", 770], ["PN", 775], ["may", 778], ["be", 782], ["encountered", 785], ["in", 797], ["other", 800], ["neurodegenerative", 806], ["diseases", 824], ["such", 833], ["as", 838], ["fragile", 841], ["X", 849], ["-", 850], ["associated", 851], ["tremor", 862], ["and", 869], ["ataxia", 873], ["syndrome", 880], ["related", 889], ["to", 897], ["premutation", 900], ["CGG", 912], ["repeat", 916], ["expansion", 923], ["in", 933], ["the", 936], ["fragile", 940], ["X", 948], ["mental", 950], ["retardation", 957], ["(", 969], ["FMR1", 970], [")", 974], ["gene", 976], [",", 980], ["Machado", 982], ["-", 989], ["Joseph", 990], ["disease", 997], ["related", 1005], ["to", 1013], ["an", 1016], ["abnormal", 1019], ["CAG", 1028], ["repeat", 1032], ["expansion", 1039], ["in", 1049], ["ataxin-3", 1052], ["(", 1061], ["ATXN3", 1062], [")", 1067], ["gene", 1069], [",", 1073], ["Kufor", 1075], ["-", 1080], ["Rakeb", 1081], ["syndrome", 1087], ["caused", 1096], ["by", 1103], ["mutations", 1106], ["in", 1116], ["ATP13A2", 1119], ["gene", 1127], [",", 1131], ["or", 1133], ["in", 1136], ["hereditary", 1139], ["systemic", 1150], ["disorders", 1159], ["such", 1169], ["as", 1174], ["Gaucher", 1177], ["disease", 1185], ["due", 1193], ["to", 1197], ["mutations", 1200], ["in", 1210], ["the", 1213], ["\u03b2", 1217], ["-", 1218], ["glucocerebrosidase", 1219], ["(", 1238], ["GBA", 1239], [")", 1242], ["gene", 1244], ["and", 1249], ["Chediak", 1253], ["-", 1260], ["Higashi", 1261], ["syndrome", 1269], ["due", 1278], ["to", 1282], ["LYST", 1285], ["gene", 1290], ["mutations", 1295], [".", 1304], ["This", 1306], ["article", 1311], ["reviews", 1319], ["conditions", 1327], ["in", 1338], ["which", 1341], ["PN", 1347], ["may", 1350], ["coexist", 1354], ["with", 1362], ["parkinsonism", 1367], [".", 1379]]}
{"context": "Diamond-Blackfan anemia (DBA) is a congenital bone marrow failure syndrome characterized by a specific deficiency in erythroid progenitors. Forty percent of the patients are blood transfusion-dependent. Recent reports show that the ribosomal protein S19 (RPS19) gene is mutated in 25% of all patients with DBA. We constructed oncoretroviral vectors containing the RPS19 gene to develop gene therapy for RPS19-deficient DBA. These vectors were used to introduce the RPS19 gene into CD34(+) bone marrow (BM) cells from 4 patients with DBA with RPS19 gene mutations. Overexpression of the RPS19 transgene increased the number of erythroid colonies by almost 3-fold. High expression levels of the RPS19 transgene improved erythroid colony-forming ability substantially whereas low expression levels had no effect. Overexpression of RPS19 had no detrimental effect on granulocyte-macrophage colony formation. Therefore, these findings suggest that gene therapy for RPS19-deficient patients with DBA using viral vectors that express the RPS19 gene is feasible.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "0bede4582a9e40d4bb498c8ee7d6c64e", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[5, 5], [164, 164], [55, 55], [71, 71], [95, 95]], "char_spans": [[25, 27], [990, 992], [306, 308], [419, 421], [533, 535]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["congenital", 35], ["bone", 46], ["marrow", 51], ["failure", 58], ["syndrome", 66], ["characterized", 75], ["by", 89], ["a", 92], ["specific", 94], ["deficiency", 103], ["in", 114], ["erythroid", 117], ["progenitors", 127], [".", 138], ["Forty", 140], ["percent", 146], ["of", 154], ["the", 157], ["patients", 161], ["are", 170], ["blood", 174], ["transfusion", 180], ["-", 191], ["dependent", 192], [".", 201], ["Recent", 203], ["reports", 210], ["show", 218], ["that", 223], ["the", 228], ["ribosomal", 232], ["protein", 242], ["S19", 250], ["(", 254], ["RPS19", 255], [")", 260], ["gene", 262], ["is", 267], ["mutated", 270], ["in", 278], ["25", 281], ["%", 283], ["of", 285], ["all", 288], ["patients", 292], ["with", 301], ["DBA", 306], [".", 309], ["We", 311], ["constructed", 314], ["oncoretroviral", 326], ["vectors", 341], ["containing", 349], ["the", 360], ["RPS19", 364], ["gene", 370], ["to", 375], ["develop", 378], ["gene", 386], ["therapy", 391], ["for", 399], ["RPS19-deficient", 403], ["DBA", 419], [".", 422], ["These", 424], ["vectors", 430], ["were", 438], ["used", 443], ["to", 448], ["introduce", 451], ["the", 461], ["RPS19", 465], ["gene", 471], ["into", 476], ["CD34(+", 481], [")", 487], ["bone", 489], ["marrow", 494], ["(", 501], ["BM", 502], [")", 504], ["cells", 506], ["from", 512], ["4", 517], ["patients", 519], ["with", 528], ["DBA", 533], ["with", 537], ["RPS19", 542], ["gene", 548], ["mutations", 553], [".", 562], ["Overexpression", 564], ["of", 579], ["the", 582], ["RPS19", 586], ["transgene", 592], ["increased", 602], ["the", 612], ["number", 616], ["of", 623], ["erythroid", 626], ["colonies", 636], ["by", 645], ["almost", 648], ["3-fold", 655], [".", 661], ["High", 663], ["expression", 668], ["levels", 679], ["of", 686], ["the", 689], ["RPS19", 693], ["transgene", 699], ["improved", 709], ["erythroid", 718], ["colony", 728], ["-", 734], ["forming", 735], ["ability", 743], ["substantially", 751], ["whereas", 765], ["low", 773], ["expression", 777], ["levels", 788], ["had", 795], ["no", 799], ["effect", 802], [".", 808], ["Overexpression", 810], ["of", 825], ["RPS19", 828], ["had", 834], ["no", 838], ["detrimental", 841], ["effect", 853], ["on", 860], ["granulocyte", 863], ["-", 874], ["macrophage", 875], ["colony", 886], ["formation", 893], [".", 902], ["Therefore", 904], [",", 913], ["these", 915], ["findings", 921], ["suggest", 930], ["that", 938], ["gene", 943], ["therapy", 948], ["for", 956], ["RPS19-deficient", 960], ["patients", 976], ["with", 985], ["DBA", 990], ["using", 994], ["viral", 1000], ["vectors", 1006], ["that", 1014], ["express", 1019], ["the", 1027], ["RPS19", 1031], ["gene", 1037], ["is", 1042], ["feasible", 1045], [".", 1053]]}
{"context": "Christianson syndrome (OMIM 300243), caused by mutations in the X-linked SLC9A6 gene, is characterized by severe global developmental delay and intellectual disability, developmental regression, epilepsy, microcephaly and impaired ocular movements. It shares many common features with Angelman syndrome. Carrier females have been described as having learning difficulties with mild to moderate intellectual disability, behavioural issues and psychiatric illnesses. There is little literature on the carrier female phenotype of Christianson syndrome. We describe a large extended family with three affected males, four carrier females, one presumed carrier female and one obligate carrier female with a c.190G>T, p.E64X mutation known to cause a premature stop codon in SLC9A6. We characterize and expand the clinical phenotype of female SLC9A6 mutation carriers by comparing our described family with female carriers previously discussed in the literature. In particular, we highlight the neurodevelopmental and psychiatric phenotypes observed in our family and previous reports.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "141c4f0d6d4d4916a34c9dae06adcc8a", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[137, 137], [15, 15], [126, 126]], "char_spans": [[837, 842], [73, 78], [769, 774]]}]}], "context_tokens": [["Christianson", 0], ["syndrome", 13], ["(", 22], ["OMIM", 23], ["300243", 28], [")", 34], [",", 35], ["caused", 37], ["by", 44], ["mutations", 47], ["in", 57], ["the", 60], ["X", 64], ["-", 65], ["linked", 66], ["SLC9A6", 73], ["gene", 80], [",", 84], ["is", 86], ["characterized", 89], ["by", 103], ["severe", 106], ["global", 113], ["developmental", 120], ["delay", 134], ["and", 140], ["intellectual", 144], ["disability", 157], [",", 167], ["developmental", 169], ["regression", 183], [",", 193], ["epilepsy", 195], [",", 203], ["microcephaly", 205], ["and", 218], ["impaired", 222], ["ocular", 231], ["movements", 238], [".", 247], ["It", 249], ["shares", 252], ["many", 259], ["common", 264], ["features", 271], ["with", 280], ["Angelman", 285], ["syndrome", 294], [".", 302], ["Carrier", 304], ["females", 312], ["have", 320], ["been", 325], ["described", 330], ["as", 340], ["having", 343], ["learning", 350], ["difficulties", 359], ["with", 372], ["mild", 377], ["to", 382], ["moderate", 385], ["intellectual", 394], ["disability", 407], [",", 417], ["behavioural", 419], ["issues", 431], ["and", 438], ["psychiatric", 442], ["illnesses", 454], [".", 463], ["There", 465], ["is", 471], ["little", 474], ["literature", 481], ["on", 492], ["the", 495], ["carrier", 499], ["female", 507], ["phenotype", 514], ["of", 524], ["Christianson", 527], ["syndrome", 540], [".", 548], ["We", 550], ["describe", 553], ["a", 562], ["large", 564], ["extended", 570], ["family", 579], ["with", 586], ["three", 591], ["affected", 597], ["males", 606], [",", 611], ["four", 613], ["carrier", 618], ["females", 626], [",", 633], ["one", 635], ["presumed", 639], ["carrier", 648], ["female", 656], ["and", 663], ["one", 667], ["obligate", 671], ["carrier", 680], ["female", 688], ["with", 695], ["a", 700], ["c.190G", 702], [">", 708], ["T", 709], [",", 710], ["p", 712], [".", 713], ["E64X", 714], ["mutation", 719], ["known", 728], ["to", 734], ["cause", 737], ["a", 743], ["premature", 745], ["stop", 755], ["codon", 760], ["in", 766], ["SLC9A6", 769], [".", 775], ["We", 777], ["characterize", 780], ["and", 793], ["expand", 797], ["the", 804], ["clinical", 808], ["phenotype", 817], ["of", 827], ["female", 830], ["SLC9A6", 837], ["mutation", 844], ["carriers", 853], ["by", 862], ["comparing", 865], ["our", 875], ["described", 879], ["family", 889], ["with", 896], ["female", 901], ["carriers", 908], ["previously", 917], ["discussed", 928], ["in", 938], ["the", 941], ["literature", 945], [".", 955], ["In", 957], ["particular", 960], [",", 970], ["we", 972], ["highlight", 975], ["the", 985], ["neurodevelopmental", 989], ["and", 1008], ["psychiatric", 1012], ["phenotypes", 1024], ["observed", 1035], ["in", 1044], ["our", 1047], ["family", 1051], ["and", 1058], ["previous", 1062], ["reports", 1071], [".", 1078]]}
{"context": "Kell antigens are encoded by the KEL gene on the long arm of chromosome 7. Kx antigen is encoded by the XK gene on the short arm of the X chromosome. Kell and Kx proteins in the red cell membrane are covalently linked by a disulphide bond. The McLeod phenotype is characterized by weakened expression of antigens in the Kell blood group system, absence of Km and Kx antigens, and acanthocytosis. It has an X-linked mode of inheritance with transmission through carrier females. Some males with the McLeod syndrome also have chronic granulomatous disease (CGD). It is generally believed that patients with non-CGD McLeod may develop anti-Km but not anti-Kx, but that those with CGD McLeod can develop both anti-Km and anti-Kx. We present serological data, DNA genotyping and gene sequencing, monocyte monolayer assay and neutrophil oxidative burst test from a patient with the McLeod phenotype without clinical evidence of CGD. We report here the second example of a patient with non-CGD McLeod who developed anti-Kx in addition to anti-Km. Sequencing of our patient's XK gene confirmed the presence of a mutation resulting in a premature stop codon and lack of Kx protein in the red cell membrane, which is consistent with the diagnosis of McLeod syndrome. Neutrophil oxidative burst test was normal, indicating that our patient did not have CGD. The challenge of providing 10 compatible blood units for multiple surgeries was met. The second case of a rare entity, a patient with non-CGD McLeod who developed anti-Kx and anti-Km, was managed successfully with a combination of autologous donations and procurement of compatible units from national and international sources.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "7ff12940e9c34f73936d58aa6f5f4f8b", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[209, 209], [22, 22]], "char_spans": [[1068, 1069], [104, 105]]}]}], "context_tokens": [["Kell", 0], ["antigens", 5], ["are", 14], ["encoded", 18], ["by", 26], ["the", 29], ["KEL", 33], ["gene", 37], ["on", 42], ["the", 45], ["long", 49], ["arm", 54], ["of", 58], ["chromosome", 61], ["7", 72], [".", 73], ["Kx", 75], ["antigen", 78], ["is", 86], ["encoded", 89], ["by", 97], ["the", 100], ["XK", 104], ["gene", 107], ["on", 112], ["the", 115], ["short", 119], ["arm", 125], ["of", 129], ["the", 132], ["X", 136], ["chromosome", 138], [".", 148], ["Kell", 150], ["and", 155], ["Kx", 159], ["proteins", 162], ["in", 171], ["the", 174], ["red", 178], ["cell", 182], ["membrane", 187], ["are", 196], ["covalently", 200], ["linked", 211], ["by", 218], ["a", 221], ["disulphide", 223], ["bond", 234], [".", 238], ["The", 240], ["McLeod", 244], ["phenotype", 251], ["is", 261], ["characterized", 264], ["by", 278], ["weakened", 281], ["expression", 290], ["of", 301], ["antigens", 304], ["in", 313], ["the", 316], ["Kell", 320], ["blood", 325], ["group", 331], ["system", 337], [",", 343], ["absence", 345], ["of", 353], ["Km", 356], ["and", 359], ["Kx", 363], ["antigens", 366], [",", 374], ["and", 376], ["acanthocytosis", 380], [".", 394], ["It", 396], ["has", 399], ["an", 403], ["X", 406], ["-", 407], ["linked", 408], ["mode", 415], ["of", 420], ["inheritance", 423], ["with", 435], ["transmission", 440], ["through", 453], ["carrier", 461], ["females", 469], [".", 476], ["Some", 478], ["males", 483], ["with", 489], ["the", 494], ["McLeod", 498], ["syndrome", 505], ["also", 514], ["have", 519], ["chronic", 524], ["granulomatous", 532], ["disease", 546], ["(", 554], ["CGD", 555], [")", 558], [".", 559], ["It", 561], ["is", 564], ["generally", 567], ["believed", 577], ["that", 586], ["patients", 591], ["with", 600], ["non", 605], ["-", 608], ["CGD", 609], ["McLeod", 613], ["may", 620], ["develop", 624], ["anti", 632], ["-", 636], ["Km", 637], ["but", 640], ["not", 644], ["anti", 648], ["-", 652], ["Kx", 653], [",", 655], ["but", 657], ["that", 661], ["those", 666], ["with", 672], ["CGD", 677], ["McLeod", 681], ["can", 688], ["develop", 692], ["both", 700], ["anti", 705], ["-", 709], ["Km", 710], ["and", 713], ["anti", 717], ["-", 721], ["Kx", 722], [".", 724], ["We", 726], ["present", 729], ["serological", 737], ["data", 749], [",", 753], ["DNA", 755], ["genotyping", 759], ["and", 770], ["gene", 774], ["sequencing", 779], [",", 789], ["monocyte", 791], ["monolayer", 800], ["assay", 810], ["and", 816], ["neutrophil", 820], ["oxidative", 831], ["burst", 841], ["test", 847], ["from", 852], ["a", 857], ["patient", 859], ["with", 867], ["the", 872], ["McLeod", 876], ["phenotype", 883], ["without", 893], ["clinical", 901], ["evidence", 910], ["of", 919], ["CGD", 922], [".", 925], ["We", 927], ["report", 930], ["here", 937], ["the", 942], ["second", 946], ["example", 953], ["of", 961], ["a", 964], ["patient", 966], ["with", 974], ["non", 979], ["-", 982], ["CGD", 983], ["McLeod", 987], ["who", 994], ["developed", 998], ["anti", 1008], ["-", 1012], ["Kx", 1013], ["in", 1016], ["addition", 1019], ["to", 1028], ["anti", 1031], ["-", 1035], ["Km", 1036], [".", 1038], ["Sequencing", 1040], ["of", 1051], ["our", 1054], ["patient", 1058], ["'s", 1065], ["XK", 1068], ["gene", 1071], ["confirmed", 1076], ["the", 1086], ["presence", 1090], ["of", 1099], ["a", 1102], ["mutation", 1104], ["resulting", 1113], ["in", 1123], ["a", 1126], ["premature", 1128], ["stop", 1138], ["codon", 1143], ["and", 1149], ["lack", 1153], ["of", 1158], ["Kx", 1161], ["protein", 1164], ["in", 1172], ["the", 1175], ["red", 1179], ["cell", 1183], ["membrane", 1188], [",", 1196], ["which", 1198], ["is", 1204], ["consistent", 1207], ["with", 1218], ["the", 1223], ["diagnosis", 1227], ["of", 1237], ["McLeod", 1240], ["syndrome", 1247], [".", 1255], ["Neutrophil", 1257], ["oxidative", 1268], ["burst", 1278], ["test", 1284], ["was", 1289], ["normal", 1293], [",", 1299], ["indicating", 1301], ["that", 1312], ["our", 1317], ["patient", 1321], ["did", 1329], ["not", 1333], ["have", 1337], ["CGD", 1342], [".", 1345], ["The", 1347], ["challenge", 1351], ["of", 1361], ["providing", 1364], ["10", 1374], ["compatible", 1377], ["blood", 1388], ["units", 1394], ["for", 1400], ["multiple", 1404], ["surgeries", 1413], ["was", 1423], ["met", 1427], [".", 1430], ["The", 1432], ["second", 1436], ["case", 1443], ["of", 1448], ["a", 1451], ["rare", 1453], ["entity", 1458], [",", 1464], ["a", 1466], ["patient", 1468], ["with", 1476], ["non", 1481], ["-", 1484], ["CGD", 1485], ["McLeod", 1489], ["who", 1496], ["developed", 1500], ["anti", 1510], ["-", 1514], ["Kx", 1515], ["and", 1518], ["anti", 1522], ["-", 1526], ["Km", 1527], [",", 1529], ["was", 1531], ["managed", 1535], ["successfully", 1543], ["with", 1556], ["a", 1561], ["combination", 1563], ["of", 1575], ["autologous", 1578], ["donations", 1589], ["and", 1599], ["procurement", 1603], ["of", 1615], ["compatible", 1618], ["units", 1629], ["from", 1635], ["national", 1640], ["and", 1649], ["international", 1653], ["sources", 1667], [".", 1674]]}
{"context": "Chronic myeloid leukemia (CML) is caused by the BCR-ABL oncogene. The Philadelphia chromosome (Ph) from a reciprocal translocation, t(9;22) (q34;q11) causes a fusion gene, BCR-ABL, that encodes a constitutively active tyrosine kinase. Treatment of CML by imatinib is effective to control the tyrosyl phosphorylation of the protein related to the cell signaling. BCR-ABL mRNA is overexpressed in the minimal residual disease (MRD), known as an early sign of relapse. Between December 2005 and June 2008, we measured BCR-ABL mRNA levels in the bone marrow (BM) from patients by quantitative real-time polymerase chain reaction (RQ-PCR) in Aomori Prefectural Central Hospital. Eighty-six samples from 26 patients were collected. Among the 26 CML patients, 11 patients (42%) were in the pretreatment group. Seven (64%) of the 11 patients achieved complete molecular response (CMR). In the post-treatment group consisting of the remaining 15 patients, 9 (60%) patients achieved CMR. The patients receiving imatinib at a dose over 300 mg per day required 13 (6-77) months [median (range)] to achieve CMR. On the other hand, the patients receiving a dose below 300 mg per day required 29.5 (11-84) months [median (range)]. When BCR-ABL mRNA was detected during the treatment course of patients with CMR, careful observation of BCR-ABL mRNA was useful for tracking the clinical course of patients. In conclusion, the BCR-ABL mRNA level was useful for monitoring the clinical course in 26 patients with CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "412a49803a00424099cd84a75d92bd63", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[295, 297], [36, 38], [101, 103], [69, 71], [10, 12], [277, 279], [259, 261]], "char_spans": [[1409, 1415], [172, 178], [515, 521], [362, 368], [48, 54], [1320, 1326], [1221, 1227]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["caused", 34], ["by", 41], ["the", 44], ["BCR", 48], ["-", 51], ["ABL", 52], ["oncogene", 56], [".", 64], ["The", 66], ["Philadelphia", 70], ["chromosome", 83], ["(", 94], ["Ph", 95], [")", 97], ["from", 99], ["a", 104], ["reciprocal", 106], ["translocation", 117], [",", 130], ["t(9;22", 132], [")", 138], ["(", 140], ["q34;q11", 141], [")", 148], ["causes", 150], ["a", 157], ["fusion", 159], ["gene", 166], [",", 170], ["BCR", 172], ["-", 175], ["ABL", 176], [",", 179], ["that", 181], ["encodes", 186], ["a", 194], ["constitutively", 196], ["active", 211], ["tyrosine", 218], ["kinase", 227], [".", 233], ["Treatment", 235], ["of", 245], ["CML", 248], ["by", 252], ["imatinib", 255], ["is", 264], ["effective", 267], ["to", 277], ["control", 280], ["the", 288], ["tyrosyl", 292], ["phosphorylation", 300], ["of", 316], ["the", 319], ["protein", 323], ["related", 331], ["to", 339], ["the", 342], ["cell", 346], ["signaling", 351], [".", 360], ["BCR", 362], ["-", 365], ["ABL", 366], ["mRNA", 370], ["is", 375], ["overexpressed", 378], ["in", 392], ["the", 395], ["minimal", 399], ["residual", 407], ["disease", 416], ["(", 424], ["MRD", 425], [")", 428], [",", 429], ["known", 431], ["as", 437], ["an", 440], ["early", 443], ["sign", 449], ["of", 454], ["relapse", 457], [".", 464], ["Between", 466], ["December", 474], ["2005", 483], ["and", 488], ["June", 492], ["2008", 497], [",", 501], ["we", 503], ["measured", 506], ["BCR", 515], ["-", 518], ["ABL", 519], ["mRNA", 523], ["levels", 528], ["in", 535], ["the", 538], ["bone", 542], ["marrow", 547], ["(", 554], ["BM", 555], [")", 557], ["from", 559], ["patients", 564], ["by", 573], ["quantitative", 576], ["real", 589], ["-", 593], ["time", 594], ["polymerase", 599], ["chain", 610], ["reaction", 616], ["(", 625], ["RQ", 626], ["-", 628], ["PCR", 629], [")", 632], ["in", 634], ["Aomori", 637], ["Prefectural", 644], ["Central", 656], ["Hospital", 664], [".", 672], ["Eighty", 674], ["-", 680], ["six", 681], ["samples", 685], ["from", 693], ["26", 698], ["patients", 701], ["were", 710], ["collected", 715], [".", 724], ["Among", 726], ["the", 732], ["26", 736], ["CML", 739], ["patients", 743], [",", 751], ["11", 753], ["patients", 756], ["(", 765], ["42", 766], ["%", 768], [")", 769], ["were", 771], ["in", 776], ["the", 779], ["pretreatment", 783], ["group", 796], [".", 801], ["Seven", 803], ["(", 809], ["64", 810], ["%", 812], [")", 813], ["of", 815], ["the", 818], ["11", 822], ["patients", 825], ["achieved", 834], ["complete", 843], ["molecular", 852], ["response", 862], ["(", 871], ["CMR", 872], [")", 875], [".", 876], ["In", 878], ["the", 881], ["post", 885], ["-", 889], ["treatment", 890], ["group", 900], ["consisting", 906], ["of", 917], ["the", 920], ["remaining", 924], ["15", 934], ["patients", 937], [",", 945], ["9", 947], ["(", 949], ["60", 950], ["%", 952], [")", 953], ["patients", 955], ["achieved", 964], ["CMR", 973], [".", 976], ["The", 978], ["patients", 982], ["receiving", 991], ["imatinib", 1001], ["at", 1010], ["a", 1013], ["dose", 1015], ["over", 1020], ["300", 1025], ["mg", 1029], ["per", 1032], ["day", 1036], ["required", 1040], ["13", 1049], ["(", 1052], ["6", 1053], ["-", 1054], ["77", 1055], [")", 1057], ["months", 1059], ["[", 1066], ["median", 1067], ["(", 1074], ["range", 1075], [")", 1080], ["]", 1081], ["to", 1083], ["achieve", 1086], ["CMR", 1094], [".", 1097], ["On", 1099], ["the", 1102], ["other", 1106], ["hand", 1112], [",", 1116], ["the", 1118], ["patients", 1122], ["receiving", 1131], ["a", 1141], ["dose", 1143], ["below", 1148], ["300", 1154], ["mg", 1158], ["per", 1161], ["day", 1165], ["required", 1169], ["29.5", 1178], ["(", 1183], ["11", 1184], ["-", 1186], ["84", 1187], [")", 1189], ["months", 1191], ["[", 1198], ["median", 1199], ["(", 1206], ["range)].", 1207], ["When", 1216], ["BCR", 1221], ["-", 1224], ["ABL", 1225], ["mRNA", 1229], ["was", 1234], ["detected", 1238], ["during", 1247], ["the", 1254], ["treatment", 1258], ["course", 1268], ["of", 1275], ["patients", 1278], ["with", 1287], ["CMR", 1292], [",", 1295], ["careful", 1297], ["observation", 1305], ["of", 1317], ["BCR", 1320], ["-", 1323], ["ABL", 1324], ["mRNA", 1328], ["was", 1333], ["useful", 1337], ["for", 1344], ["tracking", 1348], ["the", 1357], ["clinical", 1361], ["course", 1370], ["of", 1377], ["patients", 1380], [".", 1388], ["In", 1390], ["conclusion", 1393], [",", 1403], ["the", 1405], ["BCR", 1409], ["-", 1412], ["ABL", 1413], ["mRNA", 1417], ["level", 1422], ["was", 1428], ["useful", 1432], ["for", 1439], ["monitoring", 1443], ["the", 1454], ["clinical", 1458], ["course", 1467], ["in", 1474], ["26", 1477], ["patients", 1480], ["with", 1489], ["CML", 1494], [".", 1497]]}
{"context": "mDia proteins are members of the formin family of actin nucleating proteins that polymerize linear actin filaments. Such filaments form the core of thin, tubular, membrane-bound cell surface protrusions known as filopodia, which are a major feature of mammalian cell morphology. Filopodia are dynamic structures that help cells sense environmental cues, and play a role in cell migration, axon guidance, angiogenesis and other processes. RhoGTPases bind to and control the activity of mDia proteins, and several other binding partners of the three mDia1 isoforms-mDia1, mDia2 and mDia3-have been documented. Two independent pathways controlling mammalian filopodium formation have emerged, with one driven by the RhoGTPase Cdc42, and the other by Rif. While mDia2 has been the main formin implicated in forming filopodia, mDia1 has recently surfaced as the key formin utilized by both the Cdc42 and Rif pathways to drive filopodial protrusion.", "qas": [{"question": "What family do mDia proteins belong in?", "answers": ["mDia proteins are members of the formin family"], "qid": "df45d243d5b846c9b8dd26f62bbe479e", "question_tokens": [["What", 0], ["family", 5], ["do", 12], ["mDia", 15], ["proteins", 20], ["belong", 29], ["in", 36], ["?", 38]], "detected_answers": [{"text": "mDia proteins are members of the formin family", "token_spans": [[0, 7]], "char_spans": [[0, 45]]}]}], "context_tokens": [["mDia", 0], ["proteins", 5], ["are", 14], ["members", 18], ["of", 26], ["the", 29], ["formin", 33], ["family", 40], ["of", 47], ["actin", 50], ["nucleating", 56], ["proteins", 67], ["that", 76], ["polymerize", 81], ["linear", 92], ["actin", 99], ["filaments", 105], [".", 114], ["Such", 116], ["filaments", 121], ["form", 131], ["the", 136], ["core", 140], ["of", 145], ["thin", 148], [",", 152], ["tubular", 154], [",", 161], ["membrane", 163], ["-", 171], ["bound", 172], ["cell", 178], ["surface", 183], ["protrusions", 191], ["known", 203], ["as", 209], ["filopodia", 212], [",", 221], ["which", 223], ["are", 229], ["a", 233], ["major", 235], ["feature", 241], ["of", 249], ["mammalian", 252], ["cell", 262], ["morphology", 267], [".", 277], ["Filopodia", 279], ["are", 289], ["dynamic", 293], ["structures", 301], ["that", 312], ["help", 317], ["cells", 322], ["sense", 328], ["environmental", 334], ["cues", 348], [",", 352], ["and", 354], ["play", 358], ["a", 363], ["role", 365], ["in", 370], ["cell", 373], ["migration", 378], [",", 387], ["axon", 389], ["guidance", 394], [",", 402], ["angiogenesis", 404], ["and", 417], ["other", 421], ["processes", 427], [".", 436], ["RhoGTPases", 438], ["bind", 449], ["to", 454], ["and", 457], ["control", 461], ["the", 469], ["activity", 473], ["of", 482], ["mDia", 485], ["proteins", 490], [",", 498], ["and", 500], ["several", 504], ["other", 512], ["binding", 518], ["partners", 526], ["of", 535], ["the", 538], ["three", 542], ["mDia1", 548], ["isoforms", 554], ["-", 562], ["mDia1", 563], [",", 568], ["mDia2", 570], ["and", 576], ["mDia3-have", 580], ["been", 591], ["documented", 596], [".", 606], ["Two", 608], ["independent", 612], ["pathways", 624], ["controlling", 633], ["mammalian", 645], ["filopodium", 655], ["formation", 666], ["have", 676], ["emerged", 681], [",", 688], ["with", 690], ["one", 695], ["driven", 699], ["by", 706], ["the", 709], ["RhoGTPase", 713], ["Cdc42", 723], [",", 728], ["and", 730], ["the", 734], ["other", 738], ["by", 744], ["Rif", 747], [".", 750], ["While", 752], ["mDia2", 758], ["has", 764], ["been", 768], ["the", 773], ["main", 777], ["formin", 782], ["implicated", 789], ["in", 800], ["forming", 803], ["filopodia", 811], [",", 820], ["mDia1", 822], ["has", 828], ["recently", 832], ["surfaced", 841], ["as", 850], ["the", 853], ["key", 857], ["formin", 861], ["utilized", 868], ["by", 877], ["both", 880], ["the", 885], ["Cdc42", 889], ["and", 895], ["Rif", 899], ["pathways", 903], ["to", 912], ["drive", 915], ["filopodial", 921], ["protrusion", 932], [".", 942]]}
{"context": "The article briefly summarizes the milestones leading to current knowledge and the possibility of treating one of the most widespread and perhaps least known diseases, restless legs syndrome (RLS). Until the mid-twentieth century, the syndrome first described by Willis (1685), was sporadically reported in medical literature and in most cases deemed a bizzare condition. It was only with Ekbom's detailed clinical description of the syndrome (1944) and the polygraphic recordings of Coccagna et al. (1962) that RLS became well-recognised clinical entity. Since then, almost all sleep laboratories have devoted much of their research to discovering the pathogenetic mechanisms underlying the disease and devise increasingly specific treatment. Major advances have been made in recent years, but a full understanding of RLS is still a long way off.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "4f93de9591b34369ba45f43f3f6efb52", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[26, 28]], "char_spans": [[168, 189]]}]}], "context_tokens": [["The", 0], ["article", 4], ["briefly", 12], ["summarizes", 20], ["the", 31], ["milestones", 35], ["leading", 46], ["to", 54], ["current", 57], ["knowledge", 65], ["and", 75], ["the", 79], ["possibility", 83], ["of", 95], ["treating", 98], ["one", 107], ["of", 111], ["the", 114], ["most", 118], ["widespread", 123], ["and", 134], ["perhaps", 138], ["least", 146], ["known", 152], ["diseases", 158], [",", 166], ["restless", 168], ["legs", 177], ["syndrome", 182], ["(", 191], ["RLS", 192], [")", 195], [".", 196], ["Until", 198], ["the", 204], ["mid", 208], ["-", 211], ["twentieth", 212], ["century", 222], [",", 229], ["the", 231], ["syndrome", 235], ["first", 244], ["described", 250], ["by", 260], ["Willis", 263], ["(", 270], ["1685", 271], [")", 275], [",", 276], ["was", 278], ["sporadically", 282], ["reported", 295], ["in", 304], ["medical", 307], ["literature", 315], ["and", 326], ["in", 330], ["most", 333], ["cases", 338], ["deemed", 344], ["a", 351], ["bizzare", 353], ["condition", 361], [".", 370], ["It", 372], ["was", 375], ["only", 379], ["with", 384], ["Ekbom", 389], ["'s", 394], ["detailed", 397], ["clinical", 406], ["description", 415], ["of", 427], ["the", 430], ["syndrome", 434], ["(", 443], ["1944", 444], [")", 448], ["and", 450], ["the", 454], ["polygraphic", 458], ["recordings", 470], ["of", 481], ["Coccagna", 484], ["et", 493], ["al", 496], [".", 498], ["(", 500], ["1962", 501], [")", 505], ["that", 507], ["RLS", 512], ["became", 516], ["well", 523], ["-", 527], ["recognised", 528], ["clinical", 539], ["entity", 548], [".", 554], ["Since", 556], ["then", 562], [",", 566], ["almost", 568], ["all", 575], ["sleep", 579], ["laboratories", 585], ["have", 598], ["devoted", 603], ["much", 611], ["of", 616], ["their", 619], ["research", 625], ["to", 634], ["discovering", 637], ["the", 649], ["pathogenetic", 653], ["mechanisms", 666], ["underlying", 677], ["the", 688], ["disease", 692], ["and", 700], ["devise", 704], ["increasingly", 711], ["specific", 724], ["treatment", 733], [".", 742], ["Major", 744], ["advances", 750], ["have", 759], ["been", 764], ["made", 769], ["in", 774], ["recent", 777], ["years", 784], [",", 789], ["but", 791], ["a", 795], ["full", 797], ["understanding", 802], ["of", 816], ["RLS", 819], ["is", 823], ["still", 826], ["a", 832], ["long", 834], ["way", 839], ["off", 843], [".", 846]]}
{"context": "3-Methyladenine DNA glycosylase II (AlkA) is a DNA-repair enzyme that removes alkylated bases in DNA via the base-excision repair (BER) pathway. The enzyme belongs to the helix-hairpin-helix (HhH) superfamily of DNA glycosylases and possesses broad substrate specificity. In the genome of Deinococcus radiodurans, two genes encoding putative AlkA have been identified (Dr_2074 and Dr_2584). Dr_2074 is a homologue of human AlkA (MPG or AAG) and Dr_2584 is a homologue of bacterial AlkAs. Here, the three-dimensional structure of Dr_2584 (DrAlkA2) is presented and compared with the previously determined structure of Escherichia coli AlkA (EcAlkA). The results show that the enzyme consists of two helical-bundle domains separated by a wide DNA-binding cleft and contains an HhH motif. Overall, the protein fold is similar to the two helical-bundle domains of EcAlkA, while the third N-terminal mixed \u03b1/\u03b2 domain observed in EcAlkA is absent. Substrate-specificity analyses show that DrAlkA2, like EcAlkA, is able to remove both 3-methyladenine (3meA) and 7-methylguanine (7meG) from DNA; however, the enzyme possesses no activity towards 1,N(6)-ethenoadenine (\u2107A) and hypoxanthine (Hx). In addition, it shows activity towards the AlkB\u00a0dioxygenase substrates 3-methylcytosine (3meC) and 1-methyladenine (1meA). Thus, the enzyme seems to preferentially repair methylated bases with weakened N-glycosidic bonds; this is an unusual specificity for a bacterial AlkA protein and is probably dictated by a combination of the wide DNA-binding cleft and a highly accessible specificity pocket.", "qas": [{"question": "What type of DNA repair pathways is initiated by AlkA glycosylase?", "answers": ["base-excision repair (BER) pathway", "base excision repair (BER) pathway"], "qid": "250caa665c8448fb98e285306f80e63e", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["DNA", 13], ["repair", 17], ["pathways", 24], ["is", 33], ["initiated", 36], ["by", 46], ["AlkA", 49], ["glycosylase", 54], ["?", 65]], "detected_answers": [{"text": "base excision repair (BER) pathway", "token_spans": [[21, 28]], "char_spans": [[109, 142]]}]}], "context_tokens": [["3-Methyladenine", 0], ["DNA", 16], ["glycosylase", 20], ["II", 32], ["(", 35], ["AlkA", 36], [")", 40], ["is", 42], ["a", 45], ["DNA", 47], ["-", 50], ["repair", 51], ["enzyme", 58], ["that", 65], ["removes", 70], ["alkylated", 78], ["bases", 88], ["in", 94], ["DNA", 97], ["via", 101], ["the", 105], ["base", 109], ["-", 113], ["excision", 114], ["repair", 123], ["(", 130], ["BER", 131], [")", 134], ["pathway", 136], [".", 143], ["The", 145], ["enzyme", 149], ["belongs", 156], ["to", 164], ["the", 167], ["helix", 171], ["-", 176], ["hairpin", 177], ["-", 184], ["helix", 185], ["(", 191], ["HhH", 192], [")", 195], ["superfamily", 197], ["of", 209], ["DNA", 212], ["glycosylases", 216], ["and", 229], ["possesses", 233], ["broad", 243], ["substrate", 249], ["specificity", 259], [".", 270], ["In", 272], ["the", 275], ["genome", 279], ["of", 286], ["Deinococcus", 289], ["radiodurans", 301], [",", 312], ["two", 314], ["genes", 318], ["encoding", 324], ["putative", 333], ["AlkA", 342], ["have", 347], ["been", 352], ["identified", 357], ["(", 368], ["Dr_2074", 369], ["and", 377], ["Dr_2584", 381], [")", 388], [".", 389], ["Dr_2074", 391], ["is", 399], ["a", 402], ["homologue", 404], ["of", 414], ["human", 417], ["AlkA", 423], ["(", 428], ["MPG", 429], ["or", 433], ["AAG", 436], [")", 439], ["and", 441], ["Dr_2584", 445], ["is", 453], ["a", 456], ["homologue", 458], ["of", 468], ["bacterial", 471], ["AlkAs", 481], [".", 486], ["Here", 488], [",", 492], ["the", 494], ["three", 498], ["-", 503], ["dimensional", 504], ["structure", 516], ["of", 526], ["Dr_2584", 529], ["(", 537], ["DrAlkA2", 538], [")", 545], ["is", 547], ["presented", 550], ["and", 560], ["compared", 564], ["with", 573], ["the", 578], ["previously", 582], ["determined", 593], ["structure", 604], ["of", 614], ["Escherichia", 617], ["coli", 629], ["AlkA", 634], ["(", 639], ["EcAlkA", 640], [")", 646], [".", 647], ["The", 649], ["results", 653], ["show", 661], ["that", 666], ["the", 671], ["enzyme", 675], ["consists", 682], ["of", 691], ["two", 694], ["helical", 698], ["-", 705], ["bundle", 706], ["domains", 713], ["separated", 721], ["by", 731], ["a", 734], ["wide", 736], ["DNA", 741], ["-", 744], ["binding", 745], ["cleft", 753], ["and", 759], ["contains", 763], ["an", 772], ["HhH", 775], ["motif", 779], [".", 784], ["Overall", 786], [",", 793], ["the", 795], ["protein", 799], ["fold", 807], ["is", 812], ["similar", 815], ["to", 823], ["the", 826], ["two", 830], ["helical", 834], ["-", 841], ["bundle", 842], ["domains", 849], ["of", 857], ["EcAlkA", 860], [",", 866], ["while", 868], ["the", 874], ["third", 878], ["N", 884], ["-", 885], ["terminal", 886], ["mixed", 895], ["\u03b1", 901], ["/", 902], ["\u03b2", 903], ["domain", 905], ["observed", 912], ["in", 921], ["EcAlkA", 924], ["is", 931], ["absent", 934], [".", 940], ["Substrate", 942], ["-", 951], ["specificity", 952], ["analyses", 964], ["show", 973], ["that", 978], ["DrAlkA2", 983], [",", 990], ["like", 992], ["EcAlkA", 997], [",", 1003], ["is", 1005], ["able", 1008], ["to", 1013], ["remove", 1016], ["both", 1023], ["3-methyladenine", 1028], ["(", 1044], ["3meA", 1045], [")", 1049], ["and", 1051], ["7-methylguanine", 1055], ["(", 1071], ["7meG", 1072], [")", 1076], ["from", 1078], ["DNA", 1083], [";", 1086], ["however", 1088], [",", 1095], ["the", 1097], ["enzyme", 1101], ["possesses", 1108], ["no", 1118], ["activity", 1121], ["towards", 1130], ["1,N(6)-ethenoadenine", 1138], ["(", 1159], ["\u2107A", 1160], [")", 1162], ["and", 1164], ["hypoxanthine", 1168], ["(", 1181], ["Hx", 1182], [")", 1184], [".", 1185], ["In", 1187], ["addition", 1190], [",", 1198], ["it", 1200], ["shows", 1203], ["activity", 1209], ["towards", 1218], ["the", 1226], ["AlkB", 1230], ["dioxygenase", 1235], ["substrates", 1247], ["3-methylcytosine", 1258], ["(", 1275], ["3meC", 1276], [")", 1280], ["and", 1282], ["1-methyladenine", 1286], ["(", 1302], ["1meA", 1303], [")", 1307], [".", 1308], ["Thus", 1310], [",", 1314], ["the", 1316], ["enzyme", 1320], ["seems", 1327], ["to", 1333], ["preferentially", 1336], ["repair", 1351], ["methylated", 1358], ["bases", 1369], ["with", 1375], ["weakened", 1380], ["N", 1389], ["-", 1390], ["glycosidic", 1391], ["bonds", 1402], [";", 1407], ["this", 1409], ["is", 1414], ["an", 1417], ["unusual", 1420], ["specificity", 1428], ["for", 1440], ["a", 1444], ["bacterial", 1446], ["AlkA", 1456], ["protein", 1461], ["and", 1469], ["is", 1473], ["probably", 1476], ["dictated", 1485], ["by", 1494], ["a", 1497], ["combination", 1499], ["of", 1511], ["the", 1514], ["wide", 1518], ["DNA", 1523], ["-", 1526], ["binding", 1527], ["cleft", 1535], ["and", 1541], ["a", 1545], ["highly", 1547], ["accessible", 1554], ["specificity", 1565], ["pocket", 1577], [".", 1583]]}
{"context": "A diverse collection of 261 Staphylococcus aureus strains from human, animal, food, and environmental sources were tested for the presence and type of SCCmec elements, antibiotic susceptibility to various antibiotics, and non-\u00df-lactam antibiotic resistance genes. About 18.39% (48/261) of strains were methicillin-resistant S. aureus (MRSA) including 29.75% (36/121) human strains of which 29 strains were hospital-acquired MRSA (HA-MRSA) and 7 strains were community-associated MRSA (CA-MRSA) and 19.67% (12/61) animal strains that all were CA-MRSA strains. The percentage of CA-MRSA strains from animals was significantly higher than that from human (p<0.01). Most of MRSA strains and a part of methicillin-susceptible S. aureus (MSSA) strains harbored unique combinations of non-\u00df-lactamase genes aac(6')/aph(2\u2033), aph(3')-III, ant (4',4\u2033), ermA, ermC, mrsA, tetM, and tetK. Antibiotic resistance genes were detected more frequently in HA-MRSA strains than in CA-MRSA strains (p<0.01). MRSA strains and MSSA strains had 22 and 39 antibiotic profiles to 15 tested antibiotics, respectively. The resistant proportion was higher in HA-MRSA strains than in CA-MSSA strains for various antibiotics, as well as higher in MRSA strains than in MSSA strains. Animal MRSA reservoirs (particularly pigs and cows) might represent an important source of human CA-MRSA. CA-MRSA strains might acquire more different resistance genes gradually, depending on the selective pressure of antibiotics in different regions or environments. CA-MRSA is not yet endemic in China, but could be prevalent in future, contributing to its acquiring more resistance genes and huge animal sources. Infection with multidrug-resistant MSSA strains acquired from food, animal, and human sources might also become a significant problem for human medicine, which warrants further study.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "bd18e4066acc45d0970dbce4a776702f", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "methicillin-resistant S. aureus", "token_spans": [[54, 58]], "char_spans": [[302, 332]]}, {"text": "MRSA", "token_spans": [[91, 91], [245, 245], [118, 118], [202, 202], [253, 253], [299, 299], [60, 60], [196, 196], [78, 78], [135, 135], [228, 228], [174, 174], [270, 270], [274, 274], [190, 190], [82, 82], [95, 95], [110, 110]], "char_spans": [[479, 482], [1217, 1220], [580, 583], [988, 991], [1259, 1262], [1523, 1526], [335, 338], [965, 968], [424, 427], [670, 673], [1134, 1137], [855, 858], [1352, 1355], [1361, 1364], [941, 944], [433, 436], [488, 491], [545, 548]]}]}], "context_tokens": [["A", 0], ["diverse", 2], ["collection", 10], ["of", 21], ["261", 24], ["Staphylococcus", 28], ["aureus", 43], ["strains", 50], ["from", 58], ["human", 63], [",", 68], ["animal", 70], [",", 76], ["food", 78], [",", 82], ["and", 84], ["environmental", 88], ["sources", 102], ["were", 110], ["tested", 115], ["for", 122], ["the", 126], ["presence", 130], ["and", 139], ["type", 143], ["of", 148], ["SCCmec", 151], ["elements", 158], [",", 166], ["antibiotic", 168], ["susceptibility", 179], ["to", 194], ["various", 197], ["antibiotics", 205], [",", 216], ["and", 218], ["non", 222], ["-", 225], ["\u00df", 226], ["-", 227], ["lactam", 228], ["antibiotic", 235], ["resistance", 246], ["genes", 257], [".", 262], ["About", 264], ["18.39", 270], ["%", 275], ["(", 277], ["48/261", 278], [")", 284], ["of", 286], ["strains", 289], ["were", 297], ["methicillin", 302], ["-", 313], ["resistant", 314], ["S.", 324], ["aureus", 327], ["(", 334], ["MRSA", 335], [")", 339], ["including", 341], ["29.75", 351], ["%", 356], ["(", 358], ["36/121", 359], [")", 365], ["human", 367], ["strains", 373], ["of", 381], ["which", 384], ["29", 390], ["strains", 393], ["were", 401], ["hospital", 406], ["-", 414], ["acquired", 415], ["MRSA", 424], ["(", 429], ["HA", 430], ["-", 432], ["MRSA", 433], [")", 437], ["and", 439], ["7", 443], ["strains", 445], ["were", 453], ["community", 458], ["-", 467], ["associated", 468], ["MRSA", 479], ["(", 484], ["CA", 485], ["-", 487], ["MRSA", 488], [")", 492], ["and", 494], ["19.67", 498], ["%", 503], ["(", 505], ["12/61", 506], [")", 511], ["animal", 513], ["strains", 520], ["that", 528], ["all", 533], ["were", 537], ["CA", 542], ["-", 544], ["MRSA", 545], ["strains", 550], [".", 557], ["The", 559], ["percentage", 563], ["of", 574], ["CA", 577], ["-", 579], ["MRSA", 580], ["strains", 585], ["from", 593], ["animals", 598], ["was", 606], ["significantly", 610], ["higher", 624], ["than", 631], ["that", 636], ["from", 641], ["human", 646], ["(", 652], ["p<0.01", 653], [")", 659], [".", 660], ["Most", 662], ["of", 667], ["MRSA", 670], ["strains", 675], ["and", 683], ["a", 687], ["part", 689], ["of", 694], ["methicillin", 697], ["-", 708], ["susceptible", 709], ["S.", 721], ["aureus", 724], ["(", 731], ["MSSA", 732], [")", 736], ["strains", 738], ["harbored", 746], ["unique", 755], ["combinations", 762], ["of", 775], ["non", 778], ["-", 781], ["\u00df", 782], ["-", 783], ["lactamase", 784], ["genes", 794], ["aac(6')/aph(2\u2033", 800], [")", 814], [",", 815], ["aph(3')-III", 817], [",", 828], ["ant", 830], ["(", 834], ["4',4\u2033", 835], [")", 840], [",", 841], ["ermA", 843], [",", 847], ["ermC", 849], [",", 853], ["mrsA", 855], [",", 859], ["tetM", 861], [",", 865], ["and", 867], ["tetK.", 871], ["Antibiotic", 877], ["resistance", 888], ["genes", 899], ["were", 905], ["detected", 910], ["more", 919], ["frequently", 924], ["in", 935], ["HA", 938], ["-", 940], ["MRSA", 941], ["strains", 946], ["than", 954], ["in", 959], ["CA", 962], ["-", 964], ["MRSA", 965], ["strains", 970], ["(", 978], ["p<0.01", 979], [")", 985], [".", 986], ["MRSA", 988], ["strains", 993], ["and", 1001], ["MSSA", 1005], ["strains", 1010], ["had", 1018], ["22", 1022], ["and", 1025], ["39", 1029], ["antibiotic", 1032], ["profiles", 1043], ["to", 1052], ["15", 1055], ["tested", 1058], ["antibiotics", 1065], [",", 1076], ["respectively", 1078], [".", 1090], ["The", 1092], ["resistant", 1096], ["proportion", 1106], ["was", 1117], ["higher", 1121], ["in", 1128], ["HA", 1131], ["-", 1133], ["MRSA", 1134], ["strains", 1139], ["than", 1147], ["in", 1152], ["CA", 1155], ["-", 1157], ["MSSA", 1158], ["strains", 1163], ["for", 1171], ["various", 1175], ["antibiotics", 1183], [",", 1194], ["as", 1196], ["well", 1199], ["as", 1204], ["higher", 1207], ["in", 1214], ["MRSA", 1217], ["strains", 1222], ["than", 1230], ["in", 1235], ["MSSA", 1238], ["strains", 1243], [".", 1250], ["Animal", 1252], ["MRSA", 1259], ["reservoirs", 1264], ["(", 1275], ["particularly", 1276], ["pigs", 1289], ["and", 1294], ["cows", 1298], [")", 1302], ["might", 1304], ["represent", 1310], ["an", 1320], ["important", 1323], ["source", 1333], ["of", 1340], ["human", 1343], ["CA", 1349], ["-", 1351], ["MRSA", 1352], [".", 1356], ["CA", 1358], ["-", 1360], ["MRSA", 1361], ["strains", 1366], ["might", 1374], ["acquire", 1380], ["more", 1388], ["different", 1393], ["resistance", 1403], ["genes", 1414], ["gradually", 1420], [",", 1429], ["depending", 1431], ["on", 1441], ["the", 1444], ["selective", 1448], ["pressure", 1458], ["of", 1467], ["antibiotics", 1470], ["in", 1482], ["different", 1485], ["regions", 1495], ["or", 1503], ["environments", 1506], [".", 1518], ["CA", 1520], ["-", 1522], ["MRSA", 1523], ["is", 1528], ["not", 1531], ["yet", 1535], ["endemic", 1539], ["in", 1547], ["China", 1550], [",", 1555], ["but", 1557], ["could", 1561], ["be", 1567], ["prevalent", 1570], ["in", 1580], ["future", 1583], [",", 1589], ["contributing", 1591], ["to", 1604], ["its", 1607], ["acquiring", 1611], ["more", 1621], ["resistance", 1626], ["genes", 1637], ["and", 1643], ["huge", 1647], ["animal", 1652], ["sources", 1659], [".", 1666], ["Infection", 1668], ["with", 1678], ["multidrug", 1683], ["-", 1692], ["resistant", 1693], ["MSSA", 1703], ["strains", 1708], ["acquired", 1716], ["from", 1725], ["food", 1730], [",", 1734], ["animal", 1736], [",", 1742], ["and", 1744], ["human", 1748], ["sources", 1754], ["might", 1762], ["also", 1768], ["become", 1773], ["a", 1780], ["significant", 1782], ["problem", 1794], ["for", 1802], ["human", 1806], ["medicine", 1812], [",", 1820], ["which", 1822], ["warrants", 1828], ["further", 1837], ["study", 1845], [".", 1850]]}
{"context": "Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) has an unusual pathogenic mechanism. FSHD is caused by deletion of a subset of D4Z4 macrosatellite repeat units in the subtelomere of chromosome 4q. Recent studies provide compelling evidence that a retrotransposed gene in the D4Z4 repeat, DUX4, is expressed in the human germline and then epigenetically silenced in somatic tissues. In FSHD, the combination of inefficient chromatin silencing of the D4Z4 repeat and polymorphisms on the FSHD-permissive alleles that stabilize the DUX4 mRNAs emanating from the repeat result in inappropriate DUX4 protein expression in muscle cells. FSHD is thereby the first example of a human disease caused by the inefficient repression of a retrogene in a macrosatellite repeat array.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "fb6050311b794585986ab4a8b17b564e", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[6, 6], [65, 65], [104, 104], [14, 14], [81, 81]], "char_spans": [[59, 62], [402, 405], [648, 651], [102, 105], [503, 506]]}]}], "context_tokens": [["Autosomal", 0], ["dominant", 10], ["facioscapulohumeral", 19], ["muscular", 39], ["dystrophy", 48], ["(", 58], ["FSHD", 59], [")", 63], ["has", 65], ["an", 69], ["unusual", 72], ["pathogenic", 80], ["mechanism", 91], [".", 100], ["FSHD", 102], ["is", 107], ["caused", 110], ["by", 117], ["deletion", 120], ["of", 129], ["a", 132], ["subset", 134], ["of", 141], ["D4Z4", 144], ["macrosatellite", 149], ["repeat", 164], ["units", 171], ["in", 177], ["the", 180], ["subtelomere", 184], ["of", 196], ["chromosome", 199], ["4q", 210], [".", 212], ["Recent", 214], ["studies", 221], ["provide", 229], ["compelling", 237], ["evidence", 248], ["that", 257], ["a", 262], ["retrotransposed", 264], ["gene", 280], ["in", 285], ["the", 288], ["D4Z4", 292], ["repeat", 297], [",", 303], ["DUX4", 305], [",", 309], ["is", 311], ["expressed", 314], ["in", 324], ["the", 327], ["human", 331], ["germline", 337], ["and", 346], ["then", 350], ["epigenetically", 355], ["silenced", 370], ["in", 379], ["somatic", 382], ["tissues", 390], [".", 397], ["In", 399], ["FSHD", 402], [",", 406], ["the", 408], ["combination", 412], ["of", 424], ["inefficient", 427], ["chromatin", 439], ["silencing", 449], ["of", 459], ["the", 462], ["D4Z4", 466], ["repeat", 471], ["and", 478], ["polymorphisms", 482], ["on", 496], ["the", 499], ["FSHD", 503], ["-", 507], ["permissive", 508], ["alleles", 519], ["that", 527], ["stabilize", 532], ["the", 542], ["DUX4", 546], ["mRNAs", 551], ["emanating", 557], ["from", 567], ["the", 572], ["repeat", 576], ["result", 583], ["in", 590], ["inappropriate", 593], ["DUX4", 607], ["protein", 612], ["expression", 620], ["in", 631], ["muscle", 634], ["cells", 641], [".", 646], ["FSHD", 648], ["is", 653], ["thereby", 656], ["the", 664], ["first", 668], ["example", 674], ["of", 682], ["a", 685], ["human", 687], ["disease", 693], ["caused", 701], ["by", 708], ["the", 711], ["inefficient", 715], ["repression", 727], ["of", 738], ["a", 741], ["retrogene", 743], ["in", 753], ["a", 756], ["macrosatellite", 758], ["repeat", 773], ["array", 780], [".", 785]]}
{"context": "Combination microbicide vaginal rings may be more effective than single microbicide rings at reducing/preventing sexual transmission of HIV. Here, we report the pre-clinical development and macaque pharmacokinetics of matrix-type silicone elastomer vaginal rings containing dapivirine and darunavir. Macaque rings containing 25 mg dapivirine, 100 mg dapivirine, 300 mg darunavir or 100 mg dapivirine+300 mg darunavir were manufactured and characterized by differential scanning calorimetry. In vitro release was assessed into isopropanol/water and simulated vaginal fluid. Macaque vaginal fluid and blood serum concentrations for both antiretrovirals were measured during 28 day ring use. Tissue levels were measured on day 28. Ex vivo challenge studies were performed on vaginal fluid samples and IC50 values were calculated. Darunavir caused a concentration-dependent reduction in the dapivirine melting temperature in both solid drug mixes and in the combination ring. In vitro release from rings was dependent on drug loading, the number of drugs present and the release medium. In macaques, serum concentrations of both microbicides were maintained between 10(1) and 10(2) pg/mL. Vaginal fluid levels ranged between 10(3) and 10(4) ng/g and between 10(4) and 10(5) ng/g for dapivirine and darunavir, respectively. Both dapivirine and darunavir showed very similar concentrations in each tissue type; the range of drug tissue concentrations followed the general rank order: vagina (1.8\u200a\u00d7\u200a10(3)-3.8\u200a\u00d7\u200a10(3) ng/g) \u200a>\u200acervix (9.4\u200a\u00d7\u200a10(1)-3.9\u200a\u00d7\u200a10(2) ng/g) \u200a>\u200auterus (0-108 ng/g) \u200a>\u200arectum (0-40 ng/g). Measured IC50 values were >2 ng/mL for both compounds. Based on these results, and in light of recent clinical progress of the 25 mg dapivirine ring, a combination vaginal ring containing dapivirine and darunavir is a viable second-generation HIV microbicide candidate.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "dc9bceb110f546b884dbdd371fc5a5b9", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[19, 19], [341, 341]], "char_spans": [[136, 138], [1846, 1848]]}]}], "context_tokens": [["Combination", 0], ["microbicide", 12], ["vaginal", 24], ["rings", 32], ["may", 38], ["be", 42], ["more", 45], ["effective", 50], ["than", 60], ["single", 65], ["microbicide", 72], ["rings", 84], ["at", 90], ["reducing", 93], ["/", 101], ["preventing", 102], ["sexual", 113], ["transmission", 120], ["of", 133], ["HIV", 136], [".", 139], ["Here", 141], [",", 145], ["we", 147], ["report", 150], ["the", 157], ["pre", 161], ["-", 164], ["clinical", 165], ["development", 174], ["and", 186], ["macaque", 190], ["pharmacokinetics", 198], ["of", 215], ["matrix", 218], ["-", 224], ["type", 225], ["silicone", 230], ["elastomer", 239], ["vaginal", 249], ["rings", 257], ["containing", 263], ["dapivirine", 274], ["and", 285], ["darunavir", 289], [".", 298], ["Macaque", 300], ["rings", 308], ["containing", 314], ["25", 325], ["mg", 328], ["dapivirine", 331], [",", 341], ["100", 343], ["mg", 347], ["dapivirine", 350], [",", 360], ["300", 362], ["mg", 366], ["darunavir", 369], ["or", 379], ["100", 382], ["mg", 386], ["dapivirine+300", 389], ["mg", 404], ["darunavir", 407], ["were", 417], ["manufactured", 422], ["and", 435], ["characterized", 439], ["by", 453], ["differential", 456], ["scanning", 469], ["calorimetry", 478], [".", 489], ["In", 491], ["vitro", 494], ["release", 500], ["was", 508], ["assessed", 512], ["into", 521], ["isopropanol", 526], ["/", 537], ["water", 538], ["and", 544], ["simulated", 548], ["vaginal", 558], ["fluid", 566], [".", 571], ["Macaque", 573], ["vaginal", 581], ["fluid", 589], ["and", 595], ["blood", 599], ["serum", 605], ["concentrations", 611], ["for", 626], ["both", 630], ["antiretrovirals", 635], ["were", 651], ["measured", 656], ["during", 665], ["28", 672], ["day", 675], ["ring", 679], ["use", 684], [".", 687], ["Tissue", 689], ["levels", 696], ["were", 703], ["measured", 708], ["on", 717], ["day", 720], ["28", 724], [".", 726], ["Ex", 728], ["vivo", 731], ["challenge", 736], ["studies", 746], ["were", 754], ["performed", 759], ["on", 769], ["vaginal", 772], ["fluid", 780], ["samples", 786], ["and", 794], ["IC50", 798], ["values", 803], ["were", 810], ["calculated", 815], [".", 825], ["Darunavir", 827], ["caused", 837], ["a", 844], ["concentration", 846], ["-", 859], ["dependent", 860], ["reduction", 870], ["in", 880], ["the", 883], ["dapivirine", 887], ["melting", 898], ["temperature", 906], ["in", 918], ["both", 921], ["solid", 926], ["drug", 932], ["mixes", 937], ["and", 943], ["in", 947], ["the", 950], ["combination", 954], ["ring", 966], [".", 970], ["In", 972], ["vitro", 975], ["release", 981], ["from", 989], ["rings", 994], ["was", 1000], ["dependent", 1004], ["on", 1014], ["drug", 1017], ["loading", 1022], [",", 1029], ["the", 1031], ["number", 1035], ["of", 1042], ["drugs", 1045], ["present", 1051], ["and", 1059], ["the", 1063], ["release", 1067], ["medium", 1075], [".", 1081], ["In", 1083], ["macaques", 1086], [",", 1094], ["serum", 1096], ["concentrations", 1102], ["of", 1117], ["both", 1120], ["microbicides", 1125], ["were", 1138], ["maintained", 1143], ["between", 1154], ["10(1", 1162], [")", 1166], ["and", 1168], ["10(2", 1172], [")", 1176], ["pg", 1178], ["/", 1180], ["mL.", 1181], ["Vaginal", 1185], ["fluid", 1193], ["levels", 1199], ["ranged", 1206], ["between", 1213], ["10(3", 1221], [")", 1225], ["and", 1227], ["10(4", 1231], [")", 1235], ["ng", 1237], ["/", 1239], ["g", 1240], ["and", 1242], ["between", 1246], ["10(4", 1254], [")", 1258], ["and", 1260], ["10(5", 1264], [")", 1268], ["ng", 1270], ["/", 1272], ["g", 1273], ["for", 1275], ["dapivirine", 1279], ["and", 1290], ["darunavir", 1294], [",", 1303], ["respectively", 1305], [".", 1317], ["Both", 1319], ["dapivirine", 1324], ["and", 1335], ["darunavir", 1339], ["showed", 1349], ["very", 1356], ["similar", 1361], ["concentrations", 1369], ["in", 1384], ["each", 1387], ["tissue", 1392], ["type", 1399], [";", 1403], ["the", 1405], ["range", 1409], ["of", 1415], ["drug", 1418], ["tissue", 1423], ["concentrations", 1430], ["followed", 1445], ["the", 1454], ["general", 1458], ["rank", 1466], ["order", 1471], [":", 1476], ["vagina", 1478], ["(", 1485], ["1.8", 1486], ["\u00d7", 1490], ["10(3)-3.8", 1492], ["\u00d7", 1502], ["10(3", 1504], [")", 1508], ["ng", 1510], ["/", 1512], ["g", 1513], [")", 1514], [">", 1517], ["cervix", 1519], ["(", 1526], ["9.4", 1527], ["\u00d7", 1531], ["10(1)-3.9", 1533], ["\u00d7", 1543], ["10(2", 1545], [")", 1549], ["ng", 1551], ["/", 1553], ["g", 1554], [")", 1555], [">", 1558], ["uterus", 1560], ["(", 1567], ["0", 1568], ["-", 1569], ["108", 1570], ["ng", 1574], ["/", 1576], ["g", 1577], [")", 1578], [">", 1581], ["rectum", 1583], ["(", 1590], ["0", 1591], ["-", 1592], ["40", 1593], ["ng", 1596], ["/", 1598], ["g", 1599], [")", 1600], [".", 1601], ["Measured", 1603], ["IC50", 1612], ["values", 1617], ["were", 1624], [">", 1629], ["2", 1630], ["ng", 1632], ["/", 1634], ["mL", 1635], ["for", 1638], ["both", 1642], ["compounds", 1647], [".", 1656], ["Based", 1658], ["on", 1664], ["these", 1667], ["results", 1673], [",", 1680], ["and", 1682], ["in", 1686], ["light", 1689], ["of", 1695], ["recent", 1698], ["clinical", 1705], ["progress", 1714], ["of", 1723], ["the", 1726], ["25", 1730], ["mg", 1733], ["dapivirine", 1736], ["ring", 1747], [",", 1751], ["a", 1753], ["combination", 1755], ["vaginal", 1767], ["ring", 1775], ["containing", 1780], ["dapivirine", 1791], ["and", 1802], ["darunavir", 1806], ["is", 1816], ["a", 1819], ["viable", 1821], ["second", 1828], ["-", 1834], ["generation", 1835], ["HIV", 1846], ["microbicide", 1850], ["candidate", 1862], [".", 1871]]}
{"context": "Dasatinib is an oral small molecule inhibitor of Abl and Src family tyrosine kinases (SFK), including p56(Lck) (Lck). Given the central importance of Lck in transmitting signals from the T-cell receptor (TCR) signaling complex and the potent ability of dasatinib to inhibit Lck activity, we hypothesized this agent could provide a novel route of immunomodulation via targeted inhibition of antigen-induced signaling. Herein, we show that dasatinib inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-cell responses. However, dasatinib-mediated inhibition does not induce apoptosis because the effect is reversible or may be overcome by signals bypassing the TCR, such as phorbol ester. Signal transduction and proliferative responses via IL-2 remain essentially unperturbed, suggesting that dasatinib displays specificity for TCR signaling. In addition, dasatinib combined with cyclosporine A or rapamycin led to a much more potent inhibition of T-cell activation, suggesting that targeted inhibition of Lck could be a useful adjunct for enhanced immunomodulation. In combination with currently available immunomodulatory agents, SFK inhibition could potentially increase immunomodulatory efficacy while minimizing toxicity of individual agents.", "qas": [{"question": "Does dasatinib promote or inhibit T-cell proliferation?", "answers": ["inhibits"], "qid": "61ec5684d44c4296809c466509051021", "question_tokens": [["Does", 0], ["dasatinib", 5], ["promote", 15], ["or", 23], ["inhibit", 26], ["T", 34], ["-", 35], ["cell", 36], ["proliferation", 41], ["?", 54]], "detected_answers": [{"text": "inhibits", "token_spans": [[82, 82]], "char_spans": [[448, 455]]}]}], "context_tokens": [["Dasatinib", 0], ["is", 10], ["an", 13], ["oral", 16], ["small", 21], ["molecule", 27], ["inhibitor", 36], ["of", 46], ["Abl", 49], ["and", 53], ["Src", 57], ["family", 61], ["tyrosine", 68], ["kinases", 77], ["(", 85], ["SFK", 86], [")", 89], [",", 90], ["including", 92], ["p56(Lck", 102], [")", 109], ["(", 111], ["Lck", 112], [")", 115], [".", 116], ["Given", 118], ["the", 124], ["central", 128], ["importance", 136], ["of", 147], ["Lck", 150], ["in", 154], ["transmitting", 157], ["signals", 170], ["from", 178], ["the", 183], ["T", 187], ["-", 188], ["cell", 189], ["receptor", 194], ["(", 203], ["TCR", 204], [")", 207], ["signaling", 209], ["complex", 219], ["and", 227], ["the", 231], ["potent", 235], ["ability", 242], ["of", 250], ["dasatinib", 253], ["to", 263], ["inhibit", 266], ["Lck", 274], ["activity", 278], [",", 286], ["we", 288], ["hypothesized", 291], ["this", 304], ["agent", 309], ["could", 315], ["provide", 321], ["a", 329], ["novel", 331], ["route", 337], ["of", 343], ["immunomodulation", 346], ["via", 363], ["targeted", 367], ["inhibition", 376], ["of", 387], ["antigen", 390], ["-", 397], ["induced", 398], ["signaling", 406], [".", 415], ["Herein", 417], [",", 423], ["we", 425], ["show", 428], ["that", 433], ["dasatinib", 438], ["inhibits", 448], ["TCR", 457], ["-", 460], ["mediated", 461], ["signal", 470], ["transduction", 477], [",", 489], ["cellular", 491], ["proliferation", 500], [",", 513], ["cytokine", 515], ["production", 524], [",", 534], ["and", 536], ["in", 540], ["vivo", 543], ["T", 548], ["-", 549], ["cell", 550], ["responses", 555], [".", 564], ["However", 566], [",", 573], ["dasatinib", 575], ["-", 584], ["mediated", 585], ["inhibition", 594], ["does", 605], ["not", 610], ["induce", 614], ["apoptosis", 621], ["because", 631], ["the", 639], ["effect", 643], ["is", 650], ["reversible", 653], ["or", 664], ["may", 667], ["be", 671], ["overcome", 674], ["by", 683], ["signals", 686], ["bypassing", 694], ["the", 704], ["TCR", 708], [",", 711], ["such", 713], ["as", 718], ["phorbol", 721], ["ester", 729], [".", 734], ["Signal", 736], ["transduction", 743], ["and", 756], ["proliferative", 760], ["responses", 774], ["via", 784], ["IL-2", 788], ["remain", 793], ["essentially", 800], ["unperturbed", 812], [",", 823], ["suggesting", 825], ["that", 836], ["dasatinib", 841], ["displays", 851], ["specificity", 860], ["for", 872], ["TCR", 876], ["signaling", 880], [".", 889], ["In", 891], ["addition", 894], [",", 902], ["dasatinib", 904], ["combined", 914], ["with", 923], ["cyclosporine", 928], ["A", 941], ["or", 943], ["rapamycin", 946], ["led", 956], ["to", 960], ["a", 963], ["much", 965], ["more", 970], ["potent", 975], ["inhibition", 982], ["of", 993], ["T", 996], ["-", 997], ["cell", 998], ["activation", 1003], [",", 1013], ["suggesting", 1015], ["that", 1026], ["targeted", 1031], ["inhibition", 1040], ["of", 1051], ["Lck", 1054], ["could", 1058], ["be", 1064], ["a", 1067], ["useful", 1069], ["adjunct", 1076], ["for", 1084], ["enhanced", 1088], ["immunomodulation", 1097], [".", 1113], ["In", 1115], ["combination", 1118], ["with", 1130], ["currently", 1135], ["available", 1145], ["immunomodulatory", 1155], ["agents", 1172], [",", 1178], ["SFK", 1180], ["inhibition", 1184], ["could", 1195], ["potentially", 1201], ["increase", 1213], ["immunomodulatory", 1222], ["efficacy", 1239], ["while", 1248], ["minimizing", 1254], ["toxicity", 1265], ["of", 1274], ["individual", 1277], ["agents", 1288], [".", 1294]]}
{"context": "MicroRNAs (miRNAs) are non-coding, short (21-23nt) regulators of protein-coding genes that are generally transcribed first into primary miRNA (pri-miR), followed by the generation of precursor miRNA (pre-miR). This finally leads to the production of the mature miRNA. A large amount of information is available on the pre- and mature miRNAs. However, very little is known about the pri-miRs, due to a lack of knowledge about their transcription start sites (TSSs). Based on the genomic loci, miRNAs can be categorized into two types --intragenic (intra-miR) and intergenic (inter-miR). While it is already an established fact that intra-miRs are commonly transcribed in conjunction with their host genes, the transcription machinery of inter-miRs is poorly understood. Although it is assumed that miRNA promoters are similar in structure to gene promoters, since both are transcribed by RNA polymerase II (Pol II), computational validations exhibit poor performance of gene promoter prediction methods on miRNAs. In this paper, we concentrate on the problem of TSS prediction for miRNAs. The present study begins with the identification of positive and negative promoter samples from recently published data stemming from RNA-sequencing studies. From these samples of experimentally validated miRNA TSSs, a number of standard sequence features are extracted. Furthermore, to account for potential footprints related to promoter regulation by CpG dinucleotide targeted DNA methylation, a number of novel features are defined. We develop a support vector machine (SVM) with RBF kernel for the prediction of miRNA TSSs trained on human miRNA promoters. A novel feature reduction technique based on archived multi-objective simulated annealing (AMOSA) identifies the final set of features. The resulting model trained on miRNA promoters shows improved performance over the one trained on protein-coding gene promoters in terms of classification accuracy, sensitivity and specificity. Results are also reported for a completely independent biologically validated test set. In a part of the investigation, the proposed approach is used to predict protein-coding gene TSSs. It shows a significantly improved performance when compared to previously published gene TSS prediction methods.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "cdd96acd2fc94e268b146391bc401383", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[179, 181]], "char_spans": [[887, 903]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["non", 23], ["-", 26], ["coding", 27], [",", 33], ["short", 35], ["(", 41], ["21", 42], ["-", 44], ["23nt", 45], [")", 49], ["regulators", 51], ["of", 62], ["protein", 65], ["-", 72], ["coding", 73], ["genes", 80], ["that", 86], ["are", 91], ["generally", 95], ["transcribed", 105], ["first", 117], ["into", 123], ["primary", 128], ["miRNA", 136], ["(", 142], ["pri", 143], ["-", 146], ["miR", 147], [")", 150], [",", 151], ["followed", 153], ["by", 162], ["the", 165], ["generation", 169], ["of", 180], ["precursor", 183], ["miRNA", 193], ["(", 199], ["pre", 200], ["-", 203], ["miR", 204], [")", 207], [".", 208], ["This", 210], ["finally", 215], ["leads", 223], ["to", 229], ["the", 232], ["production", 236], ["of", 247], ["the", 250], ["mature", 254], ["miRNA", 261], [".", 266], ["A", 268], ["large", 270], ["amount", 276], ["of", 283], ["information", 286], ["is", 298], ["available", 301], ["on", 311], ["the", 314], ["pre-", 318], ["and", 323], ["mature", 327], ["miRNAs", 334], [".", 340], ["However", 342], [",", 349], ["very", 351], ["little", 356], ["is", 363], ["known", 366], ["about", 372], ["the", 378], ["pri", 382], ["-", 385], ["miRs", 386], [",", 390], ["due", 392], ["to", 396], ["a", 399], ["lack", 401], ["of", 406], ["knowledge", 409], ["about", 419], ["their", 425], ["transcription", 431], ["start", 445], ["sites", 451], ["(", 457], ["TSSs", 458], [")", 462], [".", 463], ["Based", 465], ["on", 471], ["the", 474], ["genomic", 478], ["loci", 486], [",", 490], ["miRNAs", 492], ["can", 499], ["be", 503], ["categorized", 506], ["into", 518], ["two", 523], ["types", 527], ["--intragenic", 533], ["(", 546], ["intra", 547], ["-", 552], ["miR", 553], [")", 556], ["and", 558], ["intergenic", 562], ["(", 573], ["inter", 574], ["-", 579], ["miR", 580], [")", 583], [".", 584], ["While", 586], ["it", 592], ["is", 595], ["already", 598], ["an", 606], ["established", 609], ["fact", 621], ["that", 626], ["intra", 631], ["-", 636], ["miRs", 637], ["are", 642], ["commonly", 646], ["transcribed", 655], ["in", 667], ["conjunction", 670], ["with", 682], ["their", 687], ["host", 693], ["genes", 698], [",", 703], ["the", 705], ["transcription", 709], ["machinery", 723], ["of", 733], ["inter", 736], ["-", 741], ["miRs", 742], ["is", 747], ["poorly", 750], ["understood", 757], [".", 767], ["Although", 769], ["it", 778], ["is", 781], ["assumed", 784], ["that", 792], ["miRNA", 797], ["promoters", 803], ["are", 813], ["similar", 817], ["in", 825], ["structure", 828], ["to", 838], ["gene", 841], ["promoters", 846], [",", 855], ["since", 857], ["both", 863], ["are", 868], ["transcribed", 872], ["by", 884], ["RNA", 887], ["polymerase", 891], ["II", 902], ["(", 905], ["Pol", 906], ["II", 910], [")", 912], [",", 913], ["computational", 915], ["validations", 929], ["exhibit", 941], ["poor", 949], ["performance", 954], ["of", 966], ["gene", 969], ["promoter", 974], ["prediction", 983], ["methods", 994], ["on", 1002], ["miRNAs", 1005], [".", 1011], ["In", 1013], ["this", 1016], ["paper", 1021], [",", 1026], ["we", 1028], ["concentrate", 1031], ["on", 1043], ["the", 1046], ["problem", 1050], ["of", 1058], ["TSS", 1061], ["prediction", 1065], ["for", 1076], ["miRNAs", 1080], [".", 1086], ["The", 1088], ["present", 1092], ["study", 1100], ["begins", 1106], ["with", 1113], ["the", 1118], ["identification", 1122], ["of", 1137], ["positive", 1140], ["and", 1149], ["negative", 1153], ["promoter", 1162], ["samples", 1171], ["from", 1179], ["recently", 1184], ["published", 1193], ["data", 1203], ["stemming", 1208], ["from", 1217], ["RNA", 1222], ["-", 1225], ["sequencing", 1226], ["studies", 1237], [".", 1244], ["From", 1246], ["these", 1251], ["samples", 1257], ["of", 1265], ["experimentally", 1268], ["validated", 1283], ["miRNA", 1293], ["TSSs", 1299], [",", 1303], ["a", 1305], ["number", 1307], ["of", 1314], ["standard", 1317], ["sequence", 1326], ["features", 1335], ["are", 1344], ["extracted", 1348], [".", 1357], ["Furthermore", 1359], [",", 1370], ["to", 1372], ["account", 1375], ["for", 1383], ["potential", 1387], ["footprints", 1397], ["related", 1408], ["to", 1416], ["promoter", 1419], ["regulation", 1428], ["by", 1439], ["CpG", 1442], ["dinucleotide", 1446], ["targeted", 1459], ["DNA", 1468], ["methylation", 1472], [",", 1483], ["a", 1485], ["number", 1487], ["of", 1494], ["novel", 1497], ["features", 1503], ["are", 1512], ["defined", 1516], [".", 1523], ["We", 1525], ["develop", 1528], ["a", 1536], ["support", 1538], ["vector", 1546], ["machine", 1553], ["(", 1561], ["SVM", 1562], [")", 1565], ["with", 1567], ["RBF", 1572], ["kernel", 1576], ["for", 1583], ["the", 1587], ["prediction", 1591], ["of", 1602], ["miRNA", 1605], ["TSSs", 1611], ["trained", 1616], ["on", 1624], ["human", 1627], ["miRNA", 1633], ["promoters", 1639], [".", 1648], ["A", 1650], ["novel", 1652], ["feature", 1658], ["reduction", 1666], ["technique", 1676], ["based", 1686], ["on", 1692], ["archived", 1695], ["multi", 1704], ["-", 1709], ["objective", 1710], ["simulated", 1720], ["annealing", 1730], ["(", 1740], ["AMOSA", 1741], [")", 1746], ["identifies", 1748], ["the", 1759], ["final", 1763], ["set", 1769], ["of", 1773], ["features", 1776], [".", 1784], ["The", 1786], ["resulting", 1790], ["model", 1800], ["trained", 1806], ["on", 1814], ["miRNA", 1817], ["promoters", 1823], ["shows", 1833], ["improved", 1839], ["performance", 1848], ["over", 1860], ["the", 1865], ["one", 1869], ["trained", 1873], ["on", 1881], ["protein", 1884], ["-", 1891], ["coding", 1892], ["gene", 1899], ["promoters", 1904], ["in", 1914], ["terms", 1917], ["of", 1923], ["classification", 1926], ["accuracy", 1941], [",", 1949], ["sensitivity", 1951], ["and", 1963], ["specificity", 1967], [".", 1978], ["Results", 1980], ["are", 1988], ["also", 1992], ["reported", 1997], ["for", 2006], ["a", 2010], ["completely", 2012], ["independent", 2023], ["biologically", 2035], ["validated", 2048], ["test", 2058], ["set", 2063], [".", 2066], ["In", 2068], ["a", 2071], ["part", 2073], ["of", 2078], ["the", 2081], ["investigation", 2085], [",", 2098], ["the", 2100], ["proposed", 2104], ["approach", 2113], ["is", 2122], ["used", 2125], ["to", 2130], ["predict", 2133], ["protein", 2141], ["-", 2148], ["coding", 2149], ["gene", 2156], ["TSSs", 2161], [".", 2165], ["It", 2167], ["shows", 2170], ["a", 2176], ["significantly", 2178], ["improved", 2192], ["performance", 2201], ["when", 2213], ["compared", 2218], ["to", 2227], ["previously", 2230], ["published", 2241], ["gene", 2251], ["TSS", 2256], ["prediction", 2260], ["methods", 2271], [".", 2278]]}
{"context": "Restless Legs Syndrome (RLS) or Willis-Ekbom Disease (WED) is highly prevalent, but patients and healthcare providers alike know little about it. Furthermore, controversy persists as to the best way of diagnosing this nosological entity. To verify whether the term used to refer to this disease entity (Restless Legs Syndrome or Willis-Ekbom Disease) affects the prevalence of self-diagnosed RLS/WED in a sample of newly graduated physicians. Newly graduated physicians were asked to self-evaluate for the presence of RLS/WED. Briefly, participants were allocated randomly across two groups. One was asked to self-assess for RLS, while the other was asked to self-assess for WED. The evaluation form given to one group asked 'Do you have Restless Legs Syndrome?' whereas the form given to participants in the other group asked 'Do you have Willis-Ekbom Disease?'. Both forms also contained the four criteria for diagnosing RLS proposed by the International Restless Legs Syndrome Study Group (IRLSSG) and instructions for self-diagnosis according to these criteria. The study sample comprised 1413 newly graduated physicians. Of the 708 participants who were given the form that used the term RLS, 87 (12.28%) diagnosed themselves with the condition. Conversely, of 705 physicians given the form with the term WED, 13 (1.84%) diagnosed themselves with the condition (p\u2009<0.0001). A greater proportion of newly graduated physicians diagnosed themselves with RLS/WED when presented with the term Restless Legs Syndrome than when presented with the term Willis-Ekbom Disease. This suggests that the term Restless Legs Syndrome may not be the most appropriate term to denote this nosological entity.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "16a25da84839436a89074d9ddedd979f", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[145, 147], [306, 308], [186, 188], [57, 59], [0, 2], [287, 289]], "char_spans": [[738, 759], [1600, 1621], [957, 978], [303, 324], [0, 21], [1493, 1514]]}]}], "context_tokens": [["Restless", 0], ["Legs", 9], ["Syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], ["or", 29], ["Willis", 32], ["-", 38], ["Ekbom", 39], ["Disease", 45], ["(", 53], ["WED", 54], [")", 57], ["is", 59], ["highly", 62], ["prevalent", 69], [",", 78], ["but", 80], ["patients", 84], ["and", 93], ["healthcare", 97], ["providers", 108], ["alike", 118], ["know", 124], ["little", 129], ["about", 136], ["it", 142], [".", 144], ["Furthermore", 146], [",", 157], ["controversy", 159], ["persists", 171], ["as", 180], ["to", 183], ["the", 186], ["best", 190], ["way", 195], ["of", 199], ["diagnosing", 202], ["this", 213], ["nosological", 218], ["entity", 230], [".", 236], ["To", 238], ["verify", 241], ["whether", 248], ["the", 256], ["term", 260], ["used", 265], ["to", 270], ["refer", 273], ["to", 279], ["this", 282], ["disease", 287], ["entity", 295], ["(", 302], ["Restless", 303], ["Legs", 312], ["Syndrome", 317], ["or", 326], ["Willis", 329], ["-", 335], ["Ekbom", 336], ["Disease", 342], [")", 349], ["affects", 351], ["the", 359], ["prevalence", 363], ["of", 374], ["self", 377], ["-", 381], ["diagnosed", 382], ["RLS", 392], ["/", 395], ["WED", 396], ["in", 400], ["a", 403], ["sample", 405], ["of", 412], ["newly", 415], ["graduated", 421], ["physicians", 431], [".", 441], ["Newly", 443], ["graduated", 449], ["physicians", 459], ["were", 470], ["asked", 475], ["to", 481], ["self", 484], ["-", 488], ["evaluate", 489], ["for", 498], ["the", 502], ["presence", 506], ["of", 515], ["RLS", 518], ["/", 521], ["WED", 522], [".", 525], ["Briefly", 527], [",", 534], ["participants", 536], ["were", 549], ["allocated", 554], ["randomly", 564], ["across", 573], ["two", 580], ["groups", 584], [".", 590], ["One", 592], ["was", 596], ["asked", 600], ["to", 606], ["self", 609], ["-", 613], ["assess", 614], ["for", 621], ["RLS", 625], [",", 628], ["while", 630], ["the", 636], ["other", 640], ["was", 646], ["asked", 650], ["to", 656], ["self", 659], ["-", 663], ["assess", 664], ["for", 671], ["WED", 675], [".", 678], ["The", 680], ["evaluation", 684], ["form", 695], ["given", 700], ["to", 706], ["one", 709], ["group", 713], ["asked", 719], ["'", 725], ["Do", 726], ["you", 729], ["have", 733], ["Restless", 738], ["Legs", 747], ["Syndrome", 752], ["?", 760], ["'", 761], ["whereas", 763], ["the", 771], ["form", 775], ["given", 780], ["to", 786], ["participants", 789], ["in", 802], ["the", 805], ["other", 809], ["group", 815], ["asked", 821], ["'", 827], ["Do", 828], ["you", 831], ["have", 835], ["Willis", 840], ["-", 846], ["Ekbom", 847], ["Disease", 853], ["?", 860], ["'", 861], [".", 862], ["Both", 864], ["forms", 869], ["also", 875], ["contained", 880], ["the", 890], ["four", 894], ["criteria", 899], ["for", 908], ["diagnosing", 912], ["RLS", 923], ["proposed", 927], ["by", 936], ["the", 939], ["International", 943], ["Restless", 957], ["Legs", 966], ["Syndrome", 971], ["Study", 980], ["Group", 986], ["(", 992], ["IRLSSG", 993], [")", 999], ["and", 1001], ["instructions", 1005], ["for", 1018], ["self", 1022], ["-", 1026], ["diagnosis", 1027], ["according", 1037], ["to", 1047], ["these", 1050], ["criteria", 1056], [".", 1064], ["The", 1066], ["study", 1070], ["sample", 1076], ["comprised", 1083], ["1413", 1093], ["newly", 1098], ["graduated", 1104], ["physicians", 1114], [".", 1124], ["Of", 1126], ["the", 1129], ["708", 1133], ["participants", 1137], ["who", 1150], ["were", 1154], ["given", 1159], ["the", 1165], ["form", 1169], ["that", 1174], ["used", 1179], ["the", 1184], ["term", 1188], ["RLS", 1193], [",", 1196], ["87", 1198], ["(", 1201], ["12.28", 1202], ["%", 1207], [")", 1208], ["diagnosed", 1210], ["themselves", 1220], ["with", 1231], ["the", 1236], ["condition", 1240], [".", 1249], ["Conversely", 1251], [",", 1261], ["of", 1263], ["705", 1266], ["physicians", 1270], ["given", 1281], ["the", 1287], ["form", 1291], ["with", 1296], ["the", 1301], ["term", 1305], ["WED", 1310], [",", 1313], ["13", 1315], ["(", 1318], ["1.84", 1319], ["%", 1323], [")", 1324], ["diagnosed", 1326], ["themselves", 1336], ["with", 1347], ["the", 1352], ["condition", 1356], ["(", 1366], ["p", 1367], ["<", 1369], ["0.0001", 1370], [")", 1376], [".", 1377], ["A", 1379], ["greater", 1381], ["proportion", 1389], ["of", 1400], ["newly", 1403], ["graduated", 1409], ["physicians", 1419], ["diagnosed", 1430], ["themselves", 1440], ["with", 1451], ["RLS", 1456], ["/", 1459], ["WED", 1460], ["when", 1464], ["presented", 1469], ["with", 1479], ["the", 1484], ["term", 1488], ["Restless", 1493], ["Legs", 1502], ["Syndrome", 1507], ["than", 1516], ["when", 1521], ["presented", 1526], ["with", 1536], ["the", 1541], ["term", 1545], ["Willis", 1550], ["-", 1556], ["Ekbom", 1557], ["Disease", 1563], [".", 1570], ["This", 1572], ["suggests", 1577], ["that", 1586], ["the", 1591], ["term", 1595], ["Restless", 1600], ["Legs", 1609], ["Syndrome", 1614], ["may", 1623], ["not", 1627], ["be", 1631], ["the", 1634], ["most", 1638], ["appropriate", 1643], ["term", 1655], ["to", 1660], ["denote", 1663], ["this", 1670], ["nosological", 1675], ["entity", 1687], [".", 1693]]}
{"context": "PDS5B is a sister chromatid cohesion protein that is crucial for faithful segregation of duplicated chromosomes in lower organisms. Mutations in cohesion proteins are associated with the developmental disorder Cornelia de Lange syndrome (CdLS) in humans. To delineate the physiological roles of PDS5B in mammals, we generated mice lacking PDS5B (APRIN). Pds5B-deficient mice died shortly after birth. They exhibited multiple congenital anomalies, including heart defects, cleft palate, fusion of the ribs, short limbs, distal colon aganglionosis, abnormal migration and axonal projections of sympathetic neurons, and germ cell depletion, many of which are similar to abnormalities found in humans with CdLS. Unexpectedly, we found no cohesion defects in Pds5B(-/-) cells and detected high PDS5B expression in post-mitotic neurons in the brain. These results, along with the developmental anomalies of Pds5B(-/-) mice, the presence of a DNA-binding domain in PDS5B in vertebrates and its nucleolar localization, suggest that PDS5B and the cohesin complex have important functions beyond their role in chromosomal dynamics.", "qas": [{"question": "Which syndrome is caused by deletion of Pds5b in mice?", "answers": ["Cornelia de Lange syndrome."], "qid": "3edca0aa7f0d4e7fba97191c13e28d28", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["caused", 18], ["by", 25], ["deletion", 28], ["of", 37], ["Pds5b", 40], ["in", 46], ["mice", 49], ["?", 53]], "detected_answers": [{"text": "Cornelia de Lange syndrome.", "token_spans": [[30, 33]], "char_spans": [[210, 235]]}]}], "context_tokens": [["PDS5B", 0], ["is", 6], ["a", 9], ["sister", 11], ["chromatid", 18], ["cohesion", 28], ["protein", 37], ["that", 45], ["is", 50], ["crucial", 53], ["for", 61], ["faithful", 65], ["segregation", 74], ["of", 86], ["duplicated", 89], ["chromosomes", 100], ["in", 112], ["lower", 115], ["organisms", 121], [".", 130], ["Mutations", 132], ["in", 142], ["cohesion", 145], ["proteins", 154], ["are", 163], ["associated", 167], ["with", 178], ["the", 183], ["developmental", 187], ["disorder", 201], ["Cornelia", 210], ["de", 219], ["Lange", 222], ["syndrome", 228], ["(", 237], ["CdLS", 238], [")", 242], ["in", 244], ["humans", 247], [".", 253], ["To", 255], ["delineate", 258], ["the", 268], ["physiological", 272], ["roles", 286], ["of", 292], ["PDS5B", 295], ["in", 301], ["mammals", 304], [",", 311], ["we", 313], ["generated", 316], ["mice", 326], ["lacking", 331], ["PDS5B", 339], ["(", 345], ["APRIN", 346], [")", 351], [".", 352], ["Pds5B", 354], ["-", 359], ["deficient", 360], ["mice", 370], ["died", 375], ["shortly", 380], ["after", 388], ["birth", 394], [".", 399], ["They", 401], ["exhibited", 406], ["multiple", 416], ["congenital", 425], ["anomalies", 436], [",", 445], ["including", 447], ["heart", 457], ["defects", 463], [",", 470], ["cleft", 472], ["palate", 478], [",", 484], ["fusion", 486], ["of", 493], ["the", 496], ["ribs", 500], [",", 504], ["short", 506], ["limbs", 512], [",", 517], ["distal", 519], ["colon", 526], ["aganglionosis", 532], [",", 545], ["abnormal", 547], ["migration", 556], ["and", 566], ["axonal", 570], ["projections", 577], ["of", 589], ["sympathetic", 592], ["neurons", 604], [",", 611], ["and", 613], ["germ", 617], ["cell", 622], ["depletion", 627], [",", 636], ["many", 638], ["of", 643], ["which", 646], ["are", 652], ["similar", 656], ["to", 664], ["abnormalities", 667], ["found", 681], ["in", 687], ["humans", 690], ["with", 697], ["CdLS", 702], [".", 706], ["Unexpectedly", 708], [",", 720], ["we", 722], ["found", 725], ["no", 731], ["cohesion", 734], ["defects", 743], ["in", 751], ["Pds5B(-/-", 754], [")", 763], ["cells", 765], ["and", 771], ["detected", 775], ["high", 784], ["PDS5B", 789], ["expression", 795], ["in", 806], ["post", 809], ["-", 813], ["mitotic", 814], ["neurons", 822], ["in", 830], ["the", 833], ["brain", 837], [".", 842], ["These", 844], ["results", 850], [",", 857], ["along", 859], ["with", 865], ["the", 870], ["developmental", 874], ["anomalies", 888], ["of", 898], ["Pds5B(-/-", 901], [")", 910], ["mice", 912], [",", 916], ["the", 918], ["presence", 922], ["of", 931], ["a", 934], ["DNA", 936], ["-", 939], ["binding", 940], ["domain", 948], ["in", 955], ["PDS5B", 958], ["in", 964], ["vertebrates", 967], ["and", 979], ["its", 983], ["nucleolar", 987], ["localization", 997], [",", 1009], ["suggest", 1011], ["that", 1019], ["PDS5B", 1024], ["and", 1030], ["the", 1034], ["cohesin", 1038], ["complex", 1046], ["have", 1054], ["important", 1059], ["functions", 1069], ["beyond", 1079], ["their", 1086], ["role", 1092], ["in", 1097], ["chromosomal", 1100], ["dynamics", 1112], [".", 1120]]}
{"context": "In a previous study, we reported that two kaempferol glycosides isolated from Laurus nobilis L., kaempferol-3-O-alpha-L-(2'',4''-di-E-p-coumaroyl)-rhamnoside (C2) and kaempferol-3-O-alpha-L-(2''-E-p-coumaroyl-4''-Z-p-coumaroyl)-rhamnoside (C3), showed strong antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci. Thereafter we found that these compounds greatly reduced the minimum inhibitory concentrations (MICs) of some fluoroquinolones in MRSA. In other words, C2 and C3 greatly potentiated anti-MRSA activity of fluoroquinolones. The effect of C2 and C3 with fluoroquinolones was found to be synergistic. The potentiation activity was observed with hydrophilic fluoroquinolones, such as norfloxacin and ciprofloxacin, but not with hydrophobic quinolones. We also found that norfloxacin reduced MICs of C2 and C3. The effect was synergistic. Possible mechanism of the synergistic effect was discussed.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "ae333a083631463086544ba27a982cf1", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[100, 100], [60, 60], [87, 87]], "char_spans": [[568, 571], [337, 340], [511, 514]]}]}], "context_tokens": [["In", 0], ["a", 3], ["previous", 5], ["study", 14], [",", 19], ["we", 21], ["reported", 24], ["that", 33], ["two", 38], ["kaempferol", 42], ["glycosides", 53], ["isolated", 64], ["from", 73], ["Laurus", 78], ["nobilis", 85], ["L.", 93], [",", 95], ["kaempferol-3-O", 97], ["-", 111], ["alpha", 112], ["-", 117], ["L-(2'',4''-di", 118], ["-", 131], ["E", 132], ["-", 133], ["p", 134], ["-", 135], ["coumaroyl)-rhamnoside", 136], ["(", 158], ["C2", 159], [")", 161], ["and", 163], ["kaempferol-3-O", 167], ["-", 181], ["alpha", 182], ["-", 187], ["L-(2''-E", 188], ["-", 196], ["p", 197], ["-", 198], ["coumaroyl-4''-Z", 199], ["-", 214], ["p", 215], ["-", 216], ["coumaroyl)-rhamnoside", 217], ["(", 239], ["C3", 240], [")", 242], [",", 243], ["showed", 245], ["strong", 252], ["antibacterial", 259], ["activities", 273], ["against", 284], ["methicillin", 292], ["-", 303], ["resistant", 304], ["Staphylococcus", 314], ["aureus", 329], ["(", 336], ["MRSA", 337], [")", 341], ["and", 343], ["vancomycin", 347], ["-", 357], ["resistant", 358], ["enterococci", 368], [".", 379], ["Thereafter", 381], ["we", 392], ["found", 395], ["that", 401], ["these", 406], ["compounds", 412], ["greatly", 422], ["reduced", 430], ["the", 438], ["minimum", 442], ["inhibitory", 450], ["concentrations", 461], ["(", 476], ["MICs", 477], [")", 481], ["of", 483], ["some", 486], ["fluoroquinolones", 491], ["in", 508], ["MRSA", 511], [".", 515], ["In", 517], ["other", 520], ["words", 526], [",", 531], ["C2", 533], ["and", 536], ["C3", 540], ["greatly", 543], ["potentiated", 551], ["anti", 563], ["-", 567], ["MRSA", 568], ["activity", 573], ["of", 582], ["fluoroquinolones", 585], [".", 601], ["The", 603], ["effect", 607], ["of", 614], ["C2", 617], ["and", 620], ["C3", 624], ["with", 627], ["fluoroquinolones", 632], ["was", 649], ["found", 653], ["to", 659], ["be", 662], ["synergistic", 665], [".", 676], ["The", 678], ["potentiation", 682], ["activity", 695], ["was", 704], ["observed", 708], ["with", 717], ["hydrophilic", 722], ["fluoroquinolones", 734], [",", 750], ["such", 752], ["as", 757], ["norfloxacin", 760], ["and", 772], ["ciprofloxacin", 776], [",", 789], ["but", 791], ["not", 795], ["with", 799], ["hydrophobic", 804], ["quinolones", 816], [".", 826], ["We", 828], ["also", 831], ["found", 836], ["that", 842], ["norfloxacin", 847], ["reduced", 859], ["MICs", 867], ["of", 872], ["C2", 875], ["and", 878], ["C3", 882], [".", 884], ["The", 886], ["effect", 890], ["was", 897], ["synergistic", 901], [".", 912], ["Possible", 914], ["mechanism", 923], ["of", 933], ["the", 936], ["synergistic", 940], ["effect", 952], ["was", 959], ["discussed", 963], [".", 972]]}
{"context": "Motion of the median nerve was compared on an axial ultrasonographic image in the mid-carpal tunnel in 30 wrists of 15 women with bilateral idiopathic carpal tunnel syndrome and 30 wrists of 15 healthy women. During passive flexion and extension of the index finger, the control wrists had transverse sliding of the nerve beneath the flexor retinaculum (1.75 +/- 0.49 mm), which was regarded as a physiological phenomenon. In contrast, the wrists of patients with carpal tunnel syndrome had significantly less sliding (0.37 +/- 0.34 mm; P = 0.0001), which indicates that physiological motion of the nerve is restricted. This decrease in nerve mobility may be of significance in the pathophysiology of carpal tunnel syndrome.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "7bd8a7a1bafe47c3abd747f77a580738", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[3, 3]], "char_spans": [[14, 19]]}]}], "context_tokens": [["Motion", 0], ["of", 7], ["the", 10], ["median", 14], ["nerve", 21], ["was", 27], ["compared", 31], ["on", 40], ["an", 43], ["axial", 46], ["ultrasonographic", 52], ["image", 69], ["in", 75], ["the", 78], ["mid", 82], ["-", 85], ["carpal", 86], ["tunnel", 93], ["in", 100], ["30", 103], ["wrists", 106], ["of", 113], ["15", 116], ["women", 119], ["with", 125], ["bilateral", 130], ["idiopathic", 140], ["carpal", 151], ["tunnel", 158], ["syndrome", 165], ["and", 174], ["30", 178], ["wrists", 181], ["of", 188], ["15", 191], ["healthy", 194], ["women", 202], [".", 207], ["During", 209], ["passive", 216], ["flexion", 224], ["and", 232], ["extension", 236], ["of", 246], ["the", 249], ["index", 253], ["finger", 259], [",", 265], ["the", 267], ["control", 271], ["wrists", 279], ["had", 286], ["transverse", 290], ["sliding", 301], ["of", 309], ["the", 312], ["nerve", 316], ["beneath", 322], ["the", 330], ["flexor", 334], ["retinaculum", 341], ["(", 353], ["1.75", 354], ["+", 359], ["/-", 360], ["0.49", 363], ["mm", 368], [")", 370], [",", 371], ["which", 373], ["was", 379], ["regarded", 383], ["as", 392], ["a", 395], ["physiological", 397], ["phenomenon", 411], [".", 421], ["In", 423], ["contrast", 426], [",", 434], ["the", 436], ["wrists", 440], ["of", 447], ["patients", 450], ["with", 459], ["carpal", 464], ["tunnel", 471], ["syndrome", 478], ["had", 487], ["significantly", 491], ["less", 505], ["sliding", 510], ["(", 518], ["0.37", 519], ["+", 524], ["/-", 525], ["0.34", 528], ["mm", 533], [";", 535], ["P", 537], ["=", 539], ["0.0001", 541], [")", 547], [",", 548], ["which", 550], ["indicates", 556], ["that", 566], ["physiological", 571], ["motion", 585], ["of", 592], ["the", 595], ["nerve", 599], ["is", 605], ["restricted", 608], [".", 618], ["This", 620], ["decrease", 625], ["in", 634], ["nerve", 637], ["mobility", 643], ["may", 652], ["be", 656], ["of", 659], ["significance", 662], ["in", 675], ["the", 678], ["pathophysiology", 682], ["of", 698], ["carpal", 701], ["tunnel", 708], ["syndrome", 715], [".", 723]]}
{"context": "Identifying and tackling the social determinants of infectious diseases has become a public health priority following the recognition that individuals with lower socioeconomic status are disproportionately affected by infectious diseases. In many parts of the world, epidemiologically and genotypically defined community-associated (CA) methicillin-resistant Staphylococcus aureus (MRSA) strains have emerged to become frequent causes of hospital infection. The aim of this study was to use spatial models with adjustment for area-level hospital attendance to determine the transmission niche of genotypically defined CA- and health-care-associated (HA)-MRSA strains across a diverse region of South East London and to explore a potential link between MRSA carriage and markers of social and material deprivation. This study involved spatial analysis of cross-sectional data linked with all MRSA isolates identified by three National Health Service (NHS) microbiology laboratories between 1 November 2011 and 29 February 2012. The cohort of hospital-based NHS microbiology diagnostic services serves 867,254 usual residents in the Lambeth, Southwark, and Lewisham boroughs in South East London, United Kingdom (UK). Isolates were classified as HA- or CA-MRSA based on whole genome sequencing. All MRSA cases identified over 4 mo within the three-borough catchment area (n = 471) were mapped to small geographies and linked to area-level aggregated socioeconomic and demographic data. Disease mapping and ecological regression models were used to infer the most likely transmission niches for each MRSA genetic classification and to describe the spatial epidemiology of MRSA in relation to social determinants. Specifically, we aimed to identify demographic and socioeconomic population traits that explain cross-area extra variation in HA- and CA-MRSA relative risks following adjustment for hospital attendance data. We explored the potential for associations with the English Indices of Deprivation 2010 (including the Index of Multiple Deprivation and several deprivation domains and subdomains) and the 2011 England and Wales census demographic and socioeconomic indicators (including numbers of households by deprivation dimension) and indicators of population health. Both CA-and HA-MRSA were associated with household deprivation (CA-MRSA relative risk [RR]: 1.72 [1.03-2.94]; HA-MRSA RR: 1.57 [1.06-2.33]), which was correlated with hospital attendance (Pearson correlation coefficient [PCC] = 0.76). HA-MRSA was also associated with poor health (RR: 1.10 [1.01-1.19]) and residence in communal care homes (RR: 1.24 [1.12-1.37]), whereas CA-MRSA was linked with household overcrowding (RR: 1.58 [1.04-2.41]) and wider barriers, which represent a combined score for household overcrowding, low income, and homelessness (RR: 1.76 [1.16-2.70]). CA-MRSA was also associated with recent immigration to the UK (RR: 1.77 [1.19-2.66]). For the area-level variation in RR for CA-MRSA, 28.67% was attributable to the spatial arrangement of target geographies, compared with only 0.09% for HA-MRSA. An advantage to our study is that it provided a representative sample of usual residents receiving care in the catchment areas. A limitation is that relationships apparent in aggregated data analyses cannot be assumed to operate at the individual level. There was no evidence of community transmission of HA-MRSA strains, implying that HA-MRSA cases identified in the community originate from the hospital reservoir and are maintained by frequent attendance at health care facilities. In contrast, there was a high risk of CA-MRSA in deprived areas linked with overcrowding, homelessness, low income, and recent immigration to the UK, which was not explainable by health care exposure. Furthermore, areas adjacent to these deprived areas were themselves at greater risk of CA-MRSA, indicating community transmission of CA-MRSA. This ongoing community transmission could lead to CA-MRSA becoming the dominant strain types carried by patients admitted to hospital, particularly if successful hospital-based MRSA infection control programmes are maintained. These results suggest that community infection control programmes targeting transmission of CA-MRSA will be required to control MRSA in both the community and hospital. These epidemiological changes will also have implications for effectiveness of risk-factor-based hospital admission MRSA screening programmes.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "c8be4f51b2ab4a5381c642b0ef7213c6", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[213, 213], [141, 141], [205, 205], [275, 275], [429, 429], [629, 629], [715, 715], [622, 622], [707, 707], [765, 765], [771, 771], [383, 383], [513, 513], [399, 399], [305, 305], [118, 118], [54, 54], [374, 374], [662, 662], [726, 726], [796, 796], [265, 265], [567, 567], [745, 745], [466, 466], [545, 545]], "char_spans": [[1297, 1300], [891, 894], [1254, 1257], [1669, 1672], [2512, 2515], [3435, 3438], [3918, 3921], [3404, 3407], [3872, 3875], [4246, 4249], [4279, 4282], [2341, 2344], [2853, 2856], [2387, 2390], [1847, 1850], [752, 755], [382, 385], [2289, 2292], [3622, 3625], [3977, 3980], [4436, 4439], [1597, 1600], [3090, 3093], [4101, 4104], [2649, 2652], [2978, 2981]]}]}], "context_tokens": [["Identifying", 0], ["and", 12], ["tackling", 16], ["the", 25], ["social", 29], ["determinants", 36], ["of", 49], ["infectious", 52], ["diseases", 63], ["has", 72], ["become", 76], ["a", 83], ["public", 85], ["health", 92], ["priority", 99], ["following", 108], ["the", 118], ["recognition", 122], ["that", 134], ["individuals", 139], ["with", 151], ["lower", 156], ["socioeconomic", 162], ["status", 176], ["are", 183], ["disproportionately", 187], ["affected", 206], ["by", 215], ["infectious", 218], ["diseases", 229], [".", 237], ["In", 239], ["many", 242], ["parts", 247], ["of", 253], ["the", 256], ["world", 260], [",", 265], ["epidemiologically", 267], ["and", 285], ["genotypically", 289], ["defined", 303], ["community", 311], ["-", 320], ["associated", 321], ["(", 332], ["CA", 333], [")", 335], ["methicillin", 337], ["-", 348], ["resistant", 349], ["Staphylococcus", 359], ["aureus", 374], ["(", 381], ["MRSA", 382], [")", 386], ["strains", 388], ["have", 396], ["emerged", 401], ["to", 409], ["become", 412], ["frequent", 419], ["causes", 428], ["of", 435], ["hospital", 438], ["infection", 447], [".", 456], ["The", 458], ["aim", 462], ["of", 466], ["this", 469], ["study", 474], ["was", 480], ["to", 484], ["use", 487], ["spatial", 491], ["models", 499], ["with", 506], ["adjustment", 511], ["for", 522], ["area", 526], ["-", 530], ["level", 531], ["hospital", 537], ["attendance", 546], ["to", 557], ["determine", 560], ["the", 570], ["transmission", 574], ["niche", 587], ["of", 593], ["genotypically", 596], ["defined", 610], ["CA-", 618], ["and", 622], ["health", 626], ["-", 632], ["care", 633], ["-", 637], ["associated", 638], ["(", 649], ["HA)-MRSA", 650], ["strains", 659], ["across", 667], ["a", 674], ["diverse", 676], ["region", 684], ["of", 691], ["South", 694], ["East", 700], ["London", 705], ["and", 712], ["to", 716], ["explore", 719], ["a", 727], ["potential", 729], ["link", 739], ["between", 744], ["MRSA", 752], ["carriage", 757], ["and", 766], ["markers", 770], ["of", 778], ["social", 781], ["and", 788], ["material", 792], ["deprivation", 801], [".", 812], ["This", 814], ["study", 819], ["involved", 825], ["spatial", 834], ["analysis", 842], ["of", 851], ["cross", 854], ["-", 859], ["sectional", 860], ["data", 870], ["linked", 875], ["with", 882], ["all", 887], ["MRSA", 891], ["isolates", 896], ["identified", 905], ["by", 916], ["three", 919], ["National", 925], ["Health", 934], ["Service", 941], ["(", 949], ["NHS", 950], [")", 953], ["microbiology", 955], ["laboratories", 968], ["between", 981], ["1", 989], ["November", 991], ["2011", 1000], ["and", 1005], ["29", 1009], ["February", 1012], ["2012", 1021], [".", 1025], ["The", 1027], ["cohort", 1031], ["of", 1038], ["hospital", 1041], ["-", 1049], ["based", 1050], ["NHS", 1056], ["microbiology", 1060], ["diagnostic", 1073], ["services", 1084], ["serves", 1093], ["867,254", 1100], ["usual", 1108], ["residents", 1114], ["in", 1124], ["the", 1127], ["Lambeth", 1131], [",", 1138], ["Southwark", 1140], [",", 1149], ["and", 1151], ["Lewisham", 1155], ["boroughs", 1164], ["in", 1173], ["South", 1176], ["East", 1182], ["London", 1187], [",", 1193], ["United", 1195], ["Kingdom", 1202], ["(", 1210], ["UK", 1211], [")", 1213], [".", 1214], ["Isolates", 1216], ["were", 1225], ["classified", 1230], ["as", 1241], ["HA-", 1244], ["or", 1248], ["CA", 1251], ["-", 1253], ["MRSA", 1254], ["based", 1259], ["on", 1265], ["whole", 1268], ["genome", 1274], ["sequencing", 1281], [".", 1291], ["All", 1293], ["MRSA", 1297], ["cases", 1302], ["identified", 1308], ["over", 1319], ["4", 1324], ["mo", 1326], ["within", 1329], ["the", 1336], ["three", 1340], ["-", 1345], ["borough", 1346], ["catchment", 1354], ["area", 1364], ["(", 1369], ["n", 1370], ["=", 1372], ["471", 1374], [")", 1377], ["were", 1379], ["mapped", 1384], ["to", 1391], ["small", 1394], ["geographies", 1400], ["and", 1412], ["linked", 1416], ["to", 1423], ["area", 1426], ["-", 1430], ["level", 1431], ["aggregated", 1437], ["socioeconomic", 1448], ["and", 1462], ["demographic", 1466], ["data", 1478], [".", 1482], ["Disease", 1484], ["mapping", 1492], ["and", 1500], ["ecological", 1504], ["regression", 1515], ["models", 1526], ["were", 1533], ["used", 1538], ["to", 1543], ["infer", 1546], ["the", 1552], ["most", 1556], ["likely", 1561], ["transmission", 1568], ["niches", 1581], ["for", 1588], ["each", 1592], ["MRSA", 1597], ["genetic", 1602], ["classification", 1610], ["and", 1625], ["to", 1629], ["describe", 1632], ["the", 1641], ["spatial", 1645], ["epidemiology", 1653], ["of", 1666], ["MRSA", 1669], ["in", 1674], ["relation", 1677], ["to", 1686], ["social", 1689], ["determinants", 1696], [".", 1708], ["Specifically", 1710], [",", 1722], ["we", 1724], ["aimed", 1727], ["to", 1733], ["identify", 1736], ["demographic", 1745], ["and", 1757], ["socioeconomic", 1761], ["population", 1775], ["traits", 1786], ["that", 1793], ["explain", 1798], ["cross", 1806], ["-", 1811], ["area", 1812], ["extra", 1817], ["variation", 1823], ["in", 1833], ["HA-", 1836], ["and", 1840], ["CA", 1844], ["-", 1846], ["MRSA", 1847], ["relative", 1852], ["risks", 1861], ["following", 1867], ["adjustment", 1877], ["for", 1888], ["hospital", 1892], ["attendance", 1901], ["data", 1912], [".", 1916], ["We", 1918], ["explored", 1921], ["the", 1930], ["potential", 1934], ["for", 1944], ["associations", 1948], ["with", 1961], ["the", 1966], ["English", 1970], ["Indices", 1978], ["of", 1986], ["Deprivation", 1989], ["2010", 2001], ["(", 2006], ["including", 2007], ["the", 2017], ["Index", 2021], ["of", 2027], ["Multiple", 2030], ["Deprivation", 2039], ["and", 2051], ["several", 2055], ["deprivation", 2063], ["domains", 2075], ["and", 2083], ["subdomains", 2087], [")", 2097], ["and", 2099], ["the", 2103], ["2011", 2107], ["England", 2112], ["and", 2120], ["Wales", 2124], ["census", 2130], ["demographic", 2137], ["and", 2149], ["socioeconomic", 2153], ["indicators", 2167], ["(", 2178], ["including", 2179], ["numbers", 2189], ["of", 2197], ["households", 2200], ["by", 2211], ["deprivation", 2214], ["dimension", 2226], [")", 2235], ["and", 2237], ["indicators", 2241], ["of", 2252], ["population", 2255], ["health", 2266], [".", 2272], ["Both", 2274], ["CA", 2279], ["-", 2281], ["and", 2282], ["HA", 2286], ["-", 2288], ["MRSA", 2289], ["were", 2294], ["associated", 2299], ["with", 2310], ["household", 2315], ["deprivation", 2325], ["(", 2337], ["CA", 2338], ["-", 2340], ["MRSA", 2341], ["relative", 2346], ["risk", 2355], ["[", 2360], ["RR", 2361], ["]", 2363], [":", 2364], ["1.72", 2366], ["[", 2371], ["1.03", 2372], ["-", 2376], ["2.94", 2377], ["]", 2381], [";", 2382], ["HA", 2384], ["-", 2386], ["MRSA", 2387], ["RR", 2392], [":", 2394], ["1.57", 2396], ["[", 2401], ["1.06", 2402], ["-", 2406], ["2.33", 2407], ["]", 2411], [")", 2412], [",", 2413], ["which", 2415], ["was", 2421], ["correlated", 2425], ["with", 2436], ["hospital", 2441], ["attendance", 2450], ["(", 2461], ["Pearson", 2462], ["correlation", 2470], ["coefficient", 2482], ["[", 2494], ["PCC", 2495], ["]", 2498], ["=", 2500], ["0.76", 2502], [")", 2506], [".", 2507], ["HA", 2509], ["-", 2511], ["MRSA", 2512], ["was", 2517], ["also", 2521], ["associated", 2526], ["with", 2537], ["poor", 2542], ["health", 2547], ["(", 2554], ["RR", 2555], [":", 2557], ["1.10", 2559], ["[", 2564], ["1.01", 2565], ["-", 2569], ["1.19", 2570], ["]", 2574], [")", 2575], ["and", 2577], ["residence", 2581], ["in", 2591], ["communal", 2594], ["care", 2603], ["homes", 2608], ["(", 2614], ["RR", 2615], [":", 2617], ["1.24", 2619], ["[", 2624], ["1.12", 2625], ["-", 2629], ["1.37", 2630], ["]", 2634], [")", 2635], [",", 2636], ["whereas", 2638], ["CA", 2646], ["-", 2648], ["MRSA", 2649], ["was", 2654], ["linked", 2658], ["with", 2665], ["household", 2670], ["overcrowding", 2680], ["(", 2693], ["RR", 2694], [":", 2696], ["1.58", 2698], ["[", 2703], ["1.04", 2704], ["-", 2708], ["2.41", 2709], ["]", 2713], [")", 2714], ["and", 2716], ["wider", 2720], ["barriers", 2726], [",", 2734], ["which", 2736], ["represent", 2742], ["a", 2752], ["combined", 2754], ["score", 2763], ["for", 2769], ["household", 2773], ["overcrowding", 2783], [",", 2795], ["low", 2797], ["income", 2801], [",", 2807], ["and", 2809], ["homelessness", 2813], ["(", 2826], ["RR", 2827], [":", 2829], ["1.76", 2831], ["[", 2836], ["1.16", 2837], ["-", 2841], ["2.70", 2842], ["]", 2846], [")", 2847], [".", 2848], ["CA", 2850], ["-", 2852], ["MRSA", 2853], ["was", 2858], ["also", 2862], ["associated", 2867], ["with", 2878], ["recent", 2883], ["immigration", 2890], ["to", 2902], ["the", 2905], ["UK", 2909], ["(", 2912], ["RR", 2913], [":", 2915], ["1.77", 2917], ["[", 2922], ["1.19", 2923], ["-", 2927], ["2.66", 2928], ["]", 2932], [")", 2933], [".", 2934], ["For", 2936], ["the", 2940], ["area", 2944], ["-", 2948], ["level", 2949], ["variation", 2955], ["in", 2965], ["RR", 2968], ["for", 2971], ["CA", 2975], ["-", 2977], ["MRSA", 2978], [",", 2982], ["28.67", 2984], ["%", 2989], ["was", 2991], ["attributable", 2995], ["to", 3008], ["the", 3011], ["spatial", 3015], ["arrangement", 3023], ["of", 3035], ["target", 3038], ["geographies", 3045], [",", 3056], ["compared", 3058], ["with", 3067], ["only", 3072], ["0.09", 3077], ["%", 3081], ["for", 3083], ["HA", 3087], ["-", 3089], ["MRSA", 3090], [".", 3094], ["An", 3096], ["advantage", 3099], ["to", 3109], ["our", 3112], ["study", 3116], ["is", 3122], ["that", 3125], ["it", 3130], ["provided", 3133], ["a", 3142], ["representative", 3144], ["sample", 3159], ["of", 3166], ["usual", 3169], ["residents", 3175], ["receiving", 3185], ["care", 3195], ["in", 3200], ["the", 3203], ["catchment", 3207], ["areas", 3217], [".", 3222], ["A", 3224], ["limitation", 3226], ["is", 3237], ["that", 3240], ["relationships", 3245], ["apparent", 3259], ["in", 3268], ["aggregated", 3271], ["data", 3282], ["analyses", 3287], ["can", 3296], ["not", 3299], ["be", 3303], ["assumed", 3306], ["to", 3314], ["operate", 3317], ["at", 3325], ["the", 3328], ["individual", 3332], ["level", 3343], [".", 3348], ["There", 3350], ["was", 3356], ["no", 3360], ["evidence", 3363], ["of", 3372], ["community", 3375], ["transmission", 3385], ["of", 3398], ["HA", 3401], ["-", 3403], ["MRSA", 3404], ["strains", 3409], [",", 3416], ["implying", 3418], ["that", 3427], ["HA", 3432], ["-", 3434], ["MRSA", 3435], ["cases", 3440], ["identified", 3446], ["in", 3457], ["the", 3460], ["community", 3464], ["originate", 3474], ["from", 3484], ["the", 3489], ["hospital", 3493], ["reservoir", 3502], ["and", 3512], ["are", 3516], ["maintained", 3520], ["by", 3531], ["frequent", 3534], ["attendance", 3543], ["at", 3554], ["health", 3557], ["care", 3564], ["facilities", 3569], [".", 3579], ["In", 3581], ["contrast", 3584], [",", 3592], ["there", 3594], ["was", 3600], ["a", 3604], ["high", 3606], ["risk", 3611], ["of", 3616], ["CA", 3619], ["-", 3621], ["MRSA", 3622], ["in", 3627], ["deprived", 3630], ["areas", 3639], ["linked", 3645], ["with", 3652], ["overcrowding", 3657], [",", 3669], ["homelessness", 3671], [",", 3683], ["low", 3685], ["income", 3689], [",", 3695], ["and", 3697], ["recent", 3701], ["immigration", 3708], ["to", 3720], ["the", 3723], ["UK", 3727], [",", 3729], ["which", 3731], ["was", 3737], ["not", 3741], ["explainable", 3745], ["by", 3757], ["health", 3760], ["care", 3767], ["exposure", 3772], [".", 3780], ["Furthermore", 3782], [",", 3793], ["areas", 3795], ["adjacent", 3801], ["to", 3810], ["these", 3813], ["deprived", 3819], ["areas", 3828], ["were", 3834], ["themselves", 3839], ["at", 3850], ["greater", 3853], ["risk", 3861], ["of", 3866], ["CA", 3869], ["-", 3871], ["MRSA", 3872], [",", 3876], ["indicating", 3878], ["community", 3889], ["transmission", 3899], ["of", 3912], ["CA", 3915], ["-", 3917], ["MRSA", 3918], [".", 3922], ["This", 3924], ["ongoing", 3929], ["community", 3937], ["transmission", 3947], ["could", 3960], ["lead", 3966], ["to", 3971], ["CA", 3974], ["-", 3976], ["MRSA", 3977], ["becoming", 3982], ["the", 3991], ["dominant", 3995], ["strain", 4004], ["types", 4011], ["carried", 4017], ["by", 4025], ["patients", 4028], ["admitted", 4037], ["to", 4046], ["hospital", 4049], [",", 4057], ["particularly", 4059], ["if", 4072], ["successful", 4075], ["hospital", 4086], ["-", 4094], ["based", 4095], ["MRSA", 4101], ["infection", 4106], ["control", 4116], ["programmes", 4124], ["are", 4135], ["maintained", 4139], [".", 4149], ["These", 4151], ["results", 4157], ["suggest", 4165], ["that", 4173], ["community", 4178], ["infection", 4188], ["control", 4198], ["programmes", 4206], ["targeting", 4217], ["transmission", 4227], ["of", 4240], ["CA", 4243], ["-", 4245], ["MRSA", 4246], ["will", 4251], ["be", 4256], ["required", 4259], ["to", 4268], ["control", 4271], ["MRSA", 4279], ["in", 4284], ["both", 4287], ["the", 4292], ["community", 4296], ["and", 4306], ["hospital", 4310], [".", 4318], ["These", 4320], ["epidemiological", 4326], ["changes", 4342], ["will", 4350], ["also", 4355], ["have", 4360], ["implications", 4365], ["for", 4378], ["effectiveness", 4382], ["of", 4396], ["risk", 4399], ["-", 4403], ["factor", 4404], ["-", 4410], ["based", 4411], ["hospital", 4417], ["admission", 4426], ["MRSA", 4436], ["screening", 4441], ["programmes", 4451], [".", 4461]]}
{"context": "Restless legs syndrome (RLS) is a common condition that is frequently unrecognized, misdiagnosed and poorly managed. It is characterized by uncomfortable sensations deep in the legs developing at rest that compel the person to move; symptoms are worst at night and sleep disturbance is common. RLS occurs in 7%-11% of the population in Western countries, and many such people experience troublesome symptoms. Primary RLS is familial in up to two thirds of patients. RLS may also be secondary to a number of conditions including iron deficiency, pregnancy and end-stage renal failure and, perhaps, neuropathy. Secondary RLS is most common in those presenting for the first time in later life. The pathogenesis of RLS probably involves the interplay of systemic or brain iron deficiency and impaired dopaminergic neurotransmission in the subcortex of the brain. RLS is very responsive to dopaminergic therapies. Rebound of RLS symptoms during the early morning and development of severe symptoms earlier in the day (augmentation) are problematic in those treated for a prolonged period with levodopa. Consequently, dopamine agonists have become first line treatment. Anti-convulsant medications and opioids are helpful in some patients. Correction of underlying problem wherever possible is important in the management of secondary RLS.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "2d73138d00bc4dfc99e39ba6f78babb8", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[138, 138], [94, 94]], "char_spans": [[769, 772], [528, 531]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], ["is", 29], ["a", 32], ["common", 34], ["condition", 41], ["that", 51], ["is", 56], ["frequently", 59], ["unrecognized", 70], [",", 82], ["misdiagnosed", 84], ["and", 97], ["poorly", 101], ["managed", 108], [".", 115], ["It", 117], ["is", 120], ["characterized", 123], ["by", 137], ["uncomfortable", 140], ["sensations", 154], ["deep", 165], ["in", 170], ["the", 173], ["legs", 177], ["developing", 182], ["at", 193], ["rest", 196], ["that", 201], ["compel", 206], ["the", 213], ["person", 217], ["to", 224], ["move", 227], [";", 231], ["symptoms", 233], ["are", 242], ["worst", 246], ["at", 252], ["night", 255], ["and", 261], ["sleep", 265], ["disturbance", 271], ["is", 283], ["common", 286], [".", 292], ["RLS", 294], ["occurs", 298], ["in", 305], ["7%-11", 308], ["%", 313], ["of", 315], ["the", 318], ["population", 322], ["in", 333], ["Western", 336], ["countries", 344], [",", 353], ["and", 355], ["many", 359], ["such", 364], ["people", 369], ["experience", 376], ["troublesome", 387], ["symptoms", 399], [".", 407], ["Primary", 409], ["RLS", 417], ["is", 421], ["familial", 424], ["in", 433], ["up", 436], ["to", 439], ["two", 442], ["thirds", 446], ["of", 453], ["patients", 456], [".", 464], ["RLS", 466], ["may", 470], ["also", 474], ["be", 479], ["secondary", 482], ["to", 492], ["a", 495], ["number", 497], ["of", 504], ["conditions", 507], ["including", 518], ["iron", 528], ["deficiency", 533], [",", 543], ["pregnancy", 545], ["and", 555], ["end", 559], ["-", 562], ["stage", 563], ["renal", 569], ["failure", 575], ["and", 583], [",", 586], ["perhaps", 588], [",", 595], ["neuropathy", 597], [".", 607], ["Secondary", 609], ["RLS", 619], ["is", 623], ["most", 626], ["common", 631], ["in", 638], ["those", 641], ["presenting", 647], ["for", 658], ["the", 662], ["first", 666], ["time", 672], ["in", 677], ["later", 680], ["life", 686], [".", 690], ["The", 692], ["pathogenesis", 696], ["of", 709], ["RLS", 712], ["probably", 716], ["involves", 725], ["the", 734], ["interplay", 738], ["of", 748], ["systemic", 751], ["or", 760], ["brain", 763], ["iron", 769], ["deficiency", 774], ["and", 785], ["impaired", 789], ["dopaminergic", 798], ["neurotransmission", 811], ["in", 829], ["the", 832], ["subcortex", 836], ["of", 846], ["the", 849], ["brain", 853], [".", 858], ["RLS", 860], ["is", 864], ["very", 867], ["responsive", 872], ["to", 883], ["dopaminergic", 886], ["therapies", 899], [".", 908], ["Rebound", 910], ["of", 918], ["RLS", 921], ["symptoms", 925], ["during", 934], ["the", 941], ["early", 945], ["morning", 951], ["and", 959], ["development", 963], ["of", 975], ["severe", 978], ["symptoms", 985], ["earlier", 994], ["in", 1002], ["the", 1005], ["day", 1009], ["(", 1013], ["augmentation", 1014], [")", 1026], ["are", 1028], ["problematic", 1032], ["in", 1044], ["those", 1047], ["treated", 1053], ["for", 1061], ["a", 1065], ["prolonged", 1067], ["period", 1077], ["with", 1084], ["levodopa", 1089], [".", 1097], ["Consequently", 1099], [",", 1111], ["dopamine", 1113], ["agonists", 1122], ["have", 1131], ["become", 1136], ["first", 1143], ["line", 1149], ["treatment", 1154], [".", 1163], ["Anti", 1165], ["-", 1169], ["convulsant", 1170], ["medications", 1181], ["and", 1193], ["opioids", 1197], ["are", 1205], ["helpful", 1209], ["in", 1217], ["some", 1220], ["patients", 1225], [".", 1233], ["Correction", 1235], ["of", 1246], ["underlying", 1249], ["problem", 1260], ["wherever", 1268], ["possible", 1277], ["is", 1286], ["important", 1289], ["in", 1299], ["the", 1302], ["management", 1306], ["of", 1317], ["secondary", 1320], ["RLS", 1330], [".", 1333]]}
{"context": "Christianson syndrome (CS) is an X-linked neurodevelopmental disorder caused by deleterious mutations in SLC9A6. Affected families organized the inaugural Christianson Syndrome Association conference to advance CS knowledge and develop questions that may be prioritized in future research.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "7bc7d50257d34f87ab4fb5cf15488ef8", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[17, 17]], "char_spans": [[105, 110]]}]}], "context_tokens": [["Christianson", 0], ["syndrome", 13], ["(", 22], ["CS", 23], [")", 25], ["is", 27], ["an", 30], ["X", 33], ["-", 34], ["linked", 35], ["neurodevelopmental", 42], ["disorder", 61], ["caused", 70], ["by", 77], ["deleterious", 80], ["mutations", 92], ["in", 102], ["SLC9A6", 105], [".", 111], ["Affected", 113], ["families", 122], ["organized", 131], ["the", 141], ["inaugural", 145], ["Christianson", 155], ["Syndrome", 168], ["Association", 177], ["conference", 189], ["to", 200], ["advance", 203], ["CS", 211], ["knowledge", 214], ["and", 224], ["develop", 228], ["questions", 236], ["that", 246], ["may", 251], ["be", 255], ["prioritized", 258], ["in", 270], ["future", 273], ["research", 280], [".", 288]]}
{"context": "NuA4 (nucleosome acetyltransferase of H4) promotes transcriptional initiation of TFIID (a complex of TBP and TBP-associated factors [TAFs])-dependent ribosomal protein genes involved in ribosome biogenesis. However, it is not clearly understood how NuA4 regulates the transcription of ribosomal protein genes. Here, we show that NuA4 is recruited to the promoters of ribosomal protein genes, such as RPS5, RPL2B, and RPS11B, for TFIID recruitment to initiate transcription, and the recruitment of NuA4 to these promoters is impaired in the absence of its Eaf1p component. Intriguingly, impaired NuA4 recruitment in a \u0394eaf1 strain depletes recruitment of TFIID (a TAF-dependent form of TBP) but not the TAF-independent form of TBP to the promoters of ribosomal protein genes. However, in the absence of NuA4, SAGA (Spt-Ada-Gcn5-acetyltransferase) is involved in targeting the TAF-independent form of TBP to the promoters of ribosomal protein genes for transcriptional initiation. Thus, NuA4 plays an important role in targeting TFIID to the promoters of ribosomal protein genes for transcriptional initiation in vivo. Such a function is mediated via its targeted histone acetyltransferase activity. In the absence of NuA4, ribosomal protein genes lose TFIID dependency and become SAGA dependent for transcriptional initiation. Collectively, these results provide significant insights into the regulation of ribosomal protein gene expression and, hence, ribosome biogenesis and functions.", "qas": [{"question": "What does the SAGA complex acronym stands for?", "answers": ["Spt-Ada-Gcn5-acetyltransferase"], "qid": "513f317b2bbb49a488431854ec8b1291", "question_tokens": [["What", 0], ["does", 5], ["the", 10], ["SAGA", 14], ["complex", 19], ["acronym", 27], ["stands", 35], ["for", 42], ["?", 45]], "detected_answers": [{"text": "Spt-Ada-Gcn5-acetyltransferase", "token_spans": [[148, 152]], "char_spans": [[814, 843]]}]}], "context_tokens": [["NuA4", 0], ["(", 5], ["nucleosome", 6], ["acetyltransferase", 17], ["of", 35], ["H4", 38], [")", 40], ["promotes", 42], ["transcriptional", 51], ["initiation", 67], ["of", 78], ["TFIID", 81], ["(", 87], ["a", 88], ["complex", 90], ["of", 98], ["TBP", 101], ["and", 105], ["TBP", 109], ["-", 112], ["associated", 113], ["factors", 124], ["[", 132], ["TAFs])-dependent", 133], ["ribosomal", 150], ["protein", 160], ["genes", 168], ["involved", 174], ["in", 183], ["ribosome", 186], ["biogenesis", 195], [".", 205], ["However", 207], [",", 214], ["it", 216], ["is", 219], ["not", 222], ["clearly", 226], ["understood", 234], ["how", 245], ["NuA4", 249], ["regulates", 254], ["the", 264], ["transcription", 268], ["of", 282], ["ribosomal", 285], ["protein", 295], ["genes", 303], [".", 308], ["Here", 310], [",", 314], ["we", 316], ["show", 319], ["that", 324], ["NuA4", 329], ["is", 334], ["recruited", 337], ["to", 347], ["the", 350], ["promoters", 354], ["of", 364], ["ribosomal", 367], ["protein", 377], ["genes", 385], [",", 390], ["such", 392], ["as", 397], ["RPS5", 400], [",", 404], ["RPL2B", 406], [",", 411], ["and", 413], ["RPS11B", 417], [",", 423], ["for", 425], ["TFIID", 429], ["recruitment", 435], ["to", 447], ["initiate", 450], ["transcription", 459], [",", 472], ["and", 474], ["the", 478], ["recruitment", 482], ["of", 494], ["NuA4", 497], ["to", 502], ["these", 505], ["promoters", 511], ["is", 521], ["impaired", 524], ["in", 533], ["the", 536], ["absence", 540], ["of", 548], ["its", 551], ["Eaf1p", 555], ["component", 561], [".", 570], ["Intriguingly", 572], [",", 584], ["impaired", 586], ["NuA4", 595], ["recruitment", 600], ["in", 612], ["a", 615], ["\u0394eaf1", 617], ["strain", 623], ["depletes", 630], ["recruitment", 639], ["of", 651], ["TFIID", 654], ["(", 660], ["a", 661], ["TAF", 663], ["-", 666], ["dependent", 667], ["form", 677], ["of", 682], ["TBP", 685], [")", 688], ["but", 690], ["not", 694], ["the", 698], ["TAF", 702], ["-", 705], ["independent", 706], ["form", 718], ["of", 723], ["TBP", 726], ["to", 730], ["the", 733], ["promoters", 737], ["of", 747], ["ribosomal", 750], ["protein", 760], ["genes", 768], [".", 773], ["However", 775], [",", 782], ["in", 784], ["the", 787], ["absence", 791], ["of", 799], ["NuA4", 802], [",", 806], ["SAGA", 808], ["(", 813], ["Spt", 814], ["-", 817], ["Ada", 818], ["-", 821], ["Gcn5-acetyltransferase", 822], [")", 844], ["is", 846], ["involved", 849], ["in", 858], ["targeting", 861], ["the", 871], ["TAF", 875], ["-", 878], ["independent", 879], ["form", 891], ["of", 896], ["TBP", 899], ["to", 903], ["the", 906], ["promoters", 910], ["of", 920], ["ribosomal", 923], ["protein", 933], ["genes", 941], ["for", 947], ["transcriptional", 951], ["initiation", 967], [".", 977], ["Thus", 979], [",", 983], ["NuA4", 985], ["plays", 990], ["an", 996], ["important", 999], ["role", 1009], ["in", 1014], ["targeting", 1017], ["TFIID", 1027], ["to", 1033], ["the", 1036], ["promoters", 1040], ["of", 1050], ["ribosomal", 1053], ["protein", 1063], ["genes", 1071], ["for", 1077], ["transcriptional", 1081], ["initiation", 1097], ["in", 1108], ["vivo", 1111], [".", 1115], ["Such", 1117], ["a", 1122], ["function", 1124], ["is", 1133], ["mediated", 1136], ["via", 1145], ["its", 1149], ["targeted", 1153], ["histone", 1162], ["acetyltransferase", 1170], ["activity", 1188], [".", 1196], ["In", 1198], ["the", 1201], ["absence", 1205], ["of", 1213], ["NuA4", 1216], [",", 1220], ["ribosomal", 1222], ["protein", 1232], ["genes", 1240], ["lose", 1246], ["TFIID", 1251], ["dependency", 1257], ["and", 1268], ["become", 1272], ["SAGA", 1279], ["dependent", 1284], ["for", 1294], ["transcriptional", 1298], ["initiation", 1314], [".", 1324], ["Collectively", 1326], [",", 1338], ["these", 1340], ["results", 1346], ["provide", 1354], ["significant", 1362], ["insights", 1374], ["into", 1383], ["the", 1388], ["regulation", 1392], ["of", 1403], ["ribosomal", 1406], ["protein", 1416], ["gene", 1424], ["expression", 1429], ["and", 1440], [",", 1443], ["hence", 1445], [",", 1450], ["ribosome", 1452], ["biogenesis", 1461], ["and", 1472], ["functions", 1476], [".", 1485]]}
{"context": "The plasma membrane Na(+)/Ca(2+) exchanger (NCX) is a bidirectional ion transporter that couples the translocation of Na(+) in one direction with that of Ca(2+) in the opposite direction. This system contributes to the regulation of intracellular Ca(2+) concentration via the forward mode (Ca(2+) efflux) or the reverse mode (Ca(2+) influx). We have previously demonstrated that the Ca(2+) paradox, an in vitro reperfusion model, causes the sustained activation of the reverse mode of the NCX, the disruption of Ca(2+) homeostasis, and subsequent delayed apoptotic-like death in astrocytes. In addition, we found that the nitric oxide (NO)-cyclic GMP signaling pathway inhibits Ca(2+) paradox-mediated astrocyte apoptosis, while a high concentration of NO induces cytotoxicity. In this way, Ca(2+) and NO may work together in the pathogenesis of several cells in the central nervous system. Concerning the role of NCX in NO cytotoxicity, we have found, using the specific inhibitor of NCX 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400), that NCX is involved in NO-induced cytotoxicity in cultured microglia, astrocytes, and neuronal cells. This review summarizes the pathological roles of the NCX as a new target for NO-mediated cellular toxicity, based on our studies on NO-NCX-mediated glial toxicity.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "5658da3cc5b84d219d6f6991552febf0", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[3, 6]], "char_spans": [[20, 41]]}, {"text": "NCX", "token_spans": [[96, 96], [224, 224], [243, 243], [177, 177], [198, 198], [8, 8], [191, 191]], "char_spans": [[489, 491], [1215, 1217], [1297, 1299], [914, 916], [1064, 1066], [44, 46], [985, 987]]}]}], "context_tokens": [["The", 0], ["plasma", 4], ["membrane", 11], ["Na(+)/Ca(2", 20], ["+", 30], [")", 31], ["exchanger", 33], ["(", 43], ["NCX", 44], [")", 47], ["is", 49], ["a", 52], ["bidirectional", 54], ["ion", 68], ["transporter", 72], ["that", 84], ["couples", 89], ["the", 97], ["translocation", 101], ["of", 115], ["Na(+", 118], [")", 122], ["in", 124], ["one", 127], ["direction", 131], ["with", 141], ["that", 146], ["of", 151], ["Ca(2", 154], ["+", 158], [")", 159], ["in", 161], ["the", 164], ["opposite", 168], ["direction", 177], [".", 186], ["This", 188], ["system", 193], ["contributes", 200], ["to", 212], ["the", 215], ["regulation", 219], ["of", 230], ["intracellular", 233], ["Ca(2", 247], ["+", 251], [")", 252], ["concentration", 254], ["via", 268], ["the", 272], ["forward", 276], ["mode", 284], ["(", 289], ["Ca(2", 290], ["+", 294], [")", 295], ["efflux", 297], [")", 303], ["or", 305], ["the", 308], ["reverse", 312], ["mode", 320], ["(", 325], ["Ca(2", 326], ["+", 330], [")", 331], ["influx", 333], [")", 339], [".", 340], ["We", 342], ["have", 345], ["previously", 350], ["demonstrated", 361], ["that", 374], ["the", 379], ["Ca(2", 383], ["+", 387], [")", 388], ["paradox", 390], [",", 397], ["an", 399], ["in", 402], ["vitro", 405], ["reperfusion", 411], ["model", 423], [",", 428], ["causes", 430], ["the", 437], ["sustained", 441], ["activation", 451], ["of", 462], ["the", 465], ["reverse", 469], ["mode", 477], ["of", 482], ["the", 485], ["NCX", 489], [",", 492], ["the", 494], ["disruption", 498], ["of", 509], ["Ca(2", 512], ["+", 516], [")", 517], ["homeostasis", 519], [",", 530], ["and", 532], ["subsequent", 536], ["delayed", 547], ["apoptotic", 555], ["-", 564], ["like", 565], ["death", 570], ["in", 576], ["astrocytes", 579], [".", 589], ["In", 591], ["addition", 594], [",", 602], ["we", 604], ["found", 607], ["that", 613], ["the", 618], ["nitric", 622], ["oxide", 629], ["(", 635], ["NO)-cyclic", 636], ["GMP", 647], ["signaling", 651], ["pathway", 661], ["inhibits", 669], ["Ca(2", 678], ["+", 682], [")", 683], ["paradox", 685], ["-", 692], ["mediated", 693], ["astrocyte", 702], ["apoptosis", 712], [",", 721], ["while", 723], ["a", 729], ["high", 731], ["concentration", 736], ["of", 750], ["NO", 753], ["induces", 756], ["cytotoxicity", 764], [".", 776], ["In", 778], ["this", 781], ["way", 786], [",", 789], ["Ca(2", 791], ["+", 795], [")", 796], ["and", 798], ["NO", 802], ["may", 805], ["work", 809], ["together", 814], ["in", 823], ["the", 826], ["pathogenesis", 830], ["of", 843], ["several", 846], ["cells", 854], ["in", 860], ["the", 863], ["central", 867], ["nervous", 875], ["system", 883], [".", 889], ["Concerning", 891], ["the", 902], ["role", 906], ["of", 911], ["NCX", 914], ["in", 918], ["NO", 921], ["cytotoxicity", 924], [",", 936], ["we", 938], ["have", 941], ["found", 946], [",", 951], ["using", 953], ["the", 959], ["specific", 963], ["inhibitor", 972], ["of", 982], ["NCX", 985], ["2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline", 989], ["(", 1048], ["SEA0400", 1049], [")", 1056], [",", 1057], ["that", 1059], ["NCX", 1064], ["is", 1068], ["involved", 1071], ["in", 1080], ["NO", 1083], ["-", 1085], ["induced", 1086], ["cytotoxicity", 1094], ["in", 1107], ["cultured", 1110], ["microglia", 1119], [",", 1128], ["astrocytes", 1130], [",", 1140], ["and", 1142], ["neuronal", 1146], ["cells", 1155], [".", 1160], ["This", 1162], ["review", 1167], ["summarizes", 1174], ["the", 1185], ["pathological", 1189], ["roles", 1202], ["of", 1208], ["the", 1211], ["NCX", 1215], ["as", 1219], ["a", 1222], ["new", 1224], ["target", 1228], ["for", 1235], ["NO", 1239], ["-", 1241], ["mediated", 1242], ["cellular", 1251], ["toxicity", 1260], [",", 1268], ["based", 1270], ["on", 1276], ["our", 1279], ["studies", 1283], ["on", 1291], ["NO", 1294], ["-", 1296], ["NCX", 1297], ["-", 1300], ["mediated", 1301], ["glial", 1310], ["toxicity", 1316], [".", 1324]]}
{"context": "Mowat-Wilson syndrome is a recently delineated autosomal dominant developmental anomaly, whereby heterozygous mutations in the ZFHX1B gene cause mental retardation, delayed motor development, epilepsy and a wide spectrum of clinically heterogeneous features, suggestive of neurocristopathies at the cephalic, cardiac and vagal levels. However, our understanding of the etiology of this condition at the cellular level remains vague. This study presents the Zfhx1b protein expression domain in mouse embryos and correlates this with a novel mouse model involving a conditional mutation in the Zfhx1b gene in neural crest precursor cells. These mutant mice display craniofacial and gastrointestinal malformations that show resemblance to those found in human patients with Mowat-Wilson syndrome. In addition to these clinically recognized alterations, we document developmental defects in the heart, melanoblasts and sympathetic and parasympathetic anlagen. The latter observations in our mouse model for Mowat-Wilson suggest a hitherto unknown role for Zfhx1b in the development of these particular neural crest derivatives, which is a set of observations that should be acknowledged in the clinical management of this genetic disorder.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "9095328339f447188880bc5412e035d4", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[163, 163], [92, 92], [71, 71], [18, 18]], "char_spans": [[1052, 1057], [592, 597], [457, 462], [127, 132]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["is", 22], ["a", 25], ["recently", 27], ["delineated", 36], ["autosomal", 47], ["dominant", 57], ["developmental", 66], ["anomaly", 80], [",", 87], ["whereby", 89], ["heterozygous", 97], ["mutations", 110], ["in", 120], ["the", 123], ["ZFHX1B", 127], ["gene", 134], ["cause", 139], ["mental", 145], ["retardation", 152], [",", 163], ["delayed", 165], ["motor", 173], ["development", 179], [",", 190], ["epilepsy", 192], ["and", 201], ["a", 205], ["wide", 207], ["spectrum", 212], ["of", 221], ["clinically", 224], ["heterogeneous", 235], ["features", 249], [",", 257], ["suggestive", 259], ["of", 270], ["neurocristopathies", 273], ["at", 292], ["the", 295], ["cephalic", 299], [",", 307], ["cardiac", 309], ["and", 317], ["vagal", 321], ["levels", 327], [".", 333], ["However", 335], [",", 342], ["our", 344], ["understanding", 348], ["of", 362], ["the", 365], ["etiology", 369], ["of", 378], ["this", 381], ["condition", 386], ["at", 396], ["the", 399], ["cellular", 403], ["level", 412], ["remains", 418], ["vague", 426], [".", 431], ["This", 433], ["study", 438], ["presents", 444], ["the", 453], ["Zfhx1b", 457], ["protein", 464], ["expression", 472], ["domain", 483], ["in", 490], ["mouse", 493], ["embryos", 499], ["and", 507], ["correlates", 511], ["this", 522], ["with", 527], ["a", 532], ["novel", 534], ["mouse", 540], ["model", 546], ["involving", 552], ["a", 562], ["conditional", 564], ["mutation", 576], ["in", 585], ["the", 588], ["Zfhx1b", 592], ["gene", 599], ["in", 604], ["neural", 607], ["crest", 614], ["precursor", 620], ["cells", 630], [".", 635], ["These", 637], ["mutant", 643], ["mice", 650], ["display", 655], ["craniofacial", 663], ["and", 676], ["gastrointestinal", 680], ["malformations", 697], ["that", 711], ["show", 716], ["resemblance", 721], ["to", 733], ["those", 736], ["found", 742], ["in", 748], ["human", 751], ["patients", 757], ["with", 766], ["Mowat", 771], ["-", 776], ["Wilson", 777], ["syndrome", 784], [".", 792], ["In", 794], ["addition", 797], ["to", 806], ["these", 809], ["clinically", 815], ["recognized", 826], ["alterations", 837], [",", 848], ["we", 850], ["document", 853], ["developmental", 862], ["defects", 876], ["in", 884], ["the", 887], ["heart", 891], [",", 896], ["melanoblasts", 898], ["and", 911], ["sympathetic", 915], ["and", 927], ["parasympathetic", 931], ["anlagen", 947], [".", 954], ["The", 956], ["latter", 960], ["observations", 967], ["in", 980], ["our", 983], ["mouse", 987], ["model", 993], ["for", 999], ["Mowat", 1003], ["-", 1008], ["Wilson", 1009], ["suggest", 1016], ["a", 1024], ["hitherto", 1026], ["unknown", 1035], ["role", 1043], ["for", 1048], ["Zfhx1b", 1052], ["in", 1059], ["the", 1062], ["development", 1066], ["of", 1078], ["these", 1081], ["particular", 1087], ["neural", 1098], ["crest", 1105], ["derivatives", 1111], [",", 1122], ["which", 1124], ["is", 1130], ["a", 1133], ["set", 1135], ["of", 1139], ["observations", 1142], ["that", 1155], ["should", 1160], ["be", 1167], ["acknowledged", 1170], ["in", 1183], ["the", 1186], ["clinical", 1190], ["management", 1199], ["of", 1210], ["this", 1213], ["genetic", 1218], ["disorder", 1226], [".", 1234]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited small-artery disease of mid-adulthood caused by mutations of the NOTCH3 gene. The disease is responsible for widespread white-matter lesions associated with lacunar infarctions in various subcortical areas. The disease is responsible for migraine with aura and ischemic strokes, and is associated with various degrees of cognitive impairment and with mood disturbances. CADASIL is considered as a unique model to investigate what is known as \"subcortical ischemic vascular dementia.\" Recent data suggest that the number of lacunar infarctions and severity of cerebral atrophy are the main magnetic resonance imaging markers associated with cognitive and motor disabilities in this disorder. Mood disturbances are reported in 10% to 20% of patients, most often in association with cognitive alterations. Their exact origin remains unknown; the presence of ischemic lesions within the basal ganglia or the frontal white matter may promote the occurrence of these symptoms. Further studies are needed to better understand the relationships between cerebral lesions and both cognitive and psychiatric symptoms in this small-vessel disease of the brain.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "b2f73e6827624d46a50622245bc0bc8c", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[28, 29]], "char_spans": [[182, 192]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["an", 104], ["inherited", 107], ["small", 117], ["-", 122], ["artery", 123], ["disease", 130], ["of", 138], ["mid", 141], ["-", 144], ["adulthood", 145], ["caused", 155], ["by", 162], ["mutations", 165], ["of", 175], ["the", 178], ["NOTCH3", 182], ["gene", 189], [".", 193], ["The", 195], ["disease", 199], ["is", 207], ["responsible", 210], ["for", 222], ["widespread", 226], ["white", 237], ["-", 242], ["matter", 243], ["lesions", 250], ["associated", 258], ["with", 269], ["lacunar", 274], ["infarctions", 282], ["in", 294], ["various", 297], ["subcortical", 305], ["areas", 317], [".", 322], ["The", 324], ["disease", 328], ["is", 336], ["responsible", 339], ["for", 351], ["migraine", 355], ["with", 364], ["aura", 369], ["and", 374], ["ischemic", 378], ["strokes", 387], [",", 394], ["and", 396], ["is", 400], ["associated", 403], ["with", 414], ["various", 419], ["degrees", 427], ["of", 435], ["cognitive", 438], ["impairment", 448], ["and", 459], ["with", 463], ["mood", 468], ["disturbances", 473], [".", 485], ["CADASIL", 487], ["is", 495], ["considered", 498], ["as", 509], ["a", 512], ["unique", 514], ["model", 521], ["to", 527], ["investigate", 530], ["what", 542], ["is", 547], ["known", 550], ["as", 556], ["\"", 559], ["subcortical", 560], ["ischemic", 572], ["vascular", 581], ["dementia", 590], [".", 598], ["\"", 599], ["Recent", 601], ["data", 608], ["suggest", 613], ["that", 621], ["the", 626], ["number", 630], ["of", 637], ["lacunar", 640], ["infarctions", 648], ["and", 660], ["severity", 664], ["of", 673], ["cerebral", 676], ["atrophy", 685], ["are", 693], ["the", 697], ["main", 701], ["magnetic", 706], ["resonance", 715], ["imaging", 725], ["markers", 733], ["associated", 741], ["with", 752], ["cognitive", 757], ["and", 767], ["motor", 771], ["disabilities", 777], ["in", 790], ["this", 793], ["disorder", 798], [".", 806], ["Mood", 808], ["disturbances", 813], ["are", 826], ["reported", 830], ["in", 839], ["10", 842], ["%", 844], ["to", 846], ["20", 849], ["%", 851], ["of", 853], ["patients", 856], [",", 864], ["most", 866], ["often", 871], ["in", 877], ["association", 880], ["with", 892], ["cognitive", 897], ["alterations", 907], [".", 918], ["Their", 920], ["exact", 926], ["origin", 932], ["remains", 939], ["unknown", 947], [";", 954], ["the", 956], ["presence", 960], ["of", 969], ["ischemic", 972], ["lesions", 981], ["within", 989], ["the", 996], ["basal", 1000], ["ganglia", 1006], ["or", 1014], ["the", 1017], ["frontal", 1021], ["white", 1029], ["matter", 1035], ["may", 1042], ["promote", 1046], ["the", 1054], ["occurrence", 1058], ["of", 1069], ["these", 1072], ["symptoms", 1078], [".", 1086], ["Further", 1088], ["studies", 1096], ["are", 1104], ["needed", 1108], ["to", 1115], ["better", 1118], ["understand", 1125], ["the", 1136], ["relationships", 1140], ["between", 1154], ["cerebral", 1162], ["lesions", 1171], ["and", 1179], ["both", 1183], ["cognitive", 1188], ["and", 1198], ["psychiatric", 1202], ["symptoms", 1214], ["in", 1223], ["this", 1226], ["small", 1231], ["-", 1236], ["vessel", 1237], ["disease", 1244], ["of", 1252], ["the", 1255], ["brain", 1259], [".", 1264]]}
{"context": "Tanezumab, a monoclonal antibody, inhibits nerve growth factor and reduces chronic pain. This randomised, double-blind, controlled multicentre study was conducted to evaluate the efficacy and safety of tanezumab added to oral diclofenac sustained release (DSR) in patients with hip or knee osteoarthritis (OA) pain. Patients (N=604) with moderate to severe knee or hip OA tolerating stable DSR were randomised and treated with DSR 75\u2005mg twice daily combined with intravenous tanezumab 10, 5 or 2.5\u2005mg or placebo at weeks 0, 8 and 16. Co-primary efficacy endpoints (Western Ontario and McMaster Universities OA Index (WOMAC) Pain and Physical Function subscales and patient's global assessment of OA) were assessed at week 16. All co-primary endpoints were significantly improved for all tanezumab+DSR groups versus placebo+DSR (p\u22640.039). The incidence of adverse events of abnormal peripheral sensation was lower than in previous tanezumab trials. No new safety signals emerged. Overall incidence of adverse events was higher with tanezumab+DSR (45.2%-49.7%) than with placebo+DSR (34.9%); serious adverse event rates were similar across treatments (5.3%-7.6%). Osteonecrosis was reported in six of 452 patients with tanezumab+DSR (1.3%), but an external adjudication committee did not confirm osteonecrosis in any patient. Addition of tanezumab to DSR resulted in significant improvements in pain, function and global assessments in patients with OA. Although no new safety signals were observed, the higher incidence of adverse events in the tanezumab+diclofenac group suggests that combination therapy is unfavourable. Further investigations of tanezumab monotherapy for OA pain treatment are required. NCT00864097.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "24a13e3726da44deb5ad15627d9c04f8", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[7, 9]], "char_spans": [[43, 61]]}]}], "context_tokens": [["Tanezumab", 0], [",", 9], ["a", 11], ["monoclonal", 13], ["antibody", 24], [",", 32], ["inhibits", 34], ["nerve", 43], ["growth", 49], ["factor", 56], ["and", 63], ["reduces", 67], ["chronic", 75], ["pain", 83], [".", 87], ["This", 89], ["randomised", 94], [",", 104], ["double", 106], ["-", 112], ["blind", 113], [",", 118], ["controlled", 120], ["multicentre", 131], ["study", 143], ["was", 149], ["conducted", 153], ["to", 163], ["evaluate", 166], ["the", 175], ["efficacy", 179], ["and", 188], ["safety", 192], ["of", 199], ["tanezumab", 202], ["added", 212], ["to", 218], ["oral", 221], ["diclofenac", 226], ["sustained", 237], ["release", 247], ["(", 255], ["DSR", 256], [")", 259], ["in", 261], ["patients", 264], ["with", 273], ["hip", 278], ["or", 282], ["knee", 285], ["osteoarthritis", 290], ["(", 305], ["OA", 306], [")", 308], ["pain", 310], [".", 314], ["Patients", 316], ["(", 325], ["N=604", 326], [")", 331], ["with", 333], ["moderate", 338], ["to", 347], ["severe", 350], ["knee", 357], ["or", 362], ["hip", 365], ["OA", 369], ["tolerating", 372], ["stable", 383], ["DSR", 390], ["were", 394], ["randomised", 399], ["and", 410], ["treated", 414], ["with", 422], ["DSR", 427], ["75", 431], ["mg", 434], ["twice", 437], ["daily", 443], ["combined", 449], ["with", 458], ["intravenous", 463], ["tanezumab", 475], ["10", 485], [",", 487], ["5", 489], ["or", 491], ["2.5", 494], ["mg", 498], ["or", 501], ["placebo", 504], ["at", 512], ["weeks", 515], ["0", 521], [",", 522], ["8", 524], ["and", 526], ["16", 530], [".", 532], ["Co", 534], ["-", 536], ["primary", 537], ["efficacy", 545], ["endpoints", 554], ["(", 564], ["Western", 565], ["Ontario", 573], ["and", 581], ["McMaster", 585], ["Universities", 594], ["OA", 607], ["Index", 610], ["(", 616], ["WOMAC", 617], [")", 622], ["Pain", 624], ["and", 629], ["Physical", 633], ["Function", 642], ["subscales", 651], ["and", 661], ["patient", 665], ["'s", 672], ["global", 675], ["assessment", 682], ["of", 693], ["OA", 696], [")", 698], ["were", 700], ["assessed", 705], ["at", 714], ["week", 717], ["16", 722], [".", 724], ["All", 726], ["co", 730], ["-", 732], ["primary", 733], ["endpoints", 741], ["were", 751], ["significantly", 756], ["improved", 770], ["for", 779], ["all", 783], ["tanezumab+DSR", 787], ["groups", 801], ["versus", 808], ["placebo+DSR", 815], ["(", 827], ["p\u22640.039", 828], [")", 835], [".", 836], ["The", 838], ["incidence", 842], ["of", 852], ["adverse", 855], ["events", 863], ["of", 870], ["abnormal", 873], ["peripheral", 882], ["sensation", 893], ["was", 903], ["lower", 907], ["than", 913], ["in", 918], ["previous", 921], ["tanezumab", 930], ["trials", 940], [".", 946], ["No", 948], ["new", 951], ["safety", 955], ["signals", 962], ["emerged", 970], [".", 977], ["Overall", 979], ["incidence", 987], ["of", 997], ["adverse", 1000], ["events", 1008], ["was", 1015], ["higher", 1019], ["with", 1026], ["tanezumab+DSR", 1031], ["(", 1045], ["45.2%-49.7", 1046], ["%", 1056], [")", 1057], ["than", 1059], ["with", 1064], ["placebo+DSR", 1069], ["(", 1081], ["34.9", 1082], ["%", 1086], [")", 1087], [";", 1088], ["serious", 1090], ["adverse", 1098], ["event", 1106], ["rates", 1112], ["were", 1118], ["similar", 1123], ["across", 1131], ["treatments", 1138], ["(", 1149], ["5.3%-7.6", 1150], ["%", 1158], [")", 1159], [".", 1160], ["Osteonecrosis", 1162], ["was", 1176], ["reported", 1180], ["in", 1189], ["six", 1192], ["of", 1196], ["452", 1199], ["patients", 1203], ["with", 1212], ["tanezumab+DSR", 1217], ["(", 1231], ["1.3", 1232], ["%", 1235], [")", 1236], [",", 1237], ["but", 1239], ["an", 1243], ["external", 1246], ["adjudication", 1255], ["committee", 1268], ["did", 1278], ["not", 1282], ["confirm", 1286], ["osteonecrosis", 1294], ["in", 1308], ["any", 1311], ["patient", 1315], [".", 1322], ["Addition", 1324], ["of", 1333], ["tanezumab", 1336], ["to", 1346], ["DSR", 1349], ["resulted", 1353], ["in", 1362], ["significant", 1365], ["improvements", 1377], ["in", 1390], ["pain", 1393], [",", 1397], ["function", 1399], ["and", 1408], ["global", 1412], ["assessments", 1419], ["in", 1431], ["patients", 1434], ["with", 1443], ["OA", 1448], [".", 1450], ["Although", 1452], ["no", 1461], ["new", 1464], ["safety", 1468], ["signals", 1475], ["were", 1483], ["observed", 1488], [",", 1496], ["the", 1498], ["higher", 1502], ["incidence", 1509], ["of", 1519], ["adverse", 1522], ["events", 1530], ["in", 1537], ["the", 1540], ["tanezumab+diclofenac", 1544], ["group", 1565], ["suggests", 1571], ["that", 1580], ["combination", 1585], ["therapy", 1597], ["is", 1605], ["unfavourable", 1608], [".", 1620], ["Further", 1622], ["investigations", 1630], ["of", 1645], ["tanezumab", 1648], ["monotherapy", 1658], ["for", 1670], ["OA", 1674], ["pain", 1677], ["treatment", 1682], ["are", 1692], ["required", 1696], [".", 1704], ["NCT00864097", 1706], [".", 1717]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), the most common form of familial vascular dementia, is caused by mutations of the NOTCH3 gene. Approximately two hundred pathogenic mutations have been reported within five exons (exons 3, 4, 6, 11 and 19) which accounted for 78% of known mutations in worldwide series. We reported twenty-one NOTCH3 pathogenic mutations (including five novel ones) identified in 53 index Italian patients. Exons 4 (28%), 7 (21%) and 19 (24%) were the most frequently involved. To dissect genetic heterogeneity, we analyzed five haplotyped tagging single nucleotide polymorphisms (rs1044009, rs4809030, rs10426042, rs10423702 and rs3815188) in 95 patients, 39 unaffected pedigree members and 50 healthy controls. SNPs were analyzed using the Illumina VeraCode Universal Capture Beads technology by Allele Specific Primer Extension (ASPE). We identified ten different haplotypes named H1-H10; H1 was the most common haplotype in patients and controls and it was associated with at least twelve out of the twenty-one mutations. Detected mutations were not associated to specific haplotypes while genotyping was compatible with a possible founder effect for the novel p.S396C mutation which clustered in a restricted geographical area of northeast Italy. The results added on to the genetic heterogeneity of CADASIL and emphasized difficulties in designing algorithms for molecular diagnosis.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "33f0175a3dd1410a979d8698198ca39b", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[28, 29]], "char_spans": [[184, 194]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], [",", 100], ["the", 102], ["most", 106], ["common", 111], ["form", 118], ["of", 123], ["familial", 126], ["vascular", 135], ["dementia", 144], [",", 152], ["is", 154], ["caused", 157], ["by", 164], ["mutations", 167], ["of", 177], ["the", 180], ["NOTCH3", 184], ["gene", 191], [".", 195], ["Approximately", 197], ["two", 211], ["hundred", 215], ["pathogenic", 223], ["mutations", 234], ["have", 244], ["been", 249], ["reported", 254], ["within", 263], ["five", 270], ["exons", 275], ["(", 281], ["exons", 282], ["3", 288], [",", 289], ["4", 291], [",", 292], ["6", 294], [",", 295], ["11", 297], ["and", 300], ["19", 304], [")", 306], ["which", 308], ["accounted", 314], ["for", 324], ["78", 328], ["%", 330], ["of", 332], ["known", 335], ["mutations", 341], ["in", 351], ["worldwide", 354], ["series", 364], [".", 370], ["We", 372], ["reported", 375], ["twenty", 384], ["-", 390], ["one", 391], ["NOTCH3", 395], ["pathogenic", 402], ["mutations", 413], ["(", 423], ["including", 424], ["five", 434], ["novel", 439], ["ones", 445], [")", 449], ["identified", 451], ["in", 462], ["53", 465], ["index", 468], ["Italian", 474], ["patients", 482], [".", 490], ["Exons", 492], ["4", 498], ["(", 500], ["28", 501], ["%", 503], [")", 504], [",", 505], ["7", 507], ["(", 509], ["21", 510], ["%", 512], [")", 513], ["and", 515], ["19", 519], ["(", 522], ["24", 523], ["%", 525], [")", 526], ["were", 528], ["the", 533], ["most", 537], ["frequently", 542], ["involved", 553], [".", 561], ["To", 563], ["dissect", 566], ["genetic", 574], ["heterogeneity", 582], [",", 595], ["we", 597], ["analyzed", 600], ["five", 609], ["haplotyped", 614], ["tagging", 625], ["single", 633], ["nucleotide", 640], ["polymorphisms", 651], ["(", 665], ["rs1044009", 666], [",", 675], ["rs4809030", 677], [",", 686], ["rs10426042", 688], [",", 698], ["rs10423702", 700], ["and", 711], ["rs3815188", 715], [")", 724], ["in", 726], ["95", 729], ["patients", 732], [",", 740], ["39", 742], ["unaffected", 745], ["pedigree", 756], ["members", 765], ["and", 773], ["50", 777], ["healthy", 780], ["controls", 788], [".", 796], ["SNPs", 798], ["were", 803], ["analyzed", 808], ["using", 817], ["the", 823], ["Illumina", 827], ["VeraCode", 836], ["Universal", 845], ["Capture", 855], ["Beads", 863], ["technology", 869], ["by", 880], ["Allele", 883], ["Specific", 890], ["Primer", 899], ["Extension", 906], ["(", 916], ["ASPE", 917], [")", 921], [".", 922], ["We", 924], ["identified", 927], ["ten", 938], ["different", 942], ["haplotypes", 952], ["named", 963], ["H1-H10", 969], [";", 975], ["H1", 977], ["was", 980], ["the", 984], ["most", 988], ["common", 993], ["haplotype", 1000], ["in", 1010], ["patients", 1013], ["and", 1022], ["controls", 1026], ["and", 1035], ["it", 1039], ["was", 1042], ["associated", 1046], ["with", 1057], ["at", 1062], ["least", 1065], ["twelve", 1071], ["out", 1078], ["of", 1082], ["the", 1085], ["twenty", 1089], ["-", 1095], ["one", 1096], ["mutations", 1100], [".", 1109], ["Detected", 1111], ["mutations", 1120], ["were", 1130], ["not", 1135], ["associated", 1139], ["to", 1150], ["specific", 1153], ["haplotypes", 1162], ["while", 1173], ["genotyping", 1179], ["was", 1190], ["compatible", 1194], ["with", 1205], ["a", 1210], ["possible", 1212], ["founder", 1221], ["effect", 1229], ["for", 1236], ["the", 1240], ["novel", 1244], ["p", 1250], [".", 1251], ["S396C", 1252], ["mutation", 1258], ["which", 1267], ["clustered", 1273], ["in", 1283], ["a", 1286], ["restricted", 1288], ["geographical", 1299], ["area", 1312], ["of", 1317], ["northeast", 1320], ["Italy", 1330], [".", 1335], ["The", 1337], ["results", 1341], ["added", 1349], ["on", 1355], ["to", 1358], ["the", 1361], ["genetic", 1365], ["heterogeneity", 1373], ["of", 1387], ["CADASIL", 1390], ["and", 1398], ["emphasized", 1402], ["difficulties", 1413], ["in", 1426], ["designing", 1429], ["algorithms", 1439], ["for", 1450], ["molecular", 1454], ["diagnosis", 1464], [".", 1473]]}
{"context": "Denosumab is a human monoclonal antibody which specifically blocks receptor activator of nuclear factor \u03baB ligand and is a very potent antiresorptive drug. Its efficacy in reducing the risk of vertebral, hip and nonskeletal fracture has been proven in a large prospective, randomized multicenter study of 7808 postmenopausal women with osteoporosis [Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial]. Denosumab causes somewhat greater increases in bone mineral density (BMD) than the class of bisphosphonate antiresorptives. Denosumab also causes an increase in bone mass and bone strength in the spine, ultradistal and diaphysis of the radius, proximal tibia and the hip. Recently long-term treatment with denosumab has been shown to cause a continued almost linear increase in total hip and femoral neck BMD beyond 3 years up to 8 years. In this respect, denosumab seems to differ from the bisphosphonate group in which the rate of improvement of BMD diminishes and for some drugs becomes negative after 3-4 years when the process of secondary mineralization flattens out. This unique property of an antiresorptive drug points towards mechanisms of action which differ from the bisphosphonate group. Both types of antiresorptives decrease cortical porosity but contrary to bisphosphonates the reduction in cortical porosity continues with denosumab which, in addition, also seems to cause a slight continuous modeling-based formation of new bone despite suppression of bone remodeling. The net effect is an increase in cortical thickening and bone mass, and increased strength of cortical bone. This may contribute substantially to the significant further reduction of the nonvertebral fracture risk which was found in the long-term denosumab arm of the FREEDOM extension trial during years 4-7.", "qas": [{"question": "Which is the target of the drug Denosumab?", "answers": ["receptor activator of nuclear factor \u03baB ligand", "RANKL", "receptor activator of nuclear factor-\u03baB ligand"], "qid": "d38d490c5d9f45a0818bec552463879b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["the", 23], ["drug", 27], ["Denosumab", 32], ["?", 41]], "detected_answers": [{"text": "receptor activator of nuclear factor-\u03baB ligand", "token_spans": [[9, 15]], "char_spans": [[67, 112]]}]}], "context_tokens": [["Denosumab", 0], ["is", 10], ["a", 13], ["human", 15], ["monoclonal", 21], ["antibody", 32], ["which", 41], ["specifically", 47], ["blocks", 60], ["receptor", 67], ["activator", 76], ["of", 86], ["nuclear", 89], ["factor", 97], ["\u03baB", 104], ["ligand", 107], ["and", 114], ["is", 118], ["a", 121], ["very", 123], ["potent", 128], ["antiresorptive", 135], ["drug", 150], [".", 154], ["Its", 156], ["efficacy", 160], ["in", 169], ["reducing", 172], ["the", 181], ["risk", 185], ["of", 190], ["vertebral", 193], [",", 202], ["hip", 204], ["and", 208], ["nonskeletal", 212], ["fracture", 224], ["has", 233], ["been", 237], ["proven", 242], ["in", 249], ["a", 252], ["large", 254], ["prospective", 260], [",", 271], ["randomized", 273], ["multicenter", 284], ["study", 296], ["of", 302], ["7808", 305], ["postmenopausal", 310], ["women", 325], ["with", 331], ["osteoporosis", 336], ["[", 349], ["Fracture", 350], ["Reduction", 359], ["Evaluation", 369], ["of", 380], ["Denosumab", 383], ["in", 393], ["Osteoporosis", 396], ["Every", 409], ["6", 415], ["Months", 417], ["(", 424], ["FREEDOM", 425], [")", 432], ["trial].", 434], ["Denosumab", 442], ["causes", 452], ["somewhat", 459], ["greater", 468], ["increases", 476], ["in", 486], ["bone", 489], ["mineral", 494], ["density", 502], ["(", 510], ["BMD", 511], [")", 514], ["than", 516], ["the", 521], ["class", 525], ["of", 531], ["bisphosphonate", 534], ["antiresorptives", 549], [".", 564], ["Denosumab", 566], ["also", 576], ["causes", 581], ["an", 588], ["increase", 591], ["in", 600], ["bone", 603], ["mass", 608], ["and", 613], ["bone", 617], ["strength", 622], ["in", 631], ["the", 634], ["spine", 638], [",", 643], ["ultradistal", 645], ["and", 657], ["diaphysis", 661], ["of", 671], ["the", 674], ["radius", 678], [",", 684], ["proximal", 686], ["tibia", 695], ["and", 701], ["the", 705], ["hip", 709], [".", 712], ["Recently", 714], ["long", 723], ["-", 727], ["term", 728], ["treatment", 733], ["with", 743], ["denosumab", 748], ["has", 758], ["been", 762], ["shown", 767], ["to", 773], ["cause", 776], ["a", 782], ["continued", 784], ["almost", 794], ["linear", 801], ["increase", 808], ["in", 817], ["total", 820], ["hip", 826], ["and", 830], ["femoral", 834], ["neck", 842], ["BMD", 847], ["beyond", 851], ["3", 858], ["years", 860], ["up", 866], ["to", 869], ["8", 872], ["years", 874], [".", 879], ["In", 881], ["this", 884], ["respect", 889], [",", 896], ["denosumab", 898], ["seems", 908], ["to", 914], ["differ", 917], ["from", 924], ["the", 929], ["bisphosphonate", 933], ["group", 948], ["in", 954], ["which", 957], ["the", 963], ["rate", 967], ["of", 972], ["improvement", 975], ["of", 987], ["BMD", 990], ["diminishes", 994], ["and", 1005], ["for", 1009], ["some", 1013], ["drugs", 1018], ["becomes", 1024], ["negative", 1032], ["after", 1041], ["3", 1047], ["-", 1048], ["4", 1049], ["years", 1051], ["when", 1057], ["the", 1062], ["process", 1066], ["of", 1074], ["secondary", 1077], ["mineralization", 1087], ["flattens", 1102], ["out", 1111], [".", 1114], ["This", 1116], ["unique", 1121], ["property", 1128], ["of", 1137], ["an", 1140], ["antiresorptive", 1143], ["drug", 1158], ["points", 1163], ["towards", 1170], ["mechanisms", 1178], ["of", 1189], ["action", 1192], ["which", 1199], ["differ", 1205], ["from", 1212], ["the", 1217], ["bisphosphonate", 1221], ["group", 1236], [".", 1241], ["Both", 1243], ["types", 1248], ["of", 1254], ["antiresorptives", 1257], ["decrease", 1273], ["cortical", 1282], ["porosity", 1291], ["but", 1300], ["contrary", 1304], ["to", 1313], ["bisphosphonates", 1316], ["the", 1332], ["reduction", 1336], ["in", 1346], ["cortical", 1349], ["porosity", 1358], ["continues", 1367], ["with", 1377], ["denosumab", 1382], ["which", 1392], [",", 1397], ["in", 1399], ["addition", 1402], [",", 1410], ["also", 1412], ["seems", 1417], ["to", 1423], ["cause", 1426], ["a", 1432], ["slight", 1434], ["continuous", 1441], ["modeling", 1452], ["-", 1460], ["based", 1461], ["formation", 1467], ["of", 1477], ["new", 1480], ["bone", 1484], ["despite", 1489], ["suppression", 1497], ["of", 1509], ["bone", 1512], ["remodeling", 1517], [".", 1527], ["The", 1529], ["net", 1533], ["effect", 1537], ["is", 1544], ["an", 1547], ["increase", 1550], ["in", 1559], ["cortical", 1562], ["thickening", 1571], ["and", 1582], ["bone", 1586], ["mass", 1591], [",", 1595], ["and", 1597], ["increased", 1601], ["strength", 1611], ["of", 1620], ["cortical", 1623], ["bone", 1632], [".", 1636], ["This", 1638], ["may", 1643], ["contribute", 1647], ["substantially", 1658], ["to", 1672], ["the", 1675], ["significant", 1679], ["further", 1691], ["reduction", 1699], ["of", 1709], ["the", 1712], ["nonvertebral", 1716], ["fracture", 1729], ["risk", 1738], ["which", 1743], ["was", 1749], ["found", 1753], ["in", 1759], ["the", 1762], ["long", 1766], ["-", 1770], ["term", 1771], ["denosumab", 1776], ["arm", 1786], ["of", 1790], ["the", 1793], ["FREEDOM", 1797], ["extension", 1805], ["trial", 1815], ["during", 1821], ["years", 1828], ["4", 1834], ["-", 1835], ["7", 1836], [".", 1837]]}
{"context": "To study the clinical and molecular characteristics of methicillin-resistant Staphylococcus aureus (MRSA) infection in children. A total of 37 MRSA strains were isolated from hospitalized patients in Children's Hospital of Fudan University from March 2009 to November 2011. The clinical characteristics were investigated by a cohort study. Furthermore, the mecA, Panton-Valentine leucocidin (PVL) genes were detected by polymerase chain reaction (PCR), and the genotypes of SCCmec were determined by multiplex PCR. (1) Among the 37 MRSA isolates, infections with 21 were acquired from hospital (HA-MRSA), and 16 isolates were acquired from community (CA-MRSA). (2) In the study, MRSA frequently caused respiratory tract infection, and most of the strains were isolated from intensive care unit (ICU). (3) CA-MRSA was most frequently associated with skin and soft tissue infections (SSTI), suppurative tonsillitis, even pneumonia and septicemia. HA-MRSA infection was more aggressive, most frequently associated with pneumonia, septicemia, and central nervous system (CNS) infections, such as meningitis. In children with fever caused by HA-MRSA or CA-MRSA infection, HA-MRSA showed a longer duration of fever, for 10.5 days. C-reactive protein (CRP) level caused by HA-MRSA (63.00 mg/L) was higher than CA-MRSA (9.50 mg/L) , and there were statistically significant differences between the groups (t = 2.5670, P < 0.05). However, there were no statistically significant differences between the groups in white blood cell count (WBC) or procalcitonin (PCT) level. (4) Among 37 MRSA isolates, the whole isolates were mecA gene positive (100%). SCCmec genotyping results showed that the most frequent SCCmec types were type III, 17 isolates, the others including type IV 8 isolates, type II1 isolates, nontypable 11 isolates, type I and type V were not found in this group. Therein, among 21 HA-MRSA isolates, SCCmec III was the most common, 15 isolates, type IV 1 isolates, nontypable 5 isolates; among 16 CA-MRSA isolates, SCCmec type IV was the most common, 7 isolates, type III 2 isolates, type II 1 isolate, nontypable 6 isolates. (5) Among the 37 MRSA isolates, 28 were PVL gene positive; and among 21 HA-MRSA isolates, 17 were PVL gene positive; Among 16 CA-MRSA isolates, 11 were PVL gene positive; There were no statistically significant differences between the groups (\u03c7(2) = 0.735, P > 0.05) . Compared with CA-MRSA, HA-MRSA infection was more aggressive, and induced higher C reactive protein; the dominant epidemic strains of CA-MRSA was SCCmec type IV, and HA-MRSA was SCCmec type III; the positive rate of PVL gene was high.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "b4d2ae32fe78473ead5fbb79a9000745", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[461, 461], [531, 531], [108, 108], [121, 121], [263, 263], [131, 131], [251, 251], [387, 387], [507, 507], [222, 222], [14, 14], [447, 447], [321, 321], [511, 511], [218, 218], [474, 474], [24, 24], [227, 227], [413, 413], [540, 540], [183, 183], [158, 158], [95, 95]], "char_spans": [[2208, 2211], [2539, 2542], [598, 601], [654, 657], [1306, 1309], [679, 682], [1269, 1272], [1892, 1895], [2419, 2422], [1151, 1154], [100, 103], [2150, 2153], [1576, 1579], [2428, 2431], [1140, 1143], [2262, 2265], [143, 146], [1170, 1173], [2007, 2010], [2571, 2574], [948, 951], [808, 811], [532, 535]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["clinical", 13], ["and", 22], ["molecular", 26], ["characteristics", 36], ["of", 52], ["methicillin", 55], ["-", 66], ["resistant", 67], ["Staphylococcus", 77], ["aureus", 92], ["(", 99], ["MRSA", 100], [")", 104], ["infection", 106], ["in", 116], ["children", 119], [".", 127], ["A", 129], ["total", 131], ["of", 137], ["37", 140], ["MRSA", 143], ["strains", 148], ["were", 156], ["isolated", 161], ["from", 170], ["hospitalized", 175], ["patients", 188], ["in", 197], ["Children", 200], ["'s", 208], ["Hospital", 211], ["of", 220], ["Fudan", 223], ["University", 229], ["from", 240], ["March", 245], ["2009", 251], ["to", 256], ["November", 259], ["2011", 268], [".", 272], ["The", 274], ["clinical", 278], ["characteristics", 287], ["were", 303], ["investigated", 308], ["by", 321], ["a", 324], ["cohort", 326], ["study", 333], [".", 338], ["Furthermore", 340], [",", 351], ["the", 353], ["mecA", 357], [",", 361], ["Panton", 363], ["-", 369], ["Valentine", 370], ["leucocidin", 380], ["(", 391], ["PVL", 392], [")", 395], ["genes", 397], ["were", 403], ["detected", 408], ["by", 417], ["polymerase", 420], ["chain", 431], ["reaction", 437], ["(", 446], ["PCR", 447], [")", 450], [",", 451], ["and", 453], ["the", 457], ["genotypes", 461], ["of", 471], ["SCCmec", 474], ["were", 481], ["determined", 486], ["by", 497], ["multiplex", 500], ["PCR", 510], [".", 513], ["(", 515], ["1", 516], [")", 517], ["Among", 519], ["the", 525], ["37", 529], ["MRSA", 532], ["isolates", 537], [",", 545], ["infections", 547], ["with", 558], ["21", 563], ["were", 566], ["acquired", 571], ["from", 580], ["hospital", 585], ["(", 594], ["HA", 595], ["-", 597], ["MRSA", 598], [")", 602], [",", 603], ["and", 605], ["16", 609], ["isolates", 612], ["were", 621], ["acquired", 626], ["from", 635], ["community", 640], ["(", 650], ["CA", 651], ["-", 653], ["MRSA", 654], [")", 658], [".", 659], ["(", 661], ["2", 662], [")", 663], ["In", 665], ["the", 668], ["study", 672], [",", 677], ["MRSA", 679], ["frequently", 684], ["caused", 695], ["respiratory", 702], ["tract", 714], ["infection", 720], [",", 729], ["and", 731], ["most", 735], ["of", 740], ["the", 743], ["strains", 747], ["were", 755], ["isolated", 760], ["from", 769], ["intensive", 774], ["care", 784], ["unit", 789], ["(", 794], ["ICU", 795], [")", 798], [".", 799], ["(", 801], ["3", 802], [")", 803], ["CA", 805], ["-", 807], ["MRSA", 808], ["was", 813], ["most", 817], ["frequently", 822], ["associated", 833], ["with", 844], ["skin", 849], ["and", 854], ["soft", 858], ["tissue", 863], ["infections", 870], ["(", 881], ["SSTI", 882], [")", 886], [",", 887], ["suppurative", 889], ["tonsillitis", 901], [",", 912], ["even", 914], ["pneumonia", 919], ["and", 929], ["septicemia", 933], [".", 943], ["HA", 945], ["-", 947], ["MRSA", 948], ["infection", 953], ["was", 963], ["more", 967], ["aggressive", 972], [",", 982], ["most", 984], ["frequently", 989], ["associated", 1000], ["with", 1011], ["pneumonia", 1016], [",", 1025], ["septicemia", 1027], [",", 1037], ["and", 1039], ["central", 1043], ["nervous", 1051], ["system", 1059], ["(", 1066], ["CNS", 1067], [")", 1070], ["infections", 1072], [",", 1082], ["such", 1084], ["as", 1089], ["meningitis", 1092], [".", 1102], ["In", 1104], ["children", 1107], ["with", 1116], ["fever", 1121], ["caused", 1127], ["by", 1134], ["HA", 1137], ["-", 1139], ["MRSA", 1140], ["or", 1145], ["CA", 1148], ["-", 1150], ["MRSA", 1151], ["infection", 1156], [",", 1165], ["HA", 1167], ["-", 1169], ["MRSA", 1170], ["showed", 1175], ["a", 1182], ["longer", 1184], ["duration", 1191], ["of", 1200], ["fever", 1203], [",", 1208], ["for", 1210], ["10.5", 1214], ["days", 1219], [".", 1223], ["C", 1225], ["-", 1226], ["reactive", 1227], ["protein", 1236], ["(", 1244], ["CRP", 1245], [")", 1248], ["level", 1250], ["caused", 1256], ["by", 1263], ["HA", 1266], ["-", 1268], ["MRSA", 1269], ["(", 1274], ["63.00", 1275], ["mg", 1281], ["/", 1283], ["L", 1284], [")", 1285], ["was", 1287], ["higher", 1291], ["than", 1298], ["CA", 1303], ["-", 1305], ["MRSA", 1306], ["(", 1311], ["9.50", 1312], ["mg", 1317], ["/", 1319], ["L", 1320], [")", 1321], [",", 1323], ["and", 1325], ["there", 1329], ["were", 1335], ["statistically", 1340], ["significant", 1354], ["differences", 1366], ["between", 1378], ["the", 1386], ["groups", 1390], ["(", 1397], ["t", 1398], ["=", 1400], ["2.5670", 1402], [",", 1408], ["P", 1410], ["<", 1412], ["0.05", 1414], [")", 1418], [".", 1419], ["However", 1421], [",", 1428], ["there", 1430], ["were", 1436], ["no", 1441], ["statistically", 1444], ["significant", 1458], ["differences", 1470], ["between", 1482], ["the", 1490], ["groups", 1494], ["in", 1501], ["white", 1504], ["blood", 1510], ["cell", 1516], ["count", 1521], ["(", 1527], ["WBC", 1528], [")", 1531], ["or", 1533], ["procalcitonin", 1536], ["(", 1550], ["PCT", 1551], [")", 1554], ["level", 1556], [".", 1561], ["(", 1563], ["4", 1564], [")", 1565], ["Among", 1567], ["37", 1573], ["MRSA", 1576], ["isolates", 1581], [",", 1589], ["the", 1591], ["whole", 1595], ["isolates", 1601], ["were", 1610], ["mecA", 1615], ["gene", 1620], ["positive", 1625], ["(", 1634], ["100", 1635], ["%", 1638], [")", 1639], [".", 1640], ["SCCmec", 1642], ["genotyping", 1649], ["results", 1660], ["showed", 1668], ["that", 1675], ["the", 1680], ["most", 1684], ["frequent", 1689], ["SCCmec", 1698], ["types", 1705], ["were", 1711], ["type", 1716], ["III", 1721], [",", 1724], ["17", 1726], ["isolates", 1729], [",", 1737], ["the", 1739], ["others", 1743], ["including", 1750], ["type", 1760], ["IV", 1765], ["8", 1768], ["isolates", 1770], [",", 1778], ["type", 1780], ["II1", 1785], ["isolates", 1789], [",", 1797], ["nontypable", 1799], ["11", 1810], ["isolates", 1813], [",", 1821], ["type", 1823], ["I", 1828], ["and", 1830], ["type", 1834], ["V", 1839], ["were", 1841], ["not", 1846], ["found", 1850], ["in", 1856], ["this", 1859], ["group", 1864], [".", 1869], ["Therein", 1871], [",", 1878], ["among", 1880], ["21", 1886], ["HA", 1889], ["-", 1891], ["MRSA", 1892], ["isolates", 1897], [",", 1905], ["SCCmec", 1907], ["III", 1914], ["was", 1918], ["the", 1922], ["most", 1926], ["common", 1931], [",", 1937], ["15", 1939], ["isolates", 1942], [",", 1950], ["type", 1952], ["IV", 1957], ["1", 1960], ["isolates", 1962], [",", 1970], ["nontypable", 1972], ["5", 1983], ["isolates", 1985], [";", 1993], ["among", 1995], ["16", 2001], ["CA", 2004], ["-", 2006], ["MRSA", 2007], ["isolates", 2012], [",", 2020], ["SCCmec", 2022], ["type", 2029], ["IV", 2034], ["was", 2037], ["the", 2041], ["most", 2045], ["common", 2050], [",", 2056], ["7", 2058], ["isolates", 2060], [",", 2068], ["type", 2070], ["III", 2075], ["2", 2079], ["isolates", 2081], [",", 2089], ["type", 2091], ["II", 2096], ["1", 2099], ["isolate", 2101], [",", 2108], ["nontypable", 2110], ["6", 2121], ["isolates", 2123], [".", 2131], ["(", 2133], ["5", 2134], [")", 2135], ["Among", 2137], ["the", 2143], ["37", 2147], ["MRSA", 2150], ["isolates", 2155], [",", 2163], ["28", 2165], ["were", 2168], ["PVL", 2173], ["gene", 2177], ["positive", 2182], [";", 2190], ["and", 2192], ["among", 2196], ["21", 2202], ["HA", 2205], ["-", 2207], ["MRSA", 2208], ["isolates", 2213], [",", 2221], ["17", 2223], ["were", 2226], ["PVL", 2231], ["gene", 2235], ["positive", 2240], [";", 2248], ["Among", 2250], ["16", 2256], ["CA", 2259], ["-", 2261], ["MRSA", 2262], ["isolates", 2267], [",", 2275], ["11", 2277], ["were", 2280], ["PVL", 2285], ["gene", 2289], ["positive", 2294], [";", 2302], ["There", 2304], ["were", 2310], ["no", 2315], ["statistically", 2318], ["significant", 2332], ["differences", 2344], ["between", 2356], ["the", 2364], ["groups", 2368], ["(", 2375], ["\u03c7(2", 2376], [")", 2379], ["=", 2381], ["0.735", 2383], [",", 2388], ["P", 2390], [">", 2392], ["0.05", 2394], [")", 2398], [".", 2400], ["Compared", 2402], ["with", 2411], ["CA", 2416], ["-", 2418], ["MRSA", 2419], [",", 2423], ["HA", 2425], ["-", 2427], ["MRSA", 2428], ["infection", 2433], ["was", 2443], ["more", 2447], ["aggressive", 2452], [",", 2462], ["and", 2464], ["induced", 2468], ["higher", 2476], ["C", 2483], ["reactive", 2485], ["protein", 2494], [";", 2501], ["the", 2503], ["dominant", 2507], ["epidemic", 2516], ["strains", 2525], ["of", 2533], ["CA", 2536], ["-", 2538], ["MRSA", 2539], ["was", 2544], ["SCCmec", 2548], ["type", 2555], ["IV", 2560], [",", 2562], ["and", 2564], ["HA", 2568], ["-", 2570], ["MRSA", 2571], ["was", 2576], ["SCCmec", 2580], ["type", 2587], ["III", 2592], [";", 2595], ["the", 2597], ["positive", 2601], ["rate", 2610], ["of", 2615], ["PVL", 2618], ["gene", 2622], ["was", 2627], ["high", 2631], [".", 2635]]}
{"context": "Myotonic dystrophy (DM), the most common form of muscular dystrophy in adults, is a clinically and genetically heterogeneous neuromuscular disorder. DM is characterized by autosomal dominant inheritance, muscular dystrophy, myotonia, and multisystem involvement. Type 1 DM (DM1) is caused by a (CTG)(n) expansion in the 3' untranslated region of DMPK in 19q13.3. Multiple families, predominantly of German descent and with clinically variable presentation that included proximal myotonic myopathy (PROMM) and type 2 DM (DM2) but without the DM1 mutation, showed linkage to the 3q21 region and were recently shown to segregate a (CCTG)(n) expansion mutation in intron 1 of ZNF9. Here, we present linkage to 3q21 and mutational confirmation in 17 kindreds of European origin with PROMM and proximal myotonic dystrophy, from geographically distinct populations. All patients have the DM2 (CCTG)(n) expansion. To study the evolution of this mutation, we constructed a comprehensive physical map of the DM2 region around ZNF9. High-resolution haplotype analysis of disease chromosomes with five microsatellite and 22 single-nucleotide polymorphism markers around the DM2 mutation identified extensive linkage disequilibrium and a single shared haplotype of at least 132 kb among patients from the different populations. With the exception of the (CCTG)(n) expansion, the available markers indicate that the DM2 haplotype is identical to the most common haplotype in normal individuals. This situation is reminiscent of that seen in DM1. Taken together, these data suggest a single founding mutation in DM2 patients of European origin. We estimate the age of the founding haplotype and of the DM2 (CCTG) expansion mutation to be approximately 200-540 generations.", "qas": [{"question": "How is myotonic dystrophy inherited?", "answers": ["autosomal dominant"], "qid": "3dff550077ca471a8137430b2d11722c", "question_tokens": [["How", 0], ["is", 4], ["myotonic", 7], ["dystrophy", 16], ["inherited", 26], ["?", 35]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[29, 30]], "char_spans": [[172, 189]]}]}], "context_tokens": [["Myotonic", 0], ["dystrophy", 9], ["(", 19], ["DM", 20], [")", 22], [",", 23], ["the", 25], ["most", 29], ["common", 34], ["form", 41], ["of", 46], ["muscular", 49], ["dystrophy", 58], ["in", 68], ["adults", 71], [",", 77], ["is", 79], ["a", 82], ["clinically", 84], ["and", 95], ["genetically", 99], ["heterogeneous", 111], ["neuromuscular", 125], ["disorder", 139], [".", 147], ["DM", 149], ["is", 152], ["characterized", 155], ["by", 169], ["autosomal", 172], ["dominant", 182], ["inheritance", 191], [",", 202], ["muscular", 204], ["dystrophy", 213], [",", 222], ["myotonia", 224], [",", 232], ["and", 234], ["multisystem", 238], ["involvement", 250], [".", 261], ["Type", 263], ["1", 268], ["DM", 270], ["(", 273], ["DM1", 274], [")", 277], ["is", 279], ["caused", 282], ["by", 289], ["a", 292], ["(", 294], ["CTG)(n", 295], [")", 301], ["expansion", 303], ["in", 313], ["the", 316], ["3", 320], ["'", 321], ["untranslated", 323], ["region", 336], ["of", 343], ["DMPK", 346], ["in", 351], ["19q13.3", 354], [".", 361], ["Multiple", 363], ["families", 372], [",", 380], ["predominantly", 382], ["of", 396], ["German", 399], ["descent", 406], ["and", 414], ["with", 418], ["clinically", 423], ["variable", 434], ["presentation", 443], ["that", 456], ["included", 461], ["proximal", 470], ["myotonic", 479], ["myopathy", 488], ["(", 497], ["PROMM", 498], [")", 503], ["and", 505], ["type", 509], ["2", 514], ["DM", 516], ["(", 519], ["DM2", 520], [")", 523], ["but", 525], ["without", 529], ["the", 537], ["DM1", 541], ["mutation", 545], [",", 553], ["showed", 555], ["linkage", 562], ["to", 570], ["the", 573], ["3q21", 577], ["region", 582], ["and", 589], ["were", 593], ["recently", 598], ["shown", 607], ["to", 613], ["segregate", 616], ["a", 626], ["(", 628], ["CCTG)(n", 629], [")", 636], ["expansion", 638], ["mutation", 648], ["in", 657], ["intron", 660], ["1", 667], ["of", 669], ["ZNF9", 672], [".", 676], ["Here", 678], [",", 682], ["we", 684], ["present", 687], ["linkage", 695], ["to", 703], ["3q21", 706], ["and", 711], ["mutational", 715], ["confirmation", 726], ["in", 739], ["17", 742], ["kindreds", 745], ["of", 754], ["European", 757], ["origin", 766], ["with", 773], ["PROMM", 778], ["and", 784], ["proximal", 788], ["myotonic", 797], ["dystrophy", 806], [",", 815], ["from", 817], ["geographically", 822], ["distinct", 837], ["populations", 846], [".", 857], ["All", 859], ["patients", 863], ["have", 872], ["the", 877], ["DM2", 881], ["(", 885], ["CCTG)(n", 886], [")", 893], ["expansion", 895], [".", 904], ["To", 906], ["study", 909], ["the", 915], ["evolution", 919], ["of", 929], ["this", 932], ["mutation", 937], [",", 945], ["we", 947], ["constructed", 950], ["a", 962], ["comprehensive", 964], ["physical", 978], ["map", 987], ["of", 991], ["the", 994], ["DM2", 998], ["region", 1002], ["around", 1009], ["ZNF9", 1016], [".", 1020], ["High", 1022], ["-", 1026], ["resolution", 1027], ["haplotype", 1038], ["analysis", 1048], ["of", 1057], ["disease", 1060], ["chromosomes", 1068], ["with", 1080], ["five", 1085], ["microsatellite", 1090], ["and", 1105], ["22", 1109], ["single", 1112], ["-", 1118], ["nucleotide", 1119], ["polymorphism", 1130], ["markers", 1143], ["around", 1151], ["the", 1158], ["DM2", 1162], ["mutation", 1166], ["identified", 1175], ["extensive", 1186], ["linkage", 1196], ["disequilibrium", 1204], ["and", 1219], ["a", 1223], ["single", 1225], ["shared", 1232], ["haplotype", 1239], ["of", 1249], ["at", 1252], ["least", 1255], ["132", 1261], ["kb", 1265], ["among", 1268], ["patients", 1274], ["from", 1283], ["the", 1288], ["different", 1292], ["populations", 1302], [".", 1313], ["With", 1315], ["the", 1320], ["exception", 1324], ["of", 1334], ["the", 1337], ["(", 1341], ["CCTG)(n", 1342], [")", 1349], ["expansion", 1351], [",", 1360], ["the", 1362], ["available", 1366], ["markers", 1376], ["indicate", 1384], ["that", 1393], ["the", 1398], ["DM2", 1402], ["haplotype", 1406], ["is", 1416], ["identical", 1419], ["to", 1429], ["the", 1432], ["most", 1436], ["common", 1441], ["haplotype", 1448], ["in", 1458], ["normal", 1461], ["individuals", 1468], [".", 1479], ["This", 1481], ["situation", 1486], ["is", 1496], ["reminiscent", 1499], ["of", 1511], ["that", 1514], ["seen", 1519], ["in", 1524], ["DM1", 1527], [".", 1530], ["Taken", 1532], ["together", 1538], [",", 1546], ["these", 1548], ["data", 1554], ["suggest", 1559], ["a", 1567], ["single", 1569], ["founding", 1576], ["mutation", 1585], ["in", 1594], ["DM2", 1597], ["patients", 1601], ["of", 1610], ["European", 1613], ["origin", 1622], [".", 1628], ["We", 1630], ["estimate", 1633], ["the", 1642], ["age", 1646], ["of", 1650], ["the", 1653], ["founding", 1657], ["haplotype", 1666], ["and", 1676], ["of", 1680], ["the", 1683], ["DM2", 1687], ["(", 1691], ["CCTG", 1692], [")", 1696], ["expansion", 1698], ["mutation", 1708], ["to", 1717], ["be", 1720], ["approximately", 1723], ["200", 1737], ["-", 1740], ["540", 1741], ["generations", 1745], [".", 1756]]}
{"context": "Tanezumab is a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for chronic pain. This phase IIB study investigated the efficacy and safety of tanezumab for chronic low back pain vs placebo and naproxen. Patients (N=1347) received intravenous tanezumab (5, 10, or 20mg every 8weeks), naproxen (500mg twice daily), or placebo. The primary efficacy end point was mean change in daily average low back pain intensity (LBPI) from baseline to week 16. Secondary end points included mean change from baseline to week 16 in the Roland Morris Disability Questionnaire and Patient's Global Assessment (PGA) of low back pain. Tanezumab 10 and 20mg had similar efficacy profiles and significantly improved LBPI, Roland Morris Disability Questionnaire, and PGA scores vs both placebo and naproxen (P\u2a7d.05). Tanezumab 5mg provided improvement of PGA scores vs placebo (P\u2a7d.05), and naproxen resulted in significant improvement of LBPI vs placebo (P\u2a7d.05). Adverse event incidence was comparable across tanezumab doses but higher than with placebo or naproxen. Arthralgia, pain in extremity, headache, and paresthesia were the most commonly reported adverse events by tanezumab-treated patients. The most frequently reported adverse events resulting in discontinuation of tanezumab treatment were arthralgia and paresthesia; the highest frequency was observed with tanezumab 20mg (both 1.4%). Serious adverse event incidence was similar across treatments. In conclusion, tanezumab provided significantly greater improvement in pain, function, and global scores vs placebo and naproxen in patients with chronic low back pain.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "ccb9b1d3df6f45b2bb19557def943330", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[9, 11]], "char_spans": [[72, 90]]}]}], "context_tokens": [["Tanezumab", 0], ["is", 10], ["a", 13], ["humanized", 15], ["monoclonal", 25], ["antibody", 36], ["that", 45], ["specifically", 50], ["inhibits", 63], ["nerve", 72], ["growth", 78], ["factor", 85], ["as", 92], ["a", 95], ["treatment", 97], ["for", 107], ["chronic", 111], ["pain", 119], [".", 123], ["This", 125], ["phase", 130], ["IIB", 136], ["study", 140], ["investigated", 146], ["the", 159], ["efficacy", 163], ["and", 172], ["safety", 176], ["of", 183], ["tanezumab", 186], ["for", 196], ["chronic", 200], ["low", 208], ["back", 212], ["pain", 217], ["vs", 222], ["placebo", 225], ["and", 233], ["naproxen", 237], [".", 245], ["Patients", 247], ["(", 256], ["N=1347", 257], [")", 263], ["received", 265], ["intravenous", 274], ["tanezumab", 286], ["(", 296], ["5", 297], [",", 298], ["10", 300], [",", 302], ["or", 304], ["20", 307], ["mg", 309], ["every", 312], ["8weeks", 318], [")", 324], [",", 325], ["naproxen", 327], ["(", 336], ["500", 337], ["mg", 340], ["twice", 343], ["daily", 349], [")", 354], [",", 355], ["or", 357], ["placebo", 360], [".", 367], ["The", 369], ["primary", 373], ["efficacy", 381], ["end", 390], ["point", 394], ["was", 400], ["mean", 404], ["change", 409], ["in", 416], ["daily", 419], ["average", 425], ["low", 433], ["back", 437], ["pain", 442], ["intensity", 447], ["(", 457], ["LBPI", 458], [")", 462], ["from", 464], ["baseline", 469], ["to", 478], ["week", 481], ["16", 486], [".", 488], ["Secondary", 490], ["end", 500], ["points", 504], ["included", 511], ["mean", 520], ["change", 525], ["from", 532], ["baseline", 537], ["to", 546], ["week", 549], ["16", 554], ["in", 557], ["the", 560], ["Roland", 564], ["Morris", 571], ["Disability", 578], ["Questionnaire", 589], ["and", 603], ["Patient", 607], ["'s", 614], ["Global", 617], ["Assessment", 624], ["(", 635], ["PGA", 636], [")", 639], ["of", 641], ["low", 644], ["back", 648], ["pain", 653], [".", 657], ["Tanezumab", 659], ["10", 669], ["and", 672], ["20", 676], ["mg", 678], ["had", 681], ["similar", 685], ["efficacy", 693], ["profiles", 702], ["and", 711], ["significantly", 715], ["improved", 729], ["LBPI", 738], [",", 742], ["Roland", 744], ["Morris", 751], ["Disability", 758], ["Questionnaire", 769], [",", 782], ["and", 784], ["PGA", 788], ["scores", 792], ["vs", 799], ["both", 802], ["placebo", 807], ["and", 815], ["naproxen", 819], ["(", 828], ["P\u2a7d.05", 829], [")", 834], [".", 835], ["Tanezumab", 837], ["5", 847], ["mg", 848], ["provided", 851], ["improvement", 860], ["of", 872], ["PGA", 875], ["scores", 879], ["vs", 886], ["placebo", 889], ["(", 897], ["P\u2a7d.05", 898], [")", 903], [",", 904], ["and", 906], ["naproxen", 910], ["resulted", 919], ["in", 928], ["significant", 931], ["improvement", 943], ["of", 955], ["LBPI", 958], ["vs", 963], ["placebo", 966], ["(", 974], ["P\u2a7d.05", 975], [")", 980], [".", 981], ["Adverse", 983], ["event", 991], ["incidence", 997], ["was", 1007], ["comparable", 1011], ["across", 1022], ["tanezumab", 1029], ["doses", 1039], ["but", 1045], ["higher", 1049], ["than", 1056], ["with", 1061], ["placebo", 1066], ["or", 1074], ["naproxen", 1077], [".", 1085], ["Arthralgia", 1087], [",", 1097], ["pain", 1099], ["in", 1104], ["extremity", 1107], [",", 1116], ["headache", 1118], [",", 1126], ["and", 1128], ["paresthesia", 1132], ["were", 1144], ["the", 1149], ["most", 1153], ["commonly", 1158], ["reported", 1167], ["adverse", 1176], ["events", 1184], ["by", 1191], ["tanezumab", 1194], ["-", 1203], ["treated", 1204], ["patients", 1212], [".", 1220], ["The", 1222], ["most", 1226], ["frequently", 1231], ["reported", 1242], ["adverse", 1251], ["events", 1259], ["resulting", 1266], ["in", 1276], ["discontinuation", 1279], ["of", 1295], ["tanezumab", 1298], ["treatment", 1308], ["were", 1318], ["arthralgia", 1323], ["and", 1334], ["paresthesia", 1338], [";", 1349], ["the", 1351], ["highest", 1355], ["frequency", 1363], ["was", 1373], ["observed", 1377], ["with", 1386], ["tanezumab", 1391], ["20", 1401], ["mg", 1403], ["(", 1406], ["both", 1407], ["1.4", 1412], ["%", 1415], [")", 1416], [".", 1417], ["Serious", 1419], ["adverse", 1427], ["event", 1435], ["incidence", 1441], ["was", 1451], ["similar", 1455], ["across", 1463], ["treatments", 1470], [".", 1480], ["In", 1482], ["conclusion", 1485], [",", 1495], ["tanezumab", 1497], ["provided", 1507], ["significantly", 1516], ["greater", 1530], ["improvement", 1538], ["in", 1550], ["pain", 1553], [",", 1557], ["function", 1559], [",", 1567], ["and", 1569], ["global", 1573], ["scores", 1580], ["vs", 1587], ["placebo", 1590], ["and", 1598], ["naproxen", 1602], ["in", 1611], ["patients", 1614], ["with", 1623], ["chronic", 1628], ["low", 1636], ["back", 1640], ["pain", 1645], [".", 1649]]}
{"context": "Interleukin-1\u03b2 (IL-1\u03b2) is a potent mediator of inflammatory responses and plays a role in the differentiation of a number of lymphoid cells. In several inflammatory and autoimmune diseases, serum levels of IL-1\u03b2 are elevated and correlate with disease development and severity. The central role of the IL-1 pathway in several diseases has been validated by inhibitors currently in clinical development or approved by the FDA. However, the need to effectively modulate IL-1\u03b2-mediated local inflammation with the systemic delivery of an efficacious, safe and convenient drug still exists. To meet these challenges, we developed XOMA 052 (gevokizumab), a potent anti-IL-1\u03b2 neutralizing antibody that was designed in silico and humanized using Human Engineering\u2122 technology. XOMA 052 has a 300 femtomolar binding affinity for human IL-1\u03b2 and an in vitro potency in the low picomolar range. XOMA 052 binds to a unique IL-1\u03b2 epitope where residues critical for binding have been identified. We have previously reported that XOMA 052 is efficacious in vivo in a diet-induced obesity mouse model thought to be driven by low levels of chronic inflammation. We report here that XOMA 052 also reduces acute inflammation in vivo, neutralizing the effect of exogenously administered human IL-1\u03b2 and blocking peritonitis in a mouse model of acute gout. Based on its high potency, novel mechanism of action, long half-life, and high affinity, XOMA 052 provides a new strategy for the treatment of a number of inflammatory, autoimmune and metabolic diseases in which the role of IL-1\u03b2 is central to pathogenesis.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "f129d78a420746cd9b0364aa8ac1fa28", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[141, 141], [35, 35], [115, 115], [2, 2], [220, 220], [276, 276], [78, 78], [159, 159]], "char_spans": [[828, 832], [206, 210], [664, 668], [16, 20], [1276, 1280], [1563, 1567], [468, 472], [913, 917]]}]}], "context_tokens": [["Interleukin-1\u03b2", 0], ["(", 15], ["IL-1\u03b2", 16], [")", 21], ["is", 23], ["a", 26], ["potent", 28], ["mediator", 35], ["of", 44], ["inflammatory", 47], ["responses", 60], ["and", 70], ["plays", 74], ["a", 80], ["role", 82], ["in", 87], ["the", 90], ["differentiation", 94], ["of", 110], ["a", 113], ["number", 115], ["of", 122], ["lymphoid", 125], ["cells", 134], [".", 139], ["In", 141], ["several", 144], ["inflammatory", 152], ["and", 165], ["autoimmune", 169], ["diseases", 180], [",", 188], ["serum", 190], ["levels", 196], ["of", 203], ["IL-1\u03b2", 206], ["are", 212], ["elevated", 216], ["and", 225], ["correlate", 229], ["with", 239], ["disease", 244], ["development", 252], ["and", 264], ["severity", 268], [".", 276], ["The", 278], ["central", 282], ["role", 290], ["of", 295], ["the", 298], ["IL-1", 302], ["pathway", 307], ["in", 315], ["several", 318], ["diseases", 326], ["has", 335], ["been", 339], ["validated", 344], ["by", 354], ["inhibitors", 357], ["currently", 368], ["in", 378], ["clinical", 381], ["development", 390], ["or", 402], ["approved", 405], ["by", 414], ["the", 417], ["FDA", 421], [".", 424], ["However", 426], [",", 433], ["the", 435], ["need", 439], ["to", 444], ["effectively", 447], ["modulate", 459], ["IL-1\u03b2", 468], ["-", 473], ["mediated", 474], ["local", 483], ["inflammation", 489], ["with", 502], ["the", 507], ["systemic", 511], ["delivery", 520], ["of", 529], ["an", 532], ["efficacious", 535], [",", 546], ["safe", 548], ["and", 553], ["convenient", 557], ["drug", 568], ["still", 573], ["exists", 579], [".", 585], ["To", 587], ["meet", 590], ["these", 595], ["challenges", 601], [",", 611], ["we", 613], ["developed", 616], ["XOMA", 626], ["052", 631], ["(", 635], ["gevokizumab", 636], [")", 647], [",", 648], ["a", 650], ["potent", 652], ["anti", 659], ["-", 663], ["IL-1\u03b2", 664], ["neutralizing", 670], ["antibody", 683], ["that", 692], ["was", 697], ["designed", 701], ["in", 710], ["silico", 713], ["and", 720], ["humanized", 724], ["using", 734], ["Human", 740], ["Engineering", 746], ["\u2122", 757], ["technology", 759], [".", 769], ["XOMA", 771], ["052", 776], ["has", 780], ["a", 784], ["300", 786], ["femtomolar", 790], ["binding", 801], ["affinity", 809], ["for", 818], ["human", 822], ["IL-1\u03b2", 828], ["and", 834], ["an", 838], ["in", 841], ["vitro", 844], ["potency", 850], ["in", 858], ["the", 861], ["low", 865], ["picomolar", 869], ["range", 879], [".", 884], ["XOMA", 886], ["052", 891], ["binds", 895], ["to", 901], ["a", 904], ["unique", 906], ["IL-1\u03b2", 913], ["epitope", 919], ["where", 927], ["residues", 933], ["critical", 942], ["for", 951], ["binding", 955], ["have", 963], ["been", 968], ["identified", 973], [".", 983], ["We", 985], ["have", 988], ["previously", 993], ["reported", 1004], ["that", 1013], ["XOMA", 1018], ["052", 1023], ["is", 1027], ["efficacious", 1030], ["in", 1042], ["vivo", 1045], ["in", 1050], ["a", 1053], ["diet", 1055], ["-", 1059], ["induced", 1060], ["obesity", 1068], ["mouse", 1076], ["model", 1082], ["thought", 1088], ["to", 1096], ["be", 1099], ["driven", 1102], ["by", 1109], ["low", 1112], ["levels", 1116], ["of", 1123], ["chronic", 1126], ["inflammation", 1134], [".", 1146], ["We", 1148], ["report", 1151], ["here", 1158], ["that", 1163], ["XOMA", 1168], ["052", 1173], ["also", 1177], ["reduces", 1182], ["acute", 1190], ["inflammation", 1196], ["in", 1209], ["vivo", 1212], [",", 1216], ["neutralizing", 1218], ["the", 1231], ["effect", 1235], ["of", 1242], ["exogenously", 1245], ["administered", 1257], ["human", 1270], ["IL-1\u03b2", 1276], ["and", 1282], ["blocking", 1286], ["peritonitis", 1295], ["in", 1307], ["a", 1310], ["mouse", 1312], ["model", 1318], ["of", 1324], ["acute", 1327], ["gout", 1333], [".", 1337], ["Based", 1339], ["on", 1345], ["its", 1348], ["high", 1352], ["potency", 1357], [",", 1364], ["novel", 1366], ["mechanism", 1372], ["of", 1382], ["action", 1385], [",", 1391], ["long", 1393], ["half", 1398], ["-", 1402], ["life", 1403], [",", 1407], ["and", 1409], ["high", 1413], ["affinity", 1418], [",", 1426], ["XOMA", 1428], ["052", 1433], ["provides", 1437], ["a", 1446], ["new", 1448], ["strategy", 1452], ["for", 1461], ["the", 1465], ["treatment", 1469], ["of", 1479], ["a", 1482], ["number", 1484], ["of", 1491], ["inflammatory", 1494], [",", 1506], ["autoimmune", 1508], ["and", 1519], ["metabolic", 1523], ["diseases", 1533], ["in", 1542], ["which", 1545], ["the", 1551], ["role", 1555], ["of", 1560], ["IL-1\u03b2", 1563], ["is", 1569], ["central", 1572], ["to", 1580], ["pathogenesis", 1583], [".", 1595]]}
{"context": "Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium. But there is no consensus as to what constitutes an alpha-proteobacterial gene. Is it a gene found in all or several alpha-proteobacteria, or in only one? Here, we examine the proportion of alpha-proteobacterial genes in alpha-proteobacterial genomes by means of sequence comparisons. We find that each alpha-proteobacterium harbours a particular collection of genes and that, depending upon the lineage examined, between 97 and 33% are alpha-proteobacterial by the nearest-neighbour criterion. Our findings bear upon attempts to reconstruct the mitochondrial ancestor and upon inferences concerning the collection of genes that the mitochondrial ancestor possessed at the time that it became an endosymbiont.", "qas": [{"question": "Which species of bacteria did the mitochondria originate from?", "answers": ["Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium."], "qid": "1bcd341d9896445e8554027ad01ed066", "question_tokens": [["Which", 0], ["species", 6], ["of", 14], ["bacteria", 17], ["did", 26], ["the", 30], ["mitochondria", 34], ["originate", 47], ["from", 57], ["?", 61]], "detected_answers": [{"text": "Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium.", "token_spans": [[0, 11]], "char_spans": [[0, 78]]}]}], "context_tokens": [["Biologists", 0], ["agree", 11], ["that", 17], ["the", 22], ["ancestor", 26], ["of", 35], ["mitochondria", 38], ["was", 51], ["an", 55], ["alpha", 58], ["-", 63], ["proteobacterium", 64], [".", 79], ["But", 81], ["there", 85], ["is", 91], ["no", 94], ["consensus", 97], ["as", 107], ["to", 110], ["what", 113], ["constitutes", 118], ["an", 130], ["alpha", 133], ["-", 138], ["proteobacterial", 139], ["gene", 155], [".", 159], ["Is", 161], ["it", 164], ["a", 167], ["gene", 169], ["found", 174], ["in", 180], ["all", 183], ["or", 187], ["several", 190], ["alpha", 198], ["-", 203], ["proteobacteria", 204], [",", 218], ["or", 220], ["in", 223], ["only", 226], ["one", 231], ["?", 234], ["Here", 236], [",", 240], ["we", 242], ["examine", 245], ["the", 253], ["proportion", 257], ["of", 268], ["alpha", 271], ["-", 276], ["proteobacterial", 277], ["genes", 293], ["in", 299], ["alpha", 302], ["-", 307], ["proteobacterial", 308], ["genomes", 324], ["by", 332], ["means", 335], ["of", 341], ["sequence", 344], ["comparisons", 353], [".", 364], ["We", 366], ["find", 369], ["that", 374], ["each", 379], ["alpha", 384], ["-", 389], ["proteobacterium", 390], ["harbours", 406], ["a", 415], ["particular", 417], ["collection", 428], ["of", 439], ["genes", 442], ["and", 448], ["that", 452], [",", 456], ["depending", 458], ["upon", 468], ["the", 473], ["lineage", 477], ["examined", 485], [",", 493], ["between", 495], ["97", 503], ["and", 506], ["33", 510], ["%", 512], ["are", 514], ["alpha", 518], ["-", 523], ["proteobacterial", 524], ["by", 540], ["the", 543], ["nearest", 547], ["-", 554], ["neighbour", 555], ["criterion", 565], [".", 574], ["Our", 576], ["findings", 580], ["bear", 589], ["upon", 594], ["attempts", 599], ["to", 608], ["reconstruct", 611], ["the", 623], ["mitochondrial", 627], ["ancestor", 641], ["and", 650], ["upon", 654], ["inferences", 659], ["concerning", 670], ["the", 681], ["collection", 685], ["of", 696], ["genes", 699], ["that", 705], ["the", 710], ["mitochondrial", 714], ["ancestor", 728], ["possessed", 737], ["at", 747], ["the", 750], ["time", 754], ["that", 759], ["it", 764], ["became", 767], ["an", 774], ["endosymbiont", 777], [".", 789]]}
{"context": "The gangliosidoses comprise a family of lysosomal storage diseases characterized by the accumulation of complex glycosphingolipids in the nervous system and other tissues, secondary to the deficient activity of lysosomal hydrolases or their associated activator proteins. GM1 and GM2 gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase respectively. All gangliosidoses are characterized by progressive neurodegeneration, the severity of which is proportional to the residual enzyme activity. The GM1 gangliosidoses are characterized by dysostosis, organomegaly and coarsening in their most severe forms, whereas children with classic infantile GM2 gangliosidosis (Tay-Sachs disease) are usually spared systemic involvement, except in the case of the Sandhoff variant, in which organomegaly may occur. Cherry-red macular spots occur in the early onset forms of the gangliosidoses, but are less frequently seen in the less severe, later onset phenotypes. Macrocephaly, an exaggerated startle response, cognitive decline, seizures, ataxia, and progressive muscular atrophy may occur in different forms of gangliosidosis. The diagnosis is made by assay of enzyme activity, and can be confirmed by mutation analysis. Carrier screening for Tay-Sachs disease has been remarkably successful in reducing the incidence of this disease in the at-risk Ashkenazi population. There are no proven disease-modifying therapies for the gangliosidoses.", "qas": [{"question": "Which enzyme deficiency can cause GM1 gangliosidoses?", "answers": ["\u03b2-galactosidase"], "qid": "91ba5f0e9cdb420b8e49daf63935d388", "question_tokens": [["Which", 0], ["enzyme", 6], ["deficiency", 13], ["can", 24], ["cause", 28], ["GM1", 34], ["gangliosidoses", 38], ["?", 52]], "detected_answers": [{"text": "\u03b2-galactosidase", "token_spans": [[47, 49]], "char_spans": [[333, 347]]}]}], "context_tokens": [["The", 0], ["gangliosidoses", 4], ["comprise", 19], ["a", 28], ["family", 30], ["of", 37], ["lysosomal", 40], ["storage", 50], ["diseases", 58], ["characterized", 67], ["by", 81], ["the", 84], ["accumulation", 88], ["of", 101], ["complex", 104], ["glycosphingolipids", 112], ["in", 131], ["the", 134], ["nervous", 138], ["system", 146], ["and", 153], ["other", 157], ["tissues", 163], [",", 170], ["secondary", 172], ["to", 182], ["the", 185], ["deficient", 189], ["activity", 199], ["of", 208], ["lysosomal", 211], ["hydrolases", 221], ["or", 232], ["their", 235], ["associated", 241], ["activator", 252], ["proteins", 262], [".", 270], ["GM1", 272], ["and", 276], ["GM2", 280], ["gangliosidosis", 284], ["are", 299], ["associated", 303], ["with", 314], ["deficiency", 319], ["of", 330], ["\u03b2", 333], ["-", 334], ["galactosidase", 335], ["and", 349], ["\u03b2", 353], ["-", 354], ["hexosaminidase", 355], ["respectively", 370], [".", 382], ["All", 384], ["gangliosidoses", 388], ["are", 403], ["characterized", 407], ["by", 421], ["progressive", 424], ["neurodegeneration", 436], [",", 453], ["the", 455], ["severity", 459], ["of", 468], ["which", 471], ["is", 477], ["proportional", 480], ["to", 493], ["the", 496], ["residual", 500], ["enzyme", 509], ["activity", 516], [".", 524], ["The", 526], ["GM1", 530], ["gangliosidoses", 534], ["are", 549], ["characterized", 553], ["by", 567], ["dysostosis", 570], [",", 580], ["organomegaly", 582], ["and", 595], ["coarsening", 599], ["in", 610], ["their", 613], ["most", 619], ["severe", 624], ["forms", 631], [",", 636], ["whereas", 638], ["children", 646], ["with", 655], ["classic", 660], ["infantile", 668], ["GM2", 678], ["gangliosidosis", 682], ["(", 697], ["Tay", 698], ["-", 701], ["Sachs", 702], ["disease", 708], [")", 715], ["are", 717], ["usually", 721], ["spared", 729], ["systemic", 736], ["involvement", 745], [",", 756], ["except", 758], ["in", 765], ["the", 768], ["case", 772], ["of", 777], ["the", 780], ["Sandhoff", 784], ["variant", 793], [",", 800], ["in", 802], ["which", 805], ["organomegaly", 811], ["may", 824], ["occur", 828], [".", 833], ["Cherry", 835], ["-", 841], ["red", 842], ["macular", 846], ["spots", 854], ["occur", 860], ["in", 866], ["the", 869], ["early", 873], ["onset", 879], ["forms", 885], ["of", 891], ["the", 894], ["gangliosidoses", 898], [",", 912], ["but", 914], ["are", 918], ["less", 922], ["frequently", 927], ["seen", 938], ["in", 943], ["the", 946], ["less", 950], ["severe", 955], [",", 961], ["later", 963], ["onset", 969], ["phenotypes", 975], [".", 985], ["Macrocephaly", 987], [",", 999], ["an", 1001], ["exaggerated", 1004], ["startle", 1016], ["response", 1024], [",", 1032], ["cognitive", 1034], ["decline", 1044], [",", 1051], ["seizures", 1053], [",", 1061], ["ataxia", 1063], [",", 1069], ["and", 1071], ["progressive", 1075], ["muscular", 1087], ["atrophy", 1096], ["may", 1104], ["occur", 1108], ["in", 1114], ["different", 1117], ["forms", 1127], ["of", 1133], ["gangliosidosis", 1136], [".", 1150], ["The", 1152], ["diagnosis", 1156], ["is", 1166], ["made", 1169], ["by", 1174], ["assay", 1177], ["of", 1183], ["enzyme", 1186], ["activity", 1193], [",", 1201], ["and", 1203], ["can", 1207], ["be", 1211], ["confirmed", 1214], ["by", 1224], ["mutation", 1227], ["analysis", 1236], [".", 1244], ["Carrier", 1246], ["screening", 1254], ["for", 1264], ["Tay", 1268], ["-", 1271], ["Sachs", 1272], ["disease", 1278], ["has", 1286], ["been", 1290], ["remarkably", 1295], ["successful", 1306], ["in", 1317], ["reducing", 1320], ["the", 1329], ["incidence", 1333], ["of", 1343], ["this", 1346], ["disease", 1351], ["in", 1359], ["the", 1362], ["at", 1366], ["-", 1368], ["risk", 1369], ["Ashkenazi", 1374], ["population", 1384], [".", 1394], ["There", 1396], ["are", 1402], ["no", 1406], ["proven", 1409], ["disease", 1416], ["-", 1423], ["modifying", 1424], ["therapies", 1434], ["for", 1444], ["the", 1448], ["gangliosidoses", 1452], [".", 1466]]}
{"context": "Human \u03b1-synuclein is a small-sized, natively unfolded protein that in fibrillar form is the primary component of Lewy bodies, the pathological hallmark of Parkinson's disease. Experimental evidence suggests that \u03b1-synuclein aggregation is the key event that triggers neurotoxicity although additional findings have proposed a protective role of \u03b1-synuclein against oxidative stress. One way to address the mechanism of this protective action is to evaluate \u03b1-synuclein-mediated protection by delivering this protein inside cells using a chimeric protein fused with the Tat-transduction domain of HIV Tat, named TAT-\u03b1-synuclein. A reliable protocol was designed to efficiently express and purify two different forms of human \u03b1-synuclein. The synthetic cDNAs encoding for the native \u03b1-synuclein and the fusion protein with the transduction domain of Tat protein from HIV were overexpressed in a BL21(DE3) E. coli strain as His-tagged proteins. The recombinant proteins largely localized (\u2265 85%) to the periplasmic space. By using a quick purification protocol, based on recovery of periplasmic space content and metal-chelating chromatography, the recombinant \u03b1-synuclein protein forms could be purified in a single step to \u2265 95% purity. Both \u03b1-synuclein recombinant proteins form fibrils and the TAT-\u03b1-synuclein is also cytotoxic in the micromolar concentration range. To further characterize the molecular mechanisms of \u03b1-synuclein neurotoxicity both in vitro and in vivo and to evaluate the relevance of extracellular \u03b1-synuclein for the pathogenesis and progression of Parkinson's disease, a suitable method to produce different high-quality forms of this pathological protein is required. Our optimized expression and purification procedure offers an easier and faster means of producing different forms (i.e., both the native and the TAT-fusion form) of soluble recombinant \u03b1-synuclein than previously described procedures.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "2270a17d1c8b4ecba24ad304bcb2f5ad", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[1, 3], [126, 128], [254, 256], [235, 237], [37, 39], [77, 79], [205, 207], [333, 335], [57, 59], [137, 139], [271, 273], [224, 226], [107, 109]], "char_spans": [[6, 16], [724, 734], [1420, 1430], [1299, 1309], [212, 222], [457, 467], [1158, 1168], [1878, 1888], [345, 355], [781, 791], [1519, 1529], [1241, 1251], [615, 625]]}]}], "context_tokens": [["Human", 0], ["\u03b1", 6], ["-", 7], ["synuclein", 8], ["is", 18], ["a", 21], ["small", 23], ["-", 28], ["sized", 29], [",", 34], ["natively", 36], ["unfolded", 45], ["protein", 54], ["that", 62], ["in", 67], ["fibrillar", 70], ["form", 80], ["is", 85], ["the", 88], ["primary", 92], ["component", 100], ["of", 110], ["Lewy", 113], ["bodies", 118], [",", 124], ["the", 126], ["pathological", 130], ["hallmark", 143], ["of", 152], ["Parkinson", 155], ["'s", 164], ["disease", 167], [".", 174], ["Experimental", 176], ["evidence", 189], ["suggests", 198], ["that", 207], ["\u03b1", 212], ["-", 213], ["synuclein", 214], ["aggregation", 224], ["is", 236], ["the", 239], ["key", 243], ["event", 247], ["that", 253], ["triggers", 258], ["neurotoxicity", 267], ["although", 281], ["additional", 290], ["findings", 301], ["have", 310], ["proposed", 315], ["a", 324], ["protective", 326], ["role", 337], ["of", 342], ["\u03b1", 345], ["-", 346], ["synuclein", 347], ["against", 357], ["oxidative", 365], ["stress", 375], [".", 381], ["One", 383], ["way", 387], ["to", 391], ["address", 394], ["the", 402], ["mechanism", 406], ["of", 416], ["this", 419], ["protective", 424], ["action", 435], ["is", 442], ["to", 445], ["evaluate", 448], ["\u03b1", 457], ["-", 458], ["synuclein", 459], ["-", 468], ["mediated", 469], ["protection", 478], ["by", 489], ["delivering", 492], ["this", 503], ["protein", 508], ["inside", 516], ["cells", 523], ["using", 529], ["a", 535], ["chimeric", 537], ["protein", 546], ["fused", 554], ["with", 560], ["the", 565], ["Tat", 569], ["-", 572], ["transduction", 573], ["domain", 586], ["of", 593], ["HIV", 596], ["Tat", 600], [",", 603], ["named", 605], ["TAT", 611], ["-", 614], ["\u03b1", 615], ["-", 616], ["synuclein", 617], [".", 626], ["A", 628], ["reliable", 630], ["protocol", 639], ["was", 648], ["designed", 652], ["to", 661], ["efficiently", 664], ["express", 676], ["and", 684], ["purify", 688], ["two", 695], ["different", 699], ["forms", 709], ["of", 715], ["human", 718], ["\u03b1", 724], ["-", 725], ["synuclein", 726], [".", 735], ["The", 737], ["synthetic", 741], ["cDNAs", 751], ["encoding", 757], ["for", 766], ["the", 770], ["native", 774], ["\u03b1", 781], ["-", 782], ["synuclein", 783], ["and", 793], ["the", 797], ["fusion", 801], ["protein", 808], ["with", 816], ["the", 821], ["transduction", 825], ["domain", 838], ["of", 845], ["Tat", 848], ["protein", 852], ["from", 860], ["HIV", 865], ["were", 869], ["overexpressed", 874], ["in", 888], ["a", 891], ["BL21(DE3", 893], [")", 901], ["E.", 903], ["coli", 906], ["strain", 911], ["as", 918], ["His", 921], ["-", 924], ["tagged", 925], ["proteins", 932], [".", 940], ["The", 942], ["recombinant", 946], ["proteins", 958], ["largely", 967], ["localized", 975], ["(", 985], ["\u2265", 986], ["85", 988], ["%", 990], [")", 991], ["to", 993], ["the", 996], ["periplasmic", 1000], ["space", 1012], [".", 1017], ["By", 1019], ["using", 1022], ["a", 1028], ["quick", 1030], ["purification", 1036], ["protocol", 1049], [",", 1057], ["based", 1059], ["on", 1065], ["recovery", 1068], ["of", 1077], ["periplasmic", 1080], ["space", 1092], ["content", 1098], ["and", 1106], ["metal", 1110], ["-", 1115], ["chelating", 1116], ["chromatography", 1126], [",", 1140], ["the", 1142], ["recombinant", 1146], ["\u03b1", 1158], ["-", 1159], ["synuclein", 1160], ["protein", 1170], ["forms", 1178], ["could", 1184], ["be", 1190], ["purified", 1193], ["in", 1202], ["a", 1205], ["single", 1207], ["step", 1214], ["to", 1219], ["\u2265", 1222], ["95", 1224], ["%", 1226], ["purity", 1228], [".", 1234], ["Both", 1236], ["\u03b1", 1241], ["-", 1242], ["synuclein", 1243], ["recombinant", 1253], ["proteins", 1265], ["form", 1274], ["fibrils", 1279], ["and", 1287], ["the", 1291], ["TAT", 1295], ["-", 1298], ["\u03b1", 1299], ["-", 1300], ["synuclein", 1301], ["is", 1311], ["also", 1314], ["cytotoxic", 1319], ["in", 1329], ["the", 1332], ["micromolar", 1336], ["concentration", 1347], ["range", 1361], [".", 1366], ["To", 1368], ["further", 1371], ["characterize", 1379], ["the", 1392], ["molecular", 1396], ["mechanisms", 1406], ["of", 1417], ["\u03b1", 1420], ["-", 1421], ["synuclein", 1422], ["neurotoxicity", 1432], ["both", 1446], ["in", 1451], ["vitro", 1454], ["and", 1460], ["in", 1464], ["vivo", 1467], ["and", 1472], ["to", 1476], ["evaluate", 1479], ["the", 1488], ["relevance", 1492], ["of", 1502], ["extracellular", 1505], ["\u03b1", 1519], ["-", 1520], ["synuclein", 1521], ["for", 1531], ["the", 1535], ["pathogenesis", 1539], ["and", 1552], ["progression", 1556], ["of", 1568], ["Parkinson", 1571], ["'s", 1580], ["disease", 1583], [",", 1590], ["a", 1592], ["suitable", 1594], ["method", 1603], ["to", 1610], ["produce", 1613], ["different", 1621], ["high", 1631], ["-", 1635], ["quality", 1636], ["forms", 1644], ["of", 1650], ["this", 1653], ["pathological", 1658], ["protein", 1671], ["is", 1679], ["required", 1682], [".", 1690], ["Our", 1692], ["optimized", 1696], ["expression", 1706], ["and", 1717], ["purification", 1721], ["procedure", 1734], ["offers", 1744], ["an", 1751], ["easier", 1754], ["and", 1761], ["faster", 1765], ["means", 1772], ["of", 1778], ["producing", 1781], ["different", 1791], ["forms", 1801], ["(", 1807], ["i.e.", 1808], [",", 1812], ["both", 1814], ["the", 1819], ["native", 1823], ["and", 1830], ["the", 1834], ["TAT", 1838], ["-", 1841], ["fusion", 1842], ["form", 1849], [")", 1853], ["of", 1855], ["soluble", 1858], ["recombinant", 1866], ["\u03b1", 1878], ["-", 1879], ["synuclein", 1880], ["than", 1890], ["previously", 1895], ["described", 1906], ["procedures", 1916], [".", 1926]]}
{"context": "Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an autosomal dominant heart muscle disorder that causes arrhythmia, heart failure, and sudden death. Previously we mapped the genetic locus for the triad of autosomal recessive ARVC, palmoplantar keratoderma, and woolly hair (Naxos disease) to chromosome 17q21, in which the gene for plakoglobin is encoded. This protein is a key component of desmosomes and adherens junctions, and is important for the tight adhesion of many cell types, including those in the heart and skin. We studied 19 individuals with Naxos disease, as well as unaffected family members and unrelated individuals from the neighbouring Greek islands of Naxos and Milos. Gene sequence was determined by reverse transcriptase PCR from RNA isolated from the skin of an affected individual and mutations in other cases were confirmed by restriction-enzyme analysis. A homozygous 2 base pair deletion in the plakoglobin gene was identified only in the 19 affected individuals. This deletion caused a frameshift and premature termination of the protein, which was shown by western blot analysis. 29 clinically unaffected family members were heterozygous for the mutation; 20 unrelated individuals from Naxos and 43 autosomal dominant ARVC probands were homozygous for the normal allele. The finding of a deletion in plakoglobin in ARVC suggests that the proteins involved in cell-cell adhesion play an important part in maintaining myocyte integrity, and when junctions are disrupted, cell death, and fibrofatty replacement occur. Therefore, the discovery of a mutation in a protein with functions in maintaining cell junction integrity has important implications for other dominant forms of ARVC, related cardiomyopathies, and other cutaneous diseases.", "qas": [{"question": "Which gene is mutated in a subtype of arrhythmogenic right ventricular cardiomyopathy known as Naxos disease?", "answers": ["The Plakoglobin gene", "plakoglobin[jup]"], "qid": "204004adaf394da29332aa0a6d83a243", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["mutated", 14], ["in", 22], ["a", 25], ["subtype", 27], ["of", 35], ["arrhythmogenic", 38], ["right", 53], ["ventricular", 59], ["cardiomyopathy", 71], ["known", 86], ["as", 92], ["Naxos", 95], ["disease", 101], ["?", 108]], "detected_answers": [{"text": "The Plakoglobin gene", "token_spans": [[160, 161]], "char_spans": [[933, 948]]}]}], "context_tokens": [["Arrhythmogenic", 0], ["right", 15], ["ventricular", 21], ["cardiomyopathy", 33], ["(", 48], ["ARVC", 49], [")", 53], ["is", 55], ["an", 58], ["autosomal", 61], ["dominant", 71], ["heart", 80], ["muscle", 86], ["disorder", 93], ["that", 102], ["causes", 107], ["arrhythmia", 114], [",", 124], ["heart", 126], ["failure", 132], [",", 139], ["and", 141], ["sudden", 145], ["death", 152], [".", 157], ["Previously", 159], ["we", 170], ["mapped", 173], ["the", 180], ["genetic", 184], ["locus", 192], ["for", 198], ["the", 202], ["triad", 206], ["of", 212], ["autosomal", 215], ["recessive", 225], ["ARVC", 235], [",", 239], ["palmoplantar", 241], ["keratoderma", 254], [",", 265], ["and", 267], ["woolly", 271], ["hair", 278], ["(", 283], ["Naxos", 284], ["disease", 290], [")", 297], ["to", 299], ["chromosome", 302], ["17q21", 313], [",", 318], ["in", 320], ["which", 323], ["the", 329], ["gene", 333], ["for", 338], ["plakoglobin", 342], ["is", 354], ["encoded", 357], [".", 364], ["This", 366], ["protein", 371], ["is", 379], ["a", 382], ["key", 384], ["component", 388], ["of", 398], ["desmosomes", 401], ["and", 412], ["adherens", 416], ["junctions", 425], [",", 434], ["and", 436], ["is", 440], ["important", 443], ["for", 453], ["the", 457], ["tight", 461], ["adhesion", 467], ["of", 476], ["many", 479], ["cell", 484], ["types", 489], [",", 494], ["including", 496], ["those", 506], ["in", 512], ["the", 515], ["heart", 519], ["and", 525], ["skin", 529], [".", 533], ["We", 535], ["studied", 538], ["19", 546], ["individuals", 549], ["with", 561], ["Naxos", 566], ["disease", 572], [",", 579], ["as", 581], ["well", 584], ["as", 589], ["unaffected", 592], ["family", 603], ["members", 610], ["and", 618], ["unrelated", 622], ["individuals", 632], ["from", 644], ["the", 649], ["neighbouring", 653], ["Greek", 666], ["islands", 672], ["of", 680], ["Naxos", 683], ["and", 689], ["Milos", 693], [".", 698], ["Gene", 700], ["sequence", 705], ["was", 714], ["determined", 718], ["by", 729], ["reverse", 732], ["transcriptase", 740], ["PCR", 754], ["from", 758], ["RNA", 763], ["isolated", 767], ["from", 776], ["the", 781], ["skin", 785], ["of", 790], ["an", 793], ["affected", 796], ["individual", 805], ["and", 816], ["mutations", 820], ["in", 830], ["other", 833], ["cases", 839], ["were", 845], ["confirmed", 850], ["by", 860], ["restriction", 863], ["-", 874], ["enzyme", 875], ["analysis", 882], [".", 890], ["A", 892], ["homozygous", 894], ["2", 905], ["base", 907], ["pair", 912], ["deletion", 917], ["in", 926], ["the", 929], ["plakoglobin", 933], ["gene", 945], ["was", 950], ["identified", 954], ["only", 965], ["in", 970], ["the", 973], ["19", 977], ["affected", 980], ["individuals", 989], [".", 1000], ["This", 1002], ["deletion", 1007], ["caused", 1016], ["a", 1023], ["frameshift", 1025], ["and", 1036], ["premature", 1040], ["termination", 1050], ["of", 1062], ["the", 1065], ["protein", 1069], [",", 1076], ["which", 1078], ["was", 1084], ["shown", 1088], ["by", 1094], ["western", 1097], ["blot", 1105], ["analysis", 1110], [".", 1118], ["29", 1120], ["clinically", 1123], ["unaffected", 1134], ["family", 1145], ["members", 1152], ["were", 1160], ["heterozygous", 1165], ["for", 1178], ["the", 1182], ["mutation", 1186], [";", 1194], ["20", 1196], ["unrelated", 1199], ["individuals", 1209], ["from", 1221], ["Naxos", 1226], ["and", 1232], ["43", 1236], ["autosomal", 1239], ["dominant", 1249], ["ARVC", 1258], ["probands", 1263], ["were", 1272], ["homozygous", 1277], ["for", 1288], ["the", 1292], ["normal", 1296], ["allele", 1303], [".", 1309], ["The", 1311], ["finding", 1315], ["of", 1323], ["a", 1326], ["deletion", 1328], ["in", 1337], ["plakoglobin", 1340], ["in", 1352], ["ARVC", 1355], ["suggests", 1360], ["that", 1369], ["the", 1374], ["proteins", 1378], ["involved", 1387], ["in", 1396], ["cell", 1399], ["-", 1403], ["cell", 1404], ["adhesion", 1409], ["play", 1418], ["an", 1423], ["important", 1426], ["part", 1436], ["in", 1441], ["maintaining", 1444], ["myocyte", 1456], ["integrity", 1464], [",", 1473], ["and", 1475], ["when", 1479], ["junctions", 1484], ["are", 1494], ["disrupted", 1498], [",", 1507], ["cell", 1509], ["death", 1514], [",", 1519], ["and", 1521], ["fibrofatty", 1525], ["replacement", 1536], ["occur", 1548], [".", 1553], ["Therefore", 1555], [",", 1564], ["the", 1566], ["discovery", 1570], ["of", 1580], ["a", 1583], ["mutation", 1585], ["in", 1594], ["a", 1597], ["protein", 1599], ["with", 1607], ["functions", 1612], ["in", 1622], ["maintaining", 1625], ["cell", 1637], ["junction", 1642], ["integrity", 1651], ["has", 1661], ["important", 1665], ["implications", 1675], ["for", 1688], ["other", 1692], ["dominant", 1698], ["forms", 1707], ["of", 1713], ["ARVC", 1716], [",", 1720], ["related", 1722], ["cardiomyopathies", 1730], [",", 1746], ["and", 1748], ["other", 1752], ["cutaneous", 1758], ["diseases", 1768], [".", 1776]]}
{"context": "Reactive oxygen species (ROS) have been known for a long time to play important roles in host defense against microbial infections. In addition, it has become apparent that they also perform regulatory roles in signal transduction and cell proliferation. The source of these chemicals are members of the NOX family of NADPH oxidases that are found in a variety of tissues. NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1), as well as the flavocytochrome component p22(phox) for maximal activity. Unlike NOX2, the phagocytic NADPH oxidase whose activity is tightly repressed in the resting state, NOX1 produces superoxide constitutively at low levels. These levels can be further increased in a stimulus-dependent manner, yet the molecular details regulating this activity are not fully understood. Here we present the first quantitative characterization of the interactions made between the cytosolic regulators NOXO1 and NOXA1 and membrane-bound p22(phox). Using isothermal titration calorimetry we show that the isolated tandem SH3 domains of NOXO1 bind to p22(phox) with high affinity, most likely adopting a superSH3 domain conformation. In contrast, complex formation is severely inhibited in the presence of the C-terminal tail of NOXO1, suggesting that this region competes for binding to p22(phox) and thereby contributes to the regulation of superoxide production. Furthermore, we provide data indicating that the molecular details of the interaction between NOXO1 and NOXA1 is significantly different from that between the homologous proteins of the phagocytic oxidase, suggesting that there are important functional differences between the two systems. Taken together, this study provides clear evidence that the assembly of the NOX1 oxidase complex can be regulated through reversible protein-protein interactions.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "976535f8681e45c9881400b1e940a908", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[316, 316], [132, 132], [67, 67]], "char_spans": [[1888, 1891], [744, 747], [373, 376]]}]}], "context_tokens": [["Reactive", 0], ["oxygen", 9], ["species", 16], ["(", 24], ["ROS", 25], [")", 28], ["have", 30], ["been", 35], ["known", 40], ["for", 46], ["a", 50], ["long", 52], ["time", 57], ["to", 62], ["play", 65], ["important", 70], ["roles", 80], ["in", 86], ["host", 89], ["defense", 94], ["against", 102], ["microbial", 110], ["infections", 120], [".", 130], ["In", 132], ["addition", 135], [",", 143], ["it", 145], ["has", 148], ["become", 152], ["apparent", 159], ["that", 168], ["they", 173], ["also", 178], ["perform", 183], ["regulatory", 191], ["roles", 202], ["in", 208], ["signal", 211], ["transduction", 218], ["and", 231], ["cell", 235], ["proliferation", 240], [".", 253], ["The", 255], ["source", 259], ["of", 266], ["these", 269], ["chemicals", 275], ["are", 285], ["members", 289], ["of", 297], ["the", 300], ["NOX", 304], ["family", 308], ["of", 315], ["NADPH", 318], ["oxidases", 324], ["that", 333], ["are", 338], ["found", 342], ["in", 348], ["a", 351], ["variety", 353], ["of", 361], ["tissues", 364], [".", 371], ["NOX1", 373], [",", 377], ["an", 379], ["NADPH", 382], ["oxidase", 388], ["homologue", 396], ["that", 406], ["is", 411], ["most", 414], ["abundantly", 419], ["expressed", 430], ["in", 440], ["colon", 443], ["epithelial", 449], ["cells", 460], [",", 465], ["requires", 467], ["the", 476], ["regulatory", 480], ["subunits", 491], ["NOXO1", 500], ["(", 506], ["NOX", 507], ["organizing", 511], ["protein", 522], ["1", 530], [")", 531], ["and", 533], ["NOXA1", 537], ["(", 543], ["NOX", 544], ["activating", 548], ["protein", 559], ["1", 567], [")", 568], [",", 569], ["as", 571], ["well", 574], ["as", 579], ["the", 582], ["flavocytochrome", 586], ["component", 602], ["p22(phox", 612], [")", 620], ["for", 622], ["maximal", 626], ["activity", 634], [".", 642], ["Unlike", 644], ["NOX2", 651], [",", 655], ["the", 657], ["phagocytic", 661], ["NADPH", 672], ["oxidase", 678], ["whose", 686], ["activity", 692], ["is", 701], ["tightly", 704], ["repressed", 712], ["in", 722], ["the", 725], ["resting", 729], ["state", 737], [",", 742], ["NOX1", 744], ["produces", 749], ["superoxide", 758], ["constitutively", 769], ["at", 784], ["low", 787], ["levels", 791], [".", 797], ["These", 799], ["levels", 805], ["can", 812], ["be", 816], ["further", 819], ["increased", 827], ["in", 837], ["a", 840], ["stimulus", 842], ["-", 850], ["dependent", 851], ["manner", 861], [",", 867], ["yet", 869], ["the", 873], ["molecular", 877], ["details", 887], ["regulating", 895], ["this", 906], ["activity", 911], ["are", 920], ["not", 924], ["fully", 928], ["understood", 934], [".", 944], ["Here", 946], ["we", 951], ["present", 954], ["the", 962], ["first", 966], ["quantitative", 972], ["characterization", 985], ["of", 1002], ["the", 1005], ["interactions", 1009], ["made", 1022], ["between", 1027], ["the", 1035], ["cytosolic", 1039], ["regulators", 1049], ["NOXO1", 1060], ["and", 1066], ["NOXA1", 1070], ["and", 1076], ["membrane", 1080], ["-", 1088], ["bound", 1089], ["p22(phox", 1095], [")", 1103], [".", 1104], ["Using", 1106], ["isothermal", 1112], ["titration", 1123], ["calorimetry", 1133], ["we", 1145], ["show", 1148], ["that", 1153], ["the", 1158], ["isolated", 1162], ["tandem", 1171], ["SH3", 1178], ["domains", 1182], ["of", 1190], ["NOXO1", 1193], ["bind", 1199], ["to", 1204], ["p22(phox", 1207], [")", 1215], ["with", 1217], ["high", 1222], ["affinity", 1227], [",", 1235], ["most", 1237], ["likely", 1242], ["adopting", 1249], ["a", 1258], ["superSH3", 1260], ["domain", 1269], ["conformation", 1276], [".", 1288], ["In", 1290], ["contrast", 1293], [",", 1301], ["complex", 1303], ["formation", 1311], ["is", 1321], ["severely", 1324], ["inhibited", 1333], ["in", 1343], ["the", 1346], ["presence", 1350], ["of", 1359], ["the", 1362], ["C", 1366], ["-", 1367], ["terminal", 1368], ["tail", 1377], ["of", 1382], ["NOXO1", 1385], [",", 1390], ["suggesting", 1392], ["that", 1403], ["this", 1408], ["region", 1413], ["competes", 1420], ["for", 1429], ["binding", 1433], ["to", 1441], ["p22(phox", 1444], [")", 1452], ["and", 1454], ["thereby", 1458], ["contributes", 1466], ["to", 1478], ["the", 1481], ["regulation", 1485], ["of", 1496], ["superoxide", 1499], ["production", 1510], [".", 1520], ["Furthermore", 1522], [",", 1533], ["we", 1535], ["provide", 1538], ["data", 1546], ["indicating", 1551], ["that", 1562], ["the", 1567], ["molecular", 1571], ["details", 1581], ["of", 1589], ["the", 1592], ["interaction", 1596], ["between", 1608], ["NOXO1", 1616], ["and", 1622], ["NOXA1", 1626], ["is", 1632], ["significantly", 1635], ["different", 1649], ["from", 1659], ["that", 1664], ["between", 1669], ["the", 1677], ["homologous", 1681], ["proteins", 1692], ["of", 1701], ["the", 1704], ["phagocytic", 1708], ["oxidase", 1719], [",", 1726], ["suggesting", 1728], ["that", 1739], ["there", 1744], ["are", 1750], ["important", 1754], ["functional", 1764], ["differences", 1775], ["between", 1787], ["the", 1795], ["two", 1799], ["systems", 1803], [".", 1810], ["Taken", 1812], ["together", 1818], [",", 1826], ["this", 1828], ["study", 1833], ["provides", 1839], ["clear", 1848], ["evidence", 1854], ["that", 1863], ["the", 1868], ["assembly", 1872], ["of", 1881], ["the", 1884], ["NOX1", 1888], ["oxidase", 1893], ["complex", 1901], ["can", 1909], ["be", 1913], ["regulated", 1916], ["through", 1926], ["reversible", 1934], ["protein", 1945], ["-", 1952], ["protein", 1953], ["interactions", 1961], [".", 1973]]}
{"context": "The Ehlers-Danlos syndromes (EDS) are a heterogeneous group of heritable connective tissue disorders characterised by joint hypermobility, involvement of skin and tissue fragility. The Villefranche criteria have simplified its diagnosis, which, however, remains difficult in children and young adults with vascular and hypermobile EDS as well as in patients without a positive family history. Diagnosis of vascular EDS is important for clinical follow-up, genetic counseling and prenatal diagnosis. We describe the biochemical and molecular-genetic diagnosis of vascular EDS. We describe five families with vascular EDS. Analysis of (pro)collagens obtained from cultured fibroblasts was done using SDS-PAGE. The structure and amounts of (pro)collagen I, III and V were determined by autoradioflourography. This was also done in 362 controls or patients without a diagnosis of vascular EDS. Molecular testing was done in Professor Anne de Paepe's laboratory in Belgium by sequencing of COL3A1. (Pro)collagen from all five patients with vascular EDS was abnormal by SDS-PAGE: intracellular retention, reduced secretion and overmodification of the a1 chains of (pro)collagen III. Molecular analysis revealed an abnormality of COL3A1 in all patients. Abnormalities of (pro)collagen III were not observed in patients without a diagnosis of vascular EDS. Among 90 patients with non-vascular EDS, one patient had an abnormality of collagen I. Biochemical analysis of (pro)collagen obtained from cultured fibroblasts is a good screening procedure for vascular EDS, but it is of limited value in non-vascular EDS. Molecular testing will disclose an abnormality of COL3A1 in many patients with abnormal (pro)collagen III on SDS-PAGE. The findings make precise genetic counselling and prenatal diagnosis possible in families with vascular EDS.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "4dddb3b7e1e446fe922c7789a90fc99f", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[14, 15]], "char_spans": [[73, 89]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndromes", 18], ["(", 28], ["EDS", 29], [")", 32], ["are", 34], ["a", 38], ["heterogeneous", 40], ["group", 54], ["of", 60], ["heritable", 63], ["connective", 73], ["tissue", 84], ["disorders", 91], ["characterised", 101], ["by", 115], ["joint", 118], ["hypermobility", 124], [",", 137], ["involvement", 139], ["of", 151], ["skin", 154], ["and", 159], ["tissue", 163], ["fragility", 170], [".", 179], ["The", 181], ["Villefranche", 185], ["criteria", 198], ["have", 207], ["simplified", 212], ["its", 223], ["diagnosis", 227], [",", 236], ["which", 238], [",", 243], ["however", 245], [",", 252], ["remains", 254], ["difficult", 262], ["in", 272], ["children", 275], ["and", 284], ["young", 288], ["adults", 294], ["with", 301], ["vascular", 306], ["and", 315], ["hypermobile", 319], ["EDS", 331], ["as", 335], ["well", 338], ["as", 343], ["in", 346], ["patients", 349], ["without", 358], ["a", 366], ["positive", 368], ["family", 377], ["history", 384], [".", 391], ["Diagnosis", 393], ["of", 403], ["vascular", 406], ["EDS", 415], ["is", 419], ["important", 422], ["for", 432], ["clinical", 436], ["follow", 445], ["-", 451], ["up", 452], [",", 454], ["genetic", 456], ["counseling", 464], ["and", 475], ["prenatal", 479], ["diagnosis", 488], [".", 497], ["We", 499], ["describe", 502], ["the", 511], ["biochemical", 515], ["and", 527], ["molecular", 531], ["-", 540], ["genetic", 541], ["diagnosis", 549], ["of", 559], ["vascular", 562], ["EDS", 571], [".", 574], ["We", 576], ["describe", 579], ["five", 588], ["families", 593], ["with", 602], ["vascular", 607], ["EDS", 616], [".", 619], ["Analysis", 621], ["of", 630], ["(", 633], ["pro)collagens", 634], ["obtained", 648], ["from", 657], ["cultured", 662], ["fibroblasts", 671], ["was", 683], ["done", 687], ["using", 692], ["SDS", 698], ["-", 701], ["PAGE", 702], [".", 706], ["The", 708], ["structure", 712], ["and", 722], ["amounts", 726], ["of", 734], ["(", 737], ["pro)collagen", 738], ["I", 751], [",", 752], ["III", 754], ["and", 758], ["V", 762], ["were", 764], ["determined", 769], ["by", 780], ["autoradioflourography", 783], [".", 804], ["This", 806], ["was", 811], ["also", 815], ["done", 820], ["in", 825], ["362", 828], ["controls", 832], ["or", 841], ["patients", 844], ["without", 853], ["a", 861], ["diagnosis", 863], ["of", 873], ["vascular", 876], ["EDS", 885], [".", 888], ["Molecular", 890], ["testing", 900], ["was", 908], ["done", 912], ["in", 917], ["Professor", 920], ["Anne", 930], ["de", 935], ["Paepe", 938], ["'s", 943], ["laboratory", 946], ["in", 957], ["Belgium", 960], ["by", 968], ["sequencing", 971], ["of", 982], ["COL3A1", 985], [".", 991], ["(", 993], ["Pro)collagen", 994], ["from", 1007], ["all", 1012], ["five", 1016], ["patients", 1021], ["with", 1030], ["vascular", 1035], ["EDS", 1044], ["was", 1048], ["abnormal", 1052], ["by", 1061], ["SDS", 1064], ["-", 1067], ["PAGE", 1068], [":", 1072], ["intracellular", 1074], ["retention", 1088], [",", 1097], ["reduced", 1099], ["secretion", 1107], ["and", 1117], ["overmodification", 1121], ["of", 1138], ["the", 1141], ["a1", 1145], ["chains", 1148], ["of", 1155], ["(", 1158], ["pro)collagen", 1159], ["III", 1172], [".", 1175], ["Molecular", 1177], ["analysis", 1187], ["revealed", 1196], ["an", 1205], ["abnormality", 1208], ["of", 1220], ["COL3A1", 1223], ["in", 1230], ["all", 1233], ["patients", 1237], [".", 1245], ["Abnormalities", 1247], ["of", 1261], ["(", 1264], ["pro)collagen", 1265], ["III", 1278], ["were", 1282], ["not", 1287], ["observed", 1291], ["in", 1300], ["patients", 1303], ["without", 1312], ["a", 1320], ["diagnosis", 1322], ["of", 1332], ["vascular", 1335], ["EDS", 1344], [".", 1347], ["Among", 1349], ["90", 1355], ["patients", 1358], ["with", 1367], ["non", 1372], ["-", 1375], ["vascular", 1376], ["EDS", 1385], [",", 1388], ["one", 1390], ["patient", 1394], ["had", 1402], ["an", 1406], ["abnormality", 1409], ["of", 1421], ["collagen", 1424], ["I.", 1433], ["Biochemical", 1436], ["analysis", 1448], ["of", 1457], ["(", 1460], ["pro)collagen", 1461], ["obtained", 1474], ["from", 1483], ["cultured", 1488], ["fibroblasts", 1497], ["is", 1509], ["a", 1512], ["good", 1514], ["screening", 1519], ["procedure", 1529], ["for", 1539], ["vascular", 1543], ["EDS", 1552], [",", 1555], ["but", 1557], ["it", 1561], ["is", 1564], ["of", 1567], ["limited", 1570], ["value", 1578], ["in", 1584], ["non", 1587], ["-", 1590], ["vascular", 1591], ["EDS", 1600], [".", 1603], ["Molecular", 1605], ["testing", 1615], ["will", 1623], ["disclose", 1628], ["an", 1637], ["abnormality", 1640], ["of", 1652], ["COL3A1", 1655], ["in", 1662], ["many", 1665], ["patients", 1670], ["with", 1679], ["abnormal", 1684], ["(", 1693], ["pro)collagen", 1694], ["III", 1707], ["on", 1711], ["SDS", 1714], ["-", 1717], ["PAGE", 1718], [".", 1722], ["The", 1724], ["findings", 1728], ["make", 1737], ["precise", 1742], ["genetic", 1750], ["counselling", 1758], ["and", 1770], ["prenatal", 1774], ["diagnosis", 1783], ["possible", 1793], ["in", 1802], ["families", 1805], ["with", 1814], ["vascular", 1819], ["EDS", 1828], [".", 1831]]}
{"context": "Malaria remains one of the few diseases those continue to scourge human civilization despite the significant advances in disease control strategies over the last century. Malaria is responsible for more than 500 million cases and 1-3 million deaths annually. Approximately 85% of these deaths are among children, mostly in Africa, primarily due to P. falciparum. Whole cell vaccines, irradiated sporozoites and genetically attenuated sporozoites have demonstrated long lasting, sterile protection against plasmodium infection in animal and experimental clinical studies. Atypical membrane protein 1 and merozoite surface protein 1 are the two most extensively studied asexual blood stage vaccine candidates. The most promising candidate vaccine under development is RTS, S combined with AS01 adjuvant. Initial results from phase III trials of this candidate vaccine show 50% reduction of malaria in 5-17 mo aged children during the 12 mo after vaccination. WHO anticipates that the RTS,S/AS01 vaccine will be recommended for the 6-14 week age group for co-administration together with other vaccines as part of routine immunization programs in malaria endemic countries. Malaria vaccine could play an important role in elimination and eventual eradication of malaria.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "34237e2593fe47159c2577f4c10f4577", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[0, 0], [197, 197], [26, 26], [210, 210], [142, 142], [193, 193]], "char_spans": [[0, 6], [1171, 1177], [171, 177], [1259, 1265], [888, 894], [1144, 1150]]}]}], "context_tokens": [["Malaria", 0], ["remains", 8], ["one", 16], ["of", 20], ["the", 23], ["few", 27], ["diseases", 31], ["those", 40], ["continue", 46], ["to", 55], ["scourge", 58], ["human", 66], ["civilization", 72], ["despite", 85], ["the", 93], ["significant", 97], ["advances", 109], ["in", 118], ["disease", 121], ["control", 129], ["strategies", 137], ["over", 148], ["the", 153], ["last", 157], ["century", 162], [".", 169], ["Malaria", 171], ["is", 179], ["responsible", 182], ["for", 194], ["more", 198], ["than", 203], ["500", 208], ["million", 212], ["cases", 220], ["and", 226], ["1", 230], ["-", 231], ["3", 232], ["million", 234], ["deaths", 242], ["annually", 249], [".", 257], ["Approximately", 259], ["85", 273], ["%", 275], ["of", 277], ["these", 280], ["deaths", 286], ["are", 293], ["among", 297], ["children", 303], [",", 311], ["mostly", 313], ["in", 320], ["Africa", 323], [",", 329], ["primarily", 331], ["due", 341], ["to", 345], ["P.", 348], ["falciparum", 351], [".", 361], ["Whole", 363], ["cell", 369], ["vaccines", 374], [",", 382], ["irradiated", 384], ["sporozoites", 395], ["and", 407], ["genetically", 411], ["attenuated", 423], ["sporozoites", 434], ["have", 446], ["demonstrated", 451], ["long", 464], ["lasting", 469], [",", 476], ["sterile", 478], ["protection", 486], ["against", 497], ["plasmodium", 505], ["infection", 516], ["in", 526], ["animal", 529], ["and", 536], ["experimental", 540], ["clinical", 553], ["studies", 562], [".", 569], ["Atypical", 571], ["membrane", 580], ["protein", 589], ["1", 597], ["and", 599], ["merozoite", 603], ["surface", 613], ["protein", 621], ["1", 629], ["are", 631], ["the", 635], ["two", 639], ["most", 643], ["extensively", 648], ["studied", 660], ["asexual", 668], ["blood", 676], ["stage", 682], ["vaccine", 688], ["candidates", 696], [".", 706], ["The", 708], ["most", 712], ["promising", 717], ["candidate", 727], ["vaccine", 737], ["under", 745], ["development", 751], ["is", 763], ["RTS", 766], [",", 769], ["S", 771], ["combined", 773], ["with", 782], ["AS01", 787], ["adjuvant", 792], [".", 800], ["Initial", 802], ["results", 810], ["from", 818], ["phase", 823], ["III", 829], ["trials", 833], ["of", 840], ["this", 843], ["candidate", 848], ["vaccine", 858], ["show", 866], ["50", 871], ["%", 873], ["reduction", 875], ["of", 885], ["malaria", 888], ["in", 896], ["5", 899], ["-", 900], ["17", 901], ["mo", 904], ["aged", 907], ["children", 912], ["during", 921], ["the", 928], ["12", 932], ["mo", 935], ["after", 938], ["vaccination", 944], [".", 955], ["WHO", 957], ["anticipates", 961], ["that", 973], ["the", 978], ["RTS", 982], [",", 985], ["S", 986], ["/", 987], ["AS01", 988], ["vaccine", 993], ["will", 1001], ["be", 1006], ["recommended", 1009], ["for", 1021], ["the", 1025], ["6", 1029], ["-", 1030], ["14", 1031], ["week", 1034], ["age", 1039], ["group", 1043], ["for", 1049], ["co", 1053], ["-", 1055], ["administration", 1056], ["together", 1071], ["with", 1080], ["other", 1085], ["vaccines", 1091], ["as", 1100], ["part", 1103], ["of", 1108], ["routine", 1111], ["immunization", 1119], ["programs", 1132], ["in", 1141], ["malaria", 1144], ["endemic", 1152], ["countries", 1160], [".", 1169], ["Malaria", 1171], ["vaccine", 1179], ["could", 1187], ["play", 1193], ["an", 1198], ["important", 1201], ["role", 1211], ["in", 1216], ["elimination", 1219], ["and", 1231], ["eventual", 1235], ["eradication", 1244], ["of", 1256], ["malaria", 1259], [".", 1266]]}
{"context": "Chaperone-mediated autophagy (CMA) is a selective autophagy-lysosome protein degradation pathway. The role of CMA in normal neuronal functions and in neural disease pathogenesis remains unclear, in part because there is no available method to monitor CMA activity at the single-cell level. We sought to establish a single-cell monitoring method by visualizing translocation of CMA substrates from the cytosol to lysosomes using the HaloTag (HT) system. GAPDH, a CMA substrate, was fused to HT (GAPDH-HT); this protein accumulated in the lysosomes of HeLa cells and cultured cerebellar Purkinje cells (PCs) after labeling with fluorescent dye-conjugated HT ligand. Lysosomal accumulation was enhanced by treatments that activate CMA and prevented by siRNA-mediated knockdown of LAMP2A, a lysosomal receptor for CMA, and by treatments that inactivate CMA. These results suggest that lysosomal accumulation of GAPDH-HT reflects CMA activity. Using this method, we revealed that mutant \u03b3PKC, which causes spinocerebellar ataxia type 14, decreased CMA activity in cultured PCs. In the present study, we established a novel fluorescent-based method to evaluate CMA activity in a single neuron. This novel method should be useful and valuable for evaluating the role of CMA in various neuronal functions and neural disease pathogenesis.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "86bd299403624adfa79bf2ac1de79528", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[141, 141]], "char_spans": [[777, 782]]}]}], "context_tokens": [["Chaperone", 0], ["-", 9], ["mediated", 10], ["autophagy", 19], ["(", 29], ["CMA", 30], [")", 33], ["is", 35], ["a", 38], ["selective", 40], ["autophagy", 50], ["-", 59], ["lysosome", 60], ["protein", 69], ["degradation", 77], ["pathway", 89], [".", 96], ["The", 98], ["role", 102], ["of", 107], ["CMA", 110], ["in", 114], ["normal", 117], ["neuronal", 124], ["functions", 133], ["and", 143], ["in", 147], ["neural", 150], ["disease", 157], ["pathogenesis", 165], ["remains", 178], ["unclear", 186], [",", 193], ["in", 195], ["part", 198], ["because", 203], ["there", 211], ["is", 217], ["no", 220], ["available", 223], ["method", 233], ["to", 240], ["monitor", 243], ["CMA", 251], ["activity", 255], ["at", 264], ["the", 267], ["single", 271], ["-", 277], ["cell", 278], ["level", 283], [".", 288], ["We", 290], ["sought", 293], ["to", 300], ["establish", 303], ["a", 313], ["single", 315], ["-", 321], ["cell", 322], ["monitoring", 327], ["method", 338], ["by", 345], ["visualizing", 348], ["translocation", 360], ["of", 374], ["CMA", 377], ["substrates", 381], ["from", 392], ["the", 397], ["cytosol", 401], ["to", 409], ["lysosomes", 412], ["using", 422], ["the", 428], ["HaloTag", 432], ["(", 440], ["HT", 441], [")", 443], ["system", 445], [".", 451], ["GAPDH", 453], [",", 458], ["a", 460], ["CMA", 462], ["substrate", 466], [",", 475], ["was", 477], ["fused", 481], ["to", 487], ["HT", 490], ["(", 493], ["GAPDH", 494], ["-", 499], ["HT", 500], [")", 502], [";", 503], ["this", 505], ["protein", 510], ["accumulated", 518], ["in", 530], ["the", 533], ["lysosomes", 537], ["of", 547], ["HeLa", 550], ["cells", 555], ["and", 561], ["cultured", 565], ["cerebellar", 574], ["Purkinje", 585], ["cells", 594], ["(", 600], ["PCs", 601], [")", 604], ["after", 606], ["labeling", 612], ["with", 621], ["fluorescent", 626], ["dye", 638], ["-", 641], ["conjugated", 642], ["HT", 653], ["ligand", 656], [".", 662], ["Lysosomal", 664], ["accumulation", 674], ["was", 687], ["enhanced", 691], ["by", 700], ["treatments", 703], ["that", 714], ["activate", 719], ["CMA", 728], ["and", 732], ["prevented", 736], ["by", 746], ["siRNA", 749], ["-", 754], ["mediated", 755], ["knockdown", 764], ["of", 774], ["LAMP2A", 777], [",", 783], ["a", 785], ["lysosomal", 787], ["receptor", 797], ["for", 806], ["CMA", 810], [",", 813], ["and", 815], ["by", 819], ["treatments", 822], ["that", 833], ["inactivate", 838], ["CMA", 849], [".", 852], ["These", 854], ["results", 860], ["suggest", 868], ["that", 876], ["lysosomal", 881], ["accumulation", 891], ["of", 904], ["GAPDH", 907], ["-", 912], ["HT", 913], ["reflects", 916], ["CMA", 925], ["activity", 929], [".", 937], ["Using", 939], ["this", 945], ["method", 950], [",", 956], ["we", 958], ["revealed", 961], ["that", 970], ["mutant", 975], ["\u03b3PKC", 982], [",", 986], ["which", 988], ["causes", 994], ["spinocerebellar", 1001], ["ataxia", 1017], ["type", 1024], ["14", 1029], [",", 1031], ["decreased", 1033], ["CMA", 1043], ["activity", 1047], ["in", 1056], ["cultured", 1059], ["PCs", 1068], [".", 1071], ["In", 1073], ["the", 1076], ["present", 1080], ["study", 1088], [",", 1093], ["we", 1095], ["established", 1098], ["a", 1110], ["novel", 1112], ["fluorescent", 1118], ["-", 1129], ["based", 1130], ["method", 1136], ["to", 1143], ["evaluate", 1146], ["CMA", 1155], ["activity", 1159], ["in", 1168], ["a", 1171], ["single", 1173], ["neuron", 1180], [".", 1186], ["This", 1188], ["novel", 1193], ["method", 1199], ["should", 1206], ["be", 1213], ["useful", 1216], ["and", 1223], ["valuable", 1227], ["for", 1236], ["evaluating", 1240], ["the", 1251], ["role", 1255], ["of", 1260], ["CMA", 1263], ["in", 1267], ["various", 1270], ["neuronal", 1278], ["functions", 1287], ["and", 1297], ["neural", 1301], ["disease", 1308], ["pathogenesis", 1316], [".", 1328]]}
{"context": "Previously we reported on L-DOPA's antinociceptive effect on substance P-induced nociceptive behaviors in mice [Shimizu T, Iwata S, Morioka H, Masuyama T, Fukuda T, Nomoto M. Antinociceptive mechanism of L-DOPA. Pain 2004;110;246-9.]. Since significant hyperalgesia was noted following antinociception, our study was designed to investigate the mechanism of this hyperalgesia. Nociceptive behaviors were enhanced 2 h after L-DOPA administration. L-DOPA induced hyperalgesia occurred after conversion to dopamine because co-administration of benserazide, a DOPA decarboxylase inhibitor, completely abolished the L-DOPA-induced hyperalgesia. The D2 receptor agonist, quinpirole, depressed these behaviors entirely, while the D1 antagonist, SCH23390, inhibited the enhancement of these behaviors by L-DOPA. The D2 receptor antagonist, sulpiride, which induced hyperalgesia of the substance P-induced behaviors in naive mice, did not have any effects on L-DOPA-induced hyperalgesia. Spinal cord dopamine content increased rapidly after L-DOPA administration, exhibiting levels 100 times greater than baseline, and then returned to control after 1 h. These results suggested that the dopaminergic inhibitory system for pain sensation was temporarily impaired by excess amounts of exogenous dopamine that were derived from L-DOPA and both D1 and D2 receptors were involved in L-DOPA-induced hyperalgesia.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "a599caa6467c4126af22518a18e24c41", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[4, 6], [228, 230], [183, 185], [240, 242], [40, 42], [138, 140], [105, 107], [169, 171], [80, 82], [75, 77]], "char_spans": [[26, 31], [1317, 1322], [1032, 1037], [1370, 1375], [204, 209], [796, 801], [611, 616], [950, 955], [446, 451], [423, 428]]}]}], "context_tokens": [["Previously", 0], ["we", 11], ["reported", 14], ["on", 23], ["L", 26], ["-", 27], ["DOPA", 28], ["'s", 32], ["antinociceptive", 35], ["effect", 51], ["on", 58], ["substance", 61], ["P", 71], ["-", 72], ["induced", 73], ["nociceptive", 81], ["behaviors", 93], ["in", 103], ["mice", 106], ["[", 111], ["Shimizu", 112], ["T", 120], [",", 121], ["Iwata", 123], ["S", 129], [",", 130], ["Morioka", 132], ["H", 140], [",", 141], ["Masuyama", 143], ["T", 152], [",", 153], ["Fukuda", 155], ["T", 162], [",", 163], ["Nomoto", 165], ["M.", 172], ["Antinociceptive", 175], ["mechanism", 191], ["of", 201], ["L", 204], ["-", 205], ["DOPA", 206], [".", 210], ["Pain", 212], ["2004;110;246", 217], ["-", 229], ["9.].", 230], ["Since", 235], ["significant", 241], ["hyperalgesia", 253], ["was", 266], ["noted", 270], ["following", 276], ["antinociception", 286], [",", 301], ["our", 303], ["study", 307], ["was", 313], ["designed", 317], ["to", 326], ["investigate", 329], ["the", 341], ["mechanism", 345], ["of", 355], ["this", 358], ["hyperalgesia", 363], [".", 375], ["Nociceptive", 377], ["behaviors", 389], ["were", 399], ["enhanced", 404], ["2", 413], ["h", 415], ["after", 417], ["L", 423], ["-", 424], ["DOPA", 425], ["administration", 430], [".", 444], ["L", 446], ["-", 447], ["DOPA", 448], ["induced", 453], ["hyperalgesia", 461], ["occurred", 474], ["after", 483], ["conversion", 489], ["to", 500], ["dopamine", 503], ["because", 512], ["co", 520], ["-", 522], ["administration", 523], ["of", 538], ["benserazide", 541], [",", 552], ["a", 554], ["DOPA", 556], ["decarboxylase", 561], ["inhibitor", 575], [",", 584], ["completely", 586], ["abolished", 597], ["the", 607], ["L", 611], ["-", 612], ["DOPA", 613], ["-", 617], ["induced", 618], ["hyperalgesia", 626], [".", 638], ["The", 640], ["D2", 644], ["receptor", 647], ["agonist", 656], [",", 663], ["quinpirole", 665], [",", 675], ["depressed", 677], ["these", 687], ["behaviors", 693], ["entirely", 703], [",", 711], ["while", 713], ["the", 719], ["D1", 723], ["antagonist", 726], [",", 736], ["SCH23390", 738], [",", 746], ["inhibited", 748], ["the", 758], ["enhancement", 762], ["of", 774], ["these", 777], ["behaviors", 783], ["by", 793], ["L", 796], ["-", 797], ["DOPA", 798], [".", 802], ["The", 804], ["D2", 808], ["receptor", 811], ["antagonist", 820], [",", 830], ["sulpiride", 832], [",", 841], ["which", 843], ["induced", 849], ["hyperalgesia", 857], ["of", 870], ["the", 873], ["substance", 877], ["P", 887], ["-", 888], ["induced", 889], ["behaviors", 897], ["in", 907], ["naive", 910], ["mice", 916], [",", 920], ["did", 922], ["not", 926], ["have", 930], ["any", 935], ["effects", 939], ["on", 947], ["L", 950], ["-", 951], ["DOPA", 952], ["-", 956], ["induced", 957], ["hyperalgesia", 965], [".", 977], ["Spinal", 979], ["cord", 986], ["dopamine", 991], ["content", 1000], ["increased", 1008], ["rapidly", 1018], ["after", 1026], ["L", 1032], ["-", 1033], ["DOPA", 1034], ["administration", 1039], [",", 1053], ["exhibiting", 1055], ["levels", 1066], ["100", 1073], ["times", 1077], ["greater", 1083], ["than", 1091], ["baseline", 1096], [",", 1104], ["and", 1106], ["then", 1110], ["returned", 1115], ["to", 1124], ["control", 1127], ["after", 1135], ["1", 1141], ["h.", 1143], ["These", 1146], ["results", 1152], ["suggested", 1160], ["that", 1170], ["the", 1175], ["dopaminergic", 1179], ["inhibitory", 1192], ["system", 1203], ["for", 1210], ["pain", 1214], ["sensation", 1219], ["was", 1229], ["temporarily", 1233], ["impaired", 1245], ["by", 1254], ["excess", 1257], ["amounts", 1264], ["of", 1272], ["exogenous", 1275], ["dopamine", 1285], ["that", 1294], ["were", 1299], ["derived", 1304], ["from", 1312], ["L", 1317], ["-", 1318], ["DOPA", 1319], ["and", 1324], ["both", 1328], ["D1", 1333], ["and", 1336], ["D2", 1340], ["receptors", 1343], ["were", 1353], ["involved", 1358], ["in", 1367], ["L", 1370], ["-", 1371], ["DOPA", 1372], ["-", 1376], ["induced", 1377], ["hyperalgesia", 1385], [".", 1397]]}
{"context": "Aging research in vertebrates is hampered by the lack of short-lived models. Annual fishes of the genus Nothobranchius live in East African seasonal ponds. Their life expectancy in the wild is limited by the duration of the wet season and their lifespan in captivity is also short. Nothobranchius are popular aquarium fishes and many different species are kept as captive strains, providing rich material for comparative studies. The present paper aims at reviving the interest in these fishes by reporting that: (1) Nothobranchius can be cultured, and their eggs stored dry at room temperature for months or years, offering inexpensive methods of embryo storage; (2) Nothobranchius show accelerated growth and expression of aging biomarkers at the level of histology and behaviour; (3) the species Nothobranchius furzeri has a maximum lifespan of only 3 months and offers the possibility to perform investigations thus far unthinkable in a vertebrate, such as drug screening with life-long pharmacological treatments and experimental evolution; (4) when the lifespan of different species is compared, a general correlation is found between wet season duration in their natural habitat and longevity in captivity; and (5) vertebrate aging-related genes, such as p66Shc and MTP, can be easily isolated in Nothobranchius by homology cloning. These fishes can become excellent models for aging studies. They can be employed to test the effects of experimental manipulation on aging at a pace comparable with that of Drosophila and to probe the effects of natural selection on the evolution of aging-related genes.", "qas": [{"question": "What can Nothobranchius furzeri be used as a model system for?", "answers": ["aging research"], "qid": "ea59c7ee76424a47bdecc74c9987666f", "question_tokens": [["What", 0], ["can", 5], ["Nothobranchius", 9], ["furzeri", 24], ["be", 32], ["used", 35], ["as", 40], ["a", 43], ["model", 45], ["system", 51], ["for", 58], ["?", 61]], "detected_answers": [{"text": "aging research", "token_spans": [[0, 1]], "char_spans": [[0, 13]]}]}], "context_tokens": [["Aging", 0], ["research", 6], ["in", 15], ["vertebrates", 18], ["is", 30], ["hampered", 33], ["by", 42], ["the", 45], ["lack", 49], ["of", 54], ["short", 57], ["-", 62], ["lived", 63], ["models", 69], [".", 75], ["Annual", 77], ["fishes", 84], ["of", 91], ["the", 94], ["genus", 98], ["Nothobranchius", 104], ["live", 119], ["in", 124], ["East", 127], ["African", 132], ["seasonal", 140], ["ponds", 149], [".", 154], ["Their", 156], ["life", 162], ["expectancy", 167], ["in", 178], ["the", 181], ["wild", 185], ["is", 190], ["limited", 193], ["by", 201], ["the", 204], ["duration", 208], ["of", 217], ["the", 220], ["wet", 224], ["season", 228], ["and", 235], ["their", 239], ["lifespan", 245], ["in", 254], ["captivity", 257], ["is", 267], ["also", 270], ["short", 275], [".", 280], ["Nothobranchius", 282], ["are", 297], ["popular", 301], ["aquarium", 309], ["fishes", 318], ["and", 325], ["many", 329], ["different", 334], ["species", 344], ["are", 352], ["kept", 356], ["as", 361], ["captive", 364], ["strains", 372], [",", 379], ["providing", 381], ["rich", 391], ["material", 396], ["for", 405], ["comparative", 409], ["studies", 421], [".", 428], ["The", 430], ["present", 434], ["paper", 442], ["aims", 448], ["at", 453], ["reviving", 456], ["the", 465], ["interest", 469], ["in", 478], ["these", 481], ["fishes", 487], ["by", 494], ["reporting", 497], ["that", 507], [":", 511], ["(", 513], ["1", 514], [")", 515], ["Nothobranchius", 517], ["can", 532], ["be", 536], ["cultured", 539], [",", 547], ["and", 549], ["their", 553], ["eggs", 559], ["stored", 564], ["dry", 571], ["at", 575], ["room", 578], ["temperature", 583], ["for", 595], ["months", 599], ["or", 606], ["years", 609], [",", 614], ["offering", 616], ["inexpensive", 625], ["methods", 637], ["of", 645], ["embryo", 648], ["storage", 655], [";", 662], ["(", 664], ["2", 665], [")", 666], ["Nothobranchius", 668], ["show", 683], ["accelerated", 688], ["growth", 700], ["and", 707], ["expression", 711], ["of", 722], ["aging", 725], ["biomarkers", 731], ["at", 742], ["the", 745], ["level", 749], ["of", 755], ["histology", 758], ["and", 768], ["behaviour", 772], [";", 781], ["(", 783], ["3", 784], [")", 785], ["the", 787], ["species", 791], ["Nothobranchius", 799], ["furzeri", 814], ["has", 822], ["a", 826], ["maximum", 828], ["lifespan", 836], ["of", 845], ["only", 848], ["3", 853], ["months", 855], ["and", 862], ["offers", 866], ["the", 873], ["possibility", 877], ["to", 889], ["perform", 892], ["investigations", 900], ["thus", 915], ["far", 920], ["unthinkable", 924], ["in", 936], ["a", 939], ["vertebrate", 941], [",", 951], ["such", 953], ["as", 958], ["drug", 961], ["screening", 966], ["with", 976], ["life", 981], ["-", 985], ["long", 986], ["pharmacological", 991], ["treatments", 1007], ["and", 1018], ["experimental", 1022], ["evolution", 1035], [";", 1044], ["(", 1046], ["4", 1047], [")", 1048], ["when", 1050], ["the", 1055], ["lifespan", 1059], ["of", 1068], ["different", 1071], ["species", 1081], ["is", 1089], ["compared", 1092], [",", 1100], ["a", 1102], ["general", 1104], ["correlation", 1112], ["is", 1124], ["found", 1127], ["between", 1133], ["wet", 1141], ["season", 1145], ["duration", 1152], ["in", 1161], ["their", 1164], ["natural", 1170], ["habitat", 1178], ["and", 1186], ["longevity", 1190], ["in", 1200], ["captivity", 1203], [";", 1212], ["and", 1214], ["(", 1218], ["5", 1219], [")", 1220], ["vertebrate", 1222], ["aging", 1233], ["-", 1238], ["related", 1239], ["genes", 1247], [",", 1252], ["such", 1254], ["as", 1259], ["p66Shc", 1262], ["and", 1269], ["MTP", 1273], [",", 1276], ["can", 1278], ["be", 1282], ["easily", 1285], ["isolated", 1292], ["in", 1301], ["Nothobranchius", 1304], ["by", 1319], ["homology", 1322], ["cloning", 1331], [".", 1338], ["These", 1340], ["fishes", 1346], ["can", 1353], ["become", 1357], ["excellent", 1364], ["models", 1374], ["for", 1381], ["aging", 1385], ["studies", 1391], [".", 1398], ["They", 1400], ["can", 1405], ["be", 1409], ["employed", 1412], ["to", 1421], ["test", 1424], ["the", 1429], ["effects", 1433], ["of", 1441], ["experimental", 1444], ["manipulation", 1457], ["on", 1470], ["aging", 1473], ["at", 1479], ["a", 1482], ["pace", 1484], ["comparable", 1489], ["with", 1500], ["that", 1505], ["of", 1510], ["Drosophila", 1513], ["and", 1524], ["to", 1528], ["probe", 1531], ["the", 1537], ["effects", 1541], ["of", 1549], ["natural", 1552], ["selection", 1560], ["on", 1570], ["the", 1573], ["evolution", 1577], ["of", 1587], ["aging", 1590], ["-", 1595], ["related", 1596], ["genes", 1604], [".", 1609]]}
{"context": "Our objective was to evaluate the efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to the anti-interleukin-17A (IL-17A) monoclonal antibody (MAb) secukinumab. We used an open-label, parallel-group, randomized single-center study of 50 healthy subjects. Subjects received a single 150-mg dose of secukinumab or no treatment, followed by vaccination with inactivated trivalent subunit influenza virus and conjugate group C meningococcal vaccine (Agrippal and Menjugate, respectively) 2 weeks later. Primary efficacy variables were responses of \u22654-fold increases in antibody titer (hemagglutination inhibition [HI; for influenza virus] and serum bactericidal assay [SBA; for Neisseria meningitides]) for meningococcus and influenza (at least two out of three serotypes), both at 4 weeks postvaccination. All subjects randomized to secukinumab (n = 25) or the control (n = 25) completed the study. Antibody responses to vaccinations measured at 4 weeks were comparable in both groups, with \u22654-fold increased responses following influenza virus vaccination of 20/25 (80%) for both groups and following meningococcal vaccination of 19/25 (76%) for the secukinumab group and 18/25 (72%) for the control group. Differences between groups were 0% (90% confidence intervals [CI], 19 and 19%) and 4% (90% CI, 16 and 24%) for influenza virus and meningococcal vaccines, respectively. Antibody responses were comparable between the 2 groups at different time points. Headache was the most frequently reported adverse effect. No deaths or serious adverse events were reported. Blockade of IL-17A by secukinumab does not appear to interfere with efficacy of influenza and meningococcal vaccinations, as assessed by the achievement of protective antibody levels. A protective (\u22654-fold) immune response to both vaccinations at 4 weeks was achieved in 80 and 76% of subjects exposed to secukinumab and the control, respectively.", "qas": [{"question": "Which molecule is targeted by a monoclonal antibody Secukinumab?", "answers": ["interleukin-17A"], "qid": "4db9416efbb340a49f9352809ab90a84", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["a", 30], ["monoclonal", 32], ["antibody", 43], ["Secukinumab", 52], ["?", 63]], "detected_answers": [{"text": "interleukin-17A", "token_spans": [[20, 20]], "char_spans": [[127, 141]]}]}], "context_tokens": [["Our", 0], ["objective", 4], ["was", 14], ["to", 18], ["evaluate", 21], ["the", 30], ["efficacy", 34], ["of", 43], ["influenza", 46], ["and", 56], ["meningococcal", 60], ["vaccinations", 74], ["in", 87], ["healthy", 90], ["subjects", 98], ["exposed", 107], ["to", 115], ["the", 118], ["anti", 122], ["-", 126], ["interleukin-17A", 127], ["(", 143], ["IL-17A", 144], [")", 150], ["monoclonal", 152], ["antibody", 163], ["(", 172], ["MAb", 173], [")", 176], ["secukinumab", 178], [".", 189], ["We", 191], ["used", 194], ["an", 199], ["open", 202], ["-", 206], ["label", 207], [",", 212], ["parallel", 214], ["-", 222], ["group", 223], [",", 228], ["randomized", 230], ["single", 241], ["-", 247], ["center", 248], ["study", 255], ["of", 261], ["50", 264], ["healthy", 267], ["subjects", 275], [".", 283], ["Subjects", 285], ["received", 294], ["a", 303], ["single", 305], ["150-mg", 312], ["dose", 319], ["of", 324], ["secukinumab", 327], ["or", 339], ["no", 342], ["treatment", 345], [",", 354], ["followed", 356], ["by", 365], ["vaccination", 368], ["with", 380], ["inactivated", 385], ["trivalent", 397], ["subunit", 407], ["influenza", 415], ["virus", 425], ["and", 431], ["conjugate", 435], ["group", 445], ["C", 451], ["meningococcal", 453], ["vaccine", 467], ["(", 475], ["Agrippal", 476], ["and", 485], ["Menjugate", 489], [",", 498], ["respectively", 500], [")", 512], ["2", 514], ["weeks", 516], ["later", 522], [".", 527], ["Primary", 529], ["efficacy", 537], ["variables", 546], ["were", 556], ["responses", 561], ["of", 571], ["\u22654-fold", 574], ["increases", 582], ["in", 592], ["antibody", 595], ["titer", 604], ["(", 610], ["hemagglutination", 611], ["inhibition", 628], ["[", 639], ["HI", 640], [";", 642], ["for", 644], ["influenza", 648], ["virus", 658], ["]", 663], ["and", 665], ["serum", 669], ["bactericidal", 675], ["assay", 688], ["[", 694], ["SBA", 695], [";", 698], ["for", 700], ["Neisseria", 704], ["meningitides", 714], ["]", 726], [")", 727], ["for", 729], ["meningococcus", 733], ["and", 747], ["influenza", 751], ["(", 761], ["at", 762], ["least", 765], ["two", 771], ["out", 775], ["of", 779], ["three", 782], ["serotypes", 788], [")", 797], [",", 798], ["both", 800], ["at", 805], ["4", 808], ["weeks", 810], ["postvaccination", 816], [".", 831], ["All", 833], ["subjects", 837], ["randomized", 846], ["to", 857], ["secukinumab", 860], ["(", 872], ["n", 873], ["=", 875], ["25", 877], [")", 879], ["or", 881], ["the", 884], ["control", 888], ["(", 896], ["n", 897], ["=", 899], ["25", 901], [")", 903], ["completed", 905], ["the", 915], ["study", 919], [".", 924], ["Antibody", 926], ["responses", 935], ["to", 945], ["vaccinations", 948], ["measured", 961], ["at", 970], ["4", 973], ["weeks", 975], ["were", 981], ["comparable", 986], ["in", 997], ["both", 1000], ["groups", 1005], [",", 1011], ["with", 1013], ["\u22654-fold", 1018], ["increased", 1026], ["responses", 1036], ["following", 1046], ["influenza", 1056], ["virus", 1066], ["vaccination", 1072], ["of", 1084], ["20/25", 1087], ["(", 1093], ["80", 1094], ["%", 1096], [")", 1097], ["for", 1099], ["both", 1103], ["groups", 1108], ["and", 1115], ["following", 1119], ["meningococcal", 1129], ["vaccination", 1143], ["of", 1155], ["19/25", 1158], ["(", 1164], ["76", 1165], ["%", 1167], [")", 1168], ["for", 1170], ["the", 1174], ["secukinumab", 1178], ["group", 1190], ["and", 1196], ["18/25", 1200], ["(", 1206], ["72", 1207], ["%", 1209], [")", 1210], ["for", 1212], ["the", 1216], ["control", 1220], ["group", 1228], [".", 1233], ["Differences", 1235], ["between", 1247], ["groups", 1255], ["were", 1262], ["0", 1267], ["%", 1268], ["(", 1270], ["90", 1271], ["%", 1273], ["confidence", 1275], ["intervals", 1286], ["[", 1296], ["CI", 1297], ["]", 1299], [",", 1300], ["19", 1302], ["and", 1305], ["19", 1309], ["%", 1311], [")", 1312], ["and", 1314], ["4", 1318], ["%", 1319], ["(", 1321], ["90", 1322], ["%", 1324], ["CI", 1326], [",", 1328], ["16", 1330], ["and", 1333], ["24", 1337], ["%", 1339], [")", 1340], ["for", 1342], ["influenza", 1346], ["virus", 1356], ["and", 1362], ["meningococcal", 1366], ["vaccines", 1380], [",", 1388], ["respectively", 1390], [".", 1402], ["Antibody", 1404], ["responses", 1413], ["were", 1423], ["comparable", 1428], ["between", 1439], ["the", 1447], ["2", 1451], ["groups", 1453], ["at", 1460], ["different", 1463], ["time", 1473], ["points", 1478], [".", 1484], ["Headache", 1486], ["was", 1495], ["the", 1499], ["most", 1503], ["frequently", 1508], ["reported", 1519], ["adverse", 1528], ["effect", 1536], [".", 1542], ["No", 1544], ["deaths", 1547], ["or", 1554], ["serious", 1557], ["adverse", 1565], ["events", 1573], ["were", 1580], ["reported", 1585], [".", 1593], ["Blockade", 1595], ["of", 1604], ["IL-17A", 1607], ["by", 1614], ["secukinumab", 1617], ["does", 1629], ["not", 1634], ["appear", 1638], ["to", 1645], ["interfere", 1648], ["with", 1658], ["efficacy", 1663], ["of", 1672], ["influenza", 1675], ["and", 1685], ["meningococcal", 1689], ["vaccinations", 1703], [",", 1715], ["as", 1717], ["assessed", 1720], ["by", 1729], ["the", 1732], ["achievement", 1736], ["of", 1748], ["protective", 1751], ["antibody", 1762], ["levels", 1771], [".", 1777], ["A", 1779], ["protective", 1781], ["(", 1792], ["\u22654-fold", 1793], [")", 1800], ["immune", 1802], ["response", 1809], ["to", 1818], ["both", 1821], ["vaccinations", 1826], ["at", 1839], ["4", 1842], ["weeks", 1844], ["was", 1850], ["achieved", 1854], ["in", 1863], ["80", 1866], ["and", 1869], ["76", 1873], ["%", 1875], ["of", 1877], ["subjects", 1880], ["exposed", 1889], ["to", 1897], ["secukinumab", 1900], ["and", 1912], ["the", 1916], ["control", 1920], [",", 1927], ["respectively", 1929], [".", 1941]]}
{"context": "The centromeric regions of all Saccharomyces cerevisiae chromosomes are found in early replicating domains, a property conserved among centromeres in fungi and some higher eukaryotes. Surprisingly, little is known about the biological significance or the mechanism of early centromere replication; however, the extensive conservation suggests that it is important for chromosome maintenance. Do centromeres ensure their early replication by promoting early activation of nearby origins, or have they migrated over evolutionary time to reside in early replicating regions? In Candida albicans, a neocentromere contains an early firing origin, supporting the first hypothesis but not addressing whether the new origin is intrinsically early firing or whether the centromere influences replication time. Because the activation time of individual origins is not an intrinsic property of S. cerevisiae origins, but is influenced by surrounding sequences, we sought to test the hypothesis that centromeres influence replication time by moving a centromere to a late replication domain. We used a modified Meselson-Stahl density transfer assay to measure the kinetics of replication for regions of chromosome XIV in which either the functional centromere or a point-mutated version had been moved near origins that reside in a late replication region. We show that a functional centromere acts in cis over a distance as great as 19 kb to advance the initiation time of origins. Our results constitute a direct link between establishment of the kinetochore and the replication initiation machinery, and suggest that the proposed higher-order structure of the pericentric chromatin influences replication initiation.", "qas": [{"question": "Do origins of replication close to yeast centromeres fire early or late?", "answers": ["Early"], "qid": "55f7e26b1a6a41c08f110ecb1c372358", "question_tokens": [["Do", 0], ["origins", 3], ["of", 11], ["replication", 14], ["close", 26], ["to", 32], ["yeast", 35], ["centromeres", 41], ["fire", 53], ["early", 58], ["or", 64], ["late", 67], ["?", 71]], "detected_answers": [{"text": "Early", "token_spans": [[11, 11], [62, 62], [40, 40], [66, 66], [82, 82], [111, 111], [94, 94]], "char_spans": [[81, 85], [420, 424], [268, 272], [451, 455], [545, 549], [733, 737], [621, 625]]}]}], "context_tokens": [["The", 0], ["centromeric", 4], ["regions", 16], ["of", 24], ["all", 27], ["Saccharomyces", 31], ["cerevisiae", 45], ["chromosomes", 56], ["are", 68], ["found", 72], ["in", 78], ["early", 81], ["replicating", 87], ["domains", 99], [",", 106], ["a", 108], ["property", 110], ["conserved", 119], ["among", 129], ["centromeres", 135], ["in", 147], ["fungi", 150], ["and", 156], ["some", 160], ["higher", 165], ["eukaryotes", 172], [".", 182], ["Surprisingly", 184], [",", 196], ["little", 198], ["is", 205], ["known", 208], ["about", 214], ["the", 220], ["biological", 224], ["significance", 235], ["or", 248], ["the", 251], ["mechanism", 255], ["of", 265], ["early", 268], ["centromere", 274], ["replication", 285], [";", 296], ["however", 298], [",", 305], ["the", 307], ["extensive", 311], ["conservation", 321], ["suggests", 334], ["that", 343], ["it", 348], ["is", 351], ["important", 354], ["for", 364], ["chromosome", 368], ["maintenance", 379], [".", 390], ["Do", 392], ["centromeres", 395], ["ensure", 407], ["their", 414], ["early", 420], ["replication", 426], ["by", 438], ["promoting", 441], ["early", 451], ["activation", 457], ["of", 468], ["nearby", 471], ["origins", 478], [",", 485], ["or", 487], ["have", 490], ["they", 495], ["migrated", 500], ["over", 509], ["evolutionary", 514], ["time", 527], ["to", 532], ["reside", 535], ["in", 542], ["early", 545], ["replicating", 551], ["regions", 563], ["?", 570], ["In", 572], ["Candida", 575], ["albicans", 583], [",", 591], ["a", 593], ["neocentromere", 595], ["contains", 609], ["an", 618], ["early", 621], ["firing", 627], ["origin", 634], [",", 640], ["supporting", 642], ["the", 653], ["first", 657], ["hypothesis", 663], ["but", 674], ["not", 678], ["addressing", 682], ["whether", 693], ["the", 701], ["new", 705], ["origin", 709], ["is", 716], ["intrinsically", 719], ["early", 733], ["firing", 739], ["or", 746], ["whether", 749], ["the", 757], ["centromere", 761], ["influences", 772], ["replication", 783], ["time", 795], [".", 799], ["Because", 801], ["the", 809], ["activation", 813], ["time", 824], ["of", 829], ["individual", 832], ["origins", 843], ["is", 851], ["not", 854], ["an", 858], ["intrinsic", 861], ["property", 871], ["of", 880], ["S.", 883], ["cerevisiae", 886], ["origins", 897], [",", 904], ["but", 906], ["is", 910], ["influenced", 913], ["by", 924], ["surrounding", 927], ["sequences", 939], [",", 948], ["we", 950], ["sought", 953], ["to", 960], ["test", 963], ["the", 968], ["hypothesis", 972], ["that", 983], ["centromeres", 988], ["influence", 1000], ["replication", 1010], ["time", 1022], ["by", 1027], ["moving", 1030], ["a", 1037], ["centromere", 1039], ["to", 1050], ["a", 1053], ["late", 1055], ["replication", 1060], ["domain", 1072], [".", 1078], ["We", 1080], ["used", 1083], ["a", 1088], ["modified", 1090], ["Meselson", 1099], ["-", 1107], ["Stahl", 1108], ["density", 1114], ["transfer", 1122], ["assay", 1131], ["to", 1137], ["measure", 1140], ["the", 1148], ["kinetics", 1152], ["of", 1161], ["replication", 1164], ["for", 1176], ["regions", 1180], ["of", 1188], ["chromosome", 1191], ["XIV", 1202], ["in", 1206], ["which", 1209], ["either", 1215], ["the", 1222], ["functional", 1226], ["centromere", 1237], ["or", 1248], ["a", 1251], ["point", 1253], ["-", 1258], ["mutated", 1259], ["version", 1267], ["had", 1275], ["been", 1279], ["moved", 1284], ["near", 1290], ["origins", 1295], ["that", 1303], ["reside", 1308], ["in", 1315], ["a", 1318], ["late", 1320], ["replication", 1325], ["region", 1337], [".", 1343], ["We", 1345], ["show", 1348], ["that", 1353], ["a", 1358], ["functional", 1360], ["centromere", 1371], ["acts", 1382], ["in", 1387], ["cis", 1390], ["over", 1394], ["a", 1399], ["distance", 1401], ["as", 1410], ["great", 1413], ["as", 1419], ["19", 1422], ["kb", 1425], ["to", 1428], ["advance", 1431], ["the", 1439], ["initiation", 1443], ["time", 1454], ["of", 1459], ["origins", 1462], [".", 1469], ["Our", 1471], ["results", 1475], ["constitute", 1483], ["a", 1494], ["direct", 1496], ["link", 1503], ["between", 1508], ["establishment", 1516], ["of", 1530], ["the", 1533], ["kinetochore", 1537], ["and", 1549], ["the", 1553], ["replication", 1557], ["initiation", 1569], ["machinery", 1580], [",", 1589], ["and", 1591], ["suggest", 1595], ["that", 1603], ["the", 1608], ["proposed", 1612], ["higher", 1621], ["-", 1627], ["order", 1628], ["structure", 1634], ["of", 1644], ["the", 1647], ["pericentric", 1651], ["chromatin", 1663], ["influences", 1673], ["replication", 1684], ["initiation", 1696], [".", 1706]]}
{"context": "TIA-1 is an RNA binding protein that promotes the assembly of stress granules (SGs), discrete cytoplasmic inclusions into which stalled translation initiation complexes are dynamically recruited in cells subjected to environmental stress. The RNA recognition motifs of TIA-1 are linked to a glutamine-rich prion-related domain (PRD). Truncation mutants lacking the PRD domain do not induce spontaneous SGs and are not recruited to arsenite-induced SGs, whereas the PRD forms aggregates that are recruited to SGs in low-level-expressing cells but prevent SG assembly in high-level-expressing cells. The PRD of TIA-1 exhibits many characteristics of prions: concentration-dependent aggregation that is inhibited by the molecular chaperone heat shock protein (HSP)70; resistance to protease digestion; sequestration of HSP27, HSP40, and HSP70; and induction of HSP70, a feedback regulator of PRD disaggregation. Substitution of the PRD with the aggregation domain of a yeast prion, SUP35-NM, reconstitutes SG assembly, confirming that a prion domain can mediate the assembly of SGs. Mouse embryomic fibroblasts (MEFs) lacking TIA-1 exhibit impaired ability to form SGs, although they exhibit normal phosphorylation of eukaryotic initiation factor (eIF)2alpha in response to arsenite. Our results reveal that prion-like aggregation of TIA-1 regulates SG formation downstream of eIF2alpha phosphorylation in response to stress.", "qas": [{"question": "Which domain of TIA-1 is necessary for stress granule assembly?", "answers": ["The glutamine-rich prion-related domain (PRD)"], "qid": "b0c5cb7e458c48f9a369b023a6f154ef", "question_tokens": [["Which", 0], ["domain", 6], ["of", 13], ["TIA-1", 16], ["is", 22], ["necessary", 25], ["for", 35], ["stress", 39], ["granule", 46], ["assembly", 54], ["?", 62]], "detected_answers": [{"text": "The glutamine-rich prion-related domain (PRD)", "token_spans": [[46, 54]], "char_spans": [[291, 330]]}]}], "context_tokens": [["TIA-1", 0], ["is", 6], ["an", 9], ["RNA", 12], ["binding", 16], ["protein", 24], ["that", 32], ["promotes", 37], ["the", 46], ["assembly", 50], ["of", 59], ["stress", 62], ["granules", 69], ["(", 78], ["SGs", 79], [")", 82], [",", 83], ["discrete", 85], ["cytoplasmic", 94], ["inclusions", 106], ["into", 117], ["which", 122], ["stalled", 128], ["translation", 136], ["initiation", 148], ["complexes", 159], ["are", 169], ["dynamically", 173], ["recruited", 185], ["in", 195], ["cells", 198], ["subjected", 204], ["to", 214], ["environmental", 217], ["stress", 231], [".", 237], ["The", 239], ["RNA", 243], ["recognition", 247], ["motifs", 259], ["of", 266], ["TIA-1", 269], ["are", 275], ["linked", 279], ["to", 286], ["a", 289], ["glutamine", 291], ["-", 300], ["rich", 301], ["prion", 306], ["-", 311], ["related", 312], ["domain", 320], ["(", 327], ["PRD", 328], [")", 331], [".", 332], ["Truncation", 334], ["mutants", 345], ["lacking", 353], ["the", 361], ["PRD", 365], ["domain", 369], ["do", 376], ["not", 379], ["induce", 383], ["spontaneous", 390], ["SGs", 402], ["and", 406], ["are", 410], ["not", 414], ["recruited", 418], ["to", 428], ["arsenite", 431], ["-", 439], ["induced", 440], ["SGs", 448], [",", 451], ["whereas", 453], ["the", 461], ["PRD", 465], ["forms", 469], ["aggregates", 475], ["that", 486], ["are", 491], ["recruited", 495], ["to", 505], ["SGs", 508], ["in", 512], ["low", 515], ["-", 518], ["level", 519], ["-", 524], ["expressing", 525], ["cells", 536], ["but", 542], ["prevent", 546], ["SG", 554], ["assembly", 557], ["in", 566], ["high", 569], ["-", 573], ["level", 574], ["-", 579], ["expressing", 580], ["cells", 591], [".", 596], ["The", 598], ["PRD", 602], ["of", 606], ["TIA-1", 609], ["exhibits", 615], ["many", 624], ["characteristics", 629], ["of", 645], ["prions", 648], [":", 654], ["concentration", 656], ["-", 669], ["dependent", 670], ["aggregation", 680], ["that", 692], ["is", 697], ["inhibited", 700], ["by", 710], ["the", 713], ["molecular", 717], ["chaperone", 727], ["heat", 737], ["shock", 742], ["protein", 748], ["(", 756], ["HSP)70", 757], [";", 763], ["resistance", 765], ["to", 776], ["protease", 779], ["digestion", 788], [";", 797], ["sequestration", 799], ["of", 813], ["HSP27", 816], [",", 821], ["HSP40", 823], [",", 828], ["and", 830], ["HSP70", 834], [";", 839], ["and", 841], ["induction", 845], ["of", 855], ["HSP70", 858], [",", 863], ["a", 865], ["feedback", 867], ["regulator", 876], ["of", 886], ["PRD", 889], ["disaggregation", 893], [".", 907], ["Substitution", 909], ["of", 922], ["the", 925], ["PRD", 929], ["with", 933], ["the", 938], ["aggregation", 942], ["domain", 954], ["of", 961], ["a", 964], ["yeast", 966], ["prion", 972], [",", 977], ["SUP35-NM", 979], [",", 987], ["reconstitutes", 989], ["SG", 1003], ["assembly", 1006], [",", 1014], ["confirming", 1016], ["that", 1027], ["a", 1032], ["prion", 1034], ["domain", 1040], ["can", 1047], ["mediate", 1051], ["the", 1059], ["assembly", 1063], ["of", 1072], ["SGs", 1075], [".", 1078], ["Mouse", 1080], ["embryomic", 1086], ["fibroblasts", 1096], ["(", 1108], ["MEFs", 1109], [")", 1113], ["lacking", 1115], ["TIA-1", 1123], ["exhibit", 1129], ["impaired", 1137], ["ability", 1146], ["to", 1154], ["form", 1157], ["SGs", 1162], [",", 1165], ["although", 1167], ["they", 1176], ["exhibit", 1181], ["normal", 1189], ["phosphorylation", 1196], ["of", 1212], ["eukaryotic", 1215], ["initiation", 1226], ["factor", 1237], ["(", 1244], ["eIF)2alpha", 1245], ["in", 1256], ["response", 1259], ["to", 1268], ["arsenite", 1271], [".", 1279], ["Our", 1281], ["results", 1285], ["reveal", 1293], ["that", 1300], ["prion", 1305], ["-", 1310], ["like", 1311], ["aggregation", 1316], ["of", 1328], ["TIA-1", 1331], ["regulates", 1337], ["SG", 1347], ["formation", 1350], ["downstream", 1360], ["of", 1371], ["eIF2alpha", 1374], ["phosphorylation", 1384], ["in", 1400], ["response", 1403], ["to", 1412], ["stress", 1415], [".", 1421]]}
{"context": "The Muenke syndrome (MS) is characterized by unicoronal or bicoronal craniosynostosis, midfacial hypoplasia, ocular hypertelorism, and a variety of minor abnormalities associated with a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. The birth prevalence is approximately one in 10,000 live births, accounting for 8-10% of patients with coronal synostosis. Although MS is a relatively common diagnosis in patients with craniosynostosis syndromes, with autosomal dominant inheritance, there has been no report of MS, in an affected Korean family with typical cephalo-facial morphology that has been confirmed by molecular studies. Here, we report a familial case of MS in a female patient with a Pro250Arg mutation in exon 7 (IgII-IGIII linker domain) of the FGFR3 gene. This patient had mild midfacial hypoplasia, hypertelorism, downslanting palpebral fissures, a beak shaped nose, plagio-brachycephaly, and mild neurodevelopmental delay. The same mutation was confirmed in the patient's mother, two of the mother's sisters and the maternal grandfather. The severity of the cephalo-facial anomalies was variable among these family members.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "d053f9773d0649b8b2acea49e06af19f", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[32, 38]], "char_spans": [[202, 243]]}]}], "context_tokens": [["The", 0], ["Muenke", 4], ["syndrome", 11], ["(", 20], ["MS", 21], [")", 23], ["is", 25], ["characterized", 28], ["by", 42], ["unicoronal", 45], ["or", 56], ["bicoronal", 59], ["craniosynostosis", 69], [",", 85], ["midfacial", 87], ["hypoplasia", 97], [",", 107], ["ocular", 109], ["hypertelorism", 116], [",", 129], ["and", 131], ["a", 135], ["variety", 137], ["of", 145], ["minor", 148], ["abnormalities", 154], ["associated", 168], ["with", 179], ["a", 184], ["mutation", 186], ["in", 195], ["the", 198], ["fibroblast", 202], ["growth", 213], ["factor", 220], ["receptor", 227], ["3", 236], ["(", 238], ["FGFR3", 239], [")", 244], ["gene", 246], [".", 250], ["The", 252], ["birth", 256], ["prevalence", 262], ["is", 273], ["approximately", 276], ["one", 290], ["in", 294], ["10,000", 297], ["live", 304], ["births", 309], [",", 315], ["accounting", 317], ["for", 328], ["8", 332], ["-", 333], ["10", 334], ["%", 336], ["of", 338], ["patients", 341], ["with", 350], ["coronal", 355], ["synostosis", 363], [".", 373], ["Although", 375], ["MS", 384], ["is", 387], ["a", 390], ["relatively", 392], ["common", 403], ["diagnosis", 410], ["in", 420], ["patients", 423], ["with", 432], ["craniosynostosis", 437], ["syndromes", 454], [",", 463], ["with", 465], ["autosomal", 470], ["dominant", 480], ["inheritance", 489], [",", 500], ["there", 502], ["has", 508], ["been", 512], ["no", 517], ["report", 520], ["of", 527], ["MS", 530], [",", 532], ["in", 534], ["an", 537], ["affected", 540], ["Korean", 549], ["family", 556], ["with", 563], ["typical", 568], ["cephalo", 576], ["-", 583], ["facial", 584], ["morphology", 591], ["that", 602], ["has", 607], ["been", 611], ["confirmed", 616], ["by", 626], ["molecular", 629], ["studies", 639], [".", 646], ["Here", 648], [",", 652], ["we", 654], ["report", 657], ["a", 664], ["familial", 666], ["case", 675], ["of", 680], ["MS", 683], ["in", 686], ["a", 689], ["female", 691], ["patient", 698], ["with", 706], ["a", 711], ["Pro250Arg", 713], ["mutation", 723], ["in", 732], ["exon", 735], ["7", 740], ["(", 742], ["IgII", 743], ["-", 747], ["IGIII", 748], ["linker", 754], ["domain", 761], [")", 767], ["of", 769], ["the", 772], ["FGFR3", 776], ["gene", 782], [".", 786], ["This", 788], ["patient", 793], ["had", 801], ["mild", 805], ["midfacial", 810], ["hypoplasia", 820], [",", 830], ["hypertelorism", 832], [",", 845], ["downslanting", 847], ["palpebral", 860], ["fissures", 870], [",", 878], ["a", 880], ["beak", 882], ["shaped", 887], ["nose", 894], [",", 898], ["plagio", 900], ["-", 906], ["brachycephaly", 907], [",", 920], ["and", 922], ["mild", 926], ["neurodevelopmental", 931], ["delay", 950], [".", 955], ["The", 957], ["same", 961], ["mutation", 966], ["was", 975], ["confirmed", 979], ["in", 989], ["the", 992], ["patient", 996], ["'s", 1003], ["mother", 1006], [",", 1012], ["two", 1014], ["of", 1018], ["the", 1021], ["mother", 1025], ["'s", 1031], ["sisters", 1034], ["and", 1042], ["the", 1046], ["maternal", 1050], ["grandfather", 1059], [".", 1070], ["The", 1072], ["severity", 1076], ["of", 1085], ["the", 1088], ["cephalo", 1092], ["-", 1099], ["facial", 1100], ["anomalies", 1107], ["was", 1117], ["variable", 1121], ["among", 1130], ["these", 1136], ["family", 1142], ["members", 1149], [".", 1156]]}
{"context": "The major constituent of senile plaques in Alzheimer's disease is a 42-aa peptide, referred to as beta-amyloid (Abeta). Abeta is generated from a family of differentially spliced, type-1 transmembrane domain (TM)-containing proteins, called APP, by endoproteolytic processing. The major, relatively ubiquitous pathway of APP metabolism in cell culture involves cleavage by alpha-secretase, which cleaves within the Abeta sequence, thus precluding Abeta formation and deposition. An alternate secretory pathway, enriched in neurons and brain, leads to cleavage of APP at the N terminus of the Abeta peptide by beta-secretase, thus generating a cell-associated beta-C-terminal fragment (beta-CTF). A pathogenic mutation at codons 670/671 in APP (APP \"Swedish\") leads to enhanced cleavage at the beta-secretase scissile bond and increased Abeta formation. An inhibitor of vacuolar ATPases, bafilomycin, selectively inhibits the action of beta-secretase in cell culture, suggesting a requirement for an acidic intracellular compartment for effective beta-secretase cleavage of APP. beta-CTF is cleaved in the TM domain by gamma-secretase(s), generating both Abeta 1-40 (90%) and Abeta 1-42 (10%). Pathogenic mutations in APP at codon 717 (APP \"London\") lead to an increased proportion of Abeta 1-42 being produced and secreted. Missense mutations in PS-1, localized to chromosome 14, are pathogenic in the majority of familial Alzheimer's pedigrees. These mutations also lead to increased production of Abeta 1-42 over Abeta 1-40. Knockout of PS-1 in transgenic animals leads to significant inhibition of production of both Abeta 1-40 and Abeta 1-42 in primary cultures, indicating that PS-1 expression is important for gamma-secretase cleavages. Peptide aldehyde inhibitors that block Abeta production by inhibiting gamma-secretase cleavage of beta-CTF have been discovered.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "2e818059dd7c4f0d898f3266677d9a3c", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[7, 9]], "char_spans": [[43, 61]]}]}], "context_tokens": [["The", 0], ["major", 4], ["constituent", 10], ["of", 22], ["senile", 25], ["plaques", 32], ["in", 40], ["Alzheimer", 43], ["'s", 52], ["disease", 55], ["is", 63], ["a", 66], ["42-aa", 68], ["peptide", 74], [",", 81], ["referred", 83], ["to", 92], ["as", 95], ["beta", 98], ["-", 102], ["amyloid", 103], ["(", 111], ["Abeta", 112], [")", 117], [".", 118], ["Abeta", 120], ["is", 126], ["generated", 129], ["from", 139], ["a", 144], ["family", 146], ["of", 153], ["differentially", 156], ["spliced", 171], [",", 178], ["type-1", 180], ["transmembrane", 187], ["domain", 201], ["(", 208], ["TM)-containing", 209], ["proteins", 224], [",", 232], ["called", 234], ["APP", 241], [",", 244], ["by", 246], ["endoproteolytic", 249], ["processing", 265], [".", 275], ["The", 277], ["major", 281], [",", 286], ["relatively", 288], ["ubiquitous", 299], ["pathway", 310], ["of", 318], ["APP", 321], ["metabolism", 325], ["in", 336], ["cell", 339], ["culture", 344], ["involves", 352], ["cleavage", 361], ["by", 370], ["alpha", 373], ["-", 378], ["secretase", 379], [",", 388], ["which", 390], ["cleaves", 396], ["within", 404], ["the", 411], ["Abeta", 415], ["sequence", 421], [",", 429], ["thus", 431], ["precluding", 436], ["Abeta", 447], ["formation", 453], ["and", 463], ["deposition", 467], [".", 477], ["An", 479], ["alternate", 482], ["secretory", 492], ["pathway", 502], [",", 509], ["enriched", 511], ["in", 520], ["neurons", 523], ["and", 531], ["brain", 535], [",", 540], ["leads", 542], ["to", 548], ["cleavage", 551], ["of", 560], ["APP", 563], ["at", 567], ["the", 570], ["N", 574], ["terminus", 576], ["of", 585], ["the", 588], ["Abeta", 592], ["peptide", 598], ["by", 606], ["beta", 609], ["-", 613], ["secretase", 614], [",", 623], ["thus", 625], ["generating", 630], ["a", 641], ["cell", 643], ["-", 647], ["associated", 648], ["beta", 659], ["-", 663], ["C", 664], ["-", 665], ["terminal", 666], ["fragment", 675], ["(", 684], ["beta", 685], ["-", 689], ["CTF", 690], [")", 693], [".", 694], ["A", 696], ["pathogenic", 698], ["mutation", 709], ["at", 718], ["codons", 721], ["670/671", 728], ["in", 736], ["APP", 739], ["(", 743], ["APP", 744], ["\"", 748], ["Swedish", 749], ["\"", 756], [")", 757], ["leads", 759], ["to", 765], ["enhanced", 768], ["cleavage", 777], ["at", 786], ["the", 789], ["beta", 793], ["-", 797], ["secretase", 798], ["scissile", 808], ["bond", 817], ["and", 822], ["increased", 826], ["Abeta", 836], ["formation", 842], [".", 851], ["An", 853], ["inhibitor", 856], ["of", 866], ["vacuolar", 869], ["ATPases", 878], [",", 885], ["bafilomycin", 887], [",", 898], ["selectively", 900], ["inhibits", 912], ["the", 921], ["action", 925], ["of", 932], ["beta", 935], ["-", 939], ["secretase", 940], ["in", 950], ["cell", 953], ["culture", 958], [",", 965], ["suggesting", 967], ["a", 978], ["requirement", 980], ["for", 992], ["an", 996], ["acidic", 999], ["intracellular", 1006], ["compartment", 1020], ["for", 1032], ["effective", 1036], ["beta", 1046], ["-", 1050], ["secretase", 1051], ["cleavage", 1061], ["of", 1070], ["APP", 1073], [".", 1076], ["beta", 1078], ["-", 1082], ["CTF", 1083], ["is", 1087], ["cleaved", 1090], ["in", 1098], ["the", 1101], ["TM", 1105], ["domain", 1108], ["by", 1115], ["gamma", 1118], ["-", 1123], ["secretase(s", 1124], [")", 1135], [",", 1136], ["generating", 1138], ["both", 1149], ["Abeta", 1154], ["1", 1160], ["-", 1161], ["40", 1162], ["(", 1165], ["90", 1166], ["%", 1168], [")", 1169], ["and", 1171], ["Abeta", 1175], ["1", 1181], ["-", 1182], ["42", 1183], ["(", 1186], ["10", 1187], ["%", 1189], [")", 1190], [".", 1191], ["Pathogenic", 1193], ["mutations", 1204], ["in", 1214], ["APP", 1217], ["at", 1221], ["codon", 1224], ["717", 1230], ["(", 1234], ["APP", 1235], ["\"", 1239], ["London", 1240], ["\"", 1246], [")", 1247], ["lead", 1249], ["to", 1254], ["an", 1257], ["increased", 1260], ["proportion", 1270], ["of", 1281], ["Abeta", 1284], ["1", 1290], ["-", 1291], ["42", 1292], ["being", 1295], ["produced", 1301], ["and", 1310], ["secreted", 1314], [".", 1322], ["Missense", 1324], ["mutations", 1333], ["in", 1343], ["PS-1", 1346], [",", 1350], ["localized", 1352], ["to", 1362], ["chromosome", 1365], ["14", 1376], [",", 1378], ["are", 1380], ["pathogenic", 1384], ["in", 1395], ["the", 1398], ["majority", 1402], ["of", 1411], ["familial", 1414], ["Alzheimer", 1423], ["'s", 1432], ["pedigrees", 1435], [".", 1444], ["These", 1446], ["mutations", 1452], ["also", 1462], ["lead", 1467], ["to", 1472], ["increased", 1475], ["production", 1485], ["of", 1496], ["Abeta", 1499], ["1", 1505], ["-", 1506], ["42", 1507], ["over", 1510], ["Abeta", 1515], ["1", 1521], ["-", 1522], ["40", 1523], [".", 1525], ["Knockout", 1527], ["of", 1536], ["PS-1", 1539], ["in", 1544], ["transgenic", 1547], ["animals", 1558], ["leads", 1566], ["to", 1572], ["significant", 1575], ["inhibition", 1587], ["of", 1598], ["production", 1601], ["of", 1612], ["both", 1615], ["Abeta", 1620], ["1", 1626], ["-", 1627], ["40", 1628], ["and", 1631], ["Abeta", 1635], ["1", 1641], ["-", 1642], ["42", 1643], ["in", 1646], ["primary", 1649], ["cultures", 1657], [",", 1665], ["indicating", 1667], ["that", 1678], ["PS-1", 1683], ["expression", 1688], ["is", 1699], ["important", 1702], ["for", 1712], ["gamma", 1716], ["-", 1721], ["secretase", 1722], ["cleavages", 1732], [".", 1741], ["Peptide", 1743], ["aldehyde", 1751], ["inhibitors", 1760], ["that", 1771], ["block", 1776], ["Abeta", 1782], ["production", 1788], ["by", 1799], ["inhibiting", 1802], ["gamma", 1813], ["-", 1818], ["secretase", 1819], ["cleavage", 1829], ["of", 1838], ["beta", 1841], ["-", 1845], ["CTF", 1846], ["have", 1850], ["been", 1855], ["discovered", 1860], [".", 1870]]}
{"context": "Bacillus anthracis plasmid pXO1 carries the structural genes for the three anthrax toxin proteins, cya (edema factor), lef (lethal factor), and pag (protective antigen). Expression of the toxin genes by B. anthracis is enhanced during growth under elevated levels of CO2. This CO2 effect is observed only in the presence of another pXO1 gene, atxA, which encodes a transactivator of anthrax toxin synthesis. Here we show that transcription of atxA does not appear to differ in cells grown in 5% CO2 compared with cells grown in air. Using a new efficient method for gene replacement in B. anthracis, we constructed an atxA-null mutant in which the atxA-coding sequence on pXO1 is replaced with an omega km-2 cassette. Transcription of all three toxin genes is decreased in the absence of atxA. The pag gene possesses two apparent transcription start sites, P1 and P2; only transcripts with 5' ends mapping to P1 are decreased in the atxA-null mutant. Deletion analysis of the pag promoter region indicates that the 111 bp region upstream of the P1 site is sufficient for atxA-mediated activation of this transcript. The cya and lef genes each have one apparent start site for transcription. Transcripts with 5' ends mapping to these sites are not detected in the atxA-null mutant. The atxA-null mutant is avirulent in mice. Moreover, the antibody response to all three toxin proteins is decreased significantly in atxA-null mutant-infected mice. These data suggest that the atxA gene product also regulates toxin gene expression during infection.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "e37eef543acc42c0902146dfb8efe1c7", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "CO2", "token_spans": [[95, 95], [53, 53], [50, 50]], "char_spans": [[495, 497], [277, 279], [267, 269]]}]}], "context_tokens": [["Bacillus", 0], ["anthracis", 9], ["plasmid", 19], ["pXO1", 27], ["carries", 32], ["the", 40], ["structural", 44], ["genes", 55], ["for", 61], ["the", 65], ["three", 69], ["anthrax", 75], ["toxin", 83], ["proteins", 89], [",", 97], ["cya", 99], ["(", 103], ["edema", 104], ["factor", 110], [")", 116], [",", 117], ["lef", 119], ["(", 123], ["lethal", 124], ["factor", 131], [")", 137], [",", 138], ["and", 140], ["pag", 144], ["(", 148], ["protective", 149], ["antigen", 160], [")", 167], [".", 168], ["Expression", 170], ["of", 181], ["the", 184], ["toxin", 188], ["genes", 194], ["by", 200], ["B.", 203], ["anthracis", 206], ["is", 216], ["enhanced", 219], ["during", 228], ["growth", 235], ["under", 242], ["elevated", 248], ["levels", 257], ["of", 264], ["CO2", 267], [".", 270], ["This", 272], ["CO2", 277], ["effect", 281], ["is", 288], ["observed", 291], ["only", 300], ["in", 305], ["the", 308], ["presence", 312], ["of", 321], ["another", 324], ["pXO1", 332], ["gene", 337], [",", 341], ["atxA", 343], [",", 347], ["which", 349], ["encodes", 355], ["a", 363], ["transactivator", 365], ["of", 380], ["anthrax", 383], ["toxin", 391], ["synthesis", 397], [".", 406], ["Here", 408], ["we", 413], ["show", 416], ["that", 421], ["transcription", 426], ["of", 440], ["atxA", 443], ["does", 448], ["not", 453], ["appear", 457], ["to", 464], ["differ", 467], ["in", 474], ["cells", 477], ["grown", 483], ["in", 489], ["5", 492], ["%", 493], ["CO2", 495], ["compared", 499], ["with", 508], ["cells", 513], ["grown", 519], ["in", 525], ["air", 528], [".", 531], ["Using", 533], ["a", 539], ["new", 541], ["efficient", 545], ["method", 555], ["for", 562], ["gene", 566], ["replacement", 571], ["in", 583], ["B.", 586], ["anthracis", 589], [",", 598], ["we", 600], ["constructed", 603], ["an", 615], ["atxA", 618], ["-", 622], ["null", 623], ["mutant", 628], ["in", 635], ["which", 638], ["the", 644], ["atxA", 648], ["-", 652], ["coding", 653], ["sequence", 660], ["on", 669], ["pXO1", 672], ["is", 677], ["replaced", 680], ["with", 689], ["an", 694], ["omega", 697], ["km-2", 703], ["cassette", 708], [".", 716], ["Transcription", 718], ["of", 732], ["all", 735], ["three", 739], ["toxin", 745], ["genes", 751], ["is", 757], ["decreased", 760], ["in", 770], ["the", 773], ["absence", 777], ["of", 785], ["atxA.", 788], ["The", 794], ["pag", 798], ["gene", 802], ["possesses", 807], ["two", 817], ["apparent", 821], ["transcription", 830], ["start", 844], ["sites", 850], [",", 855], ["P1", 857], ["and", 860], ["P2", 864], [";", 866], ["only", 868], ["transcripts", 873], ["with", 885], ["5", 890], ["'", 891], ["ends", 893], ["mapping", 898], ["to", 906], ["P1", 909], ["are", 912], ["decreased", 916], ["in", 926], ["the", 929], ["atxA", 933], ["-", 937], ["null", 938], ["mutant", 943], [".", 949], ["Deletion", 951], ["analysis", 960], ["of", 969], ["the", 972], ["pag", 976], ["promoter", 980], ["region", 989], ["indicates", 996], ["that", 1006], ["the", 1011], ["111", 1015], ["bp", 1019], ["region", 1022], ["upstream", 1029], ["of", 1038], ["the", 1041], ["P1", 1045], ["site", 1048], ["is", 1053], ["sufficient", 1056], ["for", 1067], ["atxA", 1071], ["-", 1075], ["mediated", 1076], ["activation", 1085], ["of", 1096], ["this", 1099], ["transcript", 1104], [".", 1114], ["The", 1116], ["cya", 1120], ["and", 1124], ["lef", 1128], ["genes", 1132], ["each", 1138], ["have", 1143], ["one", 1148], ["apparent", 1152], ["start", 1161], ["site", 1167], ["for", 1172], ["transcription", 1176], [".", 1189], ["Transcripts", 1191], ["with", 1203], ["5", 1208], ["'", 1209], ["ends", 1211], ["mapping", 1216], ["to", 1224], ["these", 1227], ["sites", 1233], ["are", 1239], ["not", 1243], ["detected", 1247], ["in", 1256], ["the", 1259], ["atxA", 1263], ["-", 1267], ["null", 1268], ["mutant", 1273], [".", 1279], ["The", 1281], ["atxA", 1285], ["-", 1289], ["null", 1290], ["mutant", 1295], ["is", 1302], ["avirulent", 1305], ["in", 1315], ["mice", 1318], [".", 1322], ["Moreover", 1324], [",", 1332], ["the", 1334], ["antibody", 1338], ["response", 1347], ["to", 1356], ["all", 1359], ["three", 1363], ["toxin", 1369], ["proteins", 1375], ["is", 1384], ["decreased", 1387], ["significantly", 1397], ["in", 1411], ["atxA", 1414], ["-", 1418], ["null", 1419], ["mutant", 1424], ["-", 1430], ["infected", 1431], ["mice", 1440], [".", 1444], ["These", 1446], ["data", 1452], ["suggest", 1457], ["that", 1465], ["the", 1470], ["atxA", 1474], ["gene", 1479], ["product", 1484], ["also", 1492], ["regulates", 1497], ["toxin", 1507], ["gene", 1513], ["expression", 1518], ["during", 1529], ["infection", 1536], [".", 1545]]}
{"context": "The positive regulatory machinery in the microRNA (miRNA) processing pathway is relatively well characterized, but negative regulation of the pathway is largely unknown. Here we show that a complex of nuclear factor 90 (NF90) and NF45 proteins functions as a negative regulator in miRNA biogenesis. Primary miRNA (pri-miRNA) processing into precursor miRNA (pre-miRNA) was inhibited by overexpression of the NF90 and NF45 proteins, and considerable amounts of pri-miRNAs accumulated in cells coexpressing NF90 and NF45. Treatment of cells overexpressing NF90 and NF45 with an RNA polymerase II inhibitor, alpha-amanitin, did not reduce the amounts of pri-miRNAs, suggesting that the accumulation of pri-miRNAs is not due to transcriptional activation. In addition, the NF90 and NF45 complex was not found to interact with the Microprocessor complex, which is a processing factor of pri-miRNAs, but was found to bind endogenous pri-miRNAs. NF90-NF45 exhibited higher binding activity for pri-let-7a than pri-miR-21. Of note, depletion of NF90 caused a reduction of pri-let-7a and an increase of mature let-7a miRNA, which has a potent antiproliferative activity, and caused growth suppression of transformed cells. These findings suggest that the association of the NF90-NF45 complex with pri-miRNAs impairs access of the Microprocessor complex to the pri-miRNAs, resulting in a reduction of mature miRNA production.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "8e8bc2fb6f4f494c94d828de7c279203", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[103, 105]], "char_spans": [[576, 592]]}]}], "context_tokens": [["The", 0], ["positive", 4], ["regulatory", 13], ["machinery", 24], ["in", 34], ["the", 37], ["microRNA", 41], ["(", 50], ["miRNA", 51], [")", 56], ["processing", 58], ["pathway", 69], ["is", 77], ["relatively", 80], ["well", 91], ["characterized", 96], [",", 109], ["but", 111], ["negative", 115], ["regulation", 124], ["of", 135], ["the", 138], ["pathway", 142], ["is", 150], ["largely", 153], ["unknown", 161], [".", 168], ["Here", 170], ["we", 175], ["show", 178], ["that", 183], ["a", 188], ["complex", 190], ["of", 198], ["nuclear", 201], ["factor", 209], ["90", 216], ["(", 219], ["NF90", 220], [")", 224], ["and", 226], ["NF45", 230], ["proteins", 235], ["functions", 244], ["as", 254], ["a", 257], ["negative", 259], ["regulator", 268], ["in", 278], ["miRNA", 281], ["biogenesis", 287], [".", 297], ["Primary", 299], ["miRNA", 307], ["(", 313], ["pri", 314], ["-", 317], ["miRNA", 318], [")", 323], ["processing", 325], ["into", 336], ["precursor", 341], ["miRNA", 351], ["(", 357], ["pre", 358], ["-", 361], ["miRNA", 362], [")", 367], ["was", 369], ["inhibited", 373], ["by", 383], ["overexpression", 386], ["of", 401], ["the", 404], ["NF90", 408], ["and", 413], ["NF45", 417], ["proteins", 422], [",", 430], ["and", 432], ["considerable", 436], ["amounts", 449], ["of", 457], ["pri", 460], ["-", 463], ["miRNAs", 464], ["accumulated", 471], ["in", 483], ["cells", 486], ["coexpressing", 492], ["NF90", 505], ["and", 510], ["NF45", 514], [".", 518], ["Treatment", 520], ["of", 530], ["cells", 533], ["overexpressing", 539], ["NF90", 554], ["and", 559], ["NF45", 563], ["with", 568], ["an", 573], ["RNA", 576], ["polymerase", 580], ["II", 591], ["inhibitor", 594], [",", 603], ["alpha", 605], ["-", 610], ["amanitin", 611], [",", 619], ["did", 621], ["not", 625], ["reduce", 629], ["the", 636], ["amounts", 640], ["of", 648], ["pri", 651], ["-", 654], ["miRNAs", 655], [",", 661], ["suggesting", 663], ["that", 674], ["the", 679], ["accumulation", 683], ["of", 696], ["pri", 699], ["-", 702], ["miRNAs", 703], ["is", 710], ["not", 713], ["due", 717], ["to", 721], ["transcriptional", 724], ["activation", 740], [".", 750], ["In", 752], ["addition", 755], [",", 763], ["the", 765], ["NF90", 769], ["and", 774], ["NF45", 778], ["complex", 783], ["was", 791], ["not", 795], ["found", 799], ["to", 805], ["interact", 808], ["with", 817], ["the", 822], ["Microprocessor", 826], ["complex", 841], [",", 848], ["which", 850], ["is", 856], ["a", 859], ["processing", 861], ["factor", 872], ["of", 879], ["pri", 882], ["-", 885], ["miRNAs", 886], [",", 892], ["but", 894], ["was", 898], ["found", 902], ["to", 908], ["bind", 911], ["endogenous", 916], ["pri", 927], ["-", 930], ["miRNAs", 931], [".", 937], ["NF90-NF45", 939], ["exhibited", 949], ["higher", 959], ["binding", 966], ["activity", 974], ["for", 983], ["pri", 987], ["-", 990], ["let-7a", 991], ["than", 998], ["pri", 1003], ["-", 1006], ["miR-21", 1007], [".", 1013], ["Of", 1015], ["note", 1018], [",", 1022], ["depletion", 1024], ["of", 1034], ["NF90", 1037], ["caused", 1042], ["a", 1049], ["reduction", 1051], ["of", 1061], ["pri", 1064], ["-", 1067], ["let-7a", 1068], ["and", 1075], ["an", 1079], ["increase", 1082], ["of", 1091], ["mature", 1094], ["let-7a", 1101], ["miRNA", 1108], [",", 1113], ["which", 1115], ["has", 1121], ["a", 1125], ["potent", 1127], ["antiproliferative", 1134], ["activity", 1152], [",", 1160], ["and", 1162], ["caused", 1166], ["growth", 1173], ["suppression", 1180], ["of", 1192], ["transformed", 1195], ["cells", 1207], [".", 1212], ["These", 1214], ["findings", 1220], ["suggest", 1229], ["that", 1237], ["the", 1242], ["association", 1246], ["of", 1258], ["the", 1261], ["NF90-NF45", 1265], ["complex", 1275], ["with", 1283], ["pri", 1288], ["-", 1291], ["miRNAs", 1292], ["impairs", 1299], ["access", 1307], ["of", 1314], ["the", 1317], ["Microprocessor", 1321], ["complex", 1336], ["to", 1344], ["the", 1347], ["pri", 1351], ["-", 1354], ["miRNAs", 1355], [",", 1361], ["resulting", 1363], ["in", 1373], ["a", 1376], ["reduction", 1378], ["of", 1388], ["mature", 1391], ["miRNA", 1398], ["production", 1404], [".", 1414]]}
{"context": "Mycobacterium bovis BCG is widely used as a vaccine against tuberculosis (TB), despite its variable protective efficacy. Relatively little is known about the immune response profiles following BCG vaccination in relation to protection against TB. Here we tested whether BCG vaccination results in immune responses to DosR (Rv3133c) regulon-encoded proteins. These so-called TB latency antigens are targeted by the immune system during persistent Mycobacterium tuberculosis infection and have been associated with immunity against latent M. tuberculosis infection. In silico analysis of the DosR regulon in BCG and M. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical. Transcriptional profiling of 14 different BCG strains, under hypoxia and nitric oxide exposure in vitro, revealed a functional DosR regulon similar to that observed in M. tuberculosis. Next, we assessed human immune responses to a series of immunodominant TB latency antigens and found that BCG vaccination fails to induce significant responses to latency antigens. Similar results were obtained with BCG-vaccinated BALB/c mice. In contrast, responses to latency antigens were observed in individuals with suspected exposure to TB (as indicated by positive gamma interferon responses to TB-specific antigens ESAT-6 and CFP-10) and in mice vaccinated with plasmid DNA encoding selected latency antigens. Since immune responses to TB latency antigens have been associated with control of latent M. tuberculosis infection, our findings support the development of vaccination strategies incorporating DosR regulon antigens to complement and improve the current BCG vaccine.", "qas": [{"question": "How many genes constitute the DosR regulon, controlled by the dormancy survival regulator (DosR) in Mycobacterium tuberculosis?", "answers": ["48 genes"], "qid": "f40c5ca38b964c3fbfd353444320a3b9", "question_tokens": [["How", 0], ["many", 4], ["genes", 9], ["constitute", 15], ["the", 26], ["DosR", 30], ["regulon", 35], [",", 42], ["controlled", 44], ["by", 55], ["the", 58], ["dormancy", 62], ["survival", 71], ["regulator", 80], ["(", 90], ["DosR", 91], [")", 95], ["in", 97], ["Mycobacterium", 100], ["tuberculosis", 114], ["?", 126]], "detected_answers": [{"text": "48 genes", "token_spans": [[116, 117]], "char_spans": [[695, 702]]}]}], "context_tokens": [["Mycobacterium", 0], ["bovis", 14], ["BCG", 20], ["is", 24], ["widely", 27], ["used", 34], ["as", 39], ["a", 42], ["vaccine", 44], ["against", 52], ["tuberculosis", 60], ["(", 73], ["TB", 74], [")", 76], [",", 77], ["despite", 79], ["its", 87], ["variable", 91], ["protective", 100], ["efficacy", 111], [".", 119], ["Relatively", 121], ["little", 132], ["is", 139], ["known", 142], ["about", 148], ["the", 154], ["immune", 158], ["response", 165], ["profiles", 174], ["following", 183], ["BCG", 193], ["vaccination", 197], ["in", 209], ["relation", 212], ["to", 221], ["protection", 224], ["against", 235], ["TB", 243], [".", 245], ["Here", 247], ["we", 252], ["tested", 255], ["whether", 262], ["BCG", 270], ["vaccination", 274], ["results", 286], ["in", 294], ["immune", 297], ["responses", 304], ["to", 314], ["DosR", 317], ["(", 322], ["Rv3133c", 323], [")", 330], ["regulon", 332], ["-", 339], ["encoded", 340], ["proteins", 348], [".", 356], ["These", 358], ["so", 364], ["-", 366], ["called", 367], ["TB", 374], ["latency", 377], ["antigens", 385], ["are", 394], ["targeted", 398], ["by", 407], ["the", 410], ["immune", 414], ["system", 421], ["during", 428], ["persistent", 435], ["Mycobacterium", 446], ["tuberculosis", 460], ["infection", 473], ["and", 483], ["have", 487], ["been", 492], ["associated", 497], ["with", 508], ["immunity", 513], ["against", 522], ["latent", 530], ["M.", 537], ["tuberculosis", 540], ["infection", 553], [".", 562], ["In", 564], ["silico", 567], ["analysis", 574], ["of", 583], ["the", 586], ["DosR", 590], ["regulon", 595], ["in", 603], ["BCG", 606], ["and", 610], ["M.", 614], ["tuberculosis", 617], ["showed", 630], ["at", 637], ["least", 640], ["97", 646], ["%", 648], ["amino", 650], ["acid", 656], ["sequence", 661], ["homology", 670], [",", 678], ["with", 680], ["41", 685], ["out", 688], ["of", 692], ["48", 695], ["genes", 698], ["being", 704], ["identical", 710], [".", 719], ["Transcriptional", 721], ["profiling", 737], ["of", 747], ["14", 750], ["different", 753], ["BCG", 763], ["strains", 767], [",", 774], ["under", 776], ["hypoxia", 782], ["and", 790], ["nitric", 794], ["oxide", 801], ["exposure", 807], ["in", 816], ["vitro", 819], [",", 824], ["revealed", 826], ["a", 835], ["functional", 837], ["DosR", 848], ["regulon", 853], ["similar", 861], ["to", 869], ["that", 872], ["observed", 877], ["in", 886], ["M.", 889], ["tuberculosis", 892], [".", 904], ["Next", 906], [",", 910], ["we", 912], ["assessed", 915], ["human", 924], ["immune", 930], ["responses", 937], ["to", 947], ["a", 950], ["series", 952], ["of", 959], ["immunodominant", 962], ["TB", 977], ["latency", 980], ["antigens", 988], ["and", 997], ["found", 1001], ["that", 1007], ["BCG", 1012], ["vaccination", 1016], ["fails", 1028], ["to", 1034], ["induce", 1037], ["significant", 1044], ["responses", 1056], ["to", 1066], ["latency", 1069], ["antigens", 1077], [".", 1085], ["Similar", 1087], ["results", 1095], ["were", 1103], ["obtained", 1108], ["with", 1117], ["BCG", 1122], ["-", 1125], ["vaccinated", 1126], ["BALB", 1137], ["/", 1141], ["c", 1142], ["mice", 1144], [".", 1148], ["In", 1150], ["contrast", 1153], [",", 1161], ["responses", 1163], ["to", 1173], ["latency", 1176], ["antigens", 1184], ["were", 1193], ["observed", 1198], ["in", 1207], ["individuals", 1210], ["with", 1222], ["suspected", 1227], ["exposure", 1237], ["to", 1246], ["TB", 1249], ["(", 1252], ["as", 1253], ["indicated", 1256], ["by", 1266], ["positive", 1269], ["gamma", 1278], ["interferon", 1284], ["responses", 1295], ["to", 1305], ["TB", 1308], ["-", 1310], ["specific", 1311], ["antigens", 1320], ["ESAT-6", 1329], ["and", 1336], ["CFP-10", 1340], [")", 1346], ["and", 1348], ["in", 1352], ["mice", 1355], ["vaccinated", 1360], ["with", 1371], ["plasmid", 1376], ["DNA", 1384], ["encoding", 1388], ["selected", 1397], ["latency", 1406], ["antigens", 1414], [".", 1422], ["Since", 1424], ["immune", 1430], ["responses", 1437], ["to", 1447], ["TB", 1450], ["latency", 1453], ["antigens", 1461], ["have", 1470], ["been", 1475], ["associated", 1480], ["with", 1491], ["control", 1496], ["of", 1504], ["latent", 1507], ["M.", 1514], ["tuberculosis", 1517], ["infection", 1530], [",", 1539], ["our", 1541], ["findings", 1545], ["support", 1554], ["the", 1562], ["development", 1566], ["of", 1578], ["vaccination", 1581], ["strategies", 1593], ["incorporating", 1604], ["DosR", 1618], ["regulon", 1623], ["antigens", 1631], ["to", 1640], ["complement", 1643], ["and", 1654], ["improve", 1658], ["the", 1666], ["current", 1670], ["BCG", 1678], ["vaccine", 1682], [".", 1689]]}
{"context": "The endosomal/lysosomal transmembrane protein CLN3 is mutated in the Batten disease (juvenile neuronal ceroid lipofuscinosis, JNCL). However, the molecular mechanism of JNCL pathogenesis and the exact function of the CLN3 protein have remained unclear. Previous studies have shown that deletion of BTN1, the yeast orthologue of CLN3, leads to increased expression of BTN2. BTN2 encodes Btn2p, a proposed homologue to a novel microtubule-binding protein Hook1, which regulates endocytosis in Drosophila. We analysed here the putative interconnection between CLN3 and Hook1 in the mammalian cells and discovered that overexpression of human CLN3 induces aggregation of Hook1 protein, potentially by mediating its dissociation from the microtubules. Using in vitro binding assay we were able to demonstrate a weak interaction between Hook1 and the cytoplasmic segments of CLN3. We also found receptor-mediated endocytosis to be defective in CLN3-deficient JNCL fibroblasts, connecting CLN3, Hook1 and endocytosis in the mammalian system. Moreover, co-immunoprecipitation experiments showed that Hook1 physically interacts with endocytic Rab7, Rab9 and Rab11, hence delineating a manifold role for mammalian Hook1 in membrane trafficking events. These novel interactions between the microtubule-binding Hook1 and the large family of Rab GTPases also suggest a link between CLN3 function, microtubule cytoskeleton and endocytic membrane trafficking.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "1c5db62efbc145768b9fd53df6a404d5", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[11, 12]], "char_spans": [[69, 82]]}, {"text": "JNCL", "token_spans": [[156, 156], [28, 28], [19, 19]], "char_spans": [[953, 956], [169, 172], [126, 129]]}]}], "context_tokens": [["The", 0], ["endosomal", 4], ["/", 13], ["lysosomal", 14], ["transmembrane", 24], ["protein", 38], ["CLN3", 46], ["is", 51], ["mutated", 54], ["in", 62], ["the", 65], ["Batten", 69], ["disease", 76], ["(", 84], ["juvenile", 85], ["neuronal", 94], ["ceroid", 103], ["lipofuscinosis", 110], [",", 124], ["JNCL", 126], [")", 130], [".", 131], ["However", 133], [",", 140], ["the", 142], ["molecular", 146], ["mechanism", 156], ["of", 166], ["JNCL", 169], ["pathogenesis", 174], ["and", 187], ["the", 191], ["exact", 195], ["function", 201], ["of", 210], ["the", 213], ["CLN3", 217], ["protein", 222], ["have", 230], ["remained", 235], ["unclear", 244], [".", 251], ["Previous", 253], ["studies", 262], ["have", 270], ["shown", 275], ["that", 281], ["deletion", 286], ["of", 295], ["BTN1", 298], [",", 302], ["the", 304], ["yeast", 308], ["orthologue", 314], ["of", 325], ["CLN3", 328], [",", 332], ["leads", 334], ["to", 340], ["increased", 343], ["expression", 353], ["of", 364], ["BTN2", 367], [".", 371], ["BTN2", 373], ["encodes", 378], ["Btn2p", 386], [",", 391], ["a", 393], ["proposed", 395], ["homologue", 404], ["to", 414], ["a", 417], ["novel", 419], ["microtubule", 425], ["-", 436], ["binding", 437], ["protein", 445], ["Hook1", 453], [",", 458], ["which", 460], ["regulates", 466], ["endocytosis", 476], ["in", 488], ["Drosophila", 491], [".", 501], ["We", 503], ["analysed", 506], ["here", 515], ["the", 520], ["putative", 524], ["interconnection", 533], ["between", 549], ["CLN3", 557], ["and", 562], ["Hook1", 566], ["in", 572], ["the", 575], ["mammalian", 579], ["cells", 589], ["and", 595], ["discovered", 599], ["that", 610], ["overexpression", 615], ["of", 630], ["human", 633], ["CLN3", 639], ["induces", 644], ["aggregation", 652], ["of", 664], ["Hook1", 667], ["protein", 673], [",", 680], ["potentially", 682], ["by", 694], ["mediating", 697], ["its", 707], ["dissociation", 711], ["from", 724], ["the", 729], ["microtubules", 733], [".", 745], ["Using", 747], ["in", 753], ["vitro", 756], ["binding", 762], ["assay", 770], ["we", 776], ["were", 779], ["able", 784], ["to", 789], ["demonstrate", 792], ["a", 804], ["weak", 806], ["interaction", 811], ["between", 823], ["Hook1", 831], ["and", 837], ["the", 841], ["cytoplasmic", 845], ["segments", 857], ["of", 866], ["CLN3", 869], [".", 873], ["We", 875], ["also", 878], ["found", 883], ["receptor", 889], ["-", 897], ["mediated", 898], ["endocytosis", 907], ["to", 919], ["be", 922], ["defective", 925], ["in", 935], ["CLN3-deficient", 938], ["JNCL", 953], ["fibroblasts", 958], [",", 969], ["connecting", 971], ["CLN3", 982], [",", 986], ["Hook1", 988], ["and", 994], ["endocytosis", 998], ["in", 1010], ["the", 1013], ["mammalian", 1017], ["system", 1027], [".", 1033], ["Moreover", 1035], [",", 1043], ["co", 1045], ["-", 1047], ["immunoprecipitation", 1048], ["experiments", 1068], ["showed", 1080], ["that", 1087], ["Hook1", 1092], ["physically", 1098], ["interacts", 1109], ["with", 1119], ["endocytic", 1124], ["Rab7", 1134], [",", 1138], ["Rab9", 1140], ["and", 1145], ["Rab11", 1149], [",", 1154], ["hence", 1156], ["delineating", 1162], ["a", 1174], ["manifold", 1176], ["role", 1185], ["for", 1190], ["mammalian", 1194], ["Hook1", 1204], ["in", 1210], ["membrane", 1213], ["trafficking", 1222], ["events", 1234], [".", 1240], ["These", 1242], ["novel", 1248], ["interactions", 1254], ["between", 1267], ["the", 1275], ["microtubule", 1279], ["-", 1290], ["binding", 1291], ["Hook1", 1299], ["and", 1305], ["the", 1309], ["large", 1313], ["family", 1319], ["of", 1326], ["Rab", 1329], ["GTPases", 1333], ["also", 1341], ["suggest", 1346], ["a", 1354], ["link", 1356], ["between", 1361], ["CLN3", 1369], ["function", 1374], [",", 1382], ["microtubule", 1384], ["cytoskeleton", 1396], ["and", 1409], ["endocytic", 1413], ["membrane", 1423], ["trafficking", 1432], [".", 1443]]}
{"context": "Interstitial deletions of chromosome band Xq26.3 are rare. We report on a 2-year-old boy in whom array comparative genomic hybridization analysis revealed an interstitial 314 kb deletion in Xq26.3 affecting SLC9A6 and FHL1. Mutations in SLC9A6 are associated with Christianson syndrome (OMIM 300243), a syndromic form of X-linked mental retardation (XLMR) characterized by microcephaly, severe global developmental delay, ataxia and seizures. FHL1 mutations cause Emery-Dreifuss muscular dystrophy (OMIM 310300), X-linked myopathy with postural muscle atrophy (XMPMA, OMIM 300696), scapuloperoneal myopathy (OMIM 300695), or reducing body myopathy (OMIM 300717, 300718). The clinical problems of the patient reported here comprised severe intellectual disability, absent speech, ataxia, epilepsy, and gastroesophageal reflux, and could mostly be attributed to SLC9A6 insufficiency. In contrast to the majority of reported Christianson syndrome patients who were microcephalic, this patient was normocephalic, but his head circumference had decelerated from the 50th centile at birth to the 25th centile at the age of 2 \u00b2/\u00b9\u00b2 years. Muscle problems due to the FHL1 deletion are not to be expected before late childhood, which is the earliest age of onset for FHL1 associated Emery-Dreifuss muscular dystrophy. This patient broadens the spectrum of SLC9A6 mutations and contributes to the clinical delineation of Christianson syndrome. This is also the first patient with a deletion affecting both SLC9A6 and the complete FHL1 gene.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "66ed19703ab9429588260046aacc2ac1", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[235, 235], [151, 151], [39, 39], [258, 258], [33, 33]], "char_spans": [[1346, 1351], [860, 865], [237, 242], [1495, 1500], [207, 212]]}]}], "context_tokens": [["Interstitial", 0], ["deletions", 13], ["of", 23], ["chromosome", 26], ["band", 37], ["Xq26.3", 42], ["are", 49], ["rare", 53], [".", 57], ["We", 59], ["report", 62], ["on", 69], ["a", 72], ["2-year", 74], ["-", 80], ["old", 81], ["boy", 85], ["in", 89], ["whom", 92], ["array", 97], ["comparative", 103], ["genomic", 115], ["hybridization", 123], ["analysis", 137], ["revealed", 146], ["an", 155], ["interstitial", 158], ["314", 171], ["kb", 175], ["deletion", 178], ["in", 187], ["Xq26.3", 190], ["affecting", 197], ["SLC9A6", 207], ["and", 214], ["FHL1", 218], [".", 222], ["Mutations", 224], ["in", 234], ["SLC9A6", 237], ["are", 244], ["associated", 248], ["with", 259], ["Christianson", 264], ["syndrome", 277], ["(", 286], ["OMIM", 287], ["300243", 292], [")", 298], [",", 299], ["a", 301], ["syndromic", 303], ["form", 313], ["of", 318], ["X", 321], ["-", 322], ["linked", 323], ["mental", 330], ["retardation", 337], ["(", 349], ["XLMR", 350], [")", 354], ["characterized", 356], ["by", 370], ["microcephaly", 373], [",", 385], ["severe", 387], ["global", 394], ["developmental", 401], ["delay", 415], [",", 420], ["ataxia", 422], ["and", 429], ["seizures", 433], [".", 441], ["FHL1", 443], ["mutations", 448], ["cause", 458], ["Emery", 464], ["-", 469], ["Dreifuss", 470], ["muscular", 479], ["dystrophy", 488], ["(", 498], ["OMIM", 499], ["310300", 504], [")", 510], [",", 511], ["X", 513], ["-", 514], ["linked", 515], ["myopathy", 522], ["with", 531], ["postural", 536], ["muscle", 545], ["atrophy", 552], ["(", 560], ["XMPMA", 561], [",", 566], ["OMIM", 568], ["300696", 573], [")", 579], [",", 580], ["scapuloperoneal", 582], ["myopathy", 598], ["(", 607], ["OMIM", 608], ["300695", 613], [")", 619], [",", 620], ["or", 622], ["reducing", 625], ["body", 634], ["myopathy", 639], ["(", 648], ["OMIM", 649], ["300717", 654], [",", 660], ["300718", 662], [")", 668], [".", 669], ["The", 671], ["clinical", 675], ["problems", 684], ["of", 693], ["the", 696], ["patient", 700], ["reported", 708], ["here", 717], ["comprised", 722], ["severe", 732], ["intellectual", 739], ["disability", 752], [",", 762], ["absent", 764], ["speech", 771], [",", 777], ["ataxia", 779], [",", 785], ["epilepsy", 787], [",", 795], ["and", 797], ["gastroesophageal", 801], ["reflux", 818], [",", 824], ["and", 826], ["could", 830], ["mostly", 836], ["be", 843], ["attributed", 846], ["to", 857], ["SLC9A6", 860], ["insufficiency", 867], [".", 880], ["In", 882], ["contrast", 885], ["to", 894], ["the", 897], ["majority", 901], ["of", 910], ["reported", 913], ["Christianson", 922], ["syndrome", 935], ["patients", 944], ["who", 953], ["were", 957], ["microcephalic", 962], [",", 975], ["this", 977], ["patient", 982], ["was", 990], ["normocephalic", 994], [",", 1007], ["but", 1009], ["his", 1013], ["head", 1017], ["circumference", 1022], ["had", 1036], ["decelerated", 1040], ["from", 1052], ["the", 1057], ["50th", 1061], ["centile", 1066], ["at", 1074], ["birth", 1077], ["to", 1083], ["the", 1086], ["25th", 1090], ["centile", 1095], ["at", 1103], ["the", 1106], ["age", 1110], ["of", 1114], ["2", 1117], ["\u00b2/\u00b9\u00b2", 1119], ["years", 1124], [".", 1129], ["Muscle", 1131], ["problems", 1138], ["due", 1147], ["to", 1151], ["the", 1154], ["FHL1", 1158], ["deletion", 1163], ["are", 1172], ["not", 1176], ["to", 1180], ["be", 1183], ["expected", 1186], ["before", 1195], ["late", 1202], ["childhood", 1207], [",", 1216], ["which", 1218], ["is", 1224], ["the", 1227], ["earliest", 1231], ["age", 1240], ["of", 1244], ["onset", 1247], ["for", 1253], ["FHL1", 1257], ["associated", 1262], ["Emery", 1273], ["-", 1278], ["Dreifuss", 1279], ["muscular", 1288], ["dystrophy", 1297], [".", 1306], ["This", 1308], ["patient", 1313], ["broadens", 1321], ["the", 1330], ["spectrum", 1334], ["of", 1343], ["SLC9A6", 1346], ["mutations", 1353], ["and", 1363], ["contributes", 1367], ["to", 1379], ["the", 1382], ["clinical", 1386], ["delineation", 1395], ["of", 1407], ["Christianson", 1410], ["syndrome", 1423], [".", 1431], ["This", 1433], ["is", 1438], ["also", 1441], ["the", 1446], ["first", 1450], ["patient", 1456], ["with", 1464], ["a", 1469], ["deletion", 1471], ["affecting", 1480], ["both", 1490], ["SLC9A6", 1495], ["and", 1502], ["the", 1506], ["complete", 1510], ["FHL1", 1519], ["gene", 1524], [".", 1528]]}
{"context": "Nivolumab was developed as a monoclonal antibody against programmed death receptor-1, an immune checkpoint inhibitor which negatively regulates T-cell proliferation and activation. Intravenous administration of nivolumab was approved for the treatment of unresectable malignant melanoma in 2014 in Japan. When advanced melanoma patients were treated with nivolumab, median overall survival became longer. Overall survival rate was significantly better in nivolumab-treated melanoma patients than dacarbazine-treated melanoma patients. Nivolumab had an acceptable long-term tolerability profile, with 22% of patients experiencing grade 3 or 4 adverse events related to the drug. Therefore, nivolumab can become an alternative therapy for advanced malignant melanoma.", "qas": [{"question": "Which is the target protein of the drug nivolumab?", "answers": ["programmed death receptor-1"], "qid": "2b04e73544f7459d9232316ec0e13a4a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["protein", 20], ["of", 28], ["the", 31], ["drug", 35], ["nivolumab", 40], ["?", 49]], "detected_answers": [{"text": "programmed death receptor-1", "token_spans": [[8, 10]], "char_spans": [[57, 83]]}]}], "context_tokens": [["Nivolumab", 0], ["was", 10], ["developed", 14], ["as", 24], ["a", 27], ["monoclonal", 29], ["antibody", 40], ["against", 49], ["programmed", 57], ["death", 68], ["receptor-1", 74], [",", 84], ["an", 86], ["immune", 89], ["checkpoint", 96], ["inhibitor", 107], ["which", 117], ["negatively", 123], ["regulates", 134], ["T", 144], ["-", 145], ["cell", 146], ["proliferation", 151], ["and", 165], ["activation", 169], [".", 179], ["Intravenous", 181], ["administration", 193], ["of", 208], ["nivolumab", 211], ["was", 221], ["approved", 225], ["for", 234], ["the", 238], ["treatment", 242], ["of", 252], ["unresectable", 255], ["malignant", 268], ["melanoma", 278], ["in", 287], ["2014", 290], ["in", 295], ["Japan", 298], [".", 303], ["When", 305], ["advanced", 310], ["melanoma", 319], ["patients", 328], ["were", 337], ["treated", 342], ["with", 350], ["nivolumab", 355], [",", 364], ["median", 366], ["overall", 373], ["survival", 381], ["became", 390], ["longer", 397], [".", 403], ["Overall", 405], ["survival", 413], ["rate", 422], ["was", 427], ["significantly", 431], ["better", 445], ["in", 452], ["nivolumab", 455], ["-", 464], ["treated", 465], ["melanoma", 473], ["patients", 482], ["than", 491], ["dacarbazine", 496], ["-", 507], ["treated", 508], ["melanoma", 516], ["patients", 525], [".", 533], ["Nivolumab", 535], ["had", 545], ["an", 549], ["acceptable", 552], ["long", 563], ["-", 567], ["term", 568], ["tolerability", 573], ["profile", 586], [",", 593], ["with", 595], ["22", 600], ["%", 602], ["of", 604], ["patients", 607], ["experiencing", 616], ["grade", 629], ["3", 635], ["or", 637], ["4", 640], ["adverse", 642], ["events", 650], ["related", 657], ["to", 665], ["the", 668], ["drug", 672], [".", 676], ["Therefore", 678], [",", 687], ["nivolumab", 689], ["can", 699], ["become", 703], ["an", 710], ["alternative", 713], ["therapy", 725], ["for", 733], ["advanced", 737], ["malignant", 746], ["melanoma", 756], [".", 764]]}
{"context": "The generation of reactive oxygen species (ROS) is required for proper cell signaling, but must be tightly regulated to minimize deleterious oxidizing effects. Activation of the NADPH oxidases (Nox) triggers ROS production and, thus, regulatory mechanisms exist to properly control Nox activity. In this study, we report a novel mechanism in which Nox1 activity is regulated through the proteasomal degradation of Nox organizer 1 (NoxO1). We found that through the interaction between NoxO1 and growth receptor-bound protein 2 (Grb2), the Casitas B-lineage lymphoma (Cbl) E3 ligase was recruited, leading to decreased NoxO1 stability and a subsequent reduction in ROS generation upon epidermal growth factor (EGF) stimulation. Additionally, we show that EGF-mediated phosphorylation of NoxO1 induced its release from Grb2 and facilitated its association with Nox activator 1 (NoxA1) to stimulate ROS production. Consistently, overexpression of Grb2 resulted in decreased Nox1 activity, whereas knockdown of Grb2 led to increased Nox1 activity in response to EGF. CRISPR/Cas9-mediated NoxO1 knockout in human colon cancer cells abrogated anchorage-independent growth on soft agar and tumor-forming ability in athymic nude mice. Moreover, the expression and stability of NoxO1 were significantly increased in human colon cancer tissues compared with normal colon. Taken together, these results support a model whereby Nox1 activity and ROS generation are regulated by Grb2/Cbl-mediated proteolysis of NoxO1 in response to EGF, providing new insight into the processes by which excessive ROS production may promote oncogenic signaling to drive colorectal tumorigenesis.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "9017897d71c2434d90f474f17544eebd", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[172, 172], [247, 247], [182, 182], [62, 62]], "char_spans": [[971, 974], [1416, 1419], [1029, 1032], [348, 351]]}]}], "context_tokens": [["The", 0], ["generation", 4], ["of", 15], ["reactive", 18], ["oxygen", 27], ["species", 34], ["(", 42], ["ROS", 43], [")", 46], ["is", 48], ["required", 51], ["for", 60], ["proper", 64], ["cell", 71], ["signaling", 76], [",", 85], ["but", 87], ["must", 91], ["be", 96], ["tightly", 99], ["regulated", 107], ["to", 117], ["minimize", 120], ["deleterious", 129], ["oxidizing", 141], ["effects", 151], [".", 158], ["Activation", 160], ["of", 171], ["the", 174], ["NADPH", 178], ["oxidases", 184], ["(", 193], ["Nox", 194], [")", 197], ["triggers", 199], ["ROS", 208], ["production", 212], ["and", 223], [",", 226], ["thus", 228], [",", 232], ["regulatory", 234], ["mechanisms", 245], ["exist", 256], ["to", 262], ["properly", 265], ["control", 274], ["Nox", 282], ["activity", 286], [".", 294], ["In", 296], ["this", 299], ["study", 304], [",", 309], ["we", 311], ["report", 314], ["a", 321], ["novel", 323], ["mechanism", 329], ["in", 339], ["which", 342], ["Nox1", 348], ["activity", 353], ["is", 362], ["regulated", 365], ["through", 375], ["the", 383], ["proteasomal", 387], ["degradation", 399], ["of", 411], ["Nox", 414], ["organizer", 418], ["1", 428], ["(", 430], ["NoxO1", 431], [")", 436], [".", 437], ["We", 439], ["found", 442], ["that", 448], ["through", 453], ["the", 461], ["interaction", 465], ["between", 477], ["NoxO1", 485], ["and", 491], ["growth", 495], ["receptor", 502], ["-", 510], ["bound", 511], ["protein", 517], ["2", 525], ["(", 527], ["Grb2", 528], [")", 532], [",", 533], ["the", 535], ["Casitas", 539], ["B", 547], ["-", 548], ["lineage", 549], ["lymphoma", 557], ["(", 566], ["Cbl", 567], [")", 570], ["E3", 572], ["ligase", 575], ["was", 582], ["recruited", 586], [",", 595], ["leading", 597], ["to", 605], ["decreased", 608], ["NoxO1", 618], ["stability", 624], ["and", 634], ["a", 638], ["subsequent", 640], ["reduction", 651], ["in", 661], ["ROS", 664], ["generation", 668], ["upon", 679], ["epidermal", 684], ["growth", 694], ["factor", 701], ["(", 708], ["EGF", 709], [")", 712], ["stimulation", 714], [".", 725], ["Additionally", 727], [",", 739], ["we", 741], ["show", 744], ["that", 749], ["EGF", 754], ["-", 757], ["mediated", 758], ["phosphorylation", 767], ["of", 783], ["NoxO1", 786], ["induced", 792], ["its", 800], ["release", 804], ["from", 812], ["Grb2", 817], ["and", 822], ["facilitated", 826], ["its", 838], ["association", 842], ["with", 854], ["Nox", 859], ["activator", 863], ["1", 873], ["(", 875], ["NoxA1", 876], [")", 881], ["to", 883], ["stimulate", 886], ["ROS", 896], ["production", 900], [".", 910], ["Consistently", 912], [",", 924], ["overexpression", 926], ["of", 941], ["Grb2", 944], ["resulted", 949], ["in", 958], ["decreased", 961], ["Nox1", 971], ["activity", 976], [",", 984], ["whereas", 986], ["knockdown", 994], ["of", 1004], ["Grb2", 1007], ["led", 1012], ["to", 1016], ["increased", 1019], ["Nox1", 1029], ["activity", 1034], ["in", 1043], ["response", 1046], ["to", 1055], ["EGF", 1058], [".", 1061], ["CRISPR", 1063], ["/", 1069], ["Cas9-mediated", 1070], ["NoxO1", 1084], ["knockout", 1090], ["in", 1099], ["human", 1102], ["colon", 1108], ["cancer", 1114], ["cells", 1121], ["abrogated", 1127], ["anchorage", 1137], ["-", 1146], ["independent", 1147], ["growth", 1159], ["on", 1166], ["soft", 1169], ["agar", 1174], ["and", 1179], ["tumor", 1183], ["-", 1188], ["forming", 1189], ["ability", 1197], ["in", 1205], ["athymic", 1208], ["nude", 1216], ["mice", 1221], [".", 1225], ["Moreover", 1227], [",", 1235], ["the", 1237], ["expression", 1241], ["and", 1252], ["stability", 1256], ["of", 1266], ["NoxO1", 1269], ["were", 1275], ["significantly", 1280], ["increased", 1294], ["in", 1304], ["human", 1307], ["colon", 1313], ["cancer", 1319], ["tissues", 1326], ["compared", 1334], ["with", 1343], ["normal", 1348], ["colon", 1355], [".", 1360], ["Taken", 1362], ["together", 1368], [",", 1376], ["these", 1378], ["results", 1384], ["support", 1392], ["a", 1400], ["model", 1402], ["whereby", 1408], ["Nox1", 1416], ["activity", 1421], ["and", 1430], ["ROS", 1434], ["generation", 1438], ["are", 1449], ["regulated", 1453], ["by", 1463], ["Grb2/Cbl", 1466], ["-", 1474], ["mediated", 1475], ["proteolysis", 1484], ["of", 1496], ["NoxO1", 1499], ["in", 1505], ["response", 1508], ["to", 1517], ["EGF", 1520], [",", 1523], ["providing", 1525], ["new", 1535], ["insight", 1539], ["into", 1547], ["the", 1552], ["processes", 1556], ["by", 1566], ["which", 1569], ["excessive", 1575], ["ROS", 1585], ["production", 1589], ["may", 1600], ["promote", 1604], ["oncogenic", 1612], ["signaling", 1622], ["to", 1632], ["drive", 1635], ["colorectal", 1641], ["tumorigenesis", 1652], [".", 1665]]}
{"context": "Protein kinases (PKs) and lipid kinases (LKs) are good choices for targets of signal transduction therapy as these enzymes are involved in signaling pathways, and are often related to the pathogenesis of lymphoid malignancies. The attractiveness of PKs and LKs as drug able targets is enhanced by the fact that they are enzymes whose biological activity can be turned off by drugs that block their catalytic site. In the last few years small molecular kinase inhibitors (KIs) have been synthesized and become available for preclinical studies and clinical trials. The first KI, introduced into clinical practice in 1998, was imatinib mesylate, which became the first choice drug in chronic myeloid leukemia. More recently, several KIs have been developed to target the proximal B-cell receptor (BCR) signaling pathway including spleen tyrosine kinase inhibitor (Fostamatinib) and Bruton's tyrosine kinase inhibitors (Ibrutinib, AVL-263). These agents are currently evaluated in early clinical trials in chronic lymphocytic leukemia (CLL) and other diseases. Cyclin-dependent kinase (Cdk) inhibitors, flavopiridol (alvocidib), BMS-387032 (SNS-032), sunitinib and sorafenib are currently under evaluation in clinical trials for relapsed/refractory CLL. Multi-tyrosine kinase inhibitors including vandetanib (ZD6474) bosutinib (SKI-606), TKI258 (CHIR-258), pazopanib (GW786034) and axitinib (AG013736) have been also developed for the treatment of lymphoid malignancies. Phosphatidylinositol 3-kinases (PI3K ) are a family of lipid kinases that mediate signals from cell surface receptors. CAL-101 (GS-1101) is an oral PI3K\u03b4-specific inhibitor which has shown preclinical and clinical activity against CLL. This article summarizes recent achievements in the mechanism of action, pharmacological properties and clinical activity and toxicity of PK and LK inhibitors in CLL.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "1eb2d0fe88414c37812859c1e4d6e1b5", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[161, 161]], "char_spans": [[917, 925]]}]}], "context_tokens": [["Protein", 0], ["kinases", 8], ["(", 16], ["PKs", 17], [")", 20], ["and", 22], ["lipid", 26], ["kinases", 32], ["(", 40], ["LKs", 41], [")", 44], ["are", 46], ["good", 50], ["choices", 55], ["for", 63], ["targets", 67], ["of", 75], ["signal", 78], ["transduction", 85], ["therapy", 98], ["as", 106], ["these", 109], ["enzymes", 115], ["are", 123], ["involved", 127], ["in", 136], ["signaling", 139], ["pathways", 149], [",", 157], ["and", 159], ["are", 163], ["often", 167], ["related", 173], ["to", 181], ["the", 184], ["pathogenesis", 188], ["of", 201], ["lymphoid", 204], ["malignancies", 213], [".", 225], ["The", 227], ["attractiveness", 231], ["of", 246], ["PKs", 249], ["and", 253], ["LKs", 257], ["as", 261], ["drug", 264], ["able", 269], ["targets", 274], ["is", 282], ["enhanced", 285], ["by", 294], ["the", 297], ["fact", 301], ["that", 306], ["they", 311], ["are", 316], ["enzymes", 320], ["whose", 328], ["biological", 334], ["activity", 345], ["can", 354], ["be", 358], ["turned", 361], ["off", 368], ["by", 372], ["drugs", 375], ["that", 381], ["block", 386], ["their", 392], ["catalytic", 398], ["site", 408], [".", 412], ["In", 414], ["the", 417], ["last", 421], ["few", 426], ["years", 430], ["small", 436], ["molecular", 442], ["kinase", 452], ["inhibitors", 459], ["(", 470], ["KIs", 471], [")", 474], ["have", 476], ["been", 481], ["synthesized", 486], ["and", 498], ["become", 502], ["available", 509], ["for", 519], ["preclinical", 523], ["studies", 535], ["and", 543], ["clinical", 547], ["trials", 556], [".", 562], ["The", 564], ["first", 568], ["KI", 574], [",", 576], ["introduced", 578], ["into", 589], ["clinical", 594], ["practice", 603], ["in", 612], ["1998", 615], [",", 619], ["was", 621], ["imatinib", 625], ["mesylate", 634], [",", 642], ["which", 644], ["became", 650], ["the", 657], ["first", 661], ["choice", 667], ["drug", 674], ["in", 679], ["chronic", 682], ["myeloid", 690], ["leukemia", 698], [".", 706], ["More", 708], ["recently", 713], [",", 721], ["several", 723], ["KIs", 731], ["have", 735], ["been", 740], ["developed", 745], ["to", 755], ["target", 758], ["the", 765], ["proximal", 769], ["B", 778], ["-", 779], ["cell", 780], ["receptor", 785], ["(", 794], ["BCR", 795], [")", 798], ["signaling", 800], ["pathway", 810], ["including", 818], ["spleen", 828], ["tyrosine", 835], ["kinase", 844], ["inhibitor", 851], ["(", 861], ["Fostamatinib", 862], [")", 874], ["and", 876], ["Bruton", 880], ["'s", 886], ["tyrosine", 889], ["kinase", 898], ["inhibitors", 905], ["(", 916], ["Ibrutinib", 917], [",", 926], ["AVL-263", 928], [")", 935], [".", 936], ["These", 938], ["agents", 944], ["are", 951], ["currently", 955], ["evaluated", 965], ["in", 975], ["early", 978], ["clinical", 984], ["trials", 993], ["in", 1000], ["chronic", 1003], ["lymphocytic", 1011], ["leukemia", 1023], ["(", 1032], ["CLL", 1033], [")", 1036], ["and", 1038], ["other", 1042], ["diseases", 1048], [".", 1056], ["Cyclin", 1058], ["-", 1064], ["dependent", 1065], ["kinase", 1075], ["(", 1082], ["Cdk", 1083], [")", 1086], ["inhibitors", 1088], [",", 1098], ["flavopiridol", 1100], ["(", 1113], ["alvocidib", 1114], [")", 1123], [",", 1124], ["BMS-387032", 1126], ["(", 1137], ["SNS-032", 1138], [")", 1145], [",", 1146], ["sunitinib", 1148], ["and", 1158], ["sorafenib", 1162], ["are", 1172], ["currently", 1176], ["under", 1186], ["evaluation", 1192], ["in", 1203], ["clinical", 1206], ["trials", 1215], ["for", 1222], ["relapsed", 1226], ["/", 1234], ["refractory", 1235], ["CLL", 1246], [".", 1249], ["Multi", 1251], ["-", 1256], ["tyrosine", 1257], ["kinase", 1266], ["inhibitors", 1273], ["including", 1284], ["vandetanib", 1294], ["(", 1305], ["ZD6474", 1306], [")", 1312], ["bosutinib", 1314], ["(", 1324], ["SKI-606", 1325], [")", 1332], [",", 1333], ["TKI258", 1335], ["(", 1342], ["CHIR-258", 1343], [")", 1351], [",", 1352], ["pazopanib", 1354], ["(", 1364], ["GW786034", 1365], [")", 1373], ["and", 1375], ["axitinib", 1379], ["(", 1388], ["AG013736", 1389], [")", 1397], ["have", 1399], ["been", 1404], ["also", 1409], ["developed", 1414], ["for", 1424], ["the", 1428], ["treatment", 1432], ["of", 1442], ["lymphoid", 1445], ["malignancies", 1454], [".", 1466], ["Phosphatidylinositol", 1468], ["3-kinases", 1489], ["(", 1499], ["PI3", 1500], ["K", 1503], [")", 1505], ["are", 1507], ["a", 1511], ["family", 1513], ["of", 1520], ["lipid", 1523], ["kinases", 1529], ["that", 1537], ["mediate", 1542], ["signals", 1550], ["from", 1558], ["cell", 1563], ["surface", 1568], ["receptors", 1576], [".", 1585], ["CAL-101", 1587], ["(", 1595], ["GS-1101", 1596], [")", 1603], ["is", 1605], ["an", 1608], ["oral", 1611], ["PI3K\u03b4", 1616], ["-", 1621], ["specific", 1622], ["inhibitor", 1631], ["which", 1641], ["has", 1647], ["shown", 1651], ["preclinical", 1657], ["and", 1669], ["clinical", 1673], ["activity", 1682], ["against", 1691], ["CLL", 1699], [".", 1702], ["This", 1704], ["article", 1709], ["summarizes", 1717], ["recent", 1728], ["achievements", 1735], ["in", 1748], ["the", 1751], ["mechanism", 1755], ["of", 1765], ["action", 1768], [",", 1774], ["pharmacological", 1776], ["properties", 1792], ["and", 1803], ["clinical", 1807], ["activity", 1816], ["and", 1825], ["toxicity", 1829], ["of", 1838], ["PK", 1841], ["and", 1844], ["LK", 1848], ["inhibitors", 1851], ["in", 1862], ["CLL", 1865], [".", 1868]]}
{"context": "Disease patterns in RA vary between the sexes; the condition is more commonly seen in women, who exhibit a more aggressive disease and a poorer long-term outcome. Men, however, are more likely than women to die from extra-articular complications of rheumatoid disease. This chapter discusses the outcome and mortality studies that substantiate these conclusions and then examines the possible mechanisms that may account for them, including the HLA system, seropositivity, compliance, response to therapy and pain threshold. In particular, sex and sex hormones emerge as independent risk factors in rheumatoid disease. The epidemiological evidence points towards a peak age of onset of RA at the time of the menopause in women and towards later in life in men. Premenopausal women may fare better than postmenopausal women with RA. The possible protective effects of the oral contraceptive pill and the dramatic amelioration with pregnancy are well documented. In vivo and in vitro studies have demonstrated that sex hormones interfere with a number of the putative processes involved in the pathogenesis of RA, including immunoregulation, interaction with inflammatory mediators and the cytokine system, and direct effects on cartilage itself. All these observations point towards the importance of gonadal hormones. However, trials on the potential therapeutic use of sex hormones in RA are limited and, as yet, disappointing. Further work is necessary to determine whether the roles of sex hormones are as central protagonists or just supporting cast in the complex arena of rheumatoid disease.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "dd55ff8b09a7433aa467295dae5b0c62", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[16, 16], [127, 127], [137, 137], [40, 40], [143, 143]], "char_spans": [[86, 90], [721, 725], [775, 779], [198, 202], [817, 821]]}]}], "context_tokens": [["Disease", 0], ["patterns", 8], ["in", 17], ["RA", 20], ["vary", 23], ["between", 28], ["the", 36], ["sexes", 40], [";", 45], ["the", 47], ["condition", 51], ["is", 61], ["more", 64], ["commonly", 69], ["seen", 78], ["in", 83], ["women", 86], [",", 91], ["who", 93], ["exhibit", 97], ["a", 105], ["more", 107], ["aggressive", 112], ["disease", 123], ["and", 131], ["a", 135], ["poorer", 137], ["long", 144], ["-", 148], ["term", 149], ["outcome", 154], [".", 161], ["Men", 163], [",", 166], ["however", 168], [",", 175], ["are", 177], ["more", 181], ["likely", 186], ["than", 193], ["women", 198], ["to", 204], ["die", 207], ["from", 211], ["extra", 216], ["-", 221], ["articular", 222], ["complications", 232], ["of", 246], ["rheumatoid", 249], ["disease", 260], [".", 267], ["This", 269], ["chapter", 274], ["discusses", 282], ["the", 292], ["outcome", 296], ["and", 304], ["mortality", 308], ["studies", 318], ["that", 326], ["substantiate", 331], ["these", 344], ["conclusions", 350], ["and", 362], ["then", 366], ["examines", 371], ["the", 380], ["possible", 384], ["mechanisms", 393], ["that", 404], ["may", 409], ["account", 413], ["for", 421], ["them", 425], [",", 429], ["including", 431], ["the", 441], ["HLA", 445], ["system", 449], [",", 455], ["seropositivity", 457], [",", 471], ["compliance", 473], [",", 483], ["response", 485], ["to", 494], ["therapy", 497], ["and", 505], ["pain", 509], ["threshold", 514], [".", 523], ["In", 525], ["particular", 528], [",", 538], ["sex", 540], ["and", 544], ["sex", 548], ["hormones", 552], ["emerge", 561], ["as", 568], ["independent", 571], ["risk", 583], ["factors", 588], ["in", 596], ["rheumatoid", 599], ["disease", 610], [".", 617], ["The", 619], ["epidemiological", 623], ["evidence", 639], ["points", 648], ["towards", 655], ["a", 663], ["peak", 665], ["age", 670], ["of", 674], ["onset", 677], ["of", 683], ["RA", 686], ["at", 689], ["the", 692], ["time", 696], ["of", 701], ["the", 704], ["menopause", 708], ["in", 718], ["women", 721], ["and", 727], ["towards", 731], ["later", 739], ["in", 745], ["life", 748], ["in", 753], ["men", 756], [".", 759], ["Premenopausal", 761], ["women", 775], ["may", 781], ["fare", 785], ["better", 790], ["than", 797], ["postmenopausal", 802], ["women", 817], ["with", 823], ["RA", 828], [".", 830], ["The", 832], ["possible", 836], ["protective", 845], ["effects", 856], ["of", 864], ["the", 867], ["oral", 871], ["contraceptive", 876], ["pill", 890], ["and", 895], ["the", 899], ["dramatic", 903], ["amelioration", 912], ["with", 925], ["pregnancy", 930], ["are", 940], ["well", 944], ["documented", 949], [".", 959], ["In", 961], ["vivo", 964], ["and", 969], ["in", 973], ["vitro", 976], ["studies", 982], ["have", 990], ["demonstrated", 995], ["that", 1008], ["sex", 1013], ["hormones", 1017], ["interfere", 1026], ["with", 1036], ["a", 1041], ["number", 1043], ["of", 1050], ["the", 1053], ["putative", 1057], ["processes", 1066], ["involved", 1076], ["in", 1085], ["the", 1088], ["pathogenesis", 1092], ["of", 1105], ["RA", 1108], [",", 1110], ["including", 1112], ["immunoregulation", 1122], [",", 1138], ["interaction", 1140], ["with", 1152], ["inflammatory", 1157], ["mediators", 1170], ["and", 1180], ["the", 1184], ["cytokine", 1188], ["system", 1197], [",", 1203], ["and", 1205], ["direct", 1209], ["effects", 1216], ["on", 1224], ["cartilage", 1227], ["itself", 1237], [".", 1243], ["All", 1245], ["these", 1249], ["observations", 1255], ["point", 1268], ["towards", 1274], ["the", 1282], ["importance", 1286], ["of", 1297], ["gonadal", 1300], ["hormones", 1308], [".", 1316], ["However", 1318], [",", 1325], ["trials", 1327], ["on", 1334], ["the", 1337], ["potential", 1341], ["therapeutic", 1351], ["use", 1363], ["of", 1367], ["sex", 1370], ["hormones", 1374], ["in", 1383], ["RA", 1386], ["are", 1389], ["limited", 1393], ["and", 1401], [",", 1404], ["as", 1406], ["yet", 1409], [",", 1412], ["disappointing", 1414], [".", 1427], ["Further", 1429], ["work", 1437], ["is", 1442], ["necessary", 1445], ["to", 1455], ["determine", 1458], ["whether", 1468], ["the", 1476], ["roles", 1480], ["of", 1486], ["sex", 1489], ["hormones", 1493], ["are", 1502], ["as", 1506], ["central", 1509], ["protagonists", 1517], ["or", 1530], ["just", 1533], ["supporting", 1538], ["cast", 1549], ["in", 1554], ["the", 1557], ["complex", 1561], ["arena", 1569], ["of", 1575], ["rheumatoid", 1578], ["disease", 1589], [".", 1596]]}
{"context": "The theory of positive deviance holds that in any group, some people are more effective than others even when they have the same resources at hand. The object is to identify those people, see what they're doing differently and share it with the larger group. The Plexus Institute and the Robert Wood Johnson Foundation recently collaborated on a six-hospital positive-deviance study that reduced methicillin-resistant Staphylococcus aureus (MRSA) infection rates by 70 percent. What these hospitals learned may help others cut their MRSA rates.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "54d034854e514d05b8be8c343c9d0484", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[95, 95], [78, 78]], "char_spans": [[533, 536], [441, 444]]}]}], "context_tokens": [["The", 0], ["theory", 4], ["of", 11], ["positive", 14], ["deviance", 23], ["holds", 32], ["that", 38], ["in", 43], ["any", 46], ["group", 50], [",", 55], ["some", 57], ["people", 62], ["are", 69], ["more", 73], ["effective", 78], ["than", 88], ["others", 93], ["even", 100], ["when", 105], ["they", 110], ["have", 115], ["the", 120], ["same", 124], ["resources", 129], ["at", 139], ["hand", 142], [".", 146], ["The", 148], ["object", 152], ["is", 159], ["to", 162], ["identify", 165], ["those", 174], ["people", 180], [",", 186], ["see", 188], ["what", 192], ["they", 197], ["'re", 201], ["doing", 205], ["differently", 211], ["and", 223], ["share", 227], ["it", 233], ["with", 236], ["the", 241], ["larger", 245], ["group", 252], [".", 257], ["The", 259], ["Plexus", 263], ["Institute", 270], ["and", 280], ["the", 284], ["Robert", 288], ["Wood", 295], ["Johnson", 300], ["Foundation", 308], ["recently", 319], ["collaborated", 328], ["on", 341], ["a", 344], ["six", 346], ["-", 349], ["hospital", 350], ["positive", 359], ["-", 367], ["deviance", 368], ["study", 377], ["that", 383], ["reduced", 388], ["methicillin", 396], ["-", 407], ["resistant", 408], ["Staphylococcus", 418], ["aureus", 433], ["(", 440], ["MRSA", 441], [")", 445], ["infection", 447], ["rates", 457], ["by", 463], ["70", 466], ["percent", 469], [".", 476], ["What", 478], ["these", 483], ["hospitals", 489], ["learned", 499], ["may", 507], ["help", 511], ["others", 516], ["cut", 523], ["their", 527], ["MRSA", 533], ["rates", 538], [".", 543]]}
{"context": "Using post-embedding immunogold electron microscopy, TAR DNA-binding protein of 43 kDa (TDP-43) was localized to neuronal cytoplasmic (NCI) and intranuclear (NII) inclusions, as well as unmyelinated neurites, in frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U), amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), Pick's disease (PiD) and Lewy body disease (LBD). The TDP-43 immunoreactive structures were morphologically heterogeneous. The most common was characterized by bundles of 10-20 nm diameter straight filaments with electron dense granular material within NCI, NII and neurites. This type of pathology was found in FTLD-U, ALS and some cases of AD. Less often, inclusions in neuritic processes of FTLD-U and some cases of AD contained 10-17 nm diameter straight filaments without granular material. A final type of TDP-43 immunoreactivity was labeling of filaments and granular material associated with tau filaments in neurofibrillary tangles of AD and Pick bodies of PiD or alpha-synuclein filaments in Lewy bodies of LBD. The results suggest that TDP-43 is the primary component of the granulofilamentous inclusions in FTLD-U and ALS. Similar inclusions sometimes accompany filamentous aggregates composed of other abnormal proteins in AD, PiD and LBD.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "2f91c196e1e14427999116eb471acf92", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[189, 191]], "char_spans": [[1014, 1028]]}]}], "context_tokens": [["Using", 0], ["post", 6], ["-", 10], ["embedding", 11], ["immunogold", 21], ["electron", 32], ["microscopy", 41], [",", 51], ["TAR", 53], ["DNA", 57], ["-", 60], ["binding", 61], ["protein", 69], ["of", 77], ["43", 80], ["kDa", 83], ["(", 87], ["TDP-43", 88], [")", 94], ["was", 96], ["localized", 100], ["to", 110], ["neuronal", 113], ["cytoplasmic", 122], ["(", 134], ["NCI", 135], [")", 138], ["and", 140], ["intranuclear", 144], ["(", 157], ["NII", 158], [")", 161], ["inclusions", 163], [",", 173], ["as", 175], ["well", 178], ["as", 183], ["unmyelinated", 186], ["neurites", 199], [",", 207], ["in", 209], ["frontotemporal", 212], ["lobar", 227], ["degeneration", 233], ["with", 246], ["ubiquitinated", 251], ["inclusions", 265], ["(", 276], ["FTLD", 277], ["-", 281], ["U", 282], [")", 283], [",", 284], ["amyotrophic", 286], ["lateral", 298], ["sclerosis", 306], ["(", 316], ["ALS", 317], [")", 320], [",", 321], ["Alzheimer", 323], ["'s", 332], ["(", 335], ["AD", 336], [")", 338], [",", 339], ["Pick", 341], ["'s", 345], ["disease", 348], ["(", 356], ["PiD", 357], [")", 360], ["and", 362], ["Lewy", 366], ["body", 371], ["disease", 376], ["(", 384], ["LBD", 385], [")", 388], [".", 389], ["The", 391], ["TDP-43", 395], ["immunoreactive", 402], ["structures", 417], ["were", 428], ["morphologically", 433], ["heterogeneous", 449], [".", 462], ["The", 464], ["most", 468], ["common", 473], ["was", 480], ["characterized", 484], ["by", 498], ["bundles", 501], ["of", 509], ["10", 512], ["-", 514], ["20", 515], ["nm", 518], ["diameter", 521], ["straight", 530], ["filaments", 539], ["with", 549], ["electron", 554], ["dense", 563], ["granular", 569], ["material", 578], ["within", 587], ["NCI", 594], [",", 597], ["NII", 599], ["and", 603], ["neurites", 607], [".", 615], ["This", 617], ["type", 622], ["of", 627], ["pathology", 630], ["was", 640], ["found", 644], ["in", 650], ["FTLD", 653], ["-", 657], ["U", 658], [",", 659], ["ALS", 661], ["and", 665], ["some", 669], ["cases", 674], ["of", 680], ["AD", 683], [".", 685], ["Less", 687], ["often", 692], [",", 697], ["inclusions", 699], ["in", 710], ["neuritic", 713], ["processes", 722], ["of", 732], ["FTLD", 735], ["-", 739], ["U", 740], ["and", 742], ["some", 746], ["cases", 751], ["of", 757], ["AD", 760], ["contained", 763], ["10", 773], ["-", 775], ["17", 776], ["nm", 779], ["diameter", 782], ["straight", 791], ["filaments", 800], ["without", 810], ["granular", 818], ["material", 827], [".", 835], ["A", 837], ["final", 839], ["type", 845], ["of", 850], ["TDP-43", 853], ["immunoreactivity", 860], ["was", 877], ["labeling", 881], ["of", 890], ["filaments", 893], ["and", 903], ["granular", 907], ["material", 916], ["associated", 925], ["with", 936], ["tau", 941], ["filaments", 945], ["in", 955], ["neurofibrillary", 958], ["tangles", 974], ["of", 982], ["AD", 985], ["and", 988], ["Pick", 992], ["bodies", 997], ["of", 1004], ["PiD", 1007], ["or", 1011], ["alpha", 1014], ["-", 1019], ["synuclein", 1020], ["filaments", 1030], ["in", 1040], ["Lewy", 1043], ["bodies", 1048], ["of", 1055], ["LBD", 1058], [".", 1061], ["The", 1063], ["results", 1067], ["suggest", 1075], ["that", 1083], ["TDP-43", 1088], ["is", 1095], ["the", 1098], ["primary", 1102], ["component", 1110], ["of", 1120], ["the", 1123], ["granulofilamentous", 1127], ["inclusions", 1146], ["in", 1157], ["FTLD", 1160], ["-", 1164], ["U", 1165], ["and", 1167], ["ALS", 1171], [".", 1174], ["Similar", 1176], ["inclusions", 1184], ["sometimes", 1195], ["accompany", 1205], ["filamentous", 1215], ["aggregates", 1227], ["composed", 1238], ["of", 1247], ["other", 1250], ["abnormal", 1256], ["proteins", 1265], ["in", 1274], ["AD", 1277], [",", 1279], ["PiD", 1281], ["and", 1285], ["LBD", 1289], [".", 1292]]}
{"context": "Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib to induce apoptosis. We investigated this novel combination regimen in patients with Bcr-Abl(+) malignancies. In a phase I dose-escalation study, imatinib was administered orally daily, and flavopiridol by 1\u00a0h intravenous infusion weekly for 3\u00a0weeks every 4\u00a0weeks. Adults with chronic myelogenous leukemia or Philadelphia chromosome-positive acute leukemia were eligible. Patients were divided into two strata based on peripheral blood and bone marrow blast counts. The primary objective was to identify the recommended phase II doses for the combination. Correlative pharmacokinetic and pharmacodynamic studies were also performed. A total of 21 patients received study treatment. Four dose levels were evaluated before the study was closed following the approval of the second-generation Bcr-Abl tyrosine kinase inhibitors (TKIs). Five patients responded, including four sustained responses. Four patients had stable disease. All but one responder, and all patients with stable disease had previously been treated with imatinib. One patient had a complete response sustained for 30\u00a0months. Changes in expression of phospho-Bcr/Abl, -Stat5, and Mcl-1 were monitored. No major pharmacokinetic interaction was observed. This is the first study to evaluate the combination of a CDK inhibitor and a TKI in humans. The combination of flavopiridol and imatinib is tolerable and produces encouraging responses, including in some patients with imatinib-resistant disease.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ee5c985a3d3b4cd89647bbe76b8def7b", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[66, 68], [244, 246], [184, 186], [6, 8]], "char_spans": [[376, 384], [1416, 1422], [1081, 1087], [32, 38]]}]}], "context_tokens": [["Imatinib", 0], ["is", 9], ["an", 12], ["inhibitor", 15], ["of", 25], ["the", 28], ["Bcr", 32], ["-", 35], ["Abl", 36], ["tyrosine", 40], ["kinase", 49], [";", 55], ["however", 57], [",", 64], ["resistance", 66], ["is", 77], ["common", 80], [".", 86], ["Flavopiridol", 88], [",", 100], ["a", 102], ["cyclin", 104], ["-", 110], ["dependent", 111], ["kinase", 121], ["(", 128], ["CDK", 129], [")", 132], ["inhibitor", 134], [",", 143], ["down", 145], ["-", 149], ["regulates", 150], ["short", 160], ["-", 165], ["lived", 166], ["anti", 172], ["-", 176], ["apoptotic", 177], ["proteins", 187], ["via", 196], ["inhibition", 200], ["of", 211], ["transcription", 214], [".", 227], ["In", 229], ["preclinical", 232], ["studies", 244], [",", 251], ["flavopiridol", 253], ["synergizes", 266], ["with", 277], ["imatinib", 282], ["to", 291], ["induce", 294], ["apoptosis", 301], [".", 310], ["We", 312], ["investigated", 315], ["this", 328], ["novel", 333], ["combination", 339], ["regimen", 351], ["in", 359], ["patients", 362], ["with", 371], ["Bcr", 376], ["-", 379], ["Abl(+", 380], [")", 385], ["malignancies", 387], [".", 399], ["In", 401], ["a", 404], ["phase", 406], ["I", 412], ["dose", 414], ["-", 418], ["escalation", 419], ["study", 430], [",", 435], ["imatinib", 437], ["was", 446], ["administered", 450], ["orally", 463], ["daily", 470], [",", 475], ["and", 477], ["flavopiridol", 481], ["by", 494], ["1", 497], ["h", 499], ["intravenous", 501], ["infusion", 513], ["weekly", 522], ["for", 529], ["3", 533], ["weeks", 535], ["every", 541], ["4", 547], ["weeks", 549], [".", 554], ["Adults", 556], ["with", 563], ["chronic", 568], ["myelogenous", 576], ["leukemia", 588], ["or", 597], ["Philadelphia", 600], ["chromosome", 613], ["-", 623], ["positive", 624], ["acute", 633], ["leukemia", 639], ["were", 648], ["eligible", 653], [".", 661], ["Patients", 663], ["were", 672], ["divided", 677], ["into", 685], ["two", 690], ["strata", 694], ["based", 701], ["on", 707], ["peripheral", 710], ["blood", 721], ["and", 727], ["bone", 731], ["marrow", 736], ["blast", 743], ["counts", 749], [".", 755], ["The", 757], ["primary", 761], ["objective", 769], ["was", 779], ["to", 783], ["identify", 786], ["the", 795], ["recommended", 799], ["phase", 811], ["II", 817], ["doses", 820], ["for", 826], ["the", 830], ["combination", 834], [".", 845], ["Correlative", 847], ["pharmacokinetic", 859], ["and", 875], ["pharmacodynamic", 879], ["studies", 895], ["were", 903], ["also", 908], ["performed", 913], [".", 922], ["A", 924], ["total", 926], ["of", 932], ["21", 935], ["patients", 938], ["received", 947], ["study", 956], ["treatment", 962], [".", 971], ["Four", 973], ["dose", 978], ["levels", 983], ["were", 990], ["evaluated", 995], ["before", 1005], ["the", 1012], ["study", 1016], ["was", 1022], ["closed", 1026], ["following", 1033], ["the", 1043], ["approval", 1047], ["of", 1056], ["the", 1059], ["second", 1063], ["-", 1069], ["generation", 1070], ["Bcr", 1081], ["-", 1084], ["Abl", 1085], ["tyrosine", 1089], ["kinase", 1098], ["inhibitors", 1105], ["(", 1116], ["TKIs", 1117], [")", 1121], [".", 1122], ["Five", 1124], ["patients", 1129], ["responded", 1138], [",", 1147], ["including", 1149], ["four", 1159], ["sustained", 1164], ["responses", 1174], [".", 1183], ["Four", 1185], ["patients", 1190], ["had", 1199], ["stable", 1203], ["disease", 1210], [".", 1217], ["All", 1219], ["but", 1223], ["one", 1227], ["responder", 1231], [",", 1240], ["and", 1242], ["all", 1246], ["patients", 1250], ["with", 1259], ["stable", 1264], ["disease", 1271], ["had", 1279], ["previously", 1283], ["been", 1294], ["treated", 1299], ["with", 1307], ["imatinib", 1312], [".", 1320], ["One", 1322], ["patient", 1326], ["had", 1334], ["a", 1338], ["complete", 1340], ["response", 1349], ["sustained", 1358], ["for", 1368], ["30", 1372], ["months", 1375], [".", 1381], ["Changes", 1383], ["in", 1391], ["expression", 1394], ["of", 1405], ["phospho", 1408], ["-", 1415], ["Bcr", 1416], ["/", 1419], ["Abl", 1420], [",", 1423], ["-Stat5", 1425], [",", 1431], ["and", 1433], ["Mcl-1", 1437], ["were", 1443], ["monitored", 1448], [".", 1457], ["No", 1459], ["major", 1462], ["pharmacokinetic", 1468], ["interaction", 1484], ["was", 1496], ["observed", 1500], [".", 1508], ["This", 1510], ["is", 1515], ["the", 1518], ["first", 1522], ["study", 1528], ["to", 1534], ["evaluate", 1537], ["the", 1546], ["combination", 1550], ["of", 1562], ["a", 1565], ["CDK", 1567], ["inhibitor", 1571], ["and", 1581], ["a", 1585], ["TKI", 1587], ["in", 1591], ["humans", 1594], [".", 1600], ["The", 1602], ["combination", 1606], ["of", 1618], ["flavopiridol", 1621], ["and", 1634], ["imatinib", 1638], ["is", 1647], ["tolerable", 1650], ["and", 1660], ["produces", 1664], ["encouraging", 1673], ["responses", 1685], [",", 1694], ["including", 1696], ["in", 1706], ["some", 1709], ["patients", 1714], ["with", 1723], ["imatinib", 1728], ["-", 1736], ["resistant", 1737], ["disease", 1747], [".", 1754]]}
{"context": "The multidrug resistance 1 gene (MDR1) encodes P-glycoprotein (Pgp), a member of the ATP-binding cassette (ABC) transporter family that confers tumor drug resistance by actively effluxing a number of antitumor agents. We had previously shown that MDR1 transcription is regulated by epigenetic events such as histone acetylation, and had identified the histone acetylase P/CAF and the transcription factor NF-Y as the factors mediating the enzymatic and DNA-anchoring functions, respectively, at the MDR1 promoter. It has also been shown that MDR1 activation is accompanied by increased methylation on lysine 4 of histone H3 (H3K4). In this study, we further investigated histone methylation in MDR1 regulation and function. We show that the mixed lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K4, is required for MDR1 promoter methylation, as knockdown of MLL1 resulted in a decrease in MDR1 expression. The regulation of MDR1 by MLL1 has functional consequences in that downregulation of MLL1 led to increased retention of the Pgp-specific substrate DIOC(2)(3), as well as increased cellular sensitivity to several Pgp substrates. Regulation of MDR1 by MLL1 was dependent on the CCAAT box within the proximal MDR1 promoter, similar to what we had shown for MDR1 promoter acetylation, and also requires NF-Y. Finally, overexpression of the most prevalent MLL fusion protein, MLL-AF4, led to increased MDR1 expression. This is the first identification of a histone methyltransferase and its leukemogenic rearrangement that regulates expression of an ABC drug transporter, suggesting a new target for circumvention of tumor multidrug resistance.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "c52217c869064579a2201e621fdbf60c", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[151, 151], [115, 115]], "char_spans": [[823, 826], [625, 628]]}]}], "context_tokens": [["The", 0], ["multidrug", 4], ["resistance", 14], ["1", 25], ["gene", 27], ["(", 32], ["MDR1", 33], [")", 37], ["encodes", 39], ["P", 47], ["-", 48], ["glycoprotein", 49], ["(", 62], ["Pgp", 63], [")", 66], [",", 67], ["a", 69], ["member", 71], ["of", 78], ["the", 81], ["ATP", 85], ["-", 88], ["binding", 89], ["cassette", 97], ["(", 106], ["ABC", 107], [")", 110], ["transporter", 112], ["family", 124], ["that", 131], ["confers", 136], ["tumor", 144], ["drug", 150], ["resistance", 155], ["by", 166], ["actively", 169], ["effluxing", 178], ["a", 188], ["number", 190], ["of", 197], ["antitumor", 200], ["agents", 210], [".", 216], ["We", 218], ["had", 221], ["previously", 225], ["shown", 236], ["that", 242], ["MDR1", 247], ["transcription", 252], ["is", 266], ["regulated", 269], ["by", 279], ["epigenetic", 282], ["events", 293], ["such", 300], ["as", 305], ["histone", 308], ["acetylation", 316], [",", 327], ["and", 329], ["had", 333], ["identified", 337], ["the", 348], ["histone", 352], ["acetylase", 360], ["P", 370], ["/", 371], ["CAF", 372], ["and", 376], ["the", 380], ["transcription", 384], ["factor", 398], ["NF", 405], ["-", 407], ["Y", 408], ["as", 410], ["the", 413], ["factors", 417], ["mediating", 425], ["the", 435], ["enzymatic", 439], ["and", 449], ["DNA", 453], ["-", 456], ["anchoring", 457], ["functions", 467], [",", 476], ["respectively", 478], [",", 490], ["at", 492], ["the", 495], ["MDR1", 499], ["promoter", 504], [".", 512], ["It", 514], ["has", 517], ["also", 521], ["been", 526], ["shown", 531], ["that", 537], ["MDR1", 542], ["activation", 547], ["is", 558], ["accompanied", 561], ["by", 573], ["increased", 576], ["methylation", 586], ["on", 598], ["lysine", 601], ["4", 608], ["of", 610], ["histone", 613], ["H3", 621], ["(", 624], ["H3K4", 625], [")", 629], [".", 630], ["In", 632], ["this", 635], ["study", 640], [",", 645], ["we", 647], ["further", 650], ["investigated", 658], ["histone", 671], ["methylation", 679], ["in", 691], ["MDR1", 694], ["regulation", 699], ["and", 710], ["function", 714], [".", 722], ["We", 724], ["show", 727], ["that", 732], ["the", 737], ["mixed", 741], ["lineage", 747], ["leukemia", 755], ["1", 764], ["(", 766], ["MLL1", 767], [")", 771], ["protein", 773], [",", 780], ["a", 782], ["histone", 784], ["methyltransferase", 792], ["specific", 810], ["for", 819], ["H3K4", 823], [",", 827], ["is", 829], ["required", 832], ["for", 841], ["MDR1", 845], ["promoter", 850], ["methylation", 859], [",", 870], ["as", 872], ["knockdown", 875], ["of", 885], ["MLL1", 888], ["resulted", 893], ["in", 902], ["a", 905], ["decrease", 907], ["in", 916], ["MDR1", 919], ["expression", 924], [".", 934], ["The", 936], ["regulation", 940], ["of", 951], ["MDR1", 954], ["by", 959], ["MLL1", 962], ["has", 967], ["functional", 971], ["consequences", 982], ["in", 995], ["that", 998], ["downregulation", 1003], ["of", 1018], ["MLL1", 1021], ["led", 1026], ["to", 1030], ["increased", 1033], ["retention", 1043], ["of", 1053], ["the", 1056], ["Pgp", 1060], ["-", 1063], ["specific", 1064], ["substrate", 1073], ["DIOC(2)(3", 1083], [")", 1092], [",", 1093], ["as", 1095], ["well", 1098], ["as", 1103], ["increased", 1106], ["cellular", 1116], ["sensitivity", 1125], ["to", 1137], ["several", 1140], ["Pgp", 1148], ["substrates", 1152], [".", 1162], ["Regulation", 1164], ["of", 1175], ["MDR1", 1178], ["by", 1183], ["MLL1", 1186], ["was", 1191], ["dependent", 1195], ["on", 1205], ["the", 1208], ["CCAAT", 1212], ["box", 1218], ["within", 1222], ["the", 1229], ["proximal", 1233], ["MDR1", 1242], ["promoter", 1247], [",", 1255], ["similar", 1257], ["to", 1265], ["what", 1268], ["we", 1273], ["had", 1276], ["shown", 1280], ["for", 1286], ["MDR1", 1290], ["promoter", 1295], ["acetylation", 1304], [",", 1315], ["and", 1317], ["also", 1321], ["requires", 1326], ["NF", 1335], ["-", 1337], ["Y.", 1338], ["Finally", 1341], [",", 1348], ["overexpression", 1350], ["of", 1365], ["the", 1368], ["most", 1372], ["prevalent", 1377], ["MLL", 1387], ["fusion", 1391], ["protein", 1398], [",", 1405], ["MLL", 1407], ["-", 1410], ["AF4", 1411], [",", 1414], ["led", 1416], ["to", 1420], ["increased", 1423], ["MDR1", 1433], ["expression", 1438], [".", 1448], ["This", 1450], ["is", 1455], ["the", 1458], ["first", 1462], ["identification", 1468], ["of", 1483], ["a", 1486], ["histone", 1488], ["methyltransferase", 1496], ["and", 1514], ["its", 1518], ["leukemogenic", 1522], ["rearrangement", 1535], ["that", 1549], ["regulates", 1554], ["expression", 1564], ["of", 1575], ["an", 1578], ["ABC", 1581], ["drug", 1585], ["transporter", 1590], [",", 1601], ["suggesting", 1603], ["a", 1614], ["new", 1616], ["target", 1620], ["for", 1627], ["circumvention", 1631], ["of", 1645], ["tumor", 1648], ["multidrug", 1654], ["resistance", 1664], [".", 1674]]}
{"context": "Spleen tyrosine kinase (Syk), a key mediator of immunoreceptor signaling in inflammatory cells, is essential for immune complex-mediated signal transduction initiated by activated receptors for immunoglobulin G. In collagen-induced arthritis, R788/R406, a novel and potent small molecule Syk inhibitor suppressed clinical arthritis, bone erosions, pannus formation, and synovitis. Serum anti-collagen type II antibody levels were unaltered, while the half-life of exogenous antibody was extended when co-administered with R406. Expression of the targeted kinase (Syk) in synovial tissue correlated with the joint level of inflammatory cell infiltrates and was virtually undetectable in treated rats. Syk inhibition suppressed synovial cytokines and cartilage oligomeric matrix protein (COMP) in serum, suggesting a sensitive and reliable biomarker for R406 activity. These results highlight the role of activating Fcgamma receptors in inflammatory synovitis and suggest that interruption of the signaling cascade with a novel Syk inhibitor may be a useful addition to immunosuppressive disease-modifying anti-rheumatic drugs currently used in the treatment of human autoimmune diseases such as rheumatoid arthritis.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "6058f2f8356844f09683a30ad50f344f", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["Syk", 24], [")", 27], [",", 28], ["a", 30], ["key", 32], ["mediator", 36], ["of", 45], ["immunoreceptor", 48], ["signaling", 63], ["in", 73], ["inflammatory", 76], ["cells", 89], [",", 94], ["is", 96], ["essential", 99], ["for", 109], ["immune", 113], ["complex", 120], ["-", 127], ["mediated", 128], ["signal", 137], ["transduction", 144], ["initiated", 157], ["by", 167], ["activated", 170], ["receptors", 180], ["for", 190], ["immunoglobulin", 194], ["G.", 209], ["In", 212], ["collagen", 215], ["-", 223], ["induced", 224], ["arthritis", 232], [",", 241], ["R788/R406", 243], [",", 252], ["a", 254], ["novel", 256], ["and", 262], ["potent", 266], ["small", 273], ["molecule", 279], ["Syk", 288], ["inhibitor", 292], ["suppressed", 302], ["clinical", 313], ["arthritis", 322], [",", 331], ["bone", 333], ["erosions", 338], [",", 346], ["pannus", 348], ["formation", 355], [",", 364], ["and", 366], ["synovitis", 370], [".", 379], ["Serum", 381], ["anti", 387], ["-", 391], ["collagen", 392], ["type", 401], ["II", 406], ["antibody", 409], ["levels", 418], ["were", 425], ["unaltered", 430], [",", 439], ["while", 441], ["the", 447], ["half", 451], ["-", 455], ["life", 456], ["of", 461], ["exogenous", 464], ["antibody", 474], ["was", 483], ["extended", 487], ["when", 496], ["co", 501], ["-", 503], ["administered", 504], ["with", 517], ["R406", 522], [".", 526], ["Expression", 528], ["of", 539], ["the", 542], ["targeted", 546], ["kinase", 555], ["(", 562], ["Syk", 563], [")", 566], ["in", 568], ["synovial", 571], ["tissue", 580], ["correlated", 587], ["with", 598], ["the", 603], ["joint", 607], ["level", 613], ["of", 619], ["inflammatory", 622], ["cell", 635], ["infiltrates", 640], ["and", 652], ["was", 656], ["virtually", 660], ["undetectable", 670], ["in", 683], ["treated", 686], ["rats", 694], [".", 698], ["Syk", 700], ["inhibition", 704], ["suppressed", 715], ["synovial", 726], ["cytokines", 735], ["and", 745], ["cartilage", 749], ["oligomeric", 759], ["matrix", 770], ["protein", 777], ["(", 785], ["COMP", 786], [")", 790], ["in", 792], ["serum", 795], [",", 800], ["suggesting", 802], ["a", 813], ["sensitive", 815], ["and", 825], ["reliable", 829], ["biomarker", 838], ["for", 848], ["R406", 852], ["activity", 857], [".", 865], ["These", 867], ["results", 873], ["highlight", 881], ["the", 891], ["role", 895], ["of", 900], ["activating", 903], ["Fcgamma", 914], ["receptors", 922], ["in", 932], ["inflammatory", 935], ["synovitis", 948], ["and", 958], ["suggest", 962], ["that", 970], ["interruption", 975], ["of", 988], ["the", 991], ["signaling", 995], ["cascade", 1005], ["with", 1013], ["a", 1018], ["novel", 1020], ["Syk", 1026], ["inhibitor", 1030], ["may", 1040], ["be", 1044], ["a", 1047], ["useful", 1049], ["addition", 1056], ["to", 1065], ["immunosuppressive", 1068], ["disease", 1086], ["-", 1093], ["modifying", 1094], ["anti", 1104], ["-", 1108], ["rheumatic", 1109], ["drugs", 1119], ["currently", 1125], ["used", 1135], ["in", 1140], ["the", 1143], ["treatment", 1147], ["of", 1157], ["human", 1160], ["autoimmune", 1166], ["diseases", 1177], ["such", 1186], ["as", 1191], ["rheumatoid", 1194], ["arthritis", 1205], [".", 1214]]}
{"context": "Parkinson's disease (PD) is the second most common neurodegenerative disorder, defined by the presence of resting tremor, muscular rigidity, bradykinesia, and postural instability. PD is characterized by the progressive loss of dopaminergic neurons within the substantia nigra pars compacta of the midbrain. The neuropathological hallmark of the disease is the presence of intracytoplasmic inclusions, called Lewy bodies (LBs) and Lewy neurites (LNs), containing \u03b1-synuclein, a small protein which is widely expressed in the brain. The \u03b1-synuclein gene, SNCA, is located on chromosome 4q22.1; SNCA-linked PD shows an autosomal dominant inheritance pattern with a relatively early onset age, and it usually progresses rapidly. Three missense mutations, A53T, A30P, and E46K, in addition to gene multiplications of the SNCA have been described so far. Although it is clear that LBs and LNs contain mainly the \u03b1-synuclein protein, the mechanism(s) which leads \u03b1-synuclein to accumulate needs to be elucidated. The primary question in the molecular pathology of PD is how wild-type \u03b1-synuclein aggregates in PD, and which interacting partner(s) plays role(s) in the aggregation process. It is known that dopamine synthesis is a stressfull event, and \u03b1-synuclein expression somehow affects the dopamine synthesis. The aberrant interactions of \u03b1-synuclein with the proteins in the dopamine synthesis pathway may cause disturbances in cellular mechanisms. The normal physiological folding state of \u03b1-synuclein is also important for the understanding of pathological aggregates. Recent studies on the \u03b1-synuclein protein and genome-wide association studies of the \u03b1-synuclein gene show that PD has a strong genetic component, and both familial and idiopathic PD have a common denominator, \u03b1-synuclein, at the molecular level. It is clear that the disease process in Parkinson's disease, as in other neurodegenerative disorders, is very complicated; there can be several different molecular pathways which are responsible for diverse and possibly also unrelated functions inside the neuron, playing roles in PD pathogenesis.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "d5f8f2fee1f04e1ca38a7afa3aca1b32", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[289, 291], [78, 80], [94, 96], [301, 303], [325, 327], [202, 204], [168, 170], [234, 236], [248, 250], [272, 274], [178, 180]], "char_spans": [[1593, 1603], [463, 473], [536, 546], [1656, 1666], [1781, 1791], [1078, 1088], [907, 917], [1246, 1256], [1338, 1348], [1491, 1501], [957, 967]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["the", 28], ["second", 32], ["most", 39], ["common", 44], ["neurodegenerative", 51], ["disorder", 69], [",", 77], ["defined", 79], ["by", 87], ["the", 90], ["presence", 94], ["of", 103], ["resting", 106], ["tremor", 114], [",", 120], ["muscular", 122], ["rigidity", 131], [",", 139], ["bradykinesia", 141], [",", 153], ["and", 155], ["postural", 159], ["instability", 168], [".", 179], ["PD", 181], ["is", 184], ["characterized", 187], ["by", 201], ["the", 204], ["progressive", 208], ["loss", 220], ["of", 225], ["dopaminergic", 228], ["neurons", 241], ["within", 249], ["the", 256], ["substantia", 260], ["nigra", 271], ["pars", 277], ["compacta", 282], ["of", 291], ["the", 294], ["midbrain", 298], [".", 306], ["The", 308], ["neuropathological", 312], ["hallmark", 330], ["of", 339], ["the", 342], ["disease", 346], ["is", 354], ["the", 357], ["presence", 361], ["of", 370], ["intracytoplasmic", 373], ["inclusions", 390], [",", 400], ["called", 402], ["Lewy", 409], ["bodies", 414], ["(", 421], ["LBs", 422], [")", 425], ["and", 427], ["Lewy", 431], ["neurites", 436], ["(", 445], ["LNs", 446], [")", 449], [",", 450], ["containing", 452], ["\u03b1", 463], ["-", 464], ["synuclein", 465], [",", 474], ["a", 476], ["small", 478], ["protein", 484], ["which", 492], ["is", 498], ["widely", 501], ["expressed", 508], ["in", 518], ["the", 521], ["brain", 525], [".", 530], ["The", 532], ["\u03b1", 536], ["-", 537], ["synuclein", 538], ["gene", 548], [",", 552], ["SNCA", 554], [",", 558], ["is", 560], ["located", 563], ["on", 571], ["chromosome", 574], ["4q22.1", 585], [";", 591], ["SNCA", 593], ["-", 597], ["linked", 598], ["PD", 605], ["shows", 608], ["an", 614], ["autosomal", 617], ["dominant", 627], ["inheritance", 636], ["pattern", 648], ["with", 656], ["a", 661], ["relatively", 663], ["early", 674], ["onset", 680], ["age", 686], [",", 689], ["and", 691], ["it", 695], ["usually", 698], ["progresses", 706], ["rapidly", 717], [".", 724], ["Three", 726], ["missense", 732], ["mutations", 741], [",", 750], ["A53", 752], ["T", 755], [",", 756], ["A30P", 758], [",", 762], ["and", 764], ["E46", 768], ["K", 771], [",", 772], ["in", 774], ["addition", 777], ["to", 786], ["gene", 789], ["multiplications", 794], ["of", 810], ["the", 813], ["SNCA", 817], ["have", 822], ["been", 827], ["described", 832], ["so", 842], ["far", 845], [".", 848], ["Although", 850], ["it", 859], ["is", 862], ["clear", 865], ["that", 871], ["LBs", 876], ["and", 880], ["LNs", 884], ["contain", 888], ["mainly", 896], ["the", 903], ["\u03b1", 907], ["-", 908], ["synuclein", 909], ["protein", 919], [",", 926], ["the", 928], ["mechanism(s", 932], [")", 943], ["which", 945], ["leads", 951], ["\u03b1", 957], ["-", 958], ["synuclein", 959], ["to", 969], ["accumulate", 972], ["needs", 983], ["to", 989], ["be", 992], ["elucidated", 995], [".", 1005], ["The", 1007], ["primary", 1011], ["question", 1019], ["in", 1028], ["the", 1031], ["molecular", 1035], ["pathology", 1045], ["of", 1055], ["PD", 1058], ["is", 1061], ["how", 1064], ["wild", 1068], ["-", 1072], ["type", 1073], ["\u03b1", 1078], ["-", 1079], ["synuclein", 1080], ["aggregates", 1090], ["in", 1101], ["PD", 1104], [",", 1106], ["and", 1108], ["which", 1112], ["interacting", 1118], ["partner(s", 1130], [")", 1139], ["plays", 1141], ["role(s", 1147], [")", 1153], ["in", 1155], ["the", 1158], ["aggregation", 1162], ["process", 1174], [".", 1181], ["It", 1183], ["is", 1186], ["known", 1189], ["that", 1195], ["dopamine", 1200], ["synthesis", 1209], ["is", 1219], ["a", 1222], ["stressfull", 1224], ["event", 1235], [",", 1240], ["and", 1242], ["\u03b1", 1246], ["-", 1247], ["synuclein", 1248], ["expression", 1258], ["somehow", 1269], ["affects", 1277], ["the", 1285], ["dopamine", 1289], ["synthesis", 1298], [".", 1307], ["The", 1309], ["aberrant", 1313], ["interactions", 1322], ["of", 1335], ["\u03b1", 1338], ["-", 1339], ["synuclein", 1340], ["with", 1350], ["the", 1355], ["proteins", 1359], ["in", 1368], ["the", 1371], ["dopamine", 1375], ["synthesis", 1384], ["pathway", 1394], ["may", 1402], ["cause", 1406], ["disturbances", 1412], ["in", 1425], ["cellular", 1428], ["mechanisms", 1437], [".", 1447], ["The", 1449], ["normal", 1453], ["physiological", 1460], ["folding", 1474], ["state", 1482], ["of", 1488], ["\u03b1", 1491], ["-", 1492], ["synuclein", 1493], ["is", 1503], ["also", 1506], ["important", 1511], ["for", 1521], ["the", 1525], ["understanding", 1529], ["of", 1543], ["pathological", 1546], ["aggregates", 1559], [".", 1569], ["Recent", 1571], ["studies", 1578], ["on", 1586], ["the", 1589], ["\u03b1", 1593], ["-", 1594], ["synuclein", 1595], ["protein", 1605], ["and", 1613], ["genome", 1617], ["-", 1623], ["wide", 1624], ["association", 1629], ["studies", 1641], ["of", 1649], ["the", 1652], ["\u03b1", 1656], ["-", 1657], ["synuclein", 1658], ["gene", 1668], ["show", 1673], ["that", 1678], ["PD", 1683], ["has", 1686], ["a", 1690], ["strong", 1692], ["genetic", 1699], ["component", 1707], [",", 1716], ["and", 1718], ["both", 1722], ["familial", 1727], ["and", 1736], ["idiopathic", 1740], ["PD", 1751], ["have", 1754], ["a", 1759], ["common", 1761], ["denominator", 1768], [",", 1779], ["\u03b1", 1781], ["-", 1782], ["synuclein", 1783], [",", 1792], ["at", 1794], ["the", 1797], ["molecular", 1801], ["level", 1811], [".", 1816], ["It", 1818], ["is", 1821], ["clear", 1824], ["that", 1830], ["the", 1835], ["disease", 1839], ["process", 1847], ["in", 1855], ["Parkinson", 1858], ["'s", 1867], ["disease", 1870], [",", 1877], ["as", 1879], ["in", 1882], ["other", 1885], ["neurodegenerative", 1891], ["disorders", 1909], [",", 1918], ["is", 1920], ["very", 1923], ["complicated", 1928], [";", 1939], ["there", 1941], ["can", 1947], ["be", 1951], ["several", 1954], ["different", 1962], ["molecular", 1972], ["pathways", 1982], ["which", 1991], ["are", 1997], ["responsible", 2001], ["for", 2013], ["diverse", 2017], ["and", 2025], ["possibly", 2029], ["also", 2038], ["unrelated", 2043], ["functions", 2053], ["inside", 2063], ["the", 2070], ["neuron", 2074], [",", 2080], ["playing", 2082], ["roles", 2090], ["in", 2096], ["PD", 2099], ["pathogenesis", 2102], [".", 2114]]}
{"context": "Consensual diagnostic criteria for facioscapulohumeral dystrophy (FSHD) include onset of the disease in facial or shoulder girdle muscles, facial weakness in more than 50% of affected family members, autosomal dominant inheritance in familial cases, and evidence of myopathic disease in at least one affected member without biopsy features specific to alternative diagnoses. Six patients did not meet most of these criteria but were diagnosed as FSHD by DNA testing, which showed small EcoRI fragments on chromosome 4q. Their clinical signs and symptoms and results of auxiliary investigations are reported. The patients presented with foot extensor, thigh, or calf muscle weakness. None of them had apparent facial weakness, only one complained of weakness in the shoulders, none had a positive family history. Expert physical examination, however, showed a typical facial expression, an abnormal shoulder configuration on lifting the arms, or scapular winging. This raised the suspicion of FSHD, whereupon DNA analysis was done. In conclusion, the clinical expression of FSHD is much broader than indicated by the nomenclature. The possibility to perform DNA tests is likely to greatly expand the clinical range of FSHD.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "6c9b255f11a04caa992ae6ef8de912b0", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[33, 34]], "char_spans": [[200, 217]]}]}], "context_tokens": [["Consensual", 0], ["diagnostic", 11], ["criteria", 22], ["for", 31], ["facioscapulohumeral", 35], ["dystrophy", 55], ["(", 65], ["FSHD", 66], [")", 70], ["include", 72], ["onset", 80], ["of", 86], ["the", 89], ["disease", 93], ["in", 101], ["facial", 104], ["or", 111], ["shoulder", 114], ["girdle", 123], ["muscles", 130], [",", 137], ["facial", 139], ["weakness", 146], ["in", 155], ["more", 158], ["than", 163], ["50", 168], ["%", 170], ["of", 172], ["affected", 175], ["family", 184], ["members", 191], [",", 198], ["autosomal", 200], ["dominant", 210], ["inheritance", 219], ["in", 231], ["familial", 234], ["cases", 243], [",", 248], ["and", 250], ["evidence", 254], ["of", 263], ["myopathic", 266], ["disease", 276], ["in", 284], ["at", 287], ["least", 290], ["one", 296], ["affected", 300], ["member", 309], ["without", 316], ["biopsy", 324], ["features", 331], ["specific", 340], ["to", 349], ["alternative", 352], ["diagnoses", 364], [".", 373], ["Six", 375], ["patients", 379], ["did", 388], ["not", 392], ["meet", 396], ["most", 401], ["of", 406], ["these", 409], ["criteria", 415], ["but", 424], ["were", 428], ["diagnosed", 433], ["as", 443], ["FSHD", 446], ["by", 451], ["DNA", 454], ["testing", 458], [",", 465], ["which", 467], ["showed", 473], ["small", 480], ["EcoRI", 486], ["fragments", 492], ["on", 502], ["chromosome", 505], ["4q", 516], [".", 518], ["Their", 520], ["clinical", 526], ["signs", 535], ["and", 541], ["symptoms", 545], ["and", 554], ["results", 558], ["of", 566], ["auxiliary", 569], ["investigations", 579], ["are", 594], ["reported", 598], [".", 606], ["The", 608], ["patients", 612], ["presented", 621], ["with", 631], ["foot", 636], ["extensor", 641], [",", 649], ["thigh", 651], [",", 656], ["or", 658], ["calf", 661], ["muscle", 666], ["weakness", 673], [".", 681], ["None", 683], ["of", 688], ["them", 691], ["had", 696], ["apparent", 700], ["facial", 709], ["weakness", 716], [",", 724], ["only", 726], ["one", 731], ["complained", 735], ["of", 746], ["weakness", 749], ["in", 758], ["the", 761], ["shoulders", 765], [",", 774], ["none", 776], ["had", 781], ["a", 785], ["positive", 787], ["family", 796], ["history", 803], [".", 810], ["Expert", 812], ["physical", 819], ["examination", 828], [",", 839], ["however", 841], [",", 848], ["showed", 850], ["a", 857], ["typical", 859], ["facial", 867], ["expression", 874], [",", 884], ["an", 886], ["abnormal", 889], ["shoulder", 898], ["configuration", 907], ["on", 921], ["lifting", 924], ["the", 932], ["arms", 936], [",", 940], ["or", 942], ["scapular", 945], ["winging", 954], [".", 961], ["This", 963], ["raised", 968], ["the", 975], ["suspicion", 979], ["of", 989], ["FSHD", 992], [",", 996], ["whereupon", 998], ["DNA", 1008], ["analysis", 1012], ["was", 1021], ["done", 1025], [".", 1029], ["In", 1031], ["conclusion", 1034], [",", 1044], ["the", 1046], ["clinical", 1050], ["expression", 1059], ["of", 1070], ["FSHD", 1073], ["is", 1078], ["much", 1081], ["broader", 1086], ["than", 1094], ["indicated", 1099], ["by", 1109], ["the", 1112], ["nomenclature", 1116], [".", 1128], ["The", 1130], ["possibility", 1134], ["to", 1146], ["perform", 1149], ["DNA", 1157], ["tests", 1161], ["is", 1167], ["likely", 1170], ["to", 1177], ["greatly", 1180], ["expand", 1188], ["the", 1195], ["clinical", 1199], ["range", 1208], ["of", 1214], ["FSHD", 1217], [".", 1221]]}
{"context": "Light-harvesting pigment-protein complex of Photosystem II (LHCII) is the largest photosynthetic antenna complex of plants and the most abundant membrane protein in the biosphere. Plant fitness and productivity depend directly on a balance between excitations in the photosynthetic apparatus, generated by captured light quanta, and the rate of photochemical processes. Excess excitation energy leads to oxidative damage of the photosynthetic apparatus and entire organism and therefore the balance between the excitation density and photosynthesis requires precise and efficient regulation, operating also at the level of antenna complexes. We show that illumination of the isolated LHCII leads to isomerization of the protein-bound neoxanthin from conformation 9'-cis to 9',13- and 9',13'-dicis forms. At the same time light-driven excitation quenching is observed, manifested by a decrease in chlorophyll a fluorescence intensity and shortened fluorescence lifetimes. Both processes, the neoxanthin isomerization and the chlorophyll excitation quenching, are reversible in dim light. The results of the 77K florescence measurements of LHCII show that illumination is associated with appearance of the low-energy states, which can serve as energy traps in the pigment-protein complex subjected to excess excitation. Possible sequence of the molecular events is proposed, leading to a protective excess excitation energy quenching: neoxanthin photo-isomerization\u2192formation of LHCII supramolecular structures which potentiate creation of energy traps\u2192excitation quenching.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "d30650e611f64f46abbf5b525ce53a92", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "Light-harvesting pigment-protein complex of Photosystem II", "token_spans": [[0, 9]], "char_spans": [[0, 57]]}, {"text": "LHCII", "token_spans": [[233, 233], [11, 11], [178, 178], [106, 106]], "char_spans": [[1477, 1481], [60, 64], [1138, 1142], [684, 688]]}]}], "context_tokens": [["Light", 0], ["-", 5], ["harvesting", 6], ["pigment", 17], ["-", 24], ["protein", 25], ["complex", 33], ["of", 41], ["Photosystem", 44], ["II", 56], ["(", 59], ["LHCII", 60], [")", 65], ["is", 67], ["the", 70], ["largest", 74], ["photosynthetic", 82], ["antenna", 97], ["complex", 105], ["of", 113], ["plants", 116], ["and", 123], ["the", 127], ["most", 131], ["abundant", 136], ["membrane", 145], ["protein", 154], ["in", 162], ["the", 165], ["biosphere", 169], [".", 178], ["Plant", 180], ["fitness", 186], ["and", 194], ["productivity", 198], ["depend", 211], ["directly", 218], ["on", 227], ["a", 230], ["balance", 232], ["between", 240], ["excitations", 248], ["in", 260], ["the", 263], ["photosynthetic", 267], ["apparatus", 282], [",", 291], ["generated", 293], ["by", 303], ["captured", 306], ["light", 315], ["quanta", 321], [",", 327], ["and", 329], ["the", 333], ["rate", 337], ["of", 342], ["photochemical", 345], ["processes", 359], [".", 368], ["Excess", 370], ["excitation", 377], ["energy", 388], ["leads", 395], ["to", 401], ["oxidative", 404], ["damage", 414], ["of", 421], ["the", 424], ["photosynthetic", 428], ["apparatus", 443], ["and", 453], ["entire", 457], ["organism", 464], ["and", 473], ["therefore", 477], ["the", 487], ["balance", 491], ["between", 499], ["the", 507], ["excitation", 511], ["density", 522], ["and", 530], ["photosynthesis", 534], ["requires", 549], ["precise", 558], ["and", 566], ["efficient", 570], ["regulation", 580], [",", 590], ["operating", 592], ["also", 602], ["at", 607], ["the", 610], ["level", 614], ["of", 620], ["antenna", 623], ["complexes", 631], [".", 640], ["We", 642], ["show", 645], ["that", 650], ["illumination", 655], ["of", 668], ["the", 671], ["isolated", 675], ["LHCII", 684], ["leads", 690], ["to", 696], ["isomerization", 699], ["of", 713], ["the", 716], ["protein", 720], ["-", 727], ["bound", 728], ["neoxanthin", 734], ["from", 745], ["conformation", 750], ["9'-cis", 763], ["to", 770], ["9',13-", 773], ["and", 780], ["9',13'-dicis", 784], ["forms", 797], [".", 802], ["At", 804], ["the", 807], ["same", 811], ["time", 816], ["light", 821], ["-", 826], ["driven", 827], ["excitation", 834], ["quenching", 845], ["is", 855], ["observed", 858], [",", 866], ["manifested", 868], ["by", 879], ["a", 882], ["decrease", 884], ["in", 893], ["chlorophyll", 896], ["a", 908], ["fluorescence", 910], ["intensity", 923], ["and", 933], ["shortened", 937], ["fluorescence", 947], ["lifetimes", 960], [".", 969], ["Both", 971], ["processes", 976], [",", 985], ["the", 987], ["neoxanthin", 991], ["isomerization", 1002], ["and", 1016], ["the", 1020], ["chlorophyll", 1024], ["excitation", 1036], ["quenching", 1047], [",", 1056], ["are", 1058], ["reversible", 1062], ["in", 1073], ["dim", 1076], ["light", 1080], [".", 1085], ["The", 1087], ["results", 1091], ["of", 1099], ["the", 1102], ["77", 1106], ["K", 1108], ["florescence", 1110], ["measurements", 1122], ["of", 1135], ["LHCII", 1138], ["show", 1144], ["that", 1149], ["illumination", 1154], ["is", 1167], ["associated", 1170], ["with", 1181], ["appearance", 1186], ["of", 1197], ["the", 1200], ["low", 1204], ["-", 1207], ["energy", 1208], ["states", 1215], [",", 1221], ["which", 1223], ["can", 1229], ["serve", 1233], ["as", 1239], ["energy", 1242], ["traps", 1249], ["in", 1255], ["the", 1258], ["pigment", 1262], ["-", 1269], ["protein", 1270], ["complex", 1278], ["subjected", 1286], ["to", 1296], ["excess", 1299], ["excitation", 1306], [".", 1316], ["Possible", 1318], ["sequence", 1327], ["of", 1336], ["the", 1339], ["molecular", 1343], ["events", 1353], ["is", 1360], ["proposed", 1363], [",", 1371], ["leading", 1373], ["to", 1381], ["a", 1384], ["protective", 1386], ["excess", 1397], ["excitation", 1404], ["energy", 1415], ["quenching", 1422], [":", 1431], ["neoxanthin", 1433], ["photo", 1444], ["-", 1449], ["isomerization\u2192formation", 1450], ["of", 1474], ["LHCII", 1477], ["supramolecular", 1483], ["structures", 1498], ["which", 1509], ["potentiate", 1515], ["creation", 1526], ["of", 1535], ["energy", 1538], ["traps\u2192excitation", 1545], ["quenching", 1562], [".", 1571]]}
{"context": "Ehlers-Danlos syndromes (EDS) and Marfan syndrome (MFS) are multisystemic disorders that primarily affect the soft connective tissues. Both disorders have benefited from recent advances in clinical and molecular characterization, allowing improvements in clinical diagnosis and management. EDS are a heterogeneous group of conditions characterized by skin hyperextensibility, atrophic scarring, joint hypermobility and generalized tissue fragility. The current classification proposes six subtypes based on clinical, biochemical and molecular characteristics. However, examples of unclassified variants and 'overlap phenotypes' are becoming more common. Mutations in genes encoding fibrillar collagens or collagen-modifying enzymes have been identified in most forms of EDS, including the classic and vascular subtypes (collagen type V and III, respectively), and the rare arthrochalasis, kyphoscoliosis and dermatosparaxis variants (type I collagen defects). To date, the genetic background of the hypermobility type of EDS remains unclear, although some new insights have been gained recently. MFS is an autosomal-dominant disorder that affects the cardiovascular, ocular and skeletal system with aortic root dilation/dissection, ectopia lentis and bone overgrowth, respectively. Advances in therapeutic, mainly surgical, techniques have improved median survival significantly, yet severe morbidity and a substantial risk for premature mortality remain associated. The disorder is caused by mutations in the FBN1 gene, encoding the microfibrillar protein fibrillin-1. Recently, new insights in the pathogenesis changed the prevailing concept of this type 1 fibrillinopathy as a structural disorder of the connective tissue into a developmental abnormality manifesting perturbed cytokine signalling. These findings have opened new and unexpected targets for aetiologically directed drug treatments.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "efb13b867d664aa1b52ab77cba850165", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[271, 272]], "char_spans": [[1707, 1723]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndromes", 14], ["(", 24], ["EDS", 25], [")", 28], ["and", 30], ["Marfan", 34], ["syndrome", 41], ["(", 50], ["MFS", 51], [")", 54], ["are", 56], ["multisystemic", 60], ["disorders", 74], ["that", 84], ["primarily", 89], ["affect", 99], ["the", 106], ["soft", 110], ["connective", 115], ["tissues", 126], [".", 133], ["Both", 135], ["disorders", 140], ["have", 150], ["benefited", 155], ["from", 165], ["recent", 170], ["advances", 177], ["in", 186], ["clinical", 189], ["and", 198], ["molecular", 202], ["characterization", 212], [",", 228], ["allowing", 230], ["improvements", 239], ["in", 252], ["clinical", 255], ["diagnosis", 264], ["and", 274], ["management", 278], [".", 288], ["EDS", 290], ["are", 294], ["a", 298], ["heterogeneous", 300], ["group", 314], ["of", 320], ["conditions", 323], ["characterized", 334], ["by", 348], ["skin", 351], ["hyperextensibility", 356], [",", 374], ["atrophic", 376], ["scarring", 385], [",", 393], ["joint", 395], ["hypermobility", 401], ["and", 415], ["generalized", 419], ["tissue", 431], ["fragility", 438], [".", 447], ["The", 449], ["current", 453], ["classification", 461], ["proposes", 476], ["six", 485], ["subtypes", 489], ["based", 498], ["on", 504], ["clinical", 507], [",", 515], ["biochemical", 517], ["and", 529], ["molecular", 533], ["characteristics", 543], [".", 558], ["However", 560], [",", 567], ["examples", 569], ["of", 578], ["unclassified", 581], ["variants", 594], ["and", 603], ["'", 607], ["overlap", 608], ["phenotypes", 616], ["'", 626], ["are", 628], ["becoming", 632], ["more", 641], ["common", 646], [".", 652], ["Mutations", 654], ["in", 664], ["genes", 667], ["encoding", 673], ["fibrillar", 682], ["collagens", 692], ["or", 702], ["collagen", 705], ["-", 713], ["modifying", 714], ["enzymes", 724], ["have", 732], ["been", 737], ["identified", 742], ["in", 753], ["most", 756], ["forms", 761], ["of", 767], ["EDS", 770], [",", 773], ["including", 775], ["the", 785], ["classic", 789], ["and", 797], ["vascular", 801], ["subtypes", 810], ["(", 819], ["collagen", 820], ["type", 829], ["V", 834], ["and", 836], ["III", 840], [",", 843], ["respectively", 845], [")", 857], [",", 858], ["and", 860], ["the", 864], ["rare", 868], ["arthrochalasis", 873], [",", 887], ["kyphoscoliosis", 889], ["and", 904], ["dermatosparaxis", 908], ["variants", 924], ["(", 933], ["type", 934], ["I", 939], ["collagen", 941], ["defects", 950], [")", 957], [".", 958], ["To", 960], ["date", 963], [",", 967], ["the", 969], ["genetic", 973], ["background", 981], ["of", 992], ["the", 995], ["hypermobility", 999], ["type", 1013], ["of", 1018], ["EDS", 1021], ["remains", 1025], ["unclear", 1033], [",", 1040], ["although", 1042], ["some", 1051], ["new", 1056], ["insights", 1060], ["have", 1069], ["been", 1074], ["gained", 1079], ["recently", 1086], [".", 1094], ["MFS", 1096], ["is", 1100], ["an", 1103], ["autosomal", 1106], ["-", 1115], ["dominant", 1116], ["disorder", 1125], ["that", 1134], ["affects", 1139], ["the", 1147], ["cardiovascular", 1151], [",", 1165], ["ocular", 1167], ["and", 1174], ["skeletal", 1178], ["system", 1187], ["with", 1194], ["aortic", 1199], ["root", 1206], ["dilation", 1211], ["/", 1219], ["dissection", 1220], [",", 1230], ["ectopia", 1232], ["lentis", 1240], ["and", 1247], ["bone", 1251], ["overgrowth", 1256], [",", 1266], ["respectively", 1268], [".", 1280], ["Advances", 1282], ["in", 1291], ["therapeutic", 1294], [",", 1305], ["mainly", 1307], ["surgical", 1314], [",", 1322], ["techniques", 1324], ["have", 1335], ["improved", 1340], ["median", 1349], ["survival", 1356], ["significantly", 1365], [",", 1378], ["yet", 1380], ["severe", 1384], ["morbidity", 1391], ["and", 1401], ["a", 1405], ["substantial", 1407], ["risk", 1419], ["for", 1424], ["premature", 1428], ["mortality", 1438], ["remain", 1448], ["associated", 1455], [".", 1465], ["The", 1467], ["disorder", 1471], ["is", 1480], ["caused", 1483], ["by", 1490], ["mutations", 1493], ["in", 1503], ["the", 1506], ["FBN1", 1510], ["gene", 1515], [",", 1519], ["encoding", 1521], ["the", 1530], ["microfibrillar", 1534], ["protein", 1549], ["fibrillin-1", 1557], [".", 1568], ["Recently", 1570], [",", 1578], ["new", 1580], ["insights", 1584], ["in", 1593], ["the", 1596], ["pathogenesis", 1600], ["changed", 1613], ["the", 1621], ["prevailing", 1625], ["concept", 1636], ["of", 1644], ["this", 1647], ["type", 1652], ["1", 1657], ["fibrillinopathy", 1659], ["as", 1675], ["a", 1678], ["structural", 1680], ["disorder", 1691], ["of", 1700], ["the", 1703], ["connective", 1707], ["tissue", 1718], ["into", 1725], ["a", 1730], ["developmental", 1732], ["abnormality", 1746], ["manifesting", 1758], ["perturbed", 1770], ["cytokine", 1780], ["signalling", 1789], [".", 1799], ["These", 1801], ["findings", 1807], ["have", 1816], ["opened", 1821], ["new", 1828], ["and", 1832], ["unexpected", 1836], ["targets", 1847], ["for", 1855], ["aetiologically", 1859], ["directed", 1874], ["drug", 1883], ["treatments", 1888], [".", 1898]]}
{"context": "Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI) designed as a prototypic short-acting BCR-ABL-targeted TKI that inhibits BCR-ABL with greater potency compared with imatinib, nilotinib, bosutinib, and ponatinib and has been shown to have potential immunomodulatory effects. Dasatinib is approved for the treatment of all phases of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to prior imatinib treatment and first-line treatment for CML in chronic phase. In this article, the development of dasatinib as a treatment for patients with CML is reviewed. This is a review of the relevant literature regarding dasatinib development in CML (2003-2013). Dasatinib demonstrates efficacy against most BCR-ABL mutations arising during imatinib therapy and is effective in treating patients with imatinib resistance due to other mechanisms. Randomized trial data show that first-line dasatinib provides superior responses compared with imatinib and enables patients to achieve early, deep responses correlated with improved longer-term outcomes. Dasatinib has a generally acceptable safety profile, with most adverse events (AEs) proving manageable and reversible. Cytopenias are commonly observed with dasatinib, and some nonhematologic AEs including pleural effusion have been consistently reported. Dasatinib is an effective treatment option for patients with CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "5c2cbb8eaf4742919bc8a56682ea0e5a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[138, 140], [20, 22], [28, 30]], "char_spans": [[779, 785], [98, 104], [133, 139]]}]}], "context_tokens": [["Dasatinib", 0], ["is", 10], ["a", 13], ["dual", 15], ["Abl", 20], ["/", 23], ["Src", 24], ["tyrosine", 28], ["kinase", 37], ["inhibitor", 44], ["(", 54], ["TKI", 55], [")", 58], ["designed", 60], ["as", 69], ["a", 72], ["prototypic", 74], ["short", 85], ["-", 90], ["acting", 91], ["BCR", 98], ["-", 101], ["ABL", 102], ["-", 105], ["targeted", 106], ["TKI", 115], ["that", 119], ["inhibits", 124], ["BCR", 133], ["-", 136], ["ABL", 137], ["with", 141], ["greater", 146], ["potency", 154], ["compared", 162], ["with", 171], ["imatinib", 176], [",", 184], ["nilotinib", 186], [",", 195], ["bosutinib", 197], [",", 206], ["and", 208], ["ponatinib", 212], ["and", 222], ["has", 226], ["been", 230], ["shown", 235], ["to", 241], ["have", 244], ["potential", 249], ["immunomodulatory", 259], ["effects", 276], [".", 283], ["Dasatinib", 285], ["is", 295], ["approved", 298], ["for", 307], ["the", 311], ["treatment", 315], ["of", 325], ["all", 328], ["phases", 332], ["of", 339], ["chronic", 342], ["myeloid", 350], ["leukemia", 358], ["(", 367], ["CML", 368], [")", 371], ["and", 373], ["Philadelphia", 377], ["chromosome", 390], ["-", 400], ["positive", 401], ["acute", 410], ["lymphoblastic", 416], ["leukemia", 430], ["resistant", 439], ["or", 449], ["intolerant", 452], ["to", 463], ["prior", 466], ["imatinib", 472], ["treatment", 481], ["and", 491], ["first", 495], ["-", 500], ["line", 501], ["treatment", 506], ["for", 516], ["CML", 520], ["in", 524], ["chronic", 527], ["phase", 535], [".", 540], ["In", 542], ["this", 545], ["article", 550], [",", 557], ["the", 559], ["development", 563], ["of", 575], ["dasatinib", 578], ["as", 588], ["a", 591], ["treatment", 593], ["for", 603], ["patients", 607], ["with", 616], ["CML", 621], ["is", 625], ["reviewed", 628], [".", 636], ["This", 638], ["is", 643], ["a", 646], ["review", 648], ["of", 655], ["the", 658], ["relevant", 662], ["literature", 671], ["regarding", 682], ["dasatinib", 692], ["development", 702], ["in", 714], ["CML", 717], ["(", 721], ["2003", 722], ["-", 726], ["2013", 727], [")", 731], [".", 732], ["Dasatinib", 734], ["demonstrates", 744], ["efficacy", 757], ["against", 766], ["most", 774], ["BCR", 779], ["-", 782], ["ABL", 783], ["mutations", 787], ["arising", 797], ["during", 805], ["imatinib", 812], ["therapy", 821], ["and", 829], ["is", 833], ["effective", 836], ["in", 846], ["treating", 849], ["patients", 858], ["with", 867], ["imatinib", 872], ["resistance", 881], ["due", 892], ["to", 896], ["other", 899], ["mechanisms", 905], [".", 915], ["Randomized", 917], ["trial", 928], ["data", 934], ["show", 939], ["that", 944], ["first", 949], ["-", 954], ["line", 955], ["dasatinib", 960], ["provides", 970], ["superior", 979], ["responses", 988], ["compared", 998], ["with", 1007], ["imatinib", 1012], ["and", 1021], ["enables", 1025], ["patients", 1033], ["to", 1042], ["achieve", 1045], ["early", 1053], [",", 1058], ["deep", 1060], ["responses", 1065], ["correlated", 1075], ["with", 1086], ["improved", 1091], ["longer", 1100], ["-", 1106], ["term", 1107], ["outcomes", 1112], [".", 1120], ["Dasatinib", 1122], ["has", 1132], ["a", 1136], ["generally", 1138], ["acceptable", 1148], ["safety", 1159], ["profile", 1166], [",", 1173], ["with", 1175], ["most", 1180], ["adverse", 1185], ["events", 1193], ["(", 1200], ["AEs", 1201], [")", 1204], ["proving", 1206], ["manageable", 1214], ["and", 1225], ["reversible", 1229], [".", 1239], ["Cytopenias", 1241], ["are", 1252], ["commonly", 1256], ["observed", 1265], ["with", 1274], ["dasatinib", 1279], [",", 1288], ["and", 1290], ["some", 1294], ["nonhematologic", 1299], ["AEs", 1314], ["including", 1318], ["pleural", 1328], ["effusion", 1336], ["have", 1345], ["been", 1350], ["consistently", 1355], ["reported", 1368], [".", 1376], ["Dasatinib", 1378], ["is", 1388], ["an", 1391], ["effective", 1394], ["treatment", 1404], ["option", 1414], ["for", 1421], ["patients", 1425], ["with", 1434], ["CML", 1439], [".", 1442]]}
{"context": "Neurofibromatosis type 1 (NF1) is a hereditary disorder caused by mutations in the NF1 gene. Detecting mutation in NF1 is hindered by the gene's large size, the lack of mutation hotspots, the presence of pseudogenes, and the wide variety of possible lesions. We developed a method for detecting germline mutations by combining an original RNA-based cDNA-PCR mutation detection method and denaturing high-performance liquid chromatography (DHPLC) with multiplex ligation-dependent probe amplification (MLPA). The protocol was validated in a cohort of 56 blood samples from NF1 patients who fulfilled NIH diagnostic criteria, identifying the germline mutation in 53 cases (95% sensitivity). The efficiency and reliability of this approach facilitated detection of different types of mutations, including single-base substitutions, deletions or insertions of one to several nucleotides, microdeletions, and changes in intragenic copy number. Because mutational screening for minor lesions was performed using cDNA and the characterization of mutated alleles was performed at both the RNA and genomic DNA level, the analysis provided insight into the nature of the different mutations and their effect on NF1 mRNA splicing. After validation, we implemented the protocol as a routine test. Here we present the overall unbiased spectrum of NF1 mutations identified in 93 patients in a cohort of 105. The results indicate that this protocol is a powerful new tool for the molecular diagnosis of NF1.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "c9db9e67e67b4c408b9e053169e05a70", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[21, 21], [230, 230], [258, 258], [4, 4], [104, 104], [206, 206], [15, 15]], "char_spans": [[115, 117], [1334, 1336], [1488, 1490], [26, 28], [572, 574], [1201, 1203], [83, 85]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["hereditary", 36], ["disorder", 47], ["caused", 56], ["by", 63], ["mutations", 66], ["in", 76], ["the", 79], ["NF1", 83], ["gene", 87], [".", 91], ["Detecting", 93], ["mutation", 103], ["in", 112], ["NF1", 115], ["is", 119], ["hindered", 122], ["by", 131], ["the", 134], ["gene", 138], ["'s", 142], ["large", 145], ["size", 151], [",", 155], ["the", 157], ["lack", 161], ["of", 166], ["mutation", 169], ["hotspots", 178], [",", 186], ["the", 188], ["presence", 192], ["of", 201], ["pseudogenes", 204], [",", 215], ["and", 217], ["the", 221], ["wide", 225], ["variety", 230], ["of", 238], ["possible", 241], ["lesions", 250], [".", 257], ["We", 259], ["developed", 262], ["a", 272], ["method", 274], ["for", 281], ["detecting", 285], ["germline", 295], ["mutations", 304], ["by", 314], ["combining", 317], ["an", 327], ["original", 330], ["RNA", 339], ["-", 342], ["based", 343], ["cDNA", 349], ["-", 353], ["PCR", 354], ["mutation", 358], ["detection", 367], ["method", 377], ["and", 384], ["denaturing", 388], ["high", 399], ["-", 403], ["performance", 404], ["liquid", 416], ["chromatography", 423], ["(", 438], ["DHPLC", 439], [")", 444], ["with", 446], ["multiplex", 451], ["ligation", 461], ["-", 469], ["dependent", 470], ["probe", 480], ["amplification", 486], ["(", 500], ["MLPA", 501], [")", 505], [".", 506], ["The", 508], ["protocol", 512], ["was", 521], ["validated", 525], ["in", 535], ["a", 538], ["cohort", 540], ["of", 547], ["56", 550], ["blood", 553], ["samples", 559], ["from", 567], ["NF1", 572], ["patients", 576], ["who", 585], ["fulfilled", 589], ["NIH", 599], ["diagnostic", 603], ["criteria", 614], [",", 622], ["identifying", 624], ["the", 636], ["germline", 640], ["mutation", 649], ["in", 658], ["53", 661], ["cases", 664], ["(", 670], ["95", 671], ["%", 673], ["sensitivity", 675], [")", 686], [".", 687], ["The", 689], ["efficiency", 693], ["and", 704], ["reliability", 708], ["of", 720], ["this", 723], ["approach", 728], ["facilitated", 737], ["detection", 749], ["of", 759], ["different", 762], ["types", 772], ["of", 778], ["mutations", 781], [",", 790], ["including", 792], ["single", 802], ["-", 808], ["base", 809], ["substitutions", 814], [",", 827], ["deletions", 829], ["or", 839], ["insertions", 842], ["of", 853], ["one", 856], ["to", 860], ["several", 863], ["nucleotides", 871], [",", 882], ["microdeletions", 884], [",", 898], ["and", 900], ["changes", 904], ["in", 912], ["intragenic", 915], ["copy", 926], ["number", 931], [".", 937], ["Because", 939], ["mutational", 947], ["screening", 958], ["for", 968], ["minor", 972], ["lesions", 978], ["was", 986], ["performed", 990], ["using", 1000], ["cDNA", 1006], ["and", 1011], ["the", 1015], ["characterization", 1019], ["of", 1036], ["mutated", 1039], ["alleles", 1047], ["was", 1055], ["performed", 1059], ["at", 1069], ["both", 1072], ["the", 1077], ["RNA", 1081], ["and", 1085], ["genomic", 1089], ["DNA", 1097], ["level", 1101], [",", 1106], ["the", 1108], ["analysis", 1112], ["provided", 1121], ["insight", 1130], ["into", 1138], ["the", 1143], ["nature", 1147], ["of", 1154], ["the", 1157], ["different", 1161], ["mutations", 1171], ["and", 1181], ["their", 1185], ["effect", 1191], ["on", 1198], ["NF1", 1201], ["mRNA", 1205], ["splicing", 1210], [".", 1218], ["After", 1220], ["validation", 1226], [",", 1236], ["we", 1238], ["implemented", 1241], ["the", 1253], ["protocol", 1257], ["as", 1266], ["a", 1269], ["routine", 1271], ["test", 1279], [".", 1283], ["Here", 1285], ["we", 1290], ["present", 1293], ["the", 1301], ["overall", 1305], ["unbiased", 1313], ["spectrum", 1322], ["of", 1331], ["NF1", 1334], ["mutations", 1338], ["identified", 1348], ["in", 1359], ["93", 1362], ["patients", 1365], ["in", 1374], ["a", 1377], ["cohort", 1379], ["of", 1386], ["105", 1389], [".", 1392], ["The", 1394], ["results", 1398], ["indicate", 1406], ["that", 1415], ["this", 1420], ["protocol", 1425], ["is", 1434], ["a", 1437], ["powerful", 1439], ["new", 1448], ["tool", 1452], ["for", 1457], ["the", 1461], ["molecular", 1465], ["diagnosis", 1475], ["of", 1485], ["NF1", 1488], [".", 1491]]}
{"context": "Alpha-synuclein is believed to play an important role in Parkinson's disease (PD). Mutations in the alpha-synuclein gene are responsible for familial forms of PD and alpha-synuclein protein is a major component of Lewy bodies in patients with sporadic PD. Synphilin-1 is a novel protein that we have previously found to associate in vivo with alpha-synuclein. We now show that synphilin-1 is present in Lewy bodies of patients with PD. Our data suggest that synphilin-1 could play a role in Lewy body formation and the pathogenesis of PD.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "69c3caa799bb4990932019ccbabd967e", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[65, 67], [21, 23], [0, 2], [33, 35]], "char_spans": [[343, 357], [100, 114], [0, 14], [166, 180]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["is", 16], ["believed", 19], ["to", 28], ["play", 31], ["an", 36], ["important", 39], ["role", 49], ["in", 54], ["Parkinson", 57], ["'s", 66], ["disease", 69], ["(", 77], ["PD", 78], [")", 80], [".", 81], ["Mutations", 83], ["in", 93], ["the", 96], ["alpha", 100], ["-", 105], ["synuclein", 106], ["gene", 116], ["are", 121], ["responsible", 125], ["for", 137], ["familial", 141], ["forms", 150], ["of", 156], ["PD", 159], ["and", 162], ["alpha", 166], ["-", 171], ["synuclein", 172], ["protein", 182], ["is", 190], ["a", 193], ["major", 195], ["component", 201], ["of", 211], ["Lewy", 214], ["bodies", 219], ["in", 226], ["patients", 229], ["with", 238], ["sporadic", 243], ["PD", 252], [".", 254], ["Synphilin-1", 256], ["is", 268], ["a", 271], ["novel", 273], ["protein", 279], ["that", 287], ["we", 292], ["have", 295], ["previously", 300], ["found", 311], ["to", 317], ["associate", 320], ["in", 330], ["vivo", 333], ["with", 338], ["alpha", 343], ["-", 348], ["synuclein", 349], [".", 358], ["We", 360], ["now", 363], ["show", 367], ["that", 372], ["synphilin-1", 377], ["is", 389], ["present", 392], ["in", 400], ["Lewy", 403], ["bodies", 408], ["of", 415], ["patients", 418], ["with", 427], ["PD", 432], [".", 434], ["Our", 436], ["data", 440], ["suggest", 445], ["that", 453], ["synphilin-1", 458], ["could", 470], ["play", 476], ["a", 481], ["role", 483], ["in", 488], ["Lewy", 491], ["body", 496], ["formation", 501], ["and", 511], ["the", 515], ["pathogenesis", 519], ["of", 532], ["PD", 535], [".", 537]]}
{"context": "The apolipoprotein E type 4 allele is a susceptibility gene for late-onset Alzheimer's disease. Apolipoprotein E is found in neurons, some of which contain paired helical filaments made of the microtubule-associated protein tau. Previous studies have demonstrated that the apoE3 isoform, but not the apoE4 isoform, binds tau with high avidity. Because the microtubule-associated protein MAP2c also effects microtubule assembly and stability, we examined interactions between apoE isoforms and MAP2c. Similar to the tau-binding results, apoE3, but not apoE4, bound MAP2c. Binding was detectable down to 10(-9) M MAP2c and 10(-8) M apoE3. Isoform-specific interactions of apoE with the microtubule-associated proteins MAP2c and tau might affect intracellular maintenance of microtubules and could contribute to a time-dependent pathogenesis of Alzheimer's disease.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "2a8c06afe76f42f9ab06708b3adc27fc", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[53, 54]], "char_spans": [[300, 312]]}]}], "context_tokens": [["The", 0], ["apolipoprotein", 4], ["E", 19], ["type", 21], ["4", 26], ["allele", 28], ["is", 35], ["a", 38], ["susceptibility", 40], ["gene", 55], ["for", 60], ["late", 64], ["-", 68], ["onset", 69], ["Alzheimer", 75], ["'s", 84], ["disease", 87], [".", 94], ["Apolipoprotein", 96], ["E", 111], ["is", 113], ["found", 116], ["in", 122], ["neurons", 125], [",", 132], ["some", 134], ["of", 139], ["which", 142], ["contain", 148], ["paired", 156], ["helical", 163], ["filaments", 171], ["made", 181], ["of", 186], ["the", 189], ["microtubule", 193], ["-", 204], ["associated", 205], ["protein", 216], ["tau", 224], [".", 227], ["Previous", 229], ["studies", 238], ["have", 246], ["demonstrated", 251], ["that", 264], ["the", 269], ["apoE3", 273], ["isoform", 279], [",", 286], ["but", 288], ["not", 292], ["the", 296], ["apoE4", 300], ["isoform", 306], [",", 313], ["binds", 315], ["tau", 321], ["with", 325], ["high", 330], ["avidity", 335], [".", 342], ["Because", 344], ["the", 352], ["microtubule", 356], ["-", 367], ["associated", 368], ["protein", 379], ["MAP2c", 387], ["also", 393], ["effects", 398], ["microtubule", 406], ["assembly", 418], ["and", 427], ["stability", 431], [",", 440], ["we", 442], ["examined", 445], ["interactions", 454], ["between", 467], ["apoE", 475], ["isoforms", 480], ["and", 489], ["MAP2c", 493], [".", 498], ["Similar", 500], ["to", 508], ["the", 511], ["tau", 515], ["-", 518], ["binding", 519], ["results", 527], [",", 534], ["apoE3", 536], [",", 541], ["but", 543], ["not", 547], ["apoE4", 551], [",", 556], ["bound", 558], ["MAP2c", 564], [".", 569], ["Binding", 571], ["was", 579], ["detectable", 583], ["down", 594], ["to", 599], ["10(-9", 602], [")", 607], ["M", 609], ["MAP2c", 611], ["and", 617], ["10(-8", 621], [")", 626], ["M", 628], ["apoE3", 630], [".", 635], ["Isoform", 637], ["-", 644], ["specific", 645], ["interactions", 654], ["of", 667], ["apoE", 670], ["with", 675], ["the", 680], ["microtubule", 684], ["-", 695], ["associated", 696], ["proteins", 707], ["MAP2c", 716], ["and", 722], ["tau", 726], ["might", 730], ["affect", 736], ["intracellular", 743], ["maintenance", 757], ["of", 769], ["microtubules", 772], ["and", 785], ["could", 789], ["contribute", 795], ["to", 806], ["a", 809], ["time", 811], ["-", 815], ["dependent", 816], ["pathogenesis", 826], ["of", 839], ["Alzheimer", 842], ["'s", 851], ["disease", 854], [".", 861]]}
{"context": "Normal B lymphocytes receive signals from B-cell antigen receptor (BCR) that are triggered by binding of the BCR to an external antigen. Tonic signaling through the BCR provides growth and signals to chronic lymphocytic leukemia (CLL) cells, and plays an important role in the pathogenesis and progression of the disease. Antigen engagement of BCR is followed by intracellular recruitment and activation of BCR-associated kinases including spleen tyrosine kinase (Syk), Bruton's tyrosine kinase (Btk) and phosphatidylinositol 3-kinases (PI3K). Inhibition of signaling pathways downstream of the BCR induces disruption of chemokine-mediated CLL cell migration and cell killing. BCR signal transduction inhibitors represent a promising new strategy for targeted CLL treatment. A number of therapeutic agents have recently been developed with significant activity in CLL. The compounds that are currently investigated in patients with CLL include ibrutinib -inhibitor of Btk, fostamatinib-inhibitor of Syk and idelalisib (GS-1101) -a specific isoform of the PI3K (PI3K) inhibitor. The clinical activity of ibrutinib, GS-1101 and fostamatinib in patients with CLL is associated with marked lymphocytosis due to release of tumor cells from the lymph nodes into the peripheral blood. Further studies are ongoing with single agents and their combinations with other targeted and conventional therapies. This article will review the preclinical rationale of BCR signaling inhibitors in the treatment of CLL, and the clinical evidence supporting the use of these agents in CLL patients.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "15acdfafb8db4713a4ed63acfd61cd30", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[76, 78]], "char_spans": [[440, 461]]}]}], "context_tokens": [["Normal", 0], ["B", 7], ["lymphocytes", 9], ["receive", 21], ["signals", 29], ["from", 37], ["B", 42], ["-", 43], ["cell", 44], ["antigen", 49], ["receptor", 57], ["(", 66], ["BCR", 67], [")", 70], ["that", 72], ["are", 77], ["triggered", 81], ["by", 91], ["binding", 94], ["of", 102], ["the", 105], ["BCR", 109], ["to", 113], ["an", 116], ["external", 119], ["antigen", 128], [".", 135], ["Tonic", 137], ["signaling", 143], ["through", 153], ["the", 161], ["BCR", 165], ["provides", 169], ["growth", 178], ["and", 185], ["signals", 189], ["to", 197], ["chronic", 200], ["lymphocytic", 208], ["leukemia", 220], ["(", 229], ["CLL", 230], [")", 233], ["cells", 235], [",", 240], ["and", 242], ["plays", 246], ["an", 252], ["important", 255], ["role", 265], ["in", 270], ["the", 273], ["pathogenesis", 277], ["and", 290], ["progression", 294], ["of", 306], ["the", 309], ["disease", 313], [".", 320], ["Antigen", 322], ["engagement", 330], ["of", 341], ["BCR", 344], ["is", 348], ["followed", 351], ["by", 360], ["intracellular", 363], ["recruitment", 377], ["and", 389], ["activation", 393], ["of", 404], ["BCR", 407], ["-", 410], ["associated", 411], ["kinases", 422], ["including", 430], ["spleen", 440], ["tyrosine", 447], ["kinase", 456], ["(", 463], ["Syk", 464], [")", 467], [",", 468], ["Bruton", 470], ["'s", 476], ["tyrosine", 479], ["kinase", 488], ["(", 495], ["Btk", 496], [")", 499], ["and", 501], ["phosphatidylinositol", 505], ["3-kinases", 526], ["(", 536], ["PI3", 537], ["K", 540], [")", 541], [".", 542], ["Inhibition", 544], ["of", 555], ["signaling", 558], ["pathways", 568], ["downstream", 577], ["of", 588], ["the", 591], ["BCR", 595], ["induces", 599], ["disruption", 607], ["of", 618], ["chemokine", 621], ["-", 630], ["mediated", 631], ["CLL", 640], ["cell", 644], ["migration", 649], ["and", 659], ["cell", 663], ["killing", 668], [".", 675], ["BCR", 677], ["signal", 681], ["transduction", 688], ["inhibitors", 701], ["represent", 712], ["a", 722], ["promising", 724], ["new", 734], ["strategy", 738], ["for", 747], ["targeted", 751], ["CLL", 760], ["treatment", 764], [".", 773], ["A", 775], ["number", 777], ["of", 784], ["therapeutic", 787], ["agents", 799], ["have", 806], ["recently", 811], ["been", 820], ["developed", 825], ["with", 835], ["significant", 840], ["activity", 852], ["in", 861], ["CLL", 864], [".", 867], ["The", 869], ["compounds", 873], ["that", 883], ["are", 888], ["currently", 892], ["investigated", 902], ["in", 915], ["patients", 918], ["with", 927], ["CLL", 932], ["include", 936], ["ibrutinib", 944], ["-inhibitor", 954], ["of", 965], ["Btk", 968], [",", 971], ["fostamatinib", 973], ["-", 985], ["inhibitor", 986], ["of", 996], ["Syk", 999], ["and", 1003], ["idelalisib", 1007], ["(", 1018], ["GS-1101", 1019], [")", 1026], ["-a", 1028], ["specific", 1031], ["isoform", 1040], ["of", 1048], ["the", 1051], ["PI3", 1055], ["K", 1058], ["(", 1060], ["PI3", 1061], ["K", 1064], [")", 1065], ["inhibitor", 1067], [".", 1076], ["The", 1078], ["clinical", 1082], ["activity", 1091], ["of", 1100], ["ibrutinib", 1103], [",", 1112], ["GS-1101", 1114], ["and", 1122], ["fostamatinib", 1126], ["in", 1139], ["patients", 1142], ["with", 1151], ["CLL", 1156], ["is", 1160], ["associated", 1163], ["with", 1174], ["marked", 1179], ["lymphocytosis", 1186], ["due", 1200], ["to", 1204], ["release", 1207], ["of", 1215], ["tumor", 1218], ["cells", 1224], ["from", 1230], ["the", 1235], ["lymph", 1239], ["nodes", 1245], ["into", 1251], ["the", 1256], ["peripheral", 1260], ["blood", 1271], [".", 1276], ["Further", 1278], ["studies", 1286], ["are", 1294], ["ongoing", 1298], ["with", 1306], ["single", 1311], ["agents", 1318], ["and", 1325], ["their", 1329], ["combinations", 1335], ["with", 1348], ["other", 1353], ["targeted", 1359], ["and", 1368], ["conventional", 1372], ["therapies", 1385], [".", 1394], ["This", 1396], ["article", 1401], ["will", 1409], ["review", 1414], ["the", 1421], ["preclinical", 1425], ["rationale", 1437], ["of", 1447], ["BCR", 1450], ["signaling", 1454], ["inhibitors", 1464], ["in", 1475], ["the", 1478], ["treatment", 1482], ["of", 1492], ["CLL", 1495], [",", 1498], ["and", 1500], ["the", 1504], ["clinical", 1508], ["evidence", 1517], ["supporting", 1526], ["the", 1537], ["use", 1541], ["of", 1545], ["these", 1548], ["agents", 1554], ["in", 1561], ["CLL", 1564], ["patients", 1568], [".", 1576]]}
{"context": "The molecular functions of TMEM132 genes remain poorly understood and under-investigated despite their mutations associated with non-syndromic hearing loss, panic disorder and cancer. Here we show the full domain architecture of human TMEM132 family proteins solved using in-depth sequence and structural analysis. We reveal them to be five previously unappreciated cell adhesion molecules whose domain architecture has an early holozoan origin prior to the emergence of choanoflagellates and metazoa. The extra-cellular portions of TMEM132 proteins contain five conserved domains including three tandem immunoglobulin domains, and a cohesin domain homologue, the first such domain found in animals. These findings strongly predict a cellular adhesion function for TMEM132 family, connecting the extracellular medium with the intracellular actin cytoskeleton. luis.sanchez-pulido@igmm.ed.ac.uk. Supplementary data are available at Bioinformatics online.", "qas": [{"question": "What is the function of the TMEM132 genes?", "answers": ["Cellular adhesion function"], "qid": "966b0a95d1b84227ac890a3daaef2086", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["function", 12], ["of", 21], ["the", 24], ["TMEM132", 28], ["genes", 36], ["?", 41]], "detected_answers": [{"text": "Cellular adhesion function", "token_spans": [[116, 118]], "char_spans": [[734, 759]]}]}], "context_tokens": [["The", 0], ["molecular", 4], ["functions", 14], ["of", 24], ["TMEM132", 27], ["genes", 35], ["remain", 41], ["poorly", 48], ["understood", 55], ["and", 66], ["under", 70], ["-", 75], ["investigated", 76], ["despite", 89], ["their", 97], ["mutations", 103], ["associated", 113], ["with", 124], ["non", 129], ["-", 132], ["syndromic", 133], ["hearing", 143], ["loss", 151], [",", 155], ["panic", 157], ["disorder", 163], ["and", 172], ["cancer", 176], [".", 182], ["Here", 184], ["we", 189], ["show", 192], ["the", 197], ["full", 201], ["domain", 206], ["architecture", 213], ["of", 226], ["human", 229], ["TMEM132", 235], ["family", 243], ["proteins", 250], ["solved", 259], ["using", 266], ["in", 272], ["-", 274], ["depth", 275], ["sequence", 281], ["and", 290], ["structural", 294], ["analysis", 305], [".", 313], ["We", 315], ["reveal", 318], ["them", 325], ["to", 330], ["be", 333], ["five", 336], ["previously", 341], ["unappreciated", 352], ["cell", 366], ["adhesion", 371], ["molecules", 380], ["whose", 390], ["domain", 396], ["architecture", 403], ["has", 416], ["an", 420], ["early", 423], ["holozoan", 429], ["origin", 438], ["prior", 445], ["to", 451], ["the", 454], ["emergence", 458], ["of", 468], ["choanoflagellates", 471], ["and", 489], ["metazoa", 493], [".", 500], ["The", 502], ["extra", 506], ["-", 511], ["cellular", 512], ["portions", 521], ["of", 530], ["TMEM132", 533], ["proteins", 541], ["contain", 550], ["five", 558], ["conserved", 563], ["domains", 573], ["including", 581], ["three", 591], ["tandem", 597], ["immunoglobulin", 604], ["domains", 619], [",", 626], ["and", 628], ["a", 632], ["cohesin", 634], ["domain", 642], ["homologue", 649], [",", 658], ["the", 660], ["first", 664], ["such", 670], ["domain", 675], ["found", 682], ["in", 688], ["animals", 691], [".", 698], ["These", 700], ["findings", 706], ["strongly", 715], ["predict", 724], ["a", 732], ["cellular", 734], ["adhesion", 743], ["function", 752], ["for", 761], ["TMEM132", 765], ["family", 773], [",", 779], ["connecting", 781], ["the", 792], ["extracellular", 796], ["medium", 810], ["with", 817], ["the", 822], ["intracellular", 826], ["actin", 840], ["cytoskeleton", 846], [".", 858], ["luis.sanchez-pulido@igmm.ed.ac.uk", 860], [".", 893], ["Supplementary", 895], ["data", 909], ["are", 914], ["available", 918], ["at", 928], ["Bioinformatics", 931], ["online", 946], [".", 952]]}
{"context": "Iron depletion is common in regular blood donors. The objective of the study was to investigate the frequency and severity of iron depletion in regular blood donors and whether IV iron is more effective than oral to avoid iron depletion and symptoms thereof, especially restless legs syndrome (RLS). One hundred and twenty blood donors with at least five previous whole blood donations were randomized to receive either IV iron sucrose (Venofer(\u00ae), RenaPharma/Vifor, Uppsala, Sweden), 200 mg, or to 20\u00d7100 mg of oral iron sulphate (Duroferon(\u00ae), GlaxoSmithKline, Stockholm, Sweden), after each blood donation during 1 year. Iron status and RLS incidence and severity were investigated. Iron status was generally poor among regular blood donors, especially in women, with a high incidence of iron depletion (>20%) and RLS (18%). The IV iron group increased storage iron to a greater extent than the oral iron group after 12 months (P=0\u00b70043). Female donors were more responsive to IV iron sucrose compared to oral iron sulphate, particularly female donors below 50 years of age. RLS severity scores were significantly lower in the IV iron group. The two treatments were safe. Iron status is poor in regular blood donors, restless legs syndrome is common, and the routine iron supplementation is insufficient. IV iron sucrose substitutes iron loss in blood donors more efficiently compared with oral iron sulphate, especially in women. Iron substitution to blood donors should be individualized and based on P-ferritin monitoring.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "a118373d91094ae6aca3047edf9b0bac", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[171, 171], [179, 179], [122, 122], [267, 267], [248, 248], [195, 195], [132, 132], [254, 254], [257, 257], [0, 0], [230, 230], [39, 39], [167, 167], [99, 99], [221, 221], [22, 22], [73, 73], [151, 151], [200, 200], [274, 274], [31, 31]], "char_spans": [[864, 867], [903, 906], [624, 627], [1398, 1401], [1270, 1273], [983, 986], [686, 689], [1311, 1314], [1336, 1339], [0, 3], [1175, 1178], [222, 225], [835, 838], [517, 520], [1133, 1136], [126, 129], [423, 426], [791, 794], [1013, 1016], [1434, 1437], [180, 183]]}]}], "context_tokens": [["Iron", 0], ["depletion", 5], ["is", 15], ["common", 18], ["in", 25], ["regular", 28], ["blood", 36], ["donors", 42], [".", 48], ["The", 50], ["objective", 54], ["of", 64], ["the", 67], ["study", 71], ["was", 77], ["to", 81], ["investigate", 84], ["the", 96], ["frequency", 100], ["and", 110], ["severity", 114], ["of", 123], ["iron", 126], ["depletion", 131], ["in", 141], ["regular", 144], ["blood", 152], ["donors", 158], ["and", 165], ["whether", 169], ["IV", 177], ["iron", 180], ["is", 185], ["more", 188], ["effective", 193], ["than", 203], ["oral", 208], ["to", 213], ["avoid", 216], ["iron", 222], ["depletion", 227], ["and", 237], ["symptoms", 241], ["thereof", 250], [",", 257], ["especially", 259], ["restless", 270], ["legs", 279], ["syndrome", 284], ["(", 293], ["RLS", 294], [")", 297], [".", 298], ["One", 300], ["hundred", 304], ["and", 312], ["twenty", 316], ["blood", 323], ["donors", 329], ["with", 336], ["at", 341], ["least", 344], ["five", 350], ["previous", 355], ["whole", 364], ["blood", 370], ["donations", 376], ["were", 386], ["randomized", 391], ["to", 402], ["receive", 405], ["either", 413], ["IV", 420], ["iron", 423], ["sucrose", 428], ["(", 436], ["Venofer", 437], ["(", 444], ["\u00ae", 445], [")", 446], [",", 447], ["RenaPharma", 449], ["/", 459], ["Vifor", 460], [",", 465], ["Uppsala", 467], [",", 474], ["Sweden", 476], [")", 482], [",", 483], ["200", 485], ["mg", 489], [",", 491], ["or", 493], ["to", 496], ["20\u00d7100", 499], ["mg", 506], ["of", 509], ["oral", 512], ["iron", 517], ["sulphate", 522], ["(", 531], ["Duroferon", 532], ["(", 541], ["\u00ae", 542], [")", 543], [",", 544], ["GlaxoSmithKline", 546], [",", 561], ["Stockholm", 563], [",", 572], ["Sweden", 574], [")", 580], [",", 581], ["after", 583], ["each", 589], ["blood", 594], ["donation", 600], ["during", 609], ["1", 616], ["year", 618], [".", 622], ["Iron", 624], ["status", 629], ["and", 636], ["RLS", 640], ["incidence", 644], ["and", 654], ["severity", 658], ["were", 667], ["investigated", 672], [".", 684], ["Iron", 686], ["status", 691], ["was", 698], ["generally", 702], ["poor", 712], ["among", 717], ["regular", 723], ["blood", 731], ["donors", 737], [",", 743], ["especially", 745], ["in", 756], ["women", 759], [",", 764], ["with", 766], ["a", 771], ["high", 773], ["incidence", 778], ["of", 788], ["iron", 791], ["depletion", 796], ["(", 806], [">", 807], ["20", 808], ["%", 810], [")", 811], ["and", 813], ["RLS", 817], ["(", 821], ["18", 822], ["%", 824], [")", 825], [".", 826], ["The", 828], ["IV", 832], ["iron", 835], ["group", 840], ["increased", 846], ["storage", 856], ["iron", 864], ["to", 869], ["a", 872], ["greater", 874], ["extent", 882], ["than", 889], ["the", 894], ["oral", 898], ["iron", 903], ["group", 908], ["after", 914], ["12", 920], ["months", 923], ["(", 930], ["P=0\u00b70043", 931], [")", 939], [".", 940], ["Female", 942], ["donors", 949], ["were", 956], ["more", 961], ["responsive", 966], ["to", 977], ["IV", 980], ["iron", 983], ["sucrose", 988], ["compared", 996], ["to", 1005], ["oral", 1008], ["iron", 1013], ["sulphate", 1018], [",", 1026], ["particularly", 1028], ["female", 1041], ["donors", 1048], ["below", 1055], ["50", 1061], ["years", 1064], ["of", 1070], ["age", 1073], [".", 1076], ["RLS", 1078], ["severity", 1082], ["scores", 1091], ["were", 1098], ["significantly", 1103], ["lower", 1117], ["in", 1123], ["the", 1126], ["IV", 1130], ["iron", 1133], ["group", 1138], [".", 1143], ["The", 1145], ["two", 1149], ["treatments", 1153], ["were", 1164], ["safe", 1169], [".", 1173], ["Iron", 1175], ["status", 1180], ["is", 1187], ["poor", 1190], ["in", 1195], ["regular", 1198], ["blood", 1206], ["donors", 1212], [",", 1218], ["restless", 1220], ["legs", 1229], ["syndrome", 1234], ["is", 1243], ["common", 1246], [",", 1252], ["and", 1254], ["the", 1258], ["routine", 1262], ["iron", 1270], ["supplementation", 1275], ["is", 1291], ["insufficient", 1294], [".", 1306], ["IV", 1308], ["iron", 1311], ["sucrose", 1316], ["substitutes", 1324], ["iron", 1336], ["loss", 1341], ["in", 1346], ["blood", 1349], ["donors", 1355], ["more", 1362], ["efficiently", 1367], ["compared", 1379], ["with", 1388], ["oral", 1393], ["iron", 1398], ["sulphate", 1403], [",", 1411], ["especially", 1413], ["in", 1424], ["women", 1427], [".", 1432], ["Iron", 1434], ["substitution", 1439], ["to", 1452], ["blood", 1455], ["donors", 1461], ["should", 1468], ["be", 1475], ["individualized", 1478], ["and", 1493], ["based", 1497], ["on", 1503], ["P", 1506], ["-", 1507], ["ferritin", 1508], ["monitoring", 1517], [".", 1527]]}
{"context": "DUX4, a homeobox-containing gene present in a tandem array, is implicated in facioscapulohumeral muscular dystrophy (FSHD), a dominant autosomal disease. New findings about DUX4 have raised as many fundamental questions about the molecular pathology of this unique disease as they have answered. This review discusses recent studies addressing the question of whether there is extensive FSHD-related transcription dysregulation in adult-derived myoblasts and myotubes, the precursors for muscle repair. Two models for the role of DUX4 in FSHD are presented. One involves transient pathogenic expression of DUX4 in many cells in the muscle lineage before the myoblast stage resulting in a persistent, disease-related transcription profile ('Majority Rules'), which might be enhanced by subsequent oscillatory expression of DUX4. The other model emphasizes the toxic effects of inappropriate expression of DUX4 in only an extremely small percentage of FSHD myoblasts or myotube nuclei ('Minority Rules'). The currently favored Minority Rules model is not supported by recent studies of transcription dysregulation in FSHD myoblasts and myotubes. It also presents other difficulties, for example, explaining the expression of full-length DUX4 transcripts in FSHD fibroblasts. The Majority Rules model is the simpler explanation of findings about FSHD-associated gene expression and the DUX4-encoded homeodomain-type protein.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "6a92b3312fe9468e9d709a8e59c9fadc", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[64, 64], [160, 160], [91, 91], [188, 188], [20, 20], [212, 212], [226, 226]], "char_spans": [[387, 390], [950, 953], [538, 541], [1115, 1118], [117, 120], [1255, 1258], [1343, 1346]]}]}], "context_tokens": [["DUX4", 0], [",", 4], ["a", 6], ["homeobox", 8], ["-", 16], ["containing", 17], ["gene", 28], ["present", 33], ["in", 41], ["a", 44], ["tandem", 46], ["array", 53], [",", 58], ["is", 60], ["implicated", 63], ["in", 74], ["facioscapulohumeral", 77], ["muscular", 97], ["dystrophy", 106], ["(", 116], ["FSHD", 117], [")", 121], [",", 122], ["a", 124], ["dominant", 126], ["autosomal", 135], ["disease", 145], [".", 152], ["New", 154], ["findings", 158], ["about", 167], ["DUX4", 173], ["have", 178], ["raised", 183], ["as", 190], ["many", 193], ["fundamental", 198], ["questions", 210], ["about", 220], ["the", 226], ["molecular", 230], ["pathology", 240], ["of", 250], ["this", 253], ["unique", 258], ["disease", 265], ["as", 273], ["they", 276], ["have", 281], ["answered", 286], [".", 294], ["This", 296], ["review", 301], ["discusses", 308], ["recent", 318], ["studies", 325], ["addressing", 333], ["the", 344], ["question", 348], ["of", 357], ["whether", 360], ["there", 368], ["is", 374], ["extensive", 377], ["FSHD", 387], ["-", 391], ["related", 392], ["transcription", 400], ["dysregulation", 414], ["in", 428], ["adult", 431], ["-", 436], ["derived", 437], ["myoblasts", 445], ["and", 455], ["myotubes", 459], [",", 467], ["the", 469], ["precursors", 473], ["for", 484], ["muscle", 488], ["repair", 495], [".", 501], ["Two", 503], ["models", 507], ["for", 514], ["the", 518], ["role", 522], ["of", 527], ["DUX4", 530], ["in", 535], ["FSHD", 538], ["are", 543], ["presented", 547], [".", 556], ["One", 558], ["involves", 562], ["transient", 571], ["pathogenic", 581], ["expression", 592], ["of", 603], ["DUX4", 606], ["in", 611], ["many", 614], ["cells", 619], ["in", 625], ["the", 628], ["muscle", 632], ["lineage", 639], ["before", 647], ["the", 654], ["myoblast", 658], ["stage", 667], ["resulting", 673], ["in", 683], ["a", 686], ["persistent", 688], [",", 698], ["disease", 700], ["-", 707], ["related", 708], ["transcription", 716], ["profile", 730], ["(", 738], ["'", 739], ["Majority", 740], ["Rules", 749], ["'", 754], [")", 755], [",", 756], ["which", 758], ["might", 764], ["be", 770], ["enhanced", 773], ["by", 782], ["subsequent", 785], ["oscillatory", 796], ["expression", 808], ["of", 819], ["DUX4", 822], [".", 826], ["The", 828], ["other", 832], ["model", 838], ["emphasizes", 844], ["the", 855], ["toxic", 859], ["effects", 865], ["of", 873], ["inappropriate", 876], ["expression", 890], ["of", 901], ["DUX4", 904], ["in", 909], ["only", 912], ["an", 917], ["extremely", 920], ["small", 930], ["percentage", 936], ["of", 947], ["FSHD", 950], ["myoblasts", 955], ["or", 965], ["myotube", 968], ["nuclei", 976], ["(", 983], ["'", 984], ["Minority", 985], ["Rules", 994], ["'", 999], [")", 1000], [".", 1001], ["The", 1003], ["currently", 1007], ["favored", 1017], ["Minority", 1025], ["Rules", 1034], ["model", 1040], ["is", 1046], ["not", 1049], ["supported", 1053], ["by", 1063], ["recent", 1066], ["studies", 1073], ["of", 1081], ["transcription", 1084], ["dysregulation", 1098], ["in", 1112], ["FSHD", 1115], ["myoblasts", 1120], ["and", 1130], ["myotubes", 1134], [".", 1142], ["It", 1144], ["also", 1147], ["presents", 1152], ["other", 1161], ["difficulties", 1167], [",", 1179], ["for", 1181], ["example", 1185], [",", 1192], ["explaining", 1194], ["the", 1205], ["expression", 1209], ["of", 1220], ["full", 1223], ["-", 1227], ["length", 1228], ["DUX4", 1235], ["transcripts", 1240], ["in", 1252], ["FSHD", 1255], ["fibroblasts", 1260], [".", 1271], ["The", 1273], ["Majority", 1277], ["Rules", 1286], ["model", 1292], ["is", 1298], ["the", 1301], ["simpler", 1305], ["explanation", 1313], ["of", 1325], ["findings", 1328], ["about", 1337], ["FSHD", 1343], ["-", 1347], ["associated", 1348], ["gene", 1359], ["expression", 1364], ["and", 1375], ["the", 1379], ["DUX4-encoded", 1383], ["homeodomain", 1396], ["-", 1407], ["type", 1408], ["protein", 1413], [".", 1420]]}
{"context": "Cell-mediated immunity plays a crucial role in the control of many infectious diseases, necessitating the need for adjuvants that can augment cellular immune responses elicited by vaccines. It is well established that protection against one such disease, malaria, requires strong CD8(+) T cell responses targeted against the liver stages of the causative agent, Plasmodium spp. In this report we show that the dendritic cell-specific chemokine, dendritic cell-derived CC chemokine 1 (DC-CK1), which is produced in humans and acts on naive lymphocytes, can enhance Ag-specific CD8(+) T cell responses when coadministered with either irradiated Plasmodium yoelii sporozoites or a recombinant adenovirus expressing the P. yoelii circumsporozoite protein in mice. We further show that these enhanced T cell responses result in increased protection to malaria in immunized mice challenged with live P. yoelii sporozoites, revealing an adjuvant activity for DC-CK1. DC-CK1 appears to act preferentially on naive mouse lymphocytes, and its adjuvant effect requires IL-12, but not IFN-gamma or CD40. Overall, our results show for the first time an in vivo role for DC-CK1 in the establishment of primary T cell responses and indicate the potential of this chemokine as an adjuvant for vaccines against malaria as well as other diseases in which cellular immune responses are important.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "72c14e2563a94713baea221bbf150180", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium spp.", "token_spans": [[61, 62]], "char_spans": [[362, 375]]}]}], "context_tokens": [["Cell", 0], ["-", 4], ["mediated", 5], ["immunity", 14], ["plays", 23], ["a", 29], ["crucial", 31], ["role", 39], ["in", 44], ["the", 47], ["control", 51], ["of", 59], ["many", 62], ["infectious", 67], ["diseases", 78], [",", 86], ["necessitating", 88], ["the", 102], ["need", 106], ["for", 111], ["adjuvants", 115], ["that", 125], ["can", 130], ["augment", 134], ["cellular", 142], ["immune", 151], ["responses", 158], ["elicited", 168], ["by", 177], ["vaccines", 180], [".", 188], ["It", 190], ["is", 193], ["well", 196], ["established", 201], ["that", 213], ["protection", 218], ["against", 229], ["one", 237], ["such", 241], ["disease", 246], [",", 253], ["malaria", 255], [",", 262], ["requires", 264], ["strong", 273], ["CD8(+", 280], [")", 285], ["T", 287], ["cell", 289], ["responses", 294], ["targeted", 304], ["against", 313], ["the", 321], ["liver", 325], ["stages", 331], ["of", 338], ["the", 341], ["causative", 345], ["agent", 355], [",", 360], ["Plasmodium", 362], ["spp", 373], [".", 376], ["In", 378], ["this", 381], ["report", 386], ["we", 393], ["show", 396], ["that", 401], ["the", 406], ["dendritic", 410], ["cell", 420], ["-", 424], ["specific", 425], ["chemokine", 434], [",", 443], ["dendritic", 445], ["cell", 455], ["-", 459], ["derived", 460], ["CC", 468], ["chemokine", 471], ["1", 481], ["(", 483], ["DC", 484], ["-", 486], ["CK1", 487], [")", 490], [",", 491], ["which", 493], ["is", 499], ["produced", 502], ["in", 511], ["humans", 514], ["and", 521], ["acts", 525], ["on", 530], ["naive", 533], ["lymphocytes", 539], [",", 550], ["can", 552], ["enhance", 556], ["Ag", 564], ["-", 566], ["specific", 567], ["CD8(+", 576], [")", 581], ["T", 583], ["cell", 585], ["responses", 590], ["when", 600], ["coadministered", 605], ["with", 620], ["either", 625], ["irradiated", 632], ["Plasmodium", 643], ["yoelii", 654], ["sporozoites", 661], ["or", 673], ["a", 676], ["recombinant", 678], ["adenovirus", 690], ["expressing", 701], ["the", 712], ["P.", 716], ["yoelii", 719], ["circumsporozoite", 726], ["protein", 743], ["in", 751], ["mice", 754], [".", 758], ["We", 760], ["further", 763], ["show", 771], ["that", 776], ["these", 781], ["enhanced", 787], ["T", 796], ["cell", 798], ["responses", 803], ["result", 813], ["in", 820], ["increased", 823], ["protection", 833], ["to", 844], ["malaria", 847], ["in", 855], ["immunized", 858], ["mice", 868], ["challenged", 873], ["with", 884], ["live", 889], ["P.", 894], ["yoelii", 897], ["sporozoites", 904], [",", 915], ["revealing", 917], ["an", 927], ["adjuvant", 930], ["activity", 939], ["for", 948], ["DC", 952], ["-", 954], ["CK1", 955], [".", 958], ["DC", 960], ["-", 962], ["CK1", 963], ["appears", 967], ["to", 975], ["act", 978], ["preferentially", 982], ["on", 997], ["naive", 1000], ["mouse", 1006], ["lymphocytes", 1012], [",", 1023], ["and", 1025], ["its", 1029], ["adjuvant", 1033], ["effect", 1042], ["requires", 1049], ["IL-12", 1058], [",", 1063], ["but", 1065], ["not", 1069], ["IFN", 1073], ["-", 1076], ["gamma", 1077], ["or", 1083], ["CD40", 1086], [".", 1090], ["Overall", 1092], [",", 1099], ["our", 1101], ["results", 1105], ["show", 1113], ["for", 1118], ["the", 1122], ["first", 1126], ["time", 1132], ["an", 1137], ["in", 1140], ["vivo", 1143], ["role", 1148], ["for", 1153], ["DC", 1157], ["-", 1159], ["CK1", 1160], ["in", 1164], ["the", 1167], ["establishment", 1171], ["of", 1185], ["primary", 1188], ["T", 1196], ["cell", 1198], ["responses", 1203], ["and", 1213], ["indicate", 1217], ["the", 1226], ["potential", 1230], ["of", 1240], ["this", 1243], ["chemokine", 1248], ["as", 1258], ["an", 1261], ["adjuvant", 1264], ["for", 1273], ["vaccines", 1277], ["against", 1286], ["malaria", 1294], ["as", 1302], ["well", 1305], ["as", 1310], ["other", 1313], ["diseases", 1319], ["in", 1328], ["which", 1331], ["cellular", 1337], ["immune", 1346], ["responses", 1353], ["are", 1363], ["important", 1367], [".", 1376]]}
{"context": "Prior studies published in the cardiothoracic, orthopedic and gastrointestinal surgery have identified the importance of nasal (methicillin-resistant Staphylococcus aureus) MRSA screening and subsequent decolonization to reduce MRSA surgical site infection (SSI). This is the first study to date correlating nasal MRSA colonization with postoperative spinal MRSA SSI. To assess the significance of nasal MRSA colonization in the setting of MRSA SSI. A retrospective electronic chart review of patients from year 2011 to June 2013 was conducted for patients with both nasal MRSA colonization within 30 days prior to spinal surgery. Patients who tested positive for MRSA were put on contact isolation protocol. None of these patients received topical antibiotics for decolonization of nasal MRSA. A total of 519 patients were identified; 384 negative (74%), 110 MSSA-positive (21.2%), and 25 (4.8%) MRSA-positive. Culture positive surgical site infection (SSI) was identified in 27 (5.2%) cases and was higher in MRSA-positive group than in MRSA-negative and MSSA-positive groups (12% vs. 5.73% vs. 1.82%; p=0.01). The MRSA SSI rate was 0.96% (n=5). MRSA SSI developed in 8% of the MRSA-positive group as compared to only in 0.61% of MRSA-negative group, with a calculated odds ratio of 14.23 (p=0.02). In the presence of SSI, nasal MRSA colonization was associated with MRSA-positive wound culture (66.67 vs. 12.5%; p<0.0001). Preoperative nasal MRSA colonization is associated with postoperative spinal MRSA SSI. Preoperative screening and subsequent decolonization using topical antibiotics may help in decreasing the incidence of MRSA SSI after spine surgery. Nasal MRSA+ patients undergoing spinal surgery should be informed regarding their increased risk of developing surgical site infection.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "f9b282fbb19a4becb10efa8009e39d88", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[53, 53], [309, 309], [268, 268], [263, 263], [125, 125], [68, 68], [188, 188], [316, 316], [62, 62], [48, 48], [240, 240], [24, 24], [91, 91], [157, 157], [106, 106], [182, 182], [291, 291], [220, 220], [228, 228], [284, 284], [210, 210], [31, 31]], "char_spans": [[358, 361], [1632, 1635], [1369, 1372], [1331, 1334], [789, 792], [440, 443], [1039, 1042], [1668, 1672], [404, 407], [314, 317], [1232, 1235], [173, 176], [573, 576], [897, 900], [664, 667], [1011, 1014], [1503, 1506], [1148, 1151], [1180, 1183], [1445, 1448], [1117, 1120], [228, 231]]}]}], "context_tokens": [["Prior", 0], ["studies", 6], ["published", 14], ["in", 24], ["the", 27], ["cardiothoracic", 31], [",", 45], ["orthopedic", 47], ["and", 58], ["gastrointestinal", 62], ["surgery", 79], ["have", 87], ["identified", 92], ["the", 103], ["importance", 107], ["of", 118], ["nasal", 121], ["(", 127], ["methicillin", 128], ["-", 139], ["resistant", 140], ["Staphylococcus", 150], ["aureus", 165], [")", 171], ["MRSA", 173], ["screening", 178], ["and", 188], ["subsequent", 192], ["decolonization", 203], ["to", 218], ["reduce", 221], ["MRSA", 228], ["surgical", 233], ["site", 242], ["infection", 247], ["(", 257], ["SSI", 258], [")", 261], [".", 262], ["This", 264], ["is", 269], ["the", 272], ["first", 276], ["study", 282], ["to", 288], ["date", 291], ["correlating", 296], ["nasal", 308], ["MRSA", 314], ["colonization", 319], ["with", 332], ["postoperative", 337], ["spinal", 351], ["MRSA", 358], ["SSI", 363], [".", 366], ["To", 368], ["assess", 371], ["the", 378], ["significance", 382], ["of", 395], ["nasal", 398], ["MRSA", 404], ["colonization", 409], ["in", 422], ["the", 425], ["setting", 429], ["of", 437], ["MRSA", 440], ["SSI", 445], [".", 448], ["A", 450], ["retrospective", 452], ["electronic", 466], ["chart", 477], ["review", 483], ["of", 490], ["patients", 493], ["from", 502], ["year", 507], ["2011", 512], ["to", 517], ["June", 520], ["2013", 525], ["was", 530], ["conducted", 534], ["for", 544], ["patients", 548], ["with", 557], ["both", 562], ["nasal", 567], ["MRSA", 573], ["colonization", 578], ["within", 591], ["30", 598], ["days", 601], ["prior", 606], ["to", 612], ["spinal", 615], ["surgery", 622], [".", 629], ["Patients", 631], ["who", 640], ["tested", 644], ["positive", 651], ["for", 660], ["MRSA", 664], ["were", 669], ["put", 674], ["on", 678], ["contact", 681], ["isolation", 689], ["protocol", 699], [".", 707], ["None", 709], ["of", 714], ["these", 717], ["patients", 723], ["received", 732], ["topical", 741], ["antibiotics", 749], ["for", 761], ["decolonization", 765], ["of", 780], ["nasal", 783], ["MRSA", 789], [".", 793], ["A", 795], ["total", 797], ["of", 803], ["519", 806], ["patients", 810], ["were", 819], ["identified", 824], [";", 834], ["384", 836], ["negative", 840], ["(", 849], ["74", 850], ["%", 852], [")", 853], [",", 854], ["110", 856], ["MSSA", 860], ["-", 864], ["positive", 865], ["(", 874], ["21.2", 875], ["%", 879], [")", 880], [",", 881], ["and", 883], ["25", 887], ["(", 890], ["4.8", 891], ["%", 894], [")", 895], ["MRSA", 897], ["-", 901], ["positive", 902], [".", 910], ["Culture", 912], ["positive", 920], ["surgical", 929], ["site", 938], ["infection", 943], ["(", 953], ["SSI", 954], [")", 957], ["was", 959], ["identified", 963], ["in", 974], ["27", 977], ["(", 980], ["5.2", 981], ["%", 984], [")", 985], ["cases", 987], ["and", 993], ["was", 997], ["higher", 1001], ["in", 1008], ["MRSA", 1011], ["-", 1015], ["positive", 1016], ["group", 1025], ["than", 1031], ["in", 1036], ["MRSA", 1039], ["-", 1043], ["negative", 1044], ["and", 1053], ["MSSA", 1057], ["-", 1061], ["positive", 1062], ["groups", 1071], ["(", 1078], ["12", 1079], ["%", 1081], ["vs.", 1083], ["5.73", 1087], ["%", 1091], ["vs.", 1093], ["1.82", 1097], ["%", 1101], [";", 1102], ["p=0.01", 1104], [")", 1110], [".", 1111], ["The", 1113], ["MRSA", 1117], ["SSI", 1122], ["rate", 1126], ["was", 1131], ["0.96", 1135], ["%", 1139], ["(", 1141], ["n=5", 1142], [")", 1145], [".", 1146], ["MRSA", 1148], ["SSI", 1153], ["developed", 1157], ["in", 1167], ["8", 1170], ["%", 1171], ["of", 1173], ["the", 1176], ["MRSA", 1180], ["-", 1184], ["positive", 1185], ["group", 1194], ["as", 1200], ["compared", 1203], ["to", 1212], ["only", 1215], ["in", 1220], ["0.61", 1223], ["%", 1227], ["of", 1229], ["MRSA", 1232], ["-", 1236], ["negative", 1237], ["group", 1246], [",", 1251], ["with", 1253], ["a", 1258], ["calculated", 1260], ["odds", 1271], ["ratio", 1276], ["of", 1282], ["14.23", 1285], ["(", 1291], ["p=0.02", 1292], [")", 1298], [".", 1299], ["In", 1301], ["the", 1304], ["presence", 1308], ["of", 1317], ["SSI", 1320], [",", 1323], ["nasal", 1325], ["MRSA", 1331], ["colonization", 1336], ["was", 1349], ["associated", 1353], ["with", 1364], ["MRSA", 1369], ["-", 1373], ["positive", 1374], ["wound", 1383], ["culture", 1389], ["(", 1397], ["66.67", 1398], ["vs.", 1404], ["12.5", 1408], ["%", 1412], [";", 1413], ["p<0.0001", 1415], [")", 1423], [".", 1424], ["Preoperative", 1426], ["nasal", 1439], ["MRSA", 1445], ["colonization", 1450], ["is", 1463], ["associated", 1466], ["with", 1477], ["postoperative", 1482], ["spinal", 1496], ["MRSA", 1503], ["SSI", 1508], [".", 1511], ["Preoperative", 1513], ["screening", 1526], ["and", 1536], ["subsequent", 1540], ["decolonization", 1551], ["using", 1566], ["topical", 1572], ["antibiotics", 1580], ["may", 1592], ["help", 1596], ["in", 1601], ["decreasing", 1604], ["the", 1615], ["incidence", 1619], ["of", 1629], ["MRSA", 1632], ["SSI", 1637], ["after", 1641], ["spine", 1647], ["surgery", 1653], [".", 1660], ["Nasal", 1662], ["MRSA+", 1668], ["patients", 1674], ["undergoing", 1683], ["spinal", 1694], ["surgery", 1701], ["should", 1709], ["be", 1716], ["informed", 1719], ["regarding", 1728], ["their", 1738], ["increased", 1744], ["risk", 1754], ["of", 1759], ["developing", 1762], ["surgical", 1773], ["site", 1782], ["infection", 1787], [".", 1796]]}
{"context": "Parkinson's disease and dementia with Lewy bodies are very frequent neurological disorders of the elderly. Mutations in the alpha-synuclein (alphaSYN) gene cause Parkinson's disease, often associated with dementia. Neuropathologically these diseases are characterized by the presence of Lewy bodies and Lewy neurites, intraneuronal inclusions mostly composed of alphaSYN protein fibrils. Moreover, alphaSYN is phosphorylated at S129 (phospho-serine-129 [PSer129]) in neuropathological lesions. Using our (Thy1)-[A30P]alphaSYN transgenic mouse model that develops age-dependent impairment in fear conditioning behavior, we investigated PSer129 immunostaining in the brain. We found distinct staining patterns using new, sensitive monoclonal antibodies. Somal and nuclear PSer129 immunoreactivity increased with age in hippocampal and cortical areas as well as the lateral/basolateral amygdalar nuclei and was present also in young, pre-symptomatic mice, but not wild-type controls. The tendency of PSer129 immunostaining to accumulate in the nucleus was confirmed in cell culture. (Thy1)-[A30P]alphaSYN transgenic mice further developed age-dependent, specific neuritic/terminal alphaSYN pathology in the medial parts of the central amygdalar nucleus and one of its projection areas, the lateral hypothalamus. Interestingly, this type of PSer129 neuropathology was thioflavine S negative, unlike the Lewy-like neuropathology present in the brain stem of (Thy1)-[A30P]alphaSYN mice. Thus, alphaSYN becomes phosphorylated in distinct parts of the brain in this alpha-synucleinopathy mouse model, showing age-dependent increases of nuclear PSer129 in cortical brain areas and the formation of neuritic/terminal PSer129 neuropathology with variable amyloid quality within the fear conditioning circuitry and the brain stem.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "3005311091144dfdb1464aeae598c703", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[20, 22]], "char_spans": [[124, 138]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["and", 20], ["dementia", 24], ["with", 33], ["Lewy", 38], ["bodies", 43], ["are", 50], ["very", 54], ["frequent", 59], ["neurological", 68], ["disorders", 81], ["of", 91], ["the", 94], ["elderly", 98], [".", 105], ["Mutations", 107], ["in", 117], ["the", 120], ["alpha", 124], ["-", 129], ["synuclein", 130], ["(", 140], ["alphaSYN", 141], [")", 149], ["gene", 151], ["cause", 156], ["Parkinson", 162], ["'s", 171], ["disease", 174], [",", 181], ["often", 183], ["associated", 189], ["with", 200], ["dementia", 205], [".", 213], ["Neuropathologically", 215], ["these", 235], ["diseases", 241], ["are", 250], ["characterized", 254], ["by", 268], ["the", 271], ["presence", 275], ["of", 284], ["Lewy", 287], ["bodies", 292], ["and", 299], ["Lewy", 303], ["neurites", 308], [",", 316], ["intraneuronal", 318], ["inclusions", 332], ["mostly", 343], ["composed", 350], ["of", 359], ["alphaSYN", 362], ["protein", 371], ["fibrils", 379], [".", 386], ["Moreover", 388], [",", 396], ["alphaSYN", 398], ["is", 407], ["phosphorylated", 410], ["at", 425], ["S129", 428], ["(", 433], ["phospho", 434], ["-", 441], ["serine-129", 442], ["[", 453], ["PSer129", 454], ["]", 461], [")", 462], ["in", 464], ["neuropathological", 467], ["lesions", 485], [".", 492], ["Using", 494], ["our", 500], ["(", 504], ["Thy1)-[A30P]alphaSYN", 505], ["transgenic", 526], ["mouse", 537], ["model", 543], ["that", 549], ["develops", 554], ["age", 563], ["-", 566], ["dependent", 567], ["impairment", 577], ["in", 588], ["fear", 591], ["conditioning", 596], ["behavior", 609], [",", 617], ["we", 619], ["investigated", 622], ["PSer129", 635], ["immunostaining", 643], ["in", 658], ["the", 661], ["brain", 665], [".", 670], ["We", 672], ["found", 675], ["distinct", 681], ["staining", 690], ["patterns", 699], ["using", 708], ["new", 714], [",", 717], ["sensitive", 719], ["monoclonal", 729], ["antibodies", 740], [".", 750], ["Somal", 752], ["and", 758], ["nuclear", 762], ["PSer129", 770], ["immunoreactivity", 778], ["increased", 795], ["with", 805], ["age", 810], ["in", 814], ["hippocampal", 817], ["and", 829], ["cortical", 833], ["areas", 842], ["as", 848], ["well", 851], ["as", 856], ["the", 859], ["lateral", 863], ["/", 870], ["basolateral", 871], ["amygdalar", 883], ["nuclei", 893], ["and", 900], ["was", 904], ["present", 908], ["also", 916], ["in", 921], ["young", 924], [",", 929], ["pre", 931], ["-", 934], ["symptomatic", 935], ["mice", 947], [",", 951], ["but", 953], ["not", 957], ["wild", 961], ["-", 965], ["type", 966], ["controls", 971], [".", 979], ["The", 981], ["tendency", 985], ["of", 994], ["PSer129", 997], ["immunostaining", 1005], ["to", 1020], ["accumulate", 1023], ["in", 1034], ["the", 1037], ["nucleus", 1041], ["was", 1049], ["confirmed", 1053], ["in", 1063], ["cell", 1066], ["culture", 1071], [".", 1078], ["(", 1080], ["Thy1)-[A30P]alphaSYN", 1081], ["transgenic", 1102], ["mice", 1113], ["further", 1118], ["developed", 1126], ["age", 1136], ["-", 1139], ["dependent", 1140], [",", 1149], ["specific", 1151], ["neuritic", 1160], ["/", 1168], ["terminal", 1169], ["alphaSYN", 1178], ["pathology", 1187], ["in", 1197], ["the", 1200], ["medial", 1204], ["parts", 1211], ["of", 1217], ["the", 1220], ["central", 1224], ["amygdalar", 1232], ["nucleus", 1242], ["and", 1250], ["one", 1254], ["of", 1258], ["its", 1261], ["projection", 1265], ["areas", 1276], [",", 1281], ["the", 1283], ["lateral", 1287], ["hypothalamus", 1295], [".", 1307], ["Interestingly", 1309], [",", 1322], ["this", 1324], ["type", 1329], ["of", 1334], ["PSer129", 1337], ["neuropathology", 1345], ["was", 1360], ["thioflavine", 1364], ["S", 1376], ["negative", 1378], [",", 1386], ["unlike", 1388], ["the", 1395], ["Lewy", 1399], ["-", 1403], ["like", 1404], ["neuropathology", 1409], ["present", 1424], ["in", 1432], ["the", 1435], ["brain", 1439], ["stem", 1445], ["of", 1450], ["(", 1453], ["Thy1)-[A30P]alphaSYN", 1454], ["mice", 1475], [".", 1479], ["Thus", 1481], [",", 1485], ["alphaSYN", 1487], ["becomes", 1496], ["phosphorylated", 1504], ["in", 1519], ["distinct", 1522], ["parts", 1531], ["of", 1537], ["the", 1540], ["brain", 1544], ["in", 1550], ["this", 1553], ["alpha", 1558], ["-", 1563], ["synucleinopathy", 1564], ["mouse", 1580], ["model", 1586], [",", 1591], ["showing", 1593], ["age", 1601], ["-", 1604], ["dependent", 1605], ["increases", 1615], ["of", 1625], ["nuclear", 1628], ["PSer129", 1636], ["in", 1644], ["cortical", 1647], ["brain", 1656], ["areas", 1662], ["and", 1668], ["the", 1672], ["formation", 1676], ["of", 1686], ["neuritic", 1689], ["/", 1697], ["terminal", 1698], ["PSer129", 1707], ["neuropathology", 1715], ["with", 1730], ["variable", 1735], ["amyloid", 1744], ["quality", 1752], ["within", 1760], ["the", 1767], ["fear", 1771], ["conditioning", 1776], ["circuitry", 1789], ["and", 1799], ["the", 1803], ["brain", 1807], ["stem", 1813], [".", 1817]]}
{"context": "Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to compare the levodopa pharmacokinetic profile throughout a day driven by the COMT inhibition either following repeated doses of opicapone or concomitant administration with entacapone. A randomized, double-blind, gender-balanced, parallel-group study was performed in 4 groups of 20 healthy subjects each. Four subjects in each group received placebo during the entire study. Sixteen subjects in one group received placebo once daily for 11 days and on day 12, 200 mg entacapone concomitantly with each levodopa/carbidopa dose (three times separated by a 5-h interval). Sixteen subjects in each of the remaining three groups received respectively 25, 50, and 75 mg opicapone once daily for 11 days and on day 12, placebo concomitantly with each levodopa/carbidopa dose. Levodopa minimum plasma concentration (Cmin) for each levodopa/carbidopa dose and for the mean of all levodopa/carbidopa doses increased substantially with all active treatments (entacapone and opicapone) when compared to the control group (placebo), with values ranging from 1.7-fold (200 mg entacapone) to 3.3-fold (75 mg opicapone). No statistical difference was found for levodopa peak of systemic exposure (as assessed by maximum observed plasma concentration (Cmax)) between all active treatments and placebo. A significant increase in the levodopa extent of systemic exposure (as assessed by concentration-time curve (AUC)) occurred with all opicapone treatments in relation to placebo. No statistical difference was found for levodopa AUC when entacapone was compared to placebo. When compared to entacapone, both 50 and 75 mg opicapone presented a significant increase for the levodopa AUC. All active treatments significantly inhibited both peak (as assessed by Emax) and extent (as assessed by effect-time curve (AUEC)) of the COMT activity in relation to placebo. When compared to entacapone, all opicapone treatments significantly decreased the extent (AUEC) of the COMT activity due to a long-lasting and sustained effect. The tolerability profile was favorable for all active treatments. Opicapone, a novel third generation COMT inhibitor, when compared to entacapone, provides a superior response upon the bioavailability of levodopa associated to more pronounced, long-lasting, and sustained COMT inhibition. The tolerability profile was favorable. On the basis of the results presented in this study and along with the earlier pharmacology studies, it is anticipated that opicapone adjunct therapy at the dosages of 25 and 50 mg will provide an enhancement in levodopa availability that will translate into clinical benefit for Parkinson's disease patients.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "0e5ff4402f1e44c1a1d80868713f9b9f", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[6, 10]], "char_spans": [[38, 65]]}]}], "context_tokens": [["Opicapone", 0], ["is", 10], ["a", 13], ["novel", 15], ["third", 21], ["generation", 27], ["catechol", 38], ["-", 46], ["O", 47], ["-", 48], ["methyltransferase", 49], ["(", 67], ["COMT", 68], [")", 72], ["inhibitor", 74], [".", 83], ["The", 85], ["purpose", 89], ["of", 97], ["this", 100], ["study", 105], ["was", 111], ["to", 115], ["compare", 118], ["the", 126], ["levodopa", 130], ["pharmacokinetic", 139], ["profile", 155], ["throughout", 163], ["a", 174], ["day", 176], ["driven", 180], ["by", 187], ["the", 190], ["COMT", 194], ["inhibition", 199], ["either", 210], ["following", 217], ["repeated", 227], ["doses", 236], ["of", 242], ["opicapone", 245], ["or", 255], ["concomitant", 258], ["administration", 270], ["with", 285], ["entacapone", 290], [".", 300], ["A", 302], ["randomized", 304], [",", 314], ["double", 316], ["-", 322], ["blind", 323], [",", 328], ["gender", 330], ["-", 336], ["balanced", 337], [",", 345], ["parallel", 347], ["-", 355], ["group", 356], ["study", 362], ["was", 368], ["performed", 372], ["in", 382], ["4", 385], ["groups", 387], ["of", 394], ["20", 397], ["healthy", 400], ["subjects", 408], ["each", 417], [".", 421], ["Four", 423], ["subjects", 428], ["in", 437], ["each", 440], ["group", 445], ["received", 451], ["placebo", 460], ["during", 468], ["the", 475], ["entire", 479], ["study", 486], [".", 491], ["Sixteen", 493], ["subjects", 501], ["in", 510], ["one", 513], ["group", 517], ["received", 523], ["placebo", 532], ["once", 540], ["daily", 545], ["for", 551], ["11", 555], ["days", 558], ["and", 563], ["on", 567], ["day", 570], ["12", 574], [",", 576], ["200", 578], ["mg", 582], ["entacapone", 585], ["concomitantly", 596], ["with", 610], ["each", 615], ["levodopa", 620], ["/", 628], ["carbidopa", 629], ["dose", 639], ["(", 644], ["three", 645], ["times", 651], ["separated", 657], ["by", 667], ["a", 670], ["5-h", 672], ["interval", 676], [")", 684], [".", 685], ["Sixteen", 687], ["subjects", 695], ["in", 704], ["each", 707], ["of", 712], ["the", 715], ["remaining", 719], ["three", 729], ["groups", 735], ["received", 742], ["respectively", 751], ["25", 764], [",", 766], ["50", 768], [",", 770], ["and", 772], ["75", 776], ["mg", 779], ["opicapone", 782], ["once", 792], ["daily", 797], ["for", 803], ["11", 807], ["days", 810], ["and", 815], ["on", 819], ["day", 822], ["12", 826], [",", 828], ["placebo", 830], ["concomitantly", 838], ["with", 852], ["each", 857], ["levodopa", 862], ["/", 870], ["carbidopa", 871], ["dose", 881], [".", 885], ["Levodopa", 887], ["minimum", 896], ["plasma", 904], ["concentration", 911], ["(", 925], ["Cmin", 926], [")", 930], ["for", 932], ["each", 936], ["levodopa", 941], ["/", 949], ["carbidopa", 950], ["dose", 960], ["and", 965], ["for", 969], ["the", 973], ["mean", 977], ["of", 982], ["all", 985], ["levodopa", 989], ["/", 997], ["carbidopa", 998], ["doses", 1008], ["increased", 1014], ["substantially", 1024], ["with", 1038], ["all", 1043], ["active", 1047], ["treatments", 1054], ["(", 1065], ["entacapone", 1066], ["and", 1077], ["opicapone", 1081], [")", 1090], ["when", 1092], ["compared", 1097], ["to", 1106], ["the", 1109], ["control", 1113], ["group", 1121], ["(", 1127], ["placebo", 1128], [")", 1135], [",", 1136], ["with", 1138], ["values", 1143], ["ranging", 1150], ["from", 1158], ["1.7-fold", 1163], ["(", 1172], ["200", 1173], ["mg", 1177], ["entacapone", 1180], [")", 1190], ["to", 1192], ["3.3-fold", 1195], ["(", 1204], ["75", 1205], ["mg", 1208], ["opicapone", 1211], [")", 1220], [".", 1221], ["No", 1223], ["statistical", 1226], ["difference", 1238], ["was", 1249], ["found", 1253], ["for", 1259], ["levodopa", 1263], ["peak", 1272], ["of", 1277], ["systemic", 1280], ["exposure", 1289], ["(", 1298], ["as", 1299], ["assessed", 1302], ["by", 1311], ["maximum", 1314], ["observed", 1322], ["plasma", 1331], ["concentration", 1338], ["(", 1352], ["Cmax", 1353], [")", 1357], [")", 1358], ["between", 1360], ["all", 1368], ["active", 1372], ["treatments", 1379], ["and", 1390], ["placebo", 1394], [".", 1401], ["A", 1403], ["significant", 1405], ["increase", 1417], ["in", 1426], ["the", 1429], ["levodopa", 1433], ["extent", 1442], ["of", 1449], ["systemic", 1452], ["exposure", 1461], ["(", 1470], ["as", 1471], ["assessed", 1474], ["by", 1483], ["concentration", 1486], ["-", 1499], ["time", 1500], ["curve", 1505], ["(", 1511], ["AUC", 1512], [")", 1515], [")", 1516], ["occurred", 1518], ["with", 1527], ["all", 1532], ["opicapone", 1536], ["treatments", 1546], ["in", 1557], ["relation", 1560], ["to", 1569], ["placebo", 1572], [".", 1579], ["No", 1581], ["statistical", 1584], ["difference", 1596], ["was", 1607], ["found", 1611], ["for", 1617], ["levodopa", 1621], ["AUC", 1630], ["when", 1634], ["entacapone", 1639], ["was", 1650], ["compared", 1654], ["to", 1663], ["placebo", 1666], [".", 1673], ["When", 1675], ["compared", 1680], ["to", 1689], ["entacapone", 1692], [",", 1702], ["both", 1704], ["50", 1709], ["and", 1712], ["75", 1716], ["mg", 1719], ["opicapone", 1722], ["presented", 1732], ["a", 1742], ["significant", 1744], ["increase", 1756], ["for", 1765], ["the", 1769], ["levodopa", 1773], ["AUC", 1782], [".", 1785], ["All", 1787], ["active", 1791], ["treatments", 1798], ["significantly", 1809], ["inhibited", 1823], ["both", 1833], ["peak", 1838], ["(", 1843], ["as", 1844], ["assessed", 1847], ["by", 1856], ["Emax", 1859], [")", 1863], ["and", 1865], ["extent", 1869], ["(", 1876], ["as", 1877], ["assessed", 1880], ["by", 1889], ["effect", 1892], ["-", 1898], ["time", 1899], ["curve", 1904], ["(", 1910], ["AUEC", 1911], [")", 1915], [")", 1916], ["of", 1918], ["the", 1921], ["COMT", 1925], ["activity", 1930], ["in", 1939], ["relation", 1942], ["to", 1951], ["placebo", 1954], [".", 1961], ["When", 1963], ["compared", 1968], ["to", 1977], ["entacapone", 1980], [",", 1990], ["all", 1992], ["opicapone", 1996], ["treatments", 2006], ["significantly", 2017], ["decreased", 2031], ["the", 2041], ["extent", 2045], ["(", 2052], ["AUEC", 2053], [")", 2057], ["of", 2059], ["the", 2062], ["COMT", 2066], ["activity", 2071], ["due", 2080], ["to", 2084], ["a", 2087], ["long", 2089], ["-", 2093], ["lasting", 2094], ["and", 2102], ["sustained", 2106], ["effect", 2116], [".", 2122], ["The", 2124], ["tolerability", 2128], ["profile", 2141], ["was", 2149], ["favorable", 2153], ["for", 2163], ["all", 2167], ["active", 2171], ["treatments", 2178], [".", 2188], ["Opicapone", 2190], [",", 2199], ["a", 2201], ["novel", 2203], ["third", 2209], ["generation", 2215], ["COMT", 2226], ["inhibitor", 2231], [",", 2240], ["when", 2242], ["compared", 2247], ["to", 2256], ["entacapone", 2259], [",", 2269], ["provides", 2271], ["a", 2280], ["superior", 2282], ["response", 2291], ["upon", 2300], ["the", 2305], ["bioavailability", 2309], ["of", 2325], ["levodopa", 2328], ["associated", 2337], ["to", 2348], ["more", 2351], ["pronounced", 2356], [",", 2366], ["long", 2368], ["-", 2372], ["lasting", 2373], [",", 2380], ["and", 2382], ["sustained", 2386], ["COMT", 2396], ["inhibition", 2401], [".", 2411], ["The", 2413], ["tolerability", 2417], ["profile", 2430], ["was", 2438], ["favorable", 2442], [".", 2451], ["On", 2453], ["the", 2456], ["basis", 2460], ["of", 2466], ["the", 2469], ["results", 2473], ["presented", 2481], ["in", 2491], ["this", 2494], ["study", 2499], ["and", 2505], ["along", 2509], ["with", 2515], ["the", 2520], ["earlier", 2524], ["pharmacology", 2532], ["studies", 2545], [",", 2552], ["it", 2554], ["is", 2557], ["anticipated", 2560], ["that", 2572], ["opicapone", 2577], ["adjunct", 2587], ["therapy", 2595], ["at", 2603], ["the", 2606], ["dosages", 2610], ["of", 2618], ["25", 2621], ["and", 2624], ["50", 2628], ["mg", 2631], ["will", 2634], ["provide", 2639], ["an", 2647], ["enhancement", 2650], ["in", 2662], ["levodopa", 2665], ["availability", 2674], ["that", 2687], ["will", 2692], ["translate", 2697], ["into", 2707], ["clinical", 2712], ["benefit", 2721], ["for", 2729], ["Parkinson", 2733], ["'s", 2742], ["disease", 2745], ["patients", 2753], [".", 2761]]}
{"context": "Sotos syndrome is an overgrowth syndrome with characteristic facial gestalt and mental retardation of variable severity. Haploinsufficiency of the NSD1 gene has been implicated as the major cause of Sotos syndrome, with a predominance of microdeletions reported in Japanese patients. This study was conducted to investigate into the spectrum of NSD1 gene mutations in southern Chinese patients with Sotos syndrome. Thirty-six Chinese patients with Sotos syndrome and two patients with Weaver syndrome were subject to molecular testing. NSD1 gene mutations were detected in 26 (72%) Sotos patients. Microdeletion was found in only 3 patients, while the other 23 had point mutations (6 frameshift, 8 nonsense, 2 spice site, and 7 missense). Of these, 19 mutations were never reported. NSD1 gene mutations were not found in the two patients with Weaver syndrome. Most cases of Sotos syndrome are caused by NSD1 gene defects, but the spectrum of mutations is different from that of Japanese patients. Genotype-phenotype correlation showed that patients with microdeletions might be more prone to congenital heart disease but less likely to have somatic overgrowth. The two patients with Weaver syndrome were not found to have NSD1 gene mutations, but the number was too small for any conclusion to be drawn.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "2cf9e36ee549421b84170a93d439b69d", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[160, 161], [138, 139], [20, 21], [84, 85], [53, 54], [213, 214]], "char_spans": [[903, 911], [783, 791], [147, 155], [536, 544], [345, 353], [1222, 1230]]}]}], "context_tokens": [["Sotos", 0], ["syndrome", 6], ["is", 15], ["an", 18], ["overgrowth", 21], ["syndrome", 32], ["with", 41], ["characteristic", 46], ["facial", 61], ["gestalt", 68], ["and", 76], ["mental", 80], ["retardation", 87], ["of", 99], ["variable", 102], ["severity", 111], [".", 119], ["Haploinsufficiency", 121], ["of", 140], ["the", 143], ["NSD1", 147], ["gene", 152], ["has", 157], ["been", 161], ["implicated", 166], ["as", 177], ["the", 180], ["major", 184], ["cause", 190], ["of", 196], ["Sotos", 199], ["syndrome", 205], [",", 213], ["with", 215], ["a", 220], ["predominance", 222], ["of", 235], ["microdeletions", 238], ["reported", 253], ["in", 262], ["Japanese", 265], ["patients", 274], [".", 282], ["This", 284], ["study", 289], ["was", 295], ["conducted", 299], ["to", 309], ["investigate", 312], ["into", 324], ["the", 329], ["spectrum", 333], ["of", 342], ["NSD1", 345], ["gene", 350], ["mutations", 355], ["in", 365], ["southern", 368], ["Chinese", 377], ["patients", 385], ["with", 394], ["Sotos", 399], ["syndrome", 405], [".", 413], ["Thirty", 415], ["-", 421], ["six", 422], ["Chinese", 426], ["patients", 434], ["with", 443], ["Sotos", 448], ["syndrome", 454], ["and", 463], ["two", 467], ["patients", 471], ["with", 480], ["Weaver", 485], ["syndrome", 492], ["were", 501], ["subject", 506], ["to", 514], ["molecular", 517], ["testing", 527], [".", 534], ["NSD1", 536], ["gene", 541], ["mutations", 546], ["were", 556], ["detected", 561], ["in", 570], ["26", 573], ["(", 576], ["72", 577], ["%", 579], [")", 580], ["Sotos", 582], ["patients", 588], [".", 596], ["Microdeletion", 598], ["was", 612], ["found", 616], ["in", 622], ["only", 625], ["3", 630], ["patients", 632], [",", 640], ["while", 642], ["the", 648], ["other", 652], ["23", 658], ["had", 661], ["point", 665], ["mutations", 671], ["(", 681], ["6", 682], ["frameshift", 684], [",", 694], ["8", 696], ["nonsense", 698], [",", 706], ["2", 708], ["spice", 710], ["site", 716], [",", 720], ["and", 722], ["7", 726], ["missense", 728], [")", 736], [".", 737], ["Of", 739], ["these", 742], [",", 747], ["19", 749], ["mutations", 752], ["were", 762], ["never", 767], ["reported", 773], [".", 781], ["NSD1", 783], ["gene", 788], ["mutations", 793], ["were", 803], ["not", 808], ["found", 812], ["in", 818], ["the", 821], ["two", 825], ["patients", 829], ["with", 838], ["Weaver", 843], ["syndrome", 850], [".", 858], ["Most", 860], ["cases", 865], ["of", 871], ["Sotos", 874], ["syndrome", 880], ["are", 889], ["caused", 893], ["by", 900], ["NSD1", 903], ["gene", 908], ["defects", 913], [",", 920], ["but", 922], ["the", 926], ["spectrum", 930], ["of", 939], ["mutations", 942], ["is", 952], ["different", 955], ["from", 965], ["that", 970], ["of", 975], ["Japanese", 978], ["patients", 987], [".", 995], ["Genotype", 997], ["-", 1005], ["phenotype", 1006], ["correlation", 1016], ["showed", 1028], ["that", 1035], ["patients", 1040], ["with", 1049], ["microdeletions", 1054], ["might", 1069], ["be", 1075], ["more", 1078], ["prone", 1083], ["to", 1089], ["congenital", 1092], ["heart", 1103], ["disease", 1109], ["but", 1117], ["less", 1121], ["likely", 1126], ["to", 1133], ["have", 1136], ["somatic", 1141], ["overgrowth", 1149], [".", 1159], ["The", 1161], ["two", 1165], ["patients", 1169], ["with", 1178], ["Weaver", 1183], ["syndrome", 1190], ["were", 1199], ["not", 1204], ["found", 1208], ["to", 1214], ["have", 1217], ["NSD1", 1222], ["gene", 1227], ["mutations", 1232], [",", 1241], ["but", 1243], ["the", 1247], ["number", 1251], ["was", 1258], ["too", 1262], ["small", 1266], ["for", 1272], ["any", 1276], ["conclusion", 1280], ["to", 1291], ["be", 1294], ["drawn", 1297], [".", 1302]]}
{"context": "Cis-regulatory modules are non-protein-coding regions of DNA essential for the control of gene expression. One class of regulatory modules is embryonic enhancers, which drive gene expression during development as a result of transcription factor protein binding at the enhancer sequences. Recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers. These analyses are illuminating the way that developmental biologists think about enhancers by revealing their molecular mechanism of function.", "qas": [{"question": "Are human enhancers or promoters evolving faster?", "answers": ["enhancers"], "qid": "c5f738e45b874642afbdf22cb1b0c970", "question_tokens": [["Are", 0], ["human", 4], ["enhancers", 10], ["or", 20], ["promoters", 23], ["evolving", 33], ["faster", 42], ["?", 48]], "detected_answers": [{"text": "enhancers", "token_spans": [[28, 28], [76, 76], [63, 63]], "char_spans": [[152, 160], [485, 493], [392, 400]]}]}], "context_tokens": [["Cis", 0], ["-", 3], ["regulatory", 4], ["modules", 15], ["are", 23], ["non", 27], ["-", 30], ["protein", 31], ["-", 38], ["coding", 39], ["regions", 46], ["of", 54], ["DNA", 57], ["essential", 61], ["for", 71], ["the", 75], ["control", 79], ["of", 87], ["gene", 90], ["expression", 95], [".", 105], ["One", 107], ["class", 111], ["of", 117], ["regulatory", 120], ["modules", 131], ["is", 139], ["embryonic", 142], ["enhancers", 152], [",", 161], ["which", 163], ["drive", 169], ["gene", 175], ["expression", 180], ["during", 191], ["development", 198], ["as", 210], ["a", 213], ["result", 215], ["of", 222], ["transcription", 225], ["factor", 239], ["protein", 246], ["binding", 254], ["at", 262], ["the", 265], ["enhancer", 269], ["sequences", 278], [".", 287], ["Recent", 289], ["comparative", 296], ["studies", 308], ["have", 316], ["begun", 321], ["to", 327], ["investigate", 330], ["the", 342], ["evolution", 346], ["of", 356], ["the", 359], ["sequence", 363], ["architecture", 372], ["within", 385], ["enhancers", 392], [".", 401], ["These", 403], ["analyses", 409], ["are", 418], ["illuminating", 422], ["the", 435], ["way", 439], ["that", 443], ["developmental", 448], ["biologists", 462], ["think", 473], ["about", 479], ["enhancers", 485], ["by", 495], ["revealing", 498], ["their", 508], ["molecular", 514], ["mechanism", 524], ["of", 534], ["function", 537], [".", 545]]}
{"context": "The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Data were obtained from the Psocare Registry on those patients (n\u00a0=\u00a04946) with age >\u00a018\u00a0years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Latent tuberculosis infection was diagnosed in 8\u00b73% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4\u00b73% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralen-ultraviolet A (P\u00a0<\u00a00\u00b705). Independent factors associated with LTBI were male sex [odds ratio (OR) 1\u00b730, 95% confidence interval (CI) 1\u00b704-1\u00b762; P\u00a0=\u00a00\u00b702], age over 55\u00a0years (OR 2\u00b793, 95% CI 2\u00b718-3\u00b793; P\u00a0<\u00a00\u00b7001) and being entered into a conventional treatment (OR 3\u00b783, 95% CI 3\u00b710-4\u00b774; P\u00a0<\u00a00\u00b7001). Positive history of tuberculosis was seen in 1% of patients (n\u00a0=\u00a049). The nationwide prevalence of LTBI in Italian patients with psoriasis candidate to systemic treatment is high, and screening is recommended prior to biological treatment.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "4edb95a363144efdb21977cc7f1912a8", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[104, 104], [5, 5], [101, 101], [250, 250]], "char_spans": [[615, 626], [36, 47], [594, 605], [1229, 1240]]}]}], "context_tokens": [["The", 0], ["nationwide", 4], ["prevalence", 15], ["of", 26], ["latent", 29], ["tuberculosis", 36], ["infection", 49], ["(", 59], ["LTBI", 60], [")", 64], ["in", 66], ["Italian", 69], ["patients", 77], ["with", 86], ["psoriasis", 91], ["has", 101], ["never", 105], ["been", 111], ["investigated", 116], [".", 128], ["To", 130], ["estimate", 133], ["the", 142], ["nationwide", 146], ["prevalence", 157], ["of", 168], ["LTBI", 171], ["in", 176], ["Italian", 179], ["patients", 187], ["with", 196], ["psoriasis", 201], ["who", 211], ["are", 215], ["candidates", 219], ["for", 230], ["systemic", 234], ["treatment", 243], [".", 252], ["Data", 254], ["were", 259], ["obtained", 264], ["from", 273], ["the", 278], ["Psocare", 282], ["Registry", 290], ["on", 299], ["those", 302], ["patients", 308], ["(", 317], ["n", 318], ["=", 320], ["4946", 322], [")", 326], ["with", 328], ["age", 333], [">", 337], ["18", 339], ["years", 342], [",", 347], ["systemic", 349], ["treatment", 358], ["at", 368], ["entry", 371], ["specified", 377], ["and", 387], ["tuberculin", 391], ["skin", 402], ["test", 407], ["(", 412], ["TST", 413], [")", 416], ["performed", 418], ["according", 428], ["to", 438], ["the", 441], ["Mantoux", 445], ["method", 453], [".", 459], ["LTBI", 461], ["diagnosis", 466], ["was", 476], ["based", 480], ["on", 486], ["a", 489], ["positive", 491], ["TST", 500], ["result", 504], ["in", 511], ["the", 514], ["absence", 518], ["of", 526], ["any", 529], ["clinical", 533], [",", 541], ["radiological", 543], ["or", 556], ["microbiological", 559], ["evidence", 575], ["of", 584], ["active", 587], ["tuberculosis", 594], [".", 606], ["Latent", 608], ["tuberculosis", 615], ["infection", 628], ["was", 638], ["diagnosed", 642], ["in", 652], ["8\u00b73", 655], ["%", 658], ["of", 660], ["patients", 663], ["with", 672], ["psoriasis", 677], ["(", 687], ["409", 688], ["of", 692], ["4946", 695], [")", 699], [".", 700], ["The", 702], ["prevalence", 706], ["of", 717], ["LTBI", 720], ["was", 725], ["lower", 729], ["in", 735], ["patients", 738], ["on", 747], ["biologics", 750], ["than", 760], ["in", 765], ["those", 768], ["on", 774], ["conventional", 777], ["systemic", 790], ["treatments", 799], [",", 809], ["ranging", 811], ["from", 819], ["4\u00b73", 824], ["%", 827], ["(", 829], ["19", 830], ["of", 833], ["444", 836], [")", 839], ["of", 841], ["patients", 844], ["on", 853], ["adalimumab", 856], ["to", 867], ["31", 870], ["%", 872], ["(", 874], ["eight", 875], ["of", 881], ["26", 884], [")", 886], ["of", 888], ["those", 891], ["on", 897], ["psoralen", 900], ["-", 908], ["ultraviolet", 909], ["A", 921], ["(", 923], ["P", 924], ["<", 926], ["0\u00b705", 928], [")", 932], [".", 933], ["Independent", 935], ["factors", 947], ["associated", 955], ["with", 966], ["LTBI", 971], ["were", 976], ["male", 981], ["sex", 986], ["[", 990], ["odds", 991], ["ratio", 996], ["(", 1002], ["OR", 1003], [")", 1005], ["1\u00b730", 1007], [",", 1011], ["95", 1013], ["%", 1015], ["confidence", 1017], ["interval", 1028], ["(", 1037], ["CI", 1038], [")", 1040], ["1\u00b704", 1042], ["-", 1046], ["1\u00b762", 1047], [";", 1051], ["P", 1053], ["=", 1055], ["0\u00b702", 1057], ["]", 1061], [",", 1062], ["age", 1064], ["over", 1068], ["55", 1073], ["years", 1076], ["(", 1082], ["OR", 1083], ["2\u00b793", 1086], [",", 1090], ["95", 1092], ["%", 1094], ["CI", 1096], ["2\u00b718", 1099], ["-", 1103], ["3\u00b793", 1104], [";", 1108], ["P", 1110], ["<", 1112], ["0\u00b7001", 1114], [")", 1119], ["and", 1121], ["being", 1125], ["entered", 1131], ["into", 1139], ["a", 1144], ["conventional", 1146], ["treatment", 1159], ["(", 1169], ["OR", 1170], ["3\u00b783", 1173], [",", 1177], ["95", 1179], ["%", 1181], ["CI", 1183], ["3\u00b710", 1186], ["-", 1190], ["4\u00b774", 1191], [";", 1195], ["P", 1197], ["<", 1199], ["0\u00b7001", 1201], [")", 1206], [".", 1207], ["Positive", 1209], ["history", 1218], ["of", 1226], ["tuberculosis", 1229], ["was", 1242], ["seen", 1246], ["in", 1251], ["1", 1254], ["%", 1255], ["of", 1257], ["patients", 1260], ["(", 1269], ["n", 1270], ["=", 1272], ["49", 1274], [")", 1276], [".", 1277], ["The", 1279], ["nationwide", 1283], ["prevalence", 1294], ["of", 1305], ["LTBI", 1308], ["in", 1313], ["Italian", 1316], ["patients", 1324], ["with", 1333], ["psoriasis", 1338], ["candidate", 1348], ["to", 1358], ["systemic", 1361], ["treatment", 1370], ["is", 1380], ["high", 1383], [",", 1387], ["and", 1389], ["screening", 1393], ["is", 1403], ["recommended", 1406], ["prior", 1418], ["to", 1424], ["biological", 1427], ["treatment", 1438], [".", 1447]]}
{"context": "The conserved histone variant H2A.Z functions in euchromatin to antagonize the spread of heterochromatin. The mechanism by which histone H2A is replaced by H2A.Z in the nucleosome is unknown. We identified a complex containing 13 different polypeptides associated with a soluble pool of H2A.Z in Saccharomyces cerevisiae. This complex was designated SWR1-Com in reference to the Swr1p subunit, a Swi2/Snf2-paralog. Swr1p and six other subunits were found only in SWR1-Com, whereas six other subunits were also found in the NuA4 histone acetyltransferase and/or the Ino80 chromatin remodeling complex. H2A.Z and SWR1 were essential for viability of cells lacking the EAF1 component of NuA4, pointing to a close functional connection between these two complexes. Strikingly, chromatin immunoprecipitation analysis of cells lacking Swr1p, the presumed ATPase of the complex, revealed a profound defect in the deposition of H2A.Z at euchromatic regions that flank the silent mating type cassette HMR and at 12 other chromosomal sites tested. Consistent with a specialized role for Swr1p in H2A.Z deposition, the majority of the genome-wide transcriptional defects seen in swr1Delta cells were also found in htz1Delta cells. These studies revealed a novel role for a member of the ATP-dependent chromatin remodeling enzyme family in determining the region-specific histone subunit composition of chromatin in vivo and controlling the epigenetic state of chromatin. Metazoan orthologs of Swr1p (Drosophila Domino; human SRCAP and p400) may have analogous functions.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "30f3fe33aa974d54aa12ad555cb22644", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[97, 97]], "char_spans": [[611, 614]]}]}], "context_tokens": [["The", 0], ["conserved", 4], ["histone", 14], ["variant", 22], ["H2A.Z", 30], ["functions", 36], ["in", 46], ["euchromatin", 49], ["to", 61], ["antagonize", 64], ["the", 75], ["spread", 79], ["of", 86], ["heterochromatin", 89], [".", 104], ["The", 106], ["mechanism", 110], ["by", 120], ["which", 123], ["histone", 129], ["H2A", 137], ["is", 141], ["replaced", 144], ["by", 153], ["H2A.Z", 156], ["in", 162], ["the", 165], ["nucleosome", 169], ["is", 180], ["unknown", 183], [".", 190], ["We", 192], ["identified", 195], ["a", 206], ["complex", 208], ["containing", 216], ["13", 227], ["different", 230], ["polypeptides", 240], ["associated", 253], ["with", 264], ["a", 269], ["soluble", 271], ["pool", 279], ["of", 284], ["H2A.Z", 287], ["in", 293], ["Saccharomyces", 296], ["cerevisiae", 310], [".", 320], ["This", 322], ["complex", 327], ["was", 335], ["designated", 339], ["SWR1-Com", 350], ["in", 359], ["reference", 362], ["to", 372], ["the", 375], ["Swr1p", 379], ["subunit", 385], [",", 392], ["a", 394], ["Swi2/Snf2-paralog", 396], [".", 413], ["Swr1p", 415], ["and", 421], ["six", 425], ["other", 429], ["subunits", 435], ["were", 444], ["found", 449], ["only", 455], ["in", 460], ["SWR1-Com", 463], [",", 471], ["whereas", 473], ["six", 481], ["other", 485], ["subunits", 491], ["were", 500], ["also", 505], ["found", 510], ["in", 516], ["the", 519], ["NuA4", 523], ["histone", 528], ["acetyltransferase", 536], ["and/or", 554], ["the", 561], ["Ino80", 565], ["chromatin", 571], ["remodeling", 581], ["complex", 592], [".", 599], ["H2A.Z", 601], ["and", 607], ["SWR1", 611], ["were", 616], ["essential", 621], ["for", 631], ["viability", 635], ["of", 645], ["cells", 648], ["lacking", 654], ["the", 662], ["EAF1", 666], ["component", 671], ["of", 681], ["NuA4", 684], [",", 688], ["pointing", 690], ["to", 699], ["a", 702], ["close", 704], ["functional", 710], ["connection", 721], ["between", 732], ["these", 740], ["two", 746], ["complexes", 750], [".", 759], ["Strikingly", 761], [",", 771], ["chromatin", 773], ["immunoprecipitation", 783], ["analysis", 803], ["of", 812], ["cells", 815], ["lacking", 821], ["Swr1p", 829], [",", 834], ["the", 836], ["presumed", 840], ["ATPase", 849], ["of", 856], ["the", 859], ["complex", 863], [",", 870], ["revealed", 872], ["a", 881], ["profound", 883], ["defect", 892], ["in", 899], ["the", 902], ["deposition", 906], ["of", 917], ["H2A.Z", 920], ["at", 926], ["euchromatic", 929], ["regions", 941], ["that", 949], ["flank", 954], ["the", 960], ["silent", 964], ["mating", 971], ["type", 978], ["cassette", 983], ["HMR", 992], ["and", 996], ["at", 1000], ["12", 1003], ["other", 1006], ["chromosomal", 1012], ["sites", 1024], ["tested", 1030], [".", 1036], ["Consistent", 1038], ["with", 1049], ["a", 1054], ["specialized", 1056], ["role", 1068], ["for", 1073], ["Swr1p", 1077], ["in", 1083], ["H2A.Z", 1086], ["deposition", 1092], [",", 1102], ["the", 1104], ["majority", 1108], ["of", 1117], ["the", 1120], ["genome", 1124], ["-", 1130], ["wide", 1131], ["transcriptional", 1136], ["defects", 1152], ["seen", 1160], ["in", 1165], ["swr1Delta", 1168], ["cells", 1178], ["were", 1184], ["also", 1189], ["found", 1194], ["in", 1200], ["htz1Delta", 1203], ["cells", 1213], [".", 1218], ["These", 1220], ["studies", 1226], ["revealed", 1234], ["a", 1243], ["novel", 1245], ["role", 1251], ["for", 1256], ["a", 1260], ["member", 1262], ["of", 1269], ["the", 1272], ["ATP", 1276], ["-", 1279], ["dependent", 1280], ["chromatin", 1290], ["remodeling", 1300], ["enzyme", 1311], ["family", 1318], ["in", 1325], ["determining", 1328], ["the", 1340], ["region", 1344], ["-", 1350], ["specific", 1351], ["histone", 1360], ["subunit", 1368], ["composition", 1376], ["of", 1388], ["chromatin", 1391], ["in", 1401], ["vivo", 1404], ["and", 1409], ["controlling", 1413], ["the", 1425], ["epigenetic", 1429], ["state", 1440], ["of", 1446], ["chromatin", 1449], [".", 1458], ["Metazoan", 1460], ["orthologs", 1469], ["of", 1479], ["Swr1p", 1482], ["(", 1488], ["Drosophila", 1489], ["Domino", 1500], [";", 1506], ["human", 1508], ["SRCAP", 1514], ["and", 1520], ["p400", 1524], [")", 1528], ["may", 1530], ["have", 1534], ["analogous", 1539], ["functions", 1549], [".", 1558]]}
{"context": "The t(9;22)(q34;q11) translocation leading to the Philadelphia (Ph) chromosome resulting in BCR-ABL gene fusion is associated with a poor prognosis in acute lymphoblastic leukemia (ALL). We studied the relation between t(9;22), determined by karyotype, fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR), and in vitro drug resistance, measured by the MTT assay, in precursor B-cell ALL at diagnosis. The findings in twenty-one Ph-positive (Ph+) childhood common/precursorB (c/preB) cases were compared with 254 Ph-negative (Ph-) ALL cases. A large range of LC(50) values was found within the Ph+ patients. Moreover, LC(50) values did not differ significantly between Ph+ and Ph- samples for prednisolone, dexamethasone, L-asparaginase, vincristine, anthracyclines, thiopurines, epipodophyllotoxins, and 4H00-ifosfamide, even after matching for important prognostic features (age, white blood cell count (WBC), and immunophenotype). Adult Ph+ (n = 12) ALL was more resistant to prednisolone (> 270-fold, P = 0.030), and displayed an overall tendency to resistance when compared to matched cases of Ph- (n = 15) adult precursor B-cell ALL. Within Ph+ ALL, in vitro prednisolone resistance increased significantly with age (P = 0.006). The expression of lung resistance protein (LRP), but not P-glycoprotein (P-gp) or multidrug resistance protein (MRP), was significantly higher in all Ph+ patients. Both childhood and adult Ph+ precursor B-cell ALL samples display a heterogeneous in vitro resistance profile, with relatively sensitive and resistant cases. The adult Ph+ samples, however, are generally more resistant compared to matched Ph- controls, reaching significance for prednisolone. The correlation of prednisolone resistance with age within the Ph+ cases might help explain the poorer prognosis of adult Ph+ ALL.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "b60b5fefa0974ab9bf4f02ae03d69a4c", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[14, 18]], "char_spans": [[92, 110]]}]}], "context_tokens": [["The", 0], ["t(9;22)(q34;q11", 4], [")", 19], ["translocation", 21], ["leading", 35], ["to", 43], ["the", 46], ["Philadelphia", 50], ["(", 63], ["Ph", 64], [")", 66], ["chromosome", 68], ["resulting", 79], ["in", 89], ["BCR", 92], ["-", 95], ["ABL", 96], ["gene", 100], ["fusion", 105], ["is", 112], ["associated", 115], ["with", 126], ["a", 131], ["poor", 133], ["prognosis", 138], ["in", 148], ["acute", 151], ["lymphoblastic", 157], ["leukemia", 171], ["(", 180], ["ALL", 181], [")", 184], [".", 185], ["We", 187], ["studied", 190], ["the", 198], ["relation", 202], ["between", 211], ["t(9;22", 219], [")", 225], [",", 226], ["determined", 228], ["by", 239], ["karyotype", 242], [",", 251], ["fluorescence", 253], ["in", 266], ["situ", 269], ["hybridization", 274], ["(", 288], ["FISH", 289], [")", 293], ["or", 295], ["polymerase", 298], ["chain", 309], ["reaction", 315], ["(", 324], ["PCR", 325], [")", 328], [",", 329], ["and", 331], ["in", 335], ["vitro", 338], ["drug", 344], ["resistance", 349], [",", 359], ["measured", 361], ["by", 370], ["the", 373], ["MTT", 377], ["assay", 381], [",", 386], ["in", 388], ["precursor", 391], ["B", 401], ["-", 402], ["cell", 403], ["ALL", 408], ["at", 412], ["diagnosis", 415], [".", 424], ["The", 426], ["findings", 430], ["in", 439], ["twenty", 442], ["-", 448], ["one", 449], ["Ph", 453], ["-", 455], ["positive", 456], ["(", 465], ["Ph+", 466], [")", 469], ["childhood", 471], ["common", 481], ["/", 487], ["precursorB", 488], ["(", 499], ["c", 500], ["/", 501], ["preB", 502], [")", 506], ["cases", 508], ["were", 514], ["compared", 519], ["with", 528], ["254", 533], ["Ph", 537], ["-", 539], ["negative", 540], ["(", 549], ["Ph-", 550], [")", 553], ["ALL", 555], ["cases", 559], [".", 564], ["A", 566], ["large", 568], ["range", 574], ["of", 580], ["LC(50", 583], [")", 588], ["values", 590], ["was", 597], ["found", 601], ["within", 607], ["the", 614], ["Ph+", 618], ["patients", 622], [".", 630], ["Moreover", 632], [",", 640], ["LC(50", 642], [")", 647], ["values", 649], ["did", 656], ["not", 660], ["differ", 664], ["significantly", 671], ["between", 685], ["Ph+", 693], ["and", 697], ["Ph-", 701], ["samples", 705], ["for", 713], ["prednisolone", 717], [",", 729], ["dexamethasone", 731], [",", 744], ["L", 746], ["-", 747], ["asparaginase", 748], [",", 760], ["vincristine", 762], [",", 773], ["anthracyclines", 775], [",", 789], ["thiopurines", 791], [",", 802], ["epipodophyllotoxins", 804], [",", 823], ["and", 825], ["4H00-ifosfamide", 829], [",", 844], ["even", 846], ["after", 851], ["matching", 857], ["for", 866], ["important", 870], ["prognostic", 880], ["features", 891], ["(", 900], ["age", 901], [",", 904], ["white", 906], ["blood", 912], ["cell", 918], ["count", 923], ["(", 929], ["WBC", 930], [")", 933], [",", 934], ["and", 936], ["immunophenotype", 940], [")", 955], [".", 956], ["Adult", 958], ["Ph+", 964], ["(", 968], ["n", 969], ["=", 971], ["12", 973], [")", 975], ["ALL", 977], ["was", 981], ["more", 985], ["resistant", 990], ["to", 1000], ["prednisolone", 1003], ["(", 1016], [">", 1017], ["270-fold", 1019], [",", 1027], ["P", 1029], ["=", 1031], ["0.030", 1033], [")", 1038], [",", 1039], ["and", 1041], ["displayed", 1045], ["an", 1055], ["overall", 1058], ["tendency", 1066], ["to", 1075], ["resistance", 1078], ["when", 1089], ["compared", 1094], ["to", 1103], ["matched", 1106], ["cases", 1114], ["of", 1120], ["Ph-", 1123], ["(", 1127], ["n", 1128], ["=", 1130], ["15", 1132], [")", 1134], ["adult", 1136], ["precursor", 1142], ["B", 1152], ["-", 1153], ["cell", 1154], ["ALL", 1159], [".", 1162], ["Within", 1164], ["Ph+", 1171], ["ALL", 1175], [",", 1178], ["in", 1180], ["vitro", 1183], ["prednisolone", 1189], ["resistance", 1202], ["increased", 1213], ["significantly", 1223], ["with", 1237], ["age", 1242], ["(", 1246], ["P", 1247], ["=", 1249], ["0.006", 1251], [")", 1256], [".", 1257], ["The", 1259], ["expression", 1263], ["of", 1274], ["lung", 1277], ["resistance", 1282], ["protein", 1293], ["(", 1301], ["LRP", 1302], [")", 1305], [",", 1306], ["but", 1308], ["not", 1312], ["P", 1316], ["-", 1317], ["glycoprotein", 1318], ["(", 1331], ["P", 1332], ["-", 1333], ["gp", 1334], [")", 1336], ["or", 1338], ["multidrug", 1341], ["resistance", 1351], ["protein", 1362], ["(", 1370], ["MRP", 1371], [")", 1374], [",", 1375], ["was", 1377], ["significantly", 1381], ["higher", 1395], ["in", 1402], ["all", 1405], ["Ph+", 1409], ["patients", 1413], [".", 1421], ["Both", 1423], ["childhood", 1428], ["and", 1438], ["adult", 1442], ["Ph+", 1448], ["precursor", 1452], ["B", 1462], ["-", 1463], ["cell", 1464], ["ALL", 1469], ["samples", 1473], ["display", 1481], ["a", 1489], ["heterogeneous", 1491], ["in", 1505], ["vitro", 1508], ["resistance", 1514], ["profile", 1525], [",", 1532], ["with", 1534], ["relatively", 1539], ["sensitive", 1550], ["and", 1560], ["resistant", 1564], ["cases", 1574], [".", 1579], ["The", 1581], ["adult", 1585], ["Ph+", 1591], ["samples", 1595], [",", 1602], ["however", 1604], [",", 1611], ["are", 1613], ["generally", 1617], ["more", 1627], ["resistant", 1632], ["compared", 1642], ["to", 1651], ["matched", 1654], ["Ph-", 1662], ["controls", 1666], [",", 1674], ["reaching", 1676], ["significance", 1685], ["for", 1698], ["prednisolone", 1702], [".", 1714], ["The", 1716], ["correlation", 1720], ["of", 1732], ["prednisolone", 1735], ["resistance", 1748], ["with", 1759], ["age", 1764], ["within", 1768], ["the", 1775], ["Ph+", 1779], ["cases", 1783], ["might", 1789], ["help", 1795], ["explain", 1800], ["the", 1808], ["poorer", 1812], ["prognosis", 1819], ["of", 1829], ["adult", 1832], ["Ph+", 1838], ["ALL", 1842], [".", 1845]]}
{"context": "Hospitalization for exacerbation of COPD is associated with a high risk of mortality. A risk-prediction model using information easily obtained on admission could help to identify high-risk individuals. The CURB65 score was developed to predict mortality risk in community acquired pneumonia. A retrospective study found that this score was also associated with mortality in COPD exacerbations. We conducted a prospective study to assess the utility of the CURB65 score in acute COPD exacerbations. Consecutive patients with physician diagnosed COPD exacerbations admitted to a public hospital during a 1-year period were studied prospectively. The CURB65 scores were calculated from information obtained at initial hospital presentation. CURB65\u2003=\u2003one point each for Confusion, Urea\u2003>\u20037 mmol/L, Respiratory rate\u2003\u2265\u200330/min, low Blood pressure, age\u2003\u2265\u200365 years. 30-day mortality data were available for 249 of 252 patients. CURB65 scores on admission significantly predicted risk of death during the hospital admission and at 30\u2003days. The 30-day mortality by score groups were: low risk (scores 0-1) 2.0% (2/98), moderate risk (score 2) 6.7% (6/90) and high risk (scores 3-5) 21.3% (13/61). CURB65 scores were not predictive of 1-year mortality. A simple 6-point score based on confusion, blood urea, respiratory rate, blood pressure and age can be used to stratify patients with COPD exacerbation into different management groups. The CURB65 score was as effective in predicting early mortality in our cohort of acute COPD exacerbations as it was in previous cohorts with community acquired pneumonia. Our findings suggest that CURB65 scores can help clinicians to assess patients with exacerbation of COPD.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "930ebd41e49942059fff966207ce5c03", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[288, 288], [46, 46]], "char_spans": [[1588, 1596], [282, 290]]}]}], "context_tokens": [["Hospitalization", 0], ["for", 16], ["exacerbation", 20], ["of", 33], ["COPD", 36], ["is", 41], ["associated", 44], ["with", 55], ["a", 60], ["high", 62], ["risk", 67], ["of", 72], ["mortality", 75], [".", 84], ["A", 86], ["risk", 88], ["-", 92], ["prediction", 93], ["model", 104], ["using", 110], ["information", 116], ["easily", 128], ["obtained", 135], ["on", 144], ["admission", 147], ["could", 157], ["help", 163], ["to", 168], ["identify", 171], ["high", 180], ["-", 184], ["risk", 185], ["individuals", 190], [".", 201], ["The", 203], ["CURB65", 207], ["score", 214], ["was", 220], ["developed", 224], ["to", 234], ["predict", 237], ["mortality", 245], ["risk", 255], ["in", 260], ["community", 263], ["acquired", 273], ["pneumonia", 282], [".", 291], ["A", 293], ["retrospective", 295], ["study", 309], ["found", 315], ["that", 321], ["this", 326], ["score", 331], ["was", 337], ["also", 341], ["associated", 346], ["with", 357], ["mortality", 362], ["in", 372], ["COPD", 375], ["exacerbations", 380], [".", 393], ["We", 395], ["conducted", 398], ["a", 408], ["prospective", 410], ["study", 422], ["to", 428], ["assess", 431], ["the", 438], ["utility", 442], ["of", 450], ["the", 453], ["CURB65", 457], ["score", 464], ["in", 470], ["acute", 473], ["COPD", 479], ["exacerbations", 484], [".", 497], ["Consecutive", 499], ["patients", 511], ["with", 520], ["physician", 525], ["diagnosed", 535], ["COPD", 545], ["exacerbations", 550], ["admitted", 564], ["to", 573], ["a", 576], ["public", 578], ["hospital", 585], ["during", 594], ["a", 601], ["1-year", 603], ["period", 610], ["were", 617], ["studied", 622], ["prospectively", 630], [".", 643], ["The", 645], ["CURB65", 649], ["scores", 656], ["were", 663], ["calculated", 668], ["from", 679], ["information", 684], ["obtained", 696], ["at", 705], ["initial", 708], ["hospital", 716], ["presentation", 725], [".", 737], ["CURB65", 739], ["=", 746], ["one", 748], ["point", 752], ["each", 758], ["for", 763], ["Confusion", 767], [",", 776], ["Urea", 778], [">", 783], ["7", 785], ["mmol", 787], ["/", 791], ["L", 792], [",", 793], ["Respiratory", 795], ["rate", 807], ["\u2265", 812], ["30/min", 814], [",", 820], ["low", 822], ["Blood", 826], ["pressure", 832], [",", 840], ["age", 842], ["\u2265", 846], ["65", 848], ["years", 851], [".", 856], ["30-day", 858], ["mortality", 865], ["data", 875], ["were", 880], ["available", 885], ["for", 895], ["249", 899], ["of", 903], ["252", 906], ["patients", 910], [".", 918], ["CURB65", 920], ["scores", 927], ["on", 934], ["admission", 937], ["significantly", 947], ["predicted", 961], ["risk", 971], ["of", 976], ["death", 979], ["during", 985], ["the", 992], ["hospital", 996], ["admission", 1005], ["and", 1015], ["at", 1019], ["30", 1022], ["days", 1025], [".", 1029], ["The", 1031], ["30-day", 1035], ["mortality", 1042], ["by", 1052], ["score", 1055], ["groups", 1061], ["were", 1068], [":", 1072], ["low", 1074], ["risk", 1078], ["(", 1083], ["scores", 1084], ["0", 1091], ["-", 1092], ["1", 1093], [")", 1094], ["2.0", 1096], ["%", 1099], ["(", 1101], ["2/98", 1102], [")", 1106], [",", 1107], ["moderate", 1109], ["risk", 1118], ["(", 1123], ["score", 1124], ["2", 1130], [")", 1131], ["6.7", 1133], ["%", 1136], ["(", 1138], ["6/90", 1139], [")", 1143], ["and", 1145], ["high", 1149], ["risk", 1154], ["(", 1159], ["scores", 1160], ["3", 1167], ["-", 1168], ["5", 1169], [")", 1170], ["21.3", 1172], ["%", 1176], ["(", 1178], ["13/61", 1179], [")", 1184], [".", 1185], ["CURB65", 1187], ["scores", 1194], ["were", 1201], ["not", 1206], ["predictive", 1210], ["of", 1221], ["1-year", 1224], ["mortality", 1231], [".", 1240], ["A", 1242], ["simple", 1244], ["6-point", 1251], ["score", 1259], ["based", 1265], ["on", 1271], ["confusion", 1274], [",", 1283], ["blood", 1285], ["urea", 1291], [",", 1295], ["respiratory", 1297], ["rate", 1309], [",", 1313], ["blood", 1315], ["pressure", 1321], ["and", 1330], ["age", 1334], ["can", 1338], ["be", 1342], ["used", 1345], ["to", 1350], ["stratify", 1353], ["patients", 1362], ["with", 1371], ["COPD", 1376], ["exacerbation", 1381], ["into", 1394], ["different", 1399], ["management", 1409], ["groups", 1420], [".", 1426], ["The", 1428], ["CURB65", 1432], ["score", 1439], ["was", 1445], ["as", 1449], ["effective", 1452], ["in", 1462], ["predicting", 1465], ["early", 1476], ["mortality", 1482], ["in", 1492], ["our", 1495], ["cohort", 1499], ["of", 1506], ["acute", 1509], ["COPD", 1515], ["exacerbations", 1520], ["as", 1534], ["it", 1537], ["was", 1540], ["in", 1544], ["previous", 1547], ["cohorts", 1556], ["with", 1564], ["community", 1569], ["acquired", 1579], ["pneumonia", 1588], [".", 1597], ["Our", 1599], ["findings", 1603], ["suggest", 1612], ["that", 1620], ["CURB65", 1625], ["scores", 1632], ["can", 1639], ["help", 1643], ["clinicians", 1648], ["to", 1659], ["assess", 1662], ["patients", 1669], ["with", 1678], ["exacerbation", 1683], ["of", 1696], ["COPD", 1699], [".", 1703]]}
{"context": "1. In order to investigate the biological function of the human CLN3 gene that is defective in Batten disease, we created a yeast strain by PCR-targeted disruption of the yeast gene (YHC3), which is a homologue of the human CLN3 gene. 2. The phenotypic characterization revealed that the yhc3 delta mutants are more sensitive to combined heat and alkaline stress than the wild-type strains as determined by inhibition of cell proliferation. 3. This suggests that the yhc3 delta mutant is a good model to investigate the biological function of human CLN3 gene in mammalian cells and to understand the pathophysiology of juvenile Batten disease.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "9bb5d9f90f804b34971f0a239f63343b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[18, 19], [115, 116]], "char_spans": [[95, 108], [628, 641]]}]}], "context_tokens": [["1", 0], [".", 1], ["In", 3], ["order", 6], ["to", 12], ["investigate", 15], ["the", 27], ["biological", 31], ["function", 42], ["of", 51], ["the", 54], ["human", 58], ["CLN3", 64], ["gene", 69], ["that", 74], ["is", 79], ["defective", 82], ["in", 92], ["Batten", 95], ["disease", 102], [",", 109], ["we", 111], ["created", 114], ["a", 122], ["yeast", 124], ["strain", 130], ["by", 137], ["PCR", 140], ["-", 143], ["targeted", 144], ["disruption", 153], ["of", 164], ["the", 167], ["yeast", 171], ["gene", 177], ["(", 182], ["YHC3", 183], [")", 187], [",", 188], ["which", 190], ["is", 196], ["a", 199], ["homologue", 201], ["of", 211], ["the", 214], ["human", 218], ["CLN3", 224], ["gene", 229], [".", 233], ["2", 235], [".", 236], ["The", 238], ["phenotypic", 242], ["characterization", 253], ["revealed", 270], ["that", 279], ["the", 284], ["yhc3", 288], ["delta", 293], ["mutants", 299], ["are", 307], ["more", 311], ["sensitive", 316], ["to", 326], ["combined", 329], ["heat", 338], ["and", 343], ["alkaline", 347], ["stress", 356], ["than", 363], ["the", 368], ["wild", 372], ["-", 376], ["type", 377], ["strains", 382], ["as", 390], ["determined", 393], ["by", 404], ["inhibition", 407], ["of", 418], ["cell", 421], ["proliferation", 426], [".", 439], ["3", 441], [".", 442], ["This", 444], ["suggests", 449], ["that", 458], ["the", 463], ["yhc3", 467], ["delta", 472], ["mutant", 478], ["is", 485], ["a", 488], ["good", 490], ["model", 495], ["to", 501], ["investigate", 504], ["the", 516], ["biological", 520], ["function", 531], ["of", 540], ["human", 543], ["CLN3", 549], ["gene", 554], ["in", 559], ["mammalian", 562], ["cells", 572], ["and", 578], ["to", 582], ["understand", 585], ["the", 596], ["pathophysiology", 600], ["of", 616], ["juvenile", 619], ["Batten", 628], ["disease", 635], [".", 642]]}
{"context": "Dystrophic myotonia is a sufficiently rare disease inherited mainly by the autosomal dominant type. Clinical picture is characterized by the myotonic, myopathic, and endocrine-autonomic syndrome. A clinical, genetic, and electromyographic study was carried out to elucidate the problem of this condition inheritance, its intra- and interfamilial clinical polymorphism, and effects of environmental factors on its course and outcomes.", "qas": [{"question": "How is myotonic dystrophy inherited?", "answers": ["autosomal dominant"], "qid": "52cd8f90006a41c999627c367f252ff3", "question_tokens": [["How", 0], ["is", 4], ["myotonic", 7], ["dystrophy", 16], ["inherited", 26], ["?", 35]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[11, 12]], "char_spans": [[75, 92]]}]}], "context_tokens": [["Dystrophic", 0], ["myotonia", 11], ["is", 20], ["a", 23], ["sufficiently", 25], ["rare", 38], ["disease", 43], ["inherited", 51], ["mainly", 61], ["by", 68], ["the", 71], ["autosomal", 75], ["dominant", 85], ["type", 94], [".", 98], ["Clinical", 100], ["picture", 109], ["is", 117], ["characterized", 120], ["by", 134], ["the", 137], ["myotonic", 141], [",", 149], ["myopathic", 151], [",", 160], ["and", 162], ["endocrine", 166], ["-", 175], ["autonomic", 176], ["syndrome", 186], [".", 194], ["A", 196], ["clinical", 198], [",", 206], ["genetic", 208], [",", 215], ["and", 217], ["electromyographic", 221], ["study", 239], ["was", 245], ["carried", 249], ["out", 257], ["to", 261], ["elucidate", 264], ["the", 274], ["problem", 278], ["of", 286], ["this", 289], ["condition", 294], ["inheritance", 304], [",", 315], ["its", 317], ["intra-", 321], ["and", 328], ["interfamilial", 332], ["clinical", 346], ["polymorphism", 355], [",", 367], ["and", 369], ["effects", 373], ["of", 381], ["environmental", 384], ["factors", 398], ["on", 406], ["its", 409], ["course", 413], ["and", 420], ["outcomes", 424], [".", 432]]}
{"context": "Very few human genes can be used to identify spontaneous inactivating somatic mutations. We hypothesized that because the XK gene is X-linked, it would be easy to identify spontaneously arising red cells with a phenotype resembling the McLeod syndrome, which results from inherited XK mutations. Here, by flow cytometry, we detect such phenotypic variants at a median frequency of 9 x 10(-6) in neonatal cord blood samples and 39 x 10(-6) in healthy adults (p=0.004). It may be possible to further investigate the relationship between aging, mutations, and cancer using this approach.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "5fd7a2dfb5344090b95d6ffff8d1456c", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[48, 48], [19, 19]], "char_spans": [[282, 283], [122, 123]]}]}], "context_tokens": [["Very", 0], ["few", 5], ["human", 9], ["genes", 15], ["can", 21], ["be", 25], ["used", 28], ["to", 33], ["identify", 36], ["spontaneous", 45], ["inactivating", 57], ["somatic", 70], ["mutations", 78], [".", 87], ["We", 89], ["hypothesized", 92], ["that", 105], ["because", 110], ["the", 118], ["XK", 122], ["gene", 125], ["is", 130], ["X", 133], ["-", 134], ["linked", 135], [",", 141], ["it", 143], ["would", 146], ["be", 152], ["easy", 155], ["to", 160], ["identify", 163], ["spontaneously", 172], ["arising", 186], ["red", 194], ["cells", 198], ["with", 204], ["a", 209], ["phenotype", 211], ["resembling", 221], ["the", 232], ["McLeod", 236], ["syndrome", 243], [",", 251], ["which", 253], ["results", 259], ["from", 267], ["inherited", 272], ["XK", 282], ["mutations", 285], [".", 294], ["Here", 296], [",", 300], ["by", 302], ["flow", 305], ["cytometry", 310], [",", 319], ["we", 321], ["detect", 324], ["such", 331], ["phenotypic", 336], ["variants", 347], ["at", 356], ["a", 359], ["median", 361], ["frequency", 368], ["of", 378], ["9", 381], ["x", 383], ["10(-6", 385], [")", 390], ["in", 392], ["neonatal", 395], ["cord", 404], ["blood", 409], ["samples", 415], ["and", 423], ["39", 427], ["x", 430], ["10(-6", 432], [")", 437], ["in", 439], ["healthy", 442], ["adults", 450], ["(", 457], ["p=0.004", 458], [")", 465], [".", 466], ["It", 468], ["may", 471], ["be", 475], ["possible", 478], ["to", 487], ["further", 490], ["investigate", 498], ["the", 510], ["relationship", 514], ["between", 527], ["aging", 535], [",", 540], ["mutations", 542], [",", 551], ["and", 553], ["cancer", 557], ["using", 564], ["this", 570], ["approach", 575], [".", 583]]}
{"context": "Imatinib was the first BCR-ABL tyrosine kinase inhibitor to become clinically available. In this study, we retrospectively evaluated the long-term efficacy of low-dose imatinib (final maintenance dose <300\u00a0mg per day) due to intolerance, in comparison to optimal-dose imatinib (\u2265300\u00a0mg per day) in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The Kaplan-Meier estimates of the median time to complete cytogenetic response, major molecular response, and complete molecular response were longer for 31 patients receiving low-dose imatinib (360, 1360, and 1420\u00a0days, respectively) than 74 patients receiving optimal-dose imatinib (170, 420, and 720\u00a0days, respectively). However, the differences in response shrank over time and progression-free survival were comparable between the two groups. These findings suggest that long-term treatment with low-dose imatinib is an acceptable alternative for patients with intolerance to the optimal dose.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "169d1ca25e78425dbd60b6192286d3dd", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[4, 6]], "char_spans": [[23, 29]]}]}], "context_tokens": [["Imatinib", 0], ["was", 9], ["the", 13], ["first", 17], ["BCR", 23], ["-", 26], ["ABL", 27], ["tyrosine", 31], ["kinase", 40], ["inhibitor", 47], ["to", 57], ["become", 60], ["clinically", 67], ["available", 78], [".", 87], ["In", 89], ["this", 92], ["study", 97], [",", 102], ["we", 104], ["retrospectively", 107], ["evaluated", 123], ["the", 133], ["long", 137], ["-", 141], ["term", 142], ["efficacy", 147], ["of", 156], ["low", 159], ["-", 162], ["dose", 163], ["imatinib", 168], ["(", 177], ["final", 178], ["maintenance", 184], ["dose", 196], ["<", 201], ["300", 202], ["mg", 206], ["per", 209], ["day", 213], [")", 216], ["due", 218], ["to", 222], ["intolerance", 225], [",", 236], ["in", 238], ["comparison", 241], ["to", 252], ["optimal", 255], ["-", 262], ["dose", 263], ["imatinib", 268], ["(", 277], ["\u2265300", 278], ["mg", 283], ["per", 286], ["day", 290], [")", 293], ["in", 295], ["patients", 298], ["with", 307], ["Philadelphia", 312], ["chromosome", 325], ["-", 335], ["positive", 336], ["chronic", 345], ["myeloid", 353], ["leukemia", 361], ["in", 370], ["the", 373], ["chronic", 377], ["phase", 385], [".", 390], ["The", 392], ["Kaplan", 396], ["-", 402], ["Meier", 403], ["estimates", 409], ["of", 419], ["the", 422], ["median", 426], ["time", 433], ["to", 438], ["complete", 441], ["cytogenetic", 450], ["response", 462], [",", 470], ["major", 472], ["molecular", 478], ["response", 488], [",", 496], ["and", 498], ["complete", 502], ["molecular", 511], ["response", 521], ["were", 530], ["longer", 535], ["for", 542], ["31", 546], ["patients", 549], ["receiving", 558], ["low", 568], ["-", 571], ["dose", 572], ["imatinib", 577], ["(", 586], ["360", 587], [",", 590], ["1360", 592], [",", 596], ["and", 598], ["1420", 602], ["days", 607], [",", 611], ["respectively", 613], [")", 625], ["than", 627], ["74", 632], ["patients", 635], ["receiving", 644], ["optimal", 654], ["-", 661], ["dose", 662], ["imatinib", 667], ["(", 676], ["170", 677], [",", 680], ["420", 682], [",", 685], ["and", 687], ["720", 691], ["days", 695], [",", 699], ["respectively", 701], [")", 713], [".", 714], ["However", 716], [",", 723], ["the", 725], ["differences", 729], ["in", 741], ["response", 744], ["shrank", 753], ["over", 760], ["time", 765], ["and", 770], ["progression", 774], ["-", 785], ["free", 786], ["survival", 791], ["were", 800], ["comparable", 805], ["between", 816], ["the", 824], ["two", 828], ["groups", 832], [".", 838], ["These", 840], ["findings", 846], ["suggest", 855], ["that", 863], ["long", 868], ["-", 872], ["term", 873], ["treatment", 878], ["with", 888], ["low", 893], ["-", 896], ["dose", 897], ["imatinib", 902], ["is", 911], ["an", 914], ["acceptable", 917], ["alternative", 928], ["for", 940], ["patients", 944], ["with", 953], ["intolerance", 958], ["to", 970], ["the", 973], ["optimal", 977], ["dose", 985], [".", 989]]}
{"context": "Duavee, an oral contraceptive; riociguat (Adempas) for two types of pulmonary hypertension; and macitentan (Opsumit) for pulmonary arterial hypertension.", "qas": [{"question": "What is generic name of drug Adempas?", "answers": ["riociguat"], "qid": "785d411170fb461891f9aaf5794d8c28", "question_tokens": [["What", 0], ["is", 5], ["generic", 8], ["name", 16], ["of", 21], ["drug", 24], ["Adempas", 29], ["?", 36]], "detected_answers": [{"text": "riociguat", "token_spans": [[6, 6]], "char_spans": [[31, 39]]}]}], "context_tokens": [["Duavee", 0], [",", 6], ["an", 8], ["oral", 11], ["contraceptive", 16], [";", 29], ["riociguat", 31], ["(", 41], ["Adempas", 42], [")", 49], ["for", 51], ["two", 55], ["types", 59], ["of", 65], ["pulmonary", 68], ["hypertension", 78], [";", 90], ["and", 92], ["macitentan", 96], ["(", 107], ["Opsumit", 108], [")", 115], ["for", 117], ["pulmonary", 121], ["arterial", 131], ["hypertension", 140], [".", 152]]}
{"context": "To develop a clinical prediction rule to identify patients who can be safely discharged one hour after the administration of naloxone for presumed opioid overdose. Patients who received naloxone for known or presumed opioid overdose were formally evaluated one hour later for multiple potential predictor variables. Patients were classified into two groups: those with adverse events within 24 hours and those without. Using classification and regression tree methodology, a decision rule was developed to predict safe discharge. Clinical findings from 573 patients allowed us to develop a clinical prediction rule with a sensitivity of 99% (95% CI = 96% to 100%) and a specificity of 40% (95% CI = 36% to 45%). Patients with presumed opioid overdose can be safely discharged one hour after naloxone administration if they: 1) can mobilize as usual; 2) have oxygen saturation on room air of >92%; 3) have a respiratory rate >10 breaths/min and <20 breaths/min; 4) have a temperature of >35.0 degrees C and <37.5 degrees C; 5) have a heart rate >50 beats/min and <100 beats/min; and 6) have a Glasgow Coma Scale score of 15. This prediction rule for safe early discharge of patients with presumed opioid overdose performs well in this derivation set but requires validation followed by confirmation of safe implementation.", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "70d7878277804532b313a72e5e20e286", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[20, 20], [29, 29], [143, 143]], "char_spans": [[125, 132], [186, 193], [791, 798]]}]}], "context_tokens": [["To", 0], ["develop", 3], ["a", 11], ["clinical", 13], ["prediction", 22], ["rule", 33], ["to", 38], ["identify", 41], ["patients", 50], ["who", 59], ["can", 63], ["be", 67], ["safely", 70], ["discharged", 77], ["one", 88], ["hour", 92], ["after", 97], ["the", 103], ["administration", 107], ["of", 122], ["naloxone", 125], ["for", 134], ["presumed", 138], ["opioid", 147], ["overdose", 154], [".", 162], ["Patients", 164], ["who", 173], ["received", 177], ["naloxone", 186], ["for", 195], ["known", 199], ["or", 205], ["presumed", 208], ["opioid", 217], ["overdose", 224], ["were", 233], ["formally", 238], ["evaluated", 247], ["one", 257], ["hour", 261], ["later", 266], ["for", 272], ["multiple", 276], ["potential", 285], ["predictor", 295], ["variables", 305], [".", 314], ["Patients", 316], ["were", 325], ["classified", 330], ["into", 341], ["two", 346], ["groups", 350], [":", 356], ["those", 358], ["with", 364], ["adverse", 369], ["events", 377], ["within", 384], ["24", 391], ["hours", 394], ["and", 400], ["those", 404], ["without", 410], [".", 417], ["Using", 419], ["classification", 425], ["and", 440], ["regression", 444], ["tree", 455], ["methodology", 460], [",", 471], ["a", 473], ["decision", 475], ["rule", 484], ["was", 489], ["developed", 493], ["to", 503], ["predict", 506], ["safe", 514], ["discharge", 519], [".", 528], ["Clinical", 530], ["findings", 539], ["from", 548], ["573", 553], ["patients", 557], ["allowed", 566], ["us", 574], ["to", 577], ["develop", 580], ["a", 588], ["clinical", 590], ["prediction", 599], ["rule", 610], ["with", 615], ["a", 620], ["sensitivity", 622], ["of", 634], ["99", 637], ["%", 639], ["(", 641], ["95", 642], ["%", 644], ["CI", 646], ["=", 649], ["96", 651], ["%", 653], ["to", 655], ["100", 658], ["%", 661], [")", 662], ["and", 664], ["a", 668], ["specificity", 670], ["of", 682], ["40", 685], ["%", 687], ["(", 689], ["95", 690], ["%", 692], ["CI", 694], ["=", 697], ["36", 699], ["%", 701], ["to", 703], ["45", 706], ["%", 708], [")", 709], [".", 710], ["Patients", 712], ["with", 721], ["presumed", 726], ["opioid", 735], ["overdose", 742], ["can", 751], ["be", 755], ["safely", 758], ["discharged", 765], ["one", 776], ["hour", 780], ["after", 785], ["naloxone", 791], ["administration", 800], ["if", 815], ["they", 818], [":", 822], ["1", 824], [")", 825], ["can", 827], ["mobilize", 831], ["as", 840], ["usual", 843], [";", 848], ["2", 850], [")", 851], ["have", 853], ["oxygen", 858], ["saturation", 865], ["on", 876], ["room", 879], ["air", 884], ["of", 888], [">", 891], ["92", 892], ["%", 894], [";", 895], ["3", 897], [")", 898], ["have", 900], ["a", 905], ["respiratory", 907], ["rate", 919], [">", 924], ["10", 925], ["breaths", 928], ["/", 935], ["min", 936], ["and", 940], ["<", 944], ["20", 945], ["breaths", 948], ["/", 955], ["min", 956], [";", 959], ["4", 961], [")", 962], ["have", 964], ["a", 969], ["temperature", 971], ["of", 983], [">", 986], ["35.0", 987], ["degrees", 992], ["C", 1000], ["and", 1002], ["<", 1006], ["37.5", 1007], ["degrees", 1012], ["C", 1020], [";", 1021], ["5", 1023], [")", 1024], ["have", 1026], ["a", 1031], ["heart", 1033], ["rate", 1039], [">", 1044], ["50", 1045], ["beats", 1048], ["/", 1053], ["min", 1054], ["and", 1058], ["<", 1062], ["100", 1063], ["beats", 1067], ["/", 1072], ["min", 1073], [";", 1076], ["and", 1078], ["6", 1082], [")", 1083], ["have", 1085], ["a", 1090], ["Glasgow", 1092], ["Coma", 1100], ["Scale", 1105], ["score", 1111], ["of", 1117], ["15", 1120], [".", 1122], ["This", 1124], ["prediction", 1129], ["rule", 1140], ["for", 1145], ["safe", 1149], ["early", 1154], ["discharge", 1160], ["of", 1170], ["patients", 1173], ["with", 1182], ["presumed", 1187], ["opioid", 1196], ["overdose", 1203], ["performs", 1212], ["well", 1221], ["in", 1226], ["this", 1229], ["derivation", 1234], ["set", 1245], ["but", 1249], ["requires", 1253], ["validation", 1262], ["followed", 1273], ["by", 1282], ["confirmation", 1285], ["of", 1298], ["safe", 1301], ["implementation", 1306], [".", 1320]]}
{"context": "Community-acquired pneumonia (CAP) is the leading cause of infectious death in the world. Immune dysregulation during acute lung infection plays a role in lung injury and the systemic inflammatory response. Cytokines seem to be major players in severe lung infection cases. Here, we present a review of published papers in the last 3\u00a0years regarding this topic. The cytokine response during pneumonia is different in bacterial vs viral infections; some of these cytokines correlate with clinical severity scales such as CURB65 or SOFA. Treatment focused in the cytokine environment is an interesting area that could impact the prognosis of CAP. Some of the agents that have been studied as co-adjuvant therapy are corticosteroids, macrolides, and linezolid, but anyone of those have shown a clear or proven efficacy or have been recommended as a part of the standard of care for CAP. More studies designed to define the role of immunomodulatory agents, such as co-adjuvant therapy in pneumonia, are needed.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "77c8c610c2b44cfdadd28ce51c2e8c6b", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[177, 177], [3, 3], [70, 70]], "char_spans": [[984, 992], [19, 27], [391, 399]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["acquired", 10], ["pneumonia", 19], ["(", 29], ["CAP", 30], [")", 33], ["is", 35], ["the", 38], ["leading", 42], ["cause", 50], ["of", 56], ["infectious", 59], ["death", 70], ["in", 76], ["the", 79], ["world", 83], [".", 88], ["Immune", 90], ["dysregulation", 97], ["during", 111], ["acute", 118], ["lung", 124], ["infection", 129], ["plays", 139], ["a", 145], ["role", 147], ["in", 152], ["lung", 155], ["injury", 160], ["and", 167], ["the", 171], ["systemic", 175], ["inflammatory", 184], ["response", 197], [".", 205], ["Cytokines", 207], ["seem", 217], ["to", 222], ["be", 225], ["major", 228], ["players", 234], ["in", 242], ["severe", 245], ["lung", 252], ["infection", 257], ["cases", 267], [".", 272], ["Here", 274], [",", 278], ["we", 280], ["present", 283], ["a", 291], ["review", 293], ["of", 300], ["published", 303], ["papers", 313], ["in", 320], ["the", 323], ["last", 327], ["3", 332], ["years", 334], ["regarding", 340], ["this", 350], ["topic", 355], [".", 360], ["The", 362], ["cytokine", 366], ["response", 375], ["during", 384], ["pneumonia", 391], ["is", 401], ["different", 404], ["in", 414], ["bacterial", 417], ["vs", 427], ["viral", 430], ["infections", 436], [";", 446], ["some", 448], ["of", 453], ["these", 456], ["cytokines", 462], ["correlate", 472], ["with", 482], ["clinical", 487], ["severity", 496], ["scales", 505], ["such", 512], ["as", 517], ["CURB65", 520], ["or", 527], ["SOFA", 530], [".", 534], ["Treatment", 536], ["focused", 546], ["in", 554], ["the", 557], ["cytokine", 561], ["environment", 570], ["is", 582], ["an", 585], ["interesting", 588], ["area", 600], ["that", 605], ["could", 610], ["impact", 616], ["the", 623], ["prognosis", 627], ["of", 637], ["CAP", 640], [".", 643], ["Some", 645], ["of", 650], ["the", 653], ["agents", 657], ["that", 664], ["have", 669], ["been", 674], ["studied", 679], ["as", 687], ["co", 690], ["-", 692], ["adjuvant", 693], ["therapy", 702], ["are", 710], ["corticosteroids", 714], [",", 729], ["macrolides", 731], [",", 741], ["and", 743], ["linezolid", 747], [",", 756], ["but", 758], ["anyone", 762], ["of", 769], ["those", 772], ["have", 778], ["shown", 783], ["a", 789], ["clear", 791], ["or", 797], ["proven", 800], ["efficacy", 807], ["or", 816], ["have", 819], ["been", 824], ["recommended", 829], ["as", 841], ["a", 844], ["part", 846], ["of", 851], ["the", 854], ["standard", 858], ["of", 867], ["care", 870], ["for", 875], ["CAP", 879], [".", 882], ["More", 884], ["studies", 889], ["designed", 897], ["to", 906], ["define", 909], ["the", 916], ["role", 920], ["of", 925], ["immunomodulatory", 928], ["agents", 945], [",", 951], ["such", 953], ["as", 958], ["co", 961], ["-", 963], ["adjuvant", 964], ["therapy", 973], ["in", 981], ["pneumonia", 984], [",", 993], ["are", 995], ["needed", 999], [".", 1005]]}
{"context": "Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has revolutionized the treatment of Bcr-Abl positive chronic myeloid leukemia and become the standard of care for this disease. The aim of this study was evaluation and analysis of cytogenetic response in different intervals and risk groups as well as finding association between pre-treatment characteristics and later probability of achievement of major cytogenetic response. We analyzed a total of 22 adult patients with newly diagnosed Philadelphia positive early chronic phase chronic myeloid leukemia treated at our institution from June 2006 to December 2009. The median follow-up time for patients during treatment with imatinib was 25.7 months (range, 12-42 months). A complete hematologic response was achieved in all of the analyzed patients within 6 months from the start of the treatment. The major cytogenetic response rate was 81.8%, and the complete cytogenetic response rate was 72.7%. The patients with low or moderate relative risk had the rate of complementary achieving major and complete cytogenetic response of 75-90%. A multivariate analysis identified the following independent prognostic factors for achieving major cytogenetic response: the absence of splenomegaly, white blood cell count less than 10 x 10(9)/L, the platelet count less than 450 x 10(9)/L, the presence of less than 5% of bone marrow blasts and basophils, the absence of blasts in peripheral blood, the presence of less than 7% of basophils in peripheral blood. Patients who early achieve complete and major cytogenetic response as well as those with low and moderate relative risk have a higher rate of achieving and maintaining complete cytogenetic response. There are also characteristics of patients before treatment that may indicate the treatment outcome.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "f1bd012a42904b12a152b624439f2533", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[5, 7], [17, 19]], "char_spans": [[31, 37], [102, 108]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], [",", 17], ["a", 19], ["selective", 21], ["Bcr", 31], ["-", 34], ["Abl", 35], ["tyrosine", 39], ["kinase", 48], ["inhibitor", 55], [",", 64], ["has", 66], ["revolutionized", 70], ["the", 85], ["treatment", 89], ["of", 99], ["Bcr", 102], ["-", 105], ["Abl", 106], ["positive", 110], ["chronic", 119], ["myeloid", 127], ["leukemia", 135], ["and", 144], ["become", 148], ["the", 155], ["standard", 159], ["of", 168], ["care", 171], ["for", 176], ["this", 180], ["disease", 185], [".", 192], ["The", 194], ["aim", 198], ["of", 202], ["this", 205], ["study", 210], ["was", 216], ["evaluation", 220], ["and", 231], ["analysis", 235], ["of", 244], ["cytogenetic", 247], ["response", 259], ["in", 268], ["different", 271], ["intervals", 281], ["and", 291], ["risk", 295], ["groups", 300], ["as", 307], ["well", 310], ["as", 315], ["finding", 318], ["association", 326], ["between", 338], ["pre", 346], ["-", 349], ["treatment", 350], ["characteristics", 360], ["and", 376], ["later", 380], ["probability", 386], ["of", 398], ["achievement", 401], ["of", 413], ["major", 416], ["cytogenetic", 422], ["response", 434], [".", 442], ["We", 444], ["analyzed", 447], ["a", 456], ["total", 458], ["of", 464], ["22", 467], ["adult", 470], ["patients", 476], ["with", 485], ["newly", 490], ["diagnosed", 496], ["Philadelphia", 506], ["positive", 519], ["early", 528], ["chronic", 534], ["phase", 542], ["chronic", 548], ["myeloid", 556], ["leukemia", 564], ["treated", 573], ["at", 581], ["our", 584], ["institution", 588], ["from", 600], ["June", 605], ["2006", 610], ["to", 615], ["December", 618], ["2009", 627], [".", 631], ["The", 633], ["median", 637], ["follow", 644], ["-", 650], ["up", 651], ["time", 654], ["for", 659], ["patients", 663], ["during", 672], ["treatment", 679], ["with", 689], ["imatinib", 694], ["was", 703], ["25.7", 707], ["months", 712], ["(", 719], ["range", 720], [",", 725], ["12", 727], ["-", 729], ["42", 730], ["months", 733], [")", 739], [".", 740], ["A", 742], ["complete", 744], ["hematologic", 753], ["response", 765], ["was", 774], ["achieved", 778], ["in", 787], ["all", 790], ["of", 794], ["the", 797], ["analyzed", 801], ["patients", 810], ["within", 819], ["6", 826], ["months", 828], ["from", 835], ["the", 840], ["start", 844], ["of", 850], ["the", 853], ["treatment", 857], [".", 866], ["The", 868], ["major", 872], ["cytogenetic", 878], ["response", 890], ["rate", 899], ["was", 904], ["81.8", 908], ["%", 912], [",", 913], ["and", 915], ["the", 919], ["complete", 923], ["cytogenetic", 932], ["response", 944], ["rate", 953], ["was", 958], ["72.7", 962], ["%", 966], [".", 967], ["The", 969], ["patients", 973], ["with", 982], ["low", 987], ["or", 991], ["moderate", 994], ["relative", 1003], ["risk", 1012], ["had", 1017], ["the", 1021], ["rate", 1025], ["of", 1030], ["complementary", 1033], ["achieving", 1047], ["major", 1057], ["and", 1063], ["complete", 1067], ["cytogenetic", 1076], ["response", 1088], ["of", 1097], ["75", 1100], ["-", 1102], ["90", 1103], ["%", 1105], [".", 1106], ["A", 1108], ["multivariate", 1110], ["analysis", 1123], ["identified", 1132], ["the", 1143], ["following", 1147], ["independent", 1157], ["prognostic", 1169], ["factors", 1180], ["for", 1188], ["achieving", 1192], ["major", 1202], ["cytogenetic", 1208], ["response", 1220], [":", 1228], ["the", 1230], ["absence", 1234], ["of", 1242], ["splenomegaly", 1245], [",", 1257], ["white", 1259], ["blood", 1265], ["cell", 1271], ["count", 1276], ["less", 1282], ["than", 1287], ["10", 1292], ["x", 1295], ["10(9)/L", 1297], [",", 1304], ["the", 1306], ["platelet", 1310], ["count", 1319], ["less", 1325], ["than", 1330], ["450", 1335], ["x", 1339], ["10(9)/L", 1341], [",", 1348], ["the", 1350], ["presence", 1354], ["of", 1363], ["less", 1366], ["than", 1371], ["5", 1376], ["%", 1377], ["of", 1379], ["bone", 1382], ["marrow", 1387], ["blasts", 1394], ["and", 1401], ["basophils", 1405], [",", 1414], ["the", 1416], ["absence", 1420], ["of", 1428], ["blasts", 1431], ["in", 1438], ["peripheral", 1441], ["blood", 1452], [",", 1457], ["the", 1459], ["presence", 1463], ["of", 1472], ["less", 1475], ["than", 1480], ["7", 1485], ["%", 1486], ["of", 1488], ["basophils", 1491], ["in", 1501], ["peripheral", 1504], ["blood", 1515], [".", 1520], ["Patients", 1522], ["who", 1531], ["early", 1535], ["achieve", 1541], ["complete", 1549], ["and", 1558], ["major", 1562], ["cytogenetic", 1568], ["response", 1580], ["as", 1589], ["well", 1592], ["as", 1597], ["those", 1600], ["with", 1606], ["low", 1611], ["and", 1615], ["moderate", 1619], ["relative", 1628], ["risk", 1637], ["have", 1642], ["a", 1647], ["higher", 1649], ["rate", 1656], ["of", 1661], ["achieving", 1664], ["and", 1674], ["maintaining", 1678], ["complete", 1690], ["cytogenetic", 1699], ["response", 1711], [".", 1719], ["There", 1721], ["are", 1727], ["also", 1731], ["characteristics", 1736], ["of", 1752], ["patients", 1755], ["before", 1764], ["treatment", 1771], ["that", 1781], ["may", 1786], ["indicate", 1790], ["the", 1799], ["treatment", 1803], ["outcome", 1813], [".", 1820]]}
{"context": "The translocation (9;22) gives rise to the p190(Bcr-Abl) and p210(Bcr-Abl) tyrosine kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive (Ph(+)) acute leukemia patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options. Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase. We conducted a clinical trial in 56 patients with relapsed or refractory Ph(+) acute lymphoblastic leukemia (ALL; 48 patients) or chronic myelogenous leukemia in lymphoid blast crisis (LyBC; 8 patients). Imatinib was given once daily at 400 mg or 600 mg. Imatinib induced complete hematologic responses (CHRs) and complete marrow responses (marrow-CRs) in 29% of ALL patients (CHR, 19%; marrow-CR, 10%), which were sustained for at least 4 weeks in 6% of patients. Median estimated time to progression and overall survival for ALL patients were 2.2 and 4.9 months, respectively. CHRs were reported for 3 (38%) of the patients with LyBC (one sustained CHR). Grade 3 or 4 treatment-related nonhematologic toxicity was reported for 9% of patients; none of the patients discontinued therapy because of nonhematologic adverse reactions. Grade 4 neutropenia and thrombocytopenia occurred in 54% and 27% of patients, respectively. Imatinib therapy resulted in a clinically relevant hematologic response rate in relapsed or refractory Ph(+) acute lymphoid leukemia patients, but development of resistance and subsequent disease progression were rapid. Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "51a1889816af46d0bc6c17f5001e75f4", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[65, 67]], "char_spans": [[374, 380]]}]}], "context_tokens": [["The", 0], ["translocation", 4], ["(", 18], ["9;22", 19], [")", 23], ["gives", 25], ["rise", 31], ["to", 36], ["the", 39], ["p190(Bcr", 43], ["-", 51], ["Abl", 52], [")", 55], ["and", 57], ["p210(Bcr", 61], ["-", 69], ["Abl", 70], [")", 73], ["tyrosine", 75], ["kinase", 84], ["proteins", 91], [",", 99], ["considered", 101], ["sufficient", 112], ["for", 123], ["leukemic", 127], ["transformation", 136], [".", 150], ["Philadelphia", 152], ["-", 164], ["positive", 165], ["(", 174], ["Ph(+", 175], [")", 179], [")", 180], ["acute", 182], ["leukemia", 188], ["patients", 197], ["failing", 206], ["to", 214], ["respond", 217], ["to", 225], ["initial", 228], ["induction", 236], ["therapy", 246], ["have", 254], ["a", 259], ["poor", 261], ["prognosis", 266], ["with", 276], ["few", 281], ["effective", 285], ["treatment", 295], ["options", 305], [".", 312], ["Imatinib", 314], ["is", 323], ["an", 326], ["orally", 329], ["administered", 336], [",", 348], ["potent", 350], ["inhibitor", 357], ["of", 367], ["the", 370], ["Bcr", 374], ["-", 377], ["Abl", 378], ["tyrosine", 382], ["kinase", 391], [".", 397], ["We", 399], ["conducted", 402], ["a", 412], ["clinical", 414], ["trial", 423], ["in", 429], ["56", 432], ["patients", 435], ["with", 444], ["relapsed", 449], ["or", 458], ["refractory", 461], ["Ph(+", 472], [")", 476], ["acute", 478], ["lymphoblastic", 484], ["leukemia", 498], ["(", 507], ["ALL", 508], [";", 511], ["48", 513], ["patients", 516], [")", 524], ["or", 526], ["chronic", 529], ["myelogenous", 537], ["leukemia", 549], ["in", 558], ["lymphoid", 561], ["blast", 570], ["crisis", 576], ["(", 583], ["LyBC", 584], [";", 588], ["8", 590], ["patients", 592], [")", 600], [".", 601], ["Imatinib", 603], ["was", 612], ["given", 616], ["once", 622], ["daily", 627], ["at", 633], ["400", 636], ["mg", 640], ["or", 643], ["600", 646], ["mg", 650], [".", 652], ["Imatinib", 654], ["induced", 663], ["complete", 671], ["hematologic", 680], ["responses", 692], ["(", 702], ["CHRs", 703], [")", 707], ["and", 709], ["complete", 713], ["marrow", 722], ["responses", 729], ["(", 739], ["marrow", 740], ["-", 746], ["CRs", 747], [")", 750], ["in", 752], ["29", 755], ["%", 757], ["of", 759], ["ALL", 762], ["patients", 766], ["(", 775], ["CHR", 776], [",", 779], ["19", 781], ["%", 783], [";", 784], ["marrow", 786], ["-", 792], ["CR", 793], [",", 795], ["10", 797], ["%", 799], [")", 800], [",", 801], ["which", 803], ["were", 809], ["sustained", 814], ["for", 824], ["at", 828], ["least", 831], ["4", 837], ["weeks", 839], ["in", 845], ["6", 848], ["%", 849], ["of", 851], ["patients", 854], [".", 862], ["Median", 864], ["estimated", 871], ["time", 881], ["to", 886], ["progression", 889], ["and", 901], ["overall", 905], ["survival", 913], ["for", 922], ["ALL", 926], ["patients", 930], ["were", 939], ["2.2", 944], ["and", 948], ["4.9", 952], ["months", 956], [",", 962], ["respectively", 964], [".", 976], ["CHRs", 978], ["were", 983], ["reported", 988], ["for", 997], ["3", 1001], ["(", 1003], ["38", 1004], ["%", 1006], [")", 1007], ["of", 1009], ["the", 1012], ["patients", 1016], ["with", 1025], ["LyBC", 1030], ["(", 1035], ["one", 1036], ["sustained", 1040], ["CHR", 1050], [")", 1053], [".", 1054], ["Grade", 1056], ["3", 1062], ["or", 1064], ["4", 1067], ["treatment", 1069], ["-", 1078], ["related", 1079], ["nonhematologic", 1087], ["toxicity", 1102], ["was", 1111], ["reported", 1115], ["for", 1124], ["9", 1128], ["%", 1129], ["of", 1131], ["patients", 1134], [";", 1142], ["none", 1144], ["of", 1149], ["the", 1152], ["patients", 1156], ["discontinued", 1165], ["therapy", 1178], ["because", 1186], ["of", 1194], ["nonhematologic", 1197], ["adverse", 1212], ["reactions", 1220], [".", 1229], ["Grade", 1231], ["4", 1237], ["neutropenia", 1239], ["and", 1251], ["thrombocytopenia", 1255], ["occurred", 1272], ["in", 1281], ["54", 1284], ["%", 1286], ["and", 1288], ["27", 1292], ["%", 1294], ["of", 1296], ["patients", 1299], [",", 1307], ["respectively", 1309], [".", 1321], ["Imatinib", 1323], ["therapy", 1332], ["resulted", 1340], ["in", 1349], ["a", 1352], ["clinically", 1354], ["relevant", 1365], ["hematologic", 1374], ["response", 1386], ["rate", 1395], ["in", 1400], ["relapsed", 1403], ["or", 1412], ["refractory", 1415], ["Ph(+", 1426], [")", 1430], ["acute", 1432], ["lymphoid", 1438], ["leukemia", 1447], ["patients", 1456], [",", 1464], ["but", 1466], ["development", 1470], ["of", 1482], ["resistance", 1485], ["and", 1496], ["subsequent", 1500], ["disease", 1511], ["progression", 1519], ["were", 1531], ["rapid", 1536], [".", 1541], ["Further", 1543], ["studies", 1551], ["are", 1559], ["warranted", 1563], ["to", 1573], ["test", 1576], ["the", 1581], ["effects", 1585], ["of", 1593], ["imatinib", 1596], ["in", 1605], ["combination", 1608], ["with", 1620], ["other", 1625], ["agents", 1631], ["and", 1638], ["to", 1642], ["define", 1645], ["the", 1652], ["mechanisms", 1656], ["of", 1667], ["resistance", 1670], ["to", 1681], ["imatinib", 1684], [".", 1692]]}
{"context": "We investigated the expression of Na(+)/Ca(2+) exchanger (NCX) and the functional role of NCX in retinal damage by using NCX1-heterozygous deficient mice (NCX1(+/-)) and SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy] phenoxy]-5-ethoxyaniline), a selective NCX inhibitor in vivo. We also examined the role of NCX in oxygen-glucose deprivation (OGD) stress with a retinal ganglion cell line (RGC-5) cell culture in vitro. The expression of NCX1 was confirmed and entirely localized in retina by immunoblotting and immunohistochemistry, respectively. NCX1(+/-) mice possessed significant protection against retinal damage induced by intravitreal injection of N-methyl-D-aspartate (NMDA). SEA0400 at 3 and 10 mg/kg significantly reduced NMDA- or high intraocular pressure-induced retinal cell damage in mice. Furthermore, SEA0400 reduced the number of TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling)-positive cells and the expression of phosphorylated mitogen-activated protein kinases (ERK1/2, JNK, p38) induced by NMDA injection. In RGC-5, SEA0400 at 0.3 and 1 microM significantly inhibited OGD-induced cell damage. OGD-induced cell damage was aggravated by ouabain (a Na(+),K(+)-ATPase inhibitor) at 100 microM, and this increased damage was significantly reduced by SEA0400 at 1 microM. In conclusion, these results suggest that NCX1 may play a role in retinal cell death induced by NMDA and ischemia-reperfusion.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "251f6ff810384420b6df79a29f772ff0", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[5, 8]], "char_spans": [[34, 55]]}, {"text": "NCX", "token_spans": [[40, 40], [17, 17], [51, 51], [10, 10]], "char_spans": [[253, 255], [90, 92], [305, 307], [58, 60]]}]}], "context_tokens": [["We", 0], ["investigated", 3], ["the", 16], ["expression", 20], ["of", 31], ["Na(+)/Ca(2", 34], ["+", 44], [")", 45], ["exchanger", 47], ["(", 57], ["NCX", 58], [")", 61], ["and", 63], ["the", 67], ["functional", 71], ["role", 82], ["of", 87], ["NCX", 90], ["in", 94], ["retinal", 97], ["damage", 105], ["by", 112], ["using", 115], ["NCX1-heterozygous", 121], ["deficient", 139], ["mice", 149], ["(", 154], ["NCX1(+/-", 155], [")", 163], [")", 164], ["and", 166], ["SEA0400", 170], ["(", 178], ["2-[4-[(2,5-difluorophenyl)methoxy", 179], ["]", 212], ["phenoxy]-5-ethoxyaniline", 214], [")", 238], [",", 239], ["a", 241], ["selective", 243], ["NCX", 253], ["inhibitor", 257], ["in", 267], ["vivo", 270], [".", 274], ["We", 276], ["also", 279], ["examined", 284], ["the", 293], ["role", 297], ["of", 302], ["NCX", 305], ["in", 309], ["oxygen", 312], ["-", 318], ["glucose", 319], ["deprivation", 327], ["(", 339], ["OGD", 340], [")", 343], ["stress", 345], ["with", 352], ["a", 357], ["retinal", 359], ["ganglion", 367], ["cell", 376], ["line", 381], ["(", 386], ["RGC-5", 387], [")", 392], ["cell", 394], ["culture", 399], ["in", 407], ["vitro", 410], [".", 415], ["The", 417], ["expression", 421], ["of", 432], ["NCX1", 435], ["was", 440], ["confirmed", 444], ["and", 454], ["entirely", 458], ["localized", 467], ["in", 477], ["retina", 480], ["by", 487], ["immunoblotting", 490], ["and", 505], ["immunohistochemistry", 509], [",", 529], ["respectively", 531], [".", 543], ["NCX1(+/-", 545], [")", 553], ["mice", 555], ["possessed", 560], ["significant", 570], ["protection", 582], ["against", 593], ["retinal", 601], ["damage", 609], ["induced", 616], ["by", 624], ["intravitreal", 627], ["injection", 640], ["of", 650], ["N", 653], ["-", 654], ["methyl", 655], ["-", 661], ["D", 662], ["-", 663], ["aspartate", 664], ["(", 674], ["NMDA", 675], [")", 679], [".", 680], ["SEA0400", 682], ["at", 690], ["3", 693], ["and", 695], ["10", 699], ["mg", 702], ["/", 704], ["kg", 705], ["significantly", 708], ["reduced", 722], ["NMDA-", 730], ["or", 736], ["high", 739], ["intraocular", 744], ["pressure", 756], ["-", 764], ["induced", 765], ["retinal", 773], ["cell", 781], ["damage", 786], ["in", 793], ["mice", 796], [".", 800], ["Furthermore", 802], [",", 813], ["SEA0400", 815], ["reduced", 823], ["the", 831], ["number", 835], ["of", 842], ["TUNEL", 845], ["(", 851], ["terminal", 852], ["deoxynucleotidyl", 861], ["transferase", 878], ["dUTP", 890], ["nick", 895], ["-", 899], ["end", 900], ["labeling)-positive", 904], ["cells", 923], ["and", 929], ["the", 933], ["expression", 937], ["of", 948], ["phosphorylated", 951], ["mitogen", 966], ["-", 973], ["activated", 974], ["protein", 984], ["kinases", 992], ["(", 1000], ["ERK1/2", 1001], [",", 1007], ["JNK", 1009], [",", 1012], ["p38", 1014], [")", 1017], ["induced", 1019], ["by", 1027], ["NMDA", 1030], ["injection", 1035], [".", 1044], ["In", 1046], ["RGC-5", 1049], [",", 1054], ["SEA0400", 1056], ["at", 1064], ["0.3", 1067], ["and", 1071], ["1", 1075], ["microM", 1077], ["significantly", 1084], ["inhibited", 1098], ["OGD", 1108], ["-", 1111], ["induced", 1112], ["cell", 1120], ["damage", 1125], [".", 1131], ["OGD", 1133], ["-", 1136], ["induced", 1137], ["cell", 1145], ["damage", 1150], ["was", 1157], ["aggravated", 1161], ["by", 1172], ["ouabain", 1175], ["(", 1183], ["a", 1184], ["Na(+),K(+)-ATPase", 1186], ["inhibitor", 1204], [")", 1213], ["at", 1215], ["100", 1218], ["microM", 1222], [",", 1228], ["and", 1230], ["this", 1234], ["increased", 1239], ["damage", 1249], ["was", 1256], ["significantly", 1260], ["reduced", 1274], ["by", 1282], ["SEA0400", 1285], ["at", 1293], ["1", 1296], ["microM.", 1298], ["In", 1306], ["conclusion", 1309], [",", 1319], ["these", 1321], ["results", 1327], ["suggest", 1335], ["that", 1343], ["NCX1", 1348], ["may", 1353], ["play", 1357], ["a", 1362], ["role", 1364], ["in", 1369], ["retinal", 1372], ["cell", 1380], ["death", 1385], ["induced", 1391], ["by", 1399], ["NMDA", 1402], ["and", 1407], ["ischemia", 1411], ["-", 1419], ["reperfusion", 1420], [".", 1431]]}
{"context": "Methicillin-resistant Staphylococcus aureus (MRSA) infections pose a major challenge in health care, yet the limited heterogeneity within this group hinders molecular investigations of related outbreaks. Pulsed-field gel electrophoresis (PFGE) has been the gold standard approach but is impractical for many clinical laboratories and is often replaced with PCR-based methods. Regardless, both approaches can prove problematic for identifying subclonal outbreaks. Here, we explore the use of whole-genome sequencing for clinical laboratory investigations of MRSA molecular epidemiology. We examine the relationships of 44 MRSA isolates collected over a period of 3 years by using whole-genome sequencing and two PCR-based methods, multilocus variable-number tandem-repeat analysis (MLVA) and spa typing. We find that MLVA offers higher resolution than spa typing, as it resolved 17 versus 12 discrete isolate groups, respectively. In contrast, whole-genome sequencing reproducibly cataloged genomic variants (131,424 different single nucleotide polymorphisms and indels across the strain collection) that uniquely identified each MRSA clone, recapitulating those groups but enabling higher-resolution phylogenetic inferences of the epidemiological relationships. Importantly, whole-genome sequencing detected a significant number of variants, thereby distinguishing between groups that were considered identical by both spa typing (minimum, 1,124 polymorphisms) and MLVA (minimum, 193 polymorphisms); this suggests that these more conventional approaches can lead to false-positive identification of outbreaks due to inappropriate grouping of genetically distinct strains. An analysis of the distribution of variants across the MRSA genome reveals 47 mutational hot spots (comprising \u223c 2.5% of the genome) that account for 23.5% of the observed polymorphisms, and the use of this selected data set successfully recapitulates most epidemiological relationships in this pathogen group.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "e9f8a67168b34db5ab3343fb3e9136ae", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[90, 90], [6, 6], [188, 188], [100, 100], [280, 280]], "char_spans": [[557, 560], [45, 48], [1129, 1132], [621, 624], [1727, 1730]]}]}], "context_tokens": [["Methicillin", 0], ["-", 11], ["resistant", 12], ["Staphylococcus", 22], ["aureus", 37], ["(", 44], ["MRSA", 45], [")", 49], ["infections", 51], ["pose", 62], ["a", 67], ["major", 69], ["challenge", 75], ["in", 85], ["health", 88], ["care", 95], [",", 99], ["yet", 101], ["the", 105], ["limited", 109], ["heterogeneity", 117], ["within", 131], ["this", 138], ["group", 143], ["hinders", 149], ["molecular", 157], ["investigations", 167], ["of", 182], ["related", 185], ["outbreaks", 193], [".", 202], ["Pulsed", 204], ["-", 210], ["field", 211], ["gel", 217], ["electrophoresis", 221], ["(", 237], ["PFGE", 238], [")", 242], ["has", 244], ["been", 248], ["the", 253], ["gold", 257], ["standard", 262], ["approach", 271], ["but", 280], ["is", 284], ["impractical", 287], ["for", 299], ["many", 303], ["clinical", 308], ["laboratories", 317], ["and", 330], ["is", 334], ["often", 337], ["replaced", 343], ["with", 352], ["PCR", 357], ["-", 360], ["based", 361], ["methods", 367], [".", 374], ["Regardless", 376], [",", 386], ["both", 388], ["approaches", 393], ["can", 404], ["prove", 408], ["problematic", 414], ["for", 426], ["identifying", 430], ["subclonal", 442], ["outbreaks", 452], [".", 461], ["Here", 463], [",", 467], ["we", 469], ["explore", 472], ["the", 480], ["use", 484], ["of", 488], ["whole", 491], ["-", 496], ["genome", 497], ["sequencing", 504], ["for", 515], ["clinical", 519], ["laboratory", 528], ["investigations", 539], ["of", 554], ["MRSA", 557], ["molecular", 562], ["epidemiology", 572], [".", 584], ["We", 586], ["examine", 589], ["the", 597], ["relationships", 601], ["of", 615], ["44", 618], ["MRSA", 621], ["isolates", 626], ["collected", 635], ["over", 645], ["a", 650], ["period", 652], ["of", 659], ["3", 662], ["years", 664], ["by", 670], ["using", 673], ["whole", 679], ["-", 684], ["genome", 685], ["sequencing", 692], ["and", 703], ["two", 707], ["PCR", 711], ["-", 714], ["based", 715], ["methods", 721], [",", 728], ["multilocus", 730], ["variable", 741], ["-", 749], ["number", 750], ["tandem", 757], ["-", 763], ["repeat", 764], ["analysis", 771], ["(", 780], ["MLVA", 781], [")", 785], ["and", 787], ["spa", 791], ["typing", 795], [".", 801], ["We", 803], ["find", 806], ["that", 811], ["MLVA", 816], ["offers", 821], ["higher", 828], ["resolution", 835], ["than", 846], ["spa", 851], ["typing", 855], [",", 861], ["as", 863], ["it", 866], ["resolved", 869], ["17", 878], ["versus", 881], ["12", 888], ["discrete", 891], ["isolate", 900], ["groups", 908], [",", 914], ["respectively", 916], [".", 928], ["In", 930], ["contrast", 933], [",", 941], ["whole", 943], ["-", 948], ["genome", 949], ["sequencing", 956], ["reproducibly", 967], ["cataloged", 980], ["genomic", 990], ["variants", 998], ["(", 1007], ["131,424", 1008], ["different", 1016], ["single", 1026], ["nucleotide", 1033], ["polymorphisms", 1044], ["and", 1058], ["indels", 1062], ["across", 1069], ["the", 1076], ["strain", 1080], ["collection", 1087], [")", 1097], ["that", 1099], ["uniquely", 1104], ["identified", 1113], ["each", 1124], ["MRSA", 1129], ["clone", 1134], [",", 1139], ["recapitulating", 1141], ["those", 1156], ["groups", 1162], ["but", 1169], ["enabling", 1173], ["higher", 1182], ["-", 1188], ["resolution", 1189], ["phylogenetic", 1200], ["inferences", 1213], ["of", 1224], ["the", 1227], ["epidemiological", 1231], ["relationships", 1247], [".", 1260], ["Importantly", 1262], [",", 1273], ["whole", 1275], ["-", 1280], ["genome", 1281], ["sequencing", 1288], ["detected", 1299], ["a", 1308], ["significant", 1310], ["number", 1322], ["of", 1329], ["variants", 1332], [",", 1340], ["thereby", 1342], ["distinguishing", 1350], ["between", 1365], ["groups", 1373], ["that", 1380], ["were", 1385], ["considered", 1390], ["identical", 1401], ["by", 1411], ["both", 1414], ["spa", 1419], ["typing", 1423], ["(", 1430], ["minimum", 1431], [",", 1438], ["1,124", 1440], ["polymorphisms", 1446], [")", 1459], ["and", 1461], ["MLVA", 1465], ["(", 1470], ["minimum", 1471], [",", 1478], ["193", 1480], ["polymorphisms", 1484], [")", 1497], [";", 1498], ["this", 1500], ["suggests", 1505], ["that", 1514], ["these", 1519], ["more", 1525], ["conventional", 1530], ["approaches", 1543], ["can", 1554], ["lead", 1558], ["to", 1563], ["false", 1566], ["-", 1571], ["positive", 1572], ["identification", 1581], ["of", 1596], ["outbreaks", 1599], ["due", 1609], ["to", 1613], ["inappropriate", 1616], ["grouping", 1630], ["of", 1639], ["genetically", 1642], ["distinct", 1654], ["strains", 1663], [".", 1670], ["An", 1672], ["analysis", 1675], ["of", 1684], ["the", 1687], ["distribution", 1691], ["of", 1704], ["variants", 1707], ["across", 1716], ["the", 1723], ["MRSA", 1727], ["genome", 1732], ["reveals", 1739], ["47", 1747], ["mutational", 1750], ["hot", 1761], ["spots", 1765], ["(", 1771], ["comprising", 1772], ["\u223c", 1783], ["2.5", 1785], ["%", 1788], ["of", 1790], ["the", 1793], ["genome", 1797], [")", 1803], ["that", 1805], ["account", 1810], ["for", 1818], ["23.5", 1822], ["%", 1826], ["of", 1828], ["the", 1831], ["observed", 1835], ["polymorphisms", 1844], [",", 1857], ["and", 1859], ["the", 1863], ["use", 1867], ["of", 1871], ["this", 1874], ["selected", 1879], ["data", 1888], ["set", 1893], ["successfully", 1897], ["recapitulates", 1910], ["most", 1924], ["epidemiological", 1929], ["relationships", 1945], ["in", 1959], ["this", 1962], ["pathogen", 1967], ["group", 1976], [".", 1981]]}
{"context": "The clinical efficacy of different doses of the specific benzodiazepine antagonist flumazenil was studied in a total of 72 patients with benzodiazepine or ethanol overdose. In a randomized double-blind study, 18 patients (group 1) and eight patients (group 2) with suspected benzodiazepine overdose received 5 mg (group 1) or 1 mg (group 2) flumazenil or placebo, respectively. The stage of coma, heart rate, blood pressure and respiratory rate were monitored within the following 15 min. If no change in the stage of coma was observed, 5 mg (group 1) or 1 mg (group 2) flumazenil were given, and the stage of coma, heart rate and blood pressure were again monitored. In a similar way, the effect of 5 and 1 mg flumazenil was investigated in 13 patients (group 3) and four patients (group 4) with ethanol intoxication. In an open trial, the clinical efficacy of flumazenil for the diagnosis of benzodiazepine or ethanol overdose was studied in 29 patients (group 5). In all patients, a toxicological screening confirmed benzodiazepine or ethanol overdose. None of the patients receiving placebo showed effects on stage of coma, heart rate, blood pressure or respiratory rate. Patients with benzodiazepine overdose who received 5 mg flumazenil regained consciousness about 1-2 min after the end of injection. The effect of 1 mg flumazenil (group 2) on benzodiazepine-induced coma was less pronounced. In patients with ethanol overdose (group 3), ethanol-induced coma was reversed after 5 mg flumazenil more slowly than in patients of group 1. No effect of flumazenil on ethanol-induced coma was observed in group 4. In group 5, flumazenil proved to be useful for diagnosing benzodiazepine or ethanol intoxication. In one patient with coma due to carbamazepine overdose, flumazenil was also found to be effective. Additionally, a possible analytical interference of flumazenil and its metabolites with the identification of other benzodiazepines by a toxicological screening procedure was studied. Even after an oral dose of 200 mg flumazenil, no interference with immunological benzodiazepine assays (EMIT, TDX, and RIA) was found. A metabolite and an artifact of flumazenil could be identified in urine by gas chromatography/mass spectrometry.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "09099c4d930143fdb85f846a03675594", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[304, 304], [320, 320], [147, 147], [11, 11], [177, 177], [291, 291], [342, 342], [357, 357], [116, 116], [383, 383], [408, 408], [258, 258], [239, 239], [65, 65]], "char_spans": [[1555, 1564], [1627, 1636], [711, 720], [83, 92], [862, 871], [1490, 1499], [1769, 1778], [1864, 1873], [570, 579], [2030, 2039], [2163, 2172], [1327, 1336], [1232, 1241], [341, 350]]}]}], "context_tokens": [["The", 0], ["clinical", 4], ["efficacy", 13], ["of", 22], ["different", 25], ["doses", 35], ["of", 41], ["the", 44], ["specific", 48], ["benzodiazepine", 57], ["antagonist", 72], ["flumazenil", 83], ["was", 94], ["studied", 98], ["in", 106], ["a", 109], ["total", 111], ["of", 117], ["72", 120], ["patients", 123], ["with", 132], ["benzodiazepine", 137], ["or", 152], ["ethanol", 155], ["overdose", 163], [".", 171], ["In", 173], ["a", 176], ["randomized", 178], ["double", 189], ["-", 195], ["blind", 196], ["study", 202], [",", 207], ["18", 209], ["patients", 212], ["(", 221], ["group", 222], ["1", 228], [")", 229], ["and", 231], ["eight", 235], ["patients", 241], ["(", 250], ["group", 251], ["2", 257], [")", 258], ["with", 260], ["suspected", 265], ["benzodiazepine", 275], ["overdose", 290], ["received", 299], ["5", 308], ["mg", 310], ["(", 313], ["group", 314], ["1", 320], [")", 321], ["or", 323], ["1", 326], ["mg", 328], ["(", 331], ["group", 332], ["2", 338], [")", 339], ["flumazenil", 341], ["or", 352], ["placebo", 355], [",", 362], ["respectively", 364], [".", 376], ["The", 378], ["stage", 382], ["of", 388], ["coma", 391], [",", 395], ["heart", 397], ["rate", 403], [",", 407], ["blood", 409], ["pressure", 415], ["and", 424], ["respiratory", 428], ["rate", 440], ["were", 445], ["monitored", 450], ["within", 460], ["the", 467], ["following", 471], ["15", 481], ["min", 484], [".", 487], ["If", 489], ["no", 492], ["change", 495], ["in", 502], ["the", 505], ["stage", 509], ["of", 515], ["coma", 518], ["was", 523], ["observed", 527], [",", 535], ["5", 537], ["mg", 539], ["(", 542], ["group", 543], ["1", 549], [")", 550], ["or", 552], ["1", 555], ["mg", 557], ["(", 560], ["group", 561], ["2", 567], [")", 568], ["flumazenil", 570], ["were", 581], ["given", 586], [",", 591], ["and", 593], ["the", 597], ["stage", 601], ["of", 607], ["coma", 610], [",", 614], ["heart", 616], ["rate", 622], ["and", 627], ["blood", 631], ["pressure", 637], ["were", 646], ["again", 651], ["monitored", 657], [".", 666], ["In", 668], ["a", 671], ["similar", 673], ["way", 681], [",", 684], ["the", 686], ["effect", 690], ["of", 697], ["5", 700], ["and", 702], ["1", 706], ["mg", 708], ["flumazenil", 711], ["was", 722], ["investigated", 726], ["in", 739], ["13", 742], ["patients", 745], ["(", 754], ["group", 755], ["3", 761], [")", 762], ["and", 764], ["four", 768], ["patients", 773], ["(", 782], ["group", 783], ["4", 789], [")", 790], ["with", 792], ["ethanol", 797], ["intoxication", 805], [".", 817], ["In", 819], ["an", 822], ["open", 825], ["trial", 830], [",", 835], ["the", 837], ["clinical", 841], ["efficacy", 850], ["of", 859], ["flumazenil", 862], ["for", 873], ["the", 877], ["diagnosis", 881], ["of", 891], ["benzodiazepine", 894], ["or", 909], ["ethanol", 912], ["overdose", 920], ["was", 929], ["studied", 933], ["in", 941], ["29", 944], ["patients", 947], ["(", 956], ["group", 957], ["5", 963], [")", 964], [".", 965], ["In", 967], ["all", 970], ["patients", 974], [",", 982], ["a", 984], ["toxicological", 986], ["screening", 1000], ["confirmed", 1010], ["benzodiazepine", 1020], ["or", 1035], ["ethanol", 1038], ["overdose", 1046], [".", 1054], ["None", 1056], ["of", 1061], ["the", 1064], ["patients", 1068], ["receiving", 1077], ["placebo", 1087], ["showed", 1095], ["effects", 1102], ["on", 1110], ["stage", 1113], ["of", 1119], ["coma", 1122], [",", 1126], ["heart", 1128], ["rate", 1134], [",", 1138], ["blood", 1140], ["pressure", 1146], ["or", 1155], ["respiratory", 1158], ["rate", 1170], [".", 1174], ["Patients", 1176], ["with", 1185], ["benzodiazepine", 1190], ["overdose", 1205], ["who", 1214], ["received", 1218], ["5", 1227], ["mg", 1229], ["flumazenil", 1232], ["regained", 1243], ["consciousness", 1252], ["about", 1266], ["1", 1272], ["-", 1273], ["2", 1274], ["min", 1276], ["after", 1280], ["the", 1286], ["end", 1290], ["of", 1294], ["injection", 1297], [".", 1306], ["The", 1308], ["effect", 1312], ["of", 1319], ["1", 1322], ["mg", 1324], ["flumazenil", 1327], ["(", 1338], ["group", 1339], ["2", 1345], [")", 1346], ["on", 1348], ["benzodiazepine", 1351], ["-", 1365], ["induced", 1366], ["coma", 1374], ["was", 1379], ["less", 1383], ["pronounced", 1388], [".", 1398], ["In", 1400], ["patients", 1403], ["with", 1412], ["ethanol", 1417], ["overdose", 1425], ["(", 1434], ["group", 1435], ["3", 1441], [")", 1442], [",", 1443], ["ethanol", 1445], ["-", 1452], ["induced", 1453], ["coma", 1461], ["was", 1466], ["reversed", 1470], ["after", 1479], ["5", 1485], ["mg", 1487], ["flumazenil", 1490], ["more", 1501], ["slowly", 1506], ["than", 1513], ["in", 1518], ["patients", 1521], ["of", 1530], ["group", 1533], ["1", 1539], [".", 1540], ["No", 1542], ["effect", 1545], ["of", 1552], ["flumazenil", 1555], ["on", 1566], ["ethanol", 1569], ["-", 1576], ["induced", 1577], ["coma", 1585], ["was", 1590], ["observed", 1594], ["in", 1603], ["group", 1606], ["4", 1612], [".", 1613], ["In", 1615], ["group", 1618], ["5", 1624], [",", 1625], ["flumazenil", 1627], ["proved", 1638], ["to", 1645], ["be", 1648], ["useful", 1651], ["for", 1658], ["diagnosing", 1662], ["benzodiazepine", 1673], ["or", 1688], ["ethanol", 1691], ["intoxication", 1699], [".", 1711], ["In", 1713], ["one", 1716], ["patient", 1720], ["with", 1728], ["coma", 1733], ["due", 1738], ["to", 1742], ["carbamazepine", 1745], ["overdose", 1759], [",", 1767], ["flumazenil", 1769], ["was", 1780], ["also", 1784], ["found", 1789], ["to", 1795], ["be", 1798], ["effective", 1801], [".", 1810], ["Additionally", 1812], [",", 1824], ["a", 1826], ["possible", 1828], ["analytical", 1837], ["interference", 1848], ["of", 1861], ["flumazenil", 1864], ["and", 1875], ["its", 1879], ["metabolites", 1883], ["with", 1895], ["the", 1900], ["identification", 1904], ["of", 1919], ["other", 1922], ["benzodiazepines", 1928], ["by", 1944], ["a", 1947], ["toxicological", 1949], ["screening", 1963], ["procedure", 1973], ["was", 1983], ["studied", 1987], [".", 1994], ["Even", 1996], ["after", 2001], ["an", 2007], ["oral", 2010], ["dose", 2015], ["of", 2020], ["200", 2023], ["mg", 2027], ["flumazenil", 2030], [",", 2040], ["no", 2042], ["interference", 2045], ["with", 2058], ["immunological", 2063], ["benzodiazepine", 2077], ["assays", 2092], ["(", 2099], ["EMIT", 2100], [",", 2104], ["TDX", 2106], [",", 2109], ["and", 2111], ["RIA", 2115], [")", 2118], ["was", 2120], ["found", 2124], [".", 2129], ["A", 2131], ["metabolite", 2133], ["and", 2144], ["an", 2148], ["artifact", 2151], ["of", 2160], ["flumazenil", 2163], ["could", 2174], ["be", 2180], ["identified", 2183], ["in", 2194], ["urine", 2197], ["by", 2203], ["gas", 2206], ["chromatography", 2210], ["/", 2224], ["mass", 2225], ["spectrometry", 2230], [".", 2242]]}
{"context": "Missense mutations in ubiquilin 2 (UBQLN2) cause ALS with frontotemporal dementia (ALS-FTD). Animal models of ALS are useful for understanding the mechanisms of pathogenesis and for preclinical investigations. However, previous rodent models carrying UBQLN2 mutations failed to manifest any sign of motor neuron disease. Here, we show that lines of mice expressing either the ALS-FTD-linked P497S or P506T UBQLN2 mutations have cognitive deficits, shortened lifespans, and develop motor neuron disease, mimicking the human disease. Neuropathologic analysis of the mice with end-stage disease revealed the accumulation of ubiquitinated inclusions in the brain and spinal cord, astrocytosis, a reduction in the number of hippocampal neurons, and reduced staining of TAR-DNA binding protein 43 in the nucleus, with concomitant formation of ubiquitin", "qas": [{"question": "Which human disease is associated with mutated UBQLN2", "answers": ["ALS", "amyotrophic lateral sclerosis"], "qid": "020cf00b943b468f9e50ce04bee47b9f", "question_tokens": [["Which", 0], ["human", 6], ["disease", 12], ["is", 20], ["associated", 23], ["with", 34], ["mutated", 39], ["UBQLN2", 47]], "detected_answers": [{"text": "ALS", "token_spans": [[65, 65], [22, 22], [9, 9], [14, 14]], "char_spans": [[376, 378], [110, 112], [49, 51], [83, 85]]}]}], "context_tokens": [["Missense", 0], ["mutations", 9], ["in", 19], ["ubiquilin", 22], ["2", 32], ["(", 34], ["UBQLN2", 35], [")", 41], ["cause", 43], ["ALS", 49], ["with", 53], ["frontotemporal", 58], ["dementia", 73], ["(", 82], ["ALS", 83], ["-", 86], ["FTD", 87], [")", 90], [".", 91], ["Animal", 93], ["models", 100], ["of", 107], ["ALS", 110], ["are", 114], ["useful", 118], ["for", 125], ["understanding", 129], ["the", 143], ["mechanisms", 147], ["of", 158], ["pathogenesis", 161], ["and", 174], ["for", 178], ["preclinical", 182], ["investigations", 194], [".", 208], ["However", 210], [",", 217], ["previous", 219], ["rodent", 228], ["models", 235], ["carrying", 242], ["UBQLN2", 251], ["mutations", 258], ["failed", 268], ["to", 275], ["manifest", 278], ["any", 287], ["sign", 291], ["of", 296], ["motor", 299], ["neuron", 305], ["disease", 312], [".", 319], ["Here", 321], [",", 325], ["we", 327], ["show", 330], ["that", 335], ["lines", 340], ["of", 346], ["mice", 349], ["expressing", 354], ["either", 365], ["the", 372], ["ALS", 376], ["-", 379], ["FTD", 380], ["-", 383], ["linked", 384], ["P497S", 391], ["or", 397], ["P506", 400], ["T", 404], ["UBQLN2", 406], ["mutations", 413], ["have", 423], ["cognitive", 428], ["deficits", 438], [",", 446], ["shortened", 448], ["lifespans", 458], [",", 467], ["and", 469], ["develop", 473], ["motor", 481], ["neuron", 487], ["disease", 494], [",", 501], ["mimicking", 503], ["the", 513], ["human", 517], ["disease", 523], [".", 530], ["Neuropathologic", 532], ["analysis", 548], ["of", 557], ["the", 560], ["mice", 564], ["with", 569], ["end", 574], ["-", 577], ["stage", 578], ["disease", 584], ["revealed", 592], ["the", 601], ["accumulation", 605], ["of", 618], ["ubiquitinated", 621], ["inclusions", 635], ["in", 646], ["the", 649], ["brain", 653], ["and", 659], ["spinal", 663], ["cord", 670], [",", 674], ["astrocytosis", 676], [",", 688], ["a", 690], ["reduction", 692], ["in", 702], ["the", 705], ["number", 709], ["of", 716], ["hippocampal", 719], ["neurons", 731], [",", 738], ["and", 740], ["reduced", 744], ["staining", 752], ["of", 761], ["TAR", 764], ["-", 767], ["DNA", 768], ["binding", 772], ["protein", 780], ["43", 788], ["in", 791], ["the", 794], ["nucleus", 798], [",", 805], ["with", 807], ["concomitant", 812], ["formation", 824], ["of", 834], ["ubiquitin", 837]]}
{"context": "Willis-Ekbom disease/restless legs syndrome (WED/RLS) is the most common sleep-related movement disorder in pregnancy. We designed a prospective longitudinal study to investigate the correlates of WED/RLS during and after pregnancy. A total of 138 pregnant women with WED/RLS and a control group of 251 age-matched pregnant women were enrolled prospectively. A questionnaire was administered during a face-to-face interview at first evaluation during pregnancy and three months after delivery. Among all women in the first trimester, 15.6% were diagnosed with WED/RLS, whereas 32.8% of those in the second trimester and 38.8% of those in the third trimester were diagnosed with WED/RLS (p\u2009=\u20090.032). In regression analysis, later gestational age [p\u2009<\u20090.001; odds ratio (OR) 1.054] and previous history of WED/RLS (p\u2009=\u20090.001; OR 2.795) were positively correlated with the presence of WED/RLS, while ferritin levels (p\u2009=\u20090.001; OR 0.956) were negatively correlated with the presence of WED/RLS. Ferritin levels were also negatively correlated with the International RLS Study Group severity index (p\u2009=\u20090.041). Forty-eight patients (34.8%) experienced WED/RLS symptomatology after delivery. The ferritin levels were lower, and the mean number of pregnancies was higher, in women with residual WED/RLS (p\u2009=\u20090.008). Our survey showed that WED/RLS was more common in the second and third trimesters. Emergence of WED/RLS during the second trimester was strongly associated with residual WED/RLS. Lower ferritin levels were associated with both WED/RLS in pregnancy and residual WED/RLS after delivery. A higher number of pregnancies were also associated with a greater likelihood of having residual WED/RLS after delivery.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "c13bddb9e37b47c69428caa895cea7ae", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[5, 7]], "char_spans": [[21, 42]]}]}], "context_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["/", 20], ["restless", 21], ["legs", 30], ["syndrome", 35], ["(", 44], ["WED", 45], ["/", 48], ["RLS", 49], [")", 52], ["is", 54], ["the", 57], ["most", 61], ["common", 66], ["sleep", 73], ["-", 78], ["related", 79], ["movement", 87], ["disorder", 96], ["in", 105], ["pregnancy", 108], [".", 117], ["We", 119], ["designed", 122], ["a", 131], ["prospective", 133], ["longitudinal", 145], ["study", 158], ["to", 164], ["investigate", 167], ["the", 179], ["correlates", 183], ["of", 194], ["WED", 197], ["/", 200], ["RLS", 201], ["during", 205], ["and", 212], ["after", 216], ["pregnancy", 222], [".", 231], ["A", 233], ["total", 235], ["of", 241], ["138", 244], ["pregnant", 248], ["women", 257], ["with", 263], ["WED", 268], ["/", 271], ["RLS", 272], ["and", 276], ["a", 280], ["control", 282], ["group", 290], ["of", 296], ["251", 299], ["age", 303], ["-", 306], ["matched", 307], ["pregnant", 315], ["women", 324], ["were", 330], ["enrolled", 335], ["prospectively", 344], [".", 357], ["A", 359], ["questionnaire", 361], ["was", 375], ["administered", 379], ["during", 392], ["a", 399], ["face", 401], ["-", 405], ["to", 406], ["-", 408], ["face", 409], ["interview", 414], ["at", 424], ["first", 427], ["evaluation", 433], ["during", 444], ["pregnancy", 451], ["and", 461], ["three", 465], ["months", 471], ["after", 478], ["delivery", 484], [".", 492], ["Among", 494], ["all", 500], ["women", 504], ["in", 510], ["the", 513], ["first", 517], ["trimester", 523], [",", 532], ["15.6", 534], ["%", 538], ["were", 540], ["diagnosed", 545], ["with", 555], ["WED", 560], ["/", 563], ["RLS", 564], [",", 567], ["whereas", 569], ["32.8", 577], ["%", 581], ["of", 583], ["those", 586], ["in", 592], ["the", 595], ["second", 599], ["trimester", 606], ["and", 616], ["38.8", 620], ["%", 624], ["of", 626], ["those", 629], ["in", 635], ["the", 638], ["third", 642], ["trimester", 648], ["were", 658], ["diagnosed", 663], ["with", 673], ["WED", 678], ["/", 681], ["RLS", 682], ["(", 686], ["p", 687], ["=", 689], ["0.032", 691], [")", 696], [".", 697], ["In", 699], ["regression", 702], ["analysis", 713], [",", 721], ["later", 723], ["gestational", 729], ["age", 741], ["[", 745], ["p", 746], ["<", 748], ["0.001", 750], [";", 755], ["odds", 757], ["ratio", 762], ["(", 768], ["OR", 769], [")", 771], ["1.054", 773], ["]", 778], ["and", 780], ["previous", 784], ["history", 793], ["of", 801], ["WED", 804], ["/", 807], ["RLS", 808], ["(", 812], ["p", 813], ["=", 815], ["0.001", 817], [";", 822], ["OR", 824], ["2.795", 827], [")", 832], ["were", 834], ["positively", 839], ["correlated", 850], ["with", 861], ["the", 866], ["presence", 870], ["of", 879], ["WED", 882], ["/", 885], ["RLS", 886], [",", 889], ["while", 891], ["ferritin", 897], ["levels", 906], ["(", 913], ["p", 914], ["=", 916], ["0.001", 918], [";", 923], ["OR", 925], ["0.956", 928], [")", 933], ["were", 935], ["negatively", 940], ["correlated", 951], ["with", 962], ["the", 967], ["presence", 971], ["of", 980], ["WED", 983], ["/", 986], ["RLS", 987], [".", 990], ["Ferritin", 992], ["levels", 1001], ["were", 1008], ["also", 1013], ["negatively", 1018], ["correlated", 1029], ["with", 1040], ["the", 1045], ["International", 1049], ["RLS", 1063], ["Study", 1067], ["Group", 1073], ["severity", 1079], ["index", 1088], ["(", 1094], ["p", 1095], ["=", 1097], ["0.041", 1099], [")", 1104], [".", 1105], ["Forty", 1107], ["-", 1112], ["eight", 1113], ["patients", 1119], ["(", 1128], ["34.8", 1129], ["%", 1133], [")", 1134], ["experienced", 1136], ["WED", 1148], ["/", 1151], ["RLS", 1152], ["symptomatology", 1156], ["after", 1171], ["delivery", 1177], [".", 1185], ["The", 1187], ["ferritin", 1191], ["levels", 1200], ["were", 1207], ["lower", 1212], [",", 1217], ["and", 1219], ["the", 1223], ["mean", 1227], ["number", 1232], ["of", 1239], ["pregnancies", 1242], ["was", 1254], ["higher", 1258], [",", 1264], ["in", 1266], ["women", 1269], ["with", 1275], ["residual", 1280], ["WED", 1289], ["/", 1292], ["RLS", 1293], ["(", 1297], ["p", 1298], ["=", 1300], ["0.008", 1302], [")", 1307], [".", 1308], ["Our", 1310], ["survey", 1314], ["showed", 1321], ["that", 1328], ["WED", 1333], ["/", 1336], ["RLS", 1337], ["was", 1341], ["more", 1345], ["common", 1350], ["in", 1357], ["the", 1360], ["second", 1364], ["and", 1371], ["third", 1375], ["trimesters", 1381], [".", 1391], ["Emergence", 1393], ["of", 1403], ["WED", 1406], ["/", 1409], ["RLS", 1410], ["during", 1414], ["the", 1421], ["second", 1425], ["trimester", 1432], ["was", 1442], ["strongly", 1446], ["associated", 1455], ["with", 1466], ["residual", 1471], ["WED", 1480], ["/", 1483], ["RLS", 1484], [".", 1487], ["Lower", 1489], ["ferritin", 1495], ["levels", 1504], ["were", 1511], ["associated", 1516], ["with", 1527], ["both", 1532], ["WED", 1537], ["/", 1540], ["RLS", 1541], ["in", 1545], ["pregnancy", 1548], ["and", 1558], ["residual", 1562], ["WED", 1571], ["/", 1574], ["RLS", 1575], ["after", 1579], ["delivery", 1585], [".", 1593], ["A", 1595], ["higher", 1597], ["number", 1604], ["of", 1611], ["pregnancies", 1614], ["were", 1626], ["also", 1631], ["associated", 1636], ["with", 1647], ["a", 1652], ["greater", 1654], ["likelihood", 1662], ["of", 1673], ["having", 1676], ["residual", 1683], ["WED", 1692], ["/", 1695], ["RLS", 1696], ["after", 1700], ["delivery", 1706], [".", 1714]]}
{"context": "To analyze the relationship between the type I interferon (IFN) signature and clinical response to rituximab in rheumatoid arthritis (RA) patients. Twenty RA patients were treated with rituximab (cohort 1). Clinical response was defined as a decrease in the Disease Activity Score evaluated in 28 joints (DAS28) and as a response according to the European League Against Rheumatism (EULAR) criteria at week 12 and week 24. The presence of an IFN signature was analyzed in peripheral blood mononuclear cells by measuring the expression levels of 3 IFN response genes by quantitative polymerase chain reaction analysis. After comparison with the findings in healthy controls, patients were classified as having an IFN high or an IFN low signature. The data were confirmed in a second independent cohort (n = 31). Serum IFN\u03b1 bioactivity was analyzed using a reporter assay. In cohort 1, there was a better clinical response to rituximab in the IFN low signature group. Consistent with these findings, patients with an IFN low signature had a significantly greater reduction in the DAS28 and more often achieved a EULAR response at weeks 12 and 24 as compared with the patients with an IFN high signature in cohort 2 versus cohort 1. The pooled data showed a significantly stronger decrease in the DAS28 in IFN low signature patients at weeks 12 and 24 as compared with the IFN high signature group and a more frequent EULAR response at week 12. Accordingly, serum IFN\u03b1 bioactivity at baseline was inversely associated with the clinical response, although this result did not reach statistical significance. The type I IFN signature negatively predicts the clinical response to rituximab treatment in patients with RA. This finding supports the notion that IFN signaling plays a role in the immunopathology of RA.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "0c569438ed394a3b9e7d3c5ed7abd507", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "IFN signature", "token_spans": [[290, 291], [83, 84], [10, 12]], "char_spans": [[1615, 1627], [442, 454], [59, 72]]}]}], "context_tokens": [["To", 0], ["analyze", 3], ["the", 11], ["relationship", 15], ["between", 28], ["the", 36], ["type", 40], ["I", 45], ["interferon", 47], ["(", 58], ["IFN", 59], [")", 62], ["signature", 64], ["and", 74], ["clinical", 78], ["response", 87], ["to", 96], ["rituximab", 99], ["in", 109], ["rheumatoid", 112], ["arthritis", 123], ["(", 133], ["RA", 134], [")", 136], ["patients", 138], [".", 146], ["Twenty", 148], ["RA", 155], ["patients", 158], ["were", 167], ["treated", 172], ["with", 180], ["rituximab", 185], ["(", 195], ["cohort", 196], ["1", 203], [")", 204], [".", 205], ["Clinical", 207], ["response", 216], ["was", 225], ["defined", 229], ["as", 237], ["a", 240], ["decrease", 242], ["in", 251], ["the", 254], ["Disease", 258], ["Activity", 266], ["Score", 275], ["evaluated", 281], ["in", 291], ["28", 294], ["joints", 297], ["(", 304], ["DAS28", 305], [")", 310], ["and", 312], ["as", 316], ["a", 319], ["response", 321], ["according", 330], ["to", 340], ["the", 343], ["European", 347], ["League", 356], ["Against", 363], ["Rheumatism", 371], ["(", 382], ["EULAR", 383], [")", 388], ["criteria", 390], ["at", 399], ["week", 402], ["12", 407], ["and", 410], ["week", 414], ["24", 419], [".", 421], ["The", 423], ["presence", 427], ["of", 436], ["an", 439], ["IFN", 442], ["signature", 446], ["was", 456], ["analyzed", 460], ["in", 469], ["peripheral", 472], ["blood", 483], ["mononuclear", 489], ["cells", 501], ["by", 507], ["measuring", 510], ["the", 520], ["expression", 524], ["levels", 535], ["of", 542], ["3", 545], ["IFN", 547], ["response", 551], ["genes", 560], ["by", 566], ["quantitative", 569], ["polymerase", 582], ["chain", 593], ["reaction", 599], ["analysis", 608], [".", 616], ["After", 618], ["comparison", 624], ["with", 635], ["the", 640], ["findings", 644], ["in", 653], ["healthy", 656], ["controls", 664], [",", 672], ["patients", 674], ["were", 683], ["classified", 688], ["as", 699], ["having", 702], ["an", 709], ["IFN", 712], ["high", 716], ["or", 721], ["an", 724], ["IFN", 727], ["low", 731], ["signature", 735], [".", 744], ["The", 746], ["data", 750], ["were", 755], ["confirmed", 760], ["in", 770], ["a", 773], ["second", 775], ["independent", 782], ["cohort", 794], ["(", 801], ["n", 802], ["=", 804], ["31", 806], [")", 808], [".", 809], ["Serum", 811], ["IFN\u03b1", 817], ["bioactivity", 822], ["was", 834], ["analyzed", 838], ["using", 847], ["a", 853], ["reporter", 855], ["assay", 864], [".", 869], ["In", 871], ["cohort", 874], ["1", 881], [",", 882], ["there", 884], ["was", 890], ["a", 894], ["better", 896], ["clinical", 903], ["response", 912], ["to", 921], ["rituximab", 924], ["in", 934], ["the", 937], ["IFN", 941], ["low", 945], ["signature", 949], ["group", 959], [".", 964], ["Consistent", 966], ["with", 977], ["these", 982], ["findings", 988], [",", 996], ["patients", 998], ["with", 1007], ["an", 1012], ["IFN", 1015], ["low", 1019], ["signature", 1023], ["had", 1033], ["a", 1037], ["significantly", 1039], ["greater", 1053], ["reduction", 1061], ["in", 1071], ["the", 1074], ["DAS28", 1078], ["and", 1084], ["more", 1088], ["often", 1093], ["achieved", 1099], ["a", 1108], ["EULAR", 1110], ["response", 1116], ["at", 1125], ["weeks", 1128], ["12", 1134], ["and", 1137], ["24", 1141], ["as", 1144], ["compared", 1147], ["with", 1156], ["the", 1161], ["patients", 1165], ["with", 1174], ["an", 1179], ["IFN", 1182], ["high", 1186], ["signature", 1191], ["in", 1201], ["cohort", 1204], ["2", 1211], ["versus", 1213], ["cohort", 1220], ["1", 1227], [".", 1228], ["The", 1230], ["pooled", 1234], ["data", 1241], ["showed", 1246], ["a", 1253], ["significantly", 1255], ["stronger", 1269], ["decrease", 1278], ["in", 1287], ["the", 1290], ["DAS28", 1294], ["in", 1300], ["IFN", 1303], ["low", 1307], ["signature", 1311], ["patients", 1321], ["at", 1330], ["weeks", 1333], ["12", 1339], ["and", 1342], ["24", 1346], ["as", 1349], ["compared", 1352], ["with", 1361], ["the", 1366], ["IFN", 1370], ["high", 1374], ["signature", 1379], ["group", 1389], ["and", 1395], ["a", 1399], ["more", 1401], ["frequent", 1406], ["EULAR", 1415], ["response", 1421], ["at", 1430], ["week", 1433], ["12", 1438], [".", 1440], ["Accordingly", 1442], [",", 1453], ["serum", 1455], ["IFN\u03b1", 1461], ["bioactivity", 1466], ["at", 1478], ["baseline", 1481], ["was", 1490], ["inversely", 1494], ["associated", 1504], ["with", 1515], ["the", 1520], ["clinical", 1524], ["response", 1533], [",", 1541], ["although", 1543], ["this", 1552], ["result", 1557], ["did", 1564], ["not", 1568], ["reach", 1572], ["statistical", 1578], ["significance", 1590], [".", 1602], ["The", 1604], ["type", 1608], ["I", 1613], ["IFN", 1615], ["signature", 1619], ["negatively", 1629], ["predicts", 1640], ["the", 1649], ["clinical", 1653], ["response", 1662], ["to", 1671], ["rituximab", 1674], ["treatment", 1684], ["in", 1694], ["patients", 1697], ["with", 1706], ["RA", 1711], [".", 1713], ["This", 1715], ["finding", 1720], ["supports", 1728], ["the", 1737], ["notion", 1741], ["that", 1748], ["IFN", 1753], ["signaling", 1757], ["plays", 1767], ["a", 1773], ["role", 1775], ["in", 1780], ["the", 1783], ["immunopathology", 1787], ["of", 1803], ["RA", 1806], [".", 1808]]}
{"context": "To explore potential therapeutic strategies for interrupting the interleukin-6 (IL-6) signaling pathway, we measured IL-6 expression in ovarian cancer tissues, and evaluated the effects of a monoclonal anti-IL-6 antibody; siltuximab (CNTO 328), on levels of IL-6-induced Stat3 phosphorylation, Stat3 nuclear translocation, and Stat3 downstream antiapoptotic genes. We then looked for enhancing paclitaxel sensitivity in multidrug-resistant ovarian cancer cell lines. Expressions of IL-6 in ovarian cancer patient specimens were assessed by immunohistochemistry. Effects of siltuximab on IL-6-induced activation of Stat3 in an ovarian cancer cell line were determined by Western blot and real-time analysis of Stat3 nucleocytoplasmic translocation. Influence of combination of siltuximab and paclitaxel on tumor growth was evaluated in a xenograft mouse mode in vivo. Metastatic and drug-resistant recurrent tumors have significantly higher IL-6 expression when compared with the matched primary tumors. Siltuximab specifically suppressed IL-6-induced Stat3 phosphorylation and Stat3 nuclear translocation. Treatment with siltuximab significantly decreased the levels of Stat3 downstream proteins such as MCL-1, Bcl-X(L), and survivin. Treatment with siltuximab reduced expression of multiple IL-6-induced genes in these cell lines. Furthermore, siltuximab increased the cytotoxic effects of paclitaxel in a paclitaxel resistant ovarian cancer cell line in vitro, but combination therapy with siltuximab did not have a significant effect on paclitaxel resistant tumor growth in vivo. These results show that siltuximab effectively block the IL-6 signaling pathways and IL-6-induced gene expression. Blockage of IL-6 signaling may provide benefits for the treatment of ovarian cancer.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "7a2e176738494125886c80681e52a70e", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[8, 8]], "char_spans": [[65, 77]]}]}], "context_tokens": [["To", 0], ["explore", 3], ["potential", 11], ["therapeutic", 21], ["strategies", 33], ["for", 44], ["interrupting", 48], ["the", 61], ["interleukin-6", 65], ["(", 79], ["IL-6", 80], [")", 84], ["signaling", 86], ["pathway", 96], [",", 103], ["we", 105], ["measured", 108], ["IL-6", 117], ["expression", 122], ["in", 133], ["ovarian", 136], ["cancer", 144], ["tissues", 151], [",", 158], ["and", 160], ["evaluated", 164], ["the", 174], ["effects", 178], ["of", 186], ["a", 189], ["monoclonal", 191], ["anti", 202], ["-", 206], ["IL-6", 207], ["antibody", 212], [";", 220], ["siltuximab", 222], ["(", 233], ["CNTO", 234], ["328", 239], [")", 242], [",", 243], ["on", 245], ["levels", 248], ["of", 255], ["IL-6-induced", 258], ["Stat3", 271], ["phosphorylation", 277], [",", 292], ["Stat3", 294], ["nuclear", 300], ["translocation", 308], [",", 321], ["and", 323], ["Stat3", 327], ["downstream", 333], ["antiapoptotic", 344], ["genes", 358], [".", 363], ["We", 365], ["then", 368], ["looked", 373], ["for", 380], ["enhancing", 384], ["paclitaxel", 394], ["sensitivity", 405], ["in", 417], ["multidrug", 420], ["-", 429], ["resistant", 430], ["ovarian", 440], ["cancer", 448], ["cell", 455], ["lines", 460], [".", 465], ["Expressions", 467], ["of", 479], ["IL-6", 482], ["in", 487], ["ovarian", 490], ["cancer", 498], ["patient", 505], ["specimens", 513], ["were", 523], ["assessed", 528], ["by", 537], ["immunohistochemistry", 540], [".", 560], ["Effects", 562], ["of", 570], ["siltuximab", 573], ["on", 584], ["IL-6-induced", 587], ["activation", 600], ["of", 611], ["Stat3", 614], ["in", 620], ["an", 623], ["ovarian", 626], ["cancer", 634], ["cell", 641], ["line", 646], ["were", 651], ["determined", 656], ["by", 667], ["Western", 670], ["blot", 678], ["and", 683], ["real", 687], ["-", 691], ["time", 692], ["analysis", 697], ["of", 706], ["Stat3", 709], ["nucleocytoplasmic", 715], ["translocation", 733], [".", 746], ["Influence", 748], ["of", 758], ["combination", 761], ["of", 773], ["siltuximab", 776], ["and", 787], ["paclitaxel", 791], ["on", 802], ["tumor", 805], ["growth", 811], ["was", 818], ["evaluated", 822], ["in", 832], ["a", 835], ["xenograft", 837], ["mouse", 847], ["mode", 853], ["in", 858], ["vivo", 861], [".", 865], ["Metastatic", 867], ["and", 878], ["drug", 882], ["-", 886], ["resistant", 887], ["recurrent", 897], ["tumors", 907], ["have", 914], ["significantly", 919], ["higher", 933], ["IL-6", 940], ["expression", 945], ["when", 956], ["compared", 961], ["with", 970], ["the", 975], ["matched", 979], ["primary", 987], ["tumors", 995], [".", 1001], ["Siltuximab", 1003], ["specifically", 1014], ["suppressed", 1027], ["IL-6-induced", 1038], ["Stat3", 1051], ["phosphorylation", 1057], ["and", 1073], ["Stat3", 1077], ["nuclear", 1083], ["translocation", 1091], [".", 1104], ["Treatment", 1106], ["with", 1116], ["siltuximab", 1121], ["significantly", 1132], ["decreased", 1146], ["the", 1156], ["levels", 1160], ["of", 1167], ["Stat3", 1170], ["downstream", 1176], ["proteins", 1187], ["such", 1196], ["as", 1201], ["MCL-1", 1204], [",", 1209], ["Bcl", 1211], ["-", 1214], ["X(L", 1215], [")", 1218], [",", 1219], ["and", 1221], ["survivin", 1225], [".", 1233], ["Treatment", 1235], ["with", 1245], ["siltuximab", 1250], ["reduced", 1261], ["expression", 1269], ["of", 1280], ["multiple", 1283], ["IL-6-induced", 1292], ["genes", 1305], ["in", 1311], ["these", 1314], ["cell", 1320], ["lines", 1325], [".", 1330], ["Furthermore", 1332], [",", 1343], ["siltuximab", 1345], ["increased", 1356], ["the", 1366], ["cytotoxic", 1370], ["effects", 1380], ["of", 1388], ["paclitaxel", 1391], ["in", 1402], ["a", 1405], ["paclitaxel", 1407], ["resistant", 1418], ["ovarian", 1428], ["cancer", 1436], ["cell", 1443], ["line", 1448], ["in", 1453], ["vitro", 1456], [",", 1461], ["but", 1463], ["combination", 1467], ["therapy", 1479], ["with", 1487], ["siltuximab", 1492], ["did", 1503], ["not", 1507], ["have", 1511], ["a", 1516], ["significant", 1518], ["effect", 1530], ["on", 1537], ["paclitaxel", 1540], ["resistant", 1551], ["tumor", 1561], ["growth", 1567], ["in", 1574], ["vivo", 1577], [".", 1581], ["These", 1583], ["results", 1589], ["show", 1597], ["that", 1602], ["siltuximab", 1607], ["effectively", 1618], ["block", 1630], ["the", 1636], ["IL-6", 1640], ["signaling", 1645], ["pathways", 1655], ["and", 1664], ["IL-6-induced", 1668], ["gene", 1681], ["expression", 1686], [".", 1696], ["Blockage", 1698], ["of", 1707], ["IL-6", 1710], ["signaling", 1715], ["may", 1725], ["provide", 1729], ["benefits", 1737], ["for", 1746], ["the", 1750], ["treatment", 1754], ["of", 1764], ["ovarian", 1767], ["cancer", 1775], [".", 1781]]}
{"context": "de Quervain's disease is an inadequacy into the first extensor compartment of wrist between the osteofibrous tunnel and the tendons. This mechanical conflict generates a tenosynovitis of the extensor pollicis brevis and the abductor pollicis longus tendons in first dorsal extensor compartment of the wrist. (1) To compare the clinical results obtained by longitudinal and transverse incisions and (2) the implication of clinical results in Indian population. This study was conducted at Kalpana Chawla Government Medical College, Karnal, Haryana. The inclusion criteria were positive Finkelstein's test and no response to non-surgical treatment for 6 weeks. Forty-eight patients with de Quervain's disease who did not respond to conservative treatment were operated with two different incisions. The patients were followed at 6 weeks, 3 and 6 months to compare the surgical outcomes. During a three-month follow-up, a significant difference was shown between the two methods (p = 0.0001). Results of surgical treatment with longitudinal incision were better (only one hypertrophic scar), but there were 12 postoperative complications with transverse incision. Visual analog scale (VAS) was used to evaluate the hypertrophic scar. In transverse incision group, out of five patients, four patients who developed hypertrophic scar have poor score according to VAS. Overall, longitudinal incision should be used for surgical treatment for de Quervain's disease due to lower risk of complications.", "qas": [{"question": "Which disease is diagnosed using the Finkelstein's test?", "answers": ["de Quervain's disease"], "qid": "ec3c96601d8840c58a8302933740c8a2", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["diagnosed", 17], ["using", 27], ["the", 33], ["Finkelstein", 37], ["'s", 48], ["test", 51], ["?", 55]], "detected_answers": [{"text": "de Quervain's disease", "token_spans": [[0, 3], [249, 252], [115, 118]], "char_spans": [[0, 20], [1436, 1456], [685, 705]]}]}], "context_tokens": [["de", 0], ["Quervain", 3], ["'s", 11], ["disease", 14], ["is", 22], ["an", 25], ["inadequacy", 28], ["into", 39], ["the", 44], ["first", 48], ["extensor", 54], ["compartment", 63], ["of", 75], ["wrist", 78], ["between", 84], ["the", 92], ["osteofibrous", 96], ["tunnel", 109], ["and", 116], ["the", 120], ["tendons", 124], [".", 131], ["This", 133], ["mechanical", 138], ["conflict", 149], ["generates", 158], ["a", 168], ["tenosynovitis", 170], ["of", 184], ["the", 187], ["extensor", 191], ["pollicis", 200], ["brevis", 209], ["and", 216], ["the", 220], ["abductor", 224], ["pollicis", 233], ["longus", 242], ["tendons", 249], ["in", 257], ["first", 260], ["dorsal", 266], ["extensor", 273], ["compartment", 282], ["of", 294], ["the", 297], ["wrist", 301], [".", 306], ["(", 308], ["1", 309], [")", 310], ["To", 312], ["compare", 315], ["the", 323], ["clinical", 327], ["results", 336], ["obtained", 344], ["by", 353], ["longitudinal", 356], ["and", 369], ["transverse", 373], ["incisions", 384], ["and", 394], ["(", 398], ["2", 399], [")", 400], ["the", 402], ["implication", 406], ["of", 418], ["clinical", 421], ["results", 430], ["in", 438], ["Indian", 441], ["population", 448], [".", 458], ["This", 460], ["study", 465], ["was", 471], ["conducted", 475], ["at", 485], ["Kalpana", 488], ["Chawla", 496], ["Government", 503], ["Medical", 514], ["College", 522], [",", 529], ["Karnal", 531], [",", 537], ["Haryana", 539], [".", 546], ["The", 548], ["inclusion", 552], ["criteria", 562], ["were", 571], ["positive", 576], ["Finkelstein", 585], ["'s", 596], ["test", 599], ["and", 604], ["no", 608], ["response", 611], ["to", 620], ["non", 623], ["-", 626], ["surgical", 627], ["treatment", 636], ["for", 646], ["6", 650], ["weeks", 652], [".", 657], ["Forty", 659], ["-", 664], ["eight", 665], ["patients", 671], ["with", 680], ["de", 685], ["Quervain", 688], ["'s", 696], ["disease", 699], ["who", 707], ["did", 711], ["not", 715], ["respond", 719], ["to", 727], ["conservative", 730], ["treatment", 743], ["were", 753], ["operated", 758], ["with", 767], ["two", 772], ["different", 776], ["incisions", 786], [".", 795], ["The", 797], ["patients", 801], ["were", 810], ["followed", 815], ["at", 824], ["6", 827], ["weeks", 829], [",", 834], ["3", 836], ["and", 838], ["6", 842], ["months", 844], ["to", 851], ["compare", 854], ["the", 862], ["surgical", 866], ["outcomes", 875], [".", 883], ["During", 885], ["a", 892], ["three", 894], ["-", 899], ["month", 900], ["follow", 906], ["-", 912], ["up", 913], [",", 915], ["a", 917], ["significant", 919], ["difference", 931], ["was", 942], ["shown", 946], ["between", 952], ["the", 960], ["two", 964], ["methods", 968], ["(", 976], ["p", 977], ["=", 979], ["0.0001", 981], [")", 987], [".", 988], ["Results", 990], ["of", 998], ["surgical", 1001], ["treatment", 1010], ["with", 1020], ["longitudinal", 1025], ["incision", 1038], ["were", 1047], ["better", 1052], ["(", 1059], ["only", 1060], ["one", 1065], ["hypertrophic", 1069], ["scar", 1082], [")", 1086], [",", 1087], ["but", 1089], ["there", 1093], ["were", 1099], ["12", 1104], ["postoperative", 1107], ["complications", 1121], ["with", 1135], ["transverse", 1140], ["incision", 1151], [".", 1159], ["Visual", 1161], ["analog", 1168], ["scale", 1175], ["(", 1181], ["VAS", 1182], [")", 1185], ["was", 1187], ["used", 1191], ["to", 1196], ["evaluate", 1199], ["the", 1208], ["hypertrophic", 1212], ["scar", 1225], [".", 1229], ["In", 1231], ["transverse", 1234], ["incision", 1245], ["group", 1254], [",", 1259], ["out", 1261], ["of", 1265], ["five", 1268], ["patients", 1273], [",", 1281], ["four", 1283], ["patients", 1288], ["who", 1297], ["developed", 1301], ["hypertrophic", 1311], ["scar", 1324], ["have", 1329], ["poor", 1334], ["score", 1339], ["according", 1345], ["to", 1355], ["VAS", 1358], [".", 1361], ["Overall", 1363], [",", 1370], ["longitudinal", 1372], ["incision", 1385], ["should", 1394], ["be", 1401], ["used", 1404], ["for", 1409], ["surgical", 1413], ["treatment", 1422], ["for", 1432], ["de", 1436], ["Quervain", 1439], ["'s", 1447], ["disease", 1450], ["due", 1458], ["to", 1462], ["lower", 1465], ["risk", 1471], ["of", 1476], ["complications", 1479], [".", 1492]]}
{"context": "Histone H3 lysine 4 (K4) methylation is a prevalent mark associated with transcription activation and is mainly catalyzed by the MLL/SET1 family histone methyltransferases. A common feature of the mammalian MLL/SET1 complexes is the presence of three core components (RbBP5, Ash2L and WDR5) and a catalytic subunit containing a SET domain. Unlike most other histone lysine methyltransferases, all four proteins are required for efficient H3 K4 methylation. Despite extensive efforts, mechanisms for how three core components regulate MLL/SET1 methyltransferase activity remain elusive. Here we show that a heterodimer of Ash2L and RbBP5 has intrinsic histone methyltransferase activity. This activity requires the highly conserved SPRY domain of Ash2L and a short peptide of RbBP5. We demonstrate that both Ash2L and the MLL1 SET domain are capable of binding to S-adenosyl-L- [methyl-(3)H] methionine in the MLL1 core complex. Mutations in the MLL1 SET domain that fail to support overall H3 K4 methylation also compromise SAM binding by Ash2L. Taken together, our results show that the Ash2L/RbBP5 heterodimer plays a critical role in the overall catalysis of MLL1 mediated H3 K4 methylation. The results we describe here provide mechanistic insights for unique regulation of the MLL1 methyltransferase activity. It suggests that both Ash2L/RbBP5 and the MLL1 SET domain make direct contacts with the substrates and contribute to the formation of a joint catalytic center. Given the shared core configuration among all MLL/SET1 family HMTs, it will be interesting to test whether the mechanism we describe here can be generalized to other MLL/SET1 family members in the future.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "e1caec128d5f4cb4a20159f0430b80d1", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[140, 141], [59, 60], [166, 167], [236, 237]], "char_spans": [[826, 835], [328, 337], [950, 959], [1362, 1371]]}]}], "context_tokens": [["Histone", 0], ["H3", 8], ["lysine", 11], ["4", 18], ["(", 20], ["K4", 21], [")", 23], ["methylation", 25], ["is", 37], ["a", 40], ["prevalent", 42], ["mark", 52], ["associated", 57], ["with", 68], ["transcription", 73], ["activation", 87], ["and", 98], ["is", 102], ["mainly", 105], ["catalyzed", 112], ["by", 122], ["the", 125], ["MLL", 129], ["/", 132], ["SET1", 133], ["family", 138], ["histone", 145], ["methyltransferases", 153], [".", 171], ["A", 173], ["common", 175], ["feature", 182], ["of", 190], ["the", 193], ["mammalian", 197], ["MLL", 207], ["/", 210], ["SET1", 211], ["complexes", 216], ["is", 226], ["the", 229], ["presence", 233], ["of", 242], ["three", 245], ["core", 251], ["components", 256], ["(", 267], ["RbBP5", 268], [",", 273], ["Ash2L", 275], ["and", 281], ["WDR5", 285], [")", 289], ["and", 291], ["a", 295], ["catalytic", 297], ["subunit", 307], ["containing", 315], ["a", 326], ["SET", 328], ["domain", 332], [".", 338], ["Unlike", 340], ["most", 347], ["other", 352], ["histone", 358], ["lysine", 366], ["methyltransferases", 373], [",", 391], ["all", 393], ["four", 397], ["proteins", 402], ["are", 411], ["required", 415], ["for", 424], ["efficient", 428], ["H3", 438], ["K4", 441], ["methylation", 444], [".", 455], ["Despite", 457], ["extensive", 465], ["efforts", 475], [",", 482], ["mechanisms", 484], ["for", 495], ["how", 499], ["three", 503], ["core", 509], ["components", 514], ["regulate", 525], ["MLL", 534], ["/", 537], ["SET1", 538], ["methyltransferase", 543], ["activity", 561], ["remain", 570], ["elusive", 577], [".", 584], ["Here", 586], ["we", 591], ["show", 594], ["that", 599], ["a", 604], ["heterodimer", 606], ["of", 618], ["Ash2L", 621], ["and", 627], ["RbBP5", 631], ["has", 637], ["intrinsic", 641], ["histone", 651], ["methyltransferase", 659], ["activity", 677], [".", 685], ["This", 687], ["activity", 692], ["requires", 701], ["the", 710], ["highly", 714], ["conserved", 721], ["SPRY", 731], ["domain", 736], ["of", 743], ["Ash2L", 746], ["and", 752], ["a", 756], ["short", 758], ["peptide", 764], ["of", 772], ["RbBP5", 775], [".", 780], ["We", 782], ["demonstrate", 785], ["that", 797], ["both", 802], ["Ash2L", 807], ["and", 813], ["the", 817], ["MLL1", 821], ["SET", 826], ["domain", 830], ["are", 837], ["capable", 841], ["of", 849], ["binding", 852], ["to", 860], ["S", 863], ["-", 864], ["adenosyl", 865], ["-", 873], ["L-", 874], ["[", 877], ["methyl-(3)H", 878], ["]", 889], ["methionine", 891], ["in", 902], ["the", 905], ["MLL1", 909], ["core", 914], ["complex", 919], [".", 926], ["Mutations", 928], ["in", 938], ["the", 941], ["MLL1", 945], ["SET", 950], ["domain", 954], ["that", 961], ["fail", 966], ["to", 971], ["support", 974], ["overall", 982], ["H3", 990], ["K4", 993], ["methylation", 996], ["also", 1008], ["compromise", 1013], ["SAM", 1024], ["binding", 1028], ["by", 1036], ["Ash2L.", 1039], ["Taken", 1046], ["together", 1052], [",", 1060], ["our", 1062], ["results", 1066], ["show", 1074], ["that", 1079], ["the", 1084], ["Ash2L", 1088], ["/", 1093], ["RbBP5", 1094], ["heterodimer", 1100], ["plays", 1112], ["a", 1118], ["critical", 1120], ["role", 1129], ["in", 1134], ["the", 1137], ["overall", 1141], ["catalysis", 1149], ["of", 1159], ["MLL1", 1162], ["mediated", 1167], ["H3", 1176], ["K4", 1179], ["methylation", 1182], [".", 1193], ["The", 1195], ["results", 1199], ["we", 1207], ["describe", 1210], ["here", 1219], ["provide", 1224], ["mechanistic", 1232], ["insights", 1244], ["for", 1253], ["unique", 1257], ["regulation", 1264], ["of", 1275], ["the", 1278], ["MLL1", 1282], ["methyltransferase", 1287], ["activity", 1305], [".", 1313], ["It", 1315], ["suggests", 1318], ["that", 1327], ["both", 1332], ["Ash2L", 1337], ["/", 1342], ["RbBP5", 1343], ["and", 1349], ["the", 1353], ["MLL1", 1357], ["SET", 1362], ["domain", 1366], ["make", 1373], ["direct", 1378], ["contacts", 1385], ["with", 1394], ["the", 1399], ["substrates", 1403], ["and", 1414], ["contribute", 1418], ["to", 1429], ["the", 1432], ["formation", 1436], ["of", 1446], ["a", 1449], ["joint", 1451], ["catalytic", 1457], ["center", 1467], [".", 1473], ["Given", 1475], ["the", 1481], ["shared", 1485], ["core", 1492], ["configuration", 1497], ["among", 1511], ["all", 1517], ["MLL", 1521], ["/", 1524], ["SET1", 1525], ["family", 1530], ["HMTs", 1537], [",", 1541], ["it", 1543], ["will", 1546], ["be", 1551], ["interesting", 1554], ["to", 1566], ["test", 1569], ["whether", 1574], ["the", 1582], ["mechanism", 1586], ["we", 1596], ["describe", 1599], ["here", 1608], ["can", 1613], ["be", 1617], ["generalized", 1620], ["to", 1632], ["other", 1635], ["MLL", 1641], ["/", 1644], ["SET1", 1645], ["family", 1650], ["members", 1657], ["in", 1665], ["the", 1668], ["future", 1672], [".", 1678]]}
{"context": "NSD3/WHSC1L1 histone methyltransferase gene aberrations are observed in leukemia and in breast and lung carcinomas, suggesting that NSD3 is implicated in carcinogenesis. In this study we examined in human breast cancer cells the NSD3L isoform which contains the catalytic histone methyltransferase SET-domain. siRNA directed depletion of NSD3L followed by genome-wide microarray analysis identified NSD3L regulated genes which could be functionally linked to cellular signaling pathways such as cell growth, cell cycle, cell motility, transcription, and apoptosis. Notably up-regulated genes are the cell cycle regulators E2F2 and Arl2. In accordance with a function of NSD3L in cell cycle regulation NSD3L depletion resulted in an increase in the number of cells in the S and G2/M cell cycle phases. Moreover, NSD3L depletion increased the invasiveness of MDA-MB-231 breast cancer cells indicating that NSD3L normally restrain cellular metastatic potential. Together the presented data indicates that NSD3L is a candidate tumor suppressor.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET-domain", "SET domain"], "qid": "704744227c8048f0b703848334d6ec87", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[43, 45]], "char_spans": [[298, 307]]}]}], "context_tokens": [["NSD3/WHSC1L1", 0], ["histone", 13], ["methyltransferase", 21], ["gene", 39], ["aberrations", 44], ["are", 56], ["observed", 60], ["in", 69], ["leukemia", 72], ["and", 81], ["in", 85], ["breast", 88], ["and", 95], ["lung", 99], ["carcinomas", 104], [",", 114], ["suggesting", 116], ["that", 127], ["NSD3", 132], ["is", 137], ["implicated", 140], ["in", 151], ["carcinogenesis", 154], [".", 168], ["In", 170], ["this", 173], ["study", 178], ["we", 184], ["examined", 187], ["in", 196], ["human", 199], ["breast", 205], ["cancer", 212], ["cells", 219], ["the", 225], ["NSD3L", 229], ["isoform", 235], ["which", 243], ["contains", 249], ["the", 258], ["catalytic", 262], ["histone", 272], ["methyltransferase", 280], ["SET", 298], ["-", 301], ["domain", 302], [".", 308], ["siRNA", 310], ["directed", 316], ["depletion", 325], ["of", 335], ["NSD3L", 338], ["followed", 344], ["by", 353], ["genome", 356], ["-", 362], ["wide", 363], ["microarray", 368], ["analysis", 379], ["identified", 388], ["NSD3L", 399], ["regulated", 405], ["genes", 415], ["which", 421], ["could", 427], ["be", 433], ["functionally", 436], ["linked", 449], ["to", 456], ["cellular", 459], ["signaling", 468], ["pathways", 478], ["such", 487], ["as", 492], ["cell", 495], ["growth", 500], [",", 506], ["cell", 508], ["cycle", 513], [",", 518], ["cell", 520], ["motility", 525], [",", 533], ["transcription", 535], [",", 548], ["and", 550], ["apoptosis", 554], [".", 563], ["Notably", 565], ["up", 573], ["-", 575], ["regulated", 576], ["genes", 586], ["are", 592], ["the", 596], ["cell", 600], ["cycle", 605], ["regulators", 611], ["E2F2", 622], ["and", 627], ["Arl2", 631], [".", 635], ["In", 637], ["accordance", 640], ["with", 651], ["a", 656], ["function", 658], ["of", 667], ["NSD3L", 670], ["in", 676], ["cell", 679], ["cycle", 684], ["regulation", 690], ["NSD3L", 701], ["depletion", 707], ["resulted", 717], ["in", 726], ["an", 729], ["increase", 732], ["in", 741], ["the", 744], ["number", 748], ["of", 755], ["cells", 758], ["in", 764], ["the", 767], ["S", 771], ["and", 773], ["G2/M", 777], ["cell", 782], ["cycle", 787], ["phases", 793], [".", 799], ["Moreover", 801], [",", 809], ["NSD3L", 811], ["depletion", 817], ["increased", 827], ["the", 837], ["invasiveness", 841], ["of", 854], ["MDA", 857], ["-", 860], ["MB-231", 861], ["breast", 868], ["cancer", 875], ["cells", 882], ["indicating", 888], ["that", 899], ["NSD3L", 904], ["normally", 910], ["restrain", 919], ["cellular", 928], ["metastatic", 937], ["potential", 948], [".", 957], ["Together", 959], ["the", 968], ["presented", 972], ["data", 982], ["indicates", 987], ["that", 997], ["NSD3L", 1002], ["is", 1008], ["a", 1011], ["candidate", 1013], ["tumor", 1023], ["suppressor", 1029], [".", 1039]]}
{"context": "Hallervorden-Spatz syndrome (HSS) is a rare autosomal recessive disorder clinically characterized by extrapyramidal signs and progressive dementia. In a typical case, the clinical symptoms become apparent during late childhood, and usually the course is protracted over a decade or more. We recently had an opportunity to study the brains of two cases of HSS with a clinical course of over 30 years. Case 1 was a 44-year-old female and case 2 was a 37-year-old male. Grossly, the brains showed severe fronto-temporal lobar atrophy with abundant spheroids and mild iron deposits in the globus pallidus, associated with features of motor neuron disease. In addition, there was diffuse sponginess in the atrophic cortex as well as widespread Alzheimer's neurofibrillary tangles (NFTs) and Lewy bodies (LBs) in the cortical and subcortical regions, including the spinal cord. Ultrastructurally, NFTs were composed of paired helical filaments, and LBs of central dense cores with radiating fibrils. Discrete immunostaining was demonstrated in NFTs and neuropil threads with various antibodies against phosphorylated tau, and in LBs with antibody against alpha-synuclein. In addition, diffuse, overlapping immunoreactivity of alpha-synuclein and phosphorylated tau was seen within the cytoplasm of many neurons. However, when LBs and NFTs coexisted within the same neurons, they were clearly segregated. The findings of our present cases as well as those reported in the literature may indicate that simultaneous and extensive occurrence of abnormal phosphorylation of tau and accumulation of alpha-synuclein may constitute cardinal pathological features of HSS with protracted clinical course.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "4a2d924caf4d464aa5a7837b4e6e320d", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[214, 216], [202, 204], [275, 277]], "char_spans": [[1220, 1234], [1149, 1163], [1587, 1601]]}]}], "context_tokens": [["Hallervorden", 0], ["-", 12], ["Spatz", 13], ["syndrome", 19], ["(", 28], ["HSS", 29], [")", 32], ["is", 34], ["a", 37], ["rare", 39], ["autosomal", 44], ["recessive", 54], ["disorder", 64], ["clinically", 73], ["characterized", 84], ["by", 98], ["extrapyramidal", 101], ["signs", 116], ["and", 122], ["progressive", 126], ["dementia", 138], [".", 146], ["In", 148], ["a", 151], ["typical", 153], ["case", 161], [",", 165], ["the", 167], ["clinical", 171], ["symptoms", 180], ["become", 189], ["apparent", 196], ["during", 205], ["late", 212], ["childhood", 217], [",", 226], ["and", 228], ["usually", 232], ["the", 240], ["course", 244], ["is", 251], ["protracted", 254], ["over", 265], ["a", 270], ["decade", 272], ["or", 279], ["more", 282], [".", 286], ["We", 288], ["recently", 291], ["had", 300], ["an", 304], ["opportunity", 307], ["to", 319], ["study", 322], ["the", 328], ["brains", 332], ["of", 339], ["two", 342], ["cases", 346], ["of", 352], ["HSS", 355], ["with", 359], ["a", 364], ["clinical", 366], ["course", 375], ["of", 382], ["over", 385], ["30", 390], ["years", 393], [".", 398], ["Case", 400], ["1", 405], ["was", 407], ["a", 411], ["44-year", 413], ["-", 420], ["old", 421], ["female", 425], ["and", 432], ["case", 436], ["2", 441], ["was", 443], ["a", 447], ["37-year", 449], ["-", 456], ["old", 457], ["male", 461], [".", 465], ["Grossly", 467], [",", 474], ["the", 476], ["brains", 480], ["showed", 487], ["severe", 494], ["fronto", 501], ["-", 507], ["temporal", 508], ["lobar", 517], ["atrophy", 523], ["with", 531], ["abundant", 536], ["spheroids", 545], ["and", 555], ["mild", 559], ["iron", 564], ["deposits", 569], ["in", 578], ["the", 581], ["globus", 585], ["pallidus", 592], [",", 600], ["associated", 602], ["with", 613], ["features", 618], ["of", 627], ["motor", 630], ["neuron", 636], ["disease", 643], [".", 650], ["In", 652], ["addition", 655], [",", 663], ["there", 665], ["was", 671], ["diffuse", 675], ["sponginess", 683], ["in", 694], ["the", 697], ["atrophic", 701], ["cortex", 710], ["as", 717], ["well", 720], ["as", 725], ["widespread", 728], ["Alzheimer", 739], ["'s", 748], ["neurofibrillary", 751], ["tangles", 767], ["(", 775], ["NFTs", 776], [")", 780], ["and", 782], ["Lewy", 786], ["bodies", 791], ["(", 798], ["LBs", 799], [")", 802], ["in", 804], ["the", 807], ["cortical", 811], ["and", 820], ["subcortical", 824], ["regions", 836], [",", 843], ["including", 845], ["the", 855], ["spinal", 859], ["cord", 866], [".", 870], ["Ultrastructurally", 872], [",", 889], ["NFTs", 891], ["were", 896], ["composed", 901], ["of", 910], ["paired", 913], ["helical", 920], ["filaments", 928], [",", 937], ["and", 939], ["LBs", 943], ["of", 947], ["central", 950], ["dense", 958], ["cores", 964], ["with", 970], ["radiating", 975], ["fibrils", 985], [".", 992], ["Discrete", 994], ["immunostaining", 1003], ["was", 1018], ["demonstrated", 1022], ["in", 1035], ["NFTs", 1038], ["and", 1043], ["neuropil", 1047], ["threads", 1056], ["with", 1064], ["various", 1069], ["antibodies", 1077], ["against", 1088], ["phosphorylated", 1096], ["tau", 1111], [",", 1114], ["and", 1116], ["in", 1120], ["LBs", 1123], ["with", 1127], ["antibody", 1132], ["against", 1141], ["alpha", 1149], ["-", 1154], ["synuclein", 1155], [".", 1164], ["In", 1166], ["addition", 1169], [",", 1177], ["diffuse", 1179], [",", 1186], ["overlapping", 1188], ["immunoreactivity", 1200], ["of", 1217], ["alpha", 1220], ["-", 1225], ["synuclein", 1226], ["and", 1236], ["phosphorylated", 1240], ["tau", 1255], ["was", 1259], ["seen", 1263], ["within", 1268], ["the", 1275], ["cytoplasm", 1279], ["of", 1289], ["many", 1292], ["neurons", 1297], [".", 1304], ["However", 1306], [",", 1313], ["when", 1315], ["LBs", 1320], ["and", 1324], ["NFTs", 1328], ["coexisted", 1333], ["within", 1343], ["the", 1350], ["same", 1354], ["neurons", 1359], [",", 1366], ["they", 1368], ["were", 1373], ["clearly", 1378], ["segregated", 1386], [".", 1396], ["The", 1398], ["findings", 1402], ["of", 1411], ["our", 1414], ["present", 1418], ["cases", 1426], ["as", 1432], ["well", 1435], ["as", 1440], ["those", 1443], ["reported", 1449], ["in", 1458], ["the", 1461], ["literature", 1465], ["may", 1476], ["indicate", 1480], ["that", 1489], ["simultaneous", 1494], ["and", 1507], ["extensive", 1511], ["occurrence", 1521], ["of", 1532], ["abnormal", 1535], ["phosphorylation", 1544], ["of", 1560], ["tau", 1563], ["and", 1567], ["accumulation", 1571], ["of", 1584], ["alpha", 1587], ["-", 1592], ["synuclein", 1593], ["may", 1603], ["constitute", 1607], ["cardinal", 1618], ["pathological", 1627], ["features", 1640], ["of", 1649], ["HSS", 1652], ["with", 1656], ["protracted", 1661], ["clinical", 1672], ["course", 1681], [".", 1687]]}
{"context": "Neuronal loss in specific brain regions and neurons with intracellular inclusions termed Lewy bodies are the pathologic hallmark in both Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Lewy bodies comprise of aggregated intracellular vesicles and proteins and \u03b1-synuclein is reported to be a major protein component. Using human brain tissue from control, PD and DLB and light and confocal immunohistochemistry with antibodies to superoxide dismutase 2 as a marker for mitochondria, \u03b1-synuclein for Lewy bodies and \u03b2III Tubulin for microtubules we have examined the relationship between Lewy bodies and mitochondrial loss. We have shown microtubule regression and mitochondrial and nuclear degradation in neurons with developing Lewy bodies. In PD, multiple Lewy bodies were often observed with \u03b1-synuclein interacting with DNA to cause marked nuclear degradation. In DLB, the mitochondria are drawn into the Lewy body and the mitochondrial integrity is lost. This work suggests that Lewy bodies are cytotoxic. In DLB, we suggest that microtubule regression and mitochondrial loss results in decreased cellular energy and axonal transport that leads to cell death. In PD, \u03b1-synuclein aggregations are associated with intact mitochondria but interacts with and causes nuclear degradation which may be the major cause of cell death.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a26bb24d46114aeaa1d54858c6340119", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[134, 136], [201, 203], [45, 47], [84, 86]], "char_spans": [[809, 819], [1186, 1196], [274, 284], [497, 507]]}]}], "context_tokens": [["Neuronal", 0], ["loss", 9], ["in", 14], ["specific", 17], ["brain", 26], ["regions", 32], ["and", 40], ["neurons", 44], ["with", 52], ["intracellular", 57], ["inclusions", 71], ["termed", 82], ["Lewy", 89], ["bodies", 94], ["are", 101], ["the", 105], ["pathologic", 109], ["hallmark", 120], ["in", 129], ["both", 132], ["Parkinson", 137], ["'s", 146], ["disease", 149], ["(", 157], ["PD", 158], [")", 160], ["and", 162], ["dementia", 166], ["with", 175], ["Lewy", 180], ["bodies", 185], ["(", 192], ["DLB", 193], [")", 196], [".", 197], ["Lewy", 199], ["bodies", 204], ["comprise", 211], ["of", 220], ["aggregated", 223], ["intracellular", 234], ["vesicles", 248], ["and", 257], ["proteins", 261], ["and", 270], ["\u03b1", 274], ["-", 275], ["synuclein", 276], ["is", 286], ["reported", 289], ["to", 298], ["be", 301], ["a", 304], ["major", 306], ["protein", 312], ["component", 320], [".", 329], ["Using", 331], ["human", 337], ["brain", 343], ["tissue", 349], ["from", 356], ["control", 361], [",", 368], ["PD", 370], ["and", 373], ["DLB", 377], ["and", 381], ["light", 385], ["and", 391], ["confocal", 395], ["immunohistochemistry", 404], ["with", 425], ["antibodies", 430], ["to", 441], ["superoxide", 444], ["dismutase", 455], ["2", 465], ["as", 467], ["a", 470], ["marker", 472], ["for", 479], ["mitochondria", 483], [",", 495], ["\u03b1", 497], ["-", 498], ["synuclein", 499], ["for", 509], ["Lewy", 513], ["bodies", 518], ["and", 525], ["\u03b2III", 529], ["Tubulin", 534], ["for", 542], ["microtubules", 546], ["we", 559], ["have", 562], ["examined", 567], ["the", 576], ["relationship", 580], ["between", 593], ["Lewy", 601], ["bodies", 606], ["and", 613], ["mitochondrial", 617], ["loss", 631], [".", 635], ["We", 637], ["have", 640], ["shown", 645], ["microtubule", 651], ["regression", 663], ["and", 674], ["mitochondrial", 678], ["and", 692], ["nuclear", 696], ["degradation", 704], ["in", 716], ["neurons", 719], ["with", 727], ["developing", 732], ["Lewy", 743], ["bodies", 748], [".", 754], ["In", 756], ["PD", 759], [",", 761], ["multiple", 763], ["Lewy", 772], ["bodies", 777], ["were", 784], ["often", 789], ["observed", 795], ["with", 804], ["\u03b1", 809], ["-", 810], ["synuclein", 811], ["interacting", 821], ["with", 833], ["DNA", 838], ["to", 842], ["cause", 845], ["marked", 851], ["nuclear", 858], ["degradation", 866], [".", 877], ["In", 879], ["DLB", 882], [",", 885], ["the", 887], ["mitochondria", 891], ["are", 904], ["drawn", 908], ["into", 914], ["the", 919], ["Lewy", 923], ["body", 928], ["and", 933], ["the", 937], ["mitochondrial", 941], ["integrity", 955], ["is", 965], ["lost", 968], [".", 972], ["This", 974], ["work", 979], ["suggests", 984], ["that", 993], ["Lewy", 998], ["bodies", 1003], ["are", 1010], ["cytotoxic", 1014], [".", 1023], ["In", 1025], ["DLB", 1028], [",", 1031], ["we", 1033], ["suggest", 1036], ["that", 1044], ["microtubule", 1049], ["regression", 1061], ["and", 1072], ["mitochondrial", 1076], ["loss", 1090], ["results", 1095], ["in", 1103], ["decreased", 1106], ["cellular", 1116], ["energy", 1125], ["and", 1132], ["axonal", 1136], ["transport", 1143], ["that", 1153], ["leads", 1158], ["to", 1164], ["cell", 1167], ["death", 1172], [".", 1177], ["In", 1179], ["PD", 1182], [",", 1184], ["\u03b1", 1186], ["-", 1187], ["synuclein", 1188], ["aggregations", 1198], ["are", 1211], ["associated", 1215], ["with", 1226], ["intact", 1231], ["mitochondria", 1238], ["but", 1251], ["interacts", 1255], ["with", 1265], ["and", 1270], ["causes", 1274], ["nuclear", 1281], ["degradation", 1289], ["which", 1301], ["may", 1307], ["be", 1311], ["the", 1314], ["major", 1318], ["cause", 1324], ["of", 1330], ["cell", 1333], ["death", 1338], [".", 1343]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is characterized by chromatin relaxation of the D4Z4 macrosatellite array on chromosome 4 and expression of the D4Z4-encoded DUX4 gene in skeletal muscle. The more common form, autosomal dominant FSHD1, is caused by contraction of the D4Z4 array, whereas the genetic determinants and inheritance of D4Z4 array contraction-independent FSHD2 are unclear. Here, we show that mutations in SMCHD1 (encoding structural maintenance of chromosomes flexible hinge domain containing 1) on chromosome 18 reduce SMCHD1 protein levels and segregate with genome-wide D4Z4 CpG hypomethylation in human kindreds. FSHD2 occurs in individuals who inherited both the SMCHD1 mutation and a normal-sized D4Z4 array on a chromosome 4 haplotype permissive for DUX4 expression. Reducing SMCHD1 levels in skeletal muscle results in D4Z4 contraction-independent DUX4 expression. Our study identifies SMCHD1 as an epigenetic modifier of the D4Z4 metastable epiallele and as a causal genetic determinant of FSHD2 and possibly other human diseases subject to epigenetic regulation.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "a9464ddc76874f33bc3080db5c5c07b9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[34, 35]], "char_spans": [[214, 231]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["characterized", 40], ["by", 54], ["chromatin", 57], ["relaxation", 67], ["of", 78], ["the", 81], ["D4Z4", 85], ["macrosatellite", 90], ["array", 105], ["on", 111], ["chromosome", 114], ["4", 125], ["and", 127], ["expression", 131], ["of", 142], ["the", 145], ["D4Z4-encoded", 149], ["DUX4", 162], ["gene", 167], ["in", 172], ["skeletal", 175], ["muscle", 184], [".", 190], ["The", 192], ["more", 196], ["common", 201], ["form", 208], [",", 212], ["autosomal", 214], ["dominant", 224], ["FSHD1", 233], [",", 238], ["is", 240], ["caused", 243], ["by", 250], ["contraction", 253], ["of", 265], ["the", 268], ["D4Z4", 272], ["array", 277], [",", 282], ["whereas", 284], ["the", 292], ["genetic", 296], ["determinants", 304], ["and", 317], ["inheritance", 321], ["of", 333], ["D4Z4", 336], ["array", 341], ["contraction", 347], ["-", 358], ["independent", 359], ["FSHD2", 371], ["are", 377], ["unclear", 381], [".", 388], ["Here", 390], [",", 394], ["we", 396], ["show", 399], ["that", 404], ["mutations", 409], ["in", 419], ["SMCHD1", 422], ["(", 429], ["encoding", 430], ["structural", 439], ["maintenance", 450], ["of", 462], ["chromosomes", 465], ["flexible", 477], ["hinge", 486], ["domain", 492], ["containing", 499], ["1", 510], [")", 511], ["on", 513], ["chromosome", 516], ["18", 527], ["reduce", 530], ["SMCHD1", 537], ["protein", 544], ["levels", 552], ["and", 559], ["segregate", 563], ["with", 573], ["genome", 578], ["-", 584], ["wide", 585], ["D4Z4", 590], ["CpG", 595], ["hypomethylation", 599], ["in", 615], ["human", 618], ["kindreds", 624], [".", 632], ["FSHD2", 634], ["occurs", 640], ["in", 647], ["individuals", 650], ["who", 662], ["inherited", 666], ["both", 676], ["the", 681], ["SMCHD1", 685], ["mutation", 692], ["and", 701], ["a", 705], ["normal", 707], ["-", 713], ["sized", 714], ["D4Z4", 720], ["array", 725], ["on", 731], ["a", 734], ["chromosome", 736], ["4", 747], ["haplotype", 749], ["permissive", 759], ["for", 770], ["DUX4", 774], ["expression", 779], [".", 789], ["Reducing", 791], ["SMCHD1", 800], ["levels", 807], ["in", 814], ["skeletal", 817], ["muscle", 826], ["results", 833], ["in", 841], ["D4Z4", 844], ["contraction", 849], ["-", 860], ["independent", 861], ["DUX4", 873], ["expression", 878], [".", 888], ["Our", 890], ["study", 894], ["identifies", 900], ["SMCHD1", 911], ["as", 918], ["an", 921], ["epigenetic", 924], ["modifier", 935], ["of", 944], ["the", 947], ["D4Z4", 951], ["metastable", 956], ["epiallele", 967], ["and", 977], ["as", 981], ["a", 984], ["causal", 986], ["genetic", 993], ["determinant", 1001], ["of", 1013], ["FSHD2", 1016], ["and", 1022], ["possibly", 1026], ["other", 1035], ["human", 1041], ["diseases", 1047], ["subject", 1056], ["to", 1064], ["epigenetic", 1067], ["regulation", 1078], [".", 1088]]}
{"context": "A novel 135 kDa centrosomal component (Cep135) was identified by immunoscreening of a mammalian expression library with monoclonal antibodies raised against clam centrosomes. It is predicted to be a highly coiled-coil protein with an extensive alpha-helix, suggesting that Cep135 is a structural component of the centrosome. To evaluate how the protein is arranged in the centrosomal structure, we overexpressed Cep135 polypeptides in CHO cells by transient transfection. HA- or GFP-tagged full (amino acids 1-1144) as well as truncated (#10, 29-1144; Delta3, 29-812) polypeptides become localized at the centrosome and induce cytoplasmic dots of various size and number in CHO cells. Centrosomes are associated with massive approximately 7 nm filaments and dense particles organized in a whorl-like arrangement in which parallel-oriented dense lines appear with a regular approximately 7 nm periodicity. The same filamentous aggregates are also detected in cytoplasmic dots, indicating that overexpressed Cep135 can assemble into elaborate higher-ordered structures in and outside the centrosome. Sf9 cells infected with baculovirus containing Cep135 sequences induce filamentous polymers which are distinctive from the whorl seen in CHO cells; #10 forms highly packed spheroids, but the Delta3-containing structure looks loose. Both structures show an internal repeating unit of dense and less dense stripes. Although the distance between the outer end of two adjacent dense lines is similar between two types of polymers ( approximately 120 nm), the dense stripe of Delta3 polymers ( approximately 40 nm) is wider than #10 ( approximately 30 nm). The light band of Delta3 ( approximately 40 nm) is thus narrower than #10 ( approximately 60 nm). Since thin fibers are frequently seen to extend from one dense line to the next, the coiled-coil rod of Cep135 may span the light band. These results suggest that overexpressed Cep135 assemble into distinctive polymers in a domain-specific manner.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "62f547c5c52345068b263ed7bbd85032", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[190, 190], [53, 53], [114, 114]], "char_spans": [[1086, 1095], [313, 322], [605, 614]]}]}], "context_tokens": [["A", 0], ["novel", 2], ["135", 8], ["kDa", 12], ["centrosomal", 16], ["component", 28], ["(", 38], ["Cep135", 39], [")", 45], ["was", 47], ["identified", 51], ["by", 62], ["immunoscreening", 65], ["of", 81], ["a", 84], ["mammalian", 86], ["expression", 96], ["library", 107], ["with", 115], ["monoclonal", 120], ["antibodies", 131], ["raised", 142], ["against", 149], ["clam", 157], ["centrosomes", 162], [".", 173], ["It", 175], ["is", 178], ["predicted", 181], ["to", 191], ["be", 194], ["a", 197], ["highly", 199], ["coiled", 206], ["-", 212], ["coil", 213], ["protein", 218], ["with", 226], ["an", 231], ["extensive", 234], ["alpha", 244], ["-", 249], ["helix", 250], [",", 255], ["suggesting", 257], ["that", 268], ["Cep135", 273], ["is", 280], ["a", 283], ["structural", 285], ["component", 296], ["of", 306], ["the", 309], ["centrosome", 313], [".", 323], ["To", 325], ["evaluate", 328], ["how", 337], ["the", 341], ["protein", 345], ["is", 353], ["arranged", 356], ["in", 365], ["the", 368], ["centrosomal", 372], ["structure", 384], [",", 393], ["we", 395], ["overexpressed", 398], ["Cep135", 412], ["polypeptides", 419], ["in", 432], ["CHO", 435], ["cells", 439], ["by", 445], ["transient", 448], ["transfection", 458], [".", 470], ["HA-", 472], ["or", 476], ["GFP", 479], ["-", 482], ["tagged", 483], ["full", 490], ["(", 495], ["amino", 496], ["acids", 502], ["1", 508], ["-", 509], ["1144", 510], [")", 514], ["as", 516], ["well", 519], ["as", 524], ["truncated", 527], ["(", 537], ["#", 538], ["10", 539], [",", 541], ["29", 543], ["-", 545], ["1144", 546], [";", 550], ["Delta3", 552], [",", 558], ["29", 560], ["-", 562], ["812", 563], [")", 566], ["polypeptides", 568], ["become", 581], ["localized", 588], ["at", 598], ["the", 601], ["centrosome", 605], ["and", 616], ["induce", 620], ["cytoplasmic", 627], ["dots", 639], ["of", 644], ["various", 647], ["size", 655], ["and", 660], ["number", 664], ["in", 671], ["CHO", 674], ["cells", 678], [".", 683], ["Centrosomes", 685], ["are", 697], ["associated", 701], ["with", 712], ["massive", 717], ["approximately", 725], ["7", 739], ["nm", 741], ["filaments", 744], ["and", 754], ["dense", 758], ["particles", 764], ["organized", 774], ["in", 784], ["a", 787], ["whorl", 789], ["-", 794], ["like", 795], ["arrangement", 800], ["in", 812], ["which", 815], ["parallel", 821], ["-", 829], ["oriented", 830], ["dense", 839], ["lines", 845], ["appear", 851], ["with", 858], ["a", 863], ["regular", 865], ["approximately", 873], ["7", 887], ["nm", 889], ["periodicity", 892], [".", 903], ["The", 905], ["same", 909], ["filamentous", 914], ["aggregates", 926], ["are", 937], ["also", 941], ["detected", 946], ["in", 955], ["cytoplasmic", 958], ["dots", 970], [",", 974], ["indicating", 976], ["that", 987], ["overexpressed", 992], ["Cep135", 1006], ["can", 1013], ["assemble", 1017], ["into", 1026], ["elaborate", 1031], ["higher", 1041], ["-", 1047], ["ordered", 1048], ["structures", 1056], ["in", 1067], ["and", 1070], ["outside", 1074], ["the", 1082], ["centrosome", 1086], [".", 1096], ["Sf9", 1098], ["cells", 1102], ["infected", 1108], ["with", 1117], ["baculovirus", 1122], ["containing", 1134], ["Cep135", 1145], ["sequences", 1152], ["induce", 1162], ["filamentous", 1169], ["polymers", 1181], ["which", 1190], ["are", 1196], ["distinctive", 1200], ["from", 1212], ["the", 1217], ["whorl", 1221], ["seen", 1227], ["in", 1232], ["CHO", 1235], ["cells", 1239], [";", 1244], ["#", 1246], ["10", 1247], ["forms", 1250], ["highly", 1256], ["packed", 1263], ["spheroids", 1270], [",", 1279], ["but", 1281], ["the", 1285], ["Delta3-containing", 1289], ["structure", 1307], ["looks", 1317], ["loose", 1323], [".", 1328], ["Both", 1330], ["structures", 1335], ["show", 1346], ["an", 1351], ["internal", 1354], ["repeating", 1363], ["unit", 1373], ["of", 1378], ["dense", 1381], ["and", 1387], ["less", 1391], ["dense", 1396], ["stripes", 1402], [".", 1409], ["Although", 1411], ["the", 1420], ["distance", 1424], ["between", 1433], ["the", 1441], ["outer", 1445], ["end", 1451], ["of", 1455], ["two", 1458], ["adjacent", 1462], ["dense", 1471], ["lines", 1477], ["is", 1483], ["similar", 1486], ["between", 1494], ["two", 1502], ["types", 1506], ["of", 1512], ["polymers", 1515], ["(", 1524], ["approximately", 1526], ["120", 1540], ["nm", 1544], [")", 1546], [",", 1547], ["the", 1549], ["dense", 1553], ["stripe", 1559], ["of", 1566], ["Delta3", 1569], ["polymers", 1576], ["(", 1585], ["approximately", 1587], ["40", 1601], ["nm", 1604], [")", 1606], ["is", 1608], ["wider", 1611], ["than", 1617], ["#", 1622], ["10", 1623], ["(", 1626], ["approximately", 1628], ["30", 1642], ["nm", 1645], [")", 1647], [".", 1648], ["The", 1650], ["light", 1654], ["band", 1660], ["of", 1665], ["Delta3", 1668], ["(", 1675], ["approximately", 1677], ["40", 1691], ["nm", 1694], [")", 1696], ["is", 1698], ["thus", 1701], ["narrower", 1706], ["than", 1715], ["#", 1720], ["10", 1721], ["(", 1724], ["approximately", 1726], ["60", 1740], ["nm", 1743], [")", 1745], [".", 1746], ["Since", 1748], ["thin", 1754], ["fibers", 1759], ["are", 1766], ["frequently", 1770], ["seen", 1781], ["to", 1786], ["extend", 1789], ["from", 1796], ["one", 1801], ["dense", 1805], ["line", 1811], ["to", 1816], ["the", 1819], ["next", 1823], [",", 1827], ["the", 1829], ["coiled", 1833], ["-", 1839], ["coil", 1840], ["rod", 1845], ["of", 1849], ["Cep135", 1852], ["may", 1859], ["span", 1863], ["the", 1868], ["light", 1872], ["band", 1878], [".", 1882], ["These", 1884], ["results", 1890], ["suggest", 1898], ["that", 1906], ["overexpressed", 1911], ["Cep135", 1925], ["assemble", 1932], ["into", 1941], ["distinctive", 1946], ["polymers", 1958], ["in", 1967], ["a", 1970], ["domain", 1972], ["-", 1978], ["specific", 1979], ["manner", 1988], [".", 1994]]}
{"context": "Christianson syndrome (CS) is caused by mutations in SLC9A6 and is characterized by severe intellectual disability, absent speech, microcephaly, ataxia, seizures, and behavioral abnormalities. The clinical phenotypes of CS and Angelman syndrome (AS) are similar. Differentiation between CS and AS is important in terms of genetic counseling. We report on two children with CS and confirmed mutations in SLC9A6 focusing on neuroimaging findings and review the available literature. Cerebellar atrophy (CA) occurs in approximately 60% of the patients with CS and develops after the age of 12 months. Hyperintense signal of the cerebellar cortex (CbC) is less common, and may be diffuse, patchy, or involve only the inferior part of the cerebellum and is best seen on coronal fluid attenuation inversion recovery images. CA and CbC-hyperintensity are not neuroimaging features of AS. In a child with the phenotype of AS, CA and/or CbC-hyperintensity are rather specific for CS and should prioritize sequencing of SLC9A6.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "9bcff955534e462aad930acfdb1fef0c", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[182, 182], [70, 70], [10, 10]], "char_spans": [[1010, 1015], [403, 408], [53, 58]]}]}], "context_tokens": [["Christianson", 0], ["syndrome", 13], ["(", 22], ["CS", 23], [")", 25], ["is", 27], ["caused", 30], ["by", 37], ["mutations", 40], ["in", 50], ["SLC9A6", 53], ["and", 60], ["is", 64], ["characterized", 67], ["by", 81], ["severe", 84], ["intellectual", 91], ["disability", 104], [",", 114], ["absent", 116], ["speech", 123], [",", 129], ["microcephaly", 131], [",", 143], ["ataxia", 145], [",", 151], ["seizures", 153], [",", 161], ["and", 163], ["behavioral", 167], ["abnormalities", 178], [".", 191], ["The", 193], ["clinical", 197], ["phenotypes", 206], ["of", 217], ["CS", 220], ["and", 223], ["Angelman", 227], ["syndrome", 236], ["(", 245], ["AS", 246], [")", 248], ["are", 250], ["similar", 254], [".", 261], ["Differentiation", 263], ["between", 279], ["CS", 287], ["and", 290], ["AS", 294], ["is", 297], ["important", 300], ["in", 310], ["terms", 313], ["of", 319], ["genetic", 322], ["counseling", 330], [".", 340], ["We", 342], ["report", 345], ["on", 352], ["two", 355], ["children", 359], ["with", 368], ["CS", 373], ["and", 376], ["confirmed", 380], ["mutations", 390], ["in", 400], ["SLC9A6", 403], ["focusing", 410], ["on", 419], ["neuroimaging", 422], ["findings", 435], ["and", 444], ["review", 448], ["the", 455], ["available", 459], ["literature", 469], [".", 479], ["Cerebellar", 481], ["atrophy", 492], ["(", 500], ["CA", 501], [")", 503], ["occurs", 505], ["in", 512], ["approximately", 515], ["60", 529], ["%", 531], ["of", 533], ["the", 536], ["patients", 540], ["with", 549], ["CS", 554], ["and", 557], ["develops", 561], ["after", 570], ["the", 576], ["age", 580], ["of", 584], ["12", 587], ["months", 590], [".", 596], ["Hyperintense", 598], ["signal", 611], ["of", 618], ["the", 621], ["cerebellar", 625], ["cortex", 636], ["(", 643], ["CbC", 644], [")", 647], ["is", 649], ["less", 652], ["common", 657], [",", 663], ["and", 665], ["may", 669], ["be", 673], ["diffuse", 676], [",", 683], ["patchy", 685], [",", 691], ["or", 693], ["involve", 696], ["only", 704], ["the", 709], ["inferior", 713], ["part", 722], ["of", 727], ["the", 730], ["cerebellum", 734], ["and", 745], ["is", 749], ["best", 752], ["seen", 757], ["on", 762], ["coronal", 765], ["fluid", 773], ["attenuation", 779], ["inversion", 791], ["recovery", 801], ["images", 810], [".", 816], ["CA", 818], ["and", 821], ["CbC", 825], ["-", 828], ["hyperintensity", 829], ["are", 844], ["not", 848], ["neuroimaging", 852], ["features", 865], ["of", 874], ["AS", 877], [".", 879], ["In", 881], ["a", 884], ["child", 886], ["with", 892], ["the", 897], ["phenotype", 901], ["of", 911], ["AS", 914], [",", 916], ["CA", 918], ["and/or", 921], ["CbC", 928], ["-", 931], ["hyperintensity", 932], ["are", 947], ["rather", 951], ["specific", 958], ["for", 967], ["CS", 971], ["and", 974], ["should", 978], ["prioritize", 985], ["sequencing", 996], ["of", 1007], ["SLC9A6", 1010], [".", 1016]]}
{"context": "Alpha-synuclein (\u03b1-Syn) is the principal protein component of Lewy bodies, a pathological hallmark of Parkinson's disease (PD). This protein may regulate protein phosphatase 2A (PP2A) activity, although the molecular mechanisms for \u03b1-Syn-mediated regulation of PP2A and the potential neuroprotective actions of PP2A against PD-associated pathology remain largely unexplored. We found that \u03b1-Syn gene overexpression in SK-N-SH cells and primary neurons led to PP2A/C phosphorylation at Y307, a known target of Src kinase, and consequent phosphatase inhibition. In addition, phospho-activated Src (p-Y416 Src, pSrc) was higher in SK-N-SH cells and primary neurons overexpressing \u03b1-Syn. Thus, \u03b1-Syn may promote Src activation and PP2A inactivation, leading to hyperphosphorylation of proteins. Immunoprecipitation revealed higher calmodulin/Src complex formation in \u03b1-Syn-overexpressing cells and \u03b1-Syn transgenic mice. A TUNEL apoptosis assay and an MTT cell viability assay demonstrated that the PP2A activator C2-ceramide protected neurons against \u03b1-Syn-induced cell injury. Buffering the Ca(2+) elevations induced by \u03b1-Syn overexpression ameliorated the cytotoxicity of \u03b1-Syn. Our findings define a potential molecular mechanism for \u03b1-Syn-mediated regulation of PP2A through formation of the calmodulin/Src complex, activation of Src, and Src-mediated phospho-inhibition of PP2A. Overexpression of \u03b1-Syn may lead to neurodegeneration in PD in part by suppressing the endogenous neuroprotective activity of PP2A.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "cf97c5fcf3d94305a47f705ecb7271f5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["(", 16], ["\u03b1", 17], ["-", 18], ["Syn", 19], [")", 22], ["is", 24], ["the", 27], ["principal", 31], ["protein", 41], ["component", 49], ["of", 59], ["Lewy", 62], ["bodies", 67], [",", 73], ["a", 75], ["pathological", 77], ["hallmark", 90], ["of", 99], ["Parkinson", 102], ["'s", 111], ["disease", 114], ["(", 122], ["PD", 123], [")", 125], [".", 126], ["This", 128], ["protein", 133], ["may", 141], ["regulate", 145], ["protein", 154], ["phosphatase", 162], ["2A", 174], ["(", 177], ["PP2A", 178], [")", 182], ["activity", 184], [",", 192], ["although", 194], ["the", 203], ["molecular", 207], ["mechanisms", 217], ["for", 228], ["\u03b1", 232], ["-", 233], ["Syn", 234], ["-", 237], ["mediated", 238], ["regulation", 247], ["of", 258], ["PP2A", 261], ["and", 266], ["the", 270], ["potential", 274], ["neuroprotective", 284], ["actions", 300], ["of", 308], ["PP2A", 311], ["against", 316], ["PD", 324], ["-", 326], ["associated", 327], ["pathology", 338], ["remain", 348], ["largely", 355], ["unexplored", 363], [".", 373], ["We", 375], ["found", 378], ["that", 384], ["\u03b1", 389], ["-", 390], ["Syn", 391], ["gene", 395], ["overexpression", 400], ["in", 415], ["SK", 418], ["-", 420], ["N", 421], ["-", 422], ["SH", 423], ["cells", 426], ["and", 432], ["primary", 436], ["neurons", 444], ["led", 452], ["to", 456], ["PP2A", 459], ["/", 463], ["C", 464], ["phosphorylation", 466], ["at", 482], ["Y307", 485], [",", 489], ["a", 491], ["known", 493], ["target", 499], ["of", 506], ["Src", 509], ["kinase", 513], [",", 519], ["and", 521], ["consequent", 525], ["phosphatase", 536], ["inhibition", 548], [".", 558], ["In", 560], ["addition", 563], [",", 571], ["phospho", 573], ["-", 580], ["activated", 581], ["Src", 591], ["(", 595], ["p", 596], ["-", 597], ["Y416", 598], ["Src", 603], [",", 606], ["pSrc", 608], [")", 612], ["was", 614], ["higher", 618], ["in", 625], ["SK", 628], ["-", 630], ["N", 631], ["-", 632], ["SH", 633], ["cells", 636], ["and", 642], ["primary", 646], ["neurons", 654], ["overexpressing", 662], ["\u03b1", 677], ["-", 678], ["Syn", 679], [".", 682], ["Thus", 684], [",", 688], ["\u03b1", 690], ["-", 691], ["Syn", 692], ["may", 696], ["promote", 700], ["Src", 708], ["activation", 712], ["and", 723], ["PP2A", 727], ["inactivation", 732], [",", 744], ["leading", 746], ["to", 754], ["hyperphosphorylation", 757], ["of", 778], ["proteins", 781], [".", 789], ["Immunoprecipitation", 791], ["revealed", 811], ["higher", 820], ["calmodulin", 827], ["/", 837], ["Src", 838], ["complex", 842], ["formation", 850], ["in", 860], ["\u03b1", 863], ["-", 864], ["Syn", 865], ["-", 868], ["overexpressing", 869], ["cells", 884], ["and", 890], ["\u03b1", 894], ["-", 895], ["Syn", 896], ["transgenic", 900], ["mice", 911], [".", 915], ["A", 917], ["TUNEL", 919], ["apoptosis", 925], ["assay", 935], ["and", 941], ["an", 945], ["MTT", 948], ["cell", 952], ["viability", 957], ["assay", 967], ["demonstrated", 973], ["that", 986], ["the", 991], ["PP2A", 995], ["activator", 1000], ["C2-ceramide", 1010], ["protected", 1022], ["neurons", 1032], ["against", 1040], ["\u03b1", 1048], ["-", 1049], ["Syn", 1050], ["-", 1053], ["induced", 1054], ["cell", 1062], ["injury", 1067], [".", 1073], ["Buffering", 1075], ["the", 1085], ["Ca(2", 1089], ["+", 1093], [")", 1094], ["elevations", 1096], ["induced", 1107], ["by", 1115], ["\u03b1", 1118], ["-", 1119], ["Syn", 1120], ["overexpression", 1124], ["ameliorated", 1139], ["the", 1151], ["cytotoxicity", 1155], ["of", 1168], ["\u03b1", 1171], ["-", 1172], ["Syn", 1173], [".", 1176], ["Our", 1178], ["findings", 1182], ["define", 1191], ["a", 1198], ["potential", 1200], ["molecular", 1210], ["mechanism", 1220], ["for", 1230], ["\u03b1", 1234], ["-", 1235], ["Syn", 1236], ["-", 1239], ["mediated", 1240], ["regulation", 1249], ["of", 1260], ["PP2A", 1263], ["through", 1268], ["formation", 1276], ["of", 1286], ["the", 1289], ["calmodulin", 1293], ["/", 1303], ["Src", 1304], ["complex", 1308], [",", 1315], ["activation", 1317], ["of", 1328], ["Src", 1331], [",", 1334], ["and", 1336], ["Src", 1340], ["-", 1343], ["mediated", 1344], ["phospho", 1353], ["-", 1360], ["inhibition", 1361], ["of", 1372], ["PP2A.", 1375], ["Overexpression", 1381], ["of", 1396], ["\u03b1", 1399], ["-", 1400], ["Syn", 1401], ["may", 1405], ["lead", 1409], ["to", 1414], ["neurodegeneration", 1417], ["in", 1435], ["PD", 1438], ["in", 1441], ["part", 1444], ["by", 1449], ["suppressing", 1452], ["the", 1464], ["endogenous", 1468], ["neuroprotective", 1479], ["activity", 1495], ["of", 1504], ["PP2A.", 1507]]}
{"context": "To study the impact of genetic and lifestyle factors on protein biomarkers and develop personally normalized plasma protein profiles (PNPPP) controlling for non-disease-related variance. Proximity extension assays were used to measure 145 proteins in 632 controls and 344 cases with non-communicable diseases. Genetic and lifestyle factors explained 20-88% of the variation in healthy controls. Adjusting for these factors reduced the number of candidate biomarkers by 63%. PNPPP efficiently controls for non-disease-related variance, allowing both for efficient discovery of novel biomarkers and for covariate-independent linear cut-offs suitable for clinical use.", "qas": [{"question": "What is PNPPP?", "answers": ["personally normalized plasma protein profiles"], "qid": "fd51aa90ceb147e78cd27c4328ac7962", "question_tokens": [["What", 0], ["is", 5], ["PNPPP", 8], ["?", 13]], "detected_answers": [{"text": "personally normalized plasma protein profiles", "token_spans": [[14, 18]], "char_spans": [[87, 131]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["impact", 13], ["of", 20], ["genetic", 23], ["and", 31], ["lifestyle", 35], ["factors", 45], ["on", 53], ["protein", 56], ["biomarkers", 64], ["and", 75], ["develop", 79], ["personally", 87], ["normalized", 98], ["plasma", 109], ["protein", 116], ["profiles", 124], ["(", 133], ["PNPPP", 134], [")", 139], ["controlling", 141], ["for", 153], ["non", 157], ["-", 160], ["disease", 161], ["-", 168], ["related", 169], ["variance", 177], [".", 185], ["Proximity", 187], ["extension", 197], ["assays", 207], ["were", 214], ["used", 219], ["to", 224], ["measure", 227], ["145", 235], ["proteins", 239], ["in", 248], ["632", 251], ["controls", 255], ["and", 264], ["344", 268], ["cases", 272], ["with", 278], ["non", 283], ["-", 286], ["communicable", 287], ["diseases", 300], [".", 308], ["Genetic", 310], ["and", 318], ["lifestyle", 322], ["factors", 332], ["explained", 340], ["20", 350], ["-", 352], ["88", 353], ["%", 355], ["of", 357], ["the", 360], ["variation", 364], ["in", 374], ["healthy", 377], ["controls", 385], [".", 393], ["Adjusting", 395], ["for", 405], ["these", 409], ["factors", 415], ["reduced", 423], ["the", 431], ["number", 435], ["of", 442], ["candidate", 445], ["biomarkers", 455], ["by", 466], ["63", 469], ["%", 471], [".", 472], ["PNPPP", 474], ["efficiently", 480], ["controls", 492], ["for", 501], ["non", 505], ["-", 508], ["disease", 509], ["-", 516], ["related", 517], ["variance", 525], [",", 533], ["allowing", 535], ["both", 544], ["for", 549], ["efficient", 553], ["discovery", 563], ["of", 573], ["novel", 576], ["biomarkers", 582], ["and", 593], ["for", 597], ["covariate", 601], ["-", 610], ["independent", 611], ["linear", 623], ["cut", 630], ["-", 633], ["offs", 634], ["suitable", 639], ["for", 648], ["clinical", 652], ["use", 661], [".", 664]]}
{"context": "The Shprintzen-Goldberg syndrome (SGS) is a disorder of unknown cause comprising craniosynostosis, a marfanoid habitus and skeletal, neurological, cardiovascular, and connective-tissue anomalies. There are no pathognomonic signs of SGS and diagnosis depends on recognition of a characteristic combination of anomalies. Here, we describe 14 persons with SGS and compare their clinical findings with those of 23 previously reported individuals, including two families with more than one affected individual. Our analysis suggests that there is a characteristic facial appearance, with more than two thirds of all individuals having hypertelorism, down-slanting palpebral fissures, a high-arched palate, micrognathia, and apparently low-set and posteriorly rotated ears. Other commonly reported manifestations include hypotonia in at least the neonatal period, developmental delay, and inguinal or umbilical hernia. The degree of reported intellectual impairment ranges from mild to severe. The most common skeletal manifestations in SGS were arachnodactyly, pectus deformity, camptodactyly, scoliosis, and joint hypermobility. None of the skeletal signs alone is specific for SGS. Our study includes 14 mainly German individuals with SGS evaluated over a period of 10 years. Given that only 23 other persons with SGS have been reported to date worldwide, we suggest that SGS may be more common than previously assumed.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "2406a794568840628014804927e40975", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[15, 15]], "char_spans": [[81, 96]]}]}], "context_tokens": [["The", 0], ["Shprintzen", 4], ["-", 14], ["Goldberg", 15], ["syndrome", 24], ["(", 33], ["SGS", 34], [")", 37], ["is", 39], ["a", 42], ["disorder", 44], ["of", 53], ["unknown", 56], ["cause", 64], ["comprising", 70], ["craniosynostosis", 81], [",", 97], ["a", 99], ["marfanoid", 101], ["habitus", 111], ["and", 119], ["skeletal", 123], [",", 131], ["neurological", 133], [",", 145], ["cardiovascular", 147], [",", 161], ["and", 163], ["connective", 167], ["-", 177], ["tissue", 178], ["anomalies", 185], [".", 194], ["There", 196], ["are", 202], ["no", 206], ["pathognomonic", 209], ["signs", 223], ["of", 229], ["SGS", 232], ["and", 236], ["diagnosis", 240], ["depends", 250], ["on", 258], ["recognition", 261], ["of", 273], ["a", 276], ["characteristic", 278], ["combination", 293], ["of", 305], ["anomalies", 308], [".", 317], ["Here", 319], [",", 323], ["we", 325], ["describe", 328], ["14", 337], ["persons", 340], ["with", 348], ["SGS", 353], ["and", 357], ["compare", 361], ["their", 369], ["clinical", 375], ["findings", 384], ["with", 393], ["those", 398], ["of", 404], ["23", 407], ["previously", 410], ["reported", 421], ["individuals", 430], [",", 441], ["including", 443], ["two", 453], ["families", 457], ["with", 466], ["more", 471], ["than", 476], ["one", 481], ["affected", 485], ["individual", 494], [".", 504], ["Our", 506], ["analysis", 510], ["suggests", 519], ["that", 528], ["there", 533], ["is", 539], ["a", 542], ["characteristic", 544], ["facial", 559], ["appearance", 566], [",", 576], ["with", 578], ["more", 583], ["than", 588], ["two", 593], ["thirds", 597], ["of", 604], ["all", 607], ["individuals", 611], ["having", 623], ["hypertelorism", 630], [",", 643], ["down", 645], ["-", 649], ["slanting", 650], ["palpebral", 659], ["fissures", 669], [",", 677], ["a", 679], ["high", 681], ["-", 685], ["arched", 686], ["palate", 693], [",", 699], ["micrognathia", 701], [",", 713], ["and", 715], ["apparently", 719], ["low", 730], ["-", 733], ["set", 734], ["and", 738], ["posteriorly", 742], ["rotated", 754], ["ears", 762], [".", 766], ["Other", 768], ["commonly", 774], ["reported", 783], ["manifestations", 792], ["include", 807], ["hypotonia", 815], ["in", 825], ["at", 828], ["least", 831], ["the", 837], ["neonatal", 841], ["period", 850], [",", 856], ["developmental", 858], ["delay", 872], [",", 877], ["and", 879], ["inguinal", 883], ["or", 892], ["umbilical", 895], ["hernia", 905], [".", 911], ["The", 913], ["degree", 917], ["of", 924], ["reported", 927], ["intellectual", 936], ["impairment", 949], ["ranges", 960], ["from", 967], ["mild", 972], ["to", 977], ["severe", 980], [".", 986], ["The", 988], ["most", 992], ["common", 997], ["skeletal", 1004], ["manifestations", 1013], ["in", 1028], ["SGS", 1031], ["were", 1035], ["arachnodactyly", 1040], [",", 1054], ["pectus", 1056], ["deformity", 1063], [",", 1072], ["camptodactyly", 1074], [",", 1087], ["scoliosis", 1089], [",", 1098], ["and", 1100], ["joint", 1104], ["hypermobility", 1110], [".", 1123], ["None", 1125], ["of", 1130], ["the", 1133], ["skeletal", 1137], ["signs", 1146], ["alone", 1152], ["is", 1158], ["specific", 1161], ["for", 1170], ["SGS", 1174], [".", 1177], ["Our", 1179], ["study", 1183], ["includes", 1189], ["14", 1198], ["mainly", 1201], ["German", 1208], ["individuals", 1215], ["with", 1227], ["SGS", 1232], ["evaluated", 1236], ["over", 1246], ["a", 1251], ["period", 1253], ["of", 1260], ["10", 1263], ["years", 1266], [".", 1271], ["Given", 1273], ["that", 1279], ["only", 1284], ["23", 1289], ["other", 1292], ["persons", 1298], ["with", 1306], ["SGS", 1311], ["have", 1315], ["been", 1320], ["reported", 1325], ["to", 1334], ["date", 1337], ["worldwide", 1342], [",", 1351], ["we", 1353], ["suggest", 1356], ["that", 1364], ["SGS", 1369], ["may", 1373], ["be", 1377], ["more", 1380], ["common", 1385], ["than", 1392], ["previously", 1397], ["assumed", 1408], [".", 1415]]}
{"context": "Restless legs syndrome (RLS) is a clinically important, common disease and should be diagnosed and treated early and adequately. At present, there have been no clinical biomarkers or methodologies that can contribute to the correct diagnosis of RLS, RLS should be diagnosed on the basis of 4 essential criteria: urge to move the legs, improvement after movement, and worsening or occurrence of symptoms in the evening and at rest. When applying the criteria, RLS mimics should be ruled out and comorbid diseases should be taken into account. The origin and pathogenesis of RLS are still under investigation; however, iron deficiency in the brain has been observed on imaging and cerebrospinal fluid analyses of patients with RLS. In contrast, the results of neuroimaging studies evaluating brain dopaminergic functions in patients with RLS have yielded inconclusive results, although involvement of the hypothalamus (A11) is thought to cause impaired dopaminergic modulation in the dorsal horn and intermediolateral nucleus, resulting in the restlessness of legs.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "f86ef5e1ac664cb0a799f69a2e54f94d", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[112, 112]], "char_spans": [[617, 620]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], ["is", 29], ["a", 32], ["clinically", 34], ["important", 45], [",", 54], ["common", 56], ["disease", 63], ["and", 71], ["should", 75], ["be", 82], ["diagnosed", 85], ["and", 95], ["treated", 99], ["early", 107], ["and", 113], ["adequately", 117], [".", 127], ["At", 129], ["present", 132], [",", 139], ["there", 141], ["have", 147], ["been", 152], ["no", 157], ["clinical", 160], ["biomarkers", 169], ["or", 180], ["methodologies", 183], ["that", 197], ["can", 202], ["contribute", 206], ["to", 217], ["the", 220], ["correct", 224], ["diagnosis", 232], ["of", 242], ["RLS", 245], [",", 248], ["RLS", 250], ["should", 254], ["be", 261], ["diagnosed", 264], ["on", 274], ["the", 277], ["basis", 281], ["of", 287], ["4", 290], ["essential", 292], ["criteria", 302], [":", 310], ["urge", 312], ["to", 317], ["move", 320], ["the", 325], ["legs", 329], [",", 333], ["improvement", 335], ["after", 347], ["movement", 353], [",", 361], ["and", 363], ["worsening", 367], ["or", 377], ["occurrence", 380], ["of", 391], ["symptoms", 394], ["in", 403], ["the", 406], ["evening", 410], ["and", 418], ["at", 422], ["rest", 425], [".", 429], ["When", 431], ["applying", 436], ["the", 445], ["criteria", 449], [",", 457], ["RLS", 459], ["mimics", 463], ["should", 470], ["be", 477], ["ruled", 480], ["out", 486], ["and", 490], ["comorbid", 494], ["diseases", 503], ["should", 512], ["be", 519], ["taken", 522], ["into", 528], ["account", 533], [".", 540], ["The", 542], ["origin", 546], ["and", 553], ["pathogenesis", 557], ["of", 570], ["RLS", 573], ["are", 577], ["still", 581], ["under", 587], ["investigation", 593], [";", 606], ["however", 608], [",", 615], ["iron", 617], ["deficiency", 622], ["in", 633], ["the", 636], ["brain", 640], ["has", 646], ["been", 650], ["observed", 655], ["on", 664], ["imaging", 667], ["and", 675], ["cerebrospinal", 679], ["fluid", 693], ["analyses", 699], ["of", 708], ["patients", 711], ["with", 720], ["RLS", 725], [".", 728], ["In", 730], ["contrast", 733], [",", 741], ["the", 743], ["results", 747], ["of", 755], ["neuroimaging", 758], ["studies", 771], ["evaluating", 779], ["brain", 790], ["dopaminergic", 796], ["functions", 809], ["in", 819], ["patients", 822], ["with", 831], ["RLS", 836], ["have", 840], ["yielded", 845], ["inconclusive", 853], ["results", 866], [",", 873], ["although", 875], ["involvement", 884], ["of", 896], ["the", 899], ["hypothalamus", 903], ["(", 916], ["A11", 917], [")", 920], ["is", 922], ["thought", 925], ["to", 933], ["cause", 936], ["impaired", 942], ["dopaminergic", 951], ["modulation", 964], ["in", 975], ["the", 978], ["dorsal", 982], ["horn", 989], ["and", 994], ["intermediolateral", 998], ["nucleus", 1016], [",", 1023], ["resulting", 1025], ["in", 1035], ["the", 1038], ["restlessness", 1042], ["of", 1055], ["legs", 1058], [".", 1062]]}
{"context": "Empagliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that inhibits renal glucose reabsorption and is being investigated for the treatment of type 2 diabetes mellitus (T2DM). In this open-label study, the effect of renal impairment on the pharmacokinetics, pharmacodynamics and safety of a 50\u2009mg dose of empagliflozin was investigated in 40 subjects, grouped according to estimated glomerular filtration rate (eGFR). Maximum empagliflozin plasma concentrations were similar in subjects with normal renal function and renal impairment. Area under the empagliflozin concentration-time curve (AUC0 -\u221e ) values increased by approximately 18, 20, 66 and 48% in subjects with mild, moderate, severe renal impairment and renal failure/end stage renal disease (ESRD), respectively, in comparison to healthy subjects. This was attributed to decreased renal clearance (CLR ). Urinary glucose excretion (UGE) decreased with increasing renal impairment and correlated with decreased eGFR and CLR . Empagliflozin was well tolerated, with no increase in adverse events associated with renal impairment. Renal insufficiency resulted in decreased CLR of empagliflozin, moderately increased systemic exposure and decreased UGE. A single 50\u2009mg dose of empagliflozin was well tolerated in subjects with normal renal function and any degree of renal impairment. The pharmacokinetic results of this study indicate that no dose adjustment of empagliflozin is required in patients with renal impairment.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "d298832c62de4e73ad3b013ea2443d51", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[9, 9]], "char_spans": [[61, 65]]}]}], "context_tokens": [["Empagliflozin", 0], ["is", 14], ["a", 17], ["selective", 19], ["sodium", 29], ["glucose", 36], ["cotransporter", 44], ["2", 58], ["(", 60], ["SGLT2", 61], [")", 66], ["inhibitor", 68], ["that", 78], ["inhibits", 83], ["renal", 92], ["glucose", 98], ["reabsorption", 106], ["and", 119], ["is", 123], ["being", 126], ["investigated", 132], ["for", 145], ["the", 149], ["treatment", 153], ["of", 163], ["type", 166], ["2", 171], ["diabetes", 173], ["mellitus", 182], ["(", 191], ["T2DM", 192], [")", 196], [".", 197], ["In", 199], ["this", 202], ["open", 207], ["-", 211], ["label", 212], ["study", 218], [",", 223], ["the", 225], ["effect", 229], ["of", 236], ["renal", 239], ["impairment", 245], ["on", 256], ["the", 259], ["pharmacokinetics", 263], [",", 279], ["pharmacodynamics", 281], ["and", 298], ["safety", 302], ["of", 309], ["a", 312], ["50", 314], ["mg", 317], ["dose", 320], ["of", 325], ["empagliflozin", 328], ["was", 342], ["investigated", 346], ["in", 359], ["40", 362], ["subjects", 365], [",", 373], ["grouped", 375], ["according", 383], ["to", 393], ["estimated", 396], ["glomerular", 406], ["filtration", 417], ["rate", 428], ["(", 433], ["eGFR", 434], [")", 438], [".", 439], ["Maximum", 441], ["empagliflozin", 449], ["plasma", 463], ["concentrations", 470], ["were", 485], ["similar", 490], ["in", 498], ["subjects", 501], ["with", 510], ["normal", 515], ["renal", 522], ["function", 528], ["and", 537], ["renal", 541], ["impairment", 547], [".", 557], ["Area", 559], ["under", 564], ["the", 570], ["empagliflozin", 574], ["concentration", 588], ["-", 601], ["time", 602], ["curve", 607], ["(", 613], ["AUC0", 614], ["-\u221e", 619], [")", 622], ["values", 624], ["increased", 631], ["by", 641], ["approximately", 644], ["18", 658], [",", 660], ["20", 662], [",", 664], ["66", 666], ["and", 669], ["48", 673], ["%", 675], ["in", 677], ["subjects", 680], ["with", 689], ["mild", 694], [",", 698], ["moderate", 700], [",", 708], ["severe", 710], ["renal", 717], ["impairment", 723], ["and", 734], ["renal", 738], ["failure", 744], ["/", 751], ["end", 752], ["stage", 756], ["renal", 762], ["disease", 768], ["(", 776], ["ESRD", 777], [")", 781], [",", 782], ["respectively", 784], [",", 796], ["in", 798], ["comparison", 801], ["to", 812], ["healthy", 815], ["subjects", 823], [".", 831], ["This", 833], ["was", 838], ["attributed", 842], ["to", 853], ["decreased", 856], ["renal", 866], ["clearance", 872], ["(", 882], ["CLR", 883], [")", 887], [".", 888], ["Urinary", 890], ["glucose", 898], ["excretion", 906], ["(", 916], ["UGE", 917], [")", 920], ["decreased", 922], ["with", 932], ["increasing", 937], ["renal", 948], ["impairment", 954], ["and", 965], ["correlated", 969], ["with", 980], ["decreased", 985], ["eGFR", 995], ["and", 1000], ["CLR", 1004], [".", 1008], ["Empagliflozin", 1010], ["was", 1024], ["well", 1028], ["tolerated", 1033], [",", 1042], ["with", 1044], ["no", 1049], ["increase", 1052], ["in", 1061], ["adverse", 1064], ["events", 1072], ["associated", 1079], ["with", 1090], ["renal", 1095], ["impairment", 1101], [".", 1111], ["Renal", 1113], ["insufficiency", 1119], ["resulted", 1133], ["in", 1142], ["decreased", 1145], ["CLR", 1155], ["of", 1159], ["empagliflozin", 1162], [",", 1175], ["moderately", 1177], ["increased", 1188], ["systemic", 1198], ["exposure", 1207], ["and", 1216], ["decreased", 1220], ["UGE", 1230], [".", 1233], ["A", 1235], ["single", 1237], ["50", 1244], ["mg", 1247], ["dose", 1250], ["of", 1255], ["empagliflozin", 1258], ["was", 1272], ["well", 1276], ["tolerated", 1281], ["in", 1291], ["subjects", 1294], ["with", 1303], ["normal", 1308], ["renal", 1315], ["function", 1321], ["and", 1330], ["any", 1334], ["degree", 1338], ["of", 1345], ["renal", 1348], ["impairment", 1354], [".", 1364], ["The", 1366], ["pharmacokinetic", 1370], ["results", 1386], ["of", 1394], ["this", 1397], ["study", 1402], ["indicate", 1408], ["that", 1417], ["no", 1422], ["dose", 1425], ["adjustment", 1430], ["of", 1441], ["empagliflozin", 1444], ["is", 1458], ["required", 1461], ["in", 1470], ["patients", 1473], ["with", 1482], ["renal", 1487], ["impairment", 1493], [".", 1503]]}
{"context": "To demonstrate the importance of preventive measures when a case of tuberculosis is detected, identify the causes that favored a tuberculosis outbreak in a school and determine the efficiency of obtaining induced sputum samples. Descriptive, study. The Santa Maria de la Providencia school, located in the municipality of Alcala de Henares in Spain. On April 11, 2005, a case of bacilliform pulmonary tuberculosis was notified in a teacher. Study of contacts in the collective was performed as a programmed intervention. Mantoux skin test and, if positive, chest radiograph were performed in contacts. Treatment of latent or active tuberculosis was recommended according to the result. School exposures were identified and underwent the Mantoux skin test (142 students in years 1, 2, 3, and 4 of compulsory secondary education and 22 teachers). The Mantoux test was positive in 68 students (48 %) and seven teachers (32 %). In seven students with results compatible with active tuberculosis disease, sputum induction was performed and treatment was started. A further two students, identified as contacts, were studied in another center and also started treatment for active tuberculosis disease. Due to the high risk of contagion, study of contacts was extended to the remaining students in compulsory secondary education. In this second phase, 134 students received the Mantoux skin test and seven were Mantoux positive (5.2 %). In all these students, active tuberculosis disease was ruled out. Latent tuberculosis treatment was recommended in all Mantoux-positive contacts.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "432d404973ba41318c6fe93752543d01", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[11, 11], [21, 21], [70, 70], [210, 210], [263, 263], [270, 270], [178, 178], [110, 110]], "char_spans": [[68, 79], [129, 140], [401, 412], [1175, 1186], [1461, 1472], [1504, 1515], [978, 989], [632, 643]]}]}], "context_tokens": [["To", 0], ["demonstrate", 3], ["the", 15], ["importance", 19], ["of", 30], ["preventive", 33], ["measures", 44], ["when", 53], ["a", 58], ["case", 60], ["of", 65], ["tuberculosis", 68], ["is", 81], ["detected", 84], [",", 92], ["identify", 94], ["the", 103], ["causes", 107], ["that", 114], ["favored", 119], ["a", 127], ["tuberculosis", 129], ["outbreak", 142], ["in", 151], ["a", 154], ["school", 156], ["and", 163], ["determine", 167], ["the", 177], ["efficiency", 181], ["of", 192], ["obtaining", 195], ["induced", 205], ["sputum", 213], ["samples", 220], [".", 227], ["Descriptive", 229], [",", 240], ["study", 242], [".", 247], ["The", 249], ["Santa", 253], ["Maria", 259], ["de", 265], ["la", 268], ["Providencia", 271], ["school", 283], [",", 289], ["located", 291], ["in", 299], ["the", 302], ["municipality", 306], ["of", 319], ["Alcala", 322], ["de", 329], ["Henares", 332], ["in", 340], ["Spain", 343], [".", 348], ["On", 350], ["April", 353], ["11", 359], [",", 361], ["2005", 363], [",", 367], ["a", 369], ["case", 371], ["of", 376], ["bacilliform", 379], ["pulmonary", 391], ["tuberculosis", 401], ["was", 414], ["notified", 418], ["in", 427], ["a", 430], ["teacher", 432], [".", 439], ["Study", 441], ["of", 447], ["contacts", 450], ["in", 459], ["the", 462], ["collective", 466], ["was", 477], ["performed", 481], ["as", 491], ["a", 494], ["programmed", 496], ["intervention", 507], [".", 519], ["Mantoux", 521], ["skin", 529], ["test", 534], ["and", 539], [",", 542], ["if", 544], ["positive", 547], [",", 555], ["chest", 557], ["radiograph", 563], ["were", 574], ["performed", 579], ["in", 589], ["contacts", 592], [".", 600], ["Treatment", 602], ["of", 612], ["latent", 615], ["or", 622], ["active", 625], ["tuberculosis", 632], ["was", 645], ["recommended", 649], ["according", 661], ["to", 671], ["the", 674], ["result", 678], [".", 684], ["School", 686], ["exposures", 693], ["were", 703], ["identified", 708], ["and", 719], ["underwent", 723], ["the", 733], ["Mantoux", 737], ["skin", 745], ["test", 750], ["(", 755], ["142", 756], ["students", 760], ["in", 769], ["years", 772], ["1", 778], [",", 779], ["2", 781], [",", 782], ["3", 784], [",", 785], ["and", 787], ["4", 791], ["of", 793], ["compulsory", 796], ["secondary", 807], ["education", 817], ["and", 827], ["22", 831], ["teachers", 834], [")", 842], [".", 843], ["The", 845], ["Mantoux", 849], ["test", 857], ["was", 862], ["positive", 866], ["in", 875], ["68", 878], ["students", 881], ["(", 890], ["48", 891], ["%", 894], [")", 895], ["and", 897], ["seven", 901], ["teachers", 907], ["(", 916], ["32", 917], ["%", 920], [")", 921], [".", 922], ["In", 924], ["seven", 927], ["students", 933], ["with", 942], ["results", 947], ["compatible", 955], ["with", 966], ["active", 971], ["tuberculosis", 978], ["disease", 991], [",", 998], ["sputum", 1000], ["induction", 1007], ["was", 1017], ["performed", 1021], ["and", 1031], ["treatment", 1035], ["was", 1045], ["started", 1049], [".", 1056], ["A", 1058], ["further", 1060], ["two", 1068], ["students", 1072], [",", 1080], ["identified", 1082], ["as", 1093], ["contacts", 1096], [",", 1104], ["were", 1106], ["studied", 1111], ["in", 1119], ["another", 1122], ["center", 1130], ["and", 1137], ["also", 1141], ["started", 1146], ["treatment", 1154], ["for", 1164], ["active", 1168], ["tuberculosis", 1175], ["disease", 1188], [".", 1195], ["Due", 1197], ["to", 1201], ["the", 1204], ["high", 1208], ["risk", 1213], ["of", 1218], ["contagion", 1221], [",", 1230], ["study", 1232], ["of", 1238], ["contacts", 1241], ["was", 1250], ["extended", 1254], ["to", 1263], ["the", 1266], ["remaining", 1270], ["students", 1280], ["in", 1289], ["compulsory", 1292], ["secondary", 1303], ["education", 1313], [".", 1322], ["In", 1324], ["this", 1327], ["second", 1332], ["phase", 1339], [",", 1344], ["134", 1346], ["students", 1350], ["received", 1359], ["the", 1368], ["Mantoux", 1372], ["skin", 1380], ["test", 1385], ["and", 1390], ["seven", 1394], ["were", 1400], ["Mantoux", 1405], ["positive", 1413], ["(", 1422], ["5.2", 1423], ["%", 1427], [")", 1428], [".", 1429], ["In", 1431], ["all", 1434], ["these", 1438], ["students", 1444], [",", 1452], ["active", 1454], ["tuberculosis", 1461], ["disease", 1474], ["was", 1482], ["ruled", 1486], ["out", 1492], [".", 1495], ["Latent", 1497], ["tuberculosis", 1504], ["treatment", 1517], ["was", 1527], ["recommended", 1531], ["in", 1543], ["all", 1546], ["Mantoux", 1550], ["-", 1557], ["positive", 1558], ["contacts", 1567], [".", 1575]]}
{"context": "We immunohistochemically investigated the degeneration processes of the nigro-striatal and nigro-amygdaloid pathways and the relationship between the loss of dopaminergic neurons and Lewy bodies (LB) formation in the substantia nigra using 15 autopsied cases of dementia with Lewy bodies (DLB). The number of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra and TH-positive axonal terminals in the putamen decreased with a specific pattern. The substantia nigra possessed alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed, while the putamen exhibited diffuse or granular alpha-synuclein-immunostaining. Most of the granular stains were positive for anti-phosphorylated alpha-synuclein antibody, whereas the diffuse stains were negative. These findings suggest that the axonal terminals in the putamen undergo abnormal alpha-synuclein accumulation, but may not always originate from LB-bearing neurons in the substantia nigra. The central amygdaloid nucleus contained anti-alpha-synuclein- and -phosphorylated alpha-synuclein-positive dystrophic axonal terminals, the degree of which was greater for cases with granular staining in the putamen, and which was proportional to the number of alpha-synuclein-positive neurons in the substantia nigra. Thus, the axonal terminals in the central amygdaloid nucleus may have originated from LB-bearing neurons in the substantia nigra. The results of the present study indicate that the nigro-striatal and nigro-amygdaloid pathways undergo different degeneration processes in DLB, and suggest that the degeneration of the nigro-amygdaloid pathway more strongly reflects LB formation in dopaminergic neurons of the substantia nigra than that of the nigro-striatal pathway. In addition, they indicate that there is no direct relationship between the loss of dopaminergic neurons and LB formation in the substantia nigra.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "838f259cf3d94ed1a4628e26a79fa183", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[102, 104], [170, 172], [175, 177], [119, 121], [207, 209], [80, 82], [143, 145]], "char_spans": [[619, 633], [1020, 1035], [1057, 1071], [717, 731], [1236, 1250], [490, 504], [866, 880]]}]}], "context_tokens": [["We", 0], ["immunohistochemically", 3], ["investigated", 25], ["the", 38], ["degeneration", 42], ["processes", 55], ["of", 65], ["the", 68], ["nigro", 72], ["-", 77], ["striatal", 78], ["and", 87], ["nigro", 91], ["-", 96], ["amygdaloid", 97], ["pathways", 108], ["and", 117], ["the", 121], ["relationship", 125], ["between", 138], ["the", 146], ["loss", 150], ["of", 155], ["dopaminergic", 158], ["neurons", 171], ["and", 179], ["Lewy", 183], ["bodies", 188], ["(", 195], ["LB", 196], [")", 198], ["formation", 200], ["in", 210], ["the", 213], ["substantia", 217], ["nigra", 228], ["using", 234], ["15", 240], ["autopsied", 243], ["cases", 253], ["of", 259], ["dementia", 262], ["with", 271], ["Lewy", 276], ["bodies", 281], ["(", 288], ["DLB", 289], [")", 292], [".", 293], ["The", 295], ["number", 299], ["of", 306], ["tyrosine", 309], ["hydroxylase", 318], ["(", 330], ["TH)-positive", 331], ["neurons", 344], ["in", 352], ["the", 355], ["substantia", 359], ["nigra", 370], ["and", 376], ["TH", 380], ["-", 382], ["positive", 383], ["axonal", 392], ["terminals", 399], ["in", 409], ["the", 412], ["putamen", 416], ["decreased", 424], ["with", 434], ["a", 439], ["specific", 441], ["pattern", 450], [".", 457], ["The", 459], ["substantia", 463], ["nigra", 474], ["possessed", 480], ["alpha", 490], ["-", 495], ["synuclein", 496], ["-", 505], ["positive", 506], ["LB", 515], ["-", 517], ["bearing", 518], ["neurons", 526], ["that", 534], ["were", 539], ["almost", 544], ["evenly", 551], ["distributed", 558], [",", 569], ["while", 571], ["the", 577], ["putamen", 581], ["exhibited", 589], ["diffuse", 599], ["or", 607], ["granular", 610], ["alpha", 619], ["-", 624], ["synuclein", 625], ["-", 634], ["immunostaining", 635], [".", 649], ["Most", 651], ["of", 656], ["the", 659], ["granular", 663], ["stains", 672], ["were", 679], ["positive", 684], ["for", 693], ["anti", 697], ["-", 701], ["phosphorylated", 702], ["alpha", 717], ["-", 722], ["synuclein", 723], ["antibody", 733], [",", 741], ["whereas", 743], ["the", 751], ["diffuse", 755], ["stains", 763], ["were", 770], ["negative", 775], [".", 783], ["These", 785], ["findings", 791], ["suggest", 800], ["that", 808], ["the", 813], ["axonal", 817], ["terminals", 824], ["in", 834], ["the", 837], ["putamen", 841], ["undergo", 849], ["abnormal", 857], ["alpha", 866], ["-", 871], ["synuclein", 872], ["accumulation", 882], [",", 894], ["but", 896], ["may", 900], ["not", 904], ["always", 908], ["originate", 915], ["from", 925], ["LB", 930], ["-", 932], ["bearing", 933], ["neurons", 941], ["in", 949], ["the", 952], ["substantia", 956], ["nigra", 967], [".", 972], ["The", 974], ["central", 978], ["amygdaloid", 986], ["nucleus", 997], ["contained", 1005], ["anti", 1015], ["-", 1019], ["alpha", 1020], ["-", 1025], ["synuclein-", 1026], ["and", 1037], ["-phosphorylated", 1041], ["alpha", 1057], ["-", 1062], ["synuclein", 1063], ["-", 1072], ["positive", 1073], ["dystrophic", 1082], ["axonal", 1093], ["terminals", 1100], [",", 1109], ["the", 1111], ["degree", 1115], ["of", 1122], ["which", 1125], ["was", 1131], ["greater", 1135], ["for", 1143], ["cases", 1147], ["with", 1153], ["granular", 1158], ["staining", 1167], ["in", 1176], ["the", 1179], ["putamen", 1183], [",", 1190], ["and", 1192], ["which", 1196], ["was", 1202], ["proportional", 1206], ["to", 1219], ["the", 1222], ["number", 1226], ["of", 1233], ["alpha", 1236], ["-", 1241], ["synuclein", 1242], ["-", 1251], ["positive", 1252], ["neurons", 1261], ["in", 1269], ["the", 1272], ["substantia", 1276], ["nigra", 1287], [".", 1292], ["Thus", 1294], [",", 1298], ["the", 1300], ["axonal", 1304], ["terminals", 1311], ["in", 1321], ["the", 1324], ["central", 1328], ["amygdaloid", 1336], ["nucleus", 1347], ["may", 1355], ["have", 1359], ["originated", 1364], ["from", 1375], ["LB", 1380], ["-", 1382], ["bearing", 1383], ["neurons", 1391], ["in", 1399], ["the", 1402], ["substantia", 1406], ["nigra", 1417], [".", 1422], ["The", 1424], ["results", 1428], ["of", 1436], ["the", 1439], ["present", 1443], ["study", 1451], ["indicate", 1457], ["that", 1466], ["the", 1471], ["nigro", 1475], ["-", 1480], ["striatal", 1481], ["and", 1490], ["nigro", 1494], ["-", 1499], ["amygdaloid", 1500], ["pathways", 1511], ["undergo", 1520], ["different", 1528], ["degeneration", 1538], ["processes", 1551], ["in", 1561], ["DLB", 1564], [",", 1567], ["and", 1569], ["suggest", 1573], ["that", 1581], ["the", 1586], ["degeneration", 1590], ["of", 1603], ["the", 1606], ["nigro", 1610], ["-", 1615], ["amygdaloid", 1616], ["pathway", 1627], ["more", 1635], ["strongly", 1640], ["reflects", 1649], ["LB", 1658], ["formation", 1661], ["in", 1671], ["dopaminergic", 1674], ["neurons", 1687], ["of", 1695], ["the", 1698], ["substantia", 1702], ["nigra", 1713], ["than", 1719], ["that", 1724], ["of", 1729], ["the", 1732], ["nigro", 1736], ["-", 1741], ["striatal", 1742], ["pathway", 1751], [".", 1758], ["In", 1760], ["addition", 1763], [",", 1771], ["they", 1773], ["indicate", 1778], ["that", 1787], ["there", 1792], ["is", 1798], ["no", 1801], ["direct", 1804], ["relationship", 1811], ["between", 1824], ["the", 1832], ["loss", 1836], ["of", 1841], ["dopaminergic", 1844], ["neurons", 1857], ["and", 1865], ["LB", 1869], ["formation", 1872], ["in", 1882], ["the", 1885], ["substantia", 1889], ["nigra", 1900], [".", 1905]]}
{"context": "Some neurological conditions require admission to an intensive care unit (ICU) where deep sedation and mechanical ventilation are administered to improve the patient's condition. Nevertheless, these treatments are not always helpful in disease control. At this stage, deep brain stimulation (DBS) could become a viable alternative in the treatment of critical neurological conditions with long-lasting clinical benefit. The value of deep brain stimulation has been investigated in the treatment of patients who had undergone surgical electrode implants as an emergency procedure to treat acute life-threatening conditions requiring admission to neurological ICU (NICU). A before-and-after perspective study was examined of seven patients who were treated with DBS for status dystonicus (SD) and post-stroke severe hemiballismus. Bilateral globus pallidus internus (GPi) DBS was performed in five SD patients and unilateral ventralis oralis anterior and posterior (Voa/Vop) nucleus of the thalamus DBS in two post-stroke hemiballismus patients. Bilateral GPi-DBS allowed SD resolution in a time lapse varying from 1\u00a0week to 3\u00a0months. No clear improvements compared to the baseline clinical condition were observed. Unilateral Voa/Vop-DBS intervention controlled hemiballismus after 10\u00a0h, and the patient was discharged in 2\u00a0days. The other patient was transferred from the NICU to the neurosurgery ward after 13\u00a0days. No surgical complications were observed in any of the above procedures. Neurostimulation procedures could represent a valuable choice in critical care conditions, when involuntary movements are continuous, life-threatening and refractory to intensive care procedures. DBS is feasible, safe and effective in selected cases.", "qas": [{"question": "Neurostimulation of which nucleus is used for treatment of dystonia?", "answers": ["globus pallidus internus"], "qid": "2c1bd1c29737403c884ad051c6440ed5", "question_tokens": [["Neurostimulation", 0], ["of", 17], ["which", 20], ["nucleus", 26], ["is", 34], ["used", 37], ["for", 42], ["treatment", 46], ["of", 56], ["dystonia", 59], ["?", 67]], "detected_answers": [{"text": "globus pallidus internus", "token_spans": [[141, 143]], "char_spans": [[839, 862]]}]}], "context_tokens": [["Some", 0], ["neurological", 5], ["conditions", 18], ["require", 29], ["admission", 37], ["to", 47], ["an", 50], ["intensive", 53], ["care", 63], ["unit", 68], ["(", 73], ["ICU", 74], [")", 77], ["where", 79], ["deep", 85], ["sedation", 90], ["and", 99], ["mechanical", 103], ["ventilation", 114], ["are", 126], ["administered", 130], ["to", 143], ["improve", 146], ["the", 154], ["patient", 158], ["'s", 165], ["condition", 168], [".", 177], ["Nevertheless", 179], [",", 191], ["these", 193], ["treatments", 199], ["are", 210], ["not", 214], ["always", 218], ["helpful", 225], ["in", 233], ["disease", 236], ["control", 244], [".", 251], ["At", 253], ["this", 256], ["stage", 261], [",", 266], ["deep", 268], ["brain", 273], ["stimulation", 279], ["(", 291], ["DBS", 292], [")", 295], ["could", 297], ["become", 303], ["a", 310], ["viable", 312], ["alternative", 319], ["in", 331], ["the", 334], ["treatment", 338], ["of", 348], ["critical", 351], ["neurological", 360], ["conditions", 373], ["with", 384], ["long", 389], ["-", 393], ["lasting", 394], ["clinical", 402], ["benefit", 411], [".", 418], ["The", 420], ["value", 424], ["of", 430], ["deep", 433], ["brain", 438], ["stimulation", 444], ["has", 456], ["been", 460], ["investigated", 465], ["in", 478], ["the", 481], ["treatment", 485], ["of", 495], ["patients", 498], ["who", 507], ["had", 511], ["undergone", 515], ["surgical", 525], ["electrode", 534], ["implants", 544], ["as", 553], ["an", 556], ["emergency", 559], ["procedure", 569], ["to", 579], ["treat", 582], ["acute", 588], ["life", 594], ["-", 598], ["threatening", 599], ["conditions", 611], ["requiring", 622], ["admission", 632], ["to", 642], ["neurological", 645], ["ICU", 658], ["(", 662], ["NICU", 663], [")", 667], [".", 668], ["A", 670], ["before", 672], ["-", 678], ["and", 679], ["-", 682], ["after", 683], ["perspective", 689], ["study", 701], ["was", 707], ["examined", 711], ["of", 720], ["seven", 723], ["patients", 729], ["who", 738], ["were", 742], ["treated", 747], ["with", 755], ["DBS", 760], ["for", 764], ["status", 768], ["dystonicus", 775], ["(", 786], ["SD", 787], [")", 789], ["and", 791], ["post", 795], ["-", 799], ["stroke", 800], ["severe", 807], ["hemiballismus", 814], [".", 827], ["Bilateral", 829], ["globus", 839], ["pallidus", 846], ["internus", 855], ["(", 864], ["GPi", 865], [")", 868], ["DBS", 870], ["was", 874], ["performed", 878], ["in", 888], ["five", 891], ["SD", 896], ["patients", 899], ["and", 908], ["unilateral", 912], ["ventralis", 923], ["oralis", 933], ["anterior", 940], ["and", 949], ["posterior", 953], ["(", 963], ["Voa", 964], ["/", 967], ["Vop", 968], [")", 971], ["nucleus", 973], ["of", 981], ["the", 984], ["thalamus", 988], ["DBS", 997], ["in", 1001], ["two", 1004], ["post", 1008], ["-", 1012], ["stroke", 1013], ["hemiballismus", 1020], ["patients", 1034], [".", 1042], ["Bilateral", 1044], ["GPi", 1054], ["-", 1057], ["DBS", 1058], ["allowed", 1062], ["SD", 1070], ["resolution", 1073], ["in", 1084], ["a", 1087], ["time", 1089], ["lapse", 1094], ["varying", 1100], ["from", 1108], ["1", 1113], ["week", 1115], ["to", 1120], ["3", 1123], ["months", 1125], [".", 1131], ["No", 1133], ["clear", 1136], ["improvements", 1142], ["compared", 1155], ["to", 1164], ["the", 1167], ["baseline", 1171], ["clinical", 1180], ["condition", 1189], ["were", 1199], ["observed", 1204], [".", 1212], ["Unilateral", 1214], ["Voa", 1225], ["/", 1228], ["Vop", 1229], ["-", 1232], ["DBS", 1233], ["intervention", 1237], ["controlled", 1250], ["hemiballismus", 1261], ["after", 1275], ["10", 1281], ["h", 1284], [",", 1285], ["and", 1287], ["the", 1291], ["patient", 1295], ["was", 1303], ["discharged", 1307], ["in", 1318], ["2", 1321], ["days", 1323], [".", 1327], ["The", 1329], ["other", 1333], ["patient", 1339], ["was", 1347], ["transferred", 1351], ["from", 1363], ["the", 1368], ["NICU", 1372], ["to", 1377], ["the", 1380], ["neurosurgery", 1384], ["ward", 1397], ["after", 1402], ["13", 1408], ["days", 1411], [".", 1415], ["No", 1417], ["surgical", 1420], ["complications", 1429], ["were", 1443], ["observed", 1448], ["in", 1457], ["any", 1460], ["of", 1464], ["the", 1467], ["above", 1471], ["procedures", 1477], [".", 1487], ["Neurostimulation", 1489], ["procedures", 1506], ["could", 1517], ["represent", 1523], ["a", 1533], ["valuable", 1535], ["choice", 1544], ["in", 1551], ["critical", 1554], ["care", 1563], ["conditions", 1568], [",", 1578], ["when", 1580], ["involuntary", 1585], ["movements", 1597], ["are", 1607], ["continuous", 1611], [",", 1621], ["life", 1623], ["-", 1627], ["threatening", 1628], ["and", 1640], ["refractory", 1644], ["to", 1655], ["intensive", 1658], ["care", 1668], ["procedures", 1673], [".", 1683], ["DBS", 1685], ["is", 1689], ["feasible", 1692], [",", 1700], ["safe", 1702], ["and", 1707], ["effective", 1711], ["in", 1721], ["selected", 1724], ["cases", 1733], [".", 1738]]}
{"context": "Viroids are small, circular, single-stranded RNA molecules that cause several infectious plant diseases. Viroids do not encode any pathogen-specific peptides but nonetheless, the subviral pathogens replicate autonomously and spread in the plant by recruiting host proteins via functional motifs encoded in their RNA genome. During the past couple of years, considerable progress has been made towards comprehending how viroids interact with their hosts. Here, we summarize recent findings on the structure-function relationships of viroids, their strategies and mechanisms of replication and trafficking, and the identification and characterization of interacting host proteins. We also describe the impact of the RNA silencing machinery of plants on viroid RNAs and how this has started to influence our models of viroid replication and pathogenicity.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "4bcc2386dcef433497f13c0ffbc668e1", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[68, 68], [0, 0], [87, 87], [18, 18]], "char_spans": [[419, 425], [0, 6], [532, 538], [105, 111]]}]}], "context_tokens": [["Viroids", 0], ["are", 8], ["small", 12], [",", 17], ["circular", 19], [",", 27], ["single", 29], ["-", 35], ["stranded", 36], ["RNA", 45], ["molecules", 49], ["that", 59], ["cause", 64], ["several", 70], ["infectious", 78], ["plant", 89], ["diseases", 95], [".", 103], ["Viroids", 105], ["do", 113], ["not", 116], ["encode", 120], ["any", 127], ["pathogen", 131], ["-", 139], ["specific", 140], ["peptides", 149], ["but", 158], ["nonetheless", 162], [",", 173], ["the", 175], ["subviral", 179], ["pathogens", 188], ["replicate", 198], ["autonomously", 208], ["and", 221], ["spread", 225], ["in", 232], ["the", 235], ["plant", 239], ["by", 245], ["recruiting", 248], ["host", 259], ["proteins", 264], ["via", 273], ["functional", 277], ["motifs", 288], ["encoded", 295], ["in", 303], ["their", 306], ["RNA", 312], ["genome", 316], [".", 322], ["During", 324], ["the", 331], ["past", 335], ["couple", 340], ["of", 347], ["years", 350], [",", 355], ["considerable", 357], ["progress", 370], ["has", 379], ["been", 383], ["made", 388], ["towards", 393], ["comprehending", 401], ["how", 415], ["viroids", 419], ["interact", 427], ["with", 436], ["their", 441], ["hosts", 447], [".", 452], ["Here", 454], [",", 458], ["we", 460], ["summarize", 463], ["recent", 473], ["findings", 480], ["on", 489], ["the", 492], ["structure", 496], ["-", 505], ["function", 506], ["relationships", 515], ["of", 529], ["viroids", 532], [",", 539], ["their", 541], ["strategies", 547], ["and", 558], ["mechanisms", 562], ["of", 573], ["replication", 576], ["and", 588], ["trafficking", 592], [",", 603], ["and", 605], ["the", 609], ["identification", 613], ["and", 628], ["characterization", 632], ["of", 649], ["interacting", 652], ["host", 664], ["proteins", 669], [".", 677], ["We", 679], ["also", 682], ["describe", 687], ["the", 696], ["impact", 700], ["of", 707], ["the", 710], ["RNA", 714], ["silencing", 718], ["machinery", 728], ["of", 738], ["plants", 741], ["on", 748], ["viroid", 751], ["RNAs", 758], ["and", 763], ["how", 767], ["this", 771], ["has", 776], ["started", 780], ["to", 788], ["influence", 791], ["our", 801], ["models", 805], ["of", 812], ["viroid", 815], ["replication", 822], ["and", 834], ["pathogenicity", 838], [".", 851]]}
{"context": "Methylation of lysine residues in the N-terminal tails of histones is thought to represent an important component of the mechanism that regulates chromatin structure. The evolutionarily conserved SET domain occurs in most proteins known to possess histone lysine methyltransferase activity. We present here the crystal structure of a large fragment of human SET7/9 that contains a N-terminal beta-sheet domain as well as the conserved SET domain. Mutagenesis identifies two residues in the C terminus of the protein that appear essential for catalytic activity toward lysine-4 of histone H3. Furthermore, we show how the cofactor AdoMet binds to this domain and present biochemical data supporting the role of invariant residues in catalysis, binding of AdoMet, and interactions with the peptide substrate.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "3f7b340bb0f840e98a015f2346104288", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[72, 73], [30, 31]], "char_spans": [[435, 444], [196, 205]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["lysine", 15], ["residues", 22], ["in", 31], ["the", 34], ["N", 38], ["-", 39], ["terminal", 40], ["tails", 49], ["of", 55], ["histones", 58], ["is", 67], ["thought", 70], ["to", 78], ["represent", 81], ["an", 91], ["important", 94], ["component", 104], ["of", 114], ["the", 117], ["mechanism", 121], ["that", 131], ["regulates", 136], ["chromatin", 146], ["structure", 156], [".", 165], ["The", 167], ["evolutionarily", 171], ["conserved", 186], ["SET", 196], ["domain", 200], ["occurs", 207], ["in", 214], ["most", 217], ["proteins", 222], ["known", 231], ["to", 237], ["possess", 240], ["histone", 248], ["lysine", 256], ["methyltransferase", 263], ["activity", 281], [".", 289], ["We", 291], ["present", 294], ["here", 302], ["the", 307], ["crystal", 311], ["structure", 319], ["of", 329], ["a", 332], ["large", 334], ["fragment", 340], ["of", 349], ["human", 352], ["SET7/9", 358], ["that", 365], ["contains", 370], ["a", 379], ["N", 381], ["-", 382], ["terminal", 383], ["beta", 392], ["-", 396], ["sheet", 397], ["domain", 403], ["as", 410], ["well", 413], ["as", 418], ["the", 421], ["conserved", 425], ["SET", 435], ["domain", 439], [".", 445], ["Mutagenesis", 447], ["identifies", 459], ["two", 470], ["residues", 474], ["in", 483], ["the", 486], ["C", 490], ["terminus", 492], ["of", 501], ["the", 504], ["protein", 508], ["that", 516], ["appear", 521], ["essential", 528], ["for", 538], ["catalytic", 542], ["activity", 552], ["toward", 561], ["lysine-4", 568], ["of", 577], ["histone", 580], ["H3", 588], [".", 590], ["Furthermore", 592], [",", 603], ["we", 605], ["show", 608], ["how", 613], ["the", 617], ["cofactor", 621], ["AdoMet", 630], ["binds", 637], ["to", 643], ["this", 646], ["domain", 651], ["and", 658], ["present", 662], ["biochemical", 670], ["data", 682], ["supporting", 687], ["the", 698], ["role", 702], ["of", 707], ["invariant", 710], ["residues", 720], ["in", 729], ["catalysis", 732], [",", 741], ["binding", 743], ["of", 751], ["AdoMet", 754], [",", 760], ["and", 762], ["interactions", 766], ["with", 779], ["the", 784], ["peptide", 788], ["substrate", 796], [".", 805]]}
{"context": "Osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand (RANKL) are dominant regulators of bone resorption. Many hormones, cytokines and growth factors mediate bone resorption by altering the ratio of RANKL to OPG. RANKL and OPG expression is also altered in numerous bone diseases, and these changes can reflect disease etiology or compensatory responses to disease. RANKL stimulates osteoclast formation, function and survival, and each of these effects is inhibited by OPG. OPG suppresses bone resorption and increases the density, area and strength of both cancellous and cortical bone. Denosumab (AMG 162), a fully human monoclonal antibody to RANKL, shares the pharmacologic attributes of OPG but has a significantly longer half-life that allows less frequent administration.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "bd9c8ec49b8446ba9d107c61a8280a06", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[117, 117], [67, 67], [42, 42], [38, 38], [14, 14]], "char_spans": [[670, 674], [389, 393], [236, 240], [222, 226], [78, 82]]}]}], "context_tokens": [["Osteoprotegerin", 0], ["(", 16], ["OPG", 17], [")", 20], ["and", 22], ["receptor", 26], ["activator", 35], ["of", 45], ["nuclear", 48], ["factor", 56], ["-", 62], ["kappaB", 63], ["ligand", 70], ["(", 77], ["RANKL", 78], [")", 83], ["are", 85], ["dominant", 89], ["regulators", 98], ["of", 109], ["bone", 112], ["resorption", 117], [".", 127], ["Many", 129], ["hormones", 134], [",", 142], ["cytokines", 144], ["and", 154], ["growth", 158], ["factors", 165], ["mediate", 173], ["bone", 181], ["resorption", 186], ["by", 197], ["altering", 200], ["the", 209], ["ratio", 213], ["of", 219], ["RANKL", 222], ["to", 228], ["OPG", 231], [".", 234], ["RANKL", 236], ["and", 242], ["OPG", 246], ["expression", 250], ["is", 261], ["also", 264], ["altered", 269], ["in", 277], ["numerous", 280], ["bone", 289], ["diseases", 294], [",", 302], ["and", 304], ["these", 308], ["changes", 314], ["can", 322], ["reflect", 326], ["disease", 334], ["etiology", 342], ["or", 351], ["compensatory", 354], ["responses", 367], ["to", 377], ["disease", 380], [".", 387], ["RANKL", 389], ["stimulates", 395], ["osteoclast", 406], ["formation", 417], [",", 426], ["function", 428], ["and", 437], ["survival", 441], [",", 449], ["and", 451], ["each", 455], ["of", 460], ["these", 463], ["effects", 469], ["is", 477], ["inhibited", 480], ["by", 490], ["OPG", 493], [".", 496], ["OPG", 498], ["suppresses", 502], ["bone", 513], ["resorption", 518], ["and", 529], ["increases", 533], ["the", 543], ["density", 547], [",", 554], ["area", 556], ["and", 561], ["strength", 565], ["of", 574], ["both", 577], ["cancellous", 582], ["and", 593], ["cortical", 597], ["bone", 606], [".", 610], ["Denosumab", 612], ["(", 622], ["AMG", 623], ["162", 627], [")", 630], [",", 631], ["a", 633], ["fully", 635], ["human", 641], ["monoclonal", 647], ["antibody", 658], ["to", 667], ["RANKL", 670], [",", 675], ["shares", 677], ["the", 684], ["pharmacologic", 688], ["attributes", 702], ["of", 713], ["OPG", 716], ["but", 720], ["has", 724], ["a", 728], ["significantly", 730], ["longer", 744], ["half", 751], ["-", 755], ["life", 756], ["that", 761], ["allows", 766], ["less", 773], ["frequent", 778], ["administration", 787], [".", 801]]}
{"context": "The nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 (Dapivirine) effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission. Both drugs had a favorable therapeutic index. A 24-h treatment with 1,000 nM UC-781 or 100 nM TMC120-R147681 prevented cell-free HIV infection, whereas 10-fold-higher concentrations blocked cell-associated HIV.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "c3236d984bae4fe9a702753a63371250", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[74, 74], [17, 17], [62, 62]], "char_spans": [[479, 481], [142, 144], [402, 404]]}]}], "context_tokens": [["The", 0], ["nonnucleoside", 4], ["reverse", 18], ["transcriptase", 26], ["inhibitors", 40], ["UC-781", 51], ["and", 58], ["TMC120-R147681", 62], ["(", 77], ["Dapivirine", 78], [")", 88], ["effectively", 90], ["prevented", 102], ["human", 112], ["immunodeficiency", 118], ["virus", 135], ["(", 141], ["HIV", 142], [")", 145], ["infection", 147], ["in", 157], ["cocultures", 160], ["of", 171], ["monocyte", 174], ["-", 182], ["derived", 183], ["dendritic", 191], ["cells", 201], ["and", 207], ["T", 211], ["cells", 213], [",", 218], ["representing", 220], ["primary", 233], ["targets", 241], ["in", 249], ["sexual", 252], ["transmission", 259], [".", 271], ["Both", 273], ["drugs", 278], ["had", 284], ["a", 288], ["favorable", 290], ["therapeutic", 300], ["index", 312], [".", 317], ["A", 319], ["24-h", 321], ["treatment", 326], ["with", 336], ["1,000", 341], ["nM", 347], ["UC-781", 350], ["or", 357], ["100", 360], ["nM", 364], ["TMC120-R147681", 367], ["prevented", 382], ["cell", 392], ["-", 396], ["free", 397], ["HIV", 402], ["infection", 406], [",", 415], ["whereas", 417], ["10-fold", 425], ["-", 432], ["higher", 433], ["concentrations", 440], ["blocked", 455], ["cell", 463], ["-", 467], ["associated", 468], ["HIV", 479], [".", 482]]}
{"context": "The SET domain contains the catalytic center of lysine methyltransferases that target the N-terminal tails of histones and regulate chromatin function. Here we report the structure of the SET7/9 protein in the absence and presence of its cofactor product, S-adenosyl-L-homocysteine (AdoHcy). A knot within the SET domain helps form the methyltransferase active site, where AdoHcy binds and lysine methylation is likely to occur. A structure-guided comparison of sequences within the SET protein family suggests that the knot substructure and active site environment are conserved features of the SET domain.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "cdc42c838604450c83009db175c03137", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[1, 2], [58, 59], [104, 105]], "char_spans": [[4, 13], [310, 319], [596, 605]]}]}], "context_tokens": [["The", 0], ["SET", 4], ["domain", 8], ["contains", 15], ["the", 24], ["catalytic", 28], ["center", 38], ["of", 45], ["lysine", 48], ["methyltransferases", 55], ["that", 74], ["target", 79], ["the", 86], ["N", 90], ["-", 91], ["terminal", 92], ["tails", 101], ["of", 107], ["histones", 110], ["and", 119], ["regulate", 123], ["chromatin", 132], ["function", 142], [".", 150], ["Here", 152], ["we", 157], ["report", 160], ["the", 167], ["structure", 171], ["of", 181], ["the", 184], ["SET7/9", 188], ["protein", 195], ["in", 203], ["the", 206], ["absence", 210], ["and", 218], ["presence", 222], ["of", 231], ["its", 234], ["cofactor", 238], ["product", 247], [",", 254], ["S", 256], ["-", 257], ["adenosyl", 258], ["-", 266], ["L", 267], ["-", 268], ["homocysteine", 269], ["(", 282], ["AdoHcy", 283], [")", 289], [".", 290], ["A", 292], ["knot", 294], ["within", 299], ["the", 306], ["SET", 310], ["domain", 314], ["helps", 321], ["form", 327], ["the", 332], ["methyltransferase", 336], ["active", 354], ["site", 361], [",", 365], ["where", 367], ["AdoHcy", 373], ["binds", 380], ["and", 386], ["lysine", 390], ["methylation", 397], ["is", 409], ["likely", 412], ["to", 419], ["occur", 422], [".", 427], ["A", 429], ["structure", 431], ["-", 440], ["guided", 441], ["comparison", 448], ["of", 459], ["sequences", 462], ["within", 472], ["the", 479], ["SET", 483], ["protein", 487], ["family", 495], ["suggests", 502], ["that", 511], ["the", 516], ["knot", 520], ["substructure", 525], ["and", 538], ["active", 542], ["site", 549], ["environment", 554], ["are", 566], ["conserved", 570], ["features", 580], ["of", 589], ["the", 592], ["SET", 596], ["domain", 600], [".", 606]]}
{"context": "Mitogen-activated protein kinase (MAPK) cascades are involved in the regulation of cellular proliferation, differentiation, survival, apoptosis, as well as in inflammatory responses. Signal intensity and duration have been recognized as crucial parameters determining MAPK signaling output. Phosphatases play a particularly important role in this respect, by tightly controlling MAPK phosphorylation and activation. M3/6 (DUSP8) is a dual-specificity phosphatase implicated in the dephosphorylation and inactivation of JNK and, to a lesser extent, p38 MAPKs and is found in a complex with these kinases, along with other pathway components, held together by scaffold proteins. The JNK family consists of three genes, giving rise to at least ten different splice variants. Some functional differences between these gene products have been demonstrated, but the underlying molecular mechanisms and the roles of individual splice variants are still incompletely understood. We have investigated the interaction of M3/6 with JNK isoforms, as well as scaffold proteins of the JNK interacting protein (JIP) family, in order to elucidate the contribution of M3/6 to the regulation of distinct JNK signaling modules. M3/6 exhibited stronger binding towards JNK1\u03b2 and JNK2\u03b1 isoforms and this was reflected in higher enzymatic activity towards JNK2\u03b12 when compared to JNK1\u03b11 in vitro. After activation of the pathway by exposure of cells to arsenite, the interaction of M3/6 with JNK1\u03b1 and JNK3 was enhanced, whereas that with JNK1\u03b2 or JNK2\u03b1 decreased. The modulation of binding affinities was found to be independent of JNK-mediated M3/6 phosphorylation. Furthermore, arsenite treatment resulted in an inducible recruitment of M3/6 to JNK-interacting protein 3 (JIP3) scaffold complexes, while its interaction with JIP1 or JIP2 was constitutive. The presented data suggest an isoform-specific role for the M3/6 phosphatase and the dynamic targeting of M3/6 towards distinct JNK-containing signaling complexes.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "0e17fa4dc2be4a299e36c5cf49b2fbee", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[288, 288], [81, 81], [198, 198], [330, 330], [167, 167], [270, 270], [114, 114], [177, 177]], "char_spans": [[1726, 1728], [519, 521], [1186, 1188], [1965, 1967], [1021, 1023], [1611, 1613], [681, 683], [1071, 1073]]}]}], "context_tokens": [["Mitogen", 0], ["-", 7], ["activated", 8], ["protein", 18], ["kinase", 26], ["(", 33], ["MAPK", 34], [")", 38], ["cascades", 40], ["are", 49], ["involved", 53], ["in", 62], ["the", 65], ["regulation", 69], ["of", 80], ["cellular", 83], ["proliferation", 92], [",", 105], ["differentiation", 107], [",", 122], ["survival", 124], [",", 132], ["apoptosis", 134], [",", 143], ["as", 145], ["well", 148], ["as", 153], ["in", 156], ["inflammatory", 159], ["responses", 172], [".", 181], ["Signal", 183], ["intensity", 190], ["and", 200], ["duration", 204], ["have", 213], ["been", 218], ["recognized", 223], ["as", 234], ["crucial", 237], ["parameters", 245], ["determining", 256], ["MAPK", 268], ["signaling", 273], ["output", 283], [".", 289], ["Phosphatases", 291], ["play", 304], ["a", 309], ["particularly", 311], ["important", 324], ["role", 334], ["in", 339], ["this", 342], ["respect", 347], [",", 354], ["by", 356], ["tightly", 359], ["controlling", 367], ["MAPK", 379], ["phosphorylation", 384], ["and", 400], ["activation", 404], [".", 414], ["M3/6", 416], ["(", 421], ["DUSP8", 422], [")", 427], ["is", 429], ["a", 432], ["dual", 434], ["-", 438], ["specificity", 439], ["phosphatase", 451], ["implicated", 463], ["in", 474], ["the", 477], ["dephosphorylation", 481], ["and", 499], ["inactivation", 503], ["of", 516], ["JNK", 519], ["and", 523], [",", 526], ["to", 528], ["a", 531], ["lesser", 533], ["extent", 540], [",", 546], ["p38", 548], ["MAPKs", 552], ["and", 558], ["is", 562], ["found", 565], ["in", 571], ["a", 574], ["complex", 576], ["with", 584], ["these", 589], ["kinases", 595], [",", 602], ["along", 604], ["with", 610], ["other", 615], ["pathway", 621], ["components", 629], [",", 639], ["held", 641], ["together", 646], ["by", 655], ["scaffold", 658], ["proteins", 667], [".", 675], ["The", 677], ["JNK", 681], ["family", 685], ["consists", 692], ["of", 701], ["three", 704], ["genes", 710], [",", 715], ["giving", 717], ["rise", 724], ["to", 729], ["at", 732], ["least", 735], ["ten", 741], ["different", 745], ["splice", 755], ["variants", 762], [".", 770], ["Some", 772], ["functional", 777], ["differences", 788], ["between", 800], ["these", 808], ["gene", 814], ["products", 819], ["have", 828], ["been", 833], ["demonstrated", 838], [",", 850], ["but", 852], ["the", 856], ["underlying", 860], ["molecular", 871], ["mechanisms", 881], ["and", 892], ["the", 896], ["roles", 900], ["of", 906], ["individual", 909], ["splice", 920], ["variants", 927], ["are", 936], ["still", 940], ["incompletely", 946], ["understood", 959], [".", 969], ["We", 971], ["have", 974], ["investigated", 979], ["the", 992], ["interaction", 996], ["of", 1008], ["M3/6", 1011], ["with", 1016], ["JNK", 1021], ["isoforms", 1025], [",", 1033], ["as", 1035], ["well", 1038], ["as", 1043], ["scaffold", 1046], ["proteins", 1055], ["of", 1064], ["the", 1067], ["JNK", 1071], ["interacting", 1075], ["protein", 1087], ["(", 1095], ["JIP", 1096], [")", 1099], ["family", 1101], [",", 1107], ["in", 1109], ["order", 1112], ["to", 1118], ["elucidate", 1121], ["the", 1131], ["contribution", 1135], ["of", 1148], ["M3/6", 1151], ["to", 1156], ["the", 1159], ["regulation", 1163], ["of", 1174], ["distinct", 1177], ["JNK", 1186], ["signaling", 1190], ["modules", 1200], [".", 1207], ["M3/6", 1209], ["exhibited", 1214], ["stronger", 1224], ["binding", 1233], ["towards", 1241], ["JNK1\u03b2", 1249], ["and", 1255], ["JNK2\u03b1", 1259], ["isoforms", 1265], ["and", 1274], ["this", 1278], ["was", 1283], ["reflected", 1287], ["in", 1297], ["higher", 1300], ["enzymatic", 1307], ["activity", 1317], ["towards", 1326], ["JNK2\u03b12", 1334], ["when", 1341], ["compared", 1346], ["to", 1355], ["JNK1\u03b11", 1358], ["in", 1365], ["vitro", 1368], [".", 1373], ["After", 1375], ["activation", 1381], ["of", 1392], ["the", 1395], ["pathway", 1399], ["by", 1407], ["exposure", 1410], ["of", 1419], ["cells", 1422], ["to", 1428], ["arsenite", 1431], [",", 1439], ["the", 1441], ["interaction", 1445], ["of", 1457], ["M3/6", 1460], ["with", 1465], ["JNK1\u03b1", 1470], ["and", 1476], ["JNK3", 1480], ["was", 1485], ["enhanced", 1489], [",", 1497], ["whereas", 1499], ["that", 1507], ["with", 1512], ["JNK1\u03b2", 1517], ["or", 1523], ["JNK2\u03b1", 1526], ["decreased", 1532], [".", 1541], ["The", 1543], ["modulation", 1547], ["of", 1558], ["binding", 1561], ["affinities", 1569], ["was", 1580], ["found", 1584], ["to", 1590], ["be", 1593], ["independent", 1596], ["of", 1608], ["JNK", 1611], ["-", 1614], ["mediated", 1615], ["M3/6", 1624], ["phosphorylation", 1629], [".", 1644], ["Furthermore", 1646], [",", 1657], ["arsenite", 1659], ["treatment", 1668], ["resulted", 1678], ["in", 1687], ["an", 1690], ["inducible", 1693], ["recruitment", 1703], ["of", 1715], ["M3/6", 1718], ["to", 1723], ["JNK", 1726], ["-", 1729], ["interacting", 1730], ["protein", 1742], ["3", 1750], ["(", 1752], ["JIP3", 1753], [")", 1757], ["scaffold", 1759], ["complexes", 1768], [",", 1777], ["while", 1779], ["its", 1785], ["interaction", 1789], ["with", 1801], ["JIP1", 1806], ["or", 1811], ["JIP2", 1814], ["was", 1819], ["constitutive", 1823], [".", 1835], ["The", 1837], ["presented", 1841], ["data", 1851], ["suggest", 1856], ["an", 1864], ["isoform", 1867], ["-", 1874], ["specific", 1875], ["role", 1884], ["for", 1889], ["the", 1893], ["M3/6", 1897], ["phosphatase", 1902], ["and", 1914], ["the", 1918], ["dynamic", 1922], ["targeting", 1930], ["of", 1940], ["M3/6", 1943], ["towards", 1948], ["distinct", 1956], ["JNK", 1965], ["-", 1968], ["containing", 1969], ["signaling", 1980], ["complexes", 1990], [".", 1999]]}
{"context": "Erythrasma is an uncommon vulvar infection, best diagnosed by its fluorescence under the Wood lamp. This report shows that despite a negative Wood lamp examination, the diagnosis can be made histologically. A 42-year-old woman was referred to our clinic with a persistent candidal infection. Evaluation included a Wood lamp examination, wet mount, and potassium hydroxide test of the affected skin, all of which were negative. A biopsy of the area demonstrated rods and filamentous organisms in the keratotic layer consistent with a Corynebacterium minutissimum infection. The patient was diagnosed as having erythrasma, and she responded to oral erythromycin. Persistent vulvar diseases may be caused by erythrasma despite a negative Wood lamp examination. The diagnosis can be made by biopsy of the lesion.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "c5bec275c58b4f4e81b005aac5c0e82f", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[93, 94]], "char_spans": [[533, 560]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["an", 14], ["uncommon", 17], ["vulvar", 26], ["infection", 33], [",", 42], ["best", 44], ["diagnosed", 49], ["by", 59], ["its", 62], ["fluorescence", 66], ["under", 79], ["the", 85], ["Wood", 89], ["lamp", 94], [".", 98], ["This", 100], ["report", 105], ["shows", 112], ["that", 118], ["despite", 123], ["a", 131], ["negative", 133], ["Wood", 142], ["lamp", 147], ["examination", 152], [",", 163], ["the", 165], ["diagnosis", 169], ["can", 179], ["be", 183], ["made", 186], ["histologically", 191], [".", 205], ["A", 207], ["42-year", 209], ["-", 216], ["old", 217], ["woman", 221], ["was", 227], ["referred", 231], ["to", 240], ["our", 243], ["clinic", 247], ["with", 254], ["a", 259], ["persistent", 261], ["candidal", 272], ["infection", 281], [".", 290], ["Evaluation", 292], ["included", 303], ["a", 312], ["Wood", 314], ["lamp", 319], ["examination", 324], [",", 335], ["wet", 337], ["mount", 341], [",", 346], ["and", 348], ["potassium", 352], ["hydroxide", 362], ["test", 372], ["of", 377], ["the", 380], ["affected", 384], ["skin", 393], [",", 397], ["all", 399], ["of", 403], ["which", 406], ["were", 412], ["negative", 417], [".", 425], ["A", 427], ["biopsy", 429], ["of", 436], ["the", 439], ["area", 443], ["demonstrated", 448], ["rods", 461], ["and", 466], ["filamentous", 470], ["organisms", 482], ["in", 492], ["the", 495], ["keratotic", 499], ["layer", 509], ["consistent", 515], ["with", 526], ["a", 531], ["Corynebacterium", 533], ["minutissimum", 549], ["infection", 562], [".", 571], ["The", 573], ["patient", 577], ["was", 585], ["diagnosed", 589], ["as", 599], ["having", 602], ["erythrasma", 609], [",", 619], ["and", 621], ["she", 625], ["responded", 629], ["to", 639], ["oral", 642], ["erythromycin", 647], [".", 659], ["Persistent", 661], ["vulvar", 672], ["diseases", 679], ["may", 688], ["be", 692], ["caused", 695], ["by", 702], ["erythrasma", 705], ["despite", 716], ["a", 724], ["negative", 726], ["Wood", 735], ["lamp", 740], ["examination", 745], [".", 756], ["The", 758], ["diagnosis", 762], ["can", 772], ["be", 776], ["made", 779], ["by", 784], ["biopsy", 787], ["of", 794], ["the", 797], ["lesion", 801], [".", 807]]}
{"context": "The performance of CURB65 in predicting mortality in community-acquired pneumonia (CAP) has been tested in two large observational studies. However, it has not been tested against generic sepsis and early warning scores, which are increasingly being advocated for identification of high-risk patients in acute medical wards. A retrospective analysis was performed of data prospectively collected for a CAP quality improvement study. The ability to stratify mortality and performance characteristics (sensitivity, specificity, positive predictive value, negative predictive value and area under the receiver operating curve) were calculated for stratifications of CURB65, CRB65, the systemic inflammatory response syndrome (SIRS) criteria and the standardised early warning score (SEWS). 419 patients were included in the main analysis with a median age of 74 years (men = 47%). CURB65 and CRB65 stratified mortality in a more clinically useful way and had more favourable operating characteristics than SIRS or SEWS; for example, mortality in low-risk patients was 2% when defined by CURB65, but 9% when defined by SEWS and 11-17% when defined by variations of the SIRS criteria. The sensitivity, specificity, positive predictive value and negative predictive value of CURB65 was 71%, 69%, 35% and 91%, respectively, compared with 62%, 73%, 35% and 89% for the best performing version of SIRS and 52%, 67%, 27% and 86% for SEWS. CURB65 had the greatest area under the receiver operating curve (0.78 v 0.73 for CRB65, 0.68 for SIRS and 0.64 for SEWS). CURB65 should not be supplanted by SIRS or SEWS for initial prognostic assessment in CAP. Further research to identify better generic prognostic tools is required.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "cc706a937ac44341a23ae0cae23e2bdd", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[11, 11]], "char_spans": [[72, 80]]}]}], "context_tokens": [["The", 0], ["performance", 4], ["of", 16], ["CURB65", 19], ["in", 26], ["predicting", 29], ["mortality", 40], ["in", 50], ["community", 53], ["-", 62], ["acquired", 63], ["pneumonia", 72], ["(", 82], ["CAP", 83], [")", 86], ["has", 88], ["been", 92], ["tested", 97], ["in", 104], ["two", 107], ["large", 111], ["observational", 117], ["studies", 131], [".", 138], ["However", 140], [",", 147], ["it", 149], ["has", 152], ["not", 156], ["been", 160], ["tested", 165], ["against", 172], ["generic", 180], ["sepsis", 188], ["and", 195], ["early", 199], ["warning", 205], ["scores", 213], [",", 219], ["which", 221], ["are", 227], ["increasingly", 231], ["being", 244], ["advocated", 250], ["for", 260], ["identification", 264], ["of", 279], ["high", 282], ["-", 286], ["risk", 287], ["patients", 292], ["in", 301], ["acute", 304], ["medical", 310], ["wards", 318], [".", 323], ["A", 325], ["retrospective", 327], ["analysis", 341], ["was", 350], ["performed", 354], ["of", 364], ["data", 367], ["prospectively", 372], ["collected", 386], ["for", 396], ["a", 400], ["CAP", 402], ["quality", 406], ["improvement", 414], ["study", 426], [".", 431], ["The", 433], ["ability", 437], ["to", 445], ["stratify", 448], ["mortality", 457], ["and", 467], ["performance", 471], ["characteristics", 483], ["(", 499], ["sensitivity", 500], [",", 511], ["specificity", 513], [",", 524], ["positive", 526], ["predictive", 535], ["value", 546], [",", 551], ["negative", 553], ["predictive", 562], ["value", 573], ["and", 579], ["area", 583], ["under", 588], ["the", 594], ["receiver", 598], ["operating", 607], ["curve", 617], [")", 622], ["were", 624], ["calculated", 629], ["for", 640], ["stratifications", 644], ["of", 660], ["CURB65", 663], [",", 669], ["CRB65", 671], [",", 676], ["the", 678], ["systemic", 682], ["inflammatory", 691], ["response", 704], ["syndrome", 713], ["(", 722], ["SIRS", 723], [")", 727], ["criteria", 729], ["and", 738], ["the", 742], ["standardised", 746], ["early", 759], ["warning", 765], ["score", 773], ["(", 779], ["SEWS", 780], [")", 784], [".", 785], ["419", 787], ["patients", 791], ["were", 800], ["included", 805], ["in", 814], ["the", 817], ["main", 821], ["analysis", 826], ["with", 835], ["a", 840], ["median", 842], ["age", 849], ["of", 853], ["74", 856], ["years", 859], ["(", 865], ["men", 866], ["=", 870], ["47", 872], ["%", 874], [")", 875], [".", 876], ["CURB65", 878], ["and", 885], ["CRB65", 889], ["stratified", 895], ["mortality", 906], ["in", 916], ["a", 919], ["more", 921], ["clinically", 926], ["useful", 937], ["way", 944], ["and", 948], ["had", 952], ["more", 956], ["favourable", 961], ["operating", 972], ["characteristics", 982], ["than", 998], ["SIRS", 1003], ["or", 1008], ["SEWS", 1011], [";", 1015], ["for", 1017], ["example", 1021], [",", 1028], ["mortality", 1030], ["in", 1040], ["low", 1043], ["-", 1046], ["risk", 1047], ["patients", 1052], ["was", 1061], ["2", 1065], ["%", 1066], ["when", 1068], ["defined", 1073], ["by", 1081], ["CURB65", 1084], [",", 1090], ["but", 1092], ["9", 1096], ["%", 1097], ["when", 1099], ["defined", 1104], ["by", 1112], ["SEWS", 1115], ["and", 1120], ["11", 1124], ["-", 1126], ["17", 1127], ["%", 1129], ["when", 1131], ["defined", 1136], ["by", 1144], ["variations", 1147], ["of", 1158], ["the", 1161], ["SIRS", 1165], ["criteria", 1170], [".", 1178], ["The", 1180], ["sensitivity", 1184], [",", 1195], ["specificity", 1197], [",", 1208], ["positive", 1210], ["predictive", 1219], ["value", 1230], ["and", 1236], ["negative", 1240], ["predictive", 1249], ["value", 1260], ["of", 1266], ["CURB65", 1269], ["was", 1276], ["71", 1280], ["%", 1282], [",", 1283], ["69", 1285], ["%", 1287], [",", 1288], ["35", 1290], ["%", 1292], ["and", 1294], ["91", 1298], ["%", 1300], [",", 1301], ["respectively", 1303], [",", 1315], ["compared", 1317], ["with", 1326], ["62", 1331], ["%", 1333], [",", 1334], ["73", 1336], ["%", 1338], [",", 1339], ["35", 1341], ["%", 1343], ["and", 1345], ["89", 1349], ["%", 1351], ["for", 1353], ["the", 1357], ["best", 1361], ["performing", 1366], ["version", 1377], ["of", 1385], ["SIRS", 1388], ["and", 1393], ["52", 1397], ["%", 1399], [",", 1400], ["67", 1402], ["%", 1404], [",", 1405], ["27", 1407], ["%", 1409], ["and", 1411], ["86", 1415], ["%", 1417], ["for", 1419], ["SEWS", 1423], [".", 1427], ["CURB65", 1429], ["had", 1436], ["the", 1440], ["greatest", 1444], ["area", 1453], ["under", 1458], ["the", 1464], ["receiver", 1468], ["operating", 1477], ["curve", 1487], ["(", 1493], ["0.78", 1494], ["v", 1499], ["0.73", 1501], ["for", 1506], ["CRB65", 1510], [",", 1515], ["0.68", 1517], ["for", 1522], ["SIRS", 1526], ["and", 1531], ["0.64", 1535], ["for", 1540], ["SEWS", 1544], [")", 1548], [".", 1549], ["CURB65", 1551], ["should", 1558], ["not", 1565], ["be", 1569], ["supplanted", 1572], ["by", 1583], ["SIRS", 1586], ["or", 1591], ["SEWS", 1594], ["for", 1599], ["initial", 1603], ["prognostic", 1611], ["assessment", 1622], ["in", 1633], ["CAP", 1636], [".", 1639], ["Further", 1641], ["research", 1649], ["to", 1658], ["identify", 1661], ["better", 1670], ["generic", 1677], ["prognostic", 1685], ["tools", 1696], ["is", 1702], ["required", 1705], [".", 1713]]}
{"context": "Restless legs syndrome (RLS), recently renamed Willis-Ekbom disease (WED), is a common movement disorder. It is characterised by the need to move mainly the legs due to uncomfortable, sometimes painful sensations in the legs, which have a diurnal variation and a release with movement. Management is complex. First, centres should establish the severity of RLS using a simple 10-item RLS severity rating scale (IRLS). They should also exclude secondary causes, in particular ensuring normal iron levels. Mild cases can be managed by lifestyle changes, but patients with a IRLS score above 15 usually require pharmacological treatment. Dopaminergic therapies remain the mainstay of medical therapies, with recent evidence suggesting opioids may be particularly effective. This article focuses on the different treatment strategies in RLS, their associated complications and ways to manage them.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "9cce10bf0b6546509cf2de1aba61138e", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["recently", 30], ["renamed", 39], ["Willis", 47], ["-", 53], ["Ekbom", 54], ["disease", 60], ["(", 68], ["WED", 69], [")", 72], [",", 73], ["is", 75], ["a", 78], ["common", 80], ["movement", 87], ["disorder", 96], [".", 104], ["It", 106], ["is", 109], ["characterised", 112], ["by", 126], ["the", 129], ["need", 133], ["to", 138], ["move", 141], ["mainly", 146], ["the", 153], ["legs", 157], ["due", 162], ["to", 166], ["uncomfortable", 169], [",", 182], ["sometimes", 184], ["painful", 194], ["sensations", 202], ["in", 213], ["the", 216], ["legs", 220], [",", 224], ["which", 226], ["have", 232], ["a", 237], ["diurnal", 239], ["variation", 247], ["and", 257], ["a", 261], ["release", 263], ["with", 271], ["movement", 276], [".", 284], ["Management", 286], ["is", 297], ["complex", 300], [".", 307], ["First", 309], [",", 314], ["centres", 316], ["should", 324], ["establish", 331], ["the", 341], ["severity", 345], ["of", 354], ["RLS", 357], ["using", 361], ["a", 367], ["simple", 369], ["10-item", 376], ["RLS", 384], ["severity", 388], ["rating", 397], ["scale", 404], ["(", 410], ["IRLS", 411], [")", 415], [".", 416], ["They", 418], ["should", 423], ["also", 430], ["exclude", 435], ["secondary", 443], ["causes", 453], [",", 459], ["in", 461], ["particular", 464], ["ensuring", 475], ["normal", 484], ["iron", 491], ["levels", 496], [".", 502], ["Mild", 504], ["cases", 509], ["can", 515], ["be", 519], ["managed", 522], ["by", 530], ["lifestyle", 533], ["changes", 543], [",", 550], ["but", 552], ["patients", 556], ["with", 565], ["a", 570], ["IRLS", 572], ["score", 577], ["above", 583], ["15", 589], ["usually", 592], ["require", 600], ["pharmacological", 608], ["treatment", 624], [".", 633], ["Dopaminergic", 635], ["therapies", 648], ["remain", 658], ["the", 665], ["mainstay", 669], ["of", 678], ["medical", 681], ["therapies", 689], [",", 698], ["with", 700], ["recent", 705], ["evidence", 712], ["suggesting", 721], ["opioids", 732], ["may", 740], ["be", 744], ["particularly", 747], ["effective", 760], [".", 769], ["This", 771], ["article", 776], ["focuses", 784], ["on", 792], ["the", 795], ["different", 799], ["treatment", 809], ["strategies", 819], ["in", 830], ["RLS", 833], [",", 836], ["their", 838], ["associated", 844], ["complications", 855], ["and", 869], ["ways", 873], ["to", 878], ["manage", 881], ["them", 888], [".", 892]]}
{"context": "Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) carrying pvl is an emerging problem worldwide. CA-MRSA tends to harbor staphylococcal cassette chromosome mec type IV (SCCmec IV), to be non-multiantibiotic resistant, and to have different genotypes from the local hospital-acquired MRSA (HA-MRSA). However, in Ireland, 80% of HA-MRSA isolates have the non-multiantibiotic-resistant genotype ST22-MRSA-IV. This study investigated MRSA isolates from Ireland (CA-MRSA, health care-associated MRSA, and HA-MRSA) for the carriage of pvl and determined the genotypic characteristics of all pvl-positive isolates identified. All 1,389 MRSA isolates were investigated by antibiogram-resistogram typing and SmaI DNA macrorestriction analysis. pvl-positive isolates were further characterized by multilocus sequence typing and SCCmec, agr, and toxin gene typing. Twenty-five (1.8%) MRSA isolates belonging to six genotypes (ST30, ST8, ST22, ST80, ST5, and ST154) harbored pvl. Nineteen of these (76%) were CA-MRSA isolates, but a prospective study of MRSA isolates from 401 patients showed that only 6.7% (2/30) of patients with CA-MRSA yielded pvl-positive isolates. Thus, pvl cannot be used as a sole marker for CA-MRSA. Fifty-two percent of pvl-positive MRSA isolates were recovered from patients with skin and soft tissue infections; thirty-six percent were from patients of non-Irish ethnic origin, reflecting the increasing heterogeneity of the Irish population due to immigration. All 25 pvl-positive isolates carried SCCmec IV; 14 (56%) harbored SCCmec IV.1 or IV.3, and the remaining 11 isolates could not be subtyped. This study demonstrates that pvl is not a reliable marker for CA-MRSA in Ireland and reveals the emergence and importation of diverse genotypes of pvl-positive MRSA in Ireland.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "f981f754748548ed8b74416b9b29aedd", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[362, 362], [11, 11], [173, 173], [90, 90], [214, 214], [253, 253], [346, 346], [60, 60], [108, 108], [73, 73], [23, 23], [103, 103], [263, 263], [56, 56], [232, 232], [206, 206], [130, 130], [97, 97]], "char_spans": [[1802, 1805], [67, 70], [896, 899], [453, 456], [1065, 1068], [1231, 1234], [1707, 1710], [315, 318], [526, 529], [353, 356], [123, 126], [513, 516], [1271, 1274], [306, 309], [1146, 1149], [1023, 1026], [652, 655], [484, 487]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["acquired", 10], ["methicillin", 19], ["-", 30], ["resistant", 31], ["Staphylococcus", 41], ["aureus", 56], ["(", 63], ["CA", 64], ["-", 66], ["MRSA", 67], [")", 71], ["carrying", 73], ["pvl", 82], ["is", 86], ["an", 89], ["emerging", 92], ["problem", 101], ["worldwide", 109], [".", 118], ["CA", 120], ["-", 122], ["MRSA", 123], ["tends", 128], ["to", 134], ["harbor", 137], ["staphylococcal", 144], ["cassette", 159], ["chromosome", 168], ["mec", 179], ["type", 183], ["IV", 188], ["(", 191], ["SCCmec", 192], ["IV", 199], [")", 201], [",", 202], ["to", 204], ["be", 207], ["non", 210], ["-", 213], ["multiantibiotic", 214], ["resistant", 230], [",", 239], ["and", 241], ["to", 245], ["have", 248], ["different", 253], ["genotypes", 263], ["from", 273], ["the", 278], ["local", 282], ["hospital", 288], ["-", 296], ["acquired", 297], ["MRSA", 306], ["(", 311], ["HA", 312], ["-", 314], ["MRSA", 315], [")", 319], [".", 320], ["However", 322], [",", 329], ["in", 331], ["Ireland", 334], [",", 341], ["80", 343], ["%", 345], ["of", 347], ["HA", 350], ["-", 352], ["MRSA", 353], ["isolates", 358], ["have", 367], ["the", 372], ["non", 376], ["-", 379], ["multiantibiotic", 380], ["-", 395], ["resistant", 396], ["genotype", 406], ["ST22-MRSA", 415], ["-", 424], ["IV", 425], [".", 427], ["This", 429], ["study", 434], ["investigated", 440], ["MRSA", 453], ["isolates", 458], ["from", 467], ["Ireland", 472], ["(", 480], ["CA", 481], ["-", 483], ["MRSA", 484], [",", 488], ["health", 490], ["care", 497], ["-", 501], ["associated", 502], ["MRSA", 513], [",", 517], ["and", 519], ["HA", 523], ["-", 525], ["MRSA", 526], [")", 530], ["for", 532], ["the", 536], ["carriage", 540], ["of", 549], ["pvl", 552], ["and", 556], ["determined", 560], ["the", 571], ["genotypic", 575], ["characteristics", 585], ["of", 601], ["all", 604], ["pvl", 608], ["-", 611], ["positive", 612], ["isolates", 621], ["identified", 630], [".", 640], ["All", 642], ["1,389", 646], ["MRSA", 652], ["isolates", 657], ["were", 666], ["investigated", 671], ["by", 684], ["antibiogram", 687], ["-", 698], ["resistogram", 699], ["typing", 711], ["and", 718], ["SmaI", 722], ["DNA", 727], ["macrorestriction", 731], ["analysis", 748], [".", 756], ["pvl", 758], ["-", 761], ["positive", 762], ["isolates", 771], ["were", 780], ["further", 785], ["characterized", 793], ["by", 807], ["multilocus", 810], ["sequence", 821], ["typing", 830], ["and", 837], ["SCCmec", 841], [",", 847], ["agr", 849], [",", 852], ["and", 854], ["toxin", 858], ["gene", 864], ["typing", 869], [".", 875], ["Twenty", 877], ["-", 883], ["five", 884], ["(", 889], ["1.8", 890], ["%", 893], [")", 894], ["MRSA", 896], ["isolates", 901], ["belonging", 910], ["to", 920], ["six", 923], ["genotypes", 927], ["(", 937], ["ST30", 938], [",", 942], ["ST8", 944], [",", 947], ["ST22", 949], [",", 953], ["ST80", 955], [",", 959], ["ST5", 961], [",", 964], ["and", 966], ["ST154", 970], [")", 975], ["harbored", 977], ["pvl", 986], [".", 989], ["Nineteen", 991], ["of", 1000], ["these", 1003], ["(", 1009], ["76", 1010], ["%", 1012], [")", 1013], ["were", 1015], ["CA", 1020], ["-", 1022], ["MRSA", 1023], ["isolates", 1028], [",", 1036], ["but", 1038], ["a", 1042], ["prospective", 1044], ["study", 1056], ["of", 1062], ["MRSA", 1065], ["isolates", 1070], ["from", 1079], ["401", 1084], ["patients", 1088], ["showed", 1097], ["that", 1104], ["only", 1109], ["6.7", 1114], ["%", 1117], ["(", 1119], ["2/30", 1120], [")", 1124], ["of", 1126], ["patients", 1129], ["with", 1138], ["CA", 1143], ["-", 1145], ["MRSA", 1146], ["yielded", 1151], ["pvl", 1159], ["-", 1162], ["positive", 1163], ["isolates", 1172], [".", 1180], ["Thus", 1182], [",", 1186], ["pvl", 1188], ["can", 1192], ["not", 1195], ["be", 1199], ["used", 1202], ["as", 1207], ["a", 1210], ["sole", 1212], ["marker", 1217], ["for", 1224], ["CA", 1228], ["-", 1230], ["MRSA", 1231], [".", 1235], ["Fifty", 1237], ["-", 1242], ["two", 1243], ["percent", 1247], ["of", 1255], ["pvl", 1258], ["-", 1261], ["positive", 1262], ["MRSA", 1271], ["isolates", 1276], ["were", 1285], ["recovered", 1290], ["from", 1300], ["patients", 1305], ["with", 1314], ["skin", 1319], ["and", 1324], ["soft", 1328], ["tissue", 1333], ["infections", 1340], [";", 1350], ["thirty", 1352], ["-", 1358], ["six", 1359], ["percent", 1363], ["were", 1371], ["from", 1376], ["patients", 1381], ["of", 1390], ["non", 1393], ["-", 1396], ["Irish", 1397], ["ethnic", 1403], ["origin", 1410], [",", 1416], ["reflecting", 1418], ["the", 1429], ["increasing", 1433], ["heterogeneity", 1444], ["of", 1458], ["the", 1461], ["Irish", 1465], ["population", 1471], ["due", 1482], ["to", 1486], ["immigration", 1489], [".", 1500], ["All", 1502], ["25", 1506], ["pvl", 1509], ["-", 1512], ["positive", 1513], ["isolates", 1522], ["carried", 1531], ["SCCmec", 1539], ["IV", 1546], [";", 1548], ["14", 1550], ["(", 1553], ["56", 1554], ["%", 1556], [")", 1557], ["harbored", 1559], ["SCCmec", 1568], ["IV.1", 1575], ["or", 1580], ["IV.3", 1583], [",", 1587], ["and", 1589], ["the", 1593], ["remaining", 1597], ["11", 1607], ["isolates", 1610], ["could", 1619], ["not", 1625], ["be", 1629], ["subtyped", 1632], [".", 1640], ["This", 1642], ["study", 1647], ["demonstrates", 1653], ["that", 1666], ["pvl", 1671], ["is", 1675], ["not", 1678], ["a", 1682], ["reliable", 1684], ["marker", 1693], ["for", 1700], ["CA", 1704], ["-", 1706], ["MRSA", 1707], ["in", 1712], ["Ireland", 1715], ["and", 1723], ["reveals", 1727], ["the", 1735], ["emergence", 1739], ["and", 1749], ["importation", 1753], ["of", 1765], ["diverse", 1768], ["genotypes", 1776], ["of", 1786], ["pvl", 1789], ["-", 1792], ["positive", 1793], ["MRSA", 1802], ["in", 1807], ["Ireland", 1810], [".", 1817]]}
{"context": "The Web site for the Anxiety Disorders Association of America (ADAA) receives more than 5 million visits per month and thus represents a unique medium for the study of anxiety disorders. ADAA Web site users from October 2002 to January 2003 were invited to complete a survey oriented toward trauma history and psychiatric sequelae. A diagnostic approximation of posttraumatic stress disorder (PTSD) was based on responses to the Trauma Questionnaire, the Davidson Trauma Scale, and questions about impairment. The Connor-Davidson Resilience Scale was also used. Variables were tested for their association with PTSD. Among 1558 participants, 87% had a history of trauma, and 38% had current PTSD. The population was comprised predominantly of white middle-class women, half of whom were married. More than 90% were first-time users of the site. Factors associated with PTSD included death of, or harm to, a loved one; personal history of incest, rape, or physical abuse; lower age; lower income; unemployment; missed work; increased medical care; dissatisfaction with psychotropic medication; depressive symptoms; and lower resilience. In this selective convenience sample, there were high rates of traumatization and PTSD. The demographics of this group are similar to those seen in previously studied populations that had contacted the ADAA. Furthermore, the factors associated with PTSD were like those in many community surveys. The ADAA Web site has the opportunity to benefit large numbers of highly distressed individuals.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "7b813fb8fbe444c2b8ed096bcfc51ca6", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[123, 123], [251, 251], [104, 104], [159, 159], [66, 66], [223, 223]], "char_spans": [[691, 694], [1385, 1388], [611, 614], [869, 872], [393, 396], [1218, 1221]]}]}], "context_tokens": [["The", 0], ["Web", 4], ["site", 8], ["for", 13], ["the", 17], ["Anxiety", 21], ["Disorders", 29], ["Association", 39], ["of", 51], ["America", 54], ["(", 62], ["ADAA", 63], [")", 67], ["receives", 69], ["more", 78], ["than", 83], ["5", 88], ["million", 90], ["visits", 98], ["per", 105], ["month", 109], ["and", 115], ["thus", 119], ["represents", 124], ["a", 135], ["unique", 137], ["medium", 144], ["for", 151], ["the", 155], ["study", 159], ["of", 165], ["anxiety", 168], ["disorders", 176], [".", 185], ["ADAA", 187], ["Web", 192], ["site", 196], ["users", 201], ["from", 207], ["October", 212], ["2002", 220], ["to", 225], ["January", 228], ["2003", 236], ["were", 241], ["invited", 246], ["to", 254], ["complete", 257], ["a", 266], ["survey", 268], ["oriented", 275], ["toward", 284], ["trauma", 291], ["history", 298], ["and", 306], ["psychiatric", 310], ["sequelae", 322], [".", 330], ["A", 332], ["diagnostic", 334], ["approximation", 345], ["of", 359], ["posttraumatic", 362], ["stress", 376], ["disorder", 383], ["(", 392], ["PTSD", 393], [")", 397], ["was", 399], ["based", 403], ["on", 409], ["responses", 412], ["to", 422], ["the", 425], ["Trauma", 429], ["Questionnaire", 436], [",", 449], ["the", 451], ["Davidson", 455], ["Trauma", 464], ["Scale", 471], [",", 476], ["and", 478], ["questions", 482], ["about", 492], ["impairment", 498], [".", 508], ["The", 510], ["Connor", 514], ["-", 520], ["Davidson", 521], ["Resilience", 530], ["Scale", 541], ["was", 547], ["also", 551], ["used", 556], [".", 560], ["Variables", 562], ["were", 572], ["tested", 577], ["for", 584], ["their", 588], ["association", 594], ["with", 606], ["PTSD", 611], [".", 615], ["Among", 617], ["1558", 623], ["participants", 628], [",", 640], ["87", 642], ["%", 644], ["had", 646], ["a", 650], ["history", 652], ["of", 660], ["trauma", 663], [",", 669], ["and", 671], ["38", 675], ["%", 677], ["had", 679], ["current", 683], ["PTSD", 691], [".", 695], ["The", 697], ["population", 701], ["was", 712], ["comprised", 716], ["predominantly", 726], ["of", 740], ["white", 743], ["middle", 749], ["-", 755], ["class", 756], ["women", 762], [",", 767], ["half", 769], ["of", 774], ["whom", 777], ["were", 782], ["married", 787], [".", 794], ["More", 796], ["than", 801], ["90", 806], ["%", 808], ["were", 810], ["first", 815], ["-", 820], ["time", 821], ["users", 826], ["of", 832], ["the", 835], ["site", 839], [".", 843], ["Factors", 845], ["associated", 853], ["with", 864], ["PTSD", 869], ["included", 874], ["death", 883], ["of", 889], [",", 891], ["or", 893], ["harm", 896], ["to", 901], [",", 903], ["a", 905], ["loved", 907], ["one", 913], [";", 916], ["personal", 918], ["history", 927], ["of", 935], ["incest", 938], [",", 944], ["rape", 946], [",", 950], ["or", 952], ["physical", 955], ["abuse", 964], [";", 969], ["lower", 971], ["age", 977], [";", 980], ["lower", 982], ["income", 988], [";", 994], ["unemployment", 996], [";", 1008], ["missed", 1010], ["work", 1017], [";", 1021], ["increased", 1023], ["medical", 1033], ["care", 1041], [";", 1045], ["dissatisfaction", 1047], ["with", 1063], ["psychotropic", 1068], ["medication", 1081], [";", 1091], ["depressive", 1093], ["symptoms", 1104], [";", 1112], ["and", 1114], ["lower", 1118], ["resilience", 1124], [".", 1134], ["In", 1136], ["this", 1139], ["selective", 1144], ["convenience", 1154], ["sample", 1166], [",", 1172], ["there", 1174], ["were", 1180], ["high", 1185], ["rates", 1190], ["of", 1196], ["traumatization", 1199], ["and", 1214], ["PTSD", 1218], [".", 1222], ["The", 1224], ["demographics", 1228], ["of", 1241], ["this", 1244], ["group", 1249], ["are", 1255], ["similar", 1259], ["to", 1267], ["those", 1270], ["seen", 1276], ["in", 1281], ["previously", 1284], ["studied", 1295], ["populations", 1303], ["that", 1315], ["had", 1320], ["contacted", 1324], ["the", 1334], ["ADAA", 1338], [".", 1342], ["Furthermore", 1344], [",", 1355], ["the", 1357], ["factors", 1361], ["associated", 1369], ["with", 1380], ["PTSD", 1385], ["were", 1390], ["like", 1395], ["those", 1400], ["in", 1406], ["many", 1409], ["community", 1414], ["surveys", 1424], [".", 1431], ["The", 1433], ["ADAA", 1437], ["Web", 1442], ["site", 1446], ["has", 1451], ["the", 1455], ["opportunity", 1459], ["to", 1471], ["benefit", 1474], ["large", 1482], ["numbers", 1488], ["of", 1496], ["highly", 1499], ["distressed", 1506], ["individuals", 1517], [".", 1528]]}
{"context": "Certain malignant B cells rely on B-cell receptor (BCR)-mediated survival signals. Spleen tyrosine kinase (Syk) initiates and amplifies the BCR signal. In in vivo analyses of B-cell lymphoma cell lines and primary tumors, Syk inhibition induces apoptosis. These data prompted a phase 1/2 clinical trial of fostamatinib disodium, the first clinically available oral Syk inhibitor, in patients with recurrent B-cell non-Hodgkin lymphoma (B-NHL). Dose-limiting toxicity in the phase 1 portion was neutropenia, diarrhea, and thrombocytopenia, and 200 mg twice daily was chosen for phase 2 testing. Sixty-eight patients with recurrent B-NHL were then enrolled in 3 cohorts: (1) diffuse large B-cell lymphoma (DLBCL), (2) follicular lymphoma (FL), and (3) other NHL, including mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), mucosa-associated lymphoid tissue lymphoma, lymphoplasmacytic lymphomas, and small lymphocytic leukemia/chronic lymphocytic leukemia (SLL/CLL). Common toxicities included diarrhea, fatigue, cytopenias, hypertension, and nausea. Objective response rates were 22% (5 of 23) for DLBCL, 10% (2 of 21) for FL, 55% (6 of 11) for SLL/CLL, and 11% (1/9) for MCL. Median progression-free survival was 4.2 months. Disrupting BCR-induced signaling by inhibiting Syk represents a novel and active therapeutic approach for NHL and SLL/CLL. This trial was registered at www.clinicaltrials.gov as #NCT00446095.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "09ebf96c823548e9a0908cc35606cc13", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[15, 17]], "char_spans": [[83, 104]]}]}], "context_tokens": [["Certain", 0], ["malignant", 8], ["B", 18], ["cells", 20], ["rely", 26], ["on", 31], ["B", 34], ["-", 35], ["cell", 36], ["receptor", 41], ["(", 50], ["BCR)-mediated", 51], ["survival", 65], ["signals", 74], [".", 81], ["Spleen", 83], ["tyrosine", 90], ["kinase", 99], ["(", 106], ["Syk", 107], [")", 110], ["initiates", 112], ["and", 122], ["amplifies", 126], ["the", 136], ["BCR", 140], ["signal", 144], [".", 150], ["In", 152], ["in", 155], ["vivo", 158], ["analyses", 163], ["of", 172], ["B", 175], ["-", 176], ["cell", 177], ["lymphoma", 182], ["cell", 191], ["lines", 196], ["and", 202], ["primary", 206], ["tumors", 214], [",", 220], ["Syk", 222], ["inhibition", 226], ["induces", 237], ["apoptosis", 245], [".", 254], ["These", 256], ["data", 262], ["prompted", 267], ["a", 276], ["phase", 278], ["1/2", 284], ["clinical", 288], ["trial", 297], ["of", 303], ["fostamatinib", 306], ["disodium", 319], [",", 327], ["the", 329], ["first", 333], ["clinically", 339], ["available", 350], ["oral", 360], ["Syk", 365], ["inhibitor", 369], [",", 378], ["in", 380], ["patients", 383], ["with", 392], ["recurrent", 397], ["B", 407], ["-", 408], ["cell", 409], ["non", 414], ["-", 417], ["Hodgkin", 418], ["lymphoma", 426], ["(", 435], ["B", 436], ["-", 437], ["NHL", 438], [")", 441], [".", 442], ["Dose", 444], ["-", 448], ["limiting", 449], ["toxicity", 458], ["in", 467], ["the", 470], ["phase", 474], ["1", 480], ["portion", 482], ["was", 490], ["neutropenia", 494], [",", 505], ["diarrhea", 507], [",", 515], ["and", 517], ["thrombocytopenia", 521], [",", 537], ["and", 539], ["200", 543], ["mg", 547], ["twice", 550], ["daily", 556], ["was", 562], ["chosen", 566], ["for", 573], ["phase", 577], ["2", 583], ["testing", 585], [".", 592], ["Sixty", 594], ["-", 599], ["eight", 600], ["patients", 606], ["with", 615], ["recurrent", 620], ["B", 630], ["-", 631], ["NHL", 632], ["were", 636], ["then", 641], ["enrolled", 646], ["in", 655], ["3", 658], ["cohorts", 660], [":", 667], ["(", 669], ["1", 670], [")", 671], ["diffuse", 673], ["large", 681], ["B", 687], ["-", 688], ["cell", 689], ["lymphoma", 694], ["(", 703], ["DLBCL", 704], [")", 709], [",", 710], ["(", 712], ["2", 713], [")", 714], ["follicular", 716], ["lymphoma", 727], ["(", 736], ["FL", 737], [")", 739], [",", 740], ["and", 742], ["(", 746], ["3", 747], [")", 748], ["other", 750], ["NHL", 756], [",", 759], ["including", 761], ["mantle", 771], ["cell", 778], ["lymphoma", 783], ["(", 792], ["MCL", 793], [")", 796], [",", 797], ["marginal", 799], ["zone", 808], ["lymphoma", 813], ["(", 822], ["MZL", 823], [")", 826], [",", 827], ["mucosa", 829], ["-", 835], ["associated", 836], ["lymphoid", 847], ["tissue", 856], ["lymphoma", 863], [",", 871], ["lymphoplasmacytic", 873], ["lymphomas", 891], [",", 900], ["and", 902], ["small", 906], ["lymphocytic", 912], ["leukemia", 924], ["/", 932], ["chronic", 933], ["lymphocytic", 941], ["leukemia", 953], ["(", 962], ["SLL", 963], ["/", 966], ["CLL", 967], [")", 970], [".", 971], ["Common", 973], ["toxicities", 980], ["included", 991], ["diarrhea", 1000], [",", 1008], ["fatigue", 1010], [",", 1017], ["cytopenias", 1019], [",", 1029], ["hypertension", 1031], [",", 1043], ["and", 1045], ["nausea", 1049], [".", 1055], ["Objective", 1057], ["response", 1067], ["rates", 1076], ["were", 1082], ["22", 1087], ["%", 1089], ["(", 1091], ["5", 1092], ["of", 1094], ["23", 1097], [")", 1099], ["for", 1101], ["DLBCL", 1105], [",", 1110], ["10", 1112], ["%", 1114], ["(", 1116], ["2", 1117], ["of", 1119], ["21", 1122], [")", 1124], ["for", 1126], ["FL", 1130], [",", 1132], ["55", 1134], ["%", 1136], ["(", 1138], ["6", 1139], ["of", 1141], ["11", 1144], [")", 1146], ["for", 1148], ["SLL", 1152], ["/", 1155], ["CLL", 1156], [",", 1159], ["and", 1161], ["11", 1165], ["%", 1167], ["(", 1169], ["1/9", 1170], [")", 1173], ["for", 1175], ["MCL", 1179], [".", 1182], ["Median", 1184], ["progression", 1191], ["-", 1202], ["free", 1203], ["survival", 1208], ["was", 1217], ["4.2", 1221], ["months", 1225], [".", 1231], ["Disrupting", 1233], ["BCR", 1244], ["-", 1247], ["induced", 1248], ["signaling", 1256], ["by", 1266], ["inhibiting", 1269], ["Syk", 1280], ["represents", 1284], ["a", 1295], ["novel", 1297], ["and", 1303], ["active", 1307], ["therapeutic", 1314], ["approach", 1326], ["for", 1335], ["NHL", 1339], ["and", 1343], ["SLL", 1347], ["/", 1350], ["CLL", 1351], [".", 1354], ["This", 1356], ["trial", 1361], ["was", 1367], ["registered", 1371], ["at", 1382], ["www.clinicaltrials.gov", 1385], ["as", 1408], ["#", 1411], ["NCT00446095", 1412], [".", 1423]]}
{"context": "Muenke syndrome, defined by heterozygosity for a Pro250Arg substitution in fibroblast growth factor receptor 3 (FGFR3), is the most common genetic cause of craniosynostosis in humans. We have used gene targeting to introduce the Muenke syndrome mutation (equivalent to P244R) into the murine Fgfr3 gene. A rounded skull and shortened snout (often skewed) with dental malocclusion was observed in a minority of heterozygotes and many homozygotes. Development of this incompletely penetrant skull phenotype was dependent on genetic background and sex, with males more often affected. However, these cranial abnormalities were rarely attributable to craniosynostosis, which was only present in 2/364 mutants; more commonly, we found fusion of the premaxillary and/or zygomatic sutures. We also found decreased cortical thickness and bone mineral densities in long bones. We conclude that although both cranial and long bone development is variably affected by the murine Fgfr3(P244R) mutation, coronal craniosynostosis is not reliably reproduced.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "0e24607baaa74369a7171110551ca197", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[11, 17]], "char_spans": [[75, 116]]}]}], "context_tokens": [["Muenke", 0], ["syndrome", 7], [",", 15], ["defined", 17], ["by", 25], ["heterozygosity", 28], ["for", 43], ["a", 47], ["Pro250Arg", 49], ["substitution", 59], ["in", 72], ["fibroblast", 75], ["growth", 86], ["factor", 93], ["receptor", 100], ["3", 109], ["(", 111], ["FGFR3", 112], [")", 117], [",", 118], ["is", 120], ["the", 123], ["most", 127], ["common", 132], ["genetic", 139], ["cause", 147], ["of", 153], ["craniosynostosis", 156], ["in", 173], ["humans", 176], [".", 182], ["We", 184], ["have", 187], ["used", 192], ["gene", 197], ["targeting", 202], ["to", 212], ["introduce", 215], ["the", 225], ["Muenke", 229], ["syndrome", 236], ["mutation", 245], ["(", 254], ["equivalent", 255], ["to", 266], ["P244R", 269], [")", 274], ["into", 276], ["the", 281], ["murine", 285], ["Fgfr3", 292], ["gene", 298], [".", 302], ["A", 304], ["rounded", 306], ["skull", 314], ["and", 320], ["shortened", 324], ["snout", 334], ["(", 340], ["often", 341], ["skewed", 347], [")", 353], ["with", 355], ["dental", 360], ["malocclusion", 367], ["was", 380], ["observed", 384], ["in", 393], ["a", 396], ["minority", 398], ["of", 407], ["heterozygotes", 410], ["and", 424], ["many", 428], ["homozygotes", 433], [".", 444], ["Development", 446], ["of", 458], ["this", 461], ["incompletely", 466], ["penetrant", 479], ["skull", 489], ["phenotype", 495], ["was", 505], ["dependent", 509], ["on", 519], ["genetic", 522], ["background", 530], ["and", 541], ["sex", 545], [",", 548], ["with", 550], ["males", 555], ["more", 561], ["often", 566], ["affected", 572], [".", 580], ["However", 582], [",", 589], ["these", 591], ["cranial", 597], ["abnormalities", 605], ["were", 619], ["rarely", 624], ["attributable", 631], ["to", 644], ["craniosynostosis", 647], [",", 663], ["which", 665], ["was", 671], ["only", 675], ["present", 680], ["in", 688], ["2/364", 691], ["mutants", 697], [";", 704], ["more", 706], ["commonly", 711], [",", 719], ["we", 721], ["found", 724], ["fusion", 730], ["of", 737], ["the", 740], ["premaxillary", 744], ["and/or", 757], ["zygomatic", 764], ["sutures", 774], [".", 781], ["We", 783], ["also", 786], ["found", 791], ["decreased", 797], ["cortical", 807], ["thickness", 816], ["and", 826], ["bone", 830], ["mineral", 835], ["densities", 843], ["in", 853], ["long", 856], ["bones", 861], [".", 866], ["We", 868], ["conclude", 871], ["that", 880], ["although", 885], ["both", 894], ["cranial", 899], ["and", 907], ["long", 911], ["bone", 916], ["development", 921], ["is", 933], ["variably", 936], ["affected", 945], ["by", 954], ["the", 957], ["murine", 961], ["Fgfr3(P244R", 968], [")", 979], ["mutation", 981], [",", 989], ["coronal", 991], ["craniosynostosis", 999], ["is", 1016], ["not", 1019], ["reliably", 1023], ["reproduced", 1032], [".", 1042]]}
{"context": "The Ehlers-Danlos Syndrome (EDS) is a rare connective tissue disorder characterised by fragility of the soft connective tissues and widespread manifestations in skin, ligaments, joints, blood vessels and internal organs. We report a case of a 12-year-old boy, previously diagnosed with kyphoscoliosis-type EDS (type VI), presenting with a left brachial artery pseudo-aneursym with history of multiple spontaneous and post-traumatic arterial ruptures. Surgical management of this patient was performed successfully by primary repair of brachial artery lesion.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "151aa629d0054dd180576c092fb49055", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[11, 12]], "char_spans": [[43, 59]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["Syndrome", 18], ["(", 27], ["EDS", 28], [")", 31], ["is", 33], ["a", 36], ["rare", 38], ["connective", 43], ["tissue", 54], ["disorder", 61], ["characterised", 70], ["by", 84], ["fragility", 87], ["of", 97], ["the", 100], ["soft", 104], ["connective", 109], ["tissues", 120], ["and", 128], ["widespread", 132], ["manifestations", 143], ["in", 158], ["skin", 161], [",", 165], ["ligaments", 167], [",", 176], ["joints", 178], [",", 184], ["blood", 186], ["vessels", 192], ["and", 200], ["internal", 204], ["organs", 213], [".", 219], ["We", 221], ["report", 224], ["a", 231], ["case", 233], ["of", 238], ["a", 241], ["12-year", 243], ["-", 250], ["old", 251], ["boy", 255], [",", 258], ["previously", 260], ["diagnosed", 271], ["with", 281], ["kyphoscoliosis", 286], ["-", 300], ["type", 301], ["EDS", 306], ["(", 310], ["type", 311], ["VI", 316], [")", 318], [",", 319], ["presenting", 321], ["with", 332], ["a", 337], ["left", 339], ["brachial", 344], ["artery", 353], ["pseudo", 360], ["-", 366], ["aneursym", 367], ["with", 376], ["history", 381], ["of", 389], ["multiple", 392], ["spontaneous", 401], ["and", 413], ["post", 417], ["-", 421], ["traumatic", 422], ["arterial", 432], ["ruptures", 441], [".", 449], ["Surgical", 451], ["management", 460], ["of", 471], ["this", 474], ["patient", 479], ["was", 487], ["performed", 491], ["successfully", 501], ["by", 514], ["primary", 517], ["repair", 525], ["of", 532], ["brachial", 535], ["artery", 544], ["lesion", 551], [".", 557]]}
{"context": "Siltuximab is a chimeric, anti-interleukin-6 monoclonal antibody with potential therapeutic benefit in castration-resistant prostate cancer (CRPC) patients. We assessed the safety and tolerability of siltuximab in combination with docetaxel, the pharmacokinetics of docetaxel alone and with siltuximab, and the efficacy and pharmacodynamics of siltuximab plus docetaxel. In an open-label, dose-escalation, multicenter, phase 1 study, patients with metastatic, progressive CRPC received docetaxel 75 mg/m(2) q3w plus siltuximab 6 mg/kg q2w (n=12), 9 mg/kg q3w (n=12), or 12 mg/kg q3w (n=15). Dose-limiting toxicity (DLT), PSA, and radiologic response according to WHO criteria were evaluated. DLT was reported in 1 of 11 patients receiving 6 mg/kg, 1 of 12 receiving 9 mg/kg, and in 1 of 14 receiving 12 mg/kg. Common Grade \u2265 3 adverse events were neutropenia (73 %), leukopenia (60 %), lymphopenia (30 %), dyspnea (19 %), and fatigue (14 %). Toxicities were not dose dependent. Siltuximab did not affect docetaxel pharmacokinetics. The pharmacokinetic profile for siltuximab in combination was similar to single-agent siltuximab pharmacokinetics. Twenty-three (62 %; 95 % CI 45 %, 78 %) of 37 combination-treated patients achieved a confirmed \u2265 50 % PSA decline. Of 17 patients with measurable disease at baseline, 2 confirmed and 2 unconfirmed radiologic partial responses ranging 190 to 193 days were achieved with 9- and 12-mg/kg siltuximab. C-reactive protein concentrations were suppressed throughout treatment in all patients. These results suggest that siltuximab in combination with docetaxel is safe and shows preliminary efficacy in patients with CRPC, although alternative siltuximab schedules may be better tolerated for future studies.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "af8f3fdfac2141fb802e6f2ad31ed549", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[7, 7]], "char_spans": [[31, 43]]}]}], "context_tokens": [["Siltuximab", 0], ["is", 11], ["a", 14], ["chimeric", 16], [",", 24], ["anti", 26], ["-", 30], ["interleukin-6", 31], ["monoclonal", 45], ["antibody", 56], ["with", 65], ["potential", 70], ["therapeutic", 80], ["benefit", 92], ["in", 100], ["castration", 103], ["-", 113], ["resistant", 114], ["prostate", 124], ["cancer", 133], ["(", 140], ["CRPC", 141], [")", 145], ["patients", 147], [".", 155], ["We", 157], ["assessed", 160], ["the", 169], ["safety", 173], ["and", 180], ["tolerability", 184], ["of", 197], ["siltuximab", 200], ["in", 211], ["combination", 214], ["with", 226], ["docetaxel", 231], [",", 240], ["the", 242], ["pharmacokinetics", 246], ["of", 263], ["docetaxel", 266], ["alone", 276], ["and", 282], ["with", 286], ["siltuximab", 291], [",", 301], ["and", 303], ["the", 307], ["efficacy", 311], ["and", 320], ["pharmacodynamics", 324], ["of", 341], ["siltuximab", 344], ["plus", 355], ["docetaxel", 360], [".", 369], ["In", 371], ["an", 374], ["open", 377], ["-", 381], ["label", 382], [",", 387], ["dose", 389], ["-", 393], ["escalation", 394], [",", 404], ["multicenter", 406], [",", 417], ["phase", 419], ["1", 425], ["study", 427], [",", 432], ["patients", 434], ["with", 443], ["metastatic", 448], [",", 458], ["progressive", 460], ["CRPC", 472], ["received", 477], ["docetaxel", 486], ["75", 496], ["mg", 499], ["/", 501], ["m(2", 502], [")", 505], ["q3w", 507], ["plus", 511], ["siltuximab", 516], ["6", 527], ["mg", 529], ["/", 531], ["kg", 532], ["q2w", 535], ["(", 539], ["n=12", 540], [")", 544], [",", 545], ["9", 547], ["mg", 549], ["/", 551], ["kg", 552], ["q3w", 555], ["(", 559], ["n=12", 560], [")", 564], [",", 565], ["or", 567], ["12", 570], ["mg", 573], ["/", 575], ["kg", 576], ["q3w", 579], ["(", 583], ["n=15", 584], [")", 588], [".", 589], ["Dose", 591], ["-", 595], ["limiting", 596], ["toxicity", 605], ["(", 614], ["DLT", 615], [")", 618], [",", 619], ["PSA", 621], [",", 624], ["and", 626], ["radiologic", 630], ["response", 641], ["according", 650], ["to", 660], ["WHO", 663], ["criteria", 667], ["were", 676], ["evaluated", 681], [".", 690], ["DLT", 692], ["was", 696], ["reported", 700], ["in", 709], ["1", 712], ["of", 714], ["11", 717], ["patients", 720], ["receiving", 729], ["6", 739], ["mg", 741], ["/", 743], ["kg", 744], [",", 746], ["1", 748], ["of", 750], ["12", 753], ["receiving", 756], ["9", 766], ["mg", 768], ["/", 770], ["kg", 771], [",", 773], ["and", 775], ["in", 779], ["1", 782], ["of", 784], ["14", 787], ["receiving", 790], ["12", 800], ["mg", 803], ["/", 805], ["kg", 806], [".", 808], ["Common", 810], ["Grade", 817], ["\u2265", 823], ["3", 825], ["adverse", 827], ["events", 835], ["were", 842], ["neutropenia", 847], ["(", 859], ["73", 860], ["%", 863], [")", 864], [",", 865], ["leukopenia", 867], ["(", 878], ["60", 879], ["%", 882], [")", 883], [",", 884], ["lymphopenia", 886], ["(", 898], ["30", 899], ["%", 902], [")", 903], [",", 904], ["dyspnea", 906], ["(", 914], ["19", 915], ["%", 918], [")", 919], [",", 920], ["and", 922], ["fatigue", 926], ["(", 934], ["14", 935], ["%", 938], [")", 939], [".", 940], ["Toxicities", 942], ["were", 953], ["not", 958], ["dose", 962], ["dependent", 967], [".", 976], ["Siltuximab", 978], ["did", 989], ["not", 993], ["affect", 997], ["docetaxel", 1004], ["pharmacokinetics", 1014], [".", 1030], ["The", 1032], ["pharmacokinetic", 1036], ["profile", 1052], ["for", 1060], ["siltuximab", 1064], ["in", 1075], ["combination", 1078], ["was", 1090], ["similar", 1094], ["to", 1102], ["single", 1105], ["-", 1111], ["agent", 1112], ["siltuximab", 1118], ["pharmacokinetics", 1129], [".", 1145], ["Twenty", 1147], ["-", 1153], ["three", 1154], ["(", 1160], ["62", 1161], ["%", 1164], [";", 1165], ["95", 1167], ["%", 1170], ["CI", 1172], ["45", 1175], ["%", 1178], [",", 1179], ["78", 1181], ["%", 1184], [")", 1185], ["of", 1187], ["37", 1190], ["combination", 1193], ["-", 1204], ["treated", 1205], ["patients", 1213], ["achieved", 1222], ["a", 1231], ["confirmed", 1233], ["\u2265", 1243], ["50", 1245], ["%", 1248], ["PSA", 1250], ["decline", 1254], [".", 1261], ["Of", 1263], ["17", 1266], ["patients", 1269], ["with", 1278], ["measurable", 1283], ["disease", 1294], ["at", 1302], ["baseline", 1305], [",", 1313], ["2", 1315], ["confirmed", 1317], ["and", 1327], ["2", 1331], ["unconfirmed", 1333], ["radiologic", 1345], ["partial", 1356], ["responses", 1364], ["ranging", 1374], ["190", 1382], ["to", 1386], ["193", 1389], ["days", 1393], ["were", 1398], ["achieved", 1403], ["with", 1412], ["9-", 1417], ["and", 1420], ["12-mg", 1424], ["/", 1429], ["kg", 1430], ["siltuximab", 1433], [".", 1443], ["C", 1445], ["-", 1446], ["reactive", 1447], ["protein", 1456], ["concentrations", 1464], ["were", 1479], ["suppressed", 1484], ["throughout", 1495], ["treatment", 1506], ["in", 1516], ["all", 1519], ["patients", 1523], [".", 1531], ["These", 1533], ["results", 1539], ["suggest", 1547], ["that", 1555], ["siltuximab", 1560], ["in", 1571], ["combination", 1574], ["with", 1586], ["docetaxel", 1591], ["is", 1601], ["safe", 1604], ["and", 1609], ["shows", 1613], ["preliminary", 1619], ["efficacy", 1631], ["in", 1640], ["patients", 1643], ["with", 1652], ["CRPC", 1657], [",", 1661], ["although", 1663], ["alternative", 1672], ["siltuximab", 1684], ["schedules", 1695], ["may", 1705], ["be", 1709], ["better", 1712], ["tolerated", 1719], ["for", 1729], ["future", 1733], ["studies", 1740], [".", 1747]]}
{"context": "Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of one-two cases per 100,000 adults and accounts for \u223c15% of newly diagnosed cases of leukemia in adults. CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson oncogene (ABL) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a BCR-ABL fusion oncogene, which in turn translates into a Bcr-Abl oncoprotein. Three tyrosine kinase inhibitors (TKIs), imatinib, nilotinib, and dasatinib, have been approved by the US Food and Drug Administration for the first-line treatment of patients with newly diagnosed CML in chronic phase (CML-CP). Clinical trials with 2nd generation TKIs reported significantly deeper and faster responses; their impact on long-term survival remains to be determined. For patients who fail standard-dose imatinib therapy, imatinib dose escalation is a second-line option. Alternative second-line options include 2nd generation TKIs. Although both are potent and specific BCR-ABL TKIs, dasatinib and nilotinib exhibit unique pharmacological profiles and response patterns relative to different patient characteristics, such as disease stage and BCR-ABL mutational status. Patients who develop the T315I \"gatekeeper\" mutation display resistance to all currently available TKIs and are candidate for clinical trials. Allogeneic transplantation remains an important therapeutic option for CML-CP harboring the T315I mutation, patients who fail 2nd generation TKIs, and for all patients in advanced phase disease.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "e71892e90a214ef1be0a9cb61da4dd09", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[217, 219], [93, 95], [105, 107], [243, 245]], "char_spans": [[1199, 1205], [536, 542], [593, 599], [1372, 1378]]}]}], "context_tokens": [["Chronic", 0], ["Myeloid", 8], ["Leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["myeloproliferative", 36], ["neoplasm", 55], ["with", 64], ["an", 69], ["incidence", 72], ["of", 82], ["one", 85], ["-", 88], ["two", 89], ["cases", 93], ["per", 99], ["100,000", 103], ["adults", 111], ["and", 118], ["accounts", 122], ["for", 131], ["\u223c15", 135], ["%", 138], ["of", 140], ["newly", 143], ["diagnosed", 149], ["cases", 159], ["of", 165], ["leukemia", 168], ["in", 177], ["adults", 180], [".", 186], ["CML", 188], ["is", 192], ["characterized", 195], ["by", 209], ["a", 212], ["balanced", 214], ["genetic", 223], ["translocation", 231], [",", 244], ["t(9;22)(q34;q11.2", 246], [")", 263], [",", 264], ["involving", 266], ["a", 276], ["fusion", 278], ["of", 285], ["the", 288], ["Abelson", 292], ["oncogene", 300], ["(", 309], ["ABL", 310], [")", 313], ["from", 315], ["chromosome", 320], ["9q34", 331], ["with", 336], ["the", 341], ["breakpoint", 345], ["cluster", 356], ["region", 364], ["(", 371], ["BCR", 372], [")", 375], ["gene", 377], ["on", 382], ["chromosome", 385], ["22q11.2", 396], [".", 403], ["This", 405], ["rearrangement", 410], ["is", 424], ["known", 427], ["as", 433], ["the", 436], ["Philadelphia", 440], ["chromosome", 453], [".", 463], ["The", 465], ["molecular", 469], ["consequence", 479], ["of", 491], ["this", 494], ["translocation", 499], ["is", 513], ["the", 516], ["generation", 520], ["of", 531], ["a", 534], ["BCR", 536], ["-", 539], ["ABL", 540], ["fusion", 544], ["oncogene", 551], [",", 559], ["which", 561], ["in", 567], ["turn", 570], ["translates", 575], ["into", 586], ["a", 591], ["Bcr", 593], ["-", 596], ["Abl", 597], ["oncoprotein", 601], [".", 612], ["Three", 614], ["tyrosine", 620], ["kinase", 629], ["inhibitors", 636], ["(", 647], ["TKIs", 648], [")", 652], [",", 653], ["imatinib", 655], [",", 663], ["nilotinib", 665], [",", 674], ["and", 676], ["dasatinib", 680], [",", 689], ["have", 691], ["been", 696], ["approved", 701], ["by", 710], ["the", 713], ["US", 717], ["Food", 720], ["and", 725], ["Drug", 729], ["Administration", 734], ["for", 749], ["the", 753], ["first", 757], ["-", 762], ["line", 763], ["treatment", 768], ["of", 778], ["patients", 781], ["with", 790], ["newly", 795], ["diagnosed", 801], ["CML", 811], ["in", 815], ["chronic", 818], ["phase", 826], ["(", 832], ["CML", 833], ["-", 836], ["CP", 837], [")", 839], [".", 840], ["Clinical", 842], ["trials", 851], ["with", 858], ["2nd", 863], ["generation", 867], ["TKIs", 878], ["reported", 883], ["significantly", 892], ["deeper", 906], ["and", 913], ["faster", 917], ["responses", 924], [";", 933], ["their", 935], ["impact", 941], ["on", 948], ["long", 951], ["-", 955], ["term", 956], ["survival", 961], ["remains", 970], ["to", 978], ["be", 981], ["determined", 984], [".", 994], ["For", 996], ["patients", 1000], ["who", 1009], ["fail", 1013], ["standard", 1018], ["-", 1026], ["dose", 1027], ["imatinib", 1032], ["therapy", 1041], [",", 1048], ["imatinib", 1050], ["dose", 1059], ["escalation", 1064], ["is", 1075], ["a", 1078], ["second", 1080], ["-", 1086], ["line", 1087], ["option", 1092], [".", 1098], ["Alternative", 1100], ["second", 1112], ["-", 1118], ["line", 1119], ["options", 1124], ["include", 1132], ["2nd", 1140], ["generation", 1144], ["TKIs", 1155], [".", 1159], ["Although", 1161], ["both", 1170], ["are", 1175], ["potent", 1179], ["and", 1186], ["specific", 1190], ["BCR", 1199], ["-", 1202], ["ABL", 1203], ["TKIs", 1207], [",", 1211], ["dasatinib", 1213], ["and", 1223], ["nilotinib", 1227], ["exhibit", 1237], ["unique", 1245], ["pharmacological", 1252], ["profiles", 1268], ["and", 1277], ["response", 1281], ["patterns", 1290], ["relative", 1299], ["to", 1308], ["different", 1311], ["patient", 1321], ["characteristics", 1329], [",", 1344], ["such", 1346], ["as", 1351], ["disease", 1354], ["stage", 1362], ["and", 1368], ["BCR", 1372], ["-", 1375], ["ABL", 1376], ["mutational", 1380], ["status", 1391], [".", 1397], ["Patients", 1399], ["who", 1408], ["develop", 1412], ["the", 1420], ["T315I", 1424], ["\"", 1430], ["gatekeeper", 1431], ["\"", 1441], ["mutation", 1443], ["display", 1452], ["resistance", 1460], ["to", 1471], ["all", 1474], ["currently", 1478], ["available", 1488], ["TKIs", 1498], ["and", 1503], ["are", 1507], ["candidate", 1511], ["for", 1521], ["clinical", 1525], ["trials", 1534], [".", 1540], ["Allogeneic", 1542], ["transplantation", 1553], ["remains", 1569], ["an", 1577], ["important", 1580], ["therapeutic", 1590], ["option", 1602], ["for", 1609], ["CML", 1613], ["-", 1616], ["CP", 1617], ["harboring", 1620], ["the", 1630], ["T315I", 1634], ["mutation", 1640], [",", 1648], ["patients", 1650], ["who", 1659], ["fail", 1663], ["2nd", 1668], ["generation", 1672], ["TKIs", 1683], [",", 1687], ["and", 1689], ["for", 1693], ["all", 1697], ["patients", 1701], ["in", 1710], ["advanced", 1713], ["phase", 1722], ["disease", 1728], [".", 1735]]}
{"context": "Human apolipoprotein E (apoE) is a 299-amino-acid protein with a molecular weight of 34 kDa. The difference between the apoE3 and apoE4 isoforms is a single residue substitution involving a Cys-Arg replacement at residue 112. ApoE4 is positively associated with atherosclerosis and late-onset and sporadic Alzheimer's disease (AD). ApoE4 and its C-terminal truncated fragments have been found in the senile plaques and neurofibrillary tangles in the brain of AD patients. However, detail structural information regarding isoform and domain interaction remains poorly understood. We prepared full-length, N-, and C-terminal truncated apoE3 and apoE4 proteins and studied their structural variation. Sedimentation velocity and continuous size distribution analysis using analytical ultracentrifugation revealed apoE3(72-299) as consisting of a major species with a sedimentation coefficient of 5.9. ApoE4(72-299) showed a wider and more complicated species distribution. Both apoE3 and E4 N-terminal domain (1-191) existed with monomers as the major component together with some tetramer. The oligomerization and aggregation of apoE protein increased when the C-terminal domain (192-271) was incorporated. The structural influence of the C-terminal domain on apoE is to assist self-association with no significant isoform preference. Circular dichroism and fluorescence studies demonstrated that apoE4(72-299) possessed a more alpha-helical structure with more hydrophobic residue exposure. The structural variation of the N-terminal truncated apoE3 and apoE4 protein provides useful information that helps to explain the greater aggregation of the apoE4 isoform and thus has implication for the involvement of apoE4 in AD.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "84150498c316405889993b5f785ce213", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[284, 285]], "char_spans": [[1647, 1659]]}]}], "context_tokens": [["Human", 0], ["apolipoprotein", 6], ["E", 21], ["(", 23], ["apoE", 24], [")", 28], ["is", 30], ["a", 33], ["299-amino", 35], ["-", 44], ["acid", 45], ["protein", 50], ["with", 58], ["a", 63], ["molecular", 65], ["weight", 75], ["of", 82], ["34", 85], ["kDa", 88], [".", 91], ["The", 93], ["difference", 97], ["between", 108], ["the", 116], ["apoE3", 120], ["and", 126], ["apoE4", 130], ["isoforms", 136], ["is", 145], ["a", 148], ["single", 150], ["residue", 157], ["substitution", 165], ["involving", 178], ["a", 188], ["Cys", 190], ["-", 193], ["Arg", 194], ["replacement", 198], ["at", 210], ["residue", 213], ["112", 221], [".", 224], ["ApoE4", 226], ["is", 232], ["positively", 235], ["associated", 246], ["with", 257], ["atherosclerosis", 262], ["and", 278], ["late", 282], ["-", 286], ["onset", 287], ["and", 293], ["sporadic", 297], ["Alzheimer", 306], ["'s", 315], ["disease", 318], ["(", 326], ["AD", 327], [")", 329], [".", 330], ["ApoE4", 332], ["and", 338], ["its", 342], ["C", 346], ["-", 347], ["terminal", 348], ["truncated", 357], ["fragments", 367], ["have", 377], ["been", 382], ["found", 387], ["in", 393], ["the", 396], ["senile", 400], ["plaques", 407], ["and", 415], ["neurofibrillary", 419], ["tangles", 435], ["in", 443], ["the", 446], ["brain", 450], ["of", 456], ["AD", 459], ["patients", 462], [".", 470], ["However", 472], [",", 479], ["detail", 481], ["structural", 488], ["information", 499], ["regarding", 511], ["isoform", 521], ["and", 529], ["domain", 533], ["interaction", 540], ["remains", 552], ["poorly", 560], ["understood", 567], [".", 577], ["We", 579], ["prepared", 582], ["full", 591], ["-", 595], ["length", 596], [",", 602], ["N-", 604], [",", 606], ["and", 608], ["C", 612], ["-", 613], ["terminal", 614], ["truncated", 623], ["apoE3", 633], ["and", 639], ["apoE4", 643], ["proteins", 649], ["and", 658], ["studied", 662], ["their", 670], ["structural", 676], ["variation", 687], [".", 696], ["Sedimentation", 698], ["velocity", 712], ["and", 721], ["continuous", 725], ["size", 736], ["distribution", 741], ["analysis", 754], ["using", 763], ["analytical", 769], ["ultracentrifugation", 780], ["revealed", 800], ["apoE3(72", 809], ["-", 817], ["299", 818], [")", 821], ["as", 823], ["consisting", 826], ["of", 837], ["a", 840], ["major", 842], ["species", 848], ["with", 856], ["a", 861], ["sedimentation", 863], ["coefficient", 877], ["of", 889], ["5.9", 892], [".", 895], ["ApoE4(72", 897], ["-", 905], ["299", 906], [")", 909], ["showed", 911], ["a", 918], ["wider", 920], ["and", 926], ["more", 930], ["complicated", 935], ["species", 947], ["distribution", 955], [".", 967], ["Both", 969], ["apoE3", 974], ["and", 980], ["E4", 984], ["N", 987], ["-", 988], ["terminal", 989], ["domain", 998], ["(", 1005], ["1", 1006], ["-", 1007], ["191", 1008], [")", 1011], ["existed", 1013], ["with", 1021], ["monomers", 1026], ["as", 1035], ["the", 1038], ["major", 1042], ["component", 1048], ["together", 1058], ["with", 1067], ["some", 1072], ["tetramer", 1077], [".", 1085], ["The", 1087], ["oligomerization", 1091], ["and", 1107], ["aggregation", 1111], ["of", 1123], ["apoE", 1126], ["protein", 1131], ["increased", 1139], ["when", 1149], ["the", 1154], ["C", 1158], ["-", 1159], ["terminal", 1160], ["domain", 1169], ["(", 1176], ["192", 1177], ["-", 1180], ["271", 1181], [")", 1184], ["was", 1186], ["incorporated", 1190], [".", 1202], ["The", 1204], ["structural", 1208], ["influence", 1219], ["of", 1229], ["the", 1232], ["C", 1236], ["-", 1237], ["terminal", 1238], ["domain", 1247], ["on", 1254], ["apoE", 1257], ["is", 1262], ["to", 1265], ["assist", 1268], ["self", 1275], ["-", 1279], ["association", 1280], ["with", 1292], ["no", 1297], ["significant", 1300], ["isoform", 1312], ["preference", 1320], [".", 1330], ["Circular", 1332], ["dichroism", 1341], ["and", 1351], ["fluorescence", 1355], ["studies", 1368], ["demonstrated", 1376], ["that", 1389], ["apoE4(72", 1394], ["-", 1402], ["299", 1403], [")", 1406], ["possessed", 1408], ["a", 1418], ["more", 1420], ["alpha", 1425], ["-", 1430], ["helical", 1431], ["structure", 1439], ["with", 1449], ["more", 1454], ["hydrophobic", 1459], ["residue", 1471], ["exposure", 1479], [".", 1487], ["The", 1489], ["structural", 1493], ["variation", 1504], ["of", 1514], ["the", 1517], ["N", 1521], ["-", 1522], ["terminal", 1523], ["truncated", 1532], ["apoE3", 1542], ["and", 1548], ["apoE4", 1552], ["protein", 1558], ["provides", 1566], ["useful", 1575], ["information", 1582], ["that", 1594], ["helps", 1599], ["to", 1605], ["explain", 1608], ["the", 1616], ["greater", 1620], ["aggregation", 1628], ["of", 1640], ["the", 1643], ["apoE4", 1647], ["isoform", 1653], ["and", 1661], ["thus", 1665], ["has", 1670], ["implication", 1674], ["for", 1686], ["the", 1690], ["involvement", 1694], ["of", 1706], ["apoE4", 1709], ["in", 1715], ["AD", 1718], [".", 1720]]}
{"context": "DNA damage is preferentially repaired in the transcribed strand of many active genes. Although the concept of DNA repair coupled with transcription has been widely accepted, its mechanisms remain elusive. We recently reported that in Chinese hamster ovary cells while ultraviolet light-induced cyclobutane pyrimidine dimers (CPDs) are preferentially repaired in the transcribed strand of dihydrofolate reductase gene, CPDs are efficiently repaired in both strands of adenine phosphoribosyltransferase (APRT) locus, in either a transcribed or nontranscribed APRT gene (1). These results suggested that the transcription dependence of repair may depend on genomic context. To test this hypothesis, we constructed transfectant cell lines containing a single, actively transcribed APRT gene, integrated at different genomic sites. Mapping of CPD repair in the integrated APRT genes in three transfectant cell lines revealed two distinct repair patterns, either preferential repair of CPDs in the transcribed strand or very poor repair in both strands. Similar kinetics of micrococcal nuclease digestion were seen for all three transfectant APRT gene domains and endogenous APRT locus. Our results suggest that both the efficiency and strand-specificity of repair of an actively transcribed gene are profoundly affected by genomic context but do not reflect changes in first order nucleosomal structure.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "d161b97805de4abe9ce8e5aff755c987", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[159, 160], [58, 59], [7, 8]], "char_spans": [[992, 1009], [366, 383], [45, 62]]}]}], "context_tokens": [["DNA", 0], ["damage", 4], ["is", 11], ["preferentially", 14], ["repaired", 29], ["in", 38], ["the", 41], ["transcribed", 45], ["strand", 57], ["of", 64], ["many", 67], ["active", 72], ["genes", 79], [".", 84], ["Although", 86], ["the", 95], ["concept", 99], ["of", 107], ["DNA", 110], ["repair", 114], ["coupled", 121], ["with", 129], ["transcription", 134], ["has", 148], ["been", 152], ["widely", 157], ["accepted", 164], [",", 172], ["its", 174], ["mechanisms", 178], ["remain", 189], ["elusive", 196], [".", 203], ["We", 205], ["recently", 208], ["reported", 217], ["that", 226], ["in", 231], ["Chinese", 234], ["hamster", 242], ["ovary", 250], ["cells", 256], ["while", 262], ["ultraviolet", 268], ["light", 280], ["-", 285], ["induced", 286], ["cyclobutane", 294], ["pyrimidine", 306], ["dimers", 317], ["(", 324], ["CPDs", 325], [")", 329], ["are", 331], ["preferentially", 335], ["repaired", 350], ["in", 359], ["the", 362], ["transcribed", 366], ["strand", 378], ["of", 385], ["dihydrofolate", 388], ["reductase", 402], ["gene", 412], [",", 416], ["CPDs", 418], ["are", 423], ["efficiently", 427], ["repaired", 439], ["in", 448], ["both", 451], ["strands", 456], ["of", 464], ["adenine", 467], ["phosphoribosyltransferase", 475], ["(", 501], ["APRT", 502], [")", 506], ["locus", 508], [",", 513], ["in", 515], ["either", 518], ["a", 525], ["transcribed", 527], ["or", 539], ["nontranscribed", 542], ["APRT", 557], ["gene", 562], ["(", 567], ["1", 568], [")", 569], [".", 570], ["These", 572], ["results", 578], ["suggested", 586], ["that", 596], ["the", 601], ["transcription", 605], ["dependence", 619], ["of", 630], ["repair", 633], ["may", 640], ["depend", 644], ["on", 651], ["genomic", 654], ["context", 662], [".", 669], ["To", 671], ["test", 674], ["this", 679], ["hypothesis", 684], [",", 694], ["we", 696], ["constructed", 699], ["transfectant", 711], ["cell", 724], ["lines", 729], ["containing", 735], ["a", 746], ["single", 748], [",", 754], ["actively", 756], ["transcribed", 765], ["APRT", 777], ["gene", 782], [",", 786], ["integrated", 788], ["at", 799], ["different", 802], ["genomic", 812], ["sites", 820], [".", 825], ["Mapping", 827], ["of", 835], ["CPD", 838], ["repair", 842], ["in", 849], ["the", 852], ["integrated", 856], ["APRT", 867], ["genes", 872], ["in", 878], ["three", 881], ["transfectant", 887], ["cell", 900], ["lines", 905], ["revealed", 911], ["two", 920], ["distinct", 924], ["repair", 933], ["patterns", 940], [",", 948], ["either", 950], ["preferential", 957], ["repair", 970], ["of", 977], ["CPDs", 980], ["in", 985], ["the", 988], ["transcribed", 992], ["strand", 1004], ["or", 1011], ["very", 1014], ["poor", 1019], ["repair", 1024], ["in", 1031], ["both", 1034], ["strands", 1039], [".", 1046], ["Similar", 1048], ["kinetics", 1056], ["of", 1065], ["micrococcal", 1068], ["nuclease", 1080], ["digestion", 1089], ["were", 1099], ["seen", 1104], ["for", 1109], ["all", 1113], ["three", 1117], ["transfectant", 1123], ["APRT", 1136], ["gene", 1141], ["domains", 1146], ["and", 1154], ["endogenous", 1158], ["APRT", 1169], ["locus", 1174], [".", 1179], ["Our", 1181], ["results", 1185], ["suggest", 1193], ["that", 1201], ["both", 1206], ["the", 1211], ["efficiency", 1215], ["and", 1226], ["strand", 1230], ["-", 1236], ["specificity", 1237], ["of", 1249], ["repair", 1252], ["of", 1259], ["an", 1262], ["actively", 1265], ["transcribed", 1274], ["gene", 1286], ["are", 1291], ["profoundly", 1295], ["affected", 1306], ["by", 1315], ["genomic", 1318], ["context", 1326], ["but", 1334], ["do", 1338], ["not", 1341], ["reflect", 1345], ["changes", 1353], ["in", 1361], ["first", 1364], ["order", 1370], ["nucleosomal", 1376], ["structure", 1388], [".", 1397]]}
{"context": "Alpha-synuclein (alphaS) is the primary component of Lewy bodies, the pathological hallmark of Parkinson's Disease. Aggregation of alphaS is thought to proceed from a primarily disordered state with nascent secondary structure through intermediate conformations to oligomeric forms and finally to mature amyloid fibrils. Low pH conditions lead to conformational changes associated with increased alphaS fibril formation. Here we characterize these structural and dynamic changes using solution state NMR measurements of secondary chemical shifts, relaxation parameters, residual dipolar couplings, and paramagnetic relaxation enhancement. We find that the neutralization of negatively charged side-chains eliminates electrostatic repulsion in the C-terminal tail of alphaS and leads to a collapse of this region at low pH. Hydrophobic contacts between the compact C-terminal tail and the NAC (non-amyloid-beta component) region are maintained and may lead to the formation of a globular domain. Transient long-range contacts between the C-terminus of the protein and regions N-terminal to the NAC region are also preserved. Thus, the release of long-range contacts does not play a role in the increased aggregation of alphaS at low pH, which we instead attribute to the increased hydrophobicity of the protein.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "49df234dddfb4af6b70443ee0df3e00d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["(", 16], ["alphaS", 17], [")", 23], ["is", 25], ["the", 28], ["primary", 32], ["component", 40], ["of", 50], ["Lewy", 53], ["bodies", 58], [",", 64], ["the", 66], ["pathological", 70], ["hallmark", 83], ["of", 92], ["Parkinson", 95], ["'s", 104], ["Disease", 107], [".", 114], ["Aggregation", 116], ["of", 128], ["alphaS", 131], ["is", 138], ["thought", 141], ["to", 149], ["proceed", 152], ["from", 160], ["a", 165], ["primarily", 167], ["disordered", 177], ["state", 188], ["with", 194], ["nascent", 199], ["secondary", 207], ["structure", 217], ["through", 227], ["intermediate", 235], ["conformations", 248], ["to", 262], ["oligomeric", 265], ["forms", 276], ["and", 282], ["finally", 286], ["to", 294], ["mature", 297], ["amyloid", 304], ["fibrils", 312], [".", 319], ["Low", 321], ["pH", 325], ["conditions", 328], ["lead", 339], ["to", 344], ["conformational", 347], ["changes", 362], ["associated", 370], ["with", 381], ["increased", 386], ["alphaS", 396], ["fibril", 403], ["formation", 410], [".", 419], ["Here", 421], ["we", 426], ["characterize", 429], ["these", 442], ["structural", 448], ["and", 459], ["dynamic", 463], ["changes", 471], ["using", 479], ["solution", 485], ["state", 494], ["NMR", 500], ["measurements", 504], ["of", 517], ["secondary", 520], ["chemical", 530], ["shifts", 539], [",", 545], ["relaxation", 547], ["parameters", 558], [",", 568], ["residual", 570], ["dipolar", 579], ["couplings", 587], [",", 596], ["and", 598], ["paramagnetic", 602], ["relaxation", 615], ["enhancement", 626], [".", 637], ["We", 639], ["find", 642], ["that", 647], ["the", 652], ["neutralization", 656], ["of", 671], ["negatively", 674], ["charged", 685], ["side", 693], ["-", 697], ["chains", 698], ["eliminates", 705], ["electrostatic", 716], ["repulsion", 730], ["in", 740], ["the", 743], ["C", 747], ["-", 748], ["terminal", 749], ["tail", 758], ["of", 763], ["alphaS", 766], ["and", 773], ["leads", 777], ["to", 783], ["a", 786], ["collapse", 788], ["of", 797], ["this", 800], ["region", 805], ["at", 812], ["low", 815], ["pH.", 819], ["Hydrophobic", 823], ["contacts", 835], ["between", 844], ["the", 852], ["compact", 856], ["C", 864], ["-", 865], ["terminal", 866], ["tail", 875], ["and", 880], ["the", 884], ["NAC", 888], ["(", 892], ["non", 893], ["-", 896], ["amyloid", 897], ["-", 904], ["beta", 905], ["component", 910], [")", 919], ["region", 921], ["are", 928], ["maintained", 932], ["and", 943], ["may", 947], ["lead", 951], ["to", 956], ["the", 959], ["formation", 963], ["of", 973], ["a", 976], ["globular", 978], ["domain", 987], [".", 993], ["Transient", 995], ["long", 1005], ["-", 1009], ["range", 1010], ["contacts", 1016], ["between", 1025], ["the", 1033], ["C", 1037], ["-", 1038], ["terminus", 1039], ["of", 1048], ["the", 1051], ["protein", 1055], ["and", 1063], ["regions", 1067], ["N", 1075], ["-", 1076], ["terminal", 1077], ["to", 1086], ["the", 1089], ["NAC", 1093], ["region", 1097], ["are", 1104], ["also", 1108], ["preserved", 1113], [".", 1122], ["Thus", 1124], [",", 1128], ["the", 1130], ["release", 1134], ["of", 1142], ["long", 1145], ["-", 1149], ["range", 1150], ["contacts", 1156], ["does", 1165], ["not", 1170], ["play", 1174], ["a", 1179], ["role", 1181], ["in", 1186], ["the", 1189], ["increased", 1193], ["aggregation", 1203], ["of", 1215], ["alphaS", 1218], ["at", 1225], ["low", 1228], ["pH", 1232], [",", 1234], ["which", 1236], ["we", 1242], ["instead", 1245], ["attribute", 1253], ["to", 1263], ["the", 1266], ["increased", 1270], ["hydrophobicity", 1280], ["of", 1295], ["the", 1298], ["protein", 1302], [".", 1309]]}
{"context": "Imatinib mesylate is a new drug that can inhibit the tyrosine kinase activity of Bcr-Abl, the receptors for platelet-derived growth factor receptor(PDGF) and stem cell factor, or c-kit. Chronic myeloid leukemia (CML) is distinguished by the presence of a reciprocal translocation between chromosomes 9 and 22 that results in a shortened chromosome 22, termed the Philadelphia(Ph) chromosome. As a result of the translocation, a fusion gene called the Bcr-Abl gene is created from two normal cellular genes, encoding a chimeric Bcr-Abl protein with a deregulated tyrosine kinase activity. The expression of Bcr-Abl tyrosine kinase has been shown to be necessary and sufficient for the transformed phenotype of CML cells. Imatinib can block the kinase activity of Bcr-Abl, thus inhibiting the proliferation of Ph-positive progenitors, and has shown activity against all phases of CML, though responses are most substantial and durable in patients in the chronic phase. An international phase III study which compared the efficacy of imatinib with that of interferon alpha combined with low-dose cytarabine in newly diagnosed chronic-phase CML showed the rate of major cytogenetic response at 24 months was 90%, including 82% of complete cytogenetic response. These results indicated that imatinib was superior to interferon-containing treatment as a first-line therapy. More than 10,000 patients worldwide, including those in Japan, have been treated with imatinib in clinical trials, and a lot of information has been accumulated on the use of this drug. The aim of this article is to review the use of this drug and the practical management of patients with chronic myeloid leukemia.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7eb603c02b0c40579e66fe97ee76c19f", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[113, 115], [84, 86], [14, 16], [141, 143], [99, 101]], "char_spans": [[606, 612], [451, 457], [81, 87], [762, 768], [527, 533]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["is", 18], ["a", 21], ["new", 23], ["drug", 27], ["that", 32], ["can", 37], ["inhibit", 41], ["the", 49], ["tyrosine", 53], ["kinase", 62], ["activity", 69], ["of", 78], ["Bcr", 81], ["-", 84], ["Abl", 85], [",", 88], ["the", 90], ["receptors", 94], ["for", 104], ["platelet", 108], ["-", 116], ["derived", 117], ["growth", 125], ["factor", 132], ["receptor(PDGF", 139], [")", 152], ["and", 154], ["stem", 158], ["cell", 163], ["factor", 168], [",", 174], ["or", 176], ["c", 179], ["-", 180], ["kit", 181], [".", 184], ["Chronic", 186], ["myeloid", 194], ["leukemia", 202], ["(", 211], ["CML", 212], [")", 215], ["is", 217], ["distinguished", 220], ["by", 234], ["the", 237], ["presence", 241], ["of", 250], ["a", 253], ["reciprocal", 255], ["translocation", 266], ["between", 280], ["chromosomes", 288], ["9", 300], ["and", 302], ["22", 306], ["that", 309], ["results", 314], ["in", 322], ["a", 325], ["shortened", 327], ["chromosome", 337], ["22", 348], [",", 350], ["termed", 352], ["the", 359], ["Philadelphia(Ph", 363], [")", 378], ["chromosome", 380], [".", 390], ["As", 392], ["a", 395], ["result", 397], ["of", 404], ["the", 407], ["translocation", 411], [",", 424], ["a", 426], ["fusion", 428], ["gene", 435], ["called", 440], ["the", 447], ["Bcr", 451], ["-", 454], ["Abl", 455], ["gene", 459], ["is", 464], ["created", 467], ["from", 475], ["two", 480], ["normal", 484], ["cellular", 491], ["genes", 500], [",", 505], ["encoding", 507], ["a", 516], ["chimeric", 518], ["Bcr", 527], ["-", 530], ["Abl", 531], ["protein", 535], ["with", 543], ["a", 548], ["deregulated", 550], ["tyrosine", 562], ["kinase", 571], ["activity", 578], [".", 586], ["The", 588], ["expression", 592], ["of", 603], ["Bcr", 606], ["-", 609], ["Abl", 610], ["tyrosine", 614], ["kinase", 623], ["has", 630], ["been", 634], ["shown", 639], ["to", 645], ["be", 648], ["necessary", 651], ["and", 661], ["sufficient", 665], ["for", 676], ["the", 680], ["transformed", 684], ["phenotype", 696], ["of", 706], ["CML", 709], ["cells", 713], [".", 718], ["Imatinib", 720], ["can", 729], ["block", 733], ["the", 739], ["kinase", 743], ["activity", 750], ["of", 759], ["Bcr", 762], ["-", 765], ["Abl", 766], [",", 769], ["thus", 771], ["inhibiting", 776], ["the", 787], ["proliferation", 791], ["of", 805], ["Ph", 808], ["-", 810], ["positive", 811], ["progenitors", 820], [",", 831], ["and", 833], ["has", 837], ["shown", 841], ["activity", 847], ["against", 856], ["all", 864], ["phases", 868], ["of", 875], ["CML", 878], [",", 881], ["though", 883], ["responses", 890], ["are", 900], ["most", 904], ["substantial", 909], ["and", 921], ["durable", 925], ["in", 933], ["patients", 936], ["in", 945], ["the", 948], ["chronic", 952], ["phase", 960], [".", 965], ["An", 967], ["international", 970], ["phase", 984], ["III", 990], ["study", 994], ["which", 1000], ["compared", 1006], ["the", 1015], ["efficacy", 1019], ["of", 1028], ["imatinib", 1031], ["with", 1040], ["that", 1045], ["of", 1050], ["interferon", 1053], ["alpha", 1064], ["combined", 1070], ["with", 1079], ["low", 1084], ["-", 1087], ["dose", 1088], ["cytarabine", 1093], ["in", 1104], ["newly", 1107], ["diagnosed", 1113], ["chronic", 1123], ["-", 1130], ["phase", 1131], ["CML", 1137], ["showed", 1141], ["the", 1148], ["rate", 1152], ["of", 1157], ["major", 1160], ["cytogenetic", 1166], ["response", 1178], ["at", 1187], ["24", 1190], ["months", 1193], ["was", 1200], ["90", 1204], ["%", 1206], [",", 1207], ["including", 1209], ["82", 1219], ["%", 1221], ["of", 1223], ["complete", 1226], ["cytogenetic", 1235], ["response", 1247], [".", 1255], ["These", 1257], ["results", 1263], ["indicated", 1271], ["that", 1281], ["imatinib", 1286], ["was", 1295], ["superior", 1299], ["to", 1308], ["interferon", 1311], ["-", 1321], ["containing", 1322], ["treatment", 1333], ["as", 1343], ["a", 1346], ["first", 1348], ["-", 1353], ["line", 1354], ["therapy", 1359], [".", 1366], ["More", 1368], ["than", 1373], ["10,000", 1378], ["patients", 1385], ["worldwide", 1394], [",", 1403], ["including", 1405], ["those", 1415], ["in", 1421], ["Japan", 1424], [",", 1429], ["have", 1431], ["been", 1436], ["treated", 1441], ["with", 1449], ["imatinib", 1454], ["in", 1463], ["clinical", 1466], ["trials", 1475], [",", 1481], ["and", 1483], ["a", 1487], ["lot", 1489], ["of", 1493], ["information", 1496], ["has", 1508], ["been", 1512], ["accumulated", 1517], ["on", 1529], ["the", 1532], ["use", 1536], ["of", 1540], ["this", 1543], ["drug", 1548], [".", 1552], ["The", 1554], ["aim", 1558], ["of", 1562], ["this", 1565], ["article", 1570], ["is", 1578], ["to", 1581], ["review", 1584], ["the", 1591], ["use", 1595], ["of", 1599], ["this", 1602], ["drug", 1607], ["and", 1612], ["the", 1616], ["practical", 1620], ["management", 1630], ["of", 1641], ["patients", 1644], ["with", 1653], ["chronic", 1658], ["myeloid", 1666], ["leukemia", 1674], [".", 1682]]}
{"context": "The new International League Against Epilepsy (ILAE) classification for focal cortical dysplasia (FCD) differentiates between patients with isolated FCD (type 1) and FCD with an associated hippocampal sclerosis (HS) (type 3a). In contrast to the former FCD classification by Palmini, which considered only histologic features, the novel ILAE classification also relies on magnetic resonance imaging (MRI) findings and presumed pathogenesis. We investigated in a cohort of 100 patients with exclusively temporal FCD if the new subdivision of FCD is reflected in clinical characteristics. Thirty-one patients with FCD type 1 and 50 patients with FCD type 3a in the temporal lobe were included. In all patients MRI and histology of the FCD were available. Both patient groups were compared to 19 patients with temporal FCD type 2 with clearly different histologic appearance. Patients with FCD type 1 and type 3a presented with similar clinical features in many respects. In univariate analyses, no statistically significant differences were found as to age at epilepsy onset (p = 0.07) and epilepsy surgery (p = 0.14), a normal appearing neocortical temporal lobe (p = 0.08) or diagnosis of FCD by visual inspection of MRI (p = 0.08), preoperative seizure frequency (p = 0.06), and the predominance of an epigastric aura (p = 0.08). The postoperative outcome was nearly identical 1 year (p = 0.8) and 2 (p = 0.8), 3 (p = 0.8), 5 (p = 0.7), and 8 (p = 1.0) years postoperatively. Only febrile seizures (p = 0.025) and an aura (p = 0.03) were significantly more frequently reported in patients with FCD type 3a. Similar results were obtained from a multivariate logistic regression analysis. Patients with FCD type 2 were more different: Compared to FCD type 3a, age at epilepsy surgery was significantly lower (p = 0.004) and auras (p = 0.005) were significantly less frequently reported. Epigastric auras (p = 0.04) and febrile seizures (p = 0.025) occurred significantly less frequently in patients with FCD type 2 without HS compared to FCD type 3a. The diagnosis of an FCD was significantly more frequently made (p = 0.03) by visual inspection of the MRI compared to FCD type 1. Clinical features did not allow to clear separation of temporal FCD types 1 and 3a. Statistically significant differences were seen in a history of febrile seizures and the occurrence of auras more common in FCD type 3a. However, FCD type 2 in the same localization but with different histology presented with further differences such as more frequent FCD diagnosis by visual inspection of MRI, earlier operation, and less frequent epigastric auras.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "b9e939ba9f2c4fa89af0a12d34b058f2", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[11, 13]], "char_spans": [[72, 95]]}]}], "context_tokens": [["The", 0], ["new", 4], ["International", 8], ["League", 22], ["Against", 29], ["Epilepsy", 37], ["(", 46], ["ILAE", 47], [")", 51], ["classification", 53], ["for", 68], ["focal", 72], ["cortical", 78], ["dysplasia", 87], ["(", 97], ["FCD", 98], [")", 101], ["differentiates", 103], ["between", 118], ["patients", 126], ["with", 135], ["isolated", 140], ["FCD", 149], ["(", 153], ["type", 154], ["1", 159], [")", 160], ["and", 162], ["FCD", 166], ["with", 170], ["an", 175], ["associated", 178], ["hippocampal", 189], ["sclerosis", 201], ["(", 211], ["HS", 212], [")", 214], ["(", 216], ["type", 217], ["3a", 222], [")", 224], [".", 225], ["In", 227], ["contrast", 230], ["to", 239], ["the", 242], ["former", 246], ["FCD", 253], ["classification", 257], ["by", 272], ["Palmini", 275], [",", 282], ["which", 284], ["considered", 290], ["only", 301], ["histologic", 306], ["features", 317], [",", 325], ["the", 327], ["novel", 331], ["ILAE", 337], ["classification", 342], ["also", 357], ["relies", 362], ["on", 369], ["magnetic", 372], ["resonance", 381], ["imaging", 391], ["(", 399], ["MRI", 400], [")", 403], ["findings", 405], ["and", 414], ["presumed", 418], ["pathogenesis", 427], [".", 439], ["We", 441], ["investigated", 444], ["in", 457], ["a", 460], ["cohort", 462], ["of", 469], ["100", 472], ["patients", 476], ["with", 485], ["exclusively", 490], ["temporal", 502], ["FCD", 511], ["if", 515], ["the", 518], ["new", 522], ["subdivision", 526], ["of", 538], ["FCD", 541], ["is", 545], ["reflected", 548], ["in", 558], ["clinical", 561], ["characteristics", 570], [".", 585], ["Thirty", 587], ["-", 593], ["one", 594], ["patients", 598], ["with", 607], ["FCD", 612], ["type", 616], ["1", 621], ["and", 623], ["50", 627], ["patients", 630], ["with", 639], ["FCD", 644], ["type", 648], ["3a", 653], ["in", 656], ["the", 659], ["temporal", 663], ["lobe", 672], ["were", 677], ["included", 682], [".", 690], ["In", 692], ["all", 695], ["patients", 699], ["MRI", 708], ["and", 712], ["histology", 716], ["of", 726], ["the", 729], ["FCD", 733], ["were", 737], ["available", 742], [".", 751], ["Both", 753], ["patient", 758], ["groups", 766], ["were", 773], ["compared", 778], ["to", 787], ["19", 790], ["patients", 793], ["with", 802], ["temporal", 807], ["FCD", 816], ["type", 820], ["2", 825], ["with", 827], ["clearly", 832], ["different", 840], ["histologic", 850], ["appearance", 861], [".", 871], ["Patients", 873], ["with", 882], ["FCD", 887], ["type", 891], ["1", 896], ["and", 898], ["type", 902], ["3a", 907], ["presented", 910], ["with", 920], ["similar", 925], ["clinical", 933], ["features", 942], ["in", 951], ["many", 954], ["respects", 959], [".", 967], ["In", 969], ["univariate", 972], ["analyses", 983], [",", 991], ["no", 993], ["statistically", 996], ["significant", 1010], ["differences", 1022], ["were", 1034], ["found", 1039], ["as", 1045], ["to", 1048], ["age", 1051], ["at", 1055], ["epilepsy", 1058], ["onset", 1067], ["(", 1073], ["p", 1074], ["=", 1076], ["0.07", 1078], [")", 1082], ["and", 1084], ["epilepsy", 1088], ["surgery", 1097], ["(", 1105], ["p", 1106], ["=", 1108], ["0.14", 1110], [")", 1114], [",", 1115], ["a", 1117], ["normal", 1119], ["appearing", 1126], ["neocortical", 1136], ["temporal", 1148], ["lobe", 1157], ["(", 1162], ["p", 1163], ["=", 1165], ["0.08", 1167], [")", 1171], ["or", 1173], ["diagnosis", 1176], ["of", 1186], ["FCD", 1189], ["by", 1193], ["visual", 1196], ["inspection", 1203], ["of", 1214], ["MRI", 1217], ["(", 1221], ["p", 1222], ["=", 1224], ["0.08", 1226], [")", 1230], [",", 1231], ["preoperative", 1233], ["seizure", 1246], ["frequency", 1254], ["(", 1264], ["p", 1265], ["=", 1267], ["0.06", 1269], [")", 1273], [",", 1274], ["and", 1276], ["the", 1280], ["predominance", 1284], ["of", 1297], ["an", 1300], ["epigastric", 1303], ["aura", 1314], ["(", 1319], ["p", 1320], ["=", 1322], ["0.08", 1324], [")", 1328], [".", 1329], ["The", 1331], ["postoperative", 1335], ["outcome", 1349], ["was", 1357], ["nearly", 1361], ["identical", 1368], ["1", 1378], ["year", 1380], ["(", 1385], ["p", 1386], ["=", 1388], ["0.8", 1390], [")", 1393], ["and", 1395], ["2", 1399], ["(", 1401], ["p", 1402], ["=", 1404], ["0.8", 1406], [")", 1409], [",", 1410], ["3", 1412], ["(", 1414], ["p", 1415], ["=", 1417], ["0.8", 1419], [")", 1422], [",", 1423], ["5", 1425], ["(", 1427], ["p", 1428], ["=", 1430], ["0.7", 1432], [")", 1435], [",", 1436], ["and", 1438], ["8", 1442], ["(", 1444], ["p", 1445], ["=", 1447], ["1.0", 1449], [")", 1452], ["years", 1454], ["postoperatively", 1460], [".", 1475], ["Only", 1477], ["febrile", 1482], ["seizures", 1490], ["(", 1499], ["p", 1500], ["=", 1502], ["0.025", 1504], [")", 1509], ["and", 1511], ["an", 1515], ["aura", 1518], ["(", 1523], ["p", 1524], ["=", 1526], ["0.03", 1528], [")", 1532], ["were", 1534], ["significantly", 1539], ["more", 1553], ["frequently", 1558], ["reported", 1569], ["in", 1578], ["patients", 1581], ["with", 1590], ["FCD", 1595], ["type", 1599], ["3a", 1604], [".", 1606], ["Similar", 1608], ["results", 1616], ["were", 1624], ["obtained", 1629], ["from", 1638], ["a", 1643], ["multivariate", 1645], ["logistic", 1658], ["regression", 1667], ["analysis", 1678], [".", 1686], ["Patients", 1688], ["with", 1697], ["FCD", 1702], ["type", 1706], ["2", 1711], ["were", 1713], ["more", 1718], ["different", 1723], [":", 1732], ["Compared", 1734], ["to", 1743], ["FCD", 1746], ["type", 1750], ["3a", 1755], [",", 1757], ["age", 1759], ["at", 1763], ["epilepsy", 1766], ["surgery", 1775], ["was", 1783], ["significantly", 1787], ["lower", 1801], ["(", 1807], ["p", 1808], ["=", 1810], ["0.004", 1812], [")", 1817], ["and", 1819], ["auras", 1823], ["(", 1829], ["p", 1830], ["=", 1832], ["0.005", 1834], [")", 1839], ["were", 1841], ["significantly", 1846], ["less", 1860], ["frequently", 1865], ["reported", 1876], [".", 1884], ["Epigastric", 1886], ["auras", 1897], ["(", 1903], ["p", 1904], ["=", 1906], ["0.04", 1908], [")", 1912], ["and", 1914], ["febrile", 1918], ["seizures", 1926], ["(", 1935], ["p", 1936], ["=", 1938], ["0.025", 1940], [")", 1945], ["occurred", 1947], ["significantly", 1956], ["less", 1970], ["frequently", 1975], ["in", 1986], ["patients", 1989], ["with", 1998], ["FCD", 2003], ["type", 2007], ["2", 2012], ["without", 2014], ["HS", 2022], ["compared", 2025], ["to", 2034], ["FCD", 2037], ["type", 2041], ["3a", 2046], [".", 2048], ["The", 2050], ["diagnosis", 2054], ["of", 2064], ["an", 2067], ["FCD", 2070], ["was", 2074], ["significantly", 2078], ["more", 2092], ["frequently", 2097], ["made", 2108], ["(", 2113], ["p", 2114], ["=", 2116], ["0.03", 2118], [")", 2122], ["by", 2124], ["visual", 2127], ["inspection", 2134], ["of", 2145], ["the", 2148], ["MRI", 2152], ["compared", 2156], ["to", 2165], ["FCD", 2168], ["type", 2172], ["1", 2177], [".", 2178], ["Clinical", 2180], ["features", 2189], ["did", 2198], ["not", 2202], ["allow", 2206], ["to", 2212], ["clear", 2215], ["separation", 2221], ["of", 2232], ["temporal", 2235], ["FCD", 2244], ["types", 2248], ["1", 2254], ["and", 2256], ["3a", 2260], [".", 2262], ["Statistically", 2264], ["significant", 2278], ["differences", 2290], ["were", 2302], ["seen", 2307], ["in", 2312], ["a", 2315], ["history", 2317], ["of", 2325], ["febrile", 2328], ["seizures", 2336], ["and", 2345], ["the", 2349], ["occurrence", 2353], ["of", 2364], ["auras", 2367], ["more", 2373], ["common", 2378], ["in", 2385], ["FCD", 2388], ["type", 2392], ["3a", 2397], [".", 2399], ["However", 2401], [",", 2408], ["FCD", 2410], ["type", 2414], ["2", 2419], ["in", 2421], ["the", 2424], ["same", 2428], ["localization", 2433], ["but", 2446], ["with", 2450], ["different", 2455], ["histology", 2465], ["presented", 2475], ["with", 2485], ["further", 2490], ["differences", 2498], ["such", 2510], ["as", 2515], ["more", 2518], ["frequent", 2523], ["FCD", 2532], ["diagnosis", 2536], ["by", 2546], ["visual", 2549], ["inspection", 2556], ["of", 2567], ["MRI", 2570], [",", 2573], ["earlier", 2575], ["operation", 2583], [",", 2592], ["and", 2594], ["less", 2598], ["frequent", 2603], ["epigastric", 2612], ["auras", 2623], [".", 2628]]}
{"context": "Members of the signal transducer and activator of transcription (STAT) family of transcription factors are potential targets for the treatment and prevention of cancers including non-small-cell lung cancer. STAT proteins can be phosphorylated and activated by diverse upstream kinases including cytokine receptors and tyrosine kinases. We examined STAT protein activation in lung cancer cell lines including those with activating mutations in the EGFR and examined upstream kinases responsible for STAT3 phosphorylation and activation using small molecules, antibodies, and RNA interference. We found more pronounced STAT3 activation in cells with activating EGFR mutations, yet inhibition of EGFR activity had no effect on STAT3 activation. Inhibition of JAK1 with small molecules or RNA interference resulted in loss of STAT3 tyrosine phosphorylation and inhibition of cell growth. An interleukin-6 neutralizing antibody, siltuximab (CNTO 328) could inhibit STAT3 tyrosine phosphorylation in a cell-dependent manner. Siltuximab could completely inhibit STAT3 tyrosine phosphorylation in H1650 cells, and this resulted in inhibition of lung cancer cell growth in vivo. Combined EGFR inhibition with erlotinib and siltuximab resulted in dual inhibition of both tyrosine and serine STAT3 phosphorylation, more pronounced inhibition of STAT3 transcriptional activity, and translated into combined effects on lung cancer growth in a mouse model. Our results suggest that JAK1 is responsible for STAT3 activation in lung cancer cells and that indirect attacks on JAK1-STAT3 using an IL-6 neutralizing antibody with or without EGFR inhibition can inhibit lung cancer growth in lung cancer subsets.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "fc6f88c8ca2e451284d7c33fa8b5071a", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[139, 139]], "char_spans": [[887, 899]]}]}], "context_tokens": [["Members", 0], ["of", 8], ["the", 11], ["signal", 15], ["transducer", 22], ["and", 33], ["activator", 37], ["of", 47], ["transcription", 50], ["(", 64], ["STAT", 65], [")", 69], ["family", 71], ["of", 78], ["transcription", 81], ["factors", 95], ["are", 103], ["potential", 107], ["targets", 117], ["for", 125], ["the", 129], ["treatment", 133], ["and", 143], ["prevention", 147], ["of", 158], ["cancers", 161], ["including", 169], ["non", 179], ["-", 182], ["small", 183], ["-", 188], ["cell", 189], ["lung", 194], ["cancer", 199], [".", 205], ["STAT", 207], ["proteins", 212], ["can", 221], ["be", 225], ["phosphorylated", 228], ["and", 243], ["activated", 247], ["by", 257], ["diverse", 260], ["upstream", 268], ["kinases", 277], ["including", 285], ["cytokine", 295], ["receptors", 304], ["and", 314], ["tyrosine", 318], ["kinases", 327], [".", 334], ["We", 336], ["examined", 339], ["STAT", 348], ["protein", 353], ["activation", 361], ["in", 372], ["lung", 375], ["cancer", 380], ["cell", 387], ["lines", 392], ["including", 398], ["those", 408], ["with", 414], ["activating", 419], ["mutations", 430], ["in", 440], ["the", 443], ["EGFR", 447], ["and", 452], ["examined", 456], ["upstream", 465], ["kinases", 474], ["responsible", 482], ["for", 494], ["STAT3", 498], ["phosphorylation", 504], ["and", 520], ["activation", 524], ["using", 535], ["small", 541], ["molecules", 547], [",", 556], ["antibodies", 558], [",", 568], ["and", 570], ["RNA", 574], ["interference", 578], [".", 590], ["We", 592], ["found", 595], ["more", 601], ["pronounced", 606], ["STAT3", 617], ["activation", 623], ["in", 634], ["cells", 637], ["with", 643], ["activating", 648], ["EGFR", 659], ["mutations", 664], [",", 673], ["yet", 675], ["inhibition", 679], ["of", 690], ["EGFR", 693], ["activity", 698], ["had", 707], ["no", 711], ["effect", 714], ["on", 721], ["STAT3", 724], ["activation", 730], [".", 740], ["Inhibition", 742], ["of", 753], ["JAK1", 756], ["with", 761], ["small", 766], ["molecules", 772], ["or", 782], ["RNA", 785], ["interference", 789], ["resulted", 802], ["in", 811], ["loss", 814], ["of", 819], ["STAT3", 822], ["tyrosine", 828], ["phosphorylation", 837], ["and", 853], ["inhibition", 857], ["of", 868], ["cell", 871], ["growth", 876], [".", 882], ["An", 884], ["interleukin-6", 887], ["neutralizing", 901], ["antibody", 914], [",", 922], ["siltuximab", 924], ["(", 935], ["CNTO", 936], ["328", 941], [")", 944], ["could", 946], ["inhibit", 952], ["STAT3", 960], ["tyrosine", 966], ["phosphorylation", 975], ["in", 991], ["a", 994], ["cell", 996], ["-", 1000], ["dependent", 1001], ["manner", 1011], [".", 1017], ["Siltuximab", 1019], ["could", 1030], ["completely", 1036], ["inhibit", 1047], ["STAT3", 1055], ["tyrosine", 1061], ["phosphorylation", 1070], ["in", 1086], ["H1650", 1089], ["cells", 1095], [",", 1100], ["and", 1102], ["this", 1106], ["resulted", 1111], ["in", 1120], ["inhibition", 1123], ["of", 1134], ["lung", 1137], ["cancer", 1142], ["cell", 1149], ["growth", 1154], ["in", 1161], ["vivo", 1164], [".", 1168], ["Combined", 1170], ["EGFR", 1179], ["inhibition", 1184], ["with", 1195], ["erlotinib", 1200], ["and", 1210], ["siltuximab", 1214], ["resulted", 1225], ["in", 1234], ["dual", 1237], ["inhibition", 1242], ["of", 1253], ["both", 1256], ["tyrosine", 1261], ["and", 1270], ["serine", 1274], ["STAT3", 1281], ["phosphorylation", 1287], [",", 1302], ["more", 1304], ["pronounced", 1309], ["inhibition", 1320], ["of", 1331], ["STAT3", 1334], ["transcriptional", 1340], ["activity", 1356], [",", 1364], ["and", 1366], ["translated", 1370], ["into", 1381], ["combined", 1386], ["effects", 1395], ["on", 1403], ["lung", 1406], ["cancer", 1411], ["growth", 1418], ["in", 1425], ["a", 1428], ["mouse", 1430], ["model", 1436], [".", 1441], ["Our", 1443], ["results", 1447], ["suggest", 1455], ["that", 1463], ["JAK1", 1468], ["is", 1473], ["responsible", 1476], ["for", 1488], ["STAT3", 1492], ["activation", 1498], ["in", 1509], ["lung", 1512], ["cancer", 1517], ["cells", 1524], ["and", 1530], ["that", 1534], ["indirect", 1539], ["attacks", 1548], ["on", 1556], ["JAK1-STAT3", 1559], ["using", 1570], ["an", 1576], ["IL-6", 1579], ["neutralizing", 1584], ["antibody", 1597], ["with", 1606], ["or", 1611], ["without", 1614], ["EGFR", 1622], ["inhibition", 1627], ["can", 1638], ["inhibit", 1642], ["lung", 1650], ["cancer", 1655], ["growth", 1662], ["in", 1669], ["lung", 1672], ["cancer", 1677], ["subsets", 1684], [".", 1691]]}
{"context": "Spectrins comprise \u03b1- and \u03b2-subunits made up predominantly of a series of homologous repeating units of about 106 amino acids; the \u03b1- and \u03b2-chains form antiparallel dimers by lateral association, and tetramers through head-to-head contacts between the dimers. Here we consider the first of these interactions. (1) We confirm earlier observations, showing that the first two paired repeats (\u03b2IR1 with \u03b1IR21, and \u03b2IR2 with \u03b1RI20) at one end of the erythroid spectrin (\u03b1I\u03b2I) dimer are necessary and sufficient to unite the chains; (2) we resolve a conflict in published reports by showing that the strength of the interaction is considerably increased on adding the adjoining pair of repeats (\u03b2IR3-\u03b1IR19); (3) in brain (\u03b1II\u03b2II) spectrin the first two pairs of repeats are similarly essential and sufficient for heterodimer formation; (4) this interaction is ~60-fold stronger than that in the erythroid counterpart, but no enhancement can be detected on addition of three further pairs of repeats; (5) formation of a tight \u03b1I\u03b2I dimer probably depends on structural coupling of the first two repeats in each chain; (6) an analysis of the sequences of the strongly interacting repeats, \u03b2IR1, \u03b2IIR1, \u03b1IR21 and \u03b1IIR20 and repeats in \u03b1-actinin, which also interact very strongly in forming an antiparallel dimer, affords a possible explanation for the different properties of the two spectrin isoforms in respect of the stability of the inter-chain interactions, and also suggests the evolutionary path by which the erythroid and non-erythroid sequences diverged.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "0cf3e09ca48743ab8afcd531f7b306e9", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[248, 248], [30, 30]], "char_spans": [[1285, 1296], [152, 163]]}]}], "context_tokens": [["Spectrins", 0], ["comprise", 10], ["\u03b1-", 19], ["and", 22], ["\u03b2", 26], ["-", 27], ["subunits", 28], ["made", 37], ["up", 42], ["predominantly", 45], ["of", 59], ["a", 62], ["series", 64], ["of", 71], ["homologous", 74], ["repeating", 85], ["units", 95], ["of", 101], ["about", 104], ["106", 110], ["amino", 114], ["acids", 120], [";", 125], ["the", 127], ["\u03b1-", 131], ["and", 134], ["\u03b2", 138], ["-", 139], ["chains", 140], ["form", 147], ["antiparallel", 152], ["dimers", 165], ["by", 172], ["lateral", 175], ["association", 183], [",", 194], ["and", 196], ["tetramers", 200], ["through", 210], ["head", 218], ["-", 222], ["to", 223], ["-", 225], ["head", 226], ["contacts", 231], ["between", 240], ["the", 248], ["dimers", 252], [".", 258], ["Here", 260], ["we", 265], ["consider", 268], ["the", 277], ["first", 281], ["of", 287], ["these", 290], ["interactions", 296], [".", 308], ["(", 310], ["1", 311], [")", 312], ["We", 314], ["confirm", 317], ["earlier", 325], ["observations", 333], [",", 345], ["showing", 347], ["that", 355], ["the", 360], ["first", 364], ["two", 370], ["paired", 374], ["repeats", 381], ["(", 389], ["\u03b2IR1", 390], ["with", 395], ["\u03b1IR21", 400], [",", 405], ["and", 407], ["\u03b2IR2", 411], ["with", 416], ["\u03b1RI20", 421], [")", 426], ["at", 428], ["one", 431], ["end", 435], ["of", 439], ["the", 442], ["erythroid", 446], ["spectrin", 456], ["(", 465], ["\u03b1I\u03b2I", 466], [")", 470], ["dimer", 472], ["are", 478], ["necessary", 482], ["and", 492], ["sufficient", 496], ["to", 507], ["unite", 510], ["the", 516], ["chains", 520], [";", 526], ["(", 528], ["2", 529], [")", 530], ["we", 532], ["resolve", 535], ["a", 543], ["conflict", 545], ["in", 554], ["published", 557], ["reports", 567], ["by", 575], ["showing", 578], ["that", 586], ["the", 591], ["strength", 595], ["of", 604], ["the", 607], ["interaction", 611], ["is", 623], ["considerably", 626], ["increased", 639], ["on", 649], ["adding", 652], ["the", 659], ["adjoining", 663], ["pair", 673], ["of", 678], ["repeats", 681], ["(", 689], ["\u03b2IR3-\u03b1IR19", 690], [")", 700], [";", 701], ["(", 703], ["3", 704], [")", 705], ["in", 707], ["brain", 710], ["(", 716], ["\u03b1II\u03b2II", 717], [")", 723], ["spectrin", 725], ["the", 734], ["first", 738], ["two", 744], ["pairs", 748], ["of", 754], ["repeats", 757], ["are", 765], ["similarly", 769], ["essential", 779], ["and", 789], ["sufficient", 793], ["for", 804], ["heterodimer", 808], ["formation", 820], [";", 829], ["(", 831], ["4", 832], [")", 833], ["this", 835], ["interaction", 840], ["is", 852], ["~60-fold", 855], ["stronger", 864], ["than", 873], ["that", 878], ["in", 883], ["the", 886], ["erythroid", 890], ["counterpart", 900], [",", 911], ["but", 913], ["no", 917], ["enhancement", 920], ["can", 932], ["be", 936], ["detected", 939], ["on", 948], ["addition", 951], ["of", 960], ["three", 963], ["further", 969], ["pairs", 977], ["of", 983], ["repeats", 986], [";", 993], ["(", 995], ["5", 996], [")", 997], ["formation", 999], ["of", 1009], ["a", 1012], ["tight", 1014], ["\u03b1I\u03b2I", 1020], ["dimer", 1025], ["probably", 1031], ["depends", 1040], ["on", 1048], ["structural", 1051], ["coupling", 1062], ["of", 1071], ["the", 1074], ["first", 1078], ["two", 1084], ["repeats", 1088], ["in", 1096], ["each", 1099], ["chain", 1104], [";", 1109], ["(", 1111], ["6", 1112], [")", 1113], ["an", 1115], ["analysis", 1118], ["of", 1127], ["the", 1130], ["sequences", 1134], ["of", 1144], ["the", 1147], ["strongly", 1151], ["interacting", 1160], ["repeats", 1172], [",", 1179], ["\u03b2IR1", 1181], [",", 1185], ["\u03b2IIR1", 1187], [",", 1192], ["\u03b1IR21", 1194], ["and", 1200], ["\u03b1IIR20", 1204], ["and", 1211], ["repeats", 1215], ["in", 1223], ["\u03b1", 1226], ["-", 1227], ["actinin", 1228], [",", 1235], ["which", 1237], ["also", 1243], ["interact", 1248], ["very", 1257], ["strongly", 1262], ["in", 1271], ["forming", 1274], ["an", 1282], ["antiparallel", 1285], ["dimer", 1298], [",", 1303], ["affords", 1305], ["a", 1313], ["possible", 1315], ["explanation", 1324], ["for", 1336], ["the", 1340], ["different", 1344], ["properties", 1354], ["of", 1365], ["the", 1368], ["two", 1372], ["spectrin", 1376], ["isoforms", 1385], ["in", 1394], ["respect", 1397], ["of", 1405], ["the", 1408], ["stability", 1412], ["of", 1422], ["the", 1425], ["inter", 1429], ["-", 1434], ["chain", 1435], ["interactions", 1441], [",", 1453], ["and", 1455], ["also", 1459], ["suggests", 1464], ["the", 1473], ["evolutionary", 1477], ["path", 1490], ["by", 1495], ["which", 1498], ["the", 1504], ["erythroid", 1508], ["and", 1518], ["non", 1522], ["-", 1525], ["erythroid", 1526], ["sequences", 1536], ["diverged", 1546], [".", 1554]]}
{"context": "Mutations in FOXP2 cause developmental verbal dyspraxia (DVD), but only a few cases have been described. We characterize 13 patients with DVD--5 with hemizygous paternal deletions spanning the FOXP2 gene, 1 with a translocation interrupting FOXP2, and the remaining 7 with maternal uniparental disomy of chromosome 7 (UPD7), who were also given a diagnosis of Silver-Russell Syndrome (SRS). Of these individuals with DVD, all 12 for whom parental DNA was available showed absence of a paternal copy of FOXP2. Five other individuals with deletions of paternally inherited FOXP2 but with incomplete clinical information or phenotypes too complex to properly assess are also described. Four of the patients with DVD also meet criteria for autism spectrum disorder. Individuals with paternal UPD7 or with partial maternal UPD7 or deletion starting downstream of FOXP2 do not have DVD. Using quantitative real-time polymerase chain reaction, we show the maternally inherited FOXP2 to be comparatively underexpressed. Our results indicate that absence of paternal FOXP2 is the cause of DVD in patients with SRS with maternal UPD7. The data also point to a role for differential parent-of-origin expression of FOXP2 in human speech development.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "a5597097671740739398b8d4cab19549", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[32, 32], [93, 93], [181, 181], [211, 211], [148, 148], [103, 103], [40, 40], [168, 168], [2, 2]], "char_spans": [[193, 197], [502, 506], [1058, 1062], [1203, 1207], [858, 862], [571, 575], [241, 245], [970, 974], [13, 17]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["FOXP2", 13], ["cause", 19], ["developmental", 25], ["verbal", 39], ["dyspraxia", 46], ["(", 56], ["DVD", 57], [")", 60], [",", 61], ["but", 63], ["only", 67], ["a", 72], ["few", 74], ["cases", 78], ["have", 84], ["been", 89], ["described", 94], [".", 103], ["We", 105], ["characterize", 108], ["13", 121], ["patients", 124], ["with", 133], ["DVD--5", 138], ["with", 145], ["hemizygous", 150], ["paternal", 161], ["deletions", 170], ["spanning", 180], ["the", 189], ["FOXP2", 193], ["gene", 199], [",", 203], ["1", 205], ["with", 207], ["a", 212], ["translocation", 214], ["interrupting", 228], ["FOXP2", 241], [",", 246], ["and", 248], ["the", 252], ["remaining", 256], ["7", 266], ["with", 268], ["maternal", 273], ["uniparental", 282], ["disomy", 294], ["of", 301], ["chromosome", 304], ["7", 315], ["(", 317], ["UPD7", 318], [")", 322], [",", 323], ["who", 325], ["were", 329], ["also", 334], ["given", 339], ["a", 345], ["diagnosis", 347], ["of", 357], ["Silver", 360], ["-", 366], ["Russell", 367], ["Syndrome", 375], ["(", 384], ["SRS", 385], [")", 388], [".", 389], ["Of", 391], ["these", 394], ["individuals", 400], ["with", 412], ["DVD", 417], [",", 420], ["all", 422], ["12", 426], ["for", 429], ["whom", 433], ["parental", 438], ["DNA", 447], ["was", 451], ["available", 455], ["showed", 465], ["absence", 472], ["of", 480], ["a", 483], ["paternal", 485], ["copy", 494], ["of", 499], ["FOXP2", 502], [".", 507], ["Five", 509], ["other", 514], ["individuals", 520], ["with", 532], ["deletions", 537], ["of", 547], ["paternally", 550], ["inherited", 561], ["FOXP2", 571], ["but", 577], ["with", 581], ["incomplete", 586], ["clinical", 597], ["information", 606], ["or", 618], ["phenotypes", 621], ["too", 632], ["complex", 636], ["to", 644], ["properly", 647], ["assess", 656], ["are", 663], ["also", 667], ["described", 672], [".", 681], ["Four", 683], ["of", 688], ["the", 691], ["patients", 695], ["with", 704], ["DVD", 709], ["also", 713], ["meet", 718], ["criteria", 723], ["for", 732], ["autism", 736], ["spectrum", 743], ["disorder", 752], [".", 760], ["Individuals", 762], ["with", 774], ["paternal", 779], ["UPD7", 788], ["or", 793], ["with", 796], ["partial", 801], ["maternal", 809], ["UPD7", 818], ["or", 823], ["deletion", 826], ["starting", 835], ["downstream", 844], ["of", 855], ["FOXP2", 858], ["do", 864], ["not", 867], ["have", 871], ["DVD", 876], [".", 879], ["Using", 881], ["quantitative", 887], ["real", 900], ["-", 904], ["time", 905], ["polymerase", 910], ["chain", 921], ["reaction", 927], [",", 935], ["we", 937], ["show", 940], ["the", 945], ["maternally", 949], ["inherited", 960], ["FOXP2", 970], ["to", 976], ["be", 979], ["comparatively", 982], ["underexpressed", 996], [".", 1010], ["Our", 1012], ["results", 1016], ["indicate", 1024], ["that", 1033], ["absence", 1038], ["of", 1046], ["paternal", 1049], ["FOXP2", 1058], ["is", 1064], ["the", 1067], ["cause", 1071], ["of", 1077], ["DVD", 1080], ["in", 1084], ["patients", 1087], ["with", 1096], ["SRS", 1101], ["with", 1105], ["maternal", 1110], ["UPD7", 1119], [".", 1123], ["The", 1125], ["data", 1129], ["also", 1134], ["point", 1139], ["to", 1145], ["a", 1148], ["role", 1150], ["for", 1155], ["differential", 1159], ["parent", 1172], ["-", 1178], ["of", 1179], ["-", 1181], ["origin", 1182], ["expression", 1189], ["of", 1200], ["FOXP2", 1203], ["in", 1209], ["human", 1212], ["speech", 1218], ["development", 1225], [".", 1236]]}
{"context": "We report a novel mutation in the XK gene (XK) in a Japanese patient with McLeod syndrome. A 50-year-old man showed progressive muscular atrophy, choreic movement, elevated level of serum creatinine kinase, and acanthocytosis. The expression level of all the Kell antigens in erythrocyte was decreased and molecular analysis revealed a single-base (T) deletion at the nucleotide position 1095 in XK. This deletion caused a frameshift in translation, leading to a premature stop codon at the amino acid position 408. We conclude this single-base deletion causes defective Kx protein, which is responsible for the McLeod phenotype in this patient.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "682f059c5e1247ec92d678ce3cc5a4cc", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[7, 7], [73, 73], [10, 10]], "char_spans": [[34, 35], [396, 397], [43, 44]]}]}], "context_tokens": [["We", 0], ["report", 3], ["a", 10], ["novel", 12], ["mutation", 18], ["in", 27], ["the", 30], ["XK", 34], ["gene", 37], ["(", 42], ["XK", 43], [")", 45], ["in", 47], ["a", 50], ["Japanese", 52], ["patient", 61], ["with", 69], ["McLeod", 74], ["syndrome", 81], [".", 89], ["A", 91], ["50-year", 93], ["-", 100], ["old", 101], ["man", 105], ["showed", 109], ["progressive", 116], ["muscular", 128], ["atrophy", 137], [",", 144], ["choreic", 146], ["movement", 154], [",", 162], ["elevated", 164], ["level", 173], ["of", 179], ["serum", 182], ["creatinine", 188], ["kinase", 199], [",", 205], ["and", 207], ["acanthocytosis", 211], [".", 225], ["The", 227], ["expression", 231], ["level", 242], ["of", 248], ["all", 251], ["the", 255], ["Kell", 259], ["antigens", 264], ["in", 273], ["erythrocyte", 276], ["was", 288], ["decreased", 292], ["and", 302], ["molecular", 306], ["analysis", 316], ["revealed", 325], ["a", 334], ["single", 336], ["-", 342], ["base", 343], ["(", 348], ["T", 349], [")", 350], ["deletion", 352], ["at", 361], ["the", 364], ["nucleotide", 368], ["position", 379], ["1095", 388], ["in", 393], ["XK", 396], [".", 398], ["This", 400], ["deletion", 405], ["caused", 414], ["a", 421], ["frameshift", 423], ["in", 434], ["translation", 437], [",", 448], ["leading", 450], ["to", 458], ["a", 461], ["premature", 463], ["stop", 473], ["codon", 478], ["at", 484], ["the", 487], ["amino", 491], ["acid", 497], ["position", 502], ["408", 511], [".", 514], ["We", 516], ["conclude", 519], ["this", 528], ["single", 533], ["-", 539], ["base", 540], ["deletion", 545], ["causes", 554], ["defective", 561], ["Kx", 571], ["protein", 574], [",", 581], ["which", 583], ["is", 589], ["responsible", 592], ["for", 604], ["the", 608], ["McLeod", 612], ["phenotype", 619], ["in", 629], ["this", 632], ["patient", 637], [".", 644]]}
{"context": "Sotos syndrome is an overgrowth syndrome with characteristic facial dysmorphism, variable severity of learning disabilities and macrocephaly with overgrowth. Haploinsufficiency of the nuclear receptor SET domain-containing protein 1 (NSD1) gene located on 5q35 has been implicated as the cause of Sotos syndrome. This study was performed to investigate the mutation spectrum of NSD1 abnormalities and meaningful genotype-phenotype correlations in Korean patients with Sotos syndrome. Eighteen unrelated Korean patients with Sotos syndrome were enrolled for clinical and molecular analyses. Cytogenetic studies were performed to confirm 5q35 microdeletion, and NSD1 sequencing analysis was performed to identify intragenic mutations. NSD1 abnormalities were identified in 15 (83%) patients. Among them, eight patients (53%) had 5q35 microdeletions and the other seven patients (47%) had seven different NSD1 intragenic mutations including four novel mutations. The mutation spectrum of Korean patients with Sotos syndrome was similar to that of previous studies for Japanese patients. Height was significantly shorter and age of walking alone was significantly older in the microdeletion group compared with those in the intragenic mutation group. No significant differences were observed for other clinical characteristics between the microdeletion and intragenic mutation groups. Further studies with a larger number of patients will be necessary to draw conclusive genotype-phenotype correlations.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "21b8aedf45d248998d7f1fe63ff3f685", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[33, 35]], "char_spans": [[234, 243]]}]}], "context_tokens": [["Sotos", 0], ["syndrome", 6], ["is", 15], ["an", 18], ["overgrowth", 21], ["syndrome", 32], ["with", 41], ["characteristic", 46], ["facial", 61], ["dysmorphism", 68], [",", 79], ["variable", 81], ["severity", 90], ["of", 99], ["learning", 102], ["disabilities", 111], ["and", 124], ["macrocephaly", 128], ["with", 141], ["overgrowth", 146], [".", 156], ["Haploinsufficiency", 158], ["of", 177], ["the", 180], ["nuclear", 184], ["receptor", 192], ["SET", 201], ["domain", 205], ["-", 211], ["containing", 212], ["protein", 223], ["1", 231], ["(", 233], ["NSD1", 234], [")", 238], ["gene", 240], ["located", 245], ["on", 253], ["5q35", 256], ["has", 261], ["been", 265], ["implicated", 270], ["as", 281], ["the", 284], ["cause", 288], ["of", 294], ["Sotos", 297], ["syndrome", 303], [".", 311], ["This", 313], ["study", 318], ["was", 324], ["performed", 328], ["to", 338], ["investigate", 341], ["the", 353], ["mutation", 357], ["spectrum", 366], ["of", 375], ["NSD1", 378], ["abnormalities", 383], ["and", 397], ["meaningful", 401], ["genotype", 412], ["-", 420], ["phenotype", 421], ["correlations", 431], ["in", 444], ["Korean", 447], ["patients", 454], ["with", 463], ["Sotos", 468], ["syndrome", 474], [".", 482], ["Eighteen", 484], ["unrelated", 493], ["Korean", 503], ["patients", 510], ["with", 519], ["Sotos", 524], ["syndrome", 530], ["were", 539], ["enrolled", 544], ["for", 553], ["clinical", 557], ["and", 566], ["molecular", 570], ["analyses", 580], [".", 588], ["Cytogenetic", 590], ["studies", 602], ["were", 610], ["performed", 615], ["to", 625], ["confirm", 628], ["5q35", 636], ["microdeletion", 641], [",", 654], ["and", 656], ["NSD1", 660], ["sequencing", 665], ["analysis", 676], ["was", 685], ["performed", 689], ["to", 699], ["identify", 702], ["intragenic", 711], ["mutations", 722], [".", 731], ["NSD1", 733], ["abnormalities", 738], ["were", 752], ["identified", 757], ["in", 768], ["15", 771], ["(", 774], ["83", 775], ["%", 777], [")", 778], ["patients", 780], [".", 788], ["Among", 790], ["them", 796], [",", 800], ["eight", 802], ["patients", 808], ["(", 817], ["53", 818], ["%", 820], [")", 821], ["had", 823], ["5q35", 827], ["microdeletions", 832], ["and", 847], ["the", 851], ["other", 855], ["seven", 861], ["patients", 867], ["(", 876], ["47", 877], ["%", 879], [")", 880], ["had", 882], ["seven", 886], ["different", 892], ["NSD1", 902], ["intragenic", 907], ["mutations", 918], ["including", 928], ["four", 938], ["novel", 943], ["mutations", 949], [".", 958], ["The", 960], ["mutation", 964], ["spectrum", 973], ["of", 982], ["Korean", 985], ["patients", 992], ["with", 1001], ["Sotos", 1006], ["syndrome", 1012], ["was", 1021], ["similar", 1025], ["to", 1033], ["that", 1036], ["of", 1041], ["previous", 1044], ["studies", 1053], ["for", 1061], ["Japanese", 1065], ["patients", 1074], [".", 1082], ["Height", 1084], ["was", 1091], ["significantly", 1095], ["shorter", 1109], ["and", 1117], ["age", 1121], ["of", 1125], ["walking", 1128], ["alone", 1136], ["was", 1142], ["significantly", 1146], ["older", 1160], ["in", 1166], ["the", 1169], ["microdeletion", 1173], ["group", 1187], ["compared", 1193], ["with", 1202], ["those", 1207], ["in", 1213], ["the", 1216], ["intragenic", 1220], ["mutation", 1231], ["group", 1240], [".", 1245], ["No", 1247], ["significant", 1250], ["differences", 1262], ["were", 1274], ["observed", 1279], ["for", 1288], ["other", 1292], ["clinical", 1298], ["characteristics", 1307], ["between", 1323], ["the", 1331], ["microdeletion", 1335], ["and", 1349], ["intragenic", 1353], ["mutation", 1364], ["groups", 1373], [".", 1379], ["Further", 1381], ["studies", 1389], ["with", 1397], ["a", 1402], ["larger", 1404], ["number", 1411], ["of", 1418], ["patients", 1421], ["will", 1430], ["be", 1435], ["necessary", 1438], ["to", 1448], ["draw", 1451], ["conclusive", 1456], ["genotype", 1467], ["-", 1475], ["phenotype", 1476], ["correlations", 1486], [".", 1498]]}
{"context": "Small supernumerary marker chromosomes (sSMC) can be present in numerically abnormal karyotypes like in a 'Turner-syndrome karyotype' mos 45,X/46,X,+mar. Here we report the first case of an sSMC found in Turner syndrome karyotypes (sSMCT) derived from chromosome 14 in a Turner syndrome patient. According to cytogenetic and molecular cytogenetic characterization the karyotype was 46,X,+del(14)(q11.1). The present case is the third Turner syndrome case with an sSMCT not derived from the X- or the Y-chromosome. More comprehensive characterization of such sSMCT might identify them to be more frequent than only ~0.6% in Turner syndrome cases according to available data.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "d691510d9c1e401ebf6364b876537b48", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[82, 82]], "char_spans": [[490, 491]]}]}], "context_tokens": [["Small", 0], ["supernumerary", 6], ["marker", 20], ["chromosomes", 27], ["(", 39], ["sSMC", 40], [")", 44], ["can", 46], ["be", 50], ["present", 53], ["in", 61], ["numerically", 64], ["abnormal", 76], ["karyotypes", 85], ["like", 96], ["in", 101], ["a", 104], ["'", 106], ["Turner", 107], ["-", 113], ["syndrome", 114], ["karyotype", 123], ["'", 132], ["mos", 134], ["45,X/46,X,+mar", 138], [".", 152], ["Here", 154], ["we", 159], ["report", 162], ["the", 169], ["first", 173], ["case", 179], ["of", 184], ["an", 187], ["sSMC", 190], ["found", 195], ["in", 201], ["Turner", 204], ["syndrome", 211], ["karyotypes", 220], ["(", 231], ["sSMCT", 232], [")", 237], ["derived", 239], ["from", 247], ["chromosome", 252], ["14", 263], ["in", 266], ["a", 269], ["Turner", 271], ["syndrome", 278], ["patient", 287], [".", 294], ["According", 296], ["to", 306], ["cytogenetic", 309], ["and", 321], ["molecular", 325], ["cytogenetic", 335], ["characterization", 347], ["the", 364], ["karyotype", 368], ["was", 378], ["46,X,+del(14)(q11.1", 382], [")", 401], [".", 402], ["The", 404], ["present", 408], ["case", 416], ["is", 421], ["the", 424], ["third", 428], ["Turner", 434], ["syndrome", 441], ["case", 450], ["with", 455], ["an", 460], ["sSMCT", 463], ["not", 469], ["derived", 473], ["from", 481], ["the", 486], ["X-", 490], ["or", 493], ["the", 496], ["Y", 500], ["-", 501], ["chromosome", 502], [".", 512], ["More", 514], ["comprehensive", 519], ["characterization", 533], ["of", 550], ["such", 553], ["sSMCT", 558], ["might", 564], ["identify", 570], ["them", 579], ["to", 584], ["be", 587], ["more", 590], ["frequent", 595], ["than", 604], ["only", 609], ["~0.6", 614], ["%", 618], ["in", 620], ["Turner", 623], ["syndrome", 630], ["cases", 639], ["according", 645], ["to", 655], ["available", 658], ["data", 668], [".", 672]]}
{"context": "A dedicated excision repair pathway, termed transcription-coupled repair (TCR), targets the removal of DNA lesions from transcribed strands of expressed genes. Transcription arrest at the site of the lesion has been proposed as the first step for initiation of TCR. In support of this model, a strong correlation between arrest of transcription by a lesion in vitro and TCR of that lesion in vivo has been found in most cases analyzed. TCR has been reported for oxidative DNA damage; however, very little is known about how frequently occurring and spontaneous DNA damage, such as depurination and base deamination, affects progression of the transcription complex. We have previously determined that the oxidative lesion, thymine glycol, is a significant block to transcription by T7 RNA polymerase (T7 RNAP) but has no detectable effect on transcription by RNA polymerase II (RNAP II) in a reconstituted system with all of the required factors. Another oxidative lesion, 8-oxoguanine, only slightly blocked T7 RNAP and caused RNAP II to briefly pause at the lesion before bypassing it. Because an abasic site is an intermediate in the repair of oxidative damage, it was of interest to learn whether it arrested transcription. Using in vitro transcription assays and substrates containing a specifically positioned lesion, we found that an abasic site in the transcribed strand is a 60% block to transcription by T7 RNAP but nearly a complete block to transcription by mammalian RNAP II. An abasic site in the nontranscribed strand did not block either polymerase. Our results clearly indicate that an abasic site is a much stronger block to transcription than either a thymine glycol or an 8-oxoguanine. Because the predominant model for TCR postulates that only lesions that block RNAP will be subject to TCR, our findings suggest that the abasic site may be sufficient to initiate TCR in vivo.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "6960bdbb74c3432a83bd3a3c0a6c30f1", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[242, 243]], "char_spans": [[1360, 1377]]}]}], "context_tokens": [["A", 0], ["dedicated", 2], ["excision", 12], ["repair", 21], ["pathway", 28], [",", 35], ["termed", 37], ["transcription", 44], ["-", 57], ["coupled", 58], ["repair", 66], ["(", 73], ["TCR", 74], [")", 77], [",", 78], ["targets", 80], ["the", 88], ["removal", 92], ["of", 100], ["DNA", 103], ["lesions", 107], ["from", 115], ["transcribed", 120], ["strands", 132], ["of", 140], ["expressed", 143], ["genes", 153], [".", 158], ["Transcription", 160], ["arrest", 174], ["at", 181], ["the", 184], ["site", 188], ["of", 193], ["the", 196], ["lesion", 200], ["has", 207], ["been", 211], ["proposed", 216], ["as", 225], ["the", 228], ["first", 232], ["step", 238], ["for", 243], ["initiation", 247], ["of", 258], ["TCR", 261], [".", 264], ["In", 266], ["support", 269], ["of", 277], ["this", 280], ["model", 285], [",", 290], ["a", 292], ["strong", 294], ["correlation", 301], ["between", 313], ["arrest", 321], ["of", 328], ["transcription", 331], ["by", 345], ["a", 348], ["lesion", 350], ["in", 357], ["vitro", 360], ["and", 366], ["TCR", 370], ["of", 374], ["that", 377], ["lesion", 382], ["in", 389], ["vivo", 392], ["has", 397], ["been", 401], ["found", 406], ["in", 412], ["most", 415], ["cases", 420], ["analyzed", 426], [".", 434], ["TCR", 436], ["has", 440], ["been", 444], ["reported", 449], ["for", 458], ["oxidative", 462], ["DNA", 472], ["damage", 476], [";", 482], ["however", 484], [",", 491], ["very", 493], ["little", 498], ["is", 505], ["known", 508], ["about", 514], ["how", 520], ["frequently", 524], ["occurring", 535], ["and", 545], ["spontaneous", 549], ["DNA", 561], ["damage", 565], [",", 571], ["such", 573], ["as", 578], ["depurination", 581], ["and", 594], ["base", 598], ["deamination", 603], [",", 614], ["affects", 616], ["progression", 624], ["of", 636], ["the", 639], ["transcription", 643], ["complex", 657], [".", 664], ["We", 666], ["have", 669], ["previously", 674], ["determined", 685], ["that", 696], ["the", 701], ["oxidative", 705], ["lesion", 715], [",", 721], ["thymine", 723], ["glycol", 731], [",", 737], ["is", 739], ["a", 742], ["significant", 744], ["block", 756], ["to", 762], ["transcription", 765], ["by", 779], ["T7", 782], ["RNA", 785], ["polymerase", 789], ["(", 800], ["T7", 801], ["RNAP", 804], [")", 808], ["but", 810], ["has", 814], ["no", 818], ["detectable", 821], ["effect", 832], ["on", 839], ["transcription", 842], ["by", 856], ["RNA", 859], ["polymerase", 863], ["II", 874], ["(", 877], ["RNAP", 878], ["II", 883], [")", 885], ["in", 887], ["a", 890], ["reconstituted", 892], ["system", 906], ["with", 913], ["all", 918], ["of", 922], ["the", 925], ["required", 929], ["factors", 938], [".", 945], ["Another", 947], ["oxidative", 955], ["lesion", 965], [",", 971], ["8-oxoguanine", 973], [",", 985], ["only", 987], ["slightly", 992], ["blocked", 1001], ["T7", 1009], ["RNAP", 1012], ["and", 1017], ["caused", 1021], ["RNAP", 1028], ["II", 1033], ["to", 1036], ["briefly", 1039], ["pause", 1047], ["at", 1053], ["the", 1056], ["lesion", 1060], ["before", 1067], ["bypassing", 1074], ["it", 1084], [".", 1086], ["Because", 1088], ["an", 1096], ["abasic", 1099], ["site", 1106], ["is", 1111], ["an", 1114], ["intermediate", 1117], ["in", 1130], ["the", 1133], ["repair", 1137], ["of", 1144], ["oxidative", 1147], ["damage", 1157], [",", 1163], ["it", 1165], ["was", 1168], ["of", 1172], ["interest", 1175], ["to", 1184], ["learn", 1187], ["whether", 1193], ["it", 1201], ["arrested", 1204], ["transcription", 1213], [".", 1226], ["Using", 1228], ["in", 1234], ["vitro", 1237], ["transcription", 1243], ["assays", 1257], ["and", 1264], ["substrates", 1268], ["containing", 1279], ["a", 1290], ["specifically", 1292], ["positioned", 1305], ["lesion", 1316], [",", 1322], ["we", 1324], ["found", 1327], ["that", 1333], ["an", 1338], ["abasic", 1341], ["site", 1348], ["in", 1353], ["the", 1356], ["transcribed", 1360], ["strand", 1372], ["is", 1379], ["a", 1382], ["60", 1384], ["%", 1386], ["block", 1388], ["to", 1394], ["transcription", 1397], ["by", 1411], ["T7", 1414], ["RNAP", 1417], ["but", 1422], ["nearly", 1426], ["a", 1433], ["complete", 1435], ["block", 1444], ["to", 1450], ["transcription", 1453], ["by", 1467], ["mammalian", 1470], ["RNAP", 1480], ["II", 1485], [".", 1487], ["An", 1489], ["abasic", 1492], ["site", 1499], ["in", 1504], ["the", 1507], ["nontranscribed", 1511], ["strand", 1526], ["did", 1533], ["not", 1537], ["block", 1541], ["either", 1547], ["polymerase", 1554], [".", 1564], ["Our", 1566], ["results", 1570], ["clearly", 1578], ["indicate", 1586], ["that", 1595], ["an", 1600], ["abasic", 1603], ["site", 1610], ["is", 1615], ["a", 1618], ["much", 1620], ["stronger", 1625], ["block", 1634], ["to", 1640], ["transcription", 1643], ["than", 1657], ["either", 1662], ["a", 1669], ["thymine", 1671], ["glycol", 1679], ["or", 1686], ["an", 1689], ["8-oxoguanine", 1692], [".", 1704], ["Because", 1706], ["the", 1714], ["predominant", 1718], ["model", 1730], ["for", 1736], ["TCR", 1740], ["postulates", 1744], ["that", 1755], ["only", 1760], ["lesions", 1765], ["that", 1773], ["block", 1778], ["RNAP", 1784], ["will", 1789], ["be", 1794], ["subject", 1797], ["to", 1805], ["TCR", 1808], [",", 1811], ["our", 1813], ["findings", 1817], ["suggest", 1826], ["that", 1834], ["the", 1839], ["abasic", 1843], ["site", 1850], ["may", 1855], ["be", 1859], ["sufficient", 1862], ["to", 1873], ["initiate", 1876], ["TCR", 1885], ["in", 1889], ["vivo", 1892], [".", 1896]]}
{"context": "Restless legs syndrome/Willis Ekbom disease (RLS/WED) has been recognized as a significant medical disorder since the 17th century. It was studied mostly in the last 50 years in relation to increasing interest in sleep medicine and health-related quality of life. This led to recognition that the disease is not well characterized as restless feelings in the legs. These symptoms are reported in many situations, but the subjective experience of RLS/WED patients differs from that experienced by others. Thus a new name has been introduced that avoids problems of symptom definition of a disease by naming it after those who first characterized it, i.e. 'Willis Ekbom disease'. This article emphasizes the importance of RLS/WED for psychiatry. The disease carries significant increased risk for depression and anxiety disorders. Treatment requires consideration of these co-morbid disorders. RLS/WED can exacerbate or even engender psychiatric disease, so treatment of psychiatric disease should also include consideration of RLS/WED. The need for attention to RLS/WED is particularly significant for depression. Most anti-depressants exacerbate or can even engender RLS/WED. Thus this article seeks to introduce RLS/WED in relation to psychiatric practice. It presents the RLS/WED disease, its overlap with psychiatry and the current treatment options.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "289d6353e4064a62a58db9f9192b3eff", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["/", 22], ["Willis", 23], ["Ekbom", 30], ["disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["has", 54], ["been", 58], ["recognized", 63], ["as", 74], ["a", 77], ["significant", 79], ["medical", 91], ["disorder", 99], ["since", 108], ["the", 114], ["17th", 118], ["century", 123], [".", 130], ["It", 132], ["was", 135], ["studied", 139], ["mostly", 147], ["in", 154], ["the", 157], ["last", 161], ["50", 166], ["years", 169], ["in", 175], ["relation", 178], ["to", 187], ["increasing", 190], ["interest", 201], ["in", 210], ["sleep", 213], ["medicine", 219], ["and", 228], ["health", 232], ["-", 238], ["related", 239], ["quality", 247], ["of", 255], ["life", 258], [".", 262], ["This", 264], ["led", 269], ["to", 273], ["recognition", 276], ["that", 288], ["the", 293], ["disease", 297], ["is", 305], ["not", 308], ["well", 312], ["characterized", 317], ["as", 331], ["restless", 334], ["feelings", 343], ["in", 352], ["the", 355], ["legs", 359], [".", 363], ["These", 365], ["symptoms", 371], ["are", 380], ["reported", 384], ["in", 393], ["many", 396], ["situations", 401], [",", 411], ["but", 413], ["the", 417], ["subjective", 421], ["experience", 432], ["of", 443], ["RLS", 446], ["/", 449], ["WED", 450], ["patients", 454], ["differs", 463], ["from", 471], ["that", 476], ["experienced", 481], ["by", 493], ["others", 496], [".", 502], ["Thus", 504], ["a", 509], ["new", 511], ["name", 515], ["has", 520], ["been", 524], ["introduced", 529], ["that", 540], ["avoids", 545], ["problems", 552], ["of", 561], ["symptom", 564], ["definition", 572], ["of", 583], ["a", 586], ["disease", 588], ["by", 596], ["naming", 599], ["it", 606], ["after", 609], ["those", 615], ["who", 621], ["first", 625], ["characterized", 631], ["it", 645], [",", 647], ["i.e.", 649], ["'", 654], ["Willis", 655], ["Ekbom", 662], ["disease", 668], ["'", 675], [".", 676], ["This", 678], ["article", 683], ["emphasizes", 691], ["the", 702], ["importance", 706], ["of", 717], ["RLS", 720], ["/", 723], ["WED", 724], ["for", 728], ["psychiatry", 732], [".", 742], ["The", 744], ["disease", 748], ["carries", 756], ["significant", 764], ["increased", 776], ["risk", 786], ["for", 791], ["depression", 795], ["and", 806], ["anxiety", 810], ["disorders", 818], [".", 827], ["Treatment", 829], ["requires", 839], ["consideration", 848], ["of", 862], ["these", 865], ["co", 871], ["-", 873], ["morbid", 874], ["disorders", 881], [".", 890], ["RLS", 892], ["/", 895], ["WED", 896], ["can", 900], ["exacerbate", 904], ["or", 915], ["even", 918], ["engender", 923], ["psychiatric", 932], ["disease", 944], [",", 951], ["so", 953], ["treatment", 956], ["of", 966], ["psychiatric", 969], ["disease", 981], ["should", 989], ["also", 996], ["include", 1001], ["consideration", 1009], ["of", 1023], ["RLS", 1026], ["/", 1029], ["WED", 1030], [".", 1033], ["The", 1035], ["need", 1039], ["for", 1044], ["attention", 1048], ["to", 1058], ["RLS", 1061], ["/", 1064], ["WED", 1065], ["is", 1069], ["particularly", 1072], ["significant", 1085], ["for", 1097], ["depression", 1101], [".", 1111], ["Most", 1113], ["anti", 1118], ["-", 1122], ["depressants", 1123], ["exacerbate", 1135], ["or", 1146], ["can", 1149], ["even", 1153], ["engender", 1158], ["RLS", 1167], ["/", 1170], ["WED", 1171], [".", 1174], ["Thus", 1176], ["this", 1181], ["article", 1186], ["seeks", 1194], ["to", 1200], ["introduce", 1203], ["RLS", 1213], ["/", 1216], ["WED", 1217], ["in", 1221], ["relation", 1224], ["to", 1233], ["psychiatric", 1236], ["practice", 1248], [".", 1256], ["It", 1258], ["presents", 1261], ["the", 1270], ["RLS", 1274], ["/", 1277], ["WED", 1278], ["disease", 1282], [",", 1289], ["its", 1291], ["overlap", 1295], ["with", 1303], ["psychiatry", 1308], ["and", 1319], ["the", 1323], ["current", 1327], ["treatment", 1335], ["options", 1345], [".", 1352]]}
{"context": "A 75-year-old woman presented with altered mental status, septic picture, and influenza-like symptoms. Initial investigations revealed atypical lymphocytosis, thrombocytopenia, elevated liver enzymes, and a positive monospot test result. Further investigation showed the Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus (CMV) IgM and IgG were positive, suggesting that her mononucleosis-like syndrome was due to acute CMV infection. Herein, we report the first case of a heterophile-positive mononucleosis syndrome caused by acute CMV infection in an elderly immunocompetent woman. This case conveys that monospot test can yield false-positive result in the setting of acute CMV infection.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "0460fc84d839453e88d73ec2691da940", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[54, 57], [43, 46]], "char_spans": [[324, 341], [271, 288]]}]}], "context_tokens": [["A", 0], ["75-year", 2], ["-", 9], ["old", 10], ["woman", 14], ["presented", 20], ["with", 30], ["altered", 35], ["mental", 43], ["status", 50], [",", 56], ["septic", 58], ["picture", 65], [",", 72], ["and", 74], ["influenza", 78], ["-", 87], ["like", 88], ["symptoms", 93], [".", 101], ["Initial", 103], ["investigations", 111], ["revealed", 126], ["atypical", 135], ["lymphocytosis", 144], [",", 157], ["thrombocytopenia", 159], [",", 175], ["elevated", 177], ["liver", 186], ["enzymes", 192], [",", 199], ["and", 201], ["a", 205], ["positive", 207], ["monospot", 216], ["test", 225], ["result", 230], [".", 236], ["Further", 238], ["investigation", 246], ["showed", 260], ["the", 267], ["Epstein", 271], ["-", 278], ["Barr", 279], ["virus", 284], ["viral", 290], ["capsid", 296], ["antibody", 303], ["IgM", 312], ["/", 315], ["IgG", 316], ["and", 320], ["Epstein", 324], ["-", 331], ["Barr", 332], ["virus", 337], ["DNA", 343], ["by", 347], ["polymerase", 350], ["chain", 361], ["reaction", 367], ["to", 376], ["be", 379], ["negative", 382], [";", 390], ["however", 392], [",", 399], ["interestingly", 401], ["her", 415], ["cytomegalovirus", 419], ["(", 435], ["CMV", 436], [")", 439], ["IgM", 441], ["and", 445], ["IgG", 449], ["were", 453], ["positive", 458], [",", 466], ["suggesting", 468], ["that", 479], ["her", 484], ["mononucleosis", 488], ["-", 501], ["like", 502], ["syndrome", 507], ["was", 516], ["due", 520], ["to", 524], ["acute", 527], ["CMV", 533], ["infection", 537], [".", 546], ["Herein", 548], [",", 554], ["we", 556], ["report", 559], ["the", 566], ["first", 570], ["case", 576], ["of", 581], ["a", 584], ["heterophile", 586], ["-", 597], ["positive", 598], ["mononucleosis", 607], ["syndrome", 621], ["caused", 630], ["by", 637], ["acute", 640], ["CMV", 646], ["infection", 650], ["in", 660], ["an", 663], ["elderly", 666], ["immunocompetent", 674], ["woman", 690], [".", 695], ["This", 697], ["case", 702], ["conveys", 707], ["that", 715], ["monospot", 720], ["test", 729], ["can", 734], ["yield", 738], ["false", 744], ["-", 749], ["positive", 750], ["result", 759], ["in", 766], ["the", 769], ["setting", 773], ["of", 781], ["acute", 784], ["CMV", 790], ["infection", 794], [".", 803]]}
{"context": "The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, we investigated the regulation of the catalytic component of telomerase, hTERT, by BCR-ABL at multiple levels in K562 cells. Molecular techniques such as over expression, knockdown, real-time PCR, immunoprecipitation, western blotting, reporter assay, confocal microscopy, telomerase assays and microarray were used to suggest that hTERT expression and activity is modulated by BCR-ABL at multiple levels. Our results suggest that BCR-ABL plays an important role in regulating hTERT in K562 (BCR-ABL positive human leukemia) cells. When Gleevec inhibited the tyrosine kinase activity of BCR-ABL, phosphorylation of hTERT was downregulated, therefore suggesting a positive correlation between BCR-ABL and hTERT. Gleevec treatment inhibited hTERT at mRNA level and significantly reduced telomerase activity (TA) in K562 cells, but not in HL60 or Jurkat cells (BCR-ABL negative cells). We also demonstrated that the transcription factor STAT5a plays a critical role in hTERT gene regulation in K562 cells. Knockdown of STAT5a, but not STAT5b, resulted in a marked downregulation of hTERT mRNA level, TA and hTERT protein level in K562 cells. Furthermore, translocation of hTERT from nucleoli to nucleoplasm was observed in K562 cells induced by Gleevec. Our data reveal that BCR-ABL can regulate TA at multiple levels, including transcription, post-translational level, and proper localization. Thus, suppression of cell growth and induction of apoptosis by Gleevec treatment may be partially due to TA inhibition. Additionally, we have identified STAT5a as critical mediator of the hTERT gene expression in BCR-ABL positive CML cells, suggesting that targeting STAT5a may be a promising therapeutic strategy for BCR-ABL positive CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "0641e4745b234652b621a99faaec9192", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[145, 147], [161, 163], [20, 22], [270, 272], [53, 55], [26, 28], [104, 106], [328, 330], [346, 348], [194, 196], [128, 130], [115, 117]], "char_spans": [[794, 800], [899, 905], [127, 133], [1479, 1485], [290, 296], [147, 153], [585, 591], [1812, 1818], [1917, 1923], [1065, 1071], [699, 705], [638, 644]]}]}], "context_tokens": [["The", 0], ["cytogenetic", 4], ["characteristic", 16], ["of", 31], ["Chronic", 34], ["Myeloid", 42], ["Leukemia", 50], ["(", 59], ["CML", 60], [")", 63], ["is", 65], ["the", 68], ["formation", 72], ["of", 82], ["the", 85], ["Philadelphia", 89], ["chromosome", 102], ["gene", 113], ["product", 118], [",", 125], ["BCR", 127], ["-", 130], ["ABL", 131], [".", 134], ["Given", 136], ["that", 142], ["BCR", 147], ["-", 150], ["ABL", 151], ["is", 155], ["the", 158], ["specific", 162], ["target", 171], ["of", 178], ["Gleevec", 181], ["in", 189], ["CML", 192], ["treatment", 196], [",", 205], ["we", 207], ["investigated", 210], ["the", 223], ["regulation", 227], ["of", 238], ["the", 241], ["catalytic", 245], ["component", 255], ["of", 265], ["telomerase", 268], [",", 278], ["hTERT", 280], [",", 285], ["by", 287], ["BCR", 290], ["-", 293], ["ABL", 294], ["at", 298], ["multiple", 301], ["levels", 310], ["in", 317], ["K562", 320], ["cells", 325], [".", 330], ["Molecular", 332], ["techniques", 342], ["such", 353], ["as", 358], ["over", 361], ["expression", 366], [",", 376], ["knockdown", 378], [",", 387], ["real", 389], ["-", 393], ["time", 394], ["PCR", 399], [",", 402], ["immunoprecipitation", 404], [",", 423], ["western", 425], ["blotting", 433], [",", 441], ["reporter", 443], ["assay", 452], [",", 457], ["confocal", 459], ["microscopy", 468], [",", 478], ["telomerase", 480], ["assays", 491], ["and", 498], ["microarray", 502], ["were", 513], ["used", 518], ["to", 523], ["suggest", 526], ["that", 534], ["hTERT", 539], ["expression", 545], ["and", 556], ["activity", 560], ["is", 569], ["modulated", 572], ["by", 582], ["BCR", 585], ["-", 588], ["ABL", 589], ["at", 593], ["multiple", 596], ["levels", 605], [".", 611], ["Our", 613], ["results", 617], ["suggest", 625], ["that", 633], ["BCR", 638], ["-", 641], ["ABL", 642], ["plays", 646], ["an", 652], ["important", 655], ["role", 665], ["in", 670], ["regulating", 673], ["hTERT", 684], ["in", 690], ["K562", 693], ["(", 698], ["BCR", 699], ["-", 702], ["ABL", 703], ["positive", 707], ["human", 716], ["leukemia", 722], [")", 730], ["cells", 732], [".", 737], ["When", 739], ["Gleevec", 744], ["inhibited", 752], ["the", 762], ["tyrosine", 766], ["kinase", 775], ["activity", 782], ["of", 791], ["BCR", 794], ["-", 797], ["ABL", 798], [",", 801], ["phosphorylation", 803], ["of", 819], ["hTERT", 822], ["was", 828], ["downregulated", 832], [",", 845], ["therefore", 847], ["suggesting", 857], ["a", 868], ["positive", 870], ["correlation", 879], ["between", 891], ["BCR", 899], ["-", 902], ["ABL", 903], ["and", 907], ["hTERT", 911], [".", 916], ["Gleevec", 918], ["treatment", 926], ["inhibited", 936], ["hTERT", 946], ["at", 952], ["mRNA", 955], ["level", 960], ["and", 966], ["significantly", 970], ["reduced", 984], ["telomerase", 992], ["activity", 1003], ["(", 1012], ["TA", 1013], [")", 1015], ["in", 1017], ["K562", 1020], ["cells", 1025], [",", 1030], ["but", 1032], ["not", 1036], ["in", 1040], ["HL60", 1043], ["or", 1048], ["Jurkat", 1051], ["cells", 1058], ["(", 1064], ["BCR", 1065], ["-", 1068], ["ABL", 1069], ["negative", 1073], ["cells", 1082], [")", 1087], [".", 1088], ["We", 1090], ["also", 1093], ["demonstrated", 1098], ["that", 1111], ["the", 1116], ["transcription", 1120], ["factor", 1134], ["STAT5a", 1141], ["plays", 1148], ["a", 1154], ["critical", 1156], ["role", 1165], ["in", 1170], ["hTERT", 1173], ["gene", 1179], ["regulation", 1184], ["in", 1195], ["K562", 1198], ["cells", 1203], [".", 1208], ["Knockdown", 1210], ["of", 1220], ["STAT5a", 1223], [",", 1229], ["but", 1231], ["not", 1235], ["STAT5b", 1239], [",", 1245], ["resulted", 1247], ["in", 1256], ["a", 1259], ["marked", 1261], ["downregulation", 1268], ["of", 1283], ["hTERT", 1286], ["mRNA", 1292], ["level", 1297], [",", 1302], ["TA", 1304], ["and", 1307], ["hTERT", 1311], ["protein", 1317], ["level", 1325], ["in", 1331], ["K562", 1334], ["cells", 1339], [".", 1344], ["Furthermore", 1346], [",", 1357], ["translocation", 1359], ["of", 1373], ["hTERT", 1376], ["from", 1382], ["nucleoli", 1387], ["to", 1396], ["nucleoplasm", 1399], ["was", 1411], ["observed", 1415], ["in", 1424], ["K562", 1427], ["cells", 1432], ["induced", 1438], ["by", 1446], ["Gleevec", 1449], [".", 1456], ["Our", 1458], ["data", 1462], ["reveal", 1467], ["that", 1474], ["BCR", 1479], ["-", 1482], ["ABL", 1483], ["can", 1487], ["regulate", 1491], ["TA", 1500], ["at", 1503], ["multiple", 1506], ["levels", 1515], [",", 1521], ["including", 1523], ["transcription", 1533], [",", 1546], ["post", 1548], ["-", 1552], ["translational", 1553], ["level", 1567], [",", 1572], ["and", 1574], ["proper", 1578], ["localization", 1585], [".", 1597], ["Thus", 1599], [",", 1603], ["suppression", 1605], ["of", 1617], ["cell", 1620], ["growth", 1625], ["and", 1632], ["induction", 1636], ["of", 1646], ["apoptosis", 1649], ["by", 1659], ["Gleevec", 1662], ["treatment", 1670], ["may", 1680], ["be", 1684], ["partially", 1687], ["due", 1697], ["to", 1701], ["TA", 1704], ["inhibition", 1707], [".", 1717], ["Additionally", 1719], [",", 1731], ["we", 1733], ["have", 1736], ["identified", 1741], ["STAT5a", 1752], ["as", 1759], ["critical", 1762], ["mediator", 1771], ["of", 1780], ["the", 1783], ["hTERT", 1787], ["gene", 1793], ["expression", 1798], ["in", 1809], ["BCR", 1812], ["-", 1815], ["ABL", 1816], ["positive", 1820], ["CML", 1829], ["cells", 1833], [",", 1838], ["suggesting", 1840], ["that", 1851], ["targeting", 1856], ["STAT5a", 1866], ["may", 1873], ["be", 1877], ["a", 1880], ["promising", 1882], ["therapeutic", 1892], ["strategy", 1904], ["for", 1913], ["BCR", 1917], ["-", 1920], ["ABL", 1921], ["positive", 1925], ["CML", 1934], ["patients", 1938], [".", 1946]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited cerebrovascular disease due to mutations involving loss or gain of a cysteine residue in the NOTCH3 gene. A cluster of mutations around exons 3 and 4 was originally reported. Identification of pathogenic mutation is important for diagnostic confirmation of the disease, however genetic counselling and testing of relatives at risk is critical in mutation carriers. Mutation analysis of the NOTCH3 gene was performed through direct sequencing in 140 patients with clinical suspicion of CADASIL. Patients underwent genetic counselling pre and post testing. The 2-23 exons containing all EGF-like domains were screened. 14 familial forms of the disease have been identified with 14 different causative mutations in exons 2, 3, 4, 5, 7, 10, 14, 19, 20 and 22 of the NOTCH3 gene; no pathogenetic mutations have been identified in exons 6 and 8; several genetic variations both in coding as well as in intronic regions were identified too. Our data confirm the importance of screening the whole EGF-like domains region of NOTCH3 gene for the molecular diagnosis of CADASIL among the Italian population too. Moreover genetic variants different from loss or gain of a cysteine residue are identified and presented.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "18b6217da1e544f0816a04e6db73ff7d", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[224, 224], [26, 26]], "char_spans": [[1277, 1284], [186, 193]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["an", 104], ["inherited", 107], ["cerebrovascular", 117], ["disease", 133], ["due", 141], ["to", 145], ["mutations", 148], ["involving", 158], ["loss", 168], ["or", 173], ["gain", 176], ["of", 181], ["a", 184], ["cysteine", 186], ["residue", 195], ["in", 203], ["the", 206], ["NOTCH3", 210], ["gene", 217], [".", 221], ["A", 223], ["cluster", 225], ["of", 233], ["mutations", 236], ["around", 246], ["exons", 253], ["3", 259], ["and", 261], ["4", 265], ["was", 267], ["originally", 271], ["reported", 282], [".", 290], ["Identification", 292], ["of", 307], ["pathogenic", 310], ["mutation", 321], ["is", 330], ["important", 333], ["for", 343], ["diagnostic", 347], ["confirmation", 358], ["of", 371], ["the", 374], ["disease", 378], [",", 385], ["however", 387], ["genetic", 395], ["counselling", 403], ["and", 415], ["testing", 419], ["of", 427], ["relatives", 430], ["at", 440], ["risk", 443], ["is", 448], ["critical", 451], ["in", 460], ["mutation", 463], ["carriers", 472], [".", 480], ["Mutation", 482], ["analysis", 491], ["of", 500], ["the", 503], ["NOTCH3", 507], ["gene", 514], ["was", 519], ["performed", 523], ["through", 533], ["direct", 541], ["sequencing", 548], ["in", 559], ["140", 562], ["patients", 566], ["with", 575], ["clinical", 580], ["suspicion", 589], ["of", 599], ["CADASIL", 602], [".", 609], ["Patients", 611], ["underwent", 620], ["genetic", 630], ["counselling", 638], ["pre", 650], ["and", 654], ["post", 658], ["testing", 663], [".", 670], ["The", 672], ["2", 676], ["-", 677], ["23", 678], ["exons", 681], ["containing", 687], ["all", 698], ["EGF", 702], ["-", 705], ["like", 706], ["domains", 711], ["were", 719], ["screened", 724], [".", 732], ["14", 734], ["familial", 737], ["forms", 746], ["of", 752], ["the", 755], ["disease", 759], ["have", 767], ["been", 772], ["identified", 777], ["with", 788], ["14", 793], ["different", 796], ["causative", 806], ["mutations", 816], ["in", 826], ["exons", 829], ["2", 835], [",", 836], ["3", 838], [",", 839], ["4", 841], [",", 842], ["5", 844], [",", 845], ["7", 847], [",", 848], ["10", 850], [",", 852], ["14", 854], [",", 856], ["19", 858], [",", 860], ["20", 862], ["and", 865], ["22", 869], ["of", 872], ["the", 875], ["NOTCH3", 879], ["gene", 886], [";", 890], ["no", 892], ["pathogenetic", 895], ["mutations", 908], ["have", 918], ["been", 923], ["identified", 928], ["in", 939], ["exons", 942], ["6", 948], ["and", 950], ["8", 954], [";", 955], ["several", 957], ["genetic", 965], ["variations", 973], ["both", 984], ["in", 989], ["coding", 992], ["as", 999], ["well", 1002], ["as", 1007], ["in", 1010], ["intronic", 1013], ["regions", 1022], ["were", 1030], ["identified", 1035], ["too", 1046], [".", 1049], ["Our", 1051], ["data", 1055], ["confirm", 1060], ["the", 1068], ["importance", 1072], ["of", 1083], ["screening", 1086], ["the", 1096], ["whole", 1100], ["EGF", 1106], ["-", 1109], ["like", 1110], ["domains", 1115], ["region", 1123], ["of", 1130], ["NOTCH3", 1133], ["gene", 1140], ["for", 1145], ["the", 1149], ["molecular", 1153], ["diagnosis", 1163], ["of", 1173], ["CADASIL", 1176], ["among", 1184], ["the", 1190], ["Italian", 1194], ["population", 1202], ["too", 1213], [".", 1216], ["Moreover", 1218], ["genetic", 1227], ["variants", 1235], ["different", 1244], ["from", 1254], ["loss", 1259], ["or", 1264], ["gain", 1267], ["of", 1272], ["a", 1275], ["cysteine", 1277], ["residue", 1286], ["are", 1294], ["identified", 1298], ["and", 1309], ["presented", 1313], [".", 1322]]}
{"context": "Universal surveillance upon patient admission is important in reducing the transmission of methicillin-resistant Staphylococcus aureus (MRSA) and associated disease in hospitals. High costs for the health care system in conjunction with MRSA have promoted the development of rapid screening methods to detect MRSA carriers. This study compared two real-time PCR methods, the BD GeneOhm MRSA assay (BDGO) and the Xpert MRSA assay, with broth-enriched culture to define their performance characteristics and rapidity in an area with low MRSA prevalence. In total, 414 swabs from the nose and 389 swabs from the groin from 425 patients were tested. Of those 425 patients, 378 had swabs from both the nose and groin in parallel. Two hundred thirty-one and 194 patients were randomly assigned to the BDGO group and the Xpert MRSA group, respectively. In general, sensitivity, specificity, and negative predictive value (NPV) were high for the BDGO (100%, 98.5%, and 100%, respectively) and the Xpert MRSA (100%, 98.2%, and 100%, respectively), irrespective of whether or not nasal and inguinal specimens were considered alone or combined. In contrast, the positive predictive value (PPV) was lower: before the resolution of discrepant results, the PPVs for nasal and inguinal specimens alone and combined were 87.5%, 86.7%, and 82.4% for the BDGO and 91.7%, 66.7%, and 92.9% for the Xpert MRSA, respectively. After the resolution of discrepant results, PPVs were 93.8%, 93.3% and 94.1% for the BDGO and 91.7%, 88.9% and 92.9% for the Xpert MRSA, respectively. With the BDGO, 4 of 16 carriers were each identified by nasal or inguinal swabs alone, whereas in the Xpert MRSA group, 4 of 13 carriers were exclusively identified by nasal swabs and 2 of 13 were identified by inguinal swabs alone. Both PCR methods showed no significant difference in the number of discrepant results (odds ratio, 0.70 [P = 0.789]), but specimens from wounds and other body sites (axilla, vagina, and throat) produced discrepancies more often than nasal and groin specimens (odds ratios, 4.724 [P = 0.058] and 12.163 [P < 0.001], respectively). The facts that no false-negative PCR results were detected and increased PPVs were found after the resolution of discrepant results point to PCR as the actual gold standard. Since both sensitivity and NPV were exceptionally high for PCR, backup cultures may, therefore, be unnecessary in an area with low prevalence and with a preemptive isolation strategy but may still be useful for PCR-positive specimens because of the lower PPV for both methods and the possibility of susceptibility testing. The median time for analysis, including extraction, hands-on time, and actual PCR was 2 h 20 min for the Xpert MRSA versus 5 h 40 min for the BDGO. Concerning reporting time, including administration and specimen collection, the Xpert MRSA was faster than the BDGO (7 h 50 min versus 17 h).", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "2502a276bbc94f61908c215b2f64ddd4", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[544, 544], [47, 47], [91, 91], [149, 149], [189, 189], [275, 275], [566, 566], [36, 36], [71, 71], [311, 311], [337, 337], [18, 18], [63, 63]], "char_spans": [[2726, 2729], [309, 312], [535, 538], [820, 823], [995, 998], [1384, 1387], [2850, 2853], [237, 240], [418, 421], [1535, 1538], [1663, 1666], [136, 139], [386, 389]]}]}], "context_tokens": [["Universal", 0], ["surveillance", 10], ["upon", 23], ["patient", 28], ["admission", 36], ["is", 46], ["important", 49], ["in", 59], ["reducing", 62], ["the", 71], ["transmission", 75], ["of", 88], ["methicillin", 91], ["-", 102], ["resistant", 103], ["Staphylococcus", 113], ["aureus", 128], ["(", 135], ["MRSA", 136], [")", 140], ["and", 142], ["associated", 146], ["disease", 157], ["in", 165], ["hospitals", 168], [".", 177], ["High", 179], ["costs", 184], ["for", 190], ["the", 194], ["health", 198], ["care", 205], ["system", 210], ["in", 217], ["conjunction", 220], ["with", 232], ["MRSA", 237], ["have", 242], ["promoted", 247], ["the", 256], ["development", 260], ["of", 272], ["rapid", 275], ["screening", 281], ["methods", 291], ["to", 299], ["detect", 302], ["MRSA", 309], ["carriers", 314], [".", 322], ["This", 324], ["study", 329], ["compared", 335], ["two", 344], ["real", 348], ["-", 352], ["time", 353], ["PCR", 358], ["methods", 362], [",", 369], ["the", 371], ["BD", 375], ["GeneOhm", 378], ["MRSA", 386], ["assay", 391], ["(", 397], ["BDGO", 398], [")", 402], ["and", 404], ["the", 408], ["Xpert", 412], ["MRSA", 418], ["assay", 423], [",", 428], ["with", 430], ["broth", 435], ["-", 440], ["enriched", 441], ["culture", 450], ["to", 458], ["define", 461], ["their", 468], ["performance", 474], ["characteristics", 486], ["and", 502], ["rapidity", 506], ["in", 515], ["an", 518], ["area", 521], ["with", 526], ["low", 531], ["MRSA", 535], ["prevalence", 540], [".", 550], ["In", 552], ["total", 555], [",", 560], ["414", 562], ["swabs", 566], ["from", 572], ["the", 577], ["nose", 581], ["and", 586], ["389", 590], ["swabs", 594], ["from", 600], ["the", 605], ["groin", 609], ["from", 615], ["425", 620], ["patients", 624], ["were", 633], ["tested", 638], [".", 644], ["Of", 646], ["those", 649], ["425", 655], ["patients", 659], [",", 667], ["378", 669], ["had", 673], ["swabs", 677], ["from", 683], ["both", 688], ["the", 693], ["nose", 697], ["and", 702], ["groin", 706], ["in", 712], ["parallel", 715], [".", 723], ["Two", 725], ["hundred", 729], ["thirty", 737], ["-", 743], ["one", 744], ["and", 748], ["194", 752], ["patients", 756], ["were", 765], ["randomly", 770], ["assigned", 779], ["to", 788], ["the", 791], ["BDGO", 795], ["group", 800], ["and", 806], ["the", 810], ["Xpert", 814], ["MRSA", 820], ["group", 825], [",", 830], ["respectively", 832], [".", 844], ["In", 846], ["general", 849], [",", 856], ["sensitivity", 858], [",", 869], ["specificity", 871], [",", 882], ["and", 884], ["negative", 888], ["predictive", 897], ["value", 908], ["(", 914], ["NPV", 915], [")", 918], ["were", 920], ["high", 925], ["for", 930], ["the", 934], ["BDGO", 938], ["(", 943], ["100", 944], ["%", 947], [",", 948], ["98.5", 950], ["%", 954], [",", 955], ["and", 957], ["100", 961], ["%", 964], [",", 965], ["respectively", 967], [")", 979], ["and", 981], ["the", 985], ["Xpert", 989], ["MRSA", 995], ["(", 1000], ["100", 1001], ["%", 1004], [",", 1005], ["98.2", 1007], ["%", 1011], [",", 1012], ["and", 1014], ["100", 1018], ["%", 1021], [",", 1022], ["respectively", 1024], [")", 1036], [",", 1037], ["irrespective", 1039], ["of", 1052], ["whether", 1055], ["or", 1063], ["not", 1066], ["nasal", 1070], ["and", 1076], ["inguinal", 1080], ["specimens", 1089], ["were", 1099], ["considered", 1104], ["alone", 1115], ["or", 1121], ["combined", 1124], [".", 1132], ["In", 1134], ["contrast", 1137], [",", 1145], ["the", 1147], ["positive", 1151], ["predictive", 1160], ["value", 1171], ["(", 1177], ["PPV", 1178], [")", 1181], ["was", 1183], ["lower", 1187], [":", 1192], ["before", 1194], ["the", 1201], ["resolution", 1205], ["of", 1216], ["discrepant", 1219], ["results", 1230], [",", 1237], ["the", 1239], ["PPVs", 1243], ["for", 1248], ["nasal", 1252], ["and", 1258], ["inguinal", 1262], ["specimens", 1271], ["alone", 1281], ["and", 1287], ["combined", 1291], ["were", 1300], ["87.5", 1305], ["%", 1309], [",", 1310], ["86.7", 1312], ["%", 1316], [",", 1317], ["and", 1319], ["82.4", 1323], ["%", 1327], ["for", 1329], ["the", 1333], ["BDGO", 1337], ["and", 1342], ["91.7", 1346], ["%", 1350], [",", 1351], ["66.7", 1353], ["%", 1357], [",", 1358], ["and", 1360], ["92.9", 1364], ["%", 1368], ["for", 1370], ["the", 1374], ["Xpert", 1378], ["MRSA", 1384], [",", 1388], ["respectively", 1390], [".", 1402], ["After", 1404], ["the", 1410], ["resolution", 1414], ["of", 1425], ["discrepant", 1428], ["results", 1439], [",", 1446], ["PPVs", 1448], ["were", 1453], ["93.8", 1458], ["%", 1462], [",", 1463], ["93.3", 1465], ["%", 1469], ["and", 1471], ["94.1", 1475], ["%", 1479], ["for", 1481], ["the", 1485], ["BDGO", 1489], ["and", 1494], ["91.7", 1498], ["%", 1502], [",", 1503], ["88.9", 1505], ["%", 1509], ["and", 1511], ["92.9", 1515], ["%", 1519], ["for", 1521], ["the", 1525], ["Xpert", 1529], ["MRSA", 1535], [",", 1539], ["respectively", 1541], [".", 1553], ["With", 1555], ["the", 1560], ["BDGO", 1564], [",", 1568], ["4", 1570], ["of", 1572], ["16", 1575], ["carriers", 1578], ["were", 1587], ["each", 1592], ["identified", 1597], ["by", 1608], ["nasal", 1611], ["or", 1617], ["inguinal", 1620], ["swabs", 1629], ["alone", 1635], [",", 1640], ["whereas", 1642], ["in", 1650], ["the", 1653], ["Xpert", 1657], ["MRSA", 1663], ["group", 1668], [",", 1673], ["4", 1675], ["of", 1677], ["13", 1680], ["carriers", 1683], ["were", 1692], ["exclusively", 1697], ["identified", 1709], ["by", 1720], ["nasal", 1723], ["swabs", 1729], ["and", 1735], ["2", 1739], ["of", 1741], ["13", 1744], ["were", 1747], ["identified", 1752], ["by", 1763], ["inguinal", 1766], ["swabs", 1775], ["alone", 1781], [".", 1786], ["Both", 1788], ["PCR", 1793], ["methods", 1797], ["showed", 1805], ["no", 1812], ["significant", 1815], ["difference", 1827], ["in", 1838], ["the", 1841], ["number", 1845], ["of", 1852], ["discrepant", 1855], ["results", 1866], ["(", 1874], ["odds", 1875], ["ratio", 1880], [",", 1885], ["0.70", 1887], ["[", 1892], ["P", 1893], ["=", 1895], ["0.789", 1897], ["]", 1902], [")", 1903], [",", 1904], ["but", 1906], ["specimens", 1910], ["from", 1920], ["wounds", 1925], ["and", 1932], ["other", 1936], ["body", 1942], ["sites", 1947], ["(", 1953], ["axilla", 1954], [",", 1960], ["vagina", 1962], [",", 1968], ["and", 1970], ["throat", 1974], [")", 1980], ["produced", 1982], ["discrepancies", 1991], ["more", 2005], ["often", 2010], ["than", 2016], ["nasal", 2021], ["and", 2027], ["groin", 2031], ["specimens", 2037], ["(", 2047], ["odds", 2048], ["ratios", 2053], [",", 2059], ["4.724", 2061], ["[", 2067], ["P", 2068], ["=", 2070], ["0.058", 2072], ["]", 2077], ["and", 2079], ["12.163", 2083], ["[", 2090], ["P", 2091], ["<", 2093], ["0.001", 2095], ["]", 2100], [",", 2101], ["respectively", 2103], [")", 2115], [".", 2116], ["The", 2118], ["facts", 2122], ["that", 2128], ["no", 2133], ["false", 2136], ["-", 2141], ["negative", 2142], ["PCR", 2151], ["results", 2155], ["were", 2163], ["detected", 2168], ["and", 2177], ["increased", 2181], ["PPVs", 2191], ["were", 2196], ["found", 2201], ["after", 2207], ["the", 2213], ["resolution", 2217], ["of", 2228], ["discrepant", 2231], ["results", 2242], ["point", 2250], ["to", 2256], ["PCR", 2259], ["as", 2263], ["the", 2266], ["actual", 2270], ["gold", 2277], ["standard", 2282], [".", 2290], ["Since", 2292], ["both", 2298], ["sensitivity", 2303], ["and", 2315], ["NPV", 2319], ["were", 2323], ["exceptionally", 2328], ["high", 2342], ["for", 2347], ["PCR", 2351], [",", 2354], ["backup", 2356], ["cultures", 2363], ["may", 2372], [",", 2375], ["therefore", 2377], [",", 2386], ["be", 2388], ["unnecessary", 2391], ["in", 2403], ["an", 2406], ["area", 2409], ["with", 2414], ["low", 2419], ["prevalence", 2423], ["and", 2434], ["with", 2438], ["a", 2443], ["preemptive", 2445], ["isolation", 2456], ["strategy", 2466], ["but", 2475], ["may", 2479], ["still", 2483], ["be", 2489], ["useful", 2492], ["for", 2499], ["PCR", 2503], ["-", 2506], ["positive", 2507], ["specimens", 2516], ["because", 2526], ["of", 2534], ["the", 2537], ["lower", 2541], ["PPV", 2547], ["for", 2551], ["both", 2555], ["methods", 2560], ["and", 2568], ["the", 2572], ["possibility", 2576], ["of", 2588], ["susceptibility", 2591], ["testing", 2606], [".", 2613], ["The", 2615], ["median", 2619], ["time", 2626], ["for", 2631], ["analysis", 2635], [",", 2643], ["including", 2645], ["extraction", 2655], [",", 2665], ["hands", 2667], ["-", 2672], ["on", 2673], ["time", 2676], [",", 2680], ["and", 2682], ["actual", 2686], ["PCR", 2693], ["was", 2697], ["2", 2701], ["h", 2703], ["20", 2705], ["min", 2708], ["for", 2712], ["the", 2716], ["Xpert", 2720], ["MRSA", 2726], ["versus", 2731], ["5", 2738], ["h", 2740], ["40", 2742], ["min", 2745], ["for", 2749], ["the", 2753], ["BDGO", 2757], [".", 2761], ["Concerning", 2763], ["reporting", 2774], ["time", 2784], [",", 2788], ["including", 2790], ["administration", 2800], ["and", 2815], ["specimen", 2819], ["collection", 2828], [",", 2838], ["the", 2840], ["Xpert", 2844], ["MRSA", 2850], ["was", 2855], ["faster", 2859], ["than", 2866], ["the", 2871], ["BDGO", 2875], ["(", 2880], ["7", 2881], ["h", 2883], ["50", 2885], ["min", 2888], ["versus", 2892], ["17", 2899], ["h", 2902], [")", 2903], [".", 2904]]}
{"context": "Many neurodegenerative diseases are associated with the aggregation of misfolded proteins into amyloid oligomers or fibrils that are deposited as pathological lesions within areas of the brain. An attractive therapeutic strategy for preventing or ameliorating amyloid formation is to identify agents that inhibit the onset or propagation of protein aggregation. Here we demonstrate how solid-state nuclear magnetic resonance (ssNMR) may be used to identify key residues within amyloidogenic protein sequences that may be targeted to inhibit the aggregation of the host protein. For alpha-synuclein, the major protein component of Lewy bodies associated with Parkinson's disease, we have used a combination of ssNMR and biochemical data to identify the key region for self-aggregation of the protein as residues 77-82 (VAQKTV). We used our new structural information to design a peptide derived from residues 77 to 82 of alpha-synuclein with an N-methyl group at the C-terminal residue, which was able to disrupt the aggregation of alpha-synuclein. Thus, we have shown how structural data obtained from ssNMR can guide the design of modified peptides for use as amyloid inhibitors, as a primary step toward developing therapeutic compounds for prevention and/or treatment of amyloid diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "ec3fbfeea1b541fd86801d3f230fe7ac", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[179, 181], [90, 92], [155, 157]], "char_spans": [[1031, 1045], [582, 596], [920, 934]]}]}], "context_tokens": [["Many", 0], ["neurodegenerative", 5], ["diseases", 23], ["are", 32], ["associated", 36], ["with", 47], ["the", 52], ["aggregation", 56], ["of", 68], ["misfolded", 71], ["proteins", 81], ["into", 90], ["amyloid", 95], ["oligomers", 103], ["or", 113], ["fibrils", 116], ["that", 124], ["are", 129], ["deposited", 133], ["as", 143], ["pathological", 146], ["lesions", 159], ["within", 167], ["areas", 174], ["of", 180], ["the", 183], ["brain", 187], [".", 192], ["An", 194], ["attractive", 197], ["therapeutic", 208], ["strategy", 220], ["for", 229], ["preventing", 233], ["or", 244], ["ameliorating", 247], ["amyloid", 260], ["formation", 268], ["is", 278], ["to", 281], ["identify", 284], ["agents", 293], ["that", 300], ["inhibit", 305], ["the", 313], ["onset", 317], ["or", 323], ["propagation", 326], ["of", 338], ["protein", 341], ["aggregation", 349], [".", 360], ["Here", 362], ["we", 367], ["demonstrate", 370], ["how", 382], ["solid", 386], ["-", 391], ["state", 392], ["nuclear", 398], ["magnetic", 406], ["resonance", 415], ["(", 425], ["ssNMR", 426], [")", 431], ["may", 433], ["be", 437], ["used", 440], ["to", 445], ["identify", 448], ["key", 457], ["residues", 461], ["within", 470], ["amyloidogenic", 477], ["protein", 491], ["sequences", 499], ["that", 509], ["may", 514], ["be", 518], ["targeted", 521], ["to", 530], ["inhibit", 533], ["the", 541], ["aggregation", 545], ["of", 557], ["the", 560], ["host", 564], ["protein", 569], [".", 576], ["For", 578], ["alpha", 582], ["-", 587], ["synuclein", 588], [",", 597], ["the", 599], ["major", 603], ["protein", 609], ["component", 617], ["of", 627], ["Lewy", 630], ["bodies", 635], ["associated", 642], ["with", 653], ["Parkinson", 658], ["'s", 667], ["disease", 670], [",", 677], ["we", 679], ["have", 682], ["used", 687], ["a", 692], ["combination", 694], ["of", 706], ["ssNMR", 709], ["and", 715], ["biochemical", 719], ["data", 731], ["to", 736], ["identify", 739], ["the", 748], ["key", 752], ["region", 756], ["for", 763], ["self", 767], ["-", 771], ["aggregation", 772], ["of", 784], ["the", 787], ["protein", 791], ["as", 799], ["residues", 802], ["77", 811], ["-", 813], ["82", 814], ["(", 817], ["VAQKTV", 818], [")", 824], [".", 825], ["We", 827], ["used", 830], ["our", 835], ["new", 839], ["structural", 843], ["information", 854], ["to", 866], ["design", 869], ["a", 876], ["peptide", 878], ["derived", 886], ["from", 894], ["residues", 899], ["77", 908], ["to", 911], ["82", 914], ["of", 917], ["alpha", 920], ["-", 925], ["synuclein", 926], ["with", 936], ["an", 941], ["N", 944], ["-", 945], ["methyl", 946], ["group", 953], ["at", 959], ["the", 962], ["C", 966], ["-", 967], ["terminal", 968], ["residue", 977], [",", 984], ["which", 986], ["was", 992], ["able", 996], ["to", 1001], ["disrupt", 1004], ["the", 1012], ["aggregation", 1016], ["of", 1028], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], [".", 1046], ["Thus", 1048], [",", 1052], ["we", 1054], ["have", 1057], ["shown", 1062], ["how", 1068], ["structural", 1072], ["data", 1083], ["obtained", 1088], ["from", 1097], ["ssNMR", 1102], ["can", 1108], ["guide", 1112], ["the", 1118], ["design", 1122], ["of", 1129], ["modified", 1132], ["peptides", 1141], ["for", 1150], ["use", 1154], ["as", 1158], ["amyloid", 1161], ["inhibitors", 1169], [",", 1179], ["as", 1181], ["a", 1184], ["primary", 1186], ["step", 1194], ["toward", 1199], ["developing", 1206], ["therapeutic", 1217], ["compounds", 1229], ["for", 1239], ["prevention", 1243], ["and/or", 1254], ["treatment", 1261], ["of", 1271], ["amyloid", 1274], ["diseases", 1282], [".", 1290]]}
{"context": "Chronic myelogenous leukemia (CML) accounts for 15-20% of adult leukemias but is very rare in children (2%). Fewer than 10% of CML patients are younger than 20 years. CML is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome or the BCR-ABL fusion oncogene. The objective of this paper is to present the monitoring of imatinib therapy in two children with CML by the BCR-ABL fusion gene expression assessment from peripheral blood with quantitative real-time polymerase chain reaction (PCR) method. The 18 and six months follow-up of the patients included clinical examination, routine laboratory tests, bone marrow aspirate investigation including cytogenetic tests and the major BCR-ABL fusion gene expression measurement with qRT-PCR method from the peripheral blood. Patient No. 1 diagnosed with chronic phase CML showed excellent adherence to daily 400 mg imatinib treatment and achieved complete hematologic (CHR) and cytogenetic response (CCR) by three months and major molecular response (MMR) by 12 months, with lack of side effects due to imatinib. Patient No. 2 experienced severe hematologic toxicity, which necessitated temporary withdrawal of the drug. Transient non-compliance together with imatinib dose reduction has driven to treatment failure. In this case, mutational analysis is warranted. BCR-ABL fusion gene expression level measurement from peripheral blood with qRT-PCR method is an excellent tool in the follow-up of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ee2bb6f12fef47d0a3ddeb7d9f328f4d", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[132, 134], [244, 246], [54, 56], [80, 82]], "char_spans": [[720, 726], [1350, 1356], [272, 278], [406, 412]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["accounts", 35], ["for", 44], ["15", 48], ["-", 50], ["20", 51], ["%", 53], ["of", 55], ["adult", 58], ["leukemias", 64], ["but", 74], ["is", 78], ["very", 81], ["rare", 86], ["in", 91], ["children", 94], ["(", 103], ["2", 104], ["%", 105], [")", 106], [".", 107], ["Fewer", 109], ["than", 115], ["10", 120], ["%", 122], ["of", 124], ["CML", 127], ["patients", 131], ["are", 140], ["younger", 144], ["than", 152], ["20", 157], ["years", 160], [".", 165], ["CML", 167], ["is", 171], ["a", 174], ["myeloproliferative", 176], ["disorder", 195], ["characterized", 204], ["by", 218], ["the", 221], ["presence", 225], ["of", 234], ["the", 237], ["Philadelphia", 241], ["chromosome", 254], ["or", 265], ["the", 268], ["BCR", 272], ["-", 275], ["ABL", 276], ["fusion", 280], ["oncogene", 287], [".", 295], ["The", 297], ["objective", 301], ["of", 311], ["this", 314], ["paper", 319], ["is", 325], ["to", 328], ["present", 331], ["the", 339], ["monitoring", 343], ["of", 354], ["imatinib", 357], ["therapy", 366], ["in", 374], ["two", 377], ["children", 381], ["with", 390], ["CML", 395], ["by", 399], ["the", 402], ["BCR", 406], ["-", 409], ["ABL", 410], ["fusion", 414], ["gene", 421], ["expression", 426], ["assessment", 437], ["from", 448], ["peripheral", 453], ["blood", 464], ["with", 470], ["quantitative", 475], ["real", 488], ["-", 492], ["time", 493], ["polymerase", 498], ["chain", 509], ["reaction", 515], ["(", 524], ["PCR", 525], [")", 528], ["method", 530], [".", 536], ["The", 538], ["18", 542], ["and", 545], ["six", 549], ["months", 553], ["follow", 560], ["-", 566], ["up", 567], ["of", 570], ["the", 573], ["patients", 577], ["included", 586], ["clinical", 595], ["examination", 604], [",", 615], ["routine", 617], ["laboratory", 625], ["tests", 636], [",", 641], ["bone", 643], ["marrow", 648], ["aspirate", 655], ["investigation", 664], ["including", 678], ["cytogenetic", 688], ["tests", 700], ["and", 706], ["the", 710], ["major", 714], ["BCR", 720], ["-", 723], ["ABL", 724], ["fusion", 728], ["gene", 735], ["expression", 740], ["measurement", 751], ["with", 763], ["qRT", 768], ["-", 771], ["PCR", 772], ["method", 776], ["from", 783], ["the", 788], ["peripheral", 792], ["blood", 803], [".", 808], ["Patient", 810], ["No", 818], [".", 820], ["1", 822], ["diagnosed", 824], ["with", 834], ["chronic", 839], ["phase", 847], ["CML", 853], ["showed", 857], ["excellent", 864], ["adherence", 874], ["to", 884], ["daily", 887], ["400", 893], ["mg", 897], ["imatinib", 900], ["treatment", 909], ["and", 919], ["achieved", 923], ["complete", 932], ["hematologic", 941], ["(", 953], ["CHR", 954], [")", 957], ["and", 959], ["cytogenetic", 963], ["response", 975], ["(", 984], ["CCR", 985], [")", 988], ["by", 990], ["three", 993], ["months", 999], ["and", 1006], ["major", 1010], ["molecular", 1016], ["response", 1026], ["(", 1035], ["MMR", 1036], [")", 1039], ["by", 1041], ["12", 1044], ["months", 1047], [",", 1053], ["with", 1055], ["lack", 1060], ["of", 1065], ["side", 1068], ["effects", 1073], ["due", 1081], ["to", 1085], ["imatinib", 1088], [".", 1096], ["Patient", 1098], ["No", 1106], [".", 1108], ["2", 1110], ["experienced", 1112], ["severe", 1124], ["hematologic", 1131], ["toxicity", 1143], [",", 1151], ["which", 1153], ["necessitated", 1159], ["temporary", 1172], ["withdrawal", 1182], ["of", 1193], ["the", 1196], ["drug", 1200], [".", 1204], ["Transient", 1206], ["non", 1216], ["-", 1219], ["compliance", 1220], ["together", 1231], ["with", 1240], ["imatinib", 1245], ["dose", 1254], ["reduction", 1259], ["has", 1269], ["driven", 1273], ["to", 1280], ["treatment", 1283], ["failure", 1293], [".", 1300], ["In", 1302], ["this", 1305], ["case", 1310], [",", 1314], ["mutational", 1316], ["analysis", 1327], ["is", 1336], ["warranted", 1339], [".", 1348], ["BCR", 1350], ["-", 1353], ["ABL", 1354], ["fusion", 1358], ["gene", 1365], ["expression", 1370], ["level", 1381], ["measurement", 1387], ["from", 1399], ["peripheral", 1404], ["blood", 1415], ["with", 1421], ["qRT", 1426], ["-", 1429], ["PCR", 1430], ["method", 1434], ["is", 1441], ["an", 1444], ["excellent", 1447], ["tool", 1457], ["in", 1462], ["the", 1465], ["follow", 1469], ["-", 1475], ["up", 1476], ["of", 1479], ["CML", 1482], ["patients", 1486], [".", 1494]]}
{"context": "To develop clinical rules for the safe and effective use of flumazenil in suspected benzodiazepine overdose. We assembled a retrospective series of 35 consecutive comatose patients admitted between October 1992 and July 1993 to a toxicologic ICU with the presumptive diagnosis of drug overdose. These patients were divided into two groups. Group A (low-risk) patients had a clinical picture compatible with uncomplicated benzodiazepine intoxication (calm, without abnormalities in pulse or blood pressure, lateralizing signs, hypertonia, hyperreflexia, or myoclonus) in the absence of predefined electrocardiographic or clinical signs of tricyclic antidepressant or other proconvulsant overdose, and absence of an available history of long-term benzodiazepine treatment or an underlying seizure disorder. Group B (\"non-low risk\") comprised all other patients. Efficacy of flumazenil was categorized as complete awakening (with normal level of alertness), partial awakening, or no change in alertness level. The safety of flumazenil was defined on the basis of the absence of seizures or death. In group A (n=4), flumazenil was associated with complete awakening in three patients and partial awakening in one. No seizures were observed. In group B (n=31), flumazenil was associated with complete awakening in 4 patients, partial awakening in 5, and no response in 22. In group B, five seizures occurred. Comatose patients with clinical or ECG criteria thought to contraindicate the use of flumazenil have a reasonably high risk of seizures after administration of this drug. Low-risk patients may be able to receive flumazenil safely, but they may be only a small portion of comatose patients with suspected overdose.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "0852624d3eb84ea89be6dce27c79703c", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[192, 192], [144, 144], [219, 219], [11, 11], [171, 171], [261, 261], [284, 284]], "char_spans": [[1112, 1121], [872, 881], [1256, 1265], [60, 69], [1021, 1030], [1489, 1498], [1616, 1625]]}]}], "context_tokens": [["To", 0], ["develop", 3], ["clinical", 11], ["rules", 20], ["for", 26], ["the", 30], ["safe", 34], ["and", 39], ["effective", 43], ["use", 53], ["of", 57], ["flumazenil", 60], ["in", 71], ["suspected", 74], ["benzodiazepine", 84], ["overdose", 99], [".", 107], ["We", 109], ["assembled", 112], ["a", 122], ["retrospective", 124], ["series", 138], ["of", 145], ["35", 148], ["consecutive", 151], ["comatose", 163], ["patients", 172], ["admitted", 181], ["between", 190], ["October", 198], ["1992", 206], ["and", 211], ["July", 215], ["1993", 220], ["to", 225], ["a", 228], ["toxicologic", 230], ["ICU", 242], ["with", 246], ["the", 251], ["presumptive", 255], ["diagnosis", 267], ["of", 277], ["drug", 280], ["overdose", 285], [".", 293], ["These", 295], ["patients", 301], ["were", 310], ["divided", 315], ["into", 323], ["two", 328], ["groups", 332], [".", 338], ["Group", 340], ["A", 346], ["(", 348], ["low", 349], ["-", 352], ["risk", 353], [")", 357], ["patients", 359], ["had", 368], ["a", 372], ["clinical", 374], ["picture", 383], ["compatible", 391], ["with", 402], ["uncomplicated", 407], ["benzodiazepine", 421], ["intoxication", 436], ["(", 449], ["calm", 450], [",", 454], ["without", 456], ["abnormalities", 464], ["in", 478], ["pulse", 481], ["or", 487], ["blood", 490], ["pressure", 496], [",", 504], ["lateralizing", 506], ["signs", 519], [",", 524], ["hypertonia", 526], [",", 536], ["hyperreflexia", 538], [",", 551], ["or", 553], ["myoclonus", 556], [")", 565], ["in", 567], ["the", 570], ["absence", 574], ["of", 582], ["predefined", 585], ["electrocardiographic", 596], ["or", 617], ["clinical", 620], ["signs", 629], ["of", 635], ["tricyclic", 638], ["antidepressant", 648], ["or", 663], ["other", 666], ["proconvulsant", 672], ["overdose", 686], [",", 694], ["and", 696], ["absence", 700], ["of", 708], ["an", 711], ["available", 714], ["history", 724], ["of", 732], ["long", 735], ["-", 739], ["term", 740], ["benzodiazepine", 745], ["treatment", 760], ["or", 770], ["an", 773], ["underlying", 776], ["seizure", 787], ["disorder", 795], [".", 803], ["Group", 805], ["B", 811], ["(", 813], ["\"", 814], ["non", 815], ["-", 818], ["low", 819], ["risk", 823], ["\"", 827], [")", 828], ["comprised", 830], ["all", 840], ["other", 844], ["patients", 850], [".", 858], ["Efficacy", 860], ["of", 869], ["flumazenil", 872], ["was", 883], ["categorized", 887], ["as", 899], ["complete", 902], ["awakening", 911], ["(", 921], ["with", 922], ["normal", 927], ["level", 934], ["of", 940], ["alertness", 943], [")", 952], [",", 953], ["partial", 955], ["awakening", 963], [",", 972], ["or", 974], ["no", 977], ["change", 980], ["in", 987], ["alertness", 990], ["level", 1000], [".", 1005], ["The", 1007], ["safety", 1011], ["of", 1018], ["flumazenil", 1021], ["was", 1032], ["defined", 1036], ["on", 1044], ["the", 1047], ["basis", 1051], ["of", 1057], ["the", 1060], ["absence", 1064], ["of", 1072], ["seizures", 1075], ["or", 1084], ["death", 1087], [".", 1092], ["In", 1094], ["group", 1097], ["A", 1103], ["(", 1105], ["n=4", 1106], [")", 1109], [",", 1110], ["flumazenil", 1112], ["was", 1123], ["associated", 1127], ["with", 1138], ["complete", 1143], ["awakening", 1152], ["in", 1162], ["three", 1165], ["patients", 1171], ["and", 1180], ["partial", 1184], ["awakening", 1192], ["in", 1202], ["one", 1205], [".", 1208], ["No", 1210], ["seizures", 1213], ["were", 1222], ["observed", 1227], [".", 1235], ["In", 1237], ["group", 1240], ["B", 1246], ["(", 1248], ["n=31", 1249], [")", 1253], [",", 1254], ["flumazenil", 1256], ["was", 1267], ["associated", 1271], ["with", 1282], ["complete", 1287], ["awakening", 1296], ["in", 1306], ["4", 1309], ["patients", 1311], [",", 1319], ["partial", 1321], ["awakening", 1329], ["in", 1339], ["5", 1342], [",", 1343], ["and", 1345], ["no", 1349], ["response", 1352], ["in", 1361], ["22", 1364], [".", 1366], ["In", 1368], ["group", 1371], ["B", 1377], [",", 1378], ["five", 1380], ["seizures", 1385], ["occurred", 1394], [".", 1402], ["Comatose", 1404], ["patients", 1413], ["with", 1422], ["clinical", 1427], ["or", 1436], ["ECG", 1439], ["criteria", 1443], ["thought", 1452], ["to", 1460], ["contraindicate", 1463], ["the", 1478], ["use", 1482], ["of", 1486], ["flumazenil", 1489], ["have", 1500], ["a", 1505], ["reasonably", 1507], ["high", 1518], ["risk", 1523], ["of", 1528], ["seizures", 1531], ["after", 1540], ["administration", 1546], ["of", 1561], ["this", 1564], ["drug", 1569], [".", 1573], ["Low", 1575], ["-", 1578], ["risk", 1579], ["patients", 1584], ["may", 1593], ["be", 1597], ["able", 1600], ["to", 1605], ["receive", 1608], ["flumazenil", 1616], ["safely", 1627], [",", 1633], ["but", 1635], ["they", 1639], ["may", 1644], ["be", 1648], ["only", 1651], ["a", 1656], ["small", 1658], ["portion", 1664], ["of", 1672], ["comatose", 1675], ["patients", 1684], ["with", 1693], ["suspected", 1698], ["overdose", 1708], [".", 1716]]}
{"context": "The efficacy of the BD GeneOhm methicillin-resistant Staphylococcus aureus (MRSA) assay was assessed by analyzing nasal swabs and swabs from other body sites for the presence of MRSA in a low-prevalence area. From 681 patients with a high risk for MRSA carriage, 1,601 specimens were collected and transported in Amies agar. After discordant analysis, the sensitivity, specificity, positive predictive value, and negative predictive value of the BD GeneOhm MRSA assay were 84.3%, 99.2%, 88.4%, and 98.9%, respectively, compared to culture.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "746d6125a1ae4b47b8868da9703ff04b", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[81, 81], [47, 47], [12, 12], [31, 31]], "char_spans": [[457, 460], [248, 251], [76, 79], [178, 181]]}]}], "context_tokens": [["The", 0], ["efficacy", 4], ["of", 13], ["the", 16], ["BD", 20], ["GeneOhm", 23], ["methicillin", 31], ["-", 42], ["resistant", 43], ["Staphylococcus", 53], ["aureus", 68], ["(", 75], ["MRSA", 76], [")", 80], ["assay", 82], ["was", 88], ["assessed", 92], ["by", 101], ["analyzing", 104], ["nasal", 114], ["swabs", 120], ["and", 126], ["swabs", 130], ["from", 136], ["other", 141], ["body", 147], ["sites", 152], ["for", 158], ["the", 162], ["presence", 166], ["of", 175], ["MRSA", 178], ["in", 183], ["a", 186], ["low", 188], ["-", 191], ["prevalence", 192], ["area", 203], [".", 207], ["From", 209], ["681", 214], ["patients", 218], ["with", 227], ["a", 232], ["high", 234], ["risk", 239], ["for", 244], ["MRSA", 248], ["carriage", 253], [",", 261], ["1,601", 263], ["specimens", 269], ["were", 279], ["collected", 284], ["and", 294], ["transported", 298], ["in", 310], ["Amies", 313], ["agar", 319], [".", 323], ["After", 325], ["discordant", 331], ["analysis", 342], [",", 350], ["the", 352], ["sensitivity", 356], [",", 367], ["specificity", 369], [",", 380], ["positive", 382], ["predictive", 391], ["value", 402], [",", 407], ["and", 409], ["negative", 413], ["predictive", 422], ["value", 433], ["of", 439], ["the", 442], ["BD", 446], ["GeneOhm", 449], ["MRSA", 457], ["assay", 462], ["were", 468], ["84.3", 473], ["%", 477], [",", 478], ["99.2", 480], ["%", 484], [",", 485], ["88.4", 487], ["%", 491], [",", 492], ["and", 494], ["98.9", 498], ["%", 502], [",", 503], ["respectively", 505], [",", 517], ["compared", 519], ["to", 528], ["culture", 531], [".", 538]]}
{"context": "We describe the use of four complementary biosensors (Biacore 3000, Octet QK, ProteOn XPR36, and KinExA 3000) in characterizing the kinetics of human nerve growth factor (NGF) binding to a humanized NGF-neutralizing monoclonal antibody (tanezumab, formerly known as RN624). Tanezumab is a clinical candidate as a therapy for chronic pain. Our measurements were consistent with the NGF/tanezumab binding affinity being tighter than 10 pM due to the formation of an extremely stable complex that had an estimated half-life exceeding 100 h, which was beyond the resolution of any of our methods. The system was particularly challenging to study because NGF is an obligate homodimer, and we describe various assay orientations and immobilization methods that were used to minimize avidity in our experiments while keeping NGF in as native a state as possible. We also explored the interactions of NGF with its natural receptors, TrkA and P75, and how tanezumab blocks them. The Biacore blocking assay that we designed was used to quantify the potency of tanezumab and is more precise and reproducible than the currently available cell-based functional assays.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "220f2fda6f7b4ca1a8b1ce1ca1c93bb3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[28, 30]], "char_spans": [[150, 168]]}, {"text": "NGF", "token_spans": [[32, 32], [160, 160], [70, 70], [38, 38], [119, 119], [145, 145]], "char_spans": [[171, 173], [893, 895], [381, 383], [199, 201], [650, 652], [818, 820]]}]}], "context_tokens": [["We", 0], ["describe", 3], ["the", 12], ["use", 16], ["of", 20], ["four", 23], ["complementary", 28], ["biosensors", 42], ["(", 53], ["Biacore", 54], ["3000", 62], [",", 66], ["Octet", 68], ["QK", 74], [",", 76], ["ProteOn", 78], ["XPR36", 86], [",", 91], ["and", 93], ["KinExA", 97], ["3000", 104], [")", 108], ["in", 110], ["characterizing", 113], ["the", 128], ["kinetics", 132], ["of", 141], ["human", 144], ["nerve", 150], ["growth", 156], ["factor", 163], ["(", 170], ["NGF", 171], [")", 174], ["binding", 176], ["to", 184], ["a", 187], ["humanized", 189], ["NGF", 199], ["-", 202], ["neutralizing", 203], ["monoclonal", 216], ["antibody", 227], ["(", 236], ["tanezumab", 237], [",", 246], ["formerly", 248], ["known", 257], ["as", 263], ["RN624", 266], [")", 271], [".", 272], ["Tanezumab", 274], ["is", 284], ["a", 287], ["clinical", 289], ["candidate", 298], ["as", 308], ["a", 311], ["therapy", 313], ["for", 321], ["chronic", 325], ["pain", 333], [".", 337], ["Our", 339], ["measurements", 343], ["were", 356], ["consistent", 361], ["with", 372], ["the", 377], ["NGF", 381], ["/", 384], ["tanezumab", 385], ["binding", 395], ["affinity", 403], ["being", 412], ["tighter", 418], ["than", 426], ["10", 431], ["pM", 434], ["due", 437], ["to", 441], ["the", 444], ["formation", 448], ["of", 458], ["an", 461], ["extremely", 464], ["stable", 474], ["complex", 481], ["that", 489], ["had", 494], ["an", 498], ["estimated", 501], ["half", 511], ["-", 515], ["life", 516], ["exceeding", 521], ["100", 531], ["h", 535], [",", 536], ["which", 538], ["was", 544], ["beyond", 548], ["the", 555], ["resolution", 559], ["of", 570], ["any", 573], ["of", 577], ["our", 580], ["methods", 584], [".", 591], ["The", 593], ["system", 597], ["was", 604], ["particularly", 608], ["challenging", 621], ["to", 633], ["study", 636], ["because", 642], ["NGF", 650], ["is", 654], ["an", 657], ["obligate", 660], ["homodimer", 669], [",", 678], ["and", 680], ["we", 684], ["describe", 687], ["various", 696], ["assay", 704], ["orientations", 710], ["and", 723], ["immobilization", 727], ["methods", 742], ["that", 750], ["were", 755], ["used", 760], ["to", 765], ["minimize", 768], ["avidity", 777], ["in", 785], ["our", 788], ["experiments", 792], ["while", 804], ["keeping", 810], ["NGF", 818], ["in", 822], ["as", 825], ["native", 828], ["a", 835], ["state", 837], ["as", 843], ["possible", 846], [".", 854], ["We", 856], ["also", 859], ["explored", 864], ["the", 873], ["interactions", 877], ["of", 890], ["NGF", 893], ["with", 897], ["its", 902], ["natural", 906], ["receptors", 914], [",", 923], ["TrkA", 925], ["and", 930], ["P75", 934], [",", 937], ["and", 939], ["how", 943], ["tanezumab", 947], ["blocks", 957], ["them", 964], [".", 968], ["The", 970], ["Biacore", 974], ["blocking", 982], ["assay", 991], ["that", 997], ["we", 1002], ["designed", 1005], ["was", 1014], ["used", 1018], ["to", 1023], ["quantify", 1026], ["the", 1035], ["potency", 1039], ["of", 1047], ["tanezumab", 1050], ["and", 1060], ["is", 1064], ["more", 1067], ["precise", 1072], ["and", 1080], ["reproducible", 1084], ["than", 1097], ["the", 1102], ["currently", 1106], ["available", 1116], ["cell", 1126], ["-", 1130], ["based", 1131], ["functional", 1137], ["assays", 1148], [".", 1154]]}
{"context": "CADASIL is the most prominent inherited form of vascular dementia. The main clinical features include migraine with aura, stroke, mood disturbances, and cognitive decline, with a mid-life (30s-60s) adult onset. Genetic testing is the gold standard for the diagnosis. CADASIL is caused mostly by missense mutations in the NOTCH3 gene, invariably involving a cysteine residue. Only a couple of splice site mutations have been reported. In a few pathologically defined patients, genetic mutations remain unidentified. We report a family with late-onset CADASIL phenotype carrying a novel intronic deletion in the NOTCH3 gene (c.341-26_24delAAC). Transcript analysis revealed a splicing alteration, with the complete intron 3 retention. The insertion was in-frame and encoded an extra 25 amino acids, including 1 cysteine. This is the first report of an aberrant splicing event of the NOTCH3 gene associated with a mutation far away from the canonical splice site. Our finding suggests that the assays used to evaluate splicing should be mandatory in the diagnostic setting of genetically undefined CADASIL cases.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "dabfffc898254535a9a607a6650d2562", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[65, 65], [146, 146]], "char_spans": [[357, 364], [809, 816]]}]}], "context_tokens": [["CADASIL", 0], ["is", 8], ["the", 11], ["most", 15], ["prominent", 20], ["inherited", 30], ["form", 40], ["of", 45], ["vascular", 48], ["dementia", 57], [".", 65], ["The", 67], ["main", 71], ["clinical", 76], ["features", 85], ["include", 94], ["migraine", 102], ["with", 111], ["aura", 116], [",", 120], ["stroke", 122], [",", 128], ["mood", 130], ["disturbances", 135], [",", 147], ["and", 149], ["cognitive", 153], ["decline", 163], [",", 170], ["with", 172], ["a", 177], ["mid", 179], ["-", 182], ["life", 183], ["(", 188], ["30s-60s", 189], [")", 196], ["adult", 198], ["onset", 204], [".", 209], ["Genetic", 211], ["testing", 219], ["is", 227], ["the", 230], ["gold", 234], ["standard", 239], ["for", 248], ["the", 252], ["diagnosis", 256], [".", 265], ["CADASIL", 267], ["is", 275], ["caused", 278], ["mostly", 285], ["by", 292], ["missense", 295], ["mutations", 304], ["in", 314], ["the", 317], ["NOTCH3", 321], ["gene", 328], [",", 332], ["invariably", 334], ["involving", 345], ["a", 355], ["cysteine", 357], ["residue", 366], [".", 373], ["Only", 375], ["a", 380], ["couple", 382], ["of", 389], ["splice", 392], ["site", 399], ["mutations", 404], ["have", 414], ["been", 419], ["reported", 424], [".", 432], ["In", 434], ["a", 437], ["few", 439], ["pathologically", 443], ["defined", 458], ["patients", 466], [",", 474], ["genetic", 476], ["mutations", 484], ["remain", 494], ["unidentified", 501], [".", 513], ["We", 515], ["report", 518], ["a", 525], ["family", 527], ["with", 534], ["late", 539], ["-", 543], ["onset", 544], ["CADASIL", 550], ["phenotype", 558], ["carrying", 568], ["a", 577], ["novel", 579], ["intronic", 585], ["deletion", 594], ["in", 603], ["the", 606], ["NOTCH3", 610], ["gene", 617], ["(", 622], ["c.341", 623], ["-", 628], ["26_24delAAC", 629], [")", 640], [".", 641], ["Transcript", 643], ["analysis", 654], ["revealed", 663], ["a", 672], ["splicing", 674], ["alteration", 683], [",", 693], ["with", 695], ["the", 700], ["complete", 704], ["intron", 713], ["3", 720], ["retention", 722], [".", 731], ["The", 733], ["insertion", 737], ["was", 747], ["in", 751], ["-", 753], ["frame", 754], ["and", 760], ["encoded", 764], ["an", 772], ["extra", 775], ["25", 781], ["amino", 784], ["acids", 790], [",", 795], ["including", 797], ["1", 807], ["cysteine", 809], [".", 817], ["This", 819], ["is", 824], ["the", 827], ["first", 831], ["report", 837], ["of", 844], ["an", 847], ["aberrant", 850], ["splicing", 859], ["event", 868], ["of", 874], ["the", 877], ["NOTCH3", 881], ["gene", 888], ["associated", 893], ["with", 904], ["a", 909], ["mutation", 911], ["far", 920], ["away", 924], ["from", 929], ["the", 934], ["canonical", 938], ["splice", 948], ["site", 955], [".", 959], ["Our", 961], ["finding", 965], ["suggests", 973], ["that", 982], ["the", 987], ["assays", 991], ["used", 998], ["to", 1003], ["evaluate", 1006], ["splicing", 1015], ["should", 1024], ["be", 1031], ["mandatory", 1034], ["in", 1044], ["the", 1047], ["diagnostic", 1051], ["setting", 1062], ["of", 1070], ["genetically", 1073], ["undefined", 1085], ["CADASIL", 1095], ["cases", 1103], [".", 1108]]}
{"context": "Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers are associated with increased sensitivity of these cancers to drugs that inhibit EGFR kinase activity such as gefitinib and erlotinib. Responses to TK inhibitors in the absence of EGFR gene mutation for BAC patients have not been reported. A case of a patient with BAC refractory to chemotherapy who responded to gefitinib in the absence of EGFR gene mutations is reported. Tyrosine kinase inhibitors may have a role in BAC in the absence of EGFR gene mutations. Additional studies on other molecular alterations of the EGFR family members are needed to better predict response to these agents.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "edddbb8cad694d9a8b64e23dfb8292ba", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[11, 18]], "char_spans": [[52, 95]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["tyrosine", 17], ["kinase", 26], ["(", 33], ["TK", 34], [")", 36], ["domain", 38], ["of", 45], ["the", 48], ["epidermal", 52], ["growth", 62], ["factor", 69], ["receptor", 76], ["(", 85], ["EGFR", 86], [")", 90], ["gene", 92], ["in", 97], ["non", 100], ["-", 103], ["small", 104], ["cell", 110], ["lung", 115], ["cancers", 120], ["are", 128], ["associated", 132], ["with", 143], ["increased", 148], ["sensitivity", 158], ["of", 170], ["these", 173], ["cancers", 179], ["to", 187], ["drugs", 190], ["that", 196], ["inhibit", 201], ["EGFR", 209], ["kinase", 214], ["activity", 221], ["such", 230], ["as", 235], ["gefitinib", 238], ["and", 248], ["erlotinib", 252], [".", 261], ["Responses", 263], ["to", 273], ["TK", 276], ["inhibitors", 279], ["in", 290], ["the", 293], ["absence", 297], ["of", 305], ["EGFR", 308], ["gene", 313], ["mutation", 318], ["for", 327], ["BAC", 331], ["patients", 335], ["have", 344], ["not", 349], ["been", 353], ["reported", 358], [".", 366], ["A", 368], ["case", 370], ["of", 375], ["a", 378], ["patient", 380], ["with", 388], ["BAC", 393], ["refractory", 397], ["to", 408], ["chemotherapy", 411], ["who", 424], ["responded", 428], ["to", 438], ["gefitinib", 441], ["in", 451], ["the", 454], ["absence", 458], ["of", 466], ["EGFR", 469], ["gene", 474], ["mutations", 479], ["is", 489], ["reported", 492], [".", 500], ["Tyrosine", 502], ["kinase", 511], ["inhibitors", 518], ["may", 529], ["have", 533], ["a", 538], ["role", 540], ["in", 545], ["BAC", 548], ["in", 552], ["the", 555], ["absence", 559], ["of", 567], ["EGFR", 570], ["gene", 575], ["mutations", 580], [".", 589], ["Additional", 591], ["studies", 602], ["on", 610], ["other", 613], ["molecular", 619], ["alterations", 629], ["of", 641], ["the", 644], ["EGFR", 648], ["family", 653], ["members", 660], ["are", 668], ["needed", 672], ["to", 679], ["better", 682], ["predict", 689], ["response", 697], ["to", 706], ["these", 709], ["agents", 715], [".", 721]]}
{"context": "Ch\u00e9diak-Higashi syndrome (CHS) is a rare autosomal recessive disorder characterized by immunodeficiency, neurological dysfunction, and oculocutaneous albinism. Recently, several clinical CHS phenotypes have been reported. Here, we report results of a nationwide survey performed to clarify clinical characteristics and outcomes of CHS patients in Japan. Questionnaires were sent to 287 institutions to collect data regarding CHS patients diagnosed between 2000 and 2010, including results of lysosomal trafficking regulator (LYST) gene analysis. Cytotoxicity and degranulation activity of cytotoxic T lymphocytes were analyzed in available patient samples. A total of 15 patients diagnosed with CHS were eligible for enrollment in this study. Of these, 10 (67%) had recurrent bacterial infections, five (33%) developed life-threatening hemophagocytic lymphohistiocytosis (HLH), and one patient had complicated malignant lymphoma. Hematopoietic stem cell transplantation (HSCT) was performed for six patients including three with HLH, and 10 of the enrolled patients have survived at the time of this writing. LYST analysis was performed for 10 patients; seven different mutations were detected in seven patients, whereas no mutation was identified in three patients. Cytotoxicity and degranulation activity were impaired in patients with and without LYST mutation. Results of this survey indicate that one or two patients with CHS were newly diagnosed each year in Japan. The incidence of HLH was not as high as expected. Mutations of genes other than LYST were suspected in some cases. We conclude that determining indication for HSCT for CHS patients should be based on genetic and cytotoxic analysis.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "f1f7239d2a0c4cb885c35010f04d0b4a", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[81, 83]], "char_spans": [[525, 534]]}]}], "context_tokens": [["Ch\u00e9diak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["a", 34], ["rare", 36], ["autosomal", 41], ["recessive", 51], ["disorder", 61], ["characterized", 70], ["by", 84], ["immunodeficiency", 87], [",", 103], ["neurological", 105], ["dysfunction", 118], [",", 129], ["and", 131], ["oculocutaneous", 135], ["albinism", 150], [".", 158], ["Recently", 160], [",", 168], ["several", 170], ["clinical", 178], ["CHS", 187], ["phenotypes", 191], ["have", 202], ["been", 207], ["reported", 212], [".", 220], ["Here", 222], [",", 226], ["we", 228], ["report", 231], ["results", 238], ["of", 246], ["a", 249], ["nationwide", 251], ["survey", 262], ["performed", 269], ["to", 279], ["clarify", 282], ["clinical", 290], ["characteristics", 299], ["and", 315], ["outcomes", 319], ["of", 328], ["CHS", 331], ["patients", 335], ["in", 344], ["Japan", 347], [".", 352], ["Questionnaires", 354], ["were", 369], ["sent", 374], ["to", 379], ["287", 382], ["institutions", 386], ["to", 399], ["collect", 402], ["data", 410], ["regarding", 415], ["CHS", 425], ["patients", 429], ["diagnosed", 438], ["between", 448], ["2000", 456], ["and", 461], ["2010", 465], [",", 469], ["including", 471], ["results", 481], ["of", 489], ["lysosomal", 492], ["trafficking", 502], ["regulator", 514], ["(", 524], ["LYST", 525], [")", 529], ["gene", 531], ["analysis", 536], [".", 544], ["Cytotoxicity", 546], ["and", 559], ["degranulation", 563], ["activity", 577], ["of", 586], ["cytotoxic", 589], ["T", 599], ["lymphocytes", 601], ["were", 613], ["analyzed", 618], ["in", 627], ["available", 630], ["patient", 640], ["samples", 648], [".", 655], ["A", 657], ["total", 659], ["of", 665], ["15", 668], ["patients", 671], ["diagnosed", 680], ["with", 690], ["CHS", 695], ["were", 699], ["eligible", 704], ["for", 713], ["enrollment", 717], ["in", 728], ["this", 731], ["study", 736], [".", 741], ["Of", 743], ["these", 746], [",", 751], ["10", 753], ["(", 756], ["67", 757], ["%", 759], [")", 760], ["had", 762], ["recurrent", 766], ["bacterial", 776], ["infections", 786], [",", 796], ["five", 798], ["(", 803], ["33", 804], ["%", 806], [")", 807], ["developed", 809], ["life", 819], ["-", 823], ["threatening", 824], ["hemophagocytic", 836], ["lymphohistiocytosis", 851], ["(", 871], ["HLH", 872], [")", 875], [",", 876], ["and", 878], ["one", 882], ["patient", 886], ["had", 894], ["complicated", 898], ["malignant", 910], ["lymphoma", 920], [".", 928], ["Hematopoietic", 930], ["stem", 944], ["cell", 949], ["transplantation", 954], ["(", 970], ["HSCT", 971], [")", 975], ["was", 977], ["performed", 981], ["for", 991], ["six", 995], ["patients", 999], ["including", 1008], ["three", 1018], ["with", 1024], ["HLH", 1029], [",", 1032], ["and", 1034], ["10", 1038], ["of", 1041], ["the", 1044], ["enrolled", 1048], ["patients", 1057], ["have", 1066], ["survived", 1071], ["at", 1080], ["the", 1083], ["time", 1087], ["of", 1092], ["this", 1095], ["writing", 1100], [".", 1107], ["LYST", 1109], ["analysis", 1114], ["was", 1123], ["performed", 1127], ["for", 1137], ["10", 1141], ["patients", 1144], [";", 1152], ["seven", 1154], ["different", 1160], ["mutations", 1170], ["were", 1180], ["detected", 1185], ["in", 1194], ["seven", 1197], ["patients", 1203], [",", 1211], ["whereas", 1213], ["no", 1221], ["mutation", 1224], ["was", 1233], ["identified", 1237], ["in", 1248], ["three", 1251], ["patients", 1257], [".", 1265], ["Cytotoxicity", 1267], ["and", 1280], ["degranulation", 1284], ["activity", 1298], ["were", 1307], ["impaired", 1312], ["in", 1321], ["patients", 1324], ["with", 1333], ["and", 1338], ["without", 1342], ["LYST", 1350], ["mutation", 1355], [".", 1363], ["Results", 1365], ["of", 1373], ["this", 1376], ["survey", 1381], ["indicate", 1388], ["that", 1397], ["one", 1402], ["or", 1406], ["two", 1409], ["patients", 1413], ["with", 1422], ["CHS", 1427], ["were", 1431], ["newly", 1436], ["diagnosed", 1442], ["each", 1452], ["year", 1457], ["in", 1462], ["Japan", 1465], [".", 1470], ["The", 1472], ["incidence", 1476], ["of", 1486], ["HLH", 1489], ["was", 1493], ["not", 1497], ["as", 1501], ["high", 1504], ["as", 1509], ["expected", 1512], [".", 1520], ["Mutations", 1522], ["of", 1532], ["genes", 1535], ["other", 1541], ["than", 1547], ["LYST", 1552], ["were", 1557], ["suspected", 1562], ["in", 1572], ["some", 1575], ["cases", 1580], [".", 1585], ["We", 1587], ["conclude", 1590], ["that", 1599], ["determining", 1604], ["indication", 1616], ["for", 1627], ["HSCT", 1631], ["for", 1636], ["CHS", 1640], ["patients", 1644], ["should", 1653], ["be", 1660], ["based", 1663], ["on", 1669], ["genetic", 1672], ["and", 1680], ["cytotoxic", 1684], ["analysis", 1694], [".", 1702]]}
{"context": "The restless legs syndrome is characterized by an unpleasant sensation in the legs which causes an imperative need to move the legs and is therefore considered to be a disorder of movement. When it appears before going to sleep, it may interfere with falling asleep and lead to a sleep-deficit. It is a clinical condition with a satisfactory treatment, and improvement of the associated sleep disorder. The etiology is unknown, sometimes it is familial. The syndrome is increasingly often diagnosed, particularly in association with iron deficiency, during pregnancy, in chronic renal failure and in patients with peripheral neuropathy. Polysomnography is not necessary, unless one suspects an associated disorder of periodic leg movements. Treatment is by dopaminergic, opiate, benzodiazepine, anticonvulsant drugs or clonidine.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "d4042c8ae89c41c5b5b34e283593ecf2", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[94, 94]], "char_spans": [[533, 536]]}]}], "context_tokens": [["The", 0], ["restless", 4], ["legs", 13], ["syndrome", 18], ["is", 27], ["characterized", 30], ["by", 44], ["an", 47], ["unpleasant", 50], ["sensation", 61], ["in", 71], ["the", 74], ["legs", 78], ["which", 83], ["causes", 89], ["an", 96], ["imperative", 99], ["need", 110], ["to", 115], ["move", 118], ["the", 123], ["legs", 127], ["and", 132], ["is", 136], ["therefore", 139], ["considered", 149], ["to", 160], ["be", 163], ["a", 166], ["disorder", 168], ["of", 177], ["movement", 180], [".", 188], ["When", 190], ["it", 195], ["appears", 198], ["before", 206], ["going", 213], ["to", 219], ["sleep", 222], [",", 227], ["it", 229], ["may", 232], ["interfere", 236], ["with", 246], ["falling", 251], ["asleep", 259], ["and", 266], ["lead", 270], ["to", 275], ["a", 278], ["sleep", 280], ["-", 285], ["deficit", 286], [".", 293], ["It", 295], ["is", 298], ["a", 301], ["clinical", 303], ["condition", 312], ["with", 322], ["a", 327], ["satisfactory", 329], ["treatment", 342], [",", 351], ["and", 353], ["improvement", 357], ["of", 369], ["the", 372], ["associated", 376], ["sleep", 387], ["disorder", 393], [".", 401], ["The", 403], ["etiology", 407], ["is", 416], ["unknown", 419], [",", 426], ["sometimes", 428], ["it", 438], ["is", 441], ["familial", 444], [".", 452], ["The", 454], ["syndrome", 458], ["is", 467], ["increasingly", 470], ["often", 483], ["diagnosed", 489], [",", 498], ["particularly", 500], ["in", 513], ["association", 516], ["with", 528], ["iron", 533], ["deficiency", 538], [",", 548], ["during", 550], ["pregnancy", 557], [",", 566], ["in", 568], ["chronic", 571], ["renal", 579], ["failure", 585], ["and", 593], ["in", 597], ["patients", 600], ["with", 609], ["peripheral", 614], ["neuropathy", 625], [".", 635], ["Polysomnography", 637], ["is", 653], ["not", 656], ["necessary", 660], [",", 669], ["unless", 671], ["one", 678], ["suspects", 682], ["an", 691], ["associated", 694], ["disorder", 705], ["of", 714], ["periodic", 717], ["leg", 726], ["movements", 730], [".", 739], ["Treatment", 741], ["is", 751], ["by", 754], ["dopaminergic", 757], [",", 769], ["opiate", 771], [",", 777], ["benzodiazepine", 779], [",", 793], ["anticonvulsant", 795], ["drugs", 810], ["or", 816], ["clonidine", 819], [".", 828]]}
{"context": "Throughout its history, chronic myeloid leukemia (CML) has set precedents for cancer research and therapy. These range from the identification of the first specific chromosomal abnormality associated with cancer to the development of imatinib as a specific, targeted therapy for the disease. The successful development of imatinib as a therapeutic agent for CML can be attributed directly to decades of scientific discoveries. These discoveries determined that the BCR-ABL tyrosine kinase is the critical pathogenetic event in CML and an ideal target for therapy. This was confirmed in clinical trials of imatinib, with imatinib significantly improving the long-term survival of patients with CML. Continuing in this tradition of scientific discoveries leading to improved therapies, the understanding of resistance to imatinib has rapidly led to strategies to circumvent resistance. Continued studies of hematologic malignancies will allow this paradigm of targeting molecular pathogenetic events to be applied to many additional hematologic cancers.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "fd6f4f8657ba4d22a07d09f21a98e576", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[74, 76]], "char_spans": [[465, 471]]}]}], "context_tokens": [["Throughout", 0], ["its", 11], ["history", 15], [",", 22], ["chronic", 24], ["myeloid", 32], ["leukemia", 40], ["(", 49], ["CML", 50], [")", 53], ["has", 55], ["set", 59], ["precedents", 63], ["for", 74], ["cancer", 78], ["research", 85], ["and", 94], ["therapy", 98], [".", 105], ["These", 107], ["range", 113], ["from", 119], ["the", 124], ["identification", 128], ["of", 143], ["the", 146], ["first", 150], ["specific", 156], ["chromosomal", 165], ["abnormality", 177], ["associated", 189], ["with", 200], ["cancer", 205], ["to", 212], ["the", 215], ["development", 219], ["of", 231], ["imatinib", 234], ["as", 243], ["a", 246], ["specific", 248], [",", 256], ["targeted", 258], ["therapy", 267], ["for", 275], ["the", 279], ["disease", 283], [".", 290], ["The", 292], ["successful", 296], ["development", 307], ["of", 319], ["imatinib", 322], ["as", 331], ["a", 334], ["therapeutic", 336], ["agent", 348], ["for", 354], ["CML", 358], ["can", 362], ["be", 366], ["attributed", 369], ["directly", 380], ["to", 389], ["decades", 392], ["of", 400], ["scientific", 403], ["discoveries", 414], [".", 425], ["These", 427], ["discoveries", 433], ["determined", 445], ["that", 456], ["the", 461], ["BCR", 465], ["-", 468], ["ABL", 469], ["tyrosine", 473], ["kinase", 482], ["is", 489], ["the", 492], ["critical", 496], ["pathogenetic", 505], ["event", 518], ["in", 524], ["CML", 527], ["and", 531], ["an", 535], ["ideal", 538], ["target", 544], ["for", 551], ["therapy", 555], [".", 562], ["This", 564], ["was", 569], ["confirmed", 573], ["in", 583], ["clinical", 586], ["trials", 595], ["of", 602], ["imatinib", 605], [",", 613], ["with", 615], ["imatinib", 620], ["significantly", 629], ["improving", 643], ["the", 653], ["long", 657], ["-", 661], ["term", 662], ["survival", 667], ["of", 676], ["patients", 679], ["with", 688], ["CML", 693], [".", 696], ["Continuing", 698], ["in", 709], ["this", 712], ["tradition", 717], ["of", 727], ["scientific", 730], ["discoveries", 741], ["leading", 753], ["to", 761], ["improved", 764], ["therapies", 773], [",", 782], ["the", 784], ["understanding", 788], ["of", 802], ["resistance", 805], ["to", 816], ["imatinib", 819], ["has", 828], ["rapidly", 832], ["led", 840], ["to", 844], ["strategies", 847], ["to", 858], ["circumvent", 861], ["resistance", 872], [".", 882], ["Continued", 884], ["studies", 894], ["of", 902], ["hematologic", 905], ["malignancies", 917], ["will", 930], ["allow", 935], ["this", 941], ["paradigm", 946], ["of", 955], ["targeting", 958], ["molecular", 968], ["pathogenetic", 978], ["events", 991], ["to", 998], ["be", 1001], ["applied", 1004], ["to", 1012], ["many", 1015], ["additional", 1020], ["hematologic", 1031], ["cancers", 1043], [".", 1050]]}
{"context": "X monosomic mice (39,XO) have a remarkably mild phenotype when compared to women with Turner syndrome (45,XO). The generally accepted hypothesis to explain this discrepancy is that the number of genes on the mouse X chromosome which escape X inactivation, and thus are expressed at higher levels in females, is very small. However this hypothesis has never been tested and only a small number of genes have been assayed for their X-inactivation status in the mouse. We performed a global expression analysis in four somatic tissues (brain, liver, kidney and muscle) of adult 40,XX and 39,XO mice using the Illumina Mouse WG-6 v1_1 Expression BeadChip and an extensive validation by quantitative real time PCR, in order to identify which genes are expressed from both X chromosomes. We identified several genes on the X chromosome which are overexpressed in XX females, including those previously reported as escaping X inactivation, as well as new candidates. However, the results obtained by microarray and qPCR were not fully concordant, illustrating the difficulty in ascertaining modest fold changes, such as those expected for genes escaping X inactivation. Remarkably, considerable variation was observed between tissues, suggesting that inactivation patterns may be tissue-dependent. Our analysis also exposed several autosomal genes involved in mitochondrial metabolism and in protein translation which are differentially expressed between XX and XO mice, revealing secondary transcriptional changes to the alteration in X chromosome dosage. Our results support the prediction that the mouse inactive X chromosome is largely silent, while providing a list of the genes potentially escaping X inactivation in rodents. Although the lower expression of X-linked genes in XO mice may not be relevant in the particular tissues/systems which are affected in human X chromosome monosomy, genes deregulated in XO mice are good candidates for further study in an involvement in Turner Syndrome phenotype.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "f60eb4dfa5774b8c8a56567d0989deff", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[0, 0], [43, 43], [149, 149], [203, 203], [286, 286], [140, 140], [164, 164], [39, 39], [296, 296], [318, 318], [258, 258], [79, 79], [271, 271]], "char_spans": [[0, 0], [240, 240], [817, 817], [1147, 1147], [1698, 1698], [767, 767], [917, 917], [214, 214], [1758, 1758], [1866, 1866], [1529, 1529], [430, 430], [1609, 1609]]}]}], "context_tokens": [["X", 0], ["monosomic", 2], ["mice", 12], ["(", 17], ["39,XO", 18], [")", 23], ["have", 25], ["a", 30], ["remarkably", 32], ["mild", 43], ["phenotype", 48], ["when", 58], ["compared", 63], ["to", 72], ["women", 75], ["with", 81], ["Turner", 86], ["syndrome", 93], ["(", 102], ["45,XO", 103], [")", 108], [".", 109], ["The", 111], ["generally", 115], ["accepted", 125], ["hypothesis", 134], ["to", 145], ["explain", 148], ["this", 156], ["discrepancy", 161], ["is", 173], ["that", 176], ["the", 181], ["number", 185], ["of", 192], ["genes", 195], ["on", 201], ["the", 204], ["mouse", 208], ["X", 214], ["chromosome", 216], ["which", 227], ["escape", 233], ["X", 240], ["inactivation", 242], [",", 254], ["and", 256], ["thus", 260], ["are", 265], ["expressed", 269], ["at", 279], ["higher", 282], ["levels", 289], ["in", 296], ["females", 299], [",", 306], ["is", 308], ["very", 311], ["small", 316], [".", 321], ["However", 323], ["this", 331], ["hypothesis", 336], ["has", 347], ["never", 351], ["been", 357], ["tested", 362], ["and", 369], ["only", 373], ["a", 378], ["small", 380], ["number", 386], ["of", 393], ["genes", 396], ["have", 402], ["been", 407], ["assayed", 412], ["for", 420], ["their", 424], ["X", 430], ["-", 431], ["inactivation", 432], ["status", 445], ["in", 452], ["the", 455], ["mouse", 459], [".", 464], ["We", 466], ["performed", 469], ["a", 479], ["global", 481], ["expression", 488], ["analysis", 499], ["in", 508], ["four", 511], ["somatic", 516], ["tissues", 524], ["(", 532], ["brain", 533], [",", 538], ["liver", 540], [",", 545], ["kidney", 547], ["and", 554], ["muscle", 558], [")", 564], ["of", 566], ["adult", 569], ["40,XX", 575], ["and", 581], ["39,XO", 585], ["mice", 591], ["using", 596], ["the", 602], ["Illumina", 606], ["Mouse", 615], ["WG-6", 621], ["v1_1", 626], ["Expression", 631], ["BeadChip", 642], ["and", 651], ["an", 655], ["extensive", 658], ["validation", 668], ["by", 679], ["quantitative", 682], ["real", 695], ["time", 700], ["PCR", 705], [",", 708], ["in", 710], ["order", 713], ["to", 719], ["identify", 722], ["which", 731], ["genes", 737], ["are", 743], ["expressed", 747], ["from", 757], ["both", 762], ["X", 767], ["chromosomes", 769], [".", 780], ["We", 782], ["identified", 785], ["several", 796], ["genes", 804], ["on", 810], ["the", 813], ["X", 817], ["chromosome", 819], ["which", 830], ["are", 836], ["overexpressed", 840], ["in", 854], ["XX", 857], ["females", 860], [",", 867], ["including", 869], ["those", 879], ["previously", 885], ["reported", 896], ["as", 905], ["escaping", 908], ["X", 917], ["inactivation", 919], [",", 931], ["as", 933], ["well", 936], ["as", 941], ["new", 944], ["candidates", 948], [".", 958], ["However", 960], [",", 967], ["the", 969], ["results", 973], ["obtained", 981], ["by", 990], ["microarray", 993], ["and", 1004], ["qPCR", 1008], ["were", 1013], ["not", 1018], ["fully", 1022], ["concordant", 1028], [",", 1038], ["illustrating", 1040], ["the", 1053], ["difficulty", 1057], ["in", 1068], ["ascertaining", 1071], ["modest", 1084], ["fold", 1091], ["changes", 1096], [",", 1103], ["such", 1105], ["as", 1110], ["those", 1113], ["expected", 1119], ["for", 1128], ["genes", 1132], ["escaping", 1138], ["X", 1147], ["inactivation", 1149], [".", 1161], ["Remarkably", 1163], [",", 1173], ["considerable", 1175], ["variation", 1188], ["was", 1198], ["observed", 1202], ["between", 1211], ["tissues", 1219], [",", 1226], ["suggesting", 1228], ["that", 1239], ["inactivation", 1244], ["patterns", 1257], ["may", 1266], ["be", 1270], ["tissue", 1273], ["-", 1279], ["dependent", 1280], [".", 1289], ["Our", 1291], ["analysis", 1295], ["also", 1304], ["exposed", 1309], ["several", 1317], ["autosomal", 1325], ["genes", 1335], ["involved", 1341], ["in", 1350], ["mitochondrial", 1353], ["metabolism", 1367], ["and", 1378], ["in", 1382], ["protein", 1385], ["translation", 1393], ["which", 1405], ["are", 1411], ["differentially", 1415], ["expressed", 1430], ["between", 1440], ["XX", 1448], ["and", 1451], ["XO", 1455], ["mice", 1458], [",", 1462], ["revealing", 1464], ["secondary", 1474], ["transcriptional", 1484], ["changes", 1500], ["to", 1508], ["the", 1511], ["alteration", 1515], ["in", 1526], ["X", 1529], ["chromosome", 1531], ["dosage", 1542], [".", 1548], ["Our", 1550], ["results", 1554], ["support", 1562], ["the", 1570], ["prediction", 1574], ["that", 1585], ["the", 1590], ["mouse", 1594], ["inactive", 1600], ["X", 1609], ["chromosome", 1611], ["is", 1622], ["largely", 1625], ["silent", 1633], [",", 1639], ["while", 1641], ["providing", 1647], ["a", 1657], ["list", 1659], ["of", 1664], ["the", 1667], ["genes", 1671], ["potentially", 1677], ["escaping", 1689], ["X", 1698], ["inactivation", 1700], ["in", 1713], ["rodents", 1716], [".", 1723], ["Although", 1725], ["the", 1734], ["lower", 1738], ["expression", 1744], ["of", 1755], ["X", 1758], ["-", 1759], ["linked", 1760], ["genes", 1767], ["in", 1773], ["XO", 1776], ["mice", 1779], ["may", 1784], ["not", 1788], ["be", 1792], ["relevant", 1795], ["in", 1804], ["the", 1807], ["particular", 1811], ["tissues", 1822], ["/", 1829], ["systems", 1830], ["which", 1838], ["are", 1844], ["affected", 1848], ["in", 1857], ["human", 1860], ["X", 1866], ["chromosome", 1868], ["monosomy", 1879], [",", 1887], ["genes", 1889], ["deregulated", 1895], ["in", 1907], ["XO", 1910], ["mice", 1913], ["are", 1918], ["good", 1922], ["candidates", 1927], ["for", 1938], ["further", 1942], ["study", 1950], ["in", 1956], ["an", 1959], ["involvement", 1962], ["in", 1974], ["Turner", 1977], ["Syndrome", 1984], ["phenotype", 1993], [".", 2002]]}
{"context": "Epidermal growth factor receptor (EGFR) gene mutations have been found in a subset of non-small cell lung cancer (NSCLC) with good clinical response to gefitinib therapy. A quick and sensitive method with large throughput is required to utilize the information to determine whether the molecular targeted therapy should be applied for the particular NSCLC patients. Using probes for the 13 different mutations including 11 that have already been reported, we have genotyped the EGFR mutation status in 94 NSCLC patients using the TaqMan PCR assay. We have also genotyped the EGFR mutations status in additional 182 NSCLC patients, as well as 63 gastric, 95 esophagus and 70 colon carcinoma patients. In 94 NSCLC samples, the result of the TaqMan PCR assay perfectly matched with that of the sequencing excluding one patient. In one sample in which no EGFR mutation was detected by direct sequencing, the TaqMan PCR assay detected a mutation. This patient was a gefitinib responder. In a serial dilution study, the assay could detect a mutant sample diluted in 1/10 with a wild-type sample. Of 182 NSCLC samples, 46 mutations were detected. EGFR mutation was significantly correlated with gender, smoking status, pathological subtypes, and differentiation of lung cancers. There was no mutation detected by the TaqMan PCR assay in gastric, esophagus and colon carcinomas. TaqMan PCR assay is a rapid and sensitive method of detection of EGFR mutations with high throughput, and may be useful to determine whether gefitinib should be offered for the treatment of NSCLC patients. The TaqMan PCR assay can offer us a complementary and confirmative test.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "db82e6a831de4a5e9ce53368a088128a", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[0, 7]], "char_spans": [[0, 43]]}]}], "context_tokens": [["Epidermal", 0], ["growth", 10], ["factor", 17], ["receptor", 24], ["(", 33], ["EGFR", 34], [")", 38], ["gene", 40], ["mutations", 45], ["have", 55], ["been", 60], ["found", 65], ["in", 71], ["a", 74], ["subset", 76], ["of", 83], ["non", 86], ["-", 89], ["small", 90], ["cell", 96], ["lung", 101], ["cancer", 106], ["(", 113], ["NSCLC", 114], [")", 119], ["with", 121], ["good", 126], ["clinical", 131], ["response", 140], ["to", 149], ["gefitinib", 152], ["therapy", 162], [".", 169], ["A", 171], ["quick", 173], ["and", 179], ["sensitive", 183], ["method", 193], ["with", 200], ["large", 205], ["throughput", 211], ["is", 222], ["required", 225], ["to", 234], ["utilize", 237], ["the", 245], ["information", 249], ["to", 261], ["determine", 264], ["whether", 274], ["the", 282], ["molecular", 286], ["targeted", 296], ["therapy", 305], ["should", 313], ["be", 320], ["applied", 323], ["for", 331], ["the", 335], ["particular", 339], ["NSCLC", 350], ["patients", 356], [".", 364], ["Using", 366], ["probes", 372], ["for", 379], ["the", 383], ["13", 387], ["different", 390], ["mutations", 400], ["including", 410], ["11", 420], ["that", 423], ["have", 428], ["already", 433], ["been", 441], ["reported", 446], [",", 454], ["we", 456], ["have", 459], ["genotyped", 464], ["the", 474], ["EGFR", 478], ["mutation", 483], ["status", 492], ["in", 499], ["94", 502], ["NSCLC", 505], ["patients", 511], ["using", 520], ["the", 526], ["TaqMan", 530], ["PCR", 537], ["assay", 541], [".", 546], ["We", 548], ["have", 551], ["also", 556], ["genotyped", 561], ["the", 571], ["EGFR", 575], ["mutations", 580], ["status", 590], ["in", 597], ["additional", 600], ["182", 611], ["NSCLC", 615], ["patients", 621], [",", 629], ["as", 631], ["well", 634], ["as", 639], ["63", 642], ["gastric", 645], [",", 652], ["95", 654], ["esophagus", 657], ["and", 667], ["70", 671], ["colon", 674], ["carcinoma", 680], ["patients", 690], [".", 698], ["In", 700], ["94", 703], ["NSCLC", 706], ["samples", 712], [",", 719], ["the", 721], ["result", 725], ["of", 732], ["the", 735], ["TaqMan", 739], ["PCR", 746], ["assay", 750], ["perfectly", 756], ["matched", 766], ["with", 774], ["that", 779], ["of", 784], ["the", 787], ["sequencing", 791], ["excluding", 802], ["one", 812], ["patient", 816], [".", 823], ["In", 825], ["one", 828], ["sample", 832], ["in", 839], ["which", 842], ["no", 848], ["EGFR", 851], ["mutation", 856], ["was", 865], ["detected", 869], ["by", 878], ["direct", 881], ["sequencing", 888], [",", 898], ["the", 900], ["TaqMan", 904], ["PCR", 911], ["assay", 915], ["detected", 921], ["a", 930], ["mutation", 932], [".", 940], ["This", 942], ["patient", 947], ["was", 955], ["a", 959], ["gefitinib", 961], ["responder", 971], [".", 980], ["In", 982], ["a", 985], ["serial", 987], ["dilution", 994], ["study", 1003], [",", 1008], ["the", 1010], ["assay", 1014], ["could", 1020], ["detect", 1026], ["a", 1033], ["mutant", 1035], ["sample", 1042], ["diluted", 1049], ["in", 1057], ["1/10", 1060], ["with", 1065], ["a", 1070], ["wild", 1072], ["-", 1076], ["type", 1077], ["sample", 1082], [".", 1088], ["Of", 1090], ["182", 1093], ["NSCLC", 1097], ["samples", 1103], [",", 1110], ["46", 1112], ["mutations", 1115], ["were", 1125], ["detected", 1130], [".", 1138], ["EGFR", 1140], ["mutation", 1145], ["was", 1154], ["significantly", 1158], ["correlated", 1172], ["with", 1183], ["gender", 1188], [",", 1194], ["smoking", 1196], ["status", 1204], [",", 1210], ["pathological", 1212], ["subtypes", 1225], [",", 1233], ["and", 1235], ["differentiation", 1239], ["of", 1255], ["lung", 1258], ["cancers", 1263], [".", 1270], ["There", 1272], ["was", 1278], ["no", 1282], ["mutation", 1285], ["detected", 1294], ["by", 1303], ["the", 1306], ["TaqMan", 1310], ["PCR", 1317], ["assay", 1321], ["in", 1327], ["gastric", 1330], [",", 1337], ["esophagus", 1339], ["and", 1349], ["colon", 1353], ["carcinomas", 1359], [".", 1369], ["TaqMan", 1371], ["PCR", 1378], ["assay", 1382], ["is", 1388], ["a", 1391], ["rapid", 1393], ["and", 1399], ["sensitive", 1403], ["method", 1413], ["of", 1420], ["detection", 1423], ["of", 1433], ["EGFR", 1436], ["mutations", 1441], ["with", 1451], ["high", 1456], ["throughput", 1461], [",", 1471], ["and", 1473], ["may", 1477], ["be", 1481], ["useful", 1484], ["to", 1491], ["determine", 1494], ["whether", 1504], ["gefitinib", 1512], ["should", 1522], ["be", 1529], ["offered", 1532], ["for", 1540], ["the", 1544], ["treatment", 1548], ["of", 1558], ["NSCLC", 1561], ["patients", 1567], [".", 1575], ["The", 1577], ["TaqMan", 1581], ["PCR", 1588], ["assay", 1592], ["can", 1598], ["offer", 1602], ["us", 1608], ["a", 1611], ["complementary", 1613], ["and", 1627], ["confirmative", 1631], ["test", 1644], [".", 1648]]}
{"context": "Little is known about the management of methicillin-resistant Staphylococcus aureus (MRSA) carriers in the German outpatient sector and about the impact of MRSA on their daily life. Reimbursement for MRSA related costs in the German outpatient sector is available since 2012, but its impact has not been studied yet. The aim of the study was to analyze the outpatient management of MRSA carriers from both, physicians' and MRSA carriers' perspective. Paper-based questionnaires were mailed to physicians providing outpatient care and to MRSA carriers in 2013. MRSA carriers were recruited among patients tested positive for MRSA during a hospital stay in 2012. General practitioners, specialists for internal medicine, urologists, and dermatologists working in the outpatient catchment areas of the hospitals were contacted. Out of 910 MRSA carriers 16.5\u00a0% completed the questionnaires; among 851 physicians 9.5\u00a0% participated. 27.3\u00a0% of the responding MRSA carriers stated that no healthcare professional had ever talked to them about MRSA. 17.4\u00a0% reported self-stigmatization in terms of restricting social contacts; 47.3\u00a0% remembered decolonization and 33.3\u00a0% reported that their MRSA status was checked after discharge. Physicians displayed heterogeneous attitude and activity towards MRSA (number of applied decolonization and MRSA screenings). A minority (15.2\u00a0%) were satisfied with the reimbursement of costs, 35.9\u00a0% reported full agreement with the general recommendations for the handling of MRSA carriers. MRSA carriers appear not well informed; (self-) stigmatization is occurring and should be tackled. Greater awareness of MRSA as a problem in the outpatient sector could lead to a better handling of MRSA carriers.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "78d3a470a5fc433fb380a0e051deb39c", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[176, 176], [256, 256], [13, 13], [99, 99], [26, 26], [163, 163], [253, 253], [277, 277], [68, 68], [76, 76], [108, 108], [201, 201], [215, 215], [222, 222], [292, 292], [34, 34], [143, 143], [94, 94]], "char_spans": [[1036, 1039], [1517, 1520], [85, 88], [560, 563], [156, 159], [953, 956], [1502, 1505], [1637, 1640], [382, 385], [423, 426], [624, 627], [1183, 1186], [1289, 1292], [1332, 1335], [1715, 1718], [200, 203], [836, 839], [537, 540]]}]}], "context_tokens": [["Little", 0], ["is", 7], ["known", 10], ["about", 16], ["the", 22], ["management", 26], ["of", 37], ["methicillin", 40], ["-", 51], ["resistant", 52], ["Staphylococcus", 62], ["aureus", 77], ["(", 84], ["MRSA", 85], [")", 89], ["carriers", 91], ["in", 100], ["the", 103], ["German", 107], ["outpatient", 114], ["sector", 125], ["and", 132], ["about", 136], ["the", 142], ["impact", 146], ["of", 153], ["MRSA", 156], ["on", 161], ["their", 164], ["daily", 170], ["life", 176], [".", 180], ["Reimbursement", 182], ["for", 196], ["MRSA", 200], ["related", 205], ["costs", 213], ["in", 219], ["the", 222], ["German", 226], ["outpatient", 233], ["sector", 244], ["is", 251], ["available", 254], ["since", 264], ["2012", 270], [",", 274], ["but", 276], ["its", 280], ["impact", 284], ["has", 291], ["not", 295], ["been", 299], ["studied", 304], ["yet", 312], [".", 315], ["The", 317], ["aim", 321], ["of", 325], ["the", 328], ["study", 332], ["was", 338], ["to", 342], ["analyze", 345], ["the", 353], ["outpatient", 357], ["management", 368], ["of", 379], ["MRSA", 382], ["carriers", 387], ["from", 396], ["both", 401], [",", 405], ["physicians", 407], ["'", 417], ["and", 419], ["MRSA", 423], ["carriers", 428], ["'", 436], ["perspective", 438], [".", 449], ["Paper", 451], ["-", 456], ["based", 457], ["questionnaires", 463], ["were", 478], ["mailed", 483], ["to", 490], ["physicians", 493], ["providing", 504], ["outpatient", 514], ["care", 525], ["and", 530], ["to", 534], ["MRSA", 537], ["carriers", 542], ["in", 551], ["2013", 554], [".", 558], ["MRSA", 560], ["carriers", 565], ["were", 574], ["recruited", 579], ["among", 589], ["patients", 595], ["tested", 604], ["positive", 611], ["for", 620], ["MRSA", 624], ["during", 629], ["a", 636], ["hospital", 638], ["stay", 647], ["in", 652], ["2012", 655], [".", 659], ["General", 661], ["practitioners", 669], [",", 682], ["specialists", 684], ["for", 696], ["internal", 700], ["medicine", 709], [",", 717], ["urologists", 719], [",", 729], ["and", 731], ["dermatologists", 735], ["working", 750], ["in", 758], ["the", 761], ["outpatient", 765], ["catchment", 776], ["areas", 786], ["of", 792], ["the", 795], ["hospitals", 799], ["were", 809], ["contacted", 814], [".", 823], ["Out", 825], ["of", 829], ["910", 832], ["MRSA", 836], ["carriers", 841], ["16.5", 850], ["%", 855], ["completed", 857], ["the", 867], ["questionnaires", 871], [";", 885], ["among", 887], ["851", 893], ["physicians", 897], ["9.5", 908], ["%", 912], ["participated", 914], [".", 926], ["27.3", 928], ["%", 933], ["of", 935], ["the", 938], ["responding", 942], ["MRSA", 953], ["carriers", 958], ["stated", 967], ["that", 974], ["no", 979], ["healthcare", 982], ["professional", 993], ["had", 1006], ["ever", 1010], ["talked", 1015], ["to", 1022], ["them", 1025], ["about", 1030], ["MRSA", 1036], [".", 1040], ["17.4", 1042], ["%", 1047], ["reported", 1049], ["self", 1058], ["-", 1062], ["stigmatization", 1063], ["in", 1078], ["terms", 1081], ["of", 1087], ["restricting", 1090], ["social", 1102], ["contacts", 1109], [";", 1117], ["47.3", 1119], ["%", 1124], ["remembered", 1126], ["decolonization", 1137], ["and", 1152], ["33.3", 1156], ["%", 1161], ["reported", 1163], ["that", 1172], ["their", 1177], ["MRSA", 1183], ["status", 1188], ["was", 1195], ["checked", 1199], ["after", 1207], ["discharge", 1213], [".", 1222], ["Physicians", 1224], ["displayed", 1235], ["heterogeneous", 1245], ["attitude", 1259], ["and", 1268], ["activity", 1272], ["towards", 1281], ["MRSA", 1289], ["(", 1294], ["number", 1295], ["of", 1302], ["applied", 1305], ["decolonization", 1313], ["and", 1328], ["MRSA", 1332], ["screenings", 1337], [")", 1347], [".", 1348], ["A", 1350], ["minority", 1352], ["(", 1361], ["15.2", 1362], ["%", 1367], [")", 1368], ["were", 1370], ["satisfied", 1375], ["with", 1385], ["the", 1390], ["reimbursement", 1394], ["of", 1408], ["costs", 1411], [",", 1416], ["35.9", 1418], ["%", 1423], ["reported", 1425], ["full", 1434], ["agreement", 1439], ["with", 1449], ["the", 1454], ["general", 1458], ["recommendations", 1466], ["for", 1482], ["the", 1486], ["handling", 1490], ["of", 1499], ["MRSA", 1502], ["carriers", 1507], [".", 1515], ["MRSA", 1517], ["carriers", 1522], ["appear", 1531], ["not", 1538], ["well", 1542], ["informed", 1547], [";", 1555], ["(", 1557], ["self-", 1558], [")", 1563], ["stigmatization", 1565], ["is", 1580], ["occurring", 1583], ["and", 1593], ["should", 1597], ["be", 1604], ["tackled", 1607], [".", 1614], ["Greater", 1616], ["awareness", 1624], ["of", 1634], ["MRSA", 1637], ["as", 1642], ["a", 1645], ["problem", 1647], ["in", 1655], ["the", 1658], ["outpatient", 1662], ["sector", 1673], ["could", 1680], ["lead", 1686], ["to", 1691], ["a", 1694], ["better", 1696], ["handling", 1703], ["of", 1712], ["MRSA", 1715], ["carriers", 1720], [".", 1728]]}
{"context": "Highly repetitive DNA sequences account for more than 50% of the human genome. The L1 and Alu families harbor the most common mammalian long (LINEs) and short (SINEs) interspersed elements. Alu elements are each a dimer of similar, but not identical, fragments of total size about 300 bp, and originate from the 7SL RNA gene. Each element contains a bipartite promoter for RNA polymerase III, a poly(A) tract located between the monomers, a 3'-terminal poly(A) tract, and numerous CpG islands, and is flanked by short direct repeats. Alu repeats comprise more than 10% of the human genome and are capable of retroposition. Possibly, these elements played an important part in genome evolution. Insertion of an Alu element into a functionally important genome region or other Alu-dependent alterations of gene functions cause various hereditary disorders and are probably associated with carcinogenesis. In total, 14 Alu families differing in diagnostic mutations are known. Some of these, which are present in the human genome, are polymorphic and relatively recently inserted into new loci. Alu copies transposed during ethnic divergence of the human population are useful markers for evolutionary genetic studies.", "qas": [{"question": "From which sequence does the Alu repeat originate from?", "answers": ["7SL RNA"], "qid": "7aee0395db2b4a49bbecaa0dd253b366", "question_tokens": [["From", 0], ["which", 5], ["sequence", 11], ["does", 20], ["the", 25], ["Alu", 29], ["repeat", 33], ["originate", 40], ["from", 50], ["?", 54]], "detected_answers": [{"text": "7SL RNA", "token_spans": [[62, 63]], "char_spans": [[312, 318]]}]}], "context_tokens": [["Highly", 0], ["repetitive", 7], ["DNA", 18], ["sequences", 22], ["account", 32], ["for", 40], ["more", 44], ["than", 49], ["50", 54], ["%", 56], ["of", 58], ["the", 61], ["human", 65], ["genome", 71], [".", 77], ["The", 79], ["L1", 83], ["and", 86], ["Alu", 90], ["families", 94], ["harbor", 103], ["the", 110], ["most", 114], ["common", 119], ["mammalian", 126], ["long", 136], ["(", 141], ["LINEs", 142], [")", 147], ["and", 149], ["short", 153], ["(", 159], ["SINEs", 160], [")", 165], ["interspersed", 167], ["elements", 180], [".", 188], ["Alu", 190], ["elements", 194], ["are", 203], ["each", 207], ["a", 212], ["dimer", 214], ["of", 220], ["similar", 223], [",", 230], ["but", 232], ["not", 236], ["identical", 240], [",", 249], ["fragments", 251], ["of", 261], ["total", 264], ["size", 270], ["about", 275], ["300", 281], ["bp", 285], [",", 287], ["and", 289], ["originate", 293], ["from", 303], ["the", 308], ["7SL", 312], ["RNA", 316], ["gene", 320], [".", 324], ["Each", 326], ["element", 331], ["contains", 339], ["a", 348], ["bipartite", 350], ["promoter", 360], ["for", 369], ["RNA", 373], ["polymerase", 377], ["III", 388], [",", 391], ["a", 393], ["poly(A", 395], [")", 401], ["tract", 403], ["located", 409], ["between", 417], ["the", 425], ["monomers", 429], [",", 437], ["a", 439], ["3'-terminal", 441], ["poly(A", 453], [")", 459], ["tract", 461], [",", 466], ["and", 468], ["numerous", 472], ["CpG", 481], ["islands", 485], [",", 492], ["and", 494], ["is", 498], ["flanked", 501], ["by", 509], ["short", 512], ["direct", 518], ["repeats", 525], [".", 532], ["Alu", 534], ["repeats", 538], ["comprise", 546], ["more", 555], ["than", 560], ["10", 565], ["%", 567], ["of", 569], ["the", 572], ["human", 576], ["genome", 582], ["and", 589], ["are", 593], ["capable", 597], ["of", 605], ["retroposition", 608], [".", 621], ["Possibly", 623], [",", 631], ["these", 633], ["elements", 639], ["played", 648], ["an", 655], ["important", 658], ["part", 668], ["in", 673], ["genome", 676], ["evolution", 683], [".", 692], ["Insertion", 694], ["of", 704], ["an", 707], ["Alu", 710], ["element", 714], ["into", 722], ["a", 727], ["functionally", 729], ["important", 742], ["genome", 752], ["region", 759], ["or", 766], ["other", 769], ["Alu", 775], ["-", 778], ["dependent", 779], ["alterations", 789], ["of", 801], ["gene", 804], ["functions", 809], ["cause", 819], ["various", 825], ["hereditary", 833], ["disorders", 844], ["and", 854], ["are", 858], ["probably", 862], ["associated", 871], ["with", 882], ["carcinogenesis", 887], [".", 901], ["In", 903], ["total", 906], [",", 911], ["14", 913], ["Alu", 916], ["families", 920], ["differing", 929], ["in", 939], ["diagnostic", 942], ["mutations", 953], ["are", 963], ["known", 967], [".", 972], ["Some", 974], ["of", 979], ["these", 982], [",", 987], ["which", 989], ["are", 995], ["present", 999], ["in", 1007], ["the", 1010], ["human", 1014], ["genome", 1020], [",", 1026], ["are", 1028], ["polymorphic", 1032], ["and", 1044], ["relatively", 1048], ["recently", 1059], ["inserted", 1068], ["into", 1077], ["new", 1082], ["loci", 1086], [".", 1090], ["Alu", 1092], ["copies", 1096], ["transposed", 1103], ["during", 1114], ["ethnic", 1121], ["divergence", 1128], ["of", 1139], ["the", 1142], ["human", 1146], ["population", 1152], ["are", 1163], ["useful", 1167], ["markers", 1174], ["for", 1182], ["evolutionary", 1186], ["genetic", 1199], ["studies", 1207], [".", 1214]]}
{"context": "Circular RNAs (circRNAs) are a class of newly-identified non-coding RNA molecules. CircRNAs are conserved across different species and display specific organization, sequence, and expression in disease. Moreover, circRNAs' closed ring structure, insensitivity to RNase, and stability are advantages over linear RNAs in terms of development and application as a new kind of clinical marker. In addition, according to recent studies, circular RNA-7 (ciRS-7) acts as a sponge of miR-7 and thus inhibits its activity. Numerous evidences have confirmed expression of miR-7 is dysregulated in cancer tissues, however, whether ciRS-7 invovled in oncogenesis by acting as sponge of miR-7 remains unclear. Most recently, a study reported ciRS-7 acted as an oncogene in hepatocellular carcinoma through targeting miR-7 expression. This suggest ciRS-7/ miR-7 axis affects oncogenesis, and it provides a new perspective on the mechanisms of decreased miR-7 expression in cancer tissues. Discovery of sponge role of circRNAs caused researchers to more closely explore the underlying mechanism of carcinogenesis and has significant clinical implications, and may open a new chapter in research on the pathology and treatment of cancers. This review summarizes the structure and function of circRNAs and provides evidence for the impact of ciRS-7 in promoting the development of cancer by acting as sponge of miR-7.", "qas": [{"question": "Which miRNA is associated with the circular RNA ciRS-7?", "answers": ["miR-7"], "qid": "8d3460a44ce34647a536fc55cd18a4e1", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["associated", 15], ["with", 26], ["the", 31], ["circular", 35], ["RNA", 44], ["ciRS-7", 48], ["?", 54]], "detected_answers": [{"text": "miR-7", "token_spans": [[161, 161], [139, 139], [234, 234], [100, 100], [119, 119], [87, 87], [145, 145]], "char_spans": [[939, 943], [803, 807], [1394, 1398], [562, 566], [674, 678], [476, 480], [842, 846]]}]}], "context_tokens": [["Circular", 0], ["RNAs", 9], ["(", 14], ["circRNAs", 15], [")", 23], ["are", 25], ["a", 29], ["class", 31], ["of", 37], ["newly", 40], ["-", 45], ["identified", 46], ["non", 57], ["-", 60], ["coding", 61], ["RNA", 68], ["molecules", 72], [".", 81], ["CircRNAs", 83], ["are", 92], ["conserved", 96], ["across", 106], ["different", 113], ["species", 123], ["and", 131], ["display", 135], ["specific", 143], ["organization", 152], [",", 164], ["sequence", 166], [",", 174], ["and", 176], ["expression", 180], ["in", 191], ["disease", 194], [".", 201], ["Moreover", 203], [",", 211], ["circRNAs", 213], ["'", 221], ["closed", 223], ["ring", 230], ["structure", 235], [",", 244], ["insensitivity", 246], ["to", 260], ["RNase", 263], [",", 268], ["and", 270], ["stability", 274], ["are", 284], ["advantages", 288], ["over", 299], ["linear", 304], ["RNAs", 311], ["in", 316], ["terms", 319], ["of", 325], ["development", 328], ["and", 340], ["application", 344], ["as", 356], ["a", 359], ["new", 361], ["kind", 365], ["of", 370], ["clinical", 373], ["marker", 382], [".", 388], ["In", 390], ["addition", 393], [",", 401], ["according", 403], ["to", 413], ["recent", 416], ["studies", 423], [",", 430], ["circular", 432], ["RNA-7", 441], ["(", 447], ["ciRS-7", 448], [")", 454], ["acts", 456], ["as", 461], ["a", 464], ["sponge", 466], ["of", 473], ["miR-7", 476], ["and", 482], ["thus", 486], ["inhibits", 491], ["its", 500], ["activity", 504], [".", 512], ["Numerous", 514], ["evidences", 523], ["have", 533], ["confirmed", 538], ["expression", 548], ["of", 559], ["miR-7", 562], ["is", 568], ["dysregulated", 571], ["in", 584], ["cancer", 587], ["tissues", 594], [",", 601], ["however", 603], [",", 610], ["whether", 612], ["ciRS-7", 620], ["invovled", 627], ["in", 636], ["oncogenesis", 639], ["by", 651], ["acting", 654], ["as", 661], ["sponge", 664], ["of", 671], ["miR-7", 674], ["remains", 680], ["unclear", 688], [".", 695], ["Most", 697], ["recently", 702], [",", 710], ["a", 712], ["study", 714], ["reported", 720], ["ciRS-7", 729], ["acted", 736], ["as", 742], ["an", 745], ["oncogene", 748], ["in", 757], ["hepatocellular", 760], ["carcinoma", 775], ["through", 785], ["targeting", 793], ["miR-7", 803], ["expression", 809], [".", 819], ["This", 821], ["suggest", 826], ["ciRS-7/", 834], ["miR-7", 842], ["axis", 848], ["affects", 853], ["oncogenesis", 861], [",", 872], ["and", 874], ["it", 878], ["provides", 881], ["a", 890], ["new", 892], ["perspective", 896], ["on", 908], ["the", 911], ["mechanisms", 915], ["of", 926], ["decreased", 929], ["miR-7", 939], ["expression", 945], ["in", 956], ["cancer", 959], ["tissues", 966], [".", 973], ["Discovery", 975], ["of", 985], ["sponge", 988], ["role", 995], ["of", 1000], ["circRNAs", 1003], ["caused", 1012], ["researchers", 1019], ["to", 1031], ["more", 1034], ["closely", 1039], ["explore", 1047], ["the", 1055], ["underlying", 1059], ["mechanism", 1070], ["of", 1080], ["carcinogenesis", 1083], ["and", 1098], ["has", 1102], ["significant", 1106], ["clinical", 1118], ["implications", 1127], [",", 1139], ["and", 1141], ["may", 1145], ["open", 1149], ["a", 1154], ["new", 1156], ["chapter", 1160], ["in", 1168], ["research", 1171], ["on", 1180], ["the", 1183], ["pathology", 1187], ["and", 1197], ["treatment", 1201], ["of", 1211], ["cancers", 1214], [".", 1221], ["This", 1223], ["review", 1228], ["summarizes", 1235], ["the", 1246], ["structure", 1250], ["and", 1260], ["function", 1264], ["of", 1273], ["circRNAs", 1276], ["and", 1285], ["provides", 1289], ["evidence", 1298], ["for", 1307], ["the", 1311], ["impact", 1315], ["of", 1322], ["ciRS-7", 1325], ["in", 1332], ["promoting", 1335], ["the", 1345], ["development", 1349], ["of", 1361], ["cancer", 1364], ["by", 1371], ["acting", 1374], ["as", 1381], ["sponge", 1384], ["of", 1391], ["miR-7", 1394], [".", 1399]]}
{"context": "The Ehlers-Danlos syndrome is a heritable connective-tissue disorder caused by defects in fibrillar-collagen metabolism. Mutations in the type V collagen genes account for up to 50 percent of cases of classic Ehlers-Danlos syndrome, but many other cases are unexplained. We investigated whether the deficiency of the tenascins, extracellular-matrix proteins that are highly expressed in connective tissues, was associated with the Ehlers-Danlos syndrome. We screened serum samples from 151 patients with the classic, hypermobility, or vascular types of the Ehlers-Danlos syndrome; 75 patients with psoriasis; 93 patients with rheumatoid arthritis; and 21 healthy persons for the presence of tenascin-X and tenascin-C by enzyme-linked immunosorbent assay. We examined the expression of tenascins and type V collagen in skin by immunohistochemical methods and sequenced the tenascin-X gene. Tenascin-X was present in serum from all normal subjects, all patients with psoriasis, all patients with rheumatoid arthritis, and 146 of 151 patients with the Ehlers-Danlos syndrome. Tenascin-X was absent from the serum of the 5 remaining patients with Ehlers-Danlos syndrome, who were unrelated. Tenascin-X deficiency was confirmed in these patients by analysis of skin fibroblasts and by immunostaining of skin. The expression of tenascin-C and type V collagen was normal in these patients. All five of these patients had hypermobile joints, hyperelastic skin, and easy bruising, without atrophic scarring. Tenascin-X mutations were identified in all tenascin-X-deficient patients; one patient had a homozygous tenascin-X gene deletion, one was heterozygous for the deletion, and three others had homozygous truncating point mutations, confirming a causative role for tenascin-X and a recessive pattern of inheritance. Tenascin-X deficiency causes a clinically distinct, recessive form of the Ehlers-Danlos syndrome. This finding indicates that factors other than the collagens or collagen-processing enzymes can cause the syndrome and suggests a central role for tenascin-X in maintaining the integrity of collagenous matrix.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective-tissue", "connective tissue"], "qid": "84ecb54e06cc44c78c9482f8b29d119c", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[8, 10]], "char_spans": [[42, 58]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndrome", 18], ["is", 27], ["a", 30], ["heritable", 32], ["connective", 42], ["-", 52], ["tissue", 53], ["disorder", 60], ["caused", 69], ["by", 76], ["defects", 79], ["in", 87], ["fibrillar", 90], ["-", 99], ["collagen", 100], ["metabolism", 109], [".", 119], ["Mutations", 121], ["in", 131], ["the", 134], ["type", 138], ["V", 143], ["collagen", 145], ["genes", 154], ["account", 160], ["for", 168], ["up", 172], ["to", 175], ["50", 178], ["percent", 181], ["of", 189], ["cases", 192], ["of", 198], ["classic", 201], ["Ehlers", 209], ["-", 215], ["Danlos", 216], ["syndrome", 223], [",", 231], ["but", 233], ["many", 237], ["other", 242], ["cases", 248], ["are", 254], ["unexplained", 258], [".", 269], ["We", 271], ["investigated", 274], ["whether", 287], ["the", 295], ["deficiency", 299], ["of", 310], ["the", 313], ["tenascins", 317], [",", 326], ["extracellular", 328], ["-", 341], ["matrix", 342], ["proteins", 349], ["that", 358], ["are", 363], ["highly", 367], ["expressed", 374], ["in", 384], ["connective", 387], ["tissues", 398], [",", 405], ["was", 407], ["associated", 411], ["with", 422], ["the", 427], ["Ehlers", 431], ["-", 437], ["Danlos", 438], ["syndrome", 445], [".", 453], ["We", 455], ["screened", 458], ["serum", 467], ["samples", 473], ["from", 481], ["151", 486], ["patients", 490], ["with", 499], ["the", 504], ["classic", 508], [",", 515], ["hypermobility", 517], [",", 530], ["or", 532], ["vascular", 535], ["types", 544], ["of", 550], ["the", 553], ["Ehlers", 557], ["-", 563], ["Danlos", 564], ["syndrome", 571], [";", 579], ["75", 581], ["patients", 584], ["with", 593], ["psoriasis", 598], [";", 607], ["93", 609], ["patients", 612], ["with", 621], ["rheumatoid", 626], ["arthritis", 637], [";", 646], ["and", 648], ["21", 652], ["healthy", 655], ["persons", 663], ["for", 671], ["the", 675], ["presence", 679], ["of", 688], ["tenascin", 691], ["-", 699], ["X", 700], ["and", 702], ["tenascin", 706], ["-", 714], ["C", 715], ["by", 717], ["enzyme", 720], ["-", 726], ["linked", 727], ["immunosorbent", 734], ["assay", 748], [".", 753], ["We", 755], ["examined", 758], ["the", 767], ["expression", 771], ["of", 782], ["tenascins", 785], ["and", 795], ["type", 799], ["V", 804], ["collagen", 806], ["in", 815], ["skin", 818], ["by", 823], ["immunohistochemical", 826], ["methods", 846], ["and", 854], ["sequenced", 858], ["the", 868], ["tenascin", 872], ["-", 880], ["X", 881], ["gene", 883], [".", 887], ["Tenascin", 889], ["-", 897], ["X", 898], ["was", 900], ["present", 904], ["in", 912], ["serum", 915], ["from", 921], ["all", 926], ["normal", 930], ["subjects", 937], [",", 945], ["all", 947], ["patients", 951], ["with", 960], ["psoriasis", 965], [",", 974], ["all", 976], ["patients", 980], ["with", 989], ["rheumatoid", 994], ["arthritis", 1005], [",", 1014], ["and", 1016], ["146", 1020], ["of", 1024], ["151", 1027], ["patients", 1031], ["with", 1040], ["the", 1045], ["Ehlers", 1049], ["-", 1055], ["Danlos", 1056], ["syndrome", 1063], [".", 1071], ["Tenascin", 1073], ["-", 1081], ["X", 1082], ["was", 1084], ["absent", 1088], ["from", 1095], ["the", 1100], ["serum", 1104], ["of", 1110], ["the", 1113], ["5", 1117], ["remaining", 1119], ["patients", 1129], ["with", 1138], ["Ehlers", 1143], ["-", 1149], ["Danlos", 1150], ["syndrome", 1157], [",", 1165], ["who", 1167], ["were", 1171], ["unrelated", 1176], [".", 1185], ["Tenascin", 1187], ["-", 1195], ["X", 1196], ["deficiency", 1198], ["was", 1209], ["confirmed", 1213], ["in", 1223], ["these", 1226], ["patients", 1232], ["by", 1241], ["analysis", 1244], ["of", 1253], ["skin", 1256], ["fibroblasts", 1261], ["and", 1273], ["by", 1277], ["immunostaining", 1280], ["of", 1295], ["skin", 1298], [".", 1302], ["The", 1304], ["expression", 1308], ["of", 1319], ["tenascin", 1322], ["-", 1330], ["C", 1331], ["and", 1333], ["type", 1337], ["V", 1342], ["collagen", 1344], ["was", 1353], ["normal", 1357], ["in", 1364], ["these", 1367], ["patients", 1373], [".", 1381], ["All", 1383], ["five", 1387], ["of", 1392], ["these", 1395], ["patients", 1401], ["had", 1410], ["hypermobile", 1414], ["joints", 1426], [",", 1432], ["hyperelastic", 1434], ["skin", 1447], [",", 1451], ["and", 1453], ["easy", 1457], ["bruising", 1462], [",", 1470], ["without", 1472], ["atrophic", 1480], ["scarring", 1489], [".", 1497], ["Tenascin", 1499], ["-", 1507], ["X", 1508], ["mutations", 1510], ["were", 1520], ["identified", 1525], ["in", 1536], ["all", 1539], ["tenascin", 1543], ["-", 1551], ["X", 1552], ["-", 1553], ["deficient", 1554], ["patients", 1564], [";", 1572], ["one", 1574], ["patient", 1578], ["had", 1586], ["a", 1590], ["homozygous", 1592], ["tenascin", 1603], ["-", 1611], ["X", 1612], ["gene", 1614], ["deletion", 1619], [",", 1627], ["one", 1629], ["was", 1633], ["heterozygous", 1637], ["for", 1650], ["the", 1654], ["deletion", 1658], [",", 1666], ["and", 1668], ["three", 1672], ["others", 1678], ["had", 1685], ["homozygous", 1689], ["truncating", 1700], ["point", 1711], ["mutations", 1717], [",", 1726], ["confirming", 1728], ["a", 1739], ["causative", 1741], ["role", 1751], ["for", 1756], ["tenascin", 1760], ["-", 1768], ["X", 1769], ["and", 1771], ["a", 1775], ["recessive", 1777], ["pattern", 1787], ["of", 1795], ["inheritance", 1798], [".", 1809], ["Tenascin", 1811], ["-", 1819], ["X", 1820], ["deficiency", 1822], ["causes", 1833], ["a", 1840], ["clinically", 1842], ["distinct", 1853], [",", 1861], ["recessive", 1863], ["form", 1873], ["of", 1878], ["the", 1881], ["Ehlers", 1885], ["-", 1891], ["Danlos", 1892], ["syndrome", 1899], [".", 1907], ["This", 1909], ["finding", 1914], ["indicates", 1922], ["that", 1932], ["factors", 1937], ["other", 1945], ["than", 1951], ["the", 1956], ["collagens", 1960], ["or", 1970], ["collagen", 1973], ["-", 1981], ["processing", 1982], ["enzymes", 1993], ["can", 2001], ["cause", 2005], ["the", 2011], ["syndrome", 2015], ["and", 2024], ["suggests", 2028], ["a", 2037], ["central", 2039], ["role", 2047], ["for", 2052], ["tenascin", 2056], ["-", 2064], ["X", 2065], ["in", 2067], ["maintaining", 2070], ["the", 2082], ["integrity", 2086], ["of", 2096], ["collagenous", 2099], ["matrix", 2111], [".", 2117]]}
{"context": "The effect of the newly synthesized compound 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400) on the Na+-Ca2+ exchanger (NCX) was investigated and compared against that of 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea (KB-R7943). In addition, the effects of SEA0400 on reperfusion injury in vitro and in vivo were examined. SEA0400 was extremely more potent than KB-R7943 in inhibiting Na+-dependent Ca2+ uptake in cultured neurons, astrocytes, and microglia: IC50s of SEA0400 and KB-R7943 were 5 to 33 nM and 2 to 4 microM, respectively. SEA0400 at the concentration range that inhibited NCX exhibited negligible affinities for the Ca2+ channels, Na+ channels, K+ channels, norepinephrine transporter, and 14 receptors, and did not affect the activities of the Na+/H+ exchanger, Na+,K+-ATPase, Ca2+-ATPase, and five enzymes. SEA0400, unlike KB-R7943, did not inhibit the store-operated Ca2+ entry in cultured astrocytes. SEA0400 attenuated dose- dependently paradoxical Ca2+ challenge-induced production of reactive oxygen species, DNA ladder formation, and nuclear condensation in cultured astrocytes, whereas it did not affect thapsigargin-induced cell injury. Furthermore, administration of SEA0400 reduced infarct volumes after a transient middle cerebral artery occlusion in rat cerebral cortex and striatum. These results indicate that SEA0400 is the most potent and selective inhibitor of NCX, and suggest that the compound may exert protective effects on postischemic brain damage.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "e77f03a3c71044b98123b465164c6cc7", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[240, 240], [17, 17], [102, 102]], "char_spans": [[1422, 1424], [141, 143], [614, 616]]}]}], "context_tokens": [["The", 0], ["effect", 4], ["of", 11], ["the", 14], ["newly", 18], ["synthesized", 24], ["compound", 36], ["2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline", 45], ["(", 104], ["SEA0400", 105], [")", 112], ["on", 114], ["the", 117], ["Na+-Ca2", 121], ["+", 128], ["exchanger", 130], ["(", 140], ["NCX", 141], [")", 144], ["was", 146], ["investigated", 150], ["and", 163], ["compared", 167], ["against", 176], ["that", 184], ["of", 189], ["2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea", 192], ["(", 243], ["KB", 244], ["-", 246], ["R7943", 247], [")", 252], [".", 253], ["In", 255], ["addition", 258], [",", 266], ["the", 268], ["effects", 272], ["of", 280], ["SEA0400", 283], ["on", 291], ["reperfusion", 294], ["injury", 306], ["in", 313], ["vitro", 316], ["and", 322], ["in", 326], ["vivo", 329], ["were", 334], ["examined", 339], [".", 347], ["SEA0400", 349], ["was", 357], ["extremely", 361], ["more", 371], ["potent", 376], ["than", 383], ["KB", 388], ["-", 390], ["R7943", 391], ["in", 397], ["inhibiting", 400], ["Na+-dependent", 411], ["Ca2", 425], ["+", 428], ["uptake", 430], ["in", 437], ["cultured", 440], ["neurons", 449], [",", 456], ["astrocytes", 458], [",", 468], ["and", 470], ["microglia", 474], [":", 483], ["IC50s", 485], ["of", 491], ["SEA0400", 494], ["and", 502], ["KB", 506], ["-", 508], ["R7943", 509], ["were", 515], ["5", 520], ["to", 522], ["33", 525], ["nM", 528], ["and", 531], ["2", 535], ["to", 537], ["4", 540], ["microM", 542], [",", 548], ["respectively", 550], [".", 562], ["SEA0400", 564], ["at", 572], ["the", 575], ["concentration", 579], ["range", 593], ["that", 599], ["inhibited", 604], ["NCX", 614], ["exhibited", 618], ["negligible", 628], ["affinities", 639], ["for", 650], ["the", 654], ["Ca2", 658], ["+", 661], ["channels", 663], [",", 671], ["Na+", 673], ["channels", 677], [",", 685], ["K+", 687], ["channels", 690], [",", 698], ["norepinephrine", 700], ["transporter", 715], [",", 726], ["and", 728], ["14", 732], ["receptors", 735], [",", 744], ["and", 746], ["did", 750], ["not", 754], ["affect", 758], ["the", 765], ["activities", 769], ["of", 780], ["the", 783], ["Na+/H+", 787], ["exchanger", 794], [",", 803], ["Na+,K+-ATPase", 805], [",", 818], ["Ca2", 820], ["+", 823], ["-ATPase", 824], [",", 831], ["and", 833], ["five", 837], ["enzymes", 842], [".", 849], ["SEA0400", 851], [",", 858], ["unlike", 860], ["KB", 867], ["-", 869], ["R7943", 870], [",", 875], ["did", 877], ["not", 881], ["inhibit", 885], ["the", 893], ["store", 897], ["-", 902], ["operated", 903], ["Ca2", 912], ["+", 915], ["entry", 917], ["in", 923], ["cultured", 926], ["astrocytes", 935], [".", 945], ["SEA0400", 947], ["attenuated", 955], ["dose-", 966], ["dependently", 972], ["paradoxical", 984], ["Ca2", 996], ["+", 999], ["challenge", 1001], ["-", 1010], ["induced", 1011], ["production", 1019], ["of", 1030], ["reactive", 1033], ["oxygen", 1042], ["species", 1049], [",", 1056], ["DNA", 1058], ["ladder", 1062], ["formation", 1069], [",", 1078], ["and", 1080], ["nuclear", 1084], ["condensation", 1092], ["in", 1105], ["cultured", 1108], ["astrocytes", 1117], [",", 1127], ["whereas", 1129], ["it", 1137], ["did", 1140], ["not", 1144], ["affect", 1148], ["thapsigargin", 1155], ["-", 1167], ["induced", 1168], ["cell", 1176], ["injury", 1181], [".", 1187], ["Furthermore", 1189], [",", 1200], ["administration", 1202], ["of", 1217], ["SEA0400", 1220], ["reduced", 1228], ["infarct", 1236], ["volumes", 1244], ["after", 1252], ["a", 1258], ["transient", 1260], ["middle", 1270], ["cerebral", 1277], ["artery", 1286], ["occlusion", 1293], ["in", 1303], ["rat", 1306], ["cerebral", 1310], ["cortex", 1319], ["and", 1326], ["striatum", 1330], [".", 1338], ["These", 1340], ["results", 1346], ["indicate", 1354], ["that", 1363], ["SEA0400", 1368], ["is", 1376], ["the", 1379], ["most", 1383], ["potent", 1388], ["and", 1395], ["selective", 1399], ["inhibitor", 1409], ["of", 1419], ["NCX", 1422], [",", 1425], ["and", 1427], ["suggest", 1431], ["that", 1439], ["the", 1444], ["compound", 1448], ["may", 1457], ["exert", 1461], ["protective", 1467], ["effects", 1478], ["on", 1486], ["postischemic", 1489], ["brain", 1502], ["damage", 1508], [".", 1514]]}
{"context": "On the basis of remarkable antitumor activity, programmed death receptor-1 (PD-1) inhibitors pembrolizumab and nivolumab were approved for the treatment of advanced melanoma in the second-line setting following progression on either CTLA-4 inhibitor ipilimumab or BRAF/MEK inhibitors (for BRAF mutated melanoma). Given hypothesized risk of triggering exacerbations of autoimmune diseases and/or chronic viral infections, clinical trials (including regulatory studies) evaluating checkpoint blocking antibodies PD-1 and CTLA-4 have excluded patients with autoimmune diseases, chronic hepatitis B/C virus (HBV/HCV), and/or human immunodeficiency virus (HIV) infections. Herein, we describe two patients with advanced melanoma and concomitant HCV/HIV infections treated with PD-1 inhibitor pembrolizumab. Patient 2 with HIV/HCV coinfection progressed after 2 doses of pembrolizumab. Patient 1 who had HCV alone was treated with pembrolizumab with initial partial response. HCV viral load remained stable after 9 cycles of pembrolizumab following which 12-week course of HCV-directed therapy was commenced, resulting in prompt reduction of HCV viral load below detectable levels. Response is ongoing and HCV viral load remains undetectable. In both patients, no significant toxicities were observed when pembrolizumab was initiated. We argue for the further investigation of checkpoint inhibition in cancer patients with underlying chronic viral infections in the context of carefully designed clinical trials.", "qas": [{"question": "Which is the target protein of the drug nivolumab?", "answers": ["programmed death receptor-1"], "qid": "78f0c50b8c6849b2859237d4e919f8cd", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["protein", 20], ["of", 28], ["the", 31], ["drug", 35], ["nivolumab", 40], ["?", 49]], "detected_answers": [{"text": "programmed death receptor-1", "token_spans": [[8, 10]], "char_spans": [[47, 73]]}]}], "context_tokens": [["On", 0], ["the", 3], ["basis", 7], ["of", 13], ["remarkable", 16], ["antitumor", 27], ["activity", 37], [",", 45], ["programmed", 47], ["death", 58], ["receptor-1", 64], ["(", 75], ["PD-1", 76], [")", 80], ["inhibitors", 82], ["pembrolizumab", 93], ["and", 107], ["nivolumab", 111], ["were", 121], ["approved", 126], ["for", 135], ["the", 139], ["treatment", 143], ["of", 153], ["advanced", 156], ["melanoma", 165], ["in", 174], ["the", 177], ["second", 181], ["-", 187], ["line", 188], ["setting", 193], ["following", 201], ["progression", 211], ["on", 223], ["either", 226], ["CTLA-4", 233], ["inhibitor", 240], ["ipilimumab", 250], ["or", 261], ["BRAF", 264], ["/", 268], ["MEK", 269], ["inhibitors", 273], ["(", 284], ["for", 285], ["BRAF", 289], ["mutated", 294], ["melanoma", 302], [")", 310], [".", 311], ["Given", 313], ["hypothesized", 319], ["risk", 332], ["of", 337], ["triggering", 340], ["exacerbations", 351], ["of", 365], ["autoimmune", 368], ["diseases", 379], ["and/or", 388], ["chronic", 395], ["viral", 403], ["infections", 409], [",", 419], ["clinical", 421], ["trials", 430], ["(", 437], ["including", 438], ["regulatory", 448], ["studies", 459], [")", 466], ["evaluating", 468], ["checkpoint", 479], ["blocking", 490], ["antibodies", 499], ["PD-1", 510], ["and", 515], ["CTLA-4", 519], ["have", 526], ["excluded", 531], ["patients", 540], ["with", 549], ["autoimmune", 554], ["diseases", 565], [",", 573], ["chronic", 575], ["hepatitis", 583], ["B", 593], ["/", 594], ["C", 595], ["virus", 597], ["(", 603], ["HBV", 604], ["/", 607], ["HCV", 608], [")", 611], [",", 612], ["and/or", 614], ["human", 621], ["immunodeficiency", 627], ["virus", 644], ["(", 650], ["HIV", 651], [")", 654], ["infections", 656], [".", 666], ["Herein", 668], [",", 674], ["we", 676], ["describe", 679], ["two", 688], ["patients", 692], ["with", 701], ["advanced", 706], ["melanoma", 715], ["and", 724], ["concomitant", 728], ["HCV", 740], ["/", 743], ["HIV", 744], ["infections", 748], ["treated", 759], ["with", 767], ["PD-1", 772], ["inhibitor", 777], ["pembrolizumab", 787], [".", 800], ["Patient", 802], ["2", 810], ["with", 812], ["HIV", 817], ["/", 820], ["HCV", 821], ["coinfection", 825], ["progressed", 837], ["after", 848], ["2", 854], ["doses", 856], ["of", 862], ["pembrolizumab", 865], [".", 878], ["Patient", 880], ["1", 888], ["who", 890], ["had", 894], ["HCV", 898], ["alone", 902], ["was", 908], ["treated", 912], ["with", 920], ["pembrolizumab", 925], ["with", 939], ["initial", 944], ["partial", 952], ["response", 960], [".", 968], ["HCV", 970], ["viral", 974], ["load", 980], ["remained", 985], ["stable", 994], ["after", 1001], ["9", 1007], ["cycles", 1009], ["of", 1016], ["pembrolizumab", 1019], ["following", 1033], ["which", 1043], ["12-week", 1049], ["course", 1057], ["of", 1064], ["HCV", 1067], ["-", 1070], ["directed", 1071], ["therapy", 1080], ["was", 1088], ["commenced", 1092], [",", 1101], ["resulting", 1103], ["in", 1113], ["prompt", 1116], ["reduction", 1123], ["of", 1133], ["HCV", 1136], ["viral", 1140], ["load", 1146], ["below", 1151], ["detectable", 1157], ["levels", 1168], [".", 1174], ["Response", 1176], ["is", 1185], ["ongoing", 1188], ["and", 1196], ["HCV", 1200], ["viral", 1204], ["load", 1210], ["remains", 1215], ["undetectable", 1223], [".", 1235], ["In", 1237], ["both", 1240], ["patients", 1245], [",", 1253], ["no", 1255], ["significant", 1258], ["toxicities", 1270], ["were", 1281], ["observed", 1286], ["when", 1295], ["pembrolizumab", 1300], ["was", 1314], ["initiated", 1318], [".", 1327], ["We", 1329], ["argue", 1332], ["for", 1338], ["the", 1342], ["further", 1346], ["investigation", 1354], ["of", 1368], ["checkpoint", 1371], ["inhibition", 1382], ["in", 1393], ["cancer", 1396], ["patients", 1403], ["with", 1412], ["underlying", 1417], ["chronic", 1428], ["viral", 1436], ["infections", 1442], ["in", 1453], ["the", 1456], ["context", 1460], ["of", 1468], ["carefully", 1471], ["designed", 1481], ["clinical", 1490], ["trials", 1499], [".", 1505]]}
{"context": "Imatinib mesylate is the sole BCR-ABL tyrosine kinase inhibitor approved as first-line treatment of accelerated-phase (AP) chronic myeloid leukemia (CML). Indication was based on the STI571 0109 study, in which imatinib favorably compared to historical treatments in patients failing prior therapies. The relevance of these results to currently newly diagnosed AP-CML patients remains unknown. We evaluated the benefit of imatinib in 42 newly diagnosed AP-CML patients. In all, 16 patients had hematological acceleration without chromosomal abnormalities in addition to the Philadelphia chromosome (ACAs; HEM-AP), 16 solely had ACAs (ACA-AP) and 10 had hematological acceleration plus ACAs (HEM-AP + ACA). Major cytogenetic responses were achieved in 93.7% of HEM-AP patients, 75% of patients with ACA-AP (P=NS) and 40% of patients with HEM-AP + ACA (P=0.0053). The 24-month failure-free survival rate was 87.5% in HEM-AP patients, 43.8% in ACA-AP patients and 15% in HEM-AP + ACA patients (P=0.022). The 24-month estimate of progression-free survival was 100% in HEM-AP patients, 92.8% in ACA-AP patients and 58.3% in HEM-AP + ACA patients (P=0.0052). In conclusion, frontline imatinib allows favorable outcomes in HEM-AP and ACA-AP patients but appears insufficient for patients with HEM-AP + ACA. Broader-target and/or more potent BCR-ABL tyrosine kinase inhibitors alone or in combination may be considered in this setting.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "f00ef1233f084ed28b6eacd36aca14d6", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[5, 7], [286, 288]], "char_spans": [[30, 36], [1334, 1340]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["is", 18], ["the", 21], ["sole", 25], ["BCR", 30], ["-", 33], ["ABL", 34], ["tyrosine", 38], ["kinase", 47], ["inhibitor", 54], ["approved", 64], ["as", 73], ["first", 76], ["-", 81], ["line", 82], ["treatment", 87], ["of", 97], ["accelerated", 100], ["-", 111], ["phase", 112], ["(", 118], ["AP", 119], [")", 121], ["chronic", 123], ["myeloid", 131], ["leukemia", 139], ["(", 148], ["CML", 149], [")", 152], [".", 153], ["Indication", 155], ["was", 166], ["based", 170], ["on", 176], ["the", 179], ["STI571", 183], ["0109", 190], ["study", 195], [",", 200], ["in", 202], ["which", 205], ["imatinib", 211], ["favorably", 220], ["compared", 230], ["to", 239], ["historical", 242], ["treatments", 253], ["in", 264], ["patients", 267], ["failing", 276], ["prior", 284], ["therapies", 290], [".", 299], ["The", 301], ["relevance", 305], ["of", 315], ["these", 318], ["results", 324], ["to", 332], ["currently", 335], ["newly", 345], ["diagnosed", 351], ["AP", 361], ["-", 363], ["CML", 364], ["patients", 368], ["remains", 377], ["unknown", 385], [".", 392], ["We", 394], ["evaluated", 397], ["the", 407], ["benefit", 411], ["of", 419], ["imatinib", 422], ["in", 431], ["42", 434], ["newly", 437], ["diagnosed", 443], ["AP", 453], ["-", 455], ["CML", 456], ["patients", 460], [".", 468], ["In", 470], ["all", 473], [",", 476], ["16", 478], ["patients", 481], ["had", 490], ["hematological", 494], ["acceleration", 508], ["without", 521], ["chromosomal", 529], ["abnormalities", 541], ["in", 555], ["addition", 558], ["to", 567], ["the", 570], ["Philadelphia", 574], ["chromosome", 587], ["(", 598], ["ACAs", 599], [";", 603], ["HEM", 605], ["-", 608], ["AP", 609], [")", 611], [",", 612], ["16", 614], ["solely", 617], ["had", 624], ["ACAs", 628], ["(", 633], ["ACA", 634], ["-", 637], ["AP", 638], [")", 640], ["and", 642], ["10", 646], ["had", 649], ["hematological", 653], ["acceleration", 667], ["plus", 680], ["ACAs", 685], ["(", 690], ["HEM", 691], ["-", 694], ["AP", 695], ["+", 698], ["ACA", 700], [")", 703], [".", 704], ["Major", 706], ["cytogenetic", 712], ["responses", 724], ["were", 734], ["achieved", 739], ["in", 748], ["93.7", 751], ["%", 755], ["of", 757], ["HEM", 760], ["-", 763], ["AP", 764], ["patients", 767], [",", 775], ["75", 777], ["%", 779], ["of", 781], ["patients", 784], ["with", 793], ["ACA", 798], ["-", 801], ["AP", 802], ["(", 805], ["P", 806], ["=", 807], ["NS", 808], [")", 810], ["and", 812], ["40", 816], ["%", 818], ["of", 820], ["patients", 823], ["with", 832], ["HEM", 837], ["-", 840], ["AP", 841], ["+", 844], ["ACA", 846], ["(", 850], ["P=0.0053", 851], [")", 859], [".", 860], ["The", 862], ["24-month", 866], ["failure", 875], ["-", 882], ["free", 883], ["survival", 888], ["rate", 897], ["was", 902], ["87.5", 906], ["%", 910], ["in", 912], ["HEM", 915], ["-", 918], ["AP", 919], ["patients", 922], [",", 930], ["43.8", 932], ["%", 936], ["in", 938], ["ACA", 941], ["-", 944], ["AP", 945], ["patients", 948], ["and", 957], ["15", 961], ["%", 963], ["in", 965], ["HEM", 968], ["-", 971], ["AP", 972], ["+", 975], ["ACA", 977], ["patients", 981], ["(", 990], ["P=0.022", 991], [")", 998], [".", 999], ["The", 1001], ["24-month", 1005], ["estimate", 1014], ["of", 1023], ["progression", 1026], ["-", 1037], ["free", 1038], ["survival", 1043], ["was", 1052], ["100", 1056], ["%", 1059], ["in", 1061], ["HEM", 1064], ["-", 1067], ["AP", 1068], ["patients", 1071], [",", 1079], ["92.8", 1081], ["%", 1085], ["in", 1087], ["ACA", 1090], ["-", 1093], ["AP", 1094], ["patients", 1097], ["and", 1106], ["58.3", 1110], ["%", 1114], ["in", 1116], ["HEM", 1119], ["-", 1122], ["AP", 1123], ["+", 1126], ["ACA", 1128], ["patients", 1132], ["(", 1141], ["P=0.0052", 1142], [")", 1150], [".", 1151], ["In", 1153], ["conclusion", 1156], [",", 1166], ["frontline", 1168], ["imatinib", 1178], ["allows", 1187], ["favorable", 1194], ["outcomes", 1204], ["in", 1213], ["HEM", 1216], ["-", 1219], ["AP", 1220], ["and", 1223], ["ACA", 1227], ["-", 1230], ["AP", 1231], ["patients", 1234], ["but", 1243], ["appears", 1247], ["insufficient", 1255], ["for", 1268], ["patients", 1272], ["with", 1281], ["HEM", 1286], ["-", 1289], ["AP", 1290], ["+", 1293], ["ACA", 1295], [".", 1298], ["Broader", 1300], ["-", 1307], ["target", 1308], ["and/or", 1315], ["more", 1322], ["potent", 1327], ["BCR", 1334], ["-", 1337], ["ABL", 1338], ["tyrosine", 1342], ["kinase", 1351], ["inhibitors", 1358], ["alone", 1369], ["or", 1375], ["in", 1378], ["combination", 1381], ["may", 1393], ["be", 1397], ["considered", 1400], ["in", 1411], ["this", 1414], ["setting", 1419], [".", 1426]]}
{"context": "Diamond-Blackfan anemia (DBA) features hypoplastic anemia and congenital malformations, largely caused by mutations in various ribosomal proteins. The aim of this study was to characterize the spectrum of genetic lesions causing DBA and identify genotypes that correlate with phenotypes of clinical significance. Seventy-four patients with DBA from across Canada were included. Nucleotide-level mutations or large deletions were identified in 10 ribosomal genes in 45 cases. The RPS19 mutation group was associated with higher requirement for chronic treatment for anemia than other DBA groups. Patients with RPS19 mutations, however, were more likely to maintain long-term corticosteroid response without requirement for further chronic transfusions. Conversely, patients with RPL11 mutations were less likely to need chronic treatment. Birth defects, including cardiac, skeletal, hand, cleft lip or palate and genitourinary malformations, also varied among the various genetic groups. Patients with RPS19 mutations had the fewest number of defects, while patients with RPL5 had the greatest number of birth defects. This is the first study to show differences between DBA genetic groups with regards to treatment. Previously unreported differences in the rate and types of birth defects were also identified. These data allow better patient counseling, a more personalized monitoring plan, and may also suggest differential functions of DBA genes on ribosome and extra-ribosomal functions.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "64a4ffe678aa497da235a1cde7d5712e", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[37, 37], [5, 5], [54, 54], [236, 236], [94, 94], [193, 193]], "char_spans": [[229, 231], [25, 27], [340, 342], [1439, 1441], [583, 585], [1170, 1172]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["features", 30], ["hypoplastic", 39], ["anemia", 51], ["and", 58], ["congenital", 62], ["malformations", 73], [",", 86], ["largely", 88], ["caused", 96], ["by", 103], ["mutations", 106], ["in", 116], ["various", 119], ["ribosomal", 127], ["proteins", 137], [".", 145], ["The", 147], ["aim", 151], ["of", 155], ["this", 158], ["study", 163], ["was", 169], ["to", 173], ["characterize", 176], ["the", 189], ["spectrum", 193], ["of", 202], ["genetic", 205], ["lesions", 213], ["causing", 221], ["DBA", 229], ["and", 233], ["identify", 237], ["genotypes", 246], ["that", 256], ["correlate", 261], ["with", 271], ["phenotypes", 276], ["of", 287], ["clinical", 290], ["significance", 299], [".", 311], ["Seventy", 313], ["-", 320], ["four", 321], ["patients", 326], ["with", 335], ["DBA", 340], ["from", 344], ["across", 349], ["Canada", 356], ["were", 363], ["included", 368], [".", 376], ["Nucleotide", 378], ["-", 388], ["level", 389], ["mutations", 395], ["or", 405], ["large", 408], ["deletions", 414], ["were", 424], ["identified", 429], ["in", 440], ["10", 443], ["ribosomal", 446], ["genes", 456], ["in", 462], ["45", 465], ["cases", 468], [".", 473], ["The", 475], ["RPS19", 479], ["mutation", 485], ["group", 494], ["was", 500], ["associated", 504], ["with", 515], ["higher", 520], ["requirement", 527], ["for", 539], ["chronic", 543], ["treatment", 551], ["for", 561], ["anemia", 565], ["than", 572], ["other", 577], ["DBA", 583], ["groups", 587], [".", 593], ["Patients", 595], ["with", 604], ["RPS19", 609], ["mutations", 615], [",", 624], ["however", 626], [",", 633], ["were", 635], ["more", 640], ["likely", 645], ["to", 652], ["maintain", 655], ["long", 664], ["-", 668], ["term", 669], ["corticosteroid", 674], ["response", 689], ["without", 698], ["requirement", 706], ["for", 718], ["further", 722], ["chronic", 730], ["transfusions", 738], [".", 750], ["Conversely", 752], [",", 762], ["patients", 764], ["with", 773], ["RPL11", 778], ["mutations", 784], ["were", 794], ["less", 799], ["likely", 804], ["to", 811], ["need", 814], ["chronic", 819], ["treatment", 827], [".", 836], ["Birth", 838], ["defects", 844], [",", 851], ["including", 853], ["cardiac", 863], [",", 870], ["skeletal", 872], [",", 880], ["hand", 882], [",", 886], ["cleft", 888], ["lip", 894], ["or", 898], ["palate", 901], ["and", 908], ["genitourinary", 912], ["malformations", 926], [",", 939], ["also", 941], ["varied", 946], ["among", 953], ["the", 959], ["various", 963], ["genetic", 971], ["groups", 979], [".", 985], ["Patients", 987], ["with", 996], ["RPS19", 1001], ["mutations", 1007], ["had", 1017], ["the", 1021], ["fewest", 1025], ["number", 1032], ["of", 1039], ["defects", 1042], [",", 1049], ["while", 1051], ["patients", 1057], ["with", 1066], ["RPL5", 1071], ["had", 1076], ["the", 1080], ["greatest", 1084], ["number", 1093], ["of", 1100], ["birth", 1103], ["defects", 1109], [".", 1116], ["This", 1118], ["is", 1123], ["the", 1126], ["first", 1130], ["study", 1136], ["to", 1142], ["show", 1145], ["differences", 1150], ["between", 1162], ["DBA", 1170], ["genetic", 1174], ["groups", 1182], ["with", 1189], ["regards", 1194], ["to", 1202], ["treatment", 1205], [".", 1214], ["Previously", 1216], ["unreported", 1227], ["differences", 1238], ["in", 1250], ["the", 1253], ["rate", 1257], ["and", 1262], ["types", 1266], ["of", 1272], ["birth", 1275], ["defects", 1281], ["were", 1289], ["also", 1294], ["identified", 1299], [".", 1309], ["These", 1311], ["data", 1317], ["allow", 1322], ["better", 1328], ["patient", 1335], ["counseling", 1343], [",", 1353], ["a", 1355], ["more", 1357], ["personalized", 1362], ["monitoring", 1375], ["plan", 1386], [",", 1390], ["and", 1392], ["may", 1396], ["also", 1400], ["suggest", 1405], ["differential", 1413], ["functions", 1426], ["of", 1436], ["DBA", 1439], ["genes", 1443], ["on", 1449], ["ribosome", 1452], ["and", 1461], ["extra", 1465], ["-", 1470], ["ribosomal", 1471], ["functions", 1481], [".", 1490]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is an autosomal-dominant disorder characterized by weakness of the face, upper arm, shoulder, and lower limb musculature, with an onset between the first and third decades. Coats disease is a congenital disorder of retinal vascular development characterized by unilateral peripheral retinal telangiectasia and progressive subretinal and intraretinal exudation. This condition has a predilection for children and is usually isolated. Retinal vascular changes similar to those seen in Coats disease have been demonstrated by fluorescein angiography in 40% to 75% of patients with FSHD. Most patients have asymptomatic retinal telangiectasia found at ocular screening in adulthood after diagnosis of FSHD. We report a 7-month-old infant with bilateral Coats-like retinopathy in which the eye disease was discovered before findings of FSHD were clinically evident. To our knowledge, this patient represents the youngest reported case of preclinical FSHD with ocular disease.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "a40ec3c2b8dd4fa4a955eb489be36aa0", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[7, 9]], "char_spans": [[43, 60]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["an", 40], ["autosomal", 43], ["-", 52], ["dominant", 53], ["disorder", 62], ["characterized", 71], ["by", 85], ["weakness", 88], ["of", 97], ["the", 100], ["face", 104], [",", 108], ["upper", 110], ["arm", 116], [",", 119], ["shoulder", 121], [",", 129], ["and", 131], ["lower", 135], ["limb", 141], ["musculature", 146], [",", 157], ["with", 159], ["an", 164], ["onset", 167], ["between", 173], ["the", 181], ["first", 185], ["and", 191], ["third", 195], ["decades", 201], [".", 208], ["Coats", 210], ["disease", 216], ["is", 224], ["a", 227], ["congenital", 229], ["disorder", 240], ["of", 249], ["retinal", 252], ["vascular", 260], ["development", 269], ["characterized", 281], ["by", 295], ["unilateral", 298], ["peripheral", 309], ["retinal", 320], ["telangiectasia", 328], ["and", 343], ["progressive", 347], ["subretinal", 359], ["and", 370], ["intraretinal", 374], ["exudation", 387], [".", 396], ["This", 398], ["condition", 403], ["has", 413], ["a", 417], ["predilection", 419], ["for", 432], ["children", 436], ["and", 445], ["is", 449], ["usually", 452], ["isolated", 460], [".", 468], ["Retinal", 470], ["vascular", 478], ["changes", 487], ["similar", 495], ["to", 503], ["those", 506], ["seen", 512], ["in", 517], ["Coats", 520], ["disease", 526], ["have", 534], ["been", 539], ["demonstrated", 544], ["by", 557], ["fluorescein", 560], ["angiography", 572], ["in", 584], ["40", 587], ["%", 589], ["to", 591], ["75", 594], ["%", 596], ["of", 598], ["patients", 601], ["with", 610], ["FSHD", 615], [".", 619], ["Most", 621], ["patients", 626], ["have", 635], ["asymptomatic", 640], ["retinal", 653], ["telangiectasia", 661], ["found", 676], ["at", 682], ["ocular", 685], ["screening", 692], ["in", 702], ["adulthood", 705], ["after", 715], ["diagnosis", 721], ["of", 731], ["FSHD", 734], [".", 738], ["We", 740], ["report", 743], ["a", 750], ["7-month", 752], ["-", 759], ["old", 760], ["infant", 764], ["with", 771], ["bilateral", 776], ["Coats", 786], ["-", 791], ["like", 792], ["retinopathy", 797], ["in", 809], ["which", 812], ["the", 818], ["eye", 822], ["disease", 826], ["was", 834], ["discovered", 838], ["before", 849], ["findings", 856], ["of", 865], ["FSHD", 868], ["were", 873], ["clinically", 878], ["evident", 889], [".", 896], ["To", 898], ["our", 901], ["knowledge", 905], [",", 914], ["this", 916], ["patient", 921], ["represents", 929], ["the", 940], ["youngest", 944], ["reported", 953], ["case", 962], ["of", 967], ["preclinical", 970], ["FSHD", 982], ["with", 987], ["ocular", 992], ["disease", 999], [".", 1006]]}
{"context": "Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction but lacked efficacy. Although a potent blocker of hERG, it produced no serious adverse events. We attributed the unexpected result to offsetting Multiple Ion Channel Effects (MICE). Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter. Vanoxerine terminated AF/AFL in an animal model and a dose-ranging clinical trial. Reversion to normal rhythm was associated with QT prolongation yet absent proarrhythmia markers for Torsade de Pointes (TdP). To understand the QT/TdP discordance, we used quantitative profiling and compared vanoxerine with dofetilide, a selective hERG-blocking torsadogen used for intractable AF, verapamil, a non-torsadogenic MICE comparator and bepridil, a torsadogenic MICE comparator. At clinically relevant concentrations, verapamil blocked hCav1.2 and hERG, as did vanoxerine and bepridil both of which also blocked hNav1.5. In acute experiments and simulations, dofetilide produced early after depolarizations (EADs) and arrhythmias, whereas verapamil, vanoxerine and bepridil produced no proarrhythmia markers. Of the MICE drugs only bepridil inhibited hERG trafficking following overnight exposure. The results are consistent with the emphasis on MICE of the CiPA assay. Additionally we propose that trafficking inhibition of hERG be added to CiPA.", "qas": [{"question": "What alternate indication has Vanoxerine been repositioned for?", "answers": ["atrial fibrillation and flutter"], "qid": "1a4946e6636c4ab3a37f421bb4397409", "question_tokens": [["What", 0], ["alternate", 5], ["indication", 15], ["has", 26], ["Vanoxerine", 30], ["been", 41], ["repositioned", 46], ["for", 59], ["?", 62]], "detected_answers": [{"text": "atrial fibrillation and flutter", "token_spans": [[61, 64]], "char_spans": [[367, 397]]}]}], "context_tokens": [["Vanoxerine", 0], ["has", 11], ["been", 15], ["in", 20], ["clinical", 23], ["trials", 32], ["for", 39], ["Parkinsonism", 43], [",", 55], ["depression", 57], ["and", 68], ["cocaine", 72], ["addiction", 80], ["but", 90], ["lacked", 94], ["efficacy", 101], [".", 109], ["Although", 111], ["a", 120], ["potent", 122], ["blocker", 129], ["of", 137], ["hERG", 140], [",", 144], ["it", 146], ["produced", 149], ["no", 158], ["serious", 161], ["adverse", 169], ["events", 177], [".", 183], ["We", 185], ["attributed", 188], ["the", 199], ["unexpected", 203], ["result", 214], ["to", 221], ["offsetting", 224], ["Multiple", 235], ["Ion", 244], ["Channel", 248], ["Effects", 256], ["(", 264], ["MICE", 265], [")", 269], [".", 270], ["Vanoxerine", 272], ["'s", 282], ["effects", 285], ["were", 293], ["strongly", 298], ["frequency", 307], ["-", 316], ["dependent", 317], ["and", 327], ["we", 331], ["repositioned", 334], ["it", 347], ["for", 350], ["treatment", 354], ["of", 364], ["atrial", 367], ["fibrillation", 374], ["and", 387], ["flutter", 391], [".", 398], ["Vanoxerine", 400], ["terminated", 411], ["AF", 422], ["/", 424], ["AFL", 425], ["in", 429], ["an", 432], ["animal", 435], ["model", 442], ["and", 448], ["a", 452], ["dose", 454], ["-", 458], ["ranging", 459], ["clinical", 467], ["trial", 476], [".", 481], ["Reversion", 483], ["to", 493], ["normal", 496], ["rhythm", 503], ["was", 510], ["associated", 514], ["with", 525], ["QT", 530], ["prolongation", 533], ["yet", 546], ["absent", 550], ["proarrhythmia", 557], ["markers", 571], ["for", 579], ["Torsade", 583], ["de", 591], ["Pointes", 594], ["(", 602], ["TdP", 603], [")", 606], [".", 607], ["To", 609], ["understand", 612], ["the", 623], ["QT", 627], ["/", 629], ["TdP", 630], ["discordance", 634], [",", 645], ["we", 647], ["used", 650], ["quantitative", 655], ["profiling", 668], ["and", 678], ["compared", 682], ["vanoxerine", 691], ["with", 702], ["dofetilide", 707], [",", 717], ["a", 719], ["selective", 721], ["hERG", 731], ["-", 735], ["blocking", 736], ["torsadogen", 745], ["used", 756], ["for", 761], ["intractable", 765], ["AF", 777], [",", 779], ["verapamil", 781], [",", 790], ["a", 792], ["non", 794], ["-", 797], ["torsadogenic", 798], ["MICE", 811], ["comparator", 816], ["and", 827], ["bepridil", 831], [",", 839], ["a", 841], ["torsadogenic", 843], ["MICE", 856], ["comparator", 861], [".", 871], ["At", 873], ["clinically", 876], ["relevant", 887], ["concentrations", 896], [",", 910], ["verapamil", 912], ["blocked", 922], ["hCav1.2", 930], ["and", 938], ["hERG", 942], [",", 946], ["as", 948], ["did", 951], ["vanoxerine", 955], ["and", 966], ["bepridil", 970], ["both", 979], ["of", 984], ["which", 987], ["also", 993], ["blocked", 998], ["hNav1.5", 1006], [".", 1013], ["In", 1015], ["acute", 1018], ["experiments", 1024], ["and", 1036], ["simulations", 1040], [",", 1051], ["dofetilide", 1053], ["produced", 1064], ["early", 1073], ["after", 1079], ["depolarizations", 1085], ["(", 1101], ["EADs", 1102], [")", 1106], ["and", 1108], ["arrhythmias", 1112], [",", 1123], ["whereas", 1125], ["verapamil", 1133], [",", 1142], ["vanoxerine", 1144], ["and", 1155], ["bepridil", 1159], ["produced", 1168], ["no", 1177], ["proarrhythmia", 1180], ["markers", 1194], [".", 1201], ["Of", 1203], ["the", 1206], ["MICE", 1210], ["drugs", 1215], ["only", 1221], ["bepridil", 1226], ["inhibited", 1235], ["hERG", 1245], ["trafficking", 1250], ["following", 1262], ["overnight", 1272], ["exposure", 1282], [".", 1290], ["The", 1292], ["results", 1296], ["are", 1304], ["consistent", 1308], ["with", 1319], ["the", 1324], ["emphasis", 1328], ["on", 1337], ["MICE", 1340], ["of", 1345], ["the", 1348], ["CiPA", 1352], ["assay", 1357], [".", 1362], ["Additionally", 1364], ["we", 1377], ["propose", 1380], ["that", 1388], ["trafficking", 1393], ["inhibition", 1405], ["of", 1416], ["hERG", 1419], ["be", 1424], ["added", 1427], ["to", 1433], ["CiPA", 1436], [".", 1440]]}
{"context": "Dear sir, one of the most common entrapment neuropathy syndromes in clinical practice is \"Entrapment of median nerve in carpal tunnel\" also called \"Carpal tunnel syndrome (CTS)\" (Aydin et al., 2007; Huisstede et al., 2010). This syndrome is caused by entrapment of the median nerve in the wrist (Preston and Shapiro, 2005) when the pressure increases in the carpal tunnel. A high division of the median nerve proximal to the carpal tunnel, also known as a bifid median nerve, is a rare anatomic variation that may be associated with CTS and with persistent median vessels (Lanz, 1977). This anatomic variation has an incidence of 0,8% to 2,3% in patients with CTS. Lanz (1977) has characterized this anatomic condition of the median nerve in the carpal tunnel. These anatomic variants have been classified into four groups: - Group 0: extraligamentous thenar branch (standard anatomy); - Group 1: variations of the course of the thenar branch; - Group 2: accessory branches at the distal portion of the carpal tunnel; - Group 3: divided or duplicated median nerve inside the carpal tunnel; - Group 4: accessory branches proximal to the carpal tunnel. During dissection of the wrist performed for the treatment of a CTS under local anesthesia, we found an anatomical variation of the median nerve that was divided in two branches inside the carpal tunnel (Group 3 of Lanz Classification) and in which its radial branch passed through its own compartment. The two parts of the nerve seems to be unequal in size (Fig. 1). Moreover the nerve passed in carpal tunnel associated with a median artery, so we classified this variation in the group 3b of Lanz Classification (Fig. 2). The persistence of median artery coexisting with a bifid median nerve has been widely reported in surgical literature (Lanz, 1977; Barbe et al., 2005). Before surgical intervention clinical evaluation of patient and electrophysiological examination showed no differences compared to a non bifid median nerve entrapment syndrome. In conclusion the bifid median nerve may facilitate compression of median nerve in the carpal tunnel because of its increased cross sectional area even if it has no electrophysiological or clinical differential diagnosis in case of CTS. The aim of this letter is aware the physicians in order to borne in mind the possible presence of a median nerve variation during dissection of carpal tunnel in order to avoid the damage of this non common anatomical structures.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "0460fb3061fd40ec8e30bfca61c596bb", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[256, 256], [385, 385], [315, 315], [339, 339], [58, 58], [150, 150], [214, 214], [394, 394], [84, 84], [400, 400], [345, 345], [448, 448], [18, 18], [114, 114], [97, 97]], "char_spans": [[1283, 1288], [1971, 1976], [1580, 1585], [1695, 1700], [269, 274], [726, 731], [1051, 1056], [2029, 2034], [396, 401], [2072, 2077], [1733, 1738], [2342, 2347], [104, 109], [557, 562], [462, 467]]}]}], "context_tokens": [["Dear", 0], ["sir", 5], [",", 8], ["one", 10], ["of", 14], ["the", 17], ["most", 21], ["common", 26], ["entrapment", 33], ["neuropathy", 44], ["syndromes", 55], ["in", 65], ["clinical", 68], ["practice", 77], ["is", 86], ["\"", 89], ["Entrapment", 90], ["of", 101], ["median", 104], ["nerve", 111], ["in", 117], ["carpal", 120], ["tunnel", 127], ["\"", 133], ["also", 135], ["called", 140], ["\"", 147], ["Carpal", 148], ["tunnel", 155], ["syndrome", 162], ["(", 171], ["CTS", 172], [")", 175], ["\"", 176], ["(", 178], ["Aydin", 179], ["et", 185], ["al", 188], [".", 190], [",", 191], ["2007", 193], [";", 197], ["Huisstede", 199], ["et", 209], ["al", 212], [".", 214], [",", 215], ["2010", 217], [")", 221], [".", 222], ["This", 224], ["syndrome", 229], ["is", 238], ["caused", 241], ["by", 248], ["entrapment", 251], ["of", 262], ["the", 265], ["median", 269], ["nerve", 276], ["in", 282], ["the", 285], ["wrist", 289], ["(", 295], ["Preston", 296], ["and", 304], ["Shapiro", 308], [",", 315], ["2005", 317], [")", 321], ["when", 323], ["the", 328], ["pressure", 332], ["increases", 341], ["in", 351], ["the", 354], ["carpal", 358], ["tunnel", 365], [".", 371], ["A", 373], ["high", 375], ["division", 380], ["of", 389], ["the", 392], ["median", 396], ["nerve", 403], ["proximal", 409], ["to", 418], ["the", 421], ["carpal", 425], ["tunnel", 432], [",", 438], ["also", 440], ["known", 445], ["as", 451], ["a", 454], ["bifid", 456], ["median", 462], ["nerve", 469], [",", 474], ["is", 476], ["a", 479], ["rare", 481], ["anatomic", 486], ["variation", 495], ["that", 505], ["may", 510], ["be", 514], ["associated", 517], ["with", 528], ["CTS", 533], ["and", 537], ["with", 541], ["persistent", 546], ["median", 557], ["vessels", 564], ["(", 572], ["Lanz", 573], [",", 577], ["1977", 579], [")", 583], [".", 584], ["This", 586], ["anatomic", 591], ["variation", 600], ["has", 610], ["an", 614], ["incidence", 617], ["of", 627], ["0,8", 630], ["%", 633], ["to", 635], ["2,3", 638], ["%", 641], ["in", 643], ["patients", 646], ["with", 655], ["CTS", 660], [".", 663], ["Lanz", 665], ["(", 670], ["1977", 671], [")", 675], ["has", 677], ["characterized", 681], ["this", 695], ["anatomic", 700], ["condition", 709], ["of", 719], ["the", 722], ["median", 726], ["nerve", 733], ["in", 739], ["the", 742], ["carpal", 746], ["tunnel", 753], [".", 759], ["These", 761], ["anatomic", 767], ["variants", 776], ["have", 785], ["been", 790], ["classified", 795], ["into", 806], ["four", 811], ["groups", 816], [":", 822], ["-", 824], ["Group", 826], ["0", 832], [":", 833], ["extraligamentous", 835], ["thenar", 852], ["branch", 859], ["(", 866], ["standard", 867], ["anatomy", 876], [")", 883], [";", 884], ["-", 886], ["Group", 888], ["1", 894], [":", 895], ["variations", 897], ["of", 908], ["the", 911], ["course", 915], ["of", 922], ["the", 925], ["thenar", 929], ["branch", 936], [";", 942], ["-", 944], ["Group", 946], ["2", 952], [":", 953], ["accessory", 955], ["branches", 965], ["at", 974], ["the", 977], ["distal", 981], ["portion", 988], ["of", 996], ["the", 999], ["carpal", 1003], ["tunnel", 1010], [";", 1016], ["-", 1018], ["Group", 1020], ["3", 1026], [":", 1027], ["divided", 1029], ["or", 1037], ["duplicated", 1040], ["median", 1051], ["nerve", 1058], ["inside", 1064], ["the", 1071], ["carpal", 1075], ["tunnel", 1082], [";", 1088], ["-", 1090], ["Group", 1092], ["4", 1098], [":", 1099], ["accessory", 1101], ["branches", 1111], ["proximal", 1120], ["to", 1129], ["the", 1132], ["carpal", 1136], ["tunnel", 1143], [".", 1149], ["During", 1151], ["dissection", 1158], ["of", 1169], ["the", 1172], ["wrist", 1176], ["performed", 1182], ["for", 1192], ["the", 1196], ["treatment", 1200], ["of", 1210], ["a", 1213], ["CTS", 1215], ["under", 1219], ["local", 1225], ["anesthesia", 1231], [",", 1241], ["we", 1243], ["found", 1246], ["an", 1252], ["anatomical", 1255], ["variation", 1266], ["of", 1276], ["the", 1279], ["median", 1283], ["nerve", 1290], ["that", 1296], ["was", 1301], ["divided", 1305], ["in", 1313], ["two", 1316], ["branches", 1320], ["inside", 1329], ["the", 1336], ["carpal", 1340], ["tunnel", 1347], ["(", 1354], ["Group", 1355], ["3", 1361], ["of", 1363], ["Lanz", 1366], ["Classification", 1371], [")", 1385], ["and", 1387], ["in", 1391], ["which", 1394], ["its", 1400], ["radial", 1404], ["branch", 1411], ["passed", 1418], ["through", 1425], ["its", 1433], ["own", 1437], ["compartment", 1441], [".", 1452], ["The", 1454], ["two", 1458], ["parts", 1462], ["of", 1468], ["the", 1471], ["nerve", 1475], ["seems", 1481], ["to", 1487], ["be", 1490], ["unequal", 1493], ["in", 1501], ["size", 1504], ["(", 1509], ["Fig", 1510], [".", 1513], ["1", 1515], [")", 1516], [".", 1517], ["Moreover", 1519], ["the", 1528], ["nerve", 1532], ["passed", 1538], ["in", 1545], ["carpal", 1548], ["tunnel", 1555], ["associated", 1562], ["with", 1573], ["a", 1578], ["median", 1580], ["artery", 1587], [",", 1593], ["so", 1595], ["we", 1598], ["classified", 1601], ["this", 1612], ["variation", 1617], ["in", 1627], ["the", 1630], ["group", 1634], ["3b", 1640], ["of", 1643], ["Lanz", 1646], ["Classification", 1651], ["(", 1666], ["Fig", 1667], [".", 1670], ["2", 1672], [")", 1673], [".", 1674], ["The", 1676], ["persistence", 1680], ["of", 1692], ["median", 1695], ["artery", 1702], ["coexisting", 1709], ["with", 1720], ["a", 1725], ["bifid", 1727], ["median", 1733], ["nerve", 1740], ["has", 1746], ["been", 1750], ["widely", 1755], ["reported", 1762], ["in", 1771], ["surgical", 1774], ["literature", 1783], ["(", 1794], ["Lanz", 1795], [",", 1799], ["1977", 1801], [";", 1805], ["Barbe", 1807], ["et", 1813], ["al", 1816], [".", 1818], [",", 1819], ["2005", 1821], [")", 1825], [".", 1826], ["Before", 1828], ["surgical", 1835], ["intervention", 1844], ["clinical", 1857], ["evaluation", 1866], ["of", 1877], ["patient", 1880], ["and", 1888], ["electrophysiological", 1892], ["examination", 1913], ["showed", 1925], ["no", 1932], ["differences", 1935], ["compared", 1947], ["to", 1956], ["a", 1959], ["non", 1961], ["bifid", 1965], ["median", 1971], ["nerve", 1978], ["entrapment", 1984], ["syndrome", 1995], [".", 2003], ["In", 2005], ["conclusion", 2008], ["the", 2019], ["bifid", 2023], ["median", 2029], ["nerve", 2036], ["may", 2042], ["facilitate", 2046], ["compression", 2057], ["of", 2069], ["median", 2072], ["nerve", 2079], ["in", 2085], ["the", 2088], ["carpal", 2092], ["tunnel", 2099], ["because", 2106], ["of", 2114], ["its", 2117], ["increased", 2121], ["cross", 2131], ["sectional", 2137], ["area", 2147], ["even", 2152], ["if", 2157], ["it", 2160], ["has", 2163], ["no", 2167], ["electrophysiological", 2170], ["or", 2191], ["clinical", 2194], ["differential", 2203], ["diagnosis", 2216], ["in", 2226], ["case", 2229], ["of", 2234], ["CTS", 2237], [".", 2240], ["The", 2242], ["aim", 2246], ["of", 2250], ["this", 2253], ["letter", 2258], ["is", 2265], ["aware", 2268], ["the", 2274], ["physicians", 2278], ["in", 2289], ["order", 2292], ["to", 2298], ["borne", 2301], ["in", 2307], ["mind", 2310], ["the", 2315], ["possible", 2319], ["presence", 2328], ["of", 2337], ["a", 2340], ["median", 2342], ["nerve", 2349], ["variation", 2355], ["during", 2365], ["dissection", 2372], ["of", 2383], ["carpal", 2386], ["tunnel", 2393], ["in", 2400], ["order", 2403], ["to", 2409], ["avoid", 2412], ["the", 2418], ["damage", 2422], ["of", 2429], ["this", 2432], ["non", 2437], ["common", 2441], ["anatomical", 2448], ["structures", 2459], [".", 2469]]}
{"context": "The gene encoding the ribosomal protein S19 (RPS19) is frequently mutated in Diamond-Blackfan anemia (DBA), a congenital erythroblastopenia. The consequence of these mutations on the onset of the disease remains obscure. Here, we show that RPS19 plays an essential role in biogenesis of the 40S small ribosomal subunit in human cells. Knockdown of RPS19 expression by siRNAs impairs 18S rRNA synthesis and formation of 40S subunits and induces apoptosis in HeLa cells. Pre-rRNA processing is altered, which leads to an arrest in the maturation of precursors to the 18S rRNA. Under these conditions, pre-40S particles are not exported to the cytoplasm and accumulate in the nucleoplasm of the cells in perinuclear dots. Consistently, we find that ribosome biogenesis and nucleolar organization is altered in skin fibroblasts from DBA patients bearing mutations in the RPS19 gene. In addition, maturation of the 18S rRNA is also perturbed in cells from a patient bearing no RPS19-related mutation. These results support the hypothesis that DBA is directly related to a defect in ribosome biogenesis and indicate that yet to be discovered DBA-related genes may be involved in the synthesis of the ribosomal subunits.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "85af34b4c81f4eee8ca3336339fad285", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[14, 17]], "char_spans": [[77, 99]]}, {"text": "DBA", "token_spans": [[182, 182], [19, 19], [199, 199], [146, 146]], "char_spans": [[1038, 1040], [102, 104], [1136, 1138], [829, 831]]}]}], "context_tokens": [["The", 0], ["gene", 4], ["encoding", 9], ["the", 18], ["ribosomal", 22], ["protein", 32], ["S19", 40], ["(", 44], ["RPS19", 45], [")", 50], ["is", 52], ["frequently", 55], ["mutated", 66], ["in", 74], ["Diamond", 77], ["-", 84], ["Blackfan", 85], ["anemia", 94], ["(", 101], ["DBA", 102], [")", 105], [",", 106], ["a", 108], ["congenital", 110], ["erythroblastopenia", 121], [".", 139], ["The", 141], ["consequence", 145], ["of", 157], ["these", 160], ["mutations", 166], ["on", 176], ["the", 179], ["onset", 183], ["of", 189], ["the", 192], ["disease", 196], ["remains", 204], ["obscure", 212], [".", 219], ["Here", 221], [",", 225], ["we", 227], ["show", 230], ["that", 235], ["RPS19", 240], ["plays", 246], ["an", 252], ["essential", 255], ["role", 265], ["in", 270], ["biogenesis", 273], ["of", 284], ["the", 287], ["40S", 291], ["small", 295], ["ribosomal", 301], ["subunit", 311], ["in", 319], ["human", 322], ["cells", 328], [".", 333], ["Knockdown", 335], ["of", 345], ["RPS19", 348], ["expression", 354], ["by", 365], ["siRNAs", 368], ["impairs", 375], ["18S", 383], ["rRNA", 387], ["synthesis", 392], ["and", 402], ["formation", 406], ["of", 416], ["40S", 419], ["subunits", 423], ["and", 432], ["induces", 436], ["apoptosis", 444], ["in", 454], ["HeLa", 457], ["cells", 462], [".", 467], ["Pre", 469], ["-", 472], ["rRNA", 473], ["processing", 478], ["is", 489], ["altered", 492], [",", 499], ["which", 501], ["leads", 507], ["to", 513], ["an", 516], ["arrest", 519], ["in", 526], ["the", 529], ["maturation", 533], ["of", 544], ["precursors", 547], ["to", 558], ["the", 561], ["18S", 565], ["rRNA", 569], [".", 573], ["Under", 575], ["these", 581], ["conditions", 587], [",", 597], ["pre-40S", 599], ["particles", 607], ["are", 617], ["not", 621], ["exported", 625], ["to", 634], ["the", 637], ["cytoplasm", 641], ["and", 651], ["accumulate", 655], ["in", 666], ["the", 669], ["nucleoplasm", 673], ["of", 685], ["the", 688], ["cells", 692], ["in", 698], ["perinuclear", 701], ["dots", 713], [".", 717], ["Consistently", 719], [",", 731], ["we", 733], ["find", 736], ["that", 741], ["ribosome", 746], ["biogenesis", 755], ["and", 766], ["nucleolar", 770], ["organization", 780], ["is", 793], ["altered", 796], ["in", 804], ["skin", 807], ["fibroblasts", 812], ["from", 824], ["DBA", 829], ["patients", 833], ["bearing", 842], ["mutations", 850], ["in", 860], ["the", 863], ["RPS19", 867], ["gene", 873], [".", 877], ["In", 879], ["addition", 882], [",", 890], ["maturation", 892], ["of", 903], ["the", 906], ["18S", 910], ["rRNA", 914], ["is", 919], ["also", 922], ["perturbed", 927], ["in", 937], ["cells", 940], ["from", 946], ["a", 951], ["patient", 953], ["bearing", 961], ["no", 969], ["RPS19-related", 972], ["mutation", 986], [".", 994], ["These", 996], ["results", 1002], ["support", 1010], ["the", 1018], ["hypothesis", 1022], ["that", 1033], ["DBA", 1038], ["is", 1042], ["directly", 1045], ["related", 1054], ["to", 1062], ["a", 1065], ["defect", 1067], ["in", 1074], ["ribosome", 1077], ["biogenesis", 1086], ["and", 1097], ["indicate", 1101], ["that", 1110], ["yet", 1115], ["to", 1119], ["be", 1122], ["discovered", 1125], ["DBA", 1136], ["-", 1139], ["related", 1140], ["genes", 1148], ["may", 1154], ["be", 1158], ["involved", 1161], ["in", 1170], ["the", 1173], ["synthesis", 1177], ["of", 1187], ["the", 1190], ["ribosomal", 1194], ["subunits", 1204], [".", 1212]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD), the most prevalent myopathy afflicting both children and adults, is predominantly associated with contractions in the 4q35-localized macrosatellite D4Z4 repeat array. Recent studies have proposed that FSHD pathology is caused by the misexpression of the DUX4 (double homeobox 4) gene resulting in production of a pathogenic protein, DUX4-FL, which has been detected in FSHD, but not in unaffected control myogenic cells and muscle tissue. Here, we report the analysis of DUX4 mRNA and protein expression in a much larger collection of myogenic cells and muscle biopsies derived from biceps and deltoid muscles of FSHD affected subjects and their unaffected first-degree relatives. We confirmed that stable DUX4-fl mRNA and protein were expressed in myogenic cells and muscle tissues derived from FSHD affected subjects, including several genetically diagnosed adult FSHD subjects yet to show clinical manifestations of the disease in the assayed muscles. In addition, we report DUX4-fl mRNA and protein expression in muscle biopsies and myogenic cells from genetically unaffected relatives of the FSHD subjects, although at a significantly lower frequency. These results establish that DUX4-fl expression per se is not sufficient for FSHD muscle pathology and indicate that quantitative modifiers of DUX4-fl expression and/or function and family genetic background are determinants of FSHD muscle disease progression.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "c09b13353ce8449cae19747d33b78dc2", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[226, 226], [109, 109], [35, 35], [138, 138], [147, 147], [4, 4], [184, 184], [206, 206], [66, 66]], "char_spans": [[1432, 1435], [660, 663], [248, 251], [843, 846], [913, 916], [40, 43], [1144, 1147], [1281, 1284], [416, 419]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], [",", 45], ["the", 47], ["most", 51], ["prevalent", 56], ["myopathy", 66], ["afflicting", 75], ["both", 86], ["children", 91], ["and", 100], ["adults", 104], [",", 110], ["is", 112], ["predominantly", 115], ["associated", 129], ["with", 140], ["contractions", 145], ["in", 158], ["the", 161], ["4q35-localized", 165], ["macrosatellite", 180], ["D4Z4", 195], ["repeat", 200], ["array", 207], [".", 212], ["Recent", 214], ["studies", 221], ["have", 229], ["proposed", 234], ["that", 243], ["FSHD", 248], ["pathology", 253], ["is", 263], ["caused", 266], ["by", 273], ["the", 276], ["misexpression", 280], ["of", 294], ["the", 297], ["DUX4", 301], ["(", 306], ["double", 307], ["homeobox", 314], ["4", 323], [")", 324], ["gene", 326], ["resulting", 331], ["in", 341], ["production", 344], ["of", 355], ["a", 358], ["pathogenic", 360], ["protein", 371], [",", 378], ["DUX4-FL", 380], [",", 387], ["which", 389], ["has", 395], ["been", 399], ["detected", 404], ["in", 413], ["FSHD", 416], [",", 420], ["but", 422], ["not", 426], ["in", 430], ["unaffected", 433], ["control", 444], ["myogenic", 452], ["cells", 461], ["and", 467], ["muscle", 471], ["tissue", 478], [".", 484], ["Here", 486], [",", 490], ["we", 492], ["report", 495], ["the", 502], ["analysis", 506], ["of", 515], ["DUX4", 518], ["mRNA", 523], ["and", 528], ["protein", 532], ["expression", 540], ["in", 551], ["a", 554], ["much", 556], ["larger", 561], ["collection", 568], ["of", 579], ["myogenic", 582], ["cells", 591], ["and", 597], ["muscle", 601], ["biopsies", 608], ["derived", 617], ["from", 625], ["biceps", 630], ["and", 637], ["deltoid", 641], ["muscles", 649], ["of", 657], ["FSHD", 660], ["affected", 665], ["subjects", 674], ["and", 683], ["their", 687], ["unaffected", 693], ["first", 704], ["-", 709], ["degree", 710], ["relatives", 717], [".", 726], ["We", 728], ["confirmed", 731], ["that", 741], ["stable", 746], ["DUX4-fl", 753], ["mRNA", 761], ["and", 766], ["protein", 770], ["were", 778], ["expressed", 783], ["in", 793], ["myogenic", 796], ["cells", 805], ["and", 811], ["muscle", 815], ["tissues", 822], ["derived", 830], ["from", 838], ["FSHD", 843], ["affected", 848], ["subjects", 857], [",", 865], ["including", 867], ["several", 877], ["genetically", 885], ["diagnosed", 897], ["adult", 907], ["FSHD", 913], ["subjects", 918], ["yet", 927], ["to", 931], ["show", 934], ["clinical", 939], ["manifestations", 948], ["of", 963], ["the", 966], ["disease", 970], ["in", 978], ["the", 981], ["assayed", 985], ["muscles", 993], [".", 1000], ["In", 1002], ["addition", 1005], [",", 1013], ["we", 1015], ["report", 1018], ["DUX4-fl", 1025], ["mRNA", 1033], ["and", 1038], ["protein", 1042], ["expression", 1050], ["in", 1061], ["muscle", 1064], ["biopsies", 1071], ["and", 1080], ["myogenic", 1084], ["cells", 1093], ["from", 1099], ["genetically", 1104], ["unaffected", 1116], ["relatives", 1127], ["of", 1137], ["the", 1140], ["FSHD", 1144], ["subjects", 1149], [",", 1157], ["although", 1159], ["at", 1168], ["a", 1171], ["significantly", 1173], ["lower", 1187], ["frequency", 1193], [".", 1202], ["These", 1204], ["results", 1210], ["establish", 1218], ["that", 1228], ["DUX4-fl", 1233], ["expression", 1241], ["per", 1252], ["se", 1256], ["is", 1259], ["not", 1262], ["sufficient", 1266], ["for", 1277], ["FSHD", 1281], ["muscle", 1286], ["pathology", 1293], ["and", 1303], ["indicate", 1307], ["that", 1316], ["quantitative", 1321], ["modifiers", 1334], ["of", 1344], ["DUX4-fl", 1347], ["expression", 1355], ["and/or", 1366], ["function", 1373], ["and", 1382], ["family", 1386], ["genetic", 1393], ["background", 1401], ["are", 1412], ["determinants", 1416], ["of", 1429], ["FSHD", 1432], ["muscle", 1437], ["disease", 1444], ["progression", 1452], [".", 1463]]}
{"context": "The major protein constituent of Lewy bodies (LBs), the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha-synuclein, but other proteins, in particular the microtubule-associated protein tau, have been implicated in the pathogenesis of LBs. Tau is the major structural component of neurofibrillary tangles (NFTs). Both direct immunochemical studies of partially purified LBs and indirect immunohistochemical studies have suggested that LBs may contain tau, but most of these studies were based upon a single tau antibody, and immunologic cross-reactivity was not completely excluded. To gain insight into the relation between tau and alpha-synuclein in LBs, double immunostaining was performed in Lewy body cases with a rabbit polyclonal antibody to alpha-synuclein and a panel of monoclonal antibodies to phospho- and nonphospho-tau epitopes (Alz50, CP9, CP13, PG5, TG3, PHFI) that spanned the length of the tau molecule. Tau-immunoreactive LBs were present in the medulla in 80% of the cases, irrespective of Braak stage. All tau antibodies recognized at least some LBs, arguing against nonspecific antibody cross-reactivity. In most lesions the tau immunostaining was present at the periphery of the LB. The phospho-tau antibody, TG3, detected more LBs than any of the other tau antibodies. The proportion of LBs with tau immunoreactivity was greatest in neurons vulnerable to NETs, such as those in the locus ceruleus and basal nucleus of Meynert, and least in neurons resistant to NFTs, such as the dorsal motor nucleus of the vagus in the medulla. The present results suggest that tau may coaggregate with alpha-synuclein in LBs, especially in neuronal populations vulnerable to both NFTs and LBs.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "85b37fa6f6cb4803bcf4aa988b62bbac", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[306, 308], [138, 140], [118, 120], [27, 29]], "char_spans": [[1661, 1675], [799, 813], [683, 697], [150, 164]]}]}], "context_tokens": [["The", 0], ["major", 4], ["protein", 10], ["constituent", 18], ["of", 30], ["Lewy", 33], ["bodies", 38], ["(", 45], ["LBs", 46], [")", 49], [",", 50], ["the", 52], ["pathological", 56], ["hallmark", 69], ["of", 78], ["Parkinson", 81], ["disease", 91], ["and", 99], ["dementia", 103], ["with", 112], ["Lewy", 117], ["bodies", 122], [",", 128], ["is", 130], ["considered", 133], ["to", 144], ["be", 147], ["alpha", 150], ["-", 155], ["synuclein", 156], [",", 165], ["but", 167], ["other", 171], ["proteins", 177], [",", 185], ["in", 187], ["particular", 190], ["the", 201], ["microtubule", 205], ["-", 216], ["associated", 217], ["protein", 228], ["tau", 236], [",", 239], ["have", 241], ["been", 246], ["implicated", 251], ["in", 262], ["the", 265], ["pathogenesis", 269], ["of", 282], ["LBs", 285], [".", 288], ["Tau", 290], ["is", 294], ["the", 297], ["major", 301], ["structural", 307], ["component", 318], ["of", 328], ["neurofibrillary", 331], ["tangles", 347], ["(", 355], ["NFTs", 356], [")", 360], [".", 361], ["Both", 363], ["direct", 368], ["immunochemical", 375], ["studies", 390], ["of", 398], ["partially", 401], ["purified", 411], ["LBs", 420], ["and", 424], ["indirect", 428], ["immunohistochemical", 437], ["studies", 457], ["have", 465], ["suggested", 470], ["that", 480], ["LBs", 485], ["may", 489], ["contain", 493], ["tau", 501], [",", 504], ["but", 506], ["most", 510], ["of", 515], ["these", 518], ["studies", 524], ["were", 532], ["based", 537], ["upon", 543], ["a", 548], ["single", 550], ["tau", 557], ["antibody", 561], [",", 569], ["and", 571], ["immunologic", 575], ["cross", 587], ["-", 592], ["reactivity", 593], ["was", 604], ["not", 608], ["completely", 612], ["excluded", 623], [".", 631], ["To", 633], ["gain", 636], ["insight", 641], ["into", 649], ["the", 654], ["relation", 658], ["between", 667], ["tau", 675], ["and", 679], ["alpha", 683], ["-", 688], ["synuclein", 689], ["in", 699], ["LBs", 702], [",", 705], ["double", 707], ["immunostaining", 714], ["was", 729], ["performed", 733], ["in", 743], ["Lewy", 746], ["body", 751], ["cases", 756], ["with", 762], ["a", 767], ["rabbit", 769], ["polyclonal", 776], ["antibody", 787], ["to", 796], ["alpha", 799], ["-", 804], ["synuclein", 805], ["and", 815], ["a", 819], ["panel", 821], ["of", 827], ["monoclonal", 830], ["antibodies", 841], ["to", 852], ["phospho-", 855], ["and", 864], ["nonphospho", 868], ["-", 878], ["tau", 879], ["epitopes", 883], ["(", 892], ["Alz50", 893], [",", 898], ["CP9", 900], [",", 903], ["CP13", 905], [",", 909], ["PG5", 911], [",", 914], ["TG3", 916], [",", 919], ["PHFI", 921], [")", 925], ["that", 927], ["spanned", 932], ["the", 940], ["length", 944], ["of", 951], ["the", 954], ["tau", 958], ["molecule", 962], [".", 970], ["Tau", 972], ["-", 975], ["immunoreactive", 976], ["LBs", 991], ["were", 995], ["present", 1000], ["in", 1008], ["the", 1011], ["medulla", 1015], ["in", 1023], ["80", 1026], ["%", 1028], ["of", 1030], ["the", 1033], ["cases", 1037], [",", 1042], ["irrespective", 1044], ["of", 1057], ["Braak", 1060], ["stage", 1066], [".", 1071], ["All", 1073], ["tau", 1077], ["antibodies", 1081], ["recognized", 1092], ["at", 1103], ["least", 1106], ["some", 1112], ["LBs", 1117], [",", 1120], ["arguing", 1122], ["against", 1130], ["nonspecific", 1138], ["antibody", 1150], ["cross", 1159], ["-", 1164], ["reactivity", 1165], [".", 1175], ["In", 1177], ["most", 1180], ["lesions", 1185], ["the", 1193], ["tau", 1197], ["immunostaining", 1201], ["was", 1216], ["present", 1220], ["at", 1228], ["the", 1231], ["periphery", 1235], ["of", 1245], ["the", 1248], ["LB", 1252], [".", 1254], ["The", 1256], ["phospho", 1260], ["-", 1267], ["tau", 1268], ["antibody", 1272], [",", 1280], ["TG3", 1282], [",", 1285], ["detected", 1287], ["more", 1296], ["LBs", 1301], ["than", 1305], ["any", 1310], ["of", 1314], ["the", 1317], ["other", 1321], ["tau", 1327], ["antibodies", 1331], [".", 1341], ["The", 1343], ["proportion", 1347], ["of", 1358], ["LBs", 1361], ["with", 1365], ["tau", 1370], ["immunoreactivity", 1374], ["was", 1391], ["greatest", 1395], ["in", 1404], ["neurons", 1407], ["vulnerable", 1415], ["to", 1426], ["NETs", 1429], [",", 1433], ["such", 1435], ["as", 1440], ["those", 1443], ["in", 1449], ["the", 1452], ["locus", 1456], ["ceruleus", 1462], ["and", 1471], ["basal", 1475], ["nucleus", 1481], ["of", 1489], ["Meynert", 1492], [",", 1499], ["and", 1501], ["least", 1505], ["in", 1511], ["neurons", 1514], ["resistant", 1522], ["to", 1532], ["NFTs", 1535], [",", 1539], ["such", 1541], ["as", 1546], ["the", 1549], ["dorsal", 1553], ["motor", 1560], ["nucleus", 1566], ["of", 1574], ["the", 1577], ["vagus", 1581], ["in", 1587], ["the", 1590], ["medulla", 1594], [".", 1601], ["The", 1603], ["present", 1607], ["results", 1615], ["suggest", 1623], ["that", 1631], ["tau", 1636], ["may", 1640], ["coaggregate", 1644], ["with", 1656], ["alpha", 1661], ["-", 1666], ["synuclein", 1667], ["in", 1677], ["LBs", 1680], [",", 1683], ["especially", 1685], ["in", 1696], ["neuronal", 1699], ["populations", 1708], ["vulnerable", 1720], ["to", 1731], ["both", 1734], ["NFTs", 1739], ["and", 1744], ["LBs", 1748], [".", 1751]]}
{"context": "ESET (ERG-associated protein with a SET domain, also called SETDB1) is a novel histone methyltransferase that catalyzes methylation of histone H3-lysine 9 (H3-K9). Here we describe the genomic structure and expression of the mouse ESET gene that gives rise to ESET protein and its alternative splicing product. ESET is a 36-kb single copy gene and full-length ESET transcript consisting of 22 exons. The splicing variant retains only the first 12 exons and thus lacks sequences encoding the methyl CpG-binding domain and the catalytic SET domain. The U2 type conserved GT/AG consensus sequence is present at all of the splicing junctions within the ESET gene. The transcription initiation site of the ESET gene was determined by 5'-RACE experiment and by primer extension. The 5'-flanking sequence of the ESET gene does not contain the consensus TATA box. Instead, this ESET promoter region has features such as SP1-binding sites that are typical of housekeeping genes. The ESET promoter was functionally active when tested in transfection and luciferase assay. Full-length ESET transcript appears to be ubiquitously expressed. While the SET domain-deficient splicing variant is present in immortalized cell lines, it is undetectable by RT-PCR in the majority of normal mouse tissues.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "10848a4c98c7472199863319754dae63", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[8, 9], [97, 98], [201, 202]], "char_spans": [[36, 45], [535, 544], [1138, 1147]]}]}], "context_tokens": [["ESET", 0], ["(", 5], ["ERG", 6], ["-", 9], ["associated", 10], ["protein", 21], ["with", 29], ["a", 34], ["SET", 36], ["domain", 40], [",", 46], ["also", 48], ["called", 53], ["SETDB1", 60], [")", 66], ["is", 68], ["a", 71], ["novel", 73], ["histone", 79], ["methyltransferase", 87], ["that", 105], ["catalyzes", 110], ["methylation", 120], ["of", 132], ["histone", 135], ["H3-lysine", 143], ["9", 153], ["(", 155], ["H3-K9", 156], [")", 161], [".", 162], ["Here", 164], ["we", 169], ["describe", 172], ["the", 181], ["genomic", 185], ["structure", 193], ["and", 203], ["expression", 207], ["of", 218], ["the", 221], ["mouse", 225], ["ESET", 231], ["gene", 236], ["that", 241], ["gives", 246], ["rise", 252], ["to", 257], ["ESET", 260], ["protein", 265], ["and", 273], ["its", 277], ["alternative", 281], ["splicing", 293], ["product", 302], [".", 309], ["ESET", 311], ["is", 316], ["a", 319], ["36-kb", 321], ["single", 327], ["copy", 334], ["gene", 339], ["and", 344], ["full", 348], ["-", 352], ["length", 353], ["ESET", 360], ["transcript", 365], ["consisting", 376], ["of", 387], ["22", 390], ["exons", 393], [".", 398], ["The", 400], ["splicing", 404], ["variant", 413], ["retains", 421], ["only", 429], ["the", 434], ["first", 438], ["12", 444], ["exons", 447], ["and", 453], ["thus", 457], ["lacks", 462], ["sequences", 468], ["encoding", 478], ["the", 487], ["methyl", 491], ["CpG", 498], ["-", 501], ["binding", 502], ["domain", 510], ["and", 517], ["the", 521], ["catalytic", 525], ["SET", 535], ["domain", 539], [".", 545], ["The", 547], ["U2", 551], ["type", 554], ["conserved", 559], ["GT", 569], ["/", 571], ["AG", 572], ["consensus", 575], ["sequence", 585], ["is", 594], ["present", 597], ["at", 605], ["all", 608], ["of", 612], ["the", 615], ["splicing", 619], ["junctions", 628], ["within", 638], ["the", 645], ["ESET", 649], ["gene", 654], [".", 658], ["The", 660], ["transcription", 664], ["initiation", 678], ["site", 689], ["of", 694], ["the", 697], ["ESET", 701], ["gene", 706], ["was", 711], ["determined", 715], ["by", 726], ["5'-RACE", 729], ["experiment", 737], ["and", 748], ["by", 752], ["primer", 755], ["extension", 762], [".", 771], ["The", 773], ["5'-flanking", 777], ["sequence", 789], ["of", 798], ["the", 801], ["ESET", 805], ["gene", 810], ["does", 815], ["not", 820], ["contain", 824], ["the", 832], ["consensus", 836], ["TATA", 846], ["box", 851], [".", 854], ["Instead", 856], [",", 863], ["this", 865], ["ESET", 870], ["promoter", 875], ["region", 884], ["has", 891], ["features", 895], ["such", 904], ["as", 909], ["SP1-binding", 912], ["sites", 924], ["that", 930], ["are", 935], ["typical", 939], ["of", 947], ["housekeeping", 950], ["genes", 963], [".", 968], ["The", 970], ["ESET", 974], ["promoter", 979], ["was", 988], ["functionally", 992], ["active", 1005], ["when", 1012], ["tested", 1017], ["in", 1024], ["transfection", 1027], ["and", 1040], ["luciferase", 1044], ["assay", 1055], [".", 1060], ["Full", 1062], ["-", 1066], ["length", 1067], ["ESET", 1074], ["transcript", 1079], ["appears", 1090], ["to", 1098], ["be", 1101], ["ubiquitously", 1104], ["expressed", 1117], [".", 1126], ["While", 1128], ["the", 1134], ["SET", 1138], ["domain", 1142], ["-", 1148], ["deficient", 1149], ["splicing", 1159], ["variant", 1168], ["is", 1176], ["present", 1179], ["in", 1187], ["immortalized", 1190], ["cell", 1203], ["lines", 1208], [",", 1213], ["it", 1215], ["is", 1218], ["undetectable", 1221], ["by", 1234], ["RT", 1237], ["-", 1239], ["PCR", 1240], ["in", 1244], ["the", 1247], ["majority", 1251], ["of", 1260], ["normal", 1263], ["mouse", 1270], ["tissues", 1276], [".", 1283]]}
